<SEC-DOCUMENT>0001129928-22-000017.txt : 20220303
<SEC-HEADER>0001129928-22-000017.hdr.sgml : 20220303
<ACCEPTANCE-DATETIME>20220303165508
ACCESSION NUMBER:		0001129928-22-000017
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		126
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220303
DATE AS OF CHANGE:		20220303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		22709926

	BUSINESS ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>oncyf-20211231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:04d38e4b-b411-4668-8f8c-e4013a42568d,g:242f92a0-4583-4d5d-9e63-4960e9cee1a1,d:cedb1c9c6ee74f3199d6852ba92bc59b--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:oncyf="http://www.oncolyticsbiotech.com/20211231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>oncyf-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV8yLTEtMS0xLTgxMjE_35140406-bf6e-4b13-bd45-7e19f409ce0d">0001129928</ix:nonNumeric><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV83LTEtMS0xLTgxMjE_3f7605ac-7635-4dca-bc45-aebf9c1ba795">2021</ix:nonNumeric><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV84LTEtMS0xLTgxMjE_04e1c0c8-7c86-407c-9ef7-9dbd16b69cf8">FY</ix:nonNumeric><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV85LTEtMS0xLTgxMjE_7ae27411-bacb-443e-b0a1-5b64569fb105">false</ix:nonNumeric><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV81LTEtMS0xLTE4NDI0_fe829cd6-ccbf-44aa-aff0-713996434c09">A0</ix:nonNumeric><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV81LTEtMS0xLTE4NDAx_7b0a861b-1ab0-456f-ac62-cbdc21743c1f">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i511314b0c0694411a575ec0eca0098cb_D20180522-20180522" decimals="INF" name="oncyf:StockholdersEquityNoteStockSplitConversionRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjMvZnJhZzo0YzZjZTA0ZGJmMzg0MmRhYmY2NGE1NzE3ZGEwZGRiYS90YWJsZTo1NWZhZWRlYjBhNDA0ZGJhODc4NWJmNzdmN2JiODZjYy90YWJsZXJhbmdlOjU1ZmFlZGViMGE0MDRkYmE4Nzg1YmY3N2Y3YmI4NmNjXzEtMS0xLTEtODEyMQ_f20641f7-aa1e-4e44-9b78-13d0372954df">0.105263157894737</ix:nonFraction><ix:nonNumeric contextRef="i5803ba163d63468d93a4dcc9c0042c33_D20210101-20211231" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzM1OA_3e8a9208-2071-47f7-9434-36998b16603e">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="oncyf-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe633dda267842029258e53a782fe561_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i113d492fc4cf424c8489d5302adf402d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cadPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i21ac1e8adaee40f6b58f4f0a7d541a1a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fca816bbeb24d2f9554e7f82f33d0aa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a4b3d20c0e34a60b680edd8e972dcfc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaefbcea0de304b2694dda77f60ddb9c8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f8ab54803934f9ba120d4a3bc5e6154_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i762faf08df5c4521a4f2689a278651e0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7497baf23598431f909bb5527274fe07_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb855524d3594b9281f4a4752081bdde_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1259d944f2ca4e288ad6295bde8a4c8d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb74087cec10424881ec8739a53a5f47_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77cf8a24c33d40808c7ac3ad20112a31_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dae23e4a8384544b5f5e4a7c1153719_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3c73cf11c2d41678a6efb1f84d128a2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib500d93c61d242cda9af6cc3f32d688c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea11c29de32043f3b1182fba91ce8ff8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaca09b43294947cdbd585359e3ccaae8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304f57b073284387a43a1c3c507589e0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ebb4717b09f4ceb9bf3bf6ef866ac14_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e0d0525ecbf4dbabb9d6b81ca747d24_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f455a49c64e4496ab595aaa0cba3f3e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2f790228dc448d9936518bb5cf5c8a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if543a2c06c834e58a4a76a3dab2778ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i560a323e55304acfbf5998d3542ba7c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc054b35a584c518e17f16ec259dee3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida3a1ebaced94f77b77c50976f1eb191_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c0d97615104d688ed55dd772c5d7cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f313c8714fa4ba0957f98a3704b93ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09fddfef79174f75b8bff1cf359841fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94a1d5d3239c42da9c1871d21717c343_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied32f90a78ea42c7b0c30d1104a4a175_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i477bd6213b6949fc9c3b06ce5e97889c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c09166535004a96a1e9ce08bb6369e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcaaf6e1542d40d79d27fe0f2a8794c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aafba09422b4432b91193f442b37784_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97be07f487294e63a92bac56d0415c91_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89d130fa6b8345b9bb8639ac65bf6959_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20441217b630482b9af70e8a326d5e57_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69f83b81a5514d5f825fc606476e7579_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d63c24097454dbdb7cd6dea53770f97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01941d662103459ba01338223c19f6f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2dbea1a75bc4a34b367005fb0c6ff02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d1d3557b69d4abb86a20c233c6f1c42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i928abeb5cacb4a81b5b6294857079d2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d9fb4cd4024c309548c1bf2a5386e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6a4fa14d2b2483c8f5abacada092873_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c799a9f2ad149fd871347906998cdbb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee32e2321a294a0d825d8564edea4786_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i963faf8316e44553ac2c61cbab41d123_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i982cf0e1d89f41ceba66f2d117947048_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2da45bc703e4440590e52cbb6c0cae23_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32242ff3d2e742fe9c6db2f637808bec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f3e572ad5cd4feea41d839ed408d512_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ifd1040437dbe4ddfa654981a27937d0a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9862680256f347348f49335ecd9cb274_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>oncyf:plan</xbrli:measure></xbrli:unit><xbrli:context id="i800ff2f75db84660ab49b5fd43edd4c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic58c717a06a14201a8ec51df519af985_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d43a48ed72460b82de5da9f8bc806c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb4dd3dcb3854bb3a98aeec910cf0b0b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e928b35b509443e9b3f89941d035b11_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if68c471b3ecb4bdeb645af1dc5364be4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeb2f08e8214484fbe8e7de1348ff6e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7007c392b1ea42b7bfa5f63652da1152_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ee8f344469f41d9b0a08a69b6edeba2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie86e21b5f131400fa46a3e0b45cf078a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2584f9ecb64b45a3b52d3a4ad2b34c59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6dbbc452c8f400f9ca5600d1ea5533a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e58c6e381b84e12b2792dec22095ada_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i301c21dc622442aca90541862f62c6d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9a9ad61b7c34714ab9be21ec4261caf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieae72557ba464b78b3c52ff1fde0c3e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca0c7d56dcc43cdbb15d5b8cc79a270_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief8ec86040be42ba9d536b3bf953a071_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5302452976149d498ed33786d7128b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d04cbd5984d4fffa8e832079f479563_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c331b0bbafb4b2680c749659e1c82b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b25b30c9fd4ba59fc2eafb50014834_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i204bc52fd44a4d0c816c0a2181824b55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c201bd2cec84413bbbc206341b41448_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7b48fc3177846248e8e650003e9519e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb14eb0dd43c4a709e096b2d83073f70_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b342b88388a4129a9cc8369e81686ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0edeeed139064a33990a9c7ee6e5964b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a981d61c5eb439da38fb12362dd8fad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i480c049e5a834c568af08f9e90655523_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82a3d365592c40cb897ba384875fc12d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad6b64867bef4fc0afcde57faf6fa67b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05109703e464417fa841f9c540f3678f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b165e9375644237b4496e8ca868e02d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfedcf2862364d49b2a7c3a1f4e8dfcf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa6646a5d6c34f7abe7a9ae44f606c91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f033263dc0240bd861510077d28d05f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f8794d0236d482997b1f6aa91113f6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i939b5018129e4e1e8aa83500cd6fa35a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c9a6b3f743d4662992a44369b2b7a76_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf250eba9f184833af1a42fc1ec5cb78_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d59e90707242a995284a6cface9df4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6004ba24adf34129bfd6da674261a96d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie411180fd99f4e5790c4b079d04b0000_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f0874df70594af896849c68995cffcc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e2f780ec994d4a9364ffcb20e6ff20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i680a4d77ca0147b2aae6c2c4160d7120_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifac774375ae04e15b64aebbe75cc3267_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb2705498f8a4d26910dc44f4ac0e29d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8f1299e30cf4e0c90e275bafdaaf57b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9240fcdbfad4d159109b9211c4a25dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i604b72e2ed1e45c0986b519ae61b7407_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71b8d6a28ae24cd8a53aac765710b347_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia96d51ce70dc4c5196635b560cc91d6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93dfc0b8bdb64273a5af3bd7e762ee6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i245cb0b82ebe4888bdb55d9598677214_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79bab5333acc4486b6de092783d41a58_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife652053dd47472d83f53067d84eaef0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8237782881b84c70a77a2cf4a54d5e61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76fe8a9f3db24be59863f170633d5a51_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i88fbac179750483d8af64e04435a79bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7dc0ed2ed7547d89fd4e3e287348bd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22879de6b8fa44818a5c41e8a35f3c84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32540143275947cf9a999007e5c89d46_D20190816-20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-16</xbrli:startDate><xbrli:endDate>2019-08-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60804d42d4e24611b5b61485d0a443bf_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3d6b7c66a4fc4f108fb4d53193ce2035_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29a8a4e95e79475ba60e7ba7d35e2cf9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76b8dc9ee72c4d6e999cf36c6458c7f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfae6e354e8248509fd71f314f2f7bb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="year"><xbrli:measure>oncyf:year</xbrli:measure></xbrli:unit><xbrli:context id="iedc65d68837a4eacac34675a1cd9779e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i830cca3a0f664a4d8b3b50a1c284e3b4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bed414ac6874a10b56efb160637b31e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3a11c0f144e4ff3a325f5a105f0f4d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83e860d0f0a34191b33af656961cbc19_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae5479b6b654d84bb1c05fde1394dd8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e5a099158d84fb599da0d92dcc26605_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b4be78aa4f47c695bf177fab865a55_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ab215a79e4441f2b018c7706826735d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce569aab88d48369c11f14c0bf78a25_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7c46f6b7f524d1387c1a6b6fe9dfa39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78884fc7ad21406cb0e0bd491aad0b54_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6968307567a4ac88a5fbac883bf6779_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7204566da8c8413784114e3a0277f22b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i313db08027ee47b8a313714b551d5295_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie790de8f351b420c97389308ec3102f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d55af5d6889492ba6feaef6f3089cbb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1068e88a4ef24a30afc676a512075718_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id057bd4ec78a491094f4618144a1c09d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a75af6263f486894cd6657c4bd2464_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2902b2520fea41089f98be9b8eace36f_I20180927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdc041cff18445c2bf6a95ff95de581f_D20180927-20180927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-27</xbrli:startDate><xbrli:endDate>2018-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67283f9ed1904a3db011f7a4a67ddd74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f476ff70c064f36b090da63b6c25511_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070d85f1ae5c470e839378eff83c30b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb21fdd6d32d40719bcec4f80757184e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:CommitmentSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef3c4b044f443248ece0ef8dc3ac073_I20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8604cae19b054cb08c0871ae11d35ebd_D20181024-20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-24</xbrli:startDate><xbrli:endDate>2018-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie179742cb9f841999fd8416ad5ecaf64_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e6b52351e9440c6a782ff3ab4b4b8f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32cccb978d9e4fdbb89e459a307b27ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8764aff5c6754164b0bd8ea7f5a1155f_D20190816-20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-16</xbrli:startDate><xbrli:endDate>2019-08-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i249c2d938ccb432fbaf49910859f86b3_D20190816-20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-16</xbrli:startDate><xbrli:endDate>2019-08-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5c0ca931d74739a3b6246850a2c5de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i445f25b6895b4f3a9e8820470f449122_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6952840e54e1456a84822c9606b3c424_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie82286507f1648e4b150250e27787981_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id09b9d3dab2a4150999c1ca5b995feac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f6e4d5e9ea74cf5ab41ddd51549cf33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dd8b35d2c3f4ace9728ec15e62387d6_I20210305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6351d06a26d494f80f99bf946853adb_D20210305-20210305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-05</xbrli:startDate><xbrli:endDate>2021-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ede084a4122418cb65982299416868e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd694e01e0d4b7bb354e73aa065b8bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12d8b8a2f06d4c838611847df4e4d947_D20170601-20170601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1104cc6b33de4026a773d0273129e2f2_I20170601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f80ce545f5419fa462f45df6c010da_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eb1111616934aec84de469599269b27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i886943a54e40452081d9137b1996e966_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i511314b0c0694411a575ec0eca0098cb_D20180522-20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320159cd827547e58721ba67d7836f34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74c3e389b53640549c1c373710f94064_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b105f49e63542228ae11b453f0ca87e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c605804bd334ec1907207bb23e349c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d0c21adfb3d488cb2fc325f543e0e92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83fe2b09673c484791ef8bd4e2f7f518_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88ca0ee1c2a247149de0db08710d0a11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cfd0864279f4fb89386b82c0e907044_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia23c9e23b2584b9cb0a3b24d1c38da91_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d59de09bb940c189e78dc90d63966d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5662aedb669484599906207af734e31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2aacc6b616f41dd8d5b26d42c3e9a80_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i550a47322a8b427e8965901e54efbac0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeabe67f4cdc4d9593317276ede6b031_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06a718d83ebe46fda6f2392bc946d68c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i165f5ef5cadc4c27bc78cb9fa65a9ebb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if96dbdc3a85a498cb7c50c2c3fcc5136_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f3a94bc480946578503b6bc026df946_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e6af5d5c037483e9cf8a1e5b633bf9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a76d437dabc4644966186d4b447fc15_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5803ba163d63468d93a4dcc9c0042c33_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie946e9ce17b442b0a2db67f95b9168ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id035d2b8dd6d43178b57bd66e4788c61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bdb149a74484759861585dd847d705c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56539f49321e44d8a1eef4fc8f086d52_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef39cf43fa64dfbbfb9e8655e1baa24_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b715806bf704ad08871493d7b3a4e1c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i982e2e082ae5410dbcf107355f007a0d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fc7bd5d5a9e465d989e66ae6a3abb49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814af0580d834778b5cede92893765d0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica2719d210fc449890e82fdb8d83507c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb01c95903d246608417f9782e2afe30_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic87ace5c41714cf3b1812237cd1344ef_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib775f5c95fa8484385ae22162e973750_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70523a9ebf4444508afc8076e91b525e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i127a482ddc3e443f908cd8d6e513e1e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie486096482ef4dbdbfc5aac0d2ef7dbd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f73e01a75a540b3bd81d5cbc09e5ef3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1358bb7098240d2b664975d761c15b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icca82039f3674df999dc93b86acdc4b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7062d63d6b934781a4bc28b162213372_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3bff3314ec4be6ba448395655d2141_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if548fffce7f84aaeac70a8fdef2ff771_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1da936afae14dc49119ba8ffe8ecd44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0136e4da0fc41549105d0be0238fef9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia63919fb6b0447f6a8378922a57a0e56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5017b3339eec4bedacd81c4e5981b39a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f9bf167d3e4703927ae2652aa85037_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if88b7239836e47ee87d1993c2c69f365_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3821df9c92a94be4821466bf971f7738_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6b5060463694393849921c58686af13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i754d4b44f8894e0bbeddfd1cbb8a2e24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b655fa2c2545fcbf00fef881bf589b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa114dbc78574101a453118abbe69a95_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ca59ee964074feca5cc2d804c6f3e05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7be63a4d7e934a779ffa098a8c199bbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2b331eb2ec14c0e884108fdc1e52785_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f9f805b162c4a61970dee91fe9b7b6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e1e786a729e443ba51a570b25e7dfb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c684f104e0f40f7a2835b480bb00c0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a91cd1ffa8b427ea4ede5259eb7c307_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief9049c105f7454c87536a38658d6c0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eb2c5a4d51543949a0ffbdf4ec7a8bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82c158562bdf41e7a6759b2f5d325150_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib10f6659cd90429fb750eb8ed77dc3e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ea19593d434f9b8f9057991c2ee87e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i522e5807f7804127b24ef62fe2d3d449_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c3f0b5419c0434c83941543d561ae09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i841d852358ae4ecda2e98b20193fcc61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdea1c38e3904299ae54711a02c93657_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib45ee033334041378788db209329639e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4449dd50bc6407d98849bb27aa044d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc931101e8f347f9916d973a1aeea8a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if376893af6704869aa4000196dff2a9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b10f7069e464035b0d01d42a3daefe9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68fe7581765a490288f89d0a93ec69f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd6471f6d9042109c8c9ea4e5b721a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i551872a26867455eaad5a877c53f122a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8acbc8f07e144d19384899f34b15b1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb56d715075745efb29466f96d59e553_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyFortyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c59a90a0dc54356b24f4e161e4d58b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyFortyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39699155be34d93b5eee0afd15baccc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafea390033d44f86b623be26aa1611fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaf0f7affb224fd0a519419d263a370f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691c2aef708c40e4959eda123656f876_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id89944ab2f3648f88d0e3371530558e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i569c7f4341664d4b8664d09e7fff7d81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f423bf1a59c47c5a5c56ae5a92be8fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86190dfcd5e447cd8e04730476245e4e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d5cda63e0542bfb6b7cdd527ea542d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aefcdf933a04c1591bc48676eeb3311_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id63e281c95ed4160b4cfa6e9d2499567_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbdf50475dc0456b9d7a6b17c5375332_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib796065ed9ef4953ab1452c82a71d086_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a94de62f7e941fd85969fb9eeb33c7a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i974cc837b3484870886ee47cd5811453_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbae27b666e24aa78eafbec4c720309d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b7f989f0c7451bad6b8015dcb583ef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib599fad21e614582ad5c64473790e8e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c2429705a0742a9958a515cdbca5c9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08b1e6664397457eb8e8ce0dfdc08ea1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d66e5ff5ff48138f1c4239fa19d36a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i118bcfe7943a4062a9525f725b80591f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia79a3437f60544f18719723caeb2aefd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i921a0b76be5e4a5192afdce2bfa1f576_I20200612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c241e91c964c239ec005ab7fd76cda_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13e8c5af4bf84a0ba2e3af4a542a05f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72934bebe99040b6b7e0c0c2f19de911_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06647bdfde1c470b8b4d0a645c9ba2d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd70dd98103f43b6af3a92c583cabdb7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>oncyf:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="i86f880390f904058bf8a9cf3258849d0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i631df61a67ec41a593216ea67df15be1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e7344f3cdea473fa96384f7743d95b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb584ab1725b4b40910af903b876e75c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95d0e74b706c4b069c1415f031d34f1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida85ff23b9654045a8551b3d03eece63_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd23113a5fc540bf93ca41f097c068f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic461088cc874441196432eb9bafe69bc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i803b09a886c44d92b85f0e3efad65433_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89a71f2e8ff5408fba66dd7456a26ab8_D20220101-20220302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9757885e4d9e44f386e37be5103b4760_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:AgreementAxis">oncyf:ProductionServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzg2_a1756c80-8c70-4127-a140-bbc1741196ca">20-F</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:13.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl8wLTAtMS0xLTE4MTU3_9d111858-ed3f-49b9-b817-864c37867313">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl8yLTAtMS0xLTE4MTU5_965d7fe6-f0a2-4dc6-9fdf-437b37fe42c6">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For fiscal year ended</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl81LTAtMS0xLTgxMjEvdGV4dHJlZ2lvbjo1MTY0YzNhZTYyZjM0N2M5OGQ4ODQ5MTA3OTI1ZmFjZV80_57a33e3c-83d0-4a22-841f-20e7e5d9f1e2"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl81LTAtMS0xLTgxMjEvdGV4dHJlZ2lvbjo1MTY0YzNhZTYyZjM0N2M5OGQ4ODQ5MTA3OTI1ZmFjZV80_de394497-f149-4a44-b37c-b47a3537b29a">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl84LTAtMS0xLTE4MTYx_b49d9e17-8d3e-4e9a-b439-4037c846013e">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>For the transition period from ____ to ____</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:DocumentShellCompanyReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl8xMS0wLTEtMS0xODE2Mw_1b24b76b-d0c2-4705-83f2-2d677d5085e6">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>Date of event requiring this shell company report:</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzg3_5ae9c739-2a33-4627-a674-682cf3210822">001-38512</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzg4_44cd7744-b8e0-4ffe-bc49-c7dbf7db47bc">ONCOLYTICS BIOTECH INC.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Province of Alberta, Canada</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Jurisdiction of incorporation or organization)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzky_9fa280db-d597-4356-81e3-32169eb9de55">804, 322 11th Avenue SW</ix:nonNumeric>, <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzkz_4a678b43-6e45-42eb-afc0-77de9c35e44a">Calgary</ix:nonNumeric>, <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzk0_85ec8638-c0d1-4abc-b4a4-f0757cf798e6">Alberta</ix:nonNumeric>, <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzk1_39687dc0-ab8f-4d0e-b22e-6cca8a510c2e">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzk2_13d24091-0aa7-4f30-9225-09f8ad1f4a08">T2R 0C5</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231" name="dei:ContactPersonnelName" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzk5_faf2cee8-87bc-4d45-923c-84ddd690f82b">Kirk Look</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDAx_fdf2f067-c67e-4331-9f99-f28be33c23c0">804, 322 11th Avenue SW</ix:nonNumeric>, <ix:nonNumeric contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDAy_e091cc78-beb7-4cd4-b97f-cbd306dc33b5">Calgary</ix:nonNumeric>, <ix:nonNumeric contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDAz_03a0acdd-1b98-4d57-b98d-7d484b927930">Alberta</ix:nonNumeric>, <ix:nonNumeric contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDA0_914d5dc0-bee2-4ab1-b49b-07d5bf32ad0b">Canada</ix:nonNumeric>  <ix:nonNumeric contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDA1_e54e1b2d-c112-408e-80a1-3681f3379492">T2R 0C5</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tel: (<ix:nonNumeric contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDA3_98a8a159-9247-4457-93a5-df5d1af1519a">403</ix:nonNumeric>) <ix:nonNumeric contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDEx_6e2e15fe-6115-4240-980c-23e0369fba68">670-7377</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E-mail: <ix:nonNumeric contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231" name="dei:ContactPersonnelEmailAddress" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDEy_2b5eb5cd-b265-4565-afe1-1f1420ddc17c">info@oncolytics.ca</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.578%"><tr><td style="width:1.0%"></td><td style="width:29.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares, <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6YjQwMTg4ODQ2NzA3NDgyNjk5NTMxMWZhZGRlZGQ1Y2EvdGFibGVyYW5nZTpiNDAxODg4NDY3MDc0ODI2OTk1MzExZmFkZGVkZDVjYV8xLTAtMS0xLTE4MjYyL3RleHRyZWdpb246NTUyNTJlNDkxMDBhNGQwZThiZDRjYTFiOWE0YjYzZTVfMjc0ODc3OTA2OTQ3Mw_4c908c49-163b-4cf7-ae7f-dfd5fd527c1d">no</ix:nonNumeric> par value</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6YjQwMTg4ODQ2NzA3NDgyNjk5NTMxMWZhZGRlZGQ1Y2EvdGFibGVyYW5nZTpiNDAxODg4NDY3MDc0ODI2OTk1MzExZmFkZGVkZDVjYV8xLTEtMS0xLTE4MjYy_e3a12d32-06bb-42fb-84cc-85826e98e815">ONCY</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6YjQwMTg4ODQ2NzA3NDgyNjk5NTMxMWZhZGRlZGQ1Y2EvdGFibGVyYW5nZTpiNDAxODg4NDY3MDc0ODI2OTk1MzExZmFkZGVkZDVjYV8xLTItMS0xLTE4MjYyL3RleHRyZWdpb246MmViMjgyMTYyZDJjNDkzY2JlNjk3MmNmNTQ3M2Y1MDVfNzE0NjgyNTU4MDU3NQ_4dbeac9f-257e-4665-ad21-e112e918c50d">Nasdaq</ix:nonNumeric> Stock Market LLC</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:  None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: &#160;None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of outstanding shares of each of the Registrant&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: <ix:nonFraction unitRef="shares" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8xMDk5NTExNjMxNzU5_94f3616e-fa03-478d-8ca7-4367d7552353">55,043,789</ix:nonFraction> common shares as at December&#160;31, 2021</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDE4_40f224fb-4ae5-4ab2-bdaf-40f7d47bad2b">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this report is an annual or transition report, indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDE0_84d93e9f-bffb-48d8-845a-cfb39520bf3d">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDE1_20fd70cd-b1c7-45ee-a27e-b93624a272c4">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every&#160;Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDE2_0b8d30e9-ebe9-4120-9e9a-06c2f49c64a2">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company.&#160;&#160;See definition of &#8220;large accelerated filer,&#8221;  &#8220;accelerated filer,&#8221; and &#8220;emerging growth company in Rule 12b-2 of the Exchange Act.&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6ZGM2Yzc4OTBmYTA0NDkzODgxZmIxNGYyOWQzNTYyOGIvdGFibGVyYW5nZTpkYzZjNzg5MGZhMDQ0OTM4ODFmYjE0ZjI5ZDM1NjI4Yl8wLTEtMS0xLTE4MzM1L3RleHRyZWdpb246MmVmMTAxMDA1NTY0NGFmZGE0ZTA0Mzg5ZGVmMzhmMDZfMjc0ODc3OTA2OTQ4MA_8c8c41b6-b98c-4a67-b3c0-0fd07b3c4eaf">Accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Non-accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV83MTQ2ODI1NTg0NTIz_5a491399-381e-446e-9100-2fe44895b02b">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;U.S. GAAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:DocumentAccountingStandard" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6NmRkY2I0ZmNiZGZiNDk3NGI1YmEzYjIyNzE2MzE1MzEvdGFibGVyYW5nZTo2ZGRjYjRmY2JkZmI0OTc0YjViYTNiMjI3MTYzMTUzMV8wLTEtMS0xLTE4Mzk2L3RleHRyZWdpb246NDEwMjhhZjUxZjg0NDJhOTk0NmFhNGIyOGUyM2Q1YmZfNzE0NjgyNTU4MDY5Mw_a48f2c6a-cfa7-41b2-8363-d45b6874527f">International Financial Reporting Standards</ix:nonNumeric> as issued&#160;&#160;by the International Accounting Standards Board</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 17 </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item 18&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this is an annual report, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDE3_fc9e5d51-be87-419b-9089-e11a0c8f1e95">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 20-F</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_16">&#160;Item 1. &#160;&#160;&#160;&#160; Identity of Directors, Senior Management and Advisers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_19">&#160;Item 2.&#160; &#160;&#160;&#160; Offer Statistics and Expected Timetable</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_22">&#160;Item 3. &#160;&#160;&#160; &#160;Key Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_25">&#160;Item 4.&#160;&#160;&#160;&#160;&#160; Information on the Company</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_25">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_28">&#160;Item 4A.    Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_28">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_31">&#160;Item 5.&#160; &#160;&#160;&#160; Operating and Financial Review and Prospects</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_31">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_34">&#160;Item 6.&#160; &#160;&#160; &#160;Directors, Senior Management and Employees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_34">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_37">&#160;Item 7.&#160; &#160;&#160;&#160; Major Shareholders and Related Party Transactions</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_37">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_40">&#160;Item 8.&#160;&#160; &#160;&#160;&#160;Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_40">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_43">&#160;Item 9.&#160;&#160;&#160;&#160;&#160; The Offer and Listing</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_43">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_46">&#160;Item 10.&#160;&#160;&#160; Additional Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_46">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_49">&#160;Item 11.&#160;&#160;&#160; Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_49">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_52">&#160;Item 12.&#160;&#160;&#160; Description of Securities Other Than Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_52">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_58">&#160;Item 13.&#160;&#160;&#160; Defaults, Dividend Arrearages and Delinquencies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_58">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_61">&#160;Item 14.&#160;&#160;&#160; Material Modifications to the Rights of Security Holders and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_61">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_64">&#160;Item 15.&#160;&#160;&#160;&#160; Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_64">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_67">&#160;Item 16.     [Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_67">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_70">&#160;Item 16A. &#160;Audit Committee Financial Expert</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_70">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_73">&#160;Item 16B.&#160;&#160; Code of Ethics</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_73">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_76">&#160;Item 16C.&#160;&#160;&#160;Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_76">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_79">&#160;Item 16D.&#160; &#160;Exemptions from the Listing Standards for Audit Committees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_79">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_82">&#160;Item 16E.&#160;&#160; Purchase of Equity Securities by the Issuer and Affiliated Purchases</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_82">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_85">&#160;Item 16F.&#160;&#160; Change in Registrant's Certifying Accountants</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_85">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_88">&#160;Item 16G.&#160; Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_88">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_91">&#160;Item 16H.   Mine Safety Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_91">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_1839">&#160;Item 16I.   Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_1839">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_97">&#160;Item 17.&#160;&#160;&#160;&#160;&#160; Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_97">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_100">&#160;Item 18&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_100">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_103">&#160;Item 19.&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_103">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_106">&#160;Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_106">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_109">&#160;Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icedb1c9c6ee74f3199d6852ba92bc59b_109">F1 - F29</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this annual report on Form 20-F to the terms &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, &#8220;the Company&#8221; and &#8220;Oncolytics&#8221; refer to Oncolytics Biotech Inc. Unless otherwise indicated, all references to "$" and "dollars" in this annual report mean Canadian dollars. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements in this annual report on Form 20-F and the documents attached as exhibits to this annual report, constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oncolytics Biotech Inc., or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified by the words &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;projects&#8221;, &#8220;potential&#8221;, &#8220;possible&#8221; and similar expressions, or that events or conditions &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could&#8221; or &#8220;should&#8221; occur.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this annual report on Form 20-F are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control. Some of the important risks and uncertainties that could affect forward-looking statements are described further under the section heading &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; below.&#160;If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may vary materially from those expected, estimated or projected.&#160;Forward-looking statements in this document are not a prediction of future events or circumstances, and those future events or circumstances may not occur.&#160;Given these uncertainties, users of the information included herein, including investors and prospective investors are cautioned not to place undue reliance on such forward-looking statements.&#160;Investors should consult our quarterly and annual filings with the securities commissions or similar regulatory authorities in Canada and the SEC for additional information on risks and uncertainties relating to forward-looking statements.&#160;We do not assume responsibility for the accuracy and completeness of these statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based on our beliefs, opinions and expectations at the time they are made, and we do not assume any obligation to update our forward-looking statements if those beliefs, opinions, or expectations, or other circumstances, should change, except as required by applicable law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISK FACTORS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common shares involves a high degree of risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the risks summarized below and other risks that we face, a detailed discussion of which can be found under &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; below, together with other information in this annual report on Form 20-F and our other filings with the SEC. This summary list of risks is not exhaustive of the factors that may affect any of the Company&#8217;s forward-looking statements and our business and financial results. If any of these risks actually occur, our business, financial condition and financial performance would likely be materially adversely affected. In such case, the trading price of our common shares would likely decline and you may lose part or all of your investment. Below is a summary of some of the principal risks we face: </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any failure or delay in clinical trials for our products, including pelareorep, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our candidate product, pelareorep, is being and will continue to be used in combination with third-party drugs. Those currently being partnered with pelareorep are approved; however, we have limited or no control over the supply of these drugs. If our relationships with current or future collaborators or suppliers are not successful, we may be delayed in completing the development of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business, including our research and development operations, has been and may continue to be adversely affected by the COVID-19 pandemic;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidate may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing approval;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmaceutical products are subject to intense regulatory approval processes;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations and products may be subject to other government manufacturing and testing regulations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have conducted, and may in the future conduct, clinical trials for pelareorep in sites outside the United States and the FDA may not accept data from trials conducted in such locations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on patents and proprietary rights to protect our technology;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management and could materially affect our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developments in patent law could have a negative impact on our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not obtain protection under the Hatch-Waxman amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products may fail or cause harm, subjecting us to product liability claims;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New products may not be accepted by the medical community or consumers;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our technologies may become obsolete;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third-party manufacturers to produce our clinical products and on other third parties to store, monitor and transport bulk drug substance and drug product. We and our third-party partners may encounter difficulties with respect to these activities that could delay or impair our ability to initiate or complete our clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to produce and provide suitable raw materials for pelareorep production, packaging, and testing as well as clinical trial-related testing. We and our third-party partners may encounter difficulties with sourcing these materials that could delay or impair our ability to manufacture pelareorep or complete product or clinical sample testing;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to monitor, support, conduct and oversee clinical trials of the products that we are developing and, in some cases, to maintain regulatory files for those product candidates. We may not be able to obtain regulatory approval for our products that may result from our development efforts if we are not able to maintain or secure agreements with such third parties on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatory information held by them to us;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our license, development, supply and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees, independent contractors, principal investigators, contract research organizations, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations could be adversely affected by events outside of our control, such as natural disasters, wars or health epidemics;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The cost of director and officer liability insurance may increase substantially and may affect our ability to retain quality directors and officers;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on our key employees and collaborators;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is likely a "passive foreign investment company" which may have adverse U.S. federal income tax consequences for U.S. shareholders;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential dilution of present and prospective shareholdings; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations may be adversely affected by disruptions to our information technology ("IT") systems, including disruptions from cybersecurity breaches of our IT infrastructure;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_16"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_19"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_22"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. KEY INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">[RESERVED] </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Capitalization and Indebtedness</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Reasons for the Offer and Use of Proceeds</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Risk Factors</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our common shares ("Common Shares") involves a high degree of risk. You should carefully consider, among other matters, the following risk factors in addition to the other information in this annual report on Form 20-F when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the material risks described below or in subsequent reports we file with the SEC actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results, or cash flow.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, pelareorep, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early-stage human clinical trials, whether pelareorep will prove to be safe and effective in humans. Pelareorep will require additional research and development, including extensive additional clinical testing, before we will be able to obtain the approvals of the relevant regulatory authorities in applicable countries to market pelareorep commercially. There can be no assurance that the research and development programs we conduct will result in pelareorep or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve profitable operations we, alone or with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy. Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that any current or future animal or human test, if undertaken, will yield favorable results. If we are unable to establish that pelareorep is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are inherent risks in pharmaceutical research and development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product we develop will be affected by numerous factors beyond our control, including but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger, controlled clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing costs or other production factors may make manufacturing of products ineffective, impractical, and non-competitive;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proprietary rights of third parties or competing products or technologies may preclude commercialization;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requisite regulatory approvals for the commercial distribution of products may not be obtained; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors may become apparent during the course of research, up-scaling or manufacturing which may result in the discontinuation of research and other critical projects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products under development have never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges or others that may arise in the course of development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure or delay in clinical trials for our products, including pelareorep, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our products in humans. Clinical testing, in particular, is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome.&#160;A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process, which could delay or prevent us from receiving marketing approval or commercializing our product candidates, including the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials or we may abandon projects that we expect to be promising;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of subjects required for our clinical trials may be larger than we anticipate, enrollment in our clinical trials may be slower than we anticipate, or participants may drop out of our clinical trials at a higher rate than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We might have to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulators or institutional review boards may require that we hold, suspend, or terminate clinical research for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulators may refuse to accept or consider data from clinical trials for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including guidelines specifically addressing requirements for the development of treatments for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We might have difficulty adding new clinical trial sites on a timely basis, or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The cost of our clinical trials may be greater than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The supply, storage, distribution, or quality of our products or other materials necessary to conduct our clinical trials may be insufficient or inadequate</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject enrollment, which is a significant factor in the timing of clinical trials, is affected by a variety of factors, including the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The size and nature of the subject population;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The proximity of subjects to clinical sites;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The eligibility criteria for the trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The design of the clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competing clinical trials; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinicians&#8217; and subjects&#8217; perceptions as to the potential advantages of the medication being studied in relation to other available therapies, including any new medications that may be approved for the indications we are investigating.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we plan to rely on clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Any delays or unanticipated problems during clinical testing, such as enrollment in our clinical trials being slower than we anticipate or participants dropping out of our clinical trials at a higher rate than we anticipate, could increase our costs, slow down our product development and approval process, and jeopardize our ability to commence product sales and generate revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the federal Right to Try Act, among other things, provides a federal framework for patients to access certain investigational new drug products that have completed a Phase 1 clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. While there is no obligation to make product candidates available to eligible patients as a result of the Right to Try Act, new and emerging legislation regarding expanded access to unapproved drugs could negatively impact enrollment in our clinical trials and our business in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our candidate product, pelareorep, is being and will continue to be used in combination with third-party drugs. Those currently being partnered with pelareorep are approved; however, we have limited or no control over the supply of these drugs. If our relationships with current or future collaborators or suppliers are not successful, we may be delayed in completing the development of our product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In several of our current and planned studies, pelareorep is being or will be administered in combination with immune checkpoint inhibitors ("ICIs"), a class of drugs intended to stop tumor cells from interfering with the ability of the patient&#8217;s immune system to attack their tumor. We have entered into agreements with Pfizer and Roche to supply their ICIs, avelumab and atezolizumab, respectively, for use in our ongoing Oncolytics-sponsored studies. Specifically, avelumab is being used in our currently enrolling Phase 2 study in breast cancer (BRACELET study), and atezolizumab is being used in our ongoing window-of-opportunity study in breast cancer (AWARE study) and our ongoing Phase 1/2 study in gastrointestinal cancer (GOBLET study). In addition, other ICIs are being used in combination with pelareorep in ongoing investigator-sponsored studies including retifanlimab (Incyte) in a Phase 2 study in breast cancer (IRENE study) and nivolumab (BMS) in a Phase 1 study in myeloma. Additionally, we may enter into future agreements for the supply ICIs for use in connection with the development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop pelareorep for use in combination with ICIs depends on our ability to access ICIs for use in our clinical trials on commercially reasonable terms. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs on commercially reasonable terms or at all. Any failure to maintain or enter into new successful commercial relationships or the expense of purchasing checkpoint blockade therapies in the market may delay our development timelines, increase our costs, and jeopardize our ability to develop pelareorep as a commercially viable therapy. If any of these occur, our business, financial condition, results of operations, stock price and prospects may be materially harmed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any current or any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing appropriate ICIs. Additionally, should the supply of products from any current or future collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source a supply of an alternative appropriate ICI or are unable to do so on commercially reasonable terms, our business, financial condition, results of operations, stock price, and prospects may be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the development of pelareorep for use in combination with ICIs may present challenges that are not faced for single agent product candidates. Developments related to the other product may impact our clinical trials as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other product's safety or efficacy profile, changes to the availability of the approved product, and changes to the standard of care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our business, financial condition, results of operations and prospects may be materially adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, we make estimates regarding the incidence and prevalence of target patient populations for particular diseases based on various third-party sources and internally generated analysis and use such estimates in making decisions regarding our product development strategy, including determining indications on which to focus in preclinical or clinical trials.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity will depend on, among other things, the acceptance of such data by the medical community and patient access, product pricing and reimbursement, any limitations on populations and indications in approved product labeling, as well as the approval of new or competing medicines. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, including our research and development operations, has been and may continue to be adversely affected by the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the ongoing coronavirus infectious disease 2019 (COVID-19) pandemic has touched elements of our business operations. COVID-19, including its variants, have created challenges affecting our clinical trial activities, including patient enrollment and site activation, along with our manufacturing supply chain. Some of the challenges have included, among other things, patients choosing to delay treatments, clinical sites suspending study activity temporarily, vendor and collaborator staff shortages, and raw material and components delays. While these challenges have largely impacted the timing of certain activities, we believe the impact on our overall business, to date, has not been significant. As well, we believe our financial condition, liquidity, and longer-term strategic development remain on track. However, COVID-19 continues to have a broad adverse impact on the global economy across many industries and has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions and business shutdowns, as well as significant volatility in global financial markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 might prolong and/or cause significant disruptions to our business and materially impact our results of operations and our ongoing and planned clinical studies will depend on future developments. These future developments are highly uncertain and cannot be predicted, such as the duration and severity of outbreaks, including future potential waves or cycles, travel restrictions and social distancing, business closures or business disruptions, and the effectiveness of actions taken to contain and treat the disease and to address its impact, including on financial markets. A lack of coordinated responses on risk mitigation and vaccination deployment with respect to the COVID-19 pandemic could result in significant increases to the duration and severity of the pandemic and could have a corresponding negative impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the COVID-19 pandemic worsens or continues for a prolonged period of time, particularly in regions where we or our collaborators and suppliers do business, we could experience disruptions that could significantly impact our current and planned clinical trials, preclinical research and other business activities, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption to and delays in preclinical research activities due to an extended closure or reduced capacity of lab facilities; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in enrolling patients in our ongoing and planned clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients discontinuing their treatment or follow-up visits; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions in supply, logistics, or other activities related to the procurement of materials, which could have a negative impact on our ability to conduct preclinical research, initiate, or complete our clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers, and others; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key business activities due to illness and/or quarantine of key individuals and delays associated with recruiting, hiring, and training new temporary or permanent replacements for such key individuals, both internally and at our third-party service providers and strategic partners; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in resources that would otherwise be focused on the conduct of our business or our current or planned clinical trials or preclinical research, including because of sickness, the desire to avoid contact with large groups of people, restrictions on travel, or prolonged stay-at-home or similar working arrangements; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving approvals from regulatory authorities to initiate our planned clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted and incur unexpected costs, or require us to discontinue clinical trials altogether; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with regulators (including the FDA), ethics committees and other important agencies and contractors due to limitations in employee resources or furlough of government or contractor personnel; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to our strategic partners&#8217; operations, which could delay the development of our product candidates in certain geographical regions and thereby affect the timing of development and commercial milestone payments and royalties on potential future product sales we may receive; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on our ability to recruit preclinical research, clinical, regulatory, and other professional staff on the timeframe required to support our research and development programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, COVID-19 could result in the continued significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. Such financial market volatility may continue and the value of our common shares may be adversely impacted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve, and we will continue to monitor the effects of COVID-19 on our business. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition, and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidate may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, pelareorep is generally well-tolerated and has a manageable side effect profile for most patients. However, there can be no assurance that additional undesirable side effects or serious adverse events will not be caused by or associated with pelareorep as it continues through its clinical development, including when co-administered with approved products. As with many pharmaceutical and biological products, treatment with our product candidate may produce undesirable side effects or adverse reactions or events, including potential adverse side effects related to cytokine release, and may exacerbate known adverse events associated with co-administered approved products. If our product candidates or similar products or product candidate under development by third parties demonstrate unacceptable adverse events, or unacceptably exacerbate adverse events associated with co-administered approved products, we may be required to halt or delay further clinical development of our product candidate. The FDA, the EMA or other foreign regulatory authorities could order us to cease further development of or deny approval of our product candidate for any or all targeted indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, particularly outside of the institutions that collaborate with us, as toxicities resulting from our novel technologies may not be normally encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using our product candidate to understand its side effect profiles, both for our planned clinical trials and upon any commercialization. Inadequate training in recognizing or managing the potential side effects of our product candidate could result in adverse effects to patients, including death.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if our product candidate receives marketing approval, and we or others later identify undesirable side effects caused or exacerbated by such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our product, a number of potentially significant negative consequences could result, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a risk evaluation and mitigation strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputations may suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. Furthermore, any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and therapeutic platforms that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and therapeutic platforms for specific indications may not yield any commercially viable products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition Risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no operating revenues and a history of losses. We have no products approved for commercial sale, and we may never achieve or sustain profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development-stage biopharmaceutical company. We have incurred significant losses since our inception. To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit. As of December&#160;31, 2021, we had an accumulated deficit of $393.4 million and we incurred net losses of $26.3 million, $22.5 million and $33.1 million for the years ended December&#160;31, 2021, 2020, and 2019, respectively. We anticipate that we will continue to incur significant losses during 2022 and in the foreseeable future. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. We do not expect to reach profitability at least until after the successful and profitable commercialization of one or more of our products. Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had cash and cash equivalents of $41.3 million. We anticipate that we will need additional financing in the future to fund research and development and to meet our ongoing capital requirements.&#160;The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our preclinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting and enforcing our patent claims, and costs associated with obtaining regulatory approvals.&#160;In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics, from time to time, along with all other pharmaceutical research and development entities, may have restricted access to capital, bank debt, and equity, and, from time to time, may face increased borrowing costs. Although our business and asset base have not changed, the lending capacity of all financial institutions fluctuates causing a corresponding change in risk premiums. As future operations will be financed out of funds generated from financing activities, our ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the pharmaceutical industry and our securities in particular.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we elect to satisfy our cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that our efforts to raise such funding will be successful, or achieved on terms favorable to us or our existing shareholders.&#160;If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production, and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product. There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur some of our expenses in foreign currencies and therefore we are exposed to foreign currency exchange rate fluctuations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign currencies, primarily the U.S. dollar.&#160;We are therefore exposed to foreign currency rate fluctuations.&#160;Also, as we expand to other foreign jurisdictions there may be an increase in our foreign exchange exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party credit risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of our business, we have entered into contractual arrangements with third parties which subject us to the risk that such parties may default on their obligations. Oncolytics may be exposed to third-party credit risk through our contractual arrangements with our current contract manufacturer, the institutions which operate our clinical trials, or our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract research organizations and other parties.&#160;In the event such entities fail to meet their contractual obligations to Oncolytics, such failures could have a material adverse effect on Oncolytics and our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain third-party reimbursement for the cost of our product. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Uncertainty exists regarding the reimbursement status of newly-approved pharmaceutical products and reimbursement may not be available for pelareorep.&#160;&#160;Any reimbursements granted may not be maintained or limits on reimbursements available from third-party payors may reduce the demand for, or negatively affect the price of, these products. If pelareorep does not qualify for reimbursement, if reimbursement levels diminish, or if reimbursement is denied, our sales and profitability would be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical products are subject to intense regulatory approval processes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory process for pharmaceuticals, which includes preclinical studies and multiple phases of clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Food and Drug Administration (&#8220;FDA&#8221;) and similar regulatory authorities in other countries may deny approval of a new drug application if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA and similar regulatory authorities in other countries may require further testing and surveillance programs to monitor the pharmaceutical product that has been commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions, and criminal prosecutions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in our customers&#8217; drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and possibly other regulatory authorities in other jurisdictions.&#160;Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly and time consuming. We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to the approval of the facility to manufacture a specific drug, our manufacturing facilities may never become approved of, or there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical regulatory regime in Europe and other countries is generally similar to that of the United States. We could face similar risks in these other jurisdictions as the risks described above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations and products may be subject to other government manufacturing and testing regulations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing. Approval to market products may be for limited applications or may not be received at all.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we anticipate manufacturing will have to comply with the FDA&#8217;s current Good Manufacturing Practices (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cGMP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines. Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money and effort in production, and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions: (i) restrict the release of the product; (ii) suspend manufacturing of the specific lot of the product; (iii) order a recall of the lot of the product; or (iv) order a seizure of the lot of the product.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to regulation by governments in many jurisdictions.&#160;If we do not comply with healthcare, drug, manufacturing, and environmental regulations, among others, in such jurisdiction, our existing and future operations may be curtailed, and we could be subject to liability.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal, and foreign law, including, but not limited to, requirements regarding occupational health, safety, laboratory practices, healthcare fraud and abuse, environmental protection, and hazardous substance control, and may be subject to other present and future local, provincial, state, federal, and foreign regulations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have conducted, and may in the future conduct, clinical trials for pelareorep in sites outside the United States and the FDA may not accept data from trials conducted in such locations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted, and may in the future choose to conduct, clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deem clinically meaningful. Generally, the patient population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside the United States. If the FDA does not accept the data from any clinical trials we may conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on patents and proprietary rights to protect our technology.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing the rights of third parties. We have received Granted Patents in countries throughout the world, including the United States, Canada, Europe, and Japan.&#160;We file our Applications for Patent in the United States and under the PCT, allowing us to subsequently file in other jurisdictions.&#160;Our success will depend, in part, on our ability to obtain, enforce and maintain patent protection for our technology in Canada, the United States and other countries. We cannot be assured that patents will issue from any pending applications or that claims now or in the future, if any, allowed under issued patents will be sufficiently broad to protect our technology. In addition, no assurance can be given that any patents issued to, or licensed by us, will not be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">challenged, invalidated, infringed or circumvented, or that the rights granted thereunder will provide continuing competitive advantages to us.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. In addition, it is not known whether any of our current research endeavors will result in the issuance of patents in Canada, the United States, or elsewhere, or if any patents already issued will provide significant proprietary protection or will be circumvented or invalidated. Since patent applications in the United States and Canada may be maintained in secrecy until at least 18 months after filing of the original priority application, and since publication of discoveries in the scientific or patent literature tends to lag behind actual discoveries by several months, we cannot be certain that we or any licensor were the first to create inventions claimed by pending patent applications or that we or the licensor were the first to file patent applications for such inventions. Loss of patent protection could lead to generic competition for these products, and others in the future, which would materially and adversely affect our financial prospects for these products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, since patent applications filed before November 29, 2000 in the United States may be maintained in secrecy until the patents issue or foreign counterparts, if any, publish, we cannot be certain that we or any licensor were the first creator of inventions covered by pending patent applications or that we or such licensor were the first to file patent applications for such inventions. There is no assurance that our patents, if issued, would be held valid or enforceable by a court or that a competitor&#8217;s technology or product would be found to infringe such patents.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we may not be able to obtain and enforce effective patents to protect our proprietary rights from use by competitors.&#160;If other such parties obtain patents for certain information relied on by us in conducting our business, then we may be required to stop using, or pay to use, certain intellectual property, and as such, our competitive position and profitability could suffer as a result.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management and could materially affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be claimed to infringe patents and other intellectual property rights of third parties under which we do not hold sufficient licenses or other rights. Additionally, third parties may be successful in obtaining patent protection for technologies that cover development activities in which we are already engaged. Third parties may own or control these patents and intellectual property rights in the United States and abroad. These third parties may have substantially greater financial resources than us and could bring claims against us that could cause us to incur substantial expenses to defend against these claims and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement or other similar suit were brought against us, we could be forced to stop or delay development, manufacturing, or sales of the product or product candidate that is the subject of the suit. Intellectual property litigation in the biopharmaceutical industry is common, and we expect this trend to continue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of patent infringement or other similar claims, or to avoid potential claims, we may choose or be required to seek a license from the third party and be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, if at all, or if an injunction is granted against us, which could harm our business significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">know-how, the value of our technology and products could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patented technology, we rely upon unpatented proprietary technology, processes and know-how. However, these types of trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants and third parties as well as confidentiality policies and audits, although these may not be successful in protecting our trade secrets and confidential information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known, including through a potential cybersecurity breach, or may be independently developed by competitors. If we are unable to protect the confidentiality of our proprietary information and know-how, competitors may be able to use this information to develop products that compete with our products, which could adversely impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to research and develop and to manufacture pelareorep, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. Moreover, enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. These lawsuits also may impact our ability to pursue agreements with third parties in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developments in patent law could have a negative impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, authorities in the United States, the European Union and other government authorities may change the standards of patentability, and any such changes could have a negative impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in the United States, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a "first-to-invent" system to a "first-to-file" system, changes to the way issued patents are challenged, and changes to the way patent applications are disputed during the examination process. As a result of these changes, patent law in the United States may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The USPTO has developed new and untested regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Also, case law may have a substantial impact on the way patents are prosecuted, examined and litigated. This also affects the scope of protection that is available in a specific jurisdiction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments of patent law in other jurisdictions may impact our business. For example, it is currently not clear what impact the planned introduction of the Unified Patent Court in the European Union will have. Patents that are valid and enforceable under the current system may be considered invalid and/or unenforceable under the new system. Also patents may be invalidated not just in one single jurisdiction, but across multiple countries of the European Union in one single trial. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of pelareorep, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for pelareorep will be shortened. If this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Business Risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The biotechnology industry is extremely competitive and if our competitors develop and market products that are more effective, safer or less expensive than our products, our business could be adversely impacted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technological competition in the pharmaceutical industry is intense and we expect competition to increase. Other companies are conducting research on therapeutics involving innate and adaptive immune responses as well as other novel treatments or therapeutics for the treatment of cancer which may compete with our product. Many of these competitors are more established, benefit from greater name recognition and have substantially greater financial, manufacturing, technical, marketing, drug development, and human resources than us. In addition, many of these competitors have significantly greater experience in undertaking research, preclinical studies and human clinical trials of new pharmaceutical products, obtaining regulatory approvals and manufacturing and marketing such products. In addition, there are several other companies and products with which we may compete from time to time, and which may have significantly better and larger resources than we do. Accordingly, our competitors may succeed in manufacturing and/or commercializing products more rapidly or effectively, which could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will face increased competition in the future as new products enter the market and advanced technologies become available. There can be no assurance that existing products or new products developed by our competitors will not be more effective, or be more effectively manufactured, marketed and sold, than any that may be developed or sold by us. Competitive products may render our products obsolete and uncompetitive prior to recovering research, development or commercialization expenses incurred with respect to any such products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may fail or cause harm, subjecting us to product liability claims.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use of our product during current clinical trials may entail risk of product liability. We maintain clinical trial liability insurance; however, it is possible this coverage may not provide full protection against all risks.&#160;Given the scope and complexity of the clinical development process, the uncertainty of product liability litigation, and the shrinking capacity of insurance underwriters, it is not possible at this time to assess the adequacy of current clinical trial coverage, nor the ability to secure continuing coverage at the same level and at reasonable cost in the foreseeable future.&#160;While we carry, and intend to continue carrying amounts believed to be appropriate under the circumstances, it is not possible at this time to determine the adequacy of such coverage.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the sale and commercial use of our product entails risk of product liability. We currently do not carry any product liability insurance for this purpose. There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition, and future prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future legal proceedings and the impact of any finding of liability or damages could adversely impact the company and its financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be named as a defendant in various legal actions or other proceedings, including class action lawsuits. Certain of these actions include and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other results adverse to us. Management does not currently know of any pending, material legal proceedings against the Company, but such legal action could be brought in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of possible future legal proceedings cannot be predicted with certainty. Accordingly, we cannot determine whether our insurance coverage would be sufficient to cover the costs or potential losses, if any. Regardless of merit, litigation may be both time-consuming and disruptive to our operations and cause significant expense and diversion of management attention. If </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we do not prevail in future legal proceedings, we may be faced with significant monetary damages or injunctive relief against us that may adversely affect our business, financial condition and results of operations, possibly materially.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New products may not be accepted by the medical community or consumers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary activity to date has been research and development and we have no experience in marketing or commercializing products. We will likely rely on third parties to market our products, assuming that they receive regulatory approvals. If we rely on third parties to market our products, the commercial success of such product will be subject to a number of risks that may be outside of our control, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition in relation to alternative treatments, including efficacy advantages and cost advantages;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived ease of use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage or reimbursement by third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties regarding marketing and distribution support; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution or use restrictions imposed by regulatory authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there can be no assurance that physicians, patients or the medical community will accept our product, even if it proves to be safe and effective and is approved for marketing by Health Canada, the FDA and other regulatory authorities. A failure to successfully market our product would have a material adverse effect on our revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our technologies may become obsolete.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards, and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes and the emergence of new industry standards may render our products obsolete, less competitive, or less marketable. The process of developing our products is extremely complex and requires significant continuing development efforts, and third-party commitments. Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using our new technologies or exploiting our niche markets effectively, or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of pelareorep manufacturing or formulation may result in additional costs or delay. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As pelareorep is developed through preclinical to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause pelareorep to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability, or our strategic partners&#8217; ability, to commence product sales and generate revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party manufacturers to produce our clinical products and on other third parties to store, monitor and transport bulk drug substance and drug product. We and our third-party partners may encounter difficulties with respect to these activities that could delay or impair our ability to initiate or complete our clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own or operate any manufacturing facilities. We rely on a contract manufacturer to source suitable raw materials and produce sufficient quantities of pelareorep for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards. If we are unable to arrange for such third-party manufacturing sources or materials are not available in a timely manner, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of pelareorep or we may be delayed in doing so. The manufacture of biopharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process controls. The process of manufacturing pelareorep is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the third-party manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any failure by our third-party manufacturers to comply with applicable regulatory and quality standards or any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have relied upon a contract manufacturer to manufacture small quantities of pelareorep. The manufacturer may encounter difficulties in scaling up production, including production yields, quality control and quality assurance. Only a limited number of manufacturers can supply therapeutic viruses and failure by the manufacturer to deliver the required quantities of pelareorep on a timely basis at a commercially reasonable price may have a material adverse effect on us. We have completed a program for the development of a commercial process for manufacturing pelareorep and have filed a number of patent applications related to the process. There can be no assurance that we will successfully obtain sufficient patent protection related to our manufacturing process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to third-party manufacturers, we rely on other third parties to store, monitor, and transport bulk drug substance and drug product. If we are unable to arrange for such third-party sources, or fail to do so on commercially reasonable terms, we may not be able to successfully supply sufficient product candidate or we may be delayed in doing so. Such failure or substantial delay could materially harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to produce and provide suitable raw materials for pelareorep production, packaging, and testing as well as clinical trial-related testing. We and our third-party partners may encounter difficulties with sourcing these materials that could delay or impair our ability to manufacture pelareorep or complete product or clinical sample testing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on contract manufacture and testing facilities to source required materials for production and evaluation of pelareorep, as well as testing of clinical trial-related samples. As a result, we have less control over the supply timing and cost of these materials than if we sourced these materials directly. In addition, these are often specialized materials and third-party suppliers may also encounter challenges in producing, testing, or distributing materials that can impact delivery quantities and timeframes. If we are unable to arrange for sufficient supply or materials are not available in a timely manner, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of pelareorep or we may be delayed in doing so. If we are unable to arrange for appropriate testing materials or they are not available in a timely manner, we may be unable to execute some clinical trial testing or we may be delayed in doing so.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to monitor, support, conduct and oversee clinical trials of the products that we are developing and, in some cases, to maintain regulatory files for those product candidates. We may not be able to obtain regulatory approval for our products that may result from our development efforts if we are not able to maintain or secure agreements with such third parties on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatory information held by them to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on entities outside of our control, which may include clinical and research consultants, academic institutions, and contract research organizations ("CROs"), to perform, monitor, support, conduct, and oversee preclinical studies and clinical trials of pelareorep. As a result, we have less control over the timing and cost of these studies and the ability to recruit trial subjects than if we conducted these trials with our own personnel.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain or enter into agreements with these third parties on acceptable terms, or if any such engagement is terminated prematurely, we may be unable to enroll patients on a timely basis or otherwise conduct our trials in the manner we anticipate. In addition, there is no guarantee that these third parties will devote adequate time and resources to our studies or perform as required by our contract or in accordance with regulatory requirements, including maintenance of clinical trial information regarding our products. If these third parties fail to meet expected deadlines, fail to transfer to us any regulatory information in a timely manner, fail to adhere to protocols, or fail to act in accordance with regulatory requirements or our agreements with them, or if they otherwise perform in a substandard manner or in a way that compromises the quality or accuracy of their activities or the data they obtain, then clinical trials of our product candidates may be extended or delayed with additional costs incurred, or our data may be rejected by the FDA, EMA or other regulatory agencies. Ultimately, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our CROs fail to comply with applicable regulatory regulations, the clinical data generated in our clinical trials may be deemed unreliable and our submission of marketing applications may be delayed or we may be required to perform additional clinical trials before approving our marketing applications. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and increase our costs. Moreover, our business may be implicated if any of our CROs violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our clinical trial sites terminate for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. Further, if our relationship with any of our CROs is terminated, we may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our license, development, supply and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2017, we announced that we had entered into a license, development, supply, and distribution agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan (the &#8220;Territories&#8221;). Pursuant to the Licensing Agreement, along with payments to be received by us upon meeting certain requirements and milestones, we are also eligible to receive royalty payments in excess of 10% associated with the commercialization of pelareorep for all indications, subject to regulatory approval. Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory and commercialization activities respecting pelareorep in the Territories and therefore the Company will be dependent upon Adlai in successfully undertaking those actions in a timely and economic manner and in compliance with all applicable legal and regulatory requirements within the Territories. If Adlai is unable to fulfill its obligations under the terms of the Licensing Agreement and in compliance with all applicable legal and regulatory requirements, including clinical, regulatory and commercialization of pelareorep, our prospective revenue from royalty payments related to the commercialization of pelareorep in the Territories may be materially diminished, delayed or never realized, which could negatively affect our operating results and financial condition.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting business with Adlai within the Territories, and specifically China, subjects us to certain economic, political, currency and legal risks, and uncertainties regarding, among other things, the development and commercialization of pelareorep and the release and receipt of payments under the terms of the Licensing Agreement, including the payment of royalties upon commercialization of pelareorep. These risks include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different standards of care in various countries that could complicate the evaluation of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different U.S. and foreign drug import and export rules;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in certain countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the FCPA, and other anti-corruption and anti-bribery laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. and foreign taxes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reliance on CROs, clinical trial sites, principal investigators and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by foreign distributors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The governments of the Territories, and specifically the Chinese government, exercise significant control over all aspects of their respective economies.&#160;Accordingly, any adverse change in the economy, the legal system or governmental, economic or other policies could have a material adverse effect on the business prospects of the Licensing Agreement with Adlai, including our ability to receive money out of China under the terms of the Licensing Agreement. Any disruption in relations, inability to work efficiently or disadvantageous treatment of Adlai by the governments of the Territories or other authorities could have a material adverse effect on our business prospects under the Licensing Agreement. Additionally, the regulatory environment in the Territories is evolving, and officials in the governments in the Territories exercise broad discretion in deciding how to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interpret and apply regulations. There can be no assurance that Adlai will be successful in the development and commercialization of pelareorep in the Territories.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative developments in the field of immuno-oncology could damage public perception of pelareorep and negatively affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of pelareorep depends in part on public acceptance of the use of cancer immunotherapies including ICIs. Adverse events in clinical trials of pelareorep or in clinical trials of similar products and the resulting publicity, as well as any other negative developments in the field of immuno-oncology that may occur in the future including in connection with competitor therapies, could result in decreased acceptance of and demand for pelareorep. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to pelareorep or to competitors&#8217; products, pelareorep may not be accepted by the general public or the medical community, and potential clinical trial participants may be discouraged from enrolling in our trials. As a result, we may not be able to continue or may be delayed in conducting our development programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is an oncolytic virus and, as such, adverse developments related vaccines for viral diseases or in clinical trials of other virus-based oncolytic immunotherapy products may result in a disproportionately negative effect on the perception of pelareorep compared to other products in the field of immuno-oncology that are not based on viruses.</span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future negative developments in the field of immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of pelareorep. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, contract research organizations, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (1) FDA regulations, including those laws that require the reporting of true, complete and accurate information to the FDA, (2) manufacturing standards, (3) federal and state healthcare fraud and abuse laws and regulations, or (4) laws that require the reporting of true and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and if we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from collaborators, prospective licensees and other third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our drug candidates. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our operations could be adversely affected by events outside of our control, such as natural disasters, wars&#160;or health epidemics.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19, geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods, and fires. An outbreak of infectious disease, a pandemic or a similar public health threat, such as the COVID-19 pandemic, or a fear of any of the foregoing, could adversely impact us by causing operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how we may affected if such an epidemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The cost of director and officer liability insurance may increase substantially and may affect our ability to retain quality directors and officers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry liability insurance on behalf of our directors and officers. Given a number of large director and officer liability insurance claims in the U.S. equity markets, director and officer liability insurance has become increasingly more expensive with increased restrictions. Consequently, there is no assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage may limit our ability to attract and maintain directors and officers as required to conduct our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our key employees and collaborators.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop the product will depend, to a great extent, on our ability to attract and retain highly qualified scientific personnel and to develop and maintain relationships with leading research institutions. Intense competition for attracting key skill-sets may limit our ability to retain and motivate key personnel on acceptable terms. We are highly dependent on the principal members of our management staff as well as our advisors and collaborators, the loss of whose services might impede the achievement of development objectives. The persons working with us are affected by a number of influences outside of our control. The loss of key employees and/or key collaborators may affect the speed and success of product development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Barbados law differs from the laws in effect in Canada and the United States and may afford less protection to holders of our securities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our assets and intellectual property are held by our wholly-owned subsidiary, Oncolytics Biotech (Barbados) Inc., which is organized under the laws of Barbados. It may not be possible to enforce court judgments obtained in Canada or the United States against Oncolytics Biotech (Barbados) Inc. in Barbados based on the civil liabilities provisions of applicable securities laws. In addition, there is some doubt as to whether the courts of Barbados would recognize or enforce judgments of courts in Canada or the United States obtained against us or our directors or officers based on the civil liabilities provisions of Canadian and United States securities laws or hear actions against us or those persons based on such laws.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to complex laws and regulations that address privacy and data security. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. For example, the State of California enacted the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), which came into effect on January 1, 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA could mark the beginning of a trend toward more stringent state privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the course of our business, we may obtain health information from third party that is subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;). Although we are not directly subject to HIPAA (other than potentially with respect to providing certain employee benefits) we could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA/HITECH.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be negatively impacted by existing and proposed laws and regulations, as well as government policies and practices related to cybersecurity, data privacy, data localization, and data protection outside of the U.S., such as the General Data Protection Regulation (&#8220;GDPR&#8221;), which took effect in the EU in May 2018. The GDPR extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for companies and new rights for individuals. The GDPR may increase our responsibility and potential liability in relation to personal data that we process, expose us to substantial potential fines and increase our compliance costs.&#160;The GDPR could also cause our development costs to increase in connection with clinical trials we are currently conducting and may conduct in the future in the EU for our products and product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with data protection laws and regulations both within and outside of the U.S. could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company may fail to achieve and maintain adequate internal control over financial reporting pursuant to the requirements of the Sarbanes-Oxley Act and equivalent Canadian legislation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documented and tested during its most recent fiscal year its internal control procedures in order to satisfy the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;) and equivalent Canadian legislation. SOX requires an annual assessment by management of the effectiveness of the Company&#8217;s internal control over financial reporting and an attestation report by the Company&#8217;s independent auditors addressing this assessment, if applicable. The Company may fail to achieve and maintain the adequacy of its internal control over financial reporting as such standards are modified, supplemented, or amended from time to time, and the Company may not be able to ensure that it can conclude, on an ongoing basis, that it has effective internal control over financial reporting in accordance with Section&#160;404 of SOX. The Company&#8217;s failure to satisfy the requirements of Section&#160;404 of SOX on an ongoing, timely basis could result in the loss of investor confidence in the reliability of its financial statements, which in turn could harm the Company&#8217;s business and negatively impact the trading price of the common shares or the market value of its other securities. In addition, any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company&#8217;s operating results or cause it to fail to meet its reporting obligations. Future acquisitions of companies, if any, may provide the Company with challenges in implementing the required processes, procedures and controls in its acquired operations. No evaluation can provide complete assurance that the Company&#8217;s internal control over financial reporting will detect or uncover all failures of persons within the Company to disclose material information otherwise required to be reported. The effectiveness of the Company&#8217;s processes, procedures and controls could also be limited by simple errors or faulty judgments. In addition, if the Company expands, the challenges involved in implementing appropriate internal control over financial reporting will increase and will require that the Company continue to improve its internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the Company is a Canadian Company and some of its directors and officers are resident outside the United States, it may be difficult for investors in the United States to enforce civil liabilities against the Company based solely upon the federal securities laws of the United States.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a Canadian company, with its principal place of business in Canada. Some of the Company&#8217;s directors and officers, including the Company's Chief Executive Officer and Chief Financial Officer, are residents outside the United States and a significant portion of the Company&#8217;s assets are located outside the United States. Consequently, it may be difficult for U.S. investors to effect service of process within the United States upon the Company or these directors or officers who are not residents of the United States, or to realize in the United States upon judgments of courts of the United States predicated upon civil liabilities under the U.S. Securities Act of 1933, as amended. Investors should not assume that Canadian courts (1)&#160;would enforce judgments of U.S. courts obtained in actions against the Company or such directors or officers predicated upon the civil liability provisions of the U.S. federal securities laws or the securities or &#8220;blue sky&#8221; laws of any state within the United States or (2)&#160;would enforce, in original actions, liabilities against the Company or such directors or officers predicated upon the U.S. federal securities laws or any such state securities or &#8220;blue sky&#8221; laws. In addition, the protections afforded by Canadian securities laws may not be available to investors in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a foreign private issuer, our shareholders may have less complete and timely data.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a &#8220;foreign private issuer&#8221; as defined in Rule&#160;3b-4 under the United States Securities Exchange Act of 1934, as amended (the &#8220;U.S. Exchange Act&#8221;). Equity securities of the Company are accordingly exempt from Sections&#160;14(a), 14(b), 14(c), 14(f) and 16 of the U.S. Exchange Act pursuant to Rule&#160;3a12-3 of the U.S. Exchange Act. Therefore, the Company is not required to file a Schedule&#160;14A proxy statement in relation to its annual meeting of shareholders. The submission of proxy and annual meeting of&#160;shareholder information on Form 6-K may result in shareholders having less complete and timely information in connection with shareholder actions. The exemption from Section&#160;16 rules regarding reports of beneficial ownership and purchases and sales of common shares by insiders and restrictions on insider trading in our securities may result in shareholders having less data and there being fewer restrictions on insiders&#8217; activities in our securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we were to lose our foreign private issuer status under U.S. federal securities law, we would likely incur additional expenses associated with compliance with the U.S. securities law applicable to U.S. domestic issuers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, as discussed above under the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As a foreign private issuer, our shareholders may have less complete and timely data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, we are exempt from certain provisions of the U.S. federal securities law. The determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50% of our common shares are directly or indirectly held by residents of the United States and we fail to meet additional requirements necessary to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements under the Nasdaq listing rules. As a U.S. listed public company that is not a foreign private issuer, we will incur significant additional legal, accounting and other expenses that we will not incur as a foreign private issuer, and accounting, reporting and other expenses in order to maintain a listing on a U.S. securities exchange. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors and more expensive to procure director and officer liability insurance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company is likely a "passive foreign investment company" which may have adverse U.S. federal income tax consequences for U.S. shareholders.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. holders of Common Shares should be aware that the Company believes it was classified as a passive foreign investment company (&#8220;PFIC&#8221;) during the tax year ended December&#160;31, 2021, and based on current business plans and financial expectations, the Company expects that it will be a PFIC for the current tax year and may be a PFIC in future taxable years.&#160;If the Company is a PFIC for any year during a U.S. holder&#8217;s holding period of the Common Shares, then such U.S. shareholder generally will be required to treat any gain realized upon a disposition of Common Shares, or any &#8220;excess distribution&#8221; received on its Common Shares, as ordinary income, and to pay an interest charge on a portion of such gain or distribution, unless the shareholder makes a timely and effective qualified electing fund election (&#8220;QEF Election&#8221;) or a mark-to-market election with respect to the Common Shares.&#160;A U.S. holder who makes a QEF Election generally must report on a current basis its share of the Company's net capital gain and ordinary earnings for any year in which the Company is a PFIC, whether or not the Company distributes any amounts to its shareholders.&#160;However, U.S. holders should be aware that there can be no assurance that the Company will satisfy the record keeping requirements that apply to a qualified electing fund, or that the Company will supply U.S. holders with information that such U.S. holders require to report under the QEF Election rules, in the event that the Company is a PFIC and a U.S. holder wishes to make a QEF Election. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thus, U.S. holders may not be able to make a QEF Election with respect to their Common Shares. A U.S. holder who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair market value of the Common Shares over the taxpayer&#8217;s adjusted tax basis therein.&#160;This paragraph is qualified in its entirety by the discussion below under the heading &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Material United States Federal Income Tax Considerations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;&#160;Each U.S. holder should consult its own tax advisors regarding the PFIC rules and the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our Common Shares </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Volatility of market price of the Common Shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of the Common Shares may be volatile. The volatility may affect the ability of holders of Common Shares to sell the Common Shares at an advantageous price. Market price fluctuations in the Common Shares may be due to the Company&#8217;s operating results failing to meet the expectations of securities analysts or investors in any quarter, downward </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revision in securities analysts&#8217; estimates, governmental regulatory action, adverse change in general market conditions or economic trends, acquisitions, dispositions or other material public announcements by the Company or its competitors, along with a variety of additional factors, including, without limitation, those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this annual report on Form 20-F. In addition, the market price for securities in the stock markets, including the NASDAQ and the TSX, recently experienced significant price and trading fluctuations. These fluctuations have resulted in volatility in the market prices of securities that often has been unrelated or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the market price of the Common Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential dilution of present and prospective shareholdings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to finance future operations and development efforts, the Company may raise funds through the issue of common shares or the issue of securities convertible into common shares. The Company cannot predict the size of future issues of common shares or the issue of securities convertible into common shares or the effect, if any, that future issues and sales of the Company&#8217;s common shares will have on the market price of its common shares. Any transaction involving the issue of previously authorized but unissued shares, or securities convertible into shares, would result in dilution, possibly substantial, to present and prospective holders of shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company does not intend to pay cash dividends in the foreseeable future.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not declared or paid any dividends since its incorporation. The Company intends to retain earnings, if any, to finance the growth and development of its business and does not intend to pay cash dividends on the Common Shares in the foreseeable future. Any return on an investment in the common shares will come from the appreciation, if any, in the value of the Common Shares. The payment of future cash dividends, if any, will be reviewed periodically by the board of directors and will depend upon, among other things, conditions then existing including earnings, financial condition and capital requirements, restrictions in financing agreements, business opportunities and conditions and other factors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in law could adversely affect our business and corporate structure.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurances that changes will not occur in corporate, tax, property and other laws in Canada and/or Barbados (or the interpretation thereof by regulatory or tax authorities) which may materially and adversely affect our businesses and corporate structure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may be adversely affected by disruptions to our information technology ("IT") systems, including disruptions from cybersecurity breaches of our IT infrastructure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology networks and systems, including those of third-party service providers, to process, transmit and store electronic information. In particular, we depend on our information technology infrastructure for a variety of functions, including financial reporting, data management, and email communications. Any of these systems may be susceptible to outages due to fire, floods, power loss, telecommunications failures, terrorist attacks, sabotage and similar events. Global cybersecurity threats and incidents can range from uncoordinated individual attempts to gain unauthorized access to our information technology systems to sophisticated and targeted measures known as advanced persistent threats. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our systems or in non-encrypted portable media or storage devices. We could also experience a business interruption, information theft of confidential information, or reputational damage from industrial espionage attacks, malware or other cyber attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. Despite the implementation of network security measures and disaster recovery plans, our systems and those of third parties on which we rely may also be vulnerable to computer viruses, break-ins and similar disruptions. If we or our vendors are unable (or are perceived as unable) to prevent such outages and breaches, our operations may be disrupted and our business reputation could be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that risks and exposures related to cybersecurity attacks will remain high for the foreseeable future due to the rapidly evolving nature and sophistication of these threats. In addition, as a result of the COVID-19 pandemic, we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to meet regulatory or ethical expectations on environmental impact, including climate change. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environmental issues will become more material in the marketplace as the wider healthcare system embraces net -zero climate targets. The environmental targets and performance of our business will come under increased scrutiny by investors, governments and non-governmental organizations. Environmental considerations are starting to become embedded in the public procurement of good and services, including medicinal products and devices. Specific intermediates used to manufacture medicines, or those used as excipients or propellants, are coming under increased regulation and some may be subject to time-limited exemptions or potential phase-out. The physical impacts of climate change could impact the resilience of our business operations and supply chain.</span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_25"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;INFORMATION ON THE COMPANY</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">History and Development of the Company</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was formed under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Corporations Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Alberta) on April 2, 1998 as 779738 Alberta Ltd.&#160;&#160;On April 8, 1998, we changed our name to Oncolytics Biotech Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, telephone (403) 670-7377. Our agent for service in the U.S. is Registered Agent Solutions, Inc., 838 Walker Road Suite 21-2 Delaware 19904.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of the important events in our development including licensing transactions, our principal capital expenditures and divestitures and a description of acquisitions of material assets can be found in our MD&amp;A and in the notes to our financial statements included elsewhere in this annual report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains a Website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at https://www.sec.gov. The filings are also contained on the Company&#8217;s website at https://www.oncolyticsbiotech.com. Information on the Company's website is not incorporated by reference herein. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Business Overview </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development-stage company focusing our research and development efforts on pelareorep, an intravenously delivered immunotherapeutic agent with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts.&#160;We do not expect to generate significant revenues until, if and when, pelareorep becomes commercially viable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our potential product for human use is pelareorep, an unmodified reovirus. This virus is a first-in-class systemically administered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Scientific Background</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep&#8217;s anti-tumor activity is based on three complementary modes of action (Figure 1): </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selective viral replication in permissive cancer cells which leads to tumor cell lysis.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A specific adaptive immune response targeted to tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs), infected tumor cells and/or dendritic cells to T cells.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Research and Development highlights</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical and translational research to date indicates the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep has anticancer effects in a variety of animal models demonstrating that it can reduce tumor burden and prolong survival in these models. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The anticancer effects in animal models can be enhanced when pelareorep is given in combination with chemotherapy, immunotherapy, radiotherapy, and other targeted cancer therapies, highlighting the ability of pelareorep to enhance the anticancer effects of a broad range of cancer therapeutics.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A toxic dose of pelareorep has not been reached/established in animal models nor has a maximum tolerated dose been reached in humans, and treatment with pelareorep causes minimal side-effects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical data to date indicate the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">More than 1,400 patients have been enrolled in clinical studies conducted in our global clinical studies. Of these, more than 1,100 patients received pelareorep, and over 1,000 received pelareorep by intravenous (IV) administration.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep has been administered as single or multiple doses (intratumoral or intravenous), either as a monotherapy or in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and/or radiotherapy.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep is generally well-tolerated and has a manageable side effect profile. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When combined with chemotherapy or immunotherapy, pelareorep does not appear to enhance either the frequency or severity of the adverse effects of these agents.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Efficacy analysis from clinical studies show that treatment with pelareorep can improve the outcome of cancer patients with a variety of different tumors: </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a randomized Phase 2 study with 74 metastatic breast cancer (mBC) patients, known as IND.213, treatment with pelareorep plus paclitaxel versus paclitaxel alone demonstrated a statistically significant improvement in median overall survival: 17.4 months versus 10.4 months, respectively (HR = 0.65; 80% CI 0.46&#8211;0.91; p=0.1). In a post hoc subgroup analysis of patients with hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) diseases, the median OS benefit from the addition of pelareorep to paclitaxel was even greater compared to paclitaxel alone: 21.0 months versus 10.8 months, respectively (HR = 0.60; p=0.1).</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a single-arm study with gemcitabine plus pelareorep, in first-line patients with metastatic pancreatic ductal adenocarcinoma (PDAC), known as REO 017, the median OS was 10.2 months with 1-year and 2-year survival rates of 45% and 24%, respectively. These results were encouraging when compared to 20&#8211;22% and 2&#8211;5% benchmark 1-year and 2-year survivals, respectively for metastatic PDAC patients treated with gemcitabine alone from two different phase 3 studies.  </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In a two-arm Phase 2 study (NCI 8601), patients with metastatic PDAC were randomized to receive either carboplatin, paclitaxel and pelareorep (test arm) or carboplatin and paclitaxel alone (control arm). The median OS was similar for both arms, but the probability of survival at Year 2 was 20% in the test arm vs. 9% in the control arm. Evaluation of patient samples collected during this clinical trial identified the immunomodulatory CEA cell adhesion molecule 6 (CEACAM6) as a potential predictive biomarker for response to pelareorep therapy. Specifically, low levels of CEACAM6 mRNA expression were associated with prolonged progression-free survival in pelareorep-treated patients (10.3 months in CEACAM6 low versus 5.7 months in CEACAM6 high patients, p=0.05); importantly, this effect was not seen in the control arm.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the AWARE-1 window-of-opportunity study, most HR+/HER2- early breast cancer patients treated with pelareorep showed an increase in CeLTIL score, a measure of tumor cellularity and tumor infiltrating lymphocytes (TILs) that is associated with a better prognosis in breast cancer.  Importantly, addition of the immune checkpoint inhibitor atezolizumab to pelareorep increased both the magnitude of the increase in CeLTIL score and the proportion of patients with a positive CelTIL score thereby achieving the study&#8217;s primary endpoint. Biomarker data from AWARE-1 further demonstrated that pelareorep treatment reversed immunosuppressive tumor microenvironments, generated and expanded T cell clones, upregulated PD-L1 expression, and promoted CD8+ T cell tumor infiltration into tumors. Many of these effects were even more prominent when pelareorep was combined with atezolizumab demonstrating synergy between the two agents.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Mechanism of Action</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1. Proposed mechanism of action for pelareorep</span></div><div style="text-align:justify"><img src="oncyf-20211231_g1.jpg" alt="oncyf-20211231_g1.jpg" style="height:358px;margin-bottom:5pt;vertical-align:text-bottom;width:446px"/></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Direct cell lysis - Reovirus Replication in Permissive Cancer Cells</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selective viral replication and lysis in cancer cells and not normal cells is mediated by the host cellular protein dsRNA-activated protein kinase (PKR). In non-cancer cells that are infected with reovirus, PKR activates in the presence of the virus which in turn inhibits viral gene translation. However, in permissive cancer cells, PKR activation is inhibited, allowing for viral gene translation and eventual cell lysis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It was originally established that selective lysis of tumor cells was mediated by the activated rat sarcoma virus oncogene (RAS)-pathway, since active RAS inhibits PKR activation. However, more recent investigations have revealed that reovirus replication is not restricted to cells with an active RAS pathway; rather oncogenic mutations and amplifications in upstream and downstream mediators of the RAS-pathway also allow for viral replication and oncolysis. Moreover, active RAS is known to stimulate over 18 downstream effector proteins, many of which have been shown to facilitate viral replication. Cells bearing dysfunctional or deleted tumor suppressor genes and or chemo- or radiation-induced cell stress also show increased sensitivity to reovirus replication and lysis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Induction of Innate Immunity</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical and clinical studies provide compelling evidence that pelareorep functions as a systemically-delivered immunogenic agent that acts locally at the site of the tumor. Indeed, preclinical studies demonstrated that cancer cells infected with pelareorep can produce an innate immune response triggering the release of inflammatory cytokines. This inflammatory environment promotes a chemotactic response in NK cells, dendritic cells, and cytotoxic T-cells, altering the tumor microenvironment to support bystander immune-mediated cancer cell death. Intriguingly, preclinical studies have also demonstrated that the beneficial immunogenic functions of pelareorep can occur independently of viral replication. Pelareorep performs this immunogenic function, in part, by activating dendritic cells, key regulators of both adaptive and innate immunity. Dendritic cells activated by reovirus, in turn, stimulate the innate antitumor activity of NK cells and aid in the priming of specific antitumor cytotoxic lymphocyte, demonstrating that dendritic cell recognition of reovirus may trigger a beneficial innate immune response.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial with pelareorep (REO 013) provided an opportunity to study human NK cell activation in a controlled manner. Ten colorectal cancer patients with liver metastases received between one and five doses of pelareorep prior to surgical resection of their tumor. NK cell activation peaked 24-48 hours post-infection, coincident with a peak in pro-inflammatory cytokines. NK cells within a population of reovirus-treated blood mononuclear cells were stimulated to kill tumor targets, but </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not normal hepatocytes. Moreover, peripheral blood mononuclear cells were able to hand-off virus to tumors for direct oncolytic killing. Similarly, NK cells within a liver mononuclear cell population became selectively cytotoxic towards tumor cells when activated by reovirus. These results showed that reovirus modulates human NK cell activity in vivo and suggest that this may contribute to the therapeutic effect of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Induction of Adaptive Immunity</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adaptive anti-tumor immunity allows for elimination of existing cancer cells and performs constant surveillance, preventing relapse, and increasing overall survival. An adaptive immune response requires two signals: a signal from an APC, as well as a co-stimulation signal in the form of cytokines. In the absence of either signal, the adaptive immune response fails. Therapy with pelareorep has the potential to activate both signals. Following administration, pelareorep enhances the expression of &#8216;foreign&#8217; antigens/markers on tumor cells. Oncolysis of tumor cells exposes tumor-associated antigens (TAAs) and viral-associated antigens (VAAs) for processing and presentation by APCs, such as dendritic cells. Through this process, pelareorep facilitates the display of novel &#8216;foreign&#8217; antigens on the surface of infected tumor cells and APCs. Simultaneously, pelareorep induces an inflammatory response including the expression of co-stimulatory molecules and inflammatory cytokines. Together, these pelareorep-mediated immunological events initiate adaptive anti-tumor immunity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By promoting the expression of novel antigens and the release of inflammatory cytokines, pelareorep, promotes an inflamed tumor phenotype. An inflamed tumor phenotype is characterized by NK and T-cell infiltration, increased expression of chemokines/cytokines, and increased expression of checkpoint ligands such as PD-L1. This phenotype correlates with an increase in overall survival and has a positive prognostic value for early-stage cancers. In patients with metastatic cancer, an inflamed tumor phenotype is associated with better clinical outcomes when treated with immunotherapies, including immune checkpoint inhibitors, cancer vaccines, and adaptive T-cell therapies. By promoting an inflamed tumor phenotype, pelareorep primes an anti-cancer immune response (Figure 2).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2. Pelareorep primes an anti-cancer immune response</span></div><div style="margin-bottom:8pt"><img src="oncyf-20211231_g2.jpg" alt="oncyf-20211231_g2.jpg" style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:513px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ultimate objective of our clinical development program is to obtain regulatory approval for pelareorep and is based on the compelling efficacy data from previous studies in breast cancer, pancreatic cancer, colorectal cancer, myeloma and other malignancies. Our immediate primary focus continues to be on advancing our program in HR+/HER2- metastatic breast cancer to a phase 3 licensure-enabling study.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our current clinical development approach centers on pelareorep's ability to stimulate immune-mediated tumor killing, particularly in combination with immune checkpoint inhibitors and other immune-based therapies. We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to approval. As our clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">development program advances, we anticipate that pelareorep's ability to enhance innate and adaptive immune responses when combined with different classes of immunotherapies will play an increasing role. This greatly increases the opportunities for expansion of our clinical program to address a broad range of cancers in combination with a variety of partner therapies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the results of our AWARE-1 window-of-opportunity study were presented at international conferences. This study examined the use of pelareorep with or without the checkpoint inhibitor atezolizumab (Tecentriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in patients with breast cancer. The results of this study showed that pelareorep primed the tumor microenvironment for checkpoint blockade therapy including increasing both PD-L1 expression in the tumor and T cell trafficking into the tumor. The potentially beneficial effects of pelareorep therapy, also including the creation and expansion of T cell clones, were enhanced further by combining pelareorep with atezolizumab. Notably, patients treated with pelareorep and atezolizumab reached the primary endpoint of the study with 60% of the patients showing an increase of more than 30% in the CelTIL score, a measure that correlates with efficacy in breast cancer patients. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, enrollment into our BRACELET-1 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">east c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r with the Oncolytic Reovirus Pe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">areor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">p in Combina</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ion with anti-PD-L1 and Paclitaxel) study continued. BRACELET-1 is a randomized study of HR+/HER2-metastatic breast cancer patients and is evaluating tumor and immune responses following treatment with either paclitaxel  (standard of care therapy), paclitaxel + pelareorep or paclitaxel + pelareorep + the checkpoint inhibitor avelumab (Bavencio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Also during 2021 enrollment continued into the investigator-sponsored multi-center trial known as IRENE (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NCMGA00012, and the oncolytic virus pela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orep in metastatic triple-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gative breast cancer). This trial is investigating pelareorep in combination with Incyte&#8217;s anti-PD-1, retifanlimab (INCMGA00012) in patients receiving second-line treatment for triple-negative breast cancer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our breast cancer program, we continued to explore pelareorep in gastrointestinal cancers. Notably, in 2021 enrollment began into the platform study known as GOBLET (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">astrointestinal tum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rs exploring the treatment com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inations with the oncolytic reovirus pe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orep and an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i-PD-L1). GOBLET is examining combination therapy with pelareorep and atezolizumab (Tecentriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in four gastrointestinal indications: (1) Patients with first-line locally advanced/metastatic unresectable pancreatic ductal adenocarcinoma (PDAC); (2) Patients with first-line metastatic colorectal cancer (mCRC), limited to microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors; (3) Patients with third-line mCRC independent of microsatellite instability (MSI)/dMMR status; and (4) Patients with second-line or later locally advanced/metastatic unresectable squamous cell carcinoma of the anal canal (SCCA). This study is currently enrolling patients, and the 3-patient safety run-ins for Cohort 1 has been completed and Cohort 3 is ongoing (Cohorts 2 and 4 do not require safety run-ins).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2021 the results of our second-line pancreatic cancer study in which pelareorep was given in combination with the checkpoint inhibitor pembrolizumab (Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), but without chemotherapy, was presented at ASCO. This study is an extension of an earlier phase 1 study that investigated pelareorep in combination with pembrolizumab and chemotherapy. Consistent with prior studies, the combination of pelareorep and pembrolizumab demonstrated a manageable safety profile. Thirteen patients were enrolled, and  a disease control rate of 42% was achieved in the 12 efficacy-evaluable patients. One patient achieved a partial response (PR), and four patients had stable disease (SD). These results, both in terms of disease control and overall survival, were consistent with prior studies in second-line pancreatic cancer patients despite the absence of chemotherapy in this study. Responding patients showed synergy between pelareorep and checkpoint blockade therapy as demonstrated by reductions in regulatory T cells and improved CD8+ effector T cell activation and metabolic function in both blood and tumors.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents and Trade Secrets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions and proprietary rights of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. We believe there will continue to be significant litigation in the industry regarding patent and other intellectual property rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we have 310 issued patents including 28 issued in the U.S. and 14 in Canada. We also have 16 patents pending in the U.S., Canada, and other jurisdictions, but we cannot be certain whether any given patent application filed by us will result in the issuance of a patent or if any given patent issued to us will later be challenged and invalidated. Nor can we be certain whether any given patent that may be issued to us will provide any significant proprietary protection to our product and business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other proceedings may also be necessary to enforce or defend our proprietary rights and patents. In Europe, patents can be revoked through opposition or nullity proceedings. In the United States patents may be revoked or invalidated in court actions or challenged in interference, post-grant review, inter partes review, derivation or re-examination proceedings by the United States Patent and Trademark Office ("USPTO"). Such litigation or proceedings could result in substantial cost or distraction to us, resulting in an adverse decision as to our or our licensors&#8217; patent applications and patents.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, on not infringing the patents or proprietary rights of others and not breaching licenses granted or that may be granted to us. Competitors may have filed patent applications, obtained patents, may in the future file patent applications, and/or obtain patents relevant to our product and technologies.&#160;We are not aware of competing intellectual property relating to our pelareorep project at this time.&#160;While we currently believe that we have the necessary freedom to operate in these areas, there can be no assurance that others will not challenge our position in the future.&#160;Litigation to defend our position could be costly and time consuming. We also cannot be certain that we will be successful. We may be required to obtain a license from a prevailing party in order to continue the portion of our business that relates to the proceeding. We may also be required to obtain licenses to other third-party technologies necessary in order to market our products. Such licenses may not be available to us on acceptable terms, or on any terms, and we may have to discontinue that portion of our business. Any failure to license any technologies required to commercialize our technologies or products at reasonable cost may have a material adverse effect on our business, results of operations, financial condition, cash flow and future prospects. We are not currently involved in any litigation concerning our competitors&#8217; patent applications and patents. We may be involved in such litigation in the future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. No assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our rights to our unpatented trade secrets.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require our employees and consultants to execute confidentiality agreements upon the commencement of employment and consulting relationships with us. These agreements provide that all confidential information developed by or made known to an individual during the course of the employment or consulting relationship generally must be kept confidential. In the case of employees, the agreements provide that all inventions conceived by the individual, while employed by us, relating to our business are our exclusive property. While we have implemented reasonable business processes and agreements with which to protect confidential information, these actions may not provide meaningful protection for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Strategy</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is to develop and market pelareorep in an effective and timely manner, and access additional technologies at a time and in a manner that we believe is best for our development.&#160;We intend to achieve our business strategy by focusing on these key areas:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop pelareorep through our clinical development program assessing the safety and efficacy in human subjects;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Establish collaborations with experts to assist us with scientific and clinical developments of this new potential pharmaceutical product;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implement strategic alliances with select biopharmaceutical companies and laboratories, at a time and in a manner whereby such alliances may complement and expand our own research and development efforts. Such alliances may also result in an eventual expansion to include providing additive sales and marketing capabilities;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Utilize our broadening patent base and collaborator network as a mechanism to meet our strategic objectives; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop relationships with companies that could be instrumental in assisting us to access other innovative therapeutics.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is based on attaining a number of commercial objectives, which, in turn, are supported by a number of product development goals.&#160;In the context of this annual report, statements of our "belief" are based primarily upon our results derived to date from our research and development program with animals, early-stage human trials, and our most recent data in HR+/HER2- mBC patients, upon which we believe that we have a reasonable scientific basis to expect the particular results to occur.&#160;It is not possible to predict, based upon studies in animals, or early-stage human trials, whether a new therapeutic will ultimately prove to be safe and effective in humans.&#160;There are no assurances that the particular result expected by us will occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we do not intend to become a fully integrated pharmaceutical company with substantial in-house research and development, marketing and distribution or manufacturing capabilities.&#160;We are pursuing a strategy of establishing relationships with larger companies as strategic partners.&#160;It is anticipated that future clinical development into large international or pivotal trials would generally occur in conjunction with a strategic partner or partners, who would contribute expertise and financial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assistance.&#160;In exchange for certain product rights and commitments to market our products, the strategic partners would be expected to share in proceeds from the sale of our product or products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of new pharmaceuticals is strongly influenced by a country's regulatory environment.&#160;The drug approval process in Canada is regulated by Health Canada.&#160;&#160;The primary regulatory body in the United States is the FDA and in Europe is the European Medicines Agency (the &#8220;EMA&#8221;).&#160;Similar processes are conducted in specific countries by equivalent regulatory bodies.&#160;Regulations in each jurisdiction require the licensing of manufacturing facilities and mandate strict research and product testing standards.&#160;Companies must establish the safety and efficacy of their products, comply with cGMP and potentially submit marketing materials before being allowed to market pharmaceutical products.&#160;While we plan to pursue or support the pursuit of the approval of our product, success in acquiring regulatory approval for any product is not assured.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market our pharmaceutical product in Canada, the United States, Europe and other jurisdictions, we must successfully meet the requirements of those jurisdictions. The requirements of the appropriate regulatory authority will generally include the following stages as part of the regulatory process:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Pre-Pharmacological Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Pre-Pharmacological studies involve extensive testing on laboratory animals to determine if a potential therapeutic product has utility in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease model and has any adverse toxicology in a disease model.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Investigational New Drug Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - An Investigational New Drug (IND) Submission, or the equivalent, must be submitted to the appropriate regulatory authority prior to conducting Pharmacological Studies.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmacological Studies&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or Phase 1 Clinical Trials)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Pharmacological studies are designed to assess the potential harmful or other side effects that an individual receiving the therapeutic compound may experience.&#160;&#160;These studies, usually short in duration, are often conducted with healthy volunteers or actual patients and use up to the maximum expected therapeutic dose.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Therapeutic Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(or Phase 2 and 3 Clinical Trials) - Therapeutic studies are designed primarily to determine the appropriate manner for administering a drug to produce a preventive action or a significant beneficial effect against a disease.&#160;&#160;These studies are conducted using actual patients with the condition that the therapeutic is designed to remedy. Prior to initiating these studies, the organization sponsoring the program is required to satisfy a number of requirements via the submission of documentation to support the approval for a clinical trial.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">New Drug Submission </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- After all three phases of a clinical trial have been completed, the results are submitted with the original IND Submission to the appropriate regulatory authority for marketing approval.&#160;&#160;Once marketing approval is granted, the product is approved for commercial sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing Approvals</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the preclinical and clinical testing, together with manufacturing and controls information, are submitted to regulatory agencies in order to obtain approval to commence commercial sales. In responding to such an application, regulatory agencies may grant marketing approval, request additional information or further research, or deny the application if they determine that the application does not satisfy their regulatory approval criteria. Approval for a pharmaceutical or biologic product may not be granted on a timely basis, if at all. If granted, the approval may not cover all the clinical indications for which approval is sought, or may contain significant limitations in the form of warnings, precautions or contraindications with respect to conditions of use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The satisfaction of pre-market approval requirements for new drugs and biologics typically takes several years, with the actual time required varying substantially based upon the type, complexity and novelty of the product or targeted disease. Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures upon our activities. Success in early-stage clinical trials or with prior versions of products does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Marketing Regulations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once approved, regulatory agencies may withdraw the product approval if compliance with pre- and/or post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, they may require post-marketing studies, referred to as Phase 4 studies, to monitor the effect of an approved product, and may limit further marketing of the product based on the results of these post-market studies. The FDA and other foreign regulatory agencies have broad post-market regulatory and enforcement powers, including the ability to levy fines and penalties, suspend or delay issuance of approvals, seize or recall products, or withdraw approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Regulations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our toll manufacturers are subject to periodic inspection by the FDA, the United States Drug Enforcement Administration, or DEA, and other domestic and foreign authorities where applicable, and must comply with cGMP regulations. Manufacturers of biologics also must comply with general biological product standards. Failure to comply with the statutory and regulatory requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, or mandatory or voluntary recall of a product.&#160;Adverse experiences with the product must be reported to the FDA and foreign agencies and could result in the imposition of market restrictions through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Promotion Regulations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to both pre- and post-market product advertising and promotion, the FDA and similar foreign agencies impose a number of complex regulations on entities that advertise and promote pharmaceuticals and biologics, which include, among other things, standards and regulations relating to direct-to-consumer advertising, on vs. off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet. These agencies have very broad enforcement authority and failure to abide by these regulations can result in penalties including the issuance of a warning letter directing the entity to correct deviations from requisite standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA or relevant foreign agencies. Foreign, state and federal civil and criminal investigations, fines and prosecutions are also possible if advertising and promotion regulations are breached.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Government Regulations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the government has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals, any one or more of which could have a material adverse effect upon us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market and Competition </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">According to estimates for 2022 from the American Cancer Society, more than 1.9 million Americans are expected to be diagnosed with cancer in the year, and approximately 609,360 Americans are expected to die of cancer.&#160;Cancer is the second most common cause of death in the U.S., exceeded only by heart disease.&#160;In the United States, the relative lifetime risk of a male or female developing cancer is 1 in 2 and 1 in 3, respectively (Source: American Cancer Society's Cancer Facts &amp; Figures 2022). It was projected that there will be 191,454 patients with HR+/HER2- mBc in 2021. (Source: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">https://seer.cancer.gov/statfacts/html/breast.html (accessed Jan 25, 2022); https://seer.cancer.gov/statfacts/html/breast-subtypes.html (accessed Jan 25, 2022)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of this disease state are also significant.&#160;In the United States, the American Cancer Society reported in its Cancer Facts &amp; Figures 2022 that The National Cancer Institute estimated that the 2015 direct medical costs for cancer were $183 billion and are projected to increase to $246 billion by 2030. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face substantial competition in the development of products for cancer and other diseases. This competition from other manufacturers of the same types of products and from manufacturers of different types of products designed for the same uses is expected to continue in both U.S. and international markets.&#160;&#160;Oncolytic virus therapies, our primary focus area, are rapidly evolving areas in the biotechnology industry and are expected to undergo many changes in the coming years as a result of technological advances. We are currently aware of a number of groups that are developing oncolytic virus therapies including early-stage and established biotechnology companies, pharmaceutical companies, academic institutions, government agencies and research institutions. We face competition from all of these groups in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. It is possible that our competitors could achieve earlier market commercialization, could have superior patent protection, or could have safer, more effective or more cost-effective products. These factors could render our potential products less competitive, which could adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Marketing Strategy</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for the cancer product being developed by us may be large and could require substantial sales and marketing capability.&#160;Before or upon successful completion of the development of a cancer product, we intend to enter into one or more strategic partnerships or other collaborative arrangements with a pharmaceutical company or other company with marketing and distribution expertise to address this need.&#160;If necessary, we will establish arrangements with various partners for different geographical areas or specific applications at various times in the development process.&#160;Our management and consultants have relevant experience with the partnering process.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seasonality of Business</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations have not been materially impacted by seasonality.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Social Responsibility and ESG </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a rapidly growing, development-stage biotech company, we are not yet in a position to implement a broad-based ESG policy and program. However, our corporate goals are inspired by our potential to impact the care of patients with cancer, especially those with late-stage breast cancer and are informed by our corporate values of acting with integrity, collaboration, innovation, and embracing diversity. In 2021, our corporate goals focused on certain clinical, manufacturing, and business operations and support our desire to obtain an approval for an innovative cancer treatment that extends patient lives. Each year we work hard to achieve our goals and objectives while maintaining a respectful, collaborative, and caring work environment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we do not formally report on our ESG policies and compliance, we publicly disclose elements of our ESG activities. Our governance policies like our board mandates, code of ethics and conduct, and our public filings are all on our website at https://ir.oncolyticsbiotech.com/corporate-governance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Organizational Structure</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;31, 2021, we had one material wholly-owned operating subsidiary; Oncolytics Biotech (Barbados) Inc. (&#8220;OBB&#8221;), a Barbados company.&#160;In addition, Oncolytics Biotech (U.S.) Inc., a Delaware corporation, is a material wholly-owned subsidiary of OBB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.&#160;&#160;&#160;&#160;&#160;&#160;Property, Plant and Equipment</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease our head office in Calgary, Alberta, Canada as well as our office spaces in San Diego, California, U.S. and Barbados. We do not own or lease any other office space, manufacturing facilities or equipment and do not have any current plans to construct or acquire any facilities.</span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4A.&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management Discussion and Analysis (&#8220;MD&amp;A&#8221;) contains forward-looking statements, including our belief as to the potential of pelareorep, a therapeutic reovirus, as a cancer therapeutic and our expectations as to the success of our research and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and manufacturing programs in 2022 and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.&#160;See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the forward-looking statements made within our MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our development program, our ability to receive regulatory approval to commence enrollment in our clinical trial program, the final results of our co-therapy clinical trials, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.&#160;&#160;Investors are cautioned against placing undue reliance on forward-looking statements.&#160;We do not undertake to update these forward-looking statements except as required by applicable law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Operating Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see our 2021 Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see our 2021 Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Research and Development, Patents, and Licenses, etc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see the disclosure in "Item 4.&#160;&#160;Information on the Company B. Business Overview" for information on the Company&#8217;s research and development policies.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Trend Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important to note that historical patterns of expenditures cannot be taken as an indication of future expenditures.&#160;&#160;The amount and timing of expenditures and availability of capital resources vary substantially from period to period, depending on the level of research and development activity being undertaken at any one time and the availability of funding from investors and prospective commercial partners. See our 2021 MD&amp;A in Exhibit 15.1 for our comparative discussion on our expenditures between 2019 - 2021 and our expectations for 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as disclosed elsewhere in our annual report, we know of no trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our liquidity or capital resources or that would cause reported financial information not necessarily to be indicative of future operating results or financial conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Critical Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Directors and Senior Management</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the names and places of residence of all our directors and senior management as at <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8zNC9mcmFnOjhhNWI2MmRlYjU5NDQ5ZGM4MGE1NjQyYzNjODAzZmNlL3RleHRyZWdpb246OGE1YjYyZGViNTk0NDlkYzgwYTU2NDJjM2M4MDNmY2VfMjA2_57a33e3c-83d0-4a22-841f-20e7e5d9f1e2"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8zNC9mcmFnOjhhNWI2MmRlYjU5NDQ5ZGM4MGE1NjQyYzNjODAzZmNlL3RleHRyZWdpb246OGE1YjYyZGViNTk0NDlkYzgwYTU2NDJjM2M4MDNmY2VfMjA2_de394497-f149-4a44-b37c-b47a3537b29a">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric>, as well as the positions and offices held by such persons and their principal occupations.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah M. Brown, MBA, ICD.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Brown leads Canadian Strategic Partnerships at Eversana, a leading provider of global commercial services to the life sciences industry. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company's U.S. operations, and President and Managing Director of the company's Canadian operations. In 2012, Ms. Brown was Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of the HBSPCA, Oncolytics Biotech Inc, and Sernova Corp. Ms. Brown holds an MBA from Western University&#8217;s School of Business, an Hons B.Sc. from the University of Guelph, and has completed the Institute of Corporate Directors Designation (ICD.D).</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Coffey, PhD, MBA<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A co-founder of the Company, Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey took over as Chief Executive Officer in late 2016, prior to which he was Chief Operating Officer since December 2008. Since co-founding Oncolytics he has also held the positions of Chief Scientific Officer from December 2004 to December 2008, Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2011</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro<br/>California, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro has more than 25 years of biopharmaceutical commercialization and business development experience. He has held executive and senior-level positions at leading pharmaceutical and biotechnology companies, working on initiatives across both developed and emerging markets globally.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. de Guttadauro began his career at TAP Pharmaceuticals, supporting the launch of blockbuster drugs, Lupron</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and Prevacid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. He held a variety of marketing positions at Amgen, contributing to the success of Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, and Epogen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;before joining MedImmune to lead marketing efforts for the FluMist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;inhaled influenza vaccine. Following a two-year assignment overseeing the commercial development of Zevalin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the first radioimmunotherapy product approved for use in the United States, Mr. de Guttadauro took on the role of Senior Director of Strategy at Biogen Idec. He then served as Vice President of Corporate Development at Vical, supporting the execution of distribution agreements for Allovectin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Prior to joining Oncolytics, Mr. de Guttadauro was a Principal at 1798 Consultants Inc., a healthcare consulting firm providing commercialization, market access, and compliance strategic advice to leading and emerging biopharmaceutical companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. de Guttadauro has a Bachelor of Science degree in engineering from the United States Military Academy at West Point.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman, P.Eng., PMP, MBT <br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Product Development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Professional Engineer focused on biotechnology, Ms. Hagerman joined Oncolytics in 2010 and has been integral to the progress of its product development program ever since. Prior to being appointed as Vice President of Product Development, Ms. Hagerman was the Director, Manufacturing and Engineering from 2013-2017 and Project Manager from 2010-2013, during which time she led the process performance qualification for pelareorep drug substance. Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas C. Heineman, MD, PhD<br/>California, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Heineman brings more than 20 years of experience leading clinical development programs to Oncolytics, including 15 years in the biopharmaceutical industry.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Most recently, Dr. Heineman served as Senior Vice President and Head of Clinical Development at Denovo Biopharma. Prior to his time at Denovo, Dr. Heineman served as Vice President and Head of Clinical Development at Genocea Biosciences and Halozyme Therapeutics, where he was also the Head of Translational Medicine, and oversaw clinical trials in indications such as breast and pancreatic cancer. Dr. Heineman&#8217;s experience further extends to big pharma and academia where he previously held roles as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and Associate Professor at the Saint Louis University School of Medicine. Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in Internal Medicine and Infectious Diseases. He completed his fellowship in Infectious Diseases at the National Institutes of Health and his internship and residency at the University of Maryland. Dr. Heineman earned his MD at the University of Chicago, where he also received a PhD in molecular genetics.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham, MBA, FCPA, FCMA, ICD.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer. In 2002, she joined Toronto, Ontario-based Hospital for Sick Children as Vice President, Finance and Chief Financial Officer, a position she held for eight years. Through her career she has participated in myriad initiatives ranging from traditional finance functions and operations oversight to intellectual property portfolio management and mergers and acquisitions. In more recent years she has held numerous governance roles on various Boards in both the publicly traded and not-for-profit sectors and held short term contract positions. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Holtham is an FCPA, FCMA, holds an MBA from the University of Toronto - Rotman School of Management and has completed the Institute of Corporate Directors Designation (ICD.D).</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 18, 2014</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard Kruimer, MBA, CPA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vinkeveen, The Netherlands</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Kruimer has over 30 years experience in accounting, corporate finance, and strategy, in senior management positions in private and publicly listed life science companies. Mr. Kruimer served as CFO and Executive Committee Member of Crucell from 1998 through 2011, when Crucell was acquired by JNJ. During his tenure, he led financing activities of the company and contributed to Crucell's strategic acquisition of Swiss-based Berna Biotech. Currently, Mr. Kruimer serves as independent director and Chairman of the Audit Committee for Zealand Pharma (Nasdaq: ZEAL), Chairman of the Board of BioInvent AB (OMXS: BINV) and director and Chairman of the Audit Committee of Pharming Group NV (Nasdaq: PHAR). He is a director of Advent Int. Global Investments (Netherlands) and advisor to Karmijn Kapitaal Investments, a private equity firm in Amsterdam. Previously, he was CFO of SkylineDx, a DNA diagnostics company and Chairman of ProFibrix through its acquisition by The Medicines Company (Nasdaq: MDCO) in 2013. Prior to Crucell, Mr. Kruimer held senior executive positions at TIP Europe, a GE Capital company and Continental Can Europe. He was a consultant with McKinsey and with Price Waterhouse in New York. Mr. Kruimer holds an MBA from Harvard Business School, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a BA in accounting and finance from University of Massachusetts and is a CPA in New York State.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look, CA, MSJ<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Look is a Chartered Accountant with more than twenty years of experience in accounting, finance, tax and treasury. Mr. Look joined Oncolytics as the Company's Controller in April 2003, and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst &amp; Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst &amp; Young LLP in Chile.  Mr. Look holds a Master of Science in Jurisprudence (MSJ) from the Seton Hall University School of Law and a Bachelor of Commerce from the University of Calgary.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano, MBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">                                                            Pennsylvania, USA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Pisano has served as a Director/Chairman of several publicly traded companies in the US and Canada and has more than 30 years of experience as a pharmaceutical industry executive. He served as the president and CEO of VaxInnate, a privately held biotech company from January 2012 to November 2016. Mr. Pisano is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He joined Sanofi Pasteur in 1997, assuming increasing levels of responsibility. He was promoted to President and CEO in 2007, the position he successfully held until his retirement in 2011. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor's degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2013</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger, MD, PhD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey, USA and Munich, Germany</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Seizinger has been board member/chairman in multiple public and private biotech companies in the US and Europe. From 1998 to 2009, he served as President and Chief Executive Officer of GPC Biotech. He also served as Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb. Prior to his appointments in the biotechnology and pharmaceuticals sectors, Dr. Seizinger held professorships and senior staff appointments at Harvard Medical School, Princeton University and Massachusetts General Hospital.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2015</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Audit Committee.&#160;Ms. Holtham is Chair of this Committee.</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Compensation Committee.&#160;Ms. Brown is Chair of this Committee. </span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Governance Committee.&#160;Mr. Pisano is Chair of this Committee. </span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Science and Technology Committee. Dr. Seizinger is Chair of this Committee.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Mr. Pisano, as Chair of the Board, serves as an ex-officio member of the Compensation, Audit, Governance and Science and Technology Committees.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at February&#160;28, 2022, the directors and senior management as a group beneficially owned, directly or indirectly, 756,992 of our common shares, representing 1.18% of the issued and outstanding common shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our directors are associated with other companies, which may give rise to conflicts of interest.&#160;In accordance with the Alberta Business Corporations Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABCA), directors who have a material interest in any person who is a party to a material contract or a proposed material contract with us are required, subject to certain exceptions, to disclose that interest and abstain from voting on any resolution to approve that contract.&#160;&#160;In addition, the directors are required to act honestly and in good faith with a view to the best interests of Oncolytics Biotech Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers are related by blood, marriage or adoption to any other director or officer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not aware of any arrangement or understanding with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a director or senior management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt"> Compensation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board of Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning the total compensation paid in 2021 to each director.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fees Earned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">based awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">based awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-equity incentive plan compensation<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension value<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All other compensation<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Brown</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,068</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,842</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,910</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,407</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,842</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,249</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard Kruimer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,729</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,842</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,571</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,424</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,803</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,227</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Rice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,865</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,842</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,707</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd Seizinger</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,068</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,842</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,910</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Directors are paid fees in U.S. Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a U.S./CDN exchange rate of $1.2678.</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">The value of share-based and option based awards are based on the grant date assumptions as disclosed in note 10 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 audited consolidated financial statements.  </span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Dr. Rice ceased to hold the position as a director effective June 30, 2021.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each director who is not a salaried employee of the Company is entitled to receive a base retainer of US$40,000. In addition to the base retainer directors are eligible to receive the following additional fees depending on committee involvement:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional Retainers (USD):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Committee chair</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Governance &amp; Compensation Committee chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Science &amp; Technology Committee chair</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Audit Committee</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Governance, Compensation or Science &amp; Technology  Committee</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,000</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the combined retainer, the Corporation will grant 30,000 options annually for directors other than the Chair, and 37,500 options annually for the Chair. The options cliff-vest after 1 year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also reimburse the directors for any reasonable expenses incurred by them while acting in their directors' capacity.&#160;During the year ended December 31, 2021, total compensation of $864,574 was paid to the independent directors which consisted of fee payments of $440,561 and option based awards of $424,013. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Management </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning the total compensation paid to our senior management in 2021.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salary<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-<br/>based awards<br/>($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option-<br/>based </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">awards </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bonus<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-equity incentive<br/>plan compensation<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension value<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All other compensation<br/>  ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>compensation <br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Matthew C. Coffey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">637,200</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038,690</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273,996</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,149</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,031,035</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kirk J. Look<br/>Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473,800</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425,741</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,987</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,669</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,130,197</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)(5)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519,798</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346,592</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,108</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,940</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,043,438</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President, Oncolytics Biotech (U.S.) Inc.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,373</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267,443</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,221</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,342</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">826,379</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,987</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,169</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,221</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714,877</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The value of share and option based awards are based on the grant date assumptions as disclosed in note 10 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2021 audited consolidated financial statements.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The dollar amounts set forth under this column are related to contributions to the senior management's respective retirement savings plan and amounts provided for health care benefits by the Company. </span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">None of the compensation paid to Dr. Coffey related to his role as a director of the Company.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">U.S. Employees are paid salaries, bonuses and other compensation in U.S. Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a U.S./CDN exchange rate of $1.2678.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Dr. Heineman was promoted to the role of Chief Medical Officer on December 21, 2021. He previously served as our Global Head of Clinical Development and Operations.  </span></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment agreements with each member of the Company's senior management (each an "Employment Agreement"). For 2021, the Chief Executive Officer of the Corporation is eligible for a cash bonus of up to 50% of his base salary, the Chief Financial Officer and Chief Medical Officer are eligible for a cash bonus of up to 40% of their respective base salary, the President, Oncolytics Biotech (U.S.) Inc. is eligible for a cash bonus of up to 35% of his base salary and the Vice President, Product Development is eligible for a cash bonus of up to 30% of her respective base salary. In addition, when available, the officers are eligible for a combination of Option and Share Award grants. The amount of each grant is determined and approved by the Board with the actual bonus provided and the number of Options and Share Awards granted based upon the overall performance of the Corporation as assessed by the Compensation Committee and approved by the Board. The overall performance of the Corporation is determined by the annual goals and objectives approved by the Board and includes specific objectives with respect to the clinical, manufacturing, and intellectual property plans in combination with financial goals. Previous grants are taken into account when considering new grants of Options and Share Awards. As well, the Employment Agreements provide that each member of the Company's senior management is subject to certain confidentiality and non-competition restrictions during and following the course of their respective employment with the Company. Each Employment Agreement shall continue until terminated by either party in accordance with the notice provisions thereof.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not provide pension plan benefits to its senior management and employees. The Company does not currently have a stock appreciation rights plan.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following base salaries for 2022 were approved by the Board of Directors:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Salary<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew C. Coffey<br/>President and Chief Executive Officer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look<br/>Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Oncolytics Biotech (U.S.) Inc.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">U.S. Employees are paid in U.S. Dollars and salaries above for those U.S. employees are presented in U.S. dollars. All other employees are paid in Canadian Dollars and salaries above for those Canadian employees are presented in Canadian dollars. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Termination of Employment or Change of Control </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects amounts payable to the each member of the Company's senior management based on their respective Employment Agreements assuming that their employment was terminated on December 31, 2021 without cause or due to a change of control of the Company.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Termination without Cause Severance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change of Control Severance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Matthew C. Coffey<br/>President and Chief Executive Officer</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look<br/>Chief Financial Officer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Oncolytics Biotech (U.S.) Inc.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As at December 31, 2021, all options granted to senior management had fully vested except for the options granted on August 1, 2020 (expiring August 1, 2025), December 11, 2020 (expiring December 11, 2024), March 8, 2021 (expiring March 8, 2026), and December 10, 2021 (expiring December 10, 2025). As a result, all members of senior management shall be entitled to exercise all or any part of their vested Options, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such member is terminated unless otherwise approved by the Board of Directors.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">On a change of control of the Company, senior management shall be entitled to exercise all or a part of their Options, whether vested or not, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such member is terminated.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">U.S. Employees are paid in U.S. Dollars and are presented in U.S. dollars.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As at the date of this annual report, Dr. Heineman is entitled to two month&#8217;s pay in lieu of notice in the event of his termination without cause. On August 3, 2021, being the anniversary of his commencement of employment with the Corporation, and on each subsequent anniversary of the commencement of his employment with the Corporation, Dr. Heineman will be entitled to one additional month&#8217;s pay in lieu of notice, to a maximum of 6 month&#8217;s pay in lieu of notice.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Board Practices</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors are elected by the shareholders at each Annual General Meeting (or Annual Special Meeting) and typically hold office until the next meeting, at which time they may be re-elected or replaced.&#160;Casual vacancies on the board are filled by the remaining directors and the persons filling those vacancies hold office until the next Annual General Meeting (or Annual Special Meeting), at which time they may be re-elected or replaced.&#160;The officers are appointed by the Board of Directors and hold office indefinitely at the pleasure of the Board of Directors.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.194%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Corporation Since</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Expiration of Current Term of Office</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Coffey, PhD, MBA<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2011</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2022 Annual General Meeting of the Shareholders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Brown, BSc, MBA, ICD.D<br/>Ontario, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2022 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham, MBA, FCPA, FCMA, ICD.D<br/>Ontario, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 18, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2022 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard Kruimer, MBA, CPA<br/>Vinkeveen, Netherlands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2022 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano, MBA<br/>New Jersey, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair and Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2013</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2022 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger, MD, PhD<br/>New Jersey, USA and Munich Germany</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2022 Annual General Meeting of the Shareholders</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors&#8217; Contracts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a director&#8217;s consent from each of the independent directors upon their acceptance of their director&#8217;s position.&#160;We also enter into an Indemnity Agreement and Directors Confidentiality and Intellectual Property Assignment Agreement with each director.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any contracts with any of its directors which provide for benefits upon the termination of employment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation has formed a compensation committee (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in accordance with Rule 5605(d)(1) of the Nasdaq Capital Market which consists of four outside, independent directors, Dr. Seizinger, Ms. Holtham, Ms. Brown, and Mr. Pisano, the Chair of the Board, each of whom is independent in accordance with Rule 5605(a)(2) and Rule 5605(d)(2)(A) of the Nasdaq Capital Market. Ms. Brown is the Chair of the Compensation Committee. No member of the Compensation Committee has been an employee or officer of the Company or any of its affiliates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objectives of the Corporation&#8217;s compensation arrangements are: (i)&#160;to attract and retain key personnel; (ii)&#160;to encourage commitment to the Corporation and its goals; (iii)&#160;to align executive interests with those of its shareholders; and (iv)&#160;to reward executives for performance in relation to overall corporate progress goals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key elements of the compensation program are the base salary, health benefits, and payments allocated to employees to be directed by them to their personal retirement accounts. Bonuses and the granting of Options (as defined herein) and Share Awards (as defined herein) are also part of the Corporation&#8217;s compensation program and are based on corporate performance. Part of corporate performance includes goals and objectives that are determined based on the strategic planning and budgeting process, which is conducted at least annually. The elements of the compensation plan are intended to reward performance, and the various elements are intended to provide a blend of short-term and long-term incentives to align the interests of management and the shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In arriving at its recommendations for compensation, the Compensation Committee considers the long-term interests of the Corporation as well as its current stage of development and the economic environment within which it operates. The market for biotechnology companies in the development phase is challenging. Based on these factors, the Compensation Committee recognized the need to strike a balance between compensation to retain employees and resources expended to maintain operations. In the past, the Compensation Committee has engaged specialist consultants to assist in benchmarking its </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">compensation practices and provide recommendations to the committee with respect to compensation for directors and senior management. The Compensation Committee had retained Radford, an Aon Hewitt Corporation, as a specialist consultant to assist with the benchmarking of officer and director compensation for 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following a review of the risks in the Corporation&#8217;s compensation policies and practices, the Compensation Committee found no risks that are reasonably likely to have a material adverse effect on the Corporation. The Compensation Committee&#8217;s role of approving the compensation policies and practices includes considering whether the compensation policies and practices could encourage senior management of the Company to take inappropriate or excessive risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Corporation&#8217;s corporate trading policy, insiders (including senior management and directors) are not permitted to hedge their position in Common Shares, Options, Share Awards, deferred share units, performance share units, debentures or other debt instruments by use of any financial instrument, which would include but is not limited to options, puts, calls, warrants or short sells, designed to benefit the holder from a change in the market value of the Common Shares of the Corporation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Compensation Committee's written mandate is located on the Company&#8217;s website at https://ir.oncolyticsbiotech.com/corporate-governance. </span></div><div style="text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation has formed an Audit Committee in accordance with Section 3(a)(58)(A) of the United States Securities Exchange Act of 1934, as amended ("Exchange Act"), consisting of four independent directors pursuant to the Rule 5605(a)(2) and Rule 5605(c)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act: Ms. Brown, Ms. Holtham, Mr. Kruimer and Mr. Pisano, none of whom are nor have been employees or officers of the Company or any of its affiliates.&#160;&#160;Ms. Holtham is presently the Chair of the Audit Committee.&#160;Each Audit Committee member is financially literate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee reviews and approves the scope of the annual audits of our financial statements, reviews our internal control over financial reporting, reviews and approves services performed by the independent auditors, reviews the findings and recommendations of the independent auditors and periodically reviews major accounting policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Audit Committee's written mandate is located on the Company&#8217;s website at https://ir.oncolyticsbiotech.com/corporate-governance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.78pt">Employees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the number of our employees at the end of each of the last three fiscal years by activity and geographic location.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By Function:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By Geographic Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States of America</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Share Ownership</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the share ownership and options held of our directors and officers as of February&#160;28, 2022. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common shares<br/>(#)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of&#160;&#160;<br/>ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise<br/>price<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Officers</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew C. Coffey</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/17/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/16/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/19/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,177&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/13/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/17/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/16/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/19/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas Heineman</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/3/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/14/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common shares<br/>(#)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of&#160;&#160;<br/>ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise<br/>price<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.24</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/12/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.84</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/28/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.73</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/14/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Brown</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/7/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/18/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard Kruimer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/2/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd Seizinger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/8/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL:</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,734,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Less than 1% ownership</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Based on 57,112,295 common shares issued and outstanding on February&#160;28, 2022. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Options granted to acquire common shares. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Ownership percentage assumes aggregate beneficial ownership of common shares, common shares acquirable upon exercise of options and fully diluted shares outstanding of 64,286,239.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the restricted share units held by our directors as of February&#160;28, 2022. </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs vested and undistributed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard Kruimer</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two share-based compensation plans: the Stock Option Plan and the Share Award Plan.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Corporation&#8217;s Amended and Restated Stock Option Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated effective as of May 4, 2017.  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation, with the approval of its Shareholders, has established the Stock Option Plan. The number of Common Shares reserved for issuance under the Stock Option Plan and all other security based compensation arrangements of the Corporation (including the Share Award Plan) in aggregate shall not exceed 10% of the total number of issued and outstanding Common Shares from time to time. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Stock Option Plan, the Board of Directors or the Compensation Committee may from time to time designate directors, officers, employees of, or consultants to, the Corporation or any subsidiary of the Corporation (such persons being &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eligible Persons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to whom Options may be granted and the number of Options to be granted to each. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options may be exercised at a price (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) which shall be fixed by the Board at the time the Option is granted. No Option can be granted with an Exercise Price at a discount to the market, which shall be the closing price of the Common Shares on the stock exchange upon which the Common Shares are listed on the first day preceding the date of grant on which at least one board lot of Common Shares traded on such exchange.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any Option shall be exercised or shall expire or terminate for any reason without having been exercised in full, any Common Shares to which such Option relates shall be available for the purposes of the granting of Options under the Stock Option Plan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Shares that may be acquired under an Option granted to a participant under the Stock Option Plan shall be determined by the Board as at the time the Option is granted, provided that the aggregate number of Shares reserved for issuance to any one participant under the Stock Option Plan or any other security based compensation arrangement of the Corporation, shall not exceed five percent (5%) of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without obtaining the approval of Shareholders in accordance with the rules of the TSX or the requirements of any other stock exchange on which the Common Shares are then listed, no Options shall be granted pursuant to the Stock Option Plan, if such grant together with grants pursuant to all other share compensation arrangements of the Corporation, could result, at any time, in:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a number of Common Shares issuable pursuant to Options granted to insiders exceeding ten percent (10%) of the number of outstanding Common Shares at any time;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the issuance within a one year period to insiders, of a number of Common Shares exceeding ten percent (10%) of the number of outstanding Common Shares; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the issuance to any one insider and such insider&#8217;s associates, within a one year period, of a number of Common Shares exceeding five percent (5%) of the number of outstanding Common Shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of Option grants to each non-employee director shall not exceed $150,000 annually for any individual non-employee director (other than initial Option grants to new directors).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options are generally granted for a term expiring on the tenth anniversary of the date of grant and typically either vest immediately or as to one-third on each of the first, second and third anniversary following the date of grant, as determined by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Board at the time the Option is granted. Options are not transferable or assignable except to the person or persons to whom the participant&#8217;s rights pass by the participant&#8217;s will or applicable law following the death or permanent disability of a participant.  The Stock Option Plan provides that if the expiration date of an Option occurs during a &#8220;blackout period&#8221; or within five (5) business days after a blackout period, such expiration date shall be deemed to be extended to the date which is the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) business day after the last day of the applicable blackout period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any written agreement between the Corporation and a participant providing otherwise, if any participant shall cease to be an Eligible Person for any reason other than the termination for cause or the death or permanent disability of the participant, such participant&#8217;s Option will terminate immediately as to the then unvested portion thereof and at 5:00 p.m. (Calgary time) on the earlier of the date of the expiration of the applicable option period and the ninetieth (90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) day after the date such participant ceases to be an Eligible Person as to the then vested portion of the Option. If a participant ceases to be an Eligible Person as a result of the termination of such participant for cause, effective as of the date notice is given to the participant of such termination, all outstanding Options shall be terminated and all rights to receive Common Shares thereunder shall be forfeited by such participant, and the participant shall not be entitled to receive any Common Shares or other compensation in lieu thereof.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any written agreement between the Corporation and a participant providing otherwise, if in the event of the death or permanent disability of a participant, any Option previously granted to such participant shall be exercisable until the end of the applicable option period or until the expiration of 12 months after the date of death or permanent disability of such participant, whichever is earlier, and then only: (i) by the person or persons to whom the participant&#8217;s rights under the Option shall pass by the participant&#8217;s will or applicable law; (ii) to the extent that he or she was entitled to exercise the Option as at the date of the participant&#8217;s death or permanent disability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Board may, at its sole discretion, extend the period during which any Options may be exercised, in the case of Options held by non-employee directors, by not more than one year, and in the case of Options held by other persons, by not more than three years, but in no case longer than the normal expiry of the Options.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a change of control of the Corporation (as such term is defined in the Stock Option Plan), all Options which have not otherwise vested in accordance with their terms shall immediately vest and be exercisable, notwithstanding the other terms of the Options or the Stock Option Plan for a period of time ending on the earlier of the expiry time of the Option and the ninetieth (90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) day following the change of control.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any required approval of the TSX and any other stock exchange on which the Common Shares are then listed, the Stock Option Plan and any Options granted thereunder may be amended, modified or terminated by the Board without approval of any participant or Shareholder (provided that no such amendment may be made that will materially prejudice the rights of any participant under any Option previously granted to the participant without consent by such participant). Such changes may include, without limitation: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;amending, modifying or terminating the Stock Option Plan with respect to all Common Shares in respect of Options which have not yet been granted thereunder; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;making any amendment of a &#8220;housekeeping nature&#8221;; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;changing the provisions relating to the manner of exercise of Options; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;accelerating vesting or extending the expiration date of any Option (provided that such Option is not held by an insider), provided that the period during which an Option is exercisable does not exceed 10 years from the date the Option is granted;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full deduction of the number of underlying Common Shares from the Stock Option Plan reserve; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;making any addition to, deletion from or alteration of the provisions of the Stock Option Plan or any Option that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of the Stock Option Plan.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Shareholder approval is required for any change to the Stock Option Plan or Options granted under it which:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;increases the number of Common Shares reserved for issuance under the Stock Option Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;extends eligibility to participate in the Stock Option Plan to persons other than Eligible Persons;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;permits Options to be transferred, other than for normal estate settlement purposes or to an RRSP or similar plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;permits awards other than Options to be made under the Stock Option Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;extends the term of an Option beyond the maximum expiry date set out in the Stock Option Plan (except where an expiry date would have fallen within a blackout period;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;reduces the exercise price of an Option, except for the purpose of maintaining Option value in connection with a conversion, change, reclassification, redivision, redesignation, subdivision or consolidation of shares or a reorganization, amalgamation, consolidation, merger, takeover bid or similar transaction involving the Corporation (for this purpose, cancellation or termination of an Option prior to its expiry date for the purpose of reissuing Options to the same Option-holder with a lower exercise price will be considered an amendment to reduce the exercise price of an Option);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;changes the insider participation limitation at any time under the Stock Option Plan; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;amends the amending provision of the Stock Option Plan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Award Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Corporation&#8217;s Amended and Restated Incentive Share Award Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Award Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated effective as of May 4, 2017.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation, with the approval of its Shareholders, has established the Share Award Plan. Under the Share Award Plan, the Board may, at such times and in such amounts as the Board may deem advisable in its sole and absolute discretion, issue Performance Share Awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to eligible employees, including officers, and Restricted Share Awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with PSAs, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to Eligible Persons. The number of Common Shares reserved for issuance under the Share Award Plan and all other security based compensation arrangements of the Corporation (including the Stock Option Plan) in aggregate shall not exceed 10% of the total number of issued and outstanding Common Shares from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to earlier vesting in accordance with the terms of the Share Award Plan and unless otherwise determined by the Board, Share Awards granted under the Share Award Plan vest on the third anniversary date of the date of grant. Upon vesting, each RSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) and each PSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) multiplied by the percentage (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vesting Percentage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of outstanding PSAs that will vest based upon the relative achievement of any performance-related measures or criteria as determined by the Board in its sole discretion, which may include the Corporation&#8217;s performance compared to identified operational or financial targets and the Corporation&#8217;s shareholder return.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate number of Common Shares issuable at any time to insiders, under all security based compensation arrangements of the Corporation shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis). The aggregate number of Common Shares issued pursuant to all security based compensation arrangements of the Corporation, within a one year period, shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis). The Share Award Plan further provides that the aggregate number of Common Shares reserved for issuance to any one participant under all security based compensation arrangements of the Corporation, shall not exceed 5% of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of Common Shares that may be reserved for issuance to non-employee directors pursuant to RSAs under the Share Award Plan is 1% of the Common Shares outstanding at the time of the grant (on a non-diluted basis), less the aggregate number of Common Shares reserved for issuance to such non-employee director under any other security based compensation arrangement, and the total annual grant of RSAs to any one non-employee director cannot exceed a grant value of $150,000 (less the amount awarded to such non-employee director).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Award Plan provides that if the issue date of any Share Award occurs during a blackout period, then the issue date for such Share Award shall not occur until the date which is the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) business day after the last day of the such blackout period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise determined by the Board in its sole discretion, upon a Change of Control (as such term is defined in the Share Award Plan), all unvested Share Awards shall become automatically vested (in the case of PSAs, with a deemed Vesting Percentage of 100). Common Shares issuable in respect of Share Awards shall be, and shall be deemed to be, issued to participants effective immediately prior to the completion of the transaction which would result in the Change of Control unless issued prior thereto in accordance with the Share Award Plan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise determined by the Board or unless otherwise expressly set forth in a Share Award agreement pertaining to a particular Share Award or any written employment or other agreement governing a participant&#8217;s role as an Eligible Person if a participant ceases to be an Eligible Person as a result of the termination of such participant for cause or if a participant voluntarily ceases to be an Eligible Person for any reason other than as a result of the death, permanent disability or retirement of the participant, all outstanding Share Awards Agreements under which Share Awards have been granted to such participant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall be terminated. Upon the death, permanent disability or retirement of a participant (other than the early retirement of an eligible employees), all outstanding Share Awards shall immediately vest. If a participant ceases to be an Eligible Person other than in the circumstances provided above, all Share Awards awarded to such participant under any outstanding Share Awards shall fully vest effective as of the date of cessation of employment (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cessation Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), unless otherwise determined by the Board, and the participant shall be entitled to receive the number of Common Shares equal to the number of Share Awards granted multiplied by a fraction (A) the numerator of which is the number of days from the date of grant thereof to the Cessation Date; and (B) the denominator of which is the total number of days during which such Share Award were scheduled to vest upon grant. In such circumstances, the Vesting Percentage in respect of PSAs shall be determined as of the Cessation Date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Award Plan and any Share Awards granted thereunder may be amended, modified or terminated by the Board without approval of Shareholders, subject to any required approval of the TSX. Such changes may include, without limitation: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;amending, modifying or terminating the Share Award Plan with respect to all Common Shares in respect of Share Awards which have not yet been granted thereunder; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;making any amendment of a &#8220;housekeeping nature&#8221;; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;making any addition to, deletion from or alteration of the provisions of this Plan or any Share Award that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other stock exchange on which the Common Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Share Award Plan or a Share Award may not be amended without shareholder approval to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;increase the number of Common Shares issuable pursuant to outstanding Share Awards at any time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;change the insider participation limit under the Share Award Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;expand the categories of individuals who are &#8220;eligible employees&#8221; who are eligible to participate in the Share Award Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;extend the term of any Share Award beyond the term of such awards provided for under the terms and conditions of the Share Award Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;permit the transfer or assignment of Share Awards, except to permit a transfer to a family member, an entity controlled by the holder of the Share Awards or a family member, a charity or for estate planning or estate settlement purposes; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;change the amendment provisions of the Share Award Plan.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, no amendment to the Share Award Plan or any Share Awards granted pursuant thereto may be made without the consent of an Share Award Plan participant if it adversely alters or impairs the rights of such participant in respect of any Share Award previously granted to such participant under the Share Award Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Major Shareholders</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not directly or indirectly owned or controlled by another corporation(s) or by any foreign government. To the knowledge of our directors and senior officers, as at March&#160;3, 2022, we are not aware of any shareholder who beneficially owns, directly or indirectly, or exercises control or direction over, our common shares carrying more than 5% of the voting rights.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Held in the United States </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates, as of February&#160;25, 2022, the total number of common shares issued and outstanding, the approximate total number of holders of record of common shares, the number of holders of record of common shares with U.S.&#160;addresses, the portion of the outstanding common shares held by U.S.&#160;holders of record, and the percentage of common shares held by U.S.&#160;holders of record. This table does not indicate beneficial ownership of common&#160;shares.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total number of holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total number of common shares issued and outstanding</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of U.S.&#160;holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of common shares held by U.S.&#160;holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of common shares held by U.S.&#160;holders of record&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,112,295</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,811,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change of Control</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;3, 2022, there were no arrangements known to the Company which may, at a subsequent date, result in a change of control of the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Control by Others</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the best of the Company&#8217;s knowledge, the Company is not directly or indirectly owned or controlled by another corporation, any foreign government, or any other natural or legal person, severally or jointly.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Related Party Transactions</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment contracts with each of our senior management members (see Item 6).&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of the fiscal year ended December 31, 2021 up to March&#160;3, 2022, we did not enter into any other related party transactions and we do not have any loans outstanding with any officer, director or major shareholder.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Interests of Experts and Counsel</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Consolidated Statements and Other Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements filed as part of this annual report are filed under Item 18.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The directors and the management of the Company do not know of any material, active or pending, legal proceedings against them; nor is the Company involved as a plaintiff in any material proceeding or pending litigation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The directors and the management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not paid any dividends on its common shares.&#160;The Company may pay dividends on its common shares in the future if it generates profits.&#160;Any decision to pay dividends on common shares in the future will be made by the board of directors on the basis of the earnings, financial requirements and other conditions existing at such time.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Significant Changes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No significant changes have occurred since the date of our annual financial statements included in this annual report on Form 20-F.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. THE OFFER AND LISTING</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable except for Item 9.A.4 and Item 9.C.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Shares, no par value, are traded/quoted on the Nasdaq and the TSX under the symbols &#8220;ONCY" and &#8220;ONC&#8221;, respectively.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160; ADDITIONAL INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Share Capital</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Memorandum and Articles of Association</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Articles of Continuance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are governed by our amended articles of incorporation (the "Articles") under the Business Corporations Act of Alberta (the &#8220;Act&#8221;) and by our by-laws (the&#160;"By-laws"). Our Alberta corporate access number is 207797382. Our Articles provide that there are no restrictions on the business we may carry on or on the powers we may exercise. Companies incorporated under the Act are not required to include specific objects or purposes in their articles or by-laws.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, including in respect of voting on any resolution to approve a contract that relates primarily to the director's remuneration, directors may not vote on resolutions to approve a material contract or material transaction if the director is a party to such contract or transaction. The directors are entitled to remuneration as shall from time to time be determined by the Board of Directors with no requirement for a quorum of independent directors. The directors have the ability under the Act to exercise our borrowing power, without authorization of the shareholders. The Act permits shareholders to restrict this authority through a company's articles or by-laws (or through a unanimous shareholder agreement), but no such restrictions are in place for us. Our Articles and By-laws do not require directors to hold shares for qualification.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights, Preferences and Dividends Attaching to Shares</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common shares have the right to receive dividends if and when declared. Each holder of common shares, as of the record date prior to a meeting, is entitled to attend and to cast one vote for each common share held as of such record date at such annual and/or special meeting, including with respect to the election or re-election of directors. Subject to the provisions of our By-laws, all directors may, if still qualified to serve as directors, stand for re-election. The numbers of our Board of Directors are not replaced at staggered intervals but are elected annually.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a distribution of assets on a winding-up, dissolution or other return of capital (subject to certain exceptions) the holders of common shares shall have a right to receive their </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pro&#160;rata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of such distribution. There are no sinking fund or redemption provisions in respect of the common shares. Our shareholders have no liability to further capital calls as all shares issued and outstanding are fully paid and non-assessable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other classes of shares are currently permitted to be issued.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Action Necessary to Change the Rights of Shareholders</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights attaching to the different classes of shares may be varied by special resolution passed at a meeting of that class's shareholders.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual and Special Meetings of Shareholders</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Act and our By-laws, we are required to mail a Notice of Meeting and Management Information Circular to registered shareholders not less than 21&#160;days and not more than 50 days prior to the date of the meeting. Such materials must be filed concurrently with the applicable securities regulatory authorities in Canada and the U.S..&#160;Subject to certain provisions of the By-laws, a quorum of two or more shareholders in person or represented by proxy holding or representing by proxy not less than five (5%) percent of the total number of issued and outstanding shares enjoying voting rights at such meeting is required to properly constitute a meeting of shareholders.&#160;&#160;Shareholders and their duly appointed proxies and corporate representatives are entitled to be admitted to our annual and/or special meetings.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations on the Rights to Own Shares</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Articles do not contain any limitations on the rights to own shares. Except as described below, there are currently no limitations imposed by Canadian federal or provincial laws on the rights of non-resident or foreign owners of Canadian </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities to hold or vote the securities held. There are also no such limitations imposed by the Articles and By-laws with respect to our common&#160;shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Share Ownership</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under applicable securities regulation in Canada, a person or company who beneficially owns, directly or indirectly, voting securities of an issuer or who exercises control or direction over voting securities of an issuer or a combination of both, carrying more than 10% of the voting rights attached to all the issuer's outstanding voting securities is an insider and must, within 10&#160;days of becoming an insider, file&#160;a report in the required form effective the date on which the person became an insider. The report must disclose any direct or indirect beneficial ownership of, or control or direction over, securities of the reporting issuer. Additionally, securities regulation in Canada provides for the filing of a report by an insider of a reporting issuer whose holdings change, which report must be filed within 5&#160;days from the day on which the change takes place.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules in the U.S. governing the ownership threshold above which shareholder ownership must be disclosed are more stringent than those discussed above. Section 13 of the Exchange Act imposes reporting requirements on persons who acquire beneficial ownership (as such term is defined in Rule 13d-3 under the Exchange Act) of more than 5% of a class of an equity security registered under Section 12 of the Exchange Act.&#160;In general, such persons must file, within 10&#160;days after such acquisition, a report of beneficial ownership with the SEC containing the information prescribed by the regulations under Section&#160;13 of the Exchange Act. This information is also required to be sent to the issuer of the securities and to each exchange where the securities are&#160;traded.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Provisions of Articles and By-laws</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no provisions in the Articles or By-laws:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delaying or prohibiting a change in control of our company that operate only with respect to a merger, acquisition or corporate restructuring;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discriminating against any existing or prospective holder of shares as a result of such shareholder owning a substantial number of&#160;shares;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring disclosure of share ownership; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governing changes in capital, where such provisions are more stringent than those required by&#160;law.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Material Contracts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have employment contracts with each of our officers as summarized in Item 6B. Other than these employment contracts, we have not entered into any other contract other than in the ordinary course of business over the last two years.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Exchange Controls </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada presently has no system of exchange controls. There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of our securities, except as discussed below in Section E, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restrictions on Share Ownership by Non-Canadians</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no limitations under the laws of Canada or in our organizing documents on the right of foreigners to hold or vote securities of our company, except that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Canada Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may require review and approval by the Minister of Industry (Canada) of certain acquisitions of &#8220;control&#8221; of our company by a &#8220;non-Canadian&#8221;. The threshold for acquisitions of control is generally defined as being one-third or more of the voting shares of the company. &#8220;Non-Canadian&#8221; generally means an individual who is not a Canadian citizen, or a corporation, partnership, trust or joint venture that is ultimately controlled by non-Canadians.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Taxation  </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is, as of the date of this annual report, a summary of the principal Canadian federal income tax considerations under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Canada) (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the regulations thereunder (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) generally applicable to an investor who acquires as beneficial owner Common Shares and who, for the purposes of the Tax Act and the Regulations and at all relevant times deals at arm&#8217;s length with the Corporation and the Agent, is not affiliated with the Corporation or the Agent, is not exempt from tax under Part I of the Tax Act, and who acquires and holds the Common Shares, as capital property (a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Generally, the Common Shares will be considered to be capital property to a Holder provided that the Holder does not hold the Common Shares in the course of carrying on a business as part of an adventure or concern in the nature of trade.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is generally applicable to a Holder who, at all relevant times, for purposes of the Tax Act: (i) is not, and is not deemed to be, resident in Canada for the purposes of the Tax Act or any applicable income tax treaty or convention; and (ii) does not and will not use or hold, and is not and will not be deemed to hold, the Common Shares in connection with carrying on a business in Canada (a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules, which are not discussed in this summary, may apply to certain holders that are insurers carrying on an insurance business in Canada and elsewhere. Such Holders should consult their own tax advisors with respect to an investment in Common Shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is based upon the current provisions of the Tax Act and the Regulations in force as of the date of this annual report and counsel&#8217;s understanding of the current administrative policies and assessing practices of the Canada Revenue Agency (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) published in writing by the CRA prior to the date of this annual report. This summary takes into account all specific proposals to amend the Tax Act and the Regulations publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date of this annual report (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Proposals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and assumes that the Tax Proposals will be enacted in the form proposed, although no assurance can be given that the Tax Proposals will be enacted in their current form or at all. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the Tax Proposals, this summary does not otherwise take into account or anticipate any changes in law, whether by legislative, governmental, administrative or judicial decision or action, nor does it take into account or consider any provincial, territorial or foreign income tax considerations, which considerations may differ significantly from the Canadian federal income tax considerations discussed in this summary. This summary also does not take into account any change in the administrative policies or assessing practices of the CRA.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">This summary is of a general nature only, is not exhaustive of all possible Canadian federal income tax considerations and is not intended to be, nor should it be construed to be, legal or tax advice to any particular Holder. Holders should consult their own tax advisors with respect to their particular circumstances.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of the Common Shares (including dividends, adjusted cost base and proceeds of disposition) must, to the extent such amounts are not in Canadian dollars, be converted into Canadian dollars based on an exchange rate determined in accordance with the Tax Act.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid or credited or deemed to be paid or credited on the Common Shares to a Non-Resident Holder by the Corporation are subject to Canadian withholding tax at the rate of 25% on the gross amount of the dividend, unless such rate is reduced by the terms of an applicable tax treaty. For example, under the Canada-United States Tax Convention (1980), as amended (the &#8220;Treaty&#8221;), the rate of withholding tax on dividends paid or credited to a  Non-Resident Holder who is a beneficial owner of dividends and who is a resident of the United States for purposes of the Treaty and who is entitled to the benefits of the Treaty  is generally limited to 15% of the gross amount of the dividend. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holders are urged to consult their own tax advisors to determine their entitlement to relief under an applicable income tax treaty.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dispositions of Common Shares</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a disposition (or a deemed disposition) of a Common Share (other than to the Corporation unless purchased by the Corporation in the open market in the manner in which shares are normally purchased by any member of the public in the open market), a Non-Resident Holder generally will realize a capital gain (or a capital loss) equal to the amount by which the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds of disposition of such Common Shares, net of any reasonable costs of disposition, are greater (or are less) than the adjusted cost base of such Common Share to the Non-Resident Holder.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Non-Resident Holder generally will not be subject to tax under the Tax Act in respect of a capital gain realized on the disposition or deemed disposition of a Common Share, unless the Common Share constitutes &#8220;taxable Canadian property&#8221; and is not &#8220;treaty-protected property&#8221; (each as defined under the Tax Act) of the Non-Resident Holder at the time of disposition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provided the Common Shares are listed on a &#8220;designated stock exchange&#8221;, as defined in the Tax Act (which currently includes the NASDAQ and TSX), at the time of disposition, the Common Shares generally will not constitute taxable Canadian property of a Non-Resident Holder at that time, unless at any time during the 60 month period immediately preceding the disposition the following two conditions are met concurrently: (i) one or any combination of (a) the Non-Resident Holder, (b) persons with whom the Non-Resident Holder did not deal at arm&#8217;s length, and (c) partnerships in which the Non-Resident Holder or a person with whom the Non-Resident Holder did not deal at arm&#8217;s length held a membership interest directly or indirectly through one or more partnerships, owned 25% or more of the issued shares of any class or series of shares of the Corporation; and (ii) more than 50% of the fair market value of such shares was derived directly or indirectly from one or any combination of (a) real or immovable property situated in Canada, (b) &#8220;Canadian resource properties&#8221; (as defined in the Tax Act), (c) &#8220;timber resource properties&#8221; (as defined in the Tax Act) or (d) an option in respect of, an interest in, or for civil law a right in any of the foregoing property, whether or not such property exists. Notwithstanding the foregoing, a Common Share may otherwise be deemed to be taxable Canadian property to a Non-Resident Holder for purposes of the Tax Act.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holders whose Common Shares may be taxable Canadian property should consult their own tax advisors.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a general summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of Common Shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, without limitation, specific tax consequences to a U.S. Holder under an applicable income tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. This summary does not address the U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Common Shares. In addition, except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. Each prospective U.S. Holder should consult its own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the &#8220;IRS&#8221;) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.  This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the conclusions described in this summary.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Scope of this Summary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Authorities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This summary is based on the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the &#8220;Canada-U.S. Tax Convention&#8221;), and U.S. court decisions that are applicable, and, in each case, as in effect and available, as of the date of this document. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied retroactively. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">U.S. Holders</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For purposes of this summary, the term &#8220;U.S. Holder&#8221; means a beneficial owner of Common Shares that is for U.S. federal income tax purposes:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">an individual who is a citizen or resident of the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof or the District of Columbia;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a trust that (1) is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders that: (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (d) have a &#8220;functional currency&#8221; other than the U.S. dollar; (e) own Common Shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position; (f) acquire Common Shares in connection with the exercise of employee stock options or otherwise as compensation for services; (g) hold Common Shares other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); (h) are required to accelerate the recognition of any item of gross income with respect to Common Shares as a result of such income being recognized on an applicable financial statement; or (i) own, have owned or will own (directly, indirectly, or by attribution) 10% or more of the total combined voting power or value of the outstanding shares of the Corporation. This summary also does not address the U.S. federal income tax considerations applicable to U.S. Holders who are: (a) U.S. expatriates or former long-term residents of the U.S.; (b) persons that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the Tax Act; (c) persons that use or hold, will use or hold, or that are or will be deemed to use or hold Common Shares in connection with carrying on a business in Canada; (d) persons whose Common Shares constitute &#8220;taxable Canadian property&#8221; under the Tax Act; or (e) persons that have a permanent establishment in Canada for the purposes of the Canada-U.S. Tax Convention. U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders described immediately above, should consult their own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an entity or arrangement that is classified as a partnership (or other &#8220;pass-through&#8221; entity) for U.S. federal income tax purposes holds Common Shares, the U.S. federal income tax consequences to such entity or arrangement and the partners (or other owners or participants) of such entity or arrangement generally will depend on the activities of the entity or arrangement and the status of such partners (or owners or participants). This summary does not address the tax consequences to any such partner (or owner or participants). Partners (or other owners or participants) of entities or arrangements that are classified as partnerships or as &#8220;pass-through&#8221; entities for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership, and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Passive Foreign Investment Company Rules</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">PFIC Status of the Corporation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Corporation were to constitute a &#8220;passive foreign investment company&#8221; under the meaning of Section 1297 of the Code (a &#8220;PFIC&#8221;, as defined below) for any year during a U.S. Holder&#8217;s holding period, then certain potentially adverse rules would affect the U.S. federal income tax consequences to a U.S. Holder as a result of the acquisition, ownership and disposition of Common Shares. The Corporation believes that it was classified as a PFIC during the tax year ended December 31, 2019, and based on current business plans and financial expectations, the Corporation expects that it will be a PFIC for the current tax year and may be a PFIC in future tax years. No opinion of legal counsel or ruling from the IRS concerning the status of the Corporation as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any determination made by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the Corporation (or any subsidiary of the Corporation) concerning its PFIC status. Each U.S. Holder should consult its own tax advisors regarding the PFIC status of the Corporation and each subsidiary of the Corporation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In any year in which the Corporation is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621 annually.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Corporation generally will be a PFIC if, for a tax year, (a) 75% or more of the gross income of the Corporation is passive income (the &#8220;PFIC income test&#8221;) or (b) 50% or more of the value of the Corporation&#8217;s assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the &#8220;PFIC asset test&#8221;). &#8220;Gross income&#8221; generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and &#8220;passive income&#8221; generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For purposes of the PFIC income test and PFIC asset test described above, if the Corporation owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Corporation will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes of the PFIC income test and PFIC asset test described above, and assuming certain other requirements are met, &#8220;passive income&#8221; does not include certain interest, dividends, rents, or royalties that are received or accrued by the Corporation from certain &#8220;related persons&#8221; (as defined in Section 954(d)(3) of the Code) also organized in Canada, to the extent such items are properly allocable to the income of such related person that is not passive income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under certain attribution rules, if the Corporation is a PFIC, U.S. Holders will generally be deemed to own their proportionate share of the Corporation&#8217;s direct or indirect equity interest in any company that is also a PFIC (a &#8216;&#8216;Subsidiary PFIC&#8217;&#8217;), and will generally be subject to U.S. federal income tax on their proportionate share of (a) any &#8220;excess distributions,&#8221; as described below, on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC by the Corporation or another Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC. In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition of Common Shares. Accordingly, U.S. Holders should be aware that they could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of Common Shares are made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Default PFIC Rules Under Section 1291 of the Code</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Corporation is a PFIC for any tax year during which a U.S. Holder owns Common Shares, the U.S. federal income tax consequences to such U.S. Holder of the acquisition, ownership, and disposition of Common Shares will depend on whether and when such U.S. Holder makes an election to treat the Corporation and each Subsidiary PFIC, if any, as a &#8220;qualified electing fund&#8221; or &#8220;QEF&#8221; under Section 1295 of the Code (a &#8220;QEF Election&#8221;) or makes a mark-to-market election under Section 1296 of the Code (a &#8220;Mark-to-Market Election&#8221;). A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a &#8220;Non-Electing U.S. Holder.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code (described below) with respect to (a) any gain recognized on the sale or other taxable disposition of Common Shares and (b) any &#8220;excess distribution&#8221; received on the Common Shares. A distribution generally will be an &#8220;excess distribution&#8221; to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder&#8217;s holding period for the Common Shares, if shorter).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of Common Shares (including an indirect disposition of the stock of any Subsidiary PFIC), and any &#8220;excess distribution&#8221; received on Common Shares or with respect to the stock of a Subsidiary PFIC, must be ratably allocated to each day in a Non-Electing U.S. Holder&#8217;s holding period for the respective Common Shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferred rates). The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as &#8220;personal interest,&#8221; which is not deductible.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Corporation is a PFIC for any tax year during which a Non-Electing U.S. Holder holds Common Shares, the Corporation will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Corporation </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ceases to be a PFIC in one or more subsequent tax years. A Non-Electing U.S. Holder may terminate this deemed PFIC status by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if such Common Shares were sold on the last day of the last tax year for which the Corporation was a PFIC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">QEF Election</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that makes a timely and effective QEF Election for the first tax year in which the holding period of its Common Shares begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its Common Shares. A U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder&#8217;s pro rata share of (a) the net capital gain of the Corporation, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the ordinary earnings of the Corporation, which will be taxed as ordinary income to such U.S. Holder. Generally, &#8220;net capital gain&#8221; is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and &#8220;ordinary earnings&#8221; are the excess of (a) &#8220;earnings and profits&#8221; over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Corporation is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Corporation. However, for any tax year in which the Corporation is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as &#8220;personal interest,&#8221; which is not deductible.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that makes a timely and effective QEF Election with respect to the Corporation generally (a) may receive a tax-free distribution from the Corporation to the extent that such distribution represents &#8220;earnings and profits&#8221; of the Corporation that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as &#8220;timely&#8221; if such QEF Election is made for the first year in the U.S. Holder&#8217;s holding period for the Common Shares in which the Corporation was a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year. If a U.S. Holder does not make a timely and effective QEF Election for the first year in the U.S. Holder&#8217;s holding period for the Common Shares, the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder meets certain requirements and makes a &#8220;purging&#8221; election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such Common Shares were sold for their fair market value on the day the QEF Election is effective. If a U.S. Holder makes a QEF Election but does not make a &#8220;purging&#8221; election to recognize gain as discussed in the preceding sentence, then such U.S. Holder shall be subject to the QEF Election rules and shall continue to be subject to tax under the rules of Section 1291 discussed above with respect to its Common Shares. If a U.S. Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the Subsidiary PFIC for the QEF rules to apply to both PFICs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Corporation ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Corporation is not a PFIC. Accordingly, if the Corporation becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Corporation qualifies as a PFIC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Corporation: (a) will make available to U.S. Holders, upon their written request, information as to its status as a PFIC and the PFIC status of any subsidiary in which the Corporation owns more than 50% of such subsidiary&#8217;s total aggregate voting power and (b) for each year in which the Corporation is a PFIC, provide to a U.S. Holder, upon written request, such information and documentation that a U.S. Holder making a QEF Election with respect to the Corporation and such more than 50% owned subsidiary which constitutes a PFIC is reasonably required to obtain for U.S. federal income tax purposes. The Corporation may elect to provide such information on its website. With respect to any Subsidiary PFIC in which the Corporation owns 50% or less of the aggregate voting power, upon the written request of a U.S. Holder acquiring Common Shares, the Corporation will request that such Subsidiary PFIC provide such U.S. Holder with the information that such U.S. Holder requires to report under the QEF rules; provided, however, the Corporation can provide no assurances that such Subsidiary PFIC will provide such information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed United States federal income tax return. However, if the Corporation does not provide the required information with regard to the Corporation or any of its Subsidiary PFICs, U.S. Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Mark-to-Market Election</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder may make a Mark-to-Market Election only if the Common Shares are marketable stock. The Common Shares generally will be &#8220;marketable stock&#8221; if the Common Shares are regularly traded on (a) a national securities exchange that is registered with the Securities and Exchange Commission, (b) the national market system established pursuant to section 11A of the U.S. Exchange Act, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements, and meets other requirements, and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange effectively promote active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such stock generally will be &#8220;regularly traded&#8221; for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Provided that the Common Shares are &#8220;regularly traded&#8221; as described in the preceding sentence, the Common Shares are expected to be marketable stock. However, each U.S. Holder should consult its own tax advisor in this matter. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that makes a Mark-to-Market Election with respect to its Common Shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such Common Shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder&#8217;s holding period for the Common Shares for which the Corporation is a PFIC and such U.S. Holder has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Corporation is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the Common Shares, as of the close of such tax year over (b) such U.S. Holder&#8217;s adjusted tax basis in such Common Shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder&#8217;s adjusted tax basis in the Common Shares, over (b) the fair market value of such Common Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of Common Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years). Losses that exceed this limitation are subject to the rules generally applicable to losses provided in the Code and Treasury Regulations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder makes a Mark-to-Market Election by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return. A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the Common Shares cease to be &#8220;marketable stock&#8221; or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a Mark-to-Market Election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the Common Shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to avoid the application of the default rules of Section 1291 of the Code described above with respect to deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC to its shareholder.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Other PFIC Rules</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of Common Shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations). However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which Common Shares are transferred.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain additional adverse rules may apply with respect to a U.S. Holder if the Corporation is a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example, under Section 1298(b)(6) of the Code, a U.S. Holder that uses Common Shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should consult with its own tax advisors regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The PFIC rules are complex, and each U.S. Holder should consult its own tax advisors regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Rules Applicable to the Ownership and Disposition of Common Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following discussion describes the general rules applicable to the ownership and disposition of the Common Shares but is subject in its entirety to the special rules described above under the heading &#8220;Passive Foreign Investment Company Rules.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Distributions on Common Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that receives a distribution, including a constructive distribution, with respect to a Common Share will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current and accumulated &#8220;earnings and profits&#8221; of the Corporation, as computed for U.S. federal income tax purposes. A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates if the Corporation is a PFIC for the tax year of such distribution or the preceding tax year. To the extent that a distribution exceeds the current and accumulated &#8220;earnings and profits&#8221; of the Corporation, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder&#8217;s tax basis in the Common Shares and thereafter as gain from the sale or exchange of such Common Shares. (See &#8220;Sale or Other Taxable Disposition of Common Shares&#8221; below). However, the Corporation may not maintain the calculations of its earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder may have to assume that any distribution by the Corporation with respect to the Common Shares will constitute ordinary dividend income. Dividends received on Common Shares by corporate U.S. Holders generally will not be eligible for the &#8220;dividends received deduction.&#8221; Subject to applicable limitations and provided the Corporation is eligible for the benefits of the Canada-U.S. Tax Convention or the Common Shares are readily tradable on a United States securities market, dividends paid by the Corporation to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including that the Corporation not be classified as a PFIC in the tax year of distribution or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding the application of such rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Sale or Other Taxable Disposition of Common Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the sale or other taxable disposition of Common Shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the U.S. dollar value of cash received plus the fair market value of any property received and such U.S. Holder&#8217;s tax basis in such Common Shares sold or otherwise disposed of. A U.S. Holder&#8217;s tax basis in Common Shares generally will be such holder&#8217;s U.S. dollar cost for such Common Shares. Gain or loss recognized on such sale or other disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the Common Shares have been held for more than one year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Preferential tax rates currently apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant limitations under the Code.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Additional Considerations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Receipt of Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amount of any distribution paid to a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of Common Shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time). A U.S. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holder will have a basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method of tax accounting. Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Foreign Tax Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to the PFIC rules discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Common Shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax. Generally, a credit will reduce a U.S. Holder&#8217;s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder&#8217;s income that is subject to U.S. federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year. The foreign tax credit rules are complex and involve the application of rules that depend on a U.S. Holder&#8217;s particular circumstances. Accordingly, each U.S. Holder should consult its own U.S. tax advisors regarding the foreign tax credit rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Backup Withholding and Information Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under U.S. federal income tax law, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold certain specified foreign financial assets in excess of certain thresholds. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity. U.S. Holders may be subject to these reporting requirements unless their Common Shares are held in an account at certain financial institutions. Penalties for failure to file certain of these information returns are substantial. U.S. Holders should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payments made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of, Common Shares will generally be subject to information reporting and backup withholding tax if a U.S. Holder (a) fails to furnish such U.S. Holder&#8217;s correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax. However, certain exempt persons generally are excluded from these information reporting and backup withholding rules. Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder. A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF COMMON SHARES. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Dividends and Paying Agents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Not Applicable.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Statements by Experts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Documents on Display</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the informational requirements of the Exchange Act and file reports and other information with the SEC. The SEC maintains a Website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at https://www.sec.gov. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to file reports and other information with the securities commissions in Canada. You are invited to read and copy any reports, statements or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval ("SEDAR") (https://www.sedar.com), the Canadian equivalent of the SEC's electronic document gathering and retrieval system.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We "incorporate by reference" information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this Form&#160;20-F and&#160;more recent information automatically updates and supersedes more dated information contained or incorporated by reference in this Form&#160;20-F.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide without charge to each person, including any beneficial owner, to whom a copy of this annual report has been delivered, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this annual report (not&#160;including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, Attention:&#160;Kirk Look.&#160;&#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.61pt">Subsidiary Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_49"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Please see Item 4 &#8211; &#8220;Information on the Company&#8221; and Note 17 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our audited consolidated financial statements beginning on page F-1 of this annual report on Form 20-F.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any long-term debt, nor do we currently utilize interest rate swap contracts to hedge against interest rate&#160;risk.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use financial instruments for trading purposes and are not parties to any leverage derivatives.&#160;We do not currently engage in hedging transactions. </span></div><div><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160; DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_55"></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_58"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160; &#160;DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_61"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160; MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A. - D. Material Modification to the Rights of Security Holders</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E. Use of Proceeds</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_64"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Evaluation of Disclosures and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the conclusion of our Chief Executive Officer and Chief Financial Officer that our Company's disclosure controls and procedures (as defined in Exchange Act rules 13a-15(e) and 15d-15(e)), based on their evaluation of these controls and procedures as of the end of the period covered by this annual report, are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with International Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with  IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, 2013 Framework, (COSO) in Internal Control-Integrated Framework.&#160;&#160;Based on this assessment, management believes that, as of December 31, 2021, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ernst &amp; Young LLP, the registered public accounting firm that audited the financial statements included in this annual report on Form 20-F, has issued an attestation report on management's assessment of the Company&#8217;s internal control over financial reporting.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Attestation Report of the Registered Public Accounting Firms</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Auditor Attestation Report is included in the Ernst &amp; Young LLP Independent Auditor's Report (PCAOB ID: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl82NC9mcmFnOjAxNjg5NDI5NDY4ZDQxNGZiNDM3ODQ0MTUyZWJhN2Y2L3RleHRyZWdpb246MDE2ODk0Mjk0NjhkNDE0ZmI0Mzc4NDQxNTJlYmE3ZjZfMTA5OTUxMTYzMTc3NQ_ead20a24-c7db-4a0b-b27f-c7542031f4f4">1263</ix:nonNumeric>), included in the Company's financial statements, beginning on page F-1 of this annual report on Form 20-F. </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Changes in Internal Controls over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal controls over financial reporting that occurred during the period that is covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.&#160;</span></div><div><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16 .&#160; [RESERVED]</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16A.&#160; AUDIT COMMITTEE FINANCIAL EXPERT</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has determined that each of the Audit Committee members, Angela Holtham, Wayne Pisano, Deborah Brown and Leonard Kruimer is an audit committee financial expert and each is independent pursuant to the Rule 5605(d)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act.</span></div><div><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_73"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16B.&#160; CODE OF ETHICS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has adopted a Code of Ethics for the Company that includes our Chief Executive Officer, Chief Financial Officer and Accounting Officer that applies to our Chief Executive Officer, Chief Financial Officer and Controller.&#160;A copy of this Code of Ethics may be found on the Company&#8217;s website at https://www.oncolyticsbiotech.com.&#160;&#160;Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, Attention:&#160;&#160;Kirk Look &#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no amendments to our Code of Ethics during the fiscal year ended December 31, 2021. We did not grant any waivers to the provisions of our Code of Ethics during the fiscal year ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_76"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16C.&#160; PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Fees and Services</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the financial years ended December 31, 2021 and 2020, Ernst &amp; Young LLP received the following fees:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br/>$</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit fees</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit-related fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Audit Fees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audit fees were for professional services rendered by Ernst &amp; Young, LLP for the audit of our annual financial statements and services provided in connection with statutory and regulatory filings or engagements, including review of interim financial statements, accounting consultations, assistance with prospectus filings and matters relating to the provision of a consent letter for various filings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Audit-Related Fees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audit-related fees were for assurance and related services reasonably related to the performance of the audit or review of the annual statements and are not reported under the heading Audit Fees above.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Tax Fees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax fees were for tax return preparations, scientific research and development return and other tax consultation fees.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">All Other Fees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other fees are for products and services other than those described under the headings Audit Fees, Audit-Related Fees and Tax Fees above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee pre-approves all audit services to be provided to us by our independent auditors. The Audit Committee&#8217;s policy regarding the pre-approval of non-audit services to be provided to us by our independent auditors is that all such services shall be pre-approved by the Audit Committee or by the Chair of the Audit Committee, who must report all such pre-approvals to the Audit Committee at their next meeting following the granting thereof. Non-audit services that are prohibited to be provided to us by our independent auditors may not be pre-approved. In addition, prior to the granting of any pre-approval, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audit Committee or the Chair, as the case may be, must be satisfied that the performance of the services in question will not compromise the independence of the independent auditors.</span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_82"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16E. PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16F.&#160; CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_88"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16G. CORPORATE GOVERNANCE</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NASDAQ CORPORATE GOVERNANCE</span></div><div style="margin-top:3.4pt;padding-left:4.5pt;padding-right:333pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common shares are quoted for trading on the Nasdaq Capital Market. Section 5615(a)(3) of the Nasdaq Marketplace Rules permits the Nasdaq to grant exemptions to a foreign private issuer for the provisions of the Rule 5600 series, Rule 5250 (d), and Rules 5210(c) and 5255 related to qualitative listing requirements. We are organized under the laws of the Province of Alberta and our common shares are listed for trading on The Toronto Stock Exchange. We comply with the laws of the Province of Alberta and rules and regulations of The Toronto Stock Exchange, including rules related to corporate governance practices. A description of the significant ways in which our governance practices differ from those followed by domestic companies pursuant to the Nasdaq Marketplace Rules is as follows:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shareholder Meeting Quorum Requirement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: The Nasdaq minimum quorum requirement for a shareholder meeting under Section 5620(c) of the Nasdaq Marketplace Rules is one-third of the outstanding shares of common stock. In addition, a company listed on Nasdaq is required to state our quorum requirement in our bylaws. Our quorum requirement is set forth in our corporate bylaws. A quorum for our shareholder meeting is two persons present and being, or representing by proxy, members holding not less than 5% of the issued shares entitled to be voted at such meeting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The foregoing is consistent with the laws, customs and practices in Canada and the rules of The Toronto Stock Exchange.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Board Diversity Matrix (as of February 25, 2022) </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country of Principal Executive Offices:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Private Issuer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosure Prohibited Under Home Country Law</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Number of Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Female</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Male</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Binary</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Did Not Disclose Gender</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I: Gender Identity</span></td><td colspan="12" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II: Demographic Background</span></td><td colspan="12" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underrepresented Individual in Home Country Jurisdiction</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LGBTQ+</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Did Not Disclose Demographic Background</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr></table></div><div><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_91"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16H.&#160; MINE SAFETY DISCLOSURE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_1839"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16I.&#160; DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_94"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_97"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 17. FINANCIAL STATEMENTS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 18.  &#8211; &#8220;Financial Statements&#8221;.</span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 18 FINANCIAL STATEMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements appear on pages F-1 through F-29.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 19. EXHIBITS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this annual report:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NUMBER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">DESCRIPTION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Constating Documents</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="articles.htm">Articles of Incorporation</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex12onc-2017byxlaws1636459.htm">By-laws</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Securities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex21exdescriptionofsecurit.htm">Description of Securities Registered Under Section 12 of the Exchange Act</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Material Contracts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex41august2013hagerman.htm">Employment Agreement, dated August 1, 2013 between Oncolytics Biotech Inc. and its Director, Manufacturing and Engineering, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex42hagermandec2015.htm">Amending Agreement, dated December 1, 2015 between Oncolytics Biotech Inc. and its Director, Manufacturing and Engineering, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/ex443deguttadauro.htm">Employment Agreement, dated June 29, 2017 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)#</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/ex444regionallicensingagre.htm">License, development, supply and distribution agreement with Adlai Nortye Biopharma Co., Ltd dated November 14, 2017 </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex47hagermanamendment2019.htm">Amending Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex48kirklook2019.htm">Executive Employment Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex49coffey2019.htm">Executive Employment Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex410guttadauroamendment20.htm">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex413hagermanamendment2020.htm">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex414lookamendment2020.htm">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex415coffeyamendment2020.htm">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex412employmentagreementth.htm">Employment Agreement, dated August 3, 2020 between Oncolytics Biotech (U.S.) Inc. and its Global Head of Clinical Development and Operations, Thomas C. Heineman </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex413mattcoffeyamendment-e.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex414kirklookamendment-emp.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex415allisonhagermanamendm.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex416andrewdeguttadauroame.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex417thomasheinemanamendme.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech (U.S.) Inc. and its Global Head of Clinical Development and Operations, Thomas C. Heineman </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex418mattcoffeyamendment3-.htm">Amending Agreement, dated January 1, 2022 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex419kirklookamendment3-em.htm">Amending Agreement, dated January 1, 2022 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex420allisonhagermanamendm.htm">Amending Agreement, dated January 1, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex420allisonhagermanamendm.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex420allisonhagermanamendm.htm"> between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex421andrewdeguttadauroame.htm">Amending Agreement, dated January 1, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex421andrewdeguttadauroame.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex421andrewdeguttadauroame.htm"> between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex422thomasheinemanamendme.htm">Amending Agreement, dated January 1, 2022 between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Thomas C. Heineman </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiaries</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex80subsidiaries2021.htm">List of subsidiaries</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certifications</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex121ceocertification2021.htm">Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex122cfocertification2021.htm">Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex131ceocertification2021.htm">Certificate of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex132cfocertification2021.htm">Certificate of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Exhibits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex151-2021mda.htm">The Registrant's Management's Discussion and Analysis for the Year Ended December 31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex151-2021mda.htm">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex152ey2021consent.htm">Consent of Ernst &amp; Young LLP</a></span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Schema.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Calculation Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Definition Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Label Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Presentation Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover page interactive data file (formatted as Inline XBRL and included in Exhibit 101)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">* - Denotes management contract or agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"># - Certain portions of this exhibit have been redacted pursuant to a confidential treatment request filed with the SEC on March 19, 2018</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Previously filed with the SEC on Form 20-F dated March 19, 2018, and incorporated by reference.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Previously filed with the SEC on Form 20-F dated March 6, 2020, and incorporated by reference.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Previously filed with the SEC on Form 20-F dated March 5, 2021, and incorporated by reference.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;3, 2022 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">/s/ Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">December&#160;31, 2021 and 2020</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENT OF MANAGEMENT&#8217;S RESPONSIBILITY</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for the preparation and presentation of the consolidated financial statements, Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;) and all other information in the annual report.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the accompanying consolidated financial statements have been properly prepared within reasonable limits of materiality and in accordance with the appropriately selected International Financial Reporting Standards as issued by the International Accounting Standards Board consistently applied and summarized in the consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include estimates that are necessary when transactions affecting the current accounting period cannot be finalized with certainty until after the balance sheet date.&#160;Based on careful judgments by management, such estimates have been properly reflected in the accompanying consolidated financial statements.&#160;The financial information presented elsewhere in the annual report has been reviewed to ensure consistency with that in the consolidated financial statements. The MD&amp;A also includes information regarding the impact of current transactions and events, sources of liquidity and capital resources and risks and uncertainty.&#160;Actual results in the future may differ materially from our present assessment of this information because future events and circumstances may not occur as expected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systems of internal controls, including organizational and procedural controls and internal controls over financial reporting, assessed as reasonable and appropriate in the circumstances, are designed and maintained by management to provide reasonable assurance that assets are safeguarded from loss or unauthorized use and to produce reliable records for preparation of financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTIvZnJhZzo2M2EzYjlmNDg0NDU0MzdjOTgxZTgzMGNlNWEzNzFhYy90ZXh0cmVnaW9uOjYzYTNiOWY0ODQ0NTQzN2M5ODFlODMwY2U1YTM3MWFjXzI3NDg3NzkwNzQyMjc_15d04121-f32c-4e71-8723-28ffcb0ae84d">Ernst &amp; Young LLP</ix:nonNumeric>, an independent firm of Charter Professional Accountants, has been engaged, as approved by a vote of the shareholders' at the Company's most recent Annual General Meeting, to audit and provide their independent audit opinions on the following: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the Company's consolidated financial statements as at and for the year ended December&#160;31, 2021; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the effectiveness of the Company's internal control over financial reporting as at December&#160;31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young have full and free access to our Board of Directors and its Committees to discuss audit, financial reporting and related matters.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is responsible for ensuring that management fulfills its responsibilities for financial reporting and internal control.&#160;The Board exercises this responsibility through the Audit Committee of the Board, which is comprised entirely of independent directors.&#160;This Committee meets with management and the external auditors to satisfy itself that management&#8217;s responsibilities are properly discharged and to review the consolidated financial statements and MD&amp;A before they are presented to the Board of Directors for approval. The consolidated financial statements have been approved by the Board on the recommendation of the Audit Committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;/s/&#160;&#160;Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following report is provided by management in respect of the company&#8217;s internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the U.S. Securities Exchange Act of 1934):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management is responsible for establishing and maintaining adequate internal control over the company&#8217;s financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management has used the Committee of Sponsoring Organizations of the Treadway Commission (COSO) framework (2013) in Internal Control - Integrated Framework to evaluate the effectiveness of the company&#8217;s internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management has assessed the effectiveness of the company&#8217;s internal control over financial reporting as at December&#160;31, 2021, and has concluded that such internal control over financial reporting was effective as of that date. Additionally, based on this assessment, management determined that there were no material weaknesses in internal control over financial reporting as at December&#160;31, 2021. Because of inherent limitations, systems of internal control over financial reporting may not prevent or detect misstatements and even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The effectiveness of the company&#8217;s internal control over financial reporting as at December&#160;31, 2021 has been audited by Ernst &amp; Young, independent auditor, as stated in their report which appears herein.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;/s/&#160;&#160;Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and Board of Directors of Oncolytics Biotech Inc. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated statements of financial position of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of loss and comprehensive loss, changes in equity (deficit) and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2021 and 2020, and its financial performance and cash flows for each of the three years in the period ended December 31, 2021, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;), and our report dated March 2, 2022 expressed an unqualified opinion thereon.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="oncyf-20211231_g3.jpg" alt="oncyf-20211231_g3.jpg" style="height:73px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.877%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="5" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 1999.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTUvZnJhZzo1M2I4NjZhMzliZWU0NThhOGM2OTdlY2RlZjNjYWUzZi90YWJsZTo4YWZlNmFjNzZlOGE0YmE4YjU0NTVlMjRkMTM4MmJjMi90YWJsZXJhbmdlOjhhZmU2YWM3NmU4YTRiYThiNTQ1NWUyNGQxMzgyYmMyXzMtMC0xLTEtMTkyNDc_c60c66c8-9ed3-4b0c-b4f9-916b55699d81">Calgary, Canada</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2, 2022</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Report of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and Board of Directors of Oncolytics Biotech Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Oncolytics Biotech Inc.&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, Oncolytics Biotech Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021 based on the COSO criteria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statements of financial position of Oncolytics Biotech Inc. as of December 31, 2021 and 2020, the related consolidated statements of loss and comprehensive loss, changes in equity (deficit) and cash flows for each of the three years in the period ended December 31, 2021, and the related notes, and our report dated March 2, 2022 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the consolidated financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div><span><br/></span></div><div style="text-align:justify"><img src="oncyf-20211231_g3.jpg" alt="oncyf-20211231_g3.jpg" style="height:73px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.877%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Calgary, Canada</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2, 2022</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:67.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (note 5)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMtMi0xLTEtODEyMQ_cb9f27a7-7caf-4c03-8e13-6d1482f894f4">41,262,044</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMtMy0xLTEtODEyMQ_11999d6a-d2a2-4473-9522-9a9b21d34877">31,219,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables (note 13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:OtherCurrentReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzQtMi0xLTEtODEyMQ_c882404a-1902-4e46-a751-6381feef376f">866,055</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:OtherCurrentReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzQtMy0xLTEtODEyMQ_78a2515c-0236-4b72-92d2-14362b6414a2">89,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzUtMi0xLTEtODEyMQ_1527e32f-098a-42bd-a0c0-2e51ed80f642">2,775,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzUtMy0xLTEtODEyMQ_0aa15a6e-e39c-4dd6-b1b4-6a717ee8e547">2,427,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzYtMi0xLTEtODEyMQ_563d5d2a-22ab-4964-9cb8-c2da8630295a">44,903,899</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzYtMy0xLTEtODEyMQ_fc9cd2c7-7de3-4b84-8560-486c0d1a7854">33,736,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment (note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzgtMi0xLTEtODEyMQ_588d0be7-d798-4219-8e02-67f9dc509f83">392,041</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzgtMy0xLTEtODEyMQ_f2545cdd-84aa-4187-a76e-5283d91f03d5">236,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets (note 7)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzktMi0xLTEtODEyMQ_8602f071-323a-4c2f-a39c-598bfec20759">584,251</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzktMy0xLTEtODEyMQ_ae0d3c56-0b74-4bf2-a300-ac1c19c2d902">372,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzEyLTItMS0xLTgxMjE_d8e08a2f-2b9b-498c-aaf9-fa30feb7d125">45,880,191</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzEyLTMtMS0xLTgxMjE_d31fbf65-5051-4c9a-abf7-0bc97b7764c2">34,345,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities And Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE1LTItMS0xLTgxMjE_9847beeb-024e-4e47-8407-19bbc3001d92">1,987,870</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE1LTMtMS0xLTgxMjE_bc7bd0ab-a782-4cf8-889d-c6f05b8e5b2f">1,805,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities (note 13)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE2LTItMS0xLTgxMjE_d0b1e0d7-87e8-4486-8352-59d925381fb3">352,279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE2LTMtMS0xLTgxMjE_a83757c6-c524-4390-9ea0-623571976693">123,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 7)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE3LTItMS0xLTgxMjE_52dacd4a-36a4-45f8-ba1d-384fab932133">293,672</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE3LTMtMS0xLTgxMjE_2a9f4832-f957-4a16-8656-98193f33edf4">248,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative (note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:CurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE4LTItMS0xLTgxMjE_858eb712-3e8e-4a3e-b756-9e2f6a82bf7b">56,017</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:CurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE4LTMtMS0xLTgxMjE_ffa58a32-01ae-4bd0-a2e8-511c7cb85eaf">531,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE5LTItMS0xLTgxMjE_900b56db-ec56-4721-a8c8-8b90a2057ef3">2,689,838</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE5LTMtMS0xLTgxMjE_caf5da95-a0f5-4213-8894-36d32dcffec6">2,709,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability (note 12)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzIxLTItMS0xLTgxMjE_4fa4b602-bc8f-486d-ae83-777a178fa650">6,730,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzIxLTMtMS0xLTgxMjE_326f308f-7c8e-4a7d-8e28-836012cce9dd">6,730,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 7)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzIyLTItMS0xLTgxMjE_32451b5d-4b1c-4de3-ac3d-8a9eff0bf9a9">361,081</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzIyLTMtMS0xLTgxMjE_9b73093b-dcc2-49a1-b2c9-1b020eea0b57">153,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI1LTItMS0xLTgxMjE_06c5d819-b279-4581-822f-7e19f7d03fa4">9,781,206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI1LTMtMS0xLTgxMjE_938bbb1b-ae56-4fb1-a3af-5c2777c5d53f">9,592,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (note 13, 14, 19)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" xsi:nil="true" name="oncyf:CommitmentsAndContingencies1" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzIwLTEtMS0xLTE4NDQx_7b5b5997-66b7-42da-b522-37f0a9b5c2ae"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" xsi:nil="true" name="oncyf:CommitmentsAndContingencies1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI2LTMtMS0xLTgxMjE_be71b6e1-a6e5-4d3c-9f91-43f0f5c869c8"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital (note 9)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Authorized: unlimited</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Issued: December&#160;31, 2021 &#8211; <ix:nonFraction unitRef="shares" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI4LTAtMS0xLTgxMjEvdGV4dHJlZ2lvbjo3Y2FjYzI5NDI1OTU0NGEwODY5YzQwOTA5MjViODc0OF8xNjQ5MjY3NDQxNzUz_59ffdc92-ff32-4ad5-a452-d5c5a79035c0">55,043,789</ix:nonFraction></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;December&#160;31, 2020 &#8211; <ix:nonFraction unitRef="shares" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI4LTAtMS0xLTgxMjEvdGV4dHJlZ2lvbjo3Y2FjYzI5NDI1OTU0NGEwODY5YzQwOTA5MjViODc0OF8xNjQ5MjY3NDQxNzQ2_707e7a50-8e3e-4c6a-8a00-0f4024e494d0">46,166,980</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI4LTItMS0xLTgxMjE_63c084a1-3539-49d0-9ce4-8366fddd6cc9">391,348,183</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI4LTMtMS0xLTgxMjE_f93e9a4f-5e0a-4457-9947-3bbfae53ad1f">356,824,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="oncyf:WarrantsandRightsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI5LTItMS0xLTgxMjE_e65d6dac-ee74-41bb-b1bc-14633a8fa4de">3,617,570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="oncyf:WarrantsandRightsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI5LTMtMS0xLTgxMjE_6d805283-705f-436c-8d0b-71e3ccddc204">3,617,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:AdditionalPaidinCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMwLTItMS0xLTgxMjE_93c5e739-a73d-47fc-822c-c3fa2da0ad58">34,161,103</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:AdditionalPaidinCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMwLTMtMS0xLTgxMjE_fde5b282-e66c-4a59-a982-7496614df75c">31,022,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:AccumulatedOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMxLTItMS0xLTgxMjE_708e59e0-c515-48a4-9b57-23a99bef3bff">387,738</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:AccumulatedOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMxLTMtMS0xLTgxMjE_86ada7e8-6b4d-436a-a899-b941ee096b7a">400,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMyLTItMS0xLTgxMjE_5d413079-d245-48ac-b255-f435b94ad970">393,415,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMyLTMtMS0xLTgxMjE_14f8ab86-cea9-4c4d-afb4-5912e0e1c257">367,111,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMzLTItMS0xLTgxMjE_9c5d799e-dfca-4411-8701-f0f7b4fc07b8">36,098,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMzLTMtMS0xLTgxMjE_366e67f7-7d90-4764-861f-b671a084a357">24,752,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzM0LTItMS0xLTgxMjE_64183d42-8f96-423c-b155-10e1abc321a5">45,880,191</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzM0LTMtMS0xLTgxMjE_33f6974d-08ea-4521-9862-102eaaa06d01">34,345,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">          See accompanying notes</span></div><div style="padding-left:22.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:5pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:46.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;On behalf of the Board:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Angela Holtham</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Wayne Pisano</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Director&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Director&#160;&#160;&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development (note 10, 21, 22)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzMtMi0xLTEtODEyMQ_efcd0a92-f945-4298-be1e-1584d2c55e66">12,920,371</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzMtMy0xLTEtODEyMQ_b9018e41-5e6b-42f9-bbe0-db17ca11dea8">12,944,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzMtNC0xLTEtODEyMQ_4e708f2a-630d-4809-ba66-f6a3a6db9522">10,817,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Operating (note 10, 21, 22)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzQtMi0xLTEtODEyMQ_8a3a7809-2d49-46ff-a02b-66509e0008c7">13,314,574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzQtMy0xLTEtODEyMQ_c65371a8-933a-4faf-9bf6-376eff9a5b74">12,514,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzQtNC0xLTEtODEyMQ_67caa2c5-c491-44c8-91ff-c29bf8511761">9,558,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before the following</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzUtMi0xLTEtODEyMQ_fd264b0f-66a3-4f19-a111-77e7b6bf24dd">26,234,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzUtMy0xLTEtODEyMQ_2490f1bf-8a29-430d-af9c-f56d9f22c258">25,459,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzUtNC0xLTEtODEyMQ_6c2c82b1-a8e8-40ac-ad21-9ff7d4c68d69">20,376,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Change in fair value of warrant derivative (note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzYtMi0xLTEtODEyMQ_b86717f9-d5c8-4de9-a770-e77d9eb5131a">17,117</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzYtMy0xLTEtODEyMQ_c77823ae-065e-4f86-aa72-747d519f6d0a">3,491,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzYtNC0xLTEtODEyMQ_a0556003-0f91-4c35-9e04-3c6b7e7bd4d4">12,608,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign exchange loss (note 21)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzctMi0xLTEtODEyMQ_0eb62dc6-6db4-4c83-bea9-88ac2efe0947">135,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzctMy0xLTEtODEyMQ_352b693a-8824-4377-913e-f91b31962d35">659,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzctNC0xLTEtODEyMQ_3e834915-6019-4928-a577-fbaed2271817">316,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzgtMi0xLTEtODEyMQ_7997f237-c73b-4809-8c83-c4c814ea2506">98,612</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzgtMy0xLTEtODEyMQ_2e510d65-a7c8-46bb-b0a3-df1b994cc239">121,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzgtNC0xLTEtODEyMQ_52c523f5-a0b3-439f-b9dc-106268beffd4">179,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzktMi0xLTEtODEyMQ_683612eb-d0ed-47b0-872e-71d018bbd3e5">26,254,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzktMy0xLTEtODEyMQ_e200952b-578f-4759-9781-1a1d4109dfa4">22,505,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzktNC0xLTEtODEyMQ_0da66875-0549-4274-8a84-6b183e403141">33,122,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense (note 15)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEwLTItMS0xLTgxMjE_134d13b5-da99-4001-88f0-dd5163657853">49,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEwLTMtMS0xLTgxMjE_0e609e41-72ca-4236-ad79-85c01bff12f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEwLTQtMS0xLTgxMjE_a479da37-b884-49c0-9fb9-4d5603b45c5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzExLTItMS0xLTgxMjE_bb9f64d1-8cc4-4991-b8b6-b7c2dfd40876">26,304,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzExLTMtMS0xLTgxMjE_e6eb68e0-d4fa-4914-9b0c-e1c8e25573dc">22,505,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzExLTQtMS0xLTgxMjE_230252b6-5cb0-42a8-b853-71ef43f3af34">33,122,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive loss items that may be reclassified to net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEzLTItMS0xLTgxMjE_4e0ecfcc-e019-4581-9e9d-ec264f75f7f7">12,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEzLTMtMS0xLTgxMjE_4fd59385-888c-4fa8-b380-83ea3b7ac2c6">63,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEzLTQtMS0xLTgxMjE_cd89aa9c-130e-4c15-81bf-7615ec241e32">143,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE0LTItMS0xLTgxMjE_1f90e530-8b9d-4a05-930d-6212d8cfd280">26,316,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE0LTMtMS0xLTgxMjE_e1ace500-eee7-4742-a195-d3e204745dcf">22,568,933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE0LTQtMS0xLTgxMjE_e2b8a897-5bf9-4693-ac0a-ddcf49ba71cc">33,266,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per common share (note 11)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTItMS0xLTgxMjE_752f4e6f-6e1e-4aaf-8673-687fc2de6d4e"><ix:nonFraction unitRef="cadPerShare" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTItMS0xLTgxMjE_aad3b9af-7725-4789-9641-ac4a9a6b3ae7">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTMtMS0xLTgxMjE_82ea75c3-a8ae-4c7c-aecb-87dd0b4af04f"><ix:nonFraction unitRef="cadPerShare" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTMtMS0xLTgxMjE_ee52cbdf-1577-41f4-8af2-241829c2f228">0.56</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTQtMS0xLTgxMjE_329f3733-b527-4646-9681-630e5366fd1b"><ix:nonFraction unitRef="cadPerShare" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTQtMS0xLTgxMjE_3c9e3f19-42ae-4ed8-b8ca-24f001d89068">1.50</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted) (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTItMS0xLTgxMjE_0656803f-7a88-4c46-8ab7-555d1ee032c2"><ix:nonFraction unitRef="shares" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTItMS0xLTgxMjE_79006d47-f35a-4f3e-aa15-82bb970331e9">53,513,225</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTMtMS0xLTgxMjE_3e9ac702-d7ec-41c4-a78b-640317b2a3f7"><ix:nonFraction unitRef="shares" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTMtMS0xLTgxMjE_4b6d1af4-1745-4234-82ab-9be837eaeda3">40,338,789</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTQtMS0xLTgxMjE_032279d3-cdab-438b-befd-39d2f10df08d"><ix:nonFraction unitRef="shares" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTQtMS0xLTgxMjE_555bae2e-527e-4714-99c5-933a600a7e0c">22,137,990</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.350%"><tr><td style="width:1.0%"></td><td style="width:35.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contributed Surplus</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i21ac1e8adaee40f6b58f4f0a7d541a1a_I20181231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTItMS0xLTgxMjE_f148fb07-fa76-47e7-82d5-917c2e49e8cc">285,193,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2fca816bbeb24d2f9554e7f82f33d0aa_I20181231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTMtMS0xLTgxMjE_45c4384f-8a9f-41e4-8c82-1cda41663959">3,617,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9a4b3d20c0e34a60b680edd8e972dcfc_I20181231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTQtMS0xLTgxMjE_a1cd0783-dee1-4484-bffe-04dd86a0fee5">28,260,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaefbcea0de304b2694dda77f60ddb9c8_I20181231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTUtMS0xLTgxMjE_ae0baa1b-5e4a-4f88-8fc7-c53c8b6212b6">607,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6f8ab54803934f9ba120d4a3bc5e6154_I20181231" decimals="0" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTYtMS0xLTgxMjE_7d136457-eedc-4b26-9ac6-04b6f92df1ed">311,483,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i762faf08df5c4521a4f2689a278651e0_I20181231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTctMS0xLTgxMjE_fc4f1467-fad7-4c35-a1c0-06c9413b6f09">6,195,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i7497baf23598431f909bb5527274fe07_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEyLTUtMS0xLTgxMjE_9c36bee8-89c2-44be-808a-36e64e10889f">143,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="idb855524d3594b9281f4a4752081bdde_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEyLTYtMS0xLTgxMjE_7009753a-9ad0-4adc-9cb6-c9744f9e85e7">33,122,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEyLTctMS0xLTgxMjE_edcac7b9-7657-40b4-853b-f448c14690a8">33,266,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1259d944f2ca4e288ad6295bde8a4c8d_D20190101-20191231" decimals="0" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEzLTItMS0xLTgxMjE_7104c13b-fc3d-4820-b095-9fb75d76220a">391,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icb74087cec10424881ec8739a53a5f47_D20190101-20191231" decimals="0" sign="-" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEzLTQtMS0xLTgxMjE_4ff35fff-1825-4364-a5f4-5c1b6c2d59b7">391,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEzLTctMS0xLTgxMjE_daa36371-0b0c-4287-b241-77969cc2cc52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i77cf8a24c33d40808c7ac3ad20112a31_D20190101-20191231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE0LTItMS0xLTgxMjE_bc7cb5f6-1cf6-4693-8d8d-cbae396c9f7d">5,403,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7dae23e4a8384544b5f5e4a7c1153719_D20190101-20191231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE0LTctMS0xLTgxMjE_78db193a-e9fb-401d-8907-0feb7a8e2210">5,403,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia3c73cf11c2d41678a6efb1f84d128a2_D20190101-20191231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE1LTItMS0xLTgxMjE_b89001ae-49a3-48f0-a02a-964c213b0df9">8,476,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib500d93c61d242cda9af6cc3f32d688c_D20190101-20191231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE1LTctMS0xLTgxMjE_a40406a9-cc48-42f4-9db1-4f9a1872bb7d">8,476,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iea11c29de32043f3b1182fba91ce8ff8_D20190101-20191231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE2LTItMS0xLTgxMjE_918a5266-96e8-47ea-8589-9e6ffc835d22">3,314,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaca09b43294947cdbd585359e3ccaae8_D20190101-20191231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE2LTctMS0xLTgxMjE_158a2777-8d78-4bc8-a3b7-17cbab057055">3,314,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised (note 8, 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1259d944f2ca4e288ad6295bde8a4c8d_D20190101-20191231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE3LTItMS0xLTgxMjE_e8f8815c-c692-4dc2-b95d-61baa78562e8">9,152,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE3LTctMS0xLTgxMjE_1c99ecf7-a11d-4c65-97e9-0682d1651064">9,152,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icb74087cec10424881ec8739a53a5f47_D20190101-20191231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE4LTQtMS0xLTgxMjE_31b9cc3c-20c9-4941-bf26-af6134eae92e">1,470,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE4LTctMS0xLTgxMjE_44d3f85e-8e9b-4053-a283-7e8e70e77d13">1,470,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i1259d944f2ca4e288ad6295bde8a4c8d_D20190101-20191231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE5LTItMS0xLTgxMjE_98c80540-bff6-4f1e-b9ab-039740959fce">854,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE5LTctMS0xLTgxMjE_40f2266b-521e-4141-a709-9d4e2fce5eba">854,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i304f57b073284387a43a1c3c507589e0_I20191231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTItMS0xLTgxMjE_c70cadf1-4835-4110-9c1f-0f7c100059be">311,077,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1ebb4717b09f4ceb9bf3bf6ef866ac14_I20191231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTMtMS0xLTgxMjE_1c568bf6-6f77-4e20-a2a7-6bfe3cfd1688">3,617,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i3e0d0525ecbf4dbabb9d6b81ca747d24_I20191231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTQtMS0xLTgxMjE_42db4858-16b6-4ba9-8b47-4e1b8b28dcd0">29,338,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4f455a49c64e4496ab595aaa0cba3f3e_I20191231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTUtMS0xLTgxMjE_d9a11102-7ca6-4ce2-b97f-57557d680092">464,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib2f790228dc448d9936518bb5cf5c8a5_I20191231" decimals="0" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTYtMS0xLTgxMjE_fb6da0f4-1cbd-4eff-a80a-8eb0aa84a926">344,606,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="0" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTctMS0xLTgxMjE_a37d139a-d014-4ada-91ca-6deeabc4d69c">107,894</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if543a2c06c834e58a4a76a3dab2778ee_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTUtMS0xLTgxMjE_331033bd-993b-41b9-829f-8f7392c3ed11">63,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i560a323e55304acfbf5998d3542ba7c4_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTYtMS0xLTgxMjE_8c848dd4-5cde-4eac-8f0b-73568a5524e0">22,505,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTctMS0xLTgxMjE_308cae7e-4da4-47c7-8367-1f21861c0f2c">22,568,933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9dc054b35a584c518e17f16ec259dee3_D20200101-20201231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIyLTItMS0xLTgxMjE_75d8f2a1-3c69-40ed-b44d-fb47edeb114f">385,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ida3a1ebaced94f77b77c50976f1eb191_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIyLTQtMS0xLTgxMjE_d2e49c15-bb48-4ad3-a685-adc923d2c9ea">143,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIyLTctMS0xLTgxMjE_a820e258-322b-4013-9f93-d98ae73ebcd6">241,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9dc054b35a584c518e17f16ec259dee3_D20200101-20201231" decimals="0" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIzLTItMS0xLTgxMjE_3c8447b2-21a8-42fd-a799-c305629944fe">732,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ida3a1ebaced94f77b77c50976f1eb191_D20200101-20201231" decimals="0" sign="-" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIzLTQtMS0xLTgxMjE_6a4de44e-c651-48c7-8acd-49440268f945">732,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIzLTctMS0xLTgxMjE_4fe6ccad-7709-4b9a-8ff7-f7c94a41db69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia8c0d97615104d688ed55dd772c5d7cb_D20200101-20201231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI0LTItMS0xLTgxMjE_428f7c70-fc39-4aca-aed4-5d5c408edd94">40,037,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6f313c8714fa4ba0957f98a3704b93ec_D20200101-20201231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI0LTctMS0xLTgxMjE_552a4c6b-7b79-4eff-8189-679e70b3e5da">40,037,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised (note 8, 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9dc054b35a584c518e17f16ec259dee3_D20200101-20201231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI1LTItMS0xLTgxMjE_3247fcf3-fc07-41bd-be0c-00dfc64fbb40">6,332,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI1LTctMS0xLTgxMjE_c8b20cc7-6c6b-4918-9be1-ba1c37a244f5">6,332,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ida3a1ebaced94f77b77c50976f1eb191_D20200101-20201231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTQtMS0xLTgxMjE_709db0f4-5ee2-4962-a29c-a40c374e4107">2,558,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTctMS0xLTgxMjE_c9854550-86e2-44e9-b1ae-5e5a7428b53e">2,558,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i9dc054b35a584c518e17f16ec259dee3_D20200101-20201231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI3LTItMS0xLTgxMjE_c8512ace-31a8-4383-8075-bc40afb6ec4e">1,741,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI3LTctMS0xLTgxMjE_c5c6461e-297d-4b25-af67-648d3411abab">1,741,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i09fddfef79174f75b8bff1cf359841fc_I20201231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTItMS0xLTgxMjE_132a69cf-3501-4007-8902-2b4f65e07fc3">356,824,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i94a1d5d3239c42da9c1871d21717c343_I20201231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTMtMS0xLTgxMjE_726b9426-1450-4a9e-829a-ce87ed8ff82d">3,617,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ied32f90a78ea42c7b0c30d1104a4a175_I20201231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTQtMS0xLTgxMjE_3ebc4b09-44f8-4530-a339-a93eea80b5f6">31,022,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i477bd6213b6949fc9c3b06ce5e97889c_I20201231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTUtMS0xLTgxMjE_942433bb-379f-4781-a914-80868b0a1ab8">400,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2c09166535004a96a1e9ce08bb6369e6_I20201231" decimals="0" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTYtMS0xLTgxMjE_0a69ec7a-3d36-422d-a313-9f2a3b872680">367,111,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTctMS0xLTgxMjE_464274c5-86da-49bc-a887-e7b4943b7851">24,752,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="idcaaf6e1542d40d79d27fe0f2a8794c7_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE5LTctMS0xLTg2NzA_212c71bd-4168-4ee4-a16b-c2bc568f8801">12,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i9aafba09422b4432b91193f442b37784_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE5LTktMS0xLTg2Nzc_60df7a77-41cf-4244-a980-53564b60267e">26,304,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE5LTExLTEtMS04Njg0_a92bc63c-e45b-4fab-b9da-2019096b8836">26,316,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i97be07f487294e63a92bac56d0415c91_D20210101-20211231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTEtMS0xLTg2NDg_1862a7d8-879a-44f4-b54c-0169733f14b3">381,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i89d130fa6b8345b9bb8639ac65bf6959_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTUtMS0xLTg2NjI_82ac633d-57cf-482e-96fa-0cfd57290c4f">143,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTExLTEtMS04Njg0_96e62b77-9776-4c88-9449-854b685a465b">238,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i97be07f487294e63a92bac56d0415c91_D20210101-20211231" decimals="0" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTEtMS0xLTg2NDg_5d326c88-02ed-4efe-aeb2-0835640a5cec">543,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i89d130fa6b8345b9bb8639ac65bf6959_D20210101-20211231" decimals="0" sign="-" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTUtMS0xLTg2NjI_e99cc139-220b-4573-929b-a98e4e1157ae">543,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTExLTEtMS04Njg0_9151c07a-0a47-48fa-97a4-770e63147906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i20441217b630482b9af70e8a326d5e57_D20210101-20211231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIyLTEtMS0xLTg2NDg_89333daa-397e-4963-a4e9-6f9860a95068">34,168,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i69f83b81a5514d5f825fc606476e7579_D20210101-20211231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIyLTExLTEtMS04Njg0_693edc19-4a52-4f2d-b6ce-bf56106db54a">34,168,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised (note 8, 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i97be07f487294e63a92bac56d0415c91_D20210101-20211231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIzLTEtMS0xLTg2NDg_429c7a04-28a3-48ab-b505-058d41762269">686,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIzLTExLTEtMS04Njg0_2c6ca41b-5472-477f-80e0-08ef007fa75d">686,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i89d130fa6b8345b9bb8639ac65bf6959_D20210101-20211231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI0LTUtMS0xLTg2NjI_dcb1a7c2-d0c0-4aba-91a6-23caa9a03c35">3,825,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI0LTExLTEtMS04Njg0_5dea2fed-3c45-4934-b6c1-b8b7c31b1a04">3,825,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i97be07f487294e63a92bac56d0415c91_D20210101-20211231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI1LTEtMS0xLTg2NDg_db58d175-eeec-4b14-bb54-ff89cd58419e">1,256,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI1LTExLTEtMS04Njg0_7a6e35ef-1cbd-4ab1-8a81-0f28d1004d57">1,256,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2d63c24097454dbdb7cd6dea53770f97_I20211231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTEtMS0xLTg2NDg_ef57de22-c16e-42e1-ad9e-d1c0a6b58e52">391,348,183</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i01941d662103459ba01338223c19f6f2_I20211231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTMtMS0xLTg2NTU_a4464a1f-fc04-4dfb-a40b-14c55469b87c">3,617,570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia2dbea1a75bc4a34b367005fb0c6ff02_I20211231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTUtMS0xLTg2NjI_f016f5f5-659c-4062-94dd-4e70c6325fb0">34,161,103</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2d1d3557b69d4abb86a20c233c6f1c42_I20211231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTctMS0xLTg2NzA_0329245f-b719-4f1a-a80d-7c2767e1c2a1">387,738</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i928abeb5cacb4a81b5b6294857079d2f_I20211231" decimals="0" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTktMS0xLTg2Nzc_4c421f57-94dc-4112-8edc-af1203c1d28a">393,415,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTExLTEtMS04Njg0_929722ff-7721-40b5-80ab-f32c6730eae8">36,098,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss for the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzMtMi0xLTEtODEyMQ_c3b9250d-c4f1-4a15-88ef-1078182c065e">26,304,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzMtMy0xLTEtODEyMQ_693ac9af-a78e-4bd5-b66e-b58394f62ae2">22,505,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzMtNC0xLTEtODEyMQ_e90cfd86-e9fc-4430-864f-08d9358b6cb0">33,122,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment (note 6, 21)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzQtMi0xLTEtODEyMQ_7a1bc6ec-f340-401f-b0f3-3d8b9ebdc791">130,243</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzQtMy0xLTEtODEyMQ_3ab9210d-834b-4642-9995-a8989271c568">88,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzQtNC0xLTEtODEyMQ_b4a60ea5-d153-4f6e-911e-50625443f4ec">122,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets (note 7, 21)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzUtMi0xLTEtODEyMQ_9598d829-e9c0-40c6-994f-10ad0ddac2c6">321,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzUtMy0xLTEtODEyMQ_02bf2f9f-3858-4c90-9ddd-45269d257eeb">357,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzUtNC0xLTEtODEyMQ_23c72328-c0b5-4d56-8a61-96f4fd2b82b3">362,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (note 10, 21, 22)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzYtMi0xLTEtODEyMQ_04f6ca49-7e6a-4ef4-b4c5-98eb0c846e85">3,825,901</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzYtMy0xLTEtODEyMQ_3b9ce78f-d1a0-4be8-afa1-722b721f569e">2,558,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzYtNC0xLTEtODEyMQ_405938ec-34ba-4472-b4c2-a6a0737fc11a">1,470,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities (note 7)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzctMi0xLTEtODEyMQ_84b85855-1ada-48a3-9d45-1d502719f62f">91,727</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzctMy0xLTEtODEyMQ_cb8e6db0-0911-43fc-840e-0cb28f12e4e1">68,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzctNC0xLTEtODEyMQ_102f2f3c-7611-4bdd-b2ea-8183f5c55c9e">94,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzgtMi0xLTEtODEyMQ_0464f8d6-1859-4f72-b0f6-701184203990">425,681</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzgtMy0xLTEtODEyMQ_e30d2821-b5f6-4b5d-aa9f-490ccb14e12c">645,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzgtNC0xLTEtODEyMQ_aa437245-d6cf-4f26-b678-95950858b70f">353,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative (note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzExLTItMS0xLTgxMjE_1936badf-f694-4955-be8f-6d320cfb6fe3">17,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzExLTMtMS0xLTgxMjE_c04c5c4d-9349-45ac-85ff-4de7c88345d8">3,491,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzExLTQtMS0xLTgxMjE_dd20865a-79c6-4705-b603-d2d66cb8e2fa">12,608,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-cash working capital (note 18)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEyLTItMS0xLTgxMjE_394ab962-cb0c-49fa-b85e-f47bf89a825d">907,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEyLTMtMS0xLTgxMjE_74b5075c-516c-4cfb-a110-5ff8803d118f">209,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEyLTQtMS0xLTgxMjE_3e019c69-f0a5-4da3-8102-038be47f3b81">1,795,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEzLTItMS0xLTgxMjE_78e9ecfd-9896-4397-8c2c-5cc223117e77">22,434,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEzLTMtMS0xLTgxMjE_5db55b34-2762-4a5c-800d-623187e73d50">22,068,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEzLTQtMS0xLTgxMjE_365157ea-20d8-430b-85be-052dcd3bb49f">19,906,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment (note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE1LTItMS0xLTgxMjE_b5b188b4-1dcd-4826-a033-f3aceed3d836">285,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE1LTMtMS0xLTgxMjE_cad4d9a2-b8fc-4713-a768-7b01536725df">29,305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE1LTQtMS0xLTgxMjE_ffef095e-4932-4511-b5a1-43f47177f2dc">10,905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE2LTItMS0xLTgxMjE_31b40aba-cdd2-45e5-8b7d-68ce9c170577">285,948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE2LTMtMS0xLTgxMjE_9ea04b3a-e326-4433-b0b7-a82ea7120138">29,305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE2LTQtMS0xLTgxMjE_24ef3131-cc26-4ade-9140-ba751ba2b010">10,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:ProceedsFromExerciseOfOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE4LTItMS0xLTgxMjE_cd96589a-2164-4b1c-a198-fd40e6fb4cb6">238,450</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:ProceedsFromExerciseOfOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE4LTMtMS0xLTgxMjE_73b93e2d-3b01-4b27-b9b8-92b91502f481">241,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:ProceedsFromExerciseOfOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE4LTQtMS0xLTgxMjE_dcf967b6-5ef8-4071-b866-47d21902fa90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants (note 8, 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i11d9fb4cd4024c309548c1bf2a5386e4_D20210101-20211231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE5LTItMS0xLTgxMjE_64de583a-b973-4879-b1c9-50509b78bdc4">230,946</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic6a4fa14d2b2483c8f5abacada092873_D20200101-20201231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE5LTMtMS0xLTgxMjE_a8f84b91-2c29-42d1-96bd-1799ff160e0f">1,696,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2c799a9f2ad149fd871347906998cdbb_D20190101-20191231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE5LTQtMS0xLTgxMjE_fa3fa259-e1a0-42e6-9544-3e844812711c">3,465,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from Common Stock Purchase Agreement (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iee32e2321a294a0d825d8564edea4786_D20210101-20211231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIwLTItMS0xLTgxMjE_7b525bc8-34ec-483d-bd70-fa087f64e03f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i963faf8316e44553ac2c61cbab41d123_D20200101-20201231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIwLTMtMS0xLTgxMjE_4af0bb69-71af-47c0-ab34-8acacc5d3afc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i982cf0e1d89f41ceba66f2d117947048_D20190101-20191231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIwLTQtMS0xLTgxMjE_77548975-e19d-4254-9f77-0f726061803c">5,360,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from "At the Market" equity distribution agreement (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i69f83b81a5514d5f825fc606476e7579_D20210101-20211231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIxLTItMS0xLTgxMjE_81331afc-1a62-41fd-b922-c6b5fa11f5a1">32,911,791</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6f313c8714fa4ba0957f98a3704b93ec_D20200101-20201231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIxLTMtMS0xLTgxMjE_a4551616-9bef-42a0-b361-eb0d930fc7af">38,296,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib500d93c61d242cda9af6cc3f32d688c_D20190101-20191231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIxLTQtMS0xLTgxMjE_88ddf200-6735-400b-92be-6d2a713a7f84">8,131,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2da45bc703e4440590e52cbb6c0cae23_D20210101-20211231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIyLTItMS0xLTgxMjE_034c021b-11ec-4653-bb9e-01029f61a920">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i32242ff3d2e742fe9c6db2f637808bec_D20200101-20201231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIyLTMtMS0xLTgxMjE_8fe64c7d-410a-493b-92b9-f6ed301dff52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaca09b43294947cdbd585359e3ccaae8_D20190101-20191231" decimals="0" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIyLTQtMS0xLTgxMjE_5b0ae327-66a3-40ec-b92f-88463f511367">4,505,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities (note 7)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIzLTItMS0xLTgxMjE_6d036133-3c2a-466d-97a5-10a55c89756c">365,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIzLTMtMS0xLTgxMjE_9136257f-d458-4f4c-8f37-69a46faea6a8">460,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIzLTQtMS0xLTgxMjE_8607b7a8-21a4-43ea-bcd7-650cfd58c757">447,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI0LTItMS0xLTgxMjE_7c7c77aa-e334-4d9e-a817-48302d859ae5">33,015,677</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI0LTMtMS0xLTgxMjE_50a77096-d46a-45fc-9d17-e011a6b9a3eb">39,773,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI0LTQtMS0xLTgxMjE_a68031bf-dbf6-4486-aea1-4d5676c97771">21,015,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase in cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI1LTItMS0xLTgxMjE_4ee6194b-b42c-4487-af3a-618db26ba812">10,295,720</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI1LTMtMS0xLTgxMjE_41b4283f-cf09-4c0f-9e27-dc322feaed3e">17,676,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI1LTQtMS0xLTgxMjE_b2e5d938-fcd5-4ace-97c6-50c8b4e4376a">1,098,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI2LTItMS0xLTgxMjE_55e6c3cb-cbd2-4df1-b5a0-1ea8826bdf61">31,219,574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="0" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI2LTMtMS0xLTgxMjE_94bcd93b-b6c3-4411-81f2-b48cbab50264">14,148,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i762faf08df5c4521a4f2689a278651e0_I20181231" decimals="0" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI2LTQtMS0xLTgxMjE_4564fa7f-7c71-4b3f-8d88-7332849a1b2f">13,699,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI3LTItMS0xLTgxMjE_27eeba02-baa0-4ada-96ec-a64f7b073559">253,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI3LTMtMS0xLTgxMjE_2ac1d4dd-057e-46a0-97ad-ad2d00aee224">604,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI3LTQtMS0xLTgxMjE_59a2bf5d-151c-4805-bb5b-9acf599444c5">650,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI4LTItMS0xLTgxMjE_6c2b6ef3-31c5-4d34-959f-07b9339054e6">41,262,044</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI4LTMtMS0xLTgxMjE_23d6c048-1bf4-4374-94fd-c4a87e1d9dbf">31,219,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="0" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI4LTQtMS0xLTgxMjE_c3e691e4-2165-41bf-99a6-8541715ce0e8">14,148,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_133"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 1: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzYvZnJhZzo2YmEwOTUwNjMzNjA0MTFiYWJjMDNlMTBlMzliM2Y4ZS90ZXh0cmVnaW9uOjZiYTA5NTA2MzM2MDQxMWJhYmMwM2UxMGUzOWIzZjhlXzE0NTY_7b180c82-61de-489c-88af-e7e626456917" continuedAt="iccf8e2ec10124e529498c7b3104cf39c" escape="true">Incorporation and Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="iccf8e2ec10124e529498c7b3104cf39c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2021, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;2, 2022. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development-stage biopharmaceutical company that focuses on the discovery and development of immunotherapeutic products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is an intravenously delivered immunotherapeutic agent that may be a novel treatment for certain types of cancer and may be an alternative to or used in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and/or targeted therapies.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 2: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzkvZnJhZzpmZTVmY2ZmMWMxYTk0MGM2YjQ2YTkwODE5YzA5NzU4OC90ZXh0cmVnaW9uOmZlNWZjZmYxYzFhOTQwYzZiNDZhOTA4MTljMDk3NTg4XzEzODU_cd222d95-c74d-418f-b5d0-dfd0d92534b2" continuedAt="i674e3e1e488848528f0b4845216f890f" escape="true">Basis of Financial Statement Presentation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i674e3e1e488848528f0b4845216f890f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc. and are presented in Canadian dollars, our functional currency.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of consolidation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries. Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern. Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_142"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 3: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MTk5_eeabb164-ea96-4217-bb75-f9f771722a8f" continuedAt="ia60b2f2aef154991afc925a0841b2ef0" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ia60b2f2aef154991afc925a0841b2ef0" continuedAt="i0d45c63b2c5f4bee919793aabda81945"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Deferred income taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjAz_7f07697a-9c3c-47fb-a6b4-42680e6002f2" escape="true">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.</ix:nonNumeric>  </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="i0d45c63b2c5f4bee919793aabda81945" continuedAt="iedacb6d6c0834a839a72016c47ec33df"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification and measurement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial assets</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjM1_92a0be00-7504-4c44-987f-6f6f29c43b40" continuedAt="ica3f2e7801a84ea2afae2fff9b5032c5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"IFRS 9"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent &#8216;solely payments of principal and interest&#8217; on the principal amount outstanding (the &#8216;SPPI criterion&#8217;). </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ica3f2e7801a84ea2afae2fff9b5032c5">Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjA5_410c8e1a-7dec-4036-bee3-2a63a904b68d" escape="true">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.</ix:nonNumeric>  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjI0_b2e47ca1-502c-4e24-94d9-7ed8c225982f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derecognition</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjI1_c06aff08-841a-4104-b58e-846e09ceee9e" continuedAt="i4c3ac300adc645c593654b50ae7b3845" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contractual rights to the cash flows from the financial asset expire, or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4c3ac300adc645c593654b50ae7b3845">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjI2_9251559e-874a-4dca-b6d2-07756c643b17" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="iedacb6d6c0834a839a72016c47ec33df" continuedAt="icef4c68a1bfc41cf988b97caa27abdfb"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign currency translation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjEw_85e61bcf-85b2-430a-98d1-3d29de3253b4" continuedAt="i3413ec6cefb74568bdfa1458f06a5942" escape="true">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3413ec6cefb74568bdfa1458f06a5942">Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.</ix:continuation>  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Loss per common share</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjI3_32f018ea-3264-4687-9a14-06446e30dbca" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units, and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property and equipment </span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjQw_9ffab46e-42c2-4322-82d0-33ab4b0af846" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjEx_b94cf91f-c715-4607-bc65-c9bac25bf1ff" continuedAt="if7d4575e5cd14a37a548da4b2d2fdf9e" escape="true">Depreciation is recorded using the declining balance method at the following annual rates:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="if7d4575e5cd14a37a548da4b2d2fdf9e" continuedAt="i8d7ca66cf89147509d4cb1f1b86f3c9b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f3e572ad5cd4feea41d839ed408d512_D20210101-20211231" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90YWJsZTo0OTc2ODllMjM3YjQ0MWU3YjBmZDY4MDhhOTE2ZjZiNi90YWJsZXJhbmdlOjQ5NzY4OWUyMzdiNDQxZTdiMGZkNjgwOGE5MTZmNmI2XzAtMS0xLTEtODEyMQ_0451d70d-9414-4c9e-a5b4-ae9af74ecbc0">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd1040437dbe4ddfa654981a27937d0a_D20210101-20211231" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90YWJsZTo0OTc2ODllMjM3YjQ0MWU3YjBmZDY4MDhhOTE2ZjZiNi90YWJsZXJhbmdlOjQ5NzY4OWUyMzdiNDQxZTdiMGZkNjgwOGE5MTZmNmI2XzEtMS0xLTEtODEyMQ_6652aadd-7b8f-48d7-a154-1b700789ffa0">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9862680256f347348f49335ecd9cb274_D20210101-20211231" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90YWJsZTo0OTc2ODllMjM3YjQ0MWU3YjBmZDY4MDhhOTE2ZjZiNi90YWJsZXJhbmdlOjQ5NzY4OWUyMzdiNDQxZTdiMGZkNjgwOGE5MTZmNmI2XzItMS0xLTEtODEyMQ_7db138b3-8c40-4ed0-9f04-fa246ef58269">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></ix:continuation></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjE5_3daaa352-7105-4e10-92e8-4e815d586bc5" continuedAt="i5b4a4390820148419721b937be6d227c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="icef4c68a1bfc41cf988b97caa27abdfb" continuedAt="i5ce62df4db9f418f8d56301a40ce23d9"><ix:continuation id="i5b4a4390820148419721b937be6d227c" continuedAt="ie72643ae72f64c08bca30dddad436da2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie72643ae72f64c08bca30dddad436da2">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjQ0_a7617c73-e6ba-45c0-942a-42866e7b2d2c" continuedAt="ic5528b57c6bf49da90620596e3ccb006" escape="true">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic5528b57c6bf49da90620596e3ccb006">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue recognition</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjAx_81b52a0a-eace-4e5c-ae55-d35e9638de28" continuedAt="i368ce79f31924ae1840b5d5a6652188f" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="i5ce62df4db9f418f8d56301a40ce23d9" continuedAt="ifd6f06aa29be43fea51e296b2dc4a3c2"><ix:continuation id="i368ce79f31924ae1840b5d5a6652188f"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share-based compensation </span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjA2_cc2819ac-9883-4f1b-9f87-0dc5e0ddd8fc" continuedAt="i6aad2d8840ee4d75a1d0b7dc0147ff06" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="plan" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="oncyf:NumberOfStockOptionPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE1MDIw_58a7be8d-cbbf-46d9-857b-4cc11fcbc9f1">one</ix:nonFraction> stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees, and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE1NTMw_fd4b1538-ed6b-4fb4-841e-1c76aa78f9ff">10</ix:nonNumeric> years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive share award plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incentive share award plan (the "Share Plan") is available to directors, officers, and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6aad2d8840ee4d75a1d0b7dc0147ff06">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzI3NDg3NzkwODg0NTM_332e65db-7380-47f0-a063-f5f2bb5c53cf" continuedAt="i6dba8acbb4614f468f0e35e78f39a51b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and example to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="ifd6f06aa29be43fea51e296b2dc4a3c2"><ix:continuation id="i6dba8acbb4614f468f0e35e78f39a51b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduces a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the IASB issued amendments to IAS 12, which narrows the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. We are assessing the impact of adopting this standard on our consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 4:  <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDUvZnJhZzo2YmJjMThmMmFlNTU0Mjc5OTQ4ZGE5MmFhOTBlM2I4ZS90ZXh0cmVnaW9uOjZiYmMxOGYyYWU1NTQyNzk5NDhkYTkyYWE5MGUzYjhlXzc4ODQ_b6f19668-3b3b-4013-891e-76f8b4418f07" continuedAt="i2d2c99dc767b4f83971765f7d1e3949b" escape="true">Significant Judgments, Estimates and Assumptions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i2d2c99dc767b4f83971765f7d1e3949b" continuedAt="i1f89467c23ce43ad8ed77d2c05b6e8db"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full extent to which the coronavirus infectious disease 2019 ("COVID-19") pandemic may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. We considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to our consolidated financial statements as of and for the year ended December 31, 2021, our future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Judgments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and assumptions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="i1f89467c23ce43ad8ed77d2c05b6e8db"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses represent a significant component of our research and development expenses and we outsource a significant portion of these activities to third-party contract research organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that have been performed by the contract research organizations. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted are disclosed in Note 10. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of the warrant derivative are disclosed in Note 8.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_148"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 5: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDgvZnJhZzplZGU1NjBhZmQzMGE0MWNkOWNiOTQwNmY2OTMzNDFkZi90ZXh0cmVnaW9uOmVkZTU2MGFmZDMwYTQxY2Q5Y2I5NDA2ZjY5MzM0MWRmXzIxNw_673c81d4-5866-4440-b796-0926a5beecb8" continuedAt="i6e8cfb59063a450c97a3474c56d917fa" escape="true">Cash Equivalents </ix:nonNumeric></span></div><ix:continuation id="i6e8cfb59063a450c97a3474c56d917fa"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of interest bearing deposits with our bank totaling $<ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDgvZnJhZzplZGU1NjBhZmQzMGE0MWNkOWNiOTQwNmY2OTMzNDFkZi90ZXh0cmVnaW9uOmVkZTU2MGFmZDMwYTQxY2Q5Y2I5NDA2ZjY5MzM0MWRmXzEyOA_e4bb9306-a88b-48bc-a43f-32156e9d3c8e">39,901,509</ix:nonFraction> (December&#160;31, 2020 &#8211; $<ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDgvZnJhZzplZGU1NjBhZmQzMGE0MWNkOWNiOTQwNmY2OTMzNDFkZi90ZXh0cmVnaW9uOmVkZTU2MGFmZDMwYTQxY2Q5Y2I5NDA2ZjY5MzM0MWRmXzEzNw_2ab7cc09-fe2f-4f54-9ff8-1e9421fae062">30,361,591</ix:nonFraction>).&#160;&#160;The current annual interest rate earned on these deposits is <ix:nonFraction unitRef="number" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="4" name="oncyf:CashEquivalentsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDgvZnJhZzplZGU1NjBhZmQzMGE0MWNkOWNiOTQwNmY2OTMzNDFkZi90ZXh0cmVnaW9uOmVkZTU2MGFmZDMwYTQxY2Q5Y2I5NDA2ZjY5MzM0MWRmXzIwNA_e2c1f902-537d-41b4-bc67-6c8ebfb598a7">0.45</ix:nonFraction>% (December&#160;31, 2020 &#8211; <ix:nonFraction unitRef="number" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="4" name="oncyf:CashEquivalentsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDgvZnJhZzplZGU1NjBhZmQzMGE0MWNkOWNiOTQwNmY2OTMzNDFkZi90ZXh0cmVnaW9uOmVkZTU2MGFmZDMwYTQxY2Q5Y2I5NDA2ZjY5MzM0MWRmXzIxMw_99fb10ce-a40e-489e-b456-f92f5edf3fe4">0.36</ix:nonFraction>%).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 6: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90ZXh0cmVnaW9uOmNkZDkzM2ZkNWM5NDRiMWM5NjMzOTY0YTE3NTJlYTM0XzU0_be120e77-8ea0-4db8-9eef-1624fde1b66b" continuedAt="ibdac9257b118433fa0b48ba6352c0152" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="ibdac9257b118433fa0b48ba6352c0152"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><ix:continuation id="i8d7ca66cf89147509d4cb1f1b86f3c9b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i800ff2f75db84660ab49b5fd43edd4c1_I20191231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzUtMS0xLTEtODEyMQ_49ea23c1-d482-4093-b4e1-eba8054eefe0">60,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic58c717a06a14201a8ec51df519af985_I20191231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzUtMi0xLTEtODEyMQ_376a78c4-85e4-4274-b36e-c992ea9b25db">352,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if7d43a48ed72460b82de5da9f8bc806c_I20191231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzUtMy0xLTEtODEyMQ_cae34088-ba1e-4a87-ad79-ec0f003f7ae3">352,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icb4dd3dcb3854bb3a98aeec910cf0b0b_I20191231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzUtNS0xLTEtODEyMQ_86a5c9a0-9baa-4a2b-8383-a180888b00bf">498,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2e928b35b509443e9b3f89941d035b11_I20191231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzUtNi0xLTEtODEyMQ_b33966f8-b5ce-4c83-ac70-a4753d82a76c">1,264,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if68c471b3ecb4bdeb645af1dc5364be4_D20200101-20201231" decimals="0" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzYtMS0xLTEtODEyMQ_ce4ef2f0-d245-4799-a91d-96eefe0c5e80">1,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifeb2f08e8214484fbe8e7de1348ff6e3_D20200101-20201231" decimals="0" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzYtMi0xLTEtODEyMQ_2db425a2-1539-4eeb-84f8-3b19ff1629c4">27,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7007c392b1ea42b7bfa5f63652da1152_D20200101-20201231" decimals="0" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzYtMy0xLTEtODEyMQ_e7efcbee-abb5-4fb4-8058-0138501622a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6ee8f344469f41d9b0a08a69b6edeba2_D20200101-20201231" decimals="0" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzYtNS0xLTEtODEyMQ_5b7be15e-c70b-46ee-bb28-c540ef36294c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie86e21b5f131400fa46a3e0b45cf078a_D20200101-20201231" decimals="0" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzYtNi0xLTEtODEyMQ_9e061b5d-16e4-4db6-9f6f-83cb9946733b">28,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if68c471b3ecb4bdeb645af1dc5364be4_D20200101-20201231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzctMS0xLTEtODEyMQ_818ea86d-4a3c-457c-8eb1-e84a1154c5f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ifeb2f08e8214484fbe8e7de1348ff6e3_D20200101-20201231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzctMi0xLTEtODEyMQ_93f10e45-8832-4ae4-b70e-584f935e2469">15,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7007c392b1ea42b7bfa5f63652da1152_D20200101-20201231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzctMy0xLTEtODEyMQ_57aff3e2-c11e-4287-b0db-ce424a63a03f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6ee8f344469f41d9b0a08a69b6edeba2_D20200101-20201231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzctNS0xLTEtODEyMQ_748bd45a-447d-44ba-a92d-02086a86de58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie86e21b5f131400fa46a3e0b45cf078a_D20200101-20201231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzctNi0xLTEtODEyMQ_f3acbb89-3257-4c06-8627-4141948971ef">15,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2584f9ecb64b45a3b52d3a4ad2b34c59_I20201231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzgtMS0xLTEtODEyMQ_17b01519-1e57-47b2-8f63-e29aaaa932e7">61,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia6dbbc452c8f400f9ca5600d1ea5533a_I20201231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzgtMi0xLTEtODEyMQ_2284c2fc-8daa-4e91-8c72-3a39b2652150">365,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9e58c6e381b84e12b2792dec22095ada_I20201231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzgtMy0xLTEtODEyMQ_0bfd9e80-1f1c-4b69-ae6f-15b075a94bda">352,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i301c21dc622442aca90541862f62c6d2_I20201231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzgtNS0xLTEtODEyMQ_da6ee6a3-960c-4e97-bb55-1bab4201430f">498,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia9a9ad61b7c34714ab9be21ec4261caf_I20201231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzgtNi0xLTEtODEyMQ_73641c16-bd9f-41d6-8374-87e056b834c5">1,278,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ieae72557ba464b78b3c52ff1fde0c3e8_D20210101-20211231" decimals="0" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzktMS0xLTEtODEyMQ_57165c1f-a71a-483d-b3a8-38003041af44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icca0c7d56dcc43cdbb15d5b8cc79a270_D20210101-20211231" decimals="0" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzktMi0xLTEtODEyMQ_56d2fa08-6720-4825-ab9f-67004051e1b7">40,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ief8ec86040be42ba9d536b3bf953a071_D20210101-20211231" decimals="0" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzktMy0xLTEtODEyMQ_a5512f6d-b0ec-481b-8c1e-b2951dba7d85">141,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib5302452976149d498ed33786d7128b5_D20210101-20211231" decimals="0" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzktNS0xLTEtODEyMQ_de18938d-64e1-45fe-b2cf-b395efe0b054">103,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5d04cbd5984d4fffa8e832079f479563_D20210101-20211231" decimals="0" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzktNi0xLTEtODEyMQ_c76d99c7-71f4-43b9-a307-d065d5307182">285,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ieae72557ba464b78b3c52ff1fde0c3e8_D20210101-20211231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzEwLTEtMS0xLTgxMjE_9358fb52-f05a-45a9-bd32-9048e3fbc05f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icca0c7d56dcc43cdbb15d5b8cc79a270_D20210101-20211231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzEwLTItMS0xLTgxMjE_6eb91384-3f2e-499b-bdfa-f5e6cf0c92e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ief8ec86040be42ba9d536b3bf953a071_D20210101-20211231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzEwLTMtMS0xLTgxMjE_d6d1b3ce-4042-4b6f-b840-1bc48a4669b8">276,789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib5302452976149d498ed33786d7128b5_D20210101-20211231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzEwLTUtMS0xLTgxMjE_04f31fee-93b8-4dd6-a68c-1059703b4cc6">373,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5d04cbd5984d4fffa8e832079f479563_D20210101-20211231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzEwLTYtMS0xLTgxMjE_fdb72d85-14db-4a7b-a70f-4dec65920aca">650,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6c331b0bbafb4b2680c749659e1c82b1_I20211231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzExLTEtMS0xLTgxMjE_ff7af24a-5c56-4095-b9e5-88b10a3e6b01">61,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i27b25b30c9fd4ba59fc2eafb50014834_I20211231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzExLTItMS0xLTgxMjE_3f7b73e9-f63a-4c2b-8c6b-a7f911d721d2">405,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i204bc52fd44a4d0c816c0a2181824b55_I20211231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzExLTMtMS0xLTgxMjE_376a478f-dab0-4428-b31d-1a0aefb15221">217,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5c201bd2cec84413bbbc206341b41448_I20211231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzExLTUtMS0xLTgxMjE_b26848b9-e284-47e8-87fa-39e6e50b325f">228,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib7b48fc3177846248e8e650003e9519e_I20211231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzExLTYtMS0xLTgxMjE_07893b27-70cd-4053-a765-851a572492ca">913,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icb14eb0dd43c4a709e096b2d83073f70_I20191231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE3LTEtMS0xLTgxMjE_67b5872c-a428-4034-ae3b-191146640355">44,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i3b342b88388a4129a9cc8369e81686ea_I20191231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE3LTItMS0xLTgxMjE_d4fc6812-c6a1-4e4a-8bcd-24ccd7f7668e">224,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0edeeed139064a33990a9c7ee6e5964b_I20191231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE3LTMtMS0xLTgxMjE_5ace7aa3-9fe2-45dd-8126-da278380b11f">250,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2a981d61c5eb439da38fb12362dd8fad_I20191231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE3LTUtMS0xLTgxMjE_dd22837a-948c-41f4-bc43-046baffaac53">448,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i480c049e5a834c568af08f9e90655523_I20191231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE3LTYtMS0xLTgxMjE_875e6718-d389-4682-92c3-db80222f36a7">967,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i82a3d365592c40cb897ba384875fc12d_D20200101-20201231" decimals="0" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE4LTEtMS0xLTgxMjE_feb247c1-7c9e-4500-998b-f16830aac3f7">2,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iad6b64867bef4fc0afcde57faf6fa67b_D20200101-20201231" decimals="0" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE4LTItMS0xLTgxMjE_4be5a47a-e6d5-4d58-9ab4-bed12fb75f4b">40,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i05109703e464417fa841f9c540f3678f_D20200101-20201231" decimals="0" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE4LTMtMS0xLTgxMjE_bfa122dc-0ff9-4323-9790-9dfc49a252e3">12,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9b165e9375644237b4496e8ca868e02d_D20200101-20201231" decimals="0" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE4LTUtMS0xLTgxMjE_8ef9aaf0-b695-4c72-962c-4d52ba80b596">33,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfedcf2862364d49b2a7c3a1f4e8dfcf_D20200101-20201231" decimals="0" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE4LTYtMS0xLTgxMjE_112ba700-3daa-4c50-93ab-3ede5ab586fa">88,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i82a3d365592c40cb897ba384875fc12d_D20200101-20201231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE5LTEtMS0xLTgxMjE_9187f8eb-9a52-4cc5-94ac-10a07e598bd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="iad6b64867bef4fc0afcde57faf6fa67b_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE5LTItMS0xLTgxMjE_1b6a5403-4578-4fb6-9f9d-06c0b4449059">15,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i05109703e464417fa841f9c540f3678f_D20200101-20201231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE5LTMtMS0xLTgxMjE_8d985857-7c57-43aa-a6fe-e5a43d547434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9b165e9375644237b4496e8ca868e02d_D20200101-20201231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE5LTUtMS0xLTgxMjE_edc20040-e93e-4934-a4b3-8035f8cc434d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfedcf2862364d49b2a7c3a1f4e8dfcf_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE5LTYtMS0xLTgxMjE_8ad84dd5-5dd2-45b5-83f2-d6d090bc8a55">15,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifa6646a5d6c34f7abe7a9ae44f606c91_I20201231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTEtMS0xLTgxMjE_9dc70de7-f369-470d-949b-f267e59f74af">47,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6f033263dc0240bd861510077d28d05f_I20201231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTItMS0xLTgxMjE_3f2aaf5e-2820-4b6c-9af6-638d4a16474a">248,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0f8794d0236d482997b1f6aa91113f6f_I20201231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTMtMS0xLTgxMjE_10e82511-5cb2-45aa-ae68-6fb87b6e93bb">262,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i939b5018129e4e1e8aa83500cd6fa35a_I20201231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTUtMS0xLTgxMjE_b33b9edc-2578-4988-be47-fe4868e75f1e">481,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4c9a6b3f743d4662992a44369b2b7a76_I20201231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTYtMS0xLTgxMjE_b409786d-b403-406c-8535-6729d36806b8">1,041,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaf250eba9f184833af1a42fc1ec5cb78_D20210101-20211231" decimals="0" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIxLTEtMS0xLTgxMjE_7f203152-a91b-402e-a135-39c50fa7b38d">2,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i81d59e90707242a995284a6cface9df4_D20210101-20211231" decimals="0" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIxLTItMS0xLTgxMjE_862d51d6-2d7c-4285-ade8-eacbcb680421">35,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6004ba24adf34129bfd6da674261a96d_D20210101-20211231" decimals="0" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIxLTMtMS0xLTgxMjE_e5e720f6-69a8-44d8-a5ce-b27eb9dc415d">72,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie411180fd99f4e5790c4b079d04b0000_D20210101-20211231" decimals="0" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIxLTUtMS0xLTgxMjE_3191a161-61f2-4dd7-ace5-e6953725f5d2">19,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9f0874df70594af896849c68995cffcc_D20210101-20211231" decimals="0" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIxLTYtMS0xLTgxMjE_7d96b96b-9cb1-40e9-a57b-ac731eff6014">130,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaf250eba9f184833af1a42fc1ec5cb78_D20210101-20211231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIyLTEtMS0xLTgxMjE_1dd6daea-1365-4429-87b5-9ef37812e48f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i81d59e90707242a995284a6cface9df4_D20210101-20211231" decimals="0" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIyLTItMS0xLTgxMjE_ae88eb67-3b26-433c-a4e2-6636e3005819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6004ba24adf34129bfd6da674261a96d_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIyLTMtMS0xLTgxMjE_6b38fa4b-11a5-447a-8022-e90ff406fda8">276,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie411180fd99f4e5790c4b079d04b0000_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIyLTUtMS0xLTgxMjE_4ca606f8-6354-42b5-a1ae-d14383702e69">373,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i9f0874df70594af896849c68995cffcc_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIyLTYtMS0xLTgxMjE_07deb0b5-c066-4594-acda-2c1f33d81e63">650,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i69e2f780ec994d4a9364ffcb20e6ff20_I20211231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIzLTEtMS0xLTgxMjE_e2bbf86f-26ed-40c0-966f-9e374912bd16">50,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i680a4d77ca0147b2aae6c2c4160d7120_I20211231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIzLTItMS0xLTgxMjE_19d288d4-9132-4054-9e03-5e8b0ce730a2">284,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifac774375ae04e15b64aebbe75cc3267_I20211231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIzLTMtMS0xLTgxMjE_685e8753-a890-4e9f-98b4-feccc2ec6862">58,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icb2705498f8a4d26910dc44f4ac0e29d_I20211231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIzLTUtMS0xLTgxMjE_dec1d4d0-3f53-43ba-9f36-f88d1cf6e396">127,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie8f1299e30cf4e0c90e275bafdaaf57b_I20211231" decimals="0" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIzLTYtMS0xLTgxMjE_a8c5e73c-fc10-4eba-9a80-dd02f62cb3a6">520,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9240fcdbfad4d159109b9211c4a25dc_I20201231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTEtMS0xLTE0NTE0_a9554dcc-9fec-455e-87e3-e969c807e8b1">13,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i604b72e2ed1e45c0986b519ae61b7407_I20201231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTMtMS0xLTE0NTE0_c18e4e10-942b-4890-81cf-6a59e6cbf1d9">116,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i71b8d6a28ae24cd8a53aac765710b347_I20201231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTUtMS0xLTE0NTE0_e12dbdd1-6542-4fc8-87d3-676920cf33e1">89,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia96d51ce70dc4c5196635b560cc91d6f_I20201231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTctMS0xLTE0NTE0_3c0d3334-0430-4853-9e29-8c8becb0a9bb">16,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTktMS0xLTE0NTE0_897ab224-730c-4f4b-b181-45b1e36bbcf1">236,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i93dfc0b8bdb64273a5af3bd7e762ee6a_I20211231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzI2LTEtMS0xLTgxMjE_8e4030dc-d985-4728-abfd-b75c95f1c06a">11,358</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i245cb0b82ebe4888bdb55d9598677214_I20211231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzI2LTItMS0xLTgxMjE_609e0e97-32bf-4243-b7b5-d382ab3db917">120,986</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i79bab5333acc4486b6de092783d41a58_I20211231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzI2LTMtMS0xLTgxMjE_08bd3e6c-83d4-45c2-9c53-d0ad1db08dc7">159,034</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ife652053dd47472d83f53067d84eaef0_I20211231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzI2LTUtMS0xLTgxMjE_e3c82fca-e775-4c4c-9eda-564295fcafa6">100,663</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzI2LTYtMS0xLTgxMjE_702aa4cf-6047-464c-a26f-ddda24a596aa">392,041</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 7: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfLeasesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzkyMw_424279d8-fa3a-41c9-848f-83c5b3e71dd8" continuedAt="i4057b8debaae4f6fa29add705d692e97" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4057b8debaae4f6fa29add705d692e97" continuedAt="i95ad4236e97b4e89bd5e57f6e228809a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with lease terms generally between <ix:nonNumeric contextRef="i8237782881b84c70a77a2cf4a54d5e61_D20210101-20211231" name="oncyf:OperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzEwNg_f1ad92df-0a26-433f-9417-279ba9121d81">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i76fe8a9f3db24be59863f170633d5a51_D20210101-20211231" name="oncyf:OperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzExMg_1a06a400-8d45-43e6-bcf0-6716ec26894a">6</ix:nonNumeric> years. We currently do not have leases with residual value guarantees, or leases not yet commenced to which we are committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we recorded a lease modification and an addition related to the office lease extension for one of our subsidiaries and a new office space lease for our Canadian head office, respectively. The weighted-average rate applied was <ix:nonFraction unitRef="number" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="2" name="ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzEwOTk1MTE2Mjk1MjQ_e97f0c17-87ee-432d-9154-4cc3bf4ba7d4">15</ix:nonFraction>%. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="i95ad4236e97b4e89bd5e57f6e228809a"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzkyNA_73e47e65-c6c4-4470-8a8b-95ae01a32dac" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets outstanding at December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzEtMS0xLTEtMTcyNTY_8b648257-f42b-40a0-bc7c-c52b33cfb916">372,468</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="0" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzEtMS0xLTEtODEyMQ_5ed3d6d0-b852-406f-834a-3320b65d0c81">430,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzItMS0xLTEtMTcyMjk_ec795a22-b4d1-4852-8c8c-d846d9f5d26d">208,976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzItMS0xLTEtMTQzODM_d8060513-3bce-4f74-a320-3560eefef746">297,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="oncyf:LeaseModificationRightOfUseAssets" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzMtMS0xLTEtMTc1MDA_32841e40-9bb8-4adc-a3ea-61b526ece10e">323,782</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="oncyf:LeaseModificationRightOfUseAssets" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzMtMy0xLTEtMTc1MTE_9a0b3e52-ca68-4165-95c7-7150a4d41782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzMtMS0xLTEtMTcyMjk_aefcd452-f1d2-496c-ac00-a885a44402d0">321,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzItMS0xLTEtODEyMQ_f119a12d-b0b9-4ee3-b50f-1f2640465528">357,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="oncyf:ForeignExchangeImpactRightofUseAssets" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzQtMS0xLTEtMTcyMjk_ec2e6baf-f79a-451a-aec9-f473b2c01ce5">847</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="oncyf:ForeignExchangeImpactRightofUseAssets" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzMtMS0xLTEtODEyMQ_081652f8-cbf3-4709-a05c-fb3349513df9">1,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzUtMS0xLTEtMTcyMjk_a4befef9-5107-4b90-a8df-5e96f13594e1">584,251</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzQtMS0xLTEtODEyMQ_a9d658f1-5784-4f8d-9b96-897a166d1896">372,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzkyMQ_ac908eb0-d266-427b-825d-fa774a960a53" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities outstanding at December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzEtMS0xLTEtMTcyOTk_0412ebdd-2d40-4519-b47b-424a5b0aa767">402,059</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="0" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzEtMS0xLTEtODEyMQ_53f76508-9d47-4686-80c3-3c474fc4b5ae">506,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzItMS0xLTEtMTcyNzE_1caead2c-b63c-42b9-b2d8-67eac8cddd1b">203,868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzItMS0xLTEtMTQzOTE_4bbe44dc-8c7f-4897-add1-4e9e754bb9f1">297,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="oncyf:EffectOfLeaseModificationOnLeaseLiabilities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzMtMS0xLTEtMTc1Mjc_56b11131-a69d-4934-a2c3-b3b4a390895d">323,782</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="oncyf:EffectOfLeaseModificationOnLeaseLiabilities" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzMtMy0xLTEtMTc1Mzk_ac77f12f-c192-4777-94a3-8190e517d1b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzMtMS0xLTEtMTcyNzE_ce7ba941-0e43-4177-ae85-eb18cb3a4596">365,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzItMS0xLTEtODEyMQ_1ef04030-0569-430c-9f3a-888c8cf4e452">460,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzQtMS0xLTEtMTcyNzE_4c905472-7372-4ecb-acfa-16f5f5e4a7fc">91,727</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzMtMS0xLTEtODEyMQ_3edb7fe8-55db-40f1-8c56-e355d7f64330">68,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="oncyf:GainsLossesFromForeignExchangeImpact" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzUtMS0xLTEtMTcyNzE_ba7b60d5-4457-4e8c-97b1-c99b1af2c75c">1,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="oncyf:GainsLossesFromForeignExchangeImpact" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzQtMS0xLTEtODEyMQ_fb344277-1d0e-4558-a67b-bce496240dc0">9,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzYtMS0xLTEtMTcyNzE_cdabf258-25de-40ed-b712-1aa5e66dd115">654,753</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzUtMS0xLTEtODEyMQ_fb15907d-8403-451f-b5f5-3e56171bd310">402,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzkyMg_993bbb70-d753-4d2c-be20-60d0312ddc7e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2021 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i88fbac179750483d8af64e04435a79bf_I20211231" decimals="0" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTowYTBhMjkxYmJlNDk0OWFhYWNjMTcyMTQzYTkwOWU4Ni90YWJsZXJhbmdlOjBhMGEyOTFiYmU0OTQ5YWFhY2MxNzIxNDNhOTA5ZTg2XzItMS0xLTEtODEyMQ_011eaa78-d940-458c-a964-9cb22a2f4e37">372,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic7dc0ed2ed7547d89fd4e3e287348bd7_I20211231" decimals="0" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTowYTBhMjkxYmJlNDk0OWFhYWNjMTcyMTQzYTkwOWU4Ni90YWJsZXJhbmdlOjBhMGEyOTFiYmU0OTQ5YWFhY2MxNzIxNDNhOTA5ZTg2XzMtMS0xLTEtODEyMQ_6c4788dc-c352-4777-89f0-3b2320909516">434,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i22879de6b8fa44818a5c41e8a35f3c84_I20211231" decimals="0" name="ifrs-full:GrossLeaseLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTowYTBhMjkxYmJlNDk0OWFhYWNjMTcyMTQzYTkwOWU4Ni90YWJsZXJhbmdlOjBhMGEyOTFiYmU0OTQ5YWFhY2MxNzIxNDNhOTA5ZTg2XzQtMS0xLTEtODEyMQ_b13c15d3-e91a-4819-adff-60f46063b5d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTowYTBhMjkxYmJlNDk0OWFhYWNjMTcyMTQzYTkwOWU4Ni90YWJsZXJhbmdlOjBhMGEyOTFiYmU0OTQ5YWFhY2MxNzIxNDNhOTA5ZTg2XzUtMS0xLTEtODEyMQ_c2691731-59e0-472f-831d-c105f8a2aca3">807,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_157"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 8: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzIxODQ_9bea491c-7baa-4c9a-ab86-dcee6ee25b8d" continuedAt="i8b345814874b45be9e49eea84359c780" escape="true">Warrant Derivative</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8b345814874b45be9e49eea84359c780"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2019, pursuant to an underwritten public offering, <ix:nonFraction unitRef="shares" contextRef="i32540143275947cf9a999007e5c89d46_D20190816-20190816" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzk4_752bd731-7085-469b-bb55-f286d7ebdd23">4,619,773</ix:nonFraction> units were sold at a purchase price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i60804d42d4e24611b5b61485d0a443bf_I20190816" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzE0MA_03112f2f-64f7-443d-be2e-914aca8de56d">0.81</ix:nonFraction> per unit for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i32540143275947cf9a999007e5c89d46_D20190816-20190816" decimals="0" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzE3NA_b99e54ce-b39b-4ff9-b3ef-e1296d070792">3,742,016</ix:nonFraction>. Each unit included <ix:nonFraction unitRef="shares" contextRef="i3d6b7c66a4fc4f108fb4d53193ce2035_I20190816" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzE5Nw_8c980f64-1e9e-4e4a-9831-40c8773b392f">one</ix:nonFraction> common share and <ix:nonFraction unitRef="shares" contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzIxNw_e61658fd-b24d-4b50-8362-bb8508737b26">one</ix:nonFraction> common share purchase warrant (see Note 9). Each common share purchase warrant entitled the holder to purchase <ix:nonFraction unitRef="shares" contextRef="i60804d42d4e24611b5b61485d0a443bf_I20190816" decimals="INF" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzMzMQ_147ad134-6f61-4741-a532-32e9bd482763">one</ix:nonFraction> common share at an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816" decimals="2" name="oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzM3MQ_ca6ec6d7-d600-4866-ac8e-ac18b3acb7e8">0.90</ix:nonFraction> until August 16, 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IAS 32 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments: Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816" decimals="2" name="oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzc1Nw_8028c35e-6583-4d04-b514-a9da3473be3d">0.90</ix:nonFraction> meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzIxODU_5b40a2d2-2403-4bcd-a1a6-3b6e6c4feba4" continuedAt="iff0b3563cf3f422cbb15be2b5ae61923" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in fair value of the warrant derivative is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29a8a4e95e79475ba60e7ba7d35e2cf9_I20191231" decimals="INF" name="oncyf:ClassOfWarrantOrRightOutstanding1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzEtMS0xLTEtODEyMQ_a0644d1d-1168-45b6-9742-32aa760174d2">1,684,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i29a8a4e95e79475ba60e7ba7d35e2cf9_I20191231" decimals="0" name="oncyf:WarrantsAndRightsOutstanding1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzEtMi0xLTEtODEyMQ_6e09538b-42c8-4f9d-909f-1577df72dd6d">8,508,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231" decimals="0" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzItMS0xLTEtODEyMQ_9b4c7e52-2566-4190-a98b-173f5dabc7cb">1,418,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231" decimals="0" name="oncyf:ClassofWarrantorRightWarrantsExercised" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzItMi0xLTEtODEyMQ_1a11a720-c0e7-4d92-a4bd-fca5b874ac07">4,636,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzMtMi0xLTEtODEyMQ_619645ba-ea0e-4666-9e32-2d6bf1206fbb">3,491,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231" decimals="0" name="oncyf:GainsLossesFromForeignExchangeImpact" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzQtMi0xLTEtODEyMQ_6ec76adf-3198-42d2-b032-1998a880c794">150,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76b8dc9ee72c4d6e999cf36c6458c7f1_I20201231" decimals="INF" name="oncyf:ClassOfWarrantOrRightOutstanding1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzUtMS0xLTEtODEyMQ_488db619-e75c-471e-b90c-12560393fdf3">265,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i76b8dc9ee72c4d6e999cf36c6458c7f1_I20201231" decimals="0" name="oncyf:WarrantsAndRightsOutstanding1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzUtMi0xLTEtODEyMQ_8e99c2eb-3881-4a4b-9e9a-e435349db3e5">531,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231" decimals="INF" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzYtMS0xLTEtODEyMQ_85e5ffbe-bfb1-499e-83ff-051c61eddea4">201,722</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231" decimals="0" name="oncyf:ClassofWarrantorRightWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzYtMi0xLTEtODEyMQ_94e44db9-ae86-4d41-afa7-3a4f1cd78c98">455,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzctMi0xLTEtODEyMQ_7cb86b39-394f-4e92-bde6-9bdd58088559">17,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231" decimals="0" sign="-" name="oncyf:GainsLossesFromForeignExchangeImpact" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzgtMi0xLTEtODEyMQ_f878f762-7aa4-4db0-aab1-a5c712c168ab">2,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfae6e354e8248509fd71f314f2f7bb7_I20211231" decimals="INF" name="oncyf:ClassOfWarrantOrRightOutstanding1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzktMS0xLTEtODEyMQ_ecbc3782-4bdd-461f-9815-2432bc8ff87b">64,035</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="idfae6e354e8248509fd71f314f2f7bb7_I20211231" decimals="0" name="oncyf:WarrantsAndRightsOutstanding1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzktMi0xLTEtODEyMQ_c8d54944-f9b9-4651-9c24-9ddc74074be1">56,017</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we received cash proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="oncyf:ProceedsfromWarrantExercises1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzE1MzA_04c5be87-7b02-4519-9303-284428809dd0">181,550</ix:nonFraction> (2020 - US$<ix:nonFraction unitRef="usd" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="oncyf:ProceedsfromWarrantExercises1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzE1Mzk_2c1bfaca-83f3-45fb-a9aa-a22dc5b972e7">1,276,532</ix:nonFraction>; 2019 - US$<ix:nonFraction unitRef="usd" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="oncyf:ProceedsfromWarrantExercises1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzEwOTk1MTE2Mjk5OTA_9f6477fd-4397-46fb-bace-012e7cee1ef4">2,642,082</ix:nonFraction>) with respect to the warrants exercised. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iff0b3563cf3f422cbb15be2b5ae61923"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative at December&#160;31 was determined using the following assumptions: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="idfae6e354e8248509fd71f314f2f7bb7_I20211231" decimals="2" name="oncyf:FairValueofWarrantIssuedPerWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzEtMS0xLTEtODEyMQ_c3ef961a-b1ad-49a8-8a4b-fe7366f0b77a">0.69</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="i76b8dc9ee72c4d6e999cf36c6458c7f1_I20201231" decimals="2" name="oncyf:FairValueofWarrantIssuedPerWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzEtMi0xLTEtODEyMQ_e5768764-0c31-4315-b12b-f5429288d899">1.57</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231" decimals="2" name="oncyf:WarrantIssuedUnderlyingSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzItMS0xLTEtODEyMQ_47d8466a-d80c-44d6-bf71-71830db5186c">1.39</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231" decimals="2" name="oncyf:WarrantIssuedUnderlyingSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzItMi0xLTEtODEyMQ_1f3dbe19-1d97-4dd9-be22-b7f8d7f390cd">2.38</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzMtMS0xLTEtODEyMQ_bff97ea4-7084-4df0-a27a-6a40fe6f8220">0.39</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzMtMi0xLTEtODEyMQ_5eaa8ac6-f79f-42a7-97c0-b93ad14c769b">0.10</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="year" contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzQtMS0xLTEtODEyMQ_65d87719-4063-42b5-9835-dfa38fe1dada">1.0</ix:nonFraction> year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzQtMi0xLTEtODEyMQ_35946c4c-5c55-4bcb-a27b-6149a43d9324">1.0</ix:nonFraction> year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzUtMS0xLTEtODEyMQ_ed700f6b-2aba-4a35-a09b-ee1ddd191923">90.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzUtMi0xLTEtODEyMQ_fed9dc02-5ccb-4fa4-83ea-52b30d2cadc4">90.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231" decimals="INF" name="oncyf:DividendYieldPercent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzYtMS0xLTEtODEyMQ_0fc6ba14-9e8a-4c7f-bd4e-11fabc1d94d6">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231" decimals="INF" name="oncyf:DividendYieldPercent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzYtMi0xLTEtODEyMQ_91d5e331-ac3e-4074-b8d2-81393d2aa8ab">Nil</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_160"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 9: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzYwMDQ_1744418e-7399-48e5-8f95-3698530e0f62" continuedAt="i6efb945b506f44e2913f8e9fd914a7b4" escape="true">Share Capital</ix:nonNumeric></span></div><ix:continuation id="i6efb945b506f44e2913f8e9fd914a7b4" continuedAt="i9689acc940af41c9baa423d9649eb993"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzYwMTc_12e6ab12-c4f9-49d0-97f2-36dab8146fdd" continuedAt="i708ca06cbce94a88a714c7659377a709" escape="true"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedc65d68837a4eacac34675a1cd9779e_I20181231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE1LTEtMS0xLTgxMjE_e264a366-3fc8-437f-acf5-6ddf874d1285">17,399,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iedc65d68837a4eacac34675a1cd9779e_I20181231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE1LTItMS0xLTgxMjE_101d1cef-d9d7-4903-b4f1-86a872c22b46">285,193,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i830cca3a0f664a4d8b3b50a1c284e3b4_D20190101-20191231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE2LTEtMS0xLTgxMjE_857fd0d1-4891-4419-a4d0-a69803fe1ee5">323,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i830cca3a0f664a4d8b3b50a1c284e3b4_D20190101-20191231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE2LTItMS0xLTgxMjE_773ffe3e-9350-4128-85bb-112008f00d46">391,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7bed414ac6874a10b56efb160637b31e_D20190101-20191231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE3LTEtMS0xLTgxMjE_1720b9ba-ea0b-409a-ae34-f925ed27866c">2,494,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7bed414ac6874a10b56efb160637b31e_D20190101-20191231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE3LTItMS0xLTgxMjE_f045447c-e61b-4de5-aaa5-27915180ba0f">5,403,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3a11c0f144e4ff3a325f5a105f0f4d1_D20190101-20191231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE4LTEtMS0xLTgxMjE_b55659c4-dc30-4be6-83fe-99e57a19fa40">4,425,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie3a11c0f144e4ff3a325f5a105f0f4d1_D20190101-20191231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE4LTItMS0xLTgxMjE_f6651f5d-a84e-4fcc-b89a-db46b7347f35">8,476,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83e860d0f0a34191b33af656961cbc19_D20190101-20191231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE5LTEtMS0xLTgxMjE_86865673-015c-438c-97d6-5a21168c6cfe">4,619,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i83e860d0f0a34191b33af656961cbc19_D20190101-20191231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE5LTItMS0xLTgxMjE_d19e500e-9195-4d17-9746-6751e01435cc">3,314,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idae5479b6b654d84bb1c05fde1394dd8_D20190101-20191231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIwLTEtMS0xLTgxMjE_f3ff2a24-8c8e-40b4-a0f3-3fb52b221268">2,935,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="idae5479b6b654d84bb1c05fde1394dd8_D20190101-20191231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIwLTItMS0xLTgxMjE_5e0a4166-95ae-41d2-9272-512b20a1b72d">9,152,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i7e5a099158d84fb599da0d92dcc26605_D20190101-20191231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIxLTItMS0xLTgxMjE_e4d16255-d401-4798-a8e0-d7f35449a17f">854,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11b4be78aa4f47c695bf177fab865a55_I20191231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIyLTEtMS0xLTgxMjE_6b57ed1e-ae15-4997-bef8-dd210c958cf6">32,198,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i11b4be78aa4f47c695bf177fab865a55_I20191231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIyLTItMS0xLTgxMjE_1073ead0-39b6-4913-98de-a9c6d0c20b4c">311,077,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ab215a79e4441f2b018c7706826735d_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIzLTEtMS0xLTgxMjE_fd025f5f-3e66-4041-9ee1-7d805142c33f">133,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1ab215a79e4441f2b018c7706826735d_D20200101-20201231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIzLTItMS0xLTgxMjE_644c7cd5-2d41-477a-865b-51ff11b5a14f">385,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ce569aab88d48369c11f14c0bf78a25_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI0LTEtMS0xLTgxMjE_96714005-030d-4eed-8144-5ae824ec90f8">234,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7ce569aab88d48369c11f14c0bf78a25_D20200101-20201231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI0LTItMS0xLTgxMjE_7d676b63-2777-43be-a7b4-feccdc42d321">732,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)(d)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c46f6b7f524d1387c1a6b6fe9dfa39_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI1LTEtMS0xLTgxMjE_729b3303-62e7-4fd7-88a6-a5e5e259a528">12,182,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia7c46f6b7f524d1387c1a6b6fe9dfa39_D20200101-20201231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI1LTItMS0xLTgxMjE_1a106cf3-83ff-4a88-9bd8-f0a9d8d49dbc">40,037,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78884fc7ad21406cb0e0bd491aad0b54_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI2LTEtMS0xLTgxMjE_a7bc3c3a-2422-4604-b5b4-ddaa04780ce0">1,418,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i78884fc7ad21406cb0e0bd491aad0b54_D20200101-20201231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI2LTItMS0xLTgxMjE_963d3b57-c126-433a-ba96-07d9d8359175">6,332,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib6968307567a4ac88a5fbac883bf6779_D20200101-20201231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI3LTItMS0xLTgxMjE_3b98a8e1-1fe0-4549-a2af-2d1db4eff2d9">1,741,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7204566da8c8413784114e3a0277f22b_I20201231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI4LTEtMS0xLTgxMjE_f13fe8ec-5ec1-44eb-a310-77a2d562d93e">46,166,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7204566da8c8413784114e3a0277f22b_I20201231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI4LTItMS0xLTgxMjE_73779a5a-d97a-429a-b0d4-190ece368db9">356,824,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i313db08027ee47b8a313714b551d5295_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE2LTEtMS0xLTkzODE_9582d844-4c6b-4197-a789-0b99854f7ae6">123,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i313db08027ee47b8a313714b551d5295_D20210101-20211231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE2LTItMS0xLTkzODE_f914cc54-ebcd-4e70-baea-657b333742c4">381,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie790de8f351b420c97389308ec3102f1_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE3LTEtMS0xLTkzODE_c028e1f5-050f-4989-b282-da8ae21a4c63">150,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie790de8f351b420c97389308ec3102f1_D20210101-20211231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE3LTItMS0xLTkzODE_b9b22efd-d86f-48e2-8333-bd2421548b90">543,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d55af5d6889492ba6feaef6f3089cbb_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE4LTEtMS0xLTkzODE_3a310245-f232-45c0-aa94-6d0ee2d7bebb">8,401,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d55af5d6889492ba6feaef6f3089cbb_D20210101-20211231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE4LTItMS0xLTkzODE_fc843aca-51f3-4c7a-82f6-672f8a0a6104">34,168,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1068e88a4ef24a30afc676a512075718_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE5LTEtMS0xLTkzODE_1c0e9605-4821-414f-9fd8-9206ebbfbe43">201,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1068e88a4ef24a30afc676a512075718_D20210101-20211231" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE5LTItMS0xLTkzODE_7587ac2e-bd1d-42f5-ba24-891782661329">686,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="id057bd4ec78a491094f4618144a1c09d_D20210101-20211231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIwLTItMS0xLTkzODE_af91e879-f79b-41b4-bce9-e770c097dadd">1,256,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3a75af6263f486894cd6657c4bd2464_I20211231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIxLTEtMS0xLTkzODg_5902aae4-4def-423e-a578-b8f32e92eb02">55,043,789</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic3a75af6263f486894cd6657c4bd2464_I20211231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIxLTItMS0xLTkzODg_84ff7785-022a-4788-9617-1d39292d636a">391,348,183</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement, we may sell up to US$<ix:nonFraction unitRef="usd" contextRef="i2902b2520fea41089f98be9b8eace36f_I20180927" decimals="INF" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzE2OTE_a6de4b64-ef55-4c78-9525-1d147f5cf3a7">26,000,000</ix:nonFraction> worth of common shares to LPC over the <ix:nonNumeric contextRef="ifdc041cff18445c2bf6a95ff95de581f_D20180927-20180927" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzI3NDg3NzkwNzk1NDM_190ff63d-5ecf-4409-9a69-daff4925bd4e">30-month</ix:nonNumeric> term. This agreement expired in 2021, and <ix:nonFraction unitRef="shares" contextRef="i67283f9ed1904a3db011f7a4a67ddd74_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2Mzc4MjI_c1845e2c-ff55-4de0-ba69-c795c83b3660"><ix:nonFraction unitRef="shares" contextRef="i5f476ff70c064f36b090da63b6c25511_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2Mzc4MjI_e16bbac7-5e2d-4ed1-8ae2-58948598c09a">no</ix:nonFraction></ix:nonFraction> common shares were issued during 2021 and 2020. In 2019, we sold <ix:nonFraction unitRef="shares" contextRef="i070d85f1ae5c470e839378eff83c30b7_D20190101-20191231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzMwODk_eb006432-7d98-4304-a689-624287a9b24d">2,477,665</ix:nonFraction> common shares for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i070d85f1ae5c470e839378eff83c30b7_D20190101-20191231" decimals="0" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzMxNDg_e00eeaf7-1f39-4fe2-ba78-04cb7b5aeace">4,055,725</ix:nonFraction> and issued <ix:nonFraction unitRef="shares" contextRef="ifb21fdd6d32d40719bcec4f80757184e_D20190101-20191231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzMxODE_7880fbc9-c1e4-4569-9094-b27f298fd76f">17,278</ix:nonFraction> commitment shares. The commitment shares were fair valued at US$<ix:nonFraction unitRef="usd" contextRef="ifb21fdd6d32d40719bcec4f80757184e_D20190101-20191231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzMyNjQ_36de5375-d241-41fd-b246-0a6eeebb4fbe">29,758</ix:nonFraction> and were recorded as share issue costs in addition to cash share issue costs of $<ix:nonFraction unitRef="cad" contextRef="ifb21fdd6d32d40719bcec4f80757184e_D20190101-20191231" decimals="0" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzMzNjY_b4157130-22f2-4ea0-aee5-957180ed2558">3,757</ix:nonFraction>.  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market price, with an aggregate offering value of up to US$<ix:nonFraction unitRef="usd" contextRef="ieef3c4b044f443248ece0ef8dc3ac073_I20181024" decimals="INF" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM2MTY_23a633a3-8d3d-4f16-bee4-8af9993655ef">30,000,000</ix:nonFraction> over a <ix:nonNumeric contextRef="i8604cae19b054cb08c0871ae11d35ebd_D20181024-20181024" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzYwMTg_dc2f3775-9542-4cbb-a3d1-2cf1e257ad02">19-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement expired on June 4, 2020 and <ix:nonFraction unitRef="shares" contextRef="ie179742cb9f841999fd8416ad5ecaf64_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2Mzc4MzY_4e24b14c-335a-49b1-8eed-a3f4102705a5">no</ix:nonFraction> common shares were issued during 2021. In 2020, we sold <ix:nonFraction unitRef="shares" contextRef="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM3NDA_ab5ab52e-8eeb-475b-80ff-16e2f1b65b99">6,741,518</ix:nonFraction> (2019 - <ix:nonFraction unitRef="shares" contextRef="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM3NDk_6775977d-60b7-4353-9746-94fca4a31977">4,425,040</ix:nonFraction>) common shares for gross proceeds of  US$<ix:nonFraction unitRef="usd" contextRef="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231" decimals="0" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM3OTg_4418bf5b-0e2a-4858-9e3b-2f5bd19129ba">17,538,342</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usd" contextRef="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231" decimals="0" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM4MDc_549e7e69-ebd6-400c-9673-c4665688e4a1">6,390,691</ix:nonFraction>) at an average price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i3e6b52351e9440c6a782ff3ab4b4b8f5_I20201231" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM4NDM_b5c60d0a-4e21-491f-a52a-79f5e20d0974">2.42</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usdPerShare" contextRef="i32cccb978d9e4fdbb89e459a307b27ea_I20191231" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM4NTI_dced3bc1-a6df-4013-9979-bdc8937e5d7a">1.70</ix:nonFraction>). We received, net of commissions of US$<ix:nonFraction unitRef="usd" contextRef="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231" decimals="0" name="oncyf:ShareIssueRelatedCostCommissions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM5MDE_7f8d2015-d573-45f9-ad07-fb5d85342116">526,150</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usd" contextRef="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231" decimals="0" name="oncyf:ShareIssueRelatedCostCommissions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM5MTA_85761219-0120-4b6b-b9bd-06cad9c95907">191,721</ix:nonFraction>), proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231" decimals="0" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM5MzY_251bf632-ec83-42e4-8dc7-1a82785fabfb">17,012,192</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usd" contextRef="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231" decimals="0" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM5NDU_0c3715c6-3465-46bc-8656-0d66360c5d38">6,198,970</ix:nonFraction>). In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQwMjY_d9e309aa-1d8d-4e82-807f-f28141547342">856,754</ix:nonFraction> (2019 - $<ix:nonFraction unitRef="cad" contextRef="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQwMzU_5ff451d0-accb-45dd-a8ae-445f1cbe7a68">344,834</ix:nonFraction>). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 16, 2019, pursuant to an underwritten public offering, <ix:nonFraction unitRef="shares" contextRef="i32540143275947cf9a999007e5c89d46_D20190816-20190816" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQxNTM_906d2534-3524-4285-b9eb-8cde4ec8cfa7">4,619,773</ix:nonFraction> units were sold at a purchase price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i60804d42d4e24611b5b61485d0a443bf_I20190816" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQxOTU_3b960002-0751-4dc8-b8e7-241bd569dd8c">0.81</ix:nonFraction> per unit for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i32540143275947cf9a999007e5c89d46_D20190816-20190816" decimals="0" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQyMjk_736a6b81-2abd-4720-9a9e-2538d1cc6bc7">3,742,016</ix:nonFraction>. Each unit included <ix:nonFraction unitRef="shares" contextRef="i3d6b7c66a4fc4f108fb4d53193ce2035_I20190816" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQyNTI_1d5b2ae3-1094-4a61-b4a6-721a99ba04af">one</ix:nonFraction> common share with a fair value of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i3d6b7c66a4fc4f108fb4d53193ce2035_I20190816" decimals="2" name="oncyf:SharesIssuedFairValueOfCommonShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQyODk_dacf456e-d277-48bd-a60f-2af80f3d6b9a">0.54</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQyOTY_e985ef04-67fb-4ae5-90a4-1ca5615890d2">one</ix:nonFraction> common share purchase warrant with a fair value of US$<ix:nonFraction unitRef="usdPerShare" contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816" decimals="2" name="oncyf:SharesIssuedFairValueOfCommonShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQzNTA_4293b5f4-6895-42a3-b0e5-113d5ac38d18">0.27</ix:nonFraction>. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase <ix:nonFraction unitRef="shares" contextRef="i60804d42d4e24611b5b61485d0a443bf_I20190816" decimals="INF" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ0OTE_c8f5e5c1-001b-4fb9-a634-f21c85d5fe43">one</ix:nonFraction> common share at an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816" decimals="2" name="oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ1MzE_2298fbde-28b7-4b2a-bc2d-b435cff02a63">0.90</ix:nonFraction> until August 16, 2024. We incurred transaction costs of $<ix:nonFraction unitRef="cad" contextRef="i32540143275947cf9a999007e5c89d46_D20190816-20190816" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ1OTA_79d8a1bd-4282-4515-a1fe-cdfa3e3caeeb">699,427</ix:nonFraction> of which $<ix:nonFraction unitRef="cad" contextRef="i8764aff5c6754164b0bd8ea7f5a1155f_D20190816-20190816" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ2MDI_06008078-ee99-4b1b-8b13-ea1ebada89c9">466,284</ix:nonFraction> were allocated to share issue costs and $<ix:nonFraction unitRef="cad" contextRef="i249c2d938ccb432fbaf49910859f86b3_D20190816-20190816" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ2NDU_0f729046-37b8-41f8-b803-68721eee5d14">233,143</ix:nonFraction> were allocated to operating expenses, based on their relative fair values. In 2021, our share capital included fair value of $<ix:nonFraction unitRef="cad" contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231" decimals="0" name="oncyf:ClassofWarrantorRightWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ3NzE_867e333e-67d6-4948-bce5-aa2196a1a7a5">455,670</ix:nonFraction> (2020 - $<ix:nonFraction unitRef="cad" contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231" decimals="0" name="oncyf:ClassofWarrantorRightWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ3ODA_1a11a720-c0e7-4d92-a4bd-fca5b874ac07">4,636,317</ix:nonFraction>; 2019 - $<ix:nonFraction unitRef="cad" contextRef="icc5c0ca931d74739a3b6246850a2c5de_D20190101-20191231" decimals="0" name="oncyf:ClassofWarrantorRightWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU4MzI_819d5e88-aadb-4959-a74a-a30dc6c9128e">5,687,003</ix:nonFraction>) in addition to gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="oncyf:ProceedsfromWarrantExercises1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ4MTc_04c5be87-7b02-4519-9303-284428809dd0">181,550</ix:nonFraction> (2020 </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="i9689acc940af41c9baa423d9649eb993"><ix:continuation id="i708ca06cbce94a88a714c7659377a709" continuedAt="i1d055a39b17b48a1854160a3c5997455"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- US$<ix:nonFraction unitRef="usd" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="oncyf:ProceedsfromWarrantExercises1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ4MjY_2c1bfaca-83f3-45fb-a9aa-a22dc5b972e7">1,276,532</ix:nonFraction>; 2019 - US$<ix:nonFraction unitRef="usd" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="oncyf:ProceedsfromWarrantExercises1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU4NjY_9f6477fd-4397-46fb-bace-012e7cee1ef4">2,642,082</ix:nonFraction>) for the <ix:nonFraction unitRef="shares" contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231" decimals="0" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ4Mzg_0201cc2e-0602-4942-9ec0-80022e7e836c">201,722</ix:nonFraction> (2020 - <ix:nonFraction unitRef="shares" contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231" decimals="0" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ4NDc_9b4c7e52-2566-4190-a98b-173f5dabc7cb">1,418,369</ix:nonFraction>; 2019 - <ix:nonFraction unitRef="shares" contextRef="icc5c0ca931d74739a3b6246850a2c5de_D20190101-20191231" decimals="0" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU4NzE_42f80d48-c695-4a6c-8d64-a2d81eb7805c">2,935,647</ix:nonFraction>) warrants that were exercised (see Note 8). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market price, with an aggregate offering value of up US$<ix:nonFraction unitRef="usd" contextRef="i445f25b6895b4f3a9e8820470f449122_I20200615" decimals="INF" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUxMjk_1472a87a-48f5-40fa-9056-676656a9ebb8">40,000,000</ix:nonFraction> over a <ix:nonNumeric contextRef="i6952840e54e1456a84822c9606b3c424_D20200615-20200615" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzYwMDk_157f660c-9ec9-4024-89bb-e8296318013c">25-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. In 2021, we sold <ix:nonFraction unitRef="shares" contextRef="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5Mjc_f0bc472d-9d20-4322-8d35-40cc3afaed05">5,685,097</ix:nonFraction> (2020 - <ix:nonFraction unitRef="shares" contextRef="ie82286507f1648e4b150250e27787981_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUyNDQ_2f07a4fd-062f-4f3c-82bc-09fb92235413">5,441,014</ix:nonFraction>) common shares for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231" decimals="0" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5MzE_36308bdd-6962-4a0b-a663-300329cbe30a">18,503,188</ix:nonFraction> (2020 - US$<ix:nonFraction unitRef="usd" contextRef="ie82286507f1648e4b150250e27787981_D20200101-20201231" decimals="0" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUyODM_5daec418-0eef-44e5-9b50-c736dec87191">12,628,775</ix:nonFraction>) at an average price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="id09b9d3dab2a4150999c1ca5b995feac_I20211231" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5MzY_0ec3c687-c6af-4933-954b-52f69a8050d0">3.25</ix:nonFraction> (2020 - US$<ix:nonFraction unitRef="usdPerShare" contextRef="i4f6e4d5e9ea74cf5ab41ddd51549cf33_I20201231" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUzMDk_9b852b18-f08b-4345-b12d-fd66f7cd2682">2.11</ix:nonFraction>). We received, net of commissions of US$<ix:nonFraction unitRef="usd" contextRef="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231" decimals="0" name="oncyf:ShareIssueRelatedCostCommissions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5NDE_f1cb7dc5-a524-45e4-a3e6-2f7080d4af06">555,096</ix:nonFraction> (2020 - US$<ix:nonFraction unitRef="usd" contextRef="ie82286507f1648e4b150250e27787981_D20200101-20201231" decimals="0" name="oncyf:ShareIssueRelatedCostCommissions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUzNDg_a8a07f38-7438-4d37-bd9d-295d1d861670">378,863</ix:nonFraction>), proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231" decimals="0" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5NDY_d75aaa44-bf05-46da-a1c6-c0e88070dc54">17,948,092</ix:nonFraction> (2020 - US$<ix:nonFraction unitRef="usd" contextRef="ie82286507f1648e4b150250e27787981_D20200101-20201231" decimals="0" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUzNjQ_a3ac1c3e-5018-48f7-b6ae-32c712f61dab">12,249,911</ix:nonFraction>). In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5NTE_a93fcc92-23af-4a87-b61a-39f4cb8c6dae">707,421</ix:nonFraction> (2020 - $<ix:nonFraction unitRef="cad" contextRef="ie82286507f1648e4b150250e27787981_D20200101-20201231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU0MzU_4f9b7451-47fa-49ed-b22c-976cc79181db">884,886</ix:nonFraction>). On March 4, 2021, we terminated the June 15, 2020 ATM equity distribution agreement.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1d055a39b17b48a1854160a3c5997455" continuedAt="i7f83c832d4ab47149b63a06683732a07">(e)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"><ix:continuation id="i7f83c832d4ab47149b63a06683732a07">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$<ix:nonFraction unitRef="usd" contextRef="i6dd8b35d2c3f4ace9728ec15e62387d6_I20210305" decimals="INF" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzYzMDE_bc2730e6-85da-41e8-93cf-75ddd363c682">80,000,000</ix:nonFraction> over a <ix:nonNumeric contextRef="if6351d06a26d494f80f99bf946853adb_D20210305-20210305" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzI3NDg3NzkwNzk1NDI_62125743-17c9-4e82-b238-1f913580fd09">16-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. In 2021, we sold <ix:nonFraction unitRef="shares" contextRef="i4ede084a4122418cb65982299416868e_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY0ODM_addfe673-6f89-4c2c-abb1-5a9c13f07de3">2,715,932</ix:nonFraction> common shares for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i4ede084a4122418cb65982299416868e_D20210101-20211231" decimals="0" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY1Mjc_c951ad36-695c-49f0-aee4-f763ee3bf08f">8,654,892</ix:nonFraction> at an average price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i0bd694e01e0d4b7bb354e73aa065b8bb_I20211231" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY1NTc_5adfa366-5ca2-4210-88b7-ec4811a86bd5">3.19</ix:nonFraction>. We received, net of commissions of US$<ix:nonFraction unitRef="usd" contextRef="i4ede084a4122418cb65982299416868e_D20210101-20211231" decimals="0" name="oncyf:ShareIssueRelatedCostCommissions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY1OTk_9b54025e-93ee-4e74-941a-9bc1f296c6a1">259,647</ix:nonFraction>, proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i4ede084a4122418cb65982299416868e_D20210101-20211231" decimals="0" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY2Mjk_3407dce9-03b7-49b6-bddb-3e117dc7223d">8,395,245</ix:nonFraction>. In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="i4ede084a4122418cb65982299416868e_D20210101-20211231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY3MDg_7c4570e5-7fa2-40c4-8b13-2ade38d15d4d">548,859</ix:nonFraction>.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2017, pursuant to an underwritten public offering, <ix:nonFraction unitRef="shares" contextRef="i12d8b8a2f06d4c838611847df4e4d947_D20170601-20170601" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU1MjY_a89d81fb-5996-4946-a768-d952abfc7c6a">16,445,000</ix:nonFraction> units were sold for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="i12d8b8a2f06d4c838611847df4e4d947_D20170601-20170601" decimals="0" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU1Njc_3500f0bd-63fd-4459-a52e-87531b8a070c">11,511,500</ix:nonFraction>. Each unit included <ix:nonFraction unitRef="shares" contextRef="i1104cc6b33de4026a773d0273129e2f2_I20170601" decimals="0" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU1OTA_500c36f3-bd1e-4544-b5f4-3506597fe9a4">one</ix:nonFraction> common share and <ix:nonFraction unitRef="shares" contextRef="i1104cc6b33de4026a773d0273129e2f2_I20170601" decimals="0" name="oncyf:CommonSharePurchaseWarrantPerUnit" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU2MTA_379de6b1-c0e7-424d-8a95-d142e90292ec">one</ix:nonFraction> common share purchase warrant. Following the 2018 share consolidation, <ix:nonFraction unitRef="shares" contextRef="i1104cc6b33de4026a773d0273129e2f2_I20170601" decimals="1" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU2Nzk_24922ab0-5eaa-4457-bd21-29cc9865335e">9.5</ix:nonFraction> common share purchase warrants entitled the holder to purchase <ix:nonFraction unitRef="shares" contextRef="i1104cc6b33de4026a773d0273129e2f2_I20170601" decimals="0" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU3NDU_f7ac3300-a755-4628-b0c5-36bca177ebda">one</ix:nonFraction> common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $<ix:nonFraction unitRef="cadPerShare" contextRef="i1104cc6b33de4026a773d0273129e2f2_I20170601" decimals="3" name="oncyf:SharesIssuedWarrantPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU4NDk_70076025-7deb-4a30-ae2f-4ebdcfa9125b">9.025</ix:nonFraction>. These warrants were classified as equity. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzYwMTE_f0fce19a-a735-40b7-aec5-b5bbdb7538d3" continuedAt="i173351aad3fd4cf9b64e554c8e493f08" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6f80ce545f5419fa462f45df6c010da_I20191231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzQtMS0xLTEtODEyMQ_3ae5f00d-9fef-4e3a-b09f-ebc9398b1fee">16,443,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="0" name="oncyf:WarrantsAndRightsOutstanding1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzQtMi0xLTEtODEyMQ_e31d0b8f-e576-463b-bd71-ca7494e467b7">3,617,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9eb1111616934aec84de469599269b27_I20201231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzUtMS0xLTEtODEyMQ_3e98c4af-88b9-47b6-b95d-1fcf264d681b">16,443,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="oncyf:WarrantsAndRightsOutstanding1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzUtMi0xLTEtODEyMQ_395c0baa-7b3d-41a3-894d-a50fa549eb21">3,617,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i886943a54e40452081d9137b1996e966_I20211231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzMtMS0xLTEtOTQzNg_b881adf0-77bb-4bb1-be71-1a32f5a1f4f2">16,443,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="oncyf:WarrantsAndRightsOutstanding1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzMtMi0xLTEtOTQzNg_f9e52150-5a0a-4458-af7e-aab08f3636ea">3,617,570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Exercisable into <ix:nonFraction unitRef="shares" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU5ODc_9399d050-3793-4f2a-b5bb-3d292b9a14ca">1,730,894</ix:nonFraction> common shares.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_166"></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 10: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNzA_3fcc5e31-f533-4f1f-80d7-9fb72385f39e" continuedAt="ic3606a77e1484349b46d7ceaefc1c825" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ic3606a77e1484349b46d7ceaefc1c825" continuedAt="if9de0d5f0d71496981eec694976535e0"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Option Plan </span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNjY_b39e53bd-7b73-448a-8e9a-c26a922e0b4c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted stock options to acquire common stock through our stock option plan of which the following are outstanding at December&#160;31:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItMS0xLTEtODEyMQ_0624f6b3-2a1f-4d4a-86bf-e5e843becf13">3,764,055</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItMi0xLTEtODEyMQ_5051117e-b379-4df1-af2f-28ff457ca826">4.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItMy0xLTEtODEyMQ_c7df73b5-2cf7-4934-bf3a-d4caa31df89d">2,246,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItNC0xLTEtODEyMQ_75eda1cb-924f-4623-8c50-db6849a0cf48">5.31</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i762faf08df5c4521a4f2689a278651e0_I20181231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItNS0xLTEtODEyMQ_4414a2bd-a605-4a83-bfc6-342f64614877">1,249,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i762faf08df5c4521a4f2689a278651e0_I20181231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItNi0xLTEtODEyMQ_c197562b-3f29-46d8-9618-2ff87c30fcc8">8.73</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtMS0xLTEtODEyMQ_59d573df-97d4-4cbc-8b96-b89893d61f48">1,832,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtMi0xLTEtODEyMQ_84ab4ba9-2f98-4977-ad1c-19da105a1fea">2.99</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtMy0xLTEtODEyMQ_c6cfd6a8-e1ba-4f81-8d96-5548f9df8fd9">1,817,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtNC0xLTEtODEyMQ_11d4d3bf-53fc-442f-bea8-2e4f2eaa0bb9">3.19</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtNS0xLTEtODEyMQ_ff5fe4d4-184b-4fa9-9e34-e08400ac9b6c">1,020,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtNi0xLTEtODEyMQ_5bc93a50-e932-40cb-8231-720289dc9fa3">1.42</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtMS0xLTEtODEyMQ_7fca74ec-b663-47c8-875c-fee0b437d562">110,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtMi0xLTEtODEyMQ_adddf394-a3a6-4ba9-a92e-a907e8d24b81">6.21</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtMy0xLTEtODEyMQ_48453b98-5cdb-4939-8de4-b559039ebc3e">141,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtNC0xLTEtODEyMQ_5f19a641-e15c-446c-aa8a-2db224df4dfe">3.84</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtNS0xLTEtODEyMQ_b3ad978a-4b11-45c0-aad2-da20fd4ac22a">12,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtNi0xLTEtODEyMQ_8296cce0-2214-4d88-8208-05a899c247e7">11.35</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtMS0xLTEtODEyMQ_21002b59-3dff-4153-a237-ebc5b11e834a">28,364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtMi0xLTEtODEyMQ_67902d3d-309c-47d7-9ab8-b1abeb56f642">37.63</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtMy0xLTEtODEyMQ_13d437b9-dda9-459a-97ba-fef62d02aed9">25,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtNC0xLTEtODEyMQ_ac4e4ba9-f1da-4976-9a49-2b6b3b0b91d4">62.49</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtNS0xLTEtODEyMQ_e12ab46d-295c-4b5d-ad25-c7f13b99c487">9,575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtNi0xLTEtODEyMQ_fbacac00-6952-44ea-8b65-8004a157a6d6">29.07</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtMS0xLTEtODEyMQ_40a797f7-c519-4e22-ad4b-7ab39c8ee26b">123,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtMi0xLTEtODEyMQ_e1adfb0c-51ea-4c09-815c-c0848f2bfd33">1.94</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtMy0xLTEtODEyMQ_6385555c-8178-424e-88f0-f5844c1083ab">133,454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtNC0xLTEtODEyMQ_fa0d4a5e-eb4a-4ed5-88e4-29aeaef2a85b">1.81</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtNS0xLTEtODEyMQ_3cfafdba-c6d0-4cad-a507-5e6d02ccaf80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtNi0xLTEtODEyMQ_5c9e6b62-a890-4217-80a3-388d05b01bed">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctMS0xLTEtODEyMQ_093f89cd-4fcf-4336-9e13-ffab2eac2b57">5,334,420</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctMi0xLTEtODEyMQ_9cf5e5e9-da12-46a4-82d1-289731de461d">3.53</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctMy0xLTEtODEyMQ_dcf0d639-50a1-462a-b7ea-294ca7fc52e4">3,764,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctNC0xLTEtODEyMQ_711400fb-aaca-43d3-9460-08fdfc3b1502">4.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctNS0xLTEtODEyMQ_6848ef13-375f-41f1-91ba-af52eec1a285">2,246,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctNi0xLTEtODEyMQ_c18f2c1b-c757-4ca1-bb76-7e772bcd0d8f">5.31</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtMS0xLTEtODEyMQ_0bb1ff71-c3f2-4b71-8f7e-6e88d096c09d">3,165,679</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtMi0xLTEtODEyMQ_4876e14d-8247-4271-aa0e-b4bc2cc821fd">3.82</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtMy0xLTEtODEyMQ_3be85da8-ae46-47bb-aaff-aa125da2fe3b">2,164,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtNC0xLTEtODEyMQ_64da7d7c-c60f-4231-8b56-f154a4d45f76">4.84</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtNS0xLTEtODEyMQ_c6447d41-c49d-46de-8520-3aa6369fc27d">1,327,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtNi0xLTEtODEyMQ_7b3cf49f-521f-4dbc-ad3e-1e99145c49a8">7.22</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:continuation id="i173351aad3fd4cf9b64e554c8e493f08"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNzI_aa232481-3229-4b1a-89dd-70cd43ff3fe9" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="i320159cd827547e58721ba67d7836f34_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtMC0xLTEtODEyMS90ZXh0cmVnaW9uOjAzNTcyNzg4NjA2NDQ2OTk5OThkZDU4ZmQ1YjRmMjQxXzQ_aaecebf1-aabe-4d71-8416-ee646f08449b">0.54</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="i74c3e389b53640549c1c373710f94064_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtMC0xLTEtODEyMS90ZXh0cmVnaW9uOjAzNTcyNzg4NjA2NDQ2OTk5OThkZDU4ZmQ1YjRmMjQxXzk_d03460ad-085e-4389-98cd-f6fa8a63d08c">1.79</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b105f49e63542228ae11b453f0ca87e_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtMS0xLTEtODEyMQ_1dd1f1b6-dbdb-4342-9fd9-1615d6df357d">718,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c605804bd334ec1907207bb23e349c3_D20210101-20211231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtMi0xLTEtODEyMQ_46b90a56-7e85-4dd9-b690-8931d298a931">2.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i0b105f49e63542228ae11b453f0ca87e_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtMy0xLTEtODEyMQ_2b65b9f7-5ae5-4b4d-a042-888eba1c8460">1.39</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b105f49e63542228ae11b453f0ca87e_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtNC0xLTEtODEyMQ_29237dd3-bf1c-4852-91f5-ae2aa3b3baa8">718,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i0b105f49e63542228ae11b453f0ca87e_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtNS0xLTEtODEyMQ_a14d9c1f-a246-4263-9599-967bddd66772">1.39</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="i5d0c21adfb3d488cb2fc325f543e0e92_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItMC0xLTEtODEyMS90ZXh0cmVnaW9uOjAzYjUwYWIwYzU2ZjQyODg4YjQ1ODVjNGIzZDc2N2Y2XzQ_31ac6d00-6ef4-4f15-a609-1f7bd02cc2f2">1.80</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="i83fe2b09673c484791ef8bd4e2f7f518_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItMC0xLTEtODEyMS90ZXh0cmVnaW9uOjAzYjUwYWIwYzU2ZjQyODg4YjQ1ODVjNGIzZDc2N2Y2Xzk_099cd1a3-3b08-4141-ac69-02a733ffa816">3.01</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88ca0ee1c2a247149de0db08710d0a11_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItMS0xLTEtODEyMQ_616b967b-e83c-4c16-971b-27c1044deef3">1,026,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4cfd0864279f4fb89386b82c0e907044_D20210101-20211231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItMi0xLTEtODEyMQ_394bc648-a649-48e6-801a-1f73ad8b3118">3.85</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i88ca0ee1c2a247149de0db08710d0a11_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItMy0xLTEtODEyMQ_ba67a297-bbdb-47a4-8292-7166a7b8205b">2.36</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88ca0ee1c2a247149de0db08710d0a11_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItNC0xLTEtODEyMQ_cda9c7ef-30d6-4398-b107-31836b322116">531,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i88ca0ee1c2a247149de0db08710d0a11_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItNS0xLTEtODEyMQ_cb188104-59ec-4e75-983e-755de07d1435">2.47</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="ia23c9e23b2584b9cb0a3b24d1c38da91_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtMC0xLTEtODEyMS90ZXh0cmVnaW9uOjNjNjVlNDA4OGI3MjQ2Y2M4ZDRhMzgxZmMxMTQ1ZGU2XzQ_713c07c9-c3eb-4220-9563-6fb866a20b51">3.02</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="ib7d59de09bb940c189e78dc90d63966d_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtMC0xLTEtODEyMS90ZXh0cmVnaW9uOjNjNjVlNDA4OGI3MjQ2Y2M4ZDRhMzgxZmMxMTQ1ZGU2Xzk_e3f4bc1a-0478-4d5b-bdd2-9ce9a6a1e19c">3.90</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5662aedb669484599906207af734e31_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtMS0xLTEtODEyMQ_510576d8-0926-4479-8b25-fa27933ef800">2,982,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib2aacc6b616f41dd8d5b26d42c3e9a80_D20210101-20211231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtMi0xLTEtODEyMQ_1189e82b-4148-40f5-9834-8de6d1ac44b2">3.36</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie5662aedb669484599906207af734e31_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtMy0xLTEtODEyMQ_cf9ca7eb-0a01-4114-aaca-94b9818ab391">3.29</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5662aedb669484599906207af734e31_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtNC0xLTEtODEyMQ_34794b8c-e3d3-4ff7-bc5a-4610d6c4b423">1,329,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie5662aedb669484599906207af734e31_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtNS0xLTEtODEyMQ_1e824e7a-dc90-43aa-9a69-0fd80fc81029">3.24</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="i550a47322a8b427e8965901e54efbac0_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtMC0xLTEtODEyMS90ZXh0cmVnaW9uOmFkNDBmOTYwOTIzNDQ4MTdiZjcxMDAwNTkzMzlkNTEyXzQ_0d08ab51-1dd4-4e47-8d4d-49e5833639ce">3.91</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="ifeabe67f4cdc4d9593317276ede6b031_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtMC0xLTEtODEyMS90ZXh0cmVnaW9uOmFkNDBmOTYwOTIzNDQ4MTdiZjcxMDAwNTkzMzlkNTEyXzk_8a943b3c-9974-4708-9cd5-7667865835cc">7.41</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06a718d83ebe46fda6f2392bc946d68c_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtMS0xLTEtODEyMQ_01c994a0-430d-4806-b4a8-949c39aa2917">478,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i165f5ef5cadc4c27bc78cb9fa65a9ebb_D20210101-20211231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtMi0xLTEtODEyMQ_c8b31429-ca3d-4a50-b9b0-6ac178b7ebcd">1.72</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i06a718d83ebe46fda6f2392bc946d68c_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtMy0xLTEtODEyMQ_d5ad0a50-6b1a-4231-baf0-a65b27f76803">6.09</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06a718d83ebe46fda6f2392bc946d68c_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtNC0xLTEtODEyMQ_8f80b672-f132-487d-b86b-05629a6316bf">458,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i06a718d83ebe46fda6f2392bc946d68c_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtNS0xLTEtODEyMQ_a7794173-4564-4033-a93b-0631e03ed347">6.13</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="if96dbdc3a85a498cb7c50c2c3fcc5136_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtMC0xLTEtODEyMS90ZXh0cmVnaW9uOmUyOWNhNzU0ZWZjZTQxY2Q5MzNmNmE3MGZmOWFjNGM4XzQ_b170a160-38e4-41ca-8a4d-b1dabab9fa25">7.42</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="i9f3a94bc480946578503b6bc026df946_I20211231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtMC0xLTEtODEyMS90ZXh0cmVnaW9uOmUyOWNhNzU0ZWZjZTQxY2Q5MzNmNmE3MGZmOWFjNGM4Xzk_5607e316-ee36-4207-8461-af928c2577eb">40.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e6af5d5c037483e9cf8a1e5b633bf9b_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtMS0xLTEtODEyMQ_034ac8a8-b698-4bb6-b985-2fa95928362b">128,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0a76d437dabc4644966186d4b447fc15_D20210101-20211231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtMi0xLTEtODEyMQ_422d7a9c-a743-4ea1-8e70-ba78e1b02c34">1.55</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i3e6af5d5c037483e9cf8a1e5b633bf9b_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtMy0xLTEtODEyMQ_5d983498-9eec-48b8-bde6-0808bf88e4ae">20.80</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e6af5d5c037483e9cf8a1e5b633bf9b_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtNC0xLTEtODEyMQ_310e0543-b7f7-4e47-a240-d81435cc0bd0">128,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i3e6af5d5c037483e9cf8a1e5b633bf9b_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtNS0xLTEtODEyMQ_b80b76ad-92cd-4a1d-9dca-c7f143cd8944">20.80</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzYtMS0xLTEtODEyMQ_f788bf9f-d996-4bc8-b313-2a418933a3c9">5,334,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzYtMi0xLTEtODEyMQ_690a539e-4f74-42d6-a719-51555801bf53">3.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzYtMy0xLTEtODEyMQ_11fb52b0-5749-4e99-8efe-3752edd29e80">3.53</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzYtNC0xLTEtODEyMQ_f662ee17-3ac0-4f16-bdb0-92f77476b24d">3,165,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzYtNS0xLTEtODEyMQ_801de565-4895-4b02-a400-5f0210a05e57">3.82</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants vest either immediately or annually over periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzM1OA_3e8a9208-2071-47f7-9434-36998b16603e">one</span> to <ix:nonNumeric contextRef="ie946e9ce17b442b0a2db67f95b9168ec_D20210101-20211231" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzM2NA_f13b2db4-40f2-43bd-b186-e75a60480c17">three years</ix:nonNumeric>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNTQ_38833b30-5143-4a78-8501-6d5da1e31069" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the year was determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzEtMS0xLTEtODEyMQ_1098f1f3-0670-4a3b-9db7-4e757e6cd308">0.66</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzEtMi0xLTEtODEyMQ_0d3ea3cf-18db-4331-9163-18a1a9aa30d2">0.34</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzEtMy0xLTEtODEyMQ_f9135d3a-7cea-4ca7-a846-fe301a9ed7cc">1.62</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="year" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzItMS0xLTEtODEyMQ_81ab0fb8-76f3-4e63-9d44-2bf8b4a2ba7d">3.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzItMi0xLTEtODEyMQ_fbd5e3ab-83be-41f1-ac92-67250ceb71a7">3.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzItMy0xLTEtODEyMQ_44694ee2-c1e3-41ca-82df-2b4e806526dc">3.0</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzMtMS0xLTEtODEyMQ_5c4c6f04-d460-4081-9725-4272f149af3c">110.45</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzMtMi0xLTEtODEyMQ_57fb7d7d-bddf-4fd5-8597-66f555e9c192">110.82</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzMtMy0xLTEtODEyMQ_0dcef66f-ef63-4828-ac0a-57dc0110c5d5">97.90</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzUtMS0xLTEtODEyMQ_f2e683bc-197d-4e88-aa02-f42765fba238">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzUtMi0xLTEtODEyMQ_5c967231-ac01-4138-a9e6-03557edb5a3c">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzUtMy0xLTEtODEyMQ_05649f5b-2898-494b-b61e-37cdb7bf11a0">Nil</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzYtMS0xLTEtODEyMQ_24ec8364-3197-4098-9319-d9dc952df243">1.99</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzYtMi0xLTEtODEyMQ_7609e8eb-3d0d-44c8-9c7d-5ddebff27e31">2.12</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzYtMy0xLTEtODEyMQ_33496737-58d5-4380-9009-291251b035ec">0.87</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="if9de0d5f0d71496981eec694976535e0" continuedAt="i842d787cc8ef430cbda52ebeb6187f74"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incentive Share Award Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Units</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also granted RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a <ix:nonNumeric contextRef="id035d2b8dd6d43178b57bd66e4788c61_D20210101-20211231" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzI3NDg3NzkwNzI0MDE_29dd16e8-80d4-4833-8652-e64e77e387b5">three-year</ix:nonNumeric> period. <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNzM_1fea5ad0-f862-4912-8ec7-a0506db50fd0" continuedAt="ie83ee3a690a949ec9f15904d785e82c7" escape="true">The following RSUs are outstanding at December&#160;31:</ix:nonNumeric></span></div><ix:continuation id="ie83ee3a690a949ec9f15904d785e82c7" continuedAt="id1eee0b7bc4643d1ab7a1f4166183030"><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bdb149a74484759861585dd847d705c_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzEtMS0xLTEtODEyMQ_c23e2f02-fdd3-49c9-8396-f624f87c19a7">134,618</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56539f49321e44d8a1eef4fc8f086d52_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzEtMi0xLTEtODEyMQ_79583214-0aaf-450b-a67b-b5af5385ef0d">209,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ef39cf43fa64dfbbfb9e8655e1baa24_I20181231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzEtMy0xLTEtODEyMQ_5082719a-fca1-4380-88b5-ad0130188d99">260,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id035d2b8dd6d43178b57bd66e4788c61_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzItMS0xLTEtODEyMQ_7f57c2f6-e66e-4379-acf4-ecc9bf325dcc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b715806bf704ad08871493d7b3a4e1c_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzItMi0xLTEtODEyMQ_f90baa02-c12a-4350-a8a0-a7943d7de44a">154,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i982e2e082ae5410dbcf107355f007a0d_D20190101-20191231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzItMy0xLTEtODEyMQ_e5bc63d3-9171-4e70-a0df-fd0940c24973">270,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id035d2b8dd6d43178b57bd66e4788c61_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzQtMS0xLTEtODEyMQ_f05b1d37-be4b-46bd-8e23-8ffe8dfd7a2c">94,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4b715806bf704ad08871493d7b3a4e1c_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzQtMi0xLTEtODEyMQ_2a284a4b-8ea5-4311-aebb-6489e2b17b59">229,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i982e2e082ae5410dbcf107355f007a0d_D20190101-20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzQtMy0xLTEtODEyMQ_687c86fa-ac19-4f7e-8787-94e0617fd54b">321,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4fc7bd5d5a9e465d989e66ae6a3abb49_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzUtMS0xLTEtODEyMQ_25d106f3-22d2-441c-8400-3220a846ee70">40,560</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bdb149a74484759861585dd847d705c_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzUtMi0xLTEtODEyMQ_f49966a4-0ebc-48d7-9e27-b6d3f46b3730">134,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56539f49321e44d8a1eef4fc8f086d52_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzUtMy0xLTEtODEyMQ_01fba76a-1963-4175-8a53-5cf809adbb56">209,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSUs granted was <ix:nonFraction unitRef="cad" contextRef="i4fc7bd5d5a9e465d989e66ae6a3abb49_I20211231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzE1NTk_1e2234d4-de46-4bba-9869-1886299a069d">nil</ix:nonFraction> in 2021 (2020 - $<ix:nonFraction unitRef="cad" contextRef="i8bdb149a74484759861585dd847d705c_I20201231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzE1NzQ_0bdfe54e-315e-4d5d-aee0-6c26383f5d08">2.41</ix:nonFraction> ; 2019 - $<ix:nonFraction unitRef="cad" contextRef="i56539f49321e44d8a1eef4fc8f086d52_I20191231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzE1ODQ_c8c0940d-23b0-4483-a8f7-68cd2339e464">0.80</ix:nonFraction>).</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Share Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also granted PSUs to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after <ix:nonNumeric contextRef="i814af0580d834778b5cede92893765d0_D20210101-20211231" name="oncyf:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzE3NzU_a439180a-ed5c-4433-ba09-bc041e6e7174">3</ix:nonNumeric> years or vest over a <ix:nonNumeric contextRef="i814af0580d834778b5cede92893765d0_D20210101-20211231" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzI3NDg3NzkwNzI0MDA_1cb774e0-aac4-4e7f-a523-e2671cbbe059">three-year</ix:nonNumeric> period, depending on the grant. <ix:continuation id="id1eee0b7bc4643d1ab7a1f4166183030" continuedAt="if97ae41a06834769b4a78faf4eeb7473">The following PSUs are outstanding at December&#160;31:</ix:continuation></span></div><div style="margin-top:11pt"><ix:continuation id="if97ae41a06834769b4a78faf4eeb7473"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica2719d210fc449890e82fdb8d83507c_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzEtMS0xLTEtODEyMQ_7de60f5a-3aa1-491a-ab29-6be4e3330261">56,841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb01c95903d246608417f9782e2afe30_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzEtMi0xLTEtODEyMQ_8c196552-9664-41c0-a8d0-72e1f153cff4">61,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic87ace5c41714cf3b1812237cd1344ef_I20181231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzEtMy0xLTEtODEyMQ_77f0ed52-3180-4b90-9a76-6f6fad2927e0">63,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i814af0580d834778b5cede92893765d0_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzMtMS0xLTEtODEyMQ_49dc523f-2b2f-49ca-a728-202f9ceb303e">56,841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib775f5c95fa8484385ae22162e973750_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzMtMi0xLTEtODEyMQ_416fdf6e-24e4-49e2-bc33-962a9714f646">4,210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i70523a9ebf4444508afc8076e91b525e_D20190101-20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzMtMy0xLTEtODEyMQ_8f604d72-bd9d-477e-a2de-0ad80f03f406">2,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i127a482ddc3e443f908cd8d6e513e1e6_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzQtMS0xLTEtODEyMQ_2dac8f2d-f6ce-4b61-bffc-c8a032a43efe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica2719d210fc449890e82fdb8d83507c_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzQtMi0xLTEtODEyMQ_401b5e16-95cb-4c93-aed8-a45f3c2ca77c">56,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb01c95903d246608417f9782e2afe30_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzQtMy0xLTEtODEyMQ_336fcc14-3534-41dd-993d-3f27328009da">61,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i842d787cc8ef430cbda52ebeb6187f74">We have reserved <ix:nonFraction unitRef="shares" contextRef="ie486096482ef4dbdbfc5aac0d2ef7dbd_I20211231" decimals="INF" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIxNTc_109e7e40-86d9-4b28-9d3b-7be262bf5faa">5,504,379</ix:nonFraction> common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs for the year ended December&#160;31, 2021 was $<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzMjk_106f9d6b-48da-4b4d-8693-1ffdca2a19ae">3,825,901</ix:nonFraction> (2020 - $<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzMzg_e6475d9a-4db0-42f9-82f0-2db2795612c1">2,558,974</ix:nonFraction>; 2019 - $<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNDc_e8c0bdf2-b6b8-497f-8b21-ddf54d736fa9">1,470,153</ix:nonFraction>).</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 11: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzQxMg_4c6e64eb-43a4-4e30-af3d-59a5e328dda8" continuedAt="i20e01f5d4e364d9e98893a372d4b98cb" escape="true">Loss Per Common Share</ix:nonNumeric></span></div><ix:continuation id="i20e01f5d4e364d9e98893a372d4b98cb"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended December&#160;31, 2021 of <ix:nonFraction unitRef="shares" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzE4OA_0656803f-7a88-4c46-8ab7-555d1ee032c2"><ix:nonFraction unitRef="shares" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzE4OA_79006d47-f35a-4f3e-aa15-82bb970331e9">53,513,225</ix:nonFraction></ix:nonFraction> (2020 - <ix:nonFraction unitRef="shares" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzE5Nw_3e9ac702-d7ec-41c4-a78b-640317b2a3f7"><ix:nonFraction unitRef="shares" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzE5Nw_4b6d1af4-1745-4234-82ab-9be837eaeda3">40,338,789</ix:nonFraction></ix:nonFraction>; 2019 - <ix:nonFraction unitRef="shares" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzIwNg_032279d3-cdab-438b-befd-39d2f10df08d"><ix:nonFraction unitRef="shares" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzIwNg_555bae2e-527e-4714-99c5-933a600a7e0c">22,137,990</ix:nonFraction></ix:nonFraction>). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_172"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 12: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90ZXh0cmVnaW9uOmJiYTc0OWYwNzVlYjQyZGU4N2RiMDA1MDU0YzYzZWU3XzY5NA_373d9a63-5539-46f7-977a-413a45253d1a" continuedAt="id5d1473f0254463d9158eb9c7820a72b" escape="true">Contract Liability</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id5d1473f0254463d9158eb9c7820a72b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regional licensing agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract liability</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90ZXh0cmVnaW9uOmJiYTc0OWYwNzVlYjQyZGU4N2RiMDA1MDU0YzYzZWU3XzY5MA_26046e97-2742-48e8-9c9c-9d2cd62df121" escape="true"><div style="text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:ContractLiabilityRecognitionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90ZXh0cmVnaW9uOmJiYTc0OWYwNzVlYjQyZGU4N2RiMDA1MDU0YzYzZWU3XzY2OA_dfb12821-4563-4a40-bdb7-f58a1fd71963">five years</ix:nonNumeric>, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzEtMS0xLTEtODEyMQ_5696d381-127d-40fd-bbe0-b960b4a1a358">6,730,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="0" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzEtMi0xLTEtODEyMQ_8710e12b-7c5f-4707-9200-893f8c672768">6,730,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regional licensing agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzItMS0xLTEtODEyMQ_aa0fa4b6-2b10-41d6-9e52-c4fce656bdd2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzItMi0xLTEtODEyMQ_2fa0cbbc-9027-4be5-bc5d-8426c55bbac7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzMtMS0xLTEtODEyMQ_1554eb47-1d2e-41b3-8420-f0311a8852e1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzMtMi0xLTEtODEyMQ_34f14b63-1d18-4a36-ab1a-b44a28cfeb80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzQtMS0xLTEtODEyMQ_6a3202bd-8fd0-4dde-93f2-399ad54aa1dc">6,730,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzQtMi0xLTEtODEyMQ_7d926808-9d2d-45a2-9425-daf5e911aa01">6,730,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:CurrentContractLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzYtMS0xLTEtODEyMQ_5ed4d79c-887e-43c5-bcae-c3089037a055">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:CurrentContractLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzYtMi0xLTEtODEyMQ_96e3960f-cd0e-40fa-b3fd-4e970c4ad77e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzctMS0xLTEtODEyMQ_b55793c8-be8b-4246-a14c-f432838cfee2">6,730,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzctMi0xLTEtODEyMQ_a5488ca5-e1c9-417f-b86a-f473759a0b05">6,730,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzgtMS0xLTEtODEyMQ_54d5b406-c793-4947-9471-666a83db091a">6,730,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzgtMi0xLTEtODEyMQ_4a8dc3b8-8302-4d7c-bc69-0b22c45a72f9">6,730,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 13: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfCommitmentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzExNTg_640ca6c0-02df-4c17-81ec-cbc0b5f1fe3d" continuedAt="id7e6eeaa31e24bcc8fb8d235e2f23636" escape="true">Commitments</ix:nonNumeric></span></div><ix:continuation id="id7e6eeaa31e24bcc8fb8d235e2f23636"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments totaling $<ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="oncyf:PurchaseObligation1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzY2_5fc6b087-f226-4049-a4b2-353eb3dcd902">21,516,576</ix:nonFraction> for activities related to our clinical trial, manufacturing, and translational science programs which are expected to occur over the next <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:PurchaseObligationCommitmentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzE5OA_27abfb41-0a2e-4ea8-a2f5-66dd4e73fef6">three years</ix:nonNumeric>. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include the committed payments related to our co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1, as this phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2021, we recorded US$<ix:nonFraction unitRef="usd" contextRef="i7f73e01a75a540b3bd81d5cbc09e5ef3_I20211231" decimals="0" name="ifrs-full:OtherReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzAyNjQ_59e5cf69-94a8-4b67-9f20-6e39c64215dc">616,855</ix:nonFraction> ($<ix:nonFraction unitRef="cad" contextRef="i7f73e01a75a540b3bd81d5cbc09e5ef3_I20211231" decimals="0" name="ifrs-full:OtherReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzI0NzQ_744e6045-f93c-4ade-a000-b466423b135f">782,049</ix:nonFraction>) (December&#160;31, 2020 - <ix:nonFraction unitRef="usd" contextRef="if1358bb7098240d2b664975d761c15b0_I20201231" decimals="0" name="ifrs-full:OtherReceivables" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzAyNTQ_e23dc5b1-6052-4739-8393-9e8c7ade88df">nil</ix:nonFraction>) in other receivables related to BRACELET-1 cost from Pfizer per the terms of the collaboration agreement and US$<ix:nonFraction unitRef="usd" contextRef="i7f73e01a75a540b3bd81d5cbc09e5ef3_I20211231" decimals="0" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzAzMjg_a7144bb4-00dc-47b0-b4d0-628230a593ca">277,866</ix:nonFraction> ($<ix:nonFraction unitRef="cad" contextRef="i7f73e01a75a540b3bd81d5cbc09e5ef3_I20211231" decimals="0" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzI0OTQ_35f658a3-ffa8-418d-aa9e-d86082d11fa9">352,279</ix:nonFraction>) (December&#160;31, 2020 - US$<ix:nonFraction unitRef="usd" contextRef="if1358bb7098240d2b664975d761c15b0_I20201231" decimals="0" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzAyODg_8f944ac2-45e7-4871-af2f-25b8c1568532">97,381</ix:nonFraction> ($<ix:nonFraction unitRef="cad" contextRef="if1358bb7098240d2b664975d761c15b0_I20201231" decimals="0" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzI1MTY_5ad02b35-ff3a-42fa-b200-f29363c14093">123,985</ix:nonFraction>)) in other liabilities representing future trial costs to be incurred.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $<ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="oncyf:FundedandRoyaltyRepayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzg4OQ_08d43094-686b-45e8-8c36-c4b56551e39c">400,000</ix:nonFraction> plus an overhead repayment of $<ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="oncyf:OverheadRepayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzkyMg_984664e8-8bc7-4e25-b33e-affbc7945e12">100,000</ix:nonFraction>, upon sales of a specified product.&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) <ix:nonFraction unitRef="number" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="oncyf:AnnualContingentPaymentGrossSalesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwNTM_9ecc7caf-b0d0-4b21-bff7-e66b74612eb6">5</ix:nonFraction>% of gross sales of a specified product; or (b) $<ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="oncyf:AnnualContingentPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzExMDI_7b7ebb6a-e737-4183-90e5-c9f5369961dc">100,000</ix:nonFraction> per annum once sales of a specified product commence.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 14: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfContingentLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzE4ODQ_d60c7e02-9b0a-44b9-bdae-94a6c1146978" continuedAt="ib9550207e4804a4ab1a7471121cf165a" escape="true">Contingencies</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib9550207e4804a4ab1a7471121cf165a" continuedAt="i8244b68e40094a42b65d26dd6da4be99"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumption Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1999, we entered into an agreement that assumed certain obligations (the &#8220;Assumption Agreement&#8221;) in connection with a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, a milestone payment was still outstanding for $<ix:nonFraction unitRef="cad" contextRef="icca82039f3674df999dc93b86acdc4b5_D20210101-20211231" decimals="-5" name="ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzM4MA_e5f4101c-0586-4f7c-9ae6-66abd5afe18c">1.0</ix:nonFraction> million, due within <ix:nonNumeric contextRef="icca82039f3674df999dc93b86acdc4b5_D20210101-20211231" name="oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzM5NQ_8763e198-fcfd-414f-a219-0f054dfe4725">90</ix:nonNumeric> days of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell pelareorep to the public or the approval of a new drug application for pelareorep. This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the milestone payment, payments may become due and payable in accordance with the Share Purchase Agreement upon realization of sales of pelareorep.&#160;If we receive royalty payments or other payments as a result of entering into </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="i8244b68e40094a42b65d26dd6da4be99" continuedAt="ibcd518155ce84b38b8186732122b2c81"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders <ix:nonFraction unitRef="number" contextRef="icca82039f3674df999dc93b86acdc4b5_D20210101-20211231" decimals="INF" name="oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzExMDQ_8307a9a7-f616-4236-b7d3-85f0b1f1bdbc">10.75</ix:nonFraction>% (2020 - <ix:nonFraction unitRef="number" contextRef="i7062d63d6b934781a4bc28b162213372_D20200101-20201231" decimals="INF" name="oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzExMTM_1c472250-ebdc-42ef-afd3-73cb6a17f2d9">10.75</ix:nonFraction>%) of the royalty payments and other payments received.&#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of <ix:nonFraction unitRef="number" contextRef="icca82039f3674df999dc93b86acdc4b5_D20210101-20211231" decimals="INF" name="oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzEzNzQ_4717f163-af6e-4644-863a-d146691f8122">2.15</ix:nonFraction>% (2020 - <ix:nonFraction unitRef="number" contextRef="i7062d63d6b934781a4bc28b162213372_D20200101-20201231" decimals="INF" name="oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzEzODM_aa5eeeb3-7ced-47b0-9cb2-1cc1ae868a7d">2.15</ix:nonFraction>%) of Net Sales received for such products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRI &#8220;Work in Kind&#8221; Contribution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibcd518155ce84b38b8186732122b2c81">We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&#8220;BRI&#8221;).&#160;The terms of this agreement include a &#8220;work in kind&#8221; contribution from BRI.&#160;In exchange for this &#8220;work in kind&#8221; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue at the lesser of <ix:nonFraction unitRef="number" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="INF" name="oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzE4Mzc_734325ac-22f1-4614-b1b7-dc13c9db8fa4">0.5</ix:nonFraction>% of Sales Revenue or $<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="INF" name="oncyf:ContingentRoyaltyPaymentAnnualMaximum" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzE4NjA_0ca5f860-90d3-4c7f-9bd1-ba6f2f40184b">20,000</ix:nonFraction> per year until December 31, 2028.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 15: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90ZXh0cmVnaW9uOjJkNjJhMjYwZTAzZTQ3NTM4NmM4MzM2YmIzYTk1Y2EwXzEwNDY_ead3a7ac-0d05-463b-b2f3-96fe57bc6518" continuedAt="ib7bc9bbafb1a4e1d8c2da1a483be10c9" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ib7bc9bbafb1a4e1d8c2da1a483be10c9" continuedAt="i9ed0f404953d47adbe373a20f605e25d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90ZXh0cmVnaW9uOjJkNjJhMjYwZTAzZTQ3NTM4NmM4MzM2YmIzYTk1Y2EwXzEwNDQ_4be389fc-9119-4b2c-867f-80ecc8b651f4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31, </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEtMS0xLTEtODEyMQ_7f630683-1338-4b60-ad38-a1827841f1d3">26,254,852</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEtMi0xLTEtODEyMQ_a30edeaf-f17a-4247-850c-cd147c65d894">22,505,057</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEtMy0xLTEtODEyMQ_5059b69e-2c0e-4df8-97de-929833a3ad0d">33,122,888</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzItMS0xLTEtODEyMQ_ed32e57c-b45e-4433-b291-bd87fbc7a935">23.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzItMi0xLTEtODEyMQ_d746a181-7167-42cf-ba62-7b1dd2a9db16">24.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzItMy0xLTEtODEyMQ_fd998ee8-37ed-41e3-a371-567f04f5f180">26.50</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzMtMS0xLTEtODEyMQ_ad6e5df0-2135-4db4-aa73-865f8cc1978b">6,038,616</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzMtMi0xLTEtODEyMQ_222f5a61-7ff4-498f-bb2c-aaaa09b5d417">5,401,214</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzMtMy0xLTEtODEyMQ_79d8c4f5-0460-487b-b0ad-bdffa77dcf1c">8,777,565</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdiction tax rate difference</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzQtMS0xLTEtODEyMQ_22b36d60-cc0f-4e6a-a263-e4c033f76f67">2,716,319</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzQtMi0xLTEtODEyMQ_91452b40-d1e7-4af6-809b-6811dd7ea03e">3,237,898</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzQtMy0xLTEtODEyMQ_ab2860d8-d920-4fd8-9d29-7f1f5268f51e">3,088,811</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzUtMS0xLTEtODEyMQ_06bc898d-6310-475f-8785-0e67a3adebd1">879,957</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzUtMi0xLTEtODEyMQ_4c321405-10b0-47ca-94bc-f912429c0451">614,154</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzUtMy0xLTEtODEyMQ_94595bde-47ef-4152-9440-0f73d32a6f0d">389,591</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzYtMS0xLTEtODEyMQ_509f87bf-25d7-4e6a-9b86-7897e4439395">3,937</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzYtMi0xLTEtODEyMQ_91c86422-c9da-48c0-85a2-ddf9300bbd35">838,063</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzYtMy0xLTEtODEyMQ_1912abce-d765-48e0-8b66-777ea6e6277b">3,341,334</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Alberta rate change</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:TaxEffectFromChangeInTaxRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzctMS0xLTEtODEyMQ_18c6889b-40d4-4c0b-84e1-389b31d642fc">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:TaxEffectFromChangeInTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzctMi0xLTEtODEyMQ_7f313ddb-aa81-4415-97a7-2dc6191117e4">96,028</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:TaxEffectFromChangeInTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzctMy0xLTEtODEyMQ_84d52337-62dd-456a-a3e5-0e54d7093c2f">3,758,175</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to opening tax pools</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="oncyf:TaxEffectOfTaxPools" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzgtMS0xLTEtODEyMQ_e5288ced-fc62-4e54-9212-06106699a31c">552,079</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="oncyf:TaxEffectOfTaxPools" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzgtMi0xLTEtODEyMQ_fab821ca-d77c-4007-92ce-aaf5aa87134d">20,711</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="oncyf:TaxEffectOfTaxPools" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzgtMy0xLTEtODEyMQ_f22356fa-ea44-4c20-b335-cb70bd539b57">11,973</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzktMS0xLTEtODEyMQ_e3d38d5d-a637-43a1-8295-7b232bcf33b8">44,290</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzktMi0xLTEtODEyMQ_94e57548-65b4-47cb-90c0-9fb553dc4a32">108,945</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzktMy0xLTEtODEyMQ_bc53a886-c948-42e5-936e-45745ecc94fa">149,294</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTEtMS0xLTIwNzkz_61e4dfbd-9ee2-455d-ad39-77e7df516a3f">1,661,187</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTMtMS0xLTIwODAw_a8ee25cd-4ca0-45be-923c-6b0c434b87b5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTUtMS0xLTIwODA3_174ffd20-23a6-4396-bf62-d8a4cdcfb07e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax benefits deemed not probable to be recovered</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTEtMS0xLTgxMjE_9be77e46-8fff-4fb8-a202-331e83d923a2">1,342,306</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTItMS0xLTgxMjE_99226cbe-71c5-4062-8349-62ef885e1308">2,161,541</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTMtMS0xLTgxMjE_68fd0951-d2c2-4b00-a85a-c3d1e610694c">1,961,613</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzExLTEtMS0xLTgxMjE_6276b391-ca0e-4d2f-bb1d-49e616c995fe">49,427</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzExLTItMS0xLTgxMjE_56f99be0-4c7b-4582-a221-dd75efc44ebb">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzExLTMtMS0xLTgxMjE_20943784-5728-444a-bf4e-ea7b6a09927d">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="i9ed0f404953d47adbe373a20f605e25d" continuedAt="ib875ec9d216b42e2ab1564a231fc28d9"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90ZXh0cmVnaW9uOjJkNjJhMjYwZTAzZTQ3NTM4NmM4MzM2YmIzYTk1Y2EwXzEwNjA_7af8a186-7252-4ba7-b27a-5f054b5098b6" continuedAt="i51471f74f4f348188e7499724dfc4320" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2021, we have the following approximate non-refundable federal investment tax credits and non-capital losses for income tax purposes in Canada, as well as non-capital losses in Barbados that are expected to expire in the following years, if not utilized:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Barbados</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment tax credits</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-capital losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-capital losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4d3bff3314ec4be6ba448395655d2141_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEtMS0xLTEtMTcxMDU_ab70b674-79eb-46a8-9715-51e1c31c1c93">465,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if548fffce7f84aaeac70a8fdef2ff771_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzItNS0xLTEtMjA2NzY_8ced7e92-bf83-44d7-a465-4d491c73172a">42,826,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic1da936afae14dc49119ba8ffe8ecd44_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzItMS0xLTEtMTcxMDU_95633b6b-464e-4a6b-a74c-c325d2d828a0">361,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib0136e4da0fc41549105d0be0238fef9_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzMtNS0xLTEtMjA2NzY_a9bcd54c-1b78-4c47-bd25-5483236166e9">33,063,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia63919fb6b0447f6a8378922a57a0e56_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzMtMS0xLTEtMTcxMDU_bfb46cca-e072-4868-971a-025aee329b65">228,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5017b3339eec4bedacd81c4e5981b39a_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzQtNS0xLTEtMjA2NzY_f8376c93-0bc7-4245-b8a6-6b8299edec4e">15,990,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie6f9bf167d3e4703927ae2652aa85037_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzQtMS0xLTEtMTcxMDU_7c090577-94c7-4f13-aa23-3331100caed5">271,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if88b7239836e47ee87d1993c2c69f365_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzUtNS0xLTEtMjA2NzY_1fe5948f-2f50-4208-a4c4-89521ab8dd2b">15,138,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i3821df9c92a94be4821466bf971f7738_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzUtMS0xLTEtMTcxMDU_40110da6-0348-4972-9958-748614e8206e">520,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id6b5060463694393849921c58686af13_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEtMS0xLTEtODEyMQ_ea1598df-8c1c-498b-a279-1e447a1a0055">9,809,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i754d4b44f8894e0bbeddfd1cbb8a2e24_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzYtNS0xLTEtMjA2NzY_d68cbc6d-e1ff-451a-8fde-90cbcb3c2916">16,575,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i78b655fa2c2545fcbf00fef881bf589b_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzYtMS0xLTEtMTcxMDU_6ffced95-9c96-4e4b-81b3-bd375df13740">596,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifa114dbc78574101a453118abbe69a95_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzItMS0xLTEtODEyMQ_d7fad3f3-4511-489a-8c14-4c88c6709e3f">12,170,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2ca59ee964074feca5cc2d804c6f3e05_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzctNS0xLTEtMjA2NzY_7f2e6de3-bde2-48ec-a15a-38c1ee125894">26,114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7be63a4d7e934a779ffa098a8c199bbb_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzgtMS0xLTEtMjA2OTI_e7c6ef45-f926-4b70-8837-44388492f4f6">622,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie2b331eb2ec14c0e884108fdc1e52785_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzgtNS0xLTEtMjA2OTk_bf1197ca-43db-40f7-8bda-167051ce7a35">13,280,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1f9f805b162c4a61970dee91fe9b7b6e_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzctMS0xLTEtMTcxMDU_7216df11-9d72-44ed-94f0-391f70716db1">173,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1e1e786a729e443ba51a570b25e7dfb0_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzMtMS0xLTEtODEyMQ_2272fcf5-9ac4-410c-95a9-233d00927df6">4,009,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7c684f104e0f40f7a2835b480bb00c0d_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzgtMS0xLTEtMTcxMDU_502abad9-044b-4251-a068-4b5aafbe396c">91,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4a91cd1ffa8b427ea4ede5259eb7c307_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzQtMS0xLTEtODEyMQ_4039c1fe-c607-46d7-9fd7-a8e0210ac672">4,774,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ief9049c105f7454c87536a38658d6c0f_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzktMS0xLTEtMTcxMDU_62440da8-52c9-4d0a-bf0c-e906d7086fa3">114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1eb2c5a4d51543949a0ffbdf4ec7a8bd_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzUtMS0xLTEtODEyMQ_f9de1cde-3c52-4712-9f3f-74b940369389">4,343,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i82c158562bdf41e7a6759b2f5d325150_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEwLTEtMS0xLTE3MTA1_56c91623-12b3-49e4-aad8-b5941e3b51da">381,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib10f6659cd90429fb750eb8ed77dc3e5_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzYtMS0xLTEtODEyMQ_c077049c-5818-4bbc-9d66-d2169c92d466">2,873,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i66ea19593d434f9b8f9057991c2ee87e_I20211231" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzExLTEtMS0xLTE3MTA1_adbc185e-d294-4db1-a06d-1a96461b302a">487,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i522e5807f7804127b24ef62fe2d3d449_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzctMS0xLTEtODEyMQ_700bfd10-a1cb-42f5-890e-8dfa764e753d">2,457,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2c3f0b5419c0434c83941543d561ae09_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEyLTEtMS0xLTE3MTA1_d9d2e145-7ac3-4ec9-894a-78c90be8e4ed">270,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i841d852358ae4ecda2e98b20193fcc61_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzgtMS0xLTEtODEyMQ_2ebee092-2169-49d7-bb3d-b64c997351c6">2,472,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifdea1c38e3904299ae54711a02c93657_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEzLTEtMS0xLTE3MTMw_fa747028-7372-4c4b-9273-fca0ff4020ed">183,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib45ee033334041378788db209329639e_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzktMS0xLTEtODEyMQ_f243d1e7-acb1-4cd6-bd1b-f4ddaad57b46">3,125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4449dd50bc6407d98849bb27aa044d1_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE0LTEtMS0xLTE3MTMw_1f04afc8-0b4e-4551-954c-fe870ef84b6e">41,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icc931101e8f347f9916d973a1aeea8a2_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEwLTEtMS0xLTgxMjE_923d67d0-96e2-4f14-b72d-2bb29ff39360">6,430,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if376893af6704869aa4000196dff2a9d_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE1LTEtMS0xLTE3MTMw_5731f2bc-b838-479b-8254-d362bbfb42c1">980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4b10f7069e464035b0d01d42a3daefe9_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzExLTEtMS0xLTgxMjE_1c7cc94f-da1a-4508-988d-9b8ad32e7d87">4,812,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i68fe7581765a490288f89d0a93ec69f4_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE2LTEtMS0xLTE3MTMw_e6eb1acf-6b0d-453b-954f-40ba28215f1e">22,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iccd6471f6d9042109c8c9ea4e5b721a1_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEyLTEtMS0xLTgxMjE_5ec9fd2e-f54b-49c6-bedf-4e223e19551f">5,056,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i551872a26867455eaad5a877c53f122a_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE3LTEtMS0xLTE3MTMw_eef2d424-5761-4a97-af3e-dd6f5a6c0a05">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if8acbc8f07e144d19384899f34b15b1b_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEzLTEtMS0xLTgxMjE_21c84c7d-c585-4f94-b3a2-942a33fffa14">6,864,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icb56d715075745efb29466f96d59e553_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE0LTEtMS0xLTgxMjE_2be5f470-bd03-4772-97e0-8f16be739641">9,724,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6c59a90a0dc54356b24f4e161e4d58b8_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE1LTItMS0xLTE1ODQz_8974a1a6-c95e-43e8-8303-610a3d49a3fa">10,619,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie39699155be34d93b5eee0afd15baccc_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzIwLTEtMS0xLTE3MTUy_da843ece-c5f6-4a46-8131-8cb688680a7a">4,833,980</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iafea390033d44f86b623be26aa1611fc_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE1LTEtMS0xLTgxMjE_53eb658b-4108-487c-88ec-d22ce0128393">89,537,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaaf0f7affb224fd0a519419d263a370f_I20211231" decimals="0" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzIyLTUtMS0xLTIwNzYy_fa6cbb54-b00e-4a2d-9fae-67338a3d8964">162,986,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of approximately $<ix:nonFraction unitRef="cad" contextRef="i691c2aef708c40e4959eda123656f876_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90ZXh0cmVnaW9uOjJkNjJhMjYwZTAzZTQ3NTM4NmM4MzM2YmIzYTk1Y2EwXzYxNw_b4926c8b-d655-4dc9-8e44-60172268dad8">27,663,000</ix:nonFraction>.&#160;We also have unclaimed U.S. credits for increasing research activities available to reduce future years' taxable income of approximately $<ix:nonFraction unitRef="cad" contextRef="id89944ab2f3648f88d0e3371530558e0_I20211231" decimals="0" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90ZXh0cmVnaW9uOjJkNjJhMjYwZTAzZTQ3NTM4NmM4MzM2YmIzYTk1Y2EwXzEwOTk1MTE2MzE5NjE_6650b9d4-dae0-44ce-9ecc-4c5f33608e49">1,343,000</ix:nonFraction> expiring between 2031 and 2041. We have not recorded the potential benefits of these tax pools in these consolidated financial statements.  </span></div><ix:continuation id="i51471f74f4f348188e7499724dfc4320"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i569c7f4341664d4b8664d09e7fff7d81_I20211231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzEtMS0xLTEtODEyMQ_77cbdce6-4c49-43e1-8588-1101b21f52a1">25,157,950</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9f423bf1a59c47c5a5c56ae5a92be8fc_I20201231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzEtMi0xLTEtODEyMQ_404318da-fa4a-463e-a2d1-4843198ca40b">21,487,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i86190dfcd5e447cd8e04730476245e4e_I20191231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzEtMy0xLTEtODEyMQ_74b0758f-ea20-4db3-93cf-e72ee3b0a864">19,625,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib5d5cda63e0542bfb6b7cdd527ea542d_I20211231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzItMS0xLTEtODEyMQ_7d32473e-2050-4f2c-87dd-a1eb1c8b81fc">7,705,028</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8aefcdf933a04c1591bc48676eeb3311_I20201231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzItMi0xLTEtODEyMQ_542884bb-823c-497e-abb0-749c5324c9cc">6,362,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id63e281c95ed4160b4cfa6e9d2499567_I20191231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzItMy0xLTEtODEyMQ_795b3dad-fa35-432c-b176-6c33264d4d32">6,338,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibbdf50475dc0456b9d7a6b17c5375332_I20211231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzMtMS0xLTEtODEyMQ_726014d0-6749-475f-8a34-b57e141342ad">3,715,652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib796065ed9ef4953ab1452c82a71d086_I20201231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzMtMi0xLTEtODEyMQ_7134cd93-07a3-4fe1-bff4-3119014490e9">4,068,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6a94de62f7e941fd85969fb9eeb33c7a_I20191231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzMtMy0xLTEtODEyMQ_d7dbd68c-6ec4-40b7-8721-33e8b9d60e3f">4,222,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i974cc837b3484870886ee47cd5811453_I20211231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzQtMS0xLTEtODEyMQ_8adae837-8819-4495-a91a-8cdd38d90a01">350,695</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibbae27b666e24aa78eafbec4c720309d_I20201231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzQtMi0xLTEtODEyMQ_550c922c-9cf9-4baf-93c2-7a04a3437ee8">1,927,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i75b7f989f0c7451bad6b8015dcb583ef_I20191231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzQtMy0xLTEtODEyMQ_4a4d5c17-b2ea-41ba-900a-e194b6c26f42">1,908,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib599fad21e614582ad5c64473790e8e8_I20211231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzUtMS0xLTEtODEyMQ_ced9671a-2fe9-4c25-8a8c-6d9562c3d95c">647,978</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1c2429705a0742a9958a515cdbca5c9e_I20201231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzUtMi0xLTEtODEyMQ_8b524baf-1cb3-4992-89e2-d3d06eada751">689,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i08b1e6664397457eb8e8ce0dfdc08ea1_I20191231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzUtMy0xLTEtODEyMQ_6816077b-3a1d-4e65-8c81-56527253e030">611,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id8d66e5ff5ff48138f1c4239fa19d36a_I20211231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzYtMS0xLTEtODEyMQ_02a95613-7577-4259-9f67-09e1d1e1b8de">6,472</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i118bcfe7943a4062a9525f725b80591f_I20201231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzYtMi0xLTEtODEyMQ_3dc6bae1-fc74-4121-8b9f-ac8b00c3dfe6">6,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia79a3437f60544f18719723caeb2aefd_I20191231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzYtMy0xLTEtODEyMQ_a6f5a41f-570b-4a18-9296-d87922b2e0c8">6,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzctMS0xLTEtODEyMQ_3f2d4390-e14b-4797-a559-eb085fd7120d">37,583,775</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzctMi0xLTEtODEyMQ_10ed8192-2947-4256-bae5-24bf104b52f7">34,541,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231" decimals="0" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzctMy0xLTEtODEyMQ_32b70c14-4d63-47ee-8d81-192161d20635">32,712,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib875ec9d216b42e2ab1564a231fc28d9">The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any other material income tax examination currently in progress by any taxing jurisdiction.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 16: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90ZXh0cmVnaW9uOjBhYWViYjc4MmYyMzQzY2NiYjcxMWI2YTgyMzkyZTAzXzM1OTM_8eaf1905-ea27-4dcd-a9e3-5f0b66ca4fab" continuedAt="i3e4c75896309437aa5bf923fbe24bb1a" escape="true">Capital Disclosures</ix:nonNumeric></span></div><ix:continuation id="i3e4c75896309437aa5bf923fbe24bb1a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;We include shareholders' equity and cash and cash equivalents in the definition of capital.  </span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:DisclosureOfCapitalComponentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90ZXh0cmVnaW9uOjBhYWViYjc4MmYyMzQzY2NiYjcxMWI2YTgyMzkyZTAzXzM1ODk_2e8f4e7e-4324-4771-9a41-22455d2b1ea3" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:63.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90YWJsZTpkN2NlYzVlMTk3YjE0OGY5YTY1YTVhZjc3OWE2YzljZi90YWJsZXJhbmdlOmQ3Y2VjNWUxOTdiMTQ4ZjlhNjVhNWFmNzc5YTZjOWNmXzEtMS0xLTEtODEyMQ_cb9f27a7-7caf-4c03-8e13-6d1482f894f4">41,262,044</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90YWJsZTpkN2NlYzVlMTk3YjE0OGY5YTY1YTVhZjc3OWE2YzljZi90YWJsZXJhbmdlOmQ3Y2VjNWUxOTdiMTQ4ZjlhNjVhNWFmNzc5YTZjOWNmXzEtMi0xLTEtODEyMQ_11999d6a-d2a2-4473-9522-9a9b21d34877">31,219,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe633dda267842029258e53a782fe561_I20211231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90YWJsZTpkN2NlYzVlMTk3YjE0OGY5YTY1YTVhZjc3OWE2YzljZi90YWJsZXJhbmdlOmQ3Y2VjNWUxOTdiMTQ4ZjlhNjVhNWFmNzc5YTZjOWNmXzItMS0xLTEtODEyMQ_9c5d799e-dfca-4411-8701-f0f7b4fc07b8">36,098,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90YWJsZTpkN2NlYzVlMTk3YjE0OGY5YTY1YTVhZjc3OWE2YzljZi90YWJsZXJhbmdlOmQ3Y2VjNWUxOTdiMTQ4ZjlhNjVhNWFmNzc5YTZjOWNmXzItMi0xLTEtODEyMQ_366e67f7-7d90-4764-861f-b671a084a357">24,752,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 12, 2020, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $<ix:nonFraction unitRef="cad" contextRef="i921a0b76be5e4a5192afdce2bfa1f576_I20200612" decimals="INF" name="oncyf:EquityAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90ZXh0cmVnaW9uOjBhYWViYjc4MmYyMzQzY2NiYjcxMWI2YTgyMzkyZTAzXzE4NzU_105f1560-192d-46e7-bf4e-6154fae03afe">150,000,000</ix:nonFraction> of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries, and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreement in June 2020 and March 2021 (see Note 9). We use these equity arrangements to assist us in achieving our capital objective. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_187"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 17: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzM0ODg_a1c07a24-4ba2-4608-b893-750ca5c9d837" continuedAt="i8ca05d8c87024366965385c6ef0f720c" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i8ca05d8c87024366965385c6ef0f720c" continuedAt="i238b889c40c6476fb11b79bf16e1cefe"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, accounts payable and accrued liabilities, and warrant derivative.&#160;As at December&#160;31, 2021, the carrying amount of our cash and cash equivalents,&#160;other receivables, and accounts payable and accrued liabilities approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December 31, 2021, the fair value of our warrant derivative was $<ix:nonFraction unitRef="cad" contextRef="if9c241e91c964c239ec005ab7fd76cda_I20211231" decimals="0" name="ifrs-full:CurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzU1NQ_a3c0c87c-4eb0-4887-bd86-c37055480cd8">56,017</ix:nonFraction> (December&#160;31, 2020 - $<ix:nonFraction unitRef="cad" contextRef="i13e8c5af4bf84a0ba2e3af4a542a05f4_I20201231" decimals="0" name="ifrs-full:CurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzU2NA_be94304f-33a5-4585-8ac2-426dbbf0228a">531,228</ix:nonFraction>).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents and other receivables from Pfizer in connection with the BRACELET-1 study (see Note 13) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our Pfizer other receivable by entering into collaborations with global biopharmaceutical companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar as a portion of our financial assets and liabilities are denominated in such currency. The impact of a $<ix:nonFraction unitRef="cad" contextRef="i72934bebe99040b6b7e0c0c2f19de911_D20210101-20211231" decimals="2" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzI0Mjc_53f82ff4-e72b-43f7-bf49-dd9844a19e2b">0.01</ix:nonFraction> increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2021 by approximately $<ix:nonFraction unitRef="cad" contextRef="i72934bebe99040b6b7e0c0c2f19de911_D20210101-20211231" decimals="0" sign="-" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzI1NzA_057a333f-4300-44f9-bfd5-eac777e005d5">240,000</ix:nonFraction>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable and accrued liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant b<ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzM0ODQ_dd555179-2b00-4e82-bbdc-c1dba263def5" continuedAt="i70e14cca276746b7a6ea98eec4c9d286" escape="true">alances in foreign currencies at December&#160;31, 2021 are as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i70e14cca276746b7a6ea98eec4c9d286"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06647bdfde1c470b8b4d0a645c9ba2d5_I20211231" decimals="0" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90YWJsZTpjOGYzOTM0Yjk0OTY0MzRjYmI2NmVmM2Q4OWQ2NGQ5MS90YWJsZXJhbmdlOmM4ZjM5MzRiOTQ5NjQzNGNiYjY2ZWYzZDg5ZDY0ZDkxXzEtMS0xLTEtODEyMQ_e3ed7700-6622-4e07-bb69-759a59c2a242">31,102,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i06647bdfde1c470b8b4d0a645c9ba2d5_I20211231" decimals="0" name="ifrs-full:OtherReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90YWJsZTpjOGYzOTM0Yjk0OTY0MzRjYmI2NmVmM2Q4OWQ2NGQ5MS90YWJsZXJhbmdlOmM4ZjM5MzRiOTQ5NjQzNGNiYjY2ZWYzZDg5ZDY0ZDkxXzItMS0xLTEtMTc1ODM_8298b758-47ea-4002-a6e7-c09176d294e5">621,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06647bdfde1c470b8b4d0a645c9ba2d5_I20211231" decimals="0" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90YWJsZTpjOGYzOTM0Yjk0OTY0MzRjYmI2NmVmM2Q4OWQ2NGQ5MS90YWJsZXJhbmdlOmM4ZjM5MzRiOTQ5NjQzNGNiYjY2ZWYzZDg5ZDY0ZDkxXzItMS0xLTEtODEyMQ_41b1eabb-7610-41d6-b875-a0497cfdb551">886,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06647bdfde1c470b8b4d0a645c9ba2d5_I20211231" decimals="0" name="oncyf:BalanceHeldInForeignCurrencyNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90YWJsZTpjOGYzOTM0Yjk0OTY0MzRjYmI2NmVmM2Q4OWQ2NGQ5MS90YWJsZXJhbmdlOmM4ZjM5MzRiOTQ5NjQzNGNiYjY2ZWYzZDg5ZDY0ZDkxXzQtMS0xLTEtODEyMQ_b5ed30eb-5c8e-4bb7-ada9-86f94faa373b">30,837,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><ix:continuation id="i238b889c40c6476fb11b79bf16e1cefe"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 16. Accounts payable and accrued liabilities are all due within the current operating period.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_190"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 18: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfCashFlowStatementExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90ZXh0cmVnaW9uOjhmMGNhZGVkYjc4NDQwY2FhNGFiYjMzMGQ0YTI0NmI4XzEyNg_1f42e88c-bcac-4e45-8ff6-56a7cb4df0f9" continuedAt="i1052460894354f5f9c8a2aa53d259f94" escape="true">Additional Cash Flow Disclosures</ix:nonNumeric></span></div><ix:continuation id="i1052460894354f5f9c8a2aa53d259f94"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:CashFlowOperatingCapital1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90ZXh0cmVnaW9uOjhmMGNhZGVkYjc4NDQwY2FhNGFiYjMzMGQ0YTI0NmI4XzEyOQ_9c23c108-3da6-4aa7-ba0b-8721d9079ea6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzMtMS0xLTEtODEyMQ_7583abf8-a3cc-4fae-9d5d-6aa0da968ae0">776,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzMtMi0xLTEtODEyMQ_7ea274b0-269a-4610-9001-66303ee0b6c3">1,979,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzMtMy0xLTEtODEyMQ_5125b395-c765-4578-be9a-a0071959677e">2,017,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzQtMS0xLTEtODEyMQ_d93b4001-81fb-47c6-a141-4e4387226845">348,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzQtMi0xLTEtODEyMQ_0ca166d4-8b83-443a-a24b-99ee092cd4c2">286,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzQtMy0xLTEtODEyMQ_e05b0752-d274-4e44-8fee-98aff06de5c8">2,012,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzUtMS0xLTEtODEyMQ_730fb7ab-99a4-49a9-b4e1-eb27554b643e">182,855</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzUtMi0xLTEtODEyMQ_6d10b628-499f-485e-9963-7ab8736c3316">1,368,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzUtMy0xLTEtODEyMQ_12e0e6e4-848e-4278-9661-5ae85b2d218e">1,347,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzctMS0xLTEtODEyMQ_8f6cea8e-bf45-4b5e-9336-4007c71e2fb2">228,294</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzctMi0xLTEtODEyMQ_a4c804e2-30b9-4154-bc8d-77eeac40c246">723,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzctMy0xLTEtODEyMQ_76dcf91f-152f-4d93-a4f6-e3ff2a254650">807,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" sign="-" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzgtMS0xLTEtODEyMQ_bb1efe4b-d854-45b3-bcd7-d7400c3d9b47">194,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzgtMi0xLTEtODEyMQ_83de442b-7dcb-4ac1-a985-480f9443223d">35,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzgtMy0xLTEtODEyMQ_b75db14b-922b-4bd1-a94c-e68674cf2575">78,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzktMS0xLTEtODEyMQ_37095d1e-acb9-4f77-bdfc-ba30a7abe0fb">907,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzktMi0xLTEtODEyMQ_21c5ea62-7b8a-4269-b73f-8edcba3d54d3">209,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzktMy0xLTEtODEyMQ_76b8e23b-237f-4905-8885-efb8e6c4163b">1,795,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90ZXh0cmVnaW9uOjhmMGNhZGVkYjc4NDQwY2FhNGFiYjMzMGQ0YTI0NmI4XzEzMA_32b90788-a524-4df1-8c15-fa0a26223c18" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="oncyf:ProceedsfromInterestReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzEtMS0xLTEtODEyMQ_49f61256-b996-41f4-9358-5f0c4782e198">190,339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="oncyf:ProceedsfromInterestReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzEtMi0xLTEtODEyMQ_285cbd19-27a2-4dfe-ba73-3abf8cb45a55">189,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="oncyf:ProceedsfromInterestReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzEtMy0xLTEtODEyMQ_208b1c68-f187-41a2-baed-4fedd233c0e6">274,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:IncomeTaxesPaidRefund" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzItMS0xLTEtODEyMQ_6186bfc6-7372-4fb5-af2f-3ab2e92f1a35">34,959</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:IncomeTaxesPaidRefund" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzItMi0xLTEtODEyMQ_06072600-d724-43c1-ad40-87a9d38d5c03">12,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:IncomeTaxesPaidRefund" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzItMy0xLTEtODEyMQ_542e77b5-25ae-4107-b891-417ae694a1fd">5,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 19: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTMvZnJhZzoxOGExNjM2ZTA3ZTY0NGRlYmU4NDkyZTkxYWZmNjFmZC90ZXh0cmVnaW9uOjE4YTE2MzZlMDdlNjQ0ZGViZTg0OTJlOTFhZmY2MWZkXzExNjI_63c56d54-e3eb-4dae-b61c-2a02ff4cdac6" continuedAt="i5495ed3dfd7945319747cd876b06b94d" escape="true">Indemnification of Officers and Directors</ix:nonNumeric></span></div><ix:continuation id="i5495ed3dfd7945319747cd876b06b94d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_196"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 20: <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:DisclosureOfEconomicDependenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTYvZnJhZzpkYzI5ZjViNTY3ZmI0NGUxOTYwNmE4YThjZWJhN2UzMS90ZXh0cmVnaW9uOmRjMjlmNWI1NjdmYjQ0ZTE5NjA2YThhOGNlYmE3ZTMxXzY0MQ_bf71a362-4fc1-4352-8706-6d1784a97324" continuedAt="i4487ec7c97df44cb9e365eee45d0e4c5" escape="true">Economic Dependence</ix:nonNumeric></span></div><ix:continuation id="i4487ec7c97df44cb9e365eee45d0e4c5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use <ix:nonFraction unitRef="manufacturer" contextRef="ifd70dd98103f43b6af3a92c583cabdb7_D20210101-20211231" decimals="INF" name="oncyf:ConcentrationRiskNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTYvZnJhZzpkYzI5ZjViNTY3ZmI0NGUxOTYwNmE4YThjZWJhN2UzMS90ZXh0cmVnaW9uOmRjMjlmNWI1NjdmYjQ0ZTE5NjA2YThhOGNlYmE3ZTMxXzI3NDg3NzkwNzQyNjE_70343940-0cb0-480d-a6ca-40410574d448">one</ix:nonFraction> toll manufacturer in the U.S. to produce the clinical grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_199"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 21:  <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90ZXh0cmVnaW9uOjIxMTI4MjQ1ZGJiNzQ5ZTA5NGQ1OTQ3MmUzNTQ5MzM5XzQ4Ng_0cacb5d0-2abc-4f35-8d61-200a43b8dd9f" continuedAt="i26617d556fe1441b9e3b362a2d295cb0" escape="true">Other Expenses</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i26617d556fe1441b9e3b362a2d295cb0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details highlight certain components of the research and development and operating expenses classified by nature. The foreign exchange loss as presented separately on the face of the consolidated statement of loss and comprehensive loss is also classified as a research and development expense. Remaining research and development and operating expenses include expenses paid to third parties.  </span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="oncyf:OtherExpensesAndAdjustmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90ZXh0cmVnaW9uOjIxMTI4MjQ1ZGJiNzQ5ZTA5NGQ1OTQ3MmUzNTQ5MzM5XzQ4NA_24bfd618-94ac-4e37-be7f-3f5c6ab7f3d5" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i86f880390f904058bf8a9cf3258849d0_D20210101-20211231" decimals="0" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItMS0xLTEtMTAxNDU_abefe488-9a10-4d42-bd2f-7343ff1a2654">4,645,264</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i631df61a67ec41a593216ea67df15be1_D20200101-20201231" decimals="0" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItMy0xLTEtMTAxNTk_82befe56-f786-4159-ba2b-ce5ad3ab4a00">3,775,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7e7344f3cdea473fa96384f7743d95b9_D20190101-20191231" decimals="0" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItNS0xLTEtMTAxNjk_7d8784ac-22e9-4e71-a121-24c7d6d5fe43">3,096,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i86f880390f904058bf8a9cf3258849d0_D20210101-20211231" decimals="0" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItMS0xLTEtODEyMQ_d25b213b-11f8-4778-aeee-88d127fcf387">2,086,608</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i631df61a67ec41a593216ea67df15be1_D20200101-20201231" decimals="0" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItMi0xLTEtODEyMQ_d00a2ded-f4d2-4b13-a5ca-48f08cb3f3e9">1,043,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7e7344f3cdea473fa96384f7743d95b9_D20190101-20191231" decimals="0" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItMy0xLTEtODEyMQ_8130ad36-6f65-4ba8-992b-f592256b4542">561,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ieb584ab1725b4b40910af903b876e75c_D20210101-20211231" decimals="0" name="ifrs-full:AmortisationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzUtMS0xLTEtODEyMQ_5cd8b3f4-07f8-43b0-aaab-95595b9a50e2">130,243</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i95d0e74b706c4b069c1415f031d34f1d_D20200101-20201231" decimals="0" name="ifrs-full:AmortisationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzUtMi0xLTEtODEyMQ_351c669b-26da-4dcc-8670-b43afe43372e">88,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ida85ff23b9654045a8551b3d03eece63_D20190101-20191231" decimals="0" name="ifrs-full:AmortisationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzUtMy0xLTEtODEyMQ_b296ff87-2ff9-4baa-bce0-72d90c67e841">122,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb584ab1725b4b40910af903b876e75c_D20210101-20211231" decimals="0" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzYtMS0xLTEtODEyMQ_4f8d9119-8876-4c2d-a993-fcaa958048b7">321,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d0e74b706c4b069c1415f031d34f1d_D20200101-20201231" decimals="0" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzYtMi0xLTEtODEyMQ_195fe771-c885-4150-a290-71100af87624">357,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida85ff23b9654045a8551b3d03eece63_D20190101-20191231" decimals="0" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzYtMy0xLTEtODEyMQ_93399fb8-a024-4feb-a728-91bb1c45eff5">362,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ieb584ab1725b4b40910af903b876e75c_D20210101-20211231" decimals="0" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtMS0xLTEtMTAxNTI_7c1e8bb6-c3e3-4508-8417-3d491634c769">2,542,210</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i95d0e74b706c4b069c1415f031d34f1d_D20200101-20201231" decimals="0" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtMy0xLTEtMTAxNzY_4a0bdc91-c910-4f19-aa0b-12341d8b7c56">2,635,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ida85ff23b9654045a8551b3d03eece63_D20190101-20191231" decimals="0" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtNS0xLTEtMTAxODM_060c7867-13a1-4f80-a828-79a2fb12bbc4">2,555,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ieb584ab1725b4b40910af903b876e75c_D20210101-20211231" decimals="0" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzctMS0xLTEtODEyMQ_70ce1893-1c20-432c-b5e1-e0a2f6f17b50">1,739,293</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i95d0e74b706c4b069c1415f031d34f1d_D20200101-20201231" decimals="0" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzctMi0xLTEtODEyMQ_8d03ad21-6af6-45ca-b3a2-92b84928f0c9">1,515,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ida85ff23b9654045a8551b3d03eece63_D20190101-20191231" decimals="0" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzctMy0xLTEtODEyMQ_935176eb-a771-4311-b648-601d22ad9ce8">908,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction cost, warrant derivative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifd23113a5fc540bf93ca41f097c068f4_D20210101-20211231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtMS0xLTEtODEyMQ_76be7371-c385-4350-bd52-5cc07087b23c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic461088cc874441196432eb9bafe69bc_D20200101-20201231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtMi0xLTEtODEyMQ_7ebdbee6-9b0e-4c62-bfb6-f659422734c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i803b09a886c44d92b85f0e3efad65433_D20190101-20191231" decimals="0" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtMy0xLTEtODEyMQ_ee3ae8a4-0c0d-409a-8aa0-149216ba6bd1">233,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_202"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 22:  <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90ZXh0cmVnaW9uOjdmYzhkMDI1YWYyNTQwNTRhMGQxZmVkOWEyMDdlNjY1XzM4NA_a45e5f53-9503-422f-b76c-cb2af7a97f9c" continuedAt="i5ff1ebdc501e46219126477003b8090e" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5ff1ebdc501e46219126477003b8090e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation of Key Management Personnel</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain employees of the Company.   </span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90ZXh0cmVnaW9uOjdmYzhkMDI1YWYyNTQwNTRhMGQxZmVkOWEyMDdlNjY1XzM4Mw_49883845-78fc-45cc-a20b-a788c8e48064" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzEtMS0xLTEtODEyMQ_7bf30857-5217-44bc-b4be-ddcee07ddd91">3,918,564</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzEtMi0xLTEtODEyMQ_a3106044-5410-4d76-ae4c-221cc914de30">3,514,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzEtMy0xLTEtODEyMQ_f3846c98-7a75-47a5-91cc-26388411ecd8">3,786,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzItMS0xLTEtODEyMQ_e60bf551-9c32-4a19-ae83-d63ac3cb018b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzItMi0xLTEtODEyMQ_083785e6-596c-4a73-aaaf-23ca1e8e33b7">495,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzItMy0xLTEtODEyMQ_49ab5616-9508-470f-afbf-c0ea367132b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzMtMS0xLTEtODEyMQ_069fbe01-06ad-47ce-8795-e19bf8b72610">2,703,256</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzMtMi0xLTEtODEyMQ_4eca9962-d4de-4664-9bc9-d4d263a8a6e3">1,757,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzMtMy0xLTEtODEyMQ_6400eb2d-3dbe-41ed-923d-c3ad7c88b756">1,123,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzQtMS0xLTEtODEyMQ_6b9db147-65ce-4087-b1d2-f45253c6bfc1">6,621,820</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzQtMi0xLTEtODEyMQ_678ce893-2617-4410-833c-d2315c2c03f5">5,767,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231" decimals="0" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzQtMy0xLTEtODEyMQ_5ce2e1d2-4160-41e9-b21b-cf536661bbba">4,910,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="icedb1c9c6ee74f3199d6852ba92bc59b_205"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 23:  <ix:nonNumeric contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDUvZnJhZzo0NGNiYTc1NjVlMzQ0MWZhYmNjOTY5MWQwMmJhOWZmNy90ZXh0cmVnaW9uOjQ0Y2JhNzU2NWUzNDQxZmFiY2M5NjkxZDAyYmE5ZmY3XzI3Mg_99124db6-ad71-4577-9ccf-18f1131e5b75" continuedAt="i89e3034167fb4352955fa339b400931d" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><ix:continuation id="i89e3034167fb4352955fa339b400931d" continuedAt="i1211a0513106472e8e2d744b5be529b0"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Between January 1, 2022 to March 2, 2022, we issued <ix:nonFraction unitRef="shares" contextRef="i89a71f2e8ff5408fba66dd7456a26ab8_D20220101-20220302" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDUvZnJhZzo0NGNiYTc1NjVlMzQ0MWZhYmNjOTY5MWQwMmJhOWZmNy90ZXh0cmVnaW9uOjQ0Y2JhNzU2NWUzNDQxZmFiY2M5NjkxZDAyYmE5ZmY3XzEwOTk1MTE2Mjg2MzA_c1196702-1c28-456c-bf41-2abbf67ed244">2,050,240</ix:nonFraction> common shares for gross proceeds of US$<ix:nonFraction unitRef="cad" contextRef="i89a71f2e8ff5408fba66dd7456a26ab8_D20220101-20220302" decimals="0" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDUvZnJhZzo0NGNiYTc1NjVlMzQ0MWZhYmNjOTY5MWQwMmJhOWZmNy90ZXh0cmVnaW9uOjQ0Y2JhNzU2NWUzNDQxZmFiY2M5NjkxZDAyYmE5ZmY3XzEwOTk1MTE2Mjg2NDI_c30243e6-941f-4a70-b2b5-c536b39f2134">3,560,397</ix:nonFraction> through our March 2021 ATM equity offering sales agreement. </span></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1211a0513106472e8e2d744b5be529b0" continuedAt="i084693c84ece4c349c850918ba567334">(b)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:continuation id="i084693c84ece4c349c850918ba567334">In February 2022, we paid a non-refundable deposit of US$<ix:nonFraction unitRef="usd" contextRef="i9757885e4d9e44f386e37be5103b4760_D20220201-20220228" decimals="0" name="oncyf:PaymentsForExecutoryContracts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDUvZnJhZzo0NGNiYTc1NjVlMzQ0MWZhYmNjOTY5MWQwMmJhOWZmNy90ZXh0cmVnaW9uOjQ0Y2JhNzU2NWUzNDQxZmFiY2M5NjkxZDAyYmE5ZmY3XzEwOTk1MTE2MjkwMzU_b9079984-1a2b-4f5f-95c8-aacf7c8bcbf2">1,368,000</ix:nonFraction> related to a production service agreement (the &#8220;Agreement&#8221;) entered on December 23, 2021 with our primary toll manufacturer. Under IFRS, the Agreement was deemed an executory contract at signing. As a result, the contractual obligation to pay the deposit was not recorded in our December 31, 2021, consolidated financial statements.</ix:continuation>     </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>articles.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>articles</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- articles001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles001.jpg" title="slide1" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">CORPORATE ACCESS NUMBER: 207797382 Government of Alberta BUSINESS CORPORATIONS ACT CERTIFICATE OF AMENDMENT ONCOLYTICS BIOTECH INC. AMENDED ITS ARTICLES ON 20 18/05/22. Name/Structure Change Alberta Corporation - Registration Statement Alberta Amendment Date: 2018/05/22 Service Request Number: 29037579 Corporate Access Number: 207797382 Legal Entity Name: ONCOLYTICS BIOTECH INC. French Equivalent Name: Legal Entity Status: Active Alberta Corporation Type: Named Alberta Corporation New Legal Entity Name: ONCOLYTICS BIOTECH INC. New French Equivalent Name: Nuans Number: 60651958 Nuans Date: 1998/04/06 French Nuans Number: French Nuans Date: Share Structure: SCHEDULE &#8220;A&#8221; Share Transfers Restrictions: NONE. Number of Directors: Mm Number Of Directors: 3 Max Number Of Directors: 11 Business Restricted To: NONE Business Restricted From: NONE Other Provisions: SEE ATTACHED SCHEDULE OF OTHER PROVISIONS. BCA Section/Subsection: SECTION 173(1)(F) Professional Endorsement Provided: Future Dating Required: Annual Return IFi1e YearllDate Filed I 120 17 12017/05/081 [2016 Ij6/o5/o9l 2015 12016/03/181 Attachment </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- articles002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles002.jpg" title="slide2" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">I Attachment Type IMicroflim Bar CodeliDate Recorded&#8217; Registration Authorized By: KIRK LOOK OFFICER Share Structure IIELECTRONIC 1998/04/02 Restrictions on Share Transfers IIELECTRONIC 1998/04/02 Other Rules or Provisions IIELECTRONIC 1998/04/02 Consolidation, Split, Exchange IIELECTRONIC 1999/07/29 Other Rules or Provisions IIELECTRONIC j1999/07/29 Other Rules or Provisions IIELECTRONIC 12007/02/09 Articles/Plan of Arrangement/Court Orderll 10000907103981773 12009/04/09 Consolidation, Split, Exchange IELECTRONIC 112018/05/22 SCHEDULE RE CONSOLIDATION OP SHARES The issued and outstanding Common Shares of the Corporation shall be consolidated on the basis of 1 Common Share for each 9.5 Common Shares issued and outstanding immediately prior to the consolidation without amending the stated capital account for the Common Shares of the Corporation. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- articles003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles003.jpg" title="slide3" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">DocuSign Envelope ID: 59FC34F8-OBOA-459A-B923-9F8BA834507B Articles Of Amendment Business Corporations Act Sections 29 or 177 1. Name of Corporation 2. Corporate Access Number ONCOLYTICS BIOTECH INC. 207797382 The Articles of the Corporation are amended in accordance with Section 1 73(1)(f) of the Business Corporations Act (Alberta) to change the number of the issued and outstanding Common Shares of the Corporation into a different number of Common Shares of the Corporation (the &#8220;Consolidation&#8221;) on the basis of 1 Common Share for each 9.5 Common Shares issued and outstanding immediately prior to the Consolidation without amending the stated capital account for the Common Shares of the Corporation. The applicable Schedule re Consolidation of Shares is attached hereto to form part hereof. DocuSigned by: Ki rk Look 1:o::! Name of Person Authorizing (please _7BDE7EF49ignature print) CFO 1v z&#8212;, zo&amp; Title (please print) Date REG 3054 (99/01) I9LED Mctarthy T&eacute;trault LLP Cal ry,Alberta Per:_________________ DOcS 17911400 DocuSign Envelope ID: 59FC34F8-OBOA-459A-B923-9F8BA834507B SCHEDULE RE CONSOLIDATION OF SHARES The issued and outstanding Common Shares of the Corporation shall be consolidated on the basis of 1 Common Share for each 9.5 Common Shares issued and outstanding immediate&#8217;y prior to the conso)idation without amending the stated capita&#8217; account for the Common Shares of the Corporation. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- articles004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles004.jpg" title="slide4" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">CORPORATE ACCESS NUMBER: 207797382 AberFa BUSINESS CORPORATIONS ACT CERTIFICATE OF AMENDMENT AND REGISTRATION OF RESTATED ARTICLES ONCOLYTICS BIOTECH INC. AMENDED ITS ARTICLES ON 2007/02/09. BUSINESS CORPORATIONS ACT Alberta ARTICLES OF AMENDMENT 1. Name of Corporation 2. Corporate Access Number ONCOLYTICS BIOTECH INC. 207797382 3. Pursuant to subsection 173(l)(n) of the Business Corporations Act (Alberta), paragraph 4 of the Schedule of Other Provisions to the Articles of the Corporation is hereby deleted and replaced with the following: &#8220;4. Meetings of the shareholders may be held at any place within Alberta or at any other location as determined by the directors of the Corporation.&#8221; so that the Schedule of Other Provisions shall read as set out in the attached Schedule of Other Provisions. (5649 44246-218INHS) S:\C4\CORPSERVV.LF\cRM&#8217;27015.DOC REGISTERED ON THE ALBERT REGISTRIES CORES SYSTEM J4 FEO U 9 2007 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- articles005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles005.jpg" title="slide5" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">fl SCHEDULE OF OTHER PROVISIONS 1. Thedirectorsofthecorporationinay,withoutauthorizationofthe shareholders: a. borrow money on the credit of the Corporation; b. issue, reissue, sell or pledge debt obligations of the Corporation; c. Subject to the Business Corporations Act of Alberta, give guarantee on behalf of the Corporation to secure performance of an obligation of any person, and; d. mortgage, hypothecate, pledge or otherwise create a security interest in all or any property of the Corporation, owned or subsequently acquired, to secure any obligation of the Corporation. 2. The directors may, by resolution delegate the powers referred to in subsection 1 hereof to a director, a committee of directors or an officer. 3. The directors may, between annual general meetings, appoint one or more additional directors of the Corporation to serve until the next annual general meeting, but the number of additional directors shall not at any time exceed 1/3 of the number of directors who held office at the expiration of the last annual general meeting of the Corporation. 4. Meetings of the shareholders may be held at any place within Alberta or at any other location as determined by the directors of the Corporation. Name/Structure Change Alberta Corporation - Registration (tatement Alberta Amendment Date: 2007/02/09 Service Request Number: 9691672 Corporate Access Number: 207797382 Legal Entity Name: ONCOLYTICS BIOTECH INC. French Equivalent Name: Legal Entity Status: Active Alberta Corporation Type: Named Alberta Corporation New Legal Entity Name: ONCOLYTICS BIOTECH INC. New French Equivalent Name: Nuans Number: 60651958 Nuans Date: 1998/04/06 French Nuans Number: French Nuans Date: Share Structure: SCHEDULE &#8216;A&#8221; Share Transfers Restrictions NONE Number of Directors: Mm Number Of Directors: 3 Max Number Of Directors: 11 Business Restricted To: NONE Business Restricted From: NONE Other Provisions: SEE ATTACHED SCHEDULE OF OTHER PROVISIONS. BCA Section/Subsection: 173(1)(N) Professional Endorsement Provided: Future Dating Required: Annual Return File YearJJ Date Filedi 12006 112006/05/111 12005 112005/05/131 2004 12004/05/21 Attachment </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- articles006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles006.jpg" title="slide6" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">I Attachment Type IlMicrofilm Bar Cc jiDate Recordedj Q Share Structure I1LECTRONIC 1998/04/02 ,Restrictions on Share Transfj[LECTRONIC 111998/04/02 [9r Rules or Provisions ]IELECTRONIC J8/04/02 Consolidation, Split, Exchange JIELECTRONIC I[i9/07/29 Other Rules or Provisions JIELECTRONIC 11999/07/29 [Other Rules or Provisions IIELECTRONIC ]12007102/09 Registration Authorized By: DAVID DORRANS SOLICITOR CORPORATE ACCESS NUMBER: 207797382 x3rra BUSINESS CORPORATIONS ACT CERTIFICATE OF AMENDMENT AND REGISTRATION OF RESTATED ARTICLES ONCOLYTICS BIOTECH INC. AMENDED ITS ARTICLES ON 1999/07/29. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- articles007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles007.jpg" title="slide7" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">BUSINESS CORPORATIONS ACT FOEM 4 (SECTIONS 27 or 171) Alberta ARTICLES OF AMENDMENT 1. NAME OF CORPORATION; 2 ALBERTA CORPORATE ACCESS NUMBER; ONCOLYTICS BIOTECH INC. 207797382 3. ITEM ). OF THE ARTICLES OF THE ABOVE NAMED CORPORATION ARE AMENDED IN ACCORDANCE WITH SECTION &#8212; OF THE BUSINESS CORPORATIONS ACT 1. Pursuant to subsection 167(1)(1) of the Business Corporations Act (Alberta), the share transfer restrictions as set out in the Articles of the Corporation are hereby amended by deleting the existing provisions and the inserting therefor the word &#8216;None&#8221;; 2. Pursuant to subsection 167(lXk) of the Business Corporations Act (Alberta), the number of directors set out in the Articles of the Corporation is hereby amended by increasing the minimum number of directors to three (3); 3 Pursuant to subsection 167(1)(m) of the Business Corporations Act (Alberta), the other rules and provisions as set out in the Articles of the Corporation are hereby amended by deleting the existing provisions and inserting therefor the attached Schedule of Other Provisions; and 4. Pursuant to subsection 167(lXf) of the Business Corporations Act (Alberta), the Articles of the Corporation are hereby amended by changing the 2,222,222 issued and outstanding Common Shares of the Corporation into 6,750,000 Common Shares. REGSTEREDON THE ALBERTA REGISJ. CORES SYST:Oi JUL 2 91999 4. DATE I TITLE July 29, 1999 President FILED O7/U8/4 / &#8216;; SCHEDULE OF OTHER PROVISIONS 1. The directors of the corporation may, without authorization of the shareholders: (a) borrow money on the credit of the Corporation; (b) issue, reissue, sell or pledge debt obligations of the Corporation; (c) Subject to the Business Corporations Act of Alberta, give a guarantee on behalf of the Corporation to secure performance of an obligation of any person, and; (d) mortgage, hypothecate, pledge or otherwise create a security interest in all or any property of the Corporation, owned or subsequently acquired, to secure any obligation of the Corporation. 2. The directors may, by resolution, delegate the powers referred to in subsection 1 hereof to a director, a committee of directors or an officer. 3. The directors may, between annual general meetings, appoint one or more additional directors of the Corporation to serve until the next annual general meeting, but the number of additional directors shall not at any time exceed 1/3 of the number of directors who held office at the expiration of the last annual general meeting of the Corporation. 4. Meetings of the shareholders may be held at any place within Alberta or at any of following cities: Vancouver, British Columbia; Victoria, British Columbia; Winnipeg, Manitoba; Toronto, Ontario; Ottawa, Ontario; Montreal Quebec; or Halifax, Nova Scotia. (34379-1) S:\C4\DRO1\JUL\6755.SCH </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- articles008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles008.jpg" title="slide8" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">Service Request Number: 1344977 Corporate Access Number: 207797382 Previous Legal Entity Name: Previous French Equivalent Name: Legal Entity Name: French Equivalent Name: Legal Entity Status: Alberta Corporation Type: Nuans Report Number: Nuans Report Date: French Name Nuans Report Number: French Name Nuans Report Date: Classes Of Shares and any Maximum Number(within each class): Restrictions On Share Transfers: Minimum Number Of Directors: Maximum Number Of Directors: Restrictions On Business To: Restrictions On Business From: Other Provisions: Section And Subsection of Act Change Made Under: Professional Endorsement Provided: Future Dating Required: Amendment Date: Annual Returns are outstanding Annual Returns File Year Date Filedj Court Orders ONCOLYTICS BIOTECH INC. Active Named Alberta Corporation 60651958 1998/04/06 SCHEDULE &#8220;A&#8221; NONE. 3 11 NONE NONE SEE ATTACHED SCHEDULE OF OTHER PROVISIONS. Name/Structure Change Alberta Corporation - R Statement ONCOLYTICS BIOTECH INC. ON THE ALBERTA RL COREESSY;TL,1 JUL29 l9S9 , ;LX UI 167(1), (F), (K),(L) &amp; (M) 1999/07/29 IIrder &#8216;lype1[(Jrder LflUrder NumberliJudicial Llistrictjl&#8217;l&#8217;ermination L)atej Attachments -. I pr [ Attachment Type jcrofiImBarCodc{IDateRecordedL ion 167(1 I ier Rules or Provisions [ELECTRONIC j[1999/O7/29 j Registration Authorized By: KENTON G.C. REIN SOLICITOR </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- articles009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles009.jpg" title="slide9" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">CORPORATE ACCESS NUMBER: 207797382 AlLx3rra BUSINESS CORPORATIONS ACT CERTIFICATE OF AMENDMENT 779738 ALBERTA LTD. CHANGED ITS NAME TO ONCOLYTICS BIOTECH INC. ON 1998/04/08. BUSINESS CORPORATIONS ACT (SECTION 27 OR 171) FORM 4 ARTICLES OF AMENDMENT 1. NAME OF CORPORATION: 2. CORPORATE ACCESS NUMBER 779738 ALBERTA LTD. 207797382 3. THE ARTICLES OF THE ABOVE-NAMED CORPORATION ARE AMENDED AS FOLLOWS: Pursuant to Section 167(3) of the Business Coiporations Act (Alberta), Article No. 1 of the Articles of Incorporation is amended by changing the name of the Corporation to: ONCOLYTICS BIOTECH INC. F:\053555\0001\CRPOO4.F4 DURNET DuCKWORTH &amp; PALMER APR 0 81998 FILED DATE SIGNATURE TITLE </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- articles010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles010.jpg" title="slide10" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">Name Change Alberta Corporation - Registration Statement Service Request Number: 228266 Corporate Access Number: 207797382 Legal Entity Name: ONCOLYTICS BIOTECH INC. French Equivalent Name: Legal Entity Status: Active Alberta Corporation Type: Named Alberta Corporation Nuans Report Number: 60651958 Nuans Report Date: 1998/04/06 French Name Nuans Report Number: French Name Nuans Report Date: Future Dating Required: Professional Endorsement Provided: Amendment Date: 1998/04/08 Annual Returns rFile YearfiFiled Registration Authorized By: VICTORIA C. MARSELLE SOLICITOR CORPORATE ACCESS NUMBER: 207797382 AILx3rra BUSINESS CORPORATIONS ACT CERTIFICATE OF INCORPORATION 779738 ALBERTA LTD. WAS INCORPORATED IN ALBERTA ON 1998/04/02. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- articles011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles011.jpg" title="slide11" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">Articles of Incorporation For 779738 ALBERTA LTD. Classes of Shares: SCHEDULE &#8220;A&#8221; Number of Directors: Maximum Number of Directors : 11 Minimum Number of Directors: 1 Restrictions on Business To: NONE Restrictions on Business From: NONE Restrictions on Share Transfers: SCHEDULE &#8220;B&#8221; Other Rules or Provisions: SCHEDULE &#8220;C&#8221; Registration Authorized By: VICTORIA C. MARSELLE SOLICITOR SCHEDULE &#8220;A&#8221; Unlimited number of common shares without nominal or par value to which shares shall be attached the following rights (i) to vote at any meeting of shareholders of the Corporation; (ii) to receive any dividend declared by the Corporation; and (iii) to receive the remaining property of the Corporation upon dissolution. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- articles012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="articles012.jpg" title="slide12" width="1055" height="2730">
<DIV><FONT size="1" style="font-size:1pt;color:white">SCHEDULE &#8220;B&#8221; No shares of the Corporation shall be transferred without the approval of the directors, provided that approval of any transfer of shares may be given as aforesaid after the transfer has been effected upon the records of the Corporation, in which event, unless the said approval stipulates otherwise, the said transfer shall be valid and shaf I take effect as from the date of its very entry upon the books of the Corporation. SCHEDULE NC&#8221; a. The number of shareholders of the Corporation, exclusive of persons who are in its employment or that of an affiliate, and; ii. persons who, having been formerly in its employment or that of an affiliate, were, while in that employment, shareholders of the Corporation and have continued to be shareholders of that Corporation after termination of that employment, is limited to not more than 50 persons, 2 or more persons who are the joint registered owners of I or more shares being counted as I shareholder. b. Any invitation to the public to subscribe for the securities of the Corporation is prohibited. c. The directors of the corporation may, without authorization of the shareholders: borrow money on the credit of the Corporation; ii. issue, reissue, sell or pledge debt obligations of the Corporation; iii. subject to the Business Corporations Act of Alberta, give a guarantee on behalf of the Corporation to secure performance of an obligation of any person, and; iv. mortgage, hypothecate, pledge or otherwise create a security interest in all or any property of the Corporation, owned or subsequently acquired, to secure any obligation of the Corporation. d. The directors may, by resolution, delegate the powers referred to in subsection (c) hereof to a director, a committee of directors or an officer. e. The directors may, between annual general meetings, appoint one or more additional directors of the Corporation to serve until the next annual general meeting, but the number of additional directors shall not at any time exceed 1/3 of the number of directors who held office at the expiration of the last annual general meeting of the Corporation. f. Meetings of the shareholders may be held at any place within Alberta or at any of the following cities: Vancouver, British Columbia; Victoria, British Columbia; Winnipeg, Manitoba; Toronto, Ontario; Ottawa, Ontario; Montreal Quebec; or Halifax, Nova Scotia. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>3
<FILENAME>ex12onc-2017byxlaws1636459.htm
<DESCRIPTION>EX-1.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i52e1e6ddc75b4dfa9a25d0a5c46b4e0e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 1.2</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ONCOLYTICS BIOTECH INC.<br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">BY-LAW NO. 1 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">A by-law relating generally to <br>the transaction of the business<br>and affairs of Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">BE IT ENACTED</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> as a by-law of Oncolytics Biotech Inc. as follows&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">DIVISION ONE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">INTERPRETATION</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  In the by-laws and all ordinary and special resolutions of the Corporation, unless the context otherwise requires&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.57pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Business Corporations Act </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(Alberta) and the regulations thereunder, as from time to time amended, re-enacted or replaced&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.57pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">articles</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the articles of incorporation of the Corporation, as from time to time amended or restated&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the board of directors of the Corporation&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.57pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">by-laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means this by-law and all other by-laws of the Corporation from time to time in force and effect&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.57pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; mean Oncolytics Biotech Inc.&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">meeting of shareholders</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; includes, unless the context otherwise requires, an annual or special meeting of shareholders or of any class or classes of shareholders&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.57pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">STA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%"> Securities Transfer Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> (Alberta) and the regulations made thereunder, as from time to time amended, re-enacted or replaced.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.02 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  Subject to section 1.01 of the by-laws, words and expressions defined in the Act have the same meanings when used herein and words importing the singular include the plural and vice versa&#59; words importing any gender include any other gender&#59; and words importing persons include individuals, bodies corporate, partnerships, trusts and unincorporated organizations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.03 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Subordination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> These by-laws are subordinate to and should be read subject to the Act, the articles of the Corporation and any other applicable law.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 2 -</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">DIVISION TWO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">DIRECTORS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Calling of and notice of meetings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  Meetings of the board will be held on such day and at such time and place as the President and Chief Executive Officer of the Corporation or any two directors may determine.  Notice of meetings of the board will be given to each director not less than 24 hours before the time when the meeting is to be held.  Each newly elected board may without notice hold its first meeting for the purposes of organization and the appointment of officers immediately following the meeting of shareholders at which such board was elected.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Quorum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  A majority of the directors in office constitutes a quorum at any meeting of directors.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Votes to govern</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  At all meetings of the board every question will be decided by a majority of the votes cast on the question&#59; and in case of an equality of votes the chair of the meeting will not be entitled to a second or casting vote.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Interest of directors and officers generally in contracts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  No director or officer will be disqualified by his or her office from contracting with the Corporation nor will any contract or arrangement entered into by or on behalf of the Corporation with any director or officer or in which any director or officer is in any way interested be liable to be voided nor will any director or officer so contracting or being so interested be liable to account to the Corporation for any profit realized by any such contract or arrangement by reason of such director or officer holding that office or of the fiduciary relationship thereby established provided that, in each case, the director or officer has complied with the provisions of the Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Meetings by telephonic or electronic means</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  A meeting of the directors may be held by means of a telephonic, electronic or other communication facility that permits all participants to communicate adequately with each other during the meeting. Each director so participating shall be deemed to be present at such meeting and such meeting shall be deemed to be held at the place specified in the notice calling such meeting and, in the absence of any such specification, at the place where or from which the chair of the meeting shall have presided.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">DIVISION THREE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SHAREHOLDERS&#8217; MEETINGS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Quorum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  At any meeting of shareholders a quorum will be two persons present in person or by means of a telephonic, electronic or other communication facility that permits all participants to communicate adequately with each other during the meeting and each entitled to vote at the meeting and holding or representing by proxy not less than 5% of the votes entitled to be cast at the meeting.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Meetings by telephonic or electronic means</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  A meeting of the shareholders may be held by means of a telephonic, electronic or other communication facility that permits all participants to communicate adequately with each other during the meeting.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Postponement or cancellation of meetings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  A meeting of shareholders may be postponed or cancelled by the board at any time prior to the date of the meeting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 3 -</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Procedures at meetings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  The board may determine the procedures to be followed at any meeting of shareholders including, without limitation, the rules of order.  Subject to the foregoing, the chair of a meeting may determine the procedures of the meeting in all respects.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.06&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Notice-and-access</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  Notwithstanding anything contained elsewhere in the by-laws and, subject to the Act, the Corporation shall be entitled, at its discretion, to utilize the notice-and-access method of delivering shareholder meeting materials, soliciting proxies and receiving voting instructions from registered and beneficial shareholders adopted by the Canadian Securities Administrators in the amendments to the rules for communication between reporting issuers and their shareholders, as such rules may be modified from time to time.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">DIVISION 4</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">INDEMNIFICATION</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnification of directors and officers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  The Corporation will indemnify any director or officer of the Corporation, any former director or officer of the Corporation or any individual who acts or acted at the Corporation&#8217;s request as a director or officer, or in a similar capacity, of another entity, and his or her heirs and legal representatives to the extent permitted by the Act and will, subject to the terms of any indemnification agreement between the indemnified party and the Corporation, advance moneys to the indemnified party for costs, charges and expenses reasonably incurred by the indemnified party in respect of any proceeding in which the indemnified party is, or has been or may be involved or is or may be liable for or in respect of a judgment, penalty or fine by reason of or arising, in whole or in part, out of or in connection with or incidental to (a) the fact the indemnified party&#58; (i) is or was a director or officer of the Corporation&#59; (ii) is or was acting at the Corporation&#8217;s request as a director or officer, or in a similar capacity, of any entity&#59; or (b) anything done or not done by the indemnified party in any such capacity.  Such advance of moneys will be made by the Corporation only to the extent the Corporation receives a written demand from the indemnified party which must include&#58; (x) affirmation of the indemnified party&#8217;s good faith belief that he or she is entitled to indemnification by the Corporation hereunder together with particulars of the costs to be covered by the advance of moneys by the Corporation&#59; and (y) an undertaking from the indemnified party to repay all such advances if and to the extent that it is determined pursuant to a final judicial determination (as to which all rights of appeal therefrom have been exhausted or lapsed) by a court of competent jurisdiction that the indemnified party was not entitled to indemnification hereunder or that the payment of such costs, charges or expenses was prohibited by applicable law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnity of others</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  Except as otherwise required by the Act and subject to Section 4.03, the Corporation may from time to time indemnify and save harmless any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he or she is or was an employee or agent of the Corporation, or is or was serving at the request of the Corporation as an employee, agent of or participant in another entity, against expenses (including legal fees), judgments, fines and any amount actually and reasonably incurred by him or her in connection with such action, suit or proceeding if he or she acted honestly and in good faith with a view to the best interests of the Corporation or, as the case may be, to the best interests of the other entity for which he or she served at the Corporation&#8217;s request and, with respect to any criminal or administrative action or proceeding that is enforced by a monetary penalty, had reasonable grounds for believing that his or her conduct was lawful.  The termination of any action, suit or proceeding by judgment, order, settlement or conviction will not, of itself, create a presumption that the person </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 4 -</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">did not act honestly and in good faith with a view to the best interests of the Corporation or other entity and, with respect to any criminal or administrative action or proceeding that is enforced by a monetary penalty, had no reasonable grounds for believing that his or her conduct was lawful.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Right of indemnity not exclusive</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  The provisions for indemnification contained in the by-laws will not be deemed exclusive of any other rights to which any person seeking indemnification may be entitled under any agreement, vote of shareholders or directors or otherwise, both as to action in his or her official capacity and as to action in another capacity, and will continue as to a person who has ceased to be a director, officer, employee or agent and will inure to the benefit of that person&#8217;s heirs and legal representatives.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">No liability of directors or officers for certain matters</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  To the extent permitted by law, no director or officer for the time being of the Corporation will be liable for the acts, receipts, neglects or defaults of any other director or officer or employee or for joining in any receipt or act for conformity or for any loss, damage or expense happening to the Corporation through the insufficiency or deficiency of title to any property acquired by the Corporation or for or on behalf of the Corporation or for the insufficiency or deficiency of any security in or upon which any of the moneys of or belonging to the Corporation will be placed out or invested or for any loss or damage arising from the bankruptcy, insolvency or tortious act of any person, firm or body corporate with whom or which any moneys, securities or other assets belonging to the Corporation will be lodged or deposited or for any loss, conversion, misapplication or misappropriation of or any damage resulting from any dealings with any moneys, securities or other assets belonging to the Corporation or for any other loss, damage or misfortune whatever which may happen in the execution of the duties of his or her respective office or trust or in relation thereto unless the same will happen by or through his or her failure to act honestly and in good faith with a view to the best interests of the Corporation and in connection therewith to exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances.  If any director or officer of the Corporation is employed by or performs services for the Corporation otherwise than as a director or officer or is a member of a firm or a shareholder, director or officer of a body corporate which is employed by or performs services for the Corporation, the fact that the person is a director or officer of the Corporation will not disentitle such director or officer or such firm or body corporate, as the case may be, from receiving proper remuneration for such services.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">DIVISION 5</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">BANKING ARRANGEMENTS, CONTRACTS, ETC.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Banking arrangements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  The banking business of the Corporation, or any part thereof, will be transacted with such banks, trust companies or other financial institutions as the board may designate, appoint or authorize from time to time and all such banking business, or any part thereof, will be transacted on the Corporation&#8217;s behalf by one or more officers or other persons as the board may designate, direct or authorize from time to time.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Execution of instruments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  Contracts, documents or instruments in writing requiring execution by the Corporation will be signed by hand by any two persons each of whom is an officer or director of the Corporation and all contracts, documents or instruments in writing so signed will be binding upon the Corporation without any further authorization or formality.  The board is authorized from time to time by resolution</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 5 -</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.57pt">to appoint any officer or any other person on behalf of the Corporation to sign by hand and deliver either contracts, documents or instruments in writing generally or to sign either by hand or by facsimile or mechanical signature or otherwise and deliver specific contracts, documents or instruments in writing, and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.57pt">to delegate to any two officers of the Corporation the powers to designate, direct or authorize from time to time in writing one or more officers or other persons on the Corporation&#8217;s behalf to sign either by hand or by facsimile or mechanical signature or otherwise and deliver contracts, documents or instruments in writing of such type and on such terms and conditions as such two officers see fit.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Contracts, documents or instruments in writing that are to be signed by hand may be signed electronically.  The term &#8220;contracts, documents or instruments in writing&#8221; as used in the by-laws includes without limitation deeds, mortgages, charges, conveyances, powers of attorney, transfers and assignments of property of all kinds (including specifically but without limitation transfers and assignments of shares, warrants, bonds, debentures or other securities), proxies for shares or other securities and all paper writings.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">DIVISION 6</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SHARES AND TRANSFERS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Dealings with registered holder</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Subject to the Act, the STA, the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Civil Enforcement Act </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(Alberta) and this by-law, the Corporation may treat the registered owner of a security as the person exclusively entitled to vote, to receive notices, to receive any interest, dividend or other payments in respect of the security, and otherwise to exercise all the rights and powers of an owner of the security.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Registration of transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Subject to the Act and the STA, no transfer of a security shall be registered in a securities register except (a) upon presentation of the certificate (or, where applicable, other evidence of electronic, book-based, direct registration service or other non-certificated entry or position on the register of securityholders) representing such security with an endorsement or completed stock power of attorney which complies with the STA made thereon or delivered therewith duly executed by an appropriate person as provided by the STA, together with such reasonable assurance that the endorsement is genuine and authorized as the board or the Corporation&#8217;s transfer agent may from time to time prescribe, (b) upon payment of all applicable taxes and any reasonable fees prescribed by the board, (c) upon compliance with such restrictions on transfer as are imposed by statute or the articles of the Corporation, (d) upon satisfaction of any lien referred to in section 6.06, and (e) upon compliance with and satisfaction of such other requirements as the Corporation or its transfer agent may reasonably impose.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Defaced, destroyed, stolen or lost security certificates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> In case of the defacement, destruction, theft or loss of a security certificate, the fact of such defacement, destruction, theft or loss shall be reported by the owner to the Corporation or to an agent of the Corporation (if any), on behalf of the Corporation, with a statement verified by oath or statutory declaration as to the defacement, destruction, theft or loss and the circumstances concerning the same and with a request for the issuance of a new security certificate to replace the one so defaced (together with the surrender of the defaced security certificate), destroyed, stolen or lost. Upon the giving to the Corporation (or if there be an agent, hereinafter in this section 6.03 referred to as the &#8220;Corporation&#8217;s agent&#8221;, then to the Corporation and the Corporation&#8217;s agent) of a bond of a surety company (or other security approved by the directors) in such form as is approved by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 6 -</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">directors or by any officer of the Corporation, indemnifying the Corporation (and the Corporation&#8217;s agent if any) against all loss, damage or expense, which the Corporation and&#47;or the Corporation&#8217;s agent may suffer or be liable for by reason of the issuance of a new security certificate to such owner, and subject to compliance by such owner and the Corporation with the STA, a new security certificate shall be issued in replacement of the one defaced, destroyed, stolen or lost, and such issuance may be ordered and authorized by any officer or by the directors.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Enforcement of lien for indebtedness</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Subject to the STA, if the articles of the Corporation provide that the Corporation has a lien on the shares registered in the name of a shareholder or such shareholder&#8217;s legal representative for a debt of that shareholder to the Corporation, such lien may be enforced by the sale of the shares thereby affected or by any other action, suit, remedy or proceeding authorized or permitted by law or by equity and, pending such enforcement, the Corporation may refuse to register a transfer of the whole or any part of such shares. No such sale shall be made until such time as the debt ought to be paid and until a demand and notice in writing stating the amount due and demanding payment and giving notice of intention to sell on default shall have been served on the holder or such shareholder&#8217;s legal representative of the shares subject to the lien and default shall have been made in payment of such debt for seven days after service of such notice. Upon any such sale, the proceeds shall be applied, firstly, in payment of all costs of such sale, and, secondly, in satisfaction of such debt and the residue (if any) shall be paid to such shareholder or such shareholder&#8217;s legal representative or as such shareholder shall direct. Upon any such sale, the directors may enter or cause to be entered the purchaser&#8217;s name in the securities register of the Corporation as holder of the shares, and the purchaser shall not be bound to see to the regularity or validity of, or be affected by, any irregularity or invalidity in the proceedings, or be bound to see to the application of the purchase money, and after the purchaser&#8217;s name or the name of the purchaser&#8217;s legal representative has been entered in the securities register, the regularity and validity of the sale shall not be impeached by any person.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">DIVISION 7</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Invalidity of any provisions of the by-laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  The invalidity or unenforceability of any provision of the by-laws will not affect the validity or enforceability of the remaining provisions of the by-laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Omissions and errors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  The accidental omission to give any notice to any shareholder, director, officer or auditor or the non-receipt of any notice by any shareholder, director, officer or auditor or any error in any notice not affecting its substance will not invalidate any action taken at any meeting to which the notice related or otherwise founded on the notice.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">DIVISION 7</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">REPEAL</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Repeal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">  All previous by-laws of the Corporation are repealed as of the coming into force of the by-laws provided that such repeal will not affect the previous operation of any by-laws so repealed or affect the validity of any act done or right, privilege, obligation or liability acquired or incurred under or the validity of any contract or agreement made pursuant to any such by-law prior to its repeal.  All officers and persons acting under any by-laws so repealed will continue to act as if appointed by the directors under the provisions of the by-laws or the Act until their successors are appointed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 7 -</font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This By-Law No. 1 was made by resolution of the directors of the Corporation as of March 9, 2017. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This By-Law No. 1 was confirmed by ordinary resolution of the shareholders of the Corporation as of May 4, 2017.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>4
<FILENAME>ex21exdescriptionofsecurit.htm
<DESCRIPTION>EX-2.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9eb6dd2206e843328ac5cc22b04823a4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">EXHIBIT 2.1</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Our authorized capital consists of an unlimited number of Common Shares. The following is a summary of the provisions attached to our Common Shares&#58;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">The holders of our Common Shares are entitled to one vote per share at meetings of shareholders, to receive such dividends as declared by the Board and to receive our remaining property and assets upon dissolution or wind up. Our Common Shares are not subject to any future call or assessment and there are no pre-emptive, conversion or redemption rights attached to such shares. As at March&#160;2, 2022, we have 57,112,295 Common Shares issued and outstanding. After giving effect to the exercise or distribution of all outstanding options to acquire Common Shares, all outstanding share awards granted under the Corporation&#8217;s Incentive Share Award Plan and Common Share purchase warrants, we would have 64,286,239 Common Shares issued and outstanding. As at March&#160;2, 2022, we have 16,443,500 (exercisable into 1,730,894 common shares) Common Share purchase warrants issued in 2017 (the &#8220;2017 Warrants&#8221;) and 64,035 Common Share purchase warrants issued in 2019 (the &#8220;2019 Warrants&#8221;) outstanding. 9.5 2017 Warrant entitles the holder to purchase one Common Share until June 1, 2022, at an exercise price of $9.05. The 2017 Warrants are subject to acceleration if the volume weighted average price of the Common Shares equals or exceeds $23.75 for a period of 15 consecutive trading dates. Each 2019 Warrant entitles the holder to purchase one Common Share until August 16, 2024, at an exercise price of US$0.90. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.18
<SEQUENCE>5
<FILENAME>ex418mattcoffeyamendment3-.htm
<DESCRIPTION>EX-4.18
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib031c20a42c64eb9a4c7af2f0424ccfa_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4.18</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDING AGREEMENT #3</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AMENDING AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of January, 2022.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#34;Oncolytics&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Matt Coffey</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;Employee&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2019, amended by Amending Agreement # 1 dated January 1, 2020 and Amending Agreement # 2 dated January 1, 2021 (together the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Amendment to the Employment Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Commencing January 1, 2022, Oncolytics shall pay to the Employee a salary of SIX HUNDRED FIFTY-FOUR THOUSAND FOUR HUNDRED AND FOUR ($654,404.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of TWENTY-SEVEN THOUSAND TWO HUNDRED SIXTY-SIX DOLLARS AND EIGHTY-THREE CENTS ($27,266.83) on the 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and last day of each month.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4.18</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Confirmation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ONCOLYTICS BIOTECH INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Wayne Pisano</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wayne Pisano</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chair, Board of Directors</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Deborah Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deborah Brown</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chair, Compensation Committee</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Matt Coffey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MATT COFFEY</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.19
<SEQUENCE>6
<FILENAME>ex419kirklookamendment3-em.htm
<DESCRIPTION>EX-4.19
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iea12297c56e2412cbb3cd4bde30f515b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4.19</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDING AGREEMENT #3</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AMENDING AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of January, 2022.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#34;Oncolytics&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Kirk Look</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;Employee&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2019 amended by Amending Agreement # 1 dated January 1, 2020 and by Amending Agreement # 2 dated January 1, 2021 (together the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Amendment to the Employment Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Commencing January 1, 2022, Oncolytics shall pay to the Employee a salary of FOUR HUNDRED EIGHTY-SIX THOUSAND FIVE HUNDRED AND NINETY-THREE ($486,593.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of TWENTY THOUSAND TWO HUNDRED SEVENTY-FOUR DOLLARS and SEVENTY-ONE CENTS ($20,274.71) on the 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and last day of each month.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4.19</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Confirmation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ONCOLYTICS BIOTECH INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Wayne Pisano</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wayne Pisano</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chair, Board of Directors</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Deborah Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deborah Brown</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chair, Compensation Committee</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Kirk Look</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">KIRK LOOK</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.20
<SEQUENCE>7
<FILENAME>ex420allisonhagermanamendm.htm
<DESCRIPTION>EX-4.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icf8eaf500ba64985b50882ffb3c0d6f8_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4.20</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDING AGREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AMENDING AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of January, 2022.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#34;Oncolytics&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allison Hagerman,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#34;Employee&#34;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS Oncolytics and the Employee entered into a Letter of Employment dated August 3, 2010&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND WHEREAS Oncolytics and the Employee entered into an Employment Agreement dated August 1, 2013, which has been amended by amending agreements including that dated January 1, 2021 (collectively the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND WHEREAS Oncolytics and the Employee wish to further amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Amendment to the Employment Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Commencing January 1, 2022, Oncolytics shall pay to the Employee a salary of THREE HUNDRED NINETY THOUSAND SEVEN HUNDRED AND SEVETY-FOUR ($390,774.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of SIXTEEN THOUSAND TWO HUNDRED EIGHTY-TWO DOLLARS and TWENTY-FIVE CENTS ($16,282.25) on the 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and last day of each month.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4.20</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Confirmation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ONCOLYTICS BIOTECH INC.</font></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Wayne Pisano</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wayne Pisano</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chair, Board of Directors</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Deborah Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deborah Brown</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chair, Compensation Committee</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.467%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Allison Hagerman</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ALLISON HAGERMAN</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.21
<SEQUENCE>8
<FILENAME>ex421andrewdeguttadauroame.htm
<DESCRIPTION>EX-4.21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3f9f9d15d40b48a1a509133c9642681b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4.21</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDING AGREEMENT #5</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AMENDING AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">day of January, 2022.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ONCOLYTICS BIOTECH (U.S.), INC.,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#34;OBUS&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ANDREW DE GUTTADAURO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#34;Employee&#34;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective June 29, 2017, as amended by Amending Agreement #1, Amending Agreement #2, Amending Agreement #3 and Amending Agreement #4 (collectively the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND WHEREAS OBUS and the Employee wish to further amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Interpretation</font></div><div style="padding-left:54pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Amendment to the Employment Agreement</font></div><div style="padding-left:54pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Commencing January 1, 2022, OBUS shall pay to the Employee a salary of THREE HUNDRED THIRTY-FIVE THOUSAND EIGHT HUNDRED AND SIXTEEN ($335,816.00) UNITED STATES DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of THIRTEEN THOUSAND NINE HUNDRED NINETY-TWO UNITED STATES DOLLARS and THIRTY-THREE CENTS ($13,992.33) on the 15th and last day of each month.</font></div><div><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Confirmation</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="padding-right:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4.21</font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Miscellaneous</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written. </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ONCOLYTICS BIOTECH (U.S.), INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Gilles Gosselin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gilles Gosselin</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Matt Coffey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Matt Coffey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Andrew de Guttadauro</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANDREW DE GUTTADAURO</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="padding-right:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.22
<SEQUENCE>9
<FILENAME>ex422thomasheinemanamendme.htm
<DESCRIPTION>EX-4.22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iac846e665a4945a9ae9b5c070e23d0fa_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4.22</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDING AGREEMENT #2</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AMENDING AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">day of January, 2022.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ONCOLYTICS BIOTECH (U.S.), INC.,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#34;OBUS&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THOMAS C. HEINEMAN, M.D., Ph.D.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#34;Employee&#34;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective August 3, 2020, as amended by Amending Agreement #1 (collectively the &#8220;Employment Agreement&#8221;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Interpretation</font></div><div style="padding-left:54pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Amendments to the Employment Agreement</font></div><div style="padding-left:54pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Employment Agreement Section 1 &#8211; Employment is amended by replacing all references to &#8220;Global Head of Clinical Development and Operations&#8221; to &#8220;Chief Medical Officer&#8221;.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Employment Agreement Section 3.1 &#8211; Base Salary is amended as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commencing January 1, 2022, OBUS shall pay to the Employee a Base Salary at an annual rate of FOUR HUNDRED AND FORTY-THREE THOUSAND ($443,000.00) UNITED STATES DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of EIGHTEEN THOUSAND AND FOUR HUNDRED AND FIFTY-EIGHT UNITED STATES DOLLARS and THIRTY-THREE CENTS ($18,458.33) on the 15th and last day of each month.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Employment Agreement Section 3.2 &#8211; Incentive Bonus is amended by replacing &#8220;30%&#8221; with &#8220;40%&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Exhibit A to the Employment Agreement is amended by replacing it with the version of Exhibit A attached to this Amending Agreement #2.</font></div><div><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Confirmation</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4.22</font></div></div><div style="padding-right:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="padding-right:72pt"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Miscellaneous</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="padding-right:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ONCOLYTICS BIOTECH (U.S.), INC.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Gilles Gosselin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gilles Gosselin</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Matt Coffey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Matt Coffey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Thomas C. Heineman</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THOMAS C. HEINEMAN, M.D., Ph.D.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 4.22</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">To the Employment Agreement dated August 3, 2020 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">between Oncolytics Biotech (U.S.), Inc. and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Thomas C. Heineman, M.D., Ph.D.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INITIAL DUTIES AND RESPONSIBILITIES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Position Summary&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">The primary role of the CMO will be to provide leadership and direction for the Company&#8217;s clinical development program. The CMO will be responsible for the strategy, direction and execution of the Company&#8217;s clinical development plans. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Essential Duties and Responsibilities&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:12.28pt">Direct the development of clinical strategies</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:13.98pt">Orchestrate and manage clinical aspects of regulatory strategies and interactions with Health Authorities</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:13.98pt">Oversee the analysis and interpretation of clinical trial data and the reporting of clinical trial results</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:13.98pt">Lead interactions with academic thought leaders, investigators, cooperative groups, and other clinical stakeholders</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:13.98pt">Provide clinical support and work with other members of the management team to develop and communicate the overall corporate strategy</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:13.8pt">Represent the Company and its programs to external audiences, including the investment, medical and regulatory communities, as well as pharmaceutical or biotechnology industry collaborators&#47;partners</font></div><div style="padding-right:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.0
<SEQUENCE>10
<FILENAME>ex80subsidiaries2021.htm
<DESCRIPTION>EX-8.0
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6edb6b1becba43e0b4f29594210b2699_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 8.0</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2021</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.222%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncolytics Biotech (Barbados) Inc.</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbados</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncolytics Biotech (US) Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>11
<FILENAME>ex121ceocertification2021.htm
<DESCRIPTION>EX-12.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iba8dfa566f4d4ca6af4609ea36d34747_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 12.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Matthew Coffey, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5. &#160;&#160;&#160;&#160;The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Matthew Coffey</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA<br>Chief Executive Officer<br>Principal Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>12
<FILENAME>ex122cfocertification2021.htm
<DESCRIPTION>EX-12.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib89a5a7f00f846748432daa782d5f505_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 12.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Kirk Look, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5. &#160;&#160;&#160;&#160;The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div style="margin-bottom:2pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:5.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Kirk Look</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA<br>Chief Financial Officer<br>Principal Accounting and Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>13
<FILENAME>ex131ceocertification2021.htm
<DESCRIPTION>EX-13.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic770e2a8364b42d7a6fc6bcff0ebf390_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 13.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">18 U.S.C. &#167;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Matthew Coffey, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">&#47;s&#47; Matthew Coffey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">_________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Dr. Matthew Coffey, PhD, MBA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Principal Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">March&#160;3, 2022 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>14
<FILENAME>ex132cfocertification2021.htm
<DESCRIPTION>EX-13.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1ee5f4788c2e4830aeb297640f5725a7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 13.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">18 U.S.C. &#167;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Kirk Look, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">&#47;s&#47; Kirk Look</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">__________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Kirk Look, CA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Principal Accounting and Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">March&#160;3, 2022 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>15
<FILENAME>ex151-2021mda.htm
<DESCRIPTION>EX-15.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1cdad10dec7349958d8117fdb8782b5e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><img alt="oncolyticslogotaglinebluea.jpg" src="oncolyticslogotaglinebluea.jpg" style="height:298px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT DISCUSSION &#38; ANALYSIS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">2021 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1cdad10dec7349958d8117fdb8782b5e_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;2, 2022 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BASIS OF PRESENTATION </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&#38;A&#8221;) should be read in conjunction with our 2021 audited consolidated financial statements and notes thereto, which have been prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) as issued by the International Accounting Standards Board (&#34;IASB&#34;). This MD&#38;A, along with our consolidated financial statements for the year ended December&#160;31, 2021, were authorized for issue in accordance with a resolution of the Board of Directors (the &#34;Board&#34;) on March&#160;2, 2022. Unless otherwise indicated, all references to &#34;$&#34; and &#34;dollars&#34; in this discussion and analysis mean Canadian dollars.  </font></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_7"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following discussion contains forward-looking statements, within the meaning of Section 21E of the United States </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Securities Exchange Act of 1934, as amended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as &#8220;forward-looking statements&#8221;). Forward-looking statements, including&#58; our belief as to the potential and mode of action of pelareorep, an intravenously delivered immuno-oncolytic virus, as a cancer therapeutic&#59; our expectation that we will incur substantial losses and will not generate significant revenues until and unless pelareorep becomes commercially viable&#59; our business strategy, goals, focus and objectives for the development of pelareorep, including our immediate primary focus on advancing our program in hormone receptor-positive &#47; human epidermal growth factor 2-negative metastatic breast cancer to a phase 3 licensure-enabling study&#59; the impact of the COVID-19 pandemic on our research and development activities, business operations and financial condition, our plans to mitigate any such impact&#59; the potential impact of the COVID-19 pandemic on stock markets and global economic activity&#59; our plan to actively manage the development of our clinical trial program, our preclinical and collaborative programs, our manufacturing process and pelareorep supply&#59; our plans respecting regulatory approval for pelareorep&#59; our planned clinical development program, including the timing thereof&#59; our expectations regarding the anticipated benefits and value to us of additional clinical data&#59; our current clinical development approach&#59; our exploration of additional registration program opportunities&#59; our expectations as to the purpose, design, outcomes and benefits of our current or pending clinical trials involving pelareorep&#59; our expectations regarding enrollment under our various clinical trials&#59; our expectations respecting the delivery of additional clinical data and the timing thereof&#59; our anticipated milestones and catalysts&#59; our planned 2022 development activity for pelareorep&#59; our 2022 manufacturing program&#59; our anticipated 2022 cash requirements to fund our operations&#59; our anticipated 2022 expenses relating to clinical trials, manufacturing and related process development, intellectual property, translational science, personnel-related and other and operating expenses&#59; our plans respecting the maintenance of adequate cash reserves to support our planned activities&#59; our anticipated cash usage in 2022&#59; our plans for funding our capital expenditure requirements&#59; our approach to credit rate, interest rate, foreign exchange and liquidity risk mitigation&#59; the effectiveness of our internal control systems&#59; and other statements that are not historical facts or which are related to anticipated developments in our business and technologies. In any forward-looking statement in which we express an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Forward-looking statements, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward- looking statements. We may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labor shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to the forward-looking statements made within this MD&#38;A, we have made numerous assumptions regarding among other things&#58; our ability to recruit and retain talented employees, our continued ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates, and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and&#47;or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake any obligation to update these forward-looking statements except as required by applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_10"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pelareorep Development Update For 2021</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncolytics Biotech Inc. is a Development-Stage Company</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development-stage company focusing our research and development efforts on pelareorep, an intravenously delivered immunotherapeutic agent with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal each year is to advance pelareorep through the various steps and stages of development required for potential pharmaceutical products. In order to achieve this goal, we proactively manage all aspects of the development of our clinical trial program, our translational science program, our manufacturing process and pelareorep supply, and our intellectual property.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_13"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Potential Impact of COVID-19</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the ongoing coronavirus infectious disease 2019 (COVID-19) pandemic has touched elements of our business operations. COVID-19, including its variants, have created challenges affecting our clinical trial activities, including patient enrollment and site activation, along with our manufacturing supply chain. Some of the challenges have included, among other things, patients choosing to delay treatments, clinical sites suspending study activity temporarily, vendor and collaborator staff shortages, and raw material and components delays. While these challenges have largely impacted the timing of certain activities, we believe the impact on our overall business, to date, has not been significant. As well, we believe our financial condition, liquidity, and longer-term strategic development remain on track. However, COVID-19 has caused and may continue to cause significant fluctuations in stock markets, global economic activity, and healthcare systems. The scale and duration of these developments remain uncertain and could affect our ability to finance and execute our operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 might prolong and&#47;or cause significant disruptions to our business and materially impact our results of operations and our ongoing and planned clinical studies will depend on future developments. These future developments are highly uncertain and cannot be predicted, such as the duration and severity of outbreaks, including future potential waves or cycles, travel restrictions and social distancing, business closures or business disruptions, and the effectiveness of actions taken to contain and treat the disease and to address its impact, including on financial markets. A lack of coordinated responses on risk mitigation and vaccination deployment with respect to the COVID-19 pandemic could result in significant increases to the duration and severity of the pandemic and could have a corresponding negative impact on our business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor COVID-19 and its impact on our industry and business. We are collaborating with our investigators, partners, and vendors to minimize its effect and to ensure the safety of patients and employees, minimize the effect of supply chain challenges, and maintain the advancement of our clinical programs. We expect these measures will allow us to adequately respond to any COVID-19-related challenges that may arise. Moving forward, we plan to remain in contact with relevant stakeholders and keep the market apprised of any new information that may materially impact clinical timelines.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate objective of our clinical development program is to obtain regulatory approval for pelareorep and is based on the compelling efficacy data from previous studies in breast cancer, pancreatic cancer, colorectal cancer, myeloma, and other malignancies. Our immediate primary focus continues to be on advancing our program in hormone receptor-positive &#47; human </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">epidermal growth factor 2-negative (HR+&#47;HER2-) metastatic breast cancer (mBC) to a phase 3 licensure-enabling study. In addition, we are looking to explore other registration program opportunities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current clinical development approach centers on pelareorep's ability to stimulate immune-mediated tumor killing, particularly in combination with immune checkpoint inhibitors and other immune-based therapies. We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to approval. As our clinical development program advances, we anticipate that pelareorep's ability to enhance innate and adaptive immune responses when combined with different classes of immunotherapies will play an increasing role. This greatly increases the opportunities for expansion of our clinical program along with business development and partnering to address a broad range of cancers in combination with a variety of partner therapies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%">2021 Developments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical studies aiding our breast cancer program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with SOLTI&#58; AWARE-1 study</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received approval for our AWARE-1 study from the Spanish Agency for Medicine and Health Products. This clinical collaboration with SOLTI, an academic research group dedicated to breast cancer research, is a window of opportunity study in the neoadjuvant setting for breast cancer using pelareorep in combination with F. Hoffmann-La Roche (Roche)'s anti-PD-L1 checkpoint inhibitor, atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In 2020, we published various clinical data demonstrating the ability of pelareorep to promote a pro-inflammatory tumor microenvironment (TME) and provided a basis for the findings of our prior successful phase 2 trial (IND.213) that showed a statistically significant near doubling of overall survival with pelareorep treatment in HR+&#47;HER2- breast cancer patients. These data also highlighted the potential of a predictive biomarker (T cell clonality) to identify patients with breast cancer most likely to respond to pelareorep.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we published the results at the 2021 AACR Annual Meeting showing the first two cohorts of patients receiving pelareorep plus checkpoint blockade therapy met the trial's primary endpoint. These patients were treated with pelareorep and letrozole without (cohort 1) or with (cohort 2) the PD-L1 inhibitor atezolizumab prior to surgery. Evaluation of cohorts 1 and 2 was the core objective of AWARE-1, as HR+&#47;HER2- is the breast cancer subtype we intend to examine in a future registrational study. Key data and conclusions included&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">60% of cohort 2 patients (n&#61;10) saw a CelTIL increase of at least 30% from baseline (pre-pelareorep administration) to surgery (21-days post-administration), exceeding the study's pre-specified primary endpoint&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 also showed a promising trend towards an increased CelTIL score, with 40% of patients showing a 30% increase in the CelTIL value&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Treatment with pelareorep alone or in combination with atezolizumab increased tumor PD-L1 expression and led to the conversion of PD-L1 negative tumors into PD-L1 positive tumors&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep profoundly reverses immunosuppressive tumor microenvironments and promotes immune effector cell infiltration into solid tumors, positioning it as an enabling technology for a variety of immunotherapeutic agents&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tumor-cell specific pelareorep replication was observed in all evaluated patients following intravenous pelareorep administration&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">70% of all cohort 1 and 2 patients (n&#61;20) saw an increase in CelTIL from baseline to surgery&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The addition of atezolizumab enhances pelareorep's ability to generate and expand new anti-viral and anti-tumor T cell clones in the tumor and periphery&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compared to cohort 1, cohort 2 patients had a higher ratio of CD8+ T cells to regulatory T cells, suggesting pelareorep and checkpoint inhibition enhances inflammation within the tumor microenvironment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional data analysis from AWARE-1 indicated that changes in peripheral blood T cell populations may be a predictive biomarker of pelareorep therapy. Collectively, these analyses further demonstrate pelareorep's immunotherapeutic mechanism of action and its ability to synergize with checkpoint inhibitors such as atezolizumab. They also suggest that changes in peripheral blood T cell populations are predictive of response to pelareorep therapy and could potentially serve as the basis for a blood-based biomarker to inform the design of subsequent studies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-development Agreement with Pfizer Inc. and Merck KGaA, Darmstadt, Germany&#58; BRACELET-1 study </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab (Bavencio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a human anti-PD-L1 antibody, for the treatment of HR+&#47;HER2- mBC. This phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. The study, known as BRACELET-1, is an open-label study planned to enroll 48 patients into three cohorts&#58; paclitaxel alone, paclitaxel in combination with pelareorep, </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and paclitaxel in combination with both pelareorep and avelumab. PrECOG LLC, a leading cancer research network, is managing the BRACELET-1 study. We dosed the first patient in 2020.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study is examining the expression of immune-related biomarkers to identify changes in T cell population between pretreatment and on-therapy biopsies and seek to confirm our previously identified biomarker. It is designed to assess efficacy in terms of overall response rate at week 16 per RECIST 1.1. The safety of the combination is also being evaluated.&#160;The results of this study may provide an opportunity to add an arm to our proposed registration study that includes a checkpoint inhibitor in addition to the chemotherapy-pelareorep combination. Furthermore, the results of the BRACELET-1 study may provide important confirmatory data in the same patient population where we presented compelling mBC survival data from our IND.213 study at the 2017 AACR Annual Meeting. These endpoints, including the biomarker data, are expected to further de-risk our contemplated registration study, permitting for a smaller study with a higher likelihood of clinical success. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we began data analysis activities, continued patient enrollment and treatment, and completed study initiating activities including selecting and readying additional clinical trial sites.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreement with Adlai Nortye Biopharma Co., Ltd&#58; bridging clinical trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, our partner, Adlai Nortye Biopharma Co., Ltd. (Adlai), dosed the first patient in a bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer. We entered into a regional licensing agreement (the &#34;Licensing Agreement&#34;) with Adlai in November 2017, under which Adlai will have exclusive development and commercialization rights to pelareorep in certain Asian regions and we are entitled to certain milestone payments. Results from the bridging trial are expected to allow Adlai to include data from our North American metastatic breast cancer trials in a future submission to Chinese regulators. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional checkpoint inhibitor combinations </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Triple-negative breast cancer study combining pelareorep and retifanlimab&#58; IRENE study</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we published a positive interim safety update at the 2021 San Antonio Breast Cancer Symposium (SABCS) and continued patient enrollment activities in our investigator-sponsored trial (IST) managed by Rutgers Cancer Institute of New Jersey. This single-arm, open-label, phase 2 trial, known as IRENE, is investigating the use of pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor, retifanlimab, in patients with metastatic triple-negative breast cancer (TNBC). This study plans to enroll 25 patients. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRENE study represents an expansion of our lead breast cancer program into a new disease subtype (TNBC). In addition to investigating the safety and efficacy of pelareorep-anti-PD-1 combination treatment in TNBC patients, the study is also evaluating changes in PD-L1 expression and correlations between treatment outcomes and peripheral T cell clonality, a previously identified biomarker of pelareorep response that may enable the success of future pivotal studies by facilitating the patient selection process. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Roche and AIO-Studien-gGmbH&#58; GOBLET platform study</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we received approval for our GOBLET study from the German federal agency. This phase 1&#47;2 trial, announced in 2020, is a collaboration with Roche and AIO-Studien-gGmbH, a leading academic cooperative medical oncology group based in Germany. The study is investigating the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers. The study is expected to be conducted at up to 25 centers in Germany. The primary endpoint of the study is safety, with overall response rate and blood-based biomarkers (T cell clonality and CEACAM6) as exploratory endpoints. Approximately 55 patients are planned for enrollment across four separate cohorts&#58; pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line metastatic pancreatic cancer patients, pelareorep in combination with atezolizumab in 2nd and 3rd line metastatic colorectal cancer patients that are diagnosed as MSI high (microsatellite instability), pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients, and pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we dosed our first patient, continued with patient enrollment and treatment along with study startup activities, including selecting and readying clinical trial sites. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pancreatic cancer study combining pelareorep and Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we continued patient follow-up activities. We published data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting indicating pelareorep and Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) synergize and show anti-cancer activity in </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">second-line pancreatic cancer patients, which is mediated through the complementary immunotherapeutic effects of the two agents. Key data and conclusions included&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disease control was achieved in 42% (5&#47;12) of patients, with one patient achieving a partial response and four patients achieving stable disease&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On-treatment tumor biopsies showed pelareorep replication and increased infiltration of CD8+ T cells and PD-L1+ cells relative to pre-treatment samples&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients achieving disease control showed reductions in pro-tumor regulatory T cells in the peripheral blood and tumor tissue compared to those with progressive disease&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients achieving disease control showed increased activation of anti-cancer CD8+ T cells in the peripheral blood compared to those with progressive disease&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep-pembrolizumab combination therapy was found to be well tolerated, with most treatment-related adverse events being grade 1 or 2.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CAR T preclinical activities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we published results at the CAR-TCR Summit Europe 2021, in collaboration with investigators at the Mayo Clinic, showing that loading CAR T cells with pelareorep vastly improved their persistence and efficacy in a murine solid tumor model in contrast to preclinical studies using intratumoral infection with the VSV oncolytic virus that weakened CAR T cells. For the remainder of the year, we continued with ongoing and initiated new collaboration activities to develop and evaluate pelareorep and CAR T cell combination therapy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other preclinical activities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we published preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model at The International Conference on Immunotherapy Radiotherapy Combinations. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Results showed that combining pelareorep and radiotherapy led to an increase in the number of infiltrating anti-cancer CD8+ T cells and prolonged survival, this was seen in the primary tumor that received treatment and in a secondary tumor that was on the other side of the body. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compared to single-agent radiotherapy, the pelareorep-radiotherapy combination led to a numerical increase in survival, which reached statistical significance when anti-PD-1 therapy was added to the treatment regimen.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we published preclinical data demonstrating the synergistic anti-leukemic effects of pelareorep combined with the chemotherapeutic agent azacitidine at the 2021 American Society of Hematology (ASH) Annual Meeting. Key data and conclusions included&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compared to either treatment alone, treatment with pelareorep plus azacitidine led to a statistically significant reduction (p&#60;0.01) in tumor burden in a leukemia xenograft mouse model&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compared to either treatment alone, treatment with pelareorep plus azacitidine led to a statistically significant (p&#60;0.001) synergistic enhancement of anti-leukemic activity against AML cell lines, a benefit that was confirmed in AML patient samples in vitro&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The combination of pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune responses such as IFN&#946;1, BATF2, IL-12&#946;, CCL2, TLR3, and PD-L1.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%">Post 2021 Developments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we completed enrollment for the three-patient safety run-ins for two of the four cohorts (first-line metastatic pancreatic and third-line metastatic colorectal cancer) in our GOBLET study. The safety-run in for the pancreatic cancer cohort was successfully completed in February 2022 following evaluation by the study's Data Safety Monitoring Board, while the safety run-in for the colorectal cancer remained ongoing.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Adlai advanced to the second of the three dose escalation cohorts of the bridging clinical trial after dosing in the first dose escalation cohort was completed with no safety issues reported. The second dose escalation cohort is the equivalent dose that was administered in the IND.213 study, which reported a near doubling of overall survival with pelareorep treatment in HR+&#47;HER2- breast cancer patients. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i1cdad10dec7349958d8117fdb8782b5e_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Manufacturing and Process Development </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2021, we continued distribution and storage activities, sourcing materials required for our planned product fills, and conducted various routine tests related to product fills. As well, we continued our activities to maintain clinical and commercial production capabilities to manufacture pelareorep at the 100-liter scale. Ongoing bulk manufacturing and expanded filling capabilities are both part of the process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of our submission to regulators, including the The United States Food and Drug Administration (&#34;FDA&#34;), for product approval. </font></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_19"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Intellectual Property</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2021, we had been issued 310 patents, including 28 US and 14 Canadian patents, as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028. Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.</font></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_25"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financing Activity</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we sold 8,401,029 common shares for gross proceeds of US$27,158,080 at an average price of US$3.23. We received, net of commissions of US$814,743, proceeds of US$26,343,337. In total, we incurred share issue costs (including commissions) of $1,256,280.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant exercise</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 201,722 warrants in connection with our August 2019 underwritten public offering were exercised for gross proceeds of US$181,550.</font></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_28"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financial Impact</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had estimated that our cash requirements for 2021 to fund operations for the year would be between $23 - $25 million. Our actual cash usage for the year was $22,434,009 for operating activities, $285,948 for the acquisition of property and equipment, and $365,510 for the payment of office leases. Our net loss for the year was $26,304,279.</font></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_31"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Cash Resources </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ended 2021 with cash and cash equivalents totaling $41,262,044 (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_37"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Expected Pelareorep Development For 2022</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our planned 2022 development activity for pelareorep focuses on our clinical development plan along with our manufacturing and intellectual property programs. Our primary 2022 clinical objectives will focus on BRACELET-1 and GOBLET enrollment, and the assessment of our clinical data to help form the nature of our registration strategy, our path to approval and other possible clinical development opportunities. While we are making every effort to maintain the timing of our future milestones, the full impact of the COVID-19 pandemic on these milestones is not known. Patient safety is our foremost concern and we will provide updates as they become known. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 manufacturing program includes assessing a process development plan investigating application of single-use equipment to our drug substance production process, and to complete a manufacturing production run. We also expect to fill products and perform the associated analytical testing, carry out process development activities as well as labeling, packaging and shipping of pelareorep to our various clinical sites for ongoing and upcoming activities. These activities are consistent with our process validation master plan. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently estimate the cash requirements to fund our operations for 2022 will be approximately $28 - $33 million but will depend on our ultimate clinical program.  (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity and Capital Resources&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_40"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Our Accounting Policies </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our financial statements, we use IFRS as issued by the International Accounting Standards Board. IFRS requires that we make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available in selecting our accounting policies. Our selection of accounting policies, along with our estimates and assumptions affect the reported amounts of our assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. </font></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_43"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Critical Accounting Policies </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our financial statements, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets at the date of the financial statements and the reported amounts of expenses during the periods presented. Significant estimates are used for, but not limited to, the treatment of our research and development expenditures, revenue recognition, the calculation of share-based compensation and warrant derivative (see Note 4 &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Judgments, Estimates and Assumptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;) of our audited consolidated financial statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with the Licensing Agreement with Adlai Nortye Biopharma Co., Ltd. The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collectability of consideration is probable.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and example to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduces a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</font><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the IASB issued amendments to IAS 12, which narrows the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. We are assessing the impact of adopting this standard on our consolidated financial statements.</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_46"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Significant Estimates </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial expenses</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses represent a significant component of our research and development expenses and we outsource a significant portion of these activities to third-party contract research organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. As part of preparing our audited consolidated financial statements, we estimate the expense to recognize based on services that have been performed by the contract research organizations. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. We have chosen to use the Black-Scholes valuation model (&#8220;Black-Scholes&#8221; or the &#8220;Model&#8221;) to calculate the fair value of our stock options. Black-Scholes is currently widely used and accepted by other publicly traded companies. Therefore, we have concluded that Black-Scholes is the appropriate option pricing model to use for our stock options at this time. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and  inputs used for estimating fair value for stock options granted issued are disclosed in Note 10 of our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the circumstances, we have recorded non-cash share-based compensation expense for the year of $3,825,901. However, given the above discussion, these amounts could have been different and still be in accordance with IFRS.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. We have chosen to use Black-Scholes to calculate the fair value of our warrant derivative. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for warrant derivative are disclosed in Note 8 of our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we have recorded a non-cash change in fair value of warrant derivative for the year of  $17,117. However, given the above discussion, these amounts could have been different and still be in accordance with IFRS.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_49"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Selected Annual Information</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,304,279)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,505,057)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,122,888)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.49)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.50)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,880,191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,345,567&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,657,865&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared per share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes&#58;</font></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)  Included in consolidated net loss and loss per common share for 2021 is a non-cash change in fair value of warrant derivative gain of $17,117 (2020 - gain of $3,491,928&#59; 2019 - loss of $12,608,808).</font></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)  Included in consolidated net loss and loss per common share for 2021, 2020, and 2019 are share-based compensation expenses of $3,825,901, $2,558,974 and $1,470,153, respectively.</font></div></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)   We issued 8,876,809 common shares for net cash proceeds of $33.4 million in 2021 (2020 - 13,968,527 common shares for net cash proceeds of $40.2 million&#59; 2019 - 14,798,704 common shares for net cash proceeds of $21.5 million).  </font></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)  We have not declared or paid any dividends since incorporation.</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_52"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the year was $26,304,279 compared to $22,505,057 and $33,122,888 for the years ended December&#160;31, 2020 and December&#160;31, 2019, respectively. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 10pt 0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,204,862</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054,869&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,622&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,546,826</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,384,172&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776,288&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenditures</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617,631</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906,657&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,375&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">672,653</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,757&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,966&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related, share-based compensation, and other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,878,399</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,281,055&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880,746&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,920,371</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,944,510&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,817,997&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses include those costs associated with our clinical trial program which primarily included expenses related to the preparation and development of our breast cancer program, as well as immunotherapy combinations in other selected cancers. Included in clinical trial expenses are regulatory and consulting activities, contract research organization expenses, data management expenses, and other costs associated with our clinical trial program.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,204,862</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054,869&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,622&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, our clinical trial expenses were $3,204,862 compared to $3,054,869 and $2,189,622 for the years ended December&#160;31, 2020 and December&#160;31, 2019, respectively. In all three years, our clinical trial program focused mainly on developing our breast cancer program. In 2021 and 2020, these activities included AWARE-1 direct patient costs and data analysis costs, as well as our portion (net of Pfizer's contribution) of costs related to BRACELET-1 trial initiation, patient enrollment, treatment, and data analysis. In 2019, costs related to developing our breast cancer program included startup activities and patient enrollment and treatment for AWARE-1, as well as our portion (net of Pfizer's contribution) of trial initiation activities related to BRACELET-1. We also incurred costs to complete our supporting regulatory documents and key opinion leader activities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we also incurred costs related to GOBLET trial initiation, patient enrollment and treatment, as well as costs related to our ongoing ISTs and data management consultants. In 2020, our other clinical activities included GOBLET study initiation expenses, costs related to our ongoing ISTs, data management consultant costs, and close-out costs related to our fully enrolled legacy clinical trials. In 2019, our other clinical activities included costs related to closing out our fully enrolled legacy clinical trials and an ongoing IST in pancreatic cancer.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our clinical trial expenses to increase in 2022 compared to 2021. During 2022, we will focus on BRACELET-1 and GOBLET enrollment, and the assessment of our clinical data to help form the nature of our registration strategy, our path to approval and possible other clinical development opportunities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing &#38; Related Process Development (&#8220;M&#38;P&#8221;)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">M&#38;P expenses include product manufacturing and process development activities. Product manufacturing expenses include third-party direct manufacturing costs, quality control testing, fill, label, packaging, and storage costs. Process development expenses include costs associated with studies that examine components of our manufacturing and analytical processes looking for improvements and costs associated with the creation of our process validation master plan and related conformity testing. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product manufacturing expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,272,816</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,237,960&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,535,632&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Process development expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">274,010</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,212&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,656&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,546,826</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,384,172&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776,288&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our M&#38;P expenses for 2021 were $1,546,826 compared to $3,384,172 and $3,776,288 for the years ended December&#160;31, 2020 and December&#160;31, 2019. In 2021, our product manufacturing costs primarily related to shipping and storage costs of our bulk and vialed product, sourcing materials required for our planned product fills in the upcoming years, as well as various routine tests related to product fills. In 2020, our product manufacturing costs primarily related to the completion of a current Good Manufacturing Practices (&#34;cGMP&#34;) production run, two product fills and the associated consulting and testing expenses, as well as shipping and storage costs of our bulk and vialed product. In 2019, our product manufacturing costs primarily related to the completion of training and engineering production runs and the associated product testing, shipping and storage costs of our bulk and vialed product, and an ongoing product fill. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our process development expenses for 2021 were $274,010 compared to $146,212 and $240,656 for the years ended December&#160;31, 2020 and December&#160;31, 2019, respectively. During 2021 and 2020, our process development activities focused on analytical development and stability studies. During 2019, our process development activities focused on analytic development studies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our M&#38;P expenses for 2022 to increase compared to 2021. In 2022, we intend to assess a process development plan investigating application of single-use equipment to our drug substance production process and expect to complete a manufacturing production run. We also expect to fill products and perform the associated analytical testing, carry out process development activities, as well as labeling, packaging and shipping of pelareorep to our various clinical sites for ongoing and upcoming activities. These activities are consistent with our process validation master plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property expenses include legal and filing fees associated with our patent portfolio.  </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617,631</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906,657&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,375&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property expenses for 2021 were $617,631 compared to $906,657 and $827,375 for the years ended December&#160;31, 2020 and December&#160;31, 2019, respectively. The change in intellectual property expenditures in 2021 compared to 2020 and 2019 mainly reflected the lapsing of non-core patents in certain jurisdictions and foreign exchange fluctuations. At the end of 2021, we had been issued over 310 patents, including 28 U.S. and 14 Canadian patents, as well as issuances in other jurisdictions.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our intellectual property expenses will remain consistent in 2022 compared to 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Translational Science</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translational science expenses are intended to expand our intellectual property related to pelareorep and identify potential licensing opportunities arising from our technology base.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">672,653</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,757&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,966&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, our translational science expenses were $672,653 compared to $317,757 and $143,966 for the years ended December&#160;31, 2020 and December&#160;31, 2019, respectively. In all three years, our translational science expenses included studies investigating the interaction of the immune system with pelareorep, including CAR T therapy and bispecific antibodies in 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our translational science expenses in 2022 will increase compared to 2021. We expect to complete our ongoing activities carried over from 2021 and will continue to be selective in the types of new program we enter into in 2022.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Personnel-Related, Share-Based Compensation, and Other Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D personnel-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,754,043</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,135,300&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096,231&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,086,608</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,373&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,420&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,748</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,382&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,095&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related, share-based compensation, and other expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,878,399</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,281,055&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880,746&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, our personnel-related, share-based compensation. and other expenses were $6,878,399 compared to $5,281,055 and $3,880,746 for the years ended December&#160;31, 2020 and December&#160;31, 2019, respectively. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in R&#38;D personnel-related expenses in 2021 compared to 2020 was due to a change in salary level and an increase in headcount as we expanded our U.S. office, partly offset by lower recruitment-related costs. The change in R&#38;D personnel-related expenses in 2020 compared to 2019 was due to an increase in headcount as we expanded our U.S. office, recruitment-related costs and a change in salary leve</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l, partly offset by personnel cost recovery from Pfizer related to BRACELET-1. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in non-cash share-based compensation in 2021 compared to 2020 was primarily due to the vesting of options previously granted to officers, employees and consultants. The change in non-cash share-based compensation in 2020 compared to 2019 was primarily due to the vesting of a higher number of options granted with a higher grant date fair value in 2020. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in Other R&#38;D expenses over the three years was primarily due to decreased travel expenses as a result of COVID-19.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel-related, share-based compensation and other expenses</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to increase in 2022 compared to 2021 as we look to continue expanding our U.S. office. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,161,439</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,432,418&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,089,918&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,961,777</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,120,290&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,074,416&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,739,293</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515,601&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908,733&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130,243</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,957&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,982&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321,822</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,230&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">362,592&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,314,574</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,514,496&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,558,641&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public company-related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent, and other fees relating to our U.S. and Canadian stock listings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2021, we incurred public company-related expenses of $8,161,439 compared to $7,432,418 and $5,089,918 for the years ended December&#160;31, 2020 and December&#160;31, 2019, respectively. The change in public company-related expenses in 2021 compared to 2020 was primarily due to increased directors and officers insurance premiums and increased investor relations activities, partly offset by lower business development consulting activities. The change in public company-related expenses in 2020 compared to 2019 was primarily due to increased directors and officers insurance premiums, increased investor relations and business development activities, and the associated professional expenses. This is partly offset by decreased travel related expenses as a result of COVID-19 and transaction costs of $233,143 incurred in 2019 related to our August 2019 public offering (see Note 9 of our audited consolidated financial statements). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office expenses include compensation costs (excluding share-based compensation), rent related to short-term leases, and other office-related costs. In 2021, we incurred office expenses of $2,961,777 compared to $3,120,290 and $3,074,416 for the years ended December&#160;31, 2020 and December&#160;31, 2019, respectively. The change in office expense in 2021 compared to 2020 was primarily due to costs associated with changes in personnel in 2020. The change in office expenses in 2020 compared to 2019 was primarily due to the timing of filling open positions in our U.S. office and a change in salary level. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in non-cash share-based compensation in 2021 compared to 2020 was primarily due to the vesting of options that were previously granted to officers, employees, consultants, and independent board members. This is partly offset by a lower number of vesting share awards granted to independent board members as a result of a change in compensation arrangement. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in non-cash share-based compensation in 2020 compared to 2019 was primarily due to the vesting of a higher number of options granted with a higher grant date fair value in 2020.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating expenses in 2022 to increase compared to 2021.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued warrants in connection with our August 2019 underwritten public offering. Warrants issued with an exercise price denominated in a foreign currency are reported as a liability until they are exercised or expire. These warrants are adjusted to fair value at each exercise date and at each reporting period and any change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows. </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,491,928&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,608,808)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021, we recognized a gain of $17,117 on the change in fair value of our warrant derivative compared to a gain of $3,491,928 and a loss of $12,608,808 for the years ended December&#160;31, 2020 and December&#160;31, 2019, respectively. The change in fair value in 2021 and 2020 was based on several factors, including changes in market price of our shares, and the revaluation on warrants exercised. The change in fair value in 2019 was based on several factors, including changes in the market price, the revaluation on warrants exercised, as well as a decrease in the remaining term of the warrants and changes in estimated future volatility of our common shares. The number of outstanding warrants was 64,035, 265,757, and 1,684,126 as at December&#160;31, 2021, December&#160;31, 2020, and December&#160;31, 2019, respectively.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Loss</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135,636)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659,173)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316,719)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021, our foreign exchange loss was $135,636 compared to a loss of $659,173 and a loss of $316,719 for the years ended December 31, 2020 and December&#160;31, 2019, respectively. The foreign exchange loss incurred in all three years was primarily due to unrealized translation loss on U.S. dollar denominated cash balances.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="i1cdad10dec7349958d8117fdb8782b5e_55"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Summary of Quarterly Results</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.092%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dec.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sept.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dec.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sept.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,751)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,872)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,246)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,435)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,329)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,749)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,827)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic (loss) earnings per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted loss per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,880</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,593&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,309&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,180&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,346&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,242&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,604&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,553&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,262&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,087&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,799&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,220&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,711&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,911&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,567&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net (loss) income and (loss) earnings per common share between December 2021 and January 2020 are non-cash change in fair value of warrant derivative gain (loss) of $49,522, $52,216, $80,159, $(164,780), $(213,168), $60,264, $(507,150), and $4,151,982, respectively. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in net (loss) income and (loss) earnings per common share between December 2021 and January 2020 are quarterly share-based compensation expenses of $1,128,663, $1,006,920, $1,032,242, $658,076, $1,704,453, $201,076, $260,640 and $392,805, respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Q1 2020 included the effect of dilutive warrant derivative, stock options and share awards. For all other periods presented, the effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We issued 8,876,809 common shares for net cash proceeds of $33.4 million in 2021 (2020 - 13,968,527 common shares for net cash proceeds of $40.2 million).  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We have not declared or paid any dividends since incorporation.</font></div><div style="padding-left:36pt"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_58"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Fourth Quarter</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statement of loss for the three months ended December&#160;31, 2021 and 2020 was as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,679,471</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,061,464&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Operating</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,775,386</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,010,894&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before the following</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,454,857)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,072,358)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,522</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,168)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign exchange loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(325,800)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,052,531)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,155</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,385&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,708,980)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,328,672)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(42,276)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,751,256)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,328,672)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Other comprehensive loss - translation adjustment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,712)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,433)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net comprehensive loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,769,968)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,473,105)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per common share</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55,025,655</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,108,936&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="i1cdad10dec7349958d8117fdb8782b5e_61"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Fourth Quarter Review of Operations</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the three months ended December&#160;31, 2021 was $7,751,256 compared to $9,328,672 for the three months ended December&#160;31, 2020. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">627,976</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200,998&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269,776</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,943&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenditures</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92,868</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,940&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222,138</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,815&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related, share-based compensation, and other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,466,713</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247,768&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,679,471</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,061,464&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">627,976</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200,998&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, our clinical trial expenses were $627,976 compared to $1,200,998 for the fourth quarter of 2020. In the fourth quarter of 2021, our clinical trial costs mainly related to our portion (net of Pfizer's contribution) of BRACELET-1 patient enrollment and treatment activities, GOBLET startup and patient enrollment and treatment activities, as well as costs related to our ongoing ISTs and data management consultants. In the fourth quarter of 2020, our clinical trial costs mainly related to AWARE-1 patient enrollment and treatment and data analysis activities, our portion (net of Pfizer's contribution) of BRACELET-1 patient enrollment and treatment activities, GOBLET trial initiation activities, as well as costs related to our ongoing ISTs and data management consultants.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing &#38; Related Process Development Expenses (&#8220;M&#38;P&#8221;)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product manufacturing expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">155,094</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,522&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Process development expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114,682</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,421&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269,776</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,943&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, our M&#38;P expenses were $269,776 compared to $434,943 for the fourth quarter of 2020. During the fourth quarter of 2021, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product. During the fourth quarter of 2020, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product, as well as costs related to a product fill and product test. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our process development activity for the fourth quarters of 2021 and 2020 related to analytic development studies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92,868</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,940&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property expenses for the fourth quarter of 2021 were $92,868 compared to $106,940 for the fourth quarter of 2020. At the end of the fourth quarter of 2021, we had been issued over 310 patents, including 28 U.S. and 14 Canadian patents, as well as issuances in other jurisdictions. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Translational Science </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222,138</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,815&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our translational science expenses were $222,138 for the fourth quarter of 2021 compared to $70,815 for the fourth quarter of 2020. During the fourth quarters of 2021 and 2020, our translational science activities were primarily focused on studies investigating the interaction of the immune system and pelareorep, including CAR T therapy and bispecific antibodies in 2021.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Personnel-Related, Share-Based Compensation and Other Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D personnel-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,847,924</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406,242&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">616,039</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817,601&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,750</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,925&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related, share-based compensation, and other expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,466,713</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247,768&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other research and development expenses were $2,466,713 in the fourth quarter of 2021 compared to $2,247,768 in the fourth quarter of 2020. The change in our R&#38;D personnel-related expenses in the fourth quarter of 2021 compared to the fourth quarter of 2020 was primarily due to salary adjustments and an increase in headcount as we expand our U.S. office. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in non-cash share-based compensation in the fourth quarter of 2021 compared to 2020 was primarily due to the vesting of options previously granted to officers, employees, and consultants.</font></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,094,793</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,037,925&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,070,994</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,484&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">512,624</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,852&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,264</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,437&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73,711</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,196&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,775,386</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,010,894&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses for the fourth quarter of 2021 were $3,775,386 compared to $4,010,894 for the fourth quarter of 2020. Public company-related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees, and transfer agent and other fees relating to our Canadian and U.S. stock listings. During the fourth quarter of 2021, our public company-related expenses of $2,094,793 remained consistent with $2,037,925 for the fourth quarter of 2020. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office expenses include compensation costs (excluding share-based compensation), rent related to short-term leases, and other office-related costs. During the fourth quarter of 2021, our office expenses were $1,070,994 compared to $978,484 for the fourth quarter of 2020. The change in the fourth quarter of 2021 compared to the fourth quarter of 2020 was primarily due to a change in salary level.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in non-cash share-based compensation in the fourth quarter of 2021 compared to 2020 was primarily due to a lower number of vesting share awards granted to independent board members as a result of a change in compensation arrangement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued warrants in connection with our August 2019 underwritten public offering. Warrants issued with an exercise price denominated in a foreign currency are reported as a liability until they are exercised or expire. These warrants are adjusted to fair value at each exercise date and at each reporting period and any change in fair value is recorded in the consolidated </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements of loss and comprehensive loss. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows. </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,522</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,168)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we recognized a gain of $49,522 on the change in fair value of our warrant derivative compared to a loss of $213,168 in the fourth quarter of 2020. The change in fair value in the fourth quarter of 2021 was a result of several factors, including changes in the market price of our shares. The change in fair value in the fourth quarter of 2020 was based on several factors including changes in the market price of our shares. The number of outstanding warrants was 64,035 and 265,757 as at December&#160;31, 2021 and December&#160;31, 2020, respectively.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Loss</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(325,800)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,052,531)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign exchange loss was $325,800 for the fourth quarter of 2021 compared to a loss of $1,052,531 for the fourth quarter of 2020. The foreign exchange loss incurred in 2021 and 2020 was primarily due to unrealized translation loss on U.S. dollar denominated cash balance. </font></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_64"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_67"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">2021 Financing Activities </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we sold 8,401,029 common shares for gross proceeds of US$27,158,080 at an average price of US$3.23. We received, net of commissions of US$814,743, proceeds of US$26,343,337. In total, we incurred share issue costs (including commissions) of $1,256,280.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant exercise</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 201,722 warrants in connection with our August 2019 underwritten public offering were exercised for gross proceeds of US$181,550.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_70"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">2020 Financing Activities </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we sold 12,182,532 common shares for gross proceeds of US$30,167,117 at an average price of US$2.48. We received, net of commissions of US$905,013, proceeds of US$29,262,104. In total, we incurred share issue costs (including commissions) of $1,741,640.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant exercise</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 1,418,369 warrants in connection with our August 2019 underwritten public offering were exercised for gross proceeds of US$1,276,532.</font></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_73"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Liquidity</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2021 and 2020, we had cash and cash equivalents positions and working capital ratios as follows&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,262,044</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,219,574&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital ratio</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.45&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define working capital ratio as current assets divided by current liabilities, as presented on our audited consolidated statement of financial position. The increase in our cash and cash equivalent reflects the cash usage from our operating </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities of $22.4 million, $0.3 million for the acquisition of property and equipment, $0.4 million for the payment of office leases along with the cash provided by our financing activities of $33.4 million for the year ended December&#160;31, 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to maintain adequate cash reserves to support our planned activities which include our clinical trial program, product manufacturing, administrative costs, and our intellectual property expansion and protection. To do so, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we are a development-stage biopharmaceutical company, we have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable. To date, we have funded our operations mainly through the issue of additional capital via public and private offerings and through the exercise of warrants and stock options. In 2021, we were able to raise funds through our U.S. ATM. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no assurances that we will be able to raise additional funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements. On June 12, 2020, we renewed our short form base shelf prospectus (the &#34;Base Shelf&#34;) that qualifies for distribution of up to $150 million of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries, and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.   </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreement in June 2020 and March 2021 (see Note 9 of our audited consolidated financial statements). We will use these equity arrangements to assist us in achieving our capital objective. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. Our current ATM equity distribution agreement provide us with access to, subject to terms and conditions, US$80 million of which we have raised gross proceeds of approximately US$8.7 million at December&#160;31, 2021. We expect to continue to access our equity arrangement to help support our current clinical trial, manufacturing, intellectual property, and translational science programs. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that the expected cash usage from our operations in 2022 will be approximately $28 - $33 million. We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources as we expect to fund our expenditure requirements and commitments with existing working capital. Additional activities continue to be subject to adequate resources, and we believe we will have sufficient cash resources and access to additional cash resources through our equity arrangement to fund our presently planned operations into 2023. Factors that will affect our anticipated cash usage in 2022, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&#38;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><div id="i1cdad10dec7349958d8117fdb8782b5e_76"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant contractual obligations as at December&#160;31, 2021&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 1 year</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2 -3 years</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4 - 5 years</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">More than <br>5 years</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987,870&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987,870&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807,643&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,707&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,720&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,216&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,795,513&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,360,577&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,720&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,216&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are committed to payments totaling $21,516,576 for activities related to our clinical trial, manufacturing, and translational science programs which are expected to occur over the next three years. We also have potential contingent obligations relating to the completion of our research and development of pelareorep (see Note 14 of our audited consolidated financial statements). The ultimate amount and timing of these payments is subject to changes in our research and development plan.  </font></div><div><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_79"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2021, we had not entered into any off-balance sheet arrangements.</font></div><div><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_82"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Transactions with Related Parties</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 2020, and 2019, we did not enter into any other related party transactions other than compensation paid to Key Management Personnel disclosed in Note 22 of our audited consolidated financial statements.  </font></div><div><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_85"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financial Instruments and Other Instruments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, accounts payable and accrued liabilities, and warrant derivative.&#160;As at December&#160;31, 2021, the carrying amount of our cash and cash equivalents,&#160;other receivables, and accounts payable and accrued liabilities approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December 31, 2021, the fair value of our warrant derivative was $56,017 (December&#160;31, 2020 - $531,228).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents and other receivables from Pfizer in connection with the BRACELET-1 study (see Note 13 of our audited consolidated financial statements) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalent by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our Pfizer other receivable by entering into collaborations with global biopharmaceutical companies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar as a portion of our financial assets and liabilities are denominated in such currency. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2021 by approximately $240,000.&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable and accrued liabilities.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies at December&#160;31, 2021 are as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,102,844&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621,746&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(886,891)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,837,699&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in the notes to our audited financial statements.  Accounts payable and accrued liabilities are all due within the current operating period.</font></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_88"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other MD&#38;A Requirements </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 57,112,295 common shares outstanding at March&#160;2, 2022.  If all of our options, restricted share units and performance share units (5,379,015), common share purchase warrants with a $9.025 exercise price (16,443,500 warrants exercisable into 1,730,894 common shares), and common share purchase warrants with a US$0.90 exercise price (64,035) were exercised or were to vest, we would have 64,286,239 common shares outstanding.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2021 annual report on Form 20-F will be available on www.sedar.com.</font></div><div style="text-align:justify"><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_91"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief executive and financial officers reviewed and evaluated our disclosure controls and procedures. Based on that evaluation, they have concluded that our disclosure controls and procedures are effective in providing timely material information relating to the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, and has designed such internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with International Financial Reporting Standards.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls and procedures over financial reporting will prevent all error and all fraud. A control system can provide only reasonable, not absolute, assurance that the objectives of the control system are met.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Because of the inherent </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the design and operation of our internal control over financial reporting as of December&#160;31, 2021, and has concluded that such internal control over financial reporting is effective as of December&#160;31, 2021. There are no material weaknesses that have been identified by management in this regard. This assessment was based on criteria for effective internal control over financial reporting described in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Controls over Financial Reporting</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the last fiscal year that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><font><br></font></div><div id="i1cdad10dec7349958d8117fdb8782b5e_94"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Risk Factors Affecting Future Performance</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Risk Factors</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative.  It is not possible to predict, based upon studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful.  There can be no assurance that we will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations. Many factors (e.g. competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In developing a pharmaceutical product, we rely upon our employees, contractors, consultants and collaborators and other third-party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress we have made or are making.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, pelareorep, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early-stage human clinical trials, whether pelareorep will prove to be safe and effective in humans. Pelareorep will require additional research and development, including extensive additional clinical testing, before we will be able to obtain the approvals of the relevant regulatory authorities in applicable countries to market pelareorep commercially. There can be no assurance that the research and development programs we conduct will result in pelareorep or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve profitable operations we, alone or with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy. Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that any current or future animal or human test, if undertaken, will yield favorable results. If we are unable to establish that pelareorep is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">There are inherent risks in pharmaceutical research and development.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product we develop will be affected by numerous factors beyond our control, including but not limited to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preliminary results as seen in animal and&#47;or limited human testing may not be substantiated in larger, controlled clinical trials&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing costs or other production factors may make manufacturing of products ineffective, impractical, and non-competitive&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proprietary rights of third parties or competing products or technologies may preclude commercialization&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requisite regulatory approvals for the commercial distribution of products may not be obtained&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors may become apparent during the course of research, up-scaling or manufacturing which may result in the discontinuation of research and other critical projects.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products under development have never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges or others that may arise in the course of development.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business, including our research and development operations, has been and may continue to be adversely affected by the COVID-19 pandemic.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the ongoing coronavirus infectious disease 2019 (COVID-19) pandemic has touched elements of our business operations. COVID-19, including its variants, have created challenges affecting our clinical trial activities, including patient enrollment and site activation, along with our manufacturing supply chain. Some of the challenges have included, among other things, patients choosing to delay treatments, clinical sites suspending study activity temporarily, vendor and collaborator staff shortages, and raw material and components delays. While these challenges have largely impacted the timing of certain activities, we believe the impact on our overall business, to date, has not been significant. As well, we believe our financial condition, liquidity, and longer-term strategic development remain on track. However, COVID-19 continues to have a broad adverse impact on the global economy across many industries and has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions and business shutdowns, as well as significant volatility in global financial markets.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 might prolong and&#47;or cause significant disruptions to our business and materially impact our results of operations and our ongoing and planned clinical studies will depend on future developments. These future developments are highly uncertain and cannot be predicted, such as the duration and severity of outbreaks, including future potential waves or cycles, travel restrictions and social distancing, business closures or business disruptions, and the effectiveness of actions taken to contain and treat the disease and to address its impact, including on financial markets. A lack of coordinated responses on risk mitigation and vaccination deployment with respect to the COVID-19 pandemic could result in significant increases to the duration and severity of the pandemic and could have a corresponding negative impact on our business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the COVID-19 pandemic worsens or continues for a prolonged period of time, particularly in regions where we or our collaborators and suppliers do business, we could experience disruptions that could significantly impact our current and planned clinical trials, preclinical research and other business activities, including&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption to and delays in preclinical research activities due to an extended closure or reduced capacity of lab facilities&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in enrolling patients in our ongoing and planned clinical trials&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients discontinuing their treatment or follow-up visits&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions in supply, logistics, or other activities related to the procurement of materials, which could have a negative impact on our ability to conduct preclinical research, initiate, or complete our clinical trials&#59; </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers, and others&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key business activities due to illness and&#47;or quarantine of key individuals and delays associated with recruiting, hiring, and training new temporary or permanent replacements for such key individuals, both internally and at our third-party service providers and strategic partners&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in resources that would otherwise be focused on the conduct of our business or our current or planned clinical trials or preclinical research, including because of sickness, the desire to avoid contact with large groups of people, restrictions on travel, or prolonged stay-at-home or similar working arrangements&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving approvals from regulatory authorities to initiate our planned clinical trials&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted and incur unexpected costs, or require us to discontinue clinical trials altogether&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with regulators (including the FDA), ethics committees and other important agencies and contractors due to limitations in employee resources or furlough of government or contractor personnel&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to our strategic partners&#8217; operations, which could delay the development of our product candidates in certain geographical regions and thereby affect the timing of development and commercial milestone payments and royalties on potential future product sales we may receive&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on our ability to recruit preclinical research, clinical, regulatory, and other professional staff on the timeframe required to support our research and development programs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, COVID-19 could result in the continued significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. Such financial market volatility may continue and the value of our common shares may be adversely impacted.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve, and we will continue to monitor the effects of COVID-19 on our business. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition, and operating results.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical products are subject to intense regulatory approval processes.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory process for pharmaceuticals, which includes preclinical studies and multiple phases of clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar regulatory authorities in other countries may deny approval of a new drug application if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA and similar regulatory authorities in other countries may require further testing and surveillance programs to monitor the pharmaceutical product that has been commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions, and criminal prosecutions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in our customers&#8217; drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and possibly other regulatory authorities in other jurisdictions.&#160;Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly and time consuming. We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to the approval of the facility to manufacture a specific drug, our manufacturing facilities may never become approved of, or there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical regulatory regime in Europe and other countries is generally similar to that of the United States. We could face similar risks in these other jurisdictions as the risks described above.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operations and products may be subject to other government manufacturing and testing regulations.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing. Approval to market products may be for limited applications or may not be received at all.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we anticipate manufacturing will have to comply with the FDA&#8217;s  cGMP and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines. Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money and effort in production, and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions&#58; (i) restrict the release of the product&#59; (ii) suspend manufacturing of the specific lot of the product&#59; (iii) order a recall of the lot of the product&#59; or (iv) order a seizure of the lot of the product.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to regulation by governments in many jurisdictions.&#160;If we do not comply with healthcare, drug, manufacturing, and environmental regulations, among others, in such jurisdiction, our existing and future operations may be curtailed, and we could be subject to liability.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal, and foreign law, including, but not limited to, requirements regarding occupational health, safety, laboratory practices, healthcare fraud and abuse, environmental protection, and hazardous substance control, and may be subject to other present and future local, provincial, state, federal, and foreign regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our products may fail or cause harm, subjecting us to product liability claims.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use of our product during current clinical trials may entail risk of product liability. We maintain clinical trial liability insurance&#59; however, it is possible this coverage may not provide full protection against all risks.&#160;Given the scope and complexity of the clinical development process, the uncertainty of product liability litigation, and the shrinking capacity of insurance underwriters, it is not possible at this time to assess the adequacy of current clinical trial coverage, nor the ability to secure continuing coverage at the same level and at reasonable cost in the foreseeable future.&#160;While we carry, and intend to continue carrying amounts believed to be appropriate under the circumstances, it is not possible at this time to determine the adequacy of such coverage.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the sale and commercial use of our product entails risk of product liability. We currently do not carry any product liability insurance for this purpose. There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition, and future prospects.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our technologies may become obsolete.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards, and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes and the emergence of new industry standards may render our products obsolete, less competitive, or less marketable. The process of developing our products is extremely complex and requires significant continuing development efforts, and third-party commitments. Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using our new technologies or exploiting our niche markets effectively, or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our license, development, supply and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2017, we announced that we had entered into a license, development, supply, and distribution agreement (the &#34;Licensing Agreement&#34;) with Adlai Nortye Biopharma Co., Ltd. (&#34;Adlai&#34;). Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan (the &#8220;Territories&#8221;). Pursuant to the Licensing Agreement, along with payments to be received by us upon meeting certain requirements and milestones, we are also eligible to receive royalty payments in excess of 10% associated with the commercialization of pelareorep for all indications, subject to regulatory approval. Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory and commercialization activities respecting pelareorep in the Territories and therefore the Company will be dependent upon Adlai in successfully undertaking those actions in a timely and economic manner and in compliance with all applicable legal and regulatory requirements within the Territories. If Adlai is unable to fulfill its obligations under the terms of the Licensing Agreement and in compliance with all applicable legal and regulatory requirements, including clinical, regulatory and commercialization of pelareorep, our prospective revenue from royalty payments related to the commercialization of pelareorep in the Territories may be materially diminished, delayed or never realized, which could negatively affect our operating results and financial condition.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting business with Adlai within the Territories, and specifically China, subjects us to certain economic, political, currency and legal risks, and uncertainties regarding, among other things, the development and commercialization of pelareorep and the release and receipt of payments under the terms of the Licensing Agreement, including the payment of royalties upon commercialization of pelareorep. These risks include&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different standards of care in various countries that could complicate the evaluation of our product candidates&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different U.S. and foreign drug import and export rules&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in certain countries&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the FCPA, and other anti-corruption and anti-bribery laws&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. and foreign taxes&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in reduced revenues, and other obligations incident to doing business in another country&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reliance on CROs, clinical trial sites, principal investigators and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by foreign distributors&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The governments of the Territories, and specifically the Chinese government, exercise significant control over all aspects of their respective economies.&#160;Accordingly, any adverse change in the economy, the legal system or governmental, economic or other policies could have a material adverse effect on the business prospects of the Licensing Agreement with Adlai, including </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our ability to receive money out of China under the terms of the Licensing Agreement. Any disruption in relations, inability to work efficiently or disadvantageous treatment of Adlai by the governments of the Territories or other authorities could have a material adverse effect on our business prospects under the Licensing Agreement. Additionally, the regulatory environment in the Territories is evolving, and officials in the governments in the Territories exercise broad discretion in deciding how to interpret and apply regulations. There can be no assurance that Adlai will be successful in the development and commercialization of pelareorep in the Territories.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have no operating revenues and a history of losses. We have no products approved for commercial sale, and we may never achieve or sustain profitability.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development-stage biopharmaceutical company. We have incurred significant losses since our inception. To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit. As of December&#160;31, 2021, we had an accumulated deficit of $393.4 million and we incurred net losses of $26.3 million, $22.5 million and $33.1 million for the years ended December&#160;31, 2021, 2020, and 2019, respectively. We anticipate that we will continue to incur significant losses during 2022 and in the foreseeable future. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. We do not expect to reach profitability at least until after the successful and profitable commercialization of one or more of our products. Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will need additional financing in the future to fund research and development and to meet our ongoing capital requirements.&#160;The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our pre-clinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting and enforcing our patent claims and costs associated with obtaining regulatory approvals.&#160;In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics, from time to time, along with all other pharmaceutical research and development entities, may have restricted access to capital, bank debt and equity, and, from time to time, may face increased borrowing costs. Although our business and asset base have not changed, the lending capacity of all financial institutions fluctuates causing a corresponding change in risk premiums. As future operations will be financed out of funds generated from financing activities, our ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the pharmaceutical industry and our securities in particular.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we elect to satisfy our cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that our efforts to raise such funding will be successful, or achieved on terms favorable to us or our existing shareholders.&#160;If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product. There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The cost of director and officer liability insurance may continue to increase substantially or may not be available to us and may affect our ability to retain quality directors and officers.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry liability insurance on behalf of our directors and officers. Given a number of large director and officer liability insurance claims in the U.S. equity markets, director and officer liability insurance has become increasingly more expensive with increased restrictions. Consequently, there is no assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage may limit our ability to attract and maintain directors and officers as required to conduct our business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We incur some of our expenses in foreign currencies and therefore are exposed to foreign currency exchange rate fluctuations.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign currencies, primarily the U.S. dollar.&#160;We are therefore exposed to foreign currency rate fluctuations.&#160;Also, as we expand to other foreign jurisdictions there may be an increase in our foreign exchange exposure.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>16
<FILENAME>ex152ey2021consent.htm
<DESCRIPTION>EX-15.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id58c7390fe46465381b5baa7cddd76f8_1"></div><div style="min-height:136.8pt;width:100%"><div><font><br></font></div><div style="margin-bottom:6pt"><img alt="eyheadera.jpg" src="eyheadera.jpg" style="height:106px;margin-bottom:5pt;vertical-align:text-bottom;width:93px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.721%"><tr><td style="width:1.0%"></td><td style="width:37.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">Ernst &#38; Young LLP</font></div><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">2200, 215 2nd St SW</font></div><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">Calgary, AB T2P 1M4</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">&#160;Tel&#58; +1 403 206 5000</font></div><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">&#160;Fax&#58; +1 403 290 4265</font></div><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">&#160;ey.com&#47;ca</font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 15.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:118%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Form S-8 nos. 333-171625 and 333-205708</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Form F-10 nos. 333-239025</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) and the use herein of our reports dated March 2, 2022, with respect to the consolidated statements of financial position as at December 31, 2021 and December 31, 2020 and the consolidated statements of loss and comprehensive loss, changes in equity (deficit) and cash flows for each of the years in the three-year period ended December 31, 2021, and the effectiveness of internal control over financial reporting of the Company as of December 31, 2021, included in this Annual Report on Form 20-F.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.857%"><tr><td style="width:1.0%"></td><td style="width:26.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calgary, Alberta</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;Ernst &#38; Young LLP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chartered Professional Accountants</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:324pt;text-indent:36pt"><font style="color:#666666;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">A member firm of Ernst &#38; Young Global Limited</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>articles001.jpg
<TEXT>
begin 644 articles001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
M/2H6N8([B.!Y4660$HA/+8ZXH FHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "F>6I8.5!9>AQR*?10 @%+110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 =**:R[@01P:51M4 =J %HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@O+N"PLI[RZD6."!#
M)(['A5 R34]8?C+2)]>\':MI=L<3W%NRQY.,MU S[D8H Y3PIK?B?X@)/K$&
MH)HFC"1HK:&*!)II<=69G! Y]!_+)NR>)M:\*V/B"\\5>3<6U@D1LYK:$Q"Y
M+ \<D_-NP#Z=:QO@_KUAIW@]M#U2YAT_4=/N)4EM[J01O@MNW8;'&21^%:/C
M^&+Q[\/-5AT"X:Z:UE#J85)6=DPQ53T?@]L\C% #=(F\9Z]X)?Q"NLI:7US&
M;FSLHK1&B" $JC;@7)8 <@\9[U4L?'VH>*?A;JNLZ=*=/UG2T9ID1%=247<>
M'!^4C/N".^.=#P9XMTRS^%UE=7=U!#)IMIY-Q!(X1T>,;=I!Y!.T8&.]<%X8
MT6?1/@MXKU34E^RG5HR8(Y3M)4 A>#W)8X]1CUH UH?%?BY/A1#XW_MY)9TD
M/FV<UI$(G7S3'@%0&!Z'KZUK^+_&>L1_"K3O%FEW#Z?=2B,O"8T=6W\'[RD\
M8R",<'FO-?[&OIO@_HNMV5U+=V=C<.^H:4TK-$0)F(8J#QQ@$ #@Y]2>W^)/
MB+2?$'P6AO-,DB2&66%$@&%,;*?F3'^S[=L'I0 ]/&_B70]4\&"^OH-3L_$<
M,#2(\"QR0,X3.TI@8RXQD'H1[UKOXPU?Q)\2Y_"VAW"6-EIRE[Z["+)(^, J
M@8$#YB!T/<^U7O OA?0)M!\.Z^+87.I1Z; BW$MP\OE'RQD*&8JF"2, #%<I
MX<A_X0;XTZS!J>8;+6@\EG=2#:CL6#[=QXR,L,>N/44 ;=YXNU3P7X\L-"UF
M\_M+2M4 ^SW4D:I- Q;;AMH 89QS@=?:HKC6O$)^,7_"+IKT\>G2VQN5V6L)
M=#M)V[BAX!'4CVZ\UE^-E_X37XJ>&M,TF07$.F-Y]W<0C>D.6#$,PXSB,<>I
M%0ZJ;#4_V@3;-J;VY;3S LUM<&-DFVG"[E/7V/?C':@#H?"?BW6F^)&K^#M5
MN8=12TC,T5ZD0C8#Y#M8+QT?'3J*TOB;XTE\&>'X;BT"O>S3J$0C/[M2"Y/M
M@A<^KBN(^&=_;^"?%>L^&O$HM[?4Y',L>I3-@W"GL7;L?O#WSWK6NK2[^(UU
MXDN-.O=)ETXQ'3(#/N=HE7#-(NW@;G ()SG8* .XU.^U'5O!;7WA=X_MUU D
MEHTFT@;B#DYXX!-<'K>L^+-&^(F@>&CXFDF@U&-6FE^Q0*RG+ [?EQCY>^:/
M@CXH6?2+CPM>SQ_;=.D80#>#YD1)SM]=IS^!%4O'&I6*_'7PJ[7D 2WC59F,
M@ C;>_#'L>1UH W?%6H>,/"O@37+^XUCS;NTO(S9W(MX@)8',:[63:0""S>A
MX':JMEJ/BW4_"^G7%CXH>37;NP.H+9&Q@V/&K*&4':-IRZ@$GGG\-7XT3PQ_
M"_4HWE17E>$1J6 +D2H2 ._ )_"N9\%7'AOP[I&E>*Y=;ME=-$>TN+5[O=(T
MF]7 123@_*PVCVXZT >R@Y )!'L>U<#\3?'S^#(=-6TP]S+<+)/'MSBW!^;/
MIDX /UKK;#45N-"M]6NPMI'+;)<R+(_RP@KN.6('3N>*\RFTN^^(NE>)-1L[
MK2C8Z@X@A:;+211P$E.0<+DY;GG#4 >ISZI:6VCR:K),!9I ;@R#ILV[L_E7
M >$=6\2?$1+G63J4FBZ.LC16D%I&C2R$8^9V=6&!TP ,G/IS@?#_ %/_ (37
MX3:GX1:["ZK;P20Q*9,,T?!0_P"Z"=A]L>M:/PBUVQT+PQ/X?URXBTO4K*XD
M9X+QQ$Q0X.X;L9')Z>E &Y-XCUKP?9^);[Q*YO;.Q$)L)4B6+[1OR-O'\0;&
M3^(%,\*)XI\5:''K]]X@FTYKP&2UM+2WB,<29^7=O4EB>O4=15;X@VR?$7X?
MWR:")+I[*Y66!E7"7!4?-Y9_C&'89'4C%6? 7C;1?^$'L(=1U.UL;S3X%MKJ
M"YE$3QE/D&0V#R /_P!= &-XBUWQMH7@#4M5O[_[-JECJ)AC\JW3R9X6*!6P
MRDXY;!R.^<U8@N_%%UIFES:;XIFN=;N=/@U*:PEM8?+:)BNX*0H*GYL#DYVG
MIGB/XLZ[9:K\*;B:(R0BXN$%NERGE/,JR#+JK<E<<YQT-4O#NI>'?"6DVWBE
M-:LW,N@0P2V/VC?+)<Q@<*"21W7 P!0!J>(_&;Q_$V/PU>:S)H.FI:B07**F
MZXE;& 7<,%7&>PY4CN*75O$GBKPMX:\47][,E^+9X%TRZ\A521'P"Y"\'&X9
M[9''%5]>;PQXUUG4-#\5QVVFWMG% ;2Z,OEN#)&'9=S8#%2?NGMSCJ:P/"-W
M/X7\.^(;:^8:UX5AU""TBD=2\;Q,S+*8QSNQE#@<9SB@#L=&U#4]4LM(U'0/
M%+ZO#)<0C4H9HH=T:'[^ J@ICT.>.A]>RUX3G0;YK6[EM9TA:1)H@I92HST8
M$8.,'CH:\2U+PSIF@^+M!U3X>:RDD]Y<JGV&&;S=L9Y9B>2$QP0W3UKVOQ%<
MP6?AO4I[F9(8EMI,N[  94@?K0!YEX#^)&L2ZXWASQG((;R[1)+&Y$:IG>H*
MKP-ISD8..N0:TKZ^U_3_ (=Z]JX\17DE[87LRPNT4.-L4IB"L-G.0,GWQT[P
M^(/!MIX]^&VD7VER1-JMG91FVN(V^^57YHB1[@_0CZU!H=IJFO? /48&26;5
M+C[4SJP^=Y/.9F&/[Q(/'K0!T7P^N]5\2_#F'4-1U:[^W7QD;ST6-3#M=E&P
M;<8PH/(/4UAZA>^+(_AOX=U32]=N9=8OO++"6.+9)YD9?;C9VV\?4Y]D^''B
M[2-'^%EK!=7B'4;,S1-8;_W[2>8Y6-4^\2<@# _D:T;JXMO#GA;P+8:M=06E
MS!/:K(DD@&W;$RL?H"0">E "^"OB"VI?#.XU[5'$M[I_F)<*H"F1QR@ '0L"
MH^M9'PUUOQ3XA\5:_9:]K3G^RR83#;QQJGF%F4D';DA=IQ^'6J6F>#)++XN:
MM:,[1>'#Y>KNC#$<C*24!8\85RYZ]%I/A5JFGK\1_'.;VW N;MY8#Y@Q*@DE
M8LOJ "#D=N: )_#NH^)M9USQ=I]SXQGM8]#<I;SM%" ?G?#2Y3D +SC'6FZ7
MXX\0:]\)-:UB:]-GJ&F2$1WD$:A;C '!!4CG/8#J.E8/AUO!VK>)_B%/KTEK
M+9/*9H)S)C*;WR4(()))3&.O%+X<O]0B^!OB2/7&==-V^3I?VCY6<G^%<]0#
M@CK_ !>E '1Z)?\ B/7_  787T7BK4(O$-_%<3V]OY,!A?RF(QC9D _*,Y[]
M*N_$S5?$&CS^&WT[6KFR;4)TM;B)8XV4$X^897(/)[XZ=._+?#6X\):+HFE>
M([K5[&TU&U@NHKJV,_[V8%\IA"<YP.PYS5CXH:]:ZMI?@J34O+M9Y[A+NXM?
M,.^&%L<GH1QWXZ''2@#H->\0Z[X+\>^']+35I=7L-5<1R6]TD?G1DL%W!D5>
M.<CC^%J]#?6],CUN/1GO85U*2+SDMBWSLG/(_(_D:\8O73P!\4[?Q'>M_:F@
M:J#]GOW8S&V#?W7)/0'UY4GTKOI=5\*R_%+3(ET^2?7+BPWVVH1C,7DD,1SN
MP<C/S '@XS0!T^N'5?[)E715@^WOA(WG.$CR>7/K@9..]><^&];\8Z3\5?\
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MH)Y(6A>2-7:)NJ$C.T^XZ5-5/2;V34='L[Z:V:UDN(4E:!CDQE@#M)]1FKE
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !112$X&:  G%+FLA[V>[9OL_
M[N!21O[L?;VJ,0L3D7$V>^7H VLTM9$C7%C&LXE:5,@.KGM[5I0W"3PK*A^4
MB@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *3%+10 4444 %%%% !1110!0O-$TG4)Q->Z997,H&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4QXUDC9&7*L,$'O3Z* ,9
M[*YMA\H\Z,=#_$!_6HUGY^X^?0H:W:3% &/]DN+PX9?*B[DCDUJQ1+#$L:+A
M5&!BI** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH  0>E%(!@8 Q2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M: /$M:UE;C]GS1+82GS1??9W4CDA-[<>P!2NEU2.;PG^SS;PVX>&XNXX_-;
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MNKWBZ;8LJ_Z,_P"[11M0DXXY<]3ZU[GX+U=M>\&:3J4DHEEFMU\UQWD'RO\
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MS0N'CD4.C+T8$9!H ?1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^-NK#3_ +V:MB2_F2(#G.T'>W_H('XT >:_#_1YM=\(>.;B2,S22VJA.@+R
MM)P?JJG\178_ +61/HFI:,[L7MIA/&&/ 1Q@@<] 5)_X%[UR7AGX5>*=6\-V
MU_8ZY#9VMXIE$!FD7VR0HQD@5!\+Y;CPQ\6?[(N)"-SS64VUB%9ES@\]1E>/
MK0!:^-O_ "4FQ_Z\X?\ T8]=-^T%_P @G1/^N\G_ *"*YGXV_P#)2;'_ *\X
M?_1CUTW[07_()T3_ *[R?^@B@#C[KP D_P (K?Q8U]=2WT: ^4[ QK#YFT*
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M[U\95]F>'?\ D6=*_P"O.'_T 4 :5%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^;!')'# D@_TQ5O7=<UGPG\1]"TVVU6YU*QU1@LME<!&>,%MNY6"@@<Y_P"
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M4 GJ0.M+10 4444 %-V(7#E5W#OCFG44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)&F\MH\DDXSC&2>1S6]-I?C'Q7&+36VLM'TE^+B"RE,EQ,/[N_&%![XYQD4
M=O--'!!)/*X2*-2[N>@4#)->0^'-:\037^K>(T\%W.I+K# 13"Y2-1;J-JJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIZO/I=]=0Z=:ZC]E%NDK@1;D#KCGH?G&.V!US7MOPM\1-XC\"V<TTF^ZMO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HQ110!XW\')&U'QCXPU'4,G4_.5#O^\BEWW+]
M54?@*3Q++/I_[1.AMIO^LN[:-;I0>&4EU;./1%!Y]!79MX'DTWQ;<>(_#U]'
M9W%Z"+RVN(C+#*2<[@ RD-GGKW/K4NB>"OLGBFZ\4:M>"^UB=/+1DB\N*!,
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M8Z8T."TC2O(1C[WF,.?P J]X-\"IX2T6ZT=K_P#M#3[AF8Q2P!2"P 89!Y!
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M\=%%CX N;3Q]/XL;6&>ZN 4EC\@ &/  4?@J\^U '1>+ #X-UP$9']GS\?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.>%)H7C=00PQBI** ,)6N
M(0(IXI-RC&]5R&QWIHOMX*A)#GL$.:WZ0]J ,);&XOF0R)Y46X%M_P!YJVT7
M: H7" 8%/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[);6ELH,DA498\D  #J2>,US?BO_ )*KX!^M_P#^B5J#XDQ7-QJ_AQ="E/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%% !1110 4444 % &.E%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !112$9&* %HH P** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI H!R
M* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BFF1%<(74,>@)Y-.H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'C)Y'L17R97H/PJ\9R^'=>CTVYE4:7?/B3*YV2$85A@9Y( ].<]J /I&O/\
MXD_$2/PG9_8; K)J\Z_*.T"G^,CN?0?Y.WXT\86?@[1OMEPK23R$I;PJ/ON!
MW/8>M?,&KZO?:[JDVHZC.TUS,<LQZ =@!V ]* /H#X/^(Y]=\-W,5Y<75S>V
MT^99IWW9#9*A3GH .E>B5\W_  >U\:1XS6TD65XM13[.%5N%?((8COT(_&OI
M"@ IID02",NN\@L%SR0.IQ^(_.N9\6>/=$\(*8[Z<O>M'YD5K&I+.,X&3C"C
M/<^AZUXWX/\ $^J>(_B]INH7MR^^9W3RT8A4CV,0@'IT^IYH ^C**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M63<TD)\Q8^<88KPIZ>W/!KFJ^D-0^+?AZQUW4='U*WN%2V?RO,"!UD/1LKV
M_'-/U7P-X0\?:<=0TYHXY')VWEE@98#: R]"!QD<'CJ* /FRBNY\7?"W6_"T
M,MXI6^TZ,C-Q&-K#('+)DX&>.IKAJ -CPE_R.6A_]A"W_P#1BU]<;QG%?'>D
M7W]EZU8Z@8_,^RW$<^S=C=M8-C/;.*['Q!\6O$&M"6*V,>G0M+O4VS,)=N"
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M2[*PC"1Q3%5R>^,8S[U4U#X>Z5=>"%\+V[O#;QOYD,TBB1XVW%B1TZY(^AH
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MT/POINF3,C2VT"HY3H6[XX'>M>@ HHHH **** "BBB@ HHHH **** "BBB@
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M,<-];^9F658@DH3T4*0OYBO+Z* /IS1/BMX5UH(IO&LIWD\M8;M=I/3!R,J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !112$X&: %HH!S10 A 8$$
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MOB/\2-*\6Z!%IMA'>"2.Z$K/-$JJRA6'&&)[^E 'EU>G_ K_ )':]_[!S_\
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MD$GO]BC_ /B:3_A#O"__ $+FD?\ @%'_ /$T ?)%%?6__"'>%_\ H7-(_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/ D6O7LFK:Q8M+IL(Q )#A)9,^G\0'Y9XYY% 'T$"&4,I!!&01WI:155%"J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU'!'KSVKR6@ HHHH **** "BBB@ HHHH [/7O#FJZ]XRU5-'LIKT0&/>T:]
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M-Q<27"NQ,<V0(B>H"G[O0<#TH M>*/%VJ^*M2GN+RYE%N[[HK4/^[C7G:,#
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M$CN%:1IHL(">I^;M6?IVF?$:UOI9[O7-(NX7!VP/"0J$G/!50>.G)-;>G?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ=O;Q3)AB/*9RFY>>HY/![U\\U[Y\9_%EO::(?#L$D4EW=[3<)@DQ1@A@<]
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M"26UFK*D4?V>4JV6 +D^O\/ [UFZE+HUNOFW%J);&::_CLEBP464M%LV$<
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M4"Q&8SL(B48,,Y#LTF=W3:, 9K.O5-MJ.HV.H1[M?AL=3>_NMN!<JT*^4ZG
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M3R2:QJ?%%)-*D42,\CL%55&2Q/0 5V%G\*O&-[;1SII)C5\X$TJ(PQZJ3D4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]AC&,5QK,68LQ)).23WI** "BMCPOX??Q-KT&F)=06WF')DF<+QD<*#]YN>
M.M=G\2_AM;>$K.UU#2GNI;1F\N83?,4;L<@  'ISW^M '1_!GP3#]D7Q/?PA
MY68_8?GX4#*LV!WSD<^F:TKSXW:79ZU+8MI=RT,4YB:X\P= <%MN/KQFK'P9
M\0VVH>$4T?*)=:>6!3?EG1F+;\=AEL?A[UY9\3?"4OACQ-(Z,\MG?%IXI"I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[VLPVC;*-JMDKT'#XQ[4 ?,M*"5(()!'0BM;4])&B>*Y]*E<3K;77E,Q4J'
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MI 7<TB,<CD[B3TSTK/\  '@;Q7X.\:NKE'T65")YHW3;+A3L^4G<"&/IZ]J
M/7L4F*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<]*]XH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQZY^E?/I!!((P1U%?:5>$_%?X=3VES=>)M-)FMI7,EW$<9B)_B'JN>O<?3H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *,\T48YH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHJ.>:.WA:61L*HR30!)16.)KV\.Y?W$9
M'RKGYC[DTHAOT.$G8GMDY% &O16;!?LCB&[0HY. V.#6D.E !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2$9(YQ_6EHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K,O!YVH00M_JT4R$>IZ"M.LVYD\O
M5$R>L1XSZ&@"R-P YX]*</F (%,652,;@<TY9%S@$<=* *VJP[[(R?Q1_,,>
MM6;*4S6<3DY)7FHM2E5-/E)[C ^M&EH4T^//?F@"[1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6+J5I=+?K?0*)5$>QX^^,]16U1B@#G$OV08D2164]&C
M(J4:I&"I5LG/  R1^%;NT'L*01H#D(N?I0!A2>?JDD<(1UB1LN[+M%;D:!$"
MKT P*?BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **:KALX['!IU !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4'FBB@ Q1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M&BB@ %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 44W)WXP<>M.H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ",C% &!110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*\SY#!B0X!VD\=!D$9.!Q4LOC3PY;ZL-*FU:"._,J0K V0S,V-N!CD'(Y'%
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M ))X)R./<5ER^#/#4VE'3&T.P%F?^6:P*N#C&X$<AL?Q9S[UQ^D^#/\ A'O
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M,K\,^.?E/'3KTJAXB^&NI77Q%M_%^A:I!:W)*F9;J,N%(01Y4#K\O8D<]^>
M#GOVB /[.T$XY\Z;G\%JC\;?^1-\(?\ 7,_^BTKT#QS\/6\8>%;/3CJ+G4+(
MAHKN=<^8<88.!T!XZ=,"L3Q!\*M9\5:)I=MJOB6(7-BNP"*U_=!< <#<"6XY
M;]!W +/Q9.WX//\ *IR+8<C..5Z51^&7@7P[K/PWTRZU;38;V:9G?S)<[D"R
M, H.>%XS@8!R<BNF\5>#M2\3^"[;P^^J6L##9]HG%JQW[,8VKO\ EZ<Y)K0\
M$^';OPIX:@T6XO8;N.W+>5)'"8S@L6(;+'/)/I0!Y?K-Y>R?M%65G;"T/V&%
M8;.*Y)6)<P%NV<'+'&!V%=;X:\#Z]I7Q%O\ Q/>7UB(+]6$MK;LYY.".H&<$
M?J:?X_\ AE_PE6HV^M:5?_V=K-N !+@@/@_*21R".QY[5J^&?"FJ6-W%J7B/
M7)-6U&*+RH0%V10 @!BH_B8XY8\XH ZBZB-Q9SPJ0#)&R GMD8KYZ^!C/I7Q
M$U+2[U5@N6M9(BDG#>8CKE1^ 8_\!KZ+K@_$_P ,K36=?A\0Z5?RZ1K43!O/
MB0,KD="R\<]B<\CKF@#O*RO$JI)X5UA6"LOV.8$$9'W#6'#8?$">,VU[K6B6
M\6,?:;2SD:<_@S; <=\'Z5<F\*/;^#[S0])OWAN+L/YM[=*9G=G^^[<C+$?@
M..* /*/A58VS_";QC<O'"\KQS1G*@L%6'<,^V3D>XKH/@$F? VI[WVHU\XR&
M&0/+3)]JU- ^&.H>'?"^IZ%9^(8C#J*XED>R)9"0%;;^\QRN1R*N>"/AW<>$
M=$U'2)M76[M+X,6"6_ENC,NW(;<>W8CJ!0!Y]I\%MI/A#QGI7A:Y?6+ P227
M>H7!\N&$!#A(P,^8Y&<MP.!73?L_$GP)?<]-2?'_ '[CIFB?!J]TS3=5TN7Q
M9=C3KQ2!!;1A Q(P&?.<^ZC&<#)[5O\ @'P#?^"-%U"R77!/)<N7B_T<>7$V
M,;]N<DD!<C(''XT >:_ +3K>76M<NYA"[VULL:%U#8WELD>V%Q]#5_X (TK>
M*XXW";Q %D3C:3YN"!78>#OA?<^"_P"T?[/\0^8+Z'RW$MF"%89VN/GZC<W'
M3FK'@+X<?\(!=7L\6M&ZM[J-1+');A,%<D-NW'&,M^= 'GWPUOK;X>ZIXHTO
MQ2#:7ICC*EE+B0#=P" <[MPQZUM_!_2-=\/^$O$&JW5K)#]I3SK.UD0@LR*Y
MW;>H!)4>^/I7,^%[KXCV7]J7'ANVAUFSNKUW:_DC4B=U."REBK8_0=J[OP)X
MW\4W_BVX\->+=+CMKD6YN(V2/;QD#GD@J>>1W&/H <?\)+?5]>\,^)+.TNM.
M4W<N+E[N%Y)&WH1GA@/7J.N:]5^'WA>Z\'^&VTBZU);_ ,N=GC95*B-2 =F"
M3WW'_@5<C_PIZ]TGQ'+J/A7Q--I%O.27B$6\J,YVCD!EZXSTXZUZ)H&APZ!I
MOV2*::XD=S+/<SMNDFD/5F/KP![  =J +M[>0:?8W%[=2".WMXVED<_PJHR3
M^0KR&&WU[7/"&N&7P9>3W/B)FG-Q]L@553&8,!FW84!>"!W-=_XT\,7_ (KT
MU--@UC^S[1CFX5;?S&FP00I)887KD=^*W+*&[@L$AN;F*>X4$>:D'EJ?3Y-Q
M_G^5 'AOP0UZ71/$.H^#]2#122R,T:,W"3)D.OU('_CM;/[0O_(N:/\ ]?;?
M^@&K]_\ !V>^\5OXD7Q*;;4&G$X-O8A55QCD N?3G.<\YK:\;_#ZZ\<VEA;7
MFN+!':C<WE6>3))C!;E^!Z#]30!RGQ>7/P?T([B,2VWR@\']RU,\06T#?LT6
MC&),Q6]M(AQ]UC*H)^I#-^9KKM?^'3>)?"NCZ%J.L,5T^56>>* *TJ*I4#&2
M <$<\].E4KCX::G?>'+7PO=^)<Z%;R A8K39/(BG*HS[BI ]=O4 ]J .!O;O
M4$_9JL 966.2[,1SU:+S'('TR/TK?3P5JGCWX9^';-=3TJWL8(8Y(VBMGWA@
MA5@QW8SDG. ,D5Z5J'A+2=1\)GPU+ 5TX1+$BH<,FW[I!]01FN&T3X/WNDI/
MIY\7WW]B3,6DLX(_+,GL6R<9 P<#F@#)^.$,EO\ #_PY#+<"YDCE1&G'24B(
M@M^/7\:[CPAX+T&W\.>'[J33+2:^M[>.9;IHAOWLH;=GN<],],<5#XX^'7_"
M96MA8KJ@T_3[(#R[>*U#<@8'.X8 & !BNHT+3[C2=%M=/N;M;M[>,1B81>7N
M4<#(R><4 >+Q?\G3'_KHW_I(:Z7XL6F@G5]!OKVZOCJ\4H6SL;+'F7!W@@9/
MW/FP-WOT.*T==^&+W_CJ+Q9I.MR:;?<>;^X$H)V[,KDC&5XYS47BSX4?\)'?
M:1?0:_=6MYI\*0_:'4R.X5BP?.X$/DDY_P * .'U$:E)^T'HDFKP00W,ODOY
M4)+*@VG W'[Q!!YX&:^@*\NO?@])/XHL-;M_%.HI/ %,LTX\V9V7NK$X7CC&
M"!7J & !DG'<T ?-OQ@LY]'^*T.KS1L;6X\B>-L<'RPJL,^OR_J*^CX)XKJW
MBN('#Q2H'1QT92,@_E61XH\)Z3XOTHV&JP%T!W1RH<21-ZJ>W\CW%<_I'@WQ
M1X<LQI^D^+8WT^/_ %,=]8>:\0_NA@XX_P C% '<--$LR0M*@E<$HA8;F QD
M@=\9'YUX/\*YKB\^-GB.>]!-SY-R6W<E2)D&!]!Q]*];T3PP--U";5;_ %";
M4]5F79]IF4*(DZ[(T'"+GD^M9-]\/VC\73>*/#^IC3-2GC,<Z/;B6&7.,DKD
M')P#UZC- '!>"I9[3]H3Q#;0X:&=KCS=G*J-P8$^X.!]369<Z=!J_P"TN]I?
M0QO";D.T;#<K!+?<N0?7:./YUZUX0\"VWA6ZO]0DO9M0U74&W7-W,H7/).%
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MSOCY-[#.T'N1W]* -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M110 4444 %%%% !1110 $9HZ444 %%%% !1110 4444 %%%% !1110 4444
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MD]N] 'NM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 =:3%+10 44
M44 %%%% !1110 50N=$TF\AFANM+LIXIY/-E26W5ED?&-S CDX Y-7Z* ,[3
M?#^C:,\CZ9I5E9/)P[6\"QEAUP2!T]JLWMC::E:M:WUK!=6[XW13QAT..1D'
MBK%% %)-&TN/36TU--LUL&&&M5@41$>Z8Q^E,.@Z.=-_LXZ58FQX/V;[.GE?
M]\XQ6A10!#;VEM:6JVMO;Q0VZ#:L4:!4 ] !Q4%AH^EZ493IVFV=F93F0V\"
MQ[S[X S5VB@#.O- T;4;M;J]TBPN;E0 LTULCN/H2,U:N;*TO(EBNK:&>-3N
M5)8PP!Z9 /U-3T4 46T;2V1T;3;,H[[W4P+AF]3QR>3S[T]=*TY(_+6PM508
M.T0J!P".F/0D?B:MT4 06]E:6C,UM:PPE@%8QQA<@= <>E03Z+I5S?)?3Z99
M2W<9RD\D"M(OT8C(J]10!'-!#<*%FBCD4<@.H(_6H8]-L(HDBCLK9(T)946)
M0%)ZD#'!YJU10!##:V]L7,%O%$7.7*(%W'WQUJ*WTK3K2ZENK:PM8;B8YEEC
MA57<^Y R:MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.^,!47 ( /.XCG@"O/\ 1]/UN#XX7'B.70-373)YI567[*3A67:K$$9 Z'U
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M=WKEV69BG*Q%SECGNQ)Y(XZXZUSTFA>.+7XQW>N1Z/'J,!9TM9KBXVQ0QL,
MCG(P." /7US0!E_!._:/X@Z_I\7F6]G+')*EHXV[664  CL0K$50O?#VCO\
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MG&0.!0!0U\2K^TO9&0[E,]OY8'9?+ _GDU%\5 6^-NB  DXM.!_UU-=[X_\
M!E_=^)='\7Z' MQ?Z;(AGM?,$;7$:MG"L>,X+#GL?;%06?A74?$_Q/C\7:MI
MLFFV=A&B6MM.ZM),X!PQVDA0"V>O8>] '1?$MU3X<ZYD@;K8KTSUKF_@/QX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** $Q1M%+10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:[I%&TD
MCJB*"S,QP !U)-.KRWX\:C>V7@>WAM9#'%=W8BG*L067:QV_0D<_3WH ZJ#X
M@:#=(\]J;^XLT)#WD-A,\"D=?G"XX[D<#O6]IVHVFKZ?%?V$RSVLP)CD4'#
M$C(S]*CT:SM;'0[&TLU06T4"+'M& 5P.?QZUQ7B;5)/"EYX<\(^'$CLEU6YD
M4S$;OLZ%PS; <C.7.,Y P!CT /0Z*\VTKQ5J]R?&>A37NZ\T2-FMM0$2AF7:
M2-ZXV[@1U P<G@5%X U?QOXKM=(URZO]/32R\R7,"18DE R W3CG P.PSSG
M /3J*\3T[Q?XVU/P7K>NIK%LK:+=E?*^QK_I"K@L&.>!@]@#QUK=D\=7_B#6
M?!^E:?.VF+K-JUW<S(BNZX5OD3<"!RC<D=,4 >GT5Y,?'&N3?#WQ5*;KR]7T
M&\-N+I(0!*JR  E6& 2,@C [=*U?#$OCO4]-T_7Y]2L);:;2RZV'E;3)/M_=
MLS8XW<$X( SC!ZT >B5$;JW6[6T,T8N70R+%N&XH" 6QUP"0,^XKQK1_'WB
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M6 )$!P,\?Q?-DG/4=,<5/J%C-J'[0,]O!J$]D7TH;IK<#S ,#@%@0.<<X/%
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M=C<!GTP<<9KK]5LYM1TJYLX+R2SDF0H)XU!9 >I&>,XS5RB@#GYO"Z3^!_\
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M^J61LR6B2SD15W_WR&4_-C@'M2Z;X/MK.VU"WO=3U/5TOXQ#,-1G$F$P1M4
M #[Q]ZZ.B@#F])\'6VF7MI=37UW?O80FWL1<E<6T9 !QM498@ %CDX'USHMH
MEO)XFCUUY)&GBM3:Q1G&Q 6W,P]S@#Z"M.B@#+U_0K;Q%IRV%Y)*MN)HYG6,
M@>9L8,%;(/RD@9_G5N^MY[JT:&WO)+.1B/WT2JS*,\X# CIZ@U9HH S=%T*Q
MT&T:"S5RTCF2::5M\LSGJSL>2:2ST.ULM<U+5T:5[K4/+$F\@A%1=H5>,@=2
M>O)K3HH YN_\(MJ-S>M-XAUI;2\(\VS29!'MQC:IV;E![X89[U9U;PO8:K:6
M$*M+92:>ZO9SVA"O;X&,+D$;2.""""*VZ* .7_X0:Q:SUB)[_4&NM7(^V7HD
M59G4#"J"%"JH'& .E5]+^'>GZ5>V,\>K:Y/#9',5I<7S/ "!A3LQV[8KL**
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MD5U8L%8$J<'!Z&EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3)STX
M]:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+Q=X9C\7:#)
MH\]Y/:V\KJTIA"DN%.0.0>,@'\*W:* .)7P!<Q>&U\/P^*M3CTX1>3L6.$-M
M[C>$W8_'IQ3]=^&NE:RVDS0W=[I]YI<*P6UU:N%<(O0$X[<^G4UV=% 'E'Q
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M]SI[6%Q'Y]N\?E.LI+;UQCDGD_6K%% &;)H&ES:!'H<]G'-IL<*P+#+\P"*
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MVJ_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*0,-E.N.2<\8.>E '2:9XY?2OB5XHT[Q!KL::5:!6MEG"+M+;3M7 RV V._
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "HYH(;A0LT22*#D!U!&?QJ2J>H:KIVE)&^HWUM:)*VQ&
MGE"!FQG )[T 6HXTB0)&BH@Z*HP!0(T5V<(H=L!F Y..F:@LM0L]2@,]C=P7
M4(8H9(9 ZY'49%6: &2Q1S(4EC21#_"XR*< %    '  I:* "F"&(2F41H)&
M&"X49(^M/JC::UIE_?7%E::A;3W5L2)X8Y0SQD''S <CGB@"]16=J>O:1HOE
M_P!J:E:V7F9V?:)0F['IGK56/QCX:FF@ACU[3FEN"%A07"YD). %YYR>* -N
MBBB@#F?''A:;Q?X>?1X;R*S2=T,TS0F1MJG< HW#N!U[9K=T^VDL]-M;66;S
MY(84C:7;MWD  MC)QG&<9-1ZGJ^G:-;I/J5[!:1/(L2O,X4%CT'^?<U=H **
M** "BL:\\6:#87[65UJ<$=PF/,7)(BSTWD<)G_:(K3M;NWOK9+FTGCG@D&4E
MB8,K=N".M $U%%% !12*P90RD$$9!'>EH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBJD^IV5MJ-II\UPJ75X',$1ZR; "V/H
M"* +=%%% !167K&OV6B6UI/=&1H[NYCMHC$N[+O]W\/>M2@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KC/BQ$LOPQUL-)''B-&#2 $9$BG
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MX7^)=8FO=+.J^&]5NWN7N$7<R[LC!;H#T&&X..,9-'C+58;?P#X5MO"]Z(-
MU"Z\M_,4LX&_=M.#T5MP('/&,UW-IH'B33=+U'3([C3+ZTNY)VB^T;XS )79
MBIP&$@^8_P!VL75OA7</X&T/0])U1$N])N/M"33(0LCDEB>,E>3D=>GXT :O
MB#Q+K6C7VG:9))90&6UDFGU:>!A;!U^ZF-XVDG'\1/(P#FN:OOB#K&M?!&^\
M16@AL;Z*46TQ0$@@LJDIG[I^<=<XP?:NEU?PCK^J^*M#U-]8M3;6-N5FB> D
M&8A@9$3.,\C&3QCO61I7POO[;X8ZMX1O-2MRUU/YT$T2-A<%&&[/J4[=,]Z
M*%QXH\0^"OA;X3U"-M-N(YOL\)1H77$31!D&=WW@%;+=\CBND/C34A\5KGPM
M]FMWLHK(W"% 1*S;0<9+8ZY[#J*I:S\.]6UOX9:9X;N=3M1?Z>\;Q2I&PB(C
M4HJGO]T]<=>U267@7Q!'XSO?$MWKEHUU=6+6VV&U*^4Q4!2I)/ (SGJ: &?#
M_P >ZAXMNXDEFTYAY<ANK94,4]LX(VX!<^8I!^\ ,'KBNF\+WOB&]&I'7]/A
ML_+NW2T$9SOA'1CR<_7CZ5@Z-X$O;?QI:>(]0>P2YM[=HI9+(,IO'(V[Y%(
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MHZ=!+)JVK2:E?SD>9)L$<: 9PJ(. .3SU/?L  ;-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% %'5-%TS6HDBU.Q@NTC;<GFH&*'U![?A2
M:;H>EZ07.GZ?;VS2??>.,!G^K=3^-7Z* "BBB@ HHHH **** "BBB@"G9:3I
MVFR3O8V-M;/</YDS0Q!#(WJ<=35RBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7XYI9K6\D6&WBCCS+)*3CRPO][(/MQUJ33O&5CJ+:I +6[AU#2TWW5C(B^:
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MT+[W90=@ '(P3GBLS5_'VJMX*\2W5I8V]MJFD3?9Y?\ 2/-C .,21L%&X\Y
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M!H@\3ZK8?V1J?AV#24\AXKV]\U7,V4* QJO<G!);MQ7/76F^+_\ A7'_  B
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MDDXXQQ6WJ]]/INF37=O837[Q#<;> @.P[XR>3C/'?I7(:?\ \EPUG_L#P_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5Z%10!R7PVT ^'?!5I:O 8)IF>XDC;[R[SE0WN%V@_2M'Q3H$WB/38[*._\
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MJ@*N>YQDUNQH(XU09PHQR:=0!R<W@.&7Q#=ZY'KNM07UT@C=H98@ @Z*!Y?
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M3A&N9(B SDNH)8CKR7'/N*^@-3GBM=*O+B9PD44+N['L I)- 'E?@_Q3XO\
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MOYXX-3MHU^7#,,L1TVL<9XX;![\ 'K%UJ^G:%;P1ZMJT*2E#B2X94:3:/F;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML;]_G0$!A['- 'E-M>&/P9XS\8ZY:)<IKDB6\,"J4CDC0>5&_P W*@ELY)[
MCM5SPA8WO@+QRND:U.FH)>:;FUU$*0T,<(RT9R3M3K]2%]<#U.\T^SO].ET^
MZMXY;26/RWA(^4KZ>U8UKX'T&TBN(UMIY//M39L\]U+*RP$8,:LS$JOLN* .
M \06)O/A-J&NW'G?\3/4(]3N!'C=]G,BJB\^D80_6NB\7'[=\0/!"6@$LB-=
M7?!XV",8Y[9. /K7;-I]FVF'36MXS9&'R# 5ROEXV[<>F.*H:1X8TG0Y3-8V
M[B8QB$233/*RQCI&I<DJ@_NCB@#R/Q&?$5GIVBOJOAN5+^X\0VUU-<F\A83S
M ,%B4 G:H' SP,<\DUZ+!)+K?Q")DC\I-%L0"I(;;<S@$C(X.U%'_?=='J.E
M6.K+;K?6R3BVG6YA#9^21?NL/<9-/M;"VLI;J2WB"/=2^=,V22[X"YY]E _"
M@#RO2V6P^ 6LV4JXN;87=G,BG)\XR,H'XEEX]ZFTCP]#=^.+33M:EN4FM?#-
MK##'%.\)89(DY4AC@CI[\UWD_A#0;G6/[5ET]6NS(LK'>P1W7[KLF=K,.Q(R
M*GU7P[I>M3VUQ?6Q>>UW>3-'*\;INX8!E(."."* .=^&MY?SZ9J]E>W<EY'I
MVIS6=M<RMN>2-,8RW\1'K7;56T_3K/2K&*RL+:.WMHAA(XQ@#N?J2<DGJ2:L
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(#F@!:*
M** "BBB@ HHHH **** "BDSS2T %%%% !1110 4444 %%%% !1110 44A.*6
M@ HHH/% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 445S/CZ\U#2_"%]JNF7S6MS8H9
ME_=JZR8X*L".G/;'..O2@#IL4=J\LLK_ ,4ZEX7T_4++Q'-)KNH6;7<=B;6'
MR2J%<@< J?F49)()/;MWD_BG0K:]N;*XU:TBN;5#)-%)(%9% !)(/;!'- &G
MN5RRAAE>H!Y%2=JQ/^$IT!=*@U9=0A-G=OLAE0$F5N1@ #)/!XQVI9_%OA^U
MTNUU*?5K6.QNN(9V?".?3/K[4 ;1HK'TOQ3H6MW]Q8Z9JEM=W-N-TB1-G SC
M.>A&?2FR>+-!BU<:4^IP+>F40^7S_K",A,XQNQVSF@#:I.<C&,=Z\NT[QRVE
M_$OQ18Z_KBQZ3:*IMTG"C:6VG P,GJ?7BO2K&^M=3L8;VRG2>VF4/'(AR&%
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M44 %%%% !1110 4A.*6B@ HHHH **** "DI:* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ",T444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBD!.3D4 +1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%037<%MCSI43/3)ZU#_:MIGF7;Z$@@4 7:*8DJ2+N1@R^H-/H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MII4[@0W'I3J "BBB@ HHHH **** "BBB@ HHHH **** "J>I7OV&R>4 ,_W4
M4]V/2KE8VJ+YFI6:-]Q [X]Q@#^= &=!:N6,]RYDN'Y)/(7V%66B!&"<BK 6
M,C)IP2%2 RL?I0!G%7LB+BW<KM.67/##TKH[>=+BW25#\K#(K)N8X5M9"NXN
M >,9J70#_P 2_:<_*Y H UJ**1CM7/I0 M%%% !1110 4444 %%%% !1110
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MM'2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI ,4
M+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 445%<W5O96TES=3Q001C<\LKA54>I)X% $
MBHJ9VJ!GT%& "2!R>M9&F>*] UB18K#5K2:9FVK$) KL<$\*<$\ G('8^AJU
M9ZSI>HW=Q:66H6MS<6V//CAE#F,DD8;'0Y!XH ND ]0#CFC !)P,GK2T4 %)
M@9S@9Z9I:* "DV@,6P,GJ<55U/4[+1M/EO\ 4;F.VM8L;Y9#@+D@#]2!6 ?B
M1X/$HC.NV_F'HNU\_EB@#JL#.<<BBJ&DZSIVO6/VS2[R.ZM]Q3S(SP&'4?6K
MJ J,$YH =1110 4454U+4[+1["6^U"Y2WMHAEI'/Z#N3[#F@"W169HGB#2_$
M=I)=:5=BXBCD,4GR,C(XZ@JP!!^HK3H **** "BN:U+QUX?TC6%TF^OI([YR
M D(M)G+YZ;2JD'\*MZ7XJT76;N2TL;]'NHQE[=U:.5?^ . ?TH VJ*0<TM !
M136D1616=0SG"@GECC/'X4Z@ HK*G\1Z7;>)+7P_+<;=3NH6GBBV'YD&><XP
M/NM^1K5H **89HA,L)D02LI94W#<0, D#T&1^8K-T;Q'I>OR7R:;<^>UC.;>
M?"D!7'H2,$<=10!JT444 %%%% !1110 4444 %%%% !1110 452U;4ETC3I;
MU[6YN4B&62V3>X'<XR,X]N:9H^MV.OZ/#JNF2FXM9E)0@8)(X(P<8.1CF@#0
MHK#T3Q39:Y:7UTD-Q:064KPS/=A4"LGWQG<?N]S6>?'UE]B.I+I6KMI Y_M
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MFARI"EH+1YGO7WE7RR_< VMC\#ZTOB#XC:S;>)FTR!K?2FEL(IK)+^ [9Y7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML&,A\]<YY/\ ]:KMG9V^GV<-G:0I#;PH$CC08"J.@% $]%%% !1110 4444
M%%%% !1110 4444 %)SD\TM% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#\F'5@,%#O'S>@KI]-O1J6EVE\(I(1<PI,(Y!ADW '!'J,T 6J*** "BBB@
MHHHH **** "BBB@ J"WOK2[>5+:Z@F:%ML@BD#%&]#CH:+ZTCU"PN+.8R+%/
M&T;F-RK $8.".0:\YT>W\/:5\7O[/TF%]*=-.:-[?R6C2\;=G(W##;0I.X<G
MU(!H ]-HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN6M65#E% R<8'(/7GUKV.B@#R+2M-U:W\6_$2X;1M0,5[$Z6K>3@3,,@!2<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYD+(NTC;C'SDYQVIT>O>-$\1^%;=O$88>(M/21P]HF+<E<DJHQEO<]^HQ@4
M>PZI?KI>E7=^\,LR6T32M'$ 78*,D#) S^-5/#?B.P\5:+%JNFF0V\C,H$J;
M6!!P<BO/_!^NZMJ7ASQSIFK7S7SZ6]Q#'<.H5F7:XP0/=<_CCTKB_#U[KGAK
MX26?B?3M9E6.UORIT]D7R70MA@W&XDGOG@=.>: /HJBO(=8\5Z_X@\;3Z%I$
ME];)!I(NXH[,Q!Y)V564LTF/D&\ @>GY2>,/$OC+2-"\)7#S+IVJW5S]GO+8
MK')&YR,$D9P#C/RG^+VH ]:K \0>+]-\/7-K92B6ZU*[8+;V-L TLF3C."0
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M7 !V9R<8[]:]!HH XKQ#\.H-8\2VWB"PU6[TC48D$3R6H7]X@R,<]#@XSR,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>0IY8?9@_O,[N^<X'H: /2:*X][GQPNCQ:C;RZ+>LR1RFTCLI(W=3@L%<S$
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M+RX@A6.2YD^]*P&"Q^M>.^&=+U75?%7Q*TW2+RUL1<78BEEDB+LJL\H.T @
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M W]KH]A!>'/[^*W57YZ\@9JXEA:1WTE\EM"MW*@22<( [*.@)ZD"@"Q1110
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M/(9 9#+D9&T*"6XYX'2N;\4_$S1]%\&IKNGSI?&ZW1V013M>0?WNFT#N#@T
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M/E/7TK*O/^)%<_%"SUAQ'=:JHDT])#EKA6,@7R_[V-RC Z8]J]SI" 3D@9%
M'@NOZ?=6'A[X:Z9JJ%KJWN5DN8W7=Y<1=<!^P 7@Y]#5VTUI-(^('Q'U6$LQ
MBM!Y.P'YI/E50/\ @9 S7MU)@>@H \WEAA\&^#/#.A:GI\=WIMR3!JBM$TK*
MS(TA< =@^<GL.E<OI'AO2]*^*FBS^ ]4-U9R"1]0CCE\V.",#&"P]<\!B2"
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M"NDHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "D(Y'.*6B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#8RV1SQZ9H ]QJ-YX8X7F>5%B0$L[, JXZY/;%>#Z]IL&H>./A_!=:@-1,T
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M%'.52-E"$_+T^;C)ZX48(H ]S:XA2=8&FC$K#*QEAN(]A33=VPN/LYN(A/\
M\\]XW>O3K7S[,&N_!'CS7]20+X@@U:-4D<@RVQ61 %1NHP"PXXP/:M?QE;2Z
M%=^#OB+-9EIA' NJ1JF&+E!\QS_%RPY[A: /4O%.LWUAX<O+K0%LKS482JI#
M-* N=PR#\PYQGC(Z?A6FMU(-*AEN);>VN9(EY9MT:R%>@Y&X9]QD5Y+X[\/Q
MZ7\']4NI[94O]0OUOYP5&8WDD&%'IM4[?S]:>CI?_%3PGINJ)%+81Z$CV\$X
M!1I&0@G:>"W&/P]J .N^'_BG6/$<NNV^LPV4<VF7IM/]$5E#%<AB=S'N*[&*
MXAG9UBFCD*'#!&!VGT/I7A&@3KIO@;XE_P!B7#!8+UQ;O$^YA%N(# ]?NYY_
M&KO@ZVC@L-)UO1]:T]+U=%E@&F6L!\RXD1&8F3#')#\YV\\>M '9_$OQI?>$
M=#34-(DTZ>1+A8)X)U9R-P)!^5QM^Z>"#G/;'/90W:^3:BY:.&YG0$1%QDMC
M) ]<5\XZI#HUQ\"[343)$^LRZFSS3/@S22DMN&>N-I5N?;UKUWQ!:^$KOQEX
M6N=5U"2/5DPVGQ(YV3=QNP".O3D9/'/2@#NJ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUKT4 9>B>'-'\.02PZ/80VD<S^9((P?F/U/Z#H.U0:KX0T#6[Y+W4],BN;E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN4$%K>1S.N;=44*7^4D<XR#G@=1GBN\H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME<G';H1VK3HH RV37<?++IN?>-__ (JFA-?QS+IF?:.3_P"*K6HH RMFO?\
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M_P (_;Y_X^[[_P "#1_PC\'_ #]WW_@0:UJ* ,K^P8/^?J]_\"#2?\(_;_\
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M/IU- 'HE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+P/K.LZ!-=R_9;6=HYEO[GY9$C+#AGY[=JV?##M)XON'=BS-HUF2Q.23\W-
M';4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[\UO6_Q*T*XN;*$Z#K$(O9DAAEFL J,SGCG=SZ\=J[K[-;_\\(O^^!0!Y/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0^<4#[#,%QC8&XQG.!GVH Q=]S\W_$Z\?=>/^)7T'I_JN3UIWF3?]!CX@?\
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M $O[>U6,7L<A22' ZA@>QR>>*PM.U&^UOP/X8TV^E,MUJDY2:0]9+>)RQ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K,U2-@T=P@.8\@X]#6G4<T*SPO$^=KC!Q0!467<-QQNXR,TXS!
M%)8 <^OM4(L+N%2L5PKITVNN/UJJUEJ;RD,8R#_%NZ"@!VHWK-;>4J\M@9]:
MTK*#[/:1Q]P,GZU7L]*6!O-G;S9>N<<#Z"M$=* "BBB@ HHHH *\GLVAG\(>
M&--.@V.KW-Y<W@A6]?:D>UY')SM/) KUBO*-$D,-OX'ECMS/.LVIF) X7+;9
MCCGUQC\: )CX7OB<GX;^&R?>['_Q%/7PG>$\_#SPPOUN_P#[7_G%:%[JWB_P
MY?:3=:M/I]Y9:A>1V<UM;0LAMV?[I5R3N QSG'Z\:,^JZKK?B35-*T:\CLTT
MJ)/-F:)9/-F=2RIST4 #=W.<#&,T 82^#[EGVGP#X54;<[C=-C/IQ%U_2G-X
M-N%Z>!/";?2Y;_XS70Z5K]_KW@<ZG8QV\.IA'1HY]QC25&*MG'.."1^%7/#&
MJRZCX.TW5;YU\V:U6:9E7 SC).* .2_X0R?<!_P@OA/&.OVE\#_R#2_\(7/_
M -"-X2_\"7_^,U8\(Z[K7BG4EU&'7]*;2RS.^G11YGB0YVJQ['ID].N*[^@#
MSC_A"Y_^A&\)?^!+_P#QFC_A"Y_^A&\)?^!+_P#QFO1Z* /-&\%7Q*[?!?@X
M#=ELS2'*^@_=<'W_ $I[>#KT+MC\$^#E4D$[IG.?_(7IG_(KTBB@#S*&_BL]
M+\3Z7<>&-&@EMKBVA:UMQF"<S;=NX[1G&1VJ9?!-VLI=?"'@_ .5!+DCTS\G
M/Y57U*,G7/&;%6V_VCI6"/4"+_&KGB&]\;:#IMQXEEU"Q^S6[AY-($ QY6X#
M'G=2^"/;K0 G_"(ZB-K#PCX,W@YSM;&,<<>7]::O@[4538/"7@S&,?=?TQ_<
M]ZU[_6M0U/Q79^'M,N38 V/V^[N!&KR(I;:L8# J#GDY!XZ58\*ZSJ.K:9J=
MG=M$-7TVYEM'D,9"2,.4DV9Z$$' //.* ,4>%]650!X3\%8''^J;_P"-T?\
M"+ZMG/\ PB?@K/\ UR;_ .-UN>!=5U#5_#?VO5)HY+H7,\;-&@1<(Y48'IQ6
M;I_B*[\6:K+_ &?JT.FZ5%,T4#(J//?%?O,F_("9X!"DG!Y% %;_ (1C5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX;O],#UKJ/#/_(X7'_8'L_\ V:JNM^-/"+^%-4L-/U&W5I;2:.*&&)E!=E(
M "XY)JWX;5D\972.I5ET>S!!&"#\U ':4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7)VGAC5]/TZ+3X-3TR:VA9S&+K32[*&8MR1* >N.@KK*S
MVUK3E&3=IU*\'/(^E &&FA:^9B'E\.B+'#+IC$]/3S!W]Z<F@ZX?+WW'A\97
MY]NE,=I]!^\&1UYXK7&O:8>EZG/L:7^W-."@F[49Z?*: ,O^P-7R<W>A8[?\
M2<__ !VE_L#5O^?O0_\ P3G_ ./5HGQ!I8;;]L3/I@Y_E3SK6G@_\?2>G0T
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MD=OLS4 :]%8__"00YQ]BU#_P&:E.OP@9^QW_ .%LU &O161_;\&,_8M0_P#
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M]KZD"/\ B176"H/$B<'\Z -NBL)M8U0'Y= N".W[Y10-9U4C_D7Y_P#O^O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 449HH **,C.,\T4 %%&1G&:3<I&=PQ]:
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M!<HJG_:VF_\ 00M/^_R_XT?VMIO_ $$+3_O\O^- %RBJ?]KZ;_T$+3_O\O\
MC1_:VF_]!"T_[_+_ (T 7**I_P!K:;_T$+3_ +_+_C1_:VF_]!"T_P"_R_XT
M 7**I_VMIO\ T$+3_O\ +_C1_:^F_P#00M/^_P O^- %RBJ?]KZ;_P!!"T_[
M_+_C1_:VF_\ 00M/^_R_XT 7**I_VMIO_00M/^_R_P"-(=7TP#)U&T '_3=?
M\: +M%9[:[HZ%0VJV*EAE0;A!GZ<TT>(=$9"ZZQIY48RPN4P/UH TJ*S9/$6
MAQ,5DUG3T8=FND!_G3/^$FT#_H.:;_X%Q_XT :M%97_"3:!_T'--_P# N/\
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M7_"3:!_T'--_\"X_\:/^$FT#_H.:;_X%Q_XT :M%97_"3:!_T'--_P# N/\
MQH_X2;0/^@YIO_@7'_C0!JT5E?\ "3:!_P!!S3?_  +C_P :0>*?#Y.!KFF]
M_P#EZ3M^- &M162?%'A]1DZYIN/^OI/\:1_%/A]%RVN:;C..+I#_ %H UZ*R
MO^$FT#_H.:;_ .!<?^-(WBGP^JLQUS3<#KBZ0_UH UJ*QO\ A+?#O[S_ (GF
MG_N_O?Z0OZ<\_A0GBWP[(%*ZYI_S' S<*/YF@#9HK+7Q-H+R"--:TYG., 72
M<Y_&M2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *XN7P1+_9R!)K:?46ED:>XN?.PX9B>%5Q@@$#\*[2B@#SW_ (0/4BV2
MVDY4*$(-U[YR/-Y[<U(?!&JEU;?HP('_ #SN,?EYM=]10!P3^"=58G#:,!G(
M'EW'_P =H_X0K5O[^B_]^;C_ ..UWM% '!KX*U7<-SZ*!GDB&<_^U:3_ (0O
M5O[VB?\ ?FX_^.UWM% '!?\ "%ZM_>T3_OS<?_':/^$+U;^]HG_?FX_^.UWM
M% '!?\(5JW][1?\ OS<?_':<G@G4BX#RZ.J=RMO.2/P\T5W=% '!_P#"$ZH-
MQ#Z+G.!^XGY'_?VC_A"M5S]_1<8_YXS_ /QVN\HH X'_ (0G5=Q;.B;B,$^3
M/_\ ':7_ (0K5O[^B_\ ?FX_^.UWM% ' _\ "$ZJ6#9T3(Z'R9^/_(M+'X#O
M1$P8Z*I&2BK:S$9.<_\ +48Z_K7>T4 >>I\/;E2X\K0%5@0=MI-\WH#^]I(?
MAQ+$L9"Z%Y@)W-]BE!'T(E&?TKT.B@#SQ/AW<!3E-!7 ^5%LY2I^I\W(ZG\S
M3A\.Y3:K$T?A\$-N)&FOG[V<;O,R1C_/>O0:* ."3X=[<-MT'<!MYTIFR!Z@
MRXR?I4<?PV.QA*=$8EBW_(-?C/88E' KT&B@#SX_#1=H4?V+Z%O[.DS]?]=3
M%^&<X+;;W2$7)PO]CJV!GU9R?S)KT2B@#SK_ (5E/N#?VAI60<_\@9,=,=-U
M.'PTF#[FO=(;V.C(!T/H_O\ XYKT.B@#ST?#:XP?].T<Y_Z@D?'_ (]1_P *
MVN/^?_2/_!)'_P#%5Z%10!YZ/AM< 8^WZ1_X)(__ (J@_#:?C%]I'O\ \22/
M_P"*KT*B@#ST_#:XSQ?:1_X)(_\ XJ@?#:?/S7VD$>VB1_\ Q5>A44 >>CX;
M3;3F^TG=D8/]BQ8Q_P!]4I^&T_&+[21QSG1(^O\ WU7H-% 'GO\ PK:XQ_Q_
MZ1G_ + D?_Q5*?AO/\I6^TD$#G.B1=?^^J]!HH \^'PVG_BOM)/TT6+_ .*I
M3\-I/+4+>Z4'_B)T6+!^@S7H%% ' 'X;/Y2[;W3!(.I.C1;3^&?ZTH^&QR<W
MFFD?]@>+T'OZYKOJ* . 'PV=LB34; J.%VZ/"#CG@^O7VZ4C?#69IT<ZO:%!
MG*G1X.<C'4"O0** //1\,#SG5;;KP1I%OG&.AX^M/;X;3,'QJUH"3N4?V/;X
M!QQVKOZ* .+U+X?074]O+936-D8H@K :9#()''\1R./H*I2?#>\9T==<LP5S
MRVBVYZ_A7H-% '!1_#B:)=J:S;A>P_LBV_\ B:>/AY..FLV__@HMO_B:[JB@
M#A/^%>3YS_;-OG_L$6W_ ,31_P *\GSG^V;?_P %%M_\37=T4 <+_P *\N/^
M@S;_ /@HMO\ XFC_ (5[<?\ 09M__!1;?_$UW5% '"_\*\N/^@S;_P#@HMO_
M (FC_A7EQ_T&;?\ \%%M_P#$UW5% '"_\*]N/^@S;_\ @HMO_B:/^%>W'_09
MM_\ P3VW_P 37=44 <+_ ,*\N/\ H,P?^"BV_P#B:/\ A7MQ_P!!FW_\%%M_
M\37=44 <*GP[E#DOK$)!'0:3;#Z?PTZ/X>,KLTFKQMD8&W2[88_\<-=Q10!P
MLGPZD<G&L1@=O^)7;?KA>>](/AU*5BC?7-T46=B_V?!D9.>NWVKNZ* .#/PV
M/EX362K[@^_[!!D''/1<]?>G'X=2,MNK:VS+%GY6L("O)[#;@?CFNZHH XC_
M (5RA9G.M7)D889OL\//_CG2GGX?N QCU^\5VZMY$//U^6NTHH XL_#U2C)_
M;EYM;E@88<$^_P E27O@&WN;"V@@O!;2Q1[))8[.']]R.6&WKQZUV%% '$)\
M.8D<NFLW2N1@L((03_XY0GPYC0'&LW0)(+%;> 9(YS]SUKMZ* .-'@$C.-?O
MAGD_NH?_ (BE_P"$";_H/W__ 'ZA_P#B*[&B@#C/^%?_ #;O[=O=W7/DPY_]
M IW_  @3?]!^_P#^_4/_ ,178T4 <;_P@)P1_;U]@]?W4/\ \12_\($W_0?O
M_P#OU#_\178T4 <=_P ($W_0?O\ _OU#_P#$4?\ "!-_T'[_ /[]0_\ Q%=C
M10!QX\!G!SKU^3CC]W#Q_P".4W_A F_Z#]__ -^H?_B*[*B@#CO^$";_ *#]
M_P#]^H?_ (BC_A F_P"@_?\ _?J'_P"(KL:* .-_X0)O^@_?_P#?J'_XBE_X
M0)O^@_?_ /?J'_XBNQHH Y;_ (0>UETBZT^[OI[D3LA$KQQAX]I!^4A1UQ74
MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>articles002.jpg
<TEXT>
begin 644 articles002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBDP-V<<T +1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !129&<49&<4 +1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R.J>,);#[:
M([1&-MJ%O:?,Y^82$ GIP1FNNKROQ"%#:R03N_MVQR/^!+0!ZI1110 4444
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M?+8P2=AQUSCT!.>U2W/CV[3QC>>&+/0'N[^%!(C+=*J.NU6RQ(^7KCOSCUX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0, G&< GZUAQ^)/$1.7U#P:!DC'VY\D>O2FOXF\2('(O?!TF%RH6_<;CZ<T
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M_P#T6M<A';W^J:[>:WJ-_H<KP:// D.G7)D89YW$'MR1^(KK_!G_ "(^@?\
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MTR:>TO.+K_1#"MMN7<K(Y8[EQP<_S.* -NZ\*^#[*UENKK0=&B@B4O)(]G&
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M/EZ)IJY.3BU0?TK5HH R_P#A&M"X_P")+IW&,?Z*G&/PIP\.Z(  -&T\ ?\
M3JG^%:5% &;_ ,(]HG_0'T__ ,!D_P */^$>T3_H#Z?_ . R?X5I44 9O_"/
M:)_T!]/_ / 9/\*/^$>T3_H#Z?\ ^ R?X5I44 9C>'-#88;1M.(]#:I_A2_\
M([HF<_V-I^?^O5/\*TJ* ,W_ (1[1/\ H#Z?_P" R?X4?\(]HG_0'T__ ,!D
M_P *TJ* ,W_A'M$_Z ^G_P#@,G^%'_"/:)_T!]/_ / 9/\*TJ* ,W_A'M$_Z
M ^G_ /@,G^%'_"/:)_T!]/\ _ 9/\*TJ* ,W_A'M$_Z ^G_^ R?X4?\ "/:)
M_P! ?3__  &3_"M*B@#-_P"$>T3_ * ^G_\ @,G^%'_"/:)_T!]/_P# 9/\
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M=;_^BUKF_$*JWQ'D+;<KX;N"N3SGS,<>^"?UKI?"&T>"]!V_=_L^#&?^N:T
M;=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<8&XY( )]JZK1]&&FV]\L\B3RWEU+/*X3;N#'A2/90H_"N&&LWY<H/B5;[P
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MNV$"_E&!VH VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>3Y;9).5SC\*PM)\SQI)XJDN;R\MIK._EL;189WB^S"-1MD !QN).23GTZ4
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MX%^'\TVLW\5W=:P+.>>&<JSIYDB<]F("CD@_K71VEGJ5EK7C#P_I6K70_P!
MAELWO+AI##,ZN"0S9(!(% 'I%<IIOBG4]6GT^YM-%$NCWL\T7VE;CYX50D!W
M3&,,5/0\<5A^%?+NM1U'1[RSU'2]5%@!-8SW3R0N-V/.CD#=R><8/UYK#T=W
MT+X1:"EO<?99-1U%+2YG,S *IFD!(.?ESC&1CKZT >QT5YU?Z'J6C6?B61=;
M\BTGTR2:"R@GDWPR1C/F(S,2H/ ('J*HV/A[69_A];:KI^MZC=ZIJ%A:,UO=
M7A5) N'9$(P5++E<YY[GDF@#U.BN*^']_:W<NL1Q)J%E=12QBXTJ]8M]B)3C
M83U1L9'T^E=K0 4444 %%%% !1110 4444 %%%% 'DOA\R)<>&FMX5DE&J:J
M8XV;:&.V3 )P<?7!KI?#WC+6O$^DKJFF^'[;[*6="LNH%7W+Z#R\<_6L+PVK
M1WWA5"!@ZKJ;9P#_  R=_P :B^'VE^(;SX80_P!EZ\EKYGG"&)K8?*=[#[X.
M1DY.<9&?:@#IM4\;7NGV.A7*:!([ZM*MN(I;CRGAF;HK KTX//M781ES&ID4
M*Y W*#D ]QGC-<)X]N(KFX\(M%(D@7Q# C%&R RE@1]0017<374%LT2S2JAF
M<1QAC]YB"<#WP#^5 '*:5XMUG6+G4H+70+?=I]RUK+OU#&7'<?N^G^-71XNB
ML_#MSJNN64VFM;3-!);G]XS,#\NPX&[=D8(XY]JY?PI9:K=:UXQ.G:NMB/[7
ME!4VRRY;'7)-1>-Q/::'X274;M+D:9J5HNJNK[OG"C+$GGG)/./O"@#H+WQ5
MX@TW2)]7NO"V+*./S/+6\!G1<9RZ[<#WP21Z4NI^,=0LK74=0M] :;3;*))?
MM,MQY1F#(&.Q=ASC=C.<9!KJY3$8',Q0PE3OWXV[<<YSQC%87BV6'_A7VLR6
MY#0-ILOEF'!4J8S@C'&,'\J *NG>*-9U"WTRY3PXOV;483)%*EYN$9V%U$GR
M?*#C&><$UEVOQ$U&XT&ZUL^&'^PV<KQ7/EWJM(FS[QV[1D#ZUTO@\./!>AAT
M"-]@ARH&,?(*\I4ZM;^!;R1[C'AZ;5YX]16WA(N(X3)M9@YR",]>.G&>N #U
M>Z\4Z3:>&TU^2X_T&5%>(A3ND+?=51UW'TK+N?%.M:7:?VGJWAT0:6 &E:*[
M$DUNO]YTV@'W"DXK \?6UI9:%X/EL@AT6SU.V8[3E1%_"Q[$8SS[^]=KXJDA
MB\(:R\Y41"RFW%NGW#0!C^(?'EMX<DTNZN;82Z-J&T+?Q39VY&0=F,D8P<@_
M_7TO$_B(^'_#<FM06J7T,>QF43;,HQ # X.>2/P-<+IFFR2>&?AW8W]NLPDE
MD\R*90P,;12'!!_V2/I6;XG&H>$]!OO!]UYESIM\4_L>Y9LE,2(3"_'89(/^
M0 >@:AXHU/3_ !#H^CMHL3OJ:L4E%[A49%W2 _)G@=#W]JL:IXEDBU@:+H]F
MNH:H(_-FC:;RX[=#T9VP>N1@ $]ZS?$O_)2/ _\ O7W_ *(%4O!^Z#XF^-8;
MKBXE:WEBSU:+##(]N5% &[IWB*^D\0KHFJZ4ME<O;-<1RI<B2.4*P!"\ YYS
M@@8KHZ@D:U%W")&A%R5;R@Q&\CC=M[XZ9Q[5/0 4444 %%%% !7D]N L6BH.
M0GB^X4-M #<R\@#M7K%>7/\ ZS2/^QQN?_0IJ .R?Q-L\:Q>'&T^=3+;-.MT
MS#8V,<*.IZ]\?3O3-3\1W2:Z-$T:PCOKZ.'[1<>;/Y20H3A1G!)8]ACZU0U#
M?_PMK1MH;']F7&['IO7K^.*;K&EZKH_BNX\4:9+8M;36?E7T5[*T2QA 2L@9
M5/ '48_GP 3CQW:2>&XM2AM)'O);H6*V!8*_VK.#'N/'')SZ?E5G2_$\DFK7
M6D:S9I8:C!!]J"QS>;'+#G&]6P#P1@@BN(T'PQJVN^%#KL#PVNK3ZRVL6@?/
MED'C:>,@,,]O2M'3Y=1UCXFW&H:E:VL-MHVG-#-]GD:9/,?#%"Q5<D G( X]
M3F@"]:_$-I8]-U.XT@0Z/JEV+.VN1<!I=V6"ETV\ [3T)Q71ZOK8TS5-)L4B
M2234)G5BS[?+C1"SOTYQP/QKR31HY=&N=!UNXM!)X2O;]GL[-I=YL97.$D(Q
MSPI('.,GOR>\NXY=<U7Q3<QH72RL'TVUQ_%(R;Y?QSY:_@: )H/'7F?9M1ET
M[RM N;DVL.H-.,[LE0[)CA&88!S[D 5J^+/%%GX2T234;M3(P.V*!3AI6]!Z
M#&23V K@=47[1^S]I]M#\UQ/':PPJHR3)YJ\#'?@TSQM<WTMMXDN-2T'4VV0
M-:6,ZHA@ABXW2$[\Y<]2%Z!1ZT >E3:S%!X9?6W0K$MG]J*$]!LW8S^E9$GB
MN^)AL[/25N=52R2\O+?SMBP @?(&*G+GYL#CIR16.;AM?\-^%M$-K<6WVQXF
MF2<!2T$"J['Y2>&(0#_>[5;\,CR?B5XU67AW^R2)GNGED9_.@"ZWC5+O2-,N
M]$TRXU.XU%&DAMT8($52 Y=SPN"<>YJUX8\3_P#"0_;K:XL)=/U&PD$5U:R,
M&V9&5(8<$$ \_P#ZZP_ .H6^F?#^34[R79:&[N)4?KN4RL!M'4DGH.IS6QX6
MTJ>VN=3UB_417^K2K*T /,,2C;&A]6 /)Z9- '24FT#/ YZ^]+10 F "3@9/
M4TH '08HHH X37/^2AW7_8L7'_HU:W_!S^9X*T%L@YT^ \=/]6*Y_7/^2AW7
M_8L7'_HU:Z;PU%Y/AC28]Q;99PKD]>$% &M1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5YIXA8_8M4''_(Q6O_M*O2Z\\U=]
M/CT[Q -2L);V"75HD6&)]C%V6,+@Y&.>^: .DTGPI::/K^I:S!=WKW.I$&Y6
M5U*,5^[@!1C X'M5:S\":/8:EJ5U;&X2#4@PN[ ./LTFY=K?)CC.3T]:P_\
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MPK:L H\+7Q&_<?\ B:X_]G_2@#6UOP'I.O7-E>7,U]#?6D7DK>6TYCF=/1F
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MK<&-9P!@%AC@XXR,'%8C^&4+D_\ "(ECC;N_M'G'I][I3?\ A&5B18X_"+;
M, #4L >WWJ .BN/".ESW.B3()K?^QF)M([>38@! !!'<$#'Y^IJ;2_#EAI&K
M:GJ5J9_M&I.)+@R2E@2.F >F <5QY\(VYP#X'0]!SJ _QJU)X:!C,1\*%X\
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MMT[@QXZ$$\\\\]^:I:G\.?#^JZ\VLR1W,%S* +A;:<QI< ?WP.OH?6L=O"4
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M!\(6F/\ K^/^% '?T5P!\&6:E0OA"U((Y/VXC'Z4A\&6AR/^$/M>!WOCS^E
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MN?ML">7&5G8(%/4;>F#W_P#K"I-4T&SUIXQ?M--;)@FU\PB)R#G+J/O?0Y'
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M&#G@>O Y]A5;5_"UAK%X+N22ZM[@PFWDDM9?+,L1.=C'N,_B,GFN(/@BT#1
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MDWJ)?+XX&6V\>X]:[BXLM'T?XJZ4EE%;V8FTBX$L=NH7>H8$':.I^\?7@^E
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M+;(WRAPC,I8?[.1U]Q7:7.O6%OJ%A8B837-[(R11Q$,<*I9F//  'ZB@#D]
MN_%&O7FL6[>((K?^S+QK0,E@A\W'.XY/!YQ@<<5?O/$VH^&O"ANM9CAN]1>Y
M^S68MB%%V6/[ML9.W(Y/T.*P/"MEIVI:MXS6XU"X@+ZK(H-O?O#@8ZX5@">O
M)!Z5%XFBMU\/:)/I+2WUMX2U"W6Y9!G>D:*688ZX&,^G/I0!TU_'XST[2[C4
MHM2LKVZCA:3[ +(A"<9VHP?=D=LYSZ#/%77K_P 46VG:IK\-[;V5A:P+-:V<
MEL':4! S>8<Y4DDK@>GXUT+^*-$32?[3&I6[VI7<K(X8O[*.I;MCK6;X[F$O
MPWUB8H\7F63-LD&UER.A'8^U %;15\67=II.H/K%O/;WMOOGC-HJ&#?'N5E.
M?FPV!@]0:P].\2>++GP5=>*_[0L)%M3(38FT*I(D9PQW[MP8X)].V*[+P?,L
MO@G1)<I@V$.2IX'R#/6O++/2;G4/ KZO87$FHQ6FISW%WI32GR)XQ(21MSUQ
M\P'.<]#0!Z#?^.8[3P5IVN)9M)=:D(TM;/?@O*_1<^@YYJ/4I/%^B:5)K,E]
M9WY@3S;C3TMO+78.6$;Y+9 SC.<^E8GC&\MM?\,:!XDT("ZL]+OHKN6&(89(
ME^]\O;;C&,>_05U'BC7M.7P7>W,5U%.MW:O':K&X)G=UVJJCN22* .?\1^-M
M0TZ'1/$&D,M]I%^I\RR\GYPJJ7=E;.<@*W!XXK4\5^))?^%?OXB\/:A&H79(
MK^6) ZE@I4@]""WU!7%8EGI<NAV'P[TRZ.RXCN7,B[@""T4C%?P+8]ZRO&^A
M7WA>ROK/35+^'M:FC5HB2?L4YD!W*/[C8QCUQ^(!U.M7?B*Q\8^&]+M]9C%M
MJ*R+,6M$)W1)N8_\"_2K=UKNJ:MXKNO#^AO#;)8QJ][?2Q^9L9N51%R!G'.3
MQUXJIXHN8$^)G@F-YHU=3>$J6 (#0X7\SP*HZ#/'X;^*/B2SU)U@&L&*YLY7
M.U9-H;*@],_,>/:@#HM.G\0V7B./3=3FAOK&6V>6*\BMFC<2*R_*^"5'#'!X
MSC\^DK/CUJRFU8:;;R>?<"/S9/*^98E[;CV)[#J<&M"@ HHHH **** "O*HF
MWQZ(Y;=N\7W!W>OS35ZK7DMFV^S\/N>K>+9SUSWEH [.36M4A^(EOHTOV5=.
MGLY)XMBL9&92H^8G@=3TS_A!?:OJ6K>+[GP]H]_%8?8;99[B=X!*S._W4 )
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MSL.?:E\9:3XKL]+\4ZA,ND3V=TA7S6:3STMQC:BC[HQR<=R2?2@#O+[7GL?
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MJ\._]![2_P#P,C_QKG_[%\9_\_7AG_P7O_\ %4Y='\8A6!N/#))Q@_8'X_\
M'J -[_A*O#O_ $'M+_\  R/_ !H_X2KP[_T'M+_\#(_\:PFT?QB0<3^&5.[(
M_P! DX'I]ZF'1?&1Q_I/AGC_ *A[_P#Q5 '0?\)5X=_Z#VE_^!D?^->;6]];
M#2=!OGFABMCXKGD\PR#8%)E.=Q/3WKK'T?QBP&V?PROK_H,ASQ_O?YS6*/$N
MM7/AO28XH]*74+K6)-/8O;DP@+O&X+G/\([T =4^I^"Y;];^2^T![Q2"+AI8
M3(,=/FSFI)-;\(S7<=W+J>B/<QC"3-<1%U'H&SD5CIH/BU;CSS)X7,F-I;^S
MG!(],[LT_P#L7Q>R[99?#$B'.Y38/AAZ'YJ ->ZU[PI?0F&[U;1;B(G.R:XB
M=<_0FI4\3^&XT5$US2E11A56[C  ].M<TOACQ2J%%/A,*000-,;!'_?7L/RJ
MU+HWB^0C;+X811V^P.><]>6^E %^+4/!,-X;R*\\/QW1)8S++"')/4[LYJU%
MXC\,6\?EPZUI$:9+;4NHP,DY)P#W))_&L$>'/$J$^3%X3B5EVNJZ<_S#N#\W
M>I3HWBPR;PWA<$'Y3]ADRJ]P/F[X'Y4 :<>K^#HKU[V/4="2[?[\ZSPAV^K9
MR:FF\1^&+B%X9]:TB6)QM='NHV5AZ$$\UA#0?%R-NCE\+HQ #$:>^6QTS\U2
MC2/& BVF;PR7W9W?89.GIC=0!K)K_A6.83)JVC+*(Q$'%S$&" Y"YST]JCO-
M8\'ZAL^VZCH5SY9RGG3POM/MD\5D6OA_Q1:^84'A4%QU33G7GUX;FEET+Q7(
MY8-X6#,NQB=/<DKZ<MTZT :E[JG@S4MGV^^T"Z\O.SSYH7VYZXR>.@I;+5O!
MNF!Q8:AH-H'QO$$T,>['3.#S64_AS7S'LCM/"* L"0-.<@_AN]":;#X<\1P3
M;T@\)*"NTA=.=<_B&H Z+_A*O#O_ $'M+_\  R/_ !H_X2KP[_T'M+_\#(_\
M:PET'Q"%8&U\)DN<N?L$GS'.<GYJ:OAS7%;<MCX0![8T]^/_ !Z@#?\ ^$J\
M._\ 0>TO_P #(_\ &C_A*O#O_0>TO_P,C_QK"BT#7X6+16?A*-B,$I82#(]/
MO4@\/:^BLL=GX20-PVW3W^8>A^:@#(U>_M=4\=7KZ7>VUUM\-3KOAD#J#YJ\
M$@^E=SH'_(NZ9_UZQ?\ H(KB;R[U*QOM2T2^M](A5M$EN5FTZ!HV 5P@7DGC
MDUVV@<>'M-'_ $ZQ?^@B@#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*\9=<;@&V$?CT.*V$UFWTBRU6'2_#.H-86R&18ULI5^TS2$DI&A7.WU.,#-
M&Q9>*]-U"[TVWM?.E;4;7[7$RQY58\=7(^[SQSWXJK+X[T.*XB1Y9Q;R7/V1
M;WR6^SF;^YOZ=>,],]ZY3P5IM_X*\4R:=<6$]Q9:O$MQ%<6UI)Y5B^6)@8G.
MU!DXR>.X&34/@^_OM*\/VW@[4O"MS<ZK83E82]O_ **Z[RRS^800 ,]1DY'J
M: )K'Q5:>&/''C:+4+C4;B&*2VEBA59+@QJ8MSD==J@D>@' KL[SQ;IMM;6$
MT N+]K^,RVL5G'YCR(!DL!Q@#(ZXY(%<OIHD7Q3\0KB;3K_[/=1P^26LI<7
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MK;_0A;SE$B$:?>D[NS8))/K6OJ<#:IXTTJR:W;['IT1OW<@[#*<I$OU'SM^
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M_P#7K%_Z"* -*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHO\ XY1_PE5U_P!"KKO_ 'ZB_P#CE3_\(K:?\_VK_P#@QF_^*I?^$5M/^?\
MU?\ \&,W_P 50!G7NOR:C;-;7'A37VA?&]0D0#C^Z?WG(/<5.OBFXC157PGK
MJJHP%$40 '_?RK/_  BEG_S_ .K_ /@RF_\ BJ#X4LS_ ,O^K_AJ4P_]FH @
M'BNZ/_,J:]_WZB_^.5SFH2ZC?>,=-\0#2=?B%@C1I;?9(2K*_P!_)\W.3@<]
ML"NA31=&=U1-;OV8G  U>4DG_ONK/_"*6?\ S_ZQ_P"#*;_XJ@" >*[D_P#,
MJZ[_ -^HO_CE!\5W0_YE77?^_<7_ ,<J<^%+,];[5_\ P93?_%4U?"%@KEUO
M-6#$8)&I3?\ Q5 %=_%%U+&Z?\(MX@7<"-RQQ C/<'S*BL_$#Z?;+;6WA#74
MC7)QY41)).22?,Y)/)-7_P#A%;3_ )_M7_\ !E-_\55>ST/2-0A,]EJ^H7,0
M8H7AU65P&'!&0W44 '_"677_ $*FO?\ ?J+_ ..4#Q9<G_F5=>_[]1?_ !RE
MN]!TG3[9KF\U?4K:!,!I)=5E11DX');'6IT\*V2\K>ZMSS_R$9O_ (J@"#_A
M*[G:3_PBVN_]^XO_ (Y2_P#"576T-_PBVN<C/^KB_P#CE3_\(K9_\_VK?^#&
M;_XJC_A%;/\ Y_M6_P#!C-_\50!7_P"$JN=F[_A%]<ZXQY<6?R\RC_A*[K_H
M5M=_[]1?_'*L#PM9@Y^V:KGU_M";_P"*H;PM9N #>ZK@?]1&;_XJ@"!?%-TS
M[?\ A%M<'.,F.+'_ *,JMJ&L-K&F7>G77A?7?(N8V@D $2G:P(.#YGZU>'A.
MR#EQ>ZMN.,G^T9O_ (JD7PC8*25O-6&1@XU&;_XJ@#C=/L=0AMHK&]A\67^E
MIA%M)HK9054<!V#;F7VR!78CQ-=&)I/^$9UD8_A*PY_+S*<?".GG&;G4\@8!
M^WR]/^^J3_A$-/\ ^?K5._']H2]^/[U $:^*;E@#_P (OK8R<8*19[?]-/>I
M#XDNO,"?\(UK!S_$%AQ^?F4P^"],8(#<:GA#E1]OE^7Z?-Q4H\*6014%YJNU
M1@#^T9NG_?5  ?$-T$W?\(YJV,9QB'/_ *,IG_"2W6]4_P"$9UG)&<[8L#Z_
MO*</"5B,XO-5YZ_\3&;_ .*I'\'Z>Y):YU0EAM).H3<C_OJ@"3^WKO\ Z%S5
M?_(/_P <I&\07:J3_P (YJQQV'DY_P#1E1_\(=IOS?Z1J1W8W9OY3GZ_-S3&
M\$:2S;C+J.?^OZ7_ .*H E3Q%=O_ ,RUJX^HA'_M2E;Q!=JI/_"-ZN<=@(?_
M (Y43>"M*8DM+J!)ZG[;+G^=+_PA>E[2OFZAM/8WLO\ C0!*/$%V0#_PC>K<
M_P#7'_XY3$\17Q+!_#.JJ03C!A((SQ_&.?:HO^$'T@?\M-0_\#9?_BJ!X'T@
M$D2:AS_T^R__ !5 %G^WKS_H7-6_\@__ !RF#Q!?;VW>&M4"<;2#"2?7(W\5
M%_PA&D?W[_\ \#9?_BJ:_@71W0J7U#!&#B^E_P#BJ ,"UTG5]/C\,WD>CSS?
M8;BYDFMHI(PZ+(C!>68 XR.]=*/$.I[B#X2U@>F);7D?]_N*X'3XEU'1/!EE
MJ-]="TEDNS.XN6C)"1LP+,"#QBN@?PKX*CF$3ZU,LIQA&UEP3GIQOH WO^$B
MU'?L_P"$2UG.,_?ML?GYV*8OB>_8.1X1USY.N?LXS]/WO/X5E7'@[PE;(OVG
M5;N)2N]?,U>11MSC(R_3/>K2_#W03$62XU3RW .1J<V".O\ >H M'Q3?#_F4
M==^[NX%OT_[^]?;K2GQ-?@X/A'7.H'!MSU_[:_KVK#?PYX(155]?E53\R@ZV
MX![9'S^WZ5=@^'_ARYA2:WNM1EB<95X]3E96'L0W- %S_A++W>J_\(AK^6X'
MR08ZXY/F\4O_  E5\ Q_X1'7?E)4\0=AGC][R..M94?A+P>\K0QZQ<M(F=R+
MK,A*^N1OXHG\(^$+&Y$-QJ]S;W'!"2:Q(C>W!?- &LGBF^DC,@\(ZZ #C#"
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MAQ_SUXK%/A/P8LZ0'6)Q-)MV1G67W-N^[@;^<Y&/7-6+KP'X9LH3-=WM_;Q
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MM)\/O#L,+327.HI$HR7;4Y0 /7.ZDMO OAN]MA):WVH3P$G#1:K*RD]^0V*
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MU6W?2/%&LZ-;WU_)8'PXUQY-S=/, _FA<C>3CCBO1= _Y%[31_TZQ?\ H(H
MTJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI$UTP$WF8L'99 9&&#)MVXP0,D\?A5C09)8;3P-)# T\JR7Q2)6"ESY+\9/
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MO#X_YAL?_?;?XTX^$M"(P=/3C_;;_&@"D-?\1>8RGPO& #@,=3BY_2E;7O$
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M^V_QH K?VYXBW+_Q3EN%YW9U-,^W\-0G7?%/EKM\-V>_G=G5%Q[8^6KY\'Z
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M(X8:;#D#&#DC\B<4#PGH(*G^S(/E&!U_7GF@#-?7/%05=OARQ)QSG5%'_LM
MUSQ5_%X=L1_W$U_^)K4'A;0@^[^R[?.W;RO;_/>G+X9T15 &EVQQT)3)_,T
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M$(\+?]"_IW_@.O\ A36\#>%77!T#3\9!X@ Z?2@"C_;/C?\ Z%*R_P#!J/\
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ML=0LK:70;'[1?.8H46W!!VJ6)QT  ZGZ4 )_;/C?_H4K+_P:C_XBC^V?&_\
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M;:KI.GZ)XNUZTTVT%M WAOS"D0^3=YN"3[X _(UZ3H/_ "+^F_\ 7K%_Z"*
M-&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU9WER%>S2QDW1P,2 XESM)XR>,<CIUJ]9:[XWU+Q=K.EV\>BK:Z9>6ZR2.)
M7A==Q51D_-M(Y.!GI[&@^"/$N@[='M_$D?\ PC<<I>)!$1<K&6W>6'[#J-W7
MGC%;.@:#JVF>+O$&J7=Q9R6FJ-&Z11!@\10;!G(YRN,^XXH =\1?^2<^(?\
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M5BAW  (@/8!15(>%-6TCQ)JNI^'KZRAM]6P]Q;W,)/ES 8\U2IY)ZE3C)[T
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MW&Z]\LS*67/EMV'Y_A70>'/#/B;PSX?AT>SU32GBBWE9);20MEF+=I .I]*
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M&J\GC:NV8G^9H BFU66&&&5_$OC,"7.T'20.^.I3!Z]LU*;Z6*)I+KQ1XQM
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M),;Q&V6B;N/N\=_NUC>'[;Q!J7A6]U^Z\4ZQ%<6+WZ+;DQX.W<%W@KC<"/3
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M+VVN:EIU_/>WL,NGOYD"P,@4-W)!4Y]* ,3405^,>C--_JFTN98/^N@;+?\
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MIG_7K%_Z"* -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7T>O?8DBB9/L]S #&D@(Y!#,Q!!'KW% '*^9<$@#0_&62?\ H('_ ..4GFW
M)']A>,__  8'_P".5Z!Y\.]$\U-[C*KN&6'J/6E\Z+SO)\U/-QG9N&['TH \
M^\ZX_P"@%XS_ / \_P#QRG,T^T'^Q?&//IJ)S_Z,K;\/ZYJ%SK/B*SU=[-%T
M^[2*!H@5!1T#KG<3\V&&?>NCFN(;9-\\T<29QN=@HS^- ' >9/C']B>,_P#P
M8'_XY3%:9$"KH?C, =!_:#?_ !RO0_-CV*^]=C8VMG@YZ8^M"2QR[O+D5]K;
M6VG.#Z'WH \_#SXS_8OC+Z?V@W_QRD,MP#_R _&9^FH'_P".5Z!'<03221Q3
M1N\1Q(JL"4/H1VH>X@BD6.2:-'; 568 GZ"@#SQ#)']S0/&0X _Y"#=/^_GO
M4J03W3?\@3Q>" 1E]4V]>O645Z%10!YP5DV"/^P?&148P/[0;MT_Y:4]UFB!
M0Z#XPPV20NI%L\G/26O1** /-/((0;?#WC#*9*@Z@W7_ +^4@L04+#P[XOR!
MT.I$=L_\]?:O3** /-FMI3%^[\.^*R^.C:H5'/OYGN:%TQG?8GA[Q7NV[OFU
M4JOY^;^E>DT4 >:C2Y&<@>'?%73(_P")OC.#@]9:5M+N%RR>'/%!4 @G^V>?
M0\>;SQ7I-% 'FB::[)N;PYXK7Y=P U;G'_?WK[=:9)I\GF-$OAOQ8QZ _P!K
M8'OSYN*].HH \M\S2+GPMX=&F:'JTY8S?98(+SR9H@%_>9?=SQVSSFDCTV22
M-,>%O%XE9=VTZR0HYYY,O'XBI/#GVO\ LWPD+'REN"+S8TJ%D!V\9 (.,X'!
M[UL^%=;\2^*/"<.M+<Z5;R2^9M@-G(5RK%1EO-]O2@#GVL7V@IX5\8GG#;M7
M88ZXQ^\YZ?A2FPO&78WA3Q9YJD(J_P!N';CK][S*WM6\1^);&3PQ#Y.GV]QJ
MSK#<130NY@DV@L05D&1UP/UKM<2^3C>GF[<;MIV[L=<9Z9[9_&@#RXVCP.N_
MPQXS$H SY>K%U''9A+S44=HS_>\*^,QA,G_B:MU[CF09_G[5TOAC6O$GB*/5
M7:YTJW^PW\MDH%G(V\ICYC^]&.O2I[_Q1J.@>&8KC6+&)]8FNC:6]M;MA)Y"
MY"%222%*@'GD4 <@UM*%&WPEXR+;>0=6<#=Z9W].O/Z5)]D.X'_A%?&GE\@G
M^U&R/3 \SFNGU:\\9Z-HDNJ9TJ^DB7S)K.."1-B@<['WG<1[@9[8Z4[7]7\3
M:7I6MZO$NF):68WVD<L+N\R!02S,'&WDG QVH Y5[7$9*>%?&I?L#J;@'\?,
M_I49MISLV>$?&!.,ONUAQCZ?/S^E=IIUUXKN[;3KD2:7);WMMYKN+=U-NY0,
MHQYGSKGCC![US=MXX\3-X$?Q9)#I,D,,K+-:)%(C% ^PE7+D9SSRO2@"L+1U
M4RQ^%O&?R$==58'.>./,S3%LI-XW^%/&(C;.TC5V+=>X\SC\_P Z[+5/&5O8
M^&+#5H8'EGU(QQV5LWREY9!\H/H/4U6U74?$_AS33K%X^GZA;0@->6UO T31
M)_$T;%CNQUP0,CTH Y46<K;B/"GC':K<YU=@=OJ!YG)]OUI8M/NYR=GA+Q8
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M"#C"?+RS'GZ >]3>$?$-]K*ZC9ZK:1VVI:;<>1.(23&^1E67/."/6@#E(C)
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M/?7^I?;=!DU&\MS;RRRW2'>I7;@_-P,<'')%3>&]2\)>&M$BTRV\0:4(D9W
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M_P 57248% '+_P!C>)=C+_PD,').#]A7(_6A-&\2*C*?$,#9.<M8KD?D:ZC
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M]]4'2O$9_P"8W:8[C[ O_P 572X%&!0!RD&B>(H!MBUC3HUZ8CTX#@<#^+T
MIQT;Q%*J>?K5@[(V]<Z>" 1T(RW!KJ-HI<8H X_4_#?B#5--N+&7Q!;K%.A1
M]ED <'WW5UD$7DP1QYSL4+GZ"I** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HI,G(XX-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !28YS2T4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7$:ZL_#=C:G.H3:U"T"C[V%#;F'H!D$FNPUGPWINN6L$-S$T;6S!K:>!C'+
MP[HPY%5]+\(Z=INH_P!I/)=W]^%V)<W\YF>)>X3/"Y[X S0!R_@M9+3XI>.;
M>\!^U3O!<1,?XH<,!CZ9 I_CF(WOQ#\"VUL'-U#<S7+E!]R$!=V?0'&*ZO6O
M#5AKDUO<3M<6]Y;9\F[M)3%*@/4;AU!]#D4ND>&[#1KB:ZC:>YO9QMDN[N4R
MRLHY"[CT4>@P* /*-:MM5_X3_P 6ZE9VW]I6-A>64U[I.,?:5%N<-GOL/.W!
M!.#VKUCPYXCTWQ3HT6J:7,)('X8'AHV'56'8BJVC^#]-T/5KK4[26]-U=_\
M'PTUT[B4]BP)QD=!Z56T?P!HF@:O-J6F&]MYII#),BW3^7(3G[RYP>3F@#J*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MURBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHI.=WM0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 44@ &<4M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>!110 @.0#2T44 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 444A("DDX ZDT +1FN?FU>XNY66Q 2 ''G,,[C[4S?=9S]J
MEW#OGC\J .CHK"AU:XMW NU#1'CS%ZCZUMJRLH*D$$9&* '4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 (1D8I1P*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K*UV5OLBVT9P]P^S/H.I_2M6LS58QNM
MIF'RQR'<1V!&,T 5([81J%084# J1H'";L"K$< 8<M[TK6XP/F^O- %*XM)F
MMW(VX*G-6="G>6PV2')C;;^%)>^5#$Y)Y*G S[4NAPE+)I""/,;('TH U:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *9)&DD;(X!5A@BGT4 8[6\]H2-A
MECSPR]1]137U!53!W9'&U4-;5% &#':7%^X\Q7CAZ$N,%AZ"MR-%CC5%&%48
M IU% !1110 4444 %%%% !1110 4444 %%(,]Z6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HI.:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **0C(QG%+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %&.<T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A.*6B@ [444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 C,%Z_RI:** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:[A%R:4
M4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -V+NSCFG444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&:*:5)8$-P
M.H]: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !113)94BB9Y&"JHR2>U #Z*R#?W-XP%E
M'L3J7D'4?2FYU(,3O+8/3 Q0!LT5F6VI%G$5RGER'H>QK2'2@!:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *SM3!F:&W_ (7;<P]0.<5HUGWQ,=Q;R\;0
M2I]B>E $Z)L0#CIC@=J<"&/&0?:HED.,C P.E/WA6&[ /4\]J *VH6@GMFD!
MPZ#<".^*GTZ9I[*-F^\.#3;V<16,A)!R"O%,TA"E@N[^(DB@#0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J*X@6X@>)N PZ^A]:EHH QEE:U79=QNK#_
M ):*,JU1/JD;.PC*K[GO6[@'J*A%G;+*91!&)#_%MYH Q(XKC4& 5"(PP+.W
M Q[5T"(J(%48 &!3L#THH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I <D\$4M&* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $SSBEHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBD!R 10 M%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7%CQMJ
M$NU[;0XI(9([F:)FO2I9(7VL<>6<$Y&!S7:5SMZ)E\::9,EC<-;16TT+RHF4
M5I&C(_#Y3D]J %F\4PVFIV*7K06UC>V)N8I97VOO!7*8/7AP?7@\5KPZE97&
MG_;X;N![/:7\\.-@ ZDGH,=ZRKJWEF\<Z?<-:L]M!93*)3'\L<C,A'S9Z[5(
MZ<>O/&1<:5?76BZ[9V]G/$6U-;B)/E7SHPR,P7.5YVMU&.1GK0!T^GZWIFK,
MZV%]!<,@!94?) /0X]/>K]<9H]C-+XCM;R3^VYC!%(ADO8H84C! ^7"J"_X9
M KLZ ,G6-66PFLK:.YM8[BXN(U"W#$;D+ -MQU;L!ZFM"ZN[>QMGN+J:.&%/
MO/(V *Y_Q;+<R1VEM;:;>7)CN[>Y9X44J%24,1DD<X6I->9M2T"%FT:^F5YU
M+Q(ZQSP $XD7GD@@$#/>@#5L=7T_4WD2SNXIGBQYB*?F4'H2.N#4$?B/1Y;J
M.VCU&!I9',: -D,PZJ#T)K)T&+4K>^U&4PW5Q;>0GV>6_5$GD<;CLR #M&1R
MPX)-96G6%Y%<:5'I]CJEO%'<*UQ97H1[>W7!)V,1G()^4J3[XZ4 =FVJV*)=
MNUR@6S.+C_IGQGD?0TESJ^GV=C%>SW4:V\NWRG!SYF1D;0.6)'85AWC7VGZG
MK+1:5=7GVY(_(,&W;D)M(8DC;@^OK6=<:3J,NE^&9_(U"(V%N;>XAMFC69"5
M5=ZYR"!M/3G#4 ==;:MI]W8O>P7D#VT>?,EW@!,==V>F/>L@^++2YUK2[+3K
MBWG2ZD=)<Y#!1&SJRYQD97&1D5DQZ!=2Z1J_V:VOS+<RPR!=2F0FZ\L@E2%^
MZ"!MR>O%6[DWNI>(?#UW'H5Q##9R.9Y)=@:/?&R;1SD@$@DCT'6@#KJI:AJU
MEI2(UY,4\PD(JHSLV.N H)J[7+:^-6?645%U3^SA"#&--:-6:7)R'+'(&-N,
M<<F@#8DUW2HM,BU-[^!;&4@)<%OD.??MT-.T[6=/U7>+*Y65D +*5*L >AP0
M#@]CT-<C;V&I0?#N#39M)NGNEO5\R LCML^T>:6)S@C;Q]:W+NSO+KQ1<;()
MH;>33&MQ>J5PCEB1@9SD?2@"OKGC*RL]/E;3+JWN+Q)$5(VSLE.\!E5^%+8S
MT)QZ5U-<!=P:N_A.V\/0^&YC<6WDAI%>)82(V5BZ$MR6P>.#R<UWP.0#C'L:
M *]]J%IIEJ;F]G2&($#<W<GH .I/L.:K0Z_I<]E<WD=VIAMANGRK!HQC/S*1
MN''M577[:Z^VZ7J-M:&]6SE8R6X8!MK+C>N>"R]A[FJ*V5]K%[JM\UD]BD]@
M;.%)MN^4G<=[ $X S@<]S[4 ;C:Q8)<64#7*B2]!:WX.)!C/!QCIS6:?%VGQ
M:W>Z;-YJ-;!/F6"1]Q;.>B\ 8'/?\*QHH=5O9?#,$FA74,>F2*;F5Y8Q@B-D
M^7YOF7."3Z=*U[B2^TKQ!?7<>E7-]#=PPK&;=D^5TW JVYACJ#GI0!K7^JV6
MF"/[7,4,I(C149V;'7"J"3^55;CQ#8IH%YJ]M)Y\-LC$@*P.X#[I&,@YQVXJ
MAK\<\]W82OI%[-$D;,9[*Y$<T#G'RX##<#WQD<4:=INI2^%M3LKPR">Y\Y83
M<,AD",N%\PIP3[^F* -'1=?LM<MTDMC*',2R,KQ.H7(Z L #^% \0Z6U]]C^
MTD2^;Y()B<(7_N[\;<^V:@T*[O\ [/:6-SH]S;>3;JDLTDD90. !A<,2P]\5
MRDVG>(9?L;W%CJMW?P7D=Q<,;Y%MBJR9Q&FX*>!D9 ([G/4 [&]\1Z7I]XUG
M/-(;I5#F"*!Y'*G^(!0<CWJ677=,@TV+47O8_LDQ"Q2+EMY/0*!R3P>!SP:H
M1V][_P )S<7C6+BS.GI"MQO3!<.S$8SG^+T[5AZ9I&L6>C:1.^F/)=6%U.[V
M4LT9++(6(9&!*[ER,9/]Z@#<TWQ NI>([FR@D5H([9)#&\31RQ/N((<-SR,$
M<#\:M:5JL>I7^HI%=)(D#HHB\IXWBRO.[<!G)!(QVK+LAJK^+;K4YM":WMWL
M_)1C-&9&96)&X \9S@<G&.<57T3^V8O%VJWUSX?N8+;4?( =IX6\KRT()8!R
M3U[9H V+CQ5I%M<SV[SRF6W.)U2WD;RAC.YL+PO^UTJW?:Q8Z?;PS33%A.0(
M5B0R-*2,_*J@EN.>*R(K?4/M7B=VTV11<@?9CYD?[[$6SCYN.1_%CK5&PTS5
MK#3O#]__ &>\MY861LY[(S)NP0HWJV=N<H._(/48H Z+3-=TW6))H[&X,KP8
M\U?+93&3T!R!@\'CK6C7)^$7GN-9\1W5S:K;2O=1*T2.'52L2\%AP6Y&0.F1
MUKK* .<CU77-2M9;_2[6S^RJS""*X9@]P%)&<CA,D<9!]\9J[)K]O:6UH;U)
MH[RXB$GV.*)II5X&[Y4!. 3C/2LJR.OZ%9OID&D?;TC=_LUTMPD:;221Y@)W
M C.#@'.*?-:ZMI^NKK$=@NHO/9);W$<#JC1NI)RF\CY"2>,YX'6@#0E\4:/%
M9V]T;IFBN)3#%LA=BTG]S &0W!X.#3+?Q;HMRDKQ73E(HFE9C!( 57&[&5Y*
MY&0.1GFL4:+JWVFSO&LE\R;6?M\\*RKMMT\HQ@9_B;D,<=ZAFT76DM56+3UE
M91J4.//4<3R!T?GMZCK0!M)XVT&1D NI0'"L&:VD4!&.%<DK@(2<!CQ5V_U^
MPTZY^S2M/).%WO';V[S%%]6V [1]:Y2Z\/:U+97$26:DS:1;6X4S+A)8G)*Y
M]P>O2MC9JVCZI?W-KI4FHQ:@R3';<(CPN$"[#N(RO P1G&3Q0!H77B;2+."T
MGDNBT5YQ;O%&T@D/]T%0?F/8=35K3=5M-5CD:U:3=$^R2.6-HW1L9PRL 1P0
M:YNST'4=.@T")8$G\B_EN[G;( L(D6084'J 9>W7:?6M+2K*_@\5ZY=SV^RT
MNO)\E_-!SL7:?E[9_I0!OURD^N:O>7^IPZ4^GI)I\GEK:7()DN#M!SD$;0<\
M<'..U=77%ZU8ZIJ1O+>Y\,6MW.6<65^DJ)Y2$_(6).]6'^SF@"Y?>(I],U_2
MX;P.L%Y92.;:&W:603*4.!M!)X9NW\-;,&LV5SIDFH1/(8(MPD'E-O0KU4IC
M<#[8S63_ &;J47B70YS#]I@M;%[>>Z:0!M[;?FVGD_<_\>JH]CKYL-<%O;_9
M9KB_6>,1SKNEBVHK*K#[C$(<$]-WXT ;^G:W9:G-)!#Y\<Z*',5Q \+E3_$
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MSM1NODWLUM!N5!GN20,]>!DUA-H^MCPA9V"VMJ;V&\2=E^TD)M6;S?O;<Y.
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MI):WZV,5G<O;1QM &#E0,M)GG:2>-N.,')K+T;4)+?P/X>L[6:Y6]N8,HMI
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MR9Z9YZB@#I**R_#FHRZMX<T^_G"B:>%7<+TSWQ6C,C20NB2-$[*0LB@$J?4
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M7+ 8?:I)R1VYH [MPK(RNH92,$$9R/I5+29=/N;%;G38T2"4G[L7EY()!R,
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M3]3LK6>YBO)XD7$1^568 Y'4'!('OBMBSU%;NVDG^RW<"IG*S0E6.!GA>IH
MK6_AO2;2]6[@MF25'9T'G.45FZD)G:.IZ"GIH&F1V]_ ML?*U!F>Z4RN?,+#
M!/)XX],4RTU^VNKV*T:WN[:69"\(N8"GF =<>X]#@U4F\7V44UT@M-0D2SD,
M=U*EN2D&!G<3W&"#\N3CG% %VY\/:7=VEK;36N8[0 0%9&5HP!CA@0W3WYJQ
MIVEV>DVQM[& 11EB[#<6+,>I))))]S5:_P!=M[*2*"*&XO;J5/-2"U4,VS^\
M<D #ZGGMFJ7A_6Y-0AUJX9KB>*UO7CB1H-DBJ(T8IMP#D,S#GD\=: -]T61&
M1AE6!!'M6+#X/T"WEBDBTY$,1!50[;"1T8KG#-[D$U8T"]6_L)95N99R+F9&
M\V,(T9#GY"/]GIGOBJ4/C&QG(<6E^EIYODO=R0;8XY-VW:<G/WN,@$9[T 7-
M0\-:1JEU]IO+-992H5CO90X'0, 0&_'-+)X<TB72XM-:QC^QPOYD42Y41MSR
MI!R#R>GK3+_Q!#97C6D5G>7L\:AY4M8M_E*<X+9(]#P,DXZ5:TG5;;6M/2^M
M/,\ARP0R(5+8."<'GJ#0!'8:%INF13QVEL(Q.,2L79F<=!EB23U/>H+;PKHE
MG=+=6^GQQSJP8.&;.1P._I6Q6'H6I/?ZGK"2/=(\,R+]FN(U4P@IQM*DY#=>
M>: )+OPKHE[=R75Q8*TLIW2$.RB0XQ\P! ;\0:UD18XU1%"HH 50, #TKFQX
MVM&F:%-,U-Y1,]NJB%?GE7J@.[&< G/3'?/%$_CG384A=;:]ECDM3=[XXAA8
MU)#ELD$;<<_IF@#I)(TEC:.1%='!5E89!!Z@UG:=X>TG2IO.LK*.*3;M#Y+%
M5] 23@>PJK:^+-/N+6]N)4N+5+1$D<3QX9D?.QE )SNP<#KGC%2V7B&.ZO8[
M2XL+ZPEF#& 748 EP,G!4G!QS@X/7B@!)_">@W5Z]Y-ID+W+MN:3G)/KUK9K
MCO$?BQET'4Y=-MM1V11.(]1BA4Q"1?3)R5R,%@I'7GO5W7-8FL-#L9KD74!E
M> SW-NBLL)+ID,"PX8G;QG@F@#>N[2"^M9+:YC$D,@PZ'H15/3/#^E:,\CZ=
M91V[2##%,\CK5R[G-K:R3+!+.4&1%" 78^@R0/S-9^F:XNHO=0/8W5K=VRJ[
MVTP7<5;.T@@E3G:1UZB@#6K.U+0=*UAT?4+&&X=!A6<<@>F1SBLGP]XFOM4R
MEQHE_'FZFC\XK&$C"NP ;Y\Y  !P.HJY?>(OL][+:V>F7FHR0 &X-L$Q%GD
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MGCV_&M2P\00ZG<A+6RO6MRS*MX8P(6VD@D'.<9! .,&M>@#!NM.U>TU6ZO\
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MU*NH93U!&10!S'@=8$L+U+:&!(EN2 ]K*SV\GRKS'NZ#L0,C(/-=12
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M;@06QGCIGG/;JJY:VL_$6B6QTO3H;.[M03]FN;B8HT*DD[70*=^,\$$9&.E
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M,T"EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBFNI;&&Q@YH =1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !129!.*6@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HJ&>ZAMEW32*H[9ZU6_M>T_OM]=IH OT5'%/',NZ-U=>F5.:DH *
M*** "BBB@ HHHH #GM1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5/4;W[#9--C<W1%]6/05<K
M(U5?,O;-#]Q2S8]QTH S8K=W8SW3F2=N>3POL*L&/(P35E(T/)'?G%'E(1T8
M'/% &>0]D_GV[D%3EESPPKHK>=;B!)4.589K+G@A^R2G8Q^4\FIM!&-/ _VC
M0!J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%(!@FEH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.HPNZ).BEGB.[:.X
M[BKU!Z&@#-BGBFVE1CC...:G!7R]V.@ZFF2Z8C,7@<PL>NT<&HGL;R50KW,>
M!_%LR: *VH7.^$0PC&XX SU-:5C;?9K..(]1R?K3+738K<[RQDE_OL/Y5=H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **0*%S[TM !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12#..:6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,T %%0RW4,!
MDD"D]!WJ-=0M7; E&?<$4 6J*0,",@Y![TM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !56[G>-4CB(\V0X7/;WJU6=-SJB<9V1GKV)- !#8(HS*?-EQ
M\SD\TKV$3D_)CCIFK8)VDYZT@X^M &5NFTNZ5"Y>W; )(Z9K:4@J"#D&J.JI
MOT]\]L&IK!MUC">^V@"S1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;J*
MF*2.Y'1<HWT-:5-9%="K*"#U!H II,V "HSC/6I/,PF2.V>M0&RGA)%NX,9Y
MV.>A]C4;6^HR/]Z*(;<9SN- #-4NE>%((R2SL!6G;1>3;1Q]P.?K52VTF&%E
MDD+2S YW,>_TK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,4 +1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>articles003.jpg
<TEXT>
begin 644 articles003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/=ZC.$2TM26*D[CC<0WRJ.3QG@5I^,;;08?#%S9:=J-H+FU@M/MBRH?.U&-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BB@]#0 $XHS61)>7%V^;=_+MP<!MO
MS-]/:F_9FW[I+JYSCINH V<T5S[75W83',AEBR,J_7'UK<BE6:)9$.0PH DH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJ4A2QD"G#.-H_&K=4=57_0R
MX&?+97(]0#S0 Z%(XT4+T5?E^E28!&,<>A%11S1, <J>.#GJ*F\U.,LO/O0
MRXMUN+9HVY.#M]C5+1'(6:$]4(-7GN8HT9BZ\#IZU0T56=KFX(P';"_2@#8H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH S];UJP\/:1<:IJ4WDVD !=\$GD@
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MTGAB^O6OY&M9+DQ)9[1M1P%)?/4D@@8XZ=^P![%1110 4444 %%%% !1110
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MX28!=S$EB01T_B_2O0J* .!\1?"VSUK7+K5;/6-0TJ>^C\J]6U;Y9UQC!'T
MSVJ6_P#A;HUY#X:@6XNHH-!8F% P8RY96.XGW7MCJ:[FB@#FV\'6C>/1XL-S
M/]I%I]F\GC9CUZ9JEX(^'T'@:2\%GJU]<VMP<K;3,-D9]0!_%T&?05V-% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7EB\:XF+^86\L-^&)3CZ"@#Z%HKYA\16L\/B#7-7U2.XUBV6\)CU?2]0P]F
MQPN.0,9 P0,=CWKZ.T/4;?5- L-1MI9)+>>W219)@ Y!'5L<9]<<4 <[XQ^)
M.C>"=3L+'4H[EWNQO+0J"(DSC<V3GUZ9Z&NQ5E= ZD,K#((Z$5\PZ_J/_"8>
M)?%FJC0=2U2WDB-GI]Q:0&2.W*$88D=,[<]>CFM#5/'6HZE\(M#L8[B2W*W?
M]GZA,K;6"HH* D= 5Z^NP^] 'T:[I%&TCL%1069B<  =ZS/#WB+3O%&E#4M+
MD>2U,C1J[(5R5."<'M7F:^"O"^B:CJFD:;XGNA'?:7(6TE9BQ8@;O,WC@<+T
M(Y&>QQ4_P"TNTM_!T^I12R-<W4Y29#)E5V?=PO8X/X\4 >M4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP7%JC:>VJ-YBR^27%O(4W9QC=CU[]*GUGXH^$M U6ZTS4=1:*[M0ID00.W)
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M4;[,6"2LV4:08PXV<=_3VKT'X0K%=>-]>U*UU,7L;VZI,]OIWV:W9\K@KSU
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M@O16TO3YKB6%IFF+3L"V3@=@., 5OT44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %1M;PO,DSPQM*GW7*@L
MOT/:J>O.\7A[4Y(V9'6TE*LIP00AY!KP'X<>-+VQ\-:MH&J33+%>Z?<W&F3R
M.?OJKAE![9*DCW!]: /HXC(P:9%#%;QB.&)(T'144 ?D*\>\$>-G\-_#SP7!
M+937IU6]EM/-\TCROWY /0[CSP..AYKJ]<^(\>C>*[_0_P"RWN/L>F2:@TT<
MX'W5+;"N.,@#G)ZCB@#I=>T6/6O#=]HRR"VCNH&AWJF=@(QD#BHO#7AVW\-Z
M%8::C+/)9P^4+AHPK,,D_@,GIFO.!\<Y4TJSU>X\'WL>ESR&)KI;@$!QGA?E
M&[@=]O.1VK?\/?$F;6O$T_A[4] GT>\-J;B#S9PYD7&>0%&TXY[]#0!WLUO#
M<ILGBCE3.=KJ&&?QI7BCE $D:N%(8!AG!'0U\^_#[XCZKX8\"/++X>O]3T^&
M[8S7_P!HPL0;;\HR#GDYZ@9;WKT/6_BG#:WNF6&@:-<:Y>W]JMXL,<GE;(F&
M02<'G Z=J ._EABGC,<T:2(>JNH(/X&A8HU<NL:AR I8#G Z#Z5YW+\7;$>
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M WJ*P/\ A%H\Y_MG6_\ P.>C_A%H_P#H,ZW_ .!ST ;]%8'_  BT?_09UO\
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M 4444 8^G_\ (R:S](/_ $$UKUD:?_R,FL_2#_T$UKT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5R_Q%&?A_K _Z8C_T(5U%<Q\1/^1 UC_KB/\ T(4
M=,GW%^@IU(GW%^E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <K8'_ (N9K _ZA]O_
M .A/755RE@/^+G:Q_P!@^W_]">NKH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#F?[2&F>)-2^T6EXR3)"8Y(;=I%;"D'D#BK?_"36G_/IJ7_@%)_A6U@#M2T
M8G_"3VG_ #Z:E_X!2?X4?\)/:?\ /IJ7_@%)_A6W10!B?\)/:?\ /IJ7_@%)
M_A1_PDUI_P ^FI?^ 4G^%;=% &)_PDUI_P ^FI?^ 4G^%'_"36G_ #Z:E_X!
M2?X5MT4 8G_"36G_ #Z:E_X!2?X4?\)-:?\ /IJ7_@%)_A6W10!B?\)/:?\
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MFI?^ 4G^%'_"36G_ #Z:E_X!2?X5MT4 8G_"36G_ #Z:E_X!2?X4?\)/:?\
M/IJ7_@%)_A6W10!B?\)/:?\ /IJ7_@%)_A1_PDUI_P ^FI?^ 4G^%;=% &)_
MPDUI_P ^FI?^ 4G^%'_"3VG_ #Z:E_X!2?X5MT4 8G_"36G_ #Z:E_X!2?X4
M?\)-:?\ /IJ7_@%)_A6W10!B?\)-:?\ /IJ7_@%)_A2_\)-:'_ETU'_P#D_P
MK:HH Q?^$EM?^?34?_ .3_"C_A)+7_GTU'_P#D_PK:HH Q?^$FM",_9=1_\
M *3_  J/_A+; ,5^S:EG&?\ CQE_^)K>HP/2@# ;Q;IZ=;;4OPL)3_[+2?\
M"8:=_P ^VI_^ $O_ ,3708HH Y__ (3#3O\ GVU/_P  )?\ XFC_ (2_3>/W
M&I#)Q_R#YN/_ !VN@HH Q!XJTPKG%\.,X^P3Y^GW*%\5:61G_31R1S83_P#Q
M%;=% &+_ ,)1I?K>?^ $_P#\11_PE.E>M[_X 3__ !%;5% &+_PE.E^MY_X
M3_\ Q%'_  E.E>M[_P" $_\ \16U10!B?\)5I7K>_P#@!/\ _$4O_"5:5ZWO
M_@!/_P#$5M44 8G_  E6E>M[_P" $_\ \12_\)3I8[WG_@!/_P#$5M44 8G_
M  E6E>M[_P" $_\ \11_PE6E>M[_ . $_P#\16W10!B?\)5I7K>_^ $__P 1
M1_PE6E>M[_X 3_\ Q%;=% &+_P )5I7K>_\ @!/_ /$4G_"5:5ZWO_@!/_\
M$5MT4 8G_"5:5ZWO_@OG_P#B*Y_QMKMGJ7@W4K*RCO9KF:,+'&+&<;CN!ZE*
M[NC% &$GBG3M@!2]SC_GSE_^)I__  E.G?W+W_P#E_\ B:VJ* ,7_A*=._N7
MO_@'+_\ $T?\)1IY_@O/_ .7_P")K:HH Q?^$HT_^Y>_^ <O_P 31_PE&G_W
M+S_P#E_^)K:HH QO^$GT_P#N7G_@'+_\31_PD^G_ -R\_P# 27_XFMFB@#%_
MX2?3Q_#>?^ DO_Q-0_\ "9Z-WGF'L;=_\*Z"F^7'_<7\J ,'_A,]$_Y^)/\
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M.:-9(G5T895E.01[&@!U%,CECF4M%(CJ"5)5@1D=13Z "BBB@ HHHH ****
M"BFNZQH7=@JCDEC@"G4 %%%% !1110 4444 %%(65652P!;H">M(\B1C+NJ@
MG&6..: '444A(4$D@ <DGM0 M%10W$%QGR9HY-O78P./RJ6@ HHHH **:KJQ
M8*P)4X8 ]#3J "BBB@ HHR,XSS10 444=* "BD5E= Z,&4C((.0106"XR0,G
M SWH 6BD9E12S$ #N32>8@D$9==Y&0N><>N* '4444 %%-=UC7<[!5Z9)Q3J
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT 9+76J6GQ;CO_%4-DATW0I[F.6Q=MCJ&^8X8Y! +#!^M$7Q;O8M/MM>O6T
MZ5/,%:PM[LM?0QDX#$$X)'4C X]*VHO"/B/6?$TFI>)Y-+%K-I4VG/!8-)\H
M<@YRPYR,^F..M8]G\-];@BM=%-GX9CTZWD7.JI:!KR6,,2 592-QP 3GOWH
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M-:++@:W-;(]SY);."A4@N,XSG'3ZT >E>)-4N=+\*ZAJNGPI<36UN9TC?.'
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MG<+)(O R5',9&2#@\GOUK9E\+:_X=\0PZUX>CL+\R:?'8W5O/BV&4Y$B;!M
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M2"SM*H&!P!M_PY[^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#"\7>)X/"6B?VE-;373-,D$4$/WI'8X 'ZUEP^.IX-:L=-UWP[?
M:0;^3RK:>26.6-I,9"DHQP3VK'^)UO<:[KGA3PW9W@M9Y[Q[PS&,2",0H2&*
MG@\D\'C/6L2^M]3T;XE>&8]>\1IXD4&:00&W$+69"Y\[8A(/3@M[X]0 >Q!U
M()##"]3GI2/+'&H9Y%4,< DXR:\4_M-+3X&ZA?%@NI^)[N=XX=^6DDEEVD#I
MT0>U2^*M'AGU!;F&"#Q#IGAW3ET_4-,>9HI;=@H;SHST+;>_^R1UZ 'K6I:A
M/8R6*06$UV;FY6%S&0!"I!)D;/8 =N:NB2,E0'7+?=YZ_2O&5U"WL]1\.RV-
M]=W&GZ)X<N=522[?]X1("J*V.,@':..GK63-X.M=(\%^"KH"=_$-_J%LL=PT
M[YB1R7*JN<!0,=!G))H ]\:1$V[W5=QP,G&3Z4KNL:EG8*HZDG %>$ZBEWXC
MU+Q7K&JZ39W]M87$MG ]WJAMQ8)'P&$84\G[V[.3T%:%SI.I:_X=\+::;RQU
M?5-,M/MEQIES,ZQWL3Y6-MW&2H'<]3SUY /9@RE X8%2,YSQBD21)4#QNKJ>
MA4Y%>)6UGI6N^"ET'P_=S6%S?ZE)<II.I2GRR8<>; KH,A.01SGCZUU?PTM=
M/AU#73::?=:1=0R1P7NE^<LEM'(!D/&0,\B@#J/$_BFR\+6,4]S'-//<2"&U
MM;=-TD\AZ*!_6LBR\<WD6KVFG^(O#EUHOV^7RK*9IDF21L9"L4/R,?0_G5'7
M6C7XT^&SJ+*MH-/G^PER /M)8!NO?9MQCG-;'B#Q7IEEJUOHXMC?ZF8I+J.*
M-!(+?RT+!WYRN>@QSS0!TYD0.$+J';HI/)H>6.,$NZJ ,G)Q@5X7=Z1I4WP?
M?QAJ$LDOB.]_?PWK3-YBSF3"I& > ,=![^G&W:^'XO''Q!U!_$*R36NE:9:V
MDT(D*+),R^8VXJ1G:23CUQZ4 >L-+&GWI%&6V\GOZ?6E=TC0N[*JCJ6. *\#
MT_2/#NL_#WQ5XLU5C)/+<7'V/?,5$!48B"#(RWW1R,D #USNZ%9-XN\1VNB^
M+1)/#I&C6LWV25V4/,ZJ6>3IN(Z<^_O0![!O7:&W#:>ASQ3?-CVNWF)M0X8[
MAA3[UX(6-_H>H^%]+N)(]+U+Q,MII[*Q8)$I#R%.?NJ5!':MS7/#NAQ>([?P
MKI&A7&H/;0MJ-Y!/J9@@E+83?*Q#,[?*#@8 R?4T >GZ[KUCX>T&ZUF]<_9+
M=-Y,?);)  'J22 /K0NK2/J.GVR:?<F*[MVG>?C;#C;A6]SG]#7@UM:0:MX.
MCTDP01V]_P"+UM[>""9I$@C"@.4+')&,\^_05K>(KM]&UGQ;/H@%I#I]K9Z+
M;RHQ"VPE;<[*?5>>XP2* /=%D1F95=2R_> /(^M!D1?O.HYV\GOZ5Y3J'AO2
MO"'C/P9;>'4DBU"XN76Y?S69[B +EVDR<'UZ?3I7*WNBZ?J/PW\3^,M16::Y
MO-0FDT[]\VV/,H1650<$DYYYX ]* /H!Y$C7<[JHZ98XH5$4L5506.6('4^]
M>1^*])GU+4+*80VWB%-$T](=3T:6Y:-T=EW><OJV/7TXYZ=I\.OL \#6$VFW
M%[)82AY(?MS!I(UW'Y"1V!! H L>,O&%CX+T8:A>1RSL[^7%!"/FD;!)^@ !
M)-:^E:C%J^D66I0!A#=P).@;J%90PS[\UX_?ZAJ_BWQ7?ZW9^';G5]%M8IM-
MTV2"9(P'8%9)AN^]W (XQCO4>F:G<ZE\._!/AL3/;1:E=R6-](AVL(XF.8P>
MQ88'_P"N@#V>ZOK>RL;B]GE5;>W1I)''.T*,G^50:+JL&N:-::I;)*D%U&)8
MUE #;3TR 37D/C+1/#.A^&_%-GX>FDWLMK:S:<)&:))WE!5P6/W\ Y&>W->J
MZ3HMGX8\-C3],B$,4$3$!23EL9+<YZGF@!=(U^'6M0U6WMH9/(T^<6QN21LE
MDQEU7O\ +D GU/M6=X?\=:9XB\1ZKHMK',D^GL0'<86=5;8S)[!N/Q%<;X9U
MW_A&_P!GZ'5D.;MXYO*[EYWF=5X[G)!_ U@);Z[X)L?"6KW?AN2QM=#+17]U
M]JCD,D4S .=BG/!8D>AH ]+U?Q]9Z1;^))I+*XD70F@67:5_>F4*1MY[;AG-
M=7%(LL2R+T8 X],C->*^,W631?BE(C!D:;3RK \$%8N:TVT?3?"'BKPA/X<\
MSS]165;I!<L_VM/*W!F!)_BYR.,T >LY&[&1GKB@D#J0.W-?.5E8:EKG@^?Q
M3/8VZZH9GE;79=9,3P.K\*8MI    V]2,>HKK[+P]:^+?BG?GQ #.]MIME/Y
M<$[+%YI4$D8/(SG'/0F@#TK1?$-CK[ZBMEYA_L^\>RF+K@&1,9QSR.>M:F00
M<<X]*\(T^TT;0_"OC^X*WEO_ ,3R2P0V$I64QB1-L:DG !Y!)YP3UZ5>\.V4
MF@_%;0+6WT(Z!%>6MP9;8:B;EIE"$JSCHI!''_UJ /4_#GB&W\1V$MQ##+;R
MV\[VUQ;S8WPRH<,IP2/Q]ZD?7K%/$L?A\NQOY+1KP*!P(PP7)/J23CZ&N4\.
M.;?XN^,+2$YMY(;6XD4=$E*8_,CFLG6=,LG^.PNFM5DN(O#_ -MA!9N9TE*J
M< \_*,8H ]4HKPN/1K"Z^$4WCB:]NO\ A)"CW/\ : NV#I*)" @ .T#HNW'>
MO5I]4OXO +ZL(=^HKIOVCR@-N9?+W8QVYH WJQO#'B.V\4:7)?VL,L4:7$D&
MV7&24.,\&N!\.^&O#UOX<\->*9]9N;;5[EX9)+_[0S-<RO\ >A8$D$$Y7IVK
MD+7PY8+\*];\3H;E-7L]0EDMIUG8>25E4?*H./KQF@#Z&HKQ_78;+Q-XOOK8
MZ1J'B"YL[6$31R7XM;2R+INR"#DD]2<'I[5SVG"3Q%H7P\L;F_GVR:A>03-%
M<-OV*?N;@<_<XSZ&@#Z!HKPCQ'-/X$G\9:/X=DFMK-K*UN(P)68VY>01N4).
M1D-U[8%=&?#>C^&/B+X,CT:[N%6Z-RTL#7+2+-BW;$I!.-QSU[]NE 'JE%?.
MUK%JOB/P[J7B>?2[B75O.D:/61K"6ZV90X"B,L-JCN#U!Z\U[K8*VK^%;9-3
M\J9KRR47/DO\CET&_:RGH<G!!^E &3_PG^E/H.FZS;P7MQ:ZA?"R@\J'+%RS
M*&(S]W*GWZ<5U5?.UCIUDOP/T26U\V&XO-:A%S+'*0VX2.H*\_*0N.F*W]:$
MGP\\4ZW:^&_M*P/X;:]\AIFD"S"79YHW9Y RQ_&@#VJBO!].TW5M*?PUK-AI
M<MC=7-U;K<ZA=:XDB7ZN/F7:6Y+9R, D8KT3XLRR0?"_6Y(I'C<1QC<C$'!E
M0'GZ'% ':45Y&N@IX.\:^#)].O+PRZL9(M1\ZX>07!$0.XAB><DFJEQ?R?\
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M>RDM0D,:!OEP_4N!D,/<?A)?>/+V/QOX@T.*VG6*QTTRPR+;E@)=A?>[=EZ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .)\8Z3J]OXBTGQ7H5D+^ZLD>WN;/S AF@;GY2>X/.*ABUKQ7XEUS3([
M/1;[0M*MYO-OI[X())E XB5.>#QD_P"'/8ZEJEAH]DUYJ5Y#:6R\&29PHSZ<
M]_:LG0?'/AGQ/</;Z/J\-S.@R8L,C$>H# $CZ4 <%:V?B/P]X$U#P+!X;N[R
MX?S[>TO49?L[Q2LQWNV05(#'C'4"MGPSX5U+1/'VGR2PE[*U\+Q6#7((VF99
M02H[] 3TKT6B@#QL>%-=_P"%.+I7]FS?;UU7SC!QNV>?G=UZ8Y^G-=/I>B:C
M#XF^(%Q):.L6HI"+1SC$N(64X_$@5WM% 'D\/AC6AX'^'MF=/E%SIVKV]Q=Q
MDC,,:LY+'GMD5+8IXC\'VWB#1;?PW<ZG)?WL]S874)7R")<<2DL"F._K^M>I
MT4 >8>&O!VJZ%XH\*"6#?!8:-+!<3J0465GW;??[WZ5O>!-(O]*O?%3WULT*
MWFM3W-N20=\;8PPQ767-U;V<!GNIXH(@0#)*X502<#D^I(%5XM7L)M8GTF.Y
M5K^WB6:6'!RJ-T/IVH Y7Q%=>(])\22W']CR:_X<N;=5-K"J&2VE4GD*WW@V
M?_U8YX]?">I7>G>--2LO#;:/;:CIZP6FEC:KR.O)?8O"GT'O7L]% 'GM_P"'
MM5D_X5YLM&;^RWC%YAA^ZQ" <\\\@CBN(U/PUXFU;3M7M=3T?7M1UZ22412R
M7NVP6/.59!N SCHN.N,]Q7O-9S:_I4=Y?6LE[%')8HLET9,JD*MRNYS\HR.<
M9S0!Q?AC0-5M?'&DZC<V4D5K#X5AL9'8K\LXD!*8SG.!7+77@J[TG7?$1N=
MUG5!?W+W-A-I]Z8HV+\[)0'&W!/WB#7L(U>P.M?V.+E?[0^S_:O(P<^5NV[L
M],9XJ[0!X]J'A*XMM$\.VFI^$3<VMK:,)'T>5OM5G,7W84L_S+SZGG)Z=>R^
M'%GKMCX9DBUYKKS#=2-:I=S"6:.W.-BNPZMU_/MTKKZI7VKZ?IDD,=[=Q0/,
M',8=L9"*6<^P &2>G3U% '!6PUOP5J_B6*W\.WFK0ZK>-?6<UL5*^9( "DF2
M-@!'7GBJ&@^"=8T2_P#AZDMN9/[/-_)?NC I TJY5?S..,]*]$U3Q+HVBZ5'
MJ>I:C#;6D@#1O(3E\C(VKU)QV S3-!\5:'XG@>71=2ANUC.'5<AU^JG! ]R.
M: */Q"TJ\UOP%J^G:?#YUW-"!''D#<0P.,GCH*P-%L-4OO'6@:W/I5U96\6A
M-;S"< &.428VGGN!D>WI7HM% 'BFI^!-;O\ 0M>VZ?(\\?BN;4X;8R^6;J X
M'RL#QD$X.<\>M;/A#PZ/^$YBU6V\.:G8V5M:NGVG5[EVG,C<;44N1MP3R1^5
M>I44 <5X[T35)]1T+Q'HEI'>7^C3.QM6<(9XG7:P#'N,<?4]>E59==\6>);W
M3[+2]#U'0K=+A9+Z\O1&"(QR40<[B>1G'''K7=75S!96DUU<RK%!"ADDD8X"
MJ!DD_A52#7=+N9[."&^A>6]@^TVR!N98\ [E]1@B@#S^P.O^#9?$NFQ>&KS4
MSJ6H3WUC<0%#"WF@#;)D_)C'?K1X0\&ZKX>U_P +Q74(EM['1YTDG'(CGDEW
M%,^P; QU ->BZAJEAI44<NH7<-K'+(L2-,X4,YZ*,]S@U;H \ETSQ-=:=\0_
M':6.@WNILTMN$-J@.V01%0')(PI(//;!]:@T?PGKG@@^$M2;39M26QM)[>]@
MLR&DB,KEP5!(WX+8./2O2[32M&T?6;R[MUBM[_5W5I<R\SLBG[JD]@23@>YJ
MY8ZE9:DLS6-U#<""5H)3$X;9(O53CH1Z4 >3:QX?UWQ'IOC+6&T::U;4UM+>
MSLG $SI'(I9W )P<>_0'\>A\?VNM2:KI$=NFLG0%CD%TNBN%N-^/D!.0=O\
MGTKT*B@#Q/2/"&L);^/(XM%OK6+4M.1;&.[F$DDA"L,,VX_-GMGC(JU-X=UG
MQ&GA:(Z7=V*Q:'>:?.UR@'DN8?*4M@]">1WQ7HUGXQ\/ZA<?9[75(9)=DLFT
M!A\L;;7/(['\^HR*U;*]MM1LH;RSG2>VF4/'(AR&'J* /)K^V\1:U\.[3P#_
M ,(U?6UXJP6D][)M^S+'$RGS%?/S9"#C&>371:#H>HVVM>/&EM9$COG06KM@
M"7$1''XD5WU% ''_  MTV^TCX<:38ZE;R6]W&)=\4GWE!E<C/X$5Q-KX3UNW
MN;0'3Y2D?C:2]++&$'V?:H$FT=%X->S5%+<V\$D4<T\<;S-LB5W +M@G"@]3
M@$X'I0!YKJWAS6;[X@^+)8+23[)J'AQ[2"5CB-YB %7/KU^E9VFVFN647@O7
M3X=U%FT6VDTV]LP@$V"BJ)8QGYE_+^M>JV6J6&I/<I97<-PUM*89Q&X8QN.J
MGT-6Z .'\+V%]J/CG5_%EWI]QIL$UM'96UO<J%E=5.6=U!..>![5F>-[?6[C
MQE")HO$+^'A9?*-"<+(T^[D2'(.W:3QGT]Z]+JJFHV4NHRZ<EU$UY"@DD@##
M>JGH2/2@#AOA1HNHZ-:Z\NH:;<6'VC43-#%/+YK;"BX^?)W'L3ZYI6&H^$?B
M#KNJ-HU_J6GZS' T<MD@D>*2-=I1@2, YR#T_7'H5% 'C/A[PYKL>F^&/M6D
MW$$L7B.:[GC(SY49!^8GT]^]6=1\.:S/\+K[3X].G:\?7'G6';\QC-QN#8],
M<_2O6W=8XVD=@J*"69C@ #N:AL;ZUU*RBO+*XCN+:49CEC.58=.#0!Y/XI\/
M3Z9\0]1URZ7Q))IVHP1B.70IB)(Y% 78X!!VG&0>E1:5X2U*UM_"DL>CW=N3
MKTE_<I-*99(T*@!Y6[$A1G_&O9:* /)/&FA7%I\19-?N(->?3+FQ6$W&ARLL
MT3J?NL%Y*GC\?I6?IWA/54L="N4T:_A$GBE+^6.YG,TJPXQYLOHQYS^&:]<U
M76]+T.W6XU74+:SB9MJM/(%#'T&>M7D=9$5T8,K#((Z$4 >;^(=!U*\\?:_-
M:V4A@N_"DMHDH&$DG+G:N?[V/TKH/AU-*_@32K>XLKJSGLX5M98KF/8VY %)
M [@]C70P7]I<W5Q;07,,D]L5$\:."T9(R-P[9%3.ZQHSNP5%&69C@ >IH \T
MTO0=5@T_XE)+8.C:C/<M:!5/[X-&V"OKG(_'-9-K!J?A:[\&:[<Z)J-S:6VA
MBRN8[2'?+#(<$93@^@_.O2+3QAX;O[_[#::]IT]T3M$4=RI9CZ#GG\*VZ /#
M7T/Q+J<.IWMSHEY#+=^)K6\2%D!98%!Y./[JE03ZUWMEIUY'\9-3U![:06DF
MD11I/M^4L).5SZ\=*[6B@#Q--'US3]*\/7*Z'?7#V/B&ZNYH(H_G\K<3N /J
M.GK5C6?#^J_$*Y\2:Q96%S803Z5'86:7L?E27#I,LI.TGY1\NW)]?8U[)10!
MXEHFCG4M:\.P1Z;XK>>PGCGNUU:[=;>T*?\ //(PQST [>G.._\ A[I\^GZ3
MJBW%L\$DVKW<N'7:6!D.&^A '-==10!P/BJ.]T7Q]I'BI--N+_3TLY+*Y%M'
MYDD&6W!PHY/H<=L^M<MJ^EZKK6C^/_$":3>00ZK;VT=E;2QXFD6/&6*#D9].
MM>SU7O;^TTVU:ZOKJ&VMU^]+-($4?B: &:;"T6CV<,J[76W1'4]B% (KS7PY
MJ5U\,[.Z\/:EH.J75K'<2RV-WI]OYRS1L<@-@_*PSC!_^N?0]*\0Z-KH<Z5J
MEI>;/O""4,5^H'(JW:7MIJ$'GV5U#<P[BOF0R!UR.",CN* /+M7MO%^MZ58>
M(=0TPXL-:2_ATI5'GK:J,8/.&?OCK_*EU WGC?Q3%JVGZ1J%M9:;I=W$TEY;
MF)YY98RHC53R<9SGIU_'U>B@#R"ZT6_?X0^#;--.G-U!?6DDD(B.^,;FR2,9
M'7GZU9\6:;?2^+O&$T=E</'/X6:*)TB)#OD_*".K>W6O5J* /-;O2[Y]3^&+
M"SG*V<;"Y.PXA/D*/F].01S6#JWAO6+R\\82P6$LGD:U::@D++@7<:*2RJ3P
M>#GOR,=:]:EUG3(-3BTR74+5+^89CMFE42,/9<YJ]0!YG)?3^-_'GAFZL-)U
M&UL]),UQ=3WML8<%TVJB@_>.1VK"AT34(_V;KG3GTVX%^69OL_DGS"?M.0=N
M,]/TKVFB@"HB7"Z.L<)6.Y%N%0R#(5]O&1Z9KR34=0TW4].GL?%O@2\?Q1M:
M,RV=AD3/T5DE7M]T\GCWKV:B@#QSP]H/B&Q\:^ VU>"XEEM=+N$N)R"RQD^9
MM1FY&0&4=:CU.+7M.@\<W.GZ?<9GUB$^8+;S&$./FDC5AAB..GK[5[/4,-W;
M7,LT4%Q%+) VR5$<,8VQG# =#CL: /#].L[N]^(&F:AI[^)=1L9+"ZA>\U6-
M@&;RGPJC PN=O;DGO6C-X7U:]^ .D:?:V4ZWENZW,MLH\N5E$CL0 1][D$9K
MV6J<FKZ9%?K82:C:)>,,K;M,HD(]ESF@#R+1;-->\9Z1=6A\6ZFNGK-)++K,
MBQ1P$ICR\&/+%C@$ ]/49K-TI=0L-6TVU\.PZ[9:@;T&ZT.]C,ME FX[F60@
M!5QR",FO>ZI2:QI<4S0R:E9I*IVE&G4$'TQF@#G_ (F:-?:]X"U"QTZ,RW1,
M<BQ X,@5U8KS[ US.H:HWCW7O"UOI6DW]M_9E^E[>S75LT2VRH.8LGJ3P,#C
MI^'J=9MSXAT6SO!9W6L:?!=$@"&6Y17)/3Y2<T <U\+;*ZL/#-[#>6\L$O\
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M"UB+]D70)[>97\K)G\I=N#S\N?QQ0!:TKP9I.D:@E];B9YT\\@R,",S.'D.
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MK3[-<6\H7.T)T=1R":QAXVUJT\,^%8Q>QZ#IES9EY=3ATP31I()"HCV#"J,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJBZCD7(+F/Y@0??/6O(=.T_2-3\$?#FS\FUEBFU0+>)&%^=P&)#XZG&,Y[4
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MHI6W-%ROR$^W3\*FU'QMJLFNZCIGAOP]_:QTL+]ME>Z6$!F!(1,@[FP/P/%
M'8FVMV>5V@B+2J$D8H,NHS@'U')_.H+'2=-TS?\ 8-/M+3S#E_L\*Q[C[X'-
M<M<^-=8GM]..C^%;J62[M1<R/>O]FBM_FQL9R.7R.@YP0>AK+/Q8'_"'G6ET
M9WNH=2739[-)PV'[E& PWM0!WEKH^EV-R]S::;9V]Q(,/+% J,P]R!DTCZ+I
M4EU+=/IEFUQ*I225H%+NI[$XR1[5QMUXQOUCO]'\3:%_9T]QID]S;>3>"19E
M5"7CW ?*X!]_7Z\YI^OZU_PD'PWM=-AD73;FP=C#)>D^:!'AO,.WDH!N'')]
M.P!ZQ>Z5IVI0I#?6%K=1)RJ3PJZK] 14HL[9;3[(MO"+;;L\D(-FWTV],>U>
M?:S\1];TM;R_'A"8:-9RM&]Q=7:P2R!2!N2)ADC)XZYJ?2M0:^^,MP\4TAM)
M?#T4T:$G',H(./7!_6@#M;/2]/T\ 65A:VP"[1Y,*I@9SC@=,\T^]L+/48/(
MOK2"ZASGRYXPZY^A%9'B;7=1T=;2+2]#GU2YNG9?E;RXH0!DM))@A1_/FN<M
M/BC#%9^(?[9T];6]T-4:6*WN5F6;?PNQ@!U.!STSSW% '<+IE@L1B6QMA&8O
M)*")<&/^YC'W>3QTJ9K>%S$6AC)B.8\J/D.,9'IP<5Q=GXXU>WNXAXC\-2:;
M9SV\ES'=0S^>D2HI8B4@#:<#CUSCK46E^/-;O9-.O+GPE<0:+J4HC@N8YQ+*
MH891WC4?*I]<\=^V0#K[C1=*NKHW5QIEE-<,NTRR0*SD>F2,XJ\    , 5YO
M+\3M3>WNM9L/"L]WX:M9'22^%RBNP0X9TCZE1_0]*ZG3/%$6J^);G2[>)6@C
ML8+R.X#Y\P2%N,8XX []Z -,:3IHU Z@-/M!>G@W A7S#_P+&:6ZTK3KZXBN
M+NPM;B>'_522PJ[)_NDC(_"N'O?B@UMI\]Q!H<ES-%K[Z&L"3@&1P"5<$CN<
M#'OUJOJ/CS6VT/Q187.C'2->L-/:[A3[4D@:$Y'F*P')7Z8R .* .^FT?3+B
MS2TFTVSDMD;<D+P*44YSD*1@'DTDVBZ5<7ZW\VF64EXF-MP\"F1<=,,1GBLG
MP#>ZEJ'@;2+K58?+N7M8R&,WF-*NT;9&/8L.2.<9KSO0->GT[Q!XQ\6>)-.E
M5K"8P(RWQ?RV.T+ B<*<Y!W''\Z /7I=-L)[V.\ELK:2ZC4JD[Q*74'@@-C(
M')JO'X>T6%)$BT?3T61@[JML@#,#D$\<D'G-<WIOC?5%URQTSQ)X;DT<ZD6%
MG,+I)E9@,[&QC:V/S-2>#O&>I^+;AIAX=>TTK$BK>-<JVZ1&VE0N <>_J#0!
MU<5G:P&8Q6T,9G8O-L0#S&(P2WJ<=S4,^D:9<V,=C<:=:2VD0 C@D@5HTQP,
M*1@8KBM;UW7[;XPZ-I5G 9M.DLF>2+[0$4Y;#2'CDJ ,#OVQS7*^$/'.NZ#X
M/N+R3P[=:CI-K>S&YOS=#<JF3G:AR6 SR>G7IR: /7DT72HX&@CTRR2%W61H
MU@4*67&UB,=1@8/;%3I9VL<D\B6T*R7&/.94 ,N!@;CWXXYKD=8\>S1:P-)\
M/Z2-5NT@2YG+W26\<:/RHW-U8CG ]JVO"WB2W\4Z-]NAB:"5)7@N+9V!:"53
MAE./P/T(H SO$WAG4KR.Q709]-AMK=&C?3;ZT$EI*IQ@[1]TK@XQZ]N\G@SP
MK<>'4U"ZU"[ANM2U&59)W@B\N- J[4C0?W5'2N9CM7^(GCC7;;4;ZY30M%E6
MV2PMY&B$\G5FD92"<$8 _+'.=BPTR7X?C5;V;5Y)?"\-MYL=O<R&26"0=0K-
M_"1P!GJ1^(!U\ME:33^?+:PR2^68O,>,%MAZKGT/<4S^S;'R;>'[%;>5;,&@
M3REVQ$="HQ\I';%<7:_$6^C?3+C6_"]QI>EZE(L5O>-=))AG^YO0 % 1W/2J
MU]\4;ZVFUQK?PK/<V.BW+PW=T+Q$  .,J",D]\#IQSS0!WTNG64\DTDMG;R/
M-'Y,K/$I,B?W6..5Y/!XYI?L-INMV^RP;K88@/EC]UQCY?[O''':N-TSXBS7
MNLZ-;7?AZYL;#6@S:?>27",9 %W#<B\KD8QR>HK+_P"%N7$>GSZM-X5NAHMM
M>-:7%XETC%6#8RJ$ L.1Z<G% 'HZV5HDUQ,MK");@ 3N(QNE &!N/? XYJO8
MZ)I.ER/)I^EV5I(XPS6]ND98>A( S7,:5X_GFU[^RM<T*;1FDLFOH'EN%DWQ
MKUR /E8#G')X-48OB?<&SM]9N/"]Y;^&[B81KJ37"$JI;:'>/JJY[Y_/(H [
M&?PYH=S<27$^C:=+/+_K))+5&9_J2,FK3Z=8R&8O96[&9!'*6B4[T'16XY R
M>#ZUQEW\0-4.O:UI.C^$[G4Y-)*^=(MTL:D%=W&1DMU 49)Q^%=1X<UVV\2^
M'K+6;172&Z3>%?&5()!!QZ$$4 26V@Z-9&,VNDV$!C?S$\JV1=KXQN&!P<<9
MIZZ-I:FZ*Z;9@W8Q<D0+^^'^WQ\W4]:\BUM]/D\:ZO'\0K_5K*W68?V2\+R)
M;"+G!!08W^N:F\0:EJVB^ _#=RNNMKF/$,(BN+.7+W4 WE8V(^\QQ@CUP.U
M'J>GZ#I&DP30Z?IEG:QS9\U8H54/G/WL#D<G@^M8'BGPG?>(?L&C0RV-IX73
M8UW;)$1))L8,(UQ\JIP.F",4W1_'4USK.HZ1K.AS:7?6=I]M$2SK<>;%W*[!
MU]N:IP_$6^CO-+;5/"MUI^FZI.L%M=27*,^YON;X@,KGZ\4 =Z %  & .!7(
M6/@+3_\ A(=:U35K2QO_ +9=K<6XE@#F(",*0<CZ_H:K6OQ"FNO$&IV8T"9=
M+TN>6*]U,W"[(MBDYV8R<XZ#ID5#:?$N:0Z9>7_AJ\L=%U.9(;2_DF1LE_N%
MXQRH/8\^M '<M:6S7,=RUO$9XE*QRE!N13U /4 X%1?V78;KMOL5N3>8^TDQ
M@^=@8&[UXXYKC+OXDW*:GJ<>G^&;O4=/TRX-M=W,$Z>8KC[VV'[S >M=Q<W<
M%G937EQ((K>&,RR._ 50,DGZ"@"CI/AO1-"\S^RM*M+0R_?,40!;V)ZX]JO6
MMI;6-LEM:6\5O F=L42!%7)R< <#DDUP4?Q0E6WM]6N_#%_:^'+APJ:F\J-M
M#'"NT8Y"G(YS5/29-9UKXS:G)?6M['I^F1HL")?#RHRRG:Y13\V\9/?'>@#T
M&^T;3=3GM9[ZQ@N)K202V\DB M&P[@]O_K"JS>%M ?6#JSZ/9-J!ZW!A4MGU
M^OOUKEO&_B#6]+\<^$;'3K>5[2ZFD\Y4E51.0N-ISTV@[O0\=Q7/Z#\0-5TF
MV\0R3:+J.K6=CJ]R;F\^T+BWBW<*H8Y; '08 H ]@K)MO#&A6;*UMI-I$4N3
M=+LB VRD;=X]#BL35?'ICNK.RT#1KC7+RZLUOE2&58T2%ONLSGIGL,5K>&/$
MUMXGT^6XAAEMKBWF:WNK6;&^&5>JG'7ZT :2Z?9K?2WPMHA=31B*27:-SH,D
M GN.35'3/"V@Z->2WFFZ19VMQ+G?)%$%;GL/0>PKD;]M0\8?$>_\/KJ5YI^C
MZ+#%)<"SD,4EQ+(NY07'(4#L/0^V-33](O?!^HZA?7&O3W'AE;0S-'?S---!
M(O)*L024V@\9Z]J .Q(R,&L.V\&^&K/5/[3MM#L8KW)83+" 03W'H?I7-VGQ
M-E>6RN;_ ,,W]AHM_*D=KJ,DB,IW_=+J.4!]<GK4UM\1I+WQ%J6G6WA^[>TT
MRXDAO+[S5V1!03NQU.=IX^GTH Z?6/#VC^((HX]7TVVO%C.4\Y 2I]CU%3'1
M],:"U@^P6PAM)!+;QB(!8G&<,HZ C)_.N&T_XK&ZL]/U2Y\-WUIH=Y,MNM^\
MJ$+(3C[@YV9XW?I5[5?B#<V^JW]IHWAJ^UB+36"7MQ#(J+&V,E5!Y=@.H% '
M6MI=@]]+>M9P-=2P^1)*4!9X\YVGU'M5'2_"7A_1+Q[O3-'L[6X<$&2*(!L'
ML#V'TKG-0^*%I''HQTC2KS5Y-8@>:UCMR%.4.&5L],?-GKC%37WCS48KF6WT
M_P (:I>O:QQO>'>D8A+('* D_.P!YQ0!NMX3\/OK(UAM&LCJ ;=]H,0W;O7Z
M^_6K%UH.DWPO!=:?;S"]"+<^8@/FA/NAO7':O/=2^(5_J'B'P/+H-O/+INJ"
M5Y8@Z RD#!0D]#'RQYYJUI?CC3M&TO6;CS-4U*5M?FLK>!W$CR2DC:D?HGIZ
M4 =GJOAC0M;G@GU32;2[E@_U;S1!BHZX^GMTJ.X\(^'KK2H]+FT:S>QCD:5(
M/* 5&))) [<D]*Q++XA!I-2M-6T2\TO4K&R>_%K,ZL)HE!R4<<$Y&/\ )JE8
M?%1+E]*GN_#VH6&EZI*D%M?3NFTR-G *@Y"\'YOQH ZVQ\,Z%II)LM(LX"8/
MLQ,<*C=%G.T^HSUSUING^%M"TIK=K'2K6W:V9VA9$P8RX ;'ID 9K7HH Q8?
M"'AVWU<ZM#HMDE^6W>>(AN!]1Z'WJ_#I=A;WEY=Q6D2W%[M^TR!>9=HVKN]<
M#BK=% %:PT^TTNQBLK&W2WMH@0D48PJY.>/Q)I@TJP&K'5?LD/V\Q>0;C;\^
MS.=N?3-7** ,M/#>BII$^E)IELNGW#%Y;<( CL3DDCZ@?E1=^'-&OM2BU&ZT
MVVEO8D,:3L@+*I!!&?H3^=:E% &<=!THZ7;Z8;" V5N4:&#;\J%3E2/H:J:O
MX.\.Z]>1W>J:1:W5Q&,"1UY(]#CJ/8YK<HH R=7\,:)KNGPV.IZ9;W%K"08H
MRN!'@8&W&,<<<4R+PGX?@T^[L(='LXK2["K<1)$%60*,#./3_P"O6S10!6T_
M3[32M/@L+&!8;6!=D<:]%'IS6&/A]X2%S=7']@61DN@1*63(.>N >%S[8KI:
M* *4.CZ=;SW,T5G"DEU&D4[!?]8B A0WJ "15;_A&=%_LJTTS^SH?L5G(LMO
M" =L;J201[Y)_.M:B@#G]8\$>&M?OUOM4TBWN;I0!YC9!8#H&P1N_'-:0T?3
MAJ%M?K9Q+=6T)@AD5<;(SC*@#C' ^E7J* ,P>'=("ZBIT^!EU)]]XKKN$S8Q
MD@UGZ3X#\+Z%=?:M-T>""?8R;\LQ*MU!W$Y'%='10!DV?AG1K!]/>UL(XFTZ
M-X[0@G]TK_> Y[^]9VO>&6?2-6_L&"RBU#4)%DN%ND+Q76, JXYP"N1D8]:Z
M>B@#S/PC\/I[#Q9!KMUI&F:/%:0O'!:64K3,\CC#.[L.F,@ =,_GWFLZ)IOB
M'37T_5K1+JU=@QC8D<@Y!!!!%:%% &=IVA:9I5U<7-C:)#/<I$DS@DEUC7:@
M.3V'%49?!7AR?0(="DTF%M-A8O'"2WR,222&SN!R3SGO6_10!E:%X;T?PU;/
M;Z/816D<C;GVY+.?=B23^)K5HHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '&^-M6\7:%97VK:4-$?3;2W\TI=+*9F(^\/E(7&.E4
M)_$7C/2O!UYXBU)- DB2P%Q#%;),&#G:5#;FY7!.<8.:V?B/_P DX\0?]>4G
M\JR?%_\ R1&[_P"P5'_Z"M &WX?\;Z#X@>&TM=5LY-1:%9)+:.3)!*@D#UQW
MQG&.:GO?&?AO3=532[S6[*&]8X\EY1E3V#=E//?%<'?VEGI^N_"Y[>W@M]P=
M6:- N<P+@$CKDG]:XI1!!H7B>QUOQ#8:?<&^G^TV4VF+-=RECPT;%U+9XQC@
M8STYH ^C:YZ+QWX5GU9-+AUZQDO';:L:R@[FSC:#T)SVSFGV3-IO@&W:1)[E
M[;2U+).NR20K%T8 G#''/)P?6O =:U>&3P1I%Q!?^'XBMU'-'H^GVF9(@I)_
M>2%BPZ\YZYZT >^:EXX\+Z1=O:W^NV4%Q&XC>)I1N5B,C('3ZGBI]2\6:!H\
M%M-J&K6MO%=1M+ [OQ*H )*GOPPZ=<\5YK9ZWX=TWQS\0UURYM8IY=BQ_:<9
MD01X*+GK_#\H]O2L72)+;18OA9-XF988(TOG5K@ +'NVF(MGMRI![<'M0!Z/
MXF^(-I9^ KWQ)X=N;/4?L\D:<DE06=00P!!!PV:U[;7F'B'7;6]NM-CLM.CA
MD#+*1+&&3<QESPH]/:O'_%TUKJ&C_$34=)*2:3/-8+'+",1R3*X\PKV)R1EA
MUJ?QK!//XH\=E8I);2.?2I+U$4DF!4R_ YP."?I0!Z]H_B[P]K\L\6E:O:W4
MD )D1'Y '\6#U'N.*@L?'?A;4M473;+7;*>[8X6-),[SZ*>A/T-<;K7B+P1*
MUU)HNF0:M>0Z-<LS6!*)'"0!L<J1C.?]Y<'IFN(NM4AN)?!3C5] (&J6D@L-
M+M=IM8Q@?O)2Q;(S@J>IY[4 >EZ7\3M,&KZY9:_?Z?IYL]2>TM5+$,Z+_$V<
M_GP*V+OQ-/#X^TC088X)+.^LY;EIN2V5^[M(.,5YOI6J>#]/U/XAQ>(3:"YD
MU"<A9D!>6/D!8\]3DG@<\@U5T^QUV%O"MJ=_]KCPQ>B$<@ID-Y0/'!"E!]10
M!ZW;>-O#-WK']DV^N64M]G:(ED!RWH#T)]@<UK7UVEAI]S>2*S);Q-*P7J0H
M)./RKYUL_L5UX&TC3V\2V:71GC2/3[/1PU]','_O>8ISG^(XSDU]#ZI-/;Z3
M>36UK]KGC@=X[?./-8*2$_$\?C0!P%IXL\<ZGX:'BC3M-T2YT]\RQV$;2M=-
M$#@C</EW\'@#]>*Z^^\5Z/I&D6NHZQ>)IJ7,:NL=S\L@) .W;UR,\\<5XY=7
M/@)M!FUG1M6N_#7B'R2S6%E-(N+G',9C(Y&[CC QZ<UOIJ"V_C[PUJWC0PVR
M7'AT*DET L:76_<^<\*Q4^W7% '5ZQ\0+"PU3PTT%]I[Z-JAN//O6E^5!''N
M&&S@'<0"#].M=!I/B/1M<T^2_P!,U*WN;6(D22*^ F.3NSTXYYKRN(>'=<\6
M^#_[*TD1:0VJZBZA_P#5SNL2MYBC/"[EX'3Y>G:J_BFPG35_B59Z- 4>33[-
MS#;C&X9!?@?[.[\SZT >JZ5XP\.ZW?266F:S9W5S'G,<<@)('4C^\/<9K(\7
M?$/1_#^F:FMKJFGRZQ:Q%DM))<Y<?PD CGVSFO/](CTRZ\0>#DM/%-E?RP2A
MK>WTW25CE5 GS"9A)E1@<Y!^AK,O+OPW9?![5])U8VR^*5N9!<QNH\][CSLA
MQGG;MQR.,9]>0#W+2=9M]2AMT,T0OGM(KF6W5N45QP<>F<_E65K7BZ*U;2#I
M<MK=I=:TFEW)#;O*)5RPX/# J.OK7':5K]AX<\?0/K%U%96MUX;M?+FG)569
M#]T'IG!/'M7+>&KJ6_T_1KU?]1<>.7E; P-S1@KP>?[U 'LUYXR\-Z?JZ:5=
MZU9PWSL%\EI!D$] ?[I.1UQ6Y7SI#!#:Z+XFLM>\2Z=8WSW4_P!LM;G2UFNI
M"WW6C<NI;(P5P.,YXKW7PM"]OX3T>&22:1TLXE+S1[)#A!]Y<G#>HR>: (K/
MQAX<U"[>UL];L)YDB,K+'.IVH.I)Z<=_2I-*\4Z#KER]OI>L65Y.B[FCAF#,
M!ZX]*\2M=$5OV?+B^T^RC%[)<.;J>.(&9H1-A@#UP JY&<8!K<TX6-_XU\,M
M:^*["_N8',L<6D:0(RL6W#+*ZR'8N.,$?A0!ZAXH\16WA;P_<:K<QM*(\+'"
MGWI78X51]2:Y6ZU_XB:7IO\ ;5]H6D2V28>;3[625KM$XZ'E&(Y) ]*M?%;3
M+K4/"$=S9P"XDTR\BOV@QGS43.Y<=^"3^%,U'XK^&XO#QO\ 2KV'4;Z50+;3
MXV_?22-@!2HY')YX^E '1ZAXJT/28;:34]3M['[2@>)+IO+<C_=/(ZU+/XBT
M6VL+>_GU6SCL[DXAG>90DAP3@-G!X!_*O.[*_P!+LOB;KEUXS%G93W5C:/8"
M^92B1[#YJ*QXX?MU-<E:VT%WHVBH( VBW7C<FQB=?D:V/  !_A^]Q]: /<--
M\2Z'K%O//IVK6=S%;C,SQS*1&,9RWH.#R?0TS2O%.@ZY</;Z7J]E>3(NYHX9
M@S =,X]*\WUFSTV#QQXUMYXY+;3Y- 0S?8XAN S@L%'!(K-\.7\%CXC\/:?9
M7>@Z^9+:6*TO+*'R;NU C./, .W&./FYZ_B >LOXK\/QZL-*?6K!;\OL%N9U
MW[O[N,]?;K6/K'BR]L;SQ);0I8)_9=E;SPR7<A1"\A<$.V>!\HQT^O->96VH
M>%H?@MJ&GW[6@\2?OEG@D4?:C=>8=IP?F)!V\CCCV-6_$ZW2>&_%ZW^[[8NA
M:0)]W7S-S;L_CF@#UJ]\4:+I"6PU;5;&SEN$#(DLZKNSW&>V>]9'A7QS;:KX
M*B\1:S-9Z=%)-+'EI=J85V"@%CR<#\>:Y.RN/#UAX^\0MXK>UB6?3[/[&U^5
MV/#Y(#A-W^UG('6N4T?4K:S\!>#+=K732TU_=O#>:J[BUMMK'EE! 9B#QGT[
M=: /8;_QSH=OX5U+7K+4+2^@LHRQ$,P.7_A0D="QP!]:J:+XU_MZ7P[)9_8/
ML^IV\DDZ&YS-%(J@E%7'S8)P3_*O*;9VO;WXE)#>6-^CZ0LAEL(1' Y103L&
M3POS#.><9[UMV%S!?:YX&?0WB+_V#=1IY6!MF$(!![!@W7- 'JB^*O#[:O\
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MF-IGVJXP]Q)?3E50$C:@V\[V[9]1ZUL^,_%*>$?#[:B;8W,SRI!!#O"!Y&Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ,EBCGB>*5%DC<%61QD,#V([TDD$,L#021(\++M,;*"I'
MICTJ2B@!C0Q.8RT2$Q',9*CY#C&1Z<$C\:AFTZQN+E+F:SMY)T^Y*\2EE^A(
MR*LT4 %5(]+T^$2^586J>=_K=L*C?_O<<_C5NB@#F],\'6=AK^M:K.8KMM2N
M(YU26 'R&1<<$YSZYXJ36?"L&M>)M#UB>8;-+%P/LS1!EF\U O))XQC/0YKH
M** (4L[:.V6V2WA6!<8B" *,<CCI3Q#&&D81H&D^^0HRW&.?7BGT4 5[6PL[
M)'2TM(+='.66*,(&/OCK3(M+T^!76&QM8U=@[!(5 9@<@G Y.:MT4 5IM/LK
MF19)[.WE=&W*SQ*Q4^H)'6IC%&9A,8T,JJ5#[1N /49].!^5/HH K+I]DMXU
MXMG;BY;@S",;S_P+&:LT44 5#I>GF\^V&PM3=9SYWDKOS_O8S4MS:6U["8;J
MWBGB)R4E0,N?H:FHH C%O HC AC BYCPH^3C''IP30L$*3O,L2++( '<* S
M= 3WQDU)10!6M].L;.626VL[>"23[[Q1*I;ZD#FFS:7I]S,TT]C;2RLNQG>%
M68KZ$D=/:K=% %>XL;.[$8N;2"81G*"2,-M/J,]*<+2V&,6\0Q)YH^0??_O?
M7WJ:B@"M+IUC/<I<S6=O)<)]R5XE++]"1D59HHH CB@A@B$4,21QC/R(H YZ
M\"H;73;"Q=WM+*VMW?[S11*A;ZX'-6J* "J<.D:;;W/VF#3[2*?)/FI"JMSU
MY S5RB@"O=V%G?HJ7EI!<*IRJS1AP#[9I[6T#B(-#&PB(:,%0=A' (]*EHH
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MC%6Z* ,33?!_AS1KTWNFZ)8VMR01YL4(! /7'I^%:%II=A8V!L+6S@AM#NS
MB )\Q);CIR2:MT4 8FF^#O#>D7WV[3]$L;:ZYQ+'" RYZX/;\*2\\&^&M0U+
M^T;O0K">\)!,LD"DL1W/J?K6Y10!6%A:#4?[0%O']L\GR/.V_-Y>=VW/IGFF
MZ;I=CH]F+33K2*UMPQ811+M4$G).*MT4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 95_<ZY%=%;'3[2>#'#RW)1L_3:?YU6^V^)O\ H$:?_P"!K?\ Q%;V*,4
M8'V[Q-_T"-/_ / UO_B*7[;XF_Z!&G_^!K?_ !%;V** ,'[;XF_Z!&G_ /@:
MW_Q%'VWQ-_T"-/\ _ UO_B*W2 :\>^#WBS4C%;Z3KUQ),-162XTVYF<L7V.R
MR1DGN-NX#T- 'HGVWQ-_T"+#_P #6_\ B*7[;XE_Z!.G_P#@:?\ XBN,\&>+
MI],^'MG=WD6H:M>W6I36T$49\R1V+L0"6/"@ \D\5N1_$.!%UJ+4='OK"^TF
MT^V2VTC1L7CQP596(S_C]< &M]M\2_\ 0)T__P #6_\ B*/MOB7_ *!.G_\
M@:W_ ,17,)\68F_L]G\,ZND>JH?[-)$9-RX(&W ;Y1R.3VYZ5I6_Q&TY=)UJ
M\U2RNM.GT9U2[M9-K."_W-I!PV[H.: -7[;XF_Z!&G_^!K?_ !%'VWQ-_P!
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MC;74>]-X 8=B#C/(((_"@#-_M+Q5O*_V!9$>OV__ .QI/[2\5=_#UI_X'_\
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MKF^MHD:QT\7CEL,IF$>T>N2.:SO[5\0_]"TO_@>G^%;U% &#_:OB'_H6E_\
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M-43&#G]Z2QQCG/YUR/B^V\.VLVH:79>$[^'7[I08XA*DPBW,&)54=MO"GH.
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M6NG)!?W%S<I#(BP6^["2#*L>> ,C/UH O_VYK'_0IZA_X$VW_P =H_MS6/\
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MFO5Z* /&M?\ #NKG6O#^M^(=-U74PNCK:78TAR)X[@,6W'81D'<1QQ^E=?\
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MM*@$'G->S:+:FQT'3K0Q&$P6T<7EE]Y3:H&-V!G&,9P,U>HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?B/
MK4^@^!=2N[21X[ME6&!TZJ[L%!SVQFN:"^(?"?B_PM!>>)KK53J[O!=VTZJ$
M&U =T8 ^7!//KQFM7XDZ'=^)CX>T:*"X:SEU$2WDT/'E1HIZMT&<\>XJW8^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BD.<<=:4=.: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **KWU_::;:M<WUS
M%;P+P9)6"C]:BTO5]/UJU^U:;=QW,.=I9#T/H1U!^M %VBBB@ HHHH ****
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M<LB$9##&<9Z4 =WX4UF7Q!X6T[5IH/(EN8@[Q]@<XR/8XR/8BMBN<\ 0QP>
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M@ HK+NK/5I+IGMM52"$XQ&;<.1^.:B^P:Y_T&X__  $7_&@#9HS6+_9^N_\
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M+= 'BCPO?:,;C[/]I5<2[=VTJP8<=^5J+'B[^]HGY2_XT8\7?WM$_*7_ !H
MTK33+>WT6WTMXTFMX8$@*.N5954#D'/I4MG8VFG6RVUC:P6L"DD101A%!/7@
M<5D8\7?WM$_*7_&C'B[^]HGY2_XT ;]4VTFP;5TU8VL?V](C L^/FV$YV_3/
M]?6LS'B[^]HGY2_XT8\7?WM$_*7_ !H UVL;-[U+UK6 W2 JDYC&]0>H#=0*
MKZ[8#5/#^HV&T,;BVDC /<E2!^M4,>+O[VB?E+_C1CQ=_>T3\I?\: *'PQO3
M>_#W2@_$MNC6TBXP5*,5P1ZX KKJYBTT_P 16 F%I!X?@$\IFE$<<J[W.,L?
M<X%6,>+O[VB?E+_C0!OD9&#TKG[?P-X5M;HW,6@:>)2V[)A#8/L#P/PI<>+O
M[VB?E+_C1CQ=_>T3\I?\: -Y55$"(H55&  , "EK QXN_O:)^4O^-&/%W][1
M/RE_QH WZ*P,>+O[VB?E+_C1CQ=_>T3\I?\ &@!OA;PNGAT7\\MT]WJ&HW!G
MNKAA@,<G"J.P&3_GBNAK QXN_O:)^4O^-&/%W][1/RE_QH W71)!AU5AZ$9I
MGV:#_GA'_P!\"L7'B[^]HGY2_P"--/\ PF.X8_L+;GD_OL@8_P : .AKF-8^
M'OA?7;_[??:4C71.6EBD:,L?4[2,GWI2WCG!Q%X=SGC]Y-T_[YI-_CO_ )X^
M'/\ O[/_ /$T :VDZ#I6@PM#I=A!:(Y!?RUP7/N>I_&M&N8W^._^>/AS_O[/
M_P#$T;_'?_/'PY_W]G_^)H Z>BN8W^._^>/AS_O[/_\ $U(LGC3S<M:Z 8\?
M=%S,#GZ[/Z4 ='16 9O%V#BQT3/_ %^2_P#QJCSO%W_/CHG_ (&2_P#QJ@#?
MHK \[Q=_SXZ)_P"!DO\ \:H\[Q=_SXZ)_P"!DO\ \:H WZ*P/.\7?\^.B?\
M@9+_ /&J/.\7?\^.B?\ @9+_ /&J -^BL#SO%W_/CHG_ (&2_P#QJCSO%W_/
MCHG_ (&2_P#QJ@#?HK \[Q=_SXZ)_P"!DO\ \:H\[Q=_SXZ)_P"!DO\ \:H
MWZ*P/.\7?\^.B?\ @9+_ /&J/.\7?\^.B?\ @9+_ /&J -^BL#SO%W_/CHG_
M (&2_P#QJCSO%W_/CHG_ (&2_P#QJ@#?HK \[Q=_SXZ)_P"!DO\ \:H\[Q=_
MSXZ)_P"!DO\ \:H WZ*@LVNFM(S>QPQW./G6%RZ#GL2 3Q[5/0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,!\Q_$Y/XT :E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*H/XB@#L**** "BBB@"I-I6GW$D\D]C;2O.BQRF2)6\Q5)*ALCD DD5;HHH
M**** "BBB@ HHHH BM[6WM%=;:"*%7<R,(T"AF/)8XZD]S4M%% !1110!!+9
M6LUY!>2V\3W-N&6&5E!:,-C=M/;.!GZ5/110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%&** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "CK28S]* ,  =!0 M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 (1FEHHH **** "BBB@ HHHH **#P* <T %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MST'- '5T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*LMO,@>-UZ,IZ&IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *CGMX+F/RYX8Y4SG;(H89_&I** *#:'I
M#2+(VEV1=<A6-NF1GT.*@_X1;P]_T =+_P# ./\ PK6HH R?^$6\/?\ 0!TO
M_P  X_\ "C_A%O#W_0!TO_P#C_PK6HH R?\ A%O#W_0!TO\ \ X_\*KWVB>%
M=-L9KV\T;2XK>%2\CFR0[1Z\+FMZL#QPN_P+K@W,/]"E.0<=%)H ?867AF^T
M=+NRL--?3Y4+AEME5"O<D$>QZU!H]GX1UNS-[I>G:7<0%BAD2S49(QD<J#Z5
MPEI?3:+X1U+PC:AFNGNXK2TRW.RZ7?G/L/,Y^E2:;<7&C:!;:)H,_P!BDU'7
M;BUCE=-Y@C5B"1GACA1^9]* .TUFV\(>&K!]2O\ 2]+@2/E2+6/>S=@HQDFN
M \!-X1U'4[[4]7.D+?:A)MMM/>-0D$6> !C;N./KP/[U5_&_@ZYLM/U*]U;7
M)-6,9MTMWFD.^V5WP[%<X .  >AR>]>DZEX3\,MX9DLKFRMH+"*')F155HPH
M'SAL9S\HY[XYS0!>_P"$7\/XQ_86F8]/LD?^%*/#'A\# T+3!_VZ1_X5Q_B?
M7)8=6L-.M/$KV=J+19(Q9VYN[J=CT+#:0%VX.3UY_"G#XD\0W_@S1PNH-;:E
M/K)TR:Y>W&2"'&XH<8(XXXY% ';R:'X96:&TDTK2!*P9HH6MX\D#&XJ,>XSB
MF6>A>%=0M([JSTC2)[>0922.UC*L.G!Q7-V>CZE;_$32(+S7)KV2STJ21I)(
M5'F9E"D8[<$<\GY:P]/;7O#G@K3]<362EC%= ?V:+=-IB:8@@MU)^;/Z=J /
M2/\ A&- W!O[#TS(Q@_9(^WX4EWHGA^.VEGN]+TT0Q@RR/);)A0!RQR/0=:P
M+_Q7/H6H^);:_<O]FM1?6!*@;D(V;/?$G'_ JZ;2(;P:%:1:K()[SR%%PQ4
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M#_2GKX8T!<[=#TP9&#BTCZ?E6K10 R.*.&-8XD6.-1A548 'L*?110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#D;KP?J.J>'+_2-6\23WGVIHRDWV9(S#L8-P%ZYP.M==VHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *C:9%E2)FP[YVCUQUJ2F%%+AB 2.A(Z4 /HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGN-*O8[J)&VL5R"I]P<$4 :5%%% !1110 4444 %%%% !1110 4444 %%%%
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M&[&?^^E%:H^%_A$+(/[,;YR3G[3+\OT^:H[CX5>#[B(1G3'0@<.MQ)GZ\L:
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M'^%7-.^&?ABQ82SV;:C<9R9KYS*6^H/R_I4/_"J/"/\ SY7'_@7)_P#%4?\
M"J/"/_/E<?\ @7)_\50!U4.EZ?;Q"*"PM8XUZ*D*@#\ *FA@@AW>1%&FXY;8
MH&3TYQ]*X_\ X51X1_Y\KC_P+D_^*I/^%4>$1_RXS_\ @7)_\50!VNY=V,C/
MIFFO-%'G?*BXZ[F _P ]17&?\*G\(YS]AGS_ -?4G_Q5(?A+X/;K83'ZW4G_
M ,50!V'VRU_Y^8?^_@H^V6O_ #\P_P#?P5QP^$?@T'_D&R'ZW,G^-*/A)X-
M(_LV0Y];F3C_ ,>H [96#*&4@J>00>M+4%C9P:=86]E:ILM[>-8HUR3A0, 9
M-3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%!.!0 45F27$]VV+5S'$#C
M?M^\?:FR6ESG*W,N<_WS0!JT5C&[N[*0>>#)"3@MW%:T4B2QJZ'*L,@T /HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVPRL,&J.C.5$]N3D1MQ]*N/,L43N2/E4G ZU0T4%WGG(P&- &Q1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNYGQA1DCCJ21]:YCPQX=U*W\86M];>'3X;L8HI/MT*7BR17;L,*%13@;3SG
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M^=;]<?X<L-4O/%NH>)=5TS^S6DM([.&W:99'PK%F8E>,$D8ZGCM784 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4F/FSG\*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM-V+Z4;![T +GGH:6F[![T;!0 [-%-V#WHV+0 ZBF[%]*-BT .HINQ:-B^E
M#J3-)L7THV+Z4 .HINQ:-BT .HINQ:-B^E #J,^U-V+1L H =GVHINP&C8M
M#J3-)L%+M% !GVI<TFT>E)L% #J*;L'O1L% #J,TF*-HH ,^QHS[4;11M'I0
M 9]C2YI-HH  H 6BBB@ HHHH **** "BBB@ HHHH **** "FJB)G8JKGDX&,
MTZB@ HHHH **** "BBB@ P 2<=>M%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 44QY$C7<[A1ZFJ9U>S!QYA/T4T 7Z*JVVH6UV2(90S
M#MT-6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BF1LY!\P ')QCTI] !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S2
MK!"\KDX49.*DJCJ7SQ1Q9P'D4'Z9S0!2CADN7,]U\S9Q&I'RJ#_6KL<3*V[!
MW<@GMBIP", 8S[4N#D=>M &/?6#1R&:(?=.X,.HK1TV[-Y;;G'S*=I]ZLX#(
M0>_!K*T;Y;BZ1?N ]* -FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO&;OQGXM\1^,]7TK0]
M:TC18M-G:*.*\*A[@J2#C<IR"0>F, CZUTVC^-]8T_X?:AK?B[2I+2\L&,>P
MH8_M)X"D ],E@,C(X)]J /0**\7@UCXL:QH!\4V$EC':-NEBTY80TDD?L"I)
MZ<?,"?RJ_P",OB!XCTSP/H&L16ATJ_O+@QW-O<19( ![,,@'&1WP: /6:*\Y
M^*WC:\\,^'+2ZT&^MOM,MV(W/RR838QZ?4"L3Q9XV\5Q:_X:TK1KZSM9-3TV
M*=WN(UV>8V[))(.!Q0![#17GWA,?$!M>B.N:UHEWIRJQECM"#)G'RD84=\=Z
MX[P[XF^)OC"XU0Z/J6FI'93;"D\*J3DM@#Y3G[O>@#W*BO*]#^)&KWWA?Q3#
MJ5O#:>(M#MY'(495B W.WGH1@\X.16OX;\5:IJ/P=F\27,D;ZDEG=2AQ& I:
M,OM^4<?PB@#O:*\1N/B9XDM_A%9>(!/;OJ,^IFV:1H1@(%9N%'&?E _.O:H'
M,EO$[=60$X]Q0!)17C$/B;XA>)O&GB'2_#NH:?!!IER\86ZC7[H=E&#M)/W3
M7?>#K?QE +S_ (2V]L+G.S[-]D7&WKNS\H_V<?C0!U-%>9?%;Q=X@\.:AX?L
MM GABDU!Y(V\R-6RP*!>HX^\:Q]4\8_$'P%=Z?+XI_LN_P!.N9MC-;C##U (
M P0.>AH ]EHKR7Q3XG\:3?%!O"WAN]L[<&W651<1 C[NXY.TFNF\)6OQ @U6
M1O%-_IEQ8&$A%M5PXDR,'[@XQN_2@#M**Y_QIXKM_!OAN;5KB(S,&$<4(;'F
M.<X&>PX)/L*\ZE\1?%FRTN#Q'-8V%Q92[6.GPPEI%1L8.!\P_,D9Y% 'LM%>
M=>,OB-=Z59:+9:-IQ?7M91'BMKE2/(#8'SC@YR2!VX)/3G#U'Q;\0_ <MK?^
M*HM/U#29Y1%)]D&&B)!/!P.>#U!!QC(SF@#V&BO)OB%\4;_PMKNA_P!G);SZ
M9=VR74H9,M(A8\ YXXZ>]7_&GQ!O-+U'P>VB/;RV.L29=I$W%D)C QSQPY_$
M"@#TJBO(]9\<^*=9\>WWAGPO/IFG_8OE,E\<-,PX(7(/<\ #MG/-;?A7QSJY
M\/ZU<^+M*EL9]'!:241%$G'/"YX)RN.#@Y% 'H-%>.V'B7XH^+-/?7=$M=-L
M]-#,8+>4;GG XP">O((S\O-:-I\4;S4OAIK6LQVD5KK6E%8YH7!9-Q8#<!UQ
M][@G@CO0!ZC16'X-U>YU[P?I>J7@C%Q<P!Y/+&%S["N=?QAJH^*.J>'U%M]@
ML]--TH,9+L^U3R<],MZ?XT =]17B'ASQM\4?%.ESZGI5II,]O Y1E9-K,P )
M &[/0C\Z] ^'OC<>-=&FFFMA:ZA:2>5=0@\!NQ&>0#SP>F#0!U]%>./\8;M?
MB:-,,< \/"[-F9]A+%A\N[=G&-V#_NUUGCW4/&NF WOAN+3VT^WM7FN3<\L"
MN2<#(_A% ';T5Y'X'\4?$CQ5]AU+R-)_L=[D).VW:^P, ^T;NN,X]ZM^%_BA
M<3> M:\2:]'$QLKLPQ16ZE=^0NU>2>[=?2@#U&BO'(_%/Q7O=*/B&UT?3ETY
MD\^*V*[I&CZ@XW;CQ]"?3I5[6?BK<2_"Z+Q1HT$4-V;M;::&?]X(VP21QC/&
M"#Z&@#U6BO,I?B9<77P>F\4Z>L U.W,<,\3J61)2ZJW&>A#;ASW'6N[\.WTV
MJ>&=)U"XV^?=6<,\FT8&YD#' ],F@#2HKR_7O'WB+4/&$_ACP5IT$\]GG[5=
M7(RBD#D=0!@\9/4\ =Z?X>\>^(;/QA#X5\::=;V]U=+NM;JW.$?K@$9(.2",
MC&",8YS0!Z;17C-KXU^(GB+Q/KNG^'K?2V@TVY>(F9<$+O95Y+<D[3^5>C^$
MF\3OI<I\51V:7OG'RQ:_=\O QGD\YS0!OT5YIXS\>ZY:^,K?PGX:MK(7[QB1
MI[UP%.02%4$CGCWZ]*N^"O%'BJ[UR_T/Q5HWD7%NGF1W=O$PADZ?+NY7."""
M#V(ZT =]17"?"OQAJ7C/0;V^U-(%DANS$@A4J-NU3SSUY--^'/C'4_%5]XBA
MU!;<+870BA\I"ORDN.<DY^Z* .]HKQR\^,%W#\2QID<=N?#\=VMG+.4.=QX+
M;LX&&S^"FNB^*GC+6/"%EI9T9+=I[R=HSYR%N@& .1W- 'H-%>.ZEX[^(?@L
M6UYXHT;39],DE".]LV'!(/R@[B >">01QU%7?&GCSQ/:^,]*T#PM;VDK7]FE
MPGVA>26+'J6  "IG\Z /5:*\_P#"VH_$NZUJV'B'1]-M=,8N)FC8>8N$^7&'
M/5L?F>G%<W#\1_&WBBXU&\\):3I[:9I['*7#;II0.>@8'D#H!WQDT >R45S?
M@;Q/+XM\-1ZC<6,EE<!S%+$ZD#<,'*YY*G(_4=JZ2@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "JM]"\EOF(#S$(=1ZD=JM44 9<5^)8]
MR+_O#I@U,+ASD\8HN-.220RQ,8Y3U(Z'ZU7-K?'Y?W0Y^]F@!]Q?^5;MM7/!
M&2>].TBV:"U+N,/(=QIT.F(KB29C(XZ#L*O@4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HJ*YNK>RMI+FZGB@@C&YY97"JH]23P!6/_ ,)OX3_Z&C1?_ ^+_P"*
MH W:*HVNM:5>_9_LFIV5Q]I#-!Y4ZOYH4X8K@_-@\''2KU !1139)$BC:21U
M1%!9F8X  ZDF@!U%0VMW;7UK'<VEQ%<6\@RDL+AT8>H(X-34 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3=,E\)^&M*CM)(_M.KQPPS/<*F/N(5)4MCG/Z5ZOJEO)=Z3>VT0!DE@>-<G
MR5(% 'DL'CV]T[PMX.LK,Z3HJ:C;,[WMQ$WV:+:2-BJ#P3UR3W]ZV]0\<^(M
M%\ 7&J7EEI\]XEVMK%>6LOF6KH>D[!22J]B/7'K5)?"7BK3/#'A^T&FZ=K5M
M:6C0WFC731A#)EBLB2,#R,X__73='\!^*-(\-:JVG&QL+F]OTNET<D36_D@$
M- S$?Q C)']T#C)P :NA^*?$3PZG-/>Z'K-C#8/<PWVG/@)*H_U<B;LX.,Y&
M/UX+[QMJ]K\$T\6JML=3-O%)C8?+RTJH>,YZ'UZUE:'X U*[\53ZO<Z+9>&+
M5[*:TDM+*<2_:"X(W$* H R#CU K,NO"/Q!N/A_)X&73]/%G;G"7[W>3<H)-
MZA5Y*]NN.!B@#?\ $_Q"O;?Q.OAW3]0T;2Y8;5+BZO=4<A-S8_=HN1DX(.<_
MRJK;_%Z0^$[R=K:SN=;M[Y-.C6VD)MYY'SLD#?W"%;C.>.V:G\3>#-3A\8-X
MCT_0-,\0Q7-JD%Q87Q161U& Z,X( P /\\0/\-]7U'PC<"<:9IVK?V@NHVEI
M:6R)! T8(2-B@!;(/+'./SR )<GQ9%\2O!5OXE?3)XVENY(9K%'7#" Y5@W'
M?CUY]*]'UV^N]-T.\O+"Q:^NXHRT5LK;?,;TSZ=_PKB(+#QMKWC;P[JVLZ39
MZ;9:4T^^.*[$K2,\97> !TS@ 9R,FND\?:%?>)?!&IZ3ITRQ75PB["QP&PP8
MJ3VR 1^- '$Q^/\ Q!I'B+1+;5]3\.:A%J=RMM-:Z:Q,MJSG"G[QR >"3]/>
MGV_BSQYKU]XFBT8:+#!HM_/"'N$<M*J$A5P#C.%R3[CIBLW_ (03Q#?W/A^2
MW\*:+H%MI>H0SS1Q3J\MP%8$OO /  /!))S[5V/A+PMJ6CMXQ>[6-3JNIW%Q
M;!6!S&V=I)[=>G;% &9_PL?4M7\.>%_[#M+0:WK[2(HG9FB@\K/F,0.3C' _
M/..8?#+Z\?C/=1>(DM/ML.@*@EM-PCF3SP0P#<@Y)!'JM4M-^'_B30?#'A2[
MLH[:;7-!FN':T:;:DT<S'<H?H&QCD\<FM_PUI/BJ?XA7'B?Q!9VEG#-I@M(K
M>&<2-#B0-M8@#)/S'(R.0* -7QIXGO-!73;#2K6.XU;5;C[/:B8D1(0,L[XY
MP!V%8MOXL\2>'O$4>A^*ETZX>\M9;BRNK+<@+QJ6:-U;V'!'Z]M3QUX;U'5I
M-(UC13"VK:/<&:"*?A)E; =">HR .?\ ]8QK;P[XD\6>++77/$VGV^D06%K+
M!;6L4ZSN[R*59RPX  / ]10 Z'Q[JDOP2;Q@([;^TA$QVE#Y>X3&/IG/3GK5
M2^?Q)-\<-.^QSZ>(/[)\S9*KG$!D7S. ?]86 P>F ,UA3>#?'R?#R;P);Z98
M_9(&9EU#[8!]I7S#)L5,94DD?>P./QKM=7TCQ!:?$+1-?TJQ@O;467]GWJ/,
M(VA0N&+C/7Z#/0^N: .9L?B+XIUK5+J;2_[#*VUVT T*>;RKR5%;!(9CMW=3
MZ#'0][FG-KZ?'76G+V<L$=@I>)%;>T'/EJN3@/NQDGCD]*R->\$>+==2?2[_
M ,.Z-=7;S%HO$B3+"ZINW LB@,2!QTQ]>IZ:Z\,^)+?QY=WE@(Y+/4M(^PO?
MF;;);2*IVN5/+9;'3U]N0#G]7^(_BW1K ZW>R>'+>)9 &T-IBUX%+[>H/WL?
M-Z =NU;NH>+/%>I>.IO#GAJ/2XX?[/CO1<WJ2$H&Q_=/).X8&/6N);X:^([C
MP5)H,?@_2+6_0%I=6END>2YVMN CP"4+=.2!CKBO2-!\.:G8?$"ZU6XA46;Z
M1;VJR!P<R+C<,=>W6@#*@^)5_8^$-9N]6TZ*;5]*O_[-\JU8[+F4D!2N>0.3
MQST]\#)U^?Q>/$/@RU\41Z889M8CGCFL _[IP"/*8-Z[N#GL:NW/P_UB_P!'
M\7V^Y;6[N]9.HZ;)Y@(;;@J3CIGD<\CK5AK3QUXC\0^'I]8T2STZQTN\\Z8)
M>+*TK;& D '0 \8Z_./0X ,G_A/KG1M(\4ZGINBV"W$'B(VC(BOFX!."S'/W
MSCJ..>GKT-OXD\6:-XRTG2_$L6E26NLF1;<V)<-;NB[B&W?>'('U_*N>F^'_
M (A_LG7[9;:)I+OQ(FH0XF7#0;LEN3QC/0\\'VKKO&'AO4=:\7^#[^T1#;:9
M=2S7+LX&T$+C ZG)4CB@#%D\9^+]5L-3\1Z!::2=!L&F5(KDOYUTL?WG!' '
M!P/8BNS\'ZQ<^(/".EZM>1QQW%W )'6,$*"?0$DX_&O*!-K6@>$/$^C:#)I>
MH>'XVN5%_)=!'L@0=\;H1EFR2%[$GTKTSX=HR?#KP\&4J?L,1P1CJM '(^&=
M(L/'?C'Q+K6OVZ7Z:?>OIUE;7"YCB1.IV8P2<CDYKH(O"FE>"]:U+Q58R"QT
MT:>WVK3X(@(V9#N\P<X!P", =^M9EUH7B?PEXMU/5_"VGV^K6&KMYMU92W"P
MO%,/XU9NH.2<>_TI;;PUXF\5WVIZAXHQI4-QITFGV^FV]QYJH'!S(Y!VL>>/
MZ8H IMXX\:6_AR/QE<:7I0\/OME:R5W^U+ QP'WGY2>0<8Z>E6IO'7B+5?&T
MWA_PS9:9+";"&\CN[QG 17 .6"\MD,H &,'DFLN?1?'M]X*B\"SZ+:);JJ6C
MZP+Q2GD(1AA%][.% _PK>\/^$+[1?B;>:DL(&D?V1#902F0$EDV#!&<]$ZT
M8,'Q&\9:AX:U/5K32-&B71'>+4/.ED;SG3E_* QM &#\Q/7VK4O/'VOW?BG2
M=%T#3;!SJ>CQZBDEY(RB$L6^]M^\ !C P23UQ3=.\(ZQ;?#GQ=I+VBB^U&ZO
M)+=!(G[Q7 V'.<#/OC%+HOA+6;3QYX<U6>V5+2R\.16,[^:I*S+G*X!R>O4<
M>] %"/Q]XVNM*UN2'2=&AN/#WF_VC+*\K13% 6VP@<@A5).XGJ/7C5G^(EYJ
M47ARR\/V%NVK:Y;&Y NY#Y5J@&6+;1EN0P&,9Q3[7PQJR>'_ (@6CVP6;5[F
M[>R'F+^\62(*ISGY<GUQ6';>#O$GA^#PAKUCIT=[J6E6+6=YIQG5"4;<<J^=
MN1N/K^- &G-\0-;T:'Q!INNZ?9)KFG:>U_:O;%S;W,6< X)W##8!&>>>E5A\
M0_%-GI6C^)-4TG2H=!U!XHC''.YN(]XXDR0%V]3CJ!CGO5;4?"GB3Q:VO>(=
M2TI+&]FTEM.TW3OM".V"2Q9FX ))('/<Y[5=\2^#M;U'X1Z#H%K;(^HVGV3S
MHC*H"[%PWS$X.* /3)%=HG6-]CE2%;&<'UQWKY_TZ+P]X=M+O3OB)X3OGU*6
M:0W&LM"9HY=S$AUDSE?P_J17O=[;F[L;BV6:2!IHFC$L9PR$C&X'U'6O-M/U
M#XB^'-.;0[OPR/$)CW1P:E]N4"92>#(&R>^#G_ZY .;\1;],\/?#N'2=3_X2
M"*/5U>UD)\OSMK#RT)YQC.W)Z>G:NYT3Q=KT/C+_ (1GQ18Z?'=SVIO+633G
M=E* D;&#<[N"<\#BN6L_AKKFG:?X/C6.*66UUO\ M*_6.11';*2IVH#C( 7H
M,\YKIM:\.:Q>?%FQUFTC$=G%H\MO]J+#"2DOM^7.3]X'IZT 8NJ_$7Q=I6FR
M:[=Z5HMGIR28_LR[G=+]TW8!QT!Z'&#QS6EK'C?Q')XU@\.^&M/TVX-QIJ7R
M2W<C*%!)SG:>1C  '<YSBN!'P]\07'A*YT?_ (0BW77&+//K5S>(YE^;?\F2
M2&;[N>!ZGGCT7P]X:U2Q\?6NIW5H%M8_#D-B9-ZG$RL"RX!ST!YZ4 4+WXC:
MM=:Q>Z9H[>'K673"L=W)JMX4667!W)$!@D @C<?RIM]\6BWA/2+_ $ZUMHK[
M4KEK0F^E(MK61/O%W'5>1C&,@Y[8K'U+P5?Z-XLUV\_X0FT\46FJ3FYMY9)D
M1[=VR65@W\.3V[#K6D_ACQ)IO@C3+?\ L+1]0 NGGU'1HH8T1T;[H1CP&7U'
M)]3CD ZWP?K>OZH;J'7+"Q'E!6AU#39O,MK@-SA<G<".,]?PXS'XL\5WVF:M
MI_A_0;&&\UO4%>1!<.5A@C7J[D<D=>!Z'VSSWPV\+:EI/B/5-5.D/X?TFYA6
M.+2C=>?F0$9E//'0@?6M'QAHNKVOB_2O&&A:<NIW-K ]I<V9E$9>(DD,I)QD
M$G\Z ,O4?&7B3^R?$OA_4;"QMO$-GI3WL<UO(YMY8.C.N1N#*#P#G+#L*N?!
M;2_L7@&UNFL;*"2[&_S;<DO,HS@R9'##D8&1^=41X?\ $GB&^\2^)-2TM=/G
MNM#ETNQT\S+(YR"<LPP!ENG^][5V7@72KC1/ VC:==H4N8+91*AQE6/)'''!
M.* ."U*YUZ;XB>,D\BR-E!HIBD)E?>D11V0J,8+$YR"/Q]:WAWQMXD\/?#[0
MM7N=%LCX;BBBM7*W#&Z/S;/-QC:%X^[UY'-;>M:-XC@^(&MW%CIC7>EZWI)M
MFE61%\F548+D$Y/IV'S^U)KOAC6;OX'6.@P63/JD=O:*]OO4$%60L,YQQ@]Z
M -'7?&VJ?\)9<>'/#UOIAN;**.:ZN-3N#'&N[!"*%&2Q4YST%:_@OQ;'XLT^
MZ9X!;WUC<-:W<*N'59%[JW=3V/UKBO$_A*[M_B#J.NOX1@\3Z?J4,0\LR(LE
MM(BA>-W8A?\ ..>K^'FB7FCZ+<O?Z58:7/=W#2K:6B*/*CZ*K,/O$#O[T 8G
MB^%O%/Q-TGP?>/)_8JV#:C=P1OL^T$.556(.< @' ]?Q&C<?#'2[/5-.U3PR
M4T.^M9@9'A0LL\/\4;*6QSZ__6Q%XT\/ZW%XHTSQEX<@BO+^QA:VGL9'">?"
M23A6/0@L?T^AK23^./%^J:=;R:3<>%],MIUN+J?[8KR3A>D8"XX/?/'KZ$ M
MW/B_Q'J^M:C8^$=(L;BWTJ;R;JZOIV599!]Z*,+_ !#U)P.X]<^Y^*L\OA[0
M]0TK11<7FI7S6$EE)/M,,PXQN YYP<X'![4MI!XG\#:YKT>G>'I-;T[5+Q]0
M@DBN$C:*5\;T<-VX&#Z#ZXQ;#X>:YI7_  AI:WCGGBU>74-1,3#;!OV<#)Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ-OOCN/>N?U?XBZSI.FG4/\ A.K&\U9)%>31[2Q62W"E@"OG =@1SNZY )-
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M. >.,4 >CT5YU9ZSXD\.^+O^$<UG4XM7CNK"6[MKW[.L,B.F<JRKP1Q7*?\
M"8>/;?X?:?XWDU6TFCDF$1TX60V.A8IO9P=P.X=!@<CZ4 >X45YQ;:GXMT'Q
MG::5K6KVNI0ZC8SW"^7;"+[/)& 2%Q]Y?KSS7+KXJ\?Q_#6'QY)K5BT4;C.G
MFR7;+&9/+RS#D'=V&.* /;Z*\Q@UOQ9H?CWP[I^M:M;WUOKD4K26\5JL:VSJ
MF[",.6&<<FJFFZSXY\3^&KSQAI^M6EC9H9I+/37LU=98HR1^\?.X$[2./TH
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MD=\7-KYUS&K-N*AR>?\ >//-=J_B&%/&,7APP2>?)8M>B7(VA0X3;ZYYK8H
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M=S12QG_EG+\N1GOC/2N\CUBPFUF?2([E6OX(EFDA .51C@'.,?K5Z@#S#2/
M&NR^([[7[U]+T.[GT^2TC31U8X=C_K7W #(XZ=<#H:J3^ ?%>OWVEKKD?A^
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MB@ H(S110  8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX:=3P,2+NY!!Y/\ 05M?\*PTJ70+W3[R]OKJ[N[E;N34I)!YXF481E('&T9
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M,DL3')1T)&><D<]_IC"N_A=<7D'VN;Q#(^O'4([]KUK8&/=&I55$6<!0#ZT
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MTOXIRP6=NES;3B.(JH!BC8@D#T!(/Y4 >TZ'X@L]8TZPE^T6R7=U:QW#6JS
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***;
M\V\'/R^E #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"<4M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44@.:6@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **AFN8K==TKJ@]S5;^U[8_=$C#U"'% %^BH(+
MVWN?]5("1U'0U/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAJL3O8,\8
M/F1$2+CVY/\ 6K]!Y% &=#=))%&Z\AP&Z=*E+J>@'4=ZC?2(.L&8&]4Z?B*C
M.G704(+F,KZ^7B@!UW>1VMH^TY/3UI-$AV69EQ\TIW?AVIHT4/C[1.T@!R5
MV@UIH@1%10 H& * '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%% (/2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "@#%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!11FFJZONVL#M.#@]#0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *:J*F=H R<G ZFG44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 444@;)(]* %HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **CDFCA7=(ZHOJ3BH#J=F#CS
M?_'3_A0!;HJ..>*49C<-]#4E !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !4<\RP0/*W11FI*HZES%".QF0'Z9H BCM?M&)KK+NW*KV4?2IC96[+@J0?4
M'FI%R,@FG9P03C% &?+8M;[I[:1@R@D@=ZNV-U]KM4DX#=&'H:F #*>>HYK+
MT<XGN4'W=V10!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***,@4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4A4'&>W2EHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>articles004.jpg
<TEXT>
begin 644 articles004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR3DYR>N0>]<+\)O"$?B[P+J-I>ZMJ$&GG4/WEI;,BK*0B'+$J6/;C.. <9H
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MVKH/$NLKH'AR_P!38;F@B)C3^_(>$7\6('XT <'<_$GROC3!X>$^-+\O[&_
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M8<.,D#!'3UKKKVUT7XF6VCZ-K\4EIK<FDQ:C#<1$*WSDJZ@$<C*AL'L>.F:
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M/?O6Y8WUKJ=C#>V4\=Q;3+NCEC.585Q>L:OX/\0?"QKZ_<IH#QQADM\AH6#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMEG['#G^X* +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DOI#K,SPS<.Q8JXX
M&:UJ* ,5K>YMV.Z,O&>2T?;\*='<K*#@<C\_RK8JK/803DLRX8]U.* *F1GC
M&>O2@D*G7]*<-+E5V*W7RGH"F2*<FE#(\V9G [ 8!H I!&U.Z5<GRD^\V.M;
MBKM& , =!2)&D:A44*!V%/H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **Y3QWJEQ#\/]6U#1-02.>!<K/$P
M;:5<!QW&>&'L:\<^'WCOQ1JGCS2;*^UJYGMII2)(W(PPVD^GM0!]'4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %><?%;X@KX5TS^S=.E']L72Y4@
M9\B,]7/N<$ ?CVYW_'7C.T\%Z"]W+MDO)<I:V^>7?'4_[([G_&OE/4M1N]6U
M&XO[Z9IKF=R\CMW)_I[4 >TZ+)M_9NOV?<Q99AD L<F7_/->=?"[_DI6A_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\E*T/_KLW_H#5Z3H84?LVWNUMQ,4Y;C&#YIXKS;X7?\ )2M#_P"NS?\ H#4
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M?=:3J-QI][$8KFW<QR(>Q'\_K7VI7S[\?-*BM?$6FZE&H5KR!DDQW9".3^#
M?A0!6^ F/^$YO>F?[.?Z_P"LCKZ+KYW^ 0?_ (32_(SL_L]L\]_,3']:^B*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^+DW?\ UPA_] %>C? /CP7J/_80;_T7'7 _'&W,'Q#,A*XGM(I!CM]Y>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  '_ &CCG\/>N^HH X3QXEUK&HZ5H3:1J-SH[W"S:C-;+PRC.U,@@XW8)QT
M&.:XOXE^ Y[?5-+NO"6E:G)>1?O))Q*\P&""F&=B0P(/'3D5[?10!YMXP\,W
MWQ'\"V<S6#Z?K=L=ZPW/R\X =<C/!P"#[#I4GAWQKJMEH-M8:MX0\0?VC;1B
M FWLRT<NT !M_ &?R_"O1:* ,G0I]8GTY[G6K>"WFD<O%;0DL8H\#"L>[=<X
MXKR..PUZ7XTKXK;PUJJ:<9>AB&\#R?+!(SCKSUZ5[E10 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 <EX\\=V/@?2EFE07%]/D6]L&QNQU8GLHKC?"D?CSX@6W]M7OB)
M]'TURPMXK.(!GP<$\_PY!Y))X->8?%/6)]8^(6J&9CLM)3:Q+_=5#C]3D_C7
MTSX9M5LO"ND6J*5$5G"F",'A!U]Z .%UNV\?^"K";4M.UM-?LH1YD]O?0#S$
M4#E@5() QTSQZ=:L^ M8\0^,_ UQ?'5EM-0:_DV2BW6150 $)M/;GUS[UZ,0
M",$9!K'\.^'++PQ9W-I8;A!/=/<A&QB,MCY1[#'% 'A&I?%CQUINN7>DO>6<
MD]M<O;$K;+AF5BO&?<5ZNVB_$);97C\76#W#<O%)IRA$..BL#DC/J*^>_%+*
MGQ)UEF("KJTQ)/8>::]I^)?Q+TNT\/R:?H6K)-J=PZJ)+23=Y*ALL=R\ \8Q
MG/- $?ASQ'XXM_BA#X;\33VSPO;O(!!$H608)#*V >H(P??BF_$W7_&'@EX]
M1L=:BGL+R8HL$UI'FW."0 0,L,9Y//%>D7&B65SKEGK$D9^V6<<D<3@X&U\9
M!'?I^IKS3]H#_D5=+_Z_O_9&H H>!=?\>?$"/4)8?$T&FBS"@*MA')YC-NQG
M(X'R]?TJEJ7Q1\:>"?$TFE:_'9:BL6"2J>69$(X96' S[BG_  (U.PTS3M?D
MO[VVM4,D.&GE5 >']37*?$S54\;?$(C08Y+T1Q+:Q&%"WFE2Q)7'498\^U '
MT(?$$5]X*FU_36#(UB]S#N'0A"<$>Q&#]*\X\&/\4?%FFQZI)XGAL+&7/EL]
MC$\CX.,A=@&,]\UW7A#PP^D_#NS\/:@Q9VMG2X"'[OF%BR@^V[&?;-=#8V4&
MG6%O96R[8+>-8HU]%48% 'SMIGQ0\=:MKUAHHUJ&"2>Z2V-PMG&QRS;<D%<'
MKGC%=/XWO?B?X*MAJ!\1PW^G;PAE6RA1E)Z;EV< ],@FO+O"G_)2]'_["T/_
M *-%?5FM:/::_H]SI=\K-;7"[7"G!Z@C!^H% '"_$V_\6>'=+;Q#H^O".T1X
MUELGM8F"@X&0Q!8Y;M[^U<M\/_%?CCQ[KEQ WB-+"WMHA(_E6,3EN0,#<O'?
MG/X5VGQD 7X7ZB!T#PC_ ,B+7G_[/O\ R'=9_P"O9/\ T*@#JOBIJGBWPE9I
MK.E^)"MI-<"'[(]G"?+RI((8J21\IZ^M8'P\\0>//'ES?Q_\):+*.T1&+?V=
M#(6+$X&-H_NGOZ5T7QZ_Y$*U_P"PC'_Z+DKB?@EXATCP\=?GU;4(+1&CAV>8
MV"^-^0HZD].E '6>+H/BCX;TN?4[3Q3%J-K -TBK80I(J]VV[2"!SGGISZXO
M:C?^+;KX8VGBC3O$+6]U%IRW%Q ;2%EF(R7;)7Y3CL...G-3?#WQ+)XSU[Q?
M<L\TFDL\$5K%+]U4VN&P.V< GZBMSQ+IMMH_PMU;3;166WMM+ECC#')P(SU-
M 'D7@OQWX[\6^*;31SXD%NDNYGD^Q0,0JJ2<#9UXKWF2YCT30VN=4OC(EK#O
MGNI$"EL#EMJC'X 5\V_!C_DIMA_URF_]%M7H_P >]6EM/"]AIL;[1>W!:0 _
M>5 #CZ993^ H QXO'GBKXC^+&T7PU<_V3IH)9K@1YE$0(^9CV)[!<=<$]379
MM\/=9MH!)8>/-?%Z@RK74WFQ,WNA[9QZ_C7)_L]VBBTUV\(&YGBB'J  Q/\
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MV]+J^H16BR+ 8P^<OCS,X Y/4?G0!W'B+0OB+HVEO?:3XR:_%HCN8)K.-7*
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M =P ^N,UT?PO\.7GACP5#9ZC"(;Z6:2>=-P8AB<#)!()VJM '94444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^%>FTR)S+"DA1D+*&V..5SV/O3Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO#K_ (;2]T6]6 W<(DM[AHQ($SSRN>2.A&:^:_BC?P>(_B3='2&^VJPB@C,
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M+$#!8]Z6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(W&D6>H:QJ-K+;W<[_9HDE0JRQJ<L>?5L#_@% &3^T+&D4?AF.-0J(+E54=
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M ,X)YY/_ ->MW6+^/PM\)K?P]+8W\M_<Z.81'!:LP5W3#;F' PS'/.: .A\
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M>2?#;P5J/@WXJZG;3Q2R67]GO]GN]AV2*9(\<] W!R/8]J /:**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ P,YQS1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<\-7[66K74\$P /_ !ZR,IR,\,%P?PK.C^+W@N:810ZE-+(W18[.5B>,] M
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MD[6*DX],B@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHJ&[9ELIV0D.(V*D=<XH ^;OBQX]O/$6NW&BVDK)I5I*8]B'_7R
M*<%CZC/0?C7NG@CPO:>$_#-K8P0JMPR*]U(!S)(1R2?3L/:OE#2@LWB"R%T^
MU'NH_-=N, N,D_K7VE0!XI\=?#4%O!9>)[)!#="<0SO&=I;@E&^H((SUY'I7
M1_"#QO/XJT.:RU&0R:E8;0TC=98S]UC[C!!_ ]ZF^-0!^&EX2 <30D>WSBO,
M_@(SCQU=J"=AT]]P[??3% $7QVLK:T\>026\*1M<6*2S%1C>^]UW'WPH_*O6
M?AWI^EI\+])DN+.U:,VS22F2-2#R22<UY=\?O^1XL/\ L&I_Z,DJ:\U+QS;?
M!ZPAM=/M1H<EJRS74!+RB,L1A@3\H(/) /U% '0>)/!FEZM)X:\7^%=,D3[1
M>V[S0P18'EDYWE!PN,<D<<Y]Z]EKF?AW_P D[T'_ *\T_E734 <C\3[6WNOA
MUK)GA20Q0&2,L.58$$$'M7A?P:MX;CXD6:SQ)*HAE8!U# '8>>:]Z^(__).M
M>_Z]&KYS^'&IWVC^+DO]/TQM2GAMYF-LLFPLH0Y(.#D@=@.: /0OCUX>TZTM
M=-UBUMHX+F24V\OEJ%$@P6!('<8//O["M;X"ZW>W^@ZAIMR99(;*13!(^2 '
M!R@/L5SC_:KSC6?%5Y\4O%.FV.IW%KI-F)#'"<%EC+8Y8]R2 .P^E?0GA#PE
M8>#=#33+$M)EO,FF?[TKD $^PX  [#\Z /,/V@[.W$&B7BQ(+AGEC:0#!9<*
M0">^.WU-:/P%L;2;P;J$\MM$\IU!D+N@)P(T('/U/YU5_:$_Y!6A_P#7>7_T
M%:POAK<>.(/ >H?\(I::=+%]M<L\S'S@_EIG:I(7IMQGWXH [GQ?X<T#QKH6
MOII6F1_VQI;M$LL,2H[RJH;8"/O YQSWJIXYO;_0?@7IENBRV]S+:VMG,,%6
MC'EC>#Z?=*GZT_X&R74VAZY)?%S=MJ;F;S!AM^U=V1ZYS7>>)O#UIXI\/W6D
M7I98IP,.OWD8'(8?0T >?? [6]$/A;^R8I88=665WFC8A7F!/RL/[P P..F/
M?F[\4O <>M0VVMZ99[M5MIX_,$*9:>,L <@=2O7/H#7B7B?P'XA\'W3M=VLC
M6R-\E[ "8SZ'/\)^N*Z[P%\8]3TN]AL/$5PU[IKD)Y[\RP?[1/\ $OKGGT/&
M" >D>._"/_"6^-/"\%S;2R:7 MS)=NN0N,)M4L.A) ]\9QTK#^-NEZ?I?P\L
M8;"RM[:-=0C 6&,+QY<GI]*]=5E=0RD%6&01W%>7?'S_ )$.T_["4?\ Z+DH
M Y;X!6=K?'Q%#=V\,\3) "DJ!@1^\[&NWT#P</"_Q6NY]+LFBT>]TTL2JG9%
M*)%R@/;(&['N<<"N/_9X_P"/CQ#_ +MO_.2O=* "OE7X@>+;G5?B&^L6DK+'
M9R!+&0<#;&QPP]<L":]_^(NLR:/X.NQ:L3J%[BSLT4_.\DAV_+[@$G\*\Z^*
M_@:/3/AYHD]J SZ.BV\[ ?>5\9;_ +[_ /0S0!Z_H.L0:_H-EJMLP,5U$),
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MI7G7_"D/!Y7YTOW?.6D:Y.YCWSQCFNS\/Z#:^&])33;.:ZE@0Y7[3,9&7@#
M)Z#CH..30!SOQ;=4^&&L[F W+$HSW/FI7F'[/\B+XJU-"ZAVLOE4GDX=<XKU
M+Q+\--(\5W\MUJ5_JOSE2(8[G$2$+CY5((&>]9D'P5\,6DWG6=UJUK,!A98+
MO:R\8.#M[]Z /1J^<?CV4/CFT"L2XL$W#GCYWQ7T/':B.P2T\Z9@L0B\UGS(
M>,;BW][OGUKA9_@UX4NY3-=_VC<3$#=+-=LS-]30!<^$I5OA?HP!!PLH./\
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MSE68>P&1[D^U>C:;\*/">GW?VN6RDU"XX_>7\IFR?4@\$_A7:JJHBHBA548
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MZCCI6QXG\%:'XOC@75[4R/ 3Y<D;E'4'J,CM0 >#?%EGXQ\/PZE;%5EQMN(
MV3%)W!]NX/<5O.ZQHSN0JJ,DGL*YCPQ\/]"\(WDMSI*W2/*FQU>=F4C(/3IG
MCK5WQ)X4T[Q5;QP:C)=B%,@I!<-&KYQ]X#AN@ZT ?*?A9E'C716) 4:C 23T
MQYBU]D5YU_PI+P9_S[WG_@2:[+0M"M?#U@;*TENI(MVX&YG:4C@# +=!QTH
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M.,^A-,^#7BR+7/"B:7<7)?4[#(<2,2[QELJW/4#.WVP/45T_A?P1H?@\7/\
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M/)[#-4M80$VZ(O+$C^5 &LK D;2"/2GU#!;I!&BJ.0,$^M34 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 E9ET?+U,/_?AP/P/_P!>M2J&IV[20K+&N9(CD =Q
MW% "&7.,9)'M2%E)X)^I[U4B=94#*V1W]J?MYZT 78F7J ?\*HZK(/MEF$^9
ME;.!]1C^5/R%R2V !DTRP@:ZO6NI,[5^YD8S0!M#I1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!2GTY)&WQMY3GJ5'!^HJN;*^ (5H#Z$D_X5JT4
M9J:6SD&YFW ?P*, UH!0JA5  '3VIU% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*7%W;V,]]+&Y*VT!7>_^B8XR0/?\* /8-*\>Z'K&N_V+;M=QZAL+F"XM)(2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP!*G:<X(ZCZU7N-2L+23R[F]MH9,9VR2JIQ]": ..MO%WBV[LUM8_!-W%JH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M97DNAW5P;BPO;6!IE7/!1\#(. OY'L:[;3?&*ZU=YTW2KY]-B1GN+Z>%H@,
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MPU]>2!#MVQ#Y%)Z<LP_2H?%UI+H_C?1?&26L]S;00O8WJ6\1DDCC;)60*.2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/U%D+R/D$X))4$CC(4@5OT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH#0!T%%<GH_Q$T#7_$G]BZ7-+<R>09O/5,1\'E><'/X8]ZZR@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\$<@$$5]$^)-!MO%'AZYTJ[&Q9T^5B 3&_4$>X/]:^6VN];\::Q91W%\+G4
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MW<ASC) ^[Q@GH.O2O%F\,Z^K%6T34@0<$?97_P *3_A&]=_Z NH_^ K_ .%
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M:M9:WIT>H:=-YUK+G9)L9=V#@\$ ]15V@ HHHH **** "BBB@ HHHH ****
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M\,_'1",@'GN<5X/10!]>Z'XOT'Q'A=+U*&>7RQ*T.<.J\#E>W) K<KY5\">
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM&FK.[@G/&Q06&/IVK3G_P"$;UO3M.>/QK?0110!4>'5O)>48'S2 X);ZC-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7F?Q!^%EUXPU-]4MM8\N985CAM9
MT)C!'7Y@<J#UX4\UZ910!\JZ[\,O%7A\323Z=]HMHL9N+5O,4YQT'#=3CD"N
M192K%6!# X(/45]L5P?C_1O!-EH,^I:SI=BLB;FAV@Q--,1P#Y9#-D]>O<T
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MQCC&*Z[9\3/^>WA3_OW<?XT 4?!GQ(&O:A::+-X>N]/N6B8\)B&-5SC&<$#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH8+P?8[F249"Q.0&/MC .?:MGPU>WVGZ_/X95W%[$L]CITT3"(Q3O(N9"QY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRP2@9*2H5;\C4->Q_&_7M"U%-.M;$VEY?*6=[J&3<8D[)D<')).,\8]Z\<H
M*]2^#[>&M0GN-%UW3=/FN9'\RUFN$!=R1@QC/TR/J:\MJ:SNY["]@O+:0QW$
M$BRQN!G:RG(/YB@#[-M;2WL;6*UM(4AMXE"QQQKA5'H!4U8WA;7[?Q-X<M-4
MMV!\U )%# E''WE..];- !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<OX_P#$=UX8\+37FGPF6^=UB@7R
MF==Q/)..F%!(SW%=110!\<W&B:V%%W<:5?JDY++*]LX5R>>#C!J6/PGXCFC6
M2+P_JKQL,JRV<A!'J#BOL&B@#XPGTR_MK?[1/8W,4&_R_,DB95W8SMR1C..U
M5:]F^/6ME[S3=$BG<+&K7$\6,*2<!#GOT?\ .O&: /</ASXATWQEX1E\#^()
MR9@@2W!.PO$N"H4CJRE0<'J!WP:Z#1/@IX8TT,U^)=3DW!E,K&,+CMM4\Y]\
MU\XH[Q.'C=D=>0RG!%:3^)-:DTZ/3WU2[-I&Y=(_-. Q[_J: /H;Q;\3]!\+
M:<]MID]K>:@B!8;: YC3JOS%>!C'W<@_2O(?!/A74?B!XM;4K^$R6!N#-?3D
M%4<D[B@(QR<]NF<US_A/PS>>*]?M].M8W*%@9Y!TBCS\S$_R]37U/%IX\.^&
M_L>A6"2O;Q8@@+A!(W^TWOU)H Y+QA\)-"UVRDDTNUATW454>6\*[8VQ_"R#
MCGU STKYQO["ZTR^FLKV!X+F%MLD;C!!KVGP1I_CR]^)-UJ^L1RVT499+@7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTR[M8KW3H00@'R2KZ -TQG/49YZUVM[\=-$M;2/^S=+FDFEB,C@X18Y3V/\
M>YY)'_ZO!Q;SFV:Y$,AMU<1M+M.T,02%)Z9(!./8U'0!>U?5[W7=4GU'4)C-
M<S-EF/ 'H .P'I7M/P#MK9='U:\**+@W"Q&0GG8%! _,FO"*4.P4J&(4XR >
M#0![)H?B:[LOCUJ45]>/Y-W<R6>T8((!(B''3''/N<]ZF^.?A?/V?Q-:H"#B
M"Z*@G_=8G_QW\J\5R<YR<^M:*>(-530I-$6]D&FR/O:WXVEL@Y]>H!H V_AB
MB/\ $?1!(JLOG,<,,C(1B#^>*]=^+_C6_P##5II]KHVH1P7D[L\NU5=P@ QP
M<@ D^G./K7SJ"0<@X(I69G.68L>F2<T >Q>"/C-+:QWD7BRZEN1PUO)' N[/
M.5.,#'3''K7G'B[6[3Q%XENM5L[ V27!#/$7WDO_ !-GW-8=2PVT]P)#!#)*
M(D,DFQ2VQ00"QQT'(Y]Z &QS21;O+D=-RE6VL1D'J#[4RBB@">"RNKF&>:"W
MEECMU#S.B$B-<XR3V&:@KV?X V<CW&N7+1 VYCCBW,OWFR20.W3K]174>+O@
MWI&OW%Q?Z?.^GW\S^8_&^)CSGY>H)/<'\* /G"OI3X)H$^'<3 L=]U*QR>G(
M''Y5X1XH\(ZMX0OTM=4B0&1=R2Q$LC#V.!R*]X^"CJWP[B ()6YE!P>AR#_6
M@#T2LO5O#FCZY;R0:EIT%PDA!<E<,<=/F&#V]:U** *>EZ58Z+IT6GZ=;K;V
ML6=D:DD#)R>O/4FKE%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%)D[L8XI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@444 %)SGIQ2
MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&3T]Z '44@I: "BBHVD"E0S!2QP,GJ?2@"2BF/(J*69@JCJ3VH5PQ(# X]*
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MH /I2T4 %(54D$J"1T..E+10 F!D' R.]+110 4A52P8@$CH<=*6B@ HHHH
M2E%)BEH **** "BBB@ HHHH **** "BC-% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:* $I:3%+0 4
M444 %%%% !1110 4444 %%%% !111F@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L._\ ^1NT7_KA=?\ M.MRL.^E*^+]
M(C8)M>WN-I();<-F0/3B@#;I2<4E9NK)JDDEJNG2)&A<B=F&2%QQB@#2SFF;
MPSE0PR.HJ.WCGCB1)91(0,%L<FI@@'2@   &!39H8YXFBE0.C##*1D&I,4E
M#4C6- B*%4#  %.HHH 9Y29!V+D'<.._K4AX%&*1ONF@!-W.,4 YKRW6(/B'
M?W]Q]AO+B#;<.$MP(XHEBZ1N)=I+>K+G/2O3+))TLX4NG#SA )&48!;'.* +
M%&:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMZIJ5K(FHR6HLKQIXY@<^8C#[FP<8'3)YP377(",9ZXY- %:^@N)Q$L%TUN
M^7**"77TR>GUJVIR,TM% !1110 FT>E  '04M% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8E_C_
M (2_1?7R+K_VG6W6'?!F\8Z01$Q"VUQN<#@9\OC/^>M &Y1110 4444 )BEH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *,T4E "T4"B@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHH- !FBDI: "BBB@ HHHH **** #-%)2B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HI*6@ HHHH
M **** #-%)2B@ HHHH **** "C-!I* %HHHH **** "BBB@ HHHH *,TAHH
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HS124 +12"EH **** "BB@
MT &:*2EH **** "BBB@ HHHH **** "BBB@ HS124 +10** "BBB@ JC*/\
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MYUVP>1U%P(IO)4YR1\F[V_N]: -&EHHH **** "BBB@ HHHH **** "BBB@
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MEHH 2BEHH 04M%% "44M% !1110 4444 %%%% !1110 4444 %%%% !24M%
M"4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0M4MI:O=.9905CZ =S6E;6T5I$(H5PHY^IH8T3"BBBD,**** "BBB@ HHHH
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MP]'\6Z/KEO<26D[B:U!-Q:RQE)X<?WHS\U9"_%/PI* MO>7-S-R7@@LY7DC
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M]01$CC6.-51% "JHP !V KFM)\+ZAI_BS5M<N-;%V+]!&D+6BJ8%4Y0!PW(
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M,;5!&T9'OGFEL_"-A8>,[SQ+:EHI[RW\F>%0-C-N!W_7@"@#R[QX O[0/A,
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MU[2YE,L6-Q,AW<,3_$.O- 'M-%)2B@ HHHH *2EI* %HI** %HHHH 2BBE%
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M@R>U:7_"+>+/^B@7G_@MM_\ "M;P7_R(GA[_ +!EM_Z*6MR@#C?^$6\6?]%
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M+PC_ -"SI/\ X")_A1_P@7A'_H6=)_\  1/\*Z*B@#G?^$"\(_\ 0LZ3_P"
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M1110 4444 %%%% !1110 4444 %%%% !1110 4&B@T <9\4_^2?7O_7>U_\
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MEO$)#6\=PC2 CKE0<\5XGX-N#XL\<K'J2R>'=5M]&^R010PF-YP58&4$@;2
M<@8/UXJSX@\':58?$7PY9^%[;RY=/(N]4F24DQQJRD,Y8XW$;CCJ<^E 'N5%
M-0[E##.",BG4 %%%% !1110 4444 %%%% !1110 4444 %<E!_R5N^_[ D'_
M *.EKK:Y*#_DK=]_V!(/_1TM '6BB@44 %%%% !1110 4444 %%%% !1110
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MCK,?D.]\[6]PI!#X"%) /3*]#VS3O#FI>/?#>@6WAV3P<;RYME,4%X+Q%A*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)_QI!\,O!0S_ ,4Y9<_[)_QH VO^$BT3_H,Z?_X%)_C1_P )%HG_ $&=/_\
M I/\:R(_AOX,BD#KX;T\D=-T6X?D>*ED^'W@^61';PUI8*'(VVRJ/Q &#^-
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MI8V"DAF!P,%NP)X[U>^&LWB&Z?7YM9U*&ZC35)X%148%'0A3M)/"<<+CN>:
M.^HKS);O7/\ A<VI&;584T_3].$A@$)VM QW$?>X<$?>_3M50^./$]EX8T[Q
MK?3V+:1=7(673XX"'BA9BJD29Y88R1C% 'K%%8/C+5-0T?PAJ&HZ5 9KN%%9
M%5-Y + ,VWOM4EL>U>>77COQ#%X+U+7K#6].OX+6Z@$,@M@KNCX5DDCW9C(8
M]^H''6@#UF^OK;3;&:]O)1%;PJ7D<@G:!]*AT?5['7M*@U/39O.LYP3')M*[
ML$@\$ ]0:X_5M4U9O'E]X9FNX7TV\T6:YC408>(YV8W9^;N>W6N+\)ZWXF\+
M_#KPWJRW-C-HKW0MFLO)(D"/*X+;\]<YXQCI0![E17E\WBS7F^($FE-JD&GF
M/48XX]/N[=42ZM#@,\<IY:0Y)"Y'IS5-_&OC76&O-1\-V$MS91WC16T7V6/R
MI(T;!+2&4.&."<;>XH ]<I-R[]FX;L9QGG%>>?VIXG\3ZEXA&AZFEA_9$BP6
MUL8487$H7+>8S G;DD#&.QJEHUOK5Q\6;F2[U9HKM=#@>:)(E:(.3R@)'*!L
MMD8/.,T =[H/B#3_ !)I[7VFN[P+*\)+H4.Y3@\&M2O&M.\?^(;WPEIZF^C_
M +3U/7CIJ78ME"Q1<<A>F1GC.?QK9N=1\3:#K^H>'FUE[M+C29+VPOIX8S)#
M)'U5@  P/N.X]Z /3*@O;VUTZSEN[V>.WMHANDED;:JCW->4Z)XE\3"3P3JM
M[K1NX=<=[>XM#;QHB\'#*0,Y[GU]J]=H PM/\8:'J7A^ZUZWO,Z9;&023LA4
M?)U(!Y(]/6LJW^*/A6[O;*SMKNYDGO)DAA7[%*H8L< Y90,<U@_!RQM=2^&<
MMI>V\=Q;R7TN^*1<JV"I&1]0*V+Z0:S\5],TU$5K?0[1[R8]A+)\D:^Q"Y/X
MT 7&^)'AM=7CT\W$_P"\G^S+=?9W^SF7.-GF8P3G\/>MC5?$%AI%YI]G<NS7
M6H3"&WAC7<S'NV.RJ.2>U>??$'3=6TK^QY+6ST[_ (1'3;^WF>SARDNXOC)[
M%=S=NYY%:V@SG4_C#XIEN8OGTVUMK6U+#!1&!=L?5N<^F* -^W\::%=^*&\.
MVUV9M20.9$2)BL>W@@MC&<\59TWQ'8ZGJ^HZ5'YT5]8.!+#,FTLIZ.O]Y3ZU
MS%[_ ,ESTO\ [ DO_HRE\:2-I?C;PCJMLH,[S36<J#[TL3)NVX[X*Y'H30!T
M\7B*RN/$DNA6ZS374$7FW#HF8H<XPK-V8@Y ]*U2< G&?:O*?!TUT_P4U77(
M+N2VU6Z^V:A+<QA2QE5F/0@C!" 8QT)QBH="U#6K35OA_/-KVH7@UVWF:[AN
M&4Q_+$K+M 48Y/7))Q0!Z3H6OV7B&Q-S9EU9',4T$J[9()!U1U[$5J5P2S-I
M_P ;WM8%;RM3T=9K@#&-\<C*K?EQ^--\27<^L?$>P\(OJ%S96#Z<U[+]ED\N
M2=]Y54#CD ;2W&.E ':ZGJ-MI&EW6HWC[+:VB:61L9(4#)P.Y]JRO#/B*Z\0
M)<-<Z'>Z8L8C>)KC!69'&05(XR!U';(KS#6IKV^\+^.M U+4;VXBT!E>UN6D
MVM*K D1RD</C ZUZQX<T:'0](BM8+N\N8\!@UU.96' & 3T''2@"#Q!XIL]!
MT>_U#RY+[[ 5%S#:E6>+(!RP)&."#]*TM+OAJFDV>H+$T2W4"3"-R"5#*#@X
MX[UXI'HT-OHOQ-N%NKUC;S3PJCW#,K J#E@?O-[FMW1VU#P]K?@"&+5KZ[BU
M>PE%U#/("F(X5= B]%P6Q].M 'K-97B+6_\ A'M'EU)K"ZO8H?FE6V"ED0 E
MG(8C@ =N:\GT1O&>LZ/;^+O^$AM;.+[29;M[B_<1B&-V4QF$1[%X'7=SGWX]
M2\8_\B/K_P#V#;C_ -%M0!S]M\5-+>"TO+W2]4T_3+Q@MOJ%Q$IA;)P-Q5CL
MZ=_>NZ!# $$$'D$=Z^>KNVUNW^#6BZA?:A!=^'8WA>;3$A\J1T\S[OFY)//L
M/TKOX5AN/BI;?9[FZ2SU;06N)K7SG"CYE56 SA3MXXQC'O0!Z/67K>JW&E1V
M;6^EW6H&XND@=;<<Q*V<R-_LCO\ 6O)(/M]YX%@L[:[N-52VUVX4V9NV2>]M
MHR?E1L[C@$-C-27MW')X!\/7VEZQJ[+'KRPE;F9EE16D.8I0&.[;@8R>GUH
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M8H&'+ 9&6Y'')SV]/&HK6WLSXKTM_P"R5@G\.?:DL[.7S%25.5))X,H R2H
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MIZDGN* .EAT^RMY5DAM+>-U4HK)& 0IZ@$#IP./:GW%I;W007%O%,(W$B"1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW(XS0!T5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTG3PG(\=P8V3[0RR'G:>1DBNUO?AUX4U&YLKB\TF.:2SA6&(N['**,*'Y^?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M39?@C9_/;-/;:UA,,-T>Z4G ],KS]*Z^#2?#VJ_&C5TF@LIT>Q@N(OF!!GW
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MGVSBM;X:W"6WBE]),UCJOE:5']FU:QX'V<-A8IE' D';O@<YH ])U/6=,T6
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ML-0+S::K-.T!6.)HU"LC$\YR#VQT]:[.@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KF=8\"Z1K6MKJ\LE[;79C\J9K.Y:'[1'V5]O)'T(/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!%-/%"T2R2JAD;:@9@-QP3@
M9Z]*D%(R*V"0"0<C(Z&G"@ HHHH **** "BBB@ HHHH *** <T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJE9?#."VN[>*?6KZZT2SG$]II,N#'$P)*@MU95)X!].<T <D^H^+IK[QT/\
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M!P,YZ]Z ,KXK:K>Z3X'DFLI9(!+<10S7$3[6AB9OF8'WX7_@5<_JWARQ\/\
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M&"?3!X'/ Z"@#S_6S)X2?Q_9>'GG@@BL+65(TF9S$[MM=P220=I))SV]JO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM?AUH5G;:/! +I4TJZ-Y%B;F64]6DX^;MZ=,=.*ZRB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HJN\TPF5(X=R;L.Q.,#'4>O-3J<C)H 6BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD.0..M
M "T53TU[][8G45MUGWM@6Y)7;GY>O?'6KE !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %-+#.,\TIX!-8CW/VFYD^8!8T.X#^$>GXT 7I]3BBF:$!GD"[L*,BJW
MVR^=2X"(.R["326$"PVJD'!=<G'<U:7(X.2..I[4R2FFI7<#$7,:NHZL@P?R
MK5AGCN(Q)&V5-5O($B]<>F:SXC+8:HL/'ERG!]_>@:-ZBBBD,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K,U6$@)=*,F'[P'=3UK3I" 1@C(H QHRKH&# @]*D
M'?'X43:6Z.7M' !.3&_(_"H_)O!P;;GV88IDO0D&,X)'KS3+*!;N\:Z*@(AP
MON:6+399C_I+;4_N(>3]36K'&D2!$4*HZ 4AH?1110,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *3<H;;GYL9Q2U UG UV+HQ)YX3RQ)CG;G.,^G% $]
M% X%% !1110 4444 %%%% !1110 4444 %%(#DG':EH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ I <C-+10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 448%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 8HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIK-M!)H =134;
M<H.",]C3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3-% "T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %)2TF* "EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ H-%% "4M)BEH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ADF:.>*,1.X<G++C
M"?7FIJ,9HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0G% "T5!"LPEF,DH9&
M;Y%VXVC'3WYJ<=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***#TH **:6 ZG%8UYXJT:RD,4EXKR@X\N(%VS]!347+9";L;=%8+
MZ]=R$"UT+4)<]Y (A_X\?Z4J:GKKID^'@OLUZN?Y53IR7_#H.9&[16,FJ:BH
M)N=$N%Q_SQE23/ZBI(]>L\9F6>V^;9B>(KS]>E+D871JT5''-%*H,<BL#R"#
MFGYJ1BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 &!Z4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%<SXE\4W6C:KIFE:?I?]HWV
MH"0QQ?:%B "+N))/M0!TU%<C#K/C>0'?X2L8L8QOU4<_DAJJ=2^(S,Q7P_HZ
M+N(56O23C/'('^?2@#N**X;^TOB1M4_V#HV3U'VP_+]:=_:'Q'_Z FB?^!C?
MX4 =O17$K?\ Q'9U!T;0U!."QNWP/?@5,MS\0FE9#IWA]5'1S=2X;Z83/YB@
M#L**Y-)O'Y4%K/PZI(Z?:9N/_'*'D\?E3LM?#@;'!-S,?_9* .LHKCTD^(N6
MWV_AD@_=VSS\<=_DYYS58_\ "TLG!\) =@?M% '<TF:X?'Q3_O>$?_)BF/;_
M !0F!S>>&("H)4Q),VX^AW#@4 =WN%&X5P26'Q0*G?K'A\'(P! YX[]OK3_[
M/^)F[_D-Z#MQU^S/0!W6X4;A7"#3_B;QG6M!Z\_Z._ _+Z4O]G_$O)_XGFA>
MW^C/0!W6X4;A7#?V=\2_^@YH7_@*])_9WQ+_ .@YH7_@*] '=;A1N%<,NG?$
MDL-VNZ&![6CFK)TOQ[Y@ \2:5Y>.3_9YSGZ;J .PW"L;7_$MCH%JCW6]I9FV
M001J6>5O0 ?A62^G>-XT9W\3:6J*"6)TX\#_ +[KCO#^@>,?$]PGB\^(+>UN
M'#Q6OF6(<+&#@,JDX4G!]>#UJHKJ]A,["VT76O$*^?XBN'M+4G*:=:R8X])&
M'7Z#\ZZ:RTVRTZ,1V=K# N,?NT )^I[_ (UR!T'X@E0/^$ULP1W_ ++3)_6@
M:!\0O^AVM?\ P5QTY3;!([FBN'&@?$#OXVMOPTN.L3PJ_COQ1HTE^GBZ"W9+
MJ2W*-IL; A#C.??TJ!GJ=(0",$ CT-<0= ^(&3CQM:X[9TN.K$?A_P :F,>9
MXX0/WVZ3$1_.@#?N-$LIV+JCV\I_Y:0,4/Z<'\:/*U"UC41RK=*HY$H"N?Q'
M&:P'\/\ C3C9XY3KSG28NGYT^'POXC^=KKQQ?N[-D>39PQJ!Z8*M5<SV%9'1
MQZA$7$4N89O^><A )^GK5D/D]*Y.X\'ZI=0/!-XQU5HW4JP\F#H?^ <54N_!
M_B**W1+'QEJ3JI&])4C+LN1G:^."!G&0?PI/R&CN,TN:X"U\,WEZ#$OCCQ!'
M+&3NCD,:N/\ QWD5:_X0;4_^AX\0?]_$_P#B:5FMP.US29KB_P#A!M3_ .AX
MU_\ [^)_\33H_ U^,^9XV\1-R.DR#Z_PT =GFDS7'Q>"+U3^\\9^(G&3P)T!
M_P#0:LVW@Z6$#S?%/B&<XP=]TH&?7A1_.@#I\T9KG4\)E9'8^(=>=6Z(UV,+
M],+G\R:A/@:T9RYU;6MQY)^VG_"@#J,T9KCQ\.=,\HQ'4]:9#U!OF_PJM_PJ
MK0?^?S6/_ YZ .ZS32V#BN'/PIT _P#+WJ__ ('-4B?"WPZB >9JC,#G<;^7
M)_(XH [7=QDTAD51DD >YKD!\,_#8B$;1W[@#DMJ$V3]?FH?X9>&9$"M!>D
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M-<Q_PJSP5_T 8O\ O[)_\54D7PS\&PL670;8DC!WL[C\B30!T?\ :5B!DW<
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MF+>GUKH:\4\)BZMM?B26TUC:=:FD6T;1P(MKN<2F9@-H4'=U[<5[70 4444
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MQ9!Q%8MIZ'>P80, "N<Y/ Z]>OK4[>&-&>XTNX>PC:;2UV64C$DPC & <\\
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MZ-'^?;_/%=?7(>*Q_P 5;X0/_3W+_P"BS0!UX&1S2@8I!TI: "BBB@ HHHH
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MB"W26-CT\U,C&?\ OO\ [Z%>C5PGQ3L@WA^VU>&XBM[[2[A9[=W;!;U4>I.
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M168PHHHH **** "BBB@ HHHH **** "N6\5?\A_PG_V$F_\ 1$E=37+>*O\
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M_P#[&>^_FM=U7"?#+[OB_P#[&>^_FM '=T444 0W=W;V-K)<W4R0P1C+R.V
M!7"S:WJWC82P:,&TW01E;C4Y_E>5.C"/T[\_RZ4GB[P_XF\0^(X@D%G+HMJ%
M>."XG*I,_<L%&<\].F![FMM/#$^HK$-<N4>VC4!-.M 8[=,>O=QQWX]JWBH0
M5V]2'=Z''/HNGZ_#_P ([X7TZ!;*W;_2=8N(]Q)_Z9M_$QY]!].#5?5/ 5WX
M3UO0+OPSJ3*[SM 3>X9%=D('1<X(##VXKUNWMX;6!(+>)(HD&%1%  'L!67X
METZXU'2#]CQ]NMI%N;7/0R(<@?B,C\::K7E;I_6X<NAGC7/$6GQJ-3\/&YP?
MFFTZ0."/4(>?UJPOC+2%.+HW-FV,[;FW=#_+WJ_HVKP:S8+/'\DJ_+/ W#PR
M#JK#L0:T" P((!!Z@U#<4[2C_7XC5^C,D>*=!(R-7M/^_HKE/$?B/1+3Q3H6
MM+J$,T<)DMYEC?<45UX; [ YS^%=-J][X?M"J7T5K-< 'R[<0B21O8+C/:LF
M+PS'X@=)M1TR"PTX,'2P2(*\N,X:4C&,9^[6D.2/O:B=WH5O#'B'2[NYO]?O
M]0MHY[I_+@C9QNBMU)V@CU)R3^%= /%V@L<#44/T1O\ "L8^"[W2"W_",ZC%
M:PN^YK:YA$B_@Q!(_P \U<\[QI&R 66D.I!!VRN #ZG_ .MZTY1IRU3_ !M^
M@DVC2MO$>FW=P88WF5LX!D@=0?Q(Q7(VOBJX\0_%:#3]*O3_ &58V\C7"J?D
MG;ID>H!9<?0^M:4_A[Q%XB8Q:_J4%MIQ.6L[#(,H]&<X./:JFNFR\$>(=(U:
M"U6'37A>QN%AC^X,[E/N<Y]\ T1C"[4=6T#;W9WM<GJOC$M?-I/AVV_M+4\?
M,RG,,'.,NP]/2J,\/B#QL2A:31M ;J!_Q\72_P#LH_Q[UUNEZ38Z+8I9Z?;I
M!"O91RQ]2>I/N:RY8P^+5]BKM[&%IW@U7O$U3Q#<G5=37E2PQ#%[(G3\36'J
M$#_#KQ(^LV<+MX>U!\7T*#/V>0GAU'8$G^GI7HU1SP0W4#P7$22PR#:Z.,AA
MZ$4*J[^]J@Y>PEM<PW=M'<V\JRPRJ'1U.0P/0BLSQ3I2ZQX<O+0L5?9OC8'&
M'7D?J*YAM&USP3>/<Z"LFHZ(S%I-,S\\6>\9.<\]AU]#UKH]$\6Z/X@'EVER
M%N1]^VF&R13W&#U_#-/D<7SPU7];A>^C)O#.J?VUX:L-0/WY8AO_ -\<-^H-
M:U<IX(=81K>F(5\NRU*58PO 5&^8#'L<UU=1424VD.+N@KBM*<:K\3M:U,$B
MWTRT33U8GY2Q.]_R/%:WBSQ)'X=TO,8\[4KG]U96J\M+(>!QZ#.2?\:XNWT2
M]DFM?!?G2()T.I:[=(V&E9SS&#[D $^@^M:4X^ZV^O\ 3)D]3>G\3:IXCOWL
M/"21BWBRMQJLZ$Q*>.(Q_$>>_'X<U6TFR@N]=DCL/%VHW>JZ?,OVX2/^[*\A
ME$>-O;''2NFU"_TOPCH0<Q>5;P@1PV\*Y:1N@11W)_\ UUQ/A?2M>\-ZM>^(
M=2TI9_[7S)-%:#,MJ2Q;!'<<C.#UJHZI\NG;S!^9Z=7EWB W,_CC5?#D(Q+K
MD=N!.6P(H$4^8/7) (Q[UU]QKVHW;K;:/I%SYK@;KB]C,4,0]3GEB/0#\:8G
M@NPDMQ)>,\^J%_-;40=LOF>JXZ = O2E3?LV^;J$M=C=C2VTS3TC4I!:VT04
M9.%1%&!SZ "O.-9L=3\57(\7:<TJC2I1_9MN4_X^$'^L?'^UT'LN*ZV7PQ/?
M[(M7U>XOK1#N^SF-8PQ[;BO)KH(XTAB2*)%2- %55&  .@%2I*GJM6.S91T7
M6K+7]-2^L9-T;<,IX:-NZL.Q%:%<Y=^&'@U5]6T&Y6QO)3FYC9=T-Q_O+V/N
M/ZU:AUB^B81ZAH]S&V<>9;?OD/OQ\P'U%2X)ZP!/N;-%,BD\U-VQT&< .,'\
MJ?6904444 %%%% !1110 4444 %<MXJ_Y#_A/_L)-_Z(DKJ:Y;Q5_P A_P )
M_P#82;_T1)0!U-%%% !69J^C)J?DS1S-;WMN28+A.J$]01W!]*TZ*<9.+NA-
M7W.:EUS7--_=7F@S7K#I/8,&5_<J>5-21WGB#52HBL5TJWS\\EPP>4C_ &5'
M /UKH:*OG7\J%9]S.U6WU)]&>#2;J.*^ 41S7 W#@C.>.XSV[U>B\P0IYI4R
M[1O*# )[X]J?147TL49?B62\B\,ZD]A"\UW]G<1HGWB2,9'J1UQ[4OAW38](
M\/6%A&"!#"H.1@[CR?U)K3HI\WN\HK:W"HYX8[F"2"9 \4BE'4]P>"*DHJ1F
M7H^@66AK+]D\YFEVAWFE+L0N=HR>@&3Q6I113E)R=V"5C%\1:*^JV\,UI+Y&
MI6C>9:S=@>ZGV/\ GTK.A\0>)(HO+NO"TLLZ<%X;A=CGU&>E=715JIIRM7)<
M=;HXZ?2/$7B=1%K$\6F:6W+VEJV9I!_=9^@'T_*NIL;&UTVRBL[*!(;>(;41
M!P!5BBE*;EILAI6"LO2-*N--N-3EGOY+O[9=-.@<8\E2  @Y/ Q[5J45-QA1
M112 **** "BBB@ HHHH **** "BBB@ KD?%7_(V>$/\ K\E_]%FNNKD?%?\
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M]A)O_1$E=37+>*O^0_X2_P"PDW_HB2@#J:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M1\5?\C9X0_Z_)?\ T6:ZZN0\5D#Q9X0!(&;R7'_?LT =>.E+2#I2T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<
M!\0?^1I\#?\ 85/_ *#7?UB>)/">D>++:"#5[=I4@?S(BKE"K8QG(H V0P)(
M!!(ZC/2HC>6H.#<P@^F\5QO_  J/PEG/V2XSZ_:7_P :<OPD\%@+NTDMCJ6N
M)/F^OS4 =?\ ;;7_ )^8?^_@H^VVO_/S#_W\%<I_PJCP1_T H_\ O_+_ /%4
M^/X6>"HI ZZ%"2/[TLC#\BV* .H^VVO_ #\P_P#?P4U]1L8EW27ENB^K2J!Z
M^M<Y'\,O!L4CR+H%MN?KDL1^ SQ^%2_\*Y\'D8/A^R/_  #_ .O0!K?\)!HO
M_07L/_ E/\:/^$@T7_H+V'_@2G^-9'_"M_!W_0O67_?%+_PKCP</^9>LO^^*
M -;_ (2#1?\ H+V'_@2G^-(WB+1$4LVLZ>J@9)-TF!^M97_"N?!__0O67_?%
M'_"NO"';0+,?\ /^- %T^,?# 8@^(](!';[;'_\ %4T^,_"PZ^)-'_\  Z+_
M .*J%/ /A)!@>'=-/&/FMU/\^_OUIZ^!_"J(J#P[I9"C S:H?Z4 2?\ "9^%
MO^ADT?\ \#H__BJ0^-/"HZ^)='_\#HO_ (JD_P"$(\*_]"WI/_@''_A2?\(/
MX5SD>&])_P# ./\ PH =_P )GX6SC_A)='S_ -?T7_Q5'_"9^%O^AET?_P #
MHO\ XJG2^#O#,S!I?#^ER,!M!:TC) ].E,_X0CPI_P!"WI/_ (!Q_P"% "_\
M)IX5SC_A)='SZ?;HO_BJ/^$T\*\?\5+H_/3_ $Z+_P"*I\'@_P -VTGF0:#I
ML3XQN2U0'^5)'X/\-PS&6/0=,20]66T0$_CB@!/^$R\+X!_X232,'_I^C_\
MBJ3_ (3/PL/^9DT?_P #H_\ XJK:^'M&0872K(#T$"_X4O\ 8.D?] NS_P"_
M"_X4 9/_  L/PA_T,-A_W\J"Z^)W@RT"F77[8[N@B5Y#^(4''XUO?V#I'_0+
ML_\ OPO^%)_8&D?] NS_ ._"_P"% ',_\+<\#?\ 0<'_ ("S?_$4O_"V_ ^"
M?[<''_3K-_\ $5U!T;3#NSI]K\Q!;]RO..G:I(M,L8#F*T@C_P!V,"@#DO\
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M7Y8VW_AHOGD&*8#%)';?$PD^9?\ AE1CC;#,W/Z5V]% '(?8_B!_T%= _P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 (  >!2T44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4\DD<
M3-%$97 RJ9QN/IFI%)9 2-I(Y'I2X!ZBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *0TM% %>..99IF>7>CL"B8QL&,'GOSS5BDI: "BBB@ HHHH
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M2*F!QY<&<_J*/80MK-?C_D/VDOY7^!U>?>C(]:Y+_A%=9DA"R^*+K<7R^R(
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M1+!)SY6HV&J6XNUSMVD'&\?[)SQ]:T)O"=[+X9NK3[5$-1N[I;J67!"!MP)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/2N5M=.L;;X;S7\-FD5S+IC!Y,?,V5Y/XD9JQHT%HUG8,?"G[QH8V\X)$5/
M^;.?Q]:4J*?-*4F[.W3]6-3:LDDNITMO_9L5W);VWV5+E1N>./:' ..2!SW%
M.>_LEU".Q>XB^UL-R1%OFQ@\X^@-<;>(^G^/I]99F6%9H+>0<8*21X#9] P%
M5[8"Z^(\&K R!);NXM4# ;<10A<@^[;L4?5DUS-_9O\ .U[![5[6ZV^7<]$H
MHHKA.@**** "N+^)QQX9MSC.+Q#C_@+5VE<E\1T5O!\S,H)26-E]CG'\B:WP
MK_?1]3.M_#9T>FMOT^V;&,Q*<=AP*MUFZ"2V@V#$YS G\JTJRGI)EQV"BBBI
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M35SOCI2W@O40 3PAX_WUK6A_%CZHBK\#]"[X:.?#6G9(/[A>1WXK6K&\*?\
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MNUA^,AGPAJ?_ %Q_J*UH?Q8^J(J? _07PBX?PMIVWH(0/RXK<%<UX#<R>#K
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MB@ HHHH **** "BBB@ I#2T4 )2T44 %%%% !1110 4&BB@!*4444 %)2T4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BC-&: "BC-% !111F@ HHS1F@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !0:** $I:** "BBB@ HHHH 2BEHH 2E%%% !1110
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M]QS4WQ%TI9MD,%S,H/+*H'&.V3Z_2BW^(%I,I+:;? CLJ!OZ_2NL6")  L2
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M:*** "BBB@ HHHH **** "BBB@ HI*!0 M%%% !1110 4444 %%%% !110:
M"BDHH 6BDI: "BBB@ HI** %HI*44 %%%% !1124 +10** "DI:* $HI:* $
MHI:* $HI:* $HI:* $Q2T44 %%%% !1124 +1244 +1244 +1110 444E "T
M4E% "T4E% "T4E% !0*** %HI** %HI** %HH%% !1110 4444 %%%% !111
M0 4444 &**** "BBB@ HHHH *,444 &**** "BBB@ HHHH **** "BBB@ HH
MHH ,4444 %%%% !1110 4444 %%%% !1110 4444 %&:0T4  .:6@"B@ HHH
MH **** "FALDC!&/6G4E "]:,4"B@ HHHH **** "BBB@ HHHH **** #%%%
M% !1110 4444 %%%% !1110 4444 &*,444 &**** "C-!I* %HQ110 8HHH
MH **** "C%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444AH 7-)
M110 4N*04M !BC%%% !1110 4E+24 %+BDI: $HI324 %%%% !1110 4444
M%+BDI: "BBB@ HHHH **** "DI:2@ HHHH **** "BBB@ HHHH **** %HHH
MH 2EI** %HHHH **** "DI324 %%%% !2TE** "DI:2@ I:2EH *2E-)0 44
M44 +1110 4444 %)2TE "T444 %%%% !1110 4E+24 %%%% "BBBB@ HHHH
M**** "BBB@ HHHH **** $I:2B@!:*** "BBB@ I*6DH 6BBB@ HHHH ****
M "DI:2@ HHHH 6BBB@ HHHH **** "BBB@ I*** %HHHH 2BBB@ I:2EH **
M** "BBB@ HHH- "444F<DC!_*@!:*** "BBB@ HHHH **** "EI*6@ I*6DH
M **** "BBB@ HHHH **** "BBB@!:*** "BBB@ HHHH **** "BBB@ H-%%
M"4HHQ10 4444 %%%% !1110 4444 %%%% !1110 4444 )12T8H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!#12T8H 2BEQ10 4AI:* $I:,4
M4 %%%% !1110 4444 %%%% !24M&* $%+110 E%+1B@ H-%% "4M&** "DI:
M,4  HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:,4 )2T44 %
M%%% "44N** "BBB@ HHHH #24M&*  4444 %!HHH 2E%&** "DI:,4 )12XH
MQ0 4444 )0*7%% !1110 4E+1B@ %%%% !1110 E%+BC% "44N*,4 )11BEQ
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>articles005.jpg
<TEXT>
begin 644 articles005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJAJ^K6^B
MZ3<ZE>$K;VZ;GQUQG'^% %_-&:J;+EG)6Y0#L/+SQ^=1SPZ@4_=7D2MZM!N'
M_H5 %^BJEI'=Q^8+JXCFR?E*1[,#WY-6Z "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M95_I3W>L6%\DQC-L6W#&0X/:M6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q_P 4"4^'
M>K.I*L!$01P1^]2NPKC_ (H_\DXU;Z1?^C4H Z]0 *6BB@ HHHH CFB2:%HW
M574CD,,@UC:=I.I*4DU#5)2Z3R.L<!'EE"V55LKDX''&*W:* &E03U-. P,4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%(3B@!:*:LBNS*""5X(]*=0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'_%+_DG&K?2+_T:
ME=A7(?$\%_AWJJ("S-Y0 '<^:E '7T4@-+0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 &**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *Y3XB(?^$*O&1@KK) RM_=/G)S75URGQ#02^$W@8 Q
MS7,$;CU4RK0!U('-.IJTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *Y;Q^/\ BG$_Z_+?_P!&+74UR_CHX\.=<9NK<<C.?WJT =.M+35IU !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(<
MX..M+10 U 0OS')IU%% !1110 4444 %%%% !1110 4444 %%%% !7->-V4>
M&W# G-S;[<#H?-2NEKG/&@8^')-AP!<0%O<>:G_UJ .B%+56XO[>T \U\$]%
M')JJVN0 _P"JFV_WMM &I16(WB!BP,=HY3N2<'\JL6^MP2NJ2(\+'@;NA_&@
M#3HI <TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M< _09'%=OX-\8:-=?#_3K^2_MH5M[14G1I%4QM&N&!'&.F?H10!RO@/Q'?\
MCK3=9\(^([RXAU:Q;!NK23RI&"M@G*\95@,]CD>]9/PMGNI/B/JNE>(]7U*\
MU72V=;/S[J1D8#<CG:3@Y#*1^=.^ ^BWTNI:SXIN5D$%V&BA>0\RDON=O?!
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M_KS764 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M8OB)':SC*O'&1,@3><;G+851[DD#\:VJYGQX95\.Q&%6:47]IL"9R3YZ8QCF
M@"]972W"D%-LB@;U)Y![BIY>>0!SV!J:?3X9W$G*2#^)>"?K56>RNT ,4OF@
M=CP: (CUQ3HR%)SQ54RRJQ#PR C_ &<U-##<W# K&43^\W^% #QB[U2)5'R1
MKDULU!;6JVRX!RQ.2QZFIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  C((SCWKSBR^%=UI%
MC_9^C^,]8M-/?=YL!5'SG.=AP-GX5Z/10!BZ)X5T?0?#B:#:VB/8!2LB3 /Y
MQ/WB^1@D_3'X5RL/PHCTR6[70?$VLZ39W3;GM;>1=JG/\)(R/3/7WKT2B@#A
MM0^%6AWN@QZ-#=ZE96F\R7 MIP&NW.#NF+*=YR,^WY5%I_PIL-,T&ZT:T\0^
M(8[.X()5;M5V?W@N$P W?CFN^HH X&S^$6@:;#-#IU]K5G#.H6>.WOF191D?
M>'?@$?1C4,7P8\-6I L;K6+-"P:1+>]*B7'0-Q[GI@UZ)10!Q*_"KPU'H4FC
MQ"^CM)9C-,$NW!F; 'SG^(#'0U6@^#?A""-83#?2VP;>;=[R3RV/J5!%=_10
M!!9V5MIUG%9V<$=O;0KMCBC7:JCV%<?<_"KP[)JTVHVDFHZ:]QN^T16%VT*3
M$_W@/J>!@<]*[>B@#G8O!&@V_ALZ!;VTD%@S!W$,[QO(WJSJ0S$X[G^58ME\
M(/"-A!+%!!?*)?O%;Z5,_@K '\0:[RB@#CX_AAX2CT==)739/L N?M1@^TR[
M7DP!EOFY& .#5-O@UX"=LG0R/I=3#_V>N\HH S]$T/3?#NF1Z=I-HEM:QDD(
MI)R3U))R2?<U'KOAS1_$UD+36+"*[A!RN\89#ZJPY4_0UJ44 <M8?#KPMIVI
MQ:C%IIENX1B*2YN))RGIC>Q ZU9UOP/X;\27RWNKZ5%=W*QB(2.S A020.".
MY/YUT%% &7H?AS2?#5I):Z/9):02/YC(C,06P!GDGL!6I110!R^N_#KPGXCN
MS=ZGHT,EP?O2QLT3-]2A&>O>M70_#ND>&K+['H]A%:0DY8(.6/JS'DGZFM.B
M@#$U;P?X>UV\^V:KI%M>7'EB,/,NXA1DX'IU-);>#?#UGI=[IEMI4$5C>_\
M'Q F0K\8]>.G:MRB@#F8/A[X1M9[>>#P_8QRV[K)%(L>&5EZ'/?\::/ASX-
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M;P];W2W4.@Z7'<*V]94LXPX;U! SFM:B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *YSQJR)HMJ\D@CC74;0NV,X'GIS71
MUS?C9/.TFQA^7$NIVB$,A8$><O7D<?\ ZN] '24444 )BC%+10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWQ0O+^.UN+BUC'D^;_RQ*P$;EST.\8SZCWH ]AN]1LK")9;R\M[>-SA7FE5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKG+%@ ,=:7[3#E1YJ ORHW#GZ4-;PNA1HT*MG(*C!S2&U@9E9H8R5X4E1D4
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M2?%3PK%&9Y;B\2SP2MXUC,(7([*VWD]/SH [2BF12I-$DL;;D=0RGU!Z4^@
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M7;5Y\W@&\TP^%+'1=1O6L=*O6GGDN+KGRC@^7M50'!(P,_=R?6O0: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N;\9,PM=' ?:#K%F"/[P\T<?R/X5TE<UXR4-#H@)Q
M_P 3FT/Y/F@#I:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH BM[6WM(O*MH(H8\EMD:!1D\DX%2T44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3GMDCK7F&B^#==O'UBQ@TBXT#3[_ $V2*]@FF5X7O"/E:( DA,GMQCCTKVD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KGO%4JQR:"A!)DU:%1CL=KG^E=#7.^*YO
M*E\/IMSYNKPIG/3Y7;^E '14444 %%%% !1110 4444 %%%% !1110 4444
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M\5<O;RZ/-\-_&EO;RVK1'Q*'*1N,?9S-$%;C^#&[!Z=: /?!<QSPR/;312E
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MEA+._L[.3S/.#,#$ZD<H?D(^OOBO:O"7]HGPCI7]K0K#?_9D\Z-4"!3CIM'
M.,9 [T 97Q#U6_M=#32=%W_VWJI:"SV-M*X7<[Y'(PH/([D5?\)^);?Q!X/M
M-:=Q'^Z/VG><>6Z\/GTP03]*Y+^S9/'GCS4'U:RUO3++2HO(T^1=]OYI+$22
M!QC.<+@9Z8-8VG>'=3TO4?%O@BQL=472-4B:2SU&6-BD<I0;@S]PW3.<\=.:
M .QL/B7IM_?V\":;J<<%[O&GW4L 2.\91DJA)X)Z#.,U8^'_ (NN_&.B/?W6
MFO:CS7$<@QLD4.P 'S$Y  SD 9Z5C>$_$'B&[MM'T:3PA<V4]BRPW5W>IM@1
M(UVEHCU9F&0.W/4BE^$IU/3M%D\/7^BWMHUA)*7NITVQRLTK$"/^\,<[AQ0!
MTVO>*[;0[VTTY+.[O]2NU9X;2U4%BJ_>8EB H]R:Y3Q?\05G^&.J:KHT%_%<
M*YLILJ(Y;&3(!WC.1U !&>2.E6O$HU/P_P#$>R\50Z9=:CILNG'3KF.RB,LT
M1\PR!MHZ@D@?@?:N2UO2=9O/!/BRXAT/4C=>)-022WM/(_>0QQLI#2#^'.T\
M>XH ]!\":-'ING3W2P:M:M=LI:UU&Y$Q3:,;EP3@-G/)_+BG^/=3O+301IVD
MLPUC59/L=F5;:49@2TF>H"J"<]N*V]&NVOM'M;A[2YM&9,&"Y0+(A''(!/IG
MKTK@Y])E\:_$.[.KZ=K5EIVGVOEZ?,': &7?B1U93U88 ZY )XH W_ >JR^(
M_ UL=0\S[9&KV=ZI8JXD3Y&R0<@GKGKS7F^IQ-%\+-/OY+[4(3I^NR(DD<S,
MYB^TLI'7+8 &,G.1[UN>&[74?!?Q"UJRT_P_JTOAR[",DF#)MF5,E@S-DACD
M9)ZX[5DS6'B+4_A;=Z</#E_!<VVK_:A#*GSS1/,TGR#/W@6P1Z?H =[9?$73
M98]4_M&RO]*GTZW^U2V]Y%AVA/1U )SSQCUJC8_%73KN[FM)-)U**Z2T-Y%"
M!'(TT8Y.W:Y&< G!(/'KQ6-J7AO5?'=UX@UDZ==:29=)&F65O>$))*PD\TLP
M&0%R N,G/-2Z-<:]+:M-%\/;?3);>VD2Y*QQI+<N5*JL1^7 SAB3D8R!F@!N
ML?%Z=] -[H/AS4L3&-;:[OHA' S,VW^]\W<<']*Z?5_'']D3);/HE]->+8/J
M%Q!&\68(5."22^"<]ES7'-H&OW7P7L]+DT>ZBU/29XI!;.Z,UP$<,=A4\##'
M&>?EQSUJ3Q9IOB/Q1?6=Q<>%);BUFTQUCLFO41;:Y+MAY3QNPFT@<@'(]Z /
M3M*U.VUG2;34[-BUO=1++&6&#AAG!]#3]0OH-+TVYO[IMEO;1-+(WHJC)_E7
MGGA36M8\+Z7X.\.:IH7D/=^9:LQNE9T*#(;8!R#SGGC\177>-KNWLO!&MSW1
MA\H6<JD3$A6+*0%..>20/QH Q;;XC--KFEZ3)X:U6&XU*(3P;VB(\KNQP_&!
MR1U]JR])\6Z;X9\"7NKV6D:M)9P:E,EY'/*CS0N6^8YW8*AB!USW.>37.^$[
MJ\\-:UHDOBC0]:$TL::;8W5W=QR)"S ?*L:@%<XQDDD# KJO >CZA/X?\0Z1
MXAT2:QBO[N:?$DBN'2?.5&T]5QS]10!LWWCFUT_4?(FLYC;II1U2>X1@PA3G
M"D#J3@XP?\:R])^*^DZAK%AIMU:O92:@,VKFXBF4Y^ZK[&)1CGH1UK.TCX:Z
MA%X US2M0O#+JE_$+:*61LJD4/$"\9PN!D_[WJ*DT@>+[^6RA/@[2]'G@:,W
M.IW!20OCAC$JC.X@'DGC- 'I,LL<$+S2N$CC4L['H .2:X>/XGVKC3)?^$?U
M@VVJN4L)42)C,0>NW?E1CGGM77:Q<V]GHM]<70B-O' [2"5MJ%0IR">P->#^
M%+J^\.:9HVK>)-$UI])LI#-8&)HS;VRRGAROWS]XXW'OTH ]0E^(UO%H^M:B
M-'OV&C79MKN(&/<N.KCYL$?K3]2^(=K93QPVFE7VH2G31JDBP; 8H#C!.YAD
M\]!FN-U?1O%5JGC?1;#P^]XFLW#7,5YYRK&$8<K@\E^,8_IU/$>@>+-7O[!)
M_#B7EM_8@@%NUTJP6UUSEVQ]_ ' [$CD4 =9J'Q,LK233([71=6U!M3M/M=M
M]EB1MZ!=Q'WLY ZC^=-U7XG6NF7%R@T>_FCL8()]0<;$-J)0"H*L02>1D#I7
M+Z%9>*[#6?!)G\+W<<&E6;VETZS1,") %!^]QC:&/?J/K!XY\(^)_$7B7Q"I
MT..^@EMHETRZ>X");A0"P"_Q.QR.?SQ0!W&H^/OL7B=M @\.ZM>W9@%Q$T C
M"2Q\98%F& "<<]^*R=9^(6HS^']#U+P[I<DAO=46SGAF9!)&P<AHB,X#-M/S
M= .>]5K'_A*G^(-EKMYX5GAM8M)-DRI<1LP? DS][D$C:.G)K%L-$\60>$ 5
M\/7"7UIXD355MVFC!FC).54Y/(Z'/K0!U6O_ !6T_0;ZXM)+"2:6RBCDO0MS
M$IA+CA%#,#(P[A>E/UCXJ:7ILT:6MLUXK64=^[FXB@"PN,C D8%GQSM'/(K)
M>P\5:'XAU*\MO"=IJL>M>5<?-<)_H4^T*ZNQ7++GT]/<TMSHWBKP]XG.K1:-
M:>(QJ5G%%=JI6'R9HP0"N[("8/;K[=P#O_#^NV?B70K35[ L;>Y3<H<892#@
M@^X((K"OO&]PFI:I;:3H-UJ<6DX%[+'(JD,5W;8U/+L!U''I6YX=AU.#1($U
MC[(+[YFD2T3;$F6)"K] 0,]ZXP:?XB\&:[KKZ/HYUFSUJ8W41694:VF/#"3<
M>4.<@CTH NS_ !-MC=:+!INC7^H'68#+9-$457(SO0EF&"N.?2MOPIXH3Q/:
M7K-9R65W8W3VES;2.&*.N.XX(YZ^QKA])\#ZWH6N>!X8;*.>ST2*<W=T)U4-
M)."&VJ>2%X^OM6YX"TW7--UOQ))JVE&TCU&\-[#(LZ2* >-AP<Y[T 4O%3'2
M?BMH6I6.CSZC?W-A<1>5$X7[I3#$L=J@!F!/N*MS?%/2X?#,NIRVLL%Y'>G3
MVLIW5"EQW#/G:% Y+>E6?%4&M6/BS2?$&EZ4^JPV]M/;2VT<JQNI<J0PW=1\
MN#7-S_#[6Y+)O$ BM#XC;5?[3-DSYA*8V^22>,[?XL=<_6@#,\9>,[#Q?X$U
M"1+&-K[1[VU,@AF690&<8:-UX8'E>G>O0M+\7W-UX@N-&U+0[G3;E+,WT(>5
M)?,B#!3]PG#9/3FN3U[1O'&M>'KV+^Q=-M1<R0"+3[>= 8_+D$C2/)@;B=H4
M = <]:T9M-\67_Q#@UH:3'8VZZ5)9F0WBOM=AO!( Y ? Z=L^U %CP]X^;Q#
MJ]OI.I:*+--2M'N;8-,)"\8X(D7 VD@D^X^M>?QW5]I?P+UA-/MXVMVU*>WG
M=IBK11M*J# P=V<X/(X/>M/PQX+\9Z)K>CZK_8FE*]G%-#<*;TB2Y9^3*[X;
MYCP._3L.CU\)>,7^&.I^&VT2W2YN[_[0'-ZF A<2GMZH%Z_Q9[4 >C>$]"@T
M:QFD71;/2;NZD+7$-G*7C.W(4@D#''. !UK'G\<ZG<R:M/HFA+?:=I$S0W,K
MW0C>5DY<1+M(; ]2,UUVG37<^G02W]JMK=L@,L"R>8$;TW #-< - \6>&9M>
ML/#]E:WVGZM,]S!--<^4;.23A@P()8#@C'I0!D>)]9O/%'BGP>+'3+'4=+OK
M6>[@L[R7"S-Y7/F#:0"N3CKSZ5ZII>G6VDZ7;V-G;I;P0IM2)"2J=R 3R><U
MYO#X,\0:#KOA,Z5I]K=66A6CQ/(]WY9F>;(D(!4XP26_'%>J4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-^+C^_\.?.5_P")
MQ%Q_>^23C^OX5TE<QXP_X^?#/_8:B_\ 1<M '3T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DZQX8T/Q!)#)JVEVM
MX\'^K:9 2/;W'MTK6HH I#2-.%U:7(L;<3V<9BMG$8S"A&"J^@P,<5=HHH *
MP+CP1X6NKHW4_A_37G+ES(;=<LQ;<2>.3GU]3ZFMUV"(SG.%&3@$G\AUKRO7
M/B.^O^#?$<_AN:[L+_29-P=K<_/$I4$DLNU2<M\N=WR]* /2=3T?3-9MT@U.
MPMKR%'#JD\8<*P[@&FIH>DQV]U;QZ99I#=_\?$:PJ%EXQ\PQSP,<UD>&O&VA
M>()4T^SU-;F_C@$D@\IDW@8!920 PS_=)I+;XA>%KS71HT&JHUVSF)/D81NX
MZJKXVD^P/?B@"2]TF]T334A\%Z;HULS2[IHY4,2%<$9&P?>SCK3O#/A>'1O!
MEEH%^L%ZL2'SM\89'<L7/![;CQ]!4'CWQ3-X4\.K<VD*3W]U.EI:1R'"F5\X
MS[#!/;IUK%U/P]XZMM FOK3QE<3ZO'$TAMQ90^3(0OW%&W(/H><GL* .X73;
M!;$V*V5L+,C!MQ$OED>FW&*:-)TU=/-@-/M!9$Y-N(5\L\Y^[C'7FN=O?'NE
M^'K:RM]9>Y.I-9I<7,,%LTC1+CYF<*,*,Y_*EO\ XE^$=-%J9]6!^UP?:(/+
MAD<2)SW"D \$8/.: .KCCCAC6.)%2-1A548 'H!44=C:133RQVL"2W&/.=8P
M#)C@;CW_ !KBS\8?!GDETO[B1@JL8ULI=P4\[N5Z>];-UXVT2WMM-FBFFO#J
M:E[.*T@:6250,EMH&0!WSC% &Q9:98::K+86-M:JQRP@B5 3[X%33V\-U"T-
MQ#'-$WWDD4,I[\@URD_Q+\-6^AKJ\L]TMK]H:VD_T60M#(#RL@Q\AY'!Z]LT
MR'XG>'+FW@EMFO9Y)WE5((K1VE_=@%R5QP!D<_X&@#KO(A!SY4><8SM'3I1Y
M$6S9Y2;"<[=HQ7$:A\2+==3\,PZ39SZA;ZPKS%XHBS")5.=HS]X-C<.P!JWI
M^MZ=#XH\67$NK7^RQCB>YMKE&6&U54;YH\]0P!)P.?>@#KU544*H  Z "D,:
M%MQ1=W'./2N7L/'NFW=W;V\]I?V1O8VEL&N8=HNU !.S!)S@YVG!.15"'XK:
M!.B3):ZK]D^T"UDNVLRL4,A(&UR3D')'8T =S3?+3).Q<DY/'?UK(\5ZQ<>'
M_"VHZK:V37DUK"9!$IQTZL?8#DXYP*P['QU-'X<T>74M)NSK>H1_NK" (7G*
MH&:1?FPJ=^3D9H [+RH_,\SRUW_WL<_G3ZP/#?BVR\2M=V\<-S::A9%5N[*Z
M3;)$2,CV(/."*I:_X\MM#U2>QCTZ[OWL[87=\;8I_H\1/WB&(+'&3@=J .LH
MKBM=^)6FZ.P6WL[G4&6U2\F\DH@AA894L7(Y(YVCFK$OCZQG%A'HEG<ZQ=7M
MK]LC@MBBE8<X+,6("_-E<=<@B@#K:*XS1OB-8:[J>F6EI8W:IJ,$TD,LH5</
M$<.C#.01QSTY^N(+CXH6%AHB:E?:1J46;]]/>%%1VCF4X*GYL<\XQZ&@#NJ*
M\_U+XHPZ7! MUH=Y;7]PTACM+R:*W/EICYRSMM&<X Y)(-=)X3\4Z?XPT*/5
MM.\Q8F8HZ2 !D<8R#CZB@#<HK@)?BAM&JM#X7UF1-*D*WC8C7RE SG[W/&3@
M9XY[U'XB^+FDZ-);K9PI?B6T6\+&Z2$"-ONA=W+.0#\H_K0!L7O@^ZNO'=KX
MGCUN2$V\8@%K]F1E,6<LN[KR<\]172W%Y;6AC%S<0P^8VU/,<+N/H,]37!R?
M%6&5M,72] U'4#J=J]Q:>4R#>4SO0C.1M(P3CZ9KG9+:\\;?$"6/Q+X4(LX]
M-A/D3:@!]C5W),@P =YVD$#!&W!ZT >R45Y['\2'BTJ/6DT";_A%1((%U#[0
M#(%#[/,,9&=F0.^:D'Q$U.X\1ZAHMAX/O;N>Q>,2LEW$%".,J^2<<C! S]<8
MH [ZBO-3\5KI-%N=;D\)W::79W1MKN8W4>Z,APIPG5B"1GH,GJ>M;6G^.99-
M9N-+U?1I=.N(]..I(BRBX9X0Q4\(/O<=!G- '845Y]HGQ)N-3UA-.N-":":[
MLY+RPB6Z5I)57)"NI \MF R,G'O4-C\4;JXL=*U.X\,36VEZC>K9)<&[1B'+
M,N=@&2,J?3I0!Z/17#:MXZU6*^U5-#\.'5+/2"$O)OM0C;?M#,J)M)8@'\ZQ
M_$GQDMM&O%MK;30\B01SW$=Y/Y$B;UWA N"2V,9S@ D#O0!ZC165H.O6VO>&
MK/6X@8H+B 2E6ZI_>!]<$$9]JXX?$?5$L(O$=SX?6/PI++L%TL^Z=$+;5F:/
M'W2<< Y'Y4 =U?ZMIVEB(ZA?VUH)6V1^?*J;SZ#)YJY7C6KV^J>(OC)/I]_H
MFF:C9)IP\J*>X)1+=I0#,IV\2'VZ>IZUZ3XDU>7PWH:2V.FR7DS21VT$*9"J
M6.U2[<[4'<_3UH W**\R_P"%H7\?A#5]7&DV5Y-I-VL%P;2^S Z$#]XC[>>2
M!BMG0?%^LWGBF/2-9T.*P6[LS>6CQ7(E)4%05?@<_-GC_P"O0!VE5=0U.PTJ
MV^TZC>V]I!G;YD\@1<XSC)[\'\JQ?$_B2YTF[TW2],M(KO5]3=UMXII?+151
M=S.Q )P!V%<%XS\03ZQX%\4:'XBTVV@US2XHI_W/[R)E9E"R1EN0>2/49^M
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MT7X>Z#HE['>HEU>7<(VP37UPTQ@7T3/"C\,UU59]UJT5GX>FUB5&\J&T:Z9
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M5N@#A=$\(Z_IVK>)9I]1LEM]9+,'@63S86VE4().. <GW%9VD_#G4WUZRO\
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M0 4444 %%%% !6+X@#&?10N3_P 3),@>FQS6U61K9(NM%P6'^GC[HS_RRDH
MUZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFR-L0MSQZ#)
MH =13(I!+&KKG##(W#!_*GT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-(=$T>33EADC 5;H9,CJ.HP%CYXP2<4 >QP:II]U,(;>_M9I2N\)',K,5]<
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M=K.)KA[;S&LCL211DJQ!/..>_O7)Z7;>(WU7P1=MX5U%(O#UM+8W(9XE:1C
ML>Y SC*Y'7OVK7^%4^H6&@ZC9:AH.JV<D5Q-=AIX-HD#G(5<G);CIC'O0!2B
M\8Q^'O TUWH*ZQJCOJYM?,U)=[1N67<",@XP2%''S'FNIE\>PVVKZ7I=WH6K
MV]YJ1 MTDCCP>?FR0Y VCD^U>>Z?8:Y)\/M6C'AW4X[J+7DU)+>6'8\T9E5L
M(.Y 4Y_K76>.1)K7PY'B&2UGTG4M,8:A:)<8\R-D/"L!_>'\/J1GI0!U&A^)
MK77M0U:SMK:ZC;3)_L\TDJJ$9\G(4@G/ ![?>%9=U>:?;_$Q5:\U<WXTIG^Q
MH"ULT8?[P7J7SQQ5[P3ILNG>%[9KH#[=>%KV[(&,S2G>P_#.T>RBN:UN74+'
MXP6FJ1Z%JEY9Q:0UNTMM &7>6+XR2!T&/7)% %V#XJZ%.T3BSU5+1[K[(]Y)
M:%88I<X"LV>,Y'T[XJ/3/B%)=^-?$6EW6GS6^FZ1")'N60?N]H8LS_-T( V@
M G .:X)K#76^&$UJ/#6K_:G\0?:O(-O\_EYWYQUQQC.,9K=E\.Z[<>*?&<$>
MDW M?$=E&8;MG5$@_=L,/WW;B 5&3C)Z4 =-8_%'1;V]M[8V>I0->(SV1EA4
M?:@HSA &)R>P(&<BF:?\5-%U".6Y-AJMM8PK*9KRXMML49CQE203\QR, #/(
MKF_#\-_#;V=Q#\-+:RO[':;ZZEMHPT@C'/V=1@EVQP>!D]34>E^'=>UWX8>)
M?#MQI5QIM[/=M=6YN JK('<2A=PZGC!)Z9 [< '7:?\ $S1KV>[MY[:^L9[>
MS:^\NXB&9(%&2R[6/IT.#45Q\0Y#H6J7MOX?U".XM-.74(H[DQJLL39PP97(
MP "2.N!C&>*P;*SULVUW=:)X!TW2+J*UECN5N((PUU,5 V18(_=]3DG!X'K5
M70O#VMM8^*M*T[3M2T[1+C2Y(+>PU%A\EVRD$1')/E]><X):@#T/P9K5YX@\
M*6&I7]F]M<30H[!E 63*AMZ ,WRG/&<'CH*Q1?Z;:_$S5I5BUE]3BTD.UN%!
MAEB#C#1+G)8GCL.#6A\/Y-1_X0[3;74=)GTY[2UAMU6=AODV(%+;1]T9!P#S
M6)=?VS#\5+W68?#M_<6,>D?8%D1XAYD@8RY4,X^4YVY]: +>F_%#3=4.ERPZ
M3JZ66HW M8;R2!1%YI) 4_-GMU (KM+BXCM;:6XF;;%$A=VP3A0,DX%>26.D
M>)],\">%-(/AJZEN],U-;B8+<0[=B.7R#O[[\?\  3[9]2U+[?)HEW_9RI'J
M#6[>0LQ&%D*_+NQD=: .:\/^.8/$UW%82Z1>V4=_;27%G+*ZXN( 0I;Y6W(?
MFZ'\Z\WNM.C'P>UIEENB^F:]*+4+.P9AYRILSGG(8_CS6SX7T#Q/INO:+J\_
MAB5IX[:>'4)Y;^,S32,0=_7&WC"KGOVZU#>>%?%5]\-=9T=-"EBU"\UA[M%-
MS%A4+A\[MW;&/Q% 'LD.?(CRI4[1P3DCBN%E^)L<44NJ#0[U_#44Y@?5UD0K
MD-L+"/.XINXS7:V)E;3[<SQ-#,8EWQLP8JV.02"0?P->7?\ ".>++7P)<^!$
MTM+B.1WB@U1KA?*2W+[LNN=VX D  8Z4 =+/\03_ ,)1/H-EX?U*\G@,)>5-
MH0)(V-_4G: 0??GIC-=!XBUVV\-:!=ZO=I(\-NH.R,99F)"JH^I('XUR?A_1
M=8TSXE:E>MH\D>D3VD-I#<&>,X$2X#%0Q;#8X[\C..<;GCRPUO4_!][9^'I5
MCU"0*%)?867<"RJW\)(XS_+J #'/Q+6VT_7)+_0[J&^T81O<6<<R2'8ZY5]V
M0,#N.2*L:1X_EU#6;#3KW0+O3O[3MWGTZ2::-A<!5W$$*3M."#S7$CP9XEAM
MO$EO:>%+2UBU>PAMX4BOD8PE<@[V;EB<[B?8<FNA.A^(G\2>!KTZ0%M]$M&B
MNC]IC+;I(_+;:,\A=H;WSQ0!>B^(T@\.Z]JE[H<EI-H\ZV\EFURK.[G;P"!W
MW#!Y!KMK622:TAEFA,$KH&>(L&*$CD9'7%>:ZUHMKK'Q@L([6ZWVTUHMYJ<$
M; JY@?$)/N6XQZ*:]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "LO5_\ C]T;_K^_]HRUJ5EZO_Q^Z-_U_?\ M&6@#4HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG
M]<\$>'O$>H07^J6'G74*>6LBRO&2N2=IVD9&2>M=!10!S,/P]\*6]I':0Z-"
MD"727BH'?'FH"%8\\X!/'3FNFHHH .M<N/AUX36&[A&C1^7>,'G7S'Q(0<@G
MYO6NG9@JEF(  R2>U8W_  F'AHRK$/$&EF1GV*HNT)+=<=?<4 5U\">&%NK&
MZ728A/8(J6K[WS$JDD <]B31_P ()X8&K_VJ-'@%YYWG[P6QYG]_;G;GWQ5N
M\\5^'M.GD@O-<TZWFC^_')=(K+SCD$\=13+SQ?X=T^_2QN]9LX;E]H$;2CC<
M,KGL,CIGK0 RP\&^'M,UJ36++3(X=0D+%YP[$L6^]G)QS7,>+_AY#+H]T/#.
MDV"W%Y<QRZA%([(;J)7WF,-SLRP!XQTKK;[Q3X?TRXDM[_6]/MIXP"\<URBL
MN>F03FGW'B31;728M5EU2U%A,0(IQ*"LA/&%(^\>#P/2@#@] ^'C)XAM]0;P
M_I^AZ<MO-#<V,5TURUX'7;M?@*%'7'//Z=(WP]\/V5F[:)I=I8ZC%#,+.Y"D
MF*1U*[CG.<<=<^U7G\;>%XM/AOWU[3UM9VV1R&=<,PQD?49&?3/-9J?$GP]<
M^*;/0[&[2\:YC9S<0'?&IR J@@').3TZ8YH X33/A;J<MOI]K+X?TC2;BSDB
M,NK17;R32^6P)9$' 9L=6]3QTKU-O"F@/KO]MMI-HVIY!^TF,%L@8!^OOUJL
MOCGPV]KJ%RFIHT.G &[98G/DY.,$;<YR.G6MNUN8;VSAN[=]\$\:R1O@C<K#
M(//L: ,;2O"EKI7BG6M?24O<:IY8*;0HC"+C ]23R35J^\,Z'J6I1ZC?:3:7
M-Y$ $FEB#,H!R.3Z$TNM^(=+\.VBW&IW0A#DB- "SR'T51DL?H*YSQ'\0].M
MO 6H:[H]R+B6,&&,>4^8YCT$BXRF.OS8'0=Z -&^\/W&DZ<W_"%6.BV%^[(K
MM<0%4:-<\?)SGGC\:KZ?X5O=(\!7VD6T]O<:M>K,\UQ+E(WGESN8X!( S@ #
MG:.E+X :XN-)DO9=7U&_2;RP%O[<Q-&X0;]N0"RL3D'&.U:'C'Q(OA/PO>:P
MUO)<-"OR1HI(+'@;B/NKGJ: ,WP#X/7PMHT,5W8:;'J:1B&2[M"6,RCD%B54
M@^W/3K6^^A:3)JRZL^G6K:@J[5N3$#(!]:\^U'Q4]MXQ\+ZS+J&J1:9?VUR)
M--,+@>9&J@!8]H=R6;C(/3(P*[)/&F@R>'8]=2]+64C^4FV-C(TN<>6$QNWY
M[8]^G- &I=:5IU]+YMW86MQ)LV;Y85<[?3)'3VJ!O#VB/$D3:/I[1QY*(;9"
M%SUP,<9J+0?$NE^)(IWTV=W:W?RYXI8FCDB;T96 (K4EE6"%Y7.$12S'V'-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWQCX2C\8Z9%83ZE>6<*2"1A:E1O(Y&<@]#R/>@#B/$GAS5?'6M:Q?VUC>:?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M7J__ !^Z-_U_?^T9:U*R=9Q]LT;/3[=_[2DH UJ*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** *VHZ?:ZKIUQI][$);6YC,4J$D;E(P>1R/J*YVT^'?A^U:UWK>W:6A!MX;
MN]EECB(Z80MMX[9'&!75T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6+;^$M!M->?7(--B34W+,UR"VXEA@]ZVJ* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K+U?\ X_=&_P"O[_VC+6I61K9076B[S@?;Q^?E28_6@#7HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBF2RI!"\LC;412S'T Y-
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M#(<<JR$@XR,_44 =?17)>)O'#>'=<L-)30=2OYKY6\AK<)M=@"=H)/48R>F
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M64,N0"<' .>N#UKSY/'$WA_X6:;K]CX8@CL-I06J7N/)!?:F/D.[)Y/0CWH
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MUD0^JD9'\Z ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/&<UZ[+I]E/,9IK.WDE*["[Q*6V^F2.E-FTO3[AD::QM9&084O"I*CK@9'%
M'CGAFQT#49OB&VE6MA/>PM,VG-!&I=%,; &(@<#=Z52\))X7G309M*U'5+OQ
M'%"(+:R"@+8R%2)'?Y1^[#$L<D^V<U[E;Z?96CE[:SMX788+1Q!21Z<"I(K6
MW@DDDB@BCDDY=D0 M]3WH \:\.ZUX7N?".EZ#J&EW-WXDL;P,VG(A6X>Z5B6
MD+<#&"268] <UF7-R1X4\=:!#),-3.NW%[-9PJ=[V@:,L=PX (S]<8P<U[NM
MI;+<M<K;Q"X88,H0;B/3/6G+!$LCR+$@>3[[!1ENW)[T >3ZIJ?AK7_'/AR_
MT1[6>TL;.XEU2:)0(XK3R\!)1CIG/RGISQ7/>&?^$8E^">H-<6\32^<UO>3V
M\2^=;I),-KL<9*C"MCOMQ7N\-G:VP<06T,0D.7"(%W'U..M/$,:J5$:!3U 4
M8- 'G?PLO#<WGB**2>QU":"6!&U:S&%O%\L[=PZ;E'!QZ]^I37M1T6+XTZ)%
M>26XFBTR?<9%SM)Y7)QQ\H?\#[UZ+%#%;QB.&)(T'144 #\!2F.,MN**6]2.
M: /G/^U-$A^"\0@EC29->W+\G[P8D+ Y ZB/'/X>U6?'NHQ7][XMB@%S92L]
MK*+6"U=_MR*0?/D?:=JA<D ;>G.>:^@?(BV[?*3;G.-HQFGE5))*CD8/'44
M>;>/WDM%T;Q_H2>=<VRB#R75D-S%-\J*01G(9@0"!U-:VF:EI_@6V\,>$[XS
MM=WJ&-)UC'EF4<MN.>[-QC/7FKM]X3NM2\4Q:G>:[=2:;#+'/%I0C41K(@^5
MBW4_-\V/7'I6M?:)8ZCJFGZA=1L\VGL[VXWG:K, "Q'0D#IZ9- '._%.)Y?
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M]MHH \$U.*]U/Q3XE^S:5JEUX;EO%^V1Z4R&*Y>( OG?SN+ 9V$=#U/-6_$
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MH'8_6L:;X6WMS=>)89)E_L_,D^B1[@/)N)-KL_'*[615'L6]3GUFB@#S;4/
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M6:X\XQ>03<(A?>8@V<;<_P 1Y^M>DQQI%&L<:A40!5 [ 4ZB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q/$)Q/HG_823_P!
M>MNL3Q%_K]$_["4?_H#T ;=%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !6=K>MV'A[3'U#493' K*GRJ69F8X"JHY))/05HUQ'Q5N
M+JV\'++:V9N2+R$R,D E>! V?,13QN! P3ZT =#H'B33?$EO<2Z<\I^S3&":
M.:)HGC< $@JP!'7^?I6?XG\6:9I4C:1*VHR7UQ;L^S3;=I9H8S\OF\ [<$\$
M]^U<O\*6F@U3Q);2Z7J]HL]R+N&34(VW/&5 !9V)RYZD?7TQ4%[<W7@SXMZK
MK%[INIW]CJ]I&EM)9P>:4= !Y9 QC[O'U'N: *?AWQ0O_"M= N=<\0ZI!/+J
MC!;A%:22<)(?W;G!^4C YKK=4^*7AK2=1N].G>^>\M6VRPQ6<C$<XR#C&.>O
M?MFO.;.YU&P^$MKIDV@ZW#>Q:NDH LF.5$WFEAQV QR.OKS77Z5K:W'QCNKB
M/2M82WNM/CM5GFL9(T#J2YSN (&.,GO0!M7WQ-\-Z=>O!<2W2P1SFV>]%NQ@
M649RF[N1CG (JSJOCS2]*O;VU-MJ%V;"(2W<EI;F1(%(R-S9 SCG [5Y?::
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M[DIY5T.PPI^3&3D\]L=ZU-7\+Z]8^-9?%'A:2P,MY L-]:WQ95D*\*X902"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %8GB+_7Z)_V$H_\ T!ZVZQ/$7^OT3_L)1_\ H#T
M;=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %5[2PM+!95M+:*!996FD$:A=[L<LQQU)]:L44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!GAN_P!8&KW>C6DU_E6\YTR21P">Q(P/RK=HHH **** "BBB@ HHHH ****
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M\;:L_B+6I+K0=2VV):\.U?F7DCH>O; XKV#Q'K-[IW@"^UFTB#WD=CYR*%R
MVW.<>@SG\*RO^%5>'/[.U&P+ZBT&H7"7-P&NV)=U)/XYR<YR3^ QU=AIEMIV
MDPZ9$'>UAB$2K,Q<E,8P2>O'% 'D,ULWAKPUX0\5:;?:A<:GJ<UM%?+)<M*+
MI9DW.NTG ((P-N"/K6CX!\*Z3:?$KQ8T$<X.F7$ MLW,AQOC;=N^;Y_^!9KJ
M]+^&OAW2-6AU"VBN2;=BUM;RW#/# QS\R(>AYJ7P]X T7PQK%UJFGM>FYN@1
M*9KEG#9.22#U.><G/4T <Y\1= LM7\>>"C>[O(EEN(9=LS1DXCWK@@C'(/(P
M>17*ZWH\-_K/Q,OVO+Q&TR*&2W2&Y9$\SR?O, >2-N.?4UZWXD\):-XMM[>#
M6+9IDMY/,CVR,A!Q@\J1P16.GPL\)Q6E_:Q65PD-^%%R@O)<2;7WC.6[']/Q
MH \_\10:IX[\3:1I*:A;V]NNB07T*7LDBB5WZR#8P)<?4@8->E_#UG'@ZUMY
M=9CUB2V>2%[R/<0Y5CQEOO8&!GOBH+[X8>$=0TRRT^XTK-O9$^0//DW*"<E=
MV[<5)[9X[8KI+#3;32M/AL-/MH[>TA7;'%&,!1G)_F30!XK%>066A?%26XO)
M[2-M69/,MP#(<R$;5_WNF>P)/:H=$MVM+#QSHR75IHT=Q:V9@AANFFCMWD!7
M#/@D%CM#$<#=Z8KTRS^&GA2TLM0LTTH&WU# N$-Q*0X#;AU<X(/.1@TU/A7X
M)C5@F@Q(&@\AL2R#*9SS\W7_ &NOO0!Y!J5A:P?#SQ;IMSI<^E:M8/9SS6@D
M,EOG?L$L1))&X.<Y)Z#'?'O>@P:7IWA^VM],\B.QMX\ 1/N5.[9.>N22:SK#
MX?\ AG3M'O\ 2H--S::AC[4LDSN9 /NC<3D8[8/'UK6T71--\/:9'IVDVB6M
MI&25C4D\GJ2222?<F@#Y_P!%%J/$?A_6[.XB$-SK31F[GNB+NZ1F;):,'"1C
M '/.2.QK4E\%>'Y-.^(ETS322Z7))]DW73-Y)$88'D\DM\N3GIBO2E^%'@9-
MV/#UN=T@E.7<\CL,MP/]D<'TJ2+X8>#8;:^MX]&"PWP47""XEP^&W#^+CGGC
M% '"6>BZ9XF\6^%3JIFN&U'PW'/>J+EE$SJ(\;P&''4X'<9K)T.:VATGP;<S
MS)Y=AXCFM([B1@?+BY(4MZ=/TKTZU^%?@JRO!=VVB+%.,X9;B7C((.!NQT)J
M>#X;^$+?1;C2(]%B^PW$@EDC:1V)<# (8MN! ST(ZGUH \ZFU#0=+U/XI7$%
MZD=G)%; +I\@$A9EVN4/3F23!/."3D56\$-;Z;XPUNP+Z79"XT$%+>TN T88
M ?>;.&D"Y)(]2?6O5K3P%X5L4N5M="LXQ=0^1-A/OQ]Q^@_$9J"+X;^#H8XX
MT\/V>U(6@&Y2QV$Y.23DG/\ $>1ZT 5?A/(DGPPT/8ZMMB96VG.#O;@^]>7>
M.'L[CQ=XLTF>VM=0OKTVZVE_+.D:V! SY99R OW2>.O?K7N>C:#I?AZR:STB
MRBM+=G,C)&."Q !)SWP!^5>5:G\/O$-UXDUN>?P_H.K?;KDRV^H7DSIY*8 "
ME%.3@ #COSDT 9>K>&M%_P"$NM/#UYK=IIEA:Z)']D>XB26&0L[&1E:0X#%C
MG(.?3I2V.D^&=3\3^"+-[M]3M/LUW:F>ZS$;A8R?+&,\KEF ]<8YKTK3/AWH
MT?A32M%UFU@U0Z>A"2S)R"220.X7G &>@%:MSX0\/7E]:7MQH]F]S:!5@D\L
M QA?N@8[#MZ4 >%ROY/A'4=)2Z2#1+;Q;Y4\D2B9(K<Y(+#HR;@.#P<4[Q+I
M?AVP\'>*DL-=BUB=_LMP#!;1QV\#F55^39\H<KNR%QP#FO;[+P7X:TZTO;6T
MT6SBM[T 7,8CRL@'0$'L,G [5)%X2\/0Z;%IR:+8BSB?S$A,"E0^,;N>I]SS
M0!Y?XHT[PMI,_A6VT9-.@ANWENEEO9,V+ 1JI>53]]L<* 1R>>M<YIVI6H^%
M^FVIU"&1+3Q6BQY(7$62V['8<D_C7NLGA70)=.MM.DT>R>SM7WP0-"I6-O4#
MUY-#>%?#[(R-HNGE6D>5E-NI!=QAFZ=2.] %?QO%93^!M:6_$#6WV.1OWQ^3
M<!E#QS]X+C'.<8KR*ST;P@^G_#1&BL<W3M]JRR[IB4R5DYY'F +@_3VKW.XT
MZRN[ V%Q:PS6A"J8)$#)@8(&#QQ@?E5:/P_HT0B$>DV*B'_5XMT^3G/'''/-
M 'A6K3Z?'IOC>QM9UCTL:W;/<1617*6^<,R*.,;MHZ8S@4:I::18Z%XB/A+6
M=0U26XL8GOI+>&-((X1(H(^15 DVYX_N[\U[O;Z#H]JLJV^E640E#+($@4;P
M3D@\<@GFK%M8V=G"T-K:P01-R4BC"J?P% 'A]I9>%1!JTNAZS?:Q>W7A^Y1H
MX[:-8X4$>5\T(JX;( '4YQ[5;U'6?"\GA'X?W*W%B);+4K-9'5<>6 BF;G'0
M93=Z'&>:]DMM.L;*-TM+*W@1_OK%$JAOK@<U"VAZ0\,<+:79-%&240VZ%5)Z
MX&.,X'Y4 >*:DGA.X\5?$FX<Z9*/[-62U?<K RM'\S)_M%RN2.Y]Z/$6NV]I
MX;^&.K)-:W;0(8S;7!!C?]W&C[F'"E/?IG/8U[5_86C@N1I5CEQM;_1T^8>A
MXYZ#\JXSQ?X"U;4M>TW5/#]SI<4=E T*V%];;H%W$EF50" 3P#P.G6@"+X60
M:<]WK^I0S:.;N]NO-^SZ=*LGV>+'"D@#J<DXXS4&KRV>G?&F.Z\3FV73;C2S
M%IL]UCRHY P+KD\!CSR<<$#O6SX.\%WVCZU=:[K$^GG4)X!;+#IMOY4$<8;=
M[%F) Y/ZUUM[I]EJ4(AOK2"YB#!@DT8< CH<'O0!X'J%QI\'P]\;2&2W&FWV
MKL=&5@/WA$B[VB!_AQCD<<&O>].FL;FPAFTV2"2S<;HFMR"A'MCCK0^FV$L4
M44EE;/'""(T:)2$&,<#'''I4T$$-M"L,$211(,*D:A5'T H ^<]1U71[7X5^
M*=%DG@BUI]7D)@*XD91.A].> ?R/H:ZG6K[1(_'$5GX9FM(I;GPS<6\ M2 K
MNXW0I@?Q<9&>3D5Z^;&S9W<VL!=SN9C&,L<8R?4XIPM+99%<6\0=?NL$&1QC
MC\* / O!UKX(:Y\--'?>(;OQ!;SQC^S5 Q!*"-Y.4 " @D_-G%>E_%2PO)_#
M%MJ.GV[W%UI-]#?K"N3O"'D8'7KG\#78Q65K!/+/#;0QS2\R2)& S_4CDU/0
M!Q:_%;PA)IL5W#J)FFE&$LHHF>Y+?W?+'.>,>GO7/'6+/0?BWJ=_XFD%G9ZG
MIL/V![I/E55 WQDC(!W;B1GG(]1GTV.PLXKIKJ.T@2X?[TJQ@.WU.,TZYL[:
M\55NK>&=4;<HE0, ?49[T ?/-W=:18^$=%>X$<%E/XL:^L(9H\LFGAL'(P2%
MSV[^]=GX@D\*Z+\2?#>HW,&GV^E3Z=<.DJP)Y;,<,&X'H3S[\=:]5DMX90HD
MAC<+TW*#BN0U;PMK=]X]TW78-0L$L+)#$+:2W+,T;X$@SG&2!P>WOS0!YK#:
M26,$'BJ.SF3PJOB22^^S^6>(&4*DPCQ]T') QQQCUK0UK5])U+Q'XI\2:?.&
MT,: UE<7/EGRY[MB=BC(^8@%>>U>V;5V;-HVXQC'&*8((1%Y0B3R_P"YM&/R
MH \,N;S1K?X/>%-0M;2T:1+ZVCN+L6Y8V\B!LR,JXWE><!L@[N^:J6FIH+/Q
M?([W\T<&K6&HO)<6QC=HO,7<Y4* "1@XP,C'I7T L:+&(U10@_A X_*EVCG@
M<]?>@#RO4?%6E:C\5/!5Y:[S#+;3J99;=E($H*Q=1D993C/9L]#FN9CU"VM_
MA=?^ +NWN)?$XN9($M1"S&60S;UD#8QC!SDGMZ5[W10!XY)J-K_PEWBN.2.8
MSIX?-H)3;,//EC#"3;QSRRCCKVKH/ /B6VLO"7A/2);._P#M5U&]O_Q[$+$T
M8RV\G&!TP1G^=>AT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !17F_BGQW?Q>+M(TG1EVVBZO;V>H79"D,SG)A7/<+DL1R.*](H **
M*Y?XB7,]CX%U2^M;VXL[BUB,L4L! .X< '/4$GF@#J**X/P=XX:X\ W>I>('
M"7^CM)!J(P%)=.F .,L"!QP3G%8'@/5-<N_%WB&]\4ZE<0+IMO'="T$N(($F
M0R$,,<E5"_0@T >MT5QNB_$S0];U.&Q6&_LVN(FFM9;R#RX[A%Y)0Y.> 3SC
M@5!8?%;0-0U*QM$@U")+^5HK2ZEA58IF!P,'=GD\#('- '<T5YG8>/[C7?#_
M (I.H:+K%M!;23VZO90AGC0*JD9W?ZU=Q8]@._%6;;XBZ)H.A>'8$M=>O8;Z
MU46DQ@$LDI&5V,=W,A(Z#U':@#T.BN2M?B'H\^FZS>W$%]8_V.5%W!=0A95+
M#*X )SGH.:@M?B-;2:Z-'O=#U>QNC;F[+31(R)!MSYC%6.!P1TX/'6@#M**Y
M/P]XZA\07MI FE7UM%>VSW-I<2["DJ*P!^ZQ(/(X//-=)?WT&FZ?<WUT^RWM
MHFED;T51D_RH L4TNH95+ ,W0$\FN0M_B!&U[I4%_H>I:='JQ*V4UQY>';&0
MK ,2A/;(KC/#UB_B[XD:S=ZWH5RTUA?1^5.;\ 6(1253:I^;) )QD<\^X![)
M2%E! ) )Z#/6LCQ7J-YI'A+5M1L(EDNK:UDEC#$  A2=W/7'7'?&*\MOM3U"
M7Q5\/?$-UHMP=6NH)XS#!,C&Z40J4;J%09E<GT'6@#VJBN$G^)]C:^%9-7N;
M&6&ZCOVTU[)ID!6X4\@OG:% &=U7?!'CVT\9"]A2W^S7EEL\Z-)UFC(8'!21
M>&'!H ZZFLZ)MW,J[C@9.,GTK&\5>(5\,Z.MZ84E:2>.W022^5&&=@H+O@[5
M'4G!KS[QEJ=Q?_\ "*ZQ=Z!+#J=GX@2V6".42>:NW=^[8[0RMA<$@=/K0!ZY
M17$VOQ F6SU[^UM!N;/4='5))+*&47#2HX^0J5&/KZ55LOB/=S2:K:W.A1IJ
M%AIZZA]F@OEEWIQN4G:-KKGD$?S% 'H%07-Y:V2*]U<PP(S;5:5PH)]!GO7G
M[_%&ZM/"R>(-3\.FRM+KREL"UZK>>SY^]A<HH SD@\=JY'QIXTLO'/PX\1J^
MGP+<Z3-;F.>*7SHR'D4;D<JI'&X$8H ]UHKB[+QW<)K&H:9KNC?V=-::8=4_
M=W(F!A!P0?E7##TY'7GUSE^(.LV-MI>LZUHMM!H&JR1I!+;W!>: 2#*-(I&"
M",'@\?7B@#O+?4;&\N)K>VO;>>:''FQQ2JS1Y)'S '(Y!Z^AHFU&RM[J*UFO
M+>*XF_U<3RJKO] 3D]#^5>;Z7<V'AGXB_$*^\A8;2UM+6XD2% ,GRRS8 [DY
M_$UEZO<ZUJGC+P+JVKZ-I]DMS>9MW@F+S+&5W!)<J/7/!P#GI0![+17DES\9
M;A=?DBL]'6ZTR.[-J3'YIF< X,H(39M]LY^E;4/C'Q7?>*-4TRST"Q-MI5U&
MMU(;IF=HF7=\B[1ER.?TYZT >@T5Y[\/_'.L^+[UI;BVTP:?)$[J+61C-:NK
M[0DP8\E@<@@ <&NM\2W]YI7AO4-0T^&&:YM8&F6.9BJL%Y;)'/0''OCI0!JT
M5Y3!\0/&4LFA-_9&BM'X@A/]GHL\FZ.0*&+2DC&W!)PHS[GO?B\=>(%\->(?
M-T^QEU[1[L6SB$LML0Q&)#N.0H!).2.G4=@#T>BO*M&\?>(=7T;Q%!ITVCZA
MJ^C,LJ3+%((;N J3\J[@=P((STZ?6M#0O%^N:YJ/A6&SN-/GBO;"2]U+]PR^
M6H8+\OS'!W$K@]P3[  [S4-0L]*L)KZ_N([>UA7=)+(<*H__ %\4:??VNJ6$
M%]93":UG0/'(H(#*>_-4O%*+)X2UE74,OV*;AAD?<->6^%/$GBKPQX7\)W6H
M1:;-X?O'CLDC@5_M";\['8D[<\<@?_7H ]HHKQN^^)OBZ[UB[FT#0I[K2[6\
M-LJI8O*)PK88F0,-I]  <<9KV-3N4-@C(S@]10!D:!XIT7Q/'<2:-?+=);2>
M7*0C+M;_ ($!GZCBMBO#!J?B#0-3^(.KZ#-ID=G97XDFBFA9VE;H0,$ #KGO
MFMKQ'\0?$L][90>&-.FE5],AO93'9&Y.Z4$HIPPVC //Z4 >B7'B72;7Q%:Z
M!-=E=3ND,D,'E.=Z@$D[@-H^Z>I[4WQ%XGTCPI8+?:S=&W@=_+5A&SY;!.,*
M#Z&N&M]7U'5/%OP[O-6TV2PU"6'4$G@D&PA@B L%)S@XR ><'\:YCQQJ^O\
MBOX;:WKWV^VAT'[4L$-@+?+NBS*HD,A.0V[!QC&* /=Z*!T%>7_$;Q9K^A:M
M-'9:M:V%O%9-/;PI;BYGNI!DD,O6- %/S]!SUZ  ]/R,@9Y-+7C(O-;\4>//
M!=_!K3V/VS2S=>6MNKK$<#S54$\AL=3DBO9CTH **\;T?QUXD_X3&PAOKY+F
M.[U&2RN+6"W!MK;@[ DX^\XQDC)X]#TJW?B/Q]%8^*+MO$5H!X=NPK(MBO\
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M)4+SSC.-P^]CO7N.F:?!I.F6VGVV_P BVC6)/,8LV ,#)/6@"U1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%,DFCB&78*/
M>JCZO:HV,N?HIH O455M=1M;PD0R@L.JG@U:H **** "BBB@ HHHH **** "
MBBB@ HHHH *1@2I ."1P?2EHH \.U_X?^)](M?#UE!XDFO(CK:.K1:>H:W=B
MQ\]F!)8@DYW'%>JV.KW"Z^/#UQ:W<TL%BD\FIF()#*V0I QT8G)Q['TK<HH
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MOCXLSWU_&;?2([M%CG(7<)=A3']P@9*]R2:[;PQHJ^'?#&FZ0I0FUMTC=D&
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M&APZ-+HT#6$#M)%$2V49NI#9W<_6MG3=+L=&L8['3;2*UMHQ\L<2X'U]S[T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJMJ%
MQ+:6,L\%L]S(@RL,9&YN>V:G0DC)&/:@!U%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )D9
MQGFEI",G/<4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4F:6JIAG:_BG6<K"L;*\.T88G&#GMCF@"U1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 444T-EB,'(H =1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%4M2>_2T9M.BAEN-P 6=RJXSSR >U7!G SU[XH
M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHI"0"!GD]* %HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "FNH8@XR5Y%.HH 0=*6FE@& /?I3J "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHIC.%=5[MG%  Z;\<]#FGT44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5.Z)%[9X/5F'Z5<JA?C-U9
M?]=#_*@"\.@I:*R9;F2^GG@M7PD! D(."S>@_P : -4D 9)Q2CD5EKIBL1YH
M+<YY<FI6M)(COMF\L]2N25/X4 7Z*IVMX)F:*1=DR=5SU^E7* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI-W.,4M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5'4.9K49P3)5ZL[45WW5DO
M/^LSQ0!H9P0,5E7\JP:G$7.!)&5!/3.?_KUK#I5:ZLX+M5$R;@IR.<4 "A&4
M'*D>H-.9?50,50ETR=(\6MPRA6W!6&1220ZI)$59X<GO_D4 )J,L0C\K=D]?
M:C3+L+:M&%+%"2 O4CK4L>E(75[A_-*]L8&:T(XHX\[$5<]<"@!D<DDL:,$V
M!ES\W4>U,GRP:)3EI.#_ +(JP> 3CFHH$"JQSEF)+'WH D0;5 ]*=110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% %5X9FOHYEN66%5(:':,,3W)ZU
M:I,#.<<TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5.[_X_+3_ 'F_
ME5RJ\P_TNW..F[^5 %BB@<BB@ HHHH **** &2-B)B.N*(1MB4>U174WD1>9
MMW?,!CZG%3@YH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *A%S"\\D"2HTT8!= PRH/3([5-59;*WCO)[J
M.%%GF"B20+RV!@9/XT 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **2EH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI#TJA=7SBX6TM-
MK7!&6+ E4&#R<>XH ODX(I Q(Z5D#3[^XC;[7J)8G/R0KY:GCH3R<5R-UX N
M+"ZFU#2+EXY& 8PK(W7O@T >CTR.5)-VU@<'!^M96BWUQ<P-;WG%W  )!C!.
M1U/_ -:L73_$X7XC:GX>N%51L26U('+912X/XYH [*BD'-+0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% #'7<A7UJM;V"6S+Y3N%&<J>^?7Z5<HH 04M%% %"_
MTN"^B;<&24C"S1L5=?H1S7):9\/!8>)['5FO7E%H'*[BY=V88.<DC')/ %=Y
M10 BBEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** ,"_\ &_AK2M1DT_4-8MK6ZC(#1S$J>0"#
MR,$<]1Q^5;D4L<\22Q.LD;J&1T.0P/0@]Q7EWQ>\+MXJU#P]IUJ88KV<W(25
MUZ[(]X0GJ 2/PSFN9^$?CNYT34_^$,\0$P1JYBM?-7#12EO]63Z$DX]_J* /
M9+;Q3X?O)U@MM;TZ6=W,:Q+<IO+ XP%SG.16M7)06-@OQ3O+A((/M3:5$SM@
M%@?-<9]N /R%/O/'^EV^I7MA:6FI:G-8?\??]GVWFK"?[I.1SP>!GH?2@#JJ
M*Y_P[XST?Q5I-Q?Z/)+<?9\^9!LVRJV,A<'C)['./?@US=I\9_#E_=O96MEK
M$MX =ENEIN>1AU4 $\]3S@<'F@#T2BO-])^,NCZA=7=C<Z7J5IJ4!*K9F+?)
M*X.THH'.\'J#C !.>#4^@_%>QU;Q=_PC=WI-[IM\Q**MQ@_,!G:0.G% 'H-%
M<CXC\>6VBZ_9>'K.S?4=:O,%+=9!&JJ<\LYSCH>,'^52>'_&L.K^(-0\/7MF
M;#6;$;I(/-$J.G&&1P!GAE." >?K0!?U[Q7IOARZTVVOC,9M2G\BW2*/<6;(
M'/H,L/SJK=>-K)-<GT:PT_4=5O;8#[2MC$I6#(R [NRJ">>,]C7'+GQ;\>6R
M2UCX;MN.<J9C[>N6/_?NN$\.>-[_ .&7C37;'7K22Z6ZN=UPR\2;@21(N<;@
M0V<'';IW /9--^(>DZEXB@T 6FI6VJ2;RT%S;;#$%4MECDC!Q@$$\UU,UQ#;
MA#/-'$'<(I=@NYCT SU)]*Y+2;KP[XYU;2_$^DZ@S7&FK+&T0^5B)%QMD4\X
M!Y';->5_$'Q#X@N/BWI.FW=N!;V5_!)9VD4HQ-EQM8MTW-TY^[^9(!]"T5Q7
MBOQY=>#]&LM3U+0)3'.YBE6*Y5C"_.T$XP00"<_A7.W/QQLH4TR>'P_J$MK>
M$*\Y^15;/S*A*XD89YP0/>@#U>BO/[[XI6^F^.8O"MWH]TEU+=1P)*LBE"LA
M 5_7N./K2:W\45\.^*[;0=2T*YCDN7013),C*R,^T,/Q'3K0!Z#17,^+O&^F
M^$8K=+A)+J_NG"6UE!@RR$G ..PSQFLB'XE?9/%EIX<\1:+)I5[>!3 RW"W"
M,6.U02H&,D$?EZT =T\T43QI)*B/*VV-68 N<$X'J< G\*?7@-[XM\0ZC\<K
M"&?2)6?37E2VTM9T5L-$QW%BVS<00V<] !7=^+OBB?!D]E%J?A^Y'VN 2H4N
M$.&P-Z''=2<<<'J* /0Z*X7QG\2%\&)93W6BW,]K>)F.:.50 V 2I'8\_CSZ
M59U_Q\FA^#M.\3?V7-<65Y%'(RK*JM%YB@J"#UZXXH [&BO)KKXZV,>CVNHV
MWA_49HI)#'.[?)'"V3\N_!#,0-V/0]:Z37?B-::6=%M;.PFOM4UA(Y+:RWB,
MJKXP78Y"]??H?2@#M:*X_2/':7?B^X\*ZIIYT_5HT\R,+-YL<J[0WRMA3G';
M'8UV% '/>*/&NB^$(HCJ<[F>;_4VT";Y9?H/\2!5)_&E[;6QO+[PCK4%D!N:
M4"*1D7U:-7W 8Y. 2,5X_P""[UO&?QT_M+4723RGEEA1B, ("(PH]N#QZ$U]
M'4 <?9?$C1-2T34]8L8KZYL=.=5F>.'D@J&+!20<*"<Y]#UJ_P"$_&FD^-+6
MYN-),^RWD$;^<FTY(R"!D\=OP-9>K>&;+P_X3\;3V6534;6XN&B  6-O)(./
M8G)_&O*OA%KFL:1X=U\Z/HIU"1&69WDF$<4:JISDGDL1G 'IS0!]%45Q?PY\
M?Q>/-+N96M1:WEJX6:(-N7#9VL#UP<'\JQ;#XD:SXGM=;OO#6GZ>;/2^2M[*
MXFE4 MD*HP,A2!D]: /3J*X;P7\0'\<^'+VYTZRCAU:T 5K:>0^66(^4[@,[
M3@]N,?C7.>%_BKXE\53:A96'AB"2]MU!'^D;8DYP=['] .O/I0!ZY17G/PT^
M)-SXRN=0T[5+&.UU"T^<^2"$*9VD$,20P-4]+^(VM^-?$M]IWA."P@L[*/S#
M<7X9S-A@  %(V@\^O _"@#U*BO+OA_\ $S6/%]]=)>6&FVMI81[[R43,& PW
M*J01C*\Y/ -5[3XC>)/$MMKVL:!;Z;;Z/H\;OB\1WDN=JLW!4@+PN<>XZT >
MLT5S?@?Q=;^-/#<6J0Q&&0,8IX2V=CC&<>W((^M=)0!@>,/%EEX-T0:G?*SH
MTZ0I&IY8L><?10S?ABMR&5)X8YHFW1R*&5O4$9!KQ7XMV=_XM_M>2T<_8/#4
M:%E XFF?!DY_V$V_3GUKJ/@QXD_MWP-%:2ONNM,/V=\]T_@/Y<?\!H N^-OB
M3;>!KVW@O]*NYH[E2T,T3IAMN-PP3D8R/SIWBWXC0>$;'3[ZZTF[GM+U%9)8
MG3Y6(SM()SG'.>E>?_M%_P"N\._[MQ_[3JQ\:_\ DG/AG_KI'_Z)- 'K^BZK
M#KFB66J0(Z17<*S(LF-P!&<'%7Z\:D\;>,_#7P]T;71IFBR:4888]@:0RJNW
M 9N0!G';.,BNLU+XGZ39?#VW\5QQM(+K]W!:DX9I>04)[8VMD^@]Q0!W-%>4
M7GQ \3^'-%T/Q'KD.GSZ7J94R6]K$RRP*R[E(8N0QQV('3'N#XC_ !,UOP9J
MED+&'2[O3[Z'S86='+@#&<D, <YR,4 >KU1N=9T^TU:RTN>X5;V]#FWBP27"
M#<Q]N/6O.X/''CF3QOI5C/X6^SZ3?;6!VEW2)OXW<$JK#&2I&>WO7GVFW/BN
M\^.QWW.GSZY;O-$IG+BW55C8;5 ^; !. .<\GN: /I.BO//%?CO4=(\3:%X6
MM5M8M2U%8S-=R1M)%$6;:-J@@ME@>I&!C\,^S^(FMZ3\28_"'B*.QN%G=4BN
M[-&0@N,IE23]#Z9ZF@#U.L'Q7XOTGP;I8OM5E8!VVQ11C=)*WHH_J>*WJ^;/
MBK=RZO\ &2+2[IBUK;R6UNB=MKA&;\27/Y"@#US3O$?C35=/74[?PK916LBB
M2&"YU I/(AZ<!"%)'/)'6G>'OB#_ ,)!XNE\/'1KNQN;6V:6[6Y*@QN&4 +@
MG<IW=>.U=HJA5"J  !@ =JS6T*S;Q+'KPWK>I:M:$J<!XRP8;O7!''U- &G1
M7FEKX[UCQ=XWO="\,?9+6RT]',]]=0--YC!@N%4,H&3G&3R 3[5/X+^(-YXA
MU'5O#6HQ6UKK]CYB+)&"892A*E@I.>#@XSR/2@#T2BO%M%^*/C75_$&H^'K;
M1=.N]0MDD17BW(BNCA2[EF^[UXX.2M78O&_C^V\&:OK.JZ3:V5QIDR?)<VLB
MBX1OE(7YNQ*G<,@T >N45Y)X>\9^/_%WA.ZUG3;;1;?[,\@Q(')G*@':HW?+
M@'J3R<=.36WX(^)UGXC\)7^J:BJ6EQIB;KQ5/RXP2&7//.",>HQ0!Z!17DVB
M>+O&?C+0]4\1:9/8:;9V3OY%F]L9FN-JABK/N&.PR!W-:6A?$.Z\5?#K4]6T
M[[-:ZSIT3//%)&SQ_*"W R#A@I YX/K0!Z/17A^A_%+Q[XFTG59](T&QN)K3
M8Q,:MA5(/ 4MEV.,X'^%:>M_$[Q%H?@C0KJ^TI+;6=4DD4[XFVQHK#YO+R#N
M(887/J: /7:JZEJ-KI.FW&H7THBMK=#)(Y[ ?SKRSQ-X_P#$'P_\3:=::K=V
MVJZ;>1K*[_9?)EB7.&QM.#ZC/T]ZQ_V@I=6B.EQM>K_9,VXK;(I!\Q<99C_%
MPW'IS0!ZQKGB:+2O!=QXDMX7NH4M1<11CY2X8#;GT'()]!FJG@+Q<WC7PV-5
M>P:S82M$4+;E8C'*G R.?S!KEVOO%N@_"5=4%WI4QM[."2&(VS8,&P JV6Y;
M!!S['CFKG@7Q]]O^'-YXBUF"WM(;&1T*6L91=JJI 4$GDEL=N<4 >B45Y-I'
MC'QAXG\+ZOXKL9;&QM;(R?9[![<R><$4,Q9\@]"0,8Y%7X/B1=ZU\,KGQ-I*
MVD-_IYS>6LZLZ\#D#!!&<@@_4>] 'I5%>-Z/X]\=^)O VI:WI]MI%O\ 89)6
MDE?=\R+&&V(G/S#.<L<'@8ZUUGPN\:7/C7PU+<WT2)>VTQAE,:X5^ 00,\<'
MGZ4 =Q1110 V0N(G,:AG .U6; )[ G!Q7D^N?&/4?#FN#1M2\)!;W"8V:B"K
M;NA!\OI7K5?.'QEDCB^+-E)*0(T@MV<D$C =L].?RH ],UWXEWWA&6W/B7PQ
M+;6MP<1SVEXMP-PZ@@A<''/O7;:1J]EKNE6^I:=.)K6==R./U!'8@\$5XQ\3
M_%EGX^_L_P )^%0VHWK71D<A#& 55AM!?'N2>F!UKO?"^GQ_#/X9_P#$VF#F
MT1[BX,>2-S'.U?7LON: .WHKQR#QOXQU'P/J'C:WN;&"VM[C$.FF$,&B5@&W
M2$@YY[8^Z<#D5I>)/BXFG_#[2]>TVT#WFI[DB27E(67A]V.N#P/7.: /4:XW
MXC>.)? NCVU[%IIO&GG\KE]B)P3R<$Y..!]?QXGQ5XT\;>$/#FA:N^H6=V=3
MA#2PS680PN5#8&TC/!QSZ58\9>-?%N@>#=$ULOHUW'?_ .L"V[,@+#>A&6S]
MW/;M[T >J:5??VGH]CJ'E&+[5;QS>6QY3<H;!^F:N5YAXM^(E_HGA#PQ<1>3
M!>ZS%"\MV\):*W4HI=@.Y&[@>@-;5I-XI3Q#IOE:M;:OH5Y'*WVJ.U4>6P3*
M;F0X*D]",>E '0WGB'3K'7M/T6:5OMU^':&-5SPHR2WH.*U*^;M%B\32?'2X
MA;5;:36HS,IN982T1 C/ 0$8&,#CI[UVGQ*\<^*_ =WIGE7.GW27D'SHUJ0%
MD0*'(.[.&+9 /2@#UVBO,[+7OB+-XZTU+G2(8M O%\P^4F\0QD$C?)V<<<=#
MVJIH'BOQ+XZU;Q##I^H-HXTQ\6\/V)'$G+@"5GS@D@9 Q[4 >KUFIKVG2^(I
M-!CGWZA%;_:9(U&0B;@!D]CR..N.:X3X8^/]4\<:5JEE=B&#5;1!LNDCRAW
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M^ _#&B7Z7^F:1%;748.V1';/(P1UKPQ/#?A6\U/4Y_&-S=>&-1>Y<II\4#;
MA PRL5;<"=W0X],"@#O?"_PU&B>#O$T4&K0ZAJ6IVCPEK;[B':V%'/));V_Q
MX7X2Z;X8U5-5TKQ%*\%R&4QJUZ\ D7!#+M# $C'/UKJ?AQX0&E>/A?\ AZ[O
MY] 6U(N)[J%H1,YSM500-X'#9Q@>O2O0-4^&WA#6=1;4+[1(7N6;>[H[Q[VZ
MY8*0"?K0 _P18>%]-TZ[M_"A5K1;@B9TD>16DVC.';(;C'W216MKVL6N@:'>
M:I=R(D5O$S_,V-Q X4>Y/ ^M6K2SMK"TCM;.".WMXAM2*)0JJ/8"J6M^'-(\
M1V\4&L6,=W%$^]%<D;3C&>#0!QN@^"-?'AF2&X\4S0OJ8>XO(DM(G&^49<!F
M&>^*\Q\ :@?A]\6;K1+NY7['+,UE+(2 IY_=N>PYQ]-QKZ#L-"TW2]*;3+*V
M$-DP8&(.Q&",$#)R*PG^%_@N1V=] MV=CEF9W))]3\U 'FW[11!F\.<_PW'_
M +3JS\:2&^&_ADJ009(R"/\ KB:](OOA]X4U)H6O-&AF,$2P1EW?Y47@+U[5
M=_X130C86-B^F026M@_F6T,F76-N><$G/4]: /-O$E_;6_[.-@L@4M<VEM#$
M!S\^0>_H%-<7K?A?4[3X%Z)=NDFU;Q[J6,#[D<@PC'\A_P!]U[='\.O"<5['
M=KH\>^)_,CC,CF)&ZY6,ML'X"NDN+>&[MY+>XB2:&12KQR*&5AZ$&@#QGPK9
M_#35O ^G7>M26ANH( D\4]]('5UX.V/?GGC[HYXQ7/\ QS-MO\+K:1M%;BP/
ME1."&1/EV@@\@XXY]*]BT[X=>$=)U)=0LM#MX[I7WHY+-L;U4$D#\!5C4_ _
MAG6=3;4=1T>WNKM@%:20$Y &!QG'2@#9LV#6-NRD$&-<$'KQ7SWI][:Z9^T?
M=75_<16UNEW<EI9F"*N8GQDGUR/SKW_3-+L=&L5LM.MDMK969EBC^ZI)R<#M
MR369J'@GPSJNK#5+_1K6XO<J3*ZYW8Z9'0_B* /+O'OQ$AO/%>BZ;ICPV,$G
ME.^L36X,L4<A^]&6&4&TYSU.>W?E]1FTBU^.6F36>JF[LHKFW,E[<77FY(QN
M)D)Q_05[[K'@_P /:_<0W&JZ1;74L*[(W=<$+G...H]CZGUJO>> O"NH36LM
MSH5F[6J".$!-JJHR0-HX(R3P0>M '1*P90RD%2,@CO7S]\9O#M[H_C2V\7V\
M326DKQ-*R@GRY8\ !O0$*N/?-?0(554*H 4#  ' %,F@BN(7AGC26)QM='4,
MK#T(/6@"EH^NZ;KNDPZE874<EM*NX-N&5XY##L1W%4;'Q79ZOK\NEZ7')>0P
M1DW%]#@P1/VCW?Q-WP,X_EE2?";P-+=FY;0(@Y.=JRR*G_?(;;^E=996%IIM
MHEI8VT-M;QC"Q0H%4?@* /$_@G83>'_&GB+1]1_<WD<2@(_REPK'+*#U&"#G
MWI/ %O+JOQP\1:W H^P6TMP&FSE22VU<'IR 3]*]<U?PIH6O7,5SJ>FQ3W$2
ME$E.5<*>HR"#CD\>YJS9:%I6FZ6^FV6GV\%DX(>".,!7R,'/KD<<T >'_":X
MMI?C/X@E$J%94NC"V?OYG4\>O&37I?Q<_P"26ZW_ +D7_HU*U(? ?A.WGCFA
M\/:='+&P='6!05(.00:R/BTSR_#V^L(+>YN+J]:.*"*WA:0LP=6_A!QPIZT
M<9\*?$.E:1\)M6:\O88W@EF=HBX#D%%VX!/))&![US'P\\(:GK'PX\736R/F
M\CCAMDR0)6C;>W'0GH ?4FNE^$_AC0]7\-R:9XAT!VU"VN7E4W5JZ'80H&'P
M,C(/!/X5[1;6MO96T=M:PQPP1KM2.-0JJ/0 =* /(_@_J%M8_"[65N)522SG
MG>>-CAD'EKU!^A_*L'X3:)-:^ _%FL7N8+.\LGAA=B &"J^YA^) ^N:]>U'P
M+X6U:^-[?:%937);>TACP7/JV/O?CFM.YT;3+O2AI=QI]M)8 !1;&,>6 #D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX1.BWT[/SCY0C9K<\->%_$?PM\7:A<0:3)JVBW$++YT,J(44'<"P8C!'(.2
M<YS0!J_"/QEJ5_JFJ^%]9NVN[BQ9C!<2-EV16VLI/4X."">>3[5ZU7SW\$K6
M?5_B%J^OK$8[9(Y"WS9PTKY"^_ ;\J^A* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%D0HZAE88((R#21Q1PQB.)%1!T51@#\* /G-==TRU_:';6I9#!IOVAU\YHR
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MM<OI]EMAAC7YI61. !ZDC]:YOX3:#=Z+X0:?4H&BU'4;A[JX60$.,G !!Y'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4455BU.PGF>&*^MI)8R Z)*I*D] 1GB@"U1110 444C,J(7=@JJ,DDX %
M"T4BLKH'1@RL,@@Y!%+0 4456GU&RMIA#<7EO%*4WA))55MOK@GI[T 6:*J6
M>J:?J)<6-]:W13[WD3*^WZX/%6Z "BBB@ HHHH **** "BD9E12S$*H&22<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML-O:6L3A(E'&2XRS''3U.*?8Z5XNU;P_H<DWB:2PE^Q^9=M';1M)+*^" <C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E
MOB/8W6I?#S6K6S5GG:WW*J]6"D,0/<@&LKX,SV\OPPTQ(&RT32I*"<E7\QC_
M "(/XUWU<P?A_H"7ES<VD5W8/=<SK8WDL"2'U*HP'>@#E/B[K\L>A6MEI5RA
M@NM16TU%X'&Y> ?+8CD$CKWP,=ZH31_V%\5+KPSI5OY6AWND/)<VB$^6A"/A
MP/X3D*.,=?6O29/"NAR>'FT%M.B_LPCF 9 SG.<YSG/.<YJ*Q\(:+I_VMXK>
M62>\B\BXN)KB225TQC;O9B0,<<$=!0!YI\)?"EOKOAS3-=O=1U-KFRO9&BC%
MR?+ '\.WT).3Z].E<[X8T:QU6R^(;:B[^1IPD:T7SV"P,/-(8(#VVKC([8'>
MO=M"\/:7X:LFLM(M?LULSF0Q^8[C<>I&XG'3M7E7@WX9SW'B#Q WBSP\PM+R
M;S[:0W2\8D8E2(WSR&'7CY?I0!A0ZGK&L>&?AYIFK32/IU_J#QS[\CSXTD54
M5SW&"PQW 'I6C,?['\<^/]!M+<C0/[(EGFMXU^2)O(5LJ.BG+$?_ *J]@OO#
M.C:CH\6DW.GPM8P[3#$HV>45^Z4(P5(]13;/PQHMC!?0PV"%;\$7;2LTCS@C
M!#LQ+,,$\$]S0!Y;\)/".D7GAC3/%%W)<I?6$TY603G8%&1@J<@ <GC'7G-<
M+K=]%;^$-/OM%Z6NKR&'5)V1+N9L%ON@9V#(Y+')[#I7TAHWA[2O#^GO8:79
MK;VCN7:(,S D\'[Q/I6,OPS\&);RP#P]:;)9!(V=Q.1TP<Y ]AQ[4 <5/'I<
M'[1%S+?K:1Q#3A-OGVA1(%7YLGC( Z^U<_966I>*=8\;Q3:GIME<PWZ2/=7R
ML)K=(G;88SD!5&,'ZU[+>>#O#VH:I::G=Z5!->6BJD,CY.T+RHQG!QVR*;=^
M"_#=]K(U:ZT:UEON,RLOWB.A(Z$\#DC- &Q:;_L<'F3+,_EKNE48#G'+#V/6
MO'O$^BZMXZM=?O[718IH)V$5A>2701DC@)^ZFTY#L7QR,\>@KV2:&.>"2&5=
MT<BE&7.,@C!%9UIX<TFPT1]&M+,0Z>X*M"CL!@]><Y&?K0!Y7I7C?4-2^ VI
M364S'6-,B6VE9>7$>X#S/^_9//JI-7-"TK0H/!^B>*=)NEM]9M](ECBBB=1]
MKN/*;(=>KL'W$#_ 5Z#I?A#P]HK3G3=)MK?[1'Y4H1>'7T(/!%1:3X'\,Z%J
M+7^F:-;6]TV?WB@DKGKMR2%_#% 'G7P[T?0==\(Z'KMYJ(@U>PU!Y[FY$RB2
M60R<)(S9)#+L&.,Y]ZYK2-.U'Q1)XIDO-6TO3;V+5%FFN;T$36Y0G;L;.%4<
MC\*]IMO WA>TUAM6@T2U2^9]_F;2<-G.X*> <]P*?/X*\-76N#6I]&M7U ,&
M\XKU8="1T)X')&: /(O%2W.EW&O:M=6UCXB\-W]UY-Y<1_+<VDB_)M4G.S:>
MG4<CUJQXJ@NM-U37O$2VEGK_ (:O_+M[Y6/^D6NU0N 3RK GJ,]1TKU*7P)X
M8FO9;N31K=I99#++G.R1\YW,F=K'//(I;CP/X9NK^2]GT>WDN)9/-D9LXD;.
M<LN<-^(H T+N2-_#L\D898VM&90X((&SN#TKRBZ\#/XG^%7AO5=))CUW3K)'
MMW0X,@'.S/KGD'U^M>OWMC;:E92V=Y"LUM,NV2-NC#T-1:5I&GZ)9"RTRTBM
M;8,6$<8P,GJ: /%]+N;W7/@_XXU/58U-W/<L9$*$%7C2,$D'H<C/M[5BZC>:
M;+X8^&2I>0-=V]SB1%D!,:F1<[AVY'?WKZ%BTVRACNHXK6%$NW:2=50 2,P
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M^(II=4LK-H?LD(CQ"@#;A+M7<J#L6([>M5/@IH>A:SH^JR7UE:75U#J*R(7
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MVXW;L]L9% &Y14-K=07UI#=VT@E@F021NO1E(R#^534 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4453U;4(](T:]U*4$QVD#S,!W"J3_ $H
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MC#NC9K';=1[W*W*R1<YR>"&PV<?_ %N$\&WW@RV^'XN_$*3SWD7G&5_+G9B
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M51VQAC[Y]J^H, =J:J(OW54?04 >%:L[V^F_"[6I;N:'2K6W2*>Z@ ;[.Y5
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M=YPA*]<^OO0!ZS17SW%XO\6WGPP;Q0_B"6.XTV]2VCBB10)A\I)E[L?F'H,
M]<YKJO$?BS5M1\;:!X=MX;[[/<V O)X]/G%O-,[(Y 5V9<*,9ZC/(YH ]:HK
MSI=(\9ZO\.[&TU367T/6X+D&6Y65298P2 &9#C)!!Z\E>>M>B*"% )R0.3ZT
M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC7"LH1 ,G W=6))_2K"^#-6D^)]EXKGNK'R(+06SPHK;\[""1V^\Q_"NZHH
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MR>O&.IB\"7;_ !%D\47M_:SQ2VGV62V%L1N&P*3DL<9.?P./>NYHH X+PSX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4'I35.0#@C/:@!<Y8C'3O2T44 %&><44F!G/>@!:*** "BBB@ HHHH ****
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M6L[K&C.[!549))P * %HKS7PMXGUOXBW^IW>GWS:1HEHXA@,<*/-,_4EMX8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7K1 88(!'O0% )( &>N!0!X[XU\-7\'Q5L)=)N/LR>);>2SNG"Y*A5&\CWV
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M8*TOENX4GIG:#CZFFVFOZ9J&AG6;&Y^UV(1GWP(SDXZ@*!NS[8S69\085N/
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MTK0\<#=X"\0#(&=.GY/_ %S-<0L:3_!OPC;RJKP3W6GQRQL,K(IF7*L.X]J
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MC'N0#5JS^&>O6DWBZ5M2TV5M>MWCXB= CN<DXR< ;FQR>WO7J:(L:!$4*JC
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M=SW"K7?7=G;7]L]M>6\-Q;OC?%,@=6YSR#P:?##%;PI##&D<2*%1$4!5 Z
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MAX/2O.?AY\1]5U?69= \411VNHRQ"XLY%3:)%90P7'0\'<#WY]*]$UVY@M-
MOY[F:.&);=\O(P4#((')KSK6_!L?C'X=Z#JNB2QIK5A9PO;7$>,R%$&8RP[A
MAQZ$>YH Z?PAJM^UCKEQKNJQSQV%_-;"9XDA5$BZL<<<]>>F*U[;Q3H-YIT^
MH0:O9O:6^/.E\T 19Z;L],]LUXIJ<VIZK\"KG4978S3ZPTVHB%0FU<[3E?\
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M2R:[1<9.U1NW;6'(([].15?P=\0='U30=&34=<LSK%W$-\3,J,9,D$8' Y'
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M I-HSG'-+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZJ+V'<\Y.3R., '-Z=I^L?#G6]&TX:O-JOA_4)_L4<-R!YEHY!*;3W7Y2,<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU2XLYX)$38BHR.&8#D,I.1[$5BZSK/B7PWX TCQ?!K4]^6BMY+VTNXHO+=9
M"=I50R\L!U/^(!ZM17-6_CK1)O#VFZN\TB)J"%H+=8S+,Q'W@$0$G;SG%0:O
M\0=$L?"%WXALKE+^&'Y%6#)/F'A5;NO/<X_E0!UE%<IX?\;6%]X(M/$&JW=O
M:AU59SAD19"/NKGD]>V:U+?Q/HUUI=UJ,=_&+:TS]I+@HT) R0ZGE3[$9H U
MZ*H:-K6G^(-+AU+2[E;BTESM< CD=00>015^@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **XFTU/6$^,%S
MHUSJ(FTXZ0;R&!80@C)F50">2Q !Y]^E,M;B]\5>+_$5BVJ7NGV^D/%#;I9L
MJ,Q9-S.^0=W/0=,#H<F@#N:*\HL/%^J>(!X:T*>]DM;F[O+NUU"[MP%9C;IG
M"GHI;*]/PK9BU35M,O\ Q/X>LKF:_NK.P6\TTW)#R992-A.!NPP&,\\X)- '
M?45YEX7U]M2U7P^-$UJ^U-9H)&U:*[;?Y  X)  V/OX Z$9X[TOC+Q9J=EK>
MJ_V;.T<6F6D5OC'R&[N'4(3Z[$R<'N: /3**X6[%[X.U;0)#JEY>VNHW0LK[
M[5+O!E=?D= ?N?,N,+Q@],\U0\?>,-3MI[>UT)_+@M]1MX+Z[!!^=FSY*\<G
M'+'MD#N: /2:*Y?QKJ%]!!I6FZ9.T-[J=_' )$^\D8^>1A_P%2/QKF-.GU3Q
M/X1U/QC;ZK>07>ZXETVW27$,<<9(5'3HQ;8<D^O&* /3Z*\OU'XD_;8O#EE;
M70TZ35;07EW=(GF-;Q\Y6-<'+%E8 D$#&<&NW\+OI<FBJ^D:C-J%LSL3<37#
M3,S]\ENGTX ]!0!LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F^(;VVT_P]J%S>7$
M<$"P.#)(P4 D8 R?4D#\:X'4O"ME\0?A=HTFGRQC4K.TC-K.!@AU0!HR>H!(
M_ X->G21I*A21%=#U5AD&E50JA5 "@8 '04 >&RPZO=_ +7'NQ))J4E^TEXA
MB 8%94#9 '7Y<D_6JEEK%E>^,/ADUL\DBVNGQ6\S"%P%DV;,9(Y^;C(XKWW:
MH! 48/48ZTU(HXPH1%4*,* ,8'I0!\U^)=8CO]*\86-C'+IL0U 3/IXMVDDG
M?>-\DCG/E@$ [1CDXR>^EJMS%?:Y\+)-S2K#;6@N"5)VD.JG=GW5ORKZ!\B(
M>9^Z3]Y]_P"4?-]?6I ,# Z4 >%V%SIZ>)?B;)>)--93Q$$6_5T+%6*GH2"P
MJ]X%^W:9XXTW1;;6+?Q%H<=O+)!<+&&?3^" I;JA/"[2>_05[-34C2/=L15W
M'<V!C)]30!YS\;KF%?A_+9;\W-Q-&8H@"6<*P+$#V%8/B358=;^$.D>&=&63
M4-6N;6TC-O;HS-%LVEB_&%P5QSCKGI7LU% 'B.M01^")O VA-&D-Y;H__$Y:
M)W2 NQ\P1H.&;)_B!QD''-8&D*\_@3XE1+YUQ<-<QRGS(BK,OF$[RO 4XRV,
M#'IVKZ*>*.0J716*'*DC.#ZBE$: L0B@ORW'WNW- 'SWJMXVH?#GP;>68O&L
M=#FB_M&2*,C83MP5)&"5P><$ L/6O0M M_"T-AXFU:RGU+6;>ZMQ)?33(62X
M 5OD3"J&;'7'3(Z5Z#Y,7D^3Y:>5C&S:-N/3%*D:1H$1%5!P%48 H YKX?WN
ME:CX-LKK1=,;3;!R_EV[#H0Q!.>^3GFNGIJ1I$@2-%1!T51@"G4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'G0OH$^/!D<NL;Z)]C1S&P5IO.#[ <8)V\U+XKM-$M]?EO;'^U'\231J&M-
M*N'C:Y &%$N.%4<?,2"!WKT"B@#SN/PCH.A>!=*L_$,DD=Q;S>>L]L\GG"Y?
M+$1LN7/IQUV@U%HVB:O%8^)?$MM;7D&J7EIY.F0WTIEG5$0[2^X\,S<[3TZ5
MZ310!XSI%K9VFM>&=1\-)J$6H.H77;812?,FPL[S!NC;LXSUSQ6E_8-[K7PN
MU'4Q8R#5M2N_[5\CH[!90R1]/^>:@#W->J44 >>ZI?Q^.M1\-VVE+*8+6\74
M+UWA9?LS1J=B,3CY]QQMYZ9Z=>>\7>#?$>F>%M/LK?6/MT8U*!RD6FC?YA8D
MRL0Q+<G)SUS7L=% '$Z5;7FH?$6>:^EDG30[%+5)GAV++/-\\CJ.@PH0<>M8
M>G3S>%?!NK>$/L-X^I1-<1:>(K9W2X65F,;!@" !N^;)XP:]2HH \QTG2&^'
MVO:9<7D,LME-H\=C-<PQO*()XSN/ !(1LGMU'O6W\/K21%U_4A%+#9ZEJDMS
M:1R1E"T9 'F;2,C<03SVP>]=G10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6O[Z
M'3;":]N/,\F%=S^7&TC >NU02?P%<S9_$OPYJ-M)=6+W]U:Q'$L\.GS,D9ZX
M.%S^0^M=5=0BXM)H2,B2-DZXZC'7G%?/'PTU?5].\+VL-E"$L[GQ';0W-TKC
M<%;9E"N,X;@9SWQ0![]I&KV.O:5!J>FS>=:3@F.3:5S@D'@\CD&KU>8>*+O5
M_!6L>%] \)/;16>I2RQ+;72;TC;>&+;OO8_>GC/\(Q4.N>+/%GA>+2=*UBXM
MI-2U2^91<Z?;&4QVZ[!\L9'S2$L<#!_&@#U6BO(M1\<>*K#P+K>H/'<03Z=?
M(EK<WM@8C=0.VT%D( !YR2 .W%36OC/Q7I_C#PM8ZO/87-IKELLC1P0%#$Q7
M^\2<\X/XD8'% 'J]8S^*=*B\4Q^&Y9I$U26/S8HFB;#I@G(;&/X6[]17%)XC
M\5>*]:\5VOA^[BL3H<JP6\+1(WVF3<P;>S X!V-C&.HR:P/$3:S)\;O"0\V"
MRU672D69E7S(XV/G;\ XSWQ^'6@#VVN=U_QQH'A>^AM-9NI+5YU#1NT#LC<X
M/S $<=\^HK%^&/B?5M?M=8M-9EBGNM,O6M_M$<83S ,C)4<=0?SIWC_PW9>+
M-4T32;[<(Y8[HJZ'!1PB[6_ ]J .DUSQ'IWAZPCOM0>46KN$\V*%I0">F=H/
M!Z?B*U(I!+$DBA@'4, RE3SZ@\@^U> Z?X@U/PWIM[\/?$QD6Z2:#^SK@?,&
M7SD.T'G(QRN>F"#T KN[OQ1J\/QE@\+K?(NFW5H9@K1)O1O+;A3CU7/.>_:@
M#T6BO)/"GCGQ7KG@7Q%>Q?9+G5+&81VYD"Q+MXW,Q)"\#)YP*70_'VH-\1],
M\/C6%UC3[VV+23M B&.4*Y(1D55904'.".3SQ0!ZU17B2>._&MQ!XQ:'4=."
M^'IL;FM=S2KO=< @@#[F<X_*M77/B-J5MH7A*_G=M-LM5B9[V^MH!,8F"_*J
MJV1@GDYR<9QTH ]8KG-,\=>'=6UV31+6^;^THRP:WE@DC;*]1\RC.*F\(7UW
MJ7AV&\O+^TOS*[M%<VJ[5DCW':2.S8ZCL>*\Q\4^"[K6M7\3>(=$>2/7M+U)
M'A*-S(@MXFV@?W@22/7D=^ #U,^)]+'B4>'R\XU(H9!&;:3:5 SNW[=N.V<]
M>.M;%>1>!?%__"<>.[2^\HP7=OHDL%TH7Y4D\Y,$9['KCMTJE8?$'Q3?> _$
MVK-=QI=:1=(L<@M5V2H3M*'WY!XY''K0![517D^L^-?$L5OX %A=VL<_B")5
MN#+;AE#GR_F !!Q^\/&>U9]OXJ\=S_\ "7:<NL6'F>'TDF:\-F \FT,0JKG:
M!\IY()_G0!Z9XH\6:9X0L(K[53,MO+*(@T49?#8)YQTZ&MI'62-74Y5@"#[5
MXAXW\0W'BGX":?J]VB)<37:+)LX!96=20.V<9Q6W)XH\0^%/'7AO2-2U./4M
M/U>)$*?9EC,+L=HVE>2,E>N>,T >K45XE9?$3Q9K\U[JFB6.H7$,-^L4%I%:
MJT#0?Q"1\;O,^Z>#QGTK5U?Q!XQN/BU<>%]&U:&VMGM/-7[1;(X@/EYR, $G
M=ZDCGH10!ZQ17&SZ=XZ+^&BFLV6("/[7VQ#$_J5RO3&1QMY.?IV5 !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA68=LYSVKT6B@#SZ+X6PO\/;;PA>ZM++;P7)G\^&$1L1ECM );'+'GFKFG^
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@! <TM%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5M0MYKNPF@M[N
M6SF=<)/$JLR'U 8$'\17CO@;Q!K?BCPW-J>L^,-0LYTU".RMC;V\.PN^T*&7
MR_FR6^@KV6[N[>QM);J[GC@MXEW/)(VU5'N:^??A!X?TC7],8/<11:U9:K!>
MQ N=S11E21MST/S#/KC/:@#UO2?$?]B:5IMAXRU2V@UN;S 6DPBS 2,JL"!M
MY7:<<=>@K17QEX<?1Y=636+5["*3RFF5LC?C.T <EN1P.:X#XM/9OXY\ PW3
M0-&+UC,DI! 0O",L#V.#U]#5?XM:1%HDWAF_T^$:=I5OJ7GWCV5NH\MR4(E(
M"D%@%.,@^G- 'HQ\9^'5T<:LVJP)8^;Y!F<%0LF,[2",@^Q%)I_C7PUJNIII
MVGZS:7-VZ[UCB?=N&,\'IG';K7DOBM-"A^&WBBXTC5KS4C?7MO+-=W"JL<LI
M?)$>%4$@ D@#C\*CU&]TM/&_PR>S,'E_98 ?)4#&YMHSZ?-G/XT >OZMXR\/
MZ'=/;:AJ2131H))$5&D,:D@ OM!V@DCKCK7!>(O&<^D_%[0XQKAC\/7EBMS*
MK,OE$$2 $''?:I'N:SK"_P!,\/>/O&VE>,U*VNM.)())%=EFBRV$!49SM<#C
MH5QUQ4&HSZ:/C=X*6T@^S6,>GQI##+'L://G!%*GD'E<9YY!H ]?T/Q#I/B2
MR:\TB]CNX%<HS(""K>A! (ZUPGQ6O_%.E7NE3>%]0N4N+A)E>U58W1EC7>6
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MZW?&RL-222[V;Q"\;QNR^H#@$CZ5XEH=_9CP!\0/M>F2W5O]M2=86+1;@TN
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M%S-?O9XMKZ5%9H$"D%2W<@+\V#QGWKN* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** $(!&",BFI%'']R-5Y)^48ZT^B@!"JL<E03[BD=$
MD1DD561AAE89!'O3J* &+%&D8C5%5%& H& /PI=B9!VKQTXIU% ",BL064$J
M<@D=*-H)S@9]<4M% "!0,X &>N!054G)4$^N*6B@ (!ZTA .,@'%+10 F!C&
M!CTHVKQ\HXZ<=*6B@!OEI_<7GVILEO#-&8Y88WC/564$'\*DHH 155%"J %
MP !P*3RT_N+^5.HH *38O/RCGKQUI:* $P,@XY'2C SG R.]+10 8&<XYHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M I 2>HQ2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (1D$9
MI:** "BBB@ HHHH **** "BBB@ HHHH **1F"J6)P!0#D4 +1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%4-<U!])T#4-1CA,SVMM),L8_B*J3C]*\PT75=5\4^#!J&@^+KB7Q-L\R
M>P+0A?O?,@C(^48QAOISR: /7J*\MU/QE>Z#\9%T[4=86#09+,W#QSA L9V'
M@-C/5>F3UKOHO$FBSZ(^M1:G;/IL8)>Y$@V+CJ#Z'VZT :E%9=AXCTC4KM[2
MTOXGNHTWM <K(%X^;:<''(YQWK.'Q!\(F,N?$%BH$GE$-)M(;T(//X]* .EH
MK%O_ !;H.EWQLKS4HHIU 9UP6$0/0N0"$!R,%B,YK9# KN7D$9&.] "T5Y%X
M0\3/XSBU&*X\4W>F>(3<N+>URBK$H^X%0C$G^UU/';OI:OX_O/!NE>&-+U2,
MS:[>>2+MI5+*B;@KME/O-UP!]?8@'I=%85[XR\.:;>"SOM7MK6X,0F$<[;#L
M(SGGV'2F1>./#4T.GS)K%OY>HL4M&.1YK!@I R.H) P?6@#H**S+'Q#I.I:E
M=:;9WL<M[:_Z^$ AH^<<@CUJG;^-O#=UJD>G0ZM"US([1QC#!9&7JJN1M8CT
M!- &_17"Z!\2+'7/%NN:8"L-GIZ 1.\;!Y&7?YI/8*-O (!_D-D^._"XTI=3
M.M6OV%IC )LG;Y@&=O3KCF@#H:*QK_Q;X?TJ[@MK_5K6VEN(Q+$)7VAT.>0W
M3'![U$/&OAMM)74TU:![1Y?(1X\L7D_N*H&XGGH!0!O45BOXMT&/0)-<?4H1
MIL9VO/@_*V<;2N,[L\8QFM.SO+?4+*&\M)EFMYT#QR+T93T- $]%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45Y+HNIZIXI
M77(!XHO--\4P3S+#I^$2-%4?(!&RDD$=3DD=:V]4U_6KK5O#_A.WF.GZI>V@
MNM1N0JNT" ?,J=1N+ C."!0!W]%<5J6B>(M':QO-'U[5-05+F%;NSNC$_G1%
M@&(;8"I .3CL.U5M N-1?XI^(--FUB\FL;&**:&WD9<;I5!.2 "0.P[9H [Z
MBO.;634YOB[J.A-KE^--CT_[9'$DBDJ[%5P3MS@;B0/H:H^$);S4[;4;K5O'
M-_ ;&^GMHT$L"XC3@%PR')Y)R?04 >J45Y7XEO/$.D^!+#5;3Q1-+-)>*L-R
MD*8GMYGRA=67&X CD #MBM?Q$GBGPCIDNM:=K4VL6MK^]NK&_ACWM'G+E)(U
M7;@<X((X]L4 =[17F7B37[R\OO!MYH^N75G8:_*L4T:"-L*0"-NX':W)4X[_
M $K;^(,^HVMKI$FGZK=6)GU*&RF\D(=T<K!2?F4X88X(Z<T =E17G5]=:O9?
M%_2-%BUJ].F7ELUU+ XC;YD#<!BN0IVC(SW/K7;ZS"]QHMY'%=3VLAB)6: @
M.A'.02".WI0!>HKR3PGJESK/@>#Q%K?CN_L;E1*9%C:W5%"L0/W?EDMT'').
M>.U>G:1'>Q:/9QZE<)<7JPJ)ID7:)&QRV,#&>O2@"[17"PCQ<FKQJTMQ);'Q
M!,6)10%LO*^4'/\ "&S@UH^.]:U#3-&2ST0;]<U!C%9*,$@@;G?!XP%!_$B@
M#J:*Q?"6O1^)O"]AJR<--&/-7^Y(.&'Y@US7AQ_%QU71EU)KPV@>_%T9449
MDQ#NX],X]: ._HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!"H8$, 0>H-* !THHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^GSV-LUM:26Z-#"R;2B$# Q]*O&&(P^28T\K;MV;1MQZ8]*?0 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0,JJ"1G! VCBI/#W@;7O#GA2WT:#4--N%CGE>6*X@9HKB-UQL8=>&YS7H=%
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MX;M[PW(C$;">1,DB)FSC&6/.,_T])HH \_'P[O8O&VJ>(K;5[:$7EHUFEO\
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MJ-MI[:M9B[NE#01><"9 >01]>WK7B=G'HLNJ_%B:_2V>1$E^SLXR5RT@RO\
MP/R_QQ6!?Q6=M\+/ ]S L,=R^H3O+(N Y(D(R3UX 7]* /5M>\:WV@?&#3M(
MN]3@@T&XLFN)A,BJ(R%EQ\_7[R#\\5W>FZWI>LV37NG7]O=6RDAI(I 0I'7/
MI^->6>)Y;(_M%>'?M;0F!+#:_FXVAB)]H.>,Y*X_"N46PU"YTSXF7.@H[:7+
M<!8_)Y60+-N?;CJ A/3L: />=-\2:+K!E&G:G;7)B7<XC<$A?7'I[U6@\:^&
M;E(&AURQ<3S>1%B89:3CY0/7D?G7!^!8=!OM1\.:M'XFN;W5+?3!#]D01A((
M@F&60(N5 8\;CDG')K.^"NA:#K'A[4);ZPM+J]@U0R*TBAG10JE#],[O8\T
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M?@'Q/X>O)7:/2?$6F1B1V/RI-QSU]<?02&O>K_[9]@F_L\0&\*XB\\D)N]\
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M<;^>G3V[UUFG^"M2N_$^G:UXDN+*9M,M/LUM%:JQ$A((9Y-W<@]!Q5'P_P"
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M(P=BO).,8<YX]*KWG@C6K+QO=^(?#6JVMJ-114O8KN(R $8^9 ._'0GN?7@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.UNG2'((+0@+AV)X!))X]*UK'QAX>U*\2TM-5@DED)6+J%F(Z^6Q&'Q_LDT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %!HHH 122.1@^E+110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% %74H[J;3;B*R>-+EXRL;R$A5)XR<<\5YEH'PV\2Z'X
M-U+PW%J>F+%J3DS7 21FC5E"L%'&<@=2?_K>KT4 >;ZO\*DE\'Z)HVDWXAN=
M)N/M$=Q,I_>,22V0IXR<$>F,>]-L_ 'B2/QAJOB6XURQ^VWUB]L/(MF01,4
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M23M9@V."<\#J>N.*]=HH K:?;R6FFVMM-(DDD42HSHNT,0,9 )./S-<+\0O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+DV3I<,J.QE8AB%.''W3@Y&* /6="UR\TQ[Y/%.L6IMGGC_LZ\F1;83HR!L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>0""1G.,'IU]JY6W^&^MW>G:!H6LWFGOH^D7!F#VY<33 $[5(*X7K@X/Z\T
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M=+*IXW#*]QW'&#VQ4$=Q+I7QMUV:#3KS4#-ID+&.U\O<G*KSO=1CY?7O70>
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M0M$LPJ6!L1=K",!(I9(CNQV&[K61X0GN_AU8:->7$DL_A76;2WDD<DL;&Y=
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MDFXE<+&#Z  [O?F@#TBBO/-,N?$U]INCZOI?BF+6+::Y@%] +6(;$9E$@4H
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MPH\37UW?W,,ME(TL<:SD1,ZQ@INCZ-ELCD5])W5K;WUK+:W4*302J5DC<9#
M]B*R%\%>%E8,OAW2P1_TZ)C\L<T >->-&UGQ?\&=#\07%JHDM)G\]8H]H\HD
MJ) .PX'3CG/2O;=.UG3I?#%MJXNXEL#;+*9F8!57'.3VQ6F8HVB,3(IC(VE"
M."/3'I7.1_#_ ,)Q:@M\FA6BS+R %.P'KG9G;GWQ0!F>-=0;7=#T[2=%V74V
MLLDHC:0P[[5<.Y)(RH(PO0GYNG6N"M;V]\"_&H7&JVMMIUCKRX>&WG\R-">
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M-$TUG$8B#FU3<$"[0H.,@ <8]*EDT/29M+BTR73;62PBV^7;/$K1KMZ84C%
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MPBND+X3TU="9GTL0C[.S9R5R>N><YSFMJHK6U@LK6*UM84A@B4)''&NU5 Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HI,\X[THZ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4WCDYIU0
MIYWG.'">7QL())/UH FHIB%B/F&#W%/H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FL ZE3R#UIW:F
M*I#,2Q(/8]J ' 8X["EHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBE.H62F(&\MP9FV1@RK\[>@YY/L*\IOX?[/^-YL=*MX4L+C1C_:,* ",H%<
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MOD;1*X3&X@>W]/2N%TNRM;CX+:QJ<RL]_87\4=K*TC$P*60D(.BY+,3CK^%
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M6[:@X(:Y*?O,;=F W4?+QQ5&+P#X6ATZ33X]%MQ9R2K,\/S%6=> 3S[UT=%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1M%O@/M5E-,R%23SMX/0\CZD4:5X'\0>%O$.M'1H=)NM,U.994>\)W6QRW\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M XNG*GD'[/)_\30!M45BGQ5HX7)NI /7[/)_\33O^$HTD)O-Q)M]1;R?_$T
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M 4444 %%(652 2 3TR>M+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH **** "D*AA@@'OS2T4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ')Z[HMUX@\4Z=!
M?:?YF@VJM,9!/M)N,?(< @X4;OQ/M7+CP;K/A_XG1ZUX9TB--*:)8+I'NAF4
M$_,1DDCHI^J^]>J44 >91^$O$%MKWC:_CM('36;:2*T'GC.[[J[AV!!)Z]JQ
M=1\ ^)Y_A+I'AB&QA-Y!=O-/FX7"C<Y&#GG._P#2O9Z* //XO#NM_P#"WT\1
M-9HFFFR%NSF92P.WTZ]>*YT>"/&%CI_B_1[.TL)K;5YFFANGN-IP225VXZD'
M'. #GDU[%10!Y3J7A#Q>?!WA?2;46SK828U"T6XVI<*K#:"V.5QD$?[70XJ#
M3_ OB2PO?&$HT[3HX]7L'AMX[2?:D;," H!4<#/)..G&<UZ[10!R_P /-&U'
MP_X*L=+U146Y@+_*C!@ 6+#D?6N5UOPIXDN?BS9^*+;3K:6RM@(PC704NN&4
ML<CC[W3GI7J5% 'F^@>"]<\'>-KJ70S;2>&KUE:2VEF8-$>Y48/(YQZCCMFH
M-$\&>(_"^N:I:Z1;:1)H]Y/Y\-Q=DM);CN-O5B.P)QQUY->GT4 >>2^$O$%M
M\6I?$NGO9-9WEND4SS9S$!L# *.I(3CG SSTYPI?A_XLM)/%]E8'3I;'7)/,
M62>=E9,LS8"A3S\V/3@5[!10!Y'J?PX\12_#?P_X=MFL&O-.NGN))&F8)RSD
M ?+D_?Y^GO75_$+P_JOBOP5_9=C%:K=S21O()G^5 .3M;'7.!GT)KL:* /-8
MO!>N_P#"6^#]2=+,6VCZ>EM/B8EBP1E; V\CD8KTJBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S"7Q'?02Z[J.J>*KC3[
M&WUEM.MX8K%)L856'\)8YR?RJLWBOST58/&/B"292<QP:"-QYZD&+I^-5W_X
M^9/^Q_3_ -%K79)\1-)EUB31X;/4Y=3B#&2T6UPZJ.<G) P001@]Q0!R(\1W
MA7</$OBXC.,_V!']/^>=._X2"^_Z&/Q?_P"$^G_QNNKG^(NDVVD:IJ-Q9ZG"
MNFR1QW$,MOLE!<X7 )Z<YSFK7_"<:4OB6PT%XKQ+R^A6: M#\C(5+9SGCH1T
MZB@#BAXAO<\^(_&!'MH$?_QNC_A(+[_H8_%__A/I_P#&Z]:J.XF^SVTLWER2
M^6A;RXQEFP,X [F@#RN3Q#=%OW?B'QBJXZ-H,9/Y^4*?#XBF7=Y^O^-']-FA
MQKC\X375>&_B#I'BK4YK#38+[SH 3,9H0@C[<\YSGCI6EI/B2WU?5=1TZ*TO
M(9M/<).9D 7)Y&""<Y'/T/.* //AX@O<\^(_%^/^P!'_ /&ZGD\1L0OEZYXV
M4Y&=VBQ-D>G^H'/O7J=% 'E!\1M"1Y>L^.I(^Z?V1$7R3UW-#T]OR]*CL;J+
M4+F^BN?%WC**2.W>]*O;K;9CC^\5RG^T.!C^5>MUY]XS(_X2I\MC/AN_P/7E
M./Z_A0!S=MK%C-$MQ;Z]\198G0%'6 .K CL?+(_'\J2/5H9"L3ZE\3(E!)WM
M;)^I"$]JZBR\567@SX;^&KN]L;UK22R@5Y+=581$HIRV6!Y).,9_"KL?Q'TM
M+:TN]0L-3TVQN]OD7=W"HB;<,C+*S;<CGYL4 <7_ &E$DK"/6/B/CRV 9K0,
M"2,#@I]>WIR"*&U6&3]X^J?$K>X+L%M54 ^@ 3 SVQQ7L:.DD:R1LKHP!5E.
M00>X-$CI%&TDC!$4%F9C@ #J30!XS_:D08*U_P#%!<C.3 GIG^[2G4H=JE-2
M^)SDKE@L"Y7ZY3^6:]?L;VVU*RAO+.99K:9=T<B]&'J*L4 >*C5H>?\ 3_B@
M/^V"<_\ CM']K1?\_P!\4/\ OPG_ ,37=>*OB)I_A'5+>PO]-U*5[D?N9($C
M*2'(! RX.02.H[U8'C:.+5[#3K_0]7T]K^3RH)KF.+RR^,[25D;!H \^&JQE
M2WVWXH8'!/D)_P#$U8L]8CC9I$U;XC0R 87[39)*IS_L^60?TKKI?B3ID.D:
MSJ4FG:EY.DW?V6X C7));:&7+ $9Q[\BNITV^BU32[34( XANH4GC#C#!64,
M,^^#0!YBGB&Z"MO\0^,22/E(T&,8/O\ NN?TIO\ PD%]_P!#'XO_ /"?3_XW
M7K5<_'XPT]_&#^&&ANX]0"&12\8$;IC.X'/3J.G4&@#AGUW5#HUWJ=AXLU:6
M2PNK:*:UO=.AA)\R1%P1L!^ZQKUFO)?$O_(2\>?]?.C?^AI7K5 !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >/O_Q\R?\ 8_I_Z+6JM_<ZG:?&
M;QA/I$,,MVFC;E$LI0@".$Y7 .6]!Q]15I_^/F3_ +']/_1:UT^G> M0L?&]
MUXI;Q#YMS=82:+[& K1<?)]XXX5<'V[T 8_BZ^O-'^%5IX@TV\^SZE-%:/<3
ME%D-SE N'W@YZY_"J<]Q+=?&SP5<28:671=[GIDE)B3Q7>>,/"D'B_01I,UR
M]K%YJR%HT4GY<X'/3KV]*HIX#C7Q1HNO'4YVGTJS6T1/+7$BA64D^A.XF@#@
M=-\:^,/$4=QJ^CP:E<21ZCY<5K%#']E%N.2CD_-OY'/:O;%)*@D8)'0]JX6U
M^&[:;J]Y-I7B/4+#3+V4S3V-N%&6.<[9.J#MP,^_3'= ;0 ,\<<G- 'C/CF&
MY\"?$O3_ !-I&PC6-T$]NYPK/\H)/L25;CNI]:[C4I#X!^'VHW\>+J^B0SS3
M,,>?<.0"[>VXCCT %,\8^ ?^$QO[.XGUFXM8[/YH8HHE(5\@ELGDG@>W%=%>
MZ3%JNA3:5J;?:8YX?*F?:%+<?> '0]_8T >?^#M8\87M[HMR\&HW>FWMJ7O9
M;U(D1)"NY7BV\[.@QZ<XS7.:MXU\1:!I5KJS:Q+>:@FH-#?0PJLEELY(C#A<
M!L < DC//->A^'_ LVAQ0VS>)-4NK&W1TAM69450P(Y(&6P#P"< \US[_!:R
M?0QI#>(-2-HEP;B*,JFU&(P3C&2<>_X4 ,U[5_%$_P 6CX8TO7196EU9^:NZ
MW27RCL.2,@'.5SUQS3M2M-1L+R*UU:_%_?1^&=1$MR%V[_G3''L,#\*Z0^"&
M;QO:^*&UBX:Y@@6#RVC7:Z!<'/U))X[FLWQC_P C1+_V+5__ #2@#G_'7_)O
M^C_]>MC_ .@+6EXS6,_ )/,"DC3[,KN]<Q]/?K5UO"/_  F7PR\-Z=+J4UI;
M"PMGD6*-6\PB-<9)Y&.>GK5K_A7?VRPLM-UG7K[4-+LPHCLRB1(^T84.5&Y@
M,>M ')^']3U;3O ?@L7NJ_8[*>26.:-<_:9H\GR5C 5F/;[HZ%>U9S>(]4UW
MP#X\L;Z[NV72YE6WDF413^678;)  .<+R#ZD5Z+XD\ VFOZCI-]#?W.FSZ7@
M6YM0NU5!!  (P,8'M[52L_A=86EKXAM?[4OYHM;4>=YQ5F5P2=^[&2<DG\><
MT <K=:_J'A?X6^$K73)KHW.JF)#-N5GC4@95-W /( STYKN/!\GB,:AJ\.KV
MMW'IPD5]/>\DC:;:0=RML)X! (SZU0;X6:=+X771;G5-2N&B9'M[EY?FMR@(
M41KT48/([_7&.GT/1Y])AD%SJU]J4TFT&6Z8< = JJ !U.3U/<G H \J^.2M
M_;_A5T9#)YCA4;/7<G/3I7<^&(=2O=6U]?$42M<Q7L3P!=S01KY0VM$6'!Y.
M2.<]:B\8?#J+QCJMO?7.L75O]E7%O'%&F(VR"3DC)S@=:ZZV@GBL4AFNVGG5
M-K7!15+'^]M Q0!X+;^(=6U_X1^,SJM])=M!-;I&9 ,J/,7T ]!6_+XGU*VF
M\#>&[0WRVT^BPW-P-/"&>3]T<!=W  V9/J#6];_"2SM/#>J:)!K-X(-2>*2=
MFC0G*$DXX& 3M^F/>M'4?AU;7EKH)@U2ZL]0T6%88+Z%5WL@4###&"..GN>N
M: .-UOQAXST?PSI.F:AOLM7U*_>W2[=(RX@78 Q ^4,2^/P/3@U/8V5Y8?'Z
MU@O=2EU!QIA*S2HJOMPW!V@ \YYQWKK]7^']MK6@0:?>:I?RW<-R+I+^1PT@
MD[X&,!<<;0 !@=Z99> &M_&$7B:ZU^_N[^./RSO2-59<8Q@+P,'H.<\YH Y;
MQ$Z2:AX]*.#MN]'4C!X(=*]<KR+Q V^^\?,H.P7ND+G;@;@Z9_'I7KM !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW6O7\L6@64<UC;3>5/?W+E(V(.'6( $N1Z\+[T <+_PBE_N"_P#"O[SIG/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,6L:0#YWGB(ZL#"),YWB(R; <\YQ0!W2DE02,$CD4M8?_":>%?\ H9=&_P#
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M\: ,_P"#O_),=+_WY_\ T:]3::D?_"X=<<*F\:7;@D')&6;\N@X]@:GT76_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(174E7TIR(R/F!(&>A Z=\8J-O'6F7HE@N?#^O-: 9,DVDNT;X(QQ@GN#R*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[=)+V&4R2,V1@J?E_&@!EQK%U%X(\,:+!IFM36UUI5NUY=:;:F5DB\L#8I'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY.J6NWT^Q'/Y^92"UUO<<ZK:;><#[$?P_P"6E &I166;76MHQJMJ&[DV1_\
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M?EU6T ][$G_VI0!JT5E"UUS/S:M:$>UB1_[4J1K?5RV1J5JHQT%F>N>O^LH
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MG3X\C!Y_G6<1=:I*HVE(AU9N.*VXT$:!1T P* 'T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4F*6B@"&2TMY6W/$A/KBF)86J'*P)GUQ5FB@! ,=.GI2T
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHI,<YS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>articles006.jpg
<TEXT>
begin 644 articles006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0C-+
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_:>G_P#/];?]_5_QJO+XAT2!]DVL:?&_7:]R@/ZFO.K;P/JDP8R>"/!UN0<
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M?K5A?#/B1&9DT_P0I<Y8C3I!D^I^:@#=_P"$Z\)_]#)I7_@6G^-'_"=>$_\
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M_C= #8_B$DJ!T\)^*F4\@C3?_LJ'\=WF8_*\%^)'$A(7-LB]/7+<=^N*?'X
MB4+YOB;Q/,PSDMJCKN_!<#CVJ3_A [7_ *#OB3_P;S?XT 1?\)KJ?_0D:_\
M]\Q?_%T?\)KJ?_0D:_\ ]\Q?_%T[_A7>E,BQS:CKDT:MN"2:I,5'7L&]Z5?A
MQX?"X)U-CG.XZG<9Z_[] #1XSU1E9AX)U["]<B$'\/GYJ)O&VL@R;? NMG &
MS)C&3[_-Q^M6?^%=>'O[NH_^#.X_^+J*[^'V@16<\B#40RQLP/\ :=QU _WZ
M 'Z9XWEO/$%GH][X>U+39[N*22-[G9M.P D#!.>O\JZVO(?!ES/=S_#F:XF>
M:5K/40SR,68X90,D^P%>O4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBEN',:KG8V"%R#][V]..A^'>B7UG\,XM$U.VEL[D+/$ZO@D!V8@C!.1AOTH
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MX.\0_=G\>:HRC[GEV\2$?4X.: *:>,O \-VEW'IDJW* *DRZ-('4 ;0 VS(
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M-0_BOQ,[@<M]OQG\-M #/^%B67_0!\2?^"J2C_A8EE_T ?$G_@JDJ7_A!_\
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MDU2499E!)QG%;*_#_3@6SJNOG)R,ZK-Q[?>H SSX^U#/'@'Q%C_KW7_&IO\
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M&_$=J1/A?X.= 5TZ9U;D$7]P01_W\I8_AAX&AVP#0K;=@D*\CLQ&>3RV3UH
MK'Q?XF68QRZ!I$# 9(EUQ 1[$!#SW].:JW_C/Q/$L;1VWA:U7.&:YU@,">V,
M!<=_6MA/ O@:TF2T.B:6)I TB1RJ&=@,;B-V3@9'L,TW3-"^'^H//%IEAX?N
MW48E6!(I"HZ<XSB@#%_X3'Q'_P!!CP!_X-)/\*CE\7^)V \K6_A\G7.[49&_
MPKH6M/ ,.IC26M?#J7XP!;-%"),GH,8SGVZUI_\ ")^'/^A?TK_P#C_PH X$
M^,?%P4'_ (2/X=X)Q_Q]R_XU(WC3Q JJ3XK\!99=P_>2_C_'_P#KKNO^$3\.
M?]"_I7_@''_A5J+1=*@@$,.F6<<2G<$2!0H.<YP!USS0!YU_PG.L?]#?X%_\
MB_\ Q=,E\:ZM-"\3>,/ VUU*G'FYP?\ @=>G?8;3_GU@_P"_8J.YT^S>UE4V
MT*AD()\M>.* /-O#=A%I>J_#ZS@OH+Z.*TU$"XMSE'R5/!]LX_"O5:\=\###
M?#@#H+34O_0Q7L5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 444R218HV=SA5&230 ^BL]M8M=@:,M
M)D9PHIIU=0NXVTX'^[0!I5A^,M/N=5\&:Q86<;27,]JZ1(K!2S8X&3Q5J/6[
M1WVN6C/;>*T58, 0<@\@B@#S>!=3TC7=>FM[9C?6_ARV\I",AI$#\>AY%0>%
MWO/$>CZ9J>B^+[^ZOH;B%M2M;J10NW</,3:%RO&<$<''Y>GXKS3Q;I-J/&.B
MS^'+>:V\0M=(]R]O&R1M;9.]I2!M(XQUR<T )IWBB'0/B#XTM[^XU&XMXOLT
ML,*K+<>4GEL\C <[%!8>@Z"NRG\6:1#9Z=<K</.-2_X\TAC9WFXR<*!V')SC
M%<EIKO;^-/B%<RVEXL,\,'DO]ED(E\N)D8+\OS?,1TZ]1Q6+:ZE=V7A3P7:W
M5A>V<*B6WN[R&R=KFV(7"K'E2RE\@%@.F<&@#T";QUX<MM#AUBXU#RK&68P!
MVA?*R#.490N5(P>OI3AXUT1[+[3%-<2YN&MEB2UE,KR*,E53;N.!SG&!ZUY@
M]Q';_#;4+*:VODE_X2#<(IX)&<KYP?DX.3M!).3S[FNG\;_9AK_ASQ%=V]U>
M:$89891;B3=$9%!23"D'G&#[?@* .ZTG6+'6[1KFPF\R-)&B<,I1HW'565@"
MK#T(KC/&^N367C'0],O-7GTC1KJ*1GNH,*7E!PJER#M'0_CS[;7@Q=(-O>3:
M'I,MG82R!Q/*K*UR_.X[7^; X&3U.<>II^(/$&B+K%WH/BNSB&GM#'-;SS0E
MXW#9#;F (0@CCIUH DBN]3\(Z=KM[K%W<ZIIEJB3V<Y53*RD$,A"@9P0#N(Z
M-GL:L1>/="CTG2[W4[L:<VH1+)''<(Z\X!(R5&0,]>A[5P^B6-V/ ?C>UT]K
MNYT!H9!HYGR69?+;?M!YV9QCUY/K46M>)-(N]$^'LR7VY+?4+?SGE0J0$0!R
M<CH"1DCC- 'H^D>,=!UVY6WTV_\ .E>$SHIA=-Z!BI*[E&<,".*GA\3Z--HT
M^KK?(MC;L4FED5D\MA@%2& (.2!C&<G%<EKMU8^'?BGIFJ:@5M=/DTJ6".7!
MV^;YFXK@#DD'IWS7+MJ3W>B:C?6D%U);Z;XI_M&]MF@96>W+%@<,.<8R1VQS
MB@#T.\\?:);Z5J-[%)<326,'GR6K6TD4I4\ A74';G^+&!4NF^--*OK32))F
MFMI]4 6"*2VE ,FT,5#% #UX/ /:N;UO6-'\9>'-<GT"Q>]NAI4L;7HMRI48
MW"$%@&)/)P,]/<5EW>LV,OA3P/K222M8Z5=V\=Y)Y#CR_P!SM)Y'(!P"1GDT
M =_=>+]"LIM2BN;XQ/IB(]V'AD'EJ_W3]WY@<_PYJM:?$#PO?6MS<VVJ"2*V
M2-Y&\F08#G"8!7+$GC R<\5PCZ[97GBGQK>Q?:&LKK146%S;R 2G;M& 1W+
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MCWW_ ('6W_Q=5C\*/!);<=$4MUS]IFS_ .AT_P#X5;X-_P"@.?\ P*F_^+H
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MBJJC45"G( U"88/_ 'U[F@"Q/XJUM)0D/@C5G4X&7GMUY)([.1CCKG^8R?\
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M/A['$)5T^V6-CM#B]D )],[ZL#X4>" VX:&H;U^TS9_]#H >_B;Q0I!_X1&
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MM.CDE\U&:*3N4XS]:C.G2L #<_DG/\Z (9Y1%#\H_>O\O!Z4ZRTYXYQ<RO\
M-C[H%6H[%$D$CLTCCH6/2LWQG<3V?@G6[FVE>&>*RE>.2-L,K!3@@]C0!J7-
M[#;)-EU:6*$S&(,-Q49YQZ<8S7C^J>)+'QKX8L;FPM=WC>=0;9;%'$ENHE(R
M7Z!  <Y..:VK.:Z?Q%K,T-K+?7DGAZS"QHRAY&;</O,0.IR3G\ZAT_P;K+_#
M[2#';2Z9XHT0O]E)D0B4%B2A()&Q@<8..1Z=0#J_$OC&+PK#IEO=+#/J%X"
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MVVB1QSR%SGL?RJ[_ ,*[\'_]"[I__?H4 8/_  E_B7_GX\%_^#9O\*#XO\3
MD&X\%@CJ#JK?X5T4'@+PG;3++%X>TX.O0F ']#4K>"O"[Q",^']-V!]^/LR]
M<YZX_2@#DY?%OBQMHAO? \?/)?4G?^6*=_PE?BLR[1J7@54R?G-^YP.W&?\
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MD?/9%Z$XZ]J .'8.3(8K#XHNB '<UTRD_0%LG\*L+I-S*T<S:7\0WP.!)JJ
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M[>&W'J&\SGKZ4[_A%KS_ *$[7_\ PI%_^.5ZW10!Y&_AJ>/.[P=XD))PFSQ
MK9/OB3Y1[TQ?#LS2>6_@SQ*%SAR->!XSCC]Y@UZ_10!Y!H]YI5UXB^&SZ';S
MVVGA=2C2&<Y=<)SDY/\ %D]:]?KPSP0S->_#8D# DU5<[?8U[G0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS&TM)()DA5URSY/R@YX' Y///2@"BGQ"N!X8:ZDLXWU,:LVD".)7:,R@_>P
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MM9Q!O-@BD("OYF2&/S*2NT=<9JRGB3Q+?^--4T*PM=+$5@]O(TTKR;FA?D@
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M\2O+N-Z=;G^T>9][HN/?'7KWS6L_@NXNWB74O$^KWMM',LIMG$*)(%((5]J
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MM_=,KS$=E!P %'90,4 ><:9HE^FF77B[02?[:L]3O/M$>?\ C^@$I+1-UR<
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M2]LYNK4K*Q:=6,SY/W=Q8LWJ:]&T>RTC18IA!>B6:=_,GN+B</+*V, LW?
M '0"EG@T,ZHVLRW,"7:VK6QG^T[=L1.X]\#D9SUH \R\4V\^K> _&?B+#.+V
M\BCM\'(^S6\JJ&'L3O;]:ZOXBH;\^$8+20-/)KEO-$4(/R*K,S@=P!S^5;EB
M_AFQTB/0X+VP:TCA,?D/<(Q9,9.<GG(;)/OGO6;I]CX0T2:UU/\ MF&01QF*
MRDN]1$B01D#*Q;FP!@=>3CC.* %\4@^)YV\)VH86YV2:G<J<+#$"&$61_&X
MX[*<^E=9!-#<0)+;R)+"PRCQL"I'L17G-SX:^&-W=3W,^KVCS3N7D8ZTV68]
M2?WE=;9^(/"ME91VMIK6D1VUO&$1$O(\(HP!W^E &[16/_PEOAO_ *&#2O\
MP-C_ ,:4^*_#BG!U_2@<9YO(_P#&@#7HK.AU_1K@$PZO82@)O^2Y1OESC/!Z
M9!&?:DD\1:)%!'/)K.GI#)]R1KI K?0YP: /)? JCROAVW?[7J8Z_P"P]>V5
MXIX$.;?X=D=/MFI_^@25[70 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MITCO;.S*"Z%""IP00?<5I4 >1IXLG1 O_"=:H<#JWALD_P#H-177C.>& O\
M\)_>Q<CYIO#1V_\ H(KV&B@#QG_A,KC_ **M:_\ @@-,E\;7$2;O^%IP/[)X
M>)->TUE:CXBT_2M5T_3KMIDGU!S' 1$Q0MZ%@, T >7Q^-)_E<_%.T(Z[6T
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M>OK8,4,EM8,P##J,9!R/84 <6-9FW.K>(_'&X,%V_P!DJ"">@^YUJ7^T[O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4AA2RMXYK6QBMA.TPZNTQ )C7JH.0.,YI8+FZU3XJ:1=)J-S#;3Z$+M;8*A
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M:RNK_,$+'D,D9..O()S@\BJ7B2]L+WQG8O9W5M<.NCWXD,,BN0,)C.#]?UH
MY6\2XDM?A-':W)M9WB94F"!RF4B&<'@UZ7IMEJ>DZM)<:QXB^W07*1P6\<D:
MP[9,L3A5X)(_'BN1T+2?"FN>%O"UWJ>JA+JPL8UC6/4C#Y;8&>%8$-V)&#P/
M2MF'1_!]O?V][-K[W,\);R3=ZRT@1F4J2H+\'!.".G;H* (_AA_Q[^*?^QBN
M_P#V2LSXR7<%UX.\BWG4S6^J01R[>3&Y4L!]<,#^-:MIX<\"Z>LBV6IM;+(Y
MD<0Z[,@9CU8XEY/O3+G0OAU-I1TVXO;+[)%,;F1#JK F1OXW;S,L>."Q..U
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MH&\6>&U\S=X@TH>6</F\C^4^_/% &9\0/^0)8_\ 85LO_1ZU5\ N3J?C%-C
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M  M/P3_T'H?^_4G_ ,31_P +3\$_]!Z'_OU)_P#$T <)X$_U'P[_ .OS4_\
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MU&" <]><4 <.FD7,<K2IX,\7+(_WG76""?J:D^P:A_T*7C+_ ,';?XU[4""
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MBKHVP <$ C@<$US$'BO5]?U.'3;6_:VCU;4KA;>5$7=%9P+AMAQ]]V!Y.<4
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M **** "BBB@ HHHH *SM?_Y%S5/^O27_ - -:-9VO_\ (N:I_P!>DO\ Z :
M/'KJWN+F>WBME<RO\/E5 @R6.>@^O3\:]3\$W5K>>"-%FM"OD_8XU^4 8*J
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MW37K7T-QLD6Y8DG:QSN.W"]#G%:Q\9SX6>+P9XB9F!&3:HK8SQG+Y''-1?\
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MK^X\#<D0'XG?Q0!V%%<L/%>JE5;_ (0O6\-C'SV^>?4>9Q^-)_PENJ>0)O\
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M?\(-=_\ 0Z>)O_ F/_XBNPHH \W\0Z+?>%[>SU2/Q=KTX%];121W-PIC*-*
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M44 %%%% !1110 444U=VYLXQVQ0 ZBBB@ HHHH **** "BBB@ HHHH ****
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M0:1I,$J0R7,1B>XF?@E4;YM@'<@<\>M6O^$I\5_]")-_X-;?_&@^*/%H0O\
M\(#<$ 9^74[<_P CS0!1\.66F>*-,\5:7>6MQ]FNM3EF G@>,E'"[70LHYRI
M([CC/O!X$M-4\.:KXDC\13[X;*WM(H;TJ0LL*"7#9[D @'_).N/%?B.)=UUX
M$U%0?N^3=P2G\0&&*/\ A,M8_P"A'UO_ +ZB_P#BZ /._#6C7'B#X/WVGV"*
M^JVFI&\A@?@D@@CKZC<!TKTFU^(OARXLUEEO&MKG'S6,T;+<*W.5\O&6.01Q
MGGZU$GC/5F(SX(UP#."?W7_Q=._X3681K))X-\2A]N2%M8V(YQC_ %F>_P#6
M@#IK&Z:]L8;IK>:W,J!_*F #J#T# $X/M5BN2;QK=L"(/!OB-GP#B2"-!@^Y
M?K[4S_A,M8_Z$?6_^^HO_BZ .PHKC!XM\3S2/Y'@*_,:X^::]AB)_ G^M*/%
M'BLD#_A!)A[G5;?_ !H [*BN2.N>,,G'A;3U7<0N[5P"1GCI'WJ*;Q+XIMB!
M/X>TB(MTWZV%S^<= #/BI_R)J_\ 7];?^C5K,MM3O])NO'-SI>FS:A?'442"
M&-<_,85PS<_='?\ +O4/B*[UWQ580:9/::)8PFZAEDG&KK*55'#'"[!GIZU;
MA;6=(U[7+O2[KPW/;ZC=+.IN=09&4! N"%0CMZT )X9FU&1VTP^%M1@%\[R:
MGJ.HE5,H*X) 4]2< *. /QJG%INOQ>!3X%_LFZ^T'-K_ &@&3[/]G+\R;MV<
M["1MQDGZUL'Q!XK&,MX0YZ?\3.3_ .(J*;Q3XCMMOGW'@R+=T\S5G7/YI0 ^
M+3[GP9XHU*^M-,O-0T[4X(0%M &>*6)=F&!(^5E.<YX(/'2M+POI5YX>\.7U
MQ<1-+J-Y//J$UNK[L2/R(P>^ %'USVK%_P"$SUO_ )__  /_ .#AO_B*/^$S
MUO\ Y_\ P/\ ^#AO_B* )SI&L:3\*[BTLH&DUZ\C+SA2"?/G<>8V>GR[C^"U
M;UGP]-IY\.:AHUF+B31#Y)MU*AY+=DV,%+$#<." 3SS6;_PF>M_\_P#X'_\
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M$+*+7+#5+]M7N;J<V3@HGF+GUSV_G7MU !1110 4444 %%%% !1110 4444
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M.VW&/3_"NSHH X^7PMXH8((O'EZ@5BWS6$#9Y..@''L>*/\ A&_&'_0_3?\
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MHX]J5/ 5SM'F^-/%#/C&4NT4?EL-=E10!Q__  @4G_0Y>*__  .3_P"-T?\
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M\-?]"]I/_@%'_P#$T?\ "(^&O^A>TG_P"C_^)K9HH QO^$1\-?\ 0O:3_P"
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M HHHH **** "BBB@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **X;XO6D4_PWU*=P1-:[)H)%.&1]X&0?H2/QKRF1K63P
M#X3B\(RD^+Y9OWGV.3_2"GS[O,VG[NX+][L/3- 'T?17+:QXK;PY#HNGW-N;
M_7-1VQ1V\#JBNX WL6;A5R:R;CXKZ3;^&#JIM9VNA>&P-B&7>)QU&[IC'.Z@
M#OR0!DG %,AFBN(EE@E26-NCHP8'\17!CX@+J.J:WX<ET*<7MC:RR7"BY3RV
M0+_"W!YW ?=XR,UC>&/&>B^&_AUHKZ3I\L<5]?/;017MT%5&+'+/+M("_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 C ,I!&0>*15"@ # %.HH **** "BBB@
MHHHH YKQYXCG\*^$[C5+:)'F5TC4R9V1EF"[FQV&>E5K";Q';:UI1;4X-:T6
M^5P]Q%;!&A8(65MRG:4.TCZD<FM+Q1K&EZ196R:U'$VGWUP+.5IL>6NY6(W@
M\;3MP?KFN$TBR@\-_$73=)\)ZB]WH>H0S27UBMQYT=IA?ED!YV;B0.>O3TP
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MMJ$'\!5F_NC(VC@;>^#@ ],HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (;FTMKR,1W5O%.BL&"RH& (
MZ'![U%8Z7I^F*RV%A:VBN<L((5C!^N!5NB@"G?:3INJ;/[0T^TN]GW/M$*R;
M?ID'%3_9;?[,+;R(O( V^5L&W'ICI4M% %+^Q],_Z!UG_P!^%_PI9M(TRX6%
M9].M)1!S$'@5O+_W<CC\*N44 126T$ULUM+#&\#+L,3("I7TQTQ4%CI6G:6'
M&GZ?:V@?&\6\*Q[OK@#-7** *-MHFDV5VUW:Z9907+9W316Z*YSURP&>:)]%
MTJZO5O;C3+.6[0@K/) K.,=,,1GBKU% #719$9'4,C AE89!'H:SM/\ #FB:
M5<-<:?I%C:S-G,D-NJ-SUY K3HH H7&AZ3=W@O+G2[*:Z!!$TENC.,=/F(SQ
M4L^FV%U=0W5Q96TUQ <Q2R1*SQ]_E)&1^%6J* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:
M0VX$'CN,=:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444'IZ4 %% X'7-
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 444F: %HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "D*@]1GO2T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 -9MO."?I3ATHHH *9&@C! S@G/)I]% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 -#9)X/!IU%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 444F: %HJM-?V\+;&?+_P!U1DU =5C0
M#=#*OK\O2@#0HJM#J%K.0$E&X_PG@U8S0 M%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %4=1N9(ECAAQYTS;5]AW-7JR;A-VNQ%B2!"=H]\\T 20VT<"\#
MG/+9Y)J41QRQX"_+G'I0$4,1DYQGDT[REXYY^M &=?6*%%D5,$>AY'O5O2;Q
MKF!DD(+Q':3ZU8V 1%0V >AS63I!(U.<#D$')'UH WZ*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *S=41H_)NXU),+$MC^Z>M:5(1D$4 9T<\,B[D92IP>
M.3^-2F1 "0./4U%+I$;2>9 Y@8]0HR#^%,.ESEO^/E<>OE#/\Z &WM[''$/+
MSDG&<4_2;)X-\\A(:0#Y:6#1T2423RM,RG<H(P ?I6G0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37!92 2N
M>XIU% "#@"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **09[FEH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HS128SUH 6BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,T4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 @&/SI:** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 0C-+110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%5)=0M8CAI03Z+S4:ZK;'.XNN!GYE- %^BJ]M>0W*!HW!]CP:L9% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !69?R232_98F*X7<[ X/TK3K%
MM#OU*^9CRLRKSZ8H L?8+>-4 12H&2#R2:D%M$O&Q>1CD5(\F!@%:;YO) (S
MTH J3Z:%026[E9$YXIT>I-]D<OM6:(9(/&X"KJ-GN..IJI?P1&RE8A<^I^M
M&A#*LT22(<JPR*?6;HAS9;1G:C$#Z5I4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%!&:* "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH_A?PMJL<WV_3];@9))!@^6JNNQAU#*2!]/ISK_%X@?%3PF2< "')/\ UW-
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M03UQ5*PV:=<3I(V%8_>-:Z^]9>L#?)#$BY=J -=75QE6##U!I:CAC6*-44
M#'%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!1U&T-Q#OBXFCY1AU^E5H+Z9
M9526-E=EX#< D>E:^*KW5I'=Q;),Y!RK#JI]J (1<@MD(.>O-"W!)!"53DBN
MK4_,IF3LR=1]:1;@M]V*1B!C;B@"^MR%/S;0 .:S;^\!NHYHL$H.!ZU8AM+J
M?)E8Q*?X0>:NV]E%;H%'S$?Q, 30!+"[21(S#:64$BI*,44 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 &*3 I:* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 445%=7,%E:RW5S(L4$*%Y'8\*H&2: "XN(;2VDN+B5(H8E+O(YPJ
M@=237RIXW\<ZEXSU,R3L8;&-CY%JK$JH]3ZM[UL_$KXDR^+KG[!I_F0Z1"W
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !(
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M?=?\#2^+OA5X;GT]4_M*ST^%D4@ S)Y8RF<=?3MG/KFO/O\ A3GC;_H&1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 44C9QQ0N=HSU[T +1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML+Q/XWT3PF$34)W>ZE&8K2!=\K]A@=LD8R<5K:1/9W.C64VGR>99O A@;U3
MQU]J\/\ "UP=>^/MU<:BV]X)KCR$8$@;,JH'I@<_4>M 'HLWQ)BTZR>\UKP[
MK>F6X!*2RVX96/93@_*Q/&#@=.:V-?\ &FC>&M(@U'49F07"!H(%&Z64XS@#
M\1ST]ZUM2T^VU;3+G3[R/?;W$9CD7V([>]>%>*T^T_'C2M-G8M:6LMI#$C=
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MAK7(_$OA^UU>&!X8KG<41V!8 ,5&<<9.,X[9Q7AJ2^./A',RHHO=#9R58C?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "$9[TM%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !117G/QA\83^&O#<5G82M
M%?Z@Q194;#1QKC<1[\@?B3VH M^*?BSX=\-7#6:-)J-\I*M#:X(0^C-T!]AD
M^HJG!\2]=>);B7X>ZTML1DNF6;'J%*#-<3\"_#-OJ6HW^NWL(E^R%8[<.,CS
M&R6;GN!C_OJO?: .(T3XHZ)XBURPTG38KEKBY$IE69/+,&Q2<'J"3CL>*H^(
MOBHWA2YBAUCPSJ%N903$WG1,K@=<%21W'YUJ77@R&+XCZ5XFL+=(\)-'>A,*
M"2AVOCN<G!/TKA/VA?\ 5^'?K<?^TZ -VP^,7]J0M-IWA#7+R)6VL]O%YB@]
M<$@'GD4MO\9K236[32KCP_J=I<7$Z0@3@*5+,%R0>>IJE\"[B*T\":M<SNL<
M,5Z[N[' 51$A)/X5L2Z=+\0O!WA_7?(M4U:&XBNHWP5 59/F7/)P0,X]0* .
MD\3>(;OP[:R7B:)<W]G#$99IH947RP,DY5CD\#/%<18?'"SU2]CLK#P[J5Q<
MR9V11LA9L DX'T!-=UXS_P"1%\0?]@VY_P#135\Z?"/_ )*AHWUF_P#1+T >
MMZC\88M$FC36?"NM6*R9VM(BC=],D ]N]=KX=\3:5XITX7VDW(FC!PZD8>-L
M=&'8URWQGCMW^&UZ\RQF1)8C"6QD-O .WWV[OPS7G7P#>\'BS4$BW?8VL\S]
M=NX,-GX\MCVS0!Z!KWQ5_L?Q7=^'K;P[>ZC=VY3 MVR7!0,3M"D\ _\ ZJR-
M3^-MSHMT+74_!]W:3E0XCFN=I*GH?N=.#^5>@:7X;@T_Q)K.ML$>ZU%X]K[?
MFCC6-5VY]RI/Y>E>'?'C_D?+;_L'Q_\ H<E ';Q_&#4Y=)&JQ>!M1DL""?M"
M2EDP,@G(3H,'GVK?T#QWJ'BCPR=8TCPXTSI.T+V[WBH3@ Y5BN#][OCI1\(P
M#\+=&!&01-_Z.>M?PKX83PM%J=O!,'MKJ^>ZAB"X$*L%^0?0@T ><K\?4:<0
M+X8F,I;8$^UC.[.,?<KT=M5\1#2!=#PW&;PG)L_[07(7&?O;<;L\8Z<=:^6_
M^9V_[B/_ +4K[#H \:B^/B37"6\7AB=YG<(J+=@EF)P !LZYK;N/B7XBM8C+
M-\.]75!U(<G'N<)TKP;PY_R.VD_]A&'_ -&"OJ;Q%XB&AW6CVJ1I+/J5\ELJ
M,V-J'[S_ (#]2* .?\(_$:X\9V>I/IVA;+FQ:(&&:["AP^[^+9P1M].]<U>_
M'?\ LZ^GLKKPO-'<6\C12(;P':P.".$KT+1O#,>C>*->U2#RUAU00.8U!!61
M-^\GMSN!^N:^9_B%_P E"U[_ *_)/YT ?4'A_4]3U6S6ZU#2%TY)(U>)?M(E
M8@^H"C'&.YZU1\6^/-#\'6X.H3E[EQF.UAPTC>^.P]SC\:NR:G%HW@[^TYAF
M.UL1*0.^U,X_&OFC1//\??$RS.JOYK7UT'G&>/+4;BH]!M7 H ]=TSXB>-?$
MB_:="\%*UE_#+<7&T./9CM!_#-/U/XNW/A^WDBU_PIJ%A?LI\@;E>&1A_M\<
M9QG&:]-AACMX(X(46.*-0B(HP%4#  K$\8^&X/%7AB\TR5$,K(6MW;_EG*!\
MISVYX/L30!J:9=F_TJSO&0(;B!)2H.<;E!Q^M2W-Q%:6LUS.X2&%#(['HJ@9
M)J#2+:2RT6PM)<>;!;QQOM.1E5 ./RKAOB]JUVGA^'P]I<;3:CJ[%!'']_RD
M&YR/K@#Z$T ;G@3QG!XVT::]CA\B6&=HGA)R0.JG\5(_$&NIKYE^#GB4Z'XS
MCLI6 M=3Q;ODX ?^ _7/R_\  J^FJ /*F^*VMW7B;4M&T?PB^H/97$D+-'<$
M<*Y7<?EPN<=S6;JOQNU;1-1DT_4O":6]U%@O&U[DC(!'1?0BO3?#OAR#P^-2
M,<@EDO[Z6\D?9M.7;(7W ''YU\[?&'_DI^J_[L/_ **2@#TZ3XG^+(]&36#X
M$D.GO&)5F2[W#81D,0%R!CUK>T[QCK>M^"+?Q'I>B6DI996EM9+PHPV,1\AV
M$'(!/./QK5\#HLGP^T%'4,K:?""I&01L'%2:;H4'AOPK<Z;;.6@3[1(F5QM#
MLSA?PW8_"@#S*P^.NHZI?PV-EX62:YF;9'&+S!8^G*UMZC\1/&>E6S7-Y\/Y
MDA4$LZ76\*!W.U3@?6O&OAS_ ,E$T+_KZ7^M?11\03W'Q/&@6\JO:0::T]T@
M"G$A=0N3U'!Z?[5 $W@7Q6_C+PX-6>T6U)F>/RQ)OZ8YS@>M=+6)X9\/)X;M
MKZUAD5K>>]DN88U3:(5?'R>^"#^!%;= !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMAILZ//;6ZFYBP0R2-RV01_>)YH ^=?%<FFIXNO;KP_<%K!YO/MI$1H]N><
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M?3 S[GWKU>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[%:_\^T/_?L4?8K7_GVA_P"_8J>B@"*2V@F</+#&[ 8!902!3?L5K_S[0_\
M?L5/10 U$2- B*JJ.@48%1FSMF))MH23R24%344 )L4)LVC9C&W'&/2H?L5K
M_P ^T/\ W[%3T4 1);6\;!HX(D8=U0 TZ2*.8 2QHX'0,H-/HH @^Q6O_/M#
M_P!^Q3OLMOY?E^1%LSG;L&,^N*EHH @^Q6O_ #[0_P#?L5)'%'$NV.-4&<X4
M8I]% ".BR*5=0RGJ",BEHHH 0*H8L% 8]3CDTM%% %673-/GF6:6QMI)5.0[
MQ*6!^N*LJJHH50%4<  8 I:* "BBB@ HQ110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17'>+_B3H7@Z06UT
M\ES?$9^S6^"RCU8GA?Y^U9J_$'Q,]A]N7X>ZB;8KO!%R-Y7U";=WZ4 >AT5Q
MGA+XG:!XLF-I$[V5_P!!;76%9_\ <.<-].OM71:S>:G96GFZ9I::C(,EHC<B
M$XQV)!!/Y4 :-%>,CX^J;@6X\+S&8OL""[!);.,8V=<UN7/Q+\1VD1EF^'6K
M!!U(D+8^N(^* /2J*XGP#\0T\=/?HNER61M A):7>&W;O88/RUVU !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%% !1110 4444 %%%%  3BBD(!Z@&EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVN_$3POX;U(Z=JFH^5=*H=D6%WV@],E00#[4_2/'NA:]N.EM?72+G=)'83E
M0,X+;, X' [U\\>.8+BX33_$5\&%YKAFNBI/W(PP6-1[;1^M>T?!+_DG,/\
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M9VH< 2AFW87L,8/IR:Y_XN:$/$=[X9TM9%BEN;B9%E*YVGR\C\,@4 =/X/\
M'>C^-;>=].,L4L#8>WGVB0#LV 3QVS5GQ/XG'A>S^V2Z3J-[;*I:66T1&$0'
M=@6!Q[XQQ7S#IU_K7P^\6^9L:WOK1]D\#'B1>"5..JD8/Y&OI%/$5CXK^'-_
MJED08Y;&821GDQN$.Y3]/UZT 5M+^(]KJFBW>LIHFKPZ;;0/.;F:)%63;U5?
MGY/7VXZUCVWQJTF]1GM= U^=%X+16R,!^3U?\/Z7+K'P3M=,MBB376EF)"_"
MAF!ZUU6BZ/;:#X?MM,M41([>$(=HQN8#EC[D\T >?Q_'CP[-*D<>E:P\CD*J
MK%&2Q/0 ;^M2W7QMT>Q*K=:%KMNS_=$UNB9^F7KPSP9_R/7A_P#["5M_Z-6O
MI[QMX5@\7^&Y].<1K<\/;3.,^6X/7UP>A]C0!T=%%% !7/>'O&&G^(]5UBPM
M#^\TV<1,=V1(,?>'MN##\/>HO'WB%O#7A"[O(06O)<6]JJGDROP"/IR?PKYZ
M^'7B&7PEX[MY+K?'%*YM;M7X*@G&2/56 /X&@#ZKK@/%7Q-?PA>&+4?#=^(&
M=DAN1(A27'<8)QZX/-=_7 ?%NPCU3P]I-C*Q5+G5[>$NO50VY21^= %CP5\3
M=)\:7D]G##+9W4:[UBF8$R+W*X].X]ZZ+7M5O=(L?M-GH]QJ>W)DCMW4,H'<
M GYOH.:^6M8TK6/A_P"+?)\UX+NV?S+>X0X\Q,G##!Z$ Y'U!KZ/\!>-K7QK
MH8N5"Q7T.%NK<'[C=B/]D]1^7:@"EX8^(%WXKC:?3_"]\+5=X\^2:-5+JN0H
MR1DDX'MGGI6/K7QEB\/:G)IVJ>'+V"ZC +)YT;<'D$$$@UK?"#_DG5G_ -=Y
M_P#T:U>/_&O_ )*/<?\ 7O%_Z#0!ZA'\6Y'TI-6_X1#63IC9)NHU5U !()_
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MH+T9+$X ^YZUZWI>G0:3I5KI]LBI#;Q+&H5<#@=<>_6OD?1/^1VT[_L(Q?\
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M3K@G%'@+XLVOB_4Y-,O+1-/O"-UNOF[Q-CJ,X&".N._/I5OXK6<.HZ-H=C<
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M45E88((4Y!JI^T!>6SV>BVR3QM.))7,:MDA<*,GTY_D?2@"Y^S__ ,B]J_\
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M88_2@#NJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M Q(8HT*)&BHQ)*JH )/)/XTW[+;_ //"+_O@5+10!&MO C!EAC!'0A14E%%
M!2$!E(8 @\$'O2T4 -2..,$1HJ ]=HQ0(T#EPB[R,%L<TZB@ HHHH **** "
MBBB@!CQ1RX\R-7QTW#.*$ABC),<:*3_=4"GT4 %%%% !2 !1@  =>*6B@"-8
M(D;<L2*WJ% -2444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4$9&#110 BHJ*%10JCL!@4M%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,:;]G^UZS;1"XB$T1))WH>C# Z<57/Q(\'*[(?$-EE1DX8D?GCFL'6--:W^
M[6M_;;+BWTI R2+\R.H!_,$5Y%\([&TU'X@VEO?6L-S 8I28YHPZDA3C@\4
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M9Y=2O-0.[(ENV4N!@#&549''?GFN5\2_"[3?%6K'4-1UC6=P.8HDG3RX>GW
M4..@-=S10!FZ)I#Z-9-;/JE_J.7W"6^D5W48 QD*..._K7-^(/AEIWB?4!<Z
MKK&L31+*9$M?/7RH\]0HVY X]<UVU% '$Z%\,-%\-:PFHZ3>:G;L,!X1< QR
M#T88R1GGKVKI]8TQM6L#:KJ%[8DL&\^SD"2#';)!X_"K]% 'GC?!;PE*QDG%
M_/,QW22R71+.QZL3CJ3S77:'H4>@V[V\%[?7$)VB-+J;S/*4# "D\@?G6K10
M!@^(/"=EXFC:+4+J_%NZA7MX;EDC;!R"5'7_ .L*YN+X,>$8)5EACOHY%.5=
M+I@0?8BO0J* .#N?A'X:O0HNI-3G"\J);UVQ],UN:3X.TO0M DT;2VNK2WDE
M\UI(IB)-W'.[Z*!]*Z"B@#S^Y^#GA2\N9+FY%_-/*Q9Y)+MF9B>Y)ZU*/A%X
M4*Q1SQ7US#%_JX9KR0HOT (Q7=T4 4-)T32]"MC;:7806D1Y81(!N/J3U)^M
M7Z** *.L:5#K6FRV%Q+<10RXW&WE,;$>F1SCUKF]%^&>@^'KQ;G3)M2MV#!F
M1+UPDF.@8#[P]C7944 4M5TR/5[(VLMQ=P(6#;[6=H7X[;E(./:N2_X4]X')
M_P"0._\ X%S?_%5W5% ',7'@+1+O38M-N6U&6QB0H+=M0FV$;MPW#=SCMGH*
MH0?"7P9;3I/;Z9-%*ARDD=[,K*?4$/Q7;44 54TZV73#I[J\]L8S&RW$C2EU
M/4,S$D]>YKD4^$/@F*19(])D1U(966\F!!'0@[Z[BB@"NUE$^G_8BTPB\ORM
MRS.),8QG>#NS[YS7)7/PH\'7MR]S=:=///(<O++>SLS'W)?)KM:* ,+0O"&C
M^&CC2H[J", @0F\E>,9ZG8S%<^^,U:UG0;+7H%@OC=&(!@4ANI(0X.,A@C#<
M..^>_K6G10!PR_!_P0K!ETAPP.01=S<?^/5UNFZ;!I5K]FMWN&CW;LW%Q),W
M_?3DG''3I5RB@#%U[PEH7B=$76--BN60820Y5U'H&!!Q[9KEA\%?!GF;OLMT
M1G.W[2V/IZUZ'10!EZ'X<T?PW:FVTBPBM8V.6V#+,?=CR?Q-9^N>!=!\27!F
MU>"YN3G<$:\F$:G &50-M7@=A7244 <+_P *>\#?] =O_ N;_P"*I1\'O X(
M/]CMQZW4W_Q5=S10!S]OX*T*TT :);6LL%AYOF[(KF1&+>I<-N/Y]A6._P (
M?!$ARVD,3W/VJ;)YSD_-S7<44 <+_P *>\#?] =O_ N;_P"*K9T;P/X:\/WP
MO=+TJ*WN0A02!F)P>O4FNAHH P9_!7AR\O[Z]O-(M;JXO2IFDN(PYX4*-N?N
M\#MBL9OA-X38>4+>\6U+;C:+>2>43_NYKMZ* *FFZ78Z-8I9:=:16MLGW8XE
MP,^ON?>K=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 FT9SWHQ2T4 &*,444 )BEHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M;N^;&#3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HKQWXP^/-5TW4[3POH<[6UQ<(KSW"'#C<V%56_AZ9)]Q
M[U>\3_#R'1?!%UJ.E:IJ<6LZ?;_:&O#>R$R[!N8$9QC&[& * /5**\7L?%+^
M/_A%K,]_/-%J^C1-*9+:5HMS!"4<A3SG# CIP<8K!^'WCO5?!OB0:#XIN)VL
M;K8RR3R%_(+ %6!/\!R,]AU]: /H:BO,/#MOIOAKQ+XTU&:YO6L](\LPK+=2
M2".-H0[  GYB2<#.3TKG/!<5_P#%S5]2U/Q%?72Z3:L$AL+>8QQDDD@''7
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MJM_^>\7_ 'V*43PE]@E0MG&-PS7SUI.A:5)^T1<Z8VGVS6"32LMJ8P8A^Z)
MV],9YQ2_%'PK<CQUJ&H^'K=8&L;*&_G%O\C EF!D4#N-H)QSW]: /H5Y8X\>
M9(JYZ;CC-.5E=0RD$'H0:\+F\5:9\1/AL[ZK;6[:[I<]L&RHR5>9$++[,#AA
MTSCVJQ\6?$%U#JVE> _#K"QCFV+*MLOEC]XVU(QMZ#N0.N10![&FIV$ES]F2
M^MFGSCREE4M^6<U81UD!*,& )!(.>0<$5R5K\,?"-MH::6='MY0JX-RZ#SV/
M][S!\P.?0XJUX#\.W'A;PNFDW,BR-%<3,K@YW(TC%2?<@C- '2T444 %%%%
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MS0W-AJMNQ@FMKR$,,[&61<@Y'3(R" :6XU"RM)(XKF\MX9)?N++*JE_H">:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCXK67B*ZC*:#KP?3K)BW\*. K8[9?GZ.:[KXC:W]@T*+2K>YBAO]8G2QB9V
M\M9#AI#[ 9Y]2*Y;Q_X&GMOA]QX@E:/1D6:TCD@AC *#& RJ#G&>_)Q0!T'Q
M?M()?AUJ5V\?^D6H1H) 2&0F1 <$>HK@O$&FZ+H/PLT76M-O)[+Q)-;6LL+0
MW<GF3NP0N-NXC')/3' 'M70>)_%-MXH^ MWJ(FB%Q+#$DT889642)N&.O8D>
MU8-QX:&E>%?"_C[PM#;/>Z98PM?0)@K*/+&]CC^(;FW=\<]10!Z++X;G\7Z/
MX;E\0221B"$37EFF5\Z4Q@#+ @C!+' ]:X31_"FC7/QK\0Z'-:NVF6ME'+#;
M_:),(Q6$DYW9_B;OWKU7PYXETSQ1I,.H:;<I(KJ"\>X;XCW5AV(KSWP]>VC?
MM#^)G6ZA*RV$:1L)!AV"P9 ]3P>/:@#,^(W@VT\/>$M)BBN9Y&_M<012EB'2
M"3>WEEL_-@]"?6M[QYJ%Q8WOAWP)X?D?3EU)]LD\ .^*$'G:>N3\Q)]O>E^-
MEW;P>'M'CEF1'_M:&3:6YVA7R<>@S5;XEQ3Z9XH\->.;2)KJQL6\N[:$;]L1
M)^;CMAGY]<>M '1WGPN\+SZ9+;6]C]EN63:M[$Y\]6_O;B<D^N>M<#\1=$?2
MO!7A!;R-5U*.6"QGEC8@LBH1MR.HX%>IOXU\-)I U0ZU9FU*;E*R@LW&<!>N
M[_9QFO._C!JT5YX8\-7$\;6<LFH1SFVG8"5$VMRP!X[?3I0!ZU96-KIUI':6
M<"001_=C08 [UY%XVL]'MOC/X?2^%O;Z?=0/+>>9)Y<;MB3#,<@9R%^IKOM9
M\?>'=+TJ>[BU>QNYD4^5;V]RCO*_\*@ D\GO7!>*[VQ?XS^$GU:6Q18K)OM:
MR2JT<3[9#@EO?&,X[4 =)IFF>#KGQS83^';B 7NGPR32_8W$D<D;@Q[6(;@@
MD-^'TKC+;4]%MOB9XAM?B'9I)+/(4L+B]CWPQP;CM"YX4$$$,/?D5VYU/PCI
M?B.SE\/?V=<:MJ++9^182(%,>_>\C[.ZC)R>O3Z9\.J>&/B';:SI'B?[!'>:
M=>SP(2PBD2-6PKHS'/;G'&1R,$4 ='X$\.MX9TN_LUD$EM+?R7%JX??F%@NW
M)[],?A6'\4->O8;C0O#&FW+VUQK=R(IIXSAXXMRJ<>A.[K[&J?P6CNX+#7+9
M+EKG1(+YH].G<G+@9!(]%QL/'<FI_BMI%XMSH'BNQMFN&T2Z$EQ%&N6,6Y6)
M'KC;_P"/9[&@#=E^&OA1])%@FDP0NJ82\C4"X5O[_F?>+9YYKS)K]?$_PN\2
MV>OP1WFK>&V,,5XX_>8W8!W=>J$'GG SZUZK-X_\+PZ$=7&LVLEMLW*J2 R,
M<?="==W3BO,8M'FT;X1^+=7U=4L[S7I#-'!*=C!=V47!YW<N<>GXT =)X!\2
MZAI.H+X'\5\7R)G3[ION74./E&>YP#CZ8/(YF\!Z/IME\1?&IM;"VA^SS6Z0
M>7$J^4K(2P7'0$@9 ]*T_$7AC3_B!X4LKBRN8XKV)%FL;Z,@F-P,X)'.,]<=
M",]JS/A2]_<WWB>[UF-8=7:ZA@NH5XYCB #X_P!K)/IZ4 >@WMG'?V4MI,TJ
MQRKM8Q2M&V/9E((_ UY_\$QCP3=#).-2GY)R3]WO7HD\\-K \]Q+'##&-SR2
M,%51ZDG@"O-?@C>VTWA2^MTN(GN%U":1HPPW!3MPV/0^M &5X$TFP\?:#XDU
M#Q#;I<:I-?21>9+\TEJ@4%!&3RF"3TZXKG(_%VH:SX&\':?JEU*;.XU8V>H7
M!<J9(49,*Y[C:_/KLYS76^,M*\.2W]Y%X;C>Z\3:AF)[:QN6$0;/,DX4A1MY
M/S=3V-;T7@_PSH/PYM?#_B.:U-G'\TDT\@CW3'+$H3@@]<8YP/K0!B^(+:V\
M%?$WPK+H-O#90:N[6EY:P*$CD *@-M'&1NZ@=O>JG@K1])\>+XNG\00I=ZD^
MH20;Y!EK:(#">7GE,'=T_NU+X0\)6NL>,+;Q):QW:Z'IL9CL)+R5GENY.GF?
M-DA!_"..@/K3_&^G^&9M1O$T*V:]\5:@CP&WL+IE3=W><*P4;>OS=3U'< %C
MP'XQGM?A+>ZKJUQ]H.DR2VZ2YR90H78,]R2P7/TK$O-.FMY_!'@:Y=Q%?LU_
MJF#CSW.79#C!(SN'Y=<5L?\ "*6^CZ7X5\!JPF-S=&]U%EZ2)$-S9] 7,:CV
M%6?B):OI?C#POXP=&>PL)3;WA'_+)'X#].@W'/X4 01^7X2^,T6CZ:L5GINM
M:?O^SQKMC2==V'5!@ X3'ODU1\6?#GPMX<\$WNH75I+J.L,I5;F69P\]S(=H
M;:&Q]YLX]N]:-@(?&/QB37;!UN=(T>Q\E;D+\CSL6X4]\!NW3'O6EXI!UWXA
M>&M 0;H+)FU6\&>!L^6('_@1/% !>Q3>!?A%'8V@)U".U2UA"=6N92%ROOO8
MD?2G)\,M-NTL+?6)'O-.L+*.WMK$,R1K(!\\K8.68FK.NJVL_$#0M)7YK;3D
M;4[I<\;N4A'UW;F_"L_Q]\1-.T*\C\/K?-;7EP/](NDB:3[)&0>0%Y+G^$=L
MY/H0#G?#AOO"NA?$,:/)-)I6FNZZ=O;=Y<JJWF8]E)7\OJ:K)H.D7'P03Q'
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M:O!=ZGI-K=S@* \R;N!G Y^OX\9Z5LT4 8 \#^%MJAO#VFR;5"@RVRR$ >[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%17-S!9VTES<
MS1PP1J6>21@JJ/4D]*997]IJ5HEW8W,-S;OG;+"X93@X."/<4 6**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY;;D[?\ QW%;6I:99ZO836-_;I/;S+L=&'4?T/>K,<:11I'&BHB *JJ,  =
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MQ>E-X$0+(1C)PXXSCWKH*\"^!?AY[K7+K7I-ZQ6:F*(@C#.PY![\*?U%>^T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"_#QM9I(I;V=_-GD1<8.  F>X'.#QU/%:/B;Q?HWA*T2;5;H1O*&\F( LTA
MSP #@=LGCD5\^>*/BKXB\2%X4F%A9'@0VQ(+#=D;FSDGITP/:@#U^]\4?#WP
M9J=Q)"EBFHO$\C-9PAV8YY0LO0DCH2!QSBN(UKX\7\Z-%HVFQVRO"5,D[;W1
MST9<<<#U!Y_(^0,S.Q9B2Q.22>2:2@#H=6\=>)];6);_ %FX<1$E!'B+KC.=
M@&>G>L2XO+F\96N;B:=E& 97+$#\:AHH **** 'Q32V\JRPR/'(OW71B"/H1
M6A;^(M:M;F*XBU6\$D3AT)F8@$'(X)P?QK,HH ]-T3XW>)+!HX]22VU&'S-T
MCO'LEV^BE2%'XJ:]"TGXR>%M91+;4%DL7G8QLDZ[HP#Q\S=,'WKYPHH ^JO$
M/A2P\1^ I='T-[2TMI@)K9H$'E$@[A]WL3W'KGFL_P"%W@K4_!=AJ$.I2VTC
MW,J,GV=V8  $<Y ]:\(\.^.?$'AB96L+YS""NZWF)>-@,X&.H'/8BO<_!WQ8
MT;Q!:P0:E/#8:H0 \;$K&[9P-I/KZ9X]Z /0J^>_C)XU;5=6.@6,TJVEFY6Y
M7H))0<?7"_D3]*^A*^6/$9BL/BW>3ZE 1:IJWG2I)'D/%YN3P>H(_.@#L_ O
MP;MM4T>'5M<N9-EU"QCM40HT>?NN6SU[XQCD<UQW@&[O-$^)5C:VETZK)>"U
MFQP)4W8((_7VKT+XB?%FS33I=(\.7!EFGB7-];R8$/()4<<DKD<$8S7.?!CP
MH=8U^37;Q2UO8,&CW;AOF.2"#T.W'/U% '>_$WX9IXIB;5=*6./5XU.]< "Z
M ' )[-Q@$_0\=/G2>":UN)(+B)XIHV*NCC!4CJ"*]K^)7Q8FM;]-*\,W:@P.
M&N;I #E@?N+GC'')[]/6E\3:%H?Q*\*R^*M!7RM8@BW7-O$NYI& R491U;T8
M#G^0!X?11T.#6AH;64>N64FHR&.TCF5Y2(O,RH.<;>^<8_&@#Z8^&7AY_#O@
MBSM[BU^SWLQ::Y7=DEB3MSSC[H6NPKS*X^.7A2!E6*#4IUQ]Z.%0![?,PJ+_
M (7SX9_Z!^K_ /?J/_XY0!ZE17 ^'?BUHOB;6X-*L=.U7SIL_.\*;4 '5L.2
M![X[UWU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<[XW\-)XK\*W>F87SR/,MV=B LH^Z3CMR1WZUT5%
M 'Q=>V<^GWUQ974?EW%O(T4J9!VLIP1D<=14%>S_ !L\&) R^*+)<"1UBNHD
MCXR02)"0.^,$GN17C% !6WX2\-7'BSQ%;:3;N(_,RTDI4D1H!DGC\A[D"L4
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M"K;H)&0J)$/((ZYQTZ]J ,"BBND\"^&_^$J\66>G.I-L3ON"&VD1CK@XZ^E
M'K7P1\*-I^DW&OW<($]YA+;>G*Q#DL#GHQ/_ (Z/6O6J15"J%4  < #M2T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYY('FY/ZC\ZMK\3?&:L"-?N,CIE4/].:RK&9QX;UB$8V.\#GCG(9@/\ T(T
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M]U\(^#]/\(:9]GM 9;F7YKBZDY>5N^3V'7 _F>:Z&@#YG_X4QXS_ .?2V_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%>(^-/C69(I].\.021,?E-](<,I!.0J8^G)/KQ0!ZMKOBG1/#4 EU?48;;(
MRL9.9&&<9"#YB/H*^8_&OB#3_$.O3W.G:3:V,&]MKQ AY1DG<XSC)))X /.,
MG%85W>7-].T]W/)/*Q)+R,6)).34% !7M/P^\8^"O!'AWR9-1DN;^Z<2W#16
M; I\H 3) R!S^)->+44 ?2G_  NOP=_SVO/_  '/^-'_  NOP=_SVO/_  '/
M^-?-=% 'TI_PNOP=_P ]KS_P'/\ C1_PNOP=_P ]KS_P'/\ C7S710!]%W_Q
MO\,Q6$\EBMS<72J?*B>(HK-VR>PKY\OKR34-0N;V;;YMQ*TK[1@;F))Q^=5Z
M* -W0_\ D ^)O^O&+_TJAKZ3\.ZI8:/\.M!N]1NX;6W73[8&25MHR8UP*^;=
M#_Y 'B?_ *\(O_2J&HH;B3Q)JUA;:KJB6EO%"ELD\P8I!&B848'KC\SF@#Z$
ML_B%I?BG5SH.EW<D+7=NS6U[$075UW;@4(^7 7()ZYKJK'0M/L)WN(K<-<O(
MTK3R$N^]@ Q!.=H.T9 P..E?.5OJ2_#B^6[\/ZSI6LS7,;([&W8F #'(R1C.
M3^5>N/XXO?%'AVWD\%36<NL QO=6US\IC4@Y'. 3N&.O2@#+^('B;P':V%_I
MKVT5U?22F22*Q)B)G4D9D=/X@2QP<\BL[P/\7+N^U-=-O[&ZN8!;HL;P(9YR
MZ\,S[1SG/7 QCWKB]2\.Z=IVK75YXVU4Q7T]PTDVGZ8JR2@N=VXL3M Z\<GI
MZUU:?$/PS#I<]CX17_A'9L/(T]S:!A* OW5*N2&)"X)]* /4?*UW578S3?V3
M;*S +$0\S%)?E;<<KM9!R,9YHN6T#P1HTM_*B6UO$"#(<O(VYRVW<<L<LS$#
M.,FOF&]\7^(-2TJ33;[5KNYMI)%D99I6<DCH,D].^/4"NAT3XHZAI^A-HFK6
M,&L:;Y7E)%<,05&?[V"2 .!Z<8Z4 =GXTBUGQ[I,^L^%]9-SHI58Y].\SRRF
MP%F9@2!GA3CKTKSSP'=^+;;5A_PBT=U,?,0S1(I,+=0/,[ =>217-RW)S<16
MQEAM)7W>2TF[@9V[B  Q&3S@=35_PSK]QX8\06NJVX9C"WSQ+(4$J]U)'8T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;7%LD".8R2I/G(>"0*^K*^;/&;@>)?'D>#EO*;/;B6/_ !H \ZHHHH ****
M"BBB@ HHHH *O:5H^H:Y?)9Z;:2W,SD#"*2%R<98] /<\51KZ/\ AEXU\,ZG
M;PZ-IU@-,O4A&Z(XQ+C.=KYRQ')Y'>@#(\*_ ^VLKB6;Q)/%>@8\F*W9@H.<
MDMD GTQTY->LVEG:V%LEM9VT-M;IG;%"@15R<G ' Y-3T4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@M8QAT$:@[26)R#@=,'ZFO+_ !M_R.OC;_KDO_HZ"@#@J*** "BBB@ HHHH
M**** "I;:YGL[J*YMI7BGB</'(AP58<@@U%5W2M'U#7+];+3+5[FY92PC3&<
M#J>: /<? /Q@BU>>/2_$/EVUT558KKHLSYQAAC"D\>W7IQ7K5?/.@? _7+_9
M+JUU%IL3(6"J/-E5L\ KP!QDYR:]ZTFQ?3-'L[&2YDNGMX5C:>3[TA QN/)Z
MT 7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/O%FW*V,\ $\"J^K>/=2US]WX5NEM;W3VGFO;.6,.T\,1 .T[2 3S@<$Y]J
M)O!NE_$7P]MM+[['?VTMPKRS7-X\DD:<!MN?8$X]:]'>TMI)UG>WB:9>DA0%
MA^-<5<_%?PY'HIO(IW>=D;RX .6D5%<IN^[GYU'UK/L/B#=^'18:+XL9;O7+
MB5,&T3 $3_=9S@+D'C"]L>] '?\ ]DZ;_P! ^T_[\K_A6/XAT^^AMX3X?T/1
M[F8N?,%VH0!<=L#KFN3A^)%[JM^NK6")!X=T^W1]3\X;R2^" A4$[UZ8R.O(
MJY)\2/[=T.2/PW"%UJYWBPAN2H\U5<*7&2!G!)"D_P )SQU #;\0XHI19Z#X
M;M)G0J)HG.5]_0_0UQUQX#^)]QK[ZV=1@COWVY>*Z*C Y"X QM]NE==I/Q*%
ME>IX>U^.:36;>29+F5(@J^7&A<2X!QEE&<#UJI#\1;];W_A);G*^#IIWM(PL
M&77:N5E)'S?,V5P1@8_$@'/ZAX'^)6I:^FLSRZ>+E&1@B38C.WIE<8.>^>M=
M>\?CV5R\OAGPQ)(>69G8DFJ7B+QP/$K77A#1(;B/5+BX%LS,A^6 C+2@@C&!
MV)Z4W3_B['9:>T6OZ;/%>65Q'9WS0X*1NWF<CDYP(_7DGB@#JM$MM<36 =0T
M71;6T%N")K0DR"4A<CH.,EOTKQSQQ%:-XV\<& HZ#3XW)5MP#^;;[OQSGBNY
MD\>ZSH=[;ZKJABO]!UC_ (\%MH]AA.X!02V#DJ23D'D<&O*WAV:CX\*(1"D4
MJ ]A_ID6!G\/TH XVBBB@#0T31;WQ#J\&EZ=&'N9R0H9L  #))/H ":T?&'A
M&Z\':O\ 8;J>WFWY>,Q/EMF>"P_A)KMO@1]C_P"$GO\ S_(^T_9Q]GWXWYR=
MVS//3KCM5W7OA!X@UCQW<74EQ#_9U[<RS/<J^XP(6)"E3@DXP!C(]Z /&Z*^
ME],\'^ _ R+%J,^GFZF09DU.5,OM/55;@<^GH*P_B-X#\.7WA>^\4:,BBX5%
ME5K-@T4JC"G"CC&.21Z?6@#P2BBB@#I_!$GAC^VDB\402&U9@4F1R C9Z..Z
MGO7U'I>EZ9I5KY>E6=M;6[GS,6Z!58D#GCKP!7QK7NGPL^*'VLVOAO6V'G_Z
MNTNN '_NQL/7L#WX'7D@'LE%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!X)\7]=\1ZEK$FA1Z?>0:9 0V%C)
M^T'LY(ZKZ#\^>GDLL,L$ACFC>.0=5=2"/P-?:M9UWH&C:A<&XO=)L+F8@ R3
M6R.Q Z<D9H ^.**^F?$W@?X>:=:W6MZQI4,$8 +>5-)&"<8 5%8#)QT KYJN
M#$US*;=66$N3&&ZA<\9]\4 =#\/OLY\?Z']I\S9]KCV^7C._/RYSVSC/M7H_
MQZUB[1]-T9&"VDB&X<#.68$@ \X([].M>/Z5J4VCZO::E;JC36LRS(L@)4E3
MD9P0<?C76^/OB*?&\%G#_9,%H(#N,F[?(3SP&P,+ST]0.: .&KK/!OCW4?!<
M=^MDD<OVE%VI*,HK@CYCC!/R[AC(ZU2\(>$=0\8ZRMA9#9&HW3SL,K$OJ?4^
M@[U[]H_PW\'^$M/>ZO+>"Y:.-C-=W^&7;G/W3\HQZ@9H ^9)',DC.WWF))IM
M?2MQX>^'/CF-[+3SIWVJ*-BC:>1&\><?-M7 ;H.H/ZU\[ZMI-[H>IS:?J%N\
M%Q"V&5QU'8CU!['O0!K>"-4;3?$:1^;#%%?Q/8RRS#Y8UDXW=1C!P<UI^'-1
MU"WU9=&C1?[3LXI;73&2-24N&F5BQ+\#@.,XZ'UKB:ZV]7_A);237-/9AJMO
M$C:C;_*&?: #<1XY/(RV.03GI0!N:O':6>O)9ZK.;S7HTOGU>X@7 <&W.P(2
M .%SV S6O86(ATBRN]7N9I?!4-VAL]/V"9K@LA*X*\\.6R#QP1CM7(2:U8:O
M<*T5O<F_^SWLEU>7,@=YRUL0!P!@*00/4<]37::?<IH%KIWB%+EKG4I8H(K7
M1G=8,0-\J[E.>/,RP(]0<\F@#"^'\%EJ!@LK":73O$W]H226U\(_E%N(QO3N
M"<!N"._O5S5;G2HX;73[G3WEO(M7MKK6)9)HYY)V/F!H\)P2!G@<<GOUS?".
MI22:4- O#;6>F7VH2RW%]+-@JB1J98@!R-R[1G(SG%7+JYDL(].T.TBM;F/2
MKZRE@=8Q$;^1FD(8-DY0AL9_'UH U=2L%L_"BW*ZA)<Z)=,K:5#,Z[;?]^A5
M0K?.7V>9DCC /)S6%!I]_=C69='CFLKBT.H27M^,A)X0P/DA@""W#'\:N36.
M@_\ "/V^MZ<&FGDB2&:S+F<V.^53&2W&U%",H.,Y8 YS4"VFG:AJ&LZ3-)+I
M]U8R:C-;Z@TXC27YMOE'(P0>Y!SR10!22\T[3Y;6_M8IC9QW$Z6[6ZHSI*UM
M"$(XQNW \XZ@]ZW-8L[6PUW3[*_NIM1\2WFHVDT=Q,N'CMB,"-CG ;=UQ[5S
MYN[=;&VU(Z4)K=+R57TP@H'5K5-S<9( P6SSU!S6FMAH>B:KI&E:;'+/-=7=
MC>-J+R!_)5B?W3 8"XX.>IYST% %K0(AJ'@P7<M[=VOAW3FABU&TW*$NB"#(
M%5?FR24Y/7/MBFZ<(I-6M5L&&FW-\UY!ICR0X-I)]I!Y 'R'867CIG'%9>@:
M;H%SX3NM6U2*W-YIQC,-FLIADNU#'ECG#*Q;&5&1Y?6KMY#+JT=MI]W:6UM/
M>W-]]JN'&\606X5W.>F!@C/OUH T)H;73?&UC:3%]7UN&[N&OIW0XND,'R19
M(()*?+C&,FI+NVTFXM8_&4@+^'GD6"/084V88#Y8]HP/];N8^H/?.*A@EMH?
M%&CZ3X8AC:PM+^62TNVF#&:26'>H(P#A1M&3D\<U%9-&=8;7FMH5\7M<2(NC
M1VS%Q)Y(17*G 4;LRDXZ'J: 'BQ@U_Q9JND)$^G:G=WSS1W@XQ$T2F6W)'\0
M!Z'C.>F><V2]MY;R]?5;2XE6#5-.AOXI0LDDA19UDSLX8G!Z=?UK8^QG4=<U
MJQ\0QJN@#4#<7=ZG ANDC4NN>H1LE0.">,'.:XV?6(_#6K6$.GE+VRM7@G:4
MQ>6MV\3R$,N>=OSLN>^V@#9\36(TO2;/5&O);[2[JWD72 1G[(1*K1K@G(.P
M')Y[BLS^V'3X?:S]K"&YUS4$E0*X! 0EG;;UQDX__54#P6?B74[J]L;9]*TX
M!IM1NI2'2+>V[:H  '/RHHY/YXR/$&K1ZI=PI:I)'86D*V]K'(5W!%'5MH W
M,<L?<T 9-6M-T^XU;4K>PM(VDGGD"*JJ3U[\=AUJK6M8WVM^%;V&[MFNM/GE
MC66-BI3S8R<@C/WE./H: .CUSP9XJ^'6HPW]L\C*L99;ZR#%8^S!CCY>#WX.
M>.^-V;XZ:S_8UM;6]E"E^@ FNY&W"3&<X3 QGCO7:^"?BO8>*3+IVM16]C<>
M7@&20>7.,?-UQ@]>/2L?QQ\&H[LQWWA18H?E >T+?(1S\RL3UZ<4 >17=]JG
MBWQ LMW/Y]]=R!%:1@JC)P!D\*!7LGB/6K+P7\)H?#B:M'-JLD'DH;1@<98E
MB>>%QE<^_P"7A,]O-:W$D$\;131L4='&"K X((^M1T %%%=Y\+V\-76M/I?B
M2QLY([@9@N)W92). $X.,'GKW'O0!P@1B,A21["MS3/"_BB>.WU'3-'U%UW;
MX9X86Z@]01Z$5]7Z9I5CHUA'8Z=;);6T>2L:#@9.35R@#GO!-UKMYX6M9O$5
MOY.HG(8$;69<\%EP-I]OQ[XKH:** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*3P">O\ (4VI(X)I8Y)(XG=(QF1E4D(/4GM0!'3HW\N17*J^T@[6Z'V--HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-CID8H ^+J*MZI8G3-7O=/9Q(UK.\)<# ;:Q7./PK2\,>$-8\77<D&E6^\1
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MLOJ>* +%G'Y5C$H^]L!_.K$:[4 )R>YI(T*DL>I_E4E !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >"WWPAU76_B!K8,_V;3S-]H6ZDC)\SS#NVJ,\
MD9()]O>O9O#^@6'AK1X=,TZ/9#$.6/+.W=F/<FM2B@ KY:^*/AW_ (1[QM=)
M'#'%:76+BW5&S\IX/T^8-Q7U+7FGQ>\&7?B6QT^XTJR2:^BF$3L.&\MNG_ 0
M3D^E 'AWA3PM?^+M:BT^R0A<YFG*DK"GJ?Z#N:^L=+TZWTC2[;3[2-8X+>,1
MJJC'0=:S/"/ABS\*>'[?3[:)%EV!KB13GS),?,<]^>GMBMZ@#YM^,'A1="\4
M&_M(#'8WX\SY4(1)/XESZG!;'O7G<<;S2I%&C/([!551DDGH *^LO'/A6/QA
MX9FTW>D5P")()77.QQ_($9!QZUXY\)/ \NH>*9-2OUC6#29BKV\BG<TV#MX[
M8//U XH ]1^%WA*3PKX41;N,IJ%V?.N%+9V_W5]B!C/OFLCXK^ +?7-+GURP
M@E.KVZ#Y(5W>>H/((]0"3D>F.:]-HH ^)Z^DO@UX<;1?"'V^4_OM3*S8#9 C
M ^3MP>3GK69\0OA&^O:D-5T!K>"YF;_289251S_?!&<'U&.>OU]2L[6*RLH+
M6"-(XH4"(B#"J ,8% $]>:^/OA/9>)7N=5TUVM]7< ["0(IB!W&,ACQSGZCO
M7I5% '"_";PY=^&_!@BOE>.XNKA[AX73:T7 7:?^^,_C7=444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !4,5I;P3SSQ01QRSD-,ZJ 9"!@%CWP !4U% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>articles007.jpg
<TEXT>
begin 644 articles007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
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MNQD9]* %HIN]<XW#/7K1O4C.X8]: '44F0:6@ HHHH **** "BBB@ HHS10
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M(Q4E% %2QT^#3K1+:W#"),D!G+'GW)S5NBB@"AJ6CV>K+&MVLC!"2NR5D_\
M02,TW3M#L=*,AM$D4OC=OF=^G^\36C10!F+H.GK>_;!$WG>IE;&?7&<58O=.
MM]0B$=S&7 Z8<KC\15S%)0!!!:0VT @B7;&!@#)-5K?1+&UNFN88F64]S(Q
M^@)P*T** $ Q5:]L(-0MS!<!C&2#\KE3^8JU10!D6OAO3K*Y2XA282)]TM.[
M#TZ$XJY<:?!=RP2S*Q:!MR8<C!_#K5NB@!C1AU*MR",&HK6R@LXC'!&$4G)
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M** "BBB@ HHI<4  HHHH *0TM(: ,R/0[*#6Y=6C5UNI4V2'><$<=OP%:0
MXI:* "BBB@ HHHH *J0:796U]->PVZK<S?ZR3G+5;HH ***IWFI06:XYEE)
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M7EF)P!1'*LJAD(93T(.10 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*2EI* "BBB@ HHHH **** "BBB@ HHHH *7%(*6@!**#10 N*2EH- "4444
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M+_#/_0Q:1_X&Q_\ Q5 &S16-_P )?X9_Z&+2/_ V/_XJC_A+_#/_ $,6D?\
M@;'_ /%4 ;-%8W_"7^&?^ABTC_P-C_\ BJ/^$O\ #/\ T,6D?^!L?_Q5 &S1
M6-_PE_AG_H8M(_\  V/_ .*H_P"$O\,_]#%I'_@;'_\ %4 ;-%8W_"7^&?\
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M_H8M(_\  V/_ .*H_P"$O\,_]#%I'_@;'_\ %4 ;-%8W_"7^&?\ H8M(_P#
MV/\ ^*H_X2_PS_T,6D?^!L?_ ,50!LT5C?\ "7^&?^ABTC_P-C_^*H_X2_PS
M_P!#%I'_ (&Q_P#Q5 &S17/OXZ\*)-Y1\1:9O]KE2/SSBE'C?PJ2@'B+2\LN
MX?Z4G3\^* -^BL4^,/#(_P"9BTG_ ,#8_P#&FOXS\+QC+>(M*Q[7D9[9['VH
M W**YQO'_A%3@^(M.Z \3J:3_A8'A'_H8M._[_B@#I**YO\ X6!X1_Z&+3O^
M_P"*/^%@>$?^ABT[_O\ B@#I**YO_A8'A'_H8M._[_BC_A8'A'_H8M._[_B@
M#I**YO\ X6!X1_Z&+3O^_P"*/^%@>$?^ABT[_O\ B@#I**YO_A8'A'_H8M._
M[_BC_A8'A'_H8M._[_B@#I**YO\ X6!X1_Z&+3O^_P"*/^%@>$?^ABT[_O\
MB@#I**YO_A8'A'_H8M._[_BC_A8'A'_H8M._[_B@#I**YO\ X6!X1_Z&+3O^
M_P"*/^%@>$?^ABT[_O\ B@#I**YO_A8'A'_H8M._[_BC_A8'A'_H8M._[_B@
M#I**YO\ X6!X1_Z&+3O^_P"*/^%@>$?^ABT[_O\ B@#I**YH_$+P@,9\1:?R
M<<3 TO\ PL#PC_T,6G?]_P 4 =)17-_\+ \(_P#0Q:=_W_%'_"P/"/\ T,6G
M?]_Q0!TE%<O_ ,+&\'<?\5#9<ML^_P!_\/?I2/\ $?P=&NX^(;(C(7Y6)/Y
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M!^W_ .^'_P#B:/\ A:/@K_H/V_\ WP__ ,30!UU%<C_PM'P5_P!!^W_[X?\
M^)K:T3Q%I'B."6?2+Z.[CB;8[("-IQG'(% &I1110 4444 %%%% !1110 44
M44 %%%% "T444 %(:6D- !1110 5#>3&VLKB=1DQQLX![X&:FJEK!<:->[%W
M-Y#X &<\&@# \%7,T@O1<<O*PG#D<MG(/\A^==97.^&].31M-CENCBYN2JXQ
MRN3\J_KD_P#UJZ*@ II<*.:IE[^250%CBC.0<_,P_I5B&W2++#<7;[S,<DT
M/8,W ;:._'-12VB26TL.<&1"A;J>1C-6** /$F_9\/&WQ.1QSFQSS_W\IT?[
M/J8_>^)7;G^&SQQD?[9[9KVNB@#QO_AGZQ_Z#]Q_X#K_ (T?\,_6/_0?N/\
MP'7_ !KV2B@#QO\ X9^L?^@_<?\ @.O^-'_#/UC_ -!^X_\  =?\:]DHH \;
M_P"&?K'_ *#]Q_X#K_C1_P ,_6/_ $'[C_P'7_&O9** /&_^&?K'_H/W'_@.
MO^-'_#/UC_T'[C_P'7_&O9** /&_^&?K'_H/W'_@.O\ C1_PS]8_]!^X_P#
M=?\ &O9** /&_P#AGZQ_Z#]Q_P" Z_XT?\,_6/\ T'[C_P !U_QKV2B@#QO_
M (9^L?\ H/W'_@.O^-'_  S]8_\ 0?N/_ =?\:]DHH \;_X9^L?^@_<?^ Z_
MXT?\,_6/_0?N/_ =?\:]DHH \;_X9^L?^@_<?^ Z_P"-'_#/UC_T'[C_ ,!U
M_P :]DHH \;_ .&?K'_H/W'_ (#K_C1_PS]8_P#0?N/_  '7_&O9** /&_\
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MA3_G[U;_ +_Q_P#Q%>GT4 >8?\*'\*?\_>K?]_X__B*/^%#^%/\ G[U;_O\
MQ_\ Q%>H8I* /,/^%#^%/^?O5O\ O_'_ /$4?\*'\*?\_>K?]_X__B*]/HH
M\P_X4/X4_P"?O5O^_P#'_P#$4?\ "A_"G_/WJW_?^/\ ^(KT^B@#S#_A0_A3
M_G[U;_O_ !__ !%'_"A_"G_/WJW_ '_C_P#B*]/HH \P_P"%#^%/^?O5O^_\
M?_Q%'_"A_"G_ #]ZM_W_ (__ (BO3Z* /,3\"/"9Z7.JCZ3I_P#$5+'\#O""
M1A6_M!SS\S7 R?R4"O2:* /,O^%%>$N/WVI\-G_7KR/3[G3]>:L?\*2\'?\
M/&\_\"#_ (5Z+10!YU_PI+P=_P \;S_P(/\ A1_PI+P=_P \;S_P(/\ A7HM
M% 'FC? SPB3)B34ANZ8G7Y/I\O\ /--C^!7A-'W-/JCC^ZTZ8_1!7IM% 'F)
M^!'A,@?Z3JHP.2)TY_\ '*ZSPCX,TSP79W%MIDERZ3R"1S<.&.0,<8 KHJ*
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M$\!M+;S%F0KNW)S\PP#T]#Z5L>'/%6D>*K66XTJX:00L$E1T*,C8S@@_YX-
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M- \3VOB!YTAM+RV>&..4K=1A"R29VL,$Y'RF@#;HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "E%)10 M)110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9(W1NYD9(SG.&*NJ@?[0Z5K_  P\9Z1X6T+Q"=3N'CUB1C,JS!OWQ53M7/\
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M^-LC\C[P8-]3SS4?P@M9['PSJ5G<1-&]OJMQ$0T@D.5V@Y8 9P01G'.,UZ
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MK6OV2Q%HKK=J[?O#O(R,9['L>F#7J'E)YGF;%WXV[L<X],^E*5&X,0,CH<4
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MYI** %S1FDHH 7-)110 4444 %%%% !1110 4444 +FDHHH **** %%% HH
M2BBB@!<T9I** %S124M !1FBDH **** %HI** %HHHH *,T4E !1110 4N:2
MB@ HHHH **** "ES244 +28H%+0 F**6B@!**** "EI*6@ HS124 +10** "
MC-)10 N:*2E% "8I:*2@!:3%%+0 F*,4M% !1110 E%%% !2TE% "YHS244
M+10** "BBB@ S1FDHH 7-)BBEH 2ES0:2@ HQ2BB@ S124"@ Q12TAH ****
M  4M(*6@ HHHH 3%%+0: #-)110 4N:2B@!:3%*** $HHHH **** "ES244
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M%
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M444 %%%% !1110 4444 %%%% !2TE+0 4444 %%%% !11FC- !2444 %%%%
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M7U:]ABBL[J&*XNVDCW!AN."RCKQ@?AWKM_!&B^']0\1W'BWP[:PV5DGFV")
MN$NE^0^:!QLPP88QR,'BL?QQHOB34_B/I>K67A5KNPT=!G=/$OVE<D_*">W/
M&,_F*]*T'1+#0[*2/3[+[$ES*;F2W#9"2,!N P< <=!QZ4 0>+M8?0?"M_J$
M*[KA$"0+ZRN0B#_OIA7F'P.\5W"W6H^$M6F<W44KS0>8V3NW'S5S_O?-^+5T
MGCC2->\4>(])TUM#F?P[:W/FW%Q%>QQO(Q7"NHSN786)]3BN%;X:^*O#'Q'7
M6?#6D2WMC;3>9&UU?1!I@5P^22",Y8<C/UH P?'%I+X1^(]SXBTI/)A@U7:
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MIX,CFF&HW5X=/8@9:*V?+NX^B;U]N.U9WPRT'2]4^'_C2XN+%)Y5A*Q.^-Z
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M,BCM1=:?'%+;QI@,^0V_.<#TP!785FZ ;PZ%9B_LC9W*1A'@,JR;<<?>7@Y
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MN<_X9_\ "/\ S]ZO_P!_X_\ XW1_PS_X1_Y^]7_[_P ?_P ;H Z/_A:W@?\
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M>K_]_P"/_P"-TO\ PS_X1_Y^]7_[_P ?_P ;H Z+_A:W@?\ Z&&W_P"^'_\
MB:/^%K>!_P#H8;?_ +X?_P")KGE^ 'A!6R;G5F'H9T_^(I/^&?\ PC_S]ZO_
M -_X_P#XW0!T7_"UO __ $,-O_WP_P#\31_PM;P/_P!##;_]\/\ _$USG_#/
M_A'_ )^]7_[_ ,?_ ,;H_P"&?_"/_/WJ_P#W_C_^-T ='_PM;P/_ -##;_\
M?#__ !-'_"UO _\ T,-O_P!\/_\ $USG_#/_ (1_Y^]7_P"_\?\ \;H_X9_\
M(_\ /WJ__?\ C_\ C= '1_\ "UO _P#T,-O_ -\/_P#$T?\ "UO _P#T,-O_
M -\/_P#$USG_  S_ .$?^?O5_P#O_'_\;J2/X!^#T60--JDA9< M<+\A]1A!
MS]<B@#?_ .%K>!_^AAM_^^'_ /B:/^%K>!_^AAM_^^'_ /B:P(?@'X/CF5WF
MU250>4>X4!OKA ?R-*?@)X.,3()-3#%]P<7"Y _NCY<8_#/O0!O?\+6\#_\
M0PV__?#_ /Q-'_"UO __ $,-O_WP_P#\37/+\ /""NI-SJS ')4SI@^W"5;3
MX&^"5DD8VMXX8@A&N6PG'08Y_/- &M_PM;P/_P!##;_]\/\ _$T?\+6\#_\
M0PV__?#_ /Q-8TGP*\%N6*Q7T>4*@+<]"3G<,@\CIZ>U)_PHCP9^\^2_^<@K
M_I/W.<X''?ISG@>O- &U_P +6\#_ /0PV_\ WP__ ,31_P +6\#_ /0PV_\
MWP__ ,36;_PI'P/_ ,^%Q_X%/_C1_P *0\#DC_0;D8/_ #]/S^M &E_PM;P/
M_P!##;_]\/\ _$T?\+6\#_\ 0PV__?#_ /Q-9I^"'@<X_P!!N1SVNGY_6F1_
M [P0F_=:7;[F)&ZZ;Y1Z#&./KS0!J_\ "UO _P#T,-O_ -\/_P#$T?\ "UO
M_P#T,-O_ -\/_P#$UF_\*1\#_P#/A<?^!3_XT?\ "D? _P#SX7'_ (%/_C0!
MI?\ "UO _P#T,-O_ -\/_P#$T?\ "UO _P#T,-O_ -\/_P#$UF_\*1\#_P#/
MA<?^!3_XT?\ "D? _P#SX7'_ (%/_C0!I?\ "UO _P#T,-O_ -\/_P#$T?\
M"UO _P#T,-O_ -\/_P#$UF_\*1\#_P#/A<?^!3_XT?\ "D? _P#SX7'_ (%/
M_C0!I?\ "UO _P#T,-O_ -\/_P#$T?\ "UO _P#T,-O_ -\/_P#$UG?\*0\#
M?\^%Q_X%/_C2?\*1\#_\^%Q_X%/_ (T :7_"UO __0PV_P#WP_\ \31_PM;P
M/_T,-O\ ]\/_ /$UF_\ "D? _P#SX7'_ (%/_C1_PI'P/_SX7'_@4_\ C0!I
M?\+6\#_]##;_ /?#_P#Q-'_"UO __0PV_P#WP_\ \36;_P *1\#_ //A<?\
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M ,14/_"D/ W_ #X7'_@4_P#C1_PI#P-_SX7'_@4_^- $W_"Y_ 7_ $&V_P#
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M )\+C_P*?_&G-\$_ S2%AIDR@_PBZDP/UH E_P"%S^ O^@VW_@)-_P#$4?\
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M-M_X"3?_ !%2_P#"G? 7_0 7_P "IO\ XND/P<\!$?\ (! _[>IO_BZ (_\
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M*2EH- %>:RM+B>*>:UADFBYCD>,%D^A/(J0P0F59C%&95SARHW#/!Y^E/I:
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M110 4444 %+BDI: "BBB@ HHHH *2EI* "BBB@ HHHH **** "BBB@ HHHH
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M;6HN)!+,'!R^T;2!AE_VO4$4 =C1110 444M !24M% "4444 %%%% !1110
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M-HUO=RVRD\1R2!%)![J1R/KFO8=/\#Z;IOC"[\3Q7-\]_=1^7*LDH,9&%'0
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M2Y@<21/-.SA&'0XS@^O(-=Q0 HHI*7- "4"BB@!:*,T9H **,T9H **,T9H
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M.HZ?<V-RI:"YB:&0 X)5@0>?H: .5;XK^!D&3XAM_N!^(Y#P?HO7GIU%1_\
M"WO G_0P1_\ @/+_ /$50'P/\$  ?8KD^YNG_P :/^%(>!_^?&Y_\"G_ ,:
M+_\ PM[P)_T,$?\ X#R__$4?\+>\"?\ 0P1_^ \O_P 15#_A2'@?_GQN?_ I
M_P#&C_A2'@?_ )\;G_P*?_&@"_\ \+>\"?\ 0P1_^ \O_P 11_PM[P)_T,$?
M_@/+_P#$50_X4AX'_P"?&Y_\"G_QH_X4AX'_ .?&Y_\  I_\: +_ /PM[P)_
MT,$?_@/+_P#$4?\ "WO G_0P1_\ @/+_ /$50_X4AX'_ .?&Y_\  I_\:/\
MA2'@?_GQN?\ P*?_ !H O_\ "WO G_0P1_\ @/+_ /$4?\+>\"?]#!'_ . \
MO_Q%4/\ A2'@?_GQN?\ P*?_ !H_X4AX'_Y\;G_P*?\ QH O_P#"WO G_0P1
M_P#@/+_\11_PM[P'_P!#!'_X#R__ !%4/^%(>!_^?&Y_\"G_ ,:/^%(>!_\
MGQN?_ I_\: +_P#PM[P'_P!#!'_X#R__ !%'_"WO G_0P1_^ \O_ ,15#_A2
M'@?_ )\;G_P*?_&C_A2'@?\ Y\;G_P "G_QH O\ _"WO G_0P1_^ \O_ ,11
M_P +>\"?]#!'_P" \O\ \15#_A2'@?\ Y\;G_P "G_QH_P"%(>!_^?&Y_P#
MI_\ &@"__P +>\"?]#!'_P" \O\ \11_PM[P'_T,$?\ X#R__$50_P"%(>!_
M^?&Y_P# I_\ &C_A2'@?_GQN?_ I_P#&@"__ ,+>\!_]#!'_ . \O_Q%'_"W
MO G_ $,$?_@/+_\ $50_X4AX'_Y\;G_P*?\ QH_X4AX'_P"?&Y_\"G_QH O_
M /"WO G_ $,$?_@/+_\ $4?\+>\"?]#!'_X#R_\ Q%4/^%(>!_\ GQN?_ I_
M\:/^%(>!_P#GQN?_  *?_&@"_P#\+>\"?]#!'_X#R_\ Q%'_  M[P)_T,$?_
M (#R_P#Q%4/^%(>!_P#GQN?_  *?_&E_X4?X'_Y\;G_P*?\ QH O?\+>\"?]
M#!'_ . \O_Q%'_"WO G_ $,$?_@/+_\ $51_X4?X'_Y\;G_P*?\ QH_X4AX'
M_P"?&Y_\"G_QH O?\+>\!_\ 0P1_^ \O_P 11_PM[P'_ -#!'_X#R_\ Q%4/
M^%(>!_\ GQN?_ I_\:/^%(>!_P#GQN?_  *?_&@"_P#\+>\"?]#!'_X#R_\
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M1_\ @/+_ /$50_X4AX'_ .?&Y_\  I_\:/\ A2'@?_GQN?\ P*?_ !H O?\
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M_P#03F_\!9/_ (FK'_"G/ 7_ $ !_P"!<_\ \70?@YX"((_L$#W%W/\ _%T
M5_\ A=G@7_H)S?\ @+)_\31_PNSP+_T$YO\ P%D_^)JQ_P *<\!?]  ?^!<_
M_P 71_PISP%_T !_X%S_ /Q= %?_ (79X%_Z"<W_ ("R?_$TO_"[/ O_ $$Y
MO_ 23_XFI_\ A3G@+_H #_P+G_\ BZ/^%.> O^@ /_ N?_XN@"#_ (79X%_Z
M"<W_ ("2?_$TG_"[/ O_ $$YO_ 63_XFK'_"G/ 7_0 '_@7/_P#%T?\ "G/
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MP\$1[=M[=2Y.#LM7X]SG%7/^%.> O^@ /_ N?_XNC_A3G@+_ *  _P# N?\
M^+H SG^.O@M6($E\PSU%MQ^IJ:7XW^!XXRRWUS*?[J6KY_4 5;_X4YX"_P"@
M /\ P+G_ /BZ/^%.> O^@ /_  +G_P#BZ **?'/P2^-US>)D'[ULW&/IGK2P
M?''P3+G?=W<..GF6K'/_ 'SFKO\ PISP%_T !_X%S_\ Q='_  ISP%_T !_X
M%S__ != $'_"[/ O_03F_P# 23_XFC_A=G@7_H)S?^ DG_Q-3_\ "G/ 7_0
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M+@*<].: ):*BDNK>*4123Q)(1D*S@$C.,X^O%$-U;W$1E@GBEC'!='# ?B*
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MTE "T4E&: %HI,TM !1110 444F: %HI,T9H **** %HHHH *2C-% !1110
M4444 %%%% !2BDI10 4E+1B@!**** "BBB@ HI<4E !1110 4444 %%%% !1
M110 4444 %%%% !2TE&: %HHHH *0TM% "44M)0 4M)10 &BE%% "4"EH- !
M2&BB@ HHHH **** "BBB@!:#24"@ HI:2@ HHHH **** "BBB@ HHH% !12T
M4 )12TE "BB@44 )1110 M!HHH 2EHHH **** $-%+10 4444 )2BDI10 4E
M+10 E%+10 E%+10 44E H 6D-+10 E+110 &DI324 %%+10 4444 %%%)0 M
M)12T  HHHH **** $HHHH ***6@!*6BDH 4TE*** $HHHH *44E** "BBB@
MI*6B@!**6B@!**** %I#12B@!**6DH **!2T )10:* "BB@4 %***0T +124
M4 *:2BB@ HHHH 6@T4&@!***6@!**6DH **** "BBB@ HHI10 E%+24 %%%%
M "BB@44 %%%(: %I**6@!**6DH *6DHH 6DHHH **** "BBB@ HHHH ****
M"BEH- !2444 %%%+0 E%*:2@ HI:* $HHHH 6BDHH 6DHI: "B@TE !12T4
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M3Q)XKLM<U;4C966LW\D+6]I&^Y8TB! 5G'!8\<\].V<#V6L*U\56EUXRO/#
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ME4FU<H2%!_CP1GG&17*:SJGB'Q3X6\"ZQ<ZT8IKK5!;E(XAL\P2G9*5!P2H
MX(]>F37H/BCX4P:[)I[Z?K%SI?V+3_[.4(F\/" 1M/(/0D'UJ1_A?#+X*T70
M'U>Y2?2K@7$5Y$@#;\L>%).!SQ]* .E\1+J,7@V_^R:@(K^&T9A=&%6!95R3
ML/'S8(]L^U>67'BSQBNA>#+K2=5M$?6Q]E^SO:1A$D#;=^Y>@Y' '&/PKU?6
M].O[SPK=Z987:)>2VQ@2XN5+@DC!+ 8Y(SSV)S@]*X0?#/7(].\*6<.L6"?V
M!-).LC6K'>V_<F5##(QUY'/<T ;?PX\1ZMKEMK-GK3P37FE:A)9M<0IL$H7O
MM[<@_ABL,:3K8^/GFG6V,']G&Z1'@#!8?,5&A4$_+S@[Q@^U;O@3PKK?AS4-
M=N=6OK&X74KDW(6VC9<.2<]>@QCCGZ^NAK/A6:^\20>(;#59K._M[1K94"AH
MI!DL XX)&[!(!&<=J /(_!>O>)?#&CZ'=_;('T*^UEK(67DC?\S-N??U'.<#
MVK2N/B#X\U[7=4_X1BR+VNGW7DK;I;(XD 8Y,C,P9<@=A^1&:O)\+?%BZ!I6
MF#7-*4:=?&^CVV\F?,W9&6SR.3Q@?C6A=_!F!_$UQJNGZ_>Z=;WC,;NVMQMW
MAOO*K \*>>"#C- 'I-G/-)IUO/>0BVG:%7FB+ B-B,L,]\'(S[5\\>,_%,%[
MJ+^+[1I$U"UU94T\O#)LFM(EQE7 VX+EB1G/(%>X>)M%OM0\&W6BZ)=1V<TD
M MXY)2Q"IP",]<[<C/-4[+PWJ5K\-$\.-+I\E\EG]E#M"?(/&!E>IXZGN><=
MJ ,+QKXGURW\,:+XH\.:A#%;W1A0V<]N'$AEP02^<C'3 ]^:Y8:!XTC^)^B1
M:KXN;^T+B*XF62*$21PHO!54;"_,H'88]ZOR?"[QE_PAL?AQ?$EA);0W:3P-
M)&^] HX ;G #<@8_$=*[;4/!LNK:EH6L7&JW%MJNFQ!)'M<!)B<%@0>=I(/'
MH: .&LOB!J>@?#S7-1FN;;4+Z+7I-/MKAX!"DG"G>RJ!VW'GGIS3]:O?%]KX
M7\0Z=XHO=/O;:ZTA[BSNK;:NYAC<@ QNP#G./3GG%:ND_"ZYE\)ZUH7B.^MI
M4U"^-]&]E&5,,IQEAGCG &,<#///%>#X0WEAX:U&RA\0->W]Q;?8K:2\0^5;
MP%P655R2"0.H_*@"IK_C/7=)L_!WAWP['_I=[IL4SND*RR!0@P$5B%_A;.3^
M59.H>//'VFV=E#XD\[P_$YD1M3CL$G,K8!0%,X4]>1UR..#76:W\*7\0Z#HL
M=UJYMM9TJ$01WMM%A70'Y<KG(( '(/4GUITGPF9HY$'B?4)#=0F*^:Z19_M)
M./F(;@$  *<$CUH ZKP;J5QJG@G2=1O)UN+F:U5Y9$ ^9L<\#C.>WK7F7_"<
M^.Y/"L_CJ&;31I,-P4.F-"0WEAMF2_7.2._O[5ZQX<T*W\->'[/1[6222&U3
M:KR$;FR223CW)KAQ\(ECO[R&+Q#>1^'KR<7$^E+&NUF#;MH8]%SCH,X H SX
M;?5KSXX:?>#7'\F?2?MB1_95&VW,G^H_/G?UJ_\ '"VNS\/))K6^>UM[>5/.
M@C7 G5B%"D@C &<XP<X'I5]? VM'XF#Q6VOQK;Q#R(K-;<X^SX_U>=P Y)/0
M\X/M72^*?#EKXK\.W6C7<DD<5QM_>1XW*58,",^XH \CUFS\0V_Q$\,0:?K2
M'5(]"9GOI[=<%<R,?D QT^4?SJY/\4/$$W@KPHUG$#K&L32122QQ*3B)PIV*
MQV[FR.O'7VQT$WPWUI?$%KJMMXG1GM+ V,)N[,ROM96!9B'7)W,2..!@<XYJ
MGX-I=>";+0+[62USI]Q)+9WD,&TQJ^"4(+'(W<\$=O3D WOA]J'BZ]@U%/%=
MH\)BE'V222)8WD0YSN"DC(P.GKWK.\$6UM<?$;QO?S(DE]#=QPI(W+1Q[.@]
M <?CCVKHO"'A(>%K6<2:K>ZG=W&SSKB[?)(084*.P /J?K6?X@\ M?ZZ=?T/
M6;G1=790LLD*AXYP.GF)QNXX_*@"'XB:S8>$-/E\20PVS:^EN8+82$Y=&D0-
MD C('!SVZ=ZPTUWQMX?\3Z-I.NZG:7UKKL;10W4%NJ&VFQU&.&P2O7@Y[8KH
MS\/;>^L]137M5O-5NKZ P--+M00J2&Q$@&%^95/?H*K>&_AS-HVJ6U_J7B*\
MUAK&-H[".Y7Y;?< "W4Y.!CMQ^@!R5G?_$:_7Q$T?BJU2TT*>:%Y38IYDQB4
MMPN,#. #SW-06GB_XA:7I?A[Q+JU]97>C:C<I') D**ZJY(!) '.,D8/4#-;
MLF@W?@3P]XPU76O$$=W;ZI%([QQV90+/)E01AFX)8#\N>*P?A?X7@\4Z/I-W
M>^([B_LM(F#QZ88-B03=<,Q^^!P1CU_"@!\OCKQY;>%+;QR\^FRZ5-<A&TZ.
M$?)&25#%\[L[AC&>I'TK8O-0\=2_$:XT31_$%L]K]F&I*MU:(NR)I,>5D DX
M!Z]:FMO@Y%;7AMQX@OF\/&X%R=)(^1F# @$YY7@=JVG\%ZG)\1V\4MK<7V9X
M#:O9"U/SPX/REMW7<<YQ0!PUA\3_ !#=>--.C6>.33[[5)++[,+4>4D88*K)
M./\ 6-SGCC\Q6=9Z?X@L?$?Q$NK;Q3<)<:7;^=([6Z2?:1M>15._.T#!''K[
M8KJ8_@DD1M(XO%>JQVUE*TUI$BJ# Q(.5/8Y!YQZ>G.MJOPP-S>ZQ?:=X@O;
M2?5;86]Q&ZB2*0>7Y99QP6.TL>HPQS[4 8NG^*?%.M6/A/1-(OK6UO[W3FO;
MJ]F@#853M 5  O)'8>G3O3N?%OC./P=XB:[U&.TUKPW>*)72U5ENHGX4$'@=
M=P([8X[UN2_"J>?0-#M?^$AFM=3T4.EK?6D.SY&QP1NSVZ[NYXYJW=?#>>3P
M5J.A1:[+)>:G.LM[J%Y%YKRX"C &X8^ZN.3@9H S/!7BCQ0_C.TT77[ZVOH[
M[2$U&-HH!&8MQX7@#/'7_.=?XD^*-0\/C1+;3KAK>6_NF1Y(H!<2[%7)"1'[
MW)'/;CUJ#1OA]K.F^+=.UR?7[6?['8I8>4MB4W0J.F=YP<\Y_2MCQCX+/BJ;
M3KJ#5[G2[[3S+Y%Q;J"1Y@ ;T[#L1UH \VN/'WBRY^%D/BJ'54MKNSO'M)XA
M:H5N 2NUB#]TC/;BK&M^+_B!HFM:;X8:XM[W5)XC=/-:0('=#D+&H?"Y!5B3
MC)&/0UK77P<N/^$5FT&T\3W!@N;D7$YNH1("P[J 1M)/)))S@>G-_P 1_"B/
MQ1;:5/>ZU<1ZU8VZ0&_AC $H4Y!*YR#DDY#=S^ !O^ KWQ+?>&P_BNR^S:BD
MK)T4&1."&(' ZD?A7DE[JOB'P_XB^(NN:+J$-M!97<!GA> 2&=FDV*,G[H 9
MB2/;ZCVOPUX?A\-:0MC%=7-V[.TLUS<R%Y)9&ZL3^ _+\:X"]^$^MWT7B&)_
M$]J$UV>.:Z T\Y^1BRA?WG R1^5 &9K/Q \8ZOXLN=(\*P FWM8GV1)&Q+NB
ML2QD_A!;&1CU/6GWFL_$9?$'AS2AJT-C?ZS;,TMO-;1LENT:G)! ).X+NQV)
MQ6I?_!I;_4++51XBN[/5(X8XKBXM(_+\W8H7<N#E"5 '4].E7-2^&=[)KF@7
MVD^(#91:+$L<"R6_F2/R=Y=MPR6SSQW/K0!R,GCKXBZSKNK:?H$44DFE,(94
MBCBVNR$J[G>0?F(. O08'O6GJL/BC4?B];'1[RWTO4V\.1O=&1!*JCS#E .<
M_/MY]JUM4^#.FW_BBYUFUUG4-/6\9VNH+9@IDW_> ;L#SD$'K6KK/P[^V:S:
M:KH^N7FCW5O9BP_<J'!A&<#GD'GKD]!0!YL_CWQM;1Z3K&HZDT5A!J1T_58X
MK9-JLC@DYVG[RDCY3U4^M>F^!+_4M:N=<U6;59+S2)+UXM,5H54"-2<LK 99
M<DJ,]DSWKF?%%E8^'_"[?#S2M!U/4Y;^U>6.=5#CS2QP\C<8(8 Y],5Z-X>T
MJ/0_#FG:7&BH+6W2,A>A8#YC^)R?QH \J^(WQ%U[1O%6HV&CWJI;V-BDQ$4"
M3?O3(JGS"<[!AO;G;ZU;\1:YXQN?%_AS3M"UN.S&N60G,<D",D!6,LQ!*DG@
M$_7%;'B#X2V>N:SJ>HQ:UJ-@-2"BZ@MR-DF .OJ.,X-,A^&>I67B+0=3MO$\
MLB:1&8D6\@\UV5LAANW# VG:..,9H Y<>)?'T>F^*]3;Q'"T'A^Z>V"G3DQ=
M,KX//\/&#WZ_C4^K_$'QEK/BZXT3PM#$KV]LD@1?*WN[(K'/FD?*"2/EY[UM
M#X8ZS_8GB/3G\30M_;ER+B5S8\(2Q9\#?W^7Z8INH?!N+4;VQU0:]=66K0Q)
M'<75FFSS=J[0RC.4;: ,@D<=* ,N^UKXBKX@\-:1_:4&GZEJUNYG@D@CDCA:
M/=E@0#G<JYQG&3CBF6OC[Q3J>FZ/H<%[;1:UJ&HW%HVH- -J1Q$98)TW'/IV
M]>:Z2Y^&MW%KF@ZAHVN+:1Z-;M#"ES;>>S%]V]F;<N2VX]NM4+?X-I-HS66K
M:W)+<)>M>VMW:0"&2%F^^.2<@D ]L$4 <QH.I:QX/O?B5?WMQ%?:K9I;DSE
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MXKT[38FB)MM,N+J47<[0PH#PK J02P*G ]<=LT >T9&<9&>N*6OG6YM[;7O
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MM<AA=8Y68QQF-B1DG."5'4\D5UWPW\/>'9-1O[>V\42:]::A9;I; VQ2-%W
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M%]!TBZ:ZT[1=/M+AL_O8+=$8 ]0"!P..@K5Q2T4 8>N^#M \330S:QIL=W)
MI6-F=AM!.3T(K3O;"TU&W-O>VL-S"2#Y<R!ER.AP:LT4 9.J>%]!UNXCN-4T
M>RO)H^%DFA5FQZ9/4>U5M9\%>'/$$]O-JFDP7,EN@CB)RH50<A< @8]JWZ*
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M,G.>,U[5FO,-8C\77OCO^T+CP:+_ $[3MRZ6/M\**')_U[@G)) &!CY?3/-
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M\;^&?$MMK.F^#[5(1:"UDLX[^/<5)!9F8L-S$YYY[=A3=.\->.['0/#VE_\
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M7:0$4*, $D$DX/% &-J/Q2L=&-[!IFA7VH:7HY2"ZO8641Q'A=JDG+$' /\
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M#2FET32?[3O2VU8//6( $'YB6X(!QQ[T >:_&;QKY6FW/AG2+I?MC(K7I20
MK&S!?*'.=QW D?W?K6]=^,W\,6]GX9TO2Y=:UBPT^-[N.)Q&D*(BY+,<\D=
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M.E9.D^*_&S:%X@\37GB"WEMM&GFM?L/V) LSA0%;<,, &=3CVQF@#VRBO#M
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MER#T;!Z>_#M5U[QAX;C\/Z7<:]=:BVM$SM-:VD?VF- J_NXPQVDG)Y/_ .L
M]&\:>-['P59VTUW;SSRW,GEPQQ*<$Y&<MT7@]^3V[XZ>OGWQ5J?B;4?AQ=6W
MB%)TGMM8@6VEN8%CE:,AMI=%XSQ_^NM#4;KXDV?B&[\*-XA2YOGM#J-G<0Q*
MC.%)RF O .'&.>0O.,T >Y45Y#X3UZ_\87/@TV6K7T<EG;RR:O$9\APA"+O&
M/F+DY&>V>XS76_$O7+[0/"HNM/OH;.9KA(V=UW.R$'*QK@Y<X&,C'7IUH [*
MJU]8VNIV4UE>P1SVTRE9(Y%R&%>('QKXQ7P)XBU*#5I[>31]06-1?64?VAHG
M9557XVAANR3@UI+<^-H_&6D>'F\8NR:Q9?:WN#91;H2%8E5&, '% 'KUC:1Z
M?86UG"7,5O$L2%VW-A1@9/<\58KPB7XC^*+3PWI=K<W9DO9M5N+&XNK>!#*8
MXM@.P-A=YWG!/I3;OQ7\1=-\.Z]=2W<]C%IWDRP'4+.,W,J22; "1\O'/.T]
M.U 'O%<MXM\<6?A*ZTRUGM;B>;4)UBCV#"J"P!);ID9SCO[5Q^A^,?$6F:WK
M=GK6HIJL-EH/]K(WV9(FW;%8K\N..3UKGM:T_P 4:QIO@K6-6U];F/5-3MI%
MLO)"1P,X+(5(&>%R#GN: />JS/$&N6_AS1+G5;J.:2&W7<RPQEV/Y=!ZGH*\
M1A^(/CG6H+O5=*-^\L-T=MO#:1-:1P#.0[$[RW3GCOZ\=%XBNO$7BJU\=20:
MR]AI6D));Q6T<:,+C;&3*')&[D=,'C- 'IN@ZP-<\.6&L?9W@%W;K/Y).XJ"
M,XR.M8/A#5M'\8:AJ7B.TL9%N+:8Z<DTX^;8@#94=4!+G(Z\#-7/A\Q/P\\/
M$LK?Z!",K_NCCZUXMIDOBW2/#OB;Q%H.N1VUE8:S.9[)X%;S#E 6W$'/! QQ
MT]Z /H>&SMK>:::"WABEG8-*Z(%,A'&6(ZGZU/7BEMX@UCP]X\T_4]?U>Z.A
M:_I[3PCSF\JU<HKE=IR!M/ QV8>]=[\-[758/!MM/K%[=W-W>,US_I4OF/&C
M?<7/^Z <>I- &MH^N2:KJFKV3Z9=6HT^<1)-*N$N 1G<A_SU'//&Q7E5GXC\
M2SQ_$:(:PHN='</9R&V4K$@#L0%[Y5,<YP>>>E9FA>,O%5F_A34M8UM;^PUF
M&ZDFM_L<<9B$2%OE90"3P* /9S17E7AC4?%OB'3;'Q;'XKL8[66Y9;K3IXD6
M&&+>0$#CYM_3&<9R.?6@NH>-+;6_%-Y>>*1)!X<597M8[152Y!B+A?51P >I
MY.#0![+25XEX7\6>-[[4M$O9_P"T)+*YEV7\EQ#"+7:3P8RH!4@<<DY_2JVA
M_$+Q)-XLTY6O9;V"\GN;>4^4HLV91E/); ;Y>,D]?7G- 'NU97A[6)M;TUKN
M?3KBP8321"*<88A6(#=!P>O^/6O,/AQXQUGQ#XD6UO\ 7IDNS;2FXL+FW107
M!^1XBJCY0#RI.>">0>%;Q5XK_P"%/7VOQZTBZC97\B23&U1O,02!-H!&%Y8'
MH>!B@#V2DKR2+Q3XLT/Q%JFE7NIIJYA\/OJ<)-HD9\T 8&$ R,YXYK*\+^+?
M$NK>(/#,%AXK_M,:BK3:G UG&!:;,%EX *YP0#P,X(SD4 >X44M% "44M% "
M44M% "4M%)0 M)110 444M "44M% "4HHHH **2EH **** "BBB@ HHHH **
M** "BBDH 6BDHH **6B@ I#2TAH **** "BBB@!:*** $HHHH 6BDI: "DI:
M*  4444 <QXH\#:;XJO+*^N+F^LKZRSY%U8S".10>V2#6>WPXMX?#NI:78:S
MJ$,^IOF^OIV$TUPN"I5B0!C![8K?U?Q)I^C:AIMA.SR7FHSB&""(!GYZN1GA
M!CDUE>%?$^I:QXA\0Z3J-E;PMI4L:+);N65PX)&<]\ ?G0!I>%="F\-Z#!I4
MNI2WZ0 )$\L:H40  +QV&.IYKCO$7P:TW6[^[NK76-1T];V5IKFWC8-$[MR6
MV\8)/)R3^%>ET"@#@H?AK-'K'A_47\2WLCZ+"(85,$8W+R".G0J0O<X'7-/T
M'X:QZ38:UI]UK-U?6&K"0SP/$B .^,R @9W8 QV]J[NFREUB=HTWN%)5<XR>
MPS0!YUH7P8\/:)=O,UWJ-['M=4@N)5\M0Z%"2% RV&;GWZ<9J;0?@]X>\/ZE
M!>0W>J7 MY1-%!<7 ,2N.0VU5&2#R,^E=7X;O=6U#0K>YUO3ET_4'+>9;*^X
M+AB!S[C!_&KFI375OI=W-8VXN;N.%W@@+;1(X!*KGMDX% '"CX1Z;+#J]I>Z
MG>3Z?J%TUXMLJHGD2DYWJV"2<?+Z8)X]+^G?#>STNYN+^#6M7N-5>U:U@O;Z
M<3/;J?[HP!Q[UTVC7%]=Z-9W&IV@M+Z2(--;AMPC;N,U>H \SM/A&UGX?BTF
M'Q/?*EM>)>6KK"@,$@# X[G.[N>WUKK?"OA'3_"-K=0V,D\KW<YGGEF*Y9S[
M* H'L!6_10!P-U\*[/4-9NKN\UB_>RGOOM_V!-BH)N,DG!.,#'&#CO4.L?!S
M0M5\12ZU'?ZG8W%Q(9)UMI@H;(.[!(R,G!/)'7CGCT6@T <>W@.*#Q)H^KZ7
MJ4]@NFV:6(MTC5UE@5MVTEN1GH3U[U>\6>#=,\8VEO#J#7$4EM+YL%Q;.$DC
M;V)!'IV["NAI: .0TCX=:/I1U.22XU#4;G4H#;7-S?S^9(T9&"N0![?D*JZ+
M\,--T36=+U*/5]8N6TM'CM(+F=&CC5U*D ! >C>O85W-% '*>$/!?_"(W&I&
M'5;FYM;V=IQ;2(H6)V/)!').,#MTZ5%<^!Y;CX@+XK77;J)UB$*VR1J5$>WE
M<GL6^;IWIVM>++[2OB%H.@"T@>QU2-SYQ<^8CH&)XZ8^[^9KKJ /*Y/@W--I
MUW8R^+]0>&[NQ>3*T"'?+S\Q/7/3OVKT>6P>?1'T^>Y>5Y+<P/<,H#,2NTL0
M,#)ZX'%7:* /+U^$$T>GZ39Q^++U8])F:>S'V6/]TQ;=D=SSD\D]:MVWPFMS
M9ZW::KKE[?P:O()YQY:1E9MV[S%.#@]L=,$\5Z+7)^+/%MYHVJ:9HVD:='J&
MKZB)6BADG$2JJ*6))Q[<=,X/- %/P7\,=,\&79O(;V]O+CRVB3[0PV1JQ!.U
M0."< $^W:K>I^"[C4_&ECX@DUZZ6*R;,-B(D,:@@!USUPV.<Y//TK9\.W>J7
MVA6USK5@EAJ#@^;;H^X)R<<^XP?QK*L/%TEY\1=4\*O8>6EE:I<)<^;GS =G
M&W''+XZ]J ,OQ9\,8/$OB*SUNVU272KJU0!&MH%R6#$AB>#GD#\*L^'/ =QH
M'B?4-;D\0W-Z^H#%S%) B"0C[I)7N.>@'6NBT*[U*]TE)]6L%L;PNX:!7#@*
M&(4Y'J #^-:- 'F?_"H /",WAI?$EX-/DNA<!/)3"8S\H[X)(/7^$>]6M1^$
M.DZM?V^I7FK:LNI)"D4UU;2I$9RHQN(VG!Q@<8X'XUZ&*R->\2Z=X=6S^W2'
MS;RX2V@B0C>[,P7(!(X&02>WY4 <Z/AK;V^N:#?:?JUU:6VC)L@M%16!!),F
M6//SYP<Y[XQ66GP0\.0ZO)=P7NIPVDK%I+*.8+&QSD+D#.T<\'GWKTV@T <#
M8?"O3[?6K74;O4[V[%E=R75G;L$1(F=]YR0-S?-SU XZ5T7BGPKIWB_2!IVH
MF9$259HY8'VO&XR RD@C.">W>MNL_6]:L?#^D7&IZC,L5O A8Y(!8XX5<]6/
M0"@# T[X?V^E2WU[;ZUJTVKW5O\ 9UU&\F6:2)>"-H*@=0.HI_@;P4W@JSNK
M1=7GOH)Y/-5)8E4(Y^\01R<\=^U='IU['J>F6E_"KK%<PI,@<?, R@C.._-6
M: .0\2>")M;\36.O66MSZ9>V<#0QM% DG#9R?FXZ,1TKFU^#&S28M/7Q5?B*
M*]^W(/(CP)<8W=,Y_''M783^+(+C5M3T/1A'=ZO96AN"K.!$&S@(S#)#=,C'
M?K3O WB*;Q9X.L-;G@2"6Y\S='&25&V1DXS_ +N: .<UCX/:+K'B1M;?4M3M
M[B4AIQ;RJF]@ ,@[<KG'./7C%=K8:/9:?H<&C0QDV4, MPCG)*8QR?<5?HH
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M^U1,NQ&B<@AB#@YW<9S_ '1C%/G^#&E+X>N-)L=7U*$73H;B:9EE:5$)*IC
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MF4@MU/7UH \I6UFU'X;_  ^G-[>VM]>:F-/>ZAN'600O+*/7!Z Y_I3]0\.
M>+O%FDR:UK<MKI&D?;+827[L3*(P<MZ\DGC%>FWOPT\/7NFZ3IY^VPVVE%FM
MDANF7:2<Y)]0>0>HH;X:Z$UWJ]V9-1^T:K&\5S+]K;)1B"5'MQQG/''2@#RR
M6)_$LOPNCU34+A6N89TDN5FVRG!&!NZY. ,]>:Y[5M>U?2?[1T&WURXG\/IK
M(C-^TSLVW!W(<$%EQR0,9*\=:]R7X7^%V\/VVBW-K-=6]JS-!)-,WF1%B"0K
M#&!P..E:,G@;PS)X<&@'2+<::#N$0!R&QC=N^]N_VLYH \=U:S^Q^"?$=PGB
MY=4DA2UN[2*SFF*VFZ79N5V=NH)&TD^IZ"O6? 6@Q:)X=BDBU&]O?MR1W+-=
M3>9M9D&=I]"<G\:CD^&GA9O#BZ"E@\-AY@E=89G5I6'=V!RWX].U;F@Z+:^'
M=$MM)LGF:VME*QF9]S8))QG\: /#'AEO/ 6H>,!XHU&'Q/973^=";LA(SYN/
M*"^F"",<$\5T.NZ387_QI\(27UMLN+VS:>Z03,#YBQL5Z'C!4=, X[\UV]Q\
M-/"5WXA.N3:1&]ZSF1\NVQW_ +Q3.,]^G7GK3-4^&V@ZOXLC\27+7HU!'C<;
M)R$RF,<8X' R!0!E_&#5;G3O#^E1QWL]A:W>IQ07=W!)M>.(ABP&.>@)_P"
M^]<YX1\/:5IWQ<U[1[:[DNK"YT489[GS'*N4R-PYZ9([X(KUK4]*L-9LFLM2
MLX;NV8@F.9 PR.A^OO6!I_PU\):0+@Z=I(M99X6A,Z32&1%8%3L9F)4X)Y&*
M /+);;S/A1X<N_[1NK2[_MAK'[<MRZM'"\T@;/S $  'GTH\3PW&G^.[;PDW
MBJ>TL([!C#<:C<RG,DC,<LR,OS ' +9&% QS7H4OPB\.2^'8-#:;4_L4,[7"
MK]J/+L #D8QCCT[GU-:VK?#[PSKMK80:IIPN?L,20Q2M(PD**,!692"1]>]
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M 4444 %+2"EH 2BBB@!:*** $I:2EH *2EI* "EH%% !1110 4444 %)2TE
M!2TE+0 4E*:2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *2EI* %HI!2T )1110 4444 %+24M !24M)0 HHH%%
M !1110 4444 %%%% !1110 4444 %%%% "4M)0* %I*6DH *6DI: $HHHH 6
MBBB@!*6DI: "BBB@ HHHH 0T444 +1110 444E !2TE+0 &DI324 +1110 4
M444 %)2TE !1110 M% HH **** $HHHH **** "EI*6@ HHHH **** "BBC-
M !2444 ***!10 449HS0 4AI<TE !1110 "EI*7- "4444 %95WXGT*PU)-.
MN]8LH+URH6"2=0Y+=!C/>M6O'/C?#IUC:6,S:$3]JNUDNM5MXQYL07:,!NS$
M  9X^7\@#V.EJGI5Y#J.CV5];ES!<V\<T9D^\5901GWP:N4 %%&:* "BBC-
M'/ZSXW\->'[[[%JNKP6MSL#^6^2=IZ'@>U7M(U_2-?A>72=1MKQ$QO\ )D#%
M<],CJ/QK@OB??VVD^*_!^HWEDUQ;1SS^8(HA)(WR8 "]QSFN<TIO$UEK?B7Q
MQH_ANUTC2ULV(L[]#"95C^9F"J,[_E/7 ^;J>M 'N-**\WMO'/B*]U;0K."Q
MTP+K>E&\MF9GS'*(MQ#_ .SNP.,G%<W/\9/$T&ESWK>&K,6UO>&QFO!.[1)*
M,9RH&[&#U_KQ0![925Y-<_$[7XO ]SXDM[;1;F.SOFM9S%)*4<$1[&C) )Y<
MYSCH*U7^(&J6WB'Q)I]Q86C1:7I3:E 8F;=(-JL%;/3KS@4 >B4M>3^%/B?K
M?BJYO=,M;32&U%+!+V!UED\D?,FZ.3C.X!^V1D8JMX>^+7B#49]&GU#0K.'3
M-5O!8PS13'=YF0,XYX!/M0![!D9QGI1D9QGFO*OA9<^([KQ5XL;5Y[&8)>>5
M<M%NR)E&T!,\; !CGFJVM:QXCL/C3"MW/8MIUI837D40W?+;<AR>.9/W9]J
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M(EV69WWA<1\<D;E.3P:V_%(.D>-?"?B33XP@U*Y73;U?NF991E"P[E<$_D*
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MID9]2=TBC:21E1%!+,QP !W)H AN[ZUL(XY+N=(4DE2%"YQN=B%51[DFK->
M:GXG7Q[\6O#<5O=H-+M=098(5;+,8B'\UAZ/C"^R^]='=?%'Q/J-E=ZOX9\/
M07&C6]XMJ)9M[RRG(RP1<8'(^F1[T >N54U'4K/2;&2]O[B.WMH\;I'. ,G
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M4 %%%% !24N:2@ I:2EH ***,T %%&:* $I11BCI0 449HS0 449HH ****
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M)HVFB"F2,,"R!NF1VS@UD-J*:/K>E:!9Z-.+.XBD(N+>+$%MM&0K8&!G^>*
M/-9? WC2[\&>)-%FL],2;5]4%^'6Z.$W,&<?=[%% ^I]*VM16Z\0>*O"&@I@
M/HK)?ZMY)WQP2(@\M"V,9)W<=<'->F5#!:6UJTSP011-._F2E%"EWP!N;'4X
M Y]J .9\?^$[OQ5I%J-,NTL]4L+E;JTG?H'7L>#C_P"L*Q]-\,^+HI-7\1ZG
M/IMQXFN+ 65I%""L,2;L_,<9))P?PQ]-O6?'FFZ3JNB6"Q373:O,D4,\(S$
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MX51E"^6H&#@!5(]\]*]/K-U'68;.TU)K9?MUY8P&9[*!P93P2HQU&<''Z9H
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M"Z ,6L?R8;YLL6^7/. #["LF3X&^&GUB>]%WJ*03R%WM(Y0L9!.=N0,[?QH
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MB(XK80JWGL 2Q=FZ#*D#C'ZD]WX5\*6OA2SNH;>XN+F2ZN&N9YIRNYW( Z*
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MJTW3O#UAHFAZI;RP1ZA'XI6 RB?G[.&SSST VG/O5SQO!:W_ ,1/%MI-I_\
M:EU<QP)97*3[%LW*+C=D@8]3[>YH ^C^M5Y;^S@D,<MW!&XZJ\@!'X5E>#=#
MA\.>$-,TN$JWDPCS'1BP=SR[ Y/!8DUXOJ7@KP4GCKQA;:M>_P!E65G# ]J!
M/TDDCW,0&R7(/11Z_2@#W^6\M8-OG7,,>X97>X&1[9H:[MDF6)[B)96QM0N
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M]E\!31S_  ^\//&P91IT"$CU5 "/S!H DTU]537];FU#4;*32AY0LXHR T&
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M6-/-N&"&7[2FW<1D#.<9P"<>U<Y>>)=2C^+6E>'8VB739M/DNFVC+2'D#)[
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ML7;T[U?TZU^RVBHWWS\S?6BUL(K7YAEY#U=NM6Z0)!112T#"DI:0T %+24M
M!24M)0 M%%% "444M !1110 4444 !I*** ,W5=.T35O+M=7M+&Z/6..Y17/
M)[ _3MZ5'9^%?#^GP7$-GHMA!%<J%F1+=0L@&<!ACGJ:\R^)>CZ)+\5?"L^K
MLD=K=Q2QW3RS&- J E3NR-IRW7/I5;P;XGL/"OB7Q# GB&ZO_"%G!&T4SAYQ
M#(Q&%4J#Q]\9X' ^M 'JJ>%?#T>G2:>FB:>MG*09(%MD"N0<C(QS@TY_#&@R
MZ9%ILFC6#V,1)CMVMU*(2<D@8XR:Y6R^,'AF]TR[U 1ZA%!;!,>;  9F8D!8
MP&.YN#^512_&/0&T&[U2SM;ZX:SD1;FU,826)6) <Y.-N<#@]2,T =?<>&-!
MN]/BT^?1K"2SA;?' UNNQ&]0,8!Y-5H?!_A97ED@T+2PTBM%(R6Z<@\,IP/P
M(K+B^(,$MUX<@_LJ\']NPM-$X*L(E')W8/88/'K6/X6\5>%- \(/?:8VJ3VE
MYJTD4,4D6^:6=\':@';TSSZ\T =0O@?PC;NDR^'=*C9&!5_LR##9XP<=<XKR
M^^^%VM7^I72W_A[3KR:XO);E=3747C #L25E3&Y@ !@+C'J<FNF\2>+/"WB7
MPOI=S?MJMO!)JR1Q1QQ!)?.C/1P<@+SSSG\JZ#Q7\1-$\'WD5IJ"WDL[Q><4
MMH=^Q,D;F)( &0?RH UO#&D2Z#X9T[2IKDW$EK L9D]<>GL.@]@*A;P;X9;[
M1NT#33]I.Z;-LG[PYSSQSSS6!=_&#P;:1VCF_FE6[C\R/RK=VXR5P>.#D'BK
M</Q,\-W/ARYUR">XDMK>=;9HQ PD,C8PH4]SGZ4 :=KX+\,6-U'<VOA_389X
MSE)$MD#*?4'%3V'A?0-+NC=6&BZ?:W!.?-AMT5OS XZFL0?$;3'T&[U5;#45
M^R7J6,MM+"$E$K%0!MS_ +0KL: (KBW@O+>2WN88YH)!M>.10RL/0@]:R$\&
M>&([.2T30--6WE97DB%LFUF&<$C'.,G\ZPH/BOX<GOTMMFH1QR+,\-R]L?+F
M6+=O*8.3]T]NV*AM/C+X.O;F&".ZN@99%B5FM7V[CT!.* .EO/"'AO4&B:\T
M+3IS#$L,9DMU.Q%^ZHXX ["F+X)\++:/:CP]IHMW=9&C%LNUF4$ D8Z@,WYF
MN9^(WCG3-+T_4M#2?5%U$6OF--IT>3;9QM+L?N@G ^A[9%:/PH=Y/AAHCNQ9
MC&^2QR3^\:@#H6\/:,^DG2CI5G_9Q()M?(7RR0<@[<8Z@51@\#>%+5P\'AW3
M(W"E=RVRYP001G'<$C\:Z"B@#FI/A[X/ECV-X:TP+G/RVZJ?S%>9ZS\,=;OM
M2U0WF@6&I->7;36U]#?F!K=>%5'!7YD"@< 9X.#7N-% '/\ @KP_+X7\*VFD
MS3+*\)=OD)*IN8MM4GD@9QD]:X/1?#>K:I\4=6U;Q-X,MVT^]P(9KAXI?L_E
MC"';DY+ #.._M7KE% &)<>$/#EUJ1U&XT2PEO"5/G/ I;*\*<^V!^0J>X\-Z
M'>:@NH7.D6,UXO(GDMU9Q^)&:TZ6@"K?:=9:G;B"^M8KF)760)*@8!E.0>>X
MJOJ_A_1]>6)=6TVVO1"28_/C#;,C!QG\/R'I6E10!BP^$/#D&HKJ$6AV"WBL
M&680+N4@  @XXP .E26OA?0K+5;C5+;2;2*^N<^;.L8W-GK^??U[UK44 9FF
M^'=%T:>6;3-*LK.648=X(%0L/? K/;X?^$'1U;PWI>'R2?LRY_/&>]='10!B
M1^$/#D5]'>IH6GK=1!!'*+==R[1A<''&  !]!6T0""",@]0:*6@# ;P/X4:(
MQGPWI10MNQ]D3K^51/\ #_P@ZHI\-Z8 C[P%MU'/O@<CV/%=)10!C:AX3\/:
MK<_:-0T33[J?:%\R6W5FP.@R16AI^G66E6:6>GVL-K;)DK%"@51DY. /<U8I
M: .?_P"$'\+>;<R_V!8;[D,)CY(^<$ACG\0#1%X&\*P2P2P^'M-22!@T;K;*
M"I!R#G'K7044 96F>&-!T6X:?3-'L;.9EVF2"!48CTR!TIJ>%?#\5]->IHFG
MK=3;O,F%NNYMWWLG'?)S]:UZ* ,>T\)^'K""Z@M-%L((KJ/RITB@51*G]UL#
MD<FJ_P#P@GA/RT3_ (1S2]J$E0;5."<9/3V'Y5T%% &!-X'\*W$\LTWAW3))
M96+2.UJA+$G))..N:X7Q7\/+N[UPO!H%CJ6ABTCM+:TBN?LTUJ VXLA(V\G.
M>Y!^M>LT4 <1\-O!EUX.L-02Y>%/MDRRI:P2O)'  H&-S<EB>I]A71W/AW1;
MW4AJ-UI5G->JNT7$D*LX&,8R1GH36I24 <[_ ,(#X1V[?^$:TK&<_P#'HG^%
M7Y/#>AS:DFHR:18O>H=RW#6ZEP>QW8SFM2B@#)'A?01JW]JC1K'^T-_F?:?(
M7S-W][=C.?>G1>&]#@U5M4BTBQ2_8EFN5@42$GJ=V,Y]ZU** ,>R\)^'M.OA
M?66B:?;W0SB:*W56&>#R!WR:L6NA:18W4MU::7907$N?,EB@56;/7) R<X%:
M%% &3IOAC0=&NFN=,T>QLYV4H9((%1BI.<9 Z<"K>HZ98ZO:&TU&TAN[=B&,
M4R!U)'0X-6Z* ,&?P1X6N61I_#VF2,B+&I:V0X51@#IT XJ1/"/AQ-/:P70M
M.%FS^88/LR;-^,;L8ZXXS6U24 0V=G:V%LEM9V\5O GW8HD"*OT JO>Z'I&I
M3B>^TJQNI0NT23VZ.V/3)'3DU?HH PY/!OAF2&*%] TTQ1.TD:?9DPC-C<0,
M<$[1^0J7_A&-!^UW-T=&L#/= B>1K=2902"=V1SR >?2M:B@#(C\*^'HITGB
MT+38Y4#!72U0$ C!Z#N.*EB\/:+!#<0PZ1811W$9BF6.W11(AZJV!R/:M*B@
M#G?^$!\(8Q_PC6E8_P"O1/\ "K[^&]#DU#^T)-'L&O,Y\]K9"^<YSG&<Y YK
M3I: ,G4O"V@:Q<?:-2T6PNYNGF36ZLQ_$C/:KMAI]GI=FEGI]K#:VR9VQ0H%
M5<G)P![FK-% &'<^#?#-W?/>W.@:;-<N^]Y9+9&9F]22.35^YTC3;RUBM;K3
M[2>WBQY<4L*LB8&. 1@<5=I* ,R^\-Z)J=K!;7NDV5Q;V_\ J8I(%*Q]OE&,
M#I3+#PKX?TJX>XL-%L+69T*,\-NJDJ>HX'0UKT4 9]GH.CZ<939:596WF@K)
MY-NJ;P>QP.1[50'@?PJ+@7 \.:6)0P<,+5 01WZ5OT4 9]WH.C:A<&XO=)L+
MF8@ R36R.Q Z<D9J*;PYHESJ<6IS:3927T6TQW#0*77;]W!QGCM6K24 9L7A
M_1H-1.HQ:38QWI))N%MT$F3G)W8SGD\^]:1 (((R#U!HHH HVNBZ58O(]GIM
MG;M*,2-# J%QZ' YJOIGAC0=%N6N-+T>QLYF789((%1BN0<9 Z<#\JUJ* &3
M0Q7,#PSQ)+%(I5T=0RL#U!!ZBL_3_#>AZ7<O<Z?H]A:SO]Z2&W5&/X@5IT"@
M#/N?#^CWNI1ZE=:79S7L0"I<20JSJ!G&"1GN:S_^$"\([-G_  C6E;<YQ]D3
MK^5=#10!FOX=T66[BNY-(L&N8<>7*UNA9,# P<9& !CTQ49\+Z =6_M4Z-8G
M4-_F?:?(7S-W][=C.?>M:B@ HHHH **** $HHHH *6DI: "BBB@ HHHH ***
M* "D-+2=: "EI*6@ HHHH **** "BBB@ HHHH *2EHQ0 "BBB@ HHHH *0TN
M:.M "44N*2@ %+24N: "BC-&: "BBB@ HHHH *2EHQ0 E%+BC% 'DOQ$ N?B
M5X8>?0=0U'3[%9&NO+L6FC;>/E'3!((YSTXKN==MK/1?!NJII^F;4-O(JVUA
M;#<S,,#"*.>370XHQ0!XG:VNO3_#_P (W&F:/J#7GAZ^1KFRFA,+2C!R5#?>
M&#C(]3Z5T&AZ->>)?&VMZSJWAV?2M-O-.%BT$[KNN23RS*.X' /T_#TRB@#R
MGX6>%=3T6XU*^UIKEO[.\S3=/C=?^6 ?>S*,<ACC!]C7%6>G7%QX!ATV_P!"
MUZ!4UYKAV@LY!-$C1MM=..<$ '^8R#7T7BB@#P+5+#Q-%\--'MM3TS4;J]BU
M_P"U 1VS/*T*AB7D S\Q+'J>?6NINY==T;XBW?B&#P[>ZKI.LZ?$@CB0"2$A
M1\CJ<8[Y!]>O&*]4HH ^?X]!U704\&+<:)?AX]7EU&>&V@:9;:)G0*A*@C("
MYQ4,=I=W_A[Q3:W&@ZY%%>Z\EZ&6Q<2"!I.2@QRX';GK7T-10!X_X7O=4\)^
M#M4N/$&BZGJEC'?H]F)K8&Y9 HQ(ZDG 4(N"3D'Z5ZK#>?;M'COK)=WGVXF@
M#C&=RY7/YBJ^NZ'9^(M/%A?^:;;S%D>..0H) #]UL=5/<5HQHD4:QQHJ(@"J
MJC  '0 4 ?.6G:1K>AZSH>M3^$]>FFL)YY[XH 4+.QPL,:G"J"<\=<GMBI))
M;V3PE=V:^&M>2XD\3?VG&HTU\I">01QC=@$8]_2OHNB@#Q36-0UKP[JWBU4\
M+ZEJB>(81);7<,+$QJT>T1N "1MR1C/;ISQW/PJBGMOAOI-M=6MQ;3PK(CQ3
MQ&-@?,8]#SCFNRHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC-%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&: "BBB@ HHHH
M**** "BBB@!**7%% !1110 4444 %%%% !1110 4444 )2BC%% !24M&* $%
M+110 AHH-% !0*7%% !2&EI#0 444N* $%+110 E%+1B@ H-%% "4M&** "B
MBB@ HHHH **** &L"RD X)[TH&*7%'2@ HHS10 4444 %%%% !1110 4444
M%%%% !1110 4&DHH *44E** "DI:2@ HHI: $HHHH 6BDHH 6DHHH *6DHH
M6B@44 %%%% !124HH **** "BBDH 6B@44 )12T4 %%%)F@!:*2EH ***2@!
M:*** "BBB@ HI** %HI** %HI*6@ HHHH 2@4M% !1244 +124M !1124 +1
M110 4444 %%%% !1110 44&DH **6B@ HHHH **** "BBB@ HHHH **** "B
MDI10 444E "T4E% "T4E% "T444 %%%% !1124 +124M "&BEHH **2B@!:0
MTM% "4M%% !1110 44E% "T4E% "T4E% "T4E+0 4444 %%%% !0:** $I:*
M* "BBB@ HHHH **** "BBB@ HHHH **** $HHHH *44E** "DI:2@ %+2"EH
M 2BBB@ K"\2>+]'\*K:?VI<%'NYA%%&B[F)/?'H.YK=KY<\7^.+#Q!=W=S=Q
M71U%-4C^SAHU"P6D>[Y <YW%CD_SXH ^HZ*I:5JMKK.EVFH6K-Y-U$)H@XVL
M5/<C\:NT %%%+0 4444 <CX@\?0^']?@T9]"UB\N;B,R0&TA1Q*%&6VY<$D=
M^*N^&/&FD^*VNHK'[3%=6A N+:YA,<D><XR.G8]#7'_$*\U*P^)?@^?2+!+^
M^$-VL5N\PB#DH ?F/ P,GWQ67=^'/%VBV'BCQSJ.LQV&M2PAU@L41XPB# 5M
MZGT7ISQR3F@#V2E%>46^NZ[?^.M&TI?$4D46IZ&MRZ+%&3!,4!RORGG*[OFX
MP3CM7+67BGXDW7A,Z]'JS76GPW;P7*V]K%]I1%P2XRN#P3VX SZX /H"BO#K
M[QIKLOPVC\1Z7XDNRT6J-:GSK: -*A(V[P%(# >GK6MK/B_5]%UGQW -=62*
MPLXYK(3)&/(EDY"# ^8C. #GMG/6@#UNDKQKPKXM\3:U<>(]+N=2OX&MM.CO
M+>>YM(HYXV 5C\NW;M;W'0YXJEX?\8^,[N7PI=:AK<4EKXBEN+<0QVR*80AV
M!\X^]N.<=,*/4T >U6FH6E[)<QVUPDKVTIAF"G.QP =I]\$4/J%I'J,6GO.@
MNY8VE2+NR*0"?P)'YUYM\(-*N-.N/%,;ZI<W,5OJ\]L4E"GS'7;F5FQN+$#'
M7%8VL6=[X=^,.J:K%J][.T6ARZH8V"MN42$"WY'$?RCI@_CS0![717CD7BOQ
MMIFD>&/$=YJ=I?Z?J]U'%/:K:A/)63IAASG /7OCK7;?$75-<T?PQ]KT&%Y)
MA.HG,2!Y4AP2S(IR"PP.QP,G'&0 =;67X@UF+P[H=WJ\UK<W$5LN^1+90S[1
MU."0, <GGH*\HTGQGK>HZ/H^J6_B&[DC?Q)%ILL4UO"K20N5/SX7Y6QD?*>]
M7I-;U74++XJ:9?Z@UW;:=;,MJ&C13&&24D?*!GH!SZ4 >HZ5J$6KZ19ZE KK
M#=P)/&L@ 8*RAAG'?!JY7A6C^(O&WAO1?!TC7MK?Z;J<0M;>T$*JT;;=L2EN
M"?X<GV/XR^&OB3K/F:X-0O;N2[L='EN7M+ZWCC\NY5APH4 E<$'!P?KUH ]P
MI*\-LO'7Q$@\/P^)IHK6[TD6\CRL\EN%+8.W:$(<$'&5.3UK7TJ^\8>(-)T:
MZG\4V+:9K2/!<FW6."2T=E.U8VZLX/&.N?\ OH '?:MXNTO2-,.H,SW,(O%L
MF^S@,5E+;2#DCH>M;U?/_A^XUW0OA3INKV6OW*I-JPB-JT,3H%,K*W+*6R2,
MYS77W.O>,]?U[Q3!H6H6FG0Z&?+BMI;8/)</C.6)SA3AL$>HXZF@#U&BO$[C
MQQXMU31_!VH:;J4=E<ZW*UC+"]LC0AUD*^:,@MSD<9QQ7<^ =:UC49=?L-9N
MXKN;3+\VRSI"(]XP#R!QUH T->\<:#X;U6RTW4KITN[PJ(HTB9N"VT$D# &:
MN^(/$>F>&-,^WZI.8H2XC0*I9G<]%51R37&?&.,R:5X;"(6D.O6X 49)^5^*
MR/&FGZGXH^,NEZ1::BE@NGV'VV*22(2C?N(W!#P3]WKTQF@#J]1^)FDZ-I*:
MAJ]AJNGB6<PP6]Q;!9IL $LJY^[R.3BG^"_B3I'CB>\AT^VO8&M$#R?:451@
MDC@ACZ54^'6M7?B32KRY\1VUJ^JZ1>36;7*P@< *6P>W/7&!P*Y"]U"6W^$O
MBOQ?: 1S:_=,(\##1P>9Y*C/KM#'_@5 'HA^('A]=&U#66N9!IME-Y#7(B)2
M5^.$QRW) STS[<U8N_&.EV?A2U\22"X.FW B;>L>3&LA #,,\ 9YQG\:HZS:
MP:;\)+VU2-6B@T9T"@ #B+&<=.O-3^ $63X<: CJ&1M/B!5AD$;10!HZKXET
MG1]!_MJZNU^Q%%:-T^8R[AE0@'WB>U4=9\:Z=H-G92WMM?F>[B,R6<,'F3*H
M +%@#@;=P!YKR+X>32:A\1+/0+B3S-.T&2]EM8F&<'?M&>W&<CTKJ-3LKY_V
MA=.0:O<JITSSU 1#L3>P,0XZ';U^]SUX% 'H'ASQ5H_BNR>ZTBZ\Y8VV2HRE
M7C;'1E/3^5;-<#.3I_QNM%MMJ1ZEI+?:5"CYVC<E6^N#CZ4:SJ7B?5?'-UX?
MT#4[738[*P6Y>2:W$K2R.2% S_#P,D<CWH ZW6]:L?#VDS:GJ4ICMHL D*6)
M).  !R220*H>&/%EIXJ2]:VLM0M3:2B)UO(/+))&>.3_ (_G7DOB;5-;\6?#
M"UU'4+XVMU9ZJ+.X@@C7RY9%< 2>N1GIG!]*];\0:;/<>"KVQDU6ZCE%J0]Z
M@"R':,DX4 #..V.M %;5_'>DZ/-I8D2ZGM]1NFM([F",-&DH8H58DC'S C@'
MH?2NHKYMCLM3/PJ\%R0:B\LMUK:BTADB4I;N))AD<9;+<G.?:NLUGXA>)/#>
MD>);*>[M[W4M/O;6VAO&@6-?WT98DJ#CC:<9]>: /9JY[QAXML_!FCKJE]:W
M=Q;F41'[,JL5)S@G)''&*P_!5]XXGUR=/$44']ERVPEMI#+ TI;*]/*."I!)
MSCTYK*^+,-UXBU/P[X2TR2(7MQ.]ZPFW",+&IQO(YP3N'U% '5^'?'>D^(]2
METN**]L]3AB\V2SO;<QR*O'/<=QW[UT]?/<%_P")-(NO'?B74+JW'B73$M[8
MN?GA2*1ONHH[_*F,^ISSFNOMO'M[<ZYX4TF34X89ELOMNNR$*JJ#&&5"2,*<
MD9QC&10!ZK6/HGB2RU^XU2"T697TV[:TF\U-N77J5]17DVC>-?%E]#K%[J.K
M2VITJ"Y&H6?V:)#;DJ?(:/(RQW @@GL.N:KZKXM\<:5H/A$V^K-+K>LQLSVQ
MM8BK!GS&YPO!VLH]./8T >\T5XE:_$S7M-\#76HWU];WEW<ZNUA9730[8TC"
MC,NU1RHY(')R?:K^C^)/&;:9XJU%I[NX2&%4TE+ZQ6W>:7:6<K&!DX ) YS^
M= 'KU%>%0^.O%1\$W^NVFM?;2T<3+')!$LMNZOBX 0#E0&C.XYP&&>0:](^'
ME[J>I>&C?ZC?M?1W,[26<TB(CF JNT.%  8-N!H M^(_&VA^&)X+6^N'>]N"
M!#9VZ&2:3)P,*/4C'-4= ^(5IKWB-]".C:QI]ZD)G*WUN(QM! [,3W%<_P##
M6UBUGQ1XK\2Z@BRZDFI/9Q%QGR(D  "^G&!^'UK7^(WB&/PI96^L65E'=ZZ[
M?V?9H23CS<,<J#EA^[7CKG'J: .YHKQZ_P#$_B_0=2DTS5M9AEE;1)K^X>WM
M4!L7 .W!Y#?, O([_C5[X:ZIXXUZP?7/$.I0PZ0T#B(>0J2$\8E^[C:.>O7T
MQ0!ZG17S\GC[QO;> W\53Z["T/VT6EI ]BA-QCJS$ 8& W3N.U:0\=^-V\/Z
M;XEEO+*)=2U!+>RTE+89F3<03N)W#IC\<\9% 'M]%>-Z-XB\;>(?B!JMCI.L
MQ'0-.O#YUS<6R ; W,88+R>& ]ADFH=4\>^*+S1];\3:;J45AH]O="TTR$V:
MR/>/NP3D_B>/0CL: /:2R@@$@$]!ZUFZ9KMKJNI:K8P)*)--F6&9G7"LQ0-\
MO/(YQVKR6Y.L:A\4;RYFU^XBB\/:2L]U+ BLB3>4 ZJK J"V6/(SP1]'67CG
MQ?%X2\.V*NESXE\0SLT,TL Q#;Y #E5 !XYR1PN2>E 'M=%>0R^+O$-DOC:P
MNM<6X_L6TBDBU&&UC0I.<'R]O(()^7\#T-9_@[QSXMN?%>C0^(=5@6QGL9K^
MYB,"1>3$JN%9VQP#M#?0@]#0![=17DG@_P 3^*O$'CZ>UNK\10V5S-]JT\PH
MJM;E6\IT8KN;#;<G/(*GN:]%\1Z_9^&=#N-4O6(CC&$11EI'/"JH'4DT %]X
MBT[3];T[1YY6-]?EO)B12QPH)+-Z#C&?_KUK"OG'0]>N+?XC77BC5[>].H0Z
M-->36]Q$80L@RH2,'GR]N "<]Z[SP]>_$'5O[!\17FH6T.F7DK27-@D*(L5O
MM)5MS98YQG@YP?R /4<@DC(R.HK)U/Q'8:7JEAIDADEO[Y]L-O"NY]O\3GT4
M=23Z<9K@O@U:ZC=IK?B6\U*>YCU*Z,<8E'WUC) ?/XE0!P,?EH?#R5M7\6^,
M]:NN;A=0^P1AA_JXHL@ >F<Y/N* .LUGQ)IVA7FEVE](ZS:G<"VMU5<Y<^OH
M,D#\12>)_$5MX4\/W&LWD%Q-;VY7>L 4L S!0<$CN17B?Q(UB/Q)?ZO?VD6I
MR2:1)%#IMQ!;.T */F9RXX!SW]$'K79>)/$R^)/@!>:RPQ)/;(DJQX.V3S51
MOH,\_0T =7'XXL7\6V7ATV5\D]];_:;>=D7RG39NZ[LY&".G4?C73UXQKEOJ
M5U\2O T.DWJ65VVD<7#Q"0(NQMWRG@G&163_ ,+1\8QR0^'G-O)JXU26TDNU
M6- ZIM&U2WR!B2>2.F/6@#WZH)KVV@NK>UEF5)[G<(8SU?:,MCZ"O']6U[XC
MZ+X4N;[4[J&RO8;Z.&!<02"1).,2;00"N 0>,[C[50@T#Q'I_P 9M(AUCQ1+
M<7LUM+<_:(U&U$ ;*!6&%!VD' [T >[5C:'XGTWQ!)>0VCNEU93-#<6TR[9(
MR&(!(]#C(/I^5>5Z+\2?$5YXPT:VFN-]E?:A/;R_Z.GV?:&P@BF'WSZGZ5UN
MN@V?QG\*30,4:^M+N"X Z2(B;U!^A- 'H%<[XF\8Z=X8T>[U*>.>[BLYD@N4
MM K-"S $;LD8^\O_ 'T*W9XVEMY8TE:)W0JLB@90D=1GN*^>)=+N=/\ A;\0
M8Y-5N;F*VU?[)Y<H4[V2:$>:6QNW$ #&<4 ?0]M.EU:PW$>=DJ!USUP1D5+7
MCFD>,/$?AV[U#3-4O8=12Q\-C4H<0+'M<!<+Q@L.>O'2G>$?$?Q&UN?1=2=;
M672+F;%VQEMP@0GHH4[PP'8Y.10![#6/H_B;3M=U'5K*R9VETNX%O.6& 6QG
MCVSD?53]:@\9>(E\+^%[O4POF7"@1VT6"3)*W"+@=>?Y&O&/"NL+X3^)&ER)
M;ZG#8ZO;QV]\]_ T1:Z8G+_-P?FP<^C&@#Z%K#UGQ9I>BZ1J>I2.]Q'ICK'<
MQVX#.C,5P,$@9^=3UKA?%+^,+[XA/X5TGQ,+6UO;(WFYH4WPC<5**5 8#@8.
M<\GFN.TR/6O#'@CQIJ&E^(;N)],U8P['BBD$Y#(A9BP8Y(8=#CB@#Z&1Q)&K
MC.& (S6/J7B:TTOQ'I&B3PW!N-4\SR)$0% 4&2&.<]/0&N)O/$7B;6?'M_X<
MT?6['2VLK*.6)9H!(]U(R!SUZ 9YQT'.#VBOKZYO/%GPSNM0>![P+?+<FW=7
M3S%B4/@KQU!X[=* /5:*\+T7QS\1O%,4^J:+'9/:17>'BDD@2..+LK;CO!]\
M_2K?A+QUXCO_ (AZ?I6M7ES:RRR7'VBQFMD2(H$;R_*;;N)R.YP=O4YQ0![3
M1244 %%%% !12T4 )12T4 )2T4E "T4"B@ HHHH ***#0 44E+0 4444 %%%
M% !1110 4444 %%%% !1110 E%%% !2BDI10 48HHH **** "C%%% "5S_B_
MPI#XOTVULI[E[=;>[CN@R*"6V9^7GU!/-=!0* ,J308I/%EOKYF<2PV;V@BP
M-I#.K9SZ_+^M:M+24 %&:** %HH%% '!^*?AW<^(_%]CX@B\13V,EDJB")(
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M7&I3VJSR01F9XG'E%RH)VD]1G./:@#A-3^$:-H_]F:'KMU8VQNQ=M%<*)T#
MDJ$'&T DGOGC/2K^N?#&WU7Q ^M6FM:AI=W<QB&^-F0HN$Q@_P"Z3@<\CCIG
MFNTDOK2!8S-=0QB7F,O(!O\ IGK3X;F"Y!,$T<H'4HP;'Y4 <3K7PX6\7P[%
MI&I?V9;Z$XDMXA;B7+9!W$DCG@^N2<U=\&^$M0\-7NLW-]K"ZBVIW N#MMA%
MM;G)X)ZC''M76U%)<P12)')-&CO]U68 M]!0!Q?CGP/JOBO5M*O;'Q!_9RZ<
MPEBC-N)!YH.0_4<]!@Y_4U>\1>"$UZ:QU&+4[C3]=LH_+BU&W4 D'[P9.A!R
M>.V:Z,7]FS.HNX"R-L<"095O0\\'VJ1KB%)EA::-96&50L Q^@H YZS\&VNF
M^#;[P]97=POVQ)A+=RX>5I) 0SGH">?TINI^#K:[^'<GA.)B(ELU@AD;J&4
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MY;\Z]#BM&;2DL[V7[2Q@$4TFW;YIVX8X'3//YU:IDLT4";YI$C7.,NP S^-
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MG<;YOWD6X@ A1ST)Y/'3UKLJ /-M<^#UCX@NK+4KK5[N'5XHXTN+NV4)YY0
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M **** #-&:** %HH%% !24M(: "EI*6@ HHHH **** "BBB@ I*6DH ****
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M#YTQ2(3X&2V,?PXY) Z5Z_J'A?0M5$_V[2+.9K@ 3.80'?&,98<GH._:H_\
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M49?+LYM:B29LX^4J_&>V>F>V<UZ+534=+T_5[;[-J5E;W<&<^7/&'7/K@]Z
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M#2T4 )2T8I,T +244N*  44E&: "BBB@ HHHH **** "BBB@ HHHH *!110
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MW=;)RKR* C8.,8W$'/?'TSZAX"N1=> M"8131&.RCA9)D*,&10C<'ME3CU%
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M$P;>BQGC:&!QN'0CVP:]Q?RP_!^X\*3Z'JT6HK<"9#+9OCF4MC..NT'GO^=
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M'9@PVD*2 1_$ 1VH ]Z\.^)M*\4V#7FE7'FHCF.1&4H\;#LRGD5Q5JNH^/\
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M9" .Q?!/7K["NRTKQ]INN^'M8U;38+EQIAE5X70!W9%W# !/![4 >9^%84\
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M*-%R3MC11A5SVR>@KJJ* $I110: "BDHH 6BDI: "BD-% !12T4 )2BDI10
M4E+24 %%%+0 @I:** $HI:* $HI:* $I:*2@!324"EH P_%NCWVO^&KO2K"_
M6QENE$;SF/?B,GY@!D<D9'X_B(?!&AZCX;\+VVDZE?17DEME(I(H]H$?\*GU
M(YY^E=%10 4444 %)2T4 )2T4E "T4"B@!**6B@!*4444 (P+*0&*DC 8=1[
M\UD>'O#EEX:L9;:S,DC33////,09)I&.2S$ #\@*V*2@ I:2B@!36/!X<LH/
M$UUX@+2RWT\*P R;=L,8_A3 !Y/)R2?PK8%% !1244 %%%% !1110 4M)10
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M-&:** #-&:** "BBB@ HHHH ,T444 %%%% !1110 49HHH ,T9HHH ,T444
M%&:** %HQ0** $HHHH **** "C-%% !1110 4444 %%%% !FEI*44 &*2EI*
M "C-%% "T444 )110* %Q1110 4444 %)FE-)0 4444 +1110 4444 %%%%
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M% "T4E% "T4E% "T4E% "T&DHH **** "BBB@ HHHH **6B@!**** "BBB@
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MU.D_:9+-[B666*382KA<* V>A'6@#/\ ^$&\21R2&#QSJ&TK\HE0L<CIU?\
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MN-$=5VH6VL=P&?09'7WKUBSC:*R@C<*K)&JD+T! [4 34444 +1244 %%%%
M!1110 4444 ***** "BBB@!,4N:*2@ HHHH **** "BB@4 &**6D- !1110
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MY/4\'BK-]I5GJ$UK-<0AIK602PR X9"#V/H<8([B@##UI%;Q_P"%V;JL=WM
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M*DD?W9(VEPKX_A. !C)YS7NM?/GB2POK'5-26XC:RAD6*2"SW[]D;2G8G&0
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M['\.1^M>O5XWX^W#QV &PC362MZ]7/3\*]DH **** "BBB@!:*,T4 %)2TE
M!2TE+0 4444 %%%% !1124 +1244 !HHHH 6@TE% !1110 44M)0 4444 %%
M%% !1110 4444 %%%+0 "BBDH **** "BEI* "BBEH 2BEHH 2BEHH ****
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MT56M-0M+]KA;6X25K>4PS!3RCCJ#5F@ HHJ"WO+6[+BVN89BAPWER!MI]\4
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MTE "BB@44 %(:6D- !1BBEH ,48HHH .E&:0T4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4N:2B@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!<T8I*6@ HHHH *,TAHH **** "B
MBB@ HHHH !2T@I: $HHHH ***!0 N**** "C%%% "44II* "EQ110 444&@
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M@ HHHH !2T"B@ HHHH **** "DI:2@ I:2EH **** $HHHH 6BBB@ I*6DH
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M)0 4444 %%%% !1110 4444 %%%% !1110 4444 % HHH 6BC-&: "DHS10
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MBEHH 2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **!2T )1110
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MM0!Z#17G@\5^//-/_%'KMP,#S._/?/TX_P :1O&/C:($R>"W8 X^1V/IZ9H
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M ,3>([R2,127;"X\O.<!G8G\LUZM0 4444 %%%% "TAHHH *6DHH 6DHI:
M4444 %(:6D- !2XI*6@ HS124 %%%% !1110 4444 +FDHHH **** "BBB@!
M<T9I** %S2444 %%%% !1110 4444 %%%% !1BBEH ,48HHH 2BE-)0 4444
M +FC-)10 N:2BB@ HHHH **** "BBB@ HHHH *7-)10 4444 %%%% !1110
M4444 %%%% !1110 4444 +FDHHH **** "BBB@ HHHH **** %S2444 %&:*
M* %S1FDHH 7-&:2B@ HHHH *:Q8,N -O\1)Z4ZB@ HHHH *7-)10 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 1I"B.SXR[<%B.<>F:DHHH **** "BBB@ HHI10 8I*6DH *7-)10 M% HH
M **** "DI:2@ HHHH **** "BBB@ HHHH **** "BBB@!:*** $HHHH ****
M "BBB@ HHHH 6BBB@!**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!:*2EH 2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %HHHH
M 2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *6DI: $HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %%% HH
M**** "BDS1F@!:2BB@ HHHH **** "BBB@ HHHH **** %HI*,T %%%% !2T
ME% "TE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4M)10 M)110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "BB@44
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M\7_^@J?_  (C_P */[#^+_\ T$__ "9C_P * /9Z*\8_L/XP?]!/_P F8_\
M"D_L/XP?]!3_ ,F8_P#"@#VBBO%_["^,'_05/_@3'_A1_87Q@_Z"I_\  F/_
M  H ]HHKQ?\ L+XP?]!4_P#@3'_A1_87Q@_Z"I_\"8_\* /:**\7_L+XP?\
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MZ'3/B_*,_;YTZ\-,@Z?A0![C17AHT[XOLFX7MP,+NP94]<>G7VJ4:-\8&/\
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M(V2=F@\HJLC&;C&.H(R.".* /<Z*** "BBB@ HHHH 6DHI: $HI:2@ HHHH
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MHI 7.  !UZ "NPHH **** "BBB@ HHHH **** "BBB@ HHHH **** #-%%%
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M]JVM(M]3^*>O-JFIAX/#%M*1#:;\>:P['U]S[X'?'K444<$2Q11K'&HPJ(,
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M\!:?976GWUE<6:^3(EW;M$2>N5!ZCGK[&NRHHH **** "BBB@ HHHH ****
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MBB@ HHHH **** "BBB@ HHH% !BBEI* "BBB@ HHHH **6B@!**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!11110 4AI:0T %%%% !1110 4444 %-4MSD8P>*=10 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M+24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% "T444 %(:6D- !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 44ASQ@#\:6@ HHHH **** "@444
M+2444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% "T444 %(:6D- !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 UD#8SG@YX-.HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BD.2#@X- ! Y.: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *!10* %HHHH *0TM(: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBC/- !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4449I#"BC-% @HHHI@%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1112&%%
M%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "BBBB@ I#2TAH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH #TJLB3_;)&:1?)V@*@'(/<FK-% T[ .E%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "E[4E%  :2EHQ28Q*
M6BBD 44450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *!11
M0 M%%% !24M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
M "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
M "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
M "44M% "48I:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:
M* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:
M* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:
M* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHJ*.42EQM(VL5.>_O4M !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C-M4G&:6J=CJ$
M&I1RF(,#%(8W5A@@@T 7!S12=!68^O6L>K-IKB03[U5=HR#D9_"@#4HHHH *
M#5:"V,-W<2AR8YMK;"3PPR"?QXJS0 Q8PN=O&3DT^L:YU34(M;M[)-.S!(W,
MV[.5[D>F/>MF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HI"<8]S2T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VHW2Z7'&\-O'NN
M+@(Q^Z,D'YB0/85HUAZWX?;6+VWD-V\<"+MDC'?W';- %ZZF<:<0\4,MPRA?
M)W95GZ8Y[9IFEZ6NGP.20UQ,V^5QZ^@]AVJQ!I]I:R^9!;QQOL";E7!VCM5F
M@!JN'4,IR#T(H ;?G=\N.F*4  8'2EH *@O+N&QMFGGD6-!@98\9/2IZH:OI
M,&L6?V><LI5MR.O530!F6^MSW6N6=I;R)<0[&:XEC3"9[8^G _&NBJM8646G
MV45K",(@QG'4]R?>K- !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !45Q<);(KN&(9U3Y1G!)P
M*EHH **** "BH5N$:Y> ,A91DC=S^7XC\ZFH **** "BBB@ HHHH BNKB.TM
M9;B7.R-2S8ZX%):W"W=K'<(KJLB[@'&#CZ5*RAE*L 01@@]Z4# P.E !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ";OF P>:6BB@ HHHH
M **** "BBB@ HHHH **** "@C(HI#TH Y_P[I/\ 9U[J/F2F>8.J^:>"05#=
M,GN?TKH:8D4:2/*J .^-S=SCI3Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH XJ*WFN?'LT1FE$4+^<5W'' ! _,BNCBU-+G6;G3/*.Z!
M^\-P<XX_6I+;2H;74[J^5W,ESC<#T&/2ITL[>.[DNDA59Y %=P.2!0!(D21L
M[*N"YRWN<8_D!3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEOJ-JZ7#,C[=I*,0ORG#?G6%^T)_R*FE?]?W_LC5Z9I'_(KV 9/-_P!"CR@
M^;Y!QR<<^] '$>!_B'KGC73M5NX-+T^ 62 (KSO\[GG!^7@8!_'%1^#?B+K_
M (QTG5K^WTG3X4L4^423O\[XSCA>F ?S%<=\%+'4+O0=>:SU>6Q177>B01R;
M_E/=@<?A4_P))_X1WQ8N3@)&0/\ @$E '0>&_B5XJ\4Z=-?6&B:0D44P@ N+
MXQF20C(5<CDGBK6L_$S5=,^'^E^*%T:W!N)GM[FVEE8-%(K.O''K&V<],BN
M^%NBZKJ6BVEU9RM-9VGB""6XL@J@$!1F3<>3MR./8GK76_&;5K+5_AT[V+[X
M[?6!;LP'!=5?=CU&3U^M %^]^*&KZ!I^B:MK>B6ITK5HT=9;2Y8O"&4-RK+R
M=IZ ]CS7IL<RW%LD\!#+(@=">,@C(KYKUY[^%/!5OXNGDG\*/9P2P?94",H\
MI00W4DKD9]03C&>/I.U,#6D)MBIMRBF(ITVXXQ[8H \KM/BAXCO=:U_2[?1=
M->?18YI)O](<"41.%;:=O7N,U<D^*ES=_#E_%VEZ7"5M9_(O+:>8YC8E0-K
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ML4BSEB!LVLQ.?3CGZ&@""T^)9UOP#>^(]%M(3<Z>"UY9W,A&P!23M8#GCD'
MZ'O2>!/B8?&]I>VR6MO::W "R6TDC;'7@;LXSP3@CK7FOP_LISX!^(.JJC16
M-Q9O'$N,!B%<G\@P'XUO^/O"M]8I8?$3PR#;WD<,<UY%&!W49?&.>N&]1SZT
M =&WQ1N+/P%IWB&_T^V6XU.X\FT@68A%&2-\C$< 8)X]O?&LGB?Q%8^)M$TC
M5=.T^2#4V?;?V4[;!M1GV[&&<\#G."*XZUMM#USX6^$=(UU3"NI2R);W,1"^
M1+ERN,]CTQ]*H^'K+Q/\-/B%I'AV6]_M'1]2<K$@Y"C'S,%)^0KG)QP1GKV
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MJ:P\(:%IOA^30H-/1M,D)+6\SM*I)Z_>)-;=% ',6GP]\,6=U;7"Z>TK6O\
MQ[K<7,LR0_[J.Q4=!T'&*Z>BB@"I8:79:6LZV5ND(N)GN)=O\4C'+,:QM6\!
M>&]<U![_ %+3VN+IL8E-Q*"F.FS#?+Z\8YYKI** .?O/!'AZ^N6NIK _:VVY
MNHYI$F^50H'F*P;& .,\]3S3AX,T!=%;1UL EB[F22-)74RL<Y+L#N?.><DU
MO44 8VA>%-%\-&?^Q[/[*LV-Z+*[*<9Y"DD \]1UK/N?ASX5NIYY7TO8+AMT
MT4,\D<<I_P!I%8*?RKJ:* ,C4O#&CZKH8T6YLU&FC&+>!FA48Y ^0CCVJYI^
MF6FEZ9#IMK&PM84\M$D=I/E]"6))_&K=% &'+X.\/3Z9::;-I4$ME9EC! X+
M*A;.< _4_3M2Z5X2T71;Y[VSM&^U,GE^=-,\S*G]U2[':/88K;HH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JE_=+:HC/
MT+8YJW3719%PZAAZ$9H R?[2+$!$5V;@!3FF1Z@7!3<N\GYE/45L+%&F-J*,
M>@JO>:?!>)AP58=&7@T 1+=DX 4<4JSD9./UJK]CO8&/29>@*\&C9=OD);LK
M>K'B@":>^$<$FU<G:<<]Z-&MVBM6E<8:4[N:+?2_G$ERV\C^$=*TL 8Q0 M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !@>E%%% !BBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU.Z,<;W-I%/)CA0S("<9[9- &E129&,Y&#WI#)& I+J QPISU/H* '44F0"
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M _;+EIMK+#RZ[LX+;AD#CY1Q6<DFLQ^$/B)"WB/57FTN]<P7)G_>;57(4G'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_BX'4DGGV&/6/B!;)<^ -=5_.PEE+(!#*R,2JD@9';(Y'0]ZS6^&&D-X;LM
M&H:JMA93FXA19U!#YR.=O0')'NQ]L==/9Q76GRV5R6EBEB,,A8X+J1@Y(QR1
MZ4 >(7-E%!\+OAW!!<W$4UYK5G+O,I<H2K E-V0H&1@8Q[5H7VL:KX)U#QW;
MV6I7MZEI8V]S;_;93,T4DA"E@3V&[..G%=>/A;HZZ9I^GKJ.L"#3[@75N#=[
MML@QM/*D +C@  <GUK0;P'I4VOZAJ]Q/>7#ZC%Y%U;RR PR1XP%V[>@[<]:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"<@X)B7:21[G K7\*>)%\4:5+>BRFLI(;F2VE@F(+(Z'!!Q0!N4444 %%%%
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MWMCIFKL3-8S,Y#/EA@KC&#V.,C'%==X:L?&6G>+X7OG=-$GMS$\-[J8NI/.
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M2W$UT#F$9Q&4"C<6R%SQA5[FN]H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D*
MAL9 .#D9'0TM% !2  =!BEHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2.=49MUN2HR@(P,@CZUT^B_#RYL_#WB'1M4UE;RWUJ:2X=X;;R7CDD^^1\S
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MV-^Q>\L+6;;'*2<MC^[GOCL2!@'% '7RW5PGAY[MGMH+D6ID+N^84?9G)/\
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M^SK+%&V X <#C@%0  <XJS'\.P?^$D2[UNYN(->!\^/RD3RVZ*RD>@X]\<T
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M"-RYZ'!(R/6IJ*  @$8(R*CM[>"TMTM[:&.&&,;4CC4*JCT '2I** "BBB@
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MQP>:JELVY"J64'CT/KR,9LWB+QPG@C7/$1\4+G1M5>W$*V48\\!T3YCV7YN
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M<^&+359D&^6R2Y=5Z9*!B!0!IUC:]XCM]#:SM_(EN[^^=H[2SA*AYBHRV"Q
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M=^W8H^4_+@'.,=>:]!T33]4L'U#^TM6.H+/=-+;9B">1&>D?'7'K0!K4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!7OK87NGW-J6VB>)H]V.FX$9_6O,9? ?C*7P9HVA-=
M:$[Z7>13Q-NE4%(L[03M.22>>!C'?/'JU% 'GNI^"=9UKQU?ZG>OIRZ3>:2^
ME,D<C^<J,=V\#;C=N]\8I/#7A/QMIRV&F:IXBM)-&T^16B-K&PN)U0Y2-R>
MO R!G(&,XKT.B@#)\2^'K+Q5H%UH^H!O(G ^9.&1@<AA[@BN?T_3/'^GVL>E
MC5=#FM8HQ%'?R02_: H& 3'G:3_P*NVHH X2_P# VHVVM:3K^AZF)M6L;<VL
MQU-F9;N,DD[F7D'))'!'3CBJ6H?#O4]0T+7@][9+K7B"6(WTVQC%#$GW4C'4
MXP!DXS[5Z110!Y5\2+>ZL/#/@FP:[MDOH=:LT6;!V JK /M)S@<$\UM/X&NO
M$EY>ZAXKFM?/GL&T^&+3BVR*-CN+[G&6?/3C ]ZZS4-#TC5W1M2TNRO6C!"&
MYMTD*@]<;@<5>1%C1410JJ,!0, "@#SZU\":S=6.DZ)KVHV5UHVD3QS6[0Q,
ML]P(P0BR9)50,X.,Y [5H:+X2U2PU[Q-J%UJ%LR:V%X@B96A*J54@EN?E)S[
MXZ5V5% 'E-M\,?$D>DZ'I[^(-/6+1+Y;JU"63'S"&+9D^<9//08ZGDUO6O@[
M6]-UKQ!>6&L6@M]68R^3-:EBLI3;DL&'RC).![<]:[BB@#SBW^&EY#X=T&W7
M5+>+6-!F+V5Y' =K(3EDD4MD@\]"/YU?/@S5+JYU;6;^^L6UR^L/[/B\J%A!
M;QG[V 3N8DDG.17<44 >;O\ #W6QH'A;3H=6L ^@W(N%=K9R)2I^0'Y^F"<_
MATKM?$6CKX@\.ZAI#3&$7D#0^:%W;,CKCO\ 2M.B@#SW_A7VJFUT"[;6[<ZY
MH9*6TXM<1-#M"^6Z[LG@'G(^\:W?#_AB73]<U/7]3N8;G5M0"1LT$1CCBC08
M"*"2><9))_E72T4 <MX@T'6]1U5I['4++[!+:?9YK"_@::)FW$[PH8 'G'X5
MS:_"FYTNRT*3P_K[66K:5"\!NG@#K<([ERK+GH"QQUX_ UZ;10!Y[JWPVO=5
MTBUDE\277_"16UTUW%J6SA'( **@/RIA5X![9YR15B?X?WFL>&-5T[Q!K\E_
M?:BD:&Y$ 1( C;D"Q@XX8DD]3GMQ7=44 >>6O@'Q"OB#2-;O/%4<UYI]N\ 4
M6 \LJ1C& P/3.3G/ QBK/A_X<)I7@G4O"VH:BM]97K.P=+<PNA;K_&P." 1T
MZ=Z[JB@#A/#7@76]*O+3^U_%ESJ=AIYS9VGDB,#"E5+MR6P#P,]<51^--S%%
MX5TZ(WD5M.^J0-&SD97!.6P3R!P37I-5[JPL[T*+NT@N OW?-C#X^F: .4/@
MEM;U"YU/Q%?P7SSV#6$*6D)BBCB?EF&68ECZYX]ZHZ#\/=:TM[6WO?&-S?:9
M8.'L[1K8( R_<WMG<RJ3]W..!TZ5Z  %    '  I: .4\+^%=4\-:9JEL-:M
M[F:\N)+I)C8E!'*_+$KYAW#I@9&/4UD6WPP)\"3^%=1UA;F'SC<6MS%:^5)!
M(6+9^^0W)/IP3^'H5% '(6OA'49M8M=9UK5X+W4+"W>"Q:.T,<<;,,&5UWDL
MQ&. 5 Y^M4]*\ :AI?@75/# UZ&5+X2*MP; @QB3/F?+YGS9!..1CWKNZ* /
M/Y?AS?36?A*!M>B)\..'C<V)_?;2NT$>9QA5 [YZTS5?AE<:Q>>*)KK75$>O
M)$K)'9E3#Y1'E\^9\P &",#/M7H=% 'GJ_#S6QK=IK+>+S)?V]FUD2^G+Y;1
MGH-H<8]3SD^HJNGPKNXO 5KX5C\0Q"*WO/M7GFP)+ '<%QYG][)SGI@>Y]*H
MH X"\^'%\?$EYK&C^*;G2&U%%&H0V]NK+,P&"RY/R$\G/)!)YI;_ .&;1ZI:
MZEX9U^YT.ZBM4M)66%9Q-&@ 7<&(YP!R<]!7?44 4-%TL:/I4-E]IGNG3+23
MSMEY78EF8_4D\=JY3_A7EQ:)K5EI.N&RTG6)'DN+4VHD:-G&'\M]P"Y&!RK=
M.*[JB@#B-8\ W%W-X?72=6@TZTT,J]K UEYN7 QECO7(([8ZY.:Z;6](BU[0
M+S2;J1UCNX6B=X^",CJ/\*T:* /-K;X7:E%=:'>3>,+F6YT=3%;D64:HL6T*
M%"\]AR223[=:F/PQG?P?JWAV37MT6J7OVR>868!!+!F51OXR57'I@]<\>AT4
M 4K>P/\ 8L>GZA*MX?($,[E-@F^7#':#QGTKCK7X:-#IUIH<^N2W'AVUN1<1
M6+0 2'#%@C2Y^9 3G&T'WKOJ* .0N_!5TGBG4=>T;6O[/N-2A2&Z5[83?=&
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M],*Y9$&%15Z*!@5/-X&N)]2\-7LFN2%M!CV1K]G7][D;6+'/!*@#VQFNQHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M36[X*U74M;\(V.H:O!'#>3!BXC!"L Q"L >0" #^-;KHLB%'4,K#!5AD&G4
M<%%X?\0VOQ0U3Q-':6#VEQ8?98D-TRN2N"K-\G<J ?0'OC%95C8VWA7X97WA
M[QO<Z;;I,+AHECN<M,&)<[%8 E@S#&,]J]'U+4['2+)[S4;N&UMTZR2L%&?3
MW/M69'#X8\9Q6>J)'8:LEJY,$V!)Y3'!(]CPIP?:@#F-$T*30/@K?0W1D:]N
M-,GN+EI"2Y=HC@'//RJ%7_@-9N@:'KWBOP'X4TW4(=/@TB 6US)-',TCW$2#
M*1^7M 4D;0QW'H?I7INHZ;9ZM8R65_;I<6TN \3]&P<\UGZ/)X>TNX;PYI$M
MG#/ IE:QA<;HP2,DKVY8?G0!R*>#O$6B6OB+1]&-A<:5K+R21/=3LDEHTJ[7
MX"G>.X&1T]Z6]\!:OI=QX0F\,3V+-H4,L#?;]X5Q(H#/A>I^\<9'45Z/10!Y
M@/"/BDP>.HS;:9_Q/\_9R+M_DR"GS?N_[IS]1COD5H? GB_2DT'6-&NM/AUJ
MQL%TZZMYY'DAN(E/RG=@$'IQCC P>.?6*SM4U[2-$"'5-2M;/S#A!/*%+?0'
MK0!PNO>"/%6K6&DZJ-7M/^$ITZ[>YC;:1;JK  Q+P3M^4=>N6]>(M>\%^-/$
M6@,^HZK82:D;R&X%@N\68CCW?NSU)R6R2>N .PKT#3=<TG6-W]F:E:7A50S"
M"97*@D@$X/'0_E6A0!Y=#X"\4W.KZ_-J5YHZVVN:>+:<6T<@,++&418P3]T'
M!)/4<8%0CX?>+5T#098-2TVUU_028K-H@YB> J%*R$@Y8X[#'./<>KT4 >;Z
MRWC/0?"-YJ]YKVGKK<CQJD(1C;JBYQ'$F"6D8GKC)X'0"N^TV:YN-+M)KR#R
M+J2%&FB_N.0"1^!JT0#U%-=%D1D=0R,,,I&01Z4 >*^%K#Q!JZ>/=,TMM+6Q
MO]8N[>::=V\V'=D,P51A@5/&2.176CP-J%EXK\-W6G_8!H^C61L_+E=Q+(K#
M#MPN,]^O)SZUU.C>&=$\/-,VD:;;V9GQYAB7&[&<9_,UK4 >8:/X%\8Z TV@
MZ9X@M8O#$DCNDGEG[7 C')1#C ;G[V>.H Z5-+X)\4:5J>OIX<U#2TTK6B\L
MD5ZCEX)&7#%-O!SGO[<<<]W%K.G3:S/I$=W&VH01B66W!^94/0G\Q^=7J /"
M?$?A^^T_3O!?A"ZU?2(KRS6XN?-N&DAA(& @$@(?<-S=,9QST&=/2=(NO$_A
M_5_!,RZ/%'#%'<P:EHTKRQK/OSB1F)+2'&3SG!^E>J:IHNEZW L&JZ?;7L2G
M*K/$'VGU&>E36.GV6F6JVMA:06ENI)$4$811^ XH YCPUI'C$7\5UXIUFUF6
MV1DAM[!6192>/,ESC<<9P,8!.>M3^-_"<GBBQLI+.Y6VU/3;I+NRED!*>8IS
MAP.<'';D?H>IHH X-O"6NWNKZCXAU!]*_MA]-_LZSBB,AAC4L69F8C<2=QZ#
MIQWK8\!Z'J/AOPA9Z-J3VKS6FY$>V9BK(3D$[@,'DC\/PKI** .1\3^%+V_\
M1:3XET6XMX=6T\-$4N<^5/$V<JQ&2",D@@=ZS+KX?7FK:1XF?4[RW&LZXB1E
MX%;R8$CQL09Y(R.3W[ 5Z#10!YS+X3\87>J>%+R\N=%<Z,[-((_-7<& 0A>#
MGY1G)QR>F!52;X:ZOJEQXG_M&[L88]4N4O+.6V9VDMIXR0A.0 1M//Z5ZC6;
MK.OZ5X?MXY]5O8[6.6011E\DNQZ  <F@#CAX6\<:AI-]#KFO6-Q.;*6UMHH%
M:.)S(NUI)L#E@"< # K=\#:#J'A_P=:Z)JS6<SVP:-6M]Q5HSR,[@.>3[5TU
M% 'F4'P@LX/!6K:&+H&ZNY_-M[L@Y@56+1+UZ#+9Q_>-:/BCP!<:IX2T30-)
MNK>UATR:*7=,C-O,:D#H>Y))KO** //O$?A#Q+KQU.UFNM'N-.U%$ 2[BD=K
M%Q&J,\/X@L!QS@^N8)?A[KVC:K'?^$/$"6CS6L-M?+>QF42^4H59!U^; Z<=
M^>:](HH H:-ISZ5I4-I+=RW<RY:6XE/S2.Q+,<=ADG ' '%<*_P^\1:;KNJ/
MX;\2+I^DZM*9KF%XO,DB=OO&,GH3D\Y!''7 KTFLN3Q'I,7B*'0'O%&J31F5
M+?8Q)4 DG.,#@'J: .;TWP;JFE>.QK5M>69T];%-/$#J[2^2F""7)Y;(Z]/Y
MUG#X?^)=+UO41X>\3)9:)J<[3W$#P[Y(6;[WE$Y&3SSQCCKBO2:* /,;_P"&
M>LRWNO06>N6\>E:O D<GGPF6X78FU5#$XV]R>OMWJ>#P!K]J_A6ZM]:LTOM'
MMFLIG-N2C0D #:,_> '4G!//'0^CT4 >:P?#SQ%I%[?67A_Q)'8>';Z5Y7M_
M(W2P;N&$3'IQG!SQ@<&O0)+%&TIM/665$,!@$@<EP-NW.X\Y]SWJU10!Y+%\
M+_% TK1;-O$EC%_8MT)K,169P<$G>^3\S=/;KR<UZ-X@T^_U/P]=V.FZ@UA>
MRQ[8KI1RAR#GCUY'XUJ44 ><P_#F]U77+_4_$D^GA[G3GT]AID31F4-_RT?<
M3\WTXX'IBI_#O@CQ%8K;:?K7B;[=HUDNVWMH81$T@ VJ)6')4 GY<]<<\5U&
ML^)]&\/R6<>J7JV[7D@BMP49M[$@8^4''4<GBM>@#S32?AKK6E+)HD?B>3_A
M%6F9_L:Q[9PA.?+$G4 GKCJ,],U:OO NNCQ#KMSHVN066GZW&OVI'@\R57"E
M?D).!D'KVSTZ&O0:* /,=.^'GB32Y/"S1:UIDRZ LPB\RT=2PE&UU.'YP.AX
M]ZVKGPEJTWQ0M_%:7MD+:&U%GY#1/O,>22<YQNRQP>F,<5VE% ' :=9CX;-K
MVK:SKD"Z#>7TEVL8MF+I+*R]2,DX  P!W)-)\,]&M(Y_$'B.UMY(H-7OFDM/
M,3:3 .0P! *AF+''IM]*[V6&*XB:*:-)(VZHZ@@_@:< %    '  [4 9OB&P
MNM4\/7^GV4L,4]U"T(>92RJ&&#P"#T)Q[UPEQ\.M?FT;PI8?VIIH.@3I.K&!
M_P!Z48%0?FZ8&#7H][>0:?8SWMU)Y=O;QM+*^"=JJ,DX')X%1:7J=IK6EVVI
M6,AEM;E!)&Y4KD'V/(H XVX\"ZI>^(_$]]<:A9BSUNQ:S\M(FWQ@+M0YSC/.
M3Z^U4I/AOKDNAZ)CQ%'#KFB?)8745OB-(=BIL92?FR%R2?4C&*]+HH \WUKP
M!XDUSPQ=V-]XB@N=0O9XGGFD@*QQQQG*I&BG ^;DGOFM+Q1X+U+7TTC5+758
M]/\ $NF_=NX8SY3 _?7:2?EZ]<]P>M=!I/B;1]<O]0L=-O!/<Z>P2Z01LOEL
M<X&2 #]T],]*UJ .$/A/Q8D%O=IXH276/M2S7+2Q,+:6)491%Y:D?+\Q)[D\
M]AC,NOA0]]X8UNSEO;:'4=5NTNR;: I;PLAX"IG/()R<]3[5Z=0#D9'2@"II
MD5[!IT,>I74=U> 'S9HX_+5CG/"Y. .GX5Q(\&>)!=>+9QJ6F9U^,(!Y#_NL
M+L'\7/R$_C@].*]!HH \V?P#X@_L[PE:QZEIH/A]Q)DPO^]93@=^!MQGWS78
M^*M$/B/POJ.CK/Y#7<)C63&=IZC(].*V** /-;/P!XECUKPWJMSK]BTFC1-
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M3(]*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]OE0=JMO(;ZD=>V*E?P1X@\2:%=V7C'7(I'DM_(BCT]2L2G<K"5P<;WRH[
M9QUXYC5+/Q+IGB+P%!XFU?3KDQ:CY<*VT94L H =V;&3VP !SU- &^OC3Q$-
M$\9RR?V9]L\/S,(W6WD\N9%4M@KYF02!USQZ&JS?$36-1CTJQLH?L]_-I<6H
M7<T6FS7BQL_W8Q'&=RYY.XD\$8Y-6-3\ ^(GO?%4.F:IIT>F:^A>07$3M*DA
M4KM&. I_O<D>E0#X<>(M(_L/4M UFQAUFQLEL;H2Q,MO=1J3MW 9)(! SWP#
MQC% %>?XC>,(K/PV)-!M;2^U*_:REAO(Y8MQ!7#H#RJG=W!Q@]:+[Q1XL&E^
M-=&O;JRAU32+;[5'=V\!*/"R%MH!;AAT!.<>A/-7=7\">*;^Z\/77]K6=Y<Z
M??&_N);IG4%R5_=QH <( O R/UJS+X'UR_\ $WBN[O+G3X]/URR-FGDEVEC
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M2.+ )V2;E'S?*>1QR.* /0R<#)Z5C)XM\.27$L":]IAEB&9%%VF5'?/-<?\
M%O4)Y/\ A'?"\,KP)KM^L,\J'D1*R@K^)=?R-=+KG@?0]:\+RZ";&W@@\K9
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MN[8X['V/^!YQ5*&Z^(-]:MIT^DZ;ITQ7RVU5;SS5]"Z0A<YQR Q ]?2NVHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #$+%FR"!GC-/
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI>:BDEQ#)<W+B!+<'".Q"[B7(.% Z<DT >HT5Y8/B[=S>&;#5[7P\)C+J?\
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M;S)&V)@\<..3@$\?3W&B@#SZ6TU+7O'&D^)I-$O+*VT6TG/ES;/.N99$(V*
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M#P\=EQI[7,2,XPJDJ^XK_!GKT->M=*K_ &ZS\E9OM4'E,^Q7\P;2W3 /K[4
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M0=1F\67'BC7([6"\-HMC;VUM*9%BB#;F+.57<Q8^G  ZUU=% !1110 4444
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MLP*X^7G!S@U6@\*:MX<\6>!8;;2+F^M-'M)([JYA*[/,E#;BNYAP&)//8\4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 R:)9X)(7+!)%*MM8J<$8X(Y!]Q4&
MG:;9:18QV6GVT=O;1YVQH,#DY)]R3R3WJU10 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4E+10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%!.*;NH =10#D44 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(6"C)( ]Z6@ H
MHHH **** "BBB@ HHIHEC:1HPZF10"R@\@'ID4 .HHHH **** "BBB@ HJ.*
M>&<,894D"L48HP.&'4''>I* "BBB@ HHHH **** "BBB@ HHJ..>&9I%BE1V
MC;:X5@2I]#Z&@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBHA<P-<FV$\9G"[S$'&X+TSCKB@"6BHIKF"VV>?-'%O;:N]PNX^@SU-*
ML\+3M LJ&5 "T88;E!Z$B@"2BHKBY@M(3-<S1PQ @%Y&"J"3@<GWJ6@ HHHH
M ***KPWUI<7$UO!=02SP8\V-) S1YSC<!R.AZ^E %BBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $/2N%\=Z9J;6-_JR>*+G2K>SMR\$=N=BEP"?G)^]DX&/>NZ; '-<-XNUOPE
M>RW?A[6L27*1;E@,#,Q++D%"!R>1]* .@\(W-_>>$M+N=4Q]NEMU>8@8R2*V
MJ\_\+WK>"/AWHL6M+=,[R+!&FS=(@=_D#8] 1FN_!R ?6@!:*** "BBB@!L@
M9HV"-M<@A6QG!]<5Y!XNTS5?#,'A.#_A)]:GNK[5(K:]F^VR*)%8_,%4'"CT
MKV&O*OB]J-K%JOA*W9V\VWU6&[F58V;9"&P6.!TX/OQ0 SX@:1J7AKPMJFH1
M>)=6-H+BU>!'NW+QY?9(I?.2A# @=B*[72/''A_6M7.E6-Z[W?E>:BR0N@EC
M_O(6 ##W%<]\7M0M'^'1"L9?MDUNT"HA;S%#JY. .FT$\UD^([ZRU/XH: FG
MW)A,^D3P1SI$V(FF0^5SCCKD#^6: .Q/Q#\/+J-O:O<3QQW,IA@O)+=UMI9
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MXQT&0>XKS?2+J^L_ &BVIL=3ABCUF4WLT-BQN;=#N96BRN1D$@L.0,CO6_\
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MMS$C:<GIU/IR,XMA;>(%M?"5K?\ AO66TBWTXQ2Q6@5)I)MWW)"&!6(X4X)
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M#*C,2&FD(SQG/<GIQ75: M^OQ9\17;Z5>Q6]S:Q0PW$D#)"[Q##8;T)Z'N*
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MBQXSD_L34;MIX;#=':HCM$WDC"M\V.YY!(XH U;OXN:9%;Z%-9Z7J%^-91C
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M)J\/V.^FF0O+$QR!L'*[L!N>P%=G%J]G'X^\3)I_AJ8^((+%9&FDG"K=J,!
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MJEII\EOJ%C+?(7LVO;<Q)<@<_(<]<8.#@\B@#J:*SM=URQ\.Z1-J>HR%+>+
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M)9=P R.",^NAX)^(5G:Z-X2T6XTO4H8[NVBM8;Z2$+#),J@;0<Y(SQG'Z<T
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M!6T' GL;Q+F[BB4_Z!$H!=)#P$^[MP<9QQ7KH50Q8 9/4XH5%4DJH!/)P.M
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M\O[9/"3:D;L^8\F>@!Z#.<<'FO>J* .>\=:;<ZOX%UJPLT,ES-:N(T'5VQD
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M\4V<T=W:7\>I&0:9:6A2$1[Q^_F< [F..I;'3 YS7H.@ZS8S_%R6^61UMI-
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M$CL>A[&L[5OB-I&D>(+C0FL]5N=2AA$PAM;-I#*#CA,=>#G/3@\YXJ+P!!9
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M7UMJ>GV]_9RB6VN(UEB<?Q*1D&@"Q1110 4444 %%%% !1110 4444 %%%%
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MK7H-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HI&R5(4X..#C.*\W\(>.]5O?B#J_A373:L]ON^R3V\#1B78?FX+'G!!_
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MCJ0BGC0/*J0R2>4IZ%RBD)G_ &L5/JOBW0]%BMI+Z_"BY0R0K'&\K.@&2P5
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MTNRN)A$E_:JXD#JV2H7&X9QZ#@^AYT[_ ,>>&-$O'TW4=;C6]@A6212C,Q!
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M:6Y5,[08Q@9].* /$/$NH:;8^*_B/MM[>^@.FVP:SBD90SJ40EMIS\A.3C&
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MZ9H Y+XGS10?#'6_.D6/?;;%WL.6)&![FN#U&>RM_$7PL&F7%K"QLI$#1LH
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M\#0N9682-LPP#K@[?3'7&*](^'4.AIHMW-X=L[N'39[II$FNG<M<G:N9 'Y
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M(N67:=R'@\<?B?6DT7PO>VNI1ZIKNMRZQJ$,;16[FW2!(5;&[")U)P.3VXH
MZ:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JJ=3L%OQ8-?6PO",B
MW,J^81U^[G-3S&18)#"H:4*2@/0G'%>&>$Y?".I?#^.Y\2W2QZY::D]S.R,!
M>/.'.U1GYFR"HQ_+% 'K"7E];^*-3-[JNF#2(K5)([?(6:$C[SN2>%Z\].G3
M!SF6GC*#Q3X9U>YT#4;.SN;9Y(HI[J1610IP)6 .0IYQD5CZ-8V)^-7BJ!K6
M#;/IT#R1L@(?)&XD=\G&:X^TMM'?X ZU&D-B;U'GD955/,7;.0I/?@$ 'T-
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M_3MR0HJ<-'\N<>K%L>Y.*S=&N]'@O/B1IMY):)<SW5PT<$NW+HL1.<'L,9H
M] L=>LM)\(V-_K7B&SN5:,*VH95$N&]5 Z_0>E<YXN\63?:?"]]X?\0VYTN[
MU:.RNO(6.17!Y.7.<8 Z#'7K7*64-K?^"/ "6NO1Z;KD,<[Z>TH#P.Z@;TD[
M X(Q]3QS67>7MGJ/AO0(M1TVSMF/BXI?1))F"=L_O'7)/R'=CC(H ]STG7](
MUY9FTG4K6]6%MLA@D#[3VSBL_P :^*8?!WABXU:2+SI01'!"#CS9&^ZO\S]
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MX@:3:W<#7YAL9;(I(-PFB1\[3[$A3CINH ZGXI>++SPUX;:+2-W]K7*.T3*
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M%8HP20B  8&3DYR3W-:5% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@2#V;^\/8_@16QI%IJJ6$MIKL]E?#&Q9(8"GF)C!WH21D^W% 'EFJ>(]*O\
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M44 %%%% !1110 4444 %%%% !1110 4444 (1D8I:** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ I.<GI2T4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%(:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:Q(^Z,TZ@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJO=7L-HN92<G[J@
M9+?2@"Q160UY>SR8BB$:8S\QR32^??Q*79 ZCJ" #0!K453MM0BF.Q@8Y/0U
M;S0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 1SS+!"\K?=09-9=E;FX)
MO;A TDAW(#T1?2KFIJ6TZ< 9.W./QI;;:UO&X8$$ CZ4 *L48/"@$C'%."1X
M*A1^-*0HSGD=<4HYZ'\Z *\]A'-@CY77D$4VP>1A(99"74[=IXP*NC.<UDPV
M\-]=7/FC*@XX- &Q2TU5"J%'0#'-.H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M727.A67A../7EU744@T^.26]2:Y>878V,.0S8#;B", >F.F #L:*\3L=?O\
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MUNI0WE!U); 5BHR4!X->@T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHJ$W$/G+$)D\PG[N>: )J*!10 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (1D8J)+:%)-ZQ('_O!>:FHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>articles008.jpg
<TEXT>
begin 644 articles008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHQ
M0 "BDHS0 M%)FC- "TAHS10 4444  I:2C- !1110 M!HHH 2BEQ24 %+24M
M !1129H 6BBB@ HHHH *2EHH 2EHHH **** $HHHH 6@T44 )2T8HH ****
M"BBDS0 4444 +1110 4E&:* "EI*,T +129HS0 44N*,4 )2BC%% !1129H
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M44 )1110 N*,444 &*,444 &*,444 &*,444 &**** "BBB@ HHHH *,444
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M&20I"\I/^C2YQM/HI/Y'ZFO1O"5G:P_%SQVT5M"A066TJ@&W=$2V/3)Y/J:
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M2DMSA@0$[[>.#W..W7T+4/B9:Z5X>CUN^\.^(+>U>9H6$MJB/&1C!92XP#G
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M+6XN;[6$0V5@F!(Q;&-V?NC) S[\ T>'/B';ZQXDNO#FI:=+I.M6_/V:659
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MA<K#*C3-'\IX)&5.2K8!'O5:W^+_ (BU7PY<ZWI?A)'M+%C]LD>ZR%& ?E&
M3@')XXH ]5U1;Q].F6P*BZ(Q&6Z#G_"K<881('.6"C)]ZY+PU\0])U_P7/XC
ME/V2*T#"\C8[C$RC.!C[P.1CCG..M<G'\6-=NO#=[XJM?#]F="M+D0,DETPN
M&R0-W"E1]Y<_7OUH ];HKCKCQT+GX>MXMT*S2]CC0R2V\LOELBK]\9P?F7T[
MCIVSQ-K\<=0U/1[F;3?"TL]]"XWQQN\B1QG'SL0HZDX ^IH ]GHKS36?BNVB
MZ-H)N=*\K5]6B#FWGD,<=N"P7<YP3M/)QC. :AMOBAJ6G?$"/PKXFTRRMVE9
M46YM9RR L,J?F'0Y [$4 >F7-S!96LMU<RI#!$A>21SA54<DDUF>)/$ECX7\
M.W&M7@DDMH@I"P@%G+$  =NI%>+_ !V\2ZZNIQ^'VC^RZ4R"52D@)NO=L= #
MQM/<9YXQUGB/Q/K^F?#I[S7?"^FM:^9%!):RW7F"6(J/FX& =WY?AD@'<^%/
M%%EXOT&+5K!)4B=F0I* &5@>0<<?EZUMUYWX,\::;'\+)=?DTV'3+&Q,BBVM
MCD<$8 SCEBP'/4FL)?BKXI?PU)XN&@Z=_8"7'DF+[0WVC[V-V?NXR0.F<^U
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M 8 T\8 _ZZ/7L?@CP:/!6FRZ?#J<]W:L_F)'+&B[&/4Y R<\=35+Q]\-M/\
M'@M99KF2SO+8%4GC0-N4G.U@<9QVYXR: /,/C/\ \CWX9_Z](?\ T::=\?;B
MX@\8Z&\B%[2*V\Q%)X9_,.\?D$KL-7^"=AK,UO<W/B'5I+R- DD\K*Y?'3']
MW'3 _GDGJO$7@73O%?AZVTO699KB:W4;+U0J2AL8+<#'..1C'Y4 1W/ASPKX
M@U/2_&%Q'&\R)&]O.9=J-W0D9P2">*\<^(S,GQZLV4E6$]F00<$<K7I?AKX0
MZ5X?O8+B?4K[44MG$D%O<,/)C<=&V#@D=CVJ?Q?\*]-\6:_#K1U"[L;V-54O
M;[>=IRK<C(8>OL* .;_:%_Y%C2?^OT_^@&N+\;?\D7\$?[TG]:]GUCX=:/K/
M@^'P[/)=>5 _FQW)DW2^:<Y=B?O$[FR.G/;C'/2?!'1KK2+2POM:UFX%J2(6
M,RA8U.2552I !.">_ YQQ0!1OH5G_9H1&) &GQ/QZK(K#^55?@)INGWO@_5O
MM5I%<&2]".LT092JHI4<CGDFNUF^'=I/X(3PF^L:F=/1P=P,7F% <B,G9]T'
M!Z9XZXXJ?P7X#L_ Z7$.G:C?SV\YW-!<,A4/P-PPH(.!CK0!X]\4+B2R^-6G
MRF\:PBA6V\NX\L.($SRRJ>" <G\*[J+P%:V'CG2O%&J>+Y+O4;B95@S;HGVD
M[, #9QC;W QBNF\:_#[1O'$$/V_S8;J $17,! 8 ]CD8(SV_+&:J>#?AAHW@
M^Y^V1S7%]>A2D<UR0?)!Z[ !\N1P3U_.@#MZ^7/"4+> /C-;6FJ'R8H9W@,L
M@P"CJ51_H<J<^F:^HZYSQ5X'T+QE!&FK6I:6/_5W$1VR*/3=W'L<B@#HZQ-0
MU6QOM-UVTM;A99[*!X[A5!_=L8R0,]"<>G2N=M_AI/!&+4^-/$K6"@*L N@I
M"C'R[P,X[8&.*Z"+PEI=IX9FT'3UEL;69"KR6[XE)/5BQR2Q]30!X;\&F T;
MQLN$W'3<@G[WW9.GMSS^%:'[/LB1W'B/SF @$$32!ONX!?)/X9KT#3/A%H6C
M)=IIU_J]NMW"8)PEPOSH>H^Y^HYJUX;^&&A^%;N>;3I[XQW,)AGMYI5:.53Z
MC:#QSW[T >3Z>;6_T/QJW@^V32]$BMG-Q/.QEGN!AML:@\(A^;U/OGIT/[.O
M_'AX@_ZZP?R>NBT[X'^$K"XFDD-]=QR*5$,\PV+GN-H!)';.?6M+PQ\+-$\)
MF^?3[O43-=PM 9GF7=&I_N84 '@<D$T >8_ -5/CC6&*@L+-L''3]XM2_ )P
M/&&N)@Y:WSG''$E>A:3\(= T.[DNM-O]8MII(GA=X[H E6&#_#^(]" >U6/#
M7PLT'PIK2:KID^H"X560B2<%74]0PV\CH?J!0!YCX'TV^\ _$O68;*RFU^&W
MMF@D;3L,8][!D#[L -\F".W/7%=/\+_A[K'AQ-8UC5$-O>WD#Q06J.&903NR
M2.,Y  Q7G6@>%=1\3ZOK5SX?U^+2K873YCN[IH9F&<C<JY_O$9]<UUGP]7Q5
MH7Q0AT&YUW^U;%H))+H0737$48PVTG/W&W!??D>M '*_":TAU>^U70KC7[K2
MOML(7RH"@^T@!@RDL#V)X'OZ5[5\.O#FB>%TU?3=&U2YOC'<*+GS<;8Y-OW0
M0 "<$9QG'&:IZ_\ !GPOK^M/JCF\M)I7WS):R*J2,3DM@J<$]\8KL=!T'3O#
M6DQ:9I=N(;:/G'4L3U9CW)]: +.H7]MI>GW%]=RK%;V\9DD=C@ "O*O#FD^.
MM0TC4]32W\/O#XC+7#K?RS&58G7"(=JXVA>@]Z] \5>$[+Q?8QV6H75]%;*=
MS16TVQ9.F-XP<XQQ5CP_H$/AS3!86]Y?7,*X"?:Y_,,:@8"J>RC' H ^>O E
M[=_#3XIOH^K,JI*PL[DHQV?-@I(,@<<@YXX8UV/[1/\ R"M"_P"N\O\ Z"M=
M+J/P8\.:M?R7U_>ZQ<W,A!:66Z#,<<#DKV'%7]9^%VB:_9Z?:ZC>ZM-'81F.
M(O=[B<G.6R#D]!GT ':@#SSQU_R;WX6_ZZ6__HJ2@/$O[+0$H&6<A,C/S?:C
M_3->E-\-M#E\,6WAVZDOKK3K:Y%Q&DUP21@$;,@ A.3P,=:SO^%/^'?DMVNM
M6?2DD\U=+:\8VP?UQU_6@#R&_L+Z+]G[3)F1Q ^KM,>>-A5E!/MN!_/WKH=(
M\->'_%'PUL=0UCQ=?QV>FQ$26Q:/%LPX("[<\\8ZDY%>WW>C:=?:,^D7%G"V
MGO'Y1@V@*%[  =,<8QTQ7&Z7\&?!^E:K'J$=M<3M$V](KB7?&I[<8YQ[DT >
M?_'..&'P_P"#(K9I6@2WE6-I1ARH2'!8>N.M>P^!U5? /AT*H _LVW/ [F-2
M:J>)/AYH7BR_2[U@7<[(FV.,7++''ZE5' )XSZX%;6BZ-:Z#I<6G6;W#6\0Q
M&)YFE*CH%!8G  & .@H ^?\ 1OE_:3ESQ_Q,KD\_[CUU'Q,US0G\;Z-9V>FV
M=SKLAA$>ISR-Y5L&?Y#M! ?&=WS<#CKFNVU[X7^&O$6O#6;R&X2[( D\B8H)
M<#'S8YZ<<$<4FO\ PL\*>(KRWNKNR>)X$6("VD\M61>BD#C ''&#CO0!XY91
MFT_:$MHYM4.HNEX@>\<J#(WE#/3@8/&!TQBOI:N$G^$'@R;5;>^&FF+R H^S
MQOB)]HP-R]^G///?.37=@ # & * /F;XNZ'=^&_B*-<1&:UO)$N8I",@2+C<
MI_$9^A%?1VEZG::SI=MJ-C,LMM<1AT=3V/;ZCH1VHU/2K#6;)[+4K2&ZMGY,
M<JAAGU]C[UQT'PDT"S9A87VM64#GYK>VU!T0^H]><#O0!TEQK%G>:A>:#9W2
MG5%M&E8*-PAS\J[CT!R<@'G ->-_ *"2R\3>(;2X7RYX851T;J"KD'\C7M&A
M^'M+\.69MM+M%A5CF1\EGD/JS'EC]:QM;^'.@ZYJDFIL+NROI4,<T]C.83,I
M&"'QP<CKZT >4? JSN9?'6LWT8/V2*!XY&'0LT@*C_QUC^%1?#F"%OCUJGR+
MB&:]:,#HIWD<?@37N6C^&=*T#13I.E6QM+9@0QC<AR2,%B_7=[YXXQTKG]-^
M$_A72=5AU.S@O([N&02+)]KDR3G///(/<=Z '_%K_DEVN?\ 7./_ -&)7 ?#
M>XC/P+\4).(S%$+D84'=S"#S^)KN_B]<0P_#'5TEE1&E6-8U9@"Y\Q3@>IP#
M7G'PB\(Z)XM\(:A!J#SI*MWB5+:Z:,RQ@*RAUS@C.<''KWH PO">GWUS\%?&
M<D"N8S- 0!GGRR&D_P#'2*W] NH$_9JUG(R4F>-@!_$SIC_T):]PTK2+#1-+
MATW3K9(+2%=J1J./<GU)ZDGK7)S?"3PE-<RN+6YBMII/,ELH;ETMW;.<E ?T
M& ,\4 </X"MKBW_9]\2R3 A)TNY(<Y^[Y07_ -"5JM?L\11C1=:F"CS6N(U+
M>P4D#]37J&K^&=+UK1$T:Y@9-/3:!#;R-"NU1@+\I'RX[=*J^'_ _A_PK=2W
M&BV3VCRILD47$CJPR""59B,C'7W/K0!P'QA\0:79ZWH^F_V787.KMAX[N^!\
MNU1FP"0#\W()YR!CH:\W\3*EM\6[$/K9U9DN+4S7KR*07RN[&WA0#GCL*^@O
M$W@#P[XNNH;K5[-I9X4V+(DK(=N<X.#SR3^=4[WX5>#;^YM)Y='1?LT:QHD3
MLBLJ]-P!^;W)Y/>@#RK]H56_X2;2),'8UD0&[$ASG^8_.NV^*]W977PGNX8[
MR%I[?[*7C1@S L5P#CIE22,^E=IXD\&Z%XKLX;;5K%94@.8F1BC)[ CM[=.G
MI5(_#CPJ^A0Z*^F;K&*3S=GGR*7?IN8A@6..!G..V* /&K:PN;_]G&=K;)%M
MJ1GE4#)9!@'\MP/X5IM+&W[+:H'4LLVQAGH?M6<?D0:]>T+P7X?\-PW4&E:?
MY$-T-L\3322(XY'*NQ'0D5CGX3^#S<F7^S9!"9O.-J+A_(+^OEYQ^'3MTXH
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M5[2==&JPF?[!=VUN4\Q)9U 5TP"",'N#FD\-^([/Q/IC7UF&55E:)E;J"/\
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M&XBF\/6ZP1K'&BA0%)QG&3USZ^M;U !BBEH- "4444 %+24M !1110 4444
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M'=_9&5)FC!V@G.,'H>AZ5FWOQ#\+Z?KXT6ZU-8[S>(S^[8HKGHI?&T'\>.]
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M 2 %4DDDGGTXZ5?!_@#QCX0O;K3+/5-.&ASSK*]QL8W&!U"+C:&( !SD#J*
M.^\9#/@?7\_] VX_]%M7SOH_B;3-.^#6IZ)=6DTM[?WC_9F,/[L<19.\\9&
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M[RW.C.UKIS7*LD;J8I0<F-U+$GY0V".#QSU%6/@=<:O>>&KRZO)K>6TFNY9
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M\:TZ %%%)10 4"BB@!:*2B@!:*2B@!32444 +1244 % HHH 6BDHH 6BDHH
M4TE%% !12T4 %%%% !1244 +2444 ***2B@!:*2B@!:#244 %+244 +1244
M4-=S_8&H[>OV67_T$US/PJE:3P%:(T:J8I)$R/XOFSG]<?A74:NADT>]0'!:
MWD'_ (Z:Y?X5QO'X*C5I=X$\FT8QMYY'YY/XT =K1110 4444 %%%% &7XF
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M .M7>T %%%% !112T )2T4E "T444 %)2T4 )2T44 %)2T4 )12T4 )12T4
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MIA!7?5Y[\(T\KPY>*W7[6?\ T!:]#H 2BEHH 2EHHH *2EHH !1110 4444
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M3/XJM=_*BR1.C<JP((]C7GOPA01Z+JZ#H-1<#_OE: /1**** "BBB@ HHHH
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M3[.WM(-Q;R[>)8UR>IP !FJD7AK08;S[9%HFFQW1);SEM$#Y.<G=C/.3GZT
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MU\*V5I_$VQ=H^WGCT^]0!Z-1110 4444 %%%% !1110 4444 %%%% !1110
M56U"*6?3;J*$XE>)E0^Y'%6:*:=G<&KE#1Y8'TR"*$;#"@C>,\%"!@@BK],\
MF,2F4*H<C!8 9(]"::[M$NYMA11EF+;<>IIO5W0EHB1F"*68@ <DFJ#(^IIR
MSQ6A_A&5>3USZ#]33U"ZG#ND1T@/W4/!;W^E7:/A]1;^AS[V$=SXLLO+ 2#2
MK=F5%Z>9)\HS]%!_.N@KA-+O=5'BGQ';R7EM:3FY#6\-S"<2Q[0%8/D9&!T
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M)GZ],4 >AT5YR=/^)I.1J]J!C& D?7_OFG)8?$HJROJUJ"1PQ2/C'T7VQ^-
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MG@ _C6U-\*FN$"3>(KZ50  )!N 'TSTJ9*S&BA\'I$FGUN10XW,A^8=B6/\
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M "BBB@ HI** %HI** %HI**  T4HHH **2B@!:*** "BBDH 6BDHH 6BDHH
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M+R[DM;74;2>YC!+PQ3JSKCU .15>X\2Z#:SO!<:WIL,T9VO')=HK*?0@G(H
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M88.X X/?C/4&@#TJBO$K+6;KPW\,K)=)>8ZOK>J26,=Q+(TGEXE= P#$\A0
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M^)'&H>/M#^'L(-KH0M?M-S#"2OG*N[;'D<A?DY]<U7\>Z5;?#NRL_%'A>+[
M\-RD5W;1,1%<Q-G(93QG.,'KS["@#U;=\V*6O)_'_@_18? GB'Q L)GO[EA=
MQW,F0\89DPHYZ ?SJQ%X#T4>!XM7MK<PSOH+">)/N7#-$KAF![AE# C'- 'J
M%%>"^&O^%>I\-K-]8M5FU*1#'(R1N92S2%00W R,COVKI==6?4/&GAWX=K>3
MG2[>Q$VH,C[6N%52%5B.0#M&1_M>PH ]2CFBE&8Y$<9QE6!Y]*7>NX+N&3G
MSUQUKA]5^&FE"[TF^T"SM]/N[&_AN'"%D2:-6RRD#.3CH<>W>N1T*?POX8^+
MWBN74#96*6RQ?8]XP(RR#?Y8[$Y[=B>V: /9A+'D*'7)) &>I'44/*D>-[JN
MXX&XXR?2O'_"R^']7^.NJWNEI;7%LNGBYB>-?E68E S@=F^8Y]R>]=%\9[&U
MN/AIJ-S- CSVIB>"0CYHR944D'MD$B@#O5EBD("2(Q*[@ P.1Z_2B66*!0TL
MB1J3C+L ,UX[XJ\++:Z9X-N?"=M;Z;KLK(D<\($>_$#/AL<')7'/KSQ5O7=?
MTSQ[\+;ZXO; )JFG21BXLW!$EO+YBJ<9&0&&<?D>E 'K.]=F_<-F,[L\8]:;
M'-%*NZ.1'4G&58$9KS*^2'Q1\2U\&8\GP_HMDLT]G"=B3L=NQ& Q\JAE./:M
MZX^'VG6WB31M8T.W@TU[.=FN(H%\M)HRA7[HXW#/IR": .SS1BDI: #%&***
M #%&*** #%)2T&@!*44E** "C%%% !BC%%% !BC%%% !1110!%/;QW,9CF17
M0]5850E\/:?-M$D3-&IR(RY*9^F:U**I2:V8FD]R-($C5510JKT & *DHHJ1
MA1110 4444 &*,444 &*,444 &**** "BBB@ HHHH **** "BBB@!**6DH 6
MBBB@!**** /$S+'%^U"QDD5 80H+'&2;88'UKL/&?B]C_:/A[07CN=2_LNYG
ME>*7+6^T   #^,DGC@C ]:Z"7P5X7N)GEF\.Z5)(YRSO:1DL?4G%6=.\-:%I
M$[3Z;H]A9RNNQGM[=$8KUP2!TX% 'A'P]L])U"S\-7 \0Q66KV=U+%':6EKF
MX?>22SMNR5VY^;& ,CK6)::(-9T230H[O3'G;6GF.M3WD2"6,)M;AF\P\_-C
M'.<U](VGAS1]-N;B[T[2[*TNYU(>:*!5)SZX]^3ZUXPOP8U 6LUI-HEE->2>
M9MU)=3:.)22=I\D1]@1QGMUH @^(QT;3O%CV%NZQW"Z&8&>;'V=%V$J(D SO
M/&.< G.":QVGBN/V=UBDN0TEMK "1[P2N03C'T+&O>M!\(:;I&F:;%<6UM>7
M]E:K;?;9(%,A &" 3D@<GC/2KJ^&]"2T2T71M/%M&YD2$6R;%8@C<!C&<$\T
M 1^%F1_!^C,K*R_88.0<C[@KYS\/:#'XE\1>+K!;XVSO%,T)\[RU=A*.&]1[
M5]/+:P1VHM8X(UMPNP1*@"A?3'3%4$\.:(F-NBZ>ON+5,_RH \U^)7BBPUOP
M/XHT^T>.5+ VH,\;AU:1I5RHQZ ?SKSV&#3]/U'X:75D4AN)FC:Z:,XS_I&,
ML?7[P.3T&*^D4T/2$MI+9=+LA!(P=XA;IM9AT)&,$U&OAO058,NB::"#D$6J
M<?I0!X[HIT_3/VC=8COXX(1)Q;J8P<ROY94J .&.2<_4GO7.>'H[>?P3\2TV
M12%7BEC7 . ))/F'T!ZU]'OIMC)>B]>RMVN@I03F)2^T\$;L9Q4=OHNE6@D%
MMIEE#YJ[)/+@5=Z^AP.1[4 >*6_A_2O%WP+BCTR&*76-*C\UC%'AM^260G'S
M$H3QSSBNM^$_VW7[*/Q3J\"K.MI'IMHY!RT49.^3ZLQ_\=K;\2Z!XCSIL?@V
M^L-*M8F<7%NT(",&& P"CDCGCCG%=%HNDV^A:)9:5:Y\FUA6)2>K8'4^Y//X
MT <K\4+NVM='TC[1/'%G6+1AO8#A9 2>>P')-<)\7O DNGM-XO\ #OF1B9'7
M4(X3QL=2&D'^R02&'OGUKVF\TRPU'9]ML;:YV?=\^)7V_3(XJP\221-$Z*T;
M+M9&&01Z$>E 'AOC2^TVSO/ L8N)H+\::BK>MDPQPNFPL8P,LWWL $=LY'%<
MWX4NX(O@QXVLVN5#K-$51C@\E0#@]SM_2OI%[&TDDAD>U@9X/]2S1@F/_=/;
M\*:FFV*)(BV5LJR/YCJ(E 9LYW'CDY[T ?,4Z:%Y?PZ519;&8'4<;<G]^-WF
M=^F>O:MSPR/M&M_$^RT5H_-G@N?LB6^,.@E;A,<=" ,>HQ7T%_9MC_SY6_\
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MTD21PQEV9F4@<#W-:U% 'D.D?VA;?"./PQ<^$=4NM0\B6$126X$0=F8JQ8G
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MH **** "BBB@!**** "E%)2T %%%% !24M)0 M%%% !1110 E+24M !1110
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M!'>K]C>V^I64-Y:2>9;S*'C?!&X'O@\U\UOKFK>$_#^O_#S7H9)/,7%C( 2
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MH **** "BBB@ HHHH ***,T %%&:* "BBB@ I#2T4 )2T44 %%%)0 &BEHH
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M HHI: $HI:*  4444 %%)10 44M% "44M)0 4M)2T (:*6B@ HHHH 2E%%%
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M(&<>];8OK1IXX!=0&61=R1B0;F'7('<<5X0OA#1O$7P.M[K2;>R?7+"(SS/
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M/D4.S$@ <MZX'- 'H(HH%% "44M% "44M!H 2EI** %HI*6@ HHHH 2BEHH
M**2B@!:2BEH 2EHHH **** "BBB@ HI** %HI*6@ -)2FDH **** "BBB@ H
MHHH 6DHHH **** "BBB@!:*** $I:** "BBB@ HHHH **2B@!:*** "BBB@
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M?3CVKHZ* *EKIUG9::NG6UND5FB&-85X4*>WZUA#X<^#@<CP[8@^OEUT] H
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M 2!#++,%D<*PSQCT45I?$?PIXE\3:EHW]DW%FVG6\F^YM;MF$4C!@075>77
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MRPW=1S6Y=>&?$Y\1^'KBV\2RG3;&,+>Q2$A[EAU8@##;NF#]W''6@#M:***
M"BBB@!**** "BBB@ HHHH **** %HHHH 2BBB@ HHHH *6DI: "DI:2@ KPS
M2+34O"6FQ^.='22XM7N+I-9LE;_61K<2@2C/=1_+W->WW*SM;2K;2)'.5(C=
MTW*K=B1D9'MD5C>%?#\_A[16TRYO([V/S9)%;R/+X=B[ C<0?F9OPH Y"UUR
M60>.M?\ #\]FXD^R26UQ<OLA_P!0FXL3T(!Z'O@&JVA>*-:;Q+>:2FLW%_;2
M:(U];W=Y9"(B4';N1<+NCSDC/Y]ZVI?A=IP\,:YH5I=R6UMJ=V+M-J?\>Y!4
M[0,\KE?R/M35^'^JMK2:U/XKFEU V+64C-9Q["A.<!1C _4G/(SB@#C+7Q5X
MW_X0C0O%@UZWF^T7OV1K*6T4(X:1U#,PY)R!P,<>_7I#XCU[PKX@\06FL:FF
MK16VC?VI#^X$(1PQ7RQMS\I/KD]/>K*_#&9/!FG>&H]>VP6-Y]J67[&"S'<6
M52-_9BQ]^/3G5G\%37WBBXU>^U1)X+K3SIT]H+7:'A.2?FW$@[B3G\* .;T#
M5/'=Q>:)JSQ7<^E7<8EOQ<?95ACC<!@\.QS)@ ]&R2/KQ@>);_6O%WPEU;Q.
M^K206<LV(]-2-/+\E9@@W,5+%LC.00/:NYT'X>3Z--;02^)=0O=(LY/-MM/D
M55",#\NYQRP'7;P,XXJA<?"AFTG4M%L_$EY;:)>2>:MEY*.(FW!L!CSMR.@Q
MVY/.0#O]/_Y!MK_UQ3^0KR/XA7NG^*=8U?3+IKH1:3:LEEY%M+*LEZP#$DHI
M V@*O/\ >->K06-Q:Z*MC'?2/<)#Y:74R*S;L8#%0 #CTXZ51\*Z!<>'-*DL
M[C43?N\\DYG:$1LS.=S9P3DY)YH QO"?B'_A)?AC]LD8_:HK62WN@P((E1<'
M.>YX/XUYYJ$-S+X!^%XM9!#,=1A2.9DW"-RWRDCOR,X[XKO=*^'^HZ2VOF#Q
M(<:SO>119*!%*W5U&[T)&/IZ4O\ PK96\,:+I4FL3&XT6X%Q97:0*-I4Y4,A
M)# 'Z9P/Q .8U+Q;XE^'TOB#3=0OAK1AL8[ZRNIHPK+OE$6& XP"2<>WOQHZ
M/#\0+?762>:]33)[1Q)<:A+;2F.< D/&L;=#@?*> "?05TK^ K#4(M5;6YY-
M0O-3A6"><J(]B+RHC49"X.&YSS^54M'^'<^EKFX\3:C?O!$\5A]I 9+7<"NX
M+_$P!(R>Q(Q0!P 'BW6OA)<^)K_Q;<&WDLI@UG%"JE\2E?F?WY!P!Q@>M;=K
M)?Z;X4\$6*:_?+:WMJ))8;?#7DF859(X0$.$4]2<8'4UU^E^ X+#P%/X1GOY
M[FSDC>-9"BHT88DG&/\ :)(SGTK.3X:30KHDMOXGU"*^TJ(V\=R(8CF$@+L"
MD8& ."<GDYSQ@ F^%FLZIK'AN]&KS2S7-EJ,UH'F $FU0I ?'!8;B/PK'TDO
M-^T3KWVK+"'3(Q:[_P"%2(L[?Q+_ )FNI\(^"XO"!OUM]3O;J&[G:?RK@J0C
M-C)R!DL<#D^G3KE?$?@NUU[4;35H;RYTW6+,8@O;8C.W/W64\,O7CW- &KJ]
MO9&.+4+J 22Z>7N+<[BI5MA!QCU!(Q7E\>L^([WX;/\ $"'6KI+U9'G&G@*;
M41+*4*;<9/R@G=G-=]8^%IOM\5]KFKSZO/ "(4DB2*&,G(+"-1RV"1DDXR<=
M:RD^&MM':SZ2FK7J^'9YO.;2@$V@[@Q0/C<$)'W1^= '-37/BCQ'\0$TVP\2
MW6G6E[HT>H@)"CBWW,/E'3//?KR1186?C#Q!XA\5Z8GC.Y@_LV:-862%!N9D
M8@';]U?4#D]\$8KM8?!PA\;?\),FJ7 ?[/\ 91:K&@C$(Y"=,\'G/6N"\(64
MVM>-?&PL]<N]/BN[DE#!$I$\>6!9693@C/4>M $OA_Q=K/C5/"^CRZA+8-=V
M<]S>W5JP267RY&C4*<?*3MR<?TJ/4]?\06&F>-M!76;G[1H7E7-K?D!I7B?Y
MO+<D=<$#(YZUVMQ\.],%KHB:9<7&FW&C9%I<P[2V#]X/D$,#R3[D^M1W?P[M
M[O1M5LWU6\^U:O(KW][M3S)@HPJ 8PJCT _G0!R]VFNZ3H.ES7WC2\E_M>>"
M1HHHO])(\O+16^ >22.3@# R>3GG+[4=5U'X<^-[*]U'4]ND7R)"+B8&8HS[
M?+E89W#OP>O>O3]2\!IJ6FZ'"VLWT-[HQS;7L00/T ^9<8/  _#GJ:HP?"?2
MHH=;@DU75IX=80"=)9P?GW!O,SMY;<.I[$CO0!0U--1\/:CX$L[37-0>TN+@
M03Q2LK>8,;N3M!QVQTP!WYJ,2:IXLG\67T?B*_TYM&NYK6SM;.0*BF-?OR#'
MSACG@],&MJ7X=&4:)O\ $FK2-I,OGQO,R2,[\=25X&!C'3'KR:M77@.!]4U*
M\T_5+W35U5<7\-OL*R]06&Y248@G)'K0!PT'B/Q#XDC\ S1ZU<Z>VL)=070A
M12"T61Y@!'WCC/H.,#UZ7X<ZAJ/]M^*]!OM0N=0CTN[007%T^Z0JX;@GVV_K
M6E-X M/[0\/3V5_<V<&A+MMK=%1E.>&))&26'!_,<U/X>\&KX?\ $&KZNNJ7
M5Q)JCAYHI$0+D$[2,#/ )'\\T =/1110 M(:6D- !1110 4M%% !1110 444
M4 %%%% !1110 4E+24 +1110 4444 %%%% !1110 4444 %%%% "4HI** %I
M*6DH *6DI: "BBB@ HHHH **** "DI:2@!110** "BBB@ I#2T4 )2UY3J/Q
M@E\/>.'T#7M(B@MTE"/=P7!<*K %6P5' !&1U_+!ZJY\2ZJ/'5AHEI:6,UA=
MVQNQ<F=@PB! 8@!<$Y(QSSZB@#K#24IIK,%4LQ 4#))Z"@!:*12KJ&4@J1D$
M'@BD,D:R+&74.P)52>2!UP* 'T&F^;'YOE;U\S;NV9YQZX]*BO3=+93-9)$]
MR$)B65B%9NP)'2@":BO*O#OQ)\3^)M&UC4;+0=/ TP?/$UP^Z4@$D)A>3@?J
M*ZSP#XUM_'6@OJ$5J]K+%*89H6;< V <@X&1S0!U-+42W-N\;R+/&R1DAV#@
MA<=<GM1]JM]T:^?%F0D(-X^;'7'K0!*:R=<\-Z1XD@B@UBR2[BB;>B.S !L8
MSP16C/<06R!YYHXE)P"[!03^-$EQ!#$)99XTC.,.S@ Y]Z ([&QM]-L8K*TC
M,=O"NV-"Q;:/3))-6*K7.HV5I#+-<7<$4<,?FR,S@!4_O'VK-\*^)K3Q9HJZ
MI9JR0O(ZJKL"V%8J&('3.,X- &W17EGCOXEZWX'\40VDFGV5YILB+.6C#K(L
M98K@G.W/'7&*V]2\8:A<3>&IO#TFG2V&MN8U>YC=FC8*6)^5AV!&.Q'7T .X
MHJM_:%EEQ]LM\Q_?'F#Y><<\\<\4IO[)8EE-W (V.%<R#!/L<T 6*6JHU&Q,
MTL(O;?S84\R1/-7<B_WB,\#W-<[XT\3R:9X"U#7=!NK.X>WV[9 1*ARZJ1\I
MZ\T =917*>!_%L?B'POI5UJ%U9QZI=QLS6Z2!6;#,N0A.?X<UT-WJ>GV#QI>
M7UM;/(<(LTRH6^F3S0!:JC<Z-IEWJ5OJ5S86\M[;#$,[Q@O']#VZFG2ZOIEO
M>"SFU&TCNB,B%YU#XQG[I.>E,&N:28(IQJED89G\N.07";7;^Z#GD^U $FHZ
M;9:O9/9ZC:Q75LY!:*5=RG!R./K3-*T?3M$M6M=+LH+2!G+F.% H+$ $X]>!
M^57L44 %)2T4 )2T44 %%%% !1110 4444 %)1FB@ I:2EH 0T4M&* "BBB@
M HHHH **** "BBB@ HI&944LS!549))P *\UTKQ6WC;691%XDAT?3DN&@M+6
M"2/[3>[2,R$L"54GH ,GF@#TJBO/[F[UGQ7XNUO3M*UBXTRTT6*-%:"-29[I
M@6^8L#E% P5[YS5*3XI21_#S2=5^SV_]LZE,;2.*5]D2RJQ5G8]D'!_$#/>@
M#TVEKD-%O8[+P[?ZW)XF;Q"T43/*\)3R@R@G:B(#M/;J37,_#W5K_P 3ZK%J
M,_CAIY(]\EQH0LQ$8BV1MW$Y95..0.W:@#U6BO/=5U;6[/XS>'],_M/.E7T$
M[FT2$*!MC8_,V26.0#VQZ5+JFJWVL_$P>$X-0N-.M+?33>2R6Q422N6"A<D'
M  ;/OB@#O325Y=9^.]3T_P %^)8[^0WFM:'<O9K/'%_KBQQ&Y4#''.1_L^]6
M?AW//?0WFIP>.)O$FV$JMG) (#$_4%@6)YQ@'@=>M 'I-%>&Z)XLUS4$T6XM
MM=NKCQ)/JQMK_2)0!%'"&8M\NWY0J[<L.>3W&*]RH **** "BBDS0 M%)FEH
M #24M&* $HI<44 %%%% !1110 444F: %HHHH **** "D-&:6@!*6C%% !11
M10 444F: %HHHH *0TM(: "EI*6@ HHI,T %%+10 4444 %%%% !2444 ***
M!10 444E !12XHQ0 E+1BB@ HHHH **** "BBB@ HHHH *2EHH !1110 444
M&@ HI** /,-4\(6?C37O&VFW)\N426;V\X )B<0<'Z'H1Z5RGPM&M6OQ(_X1
MW7@3)I>GSP(KG<0C.AP#W7N/8UZ]IGA+2=(U>ZU6S2Y6\NO]>[W<KB3ZJS$'
M';CCM5Y]'L'UN/63;+_:$<#6ZS@D'RR02I['D=^G/K0!\UV8B7P#X_5W(-M?
M6GV4-(<HWFNOR\]=A;\*Z[5KF"7PW\.K6XOI;B6:&$#2,?)>EMBCS')PHZC)
M!ZG KT.\^%O@Z_O[V]N=(5Y;P[I<2NHW9R6 !&"?;^IJ6;X:^$[FUTVVN-*$
ML6F@BV62:1MH+;BIRWS#/8Y';I0!X]X7D>?X0>.;>60LEK,C0Q^86$1S_#Z=
M/QQ6)':OI-K\/M7LY9VU"\FD9F>5B/EG"JH&< =<XQG)S7OJ_#;PG':ZE;1Z
M2L<6HL&N0DKKNPVX $'Y5SV&!59OA1X.:&TB;3)3':$F!?MDV$RVXX^;UH \
MG\<P7&G^,M7U?4(#J6B7-XL!OH7(ELG0@F,'^$@<8(PPQCGI]%JZM&) ?E(W
M9/I7.7'@+PU=:B]]-IV^:2?[1*IF?9))_>9,[6Q[BMO4;"WU33Y[&Z#F"==C
MB.1D)'IN4@C\#0!\S:"GB-?A]XIN]#U(QVJ7.V]M%B4EXF4AG#$9&!V';-=)
M#JEEIW[/MQ+X5::"Y:=(]2<O^\1VP&.1V("@8['US7K/A[P#X<\+74ESH]G+
M;O*FQQ]ID=6'NK,0?RI--^'GA;29;Y[/28T6^C,=Q$SLT;J3G&PDJ.>F!Q0!
MY;X;T>-=&&HIJ6E"UU#P[+#)IUL&+3/'%EI''3>&ZD]^G6N/BT>PB^#2>(XF
M==8BU81K<+*=R#'W0,\=F]??%>\'P1HWAOPWK,?AS15%W=6LL0"OF1RRX"[G
M/ S@XSBN4^&OPYB@T18?%/AQHKZTNC-$TLX>.7(P#M5B"5P?O#N,=\ &&MQ>
M^)OB]H-CXCMOM%G_ &2DJ07$8,;LUMN=]I&,[]P^J^U<S:7-Y?\ P$U1+W?+
M!9ZE$+.23G9G&Y5)Z 9_\>-?0VM^%]&\1&(ZI8I.\.1'(&9'4'J-RD'![CH:
M;<>$]!N=%AT:72[<Z;"P9+8 A 1GG Z]3UH \GA^'VCCX5S>)YI+RXOY-!)*
MS3[D#!=RD#K\N% &<  <9YKI?@A;Z5%X$MI;86PU.8.UWL8>80)9 A8=0, X
M^AKOK?1M.M-'&D0VD:Z>(VB^SXRNPYR.>W)J/1M TGP];/;Z380V<3MO=8EQ
MN/J3WH Y?6=(L]>^(MUI=_'YEM<^'BCCN/W_  1Z$'!!]17F&@:'K/@[XL:-
MX:O)'DTT7KW5HY'RN/+8;AZ'& P]17N?_",Z-_;O]M_8(_[3_P"?G)W=,>N.
ME7;C3K.[N;6YN+:*6>T8O!(RY:,D8)![9% 'SY<#3+7XB_$>*[^S10/I5T(T
MDP%:4M$RX!_BW<CWJI?QHW[.>E2%%+KJS!6(Y&?,SBO?-1\'>'-6U$ZAJ&BV
M=S=LNQI9(P2PQCGUX[U ? GA8Z4-+.B6ILEF,XAP<"3&-W7KCB@#P.QT:P;X
M@^%+ P?Z+>Z5;27,8=AYK-"7;<<Y.2!QTI?",LA^"_CB(NQC5[9E7/ )<9/Z
M#\J]^3P/X63R\>'].)C4(K-;J6"@8 R1GI4L7@_PW!:W%K#H>GQ07(59XXX%
M42 '(#8'.#S0!\^:AI%E:_#3P5JFDH(O$-Q>.BO#]^3#MR?<$(!]:OZ["^M?
M%+Q+IGB'5;/3/-@\J&XOX]RQQJR.OEDL I(&<]\MQDU[K9^$?#NGZF=2L]%L
M8+P])8X54CZ>GX5)J/AC0M8O8KS4M(L[NYB&$DFA#$#TYZCD\4 >%^(M+L[_
M ,?^ [*YNI+Z&YLK=)KET:%[A-[ %@?F&5P.><5V?BOPE\/?"^BZ38ZM+>VE
MG_:#3P^6[,68@;@QP2$P%'&#QUZUZ%<^&="O=034+K2+&:\3:5GD@4NNW[N#
MC/':K&H:1INJ^3_:%A;7?D/OB\^(/L;U&>AH MIMV+L.5P,?2G44&@ HI**
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MOJDUY>6_B*.(K:QZ9,5N;E><1[0#E2<C../6N]I/*C\WS=B^8%V[\<X],^E
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M"/7-9USP?%-JUO,XW2,E_+.'-R3(^0%ZJ%X7GCTX% '</?V<;E)+N!''!5I
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M)2T4 %%%% !0:*#0 E%%+0 E%+10 44AHH 6BDHH 6BBD- "T4E% "T4E+0
M4444 %%%% "44M% "44M% !1110 E9MOK^E7>LSZ1;7T,U_;IYDT,9W&,9QR
M1P#GMUK2KA-*@A@^,^N^3$D?F:7 [[% W,7.2<=3P.: .@UGQ?H>@7 M]1O?
M+FV>8R)$\A1,XWML!VK[G J;4?$FCZ7ID.HW=]&+6<JL#QYD\TMT"!02Q/H
M:X.WU!?"GC?Q@/$5G=R6VJA)[:XAMI)TEB5&!C)4'&T''/ YZ#&>1\-?VA8:
M/X#\0SV5U=Z-8S7BO&D)D:!78A9, $D#K[;>.M 'M6F^)='U;3[B^M+Z,V]L
M6%P9 8S"1UWJP!7IW JKI/C3P_K=ZMG87^^=U+QK)$\?FJ.IC+@!QQU7-><0
M367B7Q5\1#;3266ESZ7&EQ<3PM&%D"8W,C ,. W;)P3WK-\ :A+J_BOPII^O
M*UB^CV+G3,1,HO@PP&#'&!L X[X/3I0![1<:U96NLVVE2R$74\,DZ@#A43&Y
MF/8<CK5/2/&6@ZY?&RT^^\R?870-$Z"50<%D+ !QGNN:\U\;W,FH>'?'GB&(
ME1"8=&MG'7RTE7SL>S,Y'_ :UO&<8TEOAW+8[?,@OX;9'BS@Q,@5@,=B!0!W
M^LZ[IV@PV\NHW B6XG2WB&"2SL<  "G:SJ]KH6ERZA>;S#&5&V-=S,68*H [
MDD@5XAXN\4:1XFFM-;?5X,0:M!'961E :&!6/F3,N>KD \]%"^M>CZW=Q>)O
M$_AC3+&9;BP!.KW$D; HT<?$7U!D(./]GVH U;_QSH&F:G]@NKQED1E2:18F
M:*W9ONB20#:A/H3]<5L:EJ=CI%C)>ZC=16UM']Z25L#V'N?:O(= 5+[X+>-+
MR]RLMW<WMQ+O&2)  5'3U4?0U5M+C6O%GB?PMI]N;29M+T*'4"M_N,33LB@2
M$+RQ!9",^] 'L>CZQ;ZW9&[MH;J.'>54W,#1%QQ\P# ':<]:T*Y7P-XKE\4Z
M9=_;+5;74=/NGM+N)"2N]>ZYYP??T-=4* "BBB@ I*6DH 444"B@ HHHH 2E
MHH- !244M "4M%% !12&B@!:*** "BBB@ HHI* %HI!2T %%%% !0:*#0 E*
M*2E% !1124 +1244 %%+10 E%+10 E+110 4444 %)2T4 )12T4 %%%% !11
M10 4E+10 4444 %%%% !1110 48HHH ,48HHH **** "BBB@#BO#JW%SXS\5
MO=Z1>06=]Y/E/<Q )*J1^6PZ]^H!ZBN>\*_#F;P=\5[B\L8G;1+BRD\IR<^2
MQ9?W9[]N#Z>X->K44 ?.<_A/Q?INF>,M#A\-W-TNJ743K=1NH0)'*7RH/+9R
M..W/I6]J6E>+)M#\#V-OX?N'MK:%4OD4+'.I5@K+YAYC5E'4$9!YKVZB@#P'
M0_"_BC2_ _C32)O#MR'NV7R"CAMYWXPHZD <[JJMX8\4-IG@=%\-ZANT65WN
M00@SF<.-HW9Z>HKZ(HH \.\7^#=8U;Q3-J>F:+>V&LKJ.(+VW*^1-#D 2/\
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M!9Z')@7+0LQN9UXS'T 13R"<L2/3-7+ZQU*TTJWT_P -K8VB(GE"2<,1 @&
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M444 %%%% !1110 4E+28H 44444 %%%% !1110 4444 %%%% !1110 4444
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M&#Q2)=2!L@Y&3NYJ2X^%?@RZGOIIM%C:6]8O*WF/E23DE.?EY],>G3BNQHH
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MA2#2='TRYO)I;E9)#$@*HB@]3G@DD?D: /-O%!T=+7PFO@?R_P#A)?*C\_\
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M"\)*ORIZBK/PP^)LFD^$=936Y)KJ'3$22V'+.P=BNS)[9QR>F3]*U/A]X?\
M&O@O2M;A_P"$::6[OBIMW^V0>7&0&&7^?.!N!P!SBI])^&NO^$?AUJ\.E/;W
M'B+4-@D 8%%C4_=3<,%N2<G')]N0#=\.?%,:QXFBT&]T@6EW<VJW-J8;KS5D
M#1^8%)*KM.WZUSW@CQ]K>H^*_$NI:O;HNE6JA;@_:<)8)'YA&U,$R$D8)&#^
M@JAX2^'_ (HT?XB:'J]UHL201P8N)/MHD(<H4=V/4L2Q;:,CG&>,B_X?^'?B
M.TU'QAIES;6\6FZR)%6_,P+8^<IB,'/5@3G' (% &QHOQ>CU+5]+CNM*%IIN
MKRR06,_V@/)O5@O[Q /EW$@#!//KU'0>%?&=QXC\0Z[IDVCSV2:;*$260G]X
M,D<\8!XR,$Y!]N>-^'WA#Q1H0M]+U#PYH\44%WYYU5S'+*4&3M4#YLD]&.,
MGCI7:^%G\9MK6L#Q)%:+IXE_T PE<E<GT.<8Q][G- '5T444 %%%% !1110
ME I:* "BBD- "T4E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%)2
MB@ HHI* %HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH 0T4M% !1110 4444 %%%% !1110 44E% !0*6B@ I*6B@!*6BB@
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MSUXLTX6OB+P%:IH]Q:6]H(VFM6WS^2AGSAFQR<9R.W(KI_B?IL=CXV\"ZC%
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MCY@&)Y[8S3-'BUZT^*'B/6;CP]?FPO($CMW5X<_NE'&-_P#$0<?49QV](I:
M/*/")\2^&]'U&UO?!-W=?;[Z:Y*1W$!79(!\K9;D]1TI/%ND^,-?\-Z=;OHI
M:ZCU9;U;>*6%8[6! 42+=N^9L$-GIR?3 ]8HH \Z\1VGBWQQ8+HG]D#0]-G8
M&\N9[E)9&0'[B*A/7'4FK'B/PG>VE]X6U;P[;I/)H ,'V5G"-- R!" QXW
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M &TCDGD=O>N%_P"%A^/?^$*@\4MKT+11ZI]B-O\ 9(P9#Y>_+$#ICC P>>M
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M#<3P9E(&-S E2<>Y&: *UYX[T^WUB[TNTL-2U.XLE#79L(!(L&<X#$L/FX/
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M+E3!/_HDUTR&62$YP'VD\C'7W]JK?%FV@MOA7K_DQ)'YK12/M&-S&:/)/J:
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M1L9T 9N <@8*G/N.!7H-?-?A+7;WPG\&M6U?3;B9;RYU06<8)W1P_NU8N%/
M8C(S[+Z5UWAMO%\=M=7DT]]_8EYH[S)-<ZDDT@G$>[?&58L!GMT'>@#V:BO#
MOAY:^,?%>C6^O7'C"ZC@LKMBML^2)@H!(=@1QGC!R ,U!X!\1:NWC[3=(UZ^
MU2#45><S)-<O)!>!D8IA2<+CL5^4@#H>H![Q17'^"]*U73=1UUM2\2KK"37
M:*,.6-M@ME2,G;G(X''RUV H **** "BBDH 6B@44 %%%% !1110 4444 %%
M%% %>^DNX;&62QMX[FY5<QPR2^6KGT+8./RKG/!7CFS\8V]T@A^QZC9R&.YL
MVD#E,'&0V!N7.1G':NKKQ>Q\,WW_  BUGXN\- +KVGW-YOB .+R$7,N8V ZG
MT_+TP =]IOBRZFU;7K;5=/MM/M-& ,US]L,FX%0ZG;L&!LY/.0>,&JUGXNUS
M5]*;6-)\,";32&:'S[WRKB=!_$L?EL.>V6&?:N!U:_?QAX%\>:MI,,@2XEM&
M:/8?,'EQQ>:A'^S@\CT/:O5O"%W:W7@O1KBU91;?88@N",+A "#]""#]* .>
MU+XD)%X.A\5Z3IJZAI0(%T&N?*F@)8+C9M()!//([=CFMV3Q/'=>#'\1Z+%'
M?1"W-PD<DOE95>6!.UL,,'C'48]Z\FT>!9/A[XIOX(BFFWWB&%[16[Q_:8_T
MY []#6KXILKKX;W.KW5C$TGA;6XI5N(47BRG9"JL/]EB?Z=A0!T.I_$35=-\
M/Z!J[>'K5TUIXHXHQJ)#(T@W)G]UC&.OH:WDUGQ%#JEA;ZAX?M4MKN4Q-<6M
M^TWDD(S LIB7@[<9SU(KSGQ@DDGPQ^'"12F*1KBP"2!0VP^3P<'@XKMX-.U7
M0O$\6K:UXI:\TU[?[''%-&L1$\DB;,*@"MG!&3R/IG !V=%,21)-VQU;:=K8
M.<'TI] !1110 4444 %%%% !1110 4444 %%%% !124HH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***0T >;_\*_UT?$QO&0U33C(3M$!@?'E[-G][[VWOZU)!\,)-
M(\<R>(O#^K)96]PX^TZ>]MOC="?G .[@'J!C@^W%>B44 >8:)\*=0\/:U=_V
M5XHGM=#NI5DELTA'F, >$WY^7J1N&#C\ZGU7X876NWD8U35;:YMH[Y[J.4VK
M"YCC+EO($F_[G/4CCL.E>D"EH X(_#R>/XGOXOMM9>&*=5\^V6(;GP%&W<>B
MG:,\9ZCO4G@[P!<>%?$FL:Q+K$=Z=49GEC%IY>UBY;(.\\<GC'I7<44 >>Q?
M#%SXXU3Q%=:O%/#J44MO/9BT*_NG4+@/YAP< <X]>!2>$OAIJ/A2[$4'BR[?
M1UN//6Q2!4+'L&?)..!D  '%>B4&@#SC2_A?<Z)KVNZCIWB%X8=367;;FV#+
M&S[L%CN^<+N.!QGC/2JEG\&H8O!-SX<N]9\\&[%Y:W*6NQH)=NTY&\[@0.F1
M_+'J-% '$V7@*>+6=8UZ\U=;C6K^T-K'.MKLBMQL"Y$9<Y/ )^8=^F:Y@_!2
MZ/@X>&_^$FC^RB_^W;_[/^8OLV8_UO3%>NT4 >>:K\-;[5;>XMI?$$+6US:P
M02Q36'F!6C4+YL?[P;&..W'/?K7:Z+I,&AZ)9:5;%FAM(5B5FZM@8R?<]:OB
MB@#B'^'HT_Q5-XB\-ZB-+N[D%;J&2W\^"7)R3MW*0<@'(/\ ,U+X?\ Q:9XD
MNO$FJW[:KK4XVB=HA&D2XQA$!..,#.3Q]3GL:* /+W^$,LO]OF7Q$6.N2;[K
M%F!C$OF#;\_!SQW^E=MX2T ^%O#=MHWVLW26VX1R&/8=I8G!&3TR>:VJ* .)
MT_P/JFAW5]+HWBB6".^NI;F6"XM%F12YSE.00P]<D' R*HWOPCL+CP9#X;M]
M2F@B%V;RXG,09YY<$9/0 8.,#T%>B4M 'G]O\,Y8O%^G>))=?EDNK*%( HME
M4.BIL(//!()Y'KQ6))\"-.DLKNV_M_40DUP)U4JI52,CY@>6.&(SD=:];I*
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M "T444 %%%(: %S124M !1110 4444 &:*2@4 +1110 4444 %%%% !1110
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MX&.: /3:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH ***,T %%%% !11FB@ HHHH **** "BBB@ H-%!H 2E%)2B@ HHHH ****
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MO&_]FO)Y5PFAO-;2DG"R"< 9 Z@@D'ZYKB_"WB/5FU'1? >MPN+[3=9@>!W
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M&,@*.^?7ZU@:[\,I]6O/#\\/B"2,:*?,B-S;^>\TI<.SNV]<Y(' ''/X>AT
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MU;REOK59!%-&ICA)C8,P&,\;2P&>OY53U3Q'XKTG6]!\$WNJW5Q>$-+>W6G
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M /8RV?\ [-7>BL+Q'X3L_$[V9O;N]B6SE$\*6\@0"4?=?."<C)QSCFMU1M4
MDL0,9/4T +24M% "4M%% !1110 4444 %%%% !1110 4E+10 "BBB@ HI**
M"E%%% !1110 4444 (:*6B@ HHHH 2E%%% !1110 4444 %%%% !0:** $I1
M110 444E "T4E+0 4444 %%%% !24M)0 4M)2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !320!DD >M.K)NW-Y<F!798(_P#6D'[Q_NT 6)-2C!*P
MHTQ'7;T_.HCJ%P.EJ /0N*5(%0+M0+CTZ&I%4*"2IY[XIDW8EMJ,<S>6ZF)R
M< -WJ]69>V8DA\R$%73GCJ:ETR[:Y@*N?WB<'WI#+]%%% PI#2TAH *6O)KW
MQ'XPD^*C>#8-8MK6"0-/%=_85=PGEE@I4M@@$$9X/&:N^%/'6LR?$*^\&:Z+
M2YFME/EWMLA3?M4'YER0"0<\8P>* /3**S#XAT9=6&E-JMD-1)P+4SKYF<9Q
MMSGI3+GQ/H-GJ0TVYUFPAOBRK]G>X4/EL8&TG.3D?G0!JT5QTOQ'T5?'<?AE
M;JWR(V\Z=Y0JI-N 6(9X+')SSVQZUJ_\)KX7\B2;_A(=,\N-@KL+I,*3G //
ML?RH W:*XS2M>U"]^)&I:?\ VMI,^D1VP,-M#,K7"2#:#N Y_O9SQR*V;?Q;
MX>NM4DTR#6K%[V,D-")EW9&21[XP<XZ8YH V:*X72_BGH.K>(-6T^.^M(+:S
MC'DW4\P43M\Q<J#C*J .?QZ8J?P3X@NF\'3ZEXEUS2K@PW#J]W;3(8D7Y<!F
M&%!Y_(B@#LZ*R+'Q7H.IV-U>V6JVL]O:(7N&5_\ 5* 3EAU P#^55E\>>$V:
M!4\0Z<[3N(XPMPI);CCCIU'6@#H**RM6\3Z'H5Q#!JNJ6UI+,"R+,^,@<9]A
M[FM"UNH+VTANK:598)D$D<BG(92,@C\* )J*\ETCQGKGQ#\;7NG:)J!TC1=/
M4E[B*%))9_FVC[X(7/)''058T_QOJOAWXD?\(;XBNEOX+C9]COS$(G)<?*&"
M\$9RN0!R/R /4J*Y8_$?P<%D+>(;%?+8*P9\'/TZGIVKI+:XAN[:*YMY4E@E
M0/'(ARK*1D$'TQ0!+17D%]J?BIOC&/"D'BFYAL)XFG5A;0%HQL9@H)3D COV
M_.G^!?'VKMXI\0:)KU_#J%AI2S2'5%A$> C[?FVC&",G\#R10!ZY17--X_\
M"B:?'?MKEJ+621HDER<%U )7IU 8'\:FU3QKX<T6:"+4-4BA>>+SD&UF_=]F
M. =H/8G&: -\TE<'K/B%IO'GARWT_P 3VEK:R*'FL98VW7*R ["I(P<XP.1@
M\\]*NR_%/P3 TZ2Z]$CP/Y<B&&3<&SC &W)Y';- '7T5CW?BO0K'1(-9N-3@
M73Y\"&89;S">@4 $D\'@#/%0#QOX;.C2ZM_:L0LXIO(D)1@ZR9QL*$;MWMC/
M>@#H*#7-CQ[X9.FW.H'5 MM;3BWE+PR*RRGHFPKN+>P'8^AK0T7Q#I?B&&>7
M2[KSU@E,,N8V0HX )4A@#GF@#3HKS'QI8^*;2R\3>(/^$BO+&WM@&L+2V9=A
M0*H+-D9Y;=Q5+P'!XKUWP]H/B-?$M]<.][B\M)F3RV@5V5L<9S@ ]?6@#UNE
MKEKGXB^%K/4I;&;4\/#((9I1$YBBD/ 5I -H/!ZGM6A?>*M&TW7['0[J\$>H
M7R[H(BIPPY YQ@9(('- &S1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 457OK*+4;&6TG,HBE7:QBE:-A]&4@C\#7DOP]\7:CHM]#
MHWB&::73=1N)DTJ^GE+MN24QF)CUR2.,^H]> #V*BO+Y]33P??>/M84W5S_9
M_P!G6WAFNI)$4RHA(PS$8WL#Z@9 K5T3PA)J_A>"]UG5M4?6+Z$3M<PWLD?V
M=G (5$5@F%SZ'/- '=T5XE<:SJFO?#C4S?7=W#XET+45L5N;:X,6]VF5 6"$
M*>N#P>F1UKH].\43:[X.U_1=;62T\1:3:R"Y1)&C+[5)65""#@X!X]NQ% 'I
M5%>)>)\:?\// E_]OO86NIK7[9.;Z4;TDCW2;CNZ9&?;MBNKTK_A%;WQ=I\'
MAW7+F6ZMD>[F6*_EN89(L>64?<Y .YU(^E 'H5% HH **** "BBB@ HHHH *
M*** "BBB@!**6B@ HHHH **** "BBB@ HHHH **2B@!:*** "BBB@ HHHH *
M*** "BB@T %%)2B@ I*6B@!*6BB@ HHHH **** "DI:* $I:*2@!:*!10 44
M44 %%%% !1110 4444 %%%% !1110 5BV?64]<ROGZUM5D1CR+ZXA<XW,95
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MP9C:N<$Y-Q_!^.WI7M'PGE$OPQT3#ARL3*<'."';BNG_ +*TXG)L+7_ORO\
MA5B""&W39!$D29SM10HS^% 'A?B%]!U#]H.*/5;BW>P6V,<K--M17$3?*S \
M'/OUJM\-8YF\:^*-.T(2W/A=X[A>1E#GA,'G)(X'<CDU[NVF:>[%FL;9F)R2
M8E))_*IXHHX(Q'#&D:#HJ* !^ H ^1Y-6L%^$J:(TG_$S&N-<F+:<K%Y(7)/
M^]QCVKKO&[0-?G5]%U:.&]@TJW%W:SNH2[@:,?ZOLXP<,A^HKZ%:PLV#AK2
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MQZUZG]LTW1/$O@C1=8T)KS7?L$<2:@.?)8+M(_VL$,3_ '<Y[UZ910 4444
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MHHH ,4444 %%%% !1110 4444 %%%% !1110 8HHHH **** "BBB@ HS244
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MYB /7GTJE\/97?X@>+[Z26/2M>:&Y\G3S'E$;=N))Z-M(''?DT ?0-%>#/\
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M1110 4444 %%%% "4444 %**2EH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6DI: "BBB@ HHHH
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M#92JF'DA8+G!.#M. V!G&*[[P[I T#PYI^DB9IOLD"Q&0C&X@<G'8>U:E&*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7VTWEN2)E>TD01D9^\2,+T.,XS3[KQOHMO?7%G$]S>SVH)N5L;62<08[.4!
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M7;)#(OWD<=B* -.BBL*Z\2*-:?2--LWU"\AB,MRL<BHL QE S'C<QX _$X%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^6SI*5D(_P!X<Y/K6?8^$].T[PU)H%M)>)8N"N#<N713U56SE1[#U/K6Y2T
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M/6VCWNEQ:?BVON;HF9S)-_O2;MY_/N?6LQOA3X+>RCLVT=C;1.TB1&\GVJS
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MU-<>$K3Q#KNF^*SJ6KP7$"![6$B-%B5EP5*-&6&1G()SSVINJ?#O3]3\5?\
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M444 %%%% !1110 4444 %)2TE !112XH **** "BBB@ HHHH **** "BBB@
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MH 2BEHH 2E%%% !24M% "44M%  **** "BBB@ HHHH ***2@!:*2EH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*!2T4
M%%%% !1110 &DI:* $HI:* "BB@T %%)2T %)2T4  HHHH 2BEHH *#110 E
M%+10 E%+10 "BBB@!**6B@ HHHH ****  TE+10 "BBB@ HHHH *0TM% "44
MM% ""EHHH **** "BBB@ HHHH *2EHH !1110 4444 %%)10 M%)2T %%%%
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M** "BDHH 6BBB@ HHHH *,T4E "T4"B@ HI** %HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHI10
MF*6BB@ HHHH **** "BBB@ HHHH *3-+24 &:,T44 %%%% !FBBB@#S^\^&]
MW>>.$\6'Q"8[^)OW*K9+L6/! 4@MR=I(SQZ\5UOB'2GUWP]?:4ET;7[7"86F
M"!RJMPW!]1D?C6G10!S7A?P=!X<\)/X<FN6O[-O,4^8@0E'^\IP?4MS[USL'
MPCM ;&RO-6GNM"T^X>XM-.:%1M+')5I,Y9<]L#J:]'HH X:7X=/-\0H_&#ZW
M+]JC?Y(1;KM$>TKLSG^Z2,_C5%/A!96^OWM[8ZUJ%GI]\Q-U80':LBDY*;AR
M%SGMG!QFO2** //M3^%ZZM//#=ZW,VDS7OVPV'V=/D.>55^J@]#BG:C\+H-4
MDNH+K6+F32[F^-\]FT2':Q.2J/C<@QQQVKOJ!0!Q,?PZ2/X@OXL_M60NZ^6U
MJ8%V&/9L"9SGH!S[52B^$>F(L5A)J5Y+H,-X;V+3'QM60C&"_P!XKUX]^O7/
MHE)0!PE[\.&N_&USXG37KF"XFA:$1QP1D(ACV  G.<=>E9D/P9LD\'7'AN76
MKN2WDNUO(G$:KY<@4J>.X(/0GL,5Z=10!P&D?"NRT;Q1;:];ZUJ;W,4 B?SI
M QE(7:"3CI@#Y>G JUX&^'J>"+S49XM6GNQ?;3)&\2J-P)(;CG^(^W/TKM:*
M .$\<_#5/'6H6T]WK-Q;V]LN([>.%2 3]XY/.3@?E4MSX$U/5+VQDUGQ;>7U
MI:7$=Q]D%K%$DC(01NVCD9'.??I7;T4 >?O\*[675->U"37-16;65>*<1+$H
M\IB#LY0^F,C%.F^$VBS^#(_#4MW>20VTKS6EPY3S("W) PH!&<D@^O4<8[VE
M% '#Z3\,;#3?%$/B2;5]6O=3C0*9)YEPYV[23A<XQQC./K5:;X2:-++) M[>
MQZ--=?;)=+4KY33#C(;&X+CC /ISQ7H-)0!R.J?#W3M5\867B5]0U"&\L@BP
M1P-&L:JI)VX*$D'+9Y[U:U_P7;:_J7V]M3U&RE:T:SD6U:/;+$Q)(8.C9ZGZ
M5TE+0!P^J?"GPUJGAW3=&D6YB33E*V]Q%(!*,G+9)!!R>3Q],47OPOT>^\-G
M1)K[4S').MQ/<F96GG900-[,IX'8 "NX-)0!P2_"K3EUNPU?^W-:-Y8PI#;N
M98OE15V@?ZOT)_.IM#^%FA:)I&JZ4)[Z\LM3"B>*ZD4X*Y(92J@@YYS["NWH
MH X72?A/H&CV-[;0W&HRFY@DMUEFG#-;HXPPC^7"Y]<&JH^#'ALZ2NEO=:H]
MDD[7"1&=<*[  GA<] !7HE% '(:[\-M!\1:GIVH7_P!K\^RB$(,<VWSD'0/Q
MGN>1@\UTFIZ>FJ:9/8/-/!'.FQG@;:X7N <'&1Q^-6Z* .<\)>"M,\&0W$&E
M379@G8.T4TH=0W3(X&#C _"F:_X%TOQ'KEEJ]Y<7T=U98^SF"8($(.[/3KFN
MFI: ,7Q'X7TSQ1:P0:BDFZWE$T$L3E'B<=U-)H7A;3?#\UW<VJRRWEX^^YNK
MA]\LI[9/H/05M&B@#*TCPYINAWVIWEC$4FU*?[1<$MG+>WH,DGZDUCV'PZT.
MPUC4M3#7=Q+J22)=QW$VZ.4.<D%<?EZ5UM% 'GP^#/A$V\<$B7\D,4A>.-[Q
M]J9ZA1V&>?7('-:GB'X;>'O$U[:WM['<I=V\8C6:"<J[*.@8\Y(YYZ\]:ZVE
M% '*:M\.?#FKV.F6LEM+ FF#;:O;2E'1>,C=U.<9SUSSGFDT/X<^&_#TE_)8
MVTVZ^B:&?S)W;<C')'7]>OO764E &-X8\+:7X1TLZ=I,3I"TAE8R/N9F.!DG
MZ #\*VJ2EH **** "BBB@ HHHH **** "BBB@ I*** %HHHH ***2@ S1FBB
M@!:*!10 4E%% "T444 %%%% !1BBB@ HHHH **** "BBB@ HHHH *,444 )1
MF@T4 +1110 F:6DI10 4444 %%%% !1110 F:,T44 &:6DI10 4444 %%%%
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M ,;:?>QKI-[(UU(;5PF&F1^#_$=H)-=K?PWNE_M)QZB^FWDUO=!%B:&(L#F
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M;+JEV+N!U,<2JFP*!C;TSC!//7FNTI*6@ -)2FDH **6B@!*44E** "BBB@
MHHHH ***2@!:*2B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&+!I<6S,#D,R 98^S$CCI5K5])&KV:VIOKRSC#98V<@C9UP1M)P2!SVP>.M
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M@ HHHH **** $-%!HH 6BBB@ HHHH **** "BBB@ HI#10 M%%% !2&EI#0
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MVW_[^K_C0!;S1FJG]IV'_/[;_P#?U?\ &C^TK'_G\M_^_HH MYI*J_VE8_\
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M+0?X4[^R?%1Z:KJ@^K0_X5WE% '!_P!E>*,Y.IZI^#PC^E+_ &/XD(_Y"FK
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MSVZ_PU(GA+41PTMZ1Z_VF_/_ ([7>X'I10!PH\(WV?\ 7WG_ (-'_P#B:?\
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M##+$@=OMUQS_ ./4[_A!EX!48]?MUS_\77;TF* .*'@50,8'XW]S_P#%4?\
M"#)W4'_M_N?_ (NNUHH XK_A"(P>BX[_ .GW/_Q=+_PA,?8+_P"!US_\77:4
MM '&?\(1'C[H_P# VY_^+I?^$)C]!_X&W/\ \77944 <;_PA,?H/_ VY_P#B
MZ5?!:+G 7_P,N/\ XNNQHH XX>"8\?=7K_S^7'_Q='_"#V^02@+>]W<?_%UV
M-% ''-X(@+9\J/ICFZN/_BZ&\#6S<^3%GM_I$_\ \77848H XL^!86W?N[?/
M&,R3GIZ_/S3?^$ M2-QAM=_KOGQ^6^NVQ[4M '$CP%;!\^198]S-_P#'*!X#
M@& (K$ 9X_??_'*[:B@#BQX%A[Q6&/\ <F_^.4[_ (0:#_GA8_\ ?$W_ ,<K
MLJ* ..'@:WS_ *BRQ_NR_P#QRD_X0: GF"QQ_NR__'*[&C% ''#P+;_\\;+/
M^Y+_ /'*1O UN>D5D#GGY9?_ (Y79TE '&'P%;Y;Y+/!Z#9+Q_Y$I/\ A K?
M'W;/_>"2@G_Q^NTHH XT> [?YLI:>WRRG_V>FOX"MLYVVOI]R3_XNNTI<#TH
M X<_#^U<_O%M2.W[N0_^ST[_ (0&TSPMKGU,4F?_ $/_ #Q7:X&>E&,=J .+
M/@&V#%O+L^O3RI.GI]^A? %B!DQ6K'&,F%_Y;_Q^M=IBC ]* .(_X5Y9!@=E
MIWQB!ACZ?-0/A[9A54)9!@,9^S'_ .*_SDUV^!Z"C'M0!Q0\ 66T*(K+ ZYM
MCS_X]^'TIO\ PK^S)+>79?3[.V/_ $*NWP/2C ]* .*'@"UV\1V1Y')MVS^/
MS<_C2CP%: _-%9'/_3!OS^_^/UKM!2X'I0!Q!^'=F<@I9;>P^S'C_P >_P Y
M-)_PKFRSDQV'_@*?_BJ[BB@#AC\-M.W9$%@,CG_1?_LJ/^%;Z?CB'3\_]>G_
M -E7<44 <*/AM8YYBT_'_7I_]E2CX;:</^6&GX]/LG_V5=S10!PY^&VG'&(-
M/&/^G3_[*G#X;::,?N;#WS:?_95VU+0!PW_"MM-!/[C3^N1_H?\ ]E2+\-M/
M SY.G[NO_'G_ /95W-% '#GX;:?M&(=/SU/^A_\ V5/_ .%<Z?G(AT_)Z_Z$
M/\:[:B@#C/\ A7FG$C=#IY ]+%?\:#\/--[6^G#_ +<%_P :[.B@#BE^'FFJ
M"#%IQ)/_ #XK_P#%4[_A7NF_\^^G?^ *_P"-=G24 <>OP^TT=8-/_P# %?\
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M HHS1F@ HHS10 4444 %%%% !1110 4444 %%&:* "DI:2@!110** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,T %%%% !1110 4444 %
M%%% !111F@ HHHH 2E%)2B@ HHHH **** "BBB@ HHHH 2E%)BEH **,T9H
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M<+)O586*960[2"1C(';)_"@#VZT\6:-XB74M-L;R>*_@A?S8'C>">(8QN 8
MC!(Y]<5S7P3UO5-=\(WMSJM[-=RI?M&LDS[F"^7&<?3G]37$> KJ2U^*>KW&
MH-J$KW>E-()Y[8HS95'W,H'RKA6 [=!UK<_9]DFATK6;*;S(RLZ2K&ZD=5()
M&?\ ='Y"@!?B5>:G8?$KPY8V6M:I;6NJ2Q)<10W3*N#($.T _+Q4J:]J_ASX
MQV/ABTUJZU;3+I!YL-TPE> G<2-^,Y  //8\]JR?BW/9W?Q*\."0&:VLWC%[
MMC9@B^8&(.!_=YXJOI\3?"OXD+=>0]YX>U9-\5TL/F/&AY&#C.5R,CN"#C.*
M /6-8\?>&]"U"2ROK\K-"JM/Y<+R+ &( ,A4$+DD=?4>M<]XF^*-OI7C32-#
MLUDEB=A+>2QPM)F-D)58P.6)X.1_CCS*\L[2S^(?B*S\3)JPL-:D>XM1IYW?
M:E,F^,8P<CI]".:V=;MI= ^*7@BX?2[U((M/AB$2YGDWCS!LW<!F *@]AQVH
M ]1_X6+X;^W:G9?:IQ<Z9$\UU&UM(&5$(#$ CG&0>.W/2F_\+)\,_P#"-CQ
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M\J:8RB[\E3(8V,B.%P.^ 1Z9% 'H]G\5-!OK?6I(;;40^CQ&2XB>W^8@':<
M$]#USC Y/ -8GA+XLPW?AC4=8U^&YA2*Y;RG2#]VP)&R%&_B<>_;FN4\&:-J
MTVJ>/DDTG4+9M4L;I;7[3;/&'+%L#)&,_,.,U6T"TDG^$[Z!JGAO6'3^U0))
MXK=M]N3G+HN"6*[2",#[V,YH ])U;XH65CX9U75(-,U#S["5;=H+B'85D=<J
M6P3A.G/?(QU%0:#\2[:+P7I5]KJ7_P#:%TRPQJUJ$:[D.#NB&0"GS#YN!7G^
MG>'_ !!/\,?%]C!%<:A9O);MI\[0,DMRD;@DJK#>0$"X!Z=!4^IS:Y<_#;PE
M;VWA6]EEMW\O[4]F))80H0[HTP<!N0&8<[,]\T >G:7\1]%U;2M4O+>&]$VE
M@F[LFB'GH!U(7."!@]^QK(@^-?A:XEL@L6I)%=2^5YTEN%2-L]&.?<'C. 17
M$>#=+U31+[QTMYHVL)'<V4P@>:!I&<DG:"RCYW.X=,]SQ7/7.E:L_P ,M'TI
M=!U<WT&IRSR)]@E^5-HP<[>^?T- 'M_B?QII-GJ,GALPZC>7TT#--'IZ$O!&
M1]\D$$<<\'/YC/EG@[Q'<-\+O%4VJ:OK#0B>.%+N-C++ &X#89AP3@$ ]_QK
MH)K?4_#GQENO$S:-J>H:9JEIB)[>W9W4E$PK+C*\IC#8P"/0URVEZ+K<7PH\
M7VD^A:G%<WUU;R6\1M7+.!*"0 !G@*><8H ]#MOB;H/AKP]X=BO9-5NHKNS4
MQ7CPAC)M.QBPW$[@1DXSU')K8\/_ !*T/Q!/JT 6YL9=+5Y+A+R/8PC7[S8R
M<8[@X(KQ_7=%UB3PYX"\O1M3=K&.0W*+9R%H_P!Z#R-OL:Z/3;267XG>-KRZ
MT?5/[+OM-N(E8VDD?F\)N4$KP2%;&: .CD^-.BI';S#1]8>WNW>.SE6%,7#*
M0"%&[/5@.E>D1/YL22;&3<H;:XP5SV/O7RYX9UKPP]GH%IXCU.^%MIEQ).MM
M%9#8&9P?FD#DLOR@\)GDBOJ.*2.:))8F#QNH964Y!!Z$4 /I#2T4 )2T44 %
M)2T4  HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH 2EHHH #24M%
M !1110 4444 %)2T4 )2T4E "FDI:* "BBB@!*4444 %%%)0 M%)2T %%%%
M!1110 4AHI: $HI:* $%+110 444E "T444 %%%% !244M ""EHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:* $I:*2@!
M:2BEH 2B@T4 +124"@ I"BDY*@GUQ3J* &E%8Y*@GW%&Q,YVKQ[4ZDH 38F"
M-JX/;%)L3CY5XZ<4ZB@ P,@X&?6C QC QZ444 &!G..?6BEHH 2BEI* # )!
MP,CH:7%)2T %%%% !1110 E%+10 E%+10 E+110 &DI:* $HI:* "BBB@ HH
MHH **** "J]_9PZCIUS8W&[R;F)X9-K8.U@0<'L<&IS10!PH^&%H^B1:%<:S
M?2Z-$V5M?+A5B,Y ,@3=^H-=Q%&D,211*$C10JJHP !T IU% "T444 %%%)0
M M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%!I*
M %HHHH **2E% !1110 4E+24 ***!10 4444 %%)2B@ I*6B@!*6BB@ HHHH
M **** $I124HH **** "BBB@!**6B@ HHHH *2EHH 2EHHH **#24 +1110
M444&@ HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@
M I<TE% !1110 4"B@4 +1110 48HHH 2BE-)0 4444 +1110 4444 &****
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MQ>&'RZ)@#G]U<_\ Q-._M_Q<#@IHG//^KN3_ .RUWE% '!_\)!XM!Y71<?\
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M49HH **** "BC-% !111F@ HHHH 2@4N*.E !11FB@ HHHS0 &DHHH ****
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M*** "BBB@ HHHH **** "DI:* $HI:* "BBB@!*4444 %%%% !1110 4444
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MMTM[\_\ ;H_^%.'B.U/_ "[7_P#X!O\ X4 ;&*.E9/\ PD-M_P ^U]_X"O\
MX4A\0VVT'[-?8/\ TZOZ9]* -?-%9'_"0VV"3;7^!U_T1_KZ4?\ "0VV<?9K
M\?\ ;J_^% &O25E?\)#:_P#/M?=<?\>K^N/3UH_M^V)Q]FOO_ 5_\* -6BLK
M^W[; (M;\@],6K^F?2@:]"Q&VRU @C.?LC_X4 :M+FLK^W(@,FTOP/\ KU?_
M  H.M)@_Z#J.?^O5_P#"@#5S162VN*&P-/U$^XM'H_MQ/^?#4?\ P$>@#6HK
M(_MY=V/[.U/Z_9&Q0=>&<?V9J9]_LK4 :]&*R/[=X/\ Q+-2_P# 8THUS=@#
M3=1!/'_'N: -;I1FLC^V9#@?V;J'7KY'_P!>H(/$T$FNV^D2VEY!<3Q-+&9H
MMJL%QNP<]LCM0!O9HS244 +FBDI10 49HI* %HI*6@ HS2&B@!:*** #-%)2
MB@ HHHH **** "BBB@ Q1THH- !FBDI10 4444 %%%% !1FDHH 6BBB@ HHH
MH **** "C-!I* %HHHH ***#0 9HI*6@ HS124 +10** #-&:2B@!<T4E**
M"DI:2@ I<TE% "T4"B@ S1FDHH 7-%)2B@ HHHH *,444 '2C-(:* %HHHH
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MQ_V]I_\ $4A\&R9'_%5^(_\ P+3_ .(KPGQWY;ZUXOF2X_M*XBOHC]L8;#9
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MB@ HHHH **** "BBB@ HHHH *#110 E+24M !1110 4444 %%%% "4HI*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHI: "BBB@ HHHH *
M*** $HHHH **** %I*6DH *6DI: "DHHH 6BBB@ HHHH **** "BBB@ HHHH
M *0TM(: "EI*6@ I*6DH **** %H-)FB@ K@O'"_Z)XF/_4%8?J:[VN'\4:C
MI%KK-[8:U]I2VO\ 3_)#1P/(#R0<%0<$9!Y% $]QX!\/>(X;'4-4M9IKE;6-
M4<7,B^6 HQM ; Z9X]3733:=!<:2^FRF5[=X?(;,K;V7&#ELYSCOG-<!%XRL
M;6WBMX]?U4K'&J*1I7HONO\ DT__ (3JSP?^)[JW3_H$C_XF@#73X7^$DTQM
M-_LZ5K%KG[48&NI=OF;2H.-WH3^GI4VJ?#GPOK%C96E[IQD2RC$-NWG/O1!T
M7=G)'UK!_P"$ZLP1G7M6(_[!0_\ B*?+XUM$Y77]5=2,_+I0_+E* .[T[3K/
M2;"&QL+=+>UA7;'&@X _K]:I:]X9TGQ-!'!J]N]Q!&=PB\^1%)]2%8 GZUQK
M>.K4;?\ B>:QSV&E+_\ $TI\>6@QG6-9_P#!4O\ \30!W.CZ+8:!IZV&F0M#
M:H25C,KN%SUQN)('MTK'C^'GA6+Q"-=32(EOP_FA@S;0^<[MN=N<^WOUK C\
M;03,P35]:.."!I2__$T]/%Z2MM34]<)Q_P! I>__  'VH U[WX9^#]0N;ZYN
M=%A>XOF+S2;V!W$Y++S\ISSD8IUQ\./"=U!8P2Z2/+L5*6RK/*OE@G<<88<Y
MYR>:R?\ A*<'G4==.<_\PM?_ (FE'BC/S#4==..W]EK_ /$T ='JRXU_P[C/
M$\PZ]O(?\:Y3PGX6T;Q/X&MH-8M&NHH;VZ9$,TB@'SG&2%89/N?4^M68/$VG
MK=03WQUJ\>%RT&^P*>6Q!!^Z!G(8CFL_2M0M]&M&M;34-?2#S7E5/[,4[2S%
MCSC)Y)H ZFQ^'_A;3[JWN8-(C,MN (&FE>7RL$D;0[$+R2>*LZSX.\/^(;^W
MOM6TN&[N+==L;N6X&<X(!PPSV.>M<W_PDIVD#4M>Z8_Y!B__ !-._P"$ER#_
M ,3#7O\ P6K_ /$T ;EEX#\+Z=;W\%KHMLD5^NVY4Y8.O7').!GG QCCTI8O
M OAB#09-#CT>W_LZ1_,>$[B2W][<3NSZ'/%87_"2#OJ.O?\ @M7_ .)II\1L
M2<:GKP_[AB__ !- '4Z#X7T7PQ!+#HVGQVB2D&3:2Q<CIDL23C)_.J>N>!/#
M?B2]%YJ^GM=3A=H+7$H"CT # #\!6$/$/RX.I^(#[_V<OI_NT]/$*J!OU'Q"
MQQVT]1V_W* .S33[:/3!IRH_V41>3M:1B=F,8W$[NG?.:YV+X9^#X=.N-/CT
M=5M;AT>6,7$OSLN=ISNSQD_G6>?$$+==0\2?A9(/_9*3^WH/^@CXF_\  -/_
M (B@=F;-SX!\+WFCVFDW&D1265IG[.A=\QY.3AL[N3[U:G\):!<Z#'H<VE6[
M:;%_JX-O"'GD'J#R><YY-<Y_;T'_ $$/$W_@&G_Q%,;Q'".EWXI;Z6D?_P 1
M0'*S?T[P+X7TF^BO;'1+6&YB "2A22N.,C/?WZUR/A] GB3P@ ",66H<$8Q^
M]%75\1JRDF7Q:IQD VD7/_CM&G(VJ^,]%O\ 2M,N[+3=.M[A)A<Q^5DRX("C
M)SR#G'2@'%H]#HH'2B@044F:,T +129HS0 M%)FC- "T4F:,T %%%% "T4F:
M,T +129HS0 M%)FC-  :*** %HI,T9H 6D-&:6@!*6C%)F@!:*** $HHHH *
M!10* %HHHH **3-&: %HI,T9H **6B@ HI,T9H 6DHS10 4444 ***2C- "T
M4F:,T +0:3-% !2TE% "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%
M)FC- "T4F:,T +129I: "D-+2&@ I:2C- "T4F:,T +129HH 6@T4&@!*6DI
M: "DI:2@ HHHH **** "E%)10 M%)FEH **** "BBB@ I#2TAH *6DI: "DI
M:2@ HHHH **** "FL5'WB!GU-.KF?$7A(:[J4-Z)X T<)B\N>$R*><Y&&7!H
M Z/S(_[Z_G1YL8_C7\ZX<_#O=UFTL?2P;_X[2'X<YZSZ9_X+V_\ CM '<^;'
M_P ]$_.CS(_[Z_G7#'X<Y4CS]-!/0_V>W'_D6@_#K/\ RWTSZ?8&_P#CM '<
M^;%_ST3_ +ZH\V+_ )Z+_P!]5PO_  K@<?O]-_\ !>W_ ,=I1\.!WGTW_P %
M[?\ QR@#NO-B_P">B?\ ?5)YD7_/1/\ OJN%?X;*1\MS8*<_\^!/_M2D'PV&
MXEKJPP>PL",?^1* .[\V+_GHG_?5'F18_P!8O_?5<2/AX/,5C/IV!DD#3AR?
M^^^GM31\.1CFYT\MZ_V</7/3?]/PH [GS(O^>B?]]4AEB R9$ _WA7$#X=C&
M#<Z>5W;O^0:N?SW=/:GQ^ &B)V7&F'@#Y]*1NG3JWY^M ':>;%G'F)G_ 'J1
MIX5&6E0#U+"N._X0$M\KW&F[223MTJ-3SQUSQQ^M \ )N#&?3\@@X_LU,>_&
M?8?KZT =D)X3QYL><X^\.M)]IM_^>\7_ 'V*Y$>!!AQYNF?,<Y&E1\=^,GIG
M]./>E'@4 Y\[3.F#_P 2F+^O?- '6-=6R@[IXACKEQ2?;+3M<P\_]-!7+#P.
MNUP9M.R?NG^R8>/KQS2'P*I8XN+ *<<?V3!QZ]J .H-]9_\ /U!UQ_K!U_.C
M[?9''^EP<\_ZP?XUR[>!4)!%Q8#DY']DP=/RH_X02,CFYLP?]G2K?_XF@#I_
M[0LL9^V6^/7S5_QI#J6GCK>VW_?U?\:YG_A!(\M_I-G@]/\ B56_'_CM(/ 4
M6T W5J2._P#9=OS_ ..T =-_:>G_ //]:_\ ?Y?\:3^TM._Y_K;_ +_+_C7-
M?\(##@8N[?WSIEM_\10? ,7_ #]VW_@KMO\ XB@#IQJ>GX_X_K;_ +^K_C1_
M:>G_ //];?\ ?Y?\:YG_ (0.'(_TJV'KC3+?_P"(IQ\"0L>;N'!.2/[-MNO_
M 'Q0!TG]IZ?_ ,_UM_W^7_&C^T]/_P"?ZV_[_+_C7-CP+&L>U+]%8=#_ &=;
M<>O&RGQ^"1&H U+&,XVV%L /_(= &^VK::F-VH6BYZ9F4?UIIUG2@2#J5F".
MN9U_QK$_X0TY)&J-GU^PVWX?\L_K3E\'C<=VIR%?06=L#_Z+H V1K>DG&-3L
MCGIBX7GG'KZTG]MZ3C/]J66/^OA/\:RO^$/CS_R$9L?]>EM_\:H/@^/MJ,W_
M ("6W_QJ@#4&NZ0QP-5L2>O%PG^-*VNZ0J[FU6Q ]3<)_C60W@]<?+J4HY[V
M=L?_ &E3O^$/B_Z",W_@+;?_ !J@#3_M_1MQ7^U[#<.WVE,_SI#XAT0==8T_
M_P "4_QK,7P;$O349^@'-M;'_P!I4#P=$O349_QMK8_^TJ -/_A(M$_Z#&G_
M /@2G^-'_"1:)_T&-/\ _ E/\:RSX-A((_M&XYZXMK;_ .-4A\%PD$?VE<\G
M/_'O;_\ QJ@#5_X2+1/^@QI__@2G^-'_  D6B?\ 08T__P "4_QK)_X0J#)/
M]I7//_3"W_\ C=.'@R'<3_:-Q_X#V_\ \:H U/\ A(M$_P"@QI__ ($I_C1_
MPD6B?]!C3_\ P)3_ !K)_P"$*@Q_R$;GKG_46_\ \;I?^$*@XQJ5T"./]3!Z
MY_YYT :O_"1:)_T&-/\ _ E/\:/^$BT3_H,:?_X$I_C67_PAEN'!&H7(XQCR
M8/\ XW0/!D(55_M.[PIR/W4'_P ;H U/^$BT3_H,:?\ ^!2?XTP^)M"'76+'
MKC_7K_C5%?"$*ON&I7B\[CM2%<GZB.GCPMZZQJ))Z\Q>O^Y0!:'BC02,C6++
MM_RV6D'BG0=BO_;%EAC@?OESTSTJM_PBPXSJ^H\>\?\ \10/"P Q_;&H^_,?
M_P 10!:_X2K0-A?^V++ X/[Y<],]*7_A)M"_Z#%C_P"!"_7UJM_PBXYSJ^HG
MG/6,?^R4G_"+)QG5M1X_VX__ (B@"P?%6@*2#K%ED9_Y;#TS2-XLT!1DZQ9=
M<<2@_P">M0?\(K'D?\374N.G[Q/3_=Y_&D/A. @#^T]3X  _?+V_X#0!8;Q7
MH"[LZQ9?+UQ*/7%-/B[P\"!_;%ID_P#30>N*K_\ "'V^ /[4U7C_ *>!Z8]*
M4>$X0"/[5U0@^LR__$T 3?\ "7^'O^@Q:?\ ?RC_ (3#P\,?\3BTYQ_'ZU#_
M ,(E!D$ZIJF0/^>R_P MM(?"%N1C^U-5[_\ +P/\/:@"?_A,?#N5']L6GS<#
MYZ0^,O#@SG6+7@X/S5"?"%N23_:FJ\_]/ ]<_P!VC_A$+?(/]J:KQ_T\#US_
M ': )/\ A-/#G_08MO\ OHTO_":>&_\ H,6W_?1J$^#K8KM.J:MCC_EY]/PH
M_P"$.MA_S$]5Z8_X^?;'I0!-_P )IX<_Z#%M^9H_X3/PY_T%[;\S_A4'_"&6
M@((U/5ACM]K/^%*?!MJ5(_M/5^?^GL_X4 3?\)GX='_,7MOS/^%*?&7A[_H+
M6_YG_"H3X/M2?FU+5CSS_IC#/Y?04K>$;9PV[4]7RQR3]M8?A]* )O\ A,/#
M_P#T%8/U_P */^$O\/G_ )BD'Z_X4P>%80%']JZP<=S>MD_YP*!X5B&?^)MK
M))ZG[<P_E[_YQ0 __A+_  _G']J0?K_A36\9>'E&3JD6/8,?Z4W_ (12#D_V
MMK6<8!^WOQ^M#>%(&_YBNM8QC OW_P : '?\)EX>_P"@G%_WRW^%'_"9>'MH
M;^TXL'T5C_2D'A6#.?[6UKKT_M"3_&C_ (12#MJNM >@U"3U^OX4 '_"9^'N
M/^)G'S_L-_A1_P )IX=_Z":?]\/_ (4#PK !@ZKK1Z<G4)/\:/\ A%8.?^)K
MK1ST_P")A)Q^M !_PFGAW_H)IZ_<?TSZ4A\:^'0,_P!II_W[?_"C_A%(?^@M
MK?\ X,)/3Z_C2_\ "*P8Q_:NM=",_P!H2?XT '_":>'<D?VFG'^P_P#A2?\
M":^'< _VFG/_ $S?_"E'A6#)/]JZT<YX_M"3C]:5?"L ZZIK+?74)/\ &@!O
M_":^'?\ H)IV'^K?_"E_X37P[_T$T_[X?_"E_P"$6M\_\A+6/_!C+_C2?\(K
M!S_Q--:Y'_00DX_6@!K>-_#JKDZDN/:-S_[+1_PF_AS /]I+S_TR?TS_ ':>
M/"MN"#_:>LGV_M"3_&@^%K<G_D):R/;^T9?\: (QXX\.$C_B9#G_ *8R?_$T
MX^-?#H_YB2?]^W]<>E/7PM:J %U#5U4#  U"7'_H5'_"+V^/^0EK'_@QE_QH
M 8?&WAT?\Q)?^_;_ .%)_P )OX<_Z"2_]^G_ /B:D'A>W'_,2U@_749?\:!X
M7MN,ZAJY([_VC+_\50!$?''AP#/]I#_OS)_\30?'/AP$#^TAS_TQD_\ B:E_
MX1:UQC[?J^.O_(1E_P#BJ!X6M02?M^KY/4_VA+_\50!%_P )SX<&?^)D./\
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MTY?"EFJ[5O=5"^@U"7_XJ@"/_A.?#?\ T$AZ_P"ID_\ B:3_ (3KPW_T$O\
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M 4&B@T )112T )12T4 )12FDH **6B@!**6B@!**6DH **** "BBB@ HHHH
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MHH **** %HHHH *0TM)0 4M)2T %)2TE !1110 4444 %%%% !1110 4444
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M/ZT#4]/)XOK;KC_6K_C0!;H-53J5B.M[;#_MJO\ C33JNG?\_P#:_P#?Y?\
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M5W45I<^)_!:VFO6[V5Q?6VR[AA?!0GJ >?RYZXH \S_X2[0!QY$WU_X26/\
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M^T/"%G$\C 1Q#6G>1R3QM4*6//H*32YK/5[F6WL_!UHUS$,O!+JTD<@'KL=
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M:I&T.QV)7.!NPV.-I(^8X[5*WB.^7'_%+ZN><''D\?\ D3FL[4[B'6UB35?
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M_P!!'IQGGY*:^K>($ZZ3IW_@RQV_W* ,[PW\/X/#TNIZDU\U]KVH!_,OYXL
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M<RV-O=WELEO'&ESO0!2S;B<#KN(QCM[T :?B'0Y_$.@+IT=XEM'(%,C-#O)
MP0!\PQR*E\/Z')H^@KI-U<QWD*!E4B'9\ASD$9.>IJFNIZ_&NP6>D$+@ _V@
M>G_?'I3AJFOY!-GH^.X^WM_\10!S&A_"B?0-2N5L?$UW%H=Q,LLFG)$ 6 .0
MIDSD#L2 "1P:O:'\.[C1_B)J'BQM7CF^V^:&MA:E=JL01AMYY&!SCGGI6T-4
MU_!!M='SZ_;VP?\ QRF_VIXCZ"UT4<]?MS?_ !- &+J/PZO+[XC1^+DUN*-X
MEV16[698 ;"O)WC/WB>U<];_  0FA\-7&AMXC1K>>Z2Y9Q8X8%5*@#]YC^+T
MKO/[3\18_P"/?11_V^M_\33!JOB YS%H?3=_Q^MT_P"^: .:U+X57.H7'AF7
M_A(%C.A00PQ@660YC(.X_/QG XYZ5#-\)+R36/$>H)XBC4ZW'+%(IL<^6KN&
MX/F?[(%=6FJ^(=N6BT+GD8O6Z>OW:<NJ>("P(AT1D'7%ZW)_[YX]* ..F^#<
MMQX/T[0)/$3#[!=O<1S+:\$-C*E2_4'.#GOTK3T#X61Z+X@UC4)-;N;N#58)
M(IX7B56<ORS,P]R2, 8S6Z-3\1;@#;:*1W(O6_\ B:4:GXA*_P#'MHH;_K];
M_P"(H Y33_A%<:=X/U/P]'XEE:&_E5CNMALC4$$X7=]X[0-V>W2KJ_"]HM-\
M.B#5U35M"8_9[PVH*R(6SL=-W(]PW<^M;KZKXA4<Q:&N>A:];_XGZT-JGB(8
M_<Z&N?[UZW_Q- &"/A8L?A#6=(AU=A?:S.LUY?/!G=AMVU4W# SGN3\Q]L9C
M?""_=_#I;Q/&1H>/('V#KB3?S^\^@_"NR;5/$"YRFA+QD9O'_P#B:)-4U]5
M$>AANO-ZW/\ X[0!IZ[87.J:'>6%I=1VLMS$8O.DB,@4,,'Y=PYP3CGKZ]*\
M]TCX0W^BZ9?:3:>+98].OP!<HEDHD?C! <L< C(X%=:-4\09Z:"><8^V/]/[
MM/\ [4U[E0FAEQ_T^MTSCIM_SB@#%UGX5Z9>>!8?"VF74VG013"?S0-YE?G)
MD'&[.?;&%[#%1>'_ (7MH'C2/Q$OB"ZN6\CRIHIHES+\H7[PZ*,+@ ?PCFMU
M=4\0E<^5H;@C@K>L /\ QWFG?VEX@W?ZC1=O_7ZW'_CE '.Z+\)+32[;6]/G
MU:XN=*U-6 M-@01$D$/G)W,,#!P/I2^'?AU<^%[%UNO$-UJ5G:1RM:6?E^7'
M&S \D!B6/+<=.3Q70'4O$1(*Q:&5/_3X_P#\34,NI:]-"8I4T-4D&UB+ULX(
MYQE?2@"CX<<G5_#X#M@Z"-RD_P"TF#_GTKN*Y'3;:.T\3Z3:6\ZW$=II+Q&5
M3UPZ#D#@=#774 %&**6@!**4TE !1BE%% "8HQ2T4 )BC%+10 F*,4M% "8H
MQ2T4 )BBEHH *#10: $I:2EH *3%+10 E%*:2@ HI:* $HHI10 F**6DH **
M** %HHHH **** "L^YTN&61IT'ESDYWCO]:T*2@#&=+VV^8QB4<8,?/Z4SS;
MQCLCMI@,YY7%;F*,4"L8R65].5\UUB3'0'+5?L[-+.)D0L<G))JU1B@84444
M %9>J:%:ZK<13S3744D2,BM;SM&<,03R.OW1^5:E% '.?\(=:_\ 05UK_P #
MWI?^$-M?^@KK7_@>]=%2T <X/!UJ#_R%-9/_ &_O0?!UK_T%-9'_ &_O71T4
M <X/!UJ#_P A363[&_>E'A"T Q_:.L$^IOY/\:Z&B@#GO^$/M./^)EK''7_3
MY.?UI_\ PB-EG_C^U;_P82^OUK?HH Y\^#[$KM^W:MCN/M\G/ZTA\'6#8W7N
MJL0,9-_)T[]^_'Y5T-% & WA&Q/_ "]ZH/3&H2\?^/?C^%,'@W3<-FXU(L?X
MC?2Y'_CWKS714E '/CP;I87 EU'CH?MTO'_CU*/!NE@8\S4,'_I^E],?WO3B
MM\4M '/-X-TECDM?D^]]-_\ %4?\(9I6,"2_'.1_ITO'T^;UYKH** .>/@O2
M#G)ON>O^FR\_^/4#P7I Q@WW'3_3I>/_ !ZNAHH Y\^#-);J;XY];Z7Z?WJ;
M_P (/HO]V\_\#)?_ (JNBI: .<_X0?1?[MY_X&2__%4G_"$:+_=O/_ R7_XJ
MNDI* .>_X0G1<$;+OG_I\E_^*IO_  A&B_W;S_P,E_\ BJZ.B@#G/^$(T7^[
M>?\ @9+_ /%5)_PAFB$\PW!&,8-W+C_T*M^B@# _X0O1, &&X./6[E_^*I&\
M$Z"_WK:9N ,FZE/_ +-70T4 <\/ _AT #^SS_P!_Y/\ XJC_ (0?P[G_ )!W
M_D>3_P"*KH:2@#GO^$&\-XQ_9HQZ>=)_\51_P@WAS&/[.X]/.D_^*KH:* .?
M_P"$)\/8Q_9YQZ>?)_\ %4G_  @WAL@C^S1@]?WTG_Q5=#10!SI\">&B23I@
M)/<S2?\ Q5)_P@?AG_H%K_W^D_\ BJZ.B@#G3X$\-'KI@_[_ $G_ ,52?\('
MX9_Z!:_]_I/_ (JNCHH YS_A _#/_0+7_O\ 2?\ Q5'_  @?AG_H%K_W^D_^
M*KHZ* .<_P"$#\,_] M?^_TG_P 52CP)X:'_ #"U_P"_K_\ Q5=%2T <W_P@
M?AG_ *!:_P#?Z3_XJE_X07PUD'^RTX_Z:O\ _%5T1HH Y_\ X0CPW_T"X_\
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MM%% "4444 %%%% !1110 4M)2T (:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %H-%(:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %%% HH *
M*** "BC-&: "DHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 6D-+FDH **** "BBB@!1124N: $HHHH *44E% "TE+FDH ****
M"BBB@ HHHH *6DHH 6BC-&:  TE+28H **** "BBB@ HHHH *6DI<T %%&:,
MT )1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !2TE+F@ -)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 M%%% !2&EI#0 444M "44M)0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%+24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% "BBDHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** %%% HH *2EHH 2EHHH *2EHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH
M2BEHH 2BEHH *2EHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH
M2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH
M2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH
M2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH
M2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH
M2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44F:6@ HHHH
M**** "BL34](N+W7=.O(I2D5N<R_.<'!!  ]^];= !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0!#;:@UW<$0VS/;<XN5=2K8]!G/7C\*M0R&:!)#&\989V.,,OL:>    , =
M*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *:'5F90P++U /(IU9MGI(L[B_N$N',U
MX06;:/D(SC _'O0!<FNH8)H8I' DF;:B]R<9-35S]D-8@N3)J=O#<8&8YHE7
M='@D$>O(.>*WP<B@!:*** "BBB@ HHIJ.DB[D=67)&5.>1P: '4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAE_XG Z$9'\7%*?[2+A?^$&N>>_]K #H3ZUV>FL&TNT95"*84(4'.!M'%6J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX*\">)_#45OIEUX@A;1K:X-PD=JA660YSL8GHA/)'.>F<5V0U*]50%T*["@
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M#DGVJY8W2RVJLQ"E>"2>M6,;E*GH1S67IB(US,NW.P\>U &P"",CD44@ 4
M<"EH *X'Q?<2VD'BV>&22.5-+C*/&VU@?FY!KOJX#QFV;3Q>,?=TA?UW?X4
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M/%X-4MEL8XP1^]R=H 'MF@"WXE\*^&O#OAO4=8:PNYOLD#2B-;Z;YB!P/O\
M3-<)!H-Y+X-L?%%A):ZG'<M$US:0O<,UNKL-RJ5FR67."&]">U>P^*=5AT/P
MMJ6I7-L+J&W@9G@S@2#H5S@]<UY-XDTBW\$Z3!XS\ ZP(89I8P=/$HDCN0Y
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M":>:XWL2"<$J <;N>XQ6KXNT[P_X<^']CJD&B6KZA?&W@A,C/L$D@R6;#=
MQJ36)X8/V;V$LJ)OT]40,P&XEQP/4UUEQHFC>+OAO9V.I2J;"2TA;SXI0/+9
M5&&#=,@^O% '#3>'M*\)>,;'2M:M(M3L-0LYYHIS&8Y(Y85WNORD KM''?D<
M^N ME;P^ +?XA265H]H]S^]TI4(18#+Y7ROG=OR,Y)QSTXKJ/#FAW7B7XCP:
MQ+J=WJNBZ+;R6T-Y=JBBXE<%6"!5&Y IY8YR1UYXS_$/A"!HX? GA;5]0GL[
MN[6>ZLU,<D%A#NW,6?;N'(!5=W.#USR 2KX>TSQ7XPU[2-%@@TZ#2K:)HY0A
M<SRR+N&[=G"#I@8/O3]&B\+ZC\+[W7[C0;=-1LA);3Q*\FW[0O  ^;D$E#^.
M*W?%NCZ7X=O;G6])U+4+/7;NV6UBL;&1";Q@ J HZL>,#+#&!DU0\/\ AFXT
M2S\+>$K@B2ZFN9-7U4J=PRA!4$]_FV#/<J: ,K3_  A;ZSK4WAVR6*UFT6PA
M-]=O&7:>[D7(4@\!!@YQ@T[2=!3QOX7TC4/#VCZ?IMV)7%_)<!I$5HSC8$))
M(8X/3@<9K>TJYM/!?Q+\7G5IXK6VU2*'4+>:63"N$#*ZC/5LMT':I_AFLGAO
MX73:OJJ>1YSW&I2*01M0\C@^H (^HH PO"?A%=1\=:Y8ZY;Z;=VNFPQ1G[)
M8D\YP&[8Y"C!]SZU!9^!3X@>ZN=$M;*UL;F\F\B]F!E$,46$4(A;YB[!FR>
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M3K/P[H>G70NK+1M/MK@ J)8+5$< ]1D#-><:IXMM]%OQ::II-]:7#)O2*;7
MI92< C#>Q_\ KTEGXNBU/4X[&RT6[FNG!9(8]=^8@<D@$^A_SUH ]-U#1=*U
M9HVU+3+*\,>=AN8%DV_3<#BK4$$-K D%O%'%$@PL<:A54>P'2O+K_P 4KHDB
MV^IZ%=P3,@81/K@+,,\\ YQ[U3/C.V:V:^&BR/:PR+$\Z^(04$C#(7(/7'I0
M!Z9:>&= L+Q;RST/3;:Z7.)H;2-'&>#\P&>].E\-Z%/J/]HRZ+ITE]N#_:7M
M4,FX=#NQG(P.:\H'Q!TG=*HT[<T:G=_Q4!R!CG]:L/XVTNWG1+G2##++&LB1
M'7R2RL-RL.>AR#].: /5KO2=-U"XAGO=/M+F: YBDFA5VC/^R2,C\*;?Z)I6
MJLC:CIEE>,@PIN+=9"H]MP.*X'2]5?6[<W&F>%Y+N$]9(M?W 'T.&X.:HW_B
MF/1YA;:CX;>TG"AEA;Q Q?'KA22!SUH ]2?3[*2Q-B]I UF5V&W:,&,KZ;<8
MQ[4VPTVQTNW-OI]E;6<)8L8[>)8USZX  SP*\R/B%?[(.L+X;WZ:6 ^T_P#"
M0DH.,<X)P>V*MZ??WNK6<=]8>#Y;FUD!,<T/B L"!U[_ (?48H ] N=)TV\C
M,=UI]I.AE$Q66%6!D P'P1][ '/6I+.PL].@\BQM(+6'<6\N",(N3U.!QDUY
M/_PFFFBWGN4T9/*A8+*YU]P$8]B?7BKMEK4VJ:4^I6GA4SZ>N[-P/$#!/EZ\
MG''^% 'HEKH>D6-RUS9Z58V\['+2PVZ(Q^I SW-7Z\93Q[I1C>0Z/$B(2-TG
MB%U5N_RL>&_ FND\G66?!\"R\'ACKQ]?\F@#T*BO/A!K!!/_  @\WT.O&GI%
MK.0O_"$RK@<'^W3^5 '?45P/E:R) !X)EY[_ -NGCK_G\:4PZPI '@J0\8R-
M</I0!WM<[K6X>(;#C"FSN@3Z\+Q6*8M9!)_X0J0D'K_;A]/\BK&E7,]GJYM[
MWPV+!Y;>61)#J)N"0@&0./ESN'.1T[XH G\#65I??#O0TN[6&X06X(6:,. >
M>>:Z-M,L'L?L+6-LUG_S[F)3'US]W&.O->61ZZECX5@U=O"'V32?*S$[:\4&
MT]@#@Y/IUK6DN+V+37U"7PB([-8O.:5]>(79C.23[4 >BJB)&(U1511M"@8
M'IBH;.QM-/A,-E:P6T1.[9#&$7/K@5YEHVOKX@>5-*\,BZ:'YI%776!7/0D-
M@X/8]*B3Q5:R:S_9(\.Q?;2XC"?VZV"_78&QM+>V<T >II96D=Y)>);0K=2
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M.,L<<\9Q0!ZC'I6G10301V%JD,PQ+&L*A7'HPQ@_C5B**.")8H8TCC485$4
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ML+]XS;Z6DXF\DJN&8L..23@#M]!3]6\-ZSIWQ%3Q?H<$-Z+BS^QWEG)-Y3$
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MOP 7- O;;7?$VO7DFCO87FGQK8CSAMD>)U#_ #@97J.,$\>F:R?@. /A=:D
M FYF)P.OS5O26OC&ZUE;R8:9!:6]NXBLX;R1A<3-QF1S&,*!G  //Z8G@CPW
MXS\%^$!HD5OH5S*CN\<S7DJJ"QSRHBYP?<4 4_BW/]E\3^ ;@6\EPR:KD11*
M"[\IP,]_QK=354USQ@(KW0;BTETFT-[:R76%<NVY&QM8@KC''K^%8VN>"/%E
M^_A.2&ZT^YGT:?[9<3W=S(&GE9MS* (SA1C .>G;BNFN+?QAJ.JZ:)?[,T_3
M89Q-=&VNI)9I@O(09C4!2<9]10!S?P6 U70=1\479675=3O9#/-U*J,;4&>B
MCL/3%=;:^"]'M-;O=32W7==7$5UY0&U$F167> .Y#G/OSUKGM(\)^(O!>K7P
M\./87FA7DYG%A=R/$]NYZ[&"L-OU'0#OR>LT6TU>)KBYUF\BEN)BNV"W!$,"
M@=%SRQ))RQZ\<#% '"Z!%')\>O&L3HK1O86P92.&!1,YK.UX67@_XM^'6M=.
MGEL;31)E2VM(_-E159R3\QR0!TY]<=:Z+P]X9\36/Q+UGQ)J"Z2+/4XDB:.W
MGD:2,( $(S& >G/(Z^V*DU3P[XEN?BCIWB.V72SIEG;M;"*2>1975_O-PA (
M)X&><=1G@ POAQ#+>:GXF\=VD:0Z;J2G[-81L&<E.I<+PK$CIR?F/XVO@DOV
M_P ,W_B&ZF6XU/5+Z1[F7'*XP GT'4#_ &JT=/\ !^L^&/&=Y>^'9+#^P-2<
M27=A<.Z&*3/S-%A2!WXX';L"':+X4UOP;J6IIX?.GW6C7TQN4M+N9X6MI3C.
MUE1MRG'0@8P/?(!B:8HT+X\:EHUF!_9VKV'VNXM@@V)*,C=CMG!SZ[^>U8/A
M"^N_AQ9:7J<[SR^$M74"?>N39W'(+  ?<.WCU'N!GT#1?">I:7>ZKXDNY+2_
M\3WZA%R6CMX8QC$:G!;'')QDX%6/"_AFZM_ :>&_$L=K<@(\+^3*SK)&3D<L
MJE2,XP.F!SZ '+:NFWX:?$0\?O+VZ<$'.050@_B"*PM=EDN_!_PK\.,TBV&J
MBV%V$.!(JK'\A]CO)Q[>U=-#\.=4TCX::UX4TRYM+A[ZXD,4UR[($B=5'.%;
M+#;CT[Y[58D^'U_JWPZT?1-2N;>TUC1_+-E=V;,Z*T8PC$, >0!D>O/M0!UG
MB'PUI_B/PW<:'=1*MK+&%38H_=$?=9?0@XK6C0QQ(A9G*J!N;J?<UR-O:^/;
MJ%;/4;S1;:(C;)>67F&8CN55AM5B._./0UUT:".-4!)"@#+')/UH =1110 4
M444 %<_K6W^W;#(R?LEUCCIPE=!7/:T#_;^GD=/LEUGCV2@#A=7MX9_V<-TT
M,<C1:>KH74'8VX<C/0U>^(&GZEJ/P>L8]-MY+IHDM9I[>/DRQ* 67'?L>_3I
M3X=%U'Q'\#[+1M,^RK->6BQL]R[*J+NR2-JG)XZ<5V6FP:O8>%K2VDBLIM3@
MA2(JLS)"Q7 SNVDC@9Z'GCWH \RU/Q!9^)/BQX4F\-M<I<M87:3RO;M$ IC;
MRP<@9"N#GJ <=ZY74M8M].^!K^&;^UO+3Q':78;;):R ^9Y^\2"3&,E"0#G)
MQ7M.@^%GLM9N_$.K7*7FN748B,B*5B@B'(CC4DD#/))Y)JO<^%[[Q%KMI?>(
MI;;[!82":TTZV)9#*.DDCD L1SA< ?7N <A:7S>%OB3XAN_%=M=?9M5LH!!<
MI;/-&0J8DC^0''.>.G&?2LWP;/=3?!\Z1'))&FKZI)8Z9GG9;NPW'UP )>O-
M>F>)-)UGQ!%+I45U!8:5.-MQ/&Q:XD0CYD4$!4STSEN.PIL'A2*UUC1'MA'%
MIFCVCQ6T SN\QL+N/8_*#SURQH YOP=:Q3_%#QFLVV1+""SL+=& (2$QDE0/
M0D<U4^$NEV&K^$5&I68O/[)O[JULVN1O4(2#D*?ESSC.,C! XKH]3\,ZQ;>*
MKG7_  W<6,4U_;+;WD=XK%25/R2+M_B )&#P:LZ7X4?PWX ?P_HLR+=BVD5+
MB3*AIF!RYQDCYC[X % &#X-73TO_ !7XS6**"Q,C6\"PH$400+\SC'!W,#_W
MS6GX0T2TN-%L]?U:WB>^N#-?%I>5B\XANAX!"*@SV ([U))X->W\ 67A6PFC
M2%?+CN9'S\\>[=+C ZMSZ=:D\;Z%KVOZ;#IVCWME:VK'_2EN$8F501A..BGG
M/<_G0!PK>&KS5/#OQ$U/08O+MM9*K801<"98N'=0/[YW@>OT(K.US7(K_2OA
MWIVGV=Y;>(+2]MT"36CQ&-53;(H9@%()VDX)X'.*]+T#3?%]@]Q)JNHZ;=1I
M;B.TL[:,PQ!@>K':2. !QGZ4:=X5NIO$R>)?$%U%<ZC!&8K."W4B&U1OO8SR
MS'H6...U '5T444 %%%% &%XM_Y \?I]KM\XS_SU7TYJCX/7;K7BH9)_XF9/
M)]46K_BP9T:/'_/W;]O^FJU0\(-NUKQ40"/^)F1R/1%% '64444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>(/TZTG]M'9N_LO4L_W?(&?YUE?\(0-^?^$E\1X]/[1;_"E_X0E?^AD\1_\
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M?%Z_[]']IWG_ $!+W_ON+_XNLX>!]-!S]KU3_P #I/\ &C_A!]-_Y^M3_P#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0_)N(?[&T[RKE@\Z?94VRL#D%ACYB"2>:@_X0[PP0 ?#FD8'3_08O_B:VJ*
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MBBB@ HHHH **** "BBB@ HHHH **,XHS0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% ","<8..>:6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ]S>16J@R
MM@L<*N,DGVH L4F:S)-2F;B.WVYZ&0_TIHO+Y!EX(V /)!Q0!K45DMK#JT*F
MV/[R0(3NX%:U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$A022 !ZUB
MQ,EWJ<UPV3'$?+C].G)%:UPGF02(1G<I%9.E!?[.BSP1D8^A(S0!<VH@'!/8
MXIXY3\><"C((((QQW-('RX'44 1ZC!OLR4P"AW#%/TZ[^T6X#'YTX(]:G4<8
M[5F6D*G5YP>0N: -G.:6D"A:6@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L6
M$_9+A[21?EWEHB>-P/)'YDUM5!<VD5U'LD'3D$=0?44 0B19.F3CM3@551P
M>U4F@O;9AA!.O3<#@T?Z8Q_X]WSGN: +KSQQ1-(X PN0#W/I4.F6[*CW#J0\
MIS@]A1#8.[B2Z?>5.53L*T1P* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!",TN*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!!G)S^%+110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% "$9[TM%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** (YYA!"\K?=09-8UE;27LRWERQ)9<J!T45H:JH;3+@$
M9&PG\J6UVK:Q!3P5!&._% #U@C# A>E+Y,?(*<>II1\O'/2D.<]=Q!P10!'+
M90RPNA0'<I ..E5M(E"1?9",-'D_K6BOUK+MBPUN8(1M).[Z4 ;%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "@]*** &HQ902I4^AIU%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%&* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>articles009.jpg
<TEXT>
begin 644 articles009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH 3'-+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA0<E5XS]?4BN2^+'CKPWXD\(166DZF+FY%VDA00R+\H5@3EE [BNB^-'B?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7\/@"\\/)JELUQ-?+=I(8V"\+MVGJ?QH \>\$?\ (]Z!_P!A"#_T,56\4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HJ"]BGGLI8K6Y-K.RX28('V'UVG@U,H(4!CDXY.,9H 6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F3>;Y$GD;/.V
MGR]^=N['&<=LT^B@#R72_B/XNUCQ3>^'K/2M(:\M/,WL\LBH=AVG!Z\G&.*V
M/"/Q)FU[7;SP[J6G+8ZQ;^8HV/OC9DX8>HP1ZG/K7G'A>'7+CXO>($T:[@M;
M[?=YDNHRXV^;Z>O3\JN?#NYCTCXLW]EX@B:?7)YI8UO$?*"0Y+?* /O=CVZ8
M'8 Z?1_B1XCU+QZ?"LFGZ7%-'-)'++N<C"9)(YYR!Q76Z_K.O:?XGT?3K"#3
MWM=1=H_-G+[HV12[9 Z_*#CWZUYCX51V_:&U,J^T+/=%AG[PP1C\R#^%>K:P
MP'B[PTNX!BUR0O<_NNOZ_K0!C2>--5U?Q9J&@^&;.PE.G+_I,]]*RJ7SC:H4
M9X/&?_K9MZ-XDUW6#KMD^F6MCJNFM&B0R2F1&++NR6 '!QQC\:\]\8^!M9'B
M"^\5^"[N27,S^?%;N5FCE5B) H_B&X9Q^AKJ/A9XXG\4M?VNIVD<>K6ZJ99X
MXPAF4$@;AV8'/MSVH B^'WQ%USQOJEQ ;+3K:"VC#R,"Y8YR !SCKUJA;_&&
M[L/&DFA^(;*SM[>*=K>6Y@9B%(. W/\ #TSZ ^V*Q?@!_P A;6O^N$?_ *$:
MW-8\!Q>,='\0O %75;?5[AK9S@;N%S&3Z'U/0_C0!VFLZSK5IXHT?3;"/3Y+
M74?,/F3;]R;%W-TX.0>*Y+Q!\2/$.D>/5\+P6&F2O--''!*[2*,2$;=V.F,\
MXKF/AKXEU'4O%?A_0M21_-TO[4J/)G>%,>-C ]U(_+CM4/C]KI_CIIZVC1_:
M5FM!!YY)0-D$9QSMR><>] 'I0U_QCIWB#2;/6-+TLV5],86N+.61O+;:2 =P
M&"<>E1S^--4U7QK=^&_#4%@6L8]]S<7S/C<" 555Y[XS]?3EO@FYN[&W\377
MBB6WCNHM5+32*?W:_NHPNW/.,$ =^?6N/\8>!-3O/$5YXH\$WC/.L[I<PQ2&
M.6.9>'VDXR#W'OQG- '?:=XQN%AU]M>L(]/DT9%>6.*;S=ZE"VY3@<'&!^76
MLW3/&'BG5/"C>)K;1].EL_G=+-;AQ,8U)!.[&-W!XQS^E8/@WQHGC#1M=T3Q
M6B074=JPN+H1[&:+.T[@!PRLWZ].#7*7>E^.?A+,US97#3Z09,ED&^%O]]#]
MPGIG\C0![UH.I_VSX?T[4]JJ;JWCF95Z*64$@?0Y%<[XX^(-IX.$%JEL][JE
MS_J;5#C@G ).#WX ZFM?PAK5OXA\*:?J=K;K;12QX\E1@1E25*CV!!Q[5XS?
MS32?M%P_;6X2]C2,2'@+L&P#\P?J: /1Y==\>:;I3ZI?>']*GACB\R2VMKIU
MF08R>JE3CN 3[4_Q'\1;7PUX2TS5;J 2WVH0))#:HV,DH&))[*,C\Q7;D C!
M&0:^?/B[ R_$K2HKA0EAY$"1 ?*BIO(8>@[_ (8H [W4/%?CK2- 37KW0=*>
MR"K)-!%<.)HT/<Y&..,XS6JWCA-2^'USXGT,1,;:-GD@N0?E*C+(=IX/3!_Q
MK5\:8_X0;7L]/[/GS_W[->+_  [^T#X6^.2=PM_(^0]MVQMWZ;: .PT#X@^*
M_$GAK4=9L-,TIOL+$/;LT@9P%W$J<XZ=JZ/P9XY3QQH-S/911VNI6_RO!*V]
M5)'RMQ@E3@_D:\1\.:]XAT#X=ZM+ID-J=/N+G[/<3,&,L19 ,CD  COSS7KO
MP>TG2K#P:MWIMV]U)>,'N'==I1P,;,>W//?.?2@#G_#_ ,4?%OB>:^@TS1=+
M>:SA,S1M)("X!QA?4\]\5T?A/XIZ;KWA[4=3OX?L#::JM<KNWJ0W0J<=201C
MZ5Y5\+8M>GUW68?#\EC%<R6C*TEV7 12XY7:#\WUK6\6^ 9_ WPSF$5V;F>[
MO(3?.B@(J*'VJ,\XWD<]^.!0!VVB>,?&/C"WFU+0-)TJVTZ)RB?;Y',DY&.A
M7 7CUR,_C6AX-^(2^*+F]TBZM!IVN6F\/ QWH=IP2#QT/4?K3_A*4/PRTC:5
M) EW8]?-?K^E>:Z%Y[_M%71M<L!>7'FD= FU@<_C^N* .JL?B+XFO_'DWA2.
MQTE;B*21#,QDVG8"<XSGG%:7A[XC7=SXTF\):_IL=IJ*L522W<M&Y"[NA&0"
MO(/\J\X2?5K;XX:O/HD%O<7\<MRT<4Y(5\(<CC'..GO6I\*_L_BKX@W_ (@U
MB[<:W"3)';!-J$%=A.<Y^4<;?H<F@#VK5M3MM&TFZU*[;;;VT9D<_3L/<]*R
M/ _BE/%_AB#5-BQS;C'/&O1''4#VP0?QK ^(VK:;)>Z9X<U.:2/3KDFYU!HD
M=SY2_<3" D;GQS_LUP/P?UHZ%XWO?#LLK-:W;,L992F9$SM.UL$;ESP>>E '
MI.J^)O$<%UXCFL;'3_[+T:,MYUQOWS,L2R,H ^I&?I7/^'_B)XK\2Z!J>JV&
MF:4?[/Y>!C)ND&TM\ISUP.G>N[\9_P#(C>(/^P;<?^BVKSOX ?\ (&UG_KXC
M_P#030!/XK^*6M^'(M&G73K*:+4[)+I=P<;"0"5SGG&1Z=:[#Q/XPC\&>&8[
M_6!%-?2?(EO!E1(_7 SD@ =3_B!7EOQ\8_\ "1Z0N3M%JQ [??/^%/\ C^+G
M^V=&+9^R_9W\OTW[AN_390!V \3>/_\ A&O^$D_LC1S9F+[1]B#2>?Y6,[MV
M=N<<XQT_*M;2/'4?BCP?>:OHBQ)>VB%I;6Z).P@9P=O." <-^G!%;[F+_A%V
M,./)^Q'9CIMV<?I7AGP;$X@\52*7$ TXAB#QOPVW\<!J .T\!?%U?$VLG2]6
MMH+*>4#[*T9.UVYRIST/3'K^5=5;ZYJ@\7ZGIMV+%-.L;=;HRJK^8T;;L \X
M!&TY/.?;/'EOB/P))=_#_0/%.BH4U"VT^%[H1MAG54&'7_:7'XCZ5N?#CQ7_
M ,)'<:]JFL#8EOI<$5X^"0X3S2SX'JIZ#WQ0!LZ!XR\4>*[.[UC1K#2CIT$Q
MB2SFD<7$N #G>/E4D$8!!_K75^$];E\1>&;359H%@EG+AXES\A5V7'/?Y:\4
MO_"GBKX?S'7_  I?276CNHF62([OW9&1YD?\0P?O8]^*]9^'?BI?%OA9+XV\
M=O<1RM%/'$,)O^\2/KN!^I/6@#K*X_PAXZA\5:WKMA&B*MA,%@=<_O8^1N/X
M@_@14WQ!UH:/X7>..5H[G4)%LX612S(7X9P!R=J[CP.H'K7B5EJ%CX#^)]O>
M:7-<G1'*H7EAD0M$P ?(8 G!R>G84 ?0'B7Q'8>%=$FU34&/E)A51?O2.>BC
MW_P-<EH/B/Q[XFLO[6L]*T:ST^0$V\5XTOFRCL<C@#WQSCT.:Y;X_P ER1H2
MJY-DPE;"DX+_ "\GMT/'U->K^%C ?"6C?9CF#[%#L^FP4 <C_P )OXFGM3##
MH%M#JPU9=.-M+,6508C(7+#''&?IZUF:I\2/$NE^.(/"SV.DO<32Q1K,IDV#
MS,8)YSQFO55C1'=U159SEB!@L<8Y]>*\(\4AS^T1IWEMM;[1:Y.<<87(_+-
M'JWAW5M;N]7U?3M:L[6![,Q-#);,2LR/O^;GI]WI]:Z.BB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "HKD3FVE%JT:W!4^6TJEE#=L@$$C\14M%
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MIHKB/9(KVS$\9*D?.,<_I72>$M!UO1)]1.IZG:7D5Y</=8B@9&61L9P=Q&W
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MV+PX-4C@*>3>7[W:1HNT1AE0%?S4_G6W0 4444 %%%% !1110 4444 %%%%
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M]01D56@TS3[63S+>QMHGZ;HXE4_F!5JB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH C:"%VW/%&S>I4$U)110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ^.9O&8U)+C2FT^:P=$=&D+$EMV000"""IKLZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !574].MM7TRYT^\
MC\RVN(S'(OL?ZU:HH ^<4\/:_P#";QG!K#6<E[I4;LIG@!8-$W!#?W6Q@\\9
M ZUZS)\6/!L>E?;QJZN,<0*C>:3Z;2/U/'O7:D9&#TJB-&TL2^:--LQ(#NW>
M0N<^N<=: /G[2O"NL_%/QI<Z[=VLEGI4TP>25QC,8X"(?XC@ 9' ZGT/N^J:
MUHWA'283>S+;6\:>7!$H)9@HX55')XK8    & .U! .,CITH ^.+:1X_$4-_
M);S+$+M9F&PD@;\U]:65[H_B2TCNK9X+V&&4.C%<^7(!D'D<, ?J,UI]:* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YW4O&.G:7XNTOP[,1
M]IOT9@V[ C_N _[Q# >X]ZZ"21(8GDD8*B LS'H .IKY+\5^)+W5O&DOB%/-
M@+RB6S8C!$:'"$?]\_GF@#ZVK!\3^(+SP_;"YM]#NM2@5'DF>"1%\H+SR"<G
MC/0=JL>&=<A\2>&[#5X0 +F(,RC^%QPR_@013_$?_(L:M_UY3?\ H!H \R7X
M_P"E%P&T2\"YY(D4X%>N031W-O'/"X>*10Z,#D$$9!KY*U[0#8>&O#NL1(!#
MJ%NX<@?\M$D8'/U7;^1KW#X+>(SK'@[^SYY0USIK^5@GDQ'E#^'(_"@#L?%'
MB.S\*:!<:M>AGCBP%C3[SL3@**\_L?CE::G>P65EX=OY[J=]D<:RIEC5CQ^H
M\3^)AH)RUEI-A-J-V.S2%2(U/\_QKQ[X:?\ )1]#_P"OC_V4T >_:]XWU'P]
MI4>I7GA6]^S^4'G99XSY!+%=K8/T.1Q\U<YIOQLAUB]6RT[PSJ%S<N"5BCD4
MD@#)KK_B*R)\/-=+D ?9&'/J>!^N*\)^#/\ R4NQ_P"N4W_H!H ]4U/XK7FB
MQ>=J7@O6;:+_ )Z2 ;/^^L8S71Z5XN;6_!2>(M-TFXN&?=LLPZAVVN5.">.Q
M-"ZQ!KGBO6O"TT,$UE;V4?G@Y)9I,Y4]L;=OYU)X'\/S^%O"=MH]Q(DCP22X
M=.A5I&9?T(H X1_CWIT$[0SZ!?Q.C;75G4,I!Y!![^U>I:7J=IK&F6^H6,HE
MMIT#HP]#Z^A]J^<_%7A&YUG5_&>M6+EQIM^QFA*X)0Y+,/I@_4<U-\(_'A\.
M:L-'OY0-+O'X9CQ!)T#?0\ _@?6@#U'6/B5>:)K,&EW7A+4?M%RY2VV2HPFY
MQ\I'^1FKVM^-M3T'24U*[\)WWV<1;YRMQ$?).XC!P3GL<CU]J9XL_P"1\\$?
M]?-S_P"B:O\ Q$_Y)YKO_7H] ''Z;\;8=8O4LM.\,ZA<W+@E8XY%)( R:OCX
MQ:99Z@++7]'U71Y23S<0Y7'KQSCZ UY5\&#CXE67_7&;_P! ->P?%S0K?5_
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M(SWY%:]8WA30?^$9\,66C^?Y_P!F5AYNW;NRQ;I^-;- !1110 4444 %%%%
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MK<C\!2S*)-=8X^Y %Y]SUJ]M50".@% $'D1G@'#>F,#%5;BQ0+(=O8]!6CM
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M%R]M>:WIMO<)C?%-=HC+D9Y!.1Q0!J45EVGB70;^X6WL];TVXF8$B.&Z1V(
MR> <]*A_X3'PQ_T,>D?^!T7_ ,50!M455LM2L-23?8WMM=)UW02JX_0U99@J
MEF("@9)/:@!:*RK?Q/H%Y<+;VVN:9/.WW8XKN-F/T .:B_X3'PQ_T,>D?^!T
M7_Q5 &U16=8^(-%U.X^SV&KV%W-M+>7;W*2-@=\ YQ523QGX8BOFLI/$&FI<
M*=K(UR@P?0\]: -RBH[>XANK>.XMY4EAE4/'(C95E(R"".HJI'KFD3:@VGQ:
MK8O>J2IMEN$,@(ZC;G.10!?HJIJ&J:?I,*S:C?6]I$[;%>>4(I/IDU):7EK?
MVRW-G<PW,#?=EAD#J?H1Q0!/14$=[:S7<]I%<1O<0!3+$K L@;.W([9P:K:K
MKNE:&D;ZKJ%O9K*2$:=PH8CKC- &A14<$\-U;QSV\J2PR*'21&!5@>A!'450
MU7Q%HVAM$NJ:G:V;39\M9I I;'7 _&@#3HK!O/&OAC3Y_)N]=L89=H;:\P!P
M1D'\013M/\9>&]6O8[*PUNQN;F3.R*.8%FP,G ^@)H W**@O+RVT^SEN[R>.
M"WB7=)+(V%4>I-8/_"PO!Y_YF33?^_XH Z6N;\?7U[8>"-4DTVVFN+R2+R8D
MA0LP+D+G ] 2?PK2TGQ!I&NK*VE:C;7@A($AAD#;<YQG\C^59M]\0/"FG7OV
M.YUNV68':P3+JA]&900OXD4 7/"NB1^'/"^G:3'_ ,NT(5SZN>6/_?1-<U%8
MW>L_&*XO[JUD6PT2S$5I(Z%5>6499E)^]@$CCIQ7<V]Q#=0)/;S1S0R#<DD;
M!E8>H(ZU(2 ,DX% '#>.=0T*=QIT_A]M?U>-2;>U6U+A"PX+/C"*>,\U5^%W
M@"7PC:W>H:DD*ZK?'+QQ8VP)UV#\3SCC@>E=!=>/_"5E<&WN/$-@LH?8RB4-
MM/OCI^-;"ZI82:<=0CO()+,*6\^-PR8'?(H XN73[O6?C1'<W%M*NG:+89@=
MD.QYI.I!/!(![=-HJ76_B&NA>+9-&UC0[Q-,>(&._1#*LF1SE #QU'<\=.:Z
M/2_%6@:W<M;Z7J]G=SJN\QPRAFQZXIT_B71;;55TN?4[>._8@+;L_P Y)Z8%
M 'EGAWP-J<6E^-M2TVTFL%U6&2/2[5\1OY9)(R/X,\  X_K7*W&EV6J?#73/
M#L.B7H\86EPR",6;(V&<DEW(QMVD=3U [5]!ZKK6F:':FYU2_M[2$#[TKA<_
M0=2?85E67Q \)7]NTT&OV010"1*_E-@G&=K8)'X4 :FA64VG>'M,L;A_,GMK
M2*&1\YW,J $_F*\[L84\=?$'4+VXDU_3%LX4BTUHTDM@\?\ RT8L5QRQ7Y3R
M0!QQQZ3J.IV&DVINM1O(+2 ''F3R!%SZ9/?VK&TOQ]X5UFX6WL=;M7F<[4CD
M)B9C[!P"?PH \533[WP)\7C=Z/9:Q>:5',$GD^S2,71AB0$A?GP<D'H2!6K\
M69;O6/&.DS6&E:E<0V,:F21+1\$EPV!QZ"O9]6U_2-"6-M5U"WLUDX0S/M#?
MC2:3KNDZ[YK:5>QW:Q;=[Q9*C.< -T)X/3IWZT <1XG\>W<VA&V\/Z1K!U&Z
M*Q)(]DZ"$'JY)':N#^*UO?ZGXOL&L]-U*Y%I!''-*EHY4L&R<'&#QGVKVO7/
M%6@^''B36-1CM&E&Y-ZL=PR!Q@'N?Z]*M:1K6FZ]8F_TRY%Q:J[)YH5@"5ZX
MR!D>XXH \<^(&F:M\1_$FEQZ/HMU!%:H5DN[J/ROO%3WY(7!Z=R:SOC%8:CK
M.O646FZ9JEY'IEJMO/<?97PSDGH<?-TSD<<UZN/B9X-^R377]M*(HI%B=FAE
M!WG.  5R3P>G3O2-\4?!:0+*=>APS;0GER;\_P"YMW >^,4 <_KVOW=E-J$_
MA?PUK0U[5TBC>:>T*QQ!,J'.?XAO^GKTKE?BMHNMZQX\TZ]L-'U&[@L[:**6
M6.V;#,LC,VWU&&'->G0?$?PM=6=Q>6^J"2WMF5)V$+CRRV<9RHX.#^57M#\7
MZ)XCFDBTJ]6Y:-=S[%. /KB@#ROQIX0UC2_%ECXT\%6-T6G??/:)"R,CCKN3
M@[7&<CUSZBO5!J\E]X/DU"33+Z">2!@UD86,JO@C:!CGGOTQSQ2:WXT\.^')
MT@U;58;>=^D0#.^/4JH) ]S2:9XW\-:Q/;P6&L6TUQ<,4C@R5D) ).4(##@$
MY(H \Q^"6B:SX<U?4XM6T>_M!=Q((I)("$RNXD$]NO&:Z[QM'<Z]XCTC0)=-
MU-M$67S[ZZMXW +A?W2AEYP&.21TX]*W;KQWX9L]1FL)]6C$\#!9MJ.R1'IA
MW *K^)&*V-/U*RU6T%WI]S%<V[,RK+$VY25)!P>_(- 'BOQ4^'MTEWIE]X=@
MUG4+X9$KO+)<E54@J=[$D<YXS7K_ (<U&ZU30;2ZO[&>RO"@$\$Z;2KCKCU&
M>0:J:]XV\/>&+F.WUG4#:22+O3=!(P8>Q52/PS5:S^(_A&^O8[.+6HEGD *+
M/&\.X'I@NH!SGCUH \Q^,FBZWXF\3VC:3H6I7$5I 8GE%N=K-N)^4]Q[UVWB
MOQ7K=YX>EL_#_AS74U&[41B:6W,0MPW!;<#]X=L?7/%;^M^.O#GAN[^RZQ?O
M:2GE=]M*5;@'Y6"D-U'0\5I:7K>GZSI@U*RG+V9R1-)&T0( SD;P,CWZ4 8_
MCG[0O@34+&WL[N^NKJU>VC2WC,AW,A&3Z#W-<C\$M/U/0=*U#3-5TF_LYI)_
M/1YH2J%=JKC=Z\=*Z.7XJ^#8I77^U2\<9P\\5O(\2GT+A2*Z)M?TH:)+K*W\
M$FG1(9'N(F\Q0HZ_=S^5 'CGQ;T?6]=\;:?<Z9H6I7,%C$J22) =K$.6^4]Q
M@UJ>-])\1?$^\TRPM-&N])TJV<O/<ZB%1MQ&.$#$G SCU)[=:ZY_BKX*BCCD
MDUG8D@)1FM9@& ZX.SFK=I\0O#%]=-:VVH227"Q&7R1:3;RGJ%V9/7/':@#"
MU._\2>%O$?ACPYX?T@7&A>5'#+.T;.P .ULL" N%PWN2:]$KC[?XH^#KR0QV
MVKM.X&2L5I.Q ]<!*UM!\6Z'XFDN4T>^%R]MM\Y?*="F[./O >A_*@#:HKG=
M>\<^'?#=S':ZCJ"B[D("V\*-+)STRJ@D?CUIEAX_\,ZC<Q6MOJ/^F2L56U>&
M19<A2Q^0KGH#ST[=: .EHKC%^*?A5[Q;);F\-\9#']D%C-YP;T*[<T[5_B?X
M8T+5)--U&XNX+I#C8UG)\WH5^7D'U% '8T5!97:7UG%=1I,B2+N"S1-&X^JL
M 1^-<C=?%3PM9:JVESS7J7RR"/R#8R[RQZ +MR<Y&/7(H [6BN1U;XE^&="U
M-=/U2YN;2X958"6UD VMT.<=/7TP?2MC6O$>G:!HZZK>R2M9$C][!$TH (R&
M.T'"^_3D>M &M16?9:U9WVD#509+>TVER]U&T)"C^(AP"![US*_%CPC))*(;
MVXFCB.'FBLY71?<D+TH [:BLS1/$&E^([6:ZTF[6Z@BE\EI$! W;5; SUX85
MIT %%8>N^+=)\/2PV]W+))>3C,-G;1-+-(/4(O...IXJ'1?&NDZUJ3Z8@NK/
M447?]DOK=H9"OJ >OX4 =%17-1>/- ?Q*/#\EQ-;ZDS%4BN+=X@Y']TL #G'
M'KVK0U_Q!8^&M.-_J/GK;*</)%"T@3W;:#@>YH U:*JZ;J$.J:?#>P),D4HW
M()HFC;'KM8 BLGQ-XUT+PA'$VKW9B>7_ %<:(79O? _K0!T%%07=Y;6-C->W
M4RQ6T*&221C@*H&2:YO2?B%HFKZA;V2K?6LEV"UHUY:M"ER/^F;'AN"#^- '
M5T5SVN>,]+T+48M.D2[N[^2,RBULH#-(L8S\Q Z#BK&G>*M%U3PZ=>M[Z,:<
MJLTDLGR^7CJ&!Z$>GT]: -FBN2L?B)HU[=V,+P:C:)?OLM)[NT:.*=NP5CW/
M;/6MW6]9MM TB;4KM96BBVC9$NYW9F"JJCN22!0!H45R^L^/=(T6^ELY(KVZ
MF@A$]T+. R_9D/0R8^[].N.:Z"POK;4[""^LYEFMIT$D;KT((H L45BIXITN
M7Q:_AF*5GU&.W-Q(JC*QKD<$^OS X]*L:OK=IHOV$7(D9[V[2TA2, DNV?4C
M@ $D^U &E17):A\1=#T[5+BSD6\DBM9%BN[V*#=;VSMT5WSP>>< X[UJ:]XH
MTSP]I\%W=R/(+EUCMX[=/,>=CR @'7B@#9HKGM!\9:?KNH3Z:(+RPU*!!(]E
M?0^7+L/\0&2".1T-=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% &-J6ZVU&*Z;/D,GEN1_"<Y!-6@P*+GIC.*N31)/$T<
MBAD88(-9CZ7+%_Q[RDIV23G'T- %AMK-USGD<U%>7*QV; '<S#CVJ+[->,W^
MJ QW+"I(M)#.)+DAS_< X_\ KT 0Z#%^[DF(^\< _2MJF(BHH55"@= !@4^@
M HHHH **** "BBB@#S;XLZS?*NB^%M-F,,VNW'D2RJ?F6+*@CVSN_($5U]KX
M1\/VFB#2(])M#8A<&)X@V[CJ2>2??K7&?%O1=0+:+XKTN#SY]$G\V6%1EG3<
MIR/H5Y]F)[5T-G\2_"%YI:WXURUC4J"T,CXE4G^'9]XGZ T <#X^\*Q^%_@S
M>Z=E)DAU#S+9L99(WDX7)Z'!P:ZN'7_"B^ $LY-7TD+_ &?M:(W$?WO+Y&,]
M<U@?%77DU'X6SF[A%C<75RIM;:63][)$KC#E>"N1S@]. >>*VY&\.GX5/J44
M6F%1II59O*0_O?+QCIRV[M0 SX)6\$?PWM)8HU#2R2%V Y)W&N:^)]YJ]_K,
MVL:-*%M?"+Q%SC.^>0@L!V(5=F<^IJQ\._&&C^&/@X;J6ZM_M-LTO^C>8-[R
M$DJH'7GCGT!/:M3PSX"M=6\))<S^)-2EBU:-[B^BMKE/(DED'S]CT/'7^&@#
MT'3;VUU[1+6^C59+:\@60*P# AAG!_E7A'A_5+[X<^(+S51%N\*WNJW%E-%'
MG_1V1R%/L<=/4 CL*Z7X0^*]/TVUU/PK?:I;'^S;B9K2<R82:$%BS*>F!@M]
M&SV-:_@'^Q/%?A?7]-ED@NX+C4[J1X=P+"-W)1L=1Z@^HH T+Y++4OBCX9OH
M5@N8SIMS/%,K9!&8PK C[W#''US6#X%\GQWXUUWQ+J:FX33Y_LNG0R#*0ISD
MXQ]XX!S[GVJEX(T'6_"WQ/AT+49WN-.M;"X;3IRN T;/&6&?4'J.Q/H13O#5
MVWPM\7:OI.MI+%H>HW/G6>H,"8E8YX8]B1@'W7TYH Z7QJ?"B:QI4E]J=EI>
MKV-Q%<0RO%EFC!Y3W!&?H<5RWQ+ETU/B;X+O;H0_99/FE>1,ADW#&1CGKT]Z
M=\0]3T_Q-XS\%V^A7,6ISVUYYTXLSYOEQ[XCEBN0!P?I3/B/K6FP?%WPD9;V
M%18N&NB6XA!8$;O3CGZ4 ==97OA+Q#XTM;?3(8VO=-B-X+FW01XR/+V-P"00
MV<>PKG?#>GZ9=_''Q=#+8VTBI;QE8Y(U8 X3<0#[_P ZZ*;QQX8G\1:?_8KV
M^J:Q=E;7= Y_=0%MSL[8P N,XZ_G7%^&_%_A^P^,?BF^N=6MH[2Z1$@G+91R
M-H.&''8\T 7?BEHT7@U['QKX;6/3[Z&<03QQ*%29&!ZKT[8/KGV%>LV=RE[8
MV]W&"$GC610?1AG^M>3^,;V?XJ36'A_PW!/)HZW FO=5:)DB&,C:A;&[&3]3
MCMFO68(H;"QCA3Y(((P@R>BJ,?R% 'E7ARQ@N?C7XVMB@1)+14R@ *AE0$CW
MYJM\6]"T[0O!/A[3["VCCABU**/.T;G^1P2Q Y)[T>#?$&D7/QO\2SPZA \5
M]$D=JX;B9@$R%/?H?RJQ\=]1LXM(T:T>X07 OTN#%GYO+"N"V/3/% '<ZYX6
MAN]^HZ8J6FLPV<]O:S(-JY=<#=CJ <$>E>7^"-=\,1^'W\!^*M,&EWA+I+)<
MH%65B<ABQY5NF,\<#GM7K.IZPDG@R_UC2;J.0+92SV\Z@,I*H2#[\BO-_$?B
M3P%XU\&B769(XM;6W4+&L+"YCF*Y")QEE+'_ '>>U 'J.@:;_8WAW3=,,PF-
MI;1P>8!@/M4#..V<5YI\4_#]YJWC/06T15MM8CM;BYBN O,K1%"J9]1DXS_>
MKM?AW9ZG8> =(M=8\P7L<1#+(<LJ[B44_1=HQVQ6!K&O::OQFT.W:^BW6]G/
M%*N[/EN^W:#Z$X'Z4 9S^-(_&'PA\0K<Q^3JUE9O%>V[#!#@?> [ D'CL<BO
M0[:[MM+\+07<[+%;6UFLCG@!55 :\M^+G@JZLH[SQ5X=W1-/"T.JPQ=)8VZN
M1^ SQZ-V)K=\7ZC;7^GZ!X/:::/^TUA:]DB4_N[<#/) ."S+M'XYXH Y30+[
M5?#WQ'TOQ%K$I6T\71L65A@0$M^Z0GOA?+&>.&/ID]W\7+;[9\/KFVW!3-<V
M\8;&=N95&?UKG/B?X'L++P9/J,>I:M)=6;Q&U2YO9)U#%E7"JQ."<U-X@\51
M^(/A=97$L4Z7[75LMQ;^0^]721&<[0.F!N^A'>@"Y\(=4N(=,U'PGJ.!>Z%.
MT62?O1EB01GL#G\"M</K%Y=ZY\6O#6O2N#83ZH;2P3'6*&1 7SW#,[?E6YX[
MTK4XO&UAK?AB;Y?$D)TV>0 X4E0N\]/X1D>GET>,X;/2O%_@'3[-)6MM$D N
M'2%BL:YCP6(&,D*2: +?Q1NK6P^(_@F[O#MMXI)&D;86^4%>P!)KI+76_#GB
MCQ;9:=9VTC264/\ :<=R(G@VL"$"X906!#DGMTZ]N9\?ZE;2?$OP?=1^=);V
M,A>YDC@=A&&*D9P/2NFO?%^E2Z]8?V)8RW^L7+K:>:;:1%A@+!G9G*@8 4G'
M7- '5:MI5KK>FRZ?>JS6\I4NJMC.U@P'TR!GVKS;X@V\2?$_P"L<* &Y?(51
MS\R5ZM7D?Q!U&,_%#PD\:W!CTV9FNY4A<K&&*\9 YX!SCUH O_%>>+PEX6U+
M4]+7[-?ZPT%C))'Q\JB1L\=]I89^GI79^%]"L]"\*V&EV\,8B2!1)@9\QB/F
M8^N3FLGXD>%Y/&/@J>QL]C7:,MQ;;NC,N>,]L@D9]ZI:'\1M*M=%L[/Q!)-I
M^M0PB.>REMY#(S*,$J IW!L9&,]: ,7X>W$FB?$[Q/X.MVSI<0:\MX\#$1)3
M*CVPX'_ ?K5CXX^(+K1_!L5E:L4;493#(X[1@98?CP/IFK'P^\/ZA-XGUKQM
MJUK)97&IDQ6]I(N'2'Y<%O0G:O'L?6KOQ5\&3^,O"PBL3F_LY/.@0X'F\$%,
MD@#/K[4 1_#'PWI</PTT^.2QAE^WPF6Y,D8)DWYZY[8P*\^^$VJW&A?$W4_"
MB3.^G237")&>BO&3AAZ?*I!_#TKK_!_C_3=!\'V6E>(?M-AJ]A']F^QRV[^9
M+MX79@<Y&!_];FL7X7^%+Z'7M3\>:_;/9+(9I(8)(VW@N<L^W&<8) XYR?;(
M!PVI:-K/A*Y3QSH[,D U*XBP(\+$5E=0#ZHP&.W.1Z5ZWX;\3V7B_P ;Z-JU
MGQNT:X66(G)BD$L65/Y]>X(JSX 33]>\'ZCIUW;RRPRWMRTL%U"RC9)*S+C<
M!V(/'(/H:YGP!X&O/!7Q;O8&2273Y-.D:UN2O#*9(_E)Z;AW'X]Z ,3P^#\1
MOC;>3:OB:RTWS7BMI,E0B.$1<=.K!CV/->O>+O!]AXMT4V,RQPS(RM;W C#-
M"00>.G!&1C/>O*%T?4OAA\5)-;EM+JYT"\>0/<6Z,_EHYR0X']TX/N!D<UZ9
M_P )Y::B]M#X;L[K5YII%#,D3Q10IGYF>1E &,'Y>N1B@#RKQ)>?\)M\=;/0
M[]V_LRSN?(6%AD-M&Y\@?WB,9],5V/QQT>UF\!K?K$B7%A/&8W5<$*3M*@^G
M(/\ P$5C^,_"NH^&OB;9>.-,T^6]L&G62[BMT+O&<;7.T<X(R<^O7WL_$SQ(
MGC/08?#OA6&ZU&ZN;A3/Y=NZK$J\X8L %.=OTQSCC(!EZOKD_B3]G(W=\XFN
MX)HX7D8Y8E90 3[[2,_4^M>@?"88^%^B?]<Y/_1CUQGC'09/"_P5MO"T,%Q>
MW\C+)(;>%W ._>[$@8"@X49QVK6\!>*;;P[\.;"SO]-UI;RV1LP+ID[%RSL5
MVMMV\Y&,D4 =;XZ\+1>+_"EWI;!1/CS;9S_!*O3\^0?8FO(_AIX_NM&\-WWA
M=H7EU>*7R],A/=W;:5/H%8EC[9]*]9\#WVJW_AM]2UJ&X@N+BYFE6WFC(>&/
M<=J8QG@#TYS7D^GV]W%\>VU_^Q]4CTEKF4B?^SI@/FB9,X"YY8]<=\F@#U33
MO 6F6ND:-:76ZXDTVX-X7. )K@@[G88YY;(],#TKR;7_ /DYF#_K[M?_ $2E
M?0G;-?/FLQ7T_P =(_$46D:N^E)=0,9QITW1(U5CC;DC(/:@#TCQ]H%E:>$/
M%VI6L6RZU"S3[1@\-Y><''KAC^0KB/AAK+>'O@_XEUA%#36UW*8^,_-Y<87/
MMN89KT'XCR/<_#_4H+:VNKF:[A"11PV[NQ)(/( R/QKB_A9H,EWX#UWPSK-A
M?6;WL\CC[1:NGRLB ,"0 2&&<>U %;X$:6FI3:QXFOV^TWYF$*2R_,RDC<S9
M/<Y'Y>]>F:QX2M=3\1:9KT3+;ZC8>8!*$!,BLC* WT)!'7N.]>7?#Z75?A?J
MFHZ3XCTR]&FW+AHKVV@>:(.O&?E!.&7\?E''7'I4'B6]UJZD72M+NUTQ;9W:
M_N8FA+OCY%B1@&;U)QC\Z /%_"WC?4?AAJVI:%XBTIY[>>X:68XQ(6/REUSP
MZD#_ .OVKVKP#;Z/!X70Z#>&YTV::2>+/'E!V+>7CMMSC!KB8]7TSQ#X*MM/
M\?:#JBZI'%LC=M.E:25L</&ZJ=K'C(..>HQ6S\&_#>I^&_"$R:I%)!+=7)G2
MW?K&NU0"1V)QT^E '/?M#?\ ("T7_KY?_P!!KBO&^K1Z]I?@_03:W5A);6Z1
MM?ZI%Y"291!N!Y.WC.<]Z[?XZP7FKVVEZ=INFZC>3PR-+(8+21T52,#Y@,$]
M> >W..*Q_&46K>,_#7AS0-%\,:P)+*./SIKNW:)8SLV[-S]>F2<]AUH 3XXV
MYM/#?@ZV-P+DPPR1^>#GS<)$-WX]?QJU\5=>N-.^&/A?2+=FC74;6,S,IQE(
MXT^7\2RG_@-4?BAH&IKX>\+>'[.SU#4KK2H&2YE@LY7CR53&UMN"."..F.<5
MUGB'PI)X]^%FE0V<,\&J:=%'Y<5W"T!+K&%>,AP.O9NF0.<9H Z?P)H6GV_P
MTTK3S;I);W=DDLZL/]895#-GU^]CZ 5X[\(?](\0ZYX/NF>72[ZWD650VTY1
M@,CTR"0?P]*]%\.>,+W1/ ]O8:GX>UDZSI\(MEMHK"1UEVC:A#@;,8QDY]>M
M4/A#X U#0Y[KQ%KD?E:A=J4C@8#=&I;+,WH20..P^M &'^T+%'!;^&(HD5(T
M%RJJHP% $6 *];M=$M)Y=&U67=)>V5KY4<P.-RNH#9]>F:\O^-^FZKXDOM*L
M](T?4;MK$2F:2.V8Q_.$VA6QAONG..E>L6&H+_PC\%Y);7<>V%=\+6[^:I P
M1LQDG/H/?I0!\Y> _%D/@_7O$]]-:S-(;>18HX4W*K^8,!CV7..:]K/DZ-X>
MU'QN"W]H7.CQ2SI@>6\B1EE; &<DMCKC%>9_#W3-3TCQ#KTNM^&=9%AJEO+"
M=EHS$!FR01],UW.FS:IXGU>71&TC4],\+PZ7+9YO(RCSL<1@_@N<?B: .3^!
M5C_;&KZYXEU+-S?JZHDTAR0S[BY]C]T9]"17K.J^&K35->TC6'/EW>F2,R.%
M!+JRE2A/IDY_#WKR?P78:]\*O$^HV=]HM_J&D7I55O+& RGY2=K%5R1PQR.O
MIGOZ9I?B34=<U>-+/1+NTTJ-6,]UJ,1A>0XPJQ)UZ\DL!P#[4 >*G4HM(_:)
MN;^>*>6.*[FW);Q&1SF)APHY/7\JA^*.N6VO_$71KJU@NX42"&,K=6[0L2)7
M.0&YQSU^M;&G:=K$?QP?Q*_A_5QIANI6\PV;YVM&R X],D'Z?E4WQ7T?6M<^
M(5E?:;H6IW-M901Q22);-AF61F.WU&&'- 'O%?/?C'_DXS3/^ONR_P#9*]^M
M;A;NUCG1)45QG;+&4<>Q4\BO"/$VFZS?_&6U\16WA_5Y--M[FV=I!:,"RQ[=
MQ //8T =)\3?"K>,_&-GI,<PBG329KBW)^[Y@D08;V(R/;K7 :3XXN;'P-X@
M\$Z_YD<\5NZ6C2]48=8CGZ<?EZ5Z[<W-R_Q6TV\32=3-F-.:V>X^S-L1Y&5A
MD^@ P3V-<_\ %[X:'783KVBVY;4XP!/!$O-PO]X>K#]1]!0!A?'/Q#<1:=HO
MAZ(LD,MNMU/C^/'"#\"&/Y>E>O\ A/2;;1/"FF6%K%Y<<=NA8'J6(RQ/N237
M%_$[X>7/B_P]87.G@#5;&+"Q.<>:I RF3P#D<9J7PMXXU*UT"WT[6/"VOC5;
M2)82(K%F2?:, AN%!P.<X'I0!V>A>'K'P\M^E@'6.]O'O'0D81V"@A<#@?+G
M'O6K7G_B?7O'-AX*74;+18O[4EN@/LL*&=K> @XW8/S-D#) P-W3C-=AH=S?
M7FA6-SJ=M]FOI8$:>'^XY'(]OIVH \Q^$TW_  D'C/Q=XBN]S7?G+!%O'^KB
M);"CTX11^%7OC<)++P_I&N6K;+S3M11XW[@$$D?FJ_E1:Z/J7P[\:ZIJ=EIU
MWJ/AW5?WLJ6:AY;:7=G[F<LO+=.Q]N5\16M_\3M0T[2X]+OK#P_:S"YN[F]B
M,+3D9 C1#\W=N3_AD J^//#[>./$>C):326EY_8\M[:.<J5D#Q%0W<?>(]0>
M>V*@C\;2>(_AAXFTG6$\CQ!IUE)'=1. IDQD;P/P&?0_45T]U=W"?%.PD71M
M4-E!8R6;726Q,0=W1@<_W0%Y/_UZQ?BM\.YM:MY=>T!735DB,<\, VF[C/!!
MQC) SZY''I0!Z/I/_(&L?^O>/_T$5YY\>#M\ P-@$KJ$1&1D?=>O1=-C>'2[
M2*12KI"BL#V(49KS[XT6>I:OX9M-+TO2KR]G>Z68M!%N1%4,/F/8G</UH M_
M&&TU&]^&ETFGJS;7CDN(T7):(')Q]#M;Z*:X3X@^+-)U7P1X2;1;Z&358+B"
M1(H\-+"50@@CL=P7CO@=:]K&I+'HJW\MI>* @)MQ 6F'.,;%R<UPEIX6O/%/
MC*UUO4])32=%TUS+8V+(HDGE.,RR!?N\JO!Y^44 9NEZW#X9^,_B4>(YA9QZ
MA$C6ES<';&R)T 8\=,_BN.M9'@ZQ@\3:/\1M,M+I8=(N+II;>X9L(AW,P.#T
M7"KDYZ"O1O%VH7\H.GZ)H,U[JP_U%W/ %@MF/\?F/P2.N%SR,5B3_#FXTKX2
M:CX;TFX\S4KA?.EE'R^?)D$K[ A=HS^/>@#B= \2W'CG4/"_AG7FBLH]/E6[
M2Y)(^WF,[8U3.,9&[G)SCC!KTWQ2#K'C+PWH(!:"*1M4NP.RQ<1Y]B[?^.US
M&MV%YXRTCPUI]KX<U'3=2LIXG:YN(!$EHB##;7SSG ( ZX'3%=AX;TZ\;Q/X
MCUN^A>)KB=;6U1QR((A@,/9F+-^5 '+?"'.HR^+]2N )&N]4=&=CG<!DXQZ
M/^OM6'X!\5GPS\/]0LXD^T7:ZM)9Z=$[@;V8*>>/NKRQ/OVK<L8=5^'>O>((
MK70K[5;35I_M5@]F@98Y#NRDI)&T D<\\"IO#?PCT@>#;#3O$EJ;F[CDDN7"
MS,OEO(%#*"K<\(H_"@#$\)Z9::!\:1;#4$NKB;2#)=7+2 ^?<O("Y'IGL/0#
MZUUFL7 U/QW($C+)X;TZ2ZW'[HN95^3(]D5C_P "]JYNS^%&FV7Q4BDATB9=
M"@M%GC<S,5%R'&!DG)X&<=*[/P9IEQ)HNH7VKVKPWNLW,L]Q#(,,B$[$0_1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZXZO?+3XV^'=52YM=<TF5+9I (U*+,DB9X+J<8(ZXY_QY/XB_#N&RMU\2^&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6"ADFC.0& 888''''!]Q7UE7.>,?!NG>,M):UO$"7" _9[D#+1,?Y@X&1WH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK_GUTK_OR_\ \71_PO7Q7G/V72OIY#__ != 'T717SI_PO;Q5_SZZ5_WY?\
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MKTOX^.;LC5M(5;;8<&U8E]W;AB!CK77:)\8_"NL2I!))<V-Q)*L4<<\1.\G
M!RF0.3CDBOF:O;_@WX!G@F7Q-JMNJJT?^A1R*=PS_P M,=N.GUSZ4 >U4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-O!NJ>)=/TR]\2322:%8Y.GV,A^64[B=S+W7)(&>HX^[U]O5510J@*H&  ,
M"A$6-%1%"JHP% P /2EH *\E^.FI:S9:-80V<KPZ;<N\=TR'!=L?*A[X(W''
M?%>M5GZUHMAX@TJ;3M1@$MO*,$="I[$'L10!\;45N>*_#-[X4UZXTZ[BD"*Y
M,$K+Q*G9@>AXQGT/%8= !12@%B  23P *]P^'_P=A6"UUCQ(LGG[A+'8\!0.
MH\SN3T.WC'0]Q0!E_"GP'XA>]L]?:\ET[32P8HDA62Y0<@8Z;20.O49Q7OE
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MY>I(R..M>":]TTO_ *\(OYM5"YO9KJZ>X?8DCYW>3&L8.>O"@#O5_7NFE_\
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M&^TVUNVA:$SPI*8GZIN .T^XSB@"S1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12'..!F
MEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"*YM;>\@:"Z@BGA;[T<J!E/U!KQ
M;QC\$6S/?^&I@27:0V,O&!U"QG\^#^?K[=10!\67-K<64Y@NH)()0 2DBE6
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MQ_ 5'0CIB@#EO!_PJT/PU'!<7,*7^I*H+S2J&16SG**>F,<'K7>T44 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(!N&7<,[L$ =#U['O4^M?%33VAN;#PX'O-:<QQV<;1D+,9 "'7V .3NQ^7-
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M@#V;X3>'? ^O6K-<0O<ZO%M:2VNI<A0#]]   5)(R#G'3OS[DB+&H5%"J.@
MP*^/_#'B.\\*Z[!JMEM,D?RNC=)$/53]:^IO"WBG3O%NCIJ.GOQ]V6)OO1/C
ME3_CWH VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/+8X#8VG!SSC&:N>-9;>Q\/2:/!,^JRF6WN9=4!5E52C;8@_+. =^"<8Z=J
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M.IWMP;Z\B0%590(XI.[#UQV)Z=>O0 E^&^@:GX?^'-S#JI999_,G2%B<PH4
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MB3T +'/M7"44 ?;-%<)\*O&+^*_#31W97[?8%8I=H(W+CY'],G!SCT[9KNZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUJ_TF^*8O41H1*1LWJ3Q@_Q'<,8_NUY55O2[^32M6L]1B56DM)TG16Z$JP8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ=.U 'QC>Z;?:;*8KVTFMW#%<2H5R1UQZUV'PANX+3XC6!N)!&)%>)">[LI
M'XFOI#5]$T[7K![+4[2.XA<$88<KGN#U!]Q7(6_P@\-6/B*UUBP:\M6MI4E2
MW24-'N4YYW MS]: .^HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-\'_  _KT[7=JTNFW;-N9X,%');))4]^O0BO0@, #TH 6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 ?$Y!5BK @@X(/:M[P=X9N?%?B2VTZ!&\HL&GD"Y$<8ZD\CZ=:Z?XN^#9-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 444QY8T!+NJXZY- #Z*KB]M6.!/'
M^=3AU89# CV- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444UR54E1D
MXX% &3J=TTS16EI,1,S?,5/W0/6@:3'E6>1Y">I)SG\*9I)1O.N2%$DCD].@
MR16D9,#!*D>] %>2P@(("8/;)XJK)8O\VPX]-O%7GD'.T+[DGI3E.<8(_"@"
MG#<WD"-YB>8J@8)X(^M/T[47O)I8Y41"AX /6IY[N.&-B64D#I69IHDDUDS"
M)A$\9);''6@#;@D,L>XC!R14M0VR; YYPS9YJ:@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *0C(I:* .=LR;266SF 1@Y:-O[P-:00?=Y!JU<6L%RH$T:OCIFJ,EC/
M V;5]T?_ #R?M]#0 \ #HW.<9]:=YL<)#.5 'O5;S+M"0+5LCOMI(K"ZN6+W
M)$:^BCF@".R,=[?2"0AL9.W\:VP@10J@ #H*AMK."USY28+=6)R35B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%!H 3-+24M !29I:2@ S1FBB@!:*** "BBB@ I*6DH 6BDI: "BBB@
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M- !0:,TE !2TE% "T444 %%%&: "BC-% !1110 4E+FDH *6DI:  TE+28H
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M!**6B@!**6B@!**6B@!**6B@!*444&@ HI*6@ HHHH **** $HI:* $HI:*
M$HI:* $HI:*  4444 )12T4 %(:6B@!**6B@!**6B@!**6B@!**6B@!**6D-
M !112T )12T4 -!.X\<=C2TM% "44M% "4M%% !1124 *:2E%% "44M% !11
M10 4E+10 E%+10 E%+10 4444 %!HHH 2BEHH 2EHHH 0T4M% !1110 E***
M* "DI:2@ HH%+0 E%+10 4444 %%%% !24M% "44M% "4444 %%+0: $HHI:
M $HI:* $HI:* $HI:* $I1110 4E+10 E+110 4444 %%%(: %S1FDHH ***
M* "BBB@!<T9I** %S1FDHH 7-&:2B@!<T9I** %S1FDHH 7-&:2B@!<T9I**
M %S1FDHH 7-&:2B@!<T9I** %S2444 %+244 +FC-)10 N:,TE% "YHS244
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M** "EI*6@ I*7-)0 HHI*7- "4444 %%%% !2TE+0 4E%% "BBDI<T %%%%
M!2&EI#0 4M)2YH #2444 ***2ES0 E HQ10 M%&:,T %)2YI*  4M)2YH 2B
MBB@ H%%% "T49HS0 449HS0 449HS0 449HS0 449HS0 449HS0 4444 %%%
M% !2&EI#0!#=7,=I;23RG"(,FJ^GZC'>PH6RDK?P,,&J5\6U'4%M%&8(&#R_
M[3=A5B6S;<LT Q*K9P3Z4";-.BJUI=K<J1@K(G#*:LT#"BEHH 2BBB@ HHHH
M *6DHH 4TE%% "T4E% !1110 4444 %%%% !1110 M%)10 4444 %%+10 E+
M124 *:2BB@ HHHH **** "BBB@ HHHH *R_$<]_:^'KZYTR6".[@A:5#/&70
M[1D@@$'G&,]O0UJ5F^(?^1:U7_KSF_\ 0#0!XWIWQ3\;WGA/4/$HBT@VFGSQ
MQ31- ZEPQ ^4[^H)''OFM7Q5\4];L_!^@^)=(ALX[?40\<MO<Q,S)(I()#!A
ME>#V]/7CS#0M%AU#X7^(]0FU&Z@-A/$\=NLI\F1FX^9.[>A[?2N@\77E[KGP
M3\-W\EC'#';W;0L8(]B;0"JMM' R0>G&?KB@#UZ[UCQ!;_#!M>6XL&U)+,7I
MS;L(RFW>4QOSG'&<_A6/>^-]:A\2:#X6-UIEMJ5W;">[O)H&,2D@E41-XR>,
M<MS^E3:KJ]BOP04K<1N;G2$M855@2\K1A H'<Y/2L3Q1X0T3QSK\FB?:I+#Q
M%I=E"$E;#+<1E<\J,<J3R1Z]^P!JOXC\<VR>*+>\32DN=(M4NH)E@<QSIARW
M\?!(7IV.>M9V@>-O&6M_#K6/% DTA'L]QBA-N_*QC<^3OZX/'TK&\):AK]GH
M7CKPMK%V+N'3--FV3;_,$;%&&T/W!'8],8XYJ7X?NO\ PS_XE&X9$=YGGUA&
M* .D^''Q.?QG!<Z;?"WM-=C5FB 1O+D7'WL$YR#U7/3IWQEZOXX\:Z/X)FU^
M671G:+49+,Q+:R<A&9"V=_\ >4\8Z=ZS/&?@>\AT?2?'/ALM'J=M:PSW2Q@E
MI"%7]X!SD_WAW&3ZYHZW>RZE^SS'?SA1-<ZI),^T8&YII"<>V30!U5[XN\<6
M_ANRUV&;0)VN;07W]FK#()?)^4L5.[G 89Z=\9K3U#QOJ=]X_/A'19-/LYX;
M<32W%ZK/O<@'RT4%><,#U['TKG?".D+X7BT7QC=:I//HZZ 1*;B=6\B0[6\J
M,<'!.X!>3D8I/$'A72OBCJM[>:5/)I7B"R2$R1SD$2J\:NC-M)*D9VY&>G?B
M@#:N/B'KOA_0?$4_B'3;7[?I<L4$"VP<13&095LL>G?MZ=:LKXA\:6J^'[N=
M=&O=.U2YACEDM$<&W$A'3+$,,$C=Z]JX/0M<:^T#4?"'CF6:[M(]3BTZ.^24
M$PR'S#GS#U ,?&>S<\<4B:)XD^$WC/2(;#4?MVF:I=>2ML"<R+D [D[, V=P
M_P#K4 >]W5U#96DUU<R"."%#)(YZ*H&2?RKSS0/&/B;QW+?7?AR'3[#2;:3R
MHI;^)Y'G;&2,*P"C!'KC(Z]NG\=:;/J_@76K&U+^?):ML"#)8CYMOXXQ^-<7
M\!M0M)/!EQIRO&EY;W;M+%D!R"%PQ'IV_"@#3L/B'>V%AXDN/%=C!9OHKQQF
M.U);S6<9&TG^]QCI@'FH+/Q/XZU;PL?%%CI^E1VN&EBTZ02--+$.^\$#=P2!
MMYX]:R_C%);^(_!]Z-&G6X?2+R*2_$0) !1@.>C8W#.,XYZ5U7@K6=.3X4:9
MJ#-$MK:Z>%GR1@&-=KY]R0?SH QKKXHRW_PZF\4:!!;&>R=%OK2[W$QY('RD
M$9Y((/<9Z'BLF7XH>*[/P5IOBZ?3=(FTZ[F:%H8S(DJ$,RCDDCG8>Q[5P/AJ
MUN+7X0>,]2EC9;2\>V@@/]YEDRWX#<!G_"J5PNKVW@?PK-J<DUWX3DF=C;1[
M4V.)I R[ASDC)!)[GTH ]@\;?$N^T3POHOB+1;>TFLM1XV72/O4E<CHP'8@U
M4'Q/U_2-6\/1:_INGO8ZY#%+#-9%PT8?'!#9R1N&0/7KVK)^-$^FW/PW\.2Z
M04.G-.OV?RQ@!!&P QVQTK=\-?#B+6(/#7B#7-6N+[[)86S6=H(ECCB 4,H;
M'+8/TS@9STH T!X]U'7_ !G<>'O"EK:O'9 _;+^\W&-2#C:JJ03SQG///89H
MT;Q_?#Q=<>#_ !%:VUKJ^";6Y@W&"?Y<KP3D9'/7L1P:Y#X)(=&\8^*-$U$$
M:H-IRPY8(S!SGWWH?<<U!XLMI=:_:'TF#3VWR6IMWF9.?+"$NV>W Q^)Q0!K
M:#\1/''B'6]6TFST_05N=,5S*9/."N5;:0I!/4],XKI_AI\0SX\L;SS[);6[
MLB@E",61PV<$9Y'W3QS]:\<TV'Q$_B7QU+X;O&@N8FG:5$4%I8O..X*2.& Y
M&.?QKT3X&WN@)X0NA:J(-1A;?J!=LE@,[6'^SC/T.: .D\6?$&V\+^+="T:4
M1[+YB;F1\_N4/RHP/^]G.>P-7?&>NZSI"Z5;Z#9VMS?:A=^0JW)8(HV,Q/&/
M[O\ ]8UXQXSTG5O%.CZGXN_L.9HI;G[1;WYN$ 2S0%%7R\[L\;B:]?\ AIXG
M7Q7X+L[J1RUW;C[/<[NOF*!\WX@@_B: .4L_'OCF^\9W_A:"R\/F_LXVD9B9
MA&^-O .<Y^8=0*HZW\6O%.DZ%H^J'2]+"7IEAD1Q)NCFC<JP^\.,8QU[^U+X
M8_Y..\0_]<)/Y1U#^T*%$/AT!L'S)_EW=?N<X_K[^] ';>*?'DOA&PTZSNK:
M&^\1WVU(K2U8K&7)QG+<A<G [D^G)%+7/&GB?P4EE?>)--TZYTN=A'-+IS.'
MMW.3C#GYA@>W3MQGC_B-$^E?&WP[K&HY.FR/!Y<C?=CV/\PYZ8)#?C76?'*Y
MAB^'4D,A'FSW,21+QDD'<<?@#^= %3QU\4M2\):EID]K96-]HNHP">"3<RR,
M.,\]!PPQQWK>\0>-YT\(6?B'PREG>VUS*D6;EF7:78(. .S'!'%<CH_AH3?\
M(-H6NPF42Z/>B:.4?,H8HRCGD%00!Z$=L5QLND:_X)\46_@R>4OHVIZC;/%,
MR9#8E7#+SPW0,/\ ZQH ]5F\:ZYJ7C"Y\,^'[?2C=V$(>[EOI'57?C*QA><#
M/4__ *]OP9X@U+7H-475K&*RN["^:T:.)RP.U5.<GKG=Q[8KSGQ'X%@\;>(-
M7UKPGJ4EEK5C=M!=02ML!D08#HR\KG'XD'I73?"'Q'K&MZ1J5EK>9;K3;@0&
MX(YDXQ@D?>8;>OH1]: /0YIH[>"2:5@L<:EW8]@!DFN3^'WCB'QQI5U<A$AG
MM[AHVB7/"$Y1N?4?J#5;XEWEQ-I=EX<T^.6:]UB<1F*)@K&!/FE()( X ')'
MWJ\T\+74O@'XQ/97&GS:;IVL86.WF=6,:N?W9RIV\/E>IP": /2O&'Q".B:Y
M9>'-&LEU'7;ME A=RB1 ]"QQ^./3D]LUKSQ=XO\ #]_I5KKFA:=+#J%[%:B\
ML;A]D1=@""K+G."<<XXKA"CZ5^TU'+J#[4GF9HG?HP>!E0#_ ($0OU%>W:I>
M:7:+:KJ<ENOG7,<=NLP!+3%ALVC^]G'/;K0!Y;?_ !8\3Z=X6M/$=QX<L8].
MO)O*M\W1+MD,0< <#Y3_ (5TVA>,?$%UXFTW2]8T>SMX-1LVN[>XM[@R9  .
M,$#GD?F*Y_X_(D7@334C141=10!5& !Y<E>DZ'&AT+2Y"BEUM(P&(Y *#//X
M4 :5%+24 %%%% !1110 4444 +1110 4AI:0T %%%% !112T )12T4 %!I**
M "BEI* "BBB@ HHHH **** .)UWXAMH7BJ'0)/#VH7$]T1]CDA>/;<<<XR1C
M!XY]*LV?C6X?Q-:Z)J?AV_TR2\#FWFFDC='V)N890D#CWKC_ (F"_/Q0\&#2
MS;B]^?RC<@F/.1]['.,9Z5/XHA\<KHWB:?5S8R6ZZ1B Z?N$:MO/F'#G<&V%
MLGIC% &Z?B/_ &@UTWAOP_J&N6MJX26Z@*I&3W";CER.. .]7K3Q]IVI^$KK
M7]+MKF\%J#Y]F@59HR/O @GL,GW XJG\(EM%^&6DFT P0YE(')DWG=G_ #Z5
MPU@2OQ+^(XTY<:?_ &=-Y^.@FVCTXSN\SWZ^] '46?QCTN>PBU.YT75K72I)
M/*^W-&KQJ_H=I)'Y5M^+/'MGX4TJRU1[&[OM/N@"MS:[2BY *YR1U!X^E>#Z
M7JNIR> =.\,77V:QT#5K\H^HLI=E*NK$$9P,':?I^->N^.]"L;7X?:#H+R22
M6"7UE:LX(W-'G:3GIG% '?:=J%MJNFVVH6<@DMKB-9(V'<$9_.N8\._$;3?%
M'B6]T?3;.\<6N[?=[5\HX.,YSG!/3CFO+_#_ (AU/PYH6M_#W>PUL7@M-.*Y
MZ2'#,#V 'S#_ 'JV_@]80:7X[\8Z?:AQ!:NL*;^N%=QS^5 'LU8NF^*=*U?7
MM2T:RF:2ZT[;]H(7Y03G@'N1CFL/XG>+#X7\/PI'*;>;49A:K=8)^S*1\TN!
MR2HY '>O/_A9K7AK3OB+K%EIUVYM;V.&&Q:1'W3LJ_,3D<$G)YQR: /=J***
M "BEI* "EI*6@ HHHH *IWYG")Y+A 3\S=2![5<JO=0O.%17*IGY\=2* ,ZV
MB\K>J9W,=[%NK&K@,@4$D\'FJ5Q'_9^I6LBD^1(2C G.#CBM+!!&?QIDV*MS
M#.9O.MB ^,'GK56*;5E&-JD#^^.M:P#'@/QZTJY)]10492ZO-"X6ZM\<X)6M
M>*5)8U=&RIZ&H9X$N(G1@NY@1G%4-)D:*22U8XQ]T?SI :]%%% !1110 444
M4 %% I: $HHHH **** "BBEH 2BEHH 2BEHH 2BEHH 2E%%% !1124 +2444
M %%%% !1110 444HH 2BEI* "BBEH 2J6JZ18ZWI\EAJ5N+BUD(+QEB <<]B
M*O44 <<OPL\$*P8>'K;(.>7<C\MU=-/IMC<Z<VG36<#V3)Y9MVC&S;V&WIBK
M5% '+Z5\.O"6B7\=]8:+!%<QL620LSE"?3<3C^E3ZOX&\.:[>O>ZAIJR7;A0
M;A)'CDP!@?,I!''%=#2B@#GD\#>&H]#;1DTB!=/9P[Q*6&]AT+$')_$U6C^&
M_A&&SGM(]%C6WG96EC$LF'*YQGYNV3754E %33=,L](TZ+3[& 0VD0*I&"2%
M'7'.:Q[OP#X6OK."SN-(A>V@9WBB#LJH7.YB #ZFNCK%\1>(8]"A@CCMWO=1
MNW\JTLHV :9NIY/W5 Y+'I0!EGX7>"V5%.@PE4^Z#)(0._ W5/JGP\\+ZQJ,
MFH7>F$WDF-\T4\D;-@!1]UAV JI?>-+]O%UUX<T31$O[JQ@$]TTMV(%&Y055
M?E.2<KSP.><=:S=1^)]W9>"U\21^''D2.ZDM;NV>[V/;,K;1GY#G/&>F,CK0
M!T<O@;PS-H4&B2:1 =.@D\V. %@ ^"-Q(.2<$\DTFD>!?#>AWRWMCIH6Y0$1
MR22O*8P>R[R=OX5CIXQ\5_9K6\F\#XLYVBS)#JBR,J.0-VP)DXSFKVL^-EM/
M$4?AW1].?5M99/,EA6411P)Q\TCD''!Z8/;U&0#K*Y76/AQX1UV^:]U#1H7N
M6.YY(W>,N?4[2,_C6?J/C_4-$U%K'5O#AAF^QSW43PW@DCF$2%RJG8#NXY!
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MCVP^R@IT^N:[-5_=A6)?C!) YIU H XB+X<C2OM,7AW7]1T>TNI/,FMH@DB
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MHHH **** "BBB@!**** %HHHH **** "BBB@ HHHH **** "BBD- !2TE+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%!H 2EI*6@ HHHH ****
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M HHI* %HHHH 2E%)10 M%)2T %%%)0 M%%% !1244 +1110 444E "T4E+0
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MQ_ ]L '/?$B*-OBCX(#1H0TZA@5'(\U>#4OQ@T*ST[28?%.FJ;'5K6X0":W
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MX1?XC?\ 0^0_^"^/_"O0Z* ///\ A%_B-_T/D/\ X+X_\*/^$7^(W_0^0_\
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MG]D?%/\ Z&;1_P#P&_\ L*/[(^*?_0S:/_X#?_85Z)0: /._[(^*?_0S:/\
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M ,_7AK\I/_B:/)^+/_/UX:_*3_XFO0Z* ///)^+/_/UX:_*3_P")H\GXL_\
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MKU.B@#S:+Q)\459O.\%63K_"$NT4CZY<YJ4^)OB3QCP+;CUS?Q__ !5>B44
M>>?\)-\2/^A%M_\ P81__%4Q_%7Q'CVY\"0G<=HVWR'\\'@>]>C44 >8_P#"
M;?$+_H06_P"_QK3T+Q9XQOM6MK74O!;V=O(^)+G[1Q&N.N,<\^]=W10 M%)1
M0 M%)10 M%)2T %%%% !1110 8HQ110 E%+24 %+B@44 &*,444 &*2EI#0
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M2BQN!H\:%\LTSDK&V1GH QSWV&K.F_#WQ1IW@O5O#4=]I?V:[F\VWP9?W +
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M0 E**** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*!10 E+110 4AI:0T
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M,=S,')&,,3SGIZ]*[NB@#@/AYX'G\.3ZEK>H1E=1OOD2V-P9C!$.B&1B=S'
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M9(W6/NB$GAFZ9QP#QST[6DH \LCT_7;6_P!!\2IX9>UMM+6:S.EV\BR3BU*
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MHJO]OL_^?N#_ +^"C[?9_P#/W!_W\% %BBJ_V^S_ .?N#_OX*/M]G_S]P?\
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MPZJS@$4"]M=A;[3#M!P3Y@QF@">BH1=VQ1G%Q$47JP<8%(;ZT4X-U"#Z&04
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MTN* .$/P@\&EL_V?,!C&/M,F/KUIK?![P<Q0BSN%VG) N7^;V.3_ "Q7>44
M<$OP=\'JP)M+EAN)VFY;&/3CL*:OP;\( $&WNCUY-PW?_"N_HH X-_@]X.>-
M56SN$(ZLMR^3]<DBF/\ !OP@[$K;W: G.%N#@?GFN_HH \]_X4QX1_YYWO\
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M_P"%'_"G/"GI??\ @2?\*] HH \__P"%.>%/2^_\"3_A1_PISPIZ7W_@2?\
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M2**W25(UP'WG)VJ.0% ].3Q5CQ3X@U.Z\:Z;X,T6]%C-<PM<W=Z$#O%&,X5
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MC<9&6RHY7!P.:U:0T4 +124"@!:**0T +124M !1110 4444 %%%% !1110
M4444 %%!I* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%%
M!BBBB@ HHI#0 9I<4E+0 E%*:2@ I<444 %%%% !BDI:2@ I<4E+0 4F:4TE
M "T444 &*,444 &*,444 %)2TE !2XH%% !1110 E%%% !2TE+0 E%+24 **
M*!10 4444 &**** "C%%% "44M)0 HHH%% !0:*#0 E%%** #%&*** #%&**
M* "BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1110 4444 %%%% !
M1BBB@ Q1110 4444 &**** "C%%% "44&B@!:*** #%%%% !1BBB@ I,TII*
M %HQ0** #%%%% !1110 8I,TM)0 M%(*6@ I,T44 &:,T44 &:6DI: "BBB@
M HQ110 4444 %%%% !1110 4444 %%%% !1110 4E+28H **,48H 44449H
M**** "D-+10 E+28I: "N(^(WBG7/"T6D2Z1'I\BWMXMFPNT<[7;[I!5AQP<
M_A7;UY;\;")M.\/VGE73@ZFD\C6\;,4C4$,<KR#\XQ0!=T[XE/I_BF_\.^,!
MI]A<6L22+>02MY#Y ./FY4\C'X_CV#^)=$CN+N"35;1);./S;A&E ,2<<MZ#
MD?G7%^+/!.D:=\//$CZ-I\LUW?6XD=W>2>:3:RL.7);C&<>U<N=5&H^(]>O4
MTW4_L=QX7-LLLUG+_K0.A)7G)R,]R* /3X?'?A:YM+JZAURSD@M0AF=7R%W?
M='N3@\#FK5MXIT*[:Q6#5K1VOPQM5$@S-M.#M'?!!KS&ZL-(D^$7AD&UO;&<
MRVZ->6=JPEMKA%?]Y(H&YE#!O^^LBJ276H1Z3X*UW5M*,:V>K7!GEL[-EWJW
M_+7RP 1N()Z#.,XYH ]9_P"$N\/?V,^KKK%HVGI)Y33I(&7?_=XZGD<=:1_%
MWAV/3K74)-:LDM+LD02O,%$A'4#/IW]*\:M-3O;33;VX&A7UO'/XLDO1<3Z>
M[-9QNN!(J="X&X8(('ITJAIDT*:)8:?=66HS-!XQ%W()["0G[/MPQ8!<9Z90
M<^U 'L6H_$CPS8>&_P"WDOUN[(W M@;<98R'J,'&,#+<]A]*ZBWN(;NVCN+>
M19(95#HZG(8'H17@&L;I1XF>&QNI(HO$UO>E%MF^:$;E+ $8//\ .O?;2Y2\
MLX;F-)$29 ZK(I5@",C(/0^U &#I_CG0M1U?6M.CN@DFD<W+RX5,#[Q!/93P
M2>]7=%\4:)XB:9=)U&&Z:$ R*N00#T." <'UZ5Y1K%G?W,'Q&L;?3KPWLE]#
M="-8FV30(4/RD#!9AD[>_P"%=)I31>)?B9I>O:3:3065GI;0W4DD#PC<Q.V(
M!@-Q7KQP./:@#K/&GB0^$O"5]K2V_P!H>W"A8LX!9F"C)].<UF^&M?\ $%_/
M8RZA%IEQI5Y8FX%_I^\)'("OR-N8XX+<]\=L&M+QAJC:1H)N/[+?4[=IDBN;
M:./S&:)SM8A?XCR.*\B31Y?[5\0Z?X$BU(:'=:-*;B"XBD1!.00$CW@'<>./
M=ATZ 'L>F^+= U=;MK#5K6=;1=TY5\!%_O'/\/!YZ5F7/Q(\*PZ+?ZI%JD=S
M#8A?-6$$L2W"@ XSD]#T]Z\H&D1:WX2U-M%T?Q"=932$M[F2^9MJ!7C8PQ@C
M+9"/@#H!CO70Z_JEMXN\$^(+G2/"M[;3C3HXI9Y8-C$K(I$*J.6 &XY'0 ?@
M =O:>*H]4\0Z.MAJ>G-IU_9/,+=MWVEF!X*]MHPP.?[IZ]M"S\8>'K_5I-+M
M=7M9;V/=NB#\_+][!Z'&#G&<8->7ZY/+KFO^&!IL%[;W$VAW5NDDEN\9CD>-
MDCR<?+EE)'L0>]1VT,FMZ'X'T:PT^\M-6T6[22^,EJZ?9XX\^8=Y&#N." "<
MYZ4 >H6WCCPO>ZC!I]KKME/=SDB...4,6([<<9K>KY[LRD/A/0'6RN4N8_%G
MVDE;20.L .6/"YQADX[_ (5]"8H Y;PUXHO=9\3>)=*O+*&U&D20HA20N7#A
MCN)P.P!QCC-9^@^.YO%FM7(T<V"Z5:NR9F<M<W949)CCR-J\C#-GZ=<8WA]O
M[4\:?$6TMWGMWU&...UG>%T!*Q-&S D#HS#^8KF-,T4?V9X3T6PTB2Q\5Z=J
M>Z\G-HZ!8E+EV:4##*PVXY.: .LN/$_Q&T_4M%BU#2] CBU2]2W6"-I7FC4Y
M9B?FV_*H))&?I73GQ-?WU]K,6BZ8M[%I@\@L9E0S77!\M<G 5006)]< '%53
M;76I_%<7,L$HT_1]/VPNPPK7$Q^8KZX08/UK#\!WG_"(>$?$,-_'<W5UIFIR
MFXAMT\R9E<J5<+GD$'=GT!]* -/1O$7BRX\0:QH&H6>D?;;6R6YMYK5W,(9N
M%23)W GV X!/<5T?AO7[?Q'I7VR%#%+'(T%S 3DPS(<,A/?![]P17">$M)LW
M^)4^M^&8+ZWT>2S(O6N4D1)IV;(""3YB1U)Z#IWK3^&,;22^*]24M]EO=;G>
M D<,H.-P^IX_"@#KM8UW2_#]HMUJM[':PLVU6?)+'K@ <G@$US/B[XBZ=H6@
MZ??:?=V=P^IS+%;22.3$%SAI&V\E5[C@U2\3R2:-\4]%U^]@FDT?[!):&5(F
ME%O,26W;5!(W#"YQ7#?V==:=X=T=I;.ZA@N_&*ZC;6YMVW0VHR-S #*]1P:
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M>A- '06_C*VTO1--F\77%II.IW2;GMBQ^3DXXY(&,9)XS5[4?&/AS29V@O\
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MZWTB6MY&8VGM'4DKGY@"01SR#^-<MIGB;7-8\>6,,"P1Z7<>'TU(0-GAI&
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M!:R"6$$<(X& 0.G&>/2K5+BC% "44N*,4 )12XHQ0 4444 )2BC%% !24M%
M"44N*,4 )1110 M%)10 4HHQ10 444F: %HHHH **** $HI<48H 2E%&** "
MDI:2@ %+2"EH 2@C((!P?7TI:* .:\'^#X_"$6H)%J5U>_;;EKES.%&UCU(V
M@<GC/;C@"NE-%% "44N*,4 )2T44 !I*4TE ";%.25!)&#QU'I0B)&NU%55]
M%&!3J* $I124HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ****  UQ/C#P+<^)]=T[4H-56U%K#+ T4MOYRD2*064;AAL'K[#TKMJ*
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M:KILQDMKM8Q)M###*5) (.!^7N:R;GP!K-VVC7%SXI:ZOK"_^W23SVF1(V%
M14# (F >!W.:[^B@#S2?X7ZA<?:6?7K?>^M?VS&/L)*+(<AE93)\P^[CTP>N
M>&VWPQUNU-BO_"5QS1V>J-J:B73^6D/7=B09SEOSXKTVB@#Q#QKX:N_#^C7M
MOJ.JA['7=7%Y<WL6GDI9D9.&3<Q8,=@ XZ').<5=TCPUJ_BKP3J?AJ/4+=='
MDDB:#4AI/V4RD-N=1""N?F5/G[\CGM[%10!Y[??#W5M0U#6[VXUZU,FJZ:NG
ML%L2!&!MRP_><YPW7U'I7GVO:3+8^(;/1+O5(X9=)L(+6T:;13<I>#.YFB7#
M?,/E4@DY.[&*^@Z* ,GPU-J=QX;L)=8MTM]0:(&:)!@*>W';C!QVSBN'B^%V
MI0Z7;:9'X@@%G::N-3MXVLBQ3!)"9\P<?,<UZ=10!YM?_#&_U*?4KF7Q D5U
M/J":C9S06A4VLJC;W<[@5 !Z<@'VKK/#>BZAI,4\FJZW<:M?7#*9)I$$:*%&
M $C7A??'4]:W:* .%U/P+J%_KWB'4H]9@B75].^P"(VA;REP!G.\9.-WIU'I
M6-<?"6^FLOLR^(8D#Z5%ILC&PWG;&>"F7^4'C([GGCMZG10!YU#\/-7CO+NZ
M?7[1I9]&&DC%@0%08^<_O.3U].U);?#2]']A0W>LVTUII=E/9&-+,JTJ2J58
M[O,.#MV]CR">^*]&HH X?PGX(UCP]+:17OBNYO\ 3+%66TLU@$(7.0-[ Y<
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M*** "BBB@ HHHH *,T&DH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!F^%-3N_B/XX\1?;[V[BT?3"(;:RMYW@!)9@'8H02<(3R?XO:I?&$/BSPAX
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MY/E7&V/8<-U!QD?ETQ76:0/%U[=O=ZP+'3H4B98;&W?SM[G^.1R!P.P7UYH
MZ:BL#P?#XD@T/R_%-Q;3ZCYSD/;C V9XSP.>O;IBM^@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#110 E+28I: "B
MBB@ HHHH 2BEI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,T4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%&: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1244 +1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4AI:* $I:** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $-%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  :2EHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***2@!:*!10 4444 %%%(: %HI*6@ HHHH **** "BBB@ HHI* %HI*6@
M HHHH **** "BBB@ HHHH **** "BBB@!**6B@ HHHH **** "BBB@ HI#10
M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 44E H 6BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "DQ2T4 %%%% !1110 4444 )BEHHH **** "BBB@ HHHH **** $I:** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,4M% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 )BEHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*** %HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!*6DI10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE !1110 M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11FB@ HH
MHH **** $H%+BB@ HHHH **** "BBB@ HHHH **** "DI:* $I:,44 %%%%
M!1110 4444 %%%% !24M&*  4444 %%%% !1110 4444 %%%&: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $
M-%+1B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM% "4M%%
M!1110 4444 %%%% !1110 444E "T4E+0 4444 %%%% !1110 444E "T4"B
M@ HHHH **** "BBB@ HHHH **** "BBB@ HI*44 %%%% !24M%  **** "BD
MHH 6BBB@ HHHH **** "BBB@ HHHH **2EH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**2B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBDH 6B@44 %%%% !1110 4E+10 E+110 4444 %%%% !1110 4E+10 "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!*4444 %%%% !1110 4444 )12T
M4 %%%% !1110 4444 %%%% !1110 E+110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E
M%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&
M*** "BBB@ HHHH **** "BBB@ HHHH *,TE% "T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %&:*2@!:*2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DH
M 6BBB@ HHHH **** "BBB@ HHHH **** $HHI: "BBB@ HHHH **** "BBB@
M!*44E+0 4444 %%%% !1110 E%%% "T444 %%%% !1110 4444 %%%% "444
M4 %+24M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 )1110 M%%% !1110 4444 %%%% !1110 4444 %)2TE !2TE+0 44
M44 %%%% "4M)2T %)2TE !2T44 %%%% !1110 4444 %%%% !1110 4444 %
M%%% "4444 %+24M !1110 4444 %%%% !1110 4444 %%%% !1110 449HH
M***3- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%&: "BBB@ HHHH *#10: $I:2EH **** "BBB@ HHH
MH **** "BBB@ HHHH 0T4M&* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** $HI:,4 %%%% !24M&* $I:,44 %%%% !1110 4444 %%%%
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M<?UI,9LT444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BB@T %%)2T %)2T4  HHHH **** "@T44 )2T44 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 44&FQR+(NY#D9QF@!U%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 (*6BB
M@ HHHH **** "BBB@ HHHH **#24 +1110 4444 %%%% !1110 4444 %%%%
M &;J]E-=Q1-"<F)]_EGH_M5:TNHMI !60'#(< @UMUE:II[S;+BT"BYC.?\
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MBJ]W=+:6TLS*6"*6P.^!2VLQN+:*8H5WJ&VGMD9I6=AD]%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "@T44 )2TE+0 4444 %%%%
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M6R%(!N^\>6^M,G;?/%!QS\[ CL/_ *]6,X'L*.@$%PQ+)$/XCSCL!U-3J@0
M*, < 57MQO=ISG+_ '1Z"K-#["0M%(S;5R<8%4Y[FZR1;6RR8P0SOM!^G6DA
MEVBF1LS1@NH5L<@'.*=0 M%%% !6;JERXV64'%Q/PI'\"]V_#^>*N7%PEM \
MTK!8T!9B>P%4-+C:??J4Z,LMP/E1A]Q/X1]>Y]S51[L3+MM;QV=JD48PB+CG
MOZGZU6U&^33-/>=EW2,<)&.KN>@J\W(V]N]8%DO]M:PU_(";2T8I:KV9^C/_
M $'XTXJ^K$]-"YI%BUC9&2Y<R7<Q\R>0]2Q_A'L.@^E:,:%06)RS<DTX ,?8
M4_%2VV-(2LK6=1DM8%M[4!KVX;RX$]^['V YK1FF6")Y9&"H@+,3V %<YI4;
MZM=OJDRLK3KMMP3_ *J#L?9FIQ75B;Z&CI.GQVMM'"OS)%SN/61_XG/XUK 8
MI%0(H5> !@"G4F[NXTK!1112&%)2TE "BB@44 %%%% !1110 4444 %%%% !
M1129H 6BBB@ HHHH **** "BBB@ HHHH 3-+31&!(7YR1CK3J "BBB@ HHI,
MT +1110 4444 %%%% !1110 4444 %%%% !1110 4&BB@!*6C%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44F<&N1\0:IJR^
M*=+T?2WA_P!*CE:Y+KEHHQC#@_4X^N*:5P;L7[[Q!+#]I%C;&X2U!:>5CA0!
MU /<@<UN1R>8BNIRK $?2LR^L[>T\-WENJ@0K;2 ^_RG)JO*]R-+TZPM'V3S
MQJ"^.8T"C<WUZ"JLFM";ZFN+RW:Y^SB>,SXSY>X;ORJQ7-W6EP0W6D6UD@C:
M*X\]R.24"D')]R15VVUL7(E6&U>659714C8'*JQ7>2<!02"/7CC-')U0^9&O
M5/4;O[);KM_ULTBPQ#_:;@'\.3^%&G7_ -O6Y/E[/(G>$X;(8KU(X'?C\*JD
M_;O$>W&8M/CSTX,KCC\E_P#0Z%&SUZ WIH:PJ*XN(;2!Y[B5(HD&6=S@"I'=
M41G<A549)/85R4<O]O:W;2:E&T>GG+Z?$3\EPP)^9O?&"%/;-$(WU>PF[&E;
MW&H:U-'<0M)8Z:.1N0":?WY!VK^I]JW***4G<:5@JI87PU"*2:-,0B1DC?.?
M, X+#VSG'KC-5=?NGBL5M8"1<WKBWB(_A)ZM^ R:34[::T\.FTTU),QHD2B/
MEPF0&QG^+;G'O34=%YB;"36V>YFAL+">],!VR/&55 W]T%B,GZ=*T8)'E@22
M2%H789:-B"5/IQQ6-#J+V-B'&FM9Z? H55E/[UST 5!GJ>,D]^E:.EI>I81_
MVA*LETV6?:  N3G:,=<=,TY*R!,+[5+73]HE+O*P)2&%"\C?11SCWZ58M[B*
MZA$L+;ER0>Q!'4$=B/2L.RT[5+&2Y,<5DTTTK,UY+(S,RDD@% .PP,;L<5:M
M+F\.KFSDGBG$41:X9(M@1B1L4<GG&2<^Q[T.*MH";ZFN:R6U=YQ)_9]JTX0E
M3-(PCBR.#SR3SZ CWK490RE3T(P:Y:PO/[/,-I=!6TH.8K2ZV;1E21MD[>P;
MH<>]*$;IL&[&U;G59\?:/L]NH(.Z%BY88Z#<!CZUHT#I14MW&D%%%%(84444
M %)2T4  HHHH **** "BBB@ HHHH *0Y(X.*6LK7YYX=/1;:1HYI9HXU=1DC
M+#/Z9H6H/0TUR  3DCOZU6&)KUF_AA^4>F3UI]Q/Y%NTIQD# 'J>U+;Q>3;J
MIQNZL1W/>FA;A<2&.$D?>)V@>YIR*$C5?05 !YU]U^2+G'JQ_P !_.GWTK0V
MCE/]8?E0>YXIVZ ):_O))9CW.U?H/_KYI;ELE85'+G!]AW-/AC6"%(UZ*,5'
M;YEEDG((YV 'T'>CS&6  %I))%BB:1VVJHR30\B1QL[L%51EB3TJA"'OYO.D
M4BV',2'C=_M'^E)*XB6/S+L[Y05A/W$Z%AZFFW^HPZ<B*8WD=SA8HERQ_P#K
M5->W,=I;-+(>%QP.I/8"JMA:.TGVV[7_ $DY  /"*?X1_4^M/3=B=]D:*'*@
MX(XZ&J\5ZDUU- @8F+&YL<9/;-5]7OC8VF8EWW$I$<*>KGI^'?\ "IM/LQ8V
M:0[C(_5Y#U=CR3^)I6TN/6Y;/2J5]J*VCP1!&DEF?8J+U]S]!4]Q<0V\1DFE
M2-0,Y9@!7/6]T0+GQ#?*RQA=EK%CG9G@X]6-5"-]6)LOWQ74]173PQ\J';+/
MQP?[J_U/X5J@@*">*I:1:/;6A>X(-S,QDF8?WCV_ <?A5T$2=A@=*3?1#1BZ
M_<R^3'IUL^VZOF\I6'5$_B;\!^IK4M[6.UM([6#Y%C0*,=A6-H[G4-=U/4'^
M9(I/L=N . J\N?Q8_P#CM;Z)M]R>IJI:*PEKJ.4!1@4ZD-4-9U.+2-)N;Z8C
M;%&6 S]YNP'N3Q4*[91F:Q*^J:K%HL!_= "6];T3LGU)_3-;L$*PQA1CW-87
MA'3KJVTQ[S45(U"^?[1.K=4)Z+^ P*Z+/%5-V]U$Q75@3@5C76O&&X406K7%
MN"%DF1U #$\ 9/-0WLTVL74EA9SF&WB(^TW"=<_\\Q[^I[5:MK9+B1'6,+:6
M_$$>.,C^+^@HY;+49JJ<BEI%&!2U PI*6B@ %%%% !1110 4444 %%%% !11
M10 AHI:* "BBB@ HI#6%%IT6J7MW]NF-VD,I50LI58SUV[%QR%*_,23]*:5]
MQ,WJ*R=,E>WU"ZTJ:<RF)5E@+\MY39&">^"",GGI6M0U9@G<****0PHHHR*
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MCTVXVX_"M.BDS4MM[@E86BBBD,**** "BBB@ HHHH *2EHH **** "BDI,T
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MXD2)@^*-/C).[<MFI(]N5Z4L>C_$;<'?Q/IPP,>7]C4@^Y.,_K7?8'I1@>E
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M8_&-H&( +FQC+-]25R?QKT6BBX'FK^#O'SZDNH-XPM3<K&8E8V:$!2<G"[<
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M=QNZJ7V%M@&3@UWM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*** "BBB@ HHHH 3%&*6B@!,44M(: "C%%+0 4444 %%%% !1110 F*6BB@
MHHHH **** "BBB@!,4M%% !1110 4E+24 %+FDHH 6BBB@ HHHH **** "BB
MB@ HHHH **2B@ Q2T44 %%%% !1110 4F*6B@!,4M%% !1110 F*6BB@ HHH
MH **** $Q2T44 %)2TE !2TE+0 4444 %%%% !110: #-%)2T %%%% !1110
M 4444 %%%% !24M% !1110 4444 )1110 M%%(: %S1FDHH 6BD%+0 4444
M%%%!H ,T4E** "C-%)0 M)B@4M !1110 F**6@T )2TE+0 4444 %)BEHH *
M*** "@T4&@!*6DI: "BBB@ HHHH **** "BBB@ HHHH **** $I:2B@!:***
M "BBB@ HHHH 2BBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@ I:2EH **** "BB
MB@ HHHH **** "BBB@ HHHH *0TM% "4M)BEH ***,T %%&:,T %%&:* "BB
MB@ HHS10 4444 %%%% "448HH *6DI: "BBB@ -)2TF* %HHHH 2E%)10 M)
M2YI* "BBC% "BBBC- "444M !1110 4E+24 %+24N: "BC-&: $HHHQ0 448
MHQ0 4M)BES0 4E+28H **** %HHHH *0TM% "448HH !2TE+F@!**** %HHH
MH *2EHH 2EI*6@ HHHH ***,T %!HS10 E%&*,4 %%%% "BB@44 )111B@ I
M128I: "DI<TE !2T44 %%%% "4448H *44F*6@ HHHH **** "BBB@ HHHH
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M%!I* %HI** %HI*44 %)2T4 )2T44 %%!I* %HI** %HHHH ***,T %)110
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M  M!/^A9UO\ [\5WV*,4 <#_ ,+03_H6=;_\!Z/^%H)_T+.M_P#?BN^Q28H
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MZ .!'C/Q051QX(O]NW+ N ?R-,7QQXFD@$J>!]1 4?.'RI)]@1DUZ#@&C H
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M^"BEVB@#@/\ A,/%_P#T(UQ_W\7_ !I/^$Q\7_\ 0C7/_?P5Z#BDVB@#S_\
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MHI<44 %%%% !11FC- !1110 4444 %%&:* "D-+10 E+1BC- !1110 4444
M%%%% !24M% "4M&**  TE+1B@!**7%&* "@T4&@!*6DI: "BBC- !1110 E%
M+BC% "44N*2@ I:2EH **** "BBB@!**7%% !1110 4444 %%%% !1110 44
M44 %%%% !11FC- !1110 E%+1B@ HHHH **** "BC-% !1110 4444 %%%%
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M4 +1110 4444 %%%% !1110 4444 %(:*6@!**6DH *6DI: "BDHH *!10*
M%HHHH *2EHH 04M%% !1110 44E% "T44E "T4E+0 4444 %%%% !0:*#0 E
M+24M !24M%  ***2@!:*** "@T44 )2T44 %%%% !1110 4444 %%%)0 M%)
M10 M%)2T %%)10 M%%% !2&EI#0 444M ""EHI* %HI** %HHHH *2BB@ I:
M2EH **** "BDHH 6@TE% !2TE+0 4444 %%%% !1110 4E+10 E+110 4E+1
M0 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E+110 4E+10 E%+1
M0 E%+10 E+110 4444 %%%% "44M% !1110 4444 %%%% !1110 4444 )2T
M44 %)2T4 )2T44 %)2T4 )2T44 %%%% !1110 4444 %%%% "4M%% !24M%
M"4M%% !1110 4444 %%%% "4M%% !1110 4E+10 4444 %%%% !1110 4444
M %%%% !1110 4444 )12T4 %%%% !24M% !1110 4444 )2T44 %)2T4 )12
MT4 %%%% "44M% "4M%% !1110 E%+10 E%+10 E+110 4444 %%%% !112&@
M!<T4E+0 4444 %&:0T4 +110: #-&:2B@!<T4E+0 49H-)0 N:,TE% "T44&
M@ S124M !1110 49H-)0 M%%% !FBDI10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %&:*2@!:*2EH **** "BBB@ HHI#0 N:*
M2EH *,T&DH 6BBB@ HHHH ***2@!<T4E+0 49H-)0 M%%% !1110 49HI* %
MS124M !1110 4444 %%%% !1110 4444 %%%% !1110 9HI*44 %%%% !111
M0 4444 &:,TE% "YHS244 +FBDI: "BBB@ HS244 +1110 444E "YHI*6@
MHHHH **** #-&:2B@!<T4E+0 49HI* %HH%% !2&EHH 2BBB@ HHHH ****
M%H-%% "4M)2T %%%% !1110 4444 %!HHH 2BBB@ I:2EH **** "BBB@!**
M** "EI*6@ I*6DH **** %HHHH **** "BBB@ I*6DH **** %HHHH ****
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MSNJ*\GG^(VO?VE<:M#:Q-X:MKO[*YV_,PS][.<YQSZ<@&M&_^(5[96WB+]U
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M4&DH **** %HHHH ***2@!:*2EH **** "BBB@ HHHH **** "BBB@ HHHH
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MS1Q*3@%V"@GTYIX((R",=<T6 6BHH+F"Z0O;SQRJ#@F-PP!_"I:&K %)2T4
M%%%% "4"B@4 +112&@!:2BEH 2BEHH 2BBB@ HI:* $HI:2@ HHI: $HI324
M %%+10 E%+0: $I:2B@!:*2EH **** "BBB@ I,TM)0 M%)2T (:*#10 4"B
M@4 +1110 8I,TM)0 9HS110 M%%% "9I:2@4 +1124 %+24M !1110 4E%%
M"T444 &*2EI* "EQ24M !29I324 +1110 8HHH- "9I:2EH *2EI* %%% HH
M 2BBB@ HHHH ,TN*2EH **** "DS0:* %HHHH ***0T &:6DI: "BBB@ HHH
MH 3-+24"@!:*** "BBB@ HHHH *2BB@!:*** "BBB@ HHI* !CBN"^*>KFPT
M&&S7K>2;20>BK@G^E=YG(YKR#QG)>^)O'<&F:>%,EG_JLG&& W,3GTP*[LNI
MJ5=2EM'5G-BIVIV6[T-/X3ZEE-2TJ12CPR^8 W!YX(QZY%<]X5\,Z-XIUCQ#
M/JLSHL-R71DG"\,S9)R#D=.:G\,1ZEHWQ62'5@HNKY',A4C:Q8%LC'')%4/!
M_@NS\6WVL>?<S0);S@*;?;M8$MQSSV&*]25HRJU.;E347=:[LY5=J,+7M<J6
M>HW"?#37K%KJ26VCNX([?T&2Q;'L=H./\:34O#UMX<\,Z#XEL=0=KV=XY#&6
M7"G&[C'/!&*[/QYX:LO#OPT:STV-Q$MVDLC.V68GY<G]!Q7)V7AF'0O%?A=M
M3;S].OTCE4N,+O('RD>@9E_ UI2KPG%U(NR;;MWLOZ9,Z;BU%]EKVU/=K29K
MBS@G9"C21JY0]5)&<5YWXTABUOXD^']"O6:2Q:)I9( Q7)P_)(_W /S]:]*K
MS77=D?QMT.69Q'&+,X9B "?WHQD_45XV"_B2DNB=ON.ZO\*3[HG\%(FD>._$
M/A^RD;^S8526*%G+!&(7=C.?7'X"MOXB>?\ \(#JWV<L'\M<[>NS>N[_ ,=S
M6'X0V3_$_P 5W$1#HNU-Z\@'/(_-3^5:?Q0DND\!WOV920S(LI Y";AG^@_&
MM9J^+I]_=O\ <B(Z49?,\^MO^$>7Q-X/'A5Y6N1,HO"RL&(RI.[/&<%\XXQ^
M%>Y5X>Z:(+_P0/#I@_M,O$;OR22<_)G?^.[/MFO<*>8_8>O7??=_T@POVOEM
MML>,M;Z[I'Q0TZ[UJ[%Q<2B9T"-\HB57PH] ?2L6/2B_@.Y\8R74_P#:_P!N
M!CF60@@9 /XY)_(5VWB>:-/C#X=#Y"I:L[$GC'[WM^!KB=?TRVM_"9O-%\1R
M7&BR7>$T^3*LC$9.1GDC'I[UZ-";GR7T;4>FEKO3YG+4C;FZVO\ DM3H+JT3
MQSX^LK#5[F1(5TN.94C8#=(R*QQGI]XGZ+6-_;>IP?#/4;!+B9XH-06U216Y
M2+!.W(/0D8].2*WYM$M]:U33/[%UIM-\06^EPM*"K .GEJ,AAT.#SU[>E<9%
M(T/PWU*(R?-)JL:G_:PC$_KBG249**Z+ETMMJ]?F*;:;?>^IU_AN'3M ^(NF
M67AW4FO;.]M3]JVRAQN"L03CH> >>1GWKUZO+-.T/3?#7Q8TNQTHN%>Q=IE=
MMQSM;G)Z9V@UZG7DX^2E.,EK=;O=ZL[<,FDT^X4445P'0%%%% "4"B@4 +11
M10 8HHHH *3-*:2@!:*** $S2TE H 6BBB@ HHHH #24II* "BBB@!:#10:
M$HHHH *,T44 +10** "D-+10 E+24M !1110 AHHHH 6@T4&@!**** "EI*6
M@ HHHH **** $HHHH *6DI: "BBB@ -)110 M%%% "4444 %%%% !1110 HH
MHHH **** "@T4E !1110 4444 ***2EH **** "BBB@ HHHH **** $-%%%
M"T444 %(:6DH ****  4M)2T )1110 M%%% !1110 4E+24 ***** $HHHH
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MEQ24 %%%% !2T8HH #24M&* $HI<48H 2BEQ1B@!**7%)0 4M)2T !I*6C%
M"44N*,4 )12XHQ0 E%+BC% "44N*,4  HHHH 2BEHH *#2$XIJN'+ ,"5."!
MVH =2TE% "TE%% !1110 44M% !1110 4E+1B@!!2T44 (:*#10 44N*,4 )
M2BC%% !24M&* $HI<48H 2BEQ10 E%%% !12XHQ0 E%+24 %%%% !112T )1
M110 4M&*2@!:2BEQ0 "BBB@ HHHH *2EHH 2BEI* "BE%% !1110 4AI:0T
M%%%+0 E%+10 E%+10 E I:* "BBB@ HHHH #24M% !1110 E%+10 E+124 +
M124M !10:2@!:*** "BBB@ I*6B@!**6B@ %%%% !1110 E**** "BBB@ HH
MI*  T4HHH *#110 E**** "BBB@ HH-)0 M%%% !124"@!:2EHH 2EHHH **
M** "BBB@ HI*44 %%<5X^\<7'A V*6UDD[W.\EI"0H"XX&._-8FF_%>XEL$N
M;[2 JO=QP*T3$ JP.2,]2,=,]ZZX8&O.FJD5HS&6(IQERMZGJ%%8FA>)(==?
M4UCA:(V%R]NX9@=VW^+VS@UR=C\5_P"T)HTM_#=](CR*F]&R!DX],5$<+6DV
MDMM]ANM!6N]ST>BO/[SXJ6EAK%U9W&DW8MK6Y:WDND(*@@D9QCVZ9S7>03Q7
M-O%/"X>*5 Z..C*1D&IJT*E))S5KE0J1G=19)0>E%5[VYCL[&>ZE/[N&-I&^
M@&36-KEE.[UNQM=%NM4\]9;:W1W9HR"#MZCZ]JQ=)U :/X.G\0ZJ[(9E:^G7
M'* ]$'T&!]:Y+2;N/QM_9VEV=HEM8*WV[4UB VL^X[4XX))Y/_UJWO&LT>H:
MSH7A<N@MKF7[1>*Q !BC(8+^+ "MG"WN]2%*^I8\#^,+SQ3<ZJ]S:BU@@\E[
M="?F\MU)!;Z@ _C7:5P>AZ1J5A\2M9G\EDTF>VC:)E'R-@ !1Z$8(QZ8KNU9
M3T()'7GI45$D]"H[:BT445 PHHHH 6BDHH 6BDI10 4444 %%%% "&BEHH *
M*2B@!:*2B@!:*2EH **** "BDHH *!110 M%)2T %)2T4 )12FDH 6BDHH *
M444&@ I*** "EI*6@ HHHH **** "BBB@ I*6DH *7-)10 N:,TE% "YI***
M "ES244 +FC-)10 N:,TE% "T44&@ S1FDHH 6BDI: "C-!I* %HHHH ,T9I
M** %S2444 %+24M  :2E-)0 M%)10 M%%!H ,T4E+0 49HI* %S1FDHH 6BB
MB@ S1FDHH 7-%)2T %)BEHH *,TAHH 6BB@T &:,TE% "YHI*6@ I,4M% !1
M110 F*6BB@ HHI* %S1FDHH 7-&:2B@!:*** $Q2T44 >8?%Z::WG\.7$$/F
M2Q7#NG&<L"A"\<\D?I6;XHU/4/$]KX>74=.FTF9]4\D0RJV7!"?.,@' W$5L
M_$VRU*ZUOPR]E:RW"QSL<1H3AMR'DCH,#]#5WQ]8WMYK_A1K:SFFCAOP\LD:
M95!N0\^G /Y5[-"<8PHK2_O:]MSAJ1;E/Y$/P_5EN/%[KEF.I2@*>!D%N_XU
MS_PVUWQ#;V=CI]OH1N-*>X*M=@,-FYOF;/0@<\5+8+XXT'Q!J<6G:-OLKO4)
M)2\B9!#-@$$'@8P:/"]UX[\.64>EIX<$T G+&23J-QYY#8]>:TG!-3=XOFM;
M7LF2I-..ZM?IYFI865M+X3\>+*@(.H7F68Y)V*&7D^AYKH_A\[R> ](+YR(2
M.3G@,0/T KB[W3O&T5SKFBV&F1K8:M?S2_:V8':CG!.<\ J!VSZ5V\DO_"'^
M%+2"&SFOC;1I#L@7ECCEL<XYR:Y<3K#E33<FFM?*QK2=G=JUE^IT6:X?XG:N
M;+PU_9T&3>:E(MO$HZX)Y./T_&AOB!< ';X8U0^GR'G]*Y/Q9XZB:^T>[O\
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M4\(3(W8O=#'_ *#2^K5/+[U_F'MH_P!)G9;A1N%<7'XD\5M(8V\)MD'.[[0
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M@ I:2EH *,444 &**** $S1110 4444 %%%% !1110 4444 %%%% !2TE+0
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MM !24M)0 HHH%% !1110 449HS0 4E&:* "BBB@!:*,T9H *0TN:2@ HHHH
M!2TE+F@ HHS1F@!*!10* %HHHH ****  TE*:2@!:*2EH 2E%)10 M)2YI*
M"EI*7-  :2BB@!:**2@ HHHH **** "BBB@ HHHQ0 M%%)0 4HI** %HHS1F
M@ HHS1F@!#1110 4444 %**2B@!:*,T9H **,T9H **,T9H **,T9H **,T9
MH *2EI* "BBB@ HHHH 6BC-&: "BC-&: "BC-&: "BC-&: "BBB@ HHS1F@
MI*7-)VH ,BBHXO,*YD"AN?NG(J2DAL444E+FF(2BBB@!:*,T9H **,T9H **
M,T9H 0T444 +11FC- !11FB@ HHHH ***,T )1110 M!HS24 %%%% !1110
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M44M "4N:#24 %%%% "YI*** "BBB@ I<TE% "T4"B@ HI** "BBB@!<TE%%
M!1110 4444 +2444 %%%% !2TE+0 4E+24 %%%% "T9I** %S2444 %%%% !
M2YI** "BBB@ H%% H 6D-+2&@ I<TE% "YHS244 +FC-)10 N:,TE% "YI**
M* "ES244 %%%% !1110 4444 %%%% !1110 4444 %%%% "YHS244 +FC-)1
M0 4444 %+FDHH 7-)110 4444 +FDHHH *7-)10 4444 %%%% !1110 4444
M %%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %%% H
MH *0TM)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "TE+0: $H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** %I*6D- !1110 4444 %%%% !1110 4444 %%%%
M"  $D#K2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M***!10 4444 %%&:,T %%&:,T %%&:,T )0*** %I#2YI* "EI*7- !11FC-
M "4444 +0:,TE !1110 4444 ***2ES0 E%%% "T&C-)0 4444 %%%% !111
M0 M%)FES0 449HS0 449HS0 449HS0 AHHHH 6BDS2YH *0TN:2@ HHHH **
M** "BBB@ H%%% "T49HS0 449HS0 449HS0 449HS0 4&C-)0 4M)10 M)1F
MB@ HHHH **** "BBB@ I:2C- "TE&:* "BBB@!:*3-% !2BDHH 6BC-&: "B
MC-&: $-%%% "T4F:7- !2&ES24 %%%% !1110 4444 %%%% !1110 4444
MI:2ES0 449I,T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 HHH
MHH *0TM% "44M% "44M)0 4444 %%%% !1110 444M "4444 %%+10 E%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !112T )1110 4444 %%%% !1110 4444 %%%% !12TE !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 +1110
M 444AH 6BDI: "DI:2@ HHHH **** "BBB@ I:2B@!:2@4M !1244 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% "T4E% !1110 4444 %%%% !1110 4444 %%%% "TE%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%(84444Q!1110 M%%%
M!1110 8HS124 %%%% !1110 4444 %%%% !1110 4N:2B@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****0PHHHIB%HHHH ***
M0T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M2&%%%%,04444 %%%% !1112 ****8!1112&%%%% !1113$+1110 4AI:* $H
MI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $%+110 E%+1B@!**
M7%&* $I:,44 %)2T8H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI
M<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!*
M*7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H
M2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&*
M $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1
MB@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<
M48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**
M7%&*  4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>articles010.jpg
<TEXT>
begin 644 articles010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **I:O:37VE7%M
M;SM!,Z_)(IP5/:K48(4 ]AU- #Z*** "BBB@ HHHH P-1UBZ_MVVTK36MVE;
M+SESGRU&.,#H2#GFM^J%MIL5K>W=RJJ7N)-^=O*_* 1G\,U?H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ****  TR-/+0+DG'<T^B@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,X
MHIK(&96(Y7I0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7QOXM\'>*X[;3M:'V2Y@$Z1-:Q'R_F*[<E23]W.?>@#V^BF1,7A1CU*@FGT
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M+37I(EW264UBL!< <[&0]>^#Z4 =[17.> M8O-?\$Z;JFH$&ZN%<R;5VCAV
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M%-QRK*,GCG8P]N] ',KKQN_!U]XBN_%U^/%:W2_9[=;EE CRH("CC&"Q_P"
M]*]Z^'WB27Q7X+L=4N !<L#'/@8!=3@G\>#^->,?#3QU;^#H+W0-;T:\GF,Y
M>&.* /*'P 4*D@]A^M>]^'Y=0GT6"?4[.&RN9<O]FBS^Z4G*J?\ : QGMG-
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M]H@@C+3VLCPN5 P2Z<#CIN [DFL'X1R_9_BE)<W,4\,=TDRPEXF&69@0#Z<
MT 4=-TVXU?X[ZA8VNHSZ=++J5\/M,'WT \PMM]"0",]LUT=IK>L^ ?C#'X??
M5[W4],N)H82EW,9&Q*%P>3PP)]LCZUCZ-<KH?QOO]>U".>+2H=5O8Y;OR6:-
M&;S%&2!ZD5MP63?$3XWC6=/\R31+"2*3[44*JWE@8"DCG+@_ADT .\5>-?[=
M^*'_  C^H:O+I/ARRD>*=X)6C,K*O.YAZL-H]OK5OX9>++K4/%6L^$9]6N;_
M $UQ-]AO&F;S0JM@%7Z\J<^V*YKQ%:WGPW^+K:]<6#7&F3W,DZ-C*R))G>H)
MZ,-QX/H.QKUCP[XUB\07$FHZ?I+67A^VMV>YO;N+8[/U"QA2<@ $D\]A]0#Q
M[P/K?C3Q'XIFT>T\37:-<021M<74C2>4@(.Y5SP_&,]MQ^M;WBKPQXGT+X27
M?_"0:]/<3)>HZ0I.TBE&PN'9ADCN!T'X\9'P7G72_B%))?1RPI<VSP0L\38+
MLZ$#IQG!KUSXN:9=ZI\.-1ALXFEEC*3%%!)*JP)P!UXYH Y#X*Z7=6_@^ZUR
MUOKV:0&=(]-,H$#N "#C'#$@#-<[>76M3^#]<U_Q/K.KZ5K)N-FGVOVAH%<
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M<QF)KF!"RLH.5<'ID8Y4X(!/M7J#_%KP_>0F+P^MYK&HN,16L%K(I+'IN9E
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ML7V9+>" O(\H<?*!Z]>O'TH [W6]1\0:Y\3;C0KRYU#1O#=K"[O=6LGD[EV
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MM% !2!0#D  ^N*6B@ HHHH \!\2^&?$]]\7_ /A);?PY?/8P7UO(,&/<ZQ;
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M1KE7+A> #N4X&/EPN!CM5BY^%7AVXU^XU96OK<W6?M5M;W!CAN,G+!P.<'N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***:[I'&TDC!44$LS'  '<T .HKD&^(VD"T>_BL]5GTN,D/J,-FS0
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M(3B18U\KR\@%]V[H"<=,YJK<^.M/75I]+TZSU#5KJV8+="P@WK ?1F) SP>
M>Q'6@#J**PO#WB[2_$T]_!I_V@2V#*EPD\)C*,<_+@\Y&T@UNT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY#\#?$YL]P#:W(DQ7J(SY>?Z ^Q->Z:#!:6_A[3H;!4%FMM&(0O3;M&#7/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\P  APK<@'/Y@UT= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<\<].:K> -6L;OX=Z)/%<Q^7;V,4,S,P&QHT"L#Z<J?PYKA?B+J-OKOBSP/
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M06C6Y5)]IR;H#>R9Z8"$?C]15GQ[K6KZ#8Z;=Z9);+&]_#!<B6,LQ5V ^7G
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MJ >*;_;ND!=W]JV./,,.?M"??'5>O7D<>]>=>(5T^X\1?#Z]\.+!]HDGX-N
M-UKM7?N([ <?B:Y$Z'H"_#[X@:@UA:M<V^KS0VSJJ@PH'38$_NC+'IU QVH
M^@Z*R_#4AF\+:1(SEV>RA8L3G)V#G-:E !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 8^K^%](UV^L[S4()9+BS.Z!TN)(]A]<(P&:BU_P;H/BB6&36;)KH
MPC$:F>157G/W58#/OC/:MMI$1@K.JEN@)QFAY$C7=(ZJOJQP* .6?X;^%)+J
MQN7TV1I;$(ML3=S8B"G*@#?C@TZ?X<^%+B>XG?2MLMR[O.\=Q*AEWG+!MK#<
MI/\ ">/:NH5E=0RL&4]"#D&EH R+SPMH>H:''HMSIEN^FQX\NW"[53'0KC!!
MY/(]35*'P!X6M]%?1XM'A6PDD$LD6]OG8="QSEL>YKI** ,[3]"TS2]'_LBT
MM%33]K+Y!8LNUL[AR3P<GCWK%A^&G@Z#3KJPCT. 6]TP:4%W+$C.,,3E<9/0
MCK75T4 <S8_#WPGIFHVU_9Z);Q75L (I 6.W'0X)P6]SS[UTDD:31/%*BO&Z
ME61AD,#U!'<4QKJW1BK3Q*PZ@N 13TD21=T;JZ^JG(H Y,_"_P %FZ^T?V#
M&W;B@=Q&3SU3=M/4]N];.K>&]&US38]/U'3XIK6(@Q(,IY>!@;2N"O''&*U:
M* ,&'P9X=M]&N-)BTR);*Y8/.FYB96'=FSN;IW-,ET&UT+PEJ.G^'].*>9#(
M8[>%^KLN."YP.W>NAHH \>^&OPMMH-(F7Q=X<C-]'=>;!))(&#(47Y2%;!P0
M>#ZUZ;J_AO1]=6W&IV$5Q]G.86.5:,^Q!!'_ -:M2B@##E\&^'IM#CT5]*@_
MLV-]ZVZY5=WJ<'D\]ZL#P[I(T#^POL49TO9L^S$DKMSG'7/6M&26.( R2(@/
M3<P&:#+&(_,,BB/^]GC\Z .=MOA]X2LY[6>WT"R26U.8GV9(/J<_>/N<U._@
MOPY)K$^K-I%N;^=6628 @G(P3UP"03R.?>MQ'210R,K*>A4Y%.H Y^R\$>&M
M.L;NQM=(@2TO !<0G+))CID$GD>M2:?X-\/:4MTMCID4)NHO)F<,Q=DQC;N)
MR!@#@'M6Y10!RZ_#KPBEA+8KHD M99%E>/<V"R@@'KV#'\ZWM-TVTTC3XK"P
MA$-K",1Q@DA1G..:GCECE!,<B.!UVL#3Z ,/6O!WA_Q'<I<ZOID5W+&FQ6=F
MX&<XX-1>(K36;/PC+:^$%BBOXE1;=92" H89 +9&<9ZUT-% ',>"]"O-,M[_
M %'58H(]5U6X^TW,<'W8_E "9[XP3GU8]>M<%X0^&]Q+XGUZ?Q9X9@DLK^8W
M%O)).CM$=[';A&SR'Y[?+7LE% &5>>&M$U#28]*NM*M)+"+_ %<!B 6/ME<=
M#R>1ZU&GA/0$T%M#72;8:8QRUOL^4GU]<].>M;-% $-K:P6-I#:VL2Q6\*!(
MXT& J@8 %3444 %%%% !1110 4444 %%%% !1110 55U#3K/5;-K2_MH[FW?
M[T4BY4_45:HH @MK*UL[)+*W@CCMHUV+$J_*%],>E9]YX7T+4-+ATRZTJUEL
M8"#% 8P%C/\ LXZ?A5\WUHMZMD;J$73+N6 R#>1Z[>N*4WUH+L6ANH!<D9$/
MF#>1Z[>M &+)X$\*3/(\GAW36:0AF)MUZ@8';CBK@\-:(-0CU :7:B\B01I/
MY8WJH7:!GTQQ6G))'#&TDKJD:C+,QP /<U&MW;/:?:DN(FMMI;S@X*8'4YZ8
MH SK7PMH%E9W5I;:/91V]UC[1$L*[9<=-P[T[3O#6B:38SV5AI5I!;3Y\Z)8
MAB3/9L]1R>#5RTU"RO\ ?]CO+>XV8W>3*K[<],X/'0U*D\4DDD<<J.\9PZJP
M)4^X[4 8MKX)\+V4\<UMX?TZ.6-BR.+=<J?4'%:.J:/INMVRVVJ64%W K[Q'
M,@90V",X/U-$VKZ;;ZA%I\U_;1WDHS' \JAV'LN<FK%S=6]G#YMU/%!$#C?*
MX49^IH KW&D:==Z5_9=Q9PRV&U4^SN@*;5P5&/; _*J#^#?#4EA%8OH=@UI$
MYD2$P+M5CU('J<"M2._LYK5KJ*[@DMUSNE60%!CKD]*CT[5M.UBW^T:;?6]W
M#G!>"0. ?PH J7WA7P_J<D,E]HUC</"H2-I8%8JHZ#IT]JMW^DZ=JEC]BO[&
MWN;7C$,L891CI@'IBKE% &--X3\/7&G0:=+HMBUE Q:* PKL1CU('K4]WX?T
M>_LK:RN],M)[6VQY,,L098\# P#TXXK2HH QI_"7AVYN9[F?1-/DGG7;+(UN
MI9AC')QZ5J6UM!96T=M:PQPP1KM2.-0JJ/0 =*EHH Q]2\*>']9NOM6I:-8W
M5QC!EEA5F(]S5[^S;'^SCIWV*W^PE/+^S>6/+V^FWIBK5% &58^&M#TRTN;2
MRTFSM[>Z4K/''"H$H(QAO48)X]S6)XD\*)'X'U/1?#&D64,E\NQD7;$HSP7/
M') '%=A10!RG@CPI::#HMDTNB65EJR6ZPW$L.UFD*C!;> /O8SCW[UJW'AC0
M;O5%U.XT>QEOE(87#P*7R.ASCJ/6M:B@#-D\/:/-JZZM)IEH^HJ05N3$#("!
M@?-UZ5#<^$_#UY>RWESHFGS7,RE9)7MU+,",')QZ=ZV** ,QO#NBM+92'2K/
M?8C%J?)7]R/]GCBDL/#>B:7+<2V&DV=N]R"LS1PJ#(#U!]1[5J44 96F^&="
MT>6673=(LK225=LC0PJI9?3@=/:H4\'>&H[*>S30M/6VG97EB$"A78="1CMD
M_G6W10!!9V=MI]I%:6<$<%O$NV.*-0JJ/8"IZ** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1=9L_$&D0:I8,S6L^XQLR[20&*YQ]15^@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M);-(_*6 *-@3&-N/3'%9ND^$=!T.Z:YT[3HX9B"H<LSF-2<E4W$[%YZ+@>U
M'C>EZ23\+/$.OC4]0L]=M[V:69H;R1%616&5* X.1W(SR.:]NT*YN;SP]IMU
M>)LNIK6*29<8PY0%ACZDU2N?!GAZ\U1]2N-,B>YD(:3+-LD8="\>=C$>I!-;
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVTKC'D94G:RXZC;@\\$B@#KZ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M8'&WYF8*%[]"5_*L9_ GBFY^%-IHD>B7 U"+5GG:)V1?W9B(W9)QUXKZ(HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFGM;0SV]_;Y\ZRNX_+FCP<'(]B<>U>>-_P G0K_UP_\ ;:LN83_\--2'2V
ME4S%<E0OD+YF['OG\: /?*J3ZG96NH6EA-<HEW=[O(B)^9]HW-CZ"OGGQ)XQ
MU[3D2]M_$=Y>7\.HNMS/:3.+'&,I$JG )PI)P",'J:Z'6M..I_M!Z7 ]_?0B
M:S$N^&<JT>(W.U#_  J<<CW/K0![A17@)\0>,_%>NZ^^B/J3WVFWBK:Q0W$<
M,$,0=P1(CL-Y./0].?2O1WTG4+OQUHFKS>)A:%;,&71XY 1*VUMQ4;L%<GK@
M_=Z^@!V]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5+*#UQD$<C(]>>*OT4 <%X>^%FGZ%H^HZ/+J%Q?:9?J?,MIHT 5R -X(&0P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\,ZSK6N^"M<U_4/&6I6M]I88VRK<*L<AV9"LF/F)/ ]^E>YZ]=P6?AZ_NIY
ML*6[DL 3U''3KUKYK\-^ SXA\&ZN$M9XM?M9!/;1R(R^=$!\RC/!/IWSCUH
M]D^'OCB?4?AU)KWB>XCA%M,\3W3+M$BC;AL 8SEMO'<5T&A^-]#U\W*VUR\,
MMM&)98KJ,PLL9 (?#?PX(Y_QKR#4]1U3Q?\ !I=,73[B#4M(FB::VC@*^? H
M*AU7'8D$@="N:LPZ?9>*_#NJ7OAZWUN76WTGRKFXNRS*"&3,"Y^^S*IQCH".
M_  /0)/BUX3AA6>2YNUMY&98)S9R>7.RG!"-C!Q6E/X\T2V\4OX;D:Y_M-5+
M",0,0^$W_*>_ XQWKP3Q#KUE=?#'POHD4-Q'>V%RXN4>%E6-LMP6/!)SG Z<
M]*[/Q8LNA_'[2]:N[>X:RDB!C>&%I"[>6R;0%!RV[''N* .JUGXA:3K/@'6K
M_2-2N[(P%;=KD6S;H78C!QU /3/;/KBF:/\ $/2?#W@SP^^N:M=7KWD)VWWV
M=\2%6*D$GG(Z9/)QGO7EFBR&7X7>-[#RI!?3WD#I;;"9"/-!/ ],'/TJ37+=
M[GX;^!]/:UNFD@FG-S&L#EHT,G?CCB@#V6#XH>%+G2KW4HKYS;6DRP%C"P,C
MM]T(,98G!X]O2K5CX^T"]TO4;]IY;1=-XO8;J(QRP$] R^_;&?2N+^,^DW=W
MH^BZMI%O++!:W/G3+:H0Q#!=KX [;<9QQFN>U;0H/$O@S7-2\+Z;KGFW!@N+
MB;43E[L*6+(@SSMX8D>@ H G\0^/5UKQ_P"$IM O]9M;>XNHH[B"1I(HID\U
M0&"9VL"-P)^F:]53QEI+^-9/":F;^THXO-;Y/W?W0V,YZX(/3'O7BFH:L=7O
M/ATUEI>IR#1EACNV6S<X:-H]RKQ\Q&PGCUKUJ/6PWQ3FTD^&-KK:9&L[!EEP
M&V[MOW<G'WCR.E '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )M&X-@
M;@, ]_\ /%+6)K?B[0/#D\4.KZE%:22KO19 WS#.,\"FZ-XS\.>(+IK72M7M
MKFX"[O+4D,1Z@'&?PH V&MH',A>&-C(NUR5!W#T/J*:+.U6W-NMM"(#UC"#:
M?PZ5/10 C*K8W*#@Y&1T-1QVMO%,\T<$22O]YU0!F^I[U4UG6]-\/:<^H:K=
MI;6JD*78$Y)Z   DGV J+0?$FD>)[)[O1[P7,,<AB<[&0JP ."& /<=J -6B
MBB@ HK*UGQ)H_AYK1=5ODM3=R>5!N!.]OP!P.1R>.:U: "BBB@ HHK#M?&&@
MWGB2?P]#?YU6#.^W:%U(QR<$J >#G@]* +NMZ6NM:'>Z8\\L"W4+1&6(X901
MCBO._P#A34$^FP:;=76EBWC*[KBVTH174BCL9/,(R>YVUW/B'Q7HWA6&*;6;
MI[:*4E4D%O)(N?0E%(!^M8J_%GP2RHW]LL$<@*[6<X4D^Y3% '7VUO%:6L-M
M @2&%!&BCLH& /RJ6@$$ @Y!HH **P]9\8:%X?U&TL-5O6M[F[P(%,$C*^3C
M[P4KUQU/&16Y0!Q7Q#\"7'CJ"PMTU9+&&UD:4@VWFEV(P#G<,8&?SKL;=9DM
MHDN)%EF5 ))%7:&;') R<9/;-244 %%%% !1110 4444 %%1SSQ6T$D\\J10
MQJ6=W;"J!U)-/9@B%SD@#/R@D_@!UH 6BN+;XK^#8YYH)-2G2:#=YZ&QGS%@
MX.[Y.,&NFTC6=.U[3TO]+NX[JU<X$B>OH0>0?8T 7J*** "BBL2X\6:/;>*K
M?PU+<L-4N(_,CCV'&,$\MT!PIH VZ*R/$?B33_"NF?VCJ9F6VWA"\41?:3TS
MCH.WXU;TG5+36]*MM2L9#):W*;XV*E21]#0!<HHKGD\::._BX^%]\ZZI@ML:
M$A2 N[(;IC% '0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 >/?M"?\BUI'_7X?\ T U2LO"NM^)_&_A;78])?3-,
MT^TM2]Q.R!I]GS?=5B><XY[=?2NN^)G@C6/'*6-G:75C;65NQE9Y=YD+X(P
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M\<"NLH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH V**S=$U_2_$=BU[I%XEU;K(8RZ C#  D<@=B/SK2H **** "BBB@ HHHH
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M6N=HW  XY H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNTM[C3&NV^UP_$M=2+!0'#,YD "K_#Y0C P>@P><&O?DW>6N_&_ W8Z9IU%
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MVW;.-+U@X[_8'H Z"BN=7Q? Q _LK6 ?0V#TO_"7V^/^05K.<9Q]@?\ SVH
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M?HK#_P"$EX'_ !)]5YZX@''_ (]3!XH!EV'2-2'J3$O\MU &_17/CQ2"S?\
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M_L_3LCEO]+;]/DH [6BN''B_7&E"+INF\C.3=MZ_[E'_  EVO;G4Z;I@9?\
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MT'3%QBT3CW-+_8>G?\^X_,UHT4 4#HNGE2/LRC/7!(IIT+36!!ME_,\5HT4
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ME% %,:5IXSBS@YX/R"E73+%#E;2$'.>$%6Z* *G]EV'_ #YP?]^Q2_V98_\
M/I#_ -\"K5% %7^S;+.?LD/_ 'P*3^R[$Y_T2'D8^X*MT4 5?[-LL8^R0_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY?@X&\DL>3C'OBNH\(^!=7T#QUK'B"\N["6+4MY:.)7W(6?=QGM0!S_[0O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVLK(/FP!@GG&>2>*T-*ROCO1P4(SH#\^G[U* .\HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N;\4V/]IV.H:>+B*W>[LF@CDD8 ;B?KDUTE9NI
MZ!I>L.CZA917#(,*7'04 5K>^>RM;>U#V+^3$L;,UV%)(&#QBK#:M@_*]B1M
M!YNP.>XZ55/@SPXPPVCVI'^Y2CP=X=!S_8]I_P!^Z )QJSY3<VGJ#G=_I@X_
M\=IIU=QN^;3N,8_TWKQ_NU&?"'AX_P#,(M/^^*0^#_#S#!TBT/\ VS% $_\
M:SY'SZ?C)R?MG;U^[3CJA&,2Z?G'_/W_ /8U /"7A\  :1:8 Q_JA2'PAX?)
MS_9%I_W[% $W]JO_ ,]-._\  O\ ^QH.K' _>Z=UY_TOM_WS48\)Z $*#2+/
M:3G'E"D_X1'P]_T![/\ []"@"8ZKAP//T[;C)/VKOZ8Q35U;<>+G3"",C_2>
MWKTIG_")Z &)&D68)&/]4*#X5T,E?^)39<?],%]<T 1RW"37-M<37VGQQ02-
M(2LN2?EP.OU.:S/#S6WA[3!IZ:MILS>;)(6>Y )W.2. /0XK;'AG0@,#2+'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !12$X&:,T +129HW4 +1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >2_&/Q?XB\&W&E3
M:-J7E17HE#PO!&X4ILY!*YYW?I5+7?''BOP/XLT:UU#4X-8T_4$1VC^RK%(@
M+8.-O?T]?2L_]HR6-F\.Q+(AD3[0S(&&5!\O!(]\'\JQ)8H_ ?Q.TS6->+ZS
MH]U&)+6\F8S&->Q!)(+1G'X8( )& #WK6?%>@^'I8HM6U6VM)91E$D;YB/7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %9^H32,T=G#Q),#EL_=7N:T*R0[?VU/O*%DC79QC@T 7+:WCM
MD"(H ]NOXFIBW/TJ(/CN,_7K2%QN&3UH ?)#%."LB*0>M9D6ZQU!K7>3%*/E
M_P!FM-7'K6=J*YO[5AU)'\Z -*WD,D*D]>A^M356M/\ 5L>Q=B/IDU9H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45#/-Y.SY)
M'W,%^1<XSW/M4HZ4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%)GYL4M !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:,E<$'&<"O0** /*[3X?ZA>:WXE\2WEA;6%W?6<UO9V$,@8!GCVEW88&X_\
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MEX>T2VT^*62QC,MQ</=(-TK\LN/8YY[U<UWX<:IXG^'NF6]SI\%GXATB%+:
MB<,MQ$J@8+#@9Y(ST(/K7K]% 'FD=M\1U^&LNFB.*'7;8I'#<+<(S3Q \\GA
M6 P,D\_6NR\*1:S!X7L(_$$JRZJJ'[0ZXY.XXZ<$@8!/K6S10!Y/\2] \>^)
M=:@BTFWMUTFS=98=TR?O9 ,[F5NN#D $8_.K'AOPAXKU>SUR'QW>&47EJMK
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MN&F5&FDW$E<$_=R<X[Y [5<\"Z!X^A\0VTWBJZ0:;90.+:"%XU7>0% VQ@#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !67<6-R]X;R
M.14=8@JIC.2"3UK4HQ0!G0W_ )\6\*HP<,I/(-/,[Y!VX..1VI;C3U>3S8F\
MN0]?0_6JQBO%R@A!_P!H/P: )_M!"#*C/?FA+O'50,<DU7%E>2\NRQ_CFI$T
MO^_.QSV48H HSR?;=2C0C:"=N*W8XRC,<_*>@]*H:=I?V.>6:23S9&8[6(Z"
MM.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HP*** "C%%% "8I:** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XWX
MIZE>:3\/[^ZL;F6VN T:K+$Q5AEP#@CIQF@#LJ*^3]*\<>*DU2U_XJ'4G#2J
MI62Y9P06'9B17UA0 44@(.<$''%+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7W_(0N?^NK?S-;^N:E+_ ,(9X:T=HD$<<4UV) >3OF=<8]MGZU@7W_(0N?\
MKJW\S6IKP_XEOAUAR#II&??[1-Q0!UWP8\+VVN^)IK^\"20Z:JR"%USO=L[3
M^&TG\J^CZ\&^ 5];0ZOJ]E)*%N+B*-XDP?F"%MW/3C<*]YH *QO%'AK3_%6B
M2Z=J$1=3\\;*<,C@<$&MFB@#XKNK6>RNYK6YB:*>%S')&PY5@<$&OJ_X>_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **BN9_LUI-/Y4LWE(S^7$NYWP,X4=R>U.AD,L,<AC>,NH;8XPRY'0
M^] #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0D
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M?^.UK:-XHT/Q#N&DZG;W3(,LB-A@.F2IYQ^%>(VFL6&@_'G4]0U*?R+6.XN
M\FQFQE2!PH)ZU>\+1S>*OC5=>(M!C:'289=\TNW:"#'M(QQRY!/XYH ]W) &
M2< 57L;ZUU.RBO+*99K:4;DD7HPKGO'=W=_V,NC:7(B:KJ[&VMRQ(VKC,CY
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M'F!0P*YSCJ!Z&D@\5Z+<ZY)HL-X7U&-BKP"&3*XZY.W 'OG%?/O]FZQ\//[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ I&8*I8YP!G@9I:* /GM)[B'XT-XE_L
MG5GTS[0SB1;&7<5,97.T@'J:TK'0]7\7?&#_ (2.WTR[TW3(+B.4S7,)B+A
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M4[!; 229M[<G,BQX&#)VW$YX'08KQ_7;?5+OXQ6_B*+PYK,VFP30DM]A<$A
M 6 (['D?2O=J* &QN)8DD 8!E# ,I!&?4'H:=110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !116/XH\0VOA;P]=:O=@ND*_+&#@R.>%4'W/?MUH O7^I6.EVYN-0O+>U
MA'\<\@0?F:Q4\?\ A%Y B^(M.W' &9P!^9XKPG0;35/BYX[W:O=R?9XD,DI0
M<11 \(@Z#)./S/->^6_@GPO;6?V6/0-.\K;M.ZW5B>,<L1DGWS0!I'5M.VVS
M"^MRMU)Y<!60$2M@G"D=3@&J4WB[PY;W<EK/KNFPSQL4>.2Y12K#J#D\'FO-
MKOP!;^%/BEX<U'2]R:9=7+)Y!)(AD\MC@$GD$ G\#4GQ\L[8>&]-NQ @N!>;
M/, PVTHQ(_-1^5 'H8\9>%RI(\1Z3@9_Y?8^WXTB>,_"\B!U\1Z3@C(S>1@_
MD37DGP(TK3M2CUUKZPM;HQF (9X5?;GS,XR..@_*M;QMX,T#Q+X7U'5/#6E^
M1J&FW,D+);0A?/*-AQM7KW(.,\4 >J7VLZ7ID<3W^I6=HDO^K:>=8P_TR>>H
M_.J1\8^& ,_\)'I'_@;'_P#%5-/:0W7ALV]W DB&UVLDBY_@]#7RIX+@BN?&
M^AP3Q)+%)?1*Z.H*L"PX(/44 ?4R^+O#3N$3Q#I+,QP +V,DG_OJM=)$EC62
M-U=&&593D$>QKS/XI^"=!/@J_P!3M=,MK6]M%61)+>,1Y&X @@8!&":X[X&>
M)KV+7I/#TLC264\32Q(3GRW7DX] 1G/T'X@'M&H^*M TBY:VU#6;*VG0!FBE
MF4, >G'6JG_">>$]N[_A(M-Q_P!?"^WO[C_(KGI/ =OK?Q/U76M9L5GL(X84
MMDE&4D?:-QQW QCGC)]J\U^.&GV&G>*=/CL+2WM@UD&=((P@)WM@D"@#VN3Q
M[X2BD*-XBTW<.NVX5A^8XJPWB_PXFG+J!UNP^R-)Y8F$ZE=^,[?KCG%<'\*_
M#.AZS\-(?[1TJSN&FDE5Y'B4OC<0/FZC';GBMWX=^%I/#5KKNDW%JWV3^TGD
MM7EPPDB**%_$ 8- &K_PL'PA_P!#%I__ '^%6?\ A,?#G]F_VC_;5E]C\WR?
M.\T;=^,[<^N.:^3M2BAC\0WD,?$"W3JN%QA=Y X^G:OL46-H+06@MHOLX7;Y
M6P;<8QC'TH PO^%@^$/^ABT__O\ "C_A8/A#_H8M/_[_  KY<,$4?BTVZH/)
M6^V!#R-HDQC\J^HM8T'P?;6T(U'1=-6.>=+>/%HN3(YVJ,J,CD]>U %J'QCX
M<N+&YO8=:LGMK8J)I5E&(]QPN?3.#^55O^%@^$/^ABT__O\ "LGP3X,C\)^)
M?$L-O XTNZ%M);;^1_RTW)D]<$CKS@BOG_QY%'!X]UR.*-8XUO),*HP!SZ4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=\!2 ?KZUW= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '%^)OA=X9\47+7=Q;R6MV_+SVC!"Y]6!
M!!/OC-9%M\'XH4\A_%>O-9C@0)/L&/3N.G'2O2Z* ,7P[X4T7PK:&WTBR2'?
M_K)#\TDG^\QY/TZ"L/7OAAI'B6]:ZU34=8G)=F2-KK,<6>H12N%'3IZ5VU%
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M%% !1110 4444 %%%% !1110 4444 %%%% !15+4M7T[1[?S]2OK>TBZ!II
MH)]!GK7.CXH^"BX7^W[?.<?<?'Y[: .OHJGINJZ?K%J+G3;V"[ASC?#(& /H
M<=#3=4UG3M%@2;4KN.UB=MJO(<#.,]?H* +U%<U_PL+PA_T,6G_]_11_PL+P
MA_T,6G_]_10!TM%9ND^(-(UY96TK4+>\$) D,+[MN<XS^1K2H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "LW7]:M_#N@WFK78)AM8]Y5>K'H%'N20/QK2KSKXVO,OP
MZF$8!1KF(2\]%R3_ #"T >0Z1]O^*7Q'MTU6XD:*5VD=03B*%<ML7T'09]3G
MK7T:/"^@C2O[+&D67V'_ )X^2NW.,9^OOUKP?X$Q))X]N&89,>GR,O/0[T'\
MB:^CJ /ES59K_P"&'Q(O8]'G>.*&12L9;(EA;#!&]>#C/7C-?2&B:K:^)/#U
MIJ42 V]Y"&,;?,!GAE/K@Y'X5\^_&_\ Y*&W_7I%_6O5/@OYG_"MK3?NV^=-
MLSTQO/3VSG\<T ?/5K#$WB^& QJ8C?JA0CC;YF,8],5]0ZSI?A.QAM8]0T73
MREW<1VD2BS0Y=S\HX' X)S7RZOGCQ6/LP4W'V[]T'Z;M_&?;->L>(IO&S?$#
MPG'XE2TCLO[1A, L<^27WC).[YMV#W_#O0!VW@GPA_PB?BGQ(EM:>7IESY$E
MI)NSQAMR>O!/\J[FBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#^%>F6,/PZTR2.TA5[F)FG;8,R'<P^8]Z\:^)_AE++QIJIT>P$=E;0Q3SK$
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M1X[A6OX(5FDB'\*L<#_]7N/6K]?+&B>/;JU^)H\47;,4N)RMPO\ TQ;Y<?\
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M_DFVB?\ 7 _^AM6=8P177Q=\2V\\:R0RZ7 CHPR&4\$&M'X8?\DVT3_K@?\
MT-JH:3(A^-'B% ZEAIUOD \CI_B/S% 'BWQ'\#3^"]=\RW5CI=PY:UESRIZE
M#WR/7N/QK9D\?'Q/X6\/:9?L6U6QUBV+.QSY\8#@.?<9 /KG/?CWG7]"LO$F
MBW&EW\>Z"9>HZHW9AZ$&OF,>&;_PU\2].T>YR)DU" 13;>)%,@VN/\.QR.U
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M">F>(=0L]$.HVRK ;AQ,$\CEPI(P20<MTZ8KT/X^?\B58?\ 813_ -%R5A?
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MU:7<Q=8?M9,<9/\ <4@A?PJGI_P@\/:5<BXL+W6+67&"\%X8R1Z$J <5W]%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%&<44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 A /6EHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF]>GTY/K5WP?/J6@?$OQ5X/TZ3%J\,\EE SG9#(0&CQZ##8./Z4 >V?:8/\
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M3C'(('/O^0![917,_#_Q#/XH\$:;JMTH%Q(K)*1T9D8J6_'&?QKIJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *@NKE+:UEE)SL!X]3Z5/61JQ4RV<9P"TV<>N.>: $MK=KG;
M+>$R.P'!X5?PJR;6,!5"*JCC%(D@VX<D'MQ2ER1UP.3QVH 8VG0R.>67CL*;
M!,]M?&UFD+I@&-CUSZ5,DJ]23R/3-4M7 $D,@X;;Q^% &L[[.<].QJ05EPW,
M]Y:CS+<[6^4,ASSZX[5IJ> ,'IWH =10** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD5U
M;.U@<=<&EH **:KJ^=K!L>AS3J "BBB@ K*\3:S'X>\,ZCJTA %M SJ#_$V,
M*/Q.!^-:M0W4%M<V[PW<44L#8W)*H93SW!XZT <G\+-(?2? &GM-DW-\#?3L
M3DLTG()]]NW\JRM?(\1_&#0='4>9;:+"VH7(SP)#@1@^X(4_\"KT6-D9!Y94
MJ.!MZ#':HTM;:.ZEND@B6XE 6254 =P.@)ZG% '%?$O0_!]_IL>H>)[EK-[7
MF*X@<+,1UV*,'=SVQQ[<US/P@\(:@NK7WC#5Q<J]TK):)=N7E9&(.]F/)X
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M)J&:ZEN276WF9MN!B,C^= &_9H(K:.,=0H)%3*",Y/>J&ESW4D %U ZR=V(
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M 8I  *6B@!,4N*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?V=]AMOL.-OV;R5\O&<XVXQUYJW10!1L-&TO2F=M.TVSLVD #FW@6,L!TSM
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M+I7_ $#++_OPO^%22:;82QQQR65L\<8(16B4A,^@QQ5JB@"%+2VCMC;);Q+
M008E0!2#UXZ406EM;1&.WMXHHR<E8T"@_@*FHH K6^G6-K)YEO96\+XQNCB5
M3CZ@4XV=JUS]I-M"9Q_RU*#=^?6IZ* (Y8(IPHFB20*0P#J#@COSWH@MX+6/
MR[>&.*/.=L:A1^0J2B@!KQI+&T<B*Z,,,K#((]Q4%KI]E9%S:6=O;E^6,42I
MN^N!S5FB@!CPQ2_ZR-'Y!^90>G(I]%% #418T"(H55& JC  I656&&4$>XI:
M* &-%&T;1M&IC8$,I'!!Z@BECC2) D:*B#@*HP!3J* (S!$9_/,2><%V^9M&
M['7&?2I*** (A:VZW!N%@B$[#!D"#<1]>M2!54D@ %CDX'6EHH CFMX;E D\
M,<J@Y =0P!]>:DHHH ,#.<<BFJB("$4*"22 ,<GDFG44 -9$<@LJL5.1D9Q3
MB >HHHH *3 !)P,GJ:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0'-+110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 45'-/#;IOGECB3(&YV"C)Z#FI* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHK*U#Q-H6E7/V;4-8L;6? ;RYKA4;!Z'!- &K7,^/]";Q%X+U"QB@::X
M">9;HK;29%Y%6&\;>%D<JWB+2PP."/M:?XTG_"<>%/\ H8]*_P# M/\ &@#Y
M'=&C=D<%64X(/8TVND\=:?ING^++L:1?VUY8SGSHFMY?,";B?D)]1_(BN;H
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M$4$:A%X[9!/OUKFKW7M6U"\EN[K4;F2>4Y=O,(R?H.*SJ* +7]I7W_/[<_\
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M>%"\DC=%4=37R[XN\2ZA\0?%T<<+,\+3?9]/@(V;59L#//WCQDY_05]#>/\
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M^8C:I XXH ^D+>%;>VB@3[D:!%X X QVJ2N,_P"%L>!_^@ZO_@/+_P#$4?\
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MJZ;;J<?:+C+9^=@./P  _"NLHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)/\ A?NB_P#0'U#_ +Z3_&C_ (7[HO\ T!]0_P"^D_QH ];HKR3_ (7[HO\
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M##P*_BS6OM%[#,-'MSF5U.T2.,$1Y]^^.@],B@#Z<HH P,"B@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P# N/\ QH_X2?P__P!!W3/_  +C_P :^.Z* /L3_A)_#_\ T'=,_P# N/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 %=M\/_B)>>"KMHG1KG2YFS+;AL%3_?3WQV[^W6N)IR(TCJB*6=B
MJJ,DGT% 'U_X:\3:;XKTE-1TR4M&3M>-\!XV]& )P:V*^>/AQX3\=:7K]MJ5
MK83V5IYRQ7:W6(]\61N^1L$\'@@=:^AZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "FO&DJ[9$5U]&&13J* .)U[X5>%
MM<@8)8K8W!+,)K4;3N([CH1GG''X5XYXX^%EWX.L_P"T/[3@N;'*H&9&20N<
M_*%&1T'7-?1>L:Q8Z#IDVHZC.L-M$,LQ[GL!ZD^E?+WCCQUJ'C34_,FW06,1
M_P!'M0V0O^T?5O>@#E:*** "BI+>WFN[B.WMXGEFD8*D:#+,3V KZ#\(_!O1
MM.TVWN/$,*W>H[A*R^81''Z)@'#>^>#]* /GBBOI?4?#WPW\2:I_9.S3DU&'
M>GE6;"%P1UR%P&(QWSWKR/XC?#F3P3+;W%O<-<Z=<'8LD@ ='QDJ<=>!D'_#
MD X2BBB@#O?#/W? O_8??_T*WKW_ ,2^+]'\*VK2ZE=HDIC+Q0 _/+CLH^M?
M-$UQ-9^#- NK>1HIHM0NGCD4X*L!"01[@U[]XSUW2["YT>VNM"BUNYN),&$0
M":6.(#YG52#T...* .+T_P"/T9,@U'1&'SN4:WEZ+CY00>I[$Y'KCM6EI/B_
MX7ZW<VL4NAV%O>W; ,L^G(0)#V+A<')[^_:NL2'P'(+[99:&WV!-]UMM8SY0
MVELG ] 3QZ&LOPOJWA+4K6]O9-%TC3[C3F:1BD"']T%WK*AV@D%.>F10!TG_
M  AGA;_H6](_\ 8__B:YW6[CX:^'-0BLM1TS1HKMV0>6+!"4#=&8[< >]6;S
MXD:5;^+M+T2%DF@O$#27BMF-"X/E*,9R6(QSC&1[XL>(M;\(V(OKV_BT^ZO;
M*W61D,2/*RMPH4D<Y/H>.] &'XL^,.DZ#-/9:; VI7L)*N5;;%&>G+<YP<#
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M)W^L6D\;QL)+:6-SN/.6"G(P2,8';FO7;GQEH-O9ZE<IJ$,XTY-\ZQ,">5+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9V(86EI!;A_O"*,)GZXJQ0 4444 %%%% !1110 4444 %%%% !1110 4444
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M[(XD%W+)=A5&-H "X^OR9_&@"[I_POT/2?%DWB:2YN)9O-DN%25@$C9B26X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD) H 6BFM(B
M+N9@H]2:A-]:AMOG+F@"Q13%EC?[KJ?H:=D4 +1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,4M%  **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHI#T.*!0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>articles011.jpg
<TEXT>
begin 644 articles011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3/.*6
MC%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4455>\":A%:E#^\0MN[#':@"R3BH;2[AO$D:&3>(Y&B8XQAE."*GI%14SM
M4+DY.!C)]: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *<^FPSWL
M=V6D65$*?(<!@2#@_E5RBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1E.0: '44V21(D+R.J(.K,< 4H(90RD$$9!'>@!:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 444UW6-2S$!0,DF@!<T9XSVK!AO+VXN'O$8"W.5CC;ICU-/DN-292OFH
MN1G*H>* -L,#T-&<5SA@O&/[V\N,8Z XI[07)A*&XN-A'=N?SH Z#(I:Y])K
MZRMT ?S%4=&7)(^M:MC>+>0[U0KC@@]C0!;HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNI5A@,]O,@=ST RW6N@\4_$/Q99>)KO2O#?AM=4BLEC6XF2&20"5E#$94@#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K*U#2GGN5NK=PDH&&!'#?6M6B@#"*W-O_ *V%@,<E?F%/6YCV
MJQ8?GR*V:B-M"3DQ(3U^[0!FB[DD.VWC+-V.>*M:?8FWWR2$&63D^WM5Q45!
MA5 ^@IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %->-)
M !(BN 0P##."#D'Z@TZB@#SC61_PDOQFTG2B0UGH5J=0E _Y[,0$!^GRL/J:
M['Q!JEOX=\.ZGJ[JBB"%I3P!O<#"@^I)VC\JKZ)X7@T?6]:U<W$EQ=ZK*KNS
MC 1%&%0>P]:3QAX73Q?HJZ5->26UNTZ23>6N3*JG.SVR<'/M0!P6D^ [C7/@
MI)9>8J:KJ[_VDTDG0R,P90>^"H ]B:\X\76WB.#0?#'@S5M$BAOH)'^R21SK
M(TJNV N%)QSZGG ]*^F+BVN$TPVVF30VDJHJ0O)"940#'\(9<\<=1_2N=T'P
M);:7KDVOZE?3ZOK4@*BZN  (E_NQH.%')'_ZSD U=1O(/"_A:[U"4)BSM3(Y
MZ>8R)@#/<G  _"L'X4Z3)IW@>WN[H$WVJ.U]<.>K%SD9_P" [?S-:_C'PPOB
M_0&TB2\DM89)HWE*+N+JISMZ\9P.?:F^+/"Y\2^&SI%OJ,^F%61HYK?^';T!
M (R/;(Z"@#QWXC#Q%X.^(NE^*=1N(=6M1(?LJM%M2-1UCV\@'!R&ZYY[5)\1
M]-'BWXIK8>%D*:Y96YDNI_.\M69 "H4_WQD#.?0<8)KT:T^']W<3:2WB3Q#)
MK,>DN)+:,VPBW. ,-(=S%R,>H]\T_4O #MXV'BS1-5&G:@\?ESI);>?'*,8Y
M&Y2#PO?M0!Q_P'U2/;K6C7-EY6JQ3>=<3MDO-R00^>ZG^?KG/J'B;6XO#OAR
M^U60!C!$3&A/^LD/"J/JQ K,\(>";7PI)J%W]I>]U+49C-=73H%W$DG"J.@R
M2>IJ3Q5X7NO$D^G-'K#V4-E<)="%80XDD1LJ6.1D#T_^M@ ^>_$T1\-ZIH'B
M*R741J0VRZ@UW:S0@W>=[#+@9R&Q@$\#WKW?Q1JD&M_"+4]4MB##=:4\J\],
MIT^HZ?A5SQIX1_X3/P^FDW%Z+=/,61Y%@#$L/[N3\O?UX.*Q[/X<WECX)N/"
ML?B25K&8D;GM071&SN13NZ$G/Y^O !C_ +/W_(@WG_83D_\ 1<5=)\0=0M;G
MP+XJLX9@]Q:6F)T /R%EW*#]1S^-4?"_P[U/PA83V.D^*G2VED\W;)8HY5R,
M$@D^@7\J>GPYN5\,ZKH[>([B5]5N&FO+N6W5I'!51M&3P/E_PQ0!Y!X7T37]
M2^#>NSZ=K7D6$-U(]QI_D+^^"QQLQ\S[PXQQT^7WK>TG5],U#]GS7[.PL%LY
MK/RQ<A6W>:[,G[S)YYQC';&*Z^S^$=Q8>&+OP[:^*[J+3KN4RS(MJ@9B0 1N
MSG!"C(]OK6FWPPL;?P3+X6TN^>TM;EM]W.\0DEF.01SD ?= Z=/U /+?A]::
M[+X7T2:WND.C+XDA%S;+'A]V8\.6SRN<<<<\\]O5?B?=VLWPY\2VT$B--;QQ
MB9%_@+,K#/N0<U7\,_#S6O">D3Z;I7BWRX))FE4MIR,4) '=CGH/\*8?AG>_
M\(=JFA?\)(TD^J79N;N^FM-[N/E^4#>,?='.>YZ4 >,V^J^)-$^$'E6@MAHN
MJWDL4THC)E1MJ@H23@!@I[9X/->Z_"O2='TOP+9R:-.]Q#=YGDFD4*S/T(('
M3&,8YZ=34&@_#2/2O"E_X8O=2&H:5= E4:VV21.<98-N(X(! QP>YIW@7X>W
M/@6XG2WU^2ZTZ?#-:26X&'_O!MW';MSB@#S/XY_\E)T3_KTB_P#1SU]#$X&3
MTKSCQ9\*3XN\1+K%YKTL;Q )!'';+MC0,6 Z\\D\UV&LZ3>ZOX<ETM=4:UGG
MC\N6ZBA&2#PV%)XS]>* / _B'<67BG3-1\1LMX;QKWR]//V67RC9Q@J<28V<
MMN<\G'2O6_A-XE_X23P):-++OO+/_1I\G+97[I/U7'/J#6]9:%+:^$5T%[N.
M;9;?95F:W &S;M&4S@\5RW@/X8S>!-6N;FVU][FTN5"R6SVP7=C.#NW'D$GM
MT)% &W\1_P#DG.O_ /7F_P#*N*_9[_Y$_4_^O\_^BTKT/Q3H<WB/0KC28[[[
M'%<J4F<0B1BI[#) 'UYKE?"GPXU?P?93V6E^*PMO-*TK!M.5F#8 !!+GL/Q]
MNX!W<%_;7-W=6L,H::U95F7!^0LNX#\B#7@?B/\ Y.8M?^ONT_\ 1:5['X1\
M*_\ "+6M\DFH3:A<WMTUS-<S*%9F( QQV&/UKD[OX3WM[XUA\53>)@=025)6
M L $)4 * -_ P!US0!T?Q,_Y)MKW_7J?YBN.^ #(O@34VD("#4'+9Z8\J/-=
MYXN\/WWB;PY+I$&IQ60N%V7$IM?-W+W"C>-O3W_K7&Z/\)=3TCP]=Z!'XO==
M,O)"]PD%@$D?( (#EVP"%QT_PH X;]GZ.X;QGJDJ*YM5L2LC#[H<R)M!]\!\
M?0U]%UQD?PWTFQ\#W_AG2I);-;U,2W?WY&;CENF1QC P,$],UH>!_"K>#?#4
M>CMJ,E_LD9Q(Z; H/\*KDX'X]2: .CHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /!_A\X\=?%W6=9UF/SC9HQMK>9<B(;]JC'0
M$#/XDGK7K&I^%M/N->M/$"HL5[9Q2H611^]1T*X;Z=1^-<?<_#W6_#_CBX\3
M^#KFRVW88W-C>LRHQ8Y;:5'3/(]#ZCBNILHO&%S/<W6IOIUO"+=T@TZV8N'D
M(X:25ER!QT4=^<XH \A^%GB&Y\,?#GQ!J=GI\E_<+>1(D* GEEQDXYP*[+0_
MB5K'_"4ZMH6LV^G74EG8O=K)I9;!*H&,?S,<GG'L16%I/PP\::9X$U?0K>ZL
MK>XO+B.3S([AOWD8!#(?EX['/?&*M>&/ACXKT3Q1'JANM)@7^S3;$VX;*-Y8
M1< C[V0I+'.>>.: +/A'XJZUKTKW,]E8SV:0W$LUO9))]HM]BEDW;CA@V, @
M=3CCI5CP/\2M8\37:3W2Z5_9RI,]VMNKB:TVC*[MS8*D?Q 8SQP>M+P_\,=?
MLO$XUV7^S]/NDLY49K69F$]PZ,OF%2H"#)!('&1P*?X?^%>I1>+X]7U*.QLH
M?L4D-REA,Q%S(Z,C-M*@("&S@<9'% $.F_&:\N=0L;RYATQ-(O;XVBVT;EKR
M)<#$C<XVY/I5SP_\3];\0>+VT^WM=/6V2],$EHR2"ZCA!P9<YVG!Z@#(STQS
M2^#O ?C'PM+_ &4E[HYT@7(G^U^27N N1E5!&!G&.<XR2*CB^&NO7?CG3=;O
MSI\+V=VT\]];R,);Q ^4#1A0JG'RDCJ#SF@#N?''BN+P;X6N=6>,2R@B."(G
M >1N@^G!)]@:Y/2/B%KT'BG2M"\1V^F)+J]BEU:R6F]1$SAMJ.&)R<J1Q[5U
M'C[PBOC3PI-I0E6&X#K-;R-G:LBYQG'8@D?CGM7+:=X!UR_\9Z)KVO?884T>
MQCMHXK>5G,[H&PY)4!1N8G'/0#WH Y/X4:7=ZQXU\2G5;/3+F*"]6:[$B,S)
M<!I=ABSQC)?.>V*Z7XPV7B"&]T/Q%I, O+?2G:22V,>\*V1\Y7J1@8S_  XS
MQUK1^&_A#7O#.N^(;W5X[(1ZK(LX-O.6*,&<[<%1Q^\/.>W3GC5\0:1XE/C*
MQUW06L&C@LWMYX+N1E$P+AMH*@X/ (/J* .0\)>)]!\7RZ[JUO;-8:XVD/%=
MVH \N11D^8IZD\@'//2N&\%>+?$/@CP&VJV.FV$NER:F(II)G8R2,4!PH! 4
M +UYY(X->GV/@/4SXAU_Q-=6VG6U_>V3VUK96TK%%9EP6=]HY.!T7O7(_P#"
MIO%O_"O3X=!TX2G4A=EOM+D,OEE<8VX'/I0!V7BSQ_JVGM:KH]C;1Q2Z8=2>
M[U -Y0&"1&-I'SG&.O4BLJ7XK:LWPM@\66]E8BY6]^S7$+[BA'JN#D'IUS3?
M$/P]\7:Y>:'MNM.6SM-,%I+!-([QQRF-D9U4*-QP00>Q ]*HCX7^*T^%\OA<
MRZ;)*VH"X0B5@%0#GG;R2<<8X]3V -B/XC^)K'1KOQ%KGA^&UT4V4<MEY<FZ
M269RH4$[N%.2>@(&.IJMI'Q:U RW]MJ<.F7,R:4VI6[:<Y*@A-QB?)/S#OCT
MKI]<\%W'B7X96_AV[>&VOXH(@KJ2Z+)& !S@'! (Z<9[]\W0O#GCBV\-W%C>
MW.CPSPV+VUJ]O'N>9RN%:5F7&!CL.>_N +X \<ZYXM2:66/2YXOLC2K]E+(T
M,P8 12!B2,\D,." ?2MWP)JOB36-&GN/$^F)I]VMPR1QJC)F, 8)!)[Y&>^*
MY?P7\-]2T#Q3J.M,;/3?-M3!%;64C21>8<9?# 87(R$[9Z\5UG@BP\3Z?HTL
M?BK4H;Z]:=F1XAPJ8&!G SSD].] '2T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6-XLTB?7O"FIZ5;3"&>ZMVC1V) !/KCL>A^M;-9'BC3+O6?
M#-_I]C<+;W4\>V*5B0$;((/'/:@#R_1M>TZ6ZT3POXQTDZ'K.FW,,EG<)&JQ
M2F,\#=V#<CC@D]<\5KZ+&OB?XS^(;C4XA+%HD4=O9P3("J%N2X![\$@^C"K>
MN^%?$WC&SL=*UV+288+>9)9K^WD=I9-O4(I4;">_)Q5O5?".L:?XSE\5^%KB
MU^T74:Q7UC=[A'.!CY@PSM; ';^9! -V[\*6%SXIT[Q BK!>68D5FC0?OU9-
MN&/MU%>9_#CQ(-"B\16Z>'M:U#?K,[>;I]HLB*/E&TDL.1C./<5Z-;1>*+F[
M-[?BSMHX$<P:?;7#,)I""!YLI0<#L O4Y.< 5C> /#WB#PM8:Y%?V]C++=7D
ME[!Y-RV'9@!L.4^4?*.>>O2@#G?AHZS^&_'<HMWMP]_<MY,B[6CRA.TCL1TQ
M6;X/U4VGP@T^W_X1.:]2=VMGNI5C\AEDN"I)(8R<9Q]WJ!]:Z;PMX8\4Z+I7
MBB&YM--DGU6:6YBVW; !Y."I^3H <Y_#W">%]+\>^%O"%OH5KIFBRO;K(([A
M[U^K.S E?+[%NF><4 5_&6FVMMX_^'-@L0D@B,\($OSEE5$ W$]?QJI\6K.V
M\)S:'XOT>&.TU""\6"00@1B>,J3M;'7[N/H3Z"M+6_#/C2X\0>&-1@_LZ\?1
M8B9)KB<HUS(Z@2<!,*..,9J[+X.USQ3K]AJ/BVXL4L;"3SK?3+(LZL_8R.P&
M<>PP?;G(!4TR-!^T)K)"*#_8R-G'?='S6OK*J?BOX7)4$BRO",CI_JZ9K/AG
M6+;QS'XL\/FSFF>T^R75I=.T8D7.0RN <$87C':K.F:-K=[XH3Q#KPLH)+:U
M>VM+.UD:0+N(+.SD#DX P!TH PO!*JOQ:\>[5 ^:VZ#_ &36E\7U#?"W6B0#
MA8B,CI^]2LS2='\;:1XIU[6H])T:7^UGC;RVOG!B" @#=Y?/7T%.\0>'?&FO
M^$-7L+LV$EYJDR8B6Y80V<2%2H7Y,LQ*G/3K^% $-C/:7X\*:-/X3N;2.Z".
M;Z2.-,-#'YJE'C8D$L@ZXXS7H.M6)U30M0T]6"M=6TD 8]MRE<_K7(+:^/I-
M&M=(BM=(T_RTCA-^ETTLD:@ %E0H!NQG'/>N]'2@#AO"7@1_#?B"+4-UOL71
MH+!A&3EI5/SMC&,' Y^O%<3\3-::\\0W-]:ZI:P/X5D@>WMFF"O<S,P,F!G)
M"J%''^T*]EU-KY-,N#IL<,E[L/DK,Y5-W;) /%<EX;\$06G@\VFMZ1IUUJT@
ME:XE;$AF=R3N,A7(SG\* +OB"T7Q[\.9X=,FC4:G;)) \APH.0P#8!],'BF>
M$O!O_",ZYKM\&B,=^8!$J9RBQQX.<CC+$G )XQ5/X8:#XD\+Z VC:Y]C>WA8
MM:R02EF 8Y*D%1QG)SGO7<T %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/#/JNE6MY+#Q&\J9(&<X]Q[&I-5\.Z-KEG%::GIMM<P1',:.@PG;Y?3\* /
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M#RC%B".W!^G6^%=<TSQ)XVU3Q/IMC;R3KHL<HC?:K),&<,I;!*D@ ;L=,=J
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M/"7B6?XIZ]K-QI4MOIVIV<MJDSW$3%-R*H+*')Q\O;/:O7J* /G*Y\">/?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1'D],#DGU!^FAXLT74]"^%>L:;JM_:RBTU**2QAANVE:W1ND9) . I.!CU-
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M2^Y48COQO;<15+Q]H\_A[7V_M 3:KH45G#81W,;DR6!"J1D9P'_BP>&#'IV
M/HPLH8*6&X\@9Y-+7GM[I>A:E\2O#NM/XE*:BMF#;V.X!KA2&(;K\H(8Y&.<
M'WKT*@ I"< D#)]*6B@#G/"'BB3Q1!JDDEB;)K'4)+$QM(';*!<DD<9RQZ9Z
M=:Z.N"^%_3Q?_P!C+>?^R5WM !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !2$9!'KZ4M% '.Z;X)TG3;?5K8&[NH-59FN
MH[JX:0,6!#$>A([]>!SQ5;7_ (>Z'XBTRPTV[^UQ6-BH6"W@G*H,# )!SD@<
M9Z\FNKHH X>_^%/A_4K'3;.ZN-4>+3D*6V;QCL!.>,],8 &,< >E3?\ "L=
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M#L1N]^M;=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHK@6^*,)\5W/AJ#P]JEQJ=N6W1QF'!"C.02^,8P?QQUH [ZBN?\
M#OBD:]?:A92:5?:;=6(C,D5VJ@D2;MI&TG(^0UT% !1110 4444 %%%% !11
M6/XEUYO#>CRZFVG7-[! I>;[.4W1J.K88C(^E &Q16-I7B2TU_PXFLZ,CWL;
MKE85*J^[NAW$ ,/<X]ZS;/Q]I<W@X>*+V*;3]/<D1><59Y>2!M52>201CKQZ
M4 =717'3>.Y=.07FM>'-2TW26*!;V5HWV;CC,B*Q9!DCUZ\XJ37/B!IWAW5M
M.M=1MYX[+4"!;ZBK(8#P#D_-D#D<X[YH ZVBL3Q'XB_X1ZSMKH:=<WT<\R0#
M[,R?*SD*F=S#@D@9K+U#QR]CXI@\.CP_J$]_/!Y\2QR0A63G)RSC&"".?2@#
MKZ*PM'\1OJ>K7>F7.D7NG75M$DQ6X,;!T8D JR,P/*FMV@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHIKJ61E5BA((##&1[\T ?-XU?6-!
M^+_B_4M$L8KVX@6X:2*3<<1[TRP Y)!P<>F:WOAM?1:-X \5>-8[E+S5YBSS
MP,NT1."Q7/J&+[N/3'8UWFB_#*RT3Q5+XCBUG5)KZ<O]H\XQ%9@QRP("# R!
MTQTIFF?"C0-(U6_N[.:]2UOXWBN-/+J8'1OX<;=P /(P<CUH XWP7JGCC4WT
M'7+5]1O(+N65-3:\GB^RA?,VJ8D#;E*@'/R@Y'&0:H^#/$NM7/CN#3-<U?4;
M35);B42I)+NMKB-D;:(U'RJ0<%2,J?Y^@Z#\*M$T&XC:.\U*ZM89OM$-E<SA
MH(Y>SA0!DCMG-.TCX7:3I6I:9>/J&HWO]EA_L45RZ%8=QSQM4$X[ G H \Q^
M&MG<2?\ ">70UC4HY;2)\>7<%3(Q$N'?CE@5!!]<UM_"VW\6^+-,MM7N_%M\
MMK:7S(ULWS&= H+!FSGO@9SCG%=A:_"G1K&_U6ZL[_5+?^TE<211S@(A<,"0
M-O. [8W9QFM;PCX,M/!NC7&EZ=?7DD,LAD#3%"T;$ 97"@=@>0: /&/#?C[Q
M!IWP\\4W[:C/<WB74$-O+<-YAB+[@6&>^%_/%=;+H?BBQ\.>(;P>)+NZT&YT
M,W,,DUP7G$PB#'&1\JG#9QV8=QFM[2_@_H&FZ;J6FM=ZA=66H!?-BF=.'4Y5
MU*J"&'/MSR#5W1/AII.CV$UB]_JE_;R6TEJD=U<Y6&.08<(J@ 9SUZT >3V$
M5WI7[/TFK6>K:C%-+=C$:3E8T'F%" !V8')!SR!6_=>)]5USQ%X*\*G4;JWM
M+W3+>>]FMI-DL[M&6/SCD#Y>WJ:ZA?@]I"^&Y="_MG6C922+)M,Z$* 2=H&S
M !8Y/&<@<UHR_#73)(]%D34-0BU#1XA!:WZ,GF^6,X5LJ5( ) XH \OG\8:^
MW@'Q39OJ]Z;S0=2BC@ODF*22(TCIM8C[WW2>?4>E6M)U[7M%^('@T7_B*]O8
M=:TZ"6>.8Y0&7<%4*..#M^;KG)[UWS?"?0O^$3F\/Q7-_%#<W"W%S<"13+.P
MZ;B5(QGG@#I]<QI\)-)74]%OVU759)M'2-+;>\9&V-RZ@_)TR<?2@#@]+\2:
MU%\4!INOZGJ-C>2:HIC'FM]FFAR0(MG0 \;6'KSZUZ5\4/$UYX4\#W-_IX(N
MW=8(I-H81ENK'/L#CW(J&U^%^DV^I6%U-?ZC=Q6%P]S:VT\B&..1FW9&%#8!
MP0,X_,UU.M:-8^(-(N-+U&+S;6X7#J#@\'(((Z$$ T >/Z1K&J^'_$W@R$:O
M?W\'B.RCEOH;J8R;9)!]Y.Z $]NRURO]K>)9_"_BC4CXJU=1I%]$D$8N#\VZ
M0K\S=< =LXS7L^C?#?2M(U:TU)[R_OKFQMQ;61NI%(MHP" %"J,X#'[V:S(O
M@YH\6EZEIW]KZNT&HRQRW(,D?S,C%A_!QR: .M\)WUSJ?A#1[^\=7N;FSBED
M91@%F4$G'XUXY+%J\W[1&M1Z)<VUM>F [9;F,NJCR$[ ]>G^!KVCP]HD'AS0
M[;2;::::"V!6-IB"P4DD#( Z9Q7))\)[&/Q+-X@3Q!K::C,S-)*DL2E@W!'$
M? Q0!Y?X1O3I.B^/]/:2ZM_$5O$\\MY;SD F*0@[< 8^9OQ!/2GZYXJ\1VW@
M?P)J<.N7R7%T;E;AA<'][LF 7<,_-P2,_2O7]'^&WAO1=,U*QAMYIEU)#'=R
MSS%I)%.>,\8ZGIBL"3X(Z%);V4/]KZU_H3,;<F=#Y8+;L %, 9R>!U/- ')>
M,_$&N:3\1KV/4]4OK"TD9%TZZM96^SQ $'$B#AL_Q#J.O(P#T$.I:DWQRUO1
M#JE\=.;3V=8//;$;-&C93GY2"3@CI72:A\,-(U2YF>[OM2>UN+D7=Q9^:HAE
ME  +$;<J3CG:1U],5--\.].E\47OB)=2U.+4+M#&[1R)A4*A=H!0\8 ]_>@#
MPR'Q%XGE^'K^(7\3ZJ;FTU5((HS/\N#&6);NW0<$X'/'-=KXA\4ZQXB\;:-X
M;A?4(HGTY;B2.PF6W>>=X2X(<L/E7CCV;@UU*?!CP\FC2Z0+[5?L,EP+DP^<
MF/,"[0<[,]":OZO\+]'U@:5+)>:C;WVF0I#!>V\JI*53[N3MQD>H ZT >;^*
MM8\<Z9H6@/X@-TMO;22I?_8+L)-)AL*SLA...G8GKU%1:_XDUM/"WA34H]4U
M#4-$59&O)[:9X;AF\QE'F')((& "?E+ ]B*]/NOAEHTT4(M;K4+*6.*2%YH)
M07F60Y?S"ZMNR?6F3?"[1?L-I:65WJ%@EM:R6F;>5<R1.VYP^Y3NR2?SH T_
M %Z=1\#Z7='4)-0+QMFYE!#MAB,-G^(=#[BO'I%UE_V@M9309[>"_9) CW$9
M=/\ 4CTZ'I@GCZ]#[KHFBV/A[1[;2M.B,=K;KA%)R3DY))[DDDUST'PWTFW\
M7GQ0EYJ/]J&0R,YD3:V1@J5V],<?_7YH Y/Q+<ZCI'P+LM0AFOK'5TBMDFF+
M%)R0V"K'J1EFP#ZUGQ3^)M ^'[^/;CQ)<7T\VEQQ1VLO,<3/(BJ_7!8+R<C)
M).2:]4\4>&;+Q;HYTO4)+A+9I%=A P4MCH"2#QGG\*;;^%=-A\*+X;F62[TT
M1>3LG()V=AE0.G8]>* /)=(UO5/#&J^!IUU2_OAXBB5;ZVNYVEPS.H#J"?E^
M]^AK$&I:_J+^.T;Q-K$<&CEY+>-+ENJRE5!8Y. .P(SQGI7K>B_#'1M'U2TU
M!KJ_OIK&+RK(7<BLMLN3C: HZ9.,YJ&#X4:';C5PE[J9_M9-MV3,F7R^\G[G
M!)_F: /,%UWQ/#-X U@^(+VYNM6F:*2"63;!M658PI51SD$Y8Y/>O6X]&O?^
M%H3:K_PDF;3[(%_L@2<@X W%,XQD9SC.>*HS_"70;BRTNT>\U3RM+W&TVSJ#
M'N8,>0OJ!6S%X)TR+QJWBOS+E]1: 0D,XV'Y0N[ '7 QZ>U '24444 %<[X]
M_P"2?>(?^P?/_P"@&NBK-U[18?$&CSZ9<W%Q#;SC;*;=PK,O=<D'@]Z /*XD
MF^%]]I_B"V1V\+:M%%_:%O&"1:S,H_>*!P 3_4?W:PYBZ>!OA9++QIZ:F#<,
MV-@/F\;OP#_K7N,6B6JZ -%N#)>6?DF!A<$%G3&,$@#MQ^%4%\%Z'_PB4?AB
M:U,^F1KA4E8EAR3G<,$')ZB@"/X@F%?AYX@,Y0)]@E W=-VT[?QSC'O7FUGH
MD>NZ'\,])UF-GBN;>]5@3@A/))C(^@VD?05WR_#VQE6*#4=6U?4[&%E:*SN[
MD-$"O3.%!<>S$UI:GX6M]3UG3]4:^O;>;3]WV9(&0(FX8;@J<Y''/:@#RHZM
MJGAM[3P#X@9YI$U*R?2[S'$T N$^4^F #U]"/3.WXL@U.X^.&BQZ3>PV=V=)
M?;--#YJ@;I,C;D5Z!K?AO3?$#6#W\):6QN4NK>1#AD=3G&?0XY'^ K-U'P+9
MZEXF7Q ^IZI#J$<?E1-!,JB-.?E V].3USUH L>%[77++^T$\0ZC%>74MR7M
MVC&Q?)$:#Y4ZK\V[(]>>]=#6#I7A.UTO69=6:^U"^O7A\@27L_F>6F=Q"@
M9('Y5O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"[%5# ')**02._IFNS_X3/2=!T/0H;Z_GU"^O;2)H%MX'DFN_D&7" 9&>O-
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M?,C@9C'(!G8XZJ?8_P N:K)\6_!\L-_-'J$C1V2HSL(&^?<< )QDG/\ G'-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *9+(D,+RR$A$4LQ )X'L*?10!\NZ
M=X=M?&'Q(\1V<YD@74&NI=.N'B<#S#+O0].A7=U[$]\5T?A>YU>7P/XA^'<E
M@UGK<4<GV=DA"B< @NC,!@L0" Q/(;KQS[_10!\]> =+TW4ET>"\L?$5QKFE
MR,&MR1%!#'N+9R0" <XVYR23VIGPUBO+'Q_IT&D1SSZ;,C3W%M=P-NT\E""=
MS #=SM#+]Y6Y'.*^B** /G_P;>/HUE\0-*O-/U#[3.LS*(X&P,+( "PZ$D@#
MUS72?!&RL;;P9>37MBJ7MI>R/(\MN?,C&Q>A(ST!Z5ZY10!\J:+H^IZG\/?$
M=I96UTTXN[>\,0B;,L*^8K8]<%@<#GCI7H]O=Z9XQ\+:U<:5X=OH]>N-%,-W
M=-"RH611B($GYF;:,8&< 9/%>R44 ?-R:@)?@$VB"TO1>)>*HS;/M=FE9]JG
M')"C)^H]:UK9)-%\9^"/%&HI.=&72(K9IO)9A;R+"R%64#(^8YSCN<=*][HH
M ^8_[.O['X6^)+J[M[J*/6-1A-E \+!F"LSL^,< @CGOMK;LIA+X_P#AY=16
M]U]GL](M8)Y!;2820B1<'C^\>O3O7T#10!\Z>%K&]L?B1IZ:';3?9I[LRW>E
MW4#$685B#)N9 IP"2K+SSCOSZ?\ %_1=1USX?7,&F*\DL,J3O"F=TJ+G( '7
MJ&Q_L^N*[RB@#PC2R_B#Q[X3U/2X;F&RT+28TU"0P,@@**^Z/!7YB<XPH/7B
MN8M;>Z/@/QE;'2[]+F^O;>2VB:T?<RB1F/;L*^GJ* .>\"-N\!:"I21&CL8H
MG61"C*RJ%8$$ \$&O'];;P]XI\./=>)=,U'3O%_EN(GAL)4^V,"=AP%*L#\H
M).#^&*^@:* /G/Q?I&KQ>"_ EAJUA?7=S:^:]U#'$[LD)==J$CH=@QC.1BMO
M3C,?CEXAU(Z5<O:36LT40:W?9.RQJ,9VX^;8WY]Z]QHH ^3S_:EZ- O#H^HQ
M6=E?F-;:TM&6.(%U8+&?O-(2&R2<\**],MK477[1-Y>7-A<&T>W\I))+=O+\
MSR54J3C:?XAZ5[)10!X3XQTN71/BR^HW]MJO]@7UH+96TM2"J[%0Q87MN'3C
M[PQTKU;P5IMOI/A2SM+6RN;*W&]XX+I]TJJS%AN]"0<X[9QVKH** /'/CWYU
M_I^E:996MW<W"2FX=8;=W54P5!+ 8SG/'_UJ[3Q%>Q3?"G4)8DN)!<:6\,:+
M Y<NZ% -F-P^8CJ.*Z^B@#RKX<6B67P@EDFT/[1?VRW6ZUF@*22$@G;R,G<I
M4<=1QVQ7EEF=4?5?"%\VCZHMO::@/+M(;5A#&JRJVV+<<LQPQ8L>3WX-?5%%
M 'S_  I/!\6?%VHO97OV26SNXXY!:R$.VT# XYR0<>M9^F:-#>?">VT[5;/4
M;2>/59&6Y6TD8V^8LJS*%)9"1@XY'![8/TA10!\YZD-=N_@I':W]E<W%Y<ZJ
M7@>.W<R3Q*O,LG&>O +<D8K0\6V-[!)X#\1&SU!],L[""&Y:T#)-"RCYN."I
MQGGIQC->^44 ?/GBS1;:W^%_V;0]&UJ-+W55N(DNE:2655CP9"H'R D]^3UZ
M8KMO%^DZ3>?"S3HI--NS#(MJADM("9X=J[5<J1N8+D@@\X)[UZ;10!XQX(N]
M=TGX=>(YK[2CK=I;OLLUEA97O(^A)#KN,84@C(SC([<>G>$[UM1\*Z==MI?]
MEF2('['MV^4,D  8&!W''0ULT4 %8/C#5=1T70?MNF6,M].D\0:"*(R.\9<!
M\ =\9K>HH \9DTC3KKQWHNJ^!M.U"QOA<@ZB&LY+>!(/X]P=0-QZ87K]>:TM
M)^U_#CQIKJ:A9WT^@ZO/]JM[NWB:812$DLKJH)'7KCG:.O;U2B@#DYO%:ZAI
MM_=0:?>KI,5LX-U-;.K2R'"JL<>-[#DY) [>^.1^&%GH5O\ #C.L:(OVNR9S
M=_:--9I"&=BN,IE^,#C.,5ZU10!X;X4O3IWP0UO39M/O/MQ,T2VSV<I+&4'8
M1\OL>>Q SC(JYI6K>%;?PEHL4WAC43J^GQ02@0Z6Z.]S& >7"\@L.23SGFO9
MJ* /']1UQK+XQ6.L7UA?>7;Z.+6Z-M:RRHDY9F*J=OS ;AR.*NWBZE\1/&^A
M7$&EWMEX>T:<737%Y$8FN)!@@*C<E<J!GW/2O4Z* /+K2Z?P)\1_$MUJUG>#
M2=9:&6"^AMWE174$;&V D'+'\AZULZ-.VK^-+_Q8MK=0:7!IHLH6G@99)B',
MCLJ$;L#('3DCBNXHH \:^'_BFT\/'Q"-0L-67[;JLMS"4T^5MT;8P?N\?2D^
M(FM77B/P98.^E7B>=JPFM[<6DAD^S1[E+R#! ))Z<<$=>M>S44 >;P:YX>FU
MW3YO#_AN\75=_D(?L$EK$L;E?,9VV@$!5)&<\UZ1110!B^+KJ.T\):J\BRMN
MMI(U6*)I&+,I51A03U(YZ5XWIG]A2_"N/0KGPI?7.OF"1(RFEN'$Q9BC>9M'
M3()YZ CVKWZB@#F_ -IJ]AX'TJUUUG;48XR)-[;F W':"?4+M'X5TE%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4453U>>>VT6_N+9=UQ%;R/$H[L%) _.@#"U'Q_HMCK+:/
M MYJ6I("9+;3X#,T8'][' _/-7?#WBW1_$PG33[AA<VYVW%K/&8YH3Z,AY'/
M'IFO+/V>Q]H?Q)>SYDNGDAW2MRQSO)_,\U$$F@_::N(=.8P">,B5D&1\UMN)
M([_/@_6@#V2_UJQT^TU"X>7SC81>;<0P8>5%QD94<C(&1FJ_AGQ+I_BS1DU7
M3#+]G9V3$J;6!!YXKQ#X9#4KZV\>ZE<ZC<2#[(ZS[U#?:'*2X)8\@KCH/[WT
MK%T+7?$_A/P-I&KZ?K"I8R:F\0L/(4AN,L7;J0>F.W7.: /J&BO&?&'C?6[W
MQYJ'A[1+N]MO[-M6DA6QM?.DN;@*&"MP<)DX/&./I5?QAXV\:Z?!X/N;>1].
MOM31H[G3YK==IE1U7)W#< V[ID<8^M 'MU<1J/Q1T73/$$NA36&L/J*-A88;
M,NTO?* ')&.?I6MX2TWQ%IEG=IXCU>+4YY+@O#)&FT(A XQ@=\\=J\@\;:A=
M:5\?[>_LK!M0N((%=;99-ADQ$V<'![9/3G&* /7_  [XUT3Q1/<6UA/(E[;?
MZ^TN(FBEBYP<J?0\'&<5T->'?"E?^$O\?:YXQDN4LY_F06,+?, X #'(P0,>
MG+#)]X+'QOXID\&>-;J;7W^U:1<PI;3-!%G!D92N-N.>* /5/$?C?2?"VIZ;
M8:DMT)-0;;"\<6Y,[@#DY[;ATSUKI*^>?&FIW>L:1\,-0OY?.NIY)&DDV@;C
MOA&<#BM/6_'/BK5_%'B&WT";4$DT>98;2RM+3SEG*R;)&E.#@<$@<=N] 'N=
M%>$^+O'GB:Q\5);WE_<Z!%+812V:B%6B\UD4L)=REL;MR^JX!Q7LNIZHNE^'
M+O5I%$BVUH]RPC/#;5+<'\* -&BO 7\>>+K'PSIWCF;47F@O-1DA;3A&OD+"
M,X&<;@<AAG.>!6SJNN>-+SXLWWA71==$%O)!YJ-/!&P@!C#\$*">3M&<]: /
M8W;9&S[6;:"<*,D_2O/U^,7A\W%U!_9^M^99Y-T/L1)@ ."7P?E /7-=EH=M
MJ%GH=G;ZK>+>7\<06>X5=H=O7']>_6O!='36;CXE>/K'1=/AO)[S[5;N9;@1
M+"K2XW]#NQGH* />M%UO3O$.F1ZCI5TES:R9 =01@CJ"#R#[&M"O!M>L-;^$
M'PVT^/3=;\O4+G46>X$<:,C;H^@W G"^6O/^T?:M?Q-KGC7P)X2O]6U+5X;R
MZU.X@BLPL.U;,E'9_E(]@HSGIDT >Q45Y+I^M>(-,^(*^#)M=N+U-2TXS07D
M\:>9;3&-FW#C!'RG@^H_''\/>-?%.JV]SX6NM2N4\4C54A\U8H_D@&?-.-F,
M*$;GKEEQ0!ZK!XMTJX\87/A>-Y3J5O )Y!Y?R ':<9]<,I_&MQB%4L>@&37D
M$>N:[!\7_%.FVLB7DEMI;R6B26\0<OLC=4WJH8C<V,$U2^'GB_5]:O;JTN_$
M5X+Q+*X^T6EU&FY)AC:\1V=!SE&Z$=".@!ZEX7\5Z9XOTV6_TII6@BF:!C+'
MM.X '\L$5MU\\:=\1-<TSX1R7D,L*ZC=:PULD\=O&@B7RT<G:JA2>V2._L*Z
M?_A(=>T'QCK?A*?6[J^C_LM[FUNY40302+'OZXP0<'@CT]\@'L%%?-P\<^.?
M^$%MO%<GB"1A%JIL_LYMXU60>6'R2!\PZC';G\-[QMXX\0VGBV*.2^NM%TV[
ML8WT^>(*T7F,@8M)E26 8[3C!4 '![@'N=%<??V'BB]\3>'K_3-:@71HX@;V
M,'(G/7(P.=P/'(QUKL* "BBB@ HHHH **** "J&LZS8Z!I-QJ>HR^5;0#+$#
M)))P !W)) J_7.^.-#M?$?A:?2;F^%D;B2-89S_#+N!08R,Y.!CWH @TWQS:
M7^K6FF3Z3J^G7=X6^SK>VNP2!5+$A@2.@Z=>1Q4^M>,].T?4!IL<%YJ6IE=Y
MLM/B\V5%_O-R HY'4CJ*XG2=?U_1O%.BZ+X[TQ)Y?.:/3=8A/#.RE,,!P20<
M<@8R"1WJ?X2RF^UGQE?WK$ZJ^I>7,K$$I&N0@'MU'_ 10!T]OX^TZX:[@_L_
M58[ZTM?M4UE):%953<!P"<-USP3Q[\5/HGC*T\0Z!-K6G:?J,EK'G8#"N^;!
M(.P;N<$>WMFKVJZ?9,T^I-$OVY+*6!),\^6<$CWY ^GXUYY\*'\3+\-M/_LV
M#27M]TVPW$TBN3YC9R I'7WH Z6U^)>DWGAJZ\006&J-IUL^V23R%'KD@;N0
M.,_4>^%'Q&L!IT6HOHVNQV$BJXNFL_W81L8<D-]W!SFO/O"^?^&<M<SUS<?S
M%=#H*>,Y/"WA&,P:7/HCI:+.D 8R_9C&/]9O^4C&-V/PH Z74/B!8:=XD.@-
MI>KSZAL\U$M[8.)$Y^=3NY7@\^HJQH?CC2->N9K*%;JVU*!=TFGWD)AG QG[
MIZ_@>]<W>8/[0NFXZ?V"<8_ZZ251^)*QV_Q.\!W%E\FHR7GES-']]H=Z Y]L
M&3\,T =AH7C>QU_6+W2[:QU".YL6V7/G1!5C;TSGO2R^,DC\4OH T?49+A8?
MM&]$4J8\D;OO=,C'UKEO /'Q+\?@YXNX^OT-;T8!^+TWMH* D?\ 7=J +7A7
MQO9>+IKJ.QLKZ);0F.=[B,*%D!Y3J>14WBGQA8^$8K:;4+6]DAG?RUDMXPX#
MGHIY')YQ]*Y#X.G \8'/_,P7 Y_"G?&F;S?"%B(6C:1-8@7KD!MK\''U% '4
M0>-;:34[*PN-(UFR>\D,<,EU:;(RP4M@D$X. :T?$FOVOA?0+K6+V.:2WMPI
M985W,<L%&,D#J>YK#L8_%[^+;,Z\FF-IB6TK V0;:)MR!2V_G."V,>IK=\1:
M%;>)= N]'O&D6"Y4*S1G###!AC\0* *^E>+-+U?4M6L8'D232_+-PTJ[5PZ[
M@0<]!@@YQT].:R!\2-/N&:73M(UO4K!6VM?6=D7AXZX)(+8]@:QOB1HQT#P5
MXJU71_,6YU(6Z7) &4B4+&0O&<;<YSG[S&NQ\'V]K:^#-%ALBK6RV46QE &[
M*@[N.Y))/N: ,Z/XB:).FA20"ZDCUN>6"U81XYC8JQ8$@@9Z=^>E:GACQ)8^
M+-"AU?3UF6WE+*%F7:P(.#GJ/R-5)/!^C37.F3VZ")=-O)KI(XSN5I'W;\YS
MCYCGCH16AX?T2V\.:%;:3:%C!;A@I;KRQ8_J30!IT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5-K)<I:QF5XXV"G:.IR?05PT'QBCET!M?;POJO\ 8Z2^5)=1O$VUO]W<#C)
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M-#>0:@=4FO9+J,AH9-H6/8#N"A0@YZ?-TS7OFG7T.J:9:W]LVZ"YB6:,^JL
M1_.@#G];\9+8ZY'X?TG3WU76WC$QMDE$211Y^])(<[?I@GIQR*-/\6W;^(K;
M0=8T.;3KVXBDEBD6=9H9 F.%< '.#D@J,5R?@-9;;XP^.(;XE;J5DEA$C99H
MMQ((]L%/IP.U>F3&R^W6HG\C[7\YM]X&_I\VWOTQG% %FN)MOB Z_$9_!^IZ
M4+.5U+VMRMT)%F&"1D;1M) /&3R,>]=HCI(@>-E93R&4Y!KR'XAZ/<WNI^(=
M6T]-FI:+'97UM,O+#;YA9<>F!G\* /0/&?BRU\&>&YM7NHC,581Q0*VTRN>@
MSVZ$D^@/6K7AG5;O7/#]IJEY8I9-=1K-'"D_FX1@"I+;5Y(/3'%>/^)M9/Q%
M\,ZGKJ(5TO2=,&Q"I&;V3;OQGJ$4D9]6R,UVMUK$^D_!W1ELD>34K[3K:RLD
M0X)FDB 4Y[8Y/X4 ;OA?QII_BJ^UFUL\!],NC 3NW"1>@<>Q(8=^@/>LGQ'X
MYUG1?&%GX?M/#,5\]^K-:2_VB(O,VKEL@H=N,'OSQ]*X?2DOO GQ T&ZGT!]
M(TW4;=-*N-]S'*LD@ VR90X#9"]>HW>];WC^._E^*_@Y-+N(8+XP77DR3QET
M!V'J 1P>GMG//2@#I_"GCF+Q'JFH:-=:=-INL:?S<6LCAQC.,JP^\.1S@=15
M&/Q_J&I2:A=:'X<?4=(T^62":X%TL<CN@RVR,CD#CJ03GCI6/\)XX;C5O$&H
M:J9?^$N\\PZ@DA "J"-NP #Y3@>O0>V:/_".:A9M=^+_ (;ZJ%MIWE>ZTN[4
MF.1U8APH['(X''LP'% '1^(/B-<Z/X2T;Q%;:&MW:ZD(P4:\\MXF<94?<(8=
M>>.E:%GXE\3#5;*WU?PA]BM+F4Q&YAU!;CRVVDC<H08!QC.>,BN#\<:U'XE^
M"_A_4[>V6Q6>_A40Q@;8BID0[1TQE3CVKO[?3-5TGQ%!J>J^)C=Z>+9[;9.B
M0[9I)(]F H ;."HSR. .IH K>&_&NJ:[XMU30I]!@M!I9"W,ZW_F<L"5VKY8
MSG'J,?I6KXR\077A;PW<:Q;:<E^ML0TT37'DD(>"P.ULD$CCCC/T/*^!O^2J
M_$#_ *ZVO_H+5I_$N^MI_ 'B:SBF5[BVM4,R#^#<<KGW(!./IZB@#H?#>J76
MMZ!::G=V4=FUU&LR11S^;A& *DG:O.#TQ^-<QJ/CG7+;QRWA:S\,074YA^TQ
MRG4O+#19QN(,9P<]N?QK=\*W$-I\/M$N+B18H8M+@>1V. JB)22:X75[>YU/
MX[6RZ=JDE@[Z$'6XBC1R5WMQAP1W!_"@#N/#NNZMJE]J-EJ^@-I4]H(F4BY$
MZ3*^[E6"CIM.1[BNAKF/"5C>:(]_INK:RNI7]Q<R7D;GAS"0B@E1POS C X]
M.^.GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** ,S7]%B\0Z+<:5<7-S;P7"[)6MV569>ZY(/!KG=+^%^A:9X<O_  _Y
MU]=:9>'>T-Q(IV/Q\Z$*"#P/R^M=K10!P<7PD\.KX9DT":;4+FR,OG0^=,I:
MW?!R8R%&,YY!R#Z5G>*O!/\ 8OPVUBRT./4]4O[F..'S);@RS^6K@A <?< S
M\H SDUZ;10!X7X=L/&UAJ^A1Z=KVKWULLL:75M=Z;-;Q0P#&X%I1@X&0,<^E
M=I;_  AT.VAU*-=2UAO[19))V:X3<9%?>K@A/O YY_VC7H%% ')VGP\T6"/6
M/M#W=]/J\8BN[BZD!D9 ,  J !VYQG@5E_\ "G] /APZ%_:&L&R,RS;3= X(
MW8 !7:!ER> ,FO0** .=OO!FFZEX+3PM=S7<EBD:1K(9 )<(05YQCC '2L/3
MOA!X9TO5].U2"34C<V.-A>Z)WE>%W<=A@87 P.E=]10!Q%M\+="L=5U'4+*Y
MU.UDOED$D<-SMC4N""0N.2-S8W9 STJ.V^$OARW\,S: TE]-:/.+F-I)E\R&
M3&-R$*,<>H-=W10!R%G\.=(M%U=S=:C/>ZK"8+F^GG#3;",84[<#@#MV%9#_
M  6\.2:'#H[7VKFSBN&N$7STR'90I_@Z87]37HU% %./3Q%HRZ:ES<*%M_(6
MX##S1\NT-G&-W?..O:LO1_"-KH?A:7P_:WU\UJXD"R2NC21A^H4[<=23R#R3
M7044 <3X?^%NA>'+'4[&VGU">TU*'R;B"XF4J1R,C:HP<$\UE2_ _P +S6MO
M;O>:P4MV8PYN@?+4G.U05P!G)X&<DY)KTNB@#D=4^'6BZOXBM]=NI;X7L4:Q
MR-%/Y8G Z;]H'Z8JE_PJ7P[NU,^?J6W4Q_IB?:>)3OWY/&<Y_F:[NB@#C7^&
M7AY_#]EHP%VD5A,9[.99OWMNY.3L;'3/."#S4UG\.]#LM+U6R4W<CZMG[==R
M39GFR<D%L< Y.< =37644 8.D>$M/T3PU)H%C+=)8N' S+ET#_>"GMR2?J37
M/-\'?"S:6FF$Z@;))C.L'VH[1(0 6Z=< "N_HH Y6/X>Z$+>^@N5NKU+VW2V
MD%U.7VQH<J%_NX/(QT(J/0_AOX>T&WG@BCN;J.6*2#;=SF01QO\ >1!P%![D
M#)]:ZZB@#SX_!GPH]K':3-J<UK%(9(8)+URD.?O*J] #U/?WKN19HFGBSBDE
MC18Q$KJY+J , [CDD^YS5BB@#@K?X1^'+1+M+>XU:);Q=MR$OF'G#.<-CKU/
MYFIM4@E\ Z%8V?A+PL;ZSDN-MU!$Q+A".6R<DDXQD].*[>B@#F?!'AI/#W@Z
MWTN:W2-Y-\L\(.X*7))3/? (7/?%6O#'A'2/"%G/:Z/"\44\OFOOD+$G&._;
M K<HH **** ,W0M!T[PWI@T[2X/)M0[R!-Q/+')Y/^<"LR/P/I<7BUO$XFO3
MJ;?*7,WRE<8V[<8QC'Y5TM% ',7W@/1KO67U>W:\T[4)/];/87#0F7_? X/Y
M5JZ3H=CHJ3?9$D,LY#3SS2M)+,0, L[$DX'3L.U:5% '-Z;X)TW2_$MSK\%Q
M?M?W(Q,9;DLL@Q@ CN  ,>F*MZ]X7TKQ&+=K^%Q<6S;[>Y@D,4T)]5=>1TK9
MHH Y_3O!VDZ?JHU5_M-[J*KMCNKZ=IGB7^ZF[A1R>@[FF6'@K3-/\4W'B.*:
M^;4+@%96DN"RNO&%(]!@8],"NCHH Y9/ .D6^IW]_8S:C82WS;YUM+MXD9O[
MVT<9Z_F:K0?#+0K;PY/H$4^I+IT\@D>$7;8R.P]B<$CN0*[*B@#-OM#MM1\/
M2:)<27!M9(1 ["4^8R8P<M[C@^N34?AWP]9^&-*73;"2Y:V1B46>4R; >RYZ
M#OCW-:A;&:02*< ,"3[T 8FO>#](\17-O=WD4L5[;?ZF[MIFBF0>@93G'7\Z
M?I_A33-/N)[K%S<WD\1ADNKJX>64Q_W0Q/RCV7%;6?:EH S/#^@V/AG1H=*T
MU9%M82Q02.6/))/)]S52P\):?IWB2^UV&:]-Y>_Z\/<,R/@87Y?8<#TK>HH
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MLZ,I:0*2 ,E>!D@ D^E3_#HW=G\/=/MKO3+VVN;.$QO!-&$=R,GY03T/;.*
M.!^'O@K3?$>@:^\CSV]_;ZM-!:7D<SEK<*$*8&[!P3WZUMZ#M^)'C#7;K5)9
M)=&TBY^RV5FDA$,C#<&D< _,> 1GCFKOPFM-1TRSUJUU'2;VR:XU&2]C:= J
ME'"@#K][Y3D=N/6FVFFZKX#\7:]J,&E76J:)J\HN-MCAYH)<_-E"1D$L>F>
M* *4ZCP9\2M.T&WFEDT#7XG5K*61G$$@&,H3R%/''N?:N$TW^PK?0?%RWE]<
M6VMP:A/%I\45PYD  'EJH!Y!;(KT9-.U;Q-XZM/%6I:1<:?IND6[_8[68*;B
M=V!RQ52=N/0G.0/>N=T+P??>(-#\16>IZ5=Z;J-QJ4FHZ==S1%?+/ 3)Z@@K
MR/>@#T?P/)J\G@_3&UP$7YB&_<,,1V+>^,5TE<KX+U;6KZP%IKVE75I?VR*L
MD[J!%.>1N0CKG&2,=_>NJH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$
MXI:* *&I-FV+!VC ;:6!Q@&L2WT_^S+V/;*SO.I=\CIZ5JZP+B.SG>)1(F S
M#/(QZ5G6MZ=1:&[*A%5-F">2: -97(7'F8 '  H#DY)?GZ5 K$_QDYIZJ_.'
M'?K0!:B.[!\PL._%9L3?8]:,:_<D(S^/2KT<9W+^\]CBJ2Q^;KQ(Y$??Z"@#
M;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!" 001D&LB?0X\LUHWD.3D]<
M?E6Q10!S[FZLY!Y\3.HZ2QC(_'TJ87\(7=N3G_:K9/2HS;Q$Y,2$^ZB@#)6\
MFN-L5O&SDK@MT ^IK0LK-;2,_P 4C?>:K2J%&  !Z"EH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ I#G'!YI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 1<[?FQGVI:** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **!10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %&*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!.:6BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:
MS,.BY_&@!U%0VTDTD>9X1$V3\H?=Q]<5-0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %&*** $  Z"EHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHJI?7\=C&K."Q8X55ZDT 6Z*P(TU*_(F,OE*&*A1D$#WJVMK
M?)@+<DX'=C_A0!J45G+)>6_S3XDB_B*]15Y'61 RL"IZ&@!]%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MS10 44A&010HPH&<XH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ"Z-Q]FD^S;//
MVG9O^[GWH GHJM9&Y-M']L\O[1CY_+^[GVJS0 4444 13"0I^[^]D?EFI!1B
MEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "HYI1$H8ACD@?*,U)10 "C%%% !BBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XOQC\4/
M#W@J[2SOC<7%ZRAS;VJ!F53T))( ^F<T =I16!X;\::%XKTN;4-+O T,'^O$
MHV&'C/S9Z#&>>G%<G-\=/!D6I?91->20@X-VD!,8.?KN/X"@#TNBN:U+QYX?
MTO\ L4S79DCUE]EG)"A=7Y49)[#YQ5K7O%6E^'+O3+;4'E$NI7 M[<(F[+D@
M<^@^84 ;=%>?ZM\9?".BZM=:9=RWGVBUE,4FRW)&X<'!S5FV^*WA>[\-7VO1
MS7/V*RE2*7= 0VYL8P._7]* .WHKSNQ^-W@B]NTMS?3VY<X$D\!5,^Y&<?4\
M5TNI>,M'TKQ!I>BW,TGVS4QFVV)N4@G RWO0!OT5AZOXNTC0];TO2+Z9TO-3
M?R[=5C+ G( R1TR2!3=&\8:-KVM:GI.GSO)=Z:YCN%:,J 02IP3UY!'X4 ;U
M%8'BKQCH_@VS@NM8EDCBGD\I/+C+G.,]O:L+3?C#X-U;5X-,M;^=I[B5(H2U
MLX61V(  ...3WQ0!WE%5M0U"UTK3[B_OIEAM;=#)+(W15%4+?Q1I%UJ-CI\-
MPS7=[:_;(8O*<-Y/]YLCY >@W8R>* -BBN=UKQSX=\/:S::3JFH""\N]OE)L
M9AAFV@D@849]<5;\1^)])\)Z<E_K-R8+9Y1"K"-GRY!(&%!/130!KT5C:=XI
MTC5=;O='L[EI+ZR56GC,;*%!QCDC!ZCI6S0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !14<TJP1/(YPJC)-4EUB!@"4E4'H2A&: -&BLXZQ  "(Y2#_L5
M&VL@#(M9B/7% &K15&VU2"Y?9\T;_P!UQC-7A0 4444 %%%% !1110 4444
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MV@"_I7A.'3?%NL^(C<&6YU((FQ8PBQHH QQ]XDC.X_2NBHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#)UF7>8+,''F-N?\ W1S_ #Q4L1+IA<$*< CU
MI]]9PRYG:)GE08!5R"!^=4-*N/+N)K1CN.=ZGV]* -#8R ,!DX[B@(Q38V"#
MUXJ<%N.,D#K2#(STR: *%QIHD0F/A@,KFG:9=2/&T4K?/$>2>XK1&<8K+C7&
ML2HHPI!S0!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOVF233H)H/L4;IM,:D.",=<G:,^] 'HU%4-;UFR\/Z/<ZKJ#LEI;J&D95+$
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M7BBO(]5N+:%%A;Y8E;"%MHP!VR?2NNU[QIX>\,VUO/JNI1PK<C= %4NT@XY
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M--=A3"%)(.[ID@87Z$B@#J**YF3Q&MAXCUA-2U;2H]-LK:*7R59O/AR>6D[
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M<?\ "2 0P&Q^RMOBF60%GSC'S?-T.?FKN?#L$D/QMU995<S+H=NLTI&%D?*
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MXI!9VJW)N5MH1.>LH0;C^/6@">O"_%>DS?\ "P[WP:L;_8/%%W;7Y>,[?+5
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M@N=H1 N,]<8H \[^"5_92^!QIT4\?VVTN)?M,'1X]TC%21[C^5'QU!;X;2J
M23=P@ =^37HL5K;P/(\,$4;R'+LB %CZG'7J:=)%',FR6-77(.&&1D<B@#S;
MQ=IUO:_$[P(MA!';2/%?Q*84"8 @&T#MP2<5PUCJWA6U^"-[H>I)%_PD.Z:)
M[1X\W!NB[;&QUX^7GVQ['Z#:*-Y$D9%+IG:Q'*YZX/:JS:5I[Z@NH-86K7JK
MM6X,*F0#TW8SB@#RWPCI E^*$J:U#'=7MMX>M4<S1YPY"AN#GGC&?KZURR:=
MIL/[.>JW7V2);A[TL)0GS;A.%7D=,+QZ5]!B&(3&81IYI7:7VC<1Z9]*8+2V
M%O\ 9Q;Q>1U\O8-O7/3IUYH \)\3K&;[XCR-CSAI%@%YYP53/ZA:Z;7=&L;,
M?#9;*WCM76]A02PQJK[?+R03CH2.?6O4)+6WE\SS+>)_, 5]R [@.@/J*>T,
M3B,-$A$9!3*CY2.A'I0!\U:OJZW7AOQ')!?>']%M9KF;=I9C\^]GDW8)8OEE
M)/<8 YQC%=9X0D$OQ*\%LKAO^*/A!(.>07!_6O73H>D'47U$Z79&^=2K7/V=
M?,8$8(+8SC%6H[6WB*&.")"B[%*H!M7T'H/:@"GKZWC^'-433BPOFM)1;E3@
MB38=N/QQ7A\FI^$7^!0TB);4ZZ56+[($'VHW6\9;& WKSZ<9/2OH&J T/21J
M9U,:79"_/!NO(7S?^^L9H \X\)Z3'<?%;5VU:VBN+VVTFQ4F5 VV3RUW$9S@
MY7KG\:]6J-;>!+A[A88UFD 5Y H#,!T!/4XJ2@#P[3=0\$0GX@C7_LBZA)J%
MT3'=J/,=.=HBSSG.>G.<>U8]O=7D)\$V#PZ7::M!I#RI>ZZ[")(R[;%5<XW;
M0.<9P1Z5ZSHG@#3[#5-7O]2MK'4)KS4I+ZW>6V5FM]V. 6S@Y'48KH=2T32M
M96-=4TRSOEC.4%S L@7Z;@<4 ?.0E2X\ ^/U%Y;7>=1L\S6L0BC?]YC<JCH.
M/QKZ/TO2-/T6T6UTZS@M8@ "L487=@!03CJ< #/M22:+I4J3))IEFZS!!*&@
M4APGW-W'.WMGIVJ]0!P7Q4L)ET*R\1V@S=Z!=)>@#^*,$"1?RP?H*X*^O+>_
M\#>+_'.HZ:]W%K5W';V<,C% ((W"H6*$$#<.0#R5'KFO>)8HYHGBE19(W4JR
M,,A@>H([BH$TZQCTX:>EG;K9!/+%L(E$>W^[MQC'M0!X#9R3Q?%+P:LNH^')
MI%D=1'H*!5B4H  [ <YYP,GC/K3[>YAL?#^AWURXBM;?QK))-*P^5%!/)/85
M[E9^'M%T]8ULM(L+81R>:@AMD3:^,;A@<''&:>^AZ1)9363Z79-:3R&66 P*
M4D<G)9EQ@DGG)H \6\4:W8Z]\0_$4NAW2WCQ>%IH8Y;9MP+[MS;2,AOE8_CG
MN*YN"WMYO#&@ >*-!\SSH!;VUEIZF]CEW#@E</G.<D]??(KZ,L=!T?3)5EL-
M*L;618S$'@MT0A"<E<@=,\X]:@M_"OA^TU0ZG;Z+817Q.?/2W4/D]3G'!.>O
M6@#6&0!DY/<UXUXA5(/B7XO2P6WCU6;P_NM!C$CR8.XICDOMSTYKV:J%QHFE
MW6JV^J3V%O)?VP*PW+1@N@/8'\3^9H \)U:;P@?@KH\.CBQ_X2,FV6!8-OVE
M;K<OF$_Q#^+KQRN.U?0:9V+N^]CFLJW\*^'[75GU6WT:QBOW)9KA(%#Y/4YQ
MU/<]36O0!X3XW2YTOQKK/A:V618?&#6CQ-$/]6WF;92?J 2?K57P''?:KXEM
M-%O(R8?!T%ZC.PR&D=BB_B!T_P!VO=KC3;&ZN[>[N+.WFN;8DP321*SQ$]=I
M(R,^U.AT^SMI[B>"T@BFN2&GD2,*TI P"Q'WN/6@#YU@T73$_9LGU1;&#^T&
MN@YN=@\S(G"##=0-O&.G)]:L^*'OIM<\>R6[.TCZ58M<%/O&,K#YGZ9_#->]
M'0]).DG2?[,L_P"SCUM! HBZY^[C'7GZT^+2M/@NY[J*RMTGGC6*618P"Z*,
M*I]0 <4 >67DOPZBN?#8T2!9+]K>469TY@"B&,Y,_(..3G/.=WO7*IX=T2W_
M &;9-8-A;2:C(PD^UJ@,JM]H" ;CR !P0..O<U[CIOA/P_H]S/<:=HUE:RSJ
M5E:*$#<IZCV'MTJ8>'](&B?V*--M?[,QM^R>6/+QG/W?KS]: +&F2/-I-G+(
MQ9W@1F)[DJ,UX]X\L8Y_B1?36>H:*][_ &<B3V&O)MB:,G_EDYX!^A!!SSS7
MM*(L:*B*%10 JJ, #T%96L>%=!\021R:OI-I>21C:CRQ@L!Z9ZX]J /%+)-+
M\2Z1\-K.333!8'4+F)[:25I$?;AN"W)4GM]15W6_[+\->./'%O#IPATL^'T,
MMI8X@WLS1ID$#"_?.<#UR#7LZZ+I:BR"Z=:*+'/V0"%1Y'&/DX^7CTH?1M,D
MO+F[>PMFN+J$03R-&"98_P"ZWJ.>E 'S=>+/87'@^XC@\,V!-Y;O!%I>6NRA
M(^:9^<]0#D]3]:[S0/#]C<ZQ\1-9&GQW6KVE]/\ 8GD3S#&X0LI0'^+<1S["
MO0(? 'A&WB:.+P[IRJSJY_< G*].:V;33;*QEN9;2UBADNI?.G:-0#(^,;CZ
MGB@#Y=M;".Y^'"7<NI>$K= Y8RNDAU%9-_=@"Q/Z8KI?$%H+CQ)J=ZNHZ!JE
MX=.MOMUKKD31,O[E?F@9MI!/7@J06KV=_ WA:35SJKZ#8M>EPYE,0^\.=V.F
M<\YQFI-6\'>'-=NQ=ZIHMG=7&T+YLD0+$#H">] &=\,;VWU#X<Z-/:VTMM"(
MC&L4DA<C:Q4X8\D9''M@5S?Q?M+:]O/#43:E8VU\L\KVUOJ41:TN,*NX2'!
MQP!G^\:],MK:"SMHK:VACA@B4)''&H544=  .@JGK.@Z5XALOL>KV$-Y #N"
MRKG:<8R#U!Y/(H ^>-0U"TB\!>-M*;3;:TOA<6DDK:9<E[)R7!&Q02%X!X&>
M>PV@#O->\.Z'X0\7^!)-*L8[)5DG2:2%3OD18L_,1RQZ]<FN_M_!GANUT631
MH=&LUTZ1E>2#R\AV&""V>6/ Y-:5UI=C>W-I<W-K%+-:,7MW9<F(D8)'IQ0!
M\RZQ&MYX&U'5K'1=%@TVYN&D2]OKGS=2D?S<':0>.GW< 8R>>M=9K-U./$MY
M?>?_ *2/ OF;VY+,1R?U->H'X;>##=SW1\.6#2S9W[H\KSZ+T7\ *T_^$7T+
M<6_LJU)-H+$YC&/LX_Y9_P"[[4 9_P .O^2<^'O^O"+_ -!KC_BK;Z3J/C7P
M-IVLN@LI;B<RJ[% 1A, MZ%@!^->H6EI;V%G#:6D*0V\*!(XT&%51T %9^N>
M&-$\2I&FLZ;!>"(,(_,'*;L9P1R.@_*@#Q356B\.7OQ!M/!TGEZ>FF0-(MNQ
M9(92ZJ^TYX.QG/7CGTK#&AWFFZ+H&LV<WA72Y5DADMKZWN;AKB5B.CI\V<D_
M,-O'(X&17T/H_AC1- TZ33]+TV"WM923)&%W>9G@[B<EN..:R[#X;>#M,U./
M4;/0;:*ZC?>CY8A6]0I.!CMQQVH ZJBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LSQ#K']@:#
M=ZF+.XO&@3*V]NA9Y&)P , ]SR>PK3KEOB)I>M:SX)O['0)3'?R;2H63RRZA
M@64-D8)''/';O0!S%A\2M?M?%>F:1XFT&SL4U201P?9[Q9)8F.,;U!)Y) Y
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MD<$2;NY.W[O7O[4 :]MXPU-/C/JUK=07 TBWT[?DW"^5!$N&-P5!P0W_ 'T
M?P%R#XL,8X-3O/#&H6GAN>41QZJ[J0 3@,T8&54GOFL_4M!U6#QMK.GIIUW/
M9:WH2Z=%J")NCA<1E<R\\#OZ].N:XF'P/>'2K71_^$$U2364D5)I[F\86.T'
MEP589SZ#\/2@#Z*GGCMK>2>9ML42%W;&< #)-><_\+8F2*#5)_"M_#X<GF$4
M>J-*O0MM#&+&0I]<UWFI17<>@W<.D[$O%M76TW?=63:0F<]LXKYYU'PCKFI:
M'"I\/>*;O7871[RYO[@&%<,<B%=WSY/IG YH ]-T3Q+KEW\9=<TB>RNAIT,"
M*@:5=D  )$F!UWD\=QD9Z<=1XM\4Q>%--@N#9SWMS=7"VUM:P#YI9&S@9[=#
MS7/V-OJ5A\9-4NY-*NWL-4LH5CNT4&.-D7D.<\="/R]:/BI:Z]=Z=I2Z3'J$
MEBMV#J*::^VY:+'\'Z_IVH ETOXB3RW^H:=KGAVZTB_M+%[]86F642Q+UPP
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M6 !'/#*3QG!^E=)<:]'\1O&GA<Z#I]['%I<YN[J_FA\OREQS$,CDG@''M]0
M:\GQI\,*!)%!JDULDGEW-PEH?+MCG'SG\NF>M=@/$%BVNVVD+YS3W-J;N*01
M'RFC! ^_TSR./<>HKRW1;"9?V?-=B2TD$\ANV*",AFQ(><=3P/TKL_"6O06%
MKX9\)W-M=1:BVAPSDO'A%"H%*DDYW CIB@#7\9>(1X5\):CK&P/);Q_ND;HT
MC$*H/MDBN<^VZAI=]X&T_5?$5U'J%V)3<P?9E87;[02K-_ %+8'^34OQ=&SP
M0+MXS)!9WUM<3H!DM&L@R,=#U[U0\:@WGQ)^'=S;JTL!EN'\Q%)&"B$'/TH
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M6.>*R##3XE +84#]X26 &0?NGUXCT/XMZEI[ZS'J-V^N6UM9&YMKS[#]E/F
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MH-W1/$7BFS\<P^'/$XTN4WMFUU;R6(<>65/*'=U[_P">@!W]%9NA'6#I$/\
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M6,$D*1C&Q@_4GC/'- &S165X=T3_ (1_2A8#4+R^ D>02WDF]_F.<9]!6K0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 &,4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%&110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/6KR Q*!GA0,D]^*S;QS<7EK IY#;C^=:AQ(CKVY% $@((R*6FJNU0/04Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *J7PR(Q[FK=4[\X">YH JK&1SMR/I4,SLL@
M2*%I7QDJI&109Y9B8('/F'KCL/6M.UM%MDZ[I#]YSU- &%%J4)SNW1G."LBD
M<U*;Q <DJ /6MQK:)Q\T:$YSDCOZTU[6.5"LBJX/JHH S;&-[N^%YM*Q(-J\
M8R:U]ORX%*JA5"@  = *6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J&II+)
MY*1+EBQR>PJ_10!6L[-+2':.6/+-W-6:** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***0L%!). .: %HS6;)K$1D,<$;SD'
M!*X 'XFD_M212!+:,H/=7!H TZ*JPW]O-@!]I/0-Q5G- "T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4M%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>articles012.jpg
<TEXT>
begin 644 articles012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" JJ!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ
ME>WCV9MPMO),)9EB;8/N Y^8^W%7: $;..*CMC,UNAN%59?X@O2I:* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBHYIXK>,R32+&@ZLQP* )*9+)Y4+R;2VU2=HZFG]:*
M&HVY0W/(S@]J=28I: "BBB@!,9/2EHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H
MKBWBNH6BF0/&PPRGH:EHH  ,#%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\>:!>SRW/V33]&6"Y=YPT<DNTKL10<\$[B3P2,^E>IT %%%% !1110 4444
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M!0[D$<]]U=;\(?!^N:#>:WJ^M64&GMJ3JT=G$00@RS'@$A1\P &<^N*]4HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4C ,I!&01CFEHH RY-.>"4O: %&.3&
M3@ ^H-1_Z0&_X]F#>F>*V*3F@#)%E<7+CSU$<0Y(!R36I%$D,81%PH[4^B@
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M+L^X_/0D@C\_6M3XNV%QJGA:UL;6_MH)9KV-1;7$QB6\X/[K<,=3@]1TZ]*
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M?O'<06ZD5T?BK1;+PG8:5HTWB+Q)=?;YWFN;*T)GN;U@H&$;(V*"22.=V?\
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ME$_'ENK$Y YY[=?:JOBSQUJCZ=XROK=+632M,N(-/MH;F%9$EG$@,K$$<XZ
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M\C5-:L;&[D\RXT^TN]EO(3URA!Z__JQ7<V%C;:986]C9Q+#;6\8CBC7HJ@8
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M$?B2*R-I%_93V1N3J)N5 #!L;=O<8(.[..:UY)X8HQ))*B1D@!F8 '/3GWH
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M+G@P;?/,I)_O?+C<?7/M5C6_ ^K_ /"377B'PMKXTN\OXUCO(YH!-')M4!6
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M0/)&XF9 ^Y48@< <=,],=*]BHH AM(/LME!;[MWE1JF[&,X&,U-110 4444
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MVZM;<1SWL@EN'!)\Q@, \GCCTJEXC\*:-XKM8K?5[3SA"V^)U<H\9[E6'(H
M\3T**YTWQ1XUTN:*V\,(="9Y(K><RQP,-@5R5R<X<].?FZ5)X6M4\-^*O";Z
MGH*V<ET_E6FJZ7>[H[T,H ,J').<@_P]>GIZ[IG@#POI'F&TTF)6FMVM9F=F
M8S1M]X/DX;..]0:/\-?"NA:N-4L=-VW*9\K?(SK#GKL!) H W-=NX;#P_J-W
M<32PPPVTDCRP_?0!225]QV]Z^;=6MYM.\,:/KEAX6_LM6O(G@UB?4!+=3L<M
MDJ,=>3T[5]/3P175O);SQK)#*I1T<9#*1@@CTKB8O@_X*B\P?V9)(K?<62YD
M(BYS\G/% '%:SI=IIGCWQYJMA8H+^PTM;RUD!(,4KH2\@[9Y)JOK.@Z+H7PM
MTCQCHLTB^(1]GGCO5E+/=32,OF*XR<]7RO\ LX]<^R1^'],CUB^U06X:ZOH4
M@N"Y+*Z*" -IXZ'GUK T_P"%GA'3-8CU.WTP^;$YDBC>5FBC8]U0G ]O2@#C
M=+\,Z;K'CSQQJ]_:?:KK3+B.6SC9F"I)Y>[.T$;CE5X/I7!VFEZOJ'@8>(AH
MUK]L,IN#XCDU8),L@DZE2>,?=Q^-?1]AH=AIFH:C?6L)2XU&19+EMQ.YE&!P
M>G%<Y-\*/!MQJK:A)I0RTGFM )&$+-ZF,''X=* /-/%.EWVK>(]3O[G3[3Q0
M@TZ#SX8+[RY=-)CR2G3()!8':<Y&1V,M_J&F>)+7P;:6MIK'B5Q922KI<]RL
M(<*Y3S)7QR048#UV]>3GTWQ!\-O#/B74/MU]9R)<E!&\EO,T7F*,8# <'@8^
MGX4[4/ASX9OXM/C^PO:G3XS%;O:2M"Z(>=NY3DC))Y[D^IH \4MS<V?@'XF:
M>UM_9\=O-9;;&.X,J6Y:7#J&R<] #],5V.B:#IGC?QIJ5OXD>2Y33=/LULK0
MS.@57A5FD&T@D[CU]_I7:P?##PI;:;J6GPV$B6VHI$ERHG?Y_+.Y3UX.>2:7
M7_AIX:\126\MW;31301+"LMM,8V:->B,>X_7WH R?@HB1_#\)')YB+>SA7SG
M<-W!S69\3FM=6\6:5HG]GZCKLR0/.^CV\_D0L"<"223J,<X_IGGT3P_X>TWP
MQIG]G:5"T-J)&D"%RV"QR>3SBL[Q-X&TCQ5=6EW>FZ@O+4%8KFTF,4@4]5)'
M;_$^IH \5M;2!_!7Q%TR\L3IT&GO!/;:?]I,XM9/F& V>23@'Z^U:*>$-"B\
M6?#2WCL=L5[9&>X43/\ /((Q(#G=D?,<\8KTZS^&/A>QL=3LX+.58=3B2.Z!
MG=BX7D').0<\D^M6M8\!Z)K4&DQS+<P'20%M);:<QNB@ ;=W7&%'O[T >&6]
MGK/C&VUO6[C0AJ$\=Q*5U:75OL_V+;@@*F0 %&#R*ZB'2Y/&NM>";+Q%=FY6
M32+A[DV]QD3[6PN60\_PD^XP:[G5OA/X7U?5)KZ2*ZMS<-NN(+6<QQ3MG.64
M=_IBMV#PGHMKK%EJEM9K#<V5I]C@\LD*L6<[<?B?SH T["Q@TW3[>QM5*V]O
M&L4:EBQ"@8')Y-?.MUI-G9^&/BG<V\;QRV^HK:QE97P(C<+E2,X/3J>>OK7T
ME7%WOPO\.WU]K%S)]L0:NN+N&.<K&S;E;>%Q][<N<G/4^M '$R^%[+PA>^ ]
M8TB6ZCO[^\@MKV5YV?[0DBY8,"<>W _49KCK0:[XJT_5O$5QX<N[V\$LS0ZH
MNL"W_L]E&<!"0 %XSG&1W%?0E_X:TW4ETE9XGVZ5.EQ:A7(VL@PN?45SNI?"
M;POJ6ISWK1W=NMPX>XMK:X,<,S9SEE'K[8H V_!-[>:CX*T>[OY4FNY;5#+(
MCJP=NF<KP2>^.]<)/H%G_P +LUF_#2K+!HWVI!YK?ZUB5R.>@ Z=.>E>IVEI
M;V%G#:6D*0V\*!(XT& JC@ 5AZEX+TK4_$UOX@E-S%?PPF F&8HLL9S\KCN.
M30!Y1IND66B_"$>*KK7-5M]5U"W$!NXI&D?:9/EC12P'1<9SQDFHM):X\/\
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M =@5!1=HVC''!KF&^$NA)H]A8V=YJ=E+83236UY;W 2=#)]X;L=. .F>/<Y
M//?#NHZS8ZEXRTBR:^T6,:3]IMX=5N]S6\GRC=O;A<[CS],GBK7@>YET;Q=H
MT6I-X@T>[NU,4R7[FYMM2<C@J_&ULD'(R.@[G/>6'PJT.RN;Z>:ZU*^DO[-K
M2[:\G$AF#$'>21D,,#&.F*71/A?I>D:G9WL^IZMJGV ?Z%#?W/F1VQXY1<#!
M  Q]/84 =)XD_P"16U?_ *\IO_0#7A\&CW/A3X4:3XVT_7]2748?+?R'G)@>
M-G \D)Z#K^?MCWV]M8[ZQN+.4L(IXFB?:<'##!Q^=<%IWP=T.PN+/S-2U>\L
M;-Q+#I]S<AH!)_>V@#ZT <3K&K:OXK\;:_;O8>(;S3[!Q;PVVDW8B6)A_&W'
M+$@D<?RJI>^*_%\7@K2-%F;45NKG5I+-IHIE^U20J%Q'O&<2'?C/7Y?K7J.O
M_#>QUC6I-9L=5U31=1F01SS:=/Y?G ?WAW/X]A33\+/#O_")IH"BZ5$G^U+>
M++BX$W_/3=CKVZ8XH X/PM<^)="\4M8K;:[!I-W9S,\>L7:221R*C,)(R,'J
M #@?Q<]!68]EK=I\'X/')\7:Z^J(4:.,W1,*IYPC"E3G=USR?;%>FZ'\,[+3
M+^34M0U?4]8U%H'@CN;^;>848$'9GH<$^O?UJ[-X TN?X?+X-:XNQ8*JJ)0R
M^;P^_.<8Z^U '264[7-A;W# !I8E<@= 2 :GJ.WA6VMHH$SLC0(N>N ,5)0
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MW""2*1>C _YZ=J\'F2V\.>+?%,?B+Q'X@T6:YNWNK8V(VI>QL25Q\IRW.,9
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M$\K#^RY)(H\[GC5,L!CV!_*@#T;3?B-X9U^6[M-(U1)KR*)Y$1XV3?M!.5W
M;AQGCM6'X1^+.@WFC:/;ZUK,(UFYC F_=E4#DD ,P&U3TXSWJM)XO\)ZYJ.@
MV.CZ>NHW45I,4ECR/[-018^;C'/W<?\ UL\Y?6=O#^S)9F*!%+-#,Q"\ES.
M6^N./I0![H2 "20 .I-<I9_$OPA?ZVND6VLQ/=L_EI\C!';T5R-I_/GM6CXQ
MM;N]\%ZU:V&?M4ME*D8'4DJ>![GI7S_&UKJ/A#2M*N/&%[<S-+#%%H=OIJ>=
M!*O!Y)&,'/S9&>_>@#Z,L=:TW4GO5M+M)&L9F@N1R/*<#)!S_/I63??$#PMI
MVBVNKW&K1"SNRPMV569I=IPVU0,G![X_G7G7C]=1\,^*M5M=+21U\96R6T04
M<1W(948D]@8V)XYR?:JWB32W\)^/_#\::XVAZ=;Z.MI;:E):+.GF*QWKAN%8
M@YS[^] 'J<?C?PW+X<_X2!=5A_LL.(VGPWRL3C:1C(.2.H]^E0:1\0_"NNW<
M]KIVK1S3P(TC)Y;J651DE<CY@/;->,:E!;7OA3Q1<V>MWNIQ7NIV<-Q=-:)!
M#,V[ED"GG'&>!VZYS7HWBZS2V^)7P^%M;Q11))<Q#RQ@A1&,+@?PB@#4^'OC
MR'QK#JF'A\ZUNW5$CC9<P$_NV.[J2 <_R%=I7E/PW\3:9H?AC7VUN^MK6>UU
M>=[N-<GR][A0=HR<%L@5ZHCK(BNIRK#(/J* ,R+Q)H\^@/KL6H1-I:*SM<C.
MT!20WOU!%9^H_$#PII+F.^UNWA<1QR[#N+%7&5( &3D<\=.,]:\;A\3Z78_
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M5['%'<7(<NL((4;9&7C))Z+ZUY1X=WQ?&*-;J]T.6X;2Y@5T)-L(.#\K<<G
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MY8-V(&3[XQ7F?A_X@:UH7P_\+K+H+W]YJ,K6UJ#>?-, !M<G!QEF(P>PSWH
M]DHKS^?QMXK\ZUTZU\%O)J[0&XNHGO%2*%=Q50)",,3@'CIT[&JO_"V@G@N3
M7)=&?[5;:D-.N;))PQ5^Y5@.?;_)H ]*HK@--^(6I1Z[)I?B?PZ^D.;*2]A9
M+A9]T: E@<#@X%4O#_Q0U;69M.NY/"CQZ+J-S]FBO(+H3-&^<#S$4949'.<4
M >E@ 9P ,\G%+7A6BZH;7QUXP\6^)M'D0Z21M;[;O^SN5VK$JCAMX/7H/;-=
ME9_$;58-8TVW\1>%WTFQU2016EU]J67YV^ZKJ!QG]* /0@ HP  /04M<!H?Q
M U;Q!XLNM,LO##G3K*\DM+J_-VN$*D@';@9SCISUK8\;>,4\(:?:.EH;R]OK
MA;:U@\P1JSG^\YX4?Y]P =-M&X-@9'>EKRKQ#XKU'6OAYXOL]3T6?2-2L+=1
M(OF>8CASP4<#!X%3>&OB+JGG>';/5O#4]GIVJ(D%G?/<!VD8(,%DQD!NHSV.
M>: /3F16QN4''3(I:\SU/XH:O;MJMYIOA&:\T72IW@N;Q[I8R60_,50@D@5D
M>(]9.H?$*SO[2YN([>?PA/=6Z@D8+K(P.,\'&.?]D4 >Q,JL,, 1Z$4 !1A0
M !V%<M\-6=_AOH+R323.UJ&+R-N)))XS[=/PKS[2?&FMZ%XA\:K9^'KK5[6V
MU66XN9EN-ODQ],*"#DX7.!V% 'M01020H!/4@=:BNK=;JTGMF)59HV1B.H!&
M*XW4?B/"+/11H6F3:MJ.LPF:UM0XCV(!RTC'A<'C\#S6CX3\7GQ%+?6%[ITN
MEZO8,HN;.5]^%895E8 !@?\ /:@"[X4\.Q>%O#5CH\<[7/V5"GG.N"V6+=,G
M YZ9K89%?&Y0<=,C-8%WXI2R\<:?X;FM& O[9YH+K?PSIDLFW'7:,YS6'??$
MZ"TFUQ(M)N+I=.O(K" PODW5RX.8P,?+M(()YH [P@'&0#CI2,B/C<JMCID9
MKC- \=7E_P")O^$?UOP]/HU]);FY@#7"S"1 <'E1P?\  UQ7@?7+?R?ATFH3
MZC)>2V^H,)?M1$6 S_ZQ3DO@*<<C''7L >T[5((P,'KQUH"JOW5 XQP*\/\
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MKPOI>MZ5?6$T"0I?E/M,D"*KR!6#8)QSTQ^)Q6PB+&BHHPJ@ #T%>>CXLVQ
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M@^*&DMX?U?4KJRO[2?2"@O;&:,":,NV%P"<$'UH [*.TMH4E2*WB1969Y%5
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M!T%%5[&\BU'3[:]@#B*XB65-ZE6VL,C(/0\U8H **** "BBB@ HHHH ****
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M%GO \$CE"%5%Y) ;GT'' P*YV^\!:S?^&IHKCPAJ]YXI)=Y]1NKY3$N')S&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%1I;PQS2S1PQI++CS'50&?'3)[XJ2B@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HI,TM !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4452U">X@\HP;2"WS!NXH NT5E+J
MDJ,/.A!!/&P\T^76(UA62-"[,^S9T(H TJ*RFU:52<VI 'JU6X+^"?@-M;^Z
MW!H M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 53O_NQ_4U<JI?\ *QCW
MH HX/O33$"0<#\JFQCT/UH S@>HH 0!N6Y/:HIK?S(GQC(&1[59*J.W6IEC&
MYMP XZ4 .T^5I;-&?[^.>>M6JR+F(6DL%S$Q53(%<=B#6O0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !5._.%C/N:N53U 96,>YH I_C3E8XQN.*8%..M!&Q=
MQ; SU- $F?0]O2I$?:H^9F(/I559 QX?(]N:>K <NQ'KQ0 :FVZ*" -N9I,C
M-; Z5B6*F]O?.)+1Q<*3W-;8Z4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 (!BEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHK-U&]=98[.V_P"/B49![(.Y_G0!;FNH
M+?\ ULJ(>P)IL=];28VSH<^]4K33S'O>3YI6/+L<D_X5*^GI)_"I/KB@#0!R
M,YS2UFM;2VB^;;MP.6C[$5>@E6:%77H10!)1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "$@5BVP,VOW=PP.V("->>.E.\2EUTK>KE525"^/[N:DL%AB#"/
M # $\]>./TH T,Y%(,@8'K48<'< 1D>AZ4_<3P<=.H- #Q\P((XJCI;$&XB_
MA1^*N;]J,Q(PHR:J:9PK.?\ EJ2P^G^30!HT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!#<VZ75O)!*,HXP:RDTBXMU$4%R#!V$G)'T(K;HH Q%DO8&\N6
MV>0@':R#(/-+++>N2L=HRCZ5M48% &.NG75Q ?.E\LM_"/ZUHQ0>2L:+T1-O
M\JGHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3-+0 456O()KB-%@N# R
MN&+!0<@=1SZU848% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6DX'T'^-*-;M\_,DJCW3I0!IT5#!<Q7$>^*0,OM4PZ4 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ,S6YVALB@3(E(C+?W<U!96"V
M,"QQ1@>_J:?XA!-G !WN$X_.KJHP)YSS0!$(OX652.IR.],^PHZ<J%.>HJT-
MVT @4X$\=./2@#&G@ET^:*="-H;#8X!%;D4BRQ*ZG(89%07@#V4H('W2>:AT
MABU@N[L2!0!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1U.Q:]A78Y26
M)Q(A[9'K50W=U9SJEVJL&3AQP,^E;&*9+#'-&4D4,I[&@"H+M2W QWYIQN<
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MN?BWX:MIX[=DU)[EX4F%NEFYD"MGJ.Q'?/J,9H [NBN8;X@>&D\*)XD.H?\
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M,]>.1[@]*U=3U:'QUXNDU?0;2XDT[3-%O(I[UX3&)'>-@J+D9.#_ %_'VB@
M 8 Q0!X]?2WNC_ /0S:6,>XB#SS+9B;R%)),OEL""0<'D=36/X7NH;SXK^'K
MNUU[6=?M?*GC-]>0.D2N8V^1 0,=,GZCTKWF@  8 P* /FZSF,?@B30S'<KJ
M=EXICGGA2%BR(3@,."#R#Z]O6NQT[Q-9> ?$?B^Q\06-T9=0U"2[LWCMVD%V
MCCY8P<=0.QXY->P8&<XHP#U'2@#P7PUX?U72]<^&\=[;3*Q>^N#$4.+=7&Y5
M/IZ\]"2.U=3;W:Z%\6/'.N7-M=&RM]/MWD>.(MNPB\+Z\ _D?2O4:@O;.'4+
M"YLKE2T%Q$T4BABI*L"",CD<&@!NG7T.J:9::A;[O(NH4GCW#!VLH89'K@U\
MZ6VGVOARRU31/$>N>+K345FE"6.GR,(+Y6Z%1M(.X9SG_P"M7TA;P16MM%;P
M($AB0(B#HJ@8 _*I,"@#PS7=*GUSPQX4\!Z7I4T.H"W%W)<7A)-@F"<,ZJ!N
M/((QZ<9/$<EW.?#'AF5M*FMU\(:FD>K6,,>X_+A1,H_B&0WKRQ[<U[O10!XE
MXR\30>,] \32Z)H326<6GQ1G5GMBDLK^>A\I<C)0#+>Q'3IF]+XBM?!'Q/O+
MW6X+J&SU#2K>.WF2%G#R(.4X[D@C\LX!S7KX&.E(0#U .* /G"QBMU\!/=:S
MI>KV]N?$L\WVNVS'/8YB0J^T@Y&>#TZ=<XJU]JU'4O!7CB*VN;C6=)6"W%MJ
MD]GY<\[!U)4MC<^ 3RV<#'3.*^ANM   P.E 'B?CW^V="DTCQ-H=C,9]4TG^
MR[A4!W1NR@QDC'WAS_WSBJOB_P *'PM/X/EEDU6UTG3[)K6YOM(;;-#,V26X
M!(#$G/L3]#[M10!Y-\+[6SN/%VL:MIT_B&_M#;) -2U:7(N#D'"@J&X &#GH
M3P,BM#QG>+X:^).A^)M1M)IM(6REM'GBC9_LLA;.\@#H0<?GZ5Z3THZT >'S
MR_\ "2#XA^)M-L;B'3+G2EMHGDC93=2!>7"GTQC\NY->L^%$:/P?HB.I5UL(
M RL,$'RUX-:]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZVL 7A0BCYF+ ]1TZ^M 'LE4[C5;"UU*TTZ>ZCCO+S>;>%C\TFT9;'T%>?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S-0U&[M-6TNT@LA/!=O(
MLTQF"^2%7<#@_>R>,"HO#FK7NL6$\]]IZV,D=S)"L:SK+N53@-D=,\\>U<[X
MR _X3_P(><_:[D=?^F-97P8N(;;P?J33S1Q*VM3HI=@H+$( !GN?2@#T^BBB
M@ HHHH **** "BBB@ JM<ZA9608W5Y;P!0&8RR!<#U.3TJS7C^MZ%H.O_'E[
M77_+>)=*1X()'VB63<>.HS@$G'M[4 >N)/#) )TE1H2-PD# J1ZYJ*TU"ROT
M=[.\M[E(V*NT,JN%(['!X-?.>JW$VGZ1K?A_26#>&CXCBMT>64B%5()>)I 2
M=F0N2#G SU-;^E:/?>'_ !Q"8I?#NC-+IUP9K33KF63SD$;%7*L".&P?< XS
MB@#VN+5=.GE:*&_M9)%3S"B3*2$_O8!Z>].M-1L=0W_8KRWN?+.'\F57VGT.
M#Q7@VB>$]"3X#MJ[W$.F:E?H\;ZC*'88\_;Y9VY(5@@!P.Y]Z71)V\):S<6K
MZ''IVKW&DW,=G<Z3=^=!=,D9<,T>2<Y&0>/IZ 'NHU;36O\ [ -0M#>XS]G$
MR^9C_=SFENM4T^R61KN^MK=8\%S+,J;<],Y/'0UX+<Z)X3M/@S:>([:Y2/Q$
MJ1SQWB7!\]KG?\RXW<D'</;&>U;^BZ#I_C;XH:Y/XETP2R6VGV@$3DA=SQ@L
MV!CG.0/2@#UZ:^M+>S^US74$=MM#><\@5,'ON/&*6TO+6_MUN+.YAN8&^[)"
MX=3]".*^>8]/&I>"]&TJ/4+)KBSUF[%II^I.PCN43^#<. 1GC) .X\UW/PEN
MK.#5_$&D+I#Z3?1M'-/:Q70GMAD=8\9VYXR,GMZ8 !Z@)X3<& 2QF95W&,,-
MP'KCKBF&]M1#),;F'RHV*N_F#:A'4$]C7F7Q+U!O!GB_1O%\0Q');7%A<X7[
MQVEX@>/[W\J\XT:'4BD?P[O!,S:[>VFHRRA2O[EXQ)+UYW#:HSZH: /9O#_Q
M MM1U3Q!;:I-8V$.G:@;.WDDG"><.<?>/)^7/%=;<7UG:6GVNYNH(;;&?.DD
M"ICUR>*\;\)>#]!U_P 4?$";5-.BN6AU"2*'?TB4ES\H'0\#GVK$\+O;:S_P
M@.D^)7#Z(;"YDB2=ML4MP)I$"DY&2%"X'/7'>@#Z!M+RUO[9;BSN8;B!_NRP
MN'4_0CBIJ\K\&C2="^)?BJST>>.#08+2*:=5ES!#-W^8\+QGOV/IQZA!/%<P
M1SP2I+#(H9)$8,K ]"".HH Y/2/'5K/JVOV>KW%AIZ:=??98'EG$?FC;G^(]
M?I73W>HV-A:BZO+VWMK<XQ+-*J(<].2<5Y-HOA/0]?\ $OQ"N]4T^.ZFCO&B
MC:4']V-A)*^ASW]N*YK3[B#5= \#Z:=&?7=62RFEAMKN[$5J(Q(Z@L#]]@$Q
MC/ % 'O<6K:;/:)=PZA:26TC!$F292C,>  P."?:GWEY%:( TL(F<-Y,<D@3
MS& S@9KP/PWH<FN67Q#T9%LHGMS!=6L.GR%[>*X4.1Y9]]H4_P#UJV]"U4_$
M?6UUN92T&@Z(0<C -Y*AWD#V"G\@: /3]*UU6T&TO-;N-/LKJ6$RRJETK1@
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M+"TS-ESCH6(W'G/0'K7+:W%I_P#8OC73M(E \.+K%C]F:(YB5V!\[8WL0OL
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MM6_X1Z.QL]5ORCS2RP*Z7&T_=D!!!!&1G!ZUF_#KQZ/&C:TKE=UK?.+?9 Z
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MP(;F QN %X< \$9Q6)X/^+>B7&CZ)9:K?SOJ4Z)#-<M 1$)C_"SX STZ<<T
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M/)M&3M52QQ^ KR_1M+\:>/M,C\1S^+9]#BN27M+*RCRJ1YX+G(W$X[Y_#.*
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M>.3M5N/;%<_9C2-<U'0;*RU+QGJVH0W4+FRN9]J66,98DH0 OMCCN*^C:0*
M20!D]3ZT 4=<T[^V/#^I:9OV?;+66WW_ -W>I7/ZUY5X5^(]MX(T"+PSXHTW
M4+74=-S"OE0;TG4$[2ISSD?@<9S7L*312.Z1RHSQG#JK E3[^E.(!QD XY'M
M0!XKJ6J^([Z#0?&.O:)(=.L]7>9+.. F6&V9 $=E[D$9SZXZ9&(=3U!/'GB?
M5]?T&UNVTRS\.75M).\)07$C(^$7N3\P_P"^?I7N-(JA0 H  ["@#Q+6E^Q_
MLU:;YD ^06[M$ZXS^^!Y'O\ UJY>:XGQ#\6>%[?P_97MLVF,]Q=7,L#1"V!3
M'E_B1CCVQGFO1?%_ABW\8>')]&N;B6"*9D8R1 $C:P;O]*VXXQ%$D:Y(10HS
M[4 >!VGB*/1_A9>>!+K0KX^(,2VPM5MG=969R1(&'7KGCN..*Z3PMI5UIOQ6
MTNVN[>0RVOA2"!Y #M5U*JW..>AKUJB@#YWU_4;R^O?%%A?ZCJFEWCW4JV^A
MZ58D?:@5(5WD4?.&XSGJ.?3%^VO5T+0?A=J]]#<)96+727+K$Q\HM\HR,9ZY
M_*O><#.<<TA 88(!% 'S[=V=XL?B35(=(FO(]/\ &'V^:/8Q\Z$;^ N.0-V2
M?1L]JZ9_$$'CGXC>'=0T/3;Y[?28IY;JZE@:/&Y"!&,\$DX_/ZUZ[10!XA8V
M4B?LOSPFU=9RDC,GEG<3]I/..O0#\!7K7AU98?"FDK+&XF2QA#HPPVX(,@YZ
M'/K6K10!\QZCJ5YJNC:K:7VI:W;:H99PGA_3K$Q0+SD[]HPPX).<G@_4]WX0
MMFD\8>!Y6@8K%X7QO9#\C X//8\X_&O8:* /!O$6FZK=:EXKFMM-N[F&P\06
M=])%''N\^,(0P4?Q$94_0UMKXJLO&/Q>\(7&E6=[]GLX[L2W$UN47+0G"Y/I
MC_QX5Z]10!Q?Q9C>7X7ZXD:,[F./"J,D_O$K"\2V]SY/PS06;#RKZV,N(FS%
MA!P>RCKD'GCV->F2W$%N4$TT<9<X7>P&X^@SUJ6@#YJO-1OKN#7+/5+[6M,U
M"2XG$6AZ18F**4LN 691\X)ZYR2![UT L+V'X0^#_$VG6DKZAX?G:9XBI#-%
MYC"1<=<<#\,U[FSJ@!=@H) !)QR>@IU 'S[K'@K6;CX2Q:N;>>35+W4O[6U"
M*('S2C;@N!C.5# X[9-)I/\ 8WB'Q?X>2PU+QAKEW:W:3NM],!'9 $,2Q*G^
M[@@8SC&>E?0=(%522% )ZD#K0 M%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5RGB7QS#H6K0:19
MZ7>ZOJDL1F:ULE!:.,'&YB>F3P/_ -6>KKS36?M_A'XH7'BF33+[4-)U"Q6U
M9K)/->!U*X!7T.!^)H O?\+7T=]$MKN&QOYM1N+E[--*2+_2!,F-ZD=!C<#G
MW]>*?;_$^Q;2]9FO=+O["_TF'SY]/N%"RLAQAE[$9(^F?<5S%W)XKDU/0O&U
M]X9D\NQOKH?V?;)_I"VLJ*JR,N3EQ\Q(XZ#IU%75['6?&5QXI\1VVAWMK:RZ
M)_9]E%/'B:Z/F+)O"=1P,>_'TH ZFR^+%I<WFFBZT#5['3M2E6&TO[F(".1V
M^[T/0]C^/3IST7C/5+S5/B';ZC;ZQ;65I;YB>%U5K,(A'!SPS_>!&>GXUN^+
M='O[GP1X1M;2QFDEM;^P>6*.,DQ(BX8D#H!W]*QM5L-5CU;XE6:Z/?R'5[1'
MLYHX"T<FR+:5##^++# H UO^%FPV,NFZ#IVC:MK.I2Z;;W$>UD+,&0',C9X.
M,$G&,FM"#XG:?-H46I/IU["_]J+I4]K( )(9CUSS@@5E>#-$U2Q\?V]W=6%S
M#;CPQ:VYEDY42KLRG3@C!RO/KWK!U#PYKO\ 87B.6'2+F66+Q>VI1P!2'G@!
M'S)_>SGM[T >G7WBJTT_Q5;Z%/&ZO-9R7C7!("(B'G/?UKE8_BTK1QZG)X:U
M.+PY(^P:L^-OWMNXIU"Y[Y_"LFYCUGQIX_>Y7P_J.F:>VBW-A%/?PE"9'4\L
M!G RPQZX/TKCH_!DT.@QZ/)X,\0SZZ'$+,;AA8-S]_>#C&,'''/>@#UK7/B$
MNGZU+I6DZ)?ZW/:1B6^^R# MU(W+R?O,1R .M4_@[JMUK'@N>[NYYIG;4)]I
MF8LRJ2#C]367I\6K?#WQ/K;+X=O]3L=2A@>U>P3S=DD<>WRV).0O8$YP/7FM
MKX3:?J.G>$9UU6Q>RNIK^>8P.I!4,1Z]N#CVH S_ (I^)]9T/4_"]MID%WY=
MQJ,9D:%U47&& \C)/!;/? _(U=U+XERPZG>66D>&=0U9M/53?O"ZA;<D9*9Y
MW,.X'H?2H_BGIVH7/_",ZA8V%S>IINKQ7,\5JF^38#DD+WZ?K69IMYK?@34_
M$D?_  C&I:I!JEY)J=C-9P[LM)C,<O=,<<\]^* /0]!URQ\2:);:MILA>UN%
MRI88((.""/4$$?A7"^/-=U#1/B1X6:QM+S4&>WN5%C;R;1,Q  SV '4D],5M
M_"_P[>^&/ EE8:BI2[9GFECW ^66;(7CVQGWS65XX&JZ?\0/#6OV.B7NJ6ME
M#<)<+:)N=0X"\#N><X[XH O67Q.TU] U;4=4LKG3;G29%BN[&4;I [?<"X^]
MN.0#[9Z<T:3\0IY];M--UWPY>Z&;_/V*:X<.DK=0A('RN1_"?I7%:AX,\1>+
MM'\8:N^EM87.J36SV5C<,JN\</\ ?Q]UB/7G/'3FH_#7AA;KQ=HD]KX.UNS2
MSD\ZZN-8N7V1,!P(AGY^<<_I0![;//';6\L\SA(HD+NQ[*!DFO/=+^*KZC<:
M?._AC4(-%U&X%M:ZB75@S%MHW(.5&1CK7H%VLCV<Z0I$\K1L$67[C'' ;V]:
M\&M?#.LPZQ8#0?#>M^']:%V&O7AFQIOE@_,5))W @#Y?<CF@#<TOQMK&C^(_
M&L-MH6HZVEOJ32N4F 6"/&,#.3GY?N@=JZN]^(\9L]&.AZ/=ZM?:K;FYAM48
M1[(Q]XLQR!@\?7\,L\,Z)J5G<^.?M%H\8O[Z62U+$8E4I@$5Q3:#XD@TCPI8
M:E:ZZ-"BL#'=VVD-B83[FP) #RI&!^= '6Q_%:VC\-:YJ5_H]U:7VBRQQ7=@
M9%9@78*A#< @G/Y'VRJ_$R[CTV*XO/"6HV]S>3+%IMGYBM)=Y4L6QQM &,YS
MC=]:\]B\"Z_%X7\=V5MX>O+;^T&LI+&"6997=4E+-ELX+8.2,]<BNS^(_@Z^
MU&V\,WT-A)J::1E;JRMYC&\J$*"4/7(*_6@"?4?'4^H^&O$^EZAI=UH.MV^E
M3W$4,LH8R)L;YXW7&<'KCI^!Q1\+_$F[L]"\,Q:EX=OXM,N([>R75990?,EV
M!<[ "V"RG!)Y'-9EIX:DOU\27.E>"[S3()-(G@MI-1FD:ZED="-BH7(5<@]<
M]<YYP-[7O#VLW/PP\(6%I9,U_8RZ>\T+?\L]B8;/L#UQ0!?U/XDW*:GJ%MH'
MAF\UR#36*7ES!*$5''WD4$$N1CM6?J/BB'7/$WPZU73;J:.PO6O&=2Q7(6,
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M*/B'XB33K8S>";I=3OYBEC:K<!E= H8N[XP@&1P>O/H:J3?$/6+W2?%.ES:
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M9Y;(V-[9W+VMU;%]^QUZX; R.:P?#?@Z^T3Q_;7+PB2RM/#\%@MUN^](I 8
M9]L\^U7/ASH.I:'-XH.H6YA%WK$T\!W [XST88[4 :_BWQ'>>'[2U&G:-<ZM
M?W<OE0V\)V@'&2SM@A5%<M%\0=;N_P"W]%NO#HL=?L=/-W' E\KJZ\#(8#@C
M<#[^U3?%?1M;U>UTD:=;7=[ID4['4;&TN!#).IV[<''('S9'O^(YKP9X'U73
MO%6J:E%X9_L;3;O1I;>"W-V)G$A*8WDG(9L$^@Z4 <9I+Z]H^@>&=0T_07CD
MU35X'EO?[2RVINKL4C=2?D!);)/' )]_4M6^)]_#JES8:1H,%Y)8JHO6FU&.
M!8Y2,F-=WWR.1D>E95WX8\1V7PW\%Q0Z4;B^T34(KRYLED7>P1F.%8$CO[]?
M:LC5/!-_8>(=4U.Z\!)XCM]6G6[B OO*DM';+/&V.HW,1QQQUYP #JKKXN*^
M@:%J.D:+)>SZM</:+:M.$:.5<#:3@@Y)'IP:[S0[O4+[1[>YU73AI]ZX/F6H
ME$FSD@?,.#D8/XUYSIG@O5X&\&-=:/8P"TU"XNKJ&SQY=N&3Y,Y)W,"!R.X'
MU/JU 'E4FO:W;?'*]2:U/]DVVF;I-UW\D4&0QGV]"<C&W&:B;XS7 A.K#P_&
MWA\2[?/&H1_:"F[;O\C[W7G'IW[UH>(- UN3XDW%S!I[3Z3K&D-IDUS'* ;4
MG)WD9!('MUSUSQ7$6W@76[/3%T'_ (5WID^I(=JZU+<AH63=]]ESG..W7OCM
M0!W]]\0]5D\97'AWP_X;_M-K>*&=YVNQ$OENJG."/]I>_K65+\6]9:TU34+/
MP@T^F:3=/!=W/VU1C:V/E7;DG!!/IFMKP[X7U'2_B?K6JR6T<>FSZ?;P0/&P
M"ED5%*A<Y &T]?:LRS\)ZW'\,/%FD/9%;^^O+J6VB,B?O%<@J<YP,X[D4 7M
M+^(VJ76O:/;:EX8ET_3M:+?8+E[E6=L+N!= ,KD8_/O7.Z5\0[3P_H\DFD^'
M;B9K[Q%<6OV<WA=Y)"%.X$C@L64;>G4YKJ]9\/:G<ZQX%GAMM\6ER,;M@ZCR
MP8@N>3SR.V:XVP^'?B.U712]I&3!XK?490)5^2WR@#'GG/EDX'/(]\ '7Z+X
M^U)]<N]&\1^'9=+O8K$WT2PS"X$L8."!M'WO0?7IWQI_BKKVF1V>J:SX1^P:
M'=2B-99;Q?/52?O&/&[ISC'X\UI^*O#GB.^\=MJFBE(!_8,UI'=,X&R8N2H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?[4WD[\L#[G@=L"LG1O#EEXN^'FH>.=6U:[_ +?Q<31W2W#*+(QEMJ* < 8
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MR LDA_B/3\C]  >BZ#\0I]0URRTO6/#MWHTFHQ-+8/-*KK, ,D'&-K8YP?\
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MOZDBK)%&?W=K$.D2^N,#)]N_).'XOM8/$?Q<T3PYK.7T86#W:VQE*K/-EAR
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MEVA#L8X)Y.6Y[XH ]IHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7]5_M*^T[-RV/.,4C1B?'3>%.&_G6POA[28[ZPO8[&*.?3XFAM63*B)&&"H
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MNGVEA>Z3;2VEF1]GBVX$6/3'0<=.]5M5\ ^%=<U+^T-2T2UGN^ID((+?[P!
M;\<UT=% &>VA:4]S87)T^W\[3U*VC",#R 1@A?08JIKOA#P_XF*-K.E6]VZ#
M:LC@AP.N PP<>V:VZ* ,M/#6B1Z(VBII5HNF,,-:B(;#[D=SWSUK/TKX?^%-
M$NXKO3M#M8+F)R\<N"S*2,'!))Z=NU=)10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU?3X+R)&W(LJYVGU!ZB@#P3Q*;"+2_B3;^'R#H0-DX$/,(G,J;]AZ>O XX]
M*]XT#P]I/AS3UM=)LH;:)@I<QJ 9"!C+'N::GA;08]#?1$TFT73'P7MA$-C'
M(.2.YR <]>*U@   !@#H* /%+71]-U+QC\4I[ZQ@N9;:!?):5 WEYB?)&>A^
M4<^U9%KI&G6WPB\%ZE!90QWTFM0E[E4Q(W[UQRW7& ./:O=8=&TVWN+VXBL8
M$EOL?:G"#,V!@;O7@G\Z:-!TE=.M].&FVOV*V97A@\H;(V!R"!V(.3F@#RKP
M^?"=QJ_C<^,WL?[2_M&9&^WE586N (_+SSTX^7G[M<_H-BFKV7PQL]3A::R>
M\OC#'./O1*04#>HRO3T]J]IU;P;X<UV^2]U31K2[N4 422)DD#H#ZCZUH2:3
MITLUG,]E;F2QS]E;RQF'(P=OIQQQ0!XAK%A,/B[K-HEWH&F116L*V2:M;(8C
M%M!(B!^4?-N)[]?>NS^#,2P^'-4CAU&*]MAJ4OEM#"T<2G"[A'GJN>1BNRUK
MPOH?B,1C6-+MKPQ?<:5/F7V!ZX]JOV5E:Z=9Q6EE;Q6]M$,)%$H55'L!0!X?
MXR@AF^(7B*[L=1T3[2MO''=V&OPA%=1'UA<\G@#D%>O7I3-$.D>)?%OP[\W2
MC!9_V=<>59RDR)NC+XY;)*Y4D9] *]@U?PEX>UZZCNM5T>TNYXP LDL8+8'(
M!/<<G@\5>_LG3OM5K=?8+87%HACMY?*7=$I&"%..!CL* /$?$K:9X?U7XCVI
MT\R6,RV&+6)C%'YC#=EBN,+GDXZ].]5(#>VOQ+\%1WE]X<)24I'!H0!\E"H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO.OB[
MJUSHEAX;O;87+F/7(&>"W8AIU 8F/CKG&,4 >BT5QGAOQZ^K^('T+5M#NM%U
M(P?:(8KAPPF3."00!R/3Z^E=G0 4444 %%%% !1110 4444 %%<K\1?$C>%_
M!5]>P9-Y*!;VJCJ97X&/<#+?A7)?"Y+OPAXAU#P1J=T97:WBU"U9LC.Y0)5&
M?1OY$T >KT5Y?<?%N]/]JSZ?X1N[NPTB>2*^N?M*H$"DC*C&6X&2.PZUTVD>
M.;35O$R:-]EE@^T:?%J-E-(PQ<1. 3@?PD$XP?0T =517/\ A/Q5'XMM+Z\M
MK5XK6"[DMH96<,)PO\8QT!KB+;XAV?A_2]]AH^H7CW^NW-JL+W6]VE!'()'0
MD@!>W/- 'J]%><0_%"]A;6;+5O"UQ9:MIEG]N-HMRLHDA!4$AP,<!L]^A]*V
M[WQW:0P^&'M;:2Y;Q!-&L"!@ICC(!9S_ +H(XH ZRBO I?$FH0P>$8_#&F78
MM)M7N&-L]_S<2+)]QFP"%Y+<\<\YQ7=:S\1-;L[K4FTSP=<7FG::66YO)[I;
M<$H,OL5AEP/4=: /0Z*\FO\ QIJVI^._!,^DV$DFF7]L\JQFZ5!(6 #EAZQC
M/7KD@58L?'%EH6BSQZ5H]S<ZC?:W=V]M8_:=QFE#Y=]Q'RKR.QQG\: /4:*\
MZ7XG7=E%K%OKWAU],U>PLFO8K1KI9%N(Q_==1CK[']*CLOBAJ;W6C3:EX1N;
M#1]8F2WM+TW2.Q=_N90#(!]^W(S0!Z317%_%?4=0TOX<ZI<:=%(TI58WDCD*
MM"C'!<8Y..!^.>@K+C\?ZW'%I6CV/AB34?$#V:W-U;"\54@CZ*S2D8+-P<>_
M6@#TB@G R>E<WX.\6KXIM;Q9K&73]1L)S;WEG(P8QOCLPZ@\X/L:\X\3ZQXA
MD\3^/K22RQ81:,5\P70(A0(Y1U7')<DY';U.!D ]KHKR#P]\1]8TC0?#1U3P
MJ]OH-PEO8Q:A]K5F9MNT/Y>,@':3SV[FM74/B=?OJFIP:#HEK?6>F2&.>>?4
M4@,KJ/F6-3R2,]>AP>Y% 'I5%97AOQ!9^*/#]IK-CN$%RI(5_O(02"I]P0:\
M\C^+'B&?3KK6H/!3MHUC*\5W*;Q0X*G!*J0"<#&>#UZ\&@#UBD9U3&Y@-QP,
MGJ?2N2T?QW;ZWXS;0[6US;G2X]2CN_,^^K%<+MQQPXYSVKA/''B^?5X]-N+/
M2V>XTCQ>+**W$O-RT0..<?+N)QWQ0![02 "20 .I-"L&4,I!4C((Z&O,]0\8
MZI=:9XD\.^(M$&F:C_8MS=6[13B6*:/8P.#C@C(X]CTXSB^'O$VCZ#<>'Y;[
M3Y3<6WA)+EKQ)S_JP3^[$?0G(X.>] 'L]%<!HOC7Q1>7FES:CX1>#2-4<"">
M";S9(01E&E4#@'CGC'?TJM\7[_5K+3_#XTZ%9$DUBW#CSBAD<$LD9&/NDC)/
M8J.* /2**\^NO'7B&\UC4-.\.>'(;YM+4"^EDNMB&7:"8HSCYF!R,G'3H.,]
M/X4\26_BSPY;:Q;1/"LVY6A<@M&RD@@X]Q^6* -JBO+(?BGJ]]J-R^F^'H;O
M3[:]-I)#%=AKT@'!D$0[>WL>>XZWP]XL.N^*/$FC_9!"-&EBC$N_/F[PW.,<
M8*G\Z .D+HK*K,H9ON@GD_2G5XCJ'C/5-<UCP%KNGZ.D^H//J4$=H)B%/"Q[
MBV.  =Q^AKI6^)U]I6G>(4U[0A!JVC11S>1!-O2='8*K!L< $C/7^E 'I-%>
M>^&_'^JW\SOJ^E6BZ:+1KHZAIUS]HBB"@DK)CE6P.G^1!8>/_%5Y:V>MKX0,
MF@W<P2,P3F2Y6,G D* =._X_C0!Z0S!5+,0% R23P!31+&S!5D4L5W  \D>O
MTKS"3QIK6OV/BA9?#]B=!TTWEI=32W;*9=BM@  <9&T'G^+@US^D:OJG_"?Z
M3/X9T2&9[KPO H@FN2L=M'OSDM@D@8 ]>: /<J*\RG^++67ABYGOM)$&OV]\
M-.:P:=1'YQY#&0\!, G/MUQS5KPW\1KB_P#%-OH&K0:6)KN)I+:?3+Y;B/*C
M+(^.5.!GT- '>W-W;64!GNKB*"$<&25PJC\34D4L<T22Q.LD;J&1U.0P/0@]
MQ7EOQ<M]4U'5O"NEP6ME<V5Q?@^5<RLJR2J#\KA1]S;GD9/7CUL6WC'Q'>"]
MC\)>&[&;2-%;[*_F3E#,\:X:.  =!Q@GJ/<X !Z917EUW\4]1U*70+;PMI$-
MS<:W;221?:YMHA=&(8-CJ!M;N,\?2NA\;RZN/A9JTGE6T>H'3W-P@D8H@V_O
M-IQDD#=CWQ0!UC7$*W"6[31B9U++&6&Y@.I ZD#(J2O!K*Y\1PZS\/38V5C<
M:F^A,D"M*PB6(H-KR'&<A<9 [\ UU;_%&]T?0]8_M_3+==9TR[BLO+MY\0SO
M(I9&#-RJX!)ST ^N #TZBO--#^(U^/$UAHVNOH-Q_:186]QHUYYPB88(213R
M"<]>G]-CX@^,KGPI#ID-G'9BYU&8PI<7SLEO!@9W.1SW]N] '9T5YG_PLO4=
M*\':EJFMZ;9M=6MPEM;26=QFVO6?HR.<X &2<] /7.&:-\2[V'Q';:5X@FT"
M>.\61XKG1[PR+ 47<4E![D=", G\< 'I]%>9:;XT\;ZG:6_B*V\/64WA^YF"
M16L;R&]$>_;YAXVXX)Q_3FM_0O%EYJFF^)[N:UAC&DWUU:P[6/[P1#@M[_XT
M ==4275O(90D\3&%MLN'!V'&<'T//>O*Q\2/%.JOX<L=#TO36U#5].-VS7#.
M(XV5F!Z'.,(<>[#TKE_&VIWEQX*\81I86-C-'J\$>H-;R.?..T9()Z_.!V''
M;- 'OHGA:X:W$L9F50S1AAN /0D=<<'\JDKRJ]\8IX6\2:U>ZMI5F;^TT6V>
M6:U=\RNS[1&"W\.6'.,\<YXJII/Q9U.+6=,BUF;P[=6>HRI"%TFY9YK5GZ>8
M&."!T)'^ (![!17C=G\5O$NI:K*]E8:,UM%=F!M)EN#'J!4'&X;B%)SV&3[=
MZ]+\5^(8?"GAB^UJ>,RK;("(PV-[$@*N>V210!LU2.L:8-5&E'4;3^T2NX6O
MG+YI&,YV9STYKSH>-/&V@MI>I^*=.TD:+J4J1?Z(["6T+CY-^XX/?.,]#R.
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M#QO5=#\4>.;K6-<NM#ETQ8M'EL;"REE4R32,22QZ;?3G';WKHM?\.ZK>>%O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ2"3D'!(SUY/>M_7/#ME\/\ 5O"FH>'+R[2ZO=0BL[B-[AI1>1M]YB#D>G3
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M'^UUG^TA5)#A<D[@>^/7IS0![<2 "20 .I-96O:]%HWAB_UN)%NX[2!Y@B2
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M,T<XQ#L4-G !SG/3(K=>\M8[E;9[F%9W&5B+@,WT'6O'M5\+^'/"?Q)\$R:
MB0O<&;=&)BZOB/Y&Y/5BV,CKQ7#V&F:MXB\+ZEXDN=/TZ6Z,LDDVL7&HO%-;
M.#QA0<+CC QSQ0!]-S75O;_ZZ>*/C/SN!Q^-1S:C8V\T4,UY;QRS#,2/*JLX
M]@3S^%>*KHEIXT\?>%K7Q).+U'\,)/(8Y647#AWP=PP>^[\*R?$7AS_B<>)K
MI=.M?$&F6C['E@OS#<Z6B#A%#<?*!@?*P.T^] 'T.98Q*(BZ^81N"9Y(]<4Z
MN3\.6_A_5QH/B*(RR:D=,$=O)=2GSVAXW%ER QR>6QU/N*ZR@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KG_%WA.T\7:9%;3SS6MQ;RB>UNH#B2"4=&
M'^'\JZ"B@#A-,^'U]#=WVKZIXENKS7KFS:SCO4B6-;9#W1!WSS78Z;:R6.F6
MMI-=2W<L,2QO<2_?E(&"Q]SUJU10 4444 %%%% !1110 4444 17,"W-K+;N
M2$E0HQ'7!&*P?"'A&#PCX670H;J2X0-(QE=0I)8^G:NCHH XW_A7MK_PK/\
MX0DW\WV?;M^T[!O_ -;YG3IUXJ#5OAN+C7)=8T7Q!J&BWEQ&L=T;;#)-M& 2
MIZ'%=S10!A^%/"]EX1T4:;9232[I&FFFF;<\LC8RQ_(?E6)KGPZ&I>(+G6=+
MU[4-&N;V-8[T6I&)P!@'GH<<9_\ KUV]% '":=\+].TW3] LXKZY*Z/?M>HQ
M5<S,23AOI\HR/3WXU]*\&6&G:5K>FS.UW:ZO>3W4Z2#&/- !48[ #KUKI**
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M:K'91K>V]J+.*1<@1P@Y"@=!^58>M?#'PCX@UC^U=0TH/=,09"DC()".[!2
M3[]^]=?10!E?\(YI(UNUUA;-%OK6V^RP.I("1?W0HX[GM6K110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 (1^= !  )S[TM% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!@ZEJDMMXPT33EU&VABNHYV>T>)C)/M4$%& PN.ISC/O6]7 >(_^2R>"?^O>
M^_\ 1==9H?B#3?$=I+=:7<>?#%,T#ML9<.N,C! ]10!IT444 %%%% !1110
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MA;>'-.AU6;SM02W07$A.=SXYK2H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *1E5U*L RD8((R"*6B@".WMX;6!(+>&.&&,;4CC4*JCT ' J
M2BB@ HHHH JWVF6&IQK'?V-M=HIW*MQ$L@!]0"*F@@AM8$@MXHX84&U(XU"J
MH] !TJ2B@ HHHH **** "BBB@ HHHH **** &30Q7$1BFB22,]5=00?P-$,,
M5O$(H8DCC'144 #\!3Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK)N]
M8GMM=BTY-*O)HGMGG-W&N8U*](R>FX]AFJ.G^*+N^CT5Y/#FJ6QU(RB598L&
MSV=#+Z!NU '24444 %%%% !1110 4444 %%%,>:*)E621$+'"AF S]* 'T4F
MX!@I(R>0/6L3Q;XDC\*^&+_6FM_M7V14)@63:6W,%'.#CKZ4 ;E%5K*\2\MH
MI!M61XU=HMX8ID9P<54TG5+K4+G4HKC3);-+2Y,,4DCAA<* #O '0<]#0!J4
M5'%/%,"8I4D Z[&!Q2&Y@6<0&:,3$9$9<;C^% $M%85CXIL[_P 6ZGX>B1O/
MT^*.220L,,7!. .O QGZUK7UW%I]A<7DV?*@C:5\=<*,G'Y4 3T5D>'O$-KX
M@\-6FMQX@M[B/S")''[OG!!/2M."X@NH5FMYHYHFZ/&P93^(H DHK,\0ZY;>
M&] O=8NU9H;6/>RIC<W8 9[DD5BKXYMW\1:-IRPQBVU'3WOC<M,,1  '!XQZ
MY.: .MHJ*WNK>[@$]M/%-$W22-PRG\13+>_L[MY$MKN"9XSAUBD#%3[XZ4 6
M***\KTWXD^,-6T-M<L?!4,^FJS_,-0 <JA^8@%?8_E0!ZI16+X:\367B;P]I
M^KVY,,=Z#Y<4I ;<I(9??!4]/2M?S8][)YB[U&YESR!ZG\J 'T56M=1L;YG6
MTO+>X:/[XBE5ROUP>*S]#UM[[0[:]U2.VT^XE#EH1=+*H"L1D..#Q@GTS0!L
MT5!:WMK?1&6SN8;B,':7AD#C/ID4RWU/3[N=X+:^MIIDSNCCE5F7'J <B@"U
M151]4T^.\%F]_:K=$@"!IE#DGI\N<T7>J:?I[*M[?6MLSC*B:94)'MDT 6Z*
M0$, 000>017+>,?&+>&Y+"PL-.?4]8U%REM:(X7('5F/91Z_X4 =517GD'C'
MQ?HVJZ=;>+?#]HEIJ,RP1W6G2,XA=N@<'/?OD=#UQ7:7.MZ39WT=E=:G907<
MO^K@EG57;Z*3DT 7Z*IWNK:;I@)O]0M;4!=V9YE3C.,\GIDXJ&Y\0Z)9A?M6
ML:?!N(4>;<HN21D#D]P0: -*BJ]Q?V=I9F\N;J"&U"[C-)(%0#UW'C%16VKZ
M9>V+7UKJ-I/:)G=/%,K1KCKE@<"@"[16<FOZ-+'=21ZM8/':'%RRW"$0G_;.
M?E_&DM?$.C7UG<7=EJUC<V]N"9I8;E'6/C/S$' _&@#2HKAM"\=W/B70M"U/
M3[6P3[;>M!=P37@#PH&8?+TW.0H;;CI^8ZBY\0:+9WRV-UJ]A!=N0%@EN460
MD],*3F@#1HJC?:UI6EDC4-3L[0A/,(GG5/ESC=R>F2!GUI$UO29-,;4TU2R:
MP7[UT)U,0^KYQ^M %^BJ6FZQIFLQ/+I>HVE]'&=KM;3+(%/H2I.*NT %%>;:
M!\3)]6^)%YH<UK''I4DDMOI]R <RRPX\P$DX.<Y&!Z>M=SJVO:3H,*3:MJ5K
M9(YVH9Y0NX^V>M &A17(^(/B#H^ARZ)B\LIH-3N GGBZ4)'%@YER,Y7( ST]
MZZU65U#*05(R"#P10 M%8]_XL\/:7J"V%_K=A;7;?\L9;A58<9&<GC/;/6N2
M\>>.[S2/$.D:!HE]H\%W=[WGGU&3]W"H&5#8/&[G'KQZT >BT4R(2"%!*5,F
MT;RHP">^/:O-O'?Q*O?#'BVRTZRM8I[&!(YM6E923#&\@08.1@\YYSU% 'IE
M%<?XT\57GAZ]\,Q62021ZIJ<=K,7!/[MB!E2#UY]ZS?#7Q/TRZGU6UU_4]/L
M;JWU.:U@1GV;HU("DY/Z\"@#T*BL[5=?TC0[5+G5-2M;2%_N--(%W_[OK^%1
MKXFT)]&_MA=7LCINX*;KSE\L$D#!;H#DCK0!JT5Y[K?Q:T"QO]'@T_5-/NH;
MJ[\J[E\W(@CQ][CW(Y/'6NDU/QKX9T6]-GJ6MV5M<A0QBDD&X ],^E &]14<
M$\-S;QSV\J2PR*'22-@RLIY!!'45)0 45SM[X\\*Z=JCZ9>:]8P7: ET>4 )
MCL6Z ^Q.:KR^*X(]?CD_MG2!H9TPWC9D)F/SX$@[;,<>N: .JHK/N]<TNQL(
M+ZZO[>*TN&189F<;9"WW0I[Y[8K-U+QYX6T?51IFH:Y:6]X2 8W?[A_VCT7\
M2* .BHI$=9$5T8,K#(8'((]:Q=>\8>'_  P8UUG58+1Y!E(V)9R/7:H)QP><
M8H VZ*HZ3K&G:]IT=_I=W%=6LG"R1GC/<'N#[&C5M8T[0=/DO]4O(K6UC^])
M(>_H!U)]A0!>HKGM+\<^%]:#?V=K5K.RQ/,R*Q#*B_>8J>0![U<N/$FCVOA]
M->FOHTTMT1UN2#M(8@*>F>210!JT5SNN^._#'AJ]6SU?6(;:Y*[_ "BK.P'8
MD*#C\:DO_&OAO3-+M-2N]7MX[*\!-O-RRR8&3C /^>* -ZBN3O/B7X0L-+M-
M0N-9B6&[0R0 *Q=U!()V@9 R",G'0U='C;PTVAIK0UBV.FO*(1<9. YZ*>,J
M?KC'6@#?HKF-.^(?A/5GNDL=:@F:UA:>8!6&(U^\PR.<>V:Q?!/Q.T_7/!]U
MK6M7MK9R6DS+<J 56)68^6!G.XD#MR3VH ]!HKG_  ]XV\/>*9)HM(U%)YH1
MEXF5D<+G ;# 9'N/4>M5(OB5X/FUDZ2FNVWVL/Y8SD(6Y& ^-O;U[B@#JZ**
MYGQ%X_\ #7A6Y2UU74ECN6P?)12[JI_B8*#@?6@#IJ*P;KQKX;L]'M-6N-7M
MTT^\<)!/DE68@G' XZ'.<8QS5?P]\0/#/BF_FL=)U-)KF+GRV4H7'JN0-P^E
M '34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YOXHG
MEC^*U@J2NJ_V#=G 8@9YY_0?E7'^#+F?^SOA4/.DP]SJ(8;C\P!; /K7L%WX
M9TV^U^/6KB-VNX[1[1</A?+8\\#OR?SK/TWP!H&EIHBV\$N=%,K6C/*209,E
MMWKR: .HHK.T;1++0K:>"Q601S7$EP^]RQWN<GD]JT: "BBB@ HHHH ****
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M-TB.*[7.R1I'DV9S]T,2%ZGIB@#J*^?O!/AZ75/AXSGX@7&DP2&<-9K(JI&
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MCY<#=@\<KUYKTS4+^UTO3[B_O91%:V\9DED()VJ!DG Y/X5P7AZ-1\;/%)=
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M9K6&47;6WDF=1O)?9V'].:U;:X/B&Z\(QZ1>;[D^&+BT$N,E9UB"E3GOG^=
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M0O'\6K>)3H%[HNHZ3?- ;B!;Q5'FH#VP3@^WL>:\WB\(^(2FBZM<:5/'/?\
MBM=4FMHP7-K"S _.,?+CG/MC..E=WJVDZA/\:] U2.TE:P@TZ9);@+\B,=X
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M$UK;W-J]K/!%+;NNQHI$#(R^A!X(J"PTC3=+@>#3]/M+2%SEX[>%8U8],D
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M_N%'ER,WW,X^[G_/'-077Q9*WVKVFG^%]4U!M)GEBNWA(V(J'&[/OAN.N%H
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M).:]2J.>WANH'@N(HYHG&&CD4,K#W!ZT -M)Q=6<%P%VB6-7VYSC(SBIJ**
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM:Q9:!H]SJNH2&.TMEW2,%+'K@8 ]20*\ETO5-2^)&J:#I%_JM]IMN-&^WW
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M8[*JY"!O<G]!7,:C8+X(\2:KH.AW5T-,N_#EU<O;27#.()%5@'3)R#P!_D4
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M[TZSN)K7[1(JW2-&%& 65LX*\CD$CD<U-KT<47@[4XX$1(4T^58U0 *%$9P
M!VQ7CVA:/8:WJ_PVM-2MDN;8:1-(89!E6*Y(R.XSSCVH ]MTW5=/UBU^U:9?
M6UY!G;YEO*'4'TR._(XIU_J-EI=H]WJ%W#:VZ?>EF<(H_$UYSX)MK'2OB]XQ
MTO38TMK58+>1;:,;45MHW%0.!]X?G2?%N>U?4O#&GOI\%[>37+M;I?3>79Y
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M:;I-S8ZMJM[/JMS=QWLB-%;R8V6P5<83Z]3]![DZM%% !1110 4444 %%%%
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MIK6N6]A#I>C-+]@6%B\DY8X5GSTP #[$4 ==H.D0Z#H%AI-N!Y=I L0(&-Q
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MXK=] LQITE[C9M\M=X!;C.[=^OO7/RV]E?Z1-'91%O#MUXSMTM$P1&R%7#[
M>B\BO?;_ $'2-5MXK?4-+LKJ&'B))H%<1_[H(X_"I?[+T_[-!;?8+7[/;NKP
MQ>2NV-E^Z5&, CL1TH \_O+.STWXYZ EE!;6BRZ5,KK%&$\S&<#C'0 >O KO
MM)UC3]<L%OM+NX[JU8E1)&<C(."*F>RM7O$O'MH6NHT*).8P753U ;J ?2L[
MPQX=M/"NA1:59L[QHSNSOC<[,Q8DX '?\@* .1^,JM_PBVFR3*6TR/5;=]0
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M@D\\$_7-?3MK86=BK+:6D%N&.6$,83/UQ2+IUDEVUVMG;K<MUF$2AS_P+&:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3E0<GMWYSS7HU% %33M.MM+TRUT^UC"V]M&L4:GG  P*M8'/'7K2T4 ( !T
M%&T YP,^M+10 4444 ! /4=**** "BBB@ HHHH **** "BBB@#!U[PK:Z_J^
MAZC//+&^DW!N(T3&')QP?Q K>HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ+SD,S1
M"13(H!*@C('TJ4=* "BBB@ HHHH **** "BBB@ HJM/J%E;2>7/>6\3XSMDE
M53CZ$TV/5-/FD$<5]:NYZ*LRDG\,T 6Z*;'+'-&LD3JZ,,AE.0?QIU !1110
M 45$;JW$[P&>+SD3>T>\;E7U([#WI\<B2QK)&ZNC#*LIR"/8T .HHHH ***1
M65U#*0RD9!!R"* %HHHH **** "BBB@ HHHH ***CGN(;6!Y[B:.&&,;GDD8
M*JCU)/ H DHIL<D<T22Q.KQNH974Y# ]"#W%.H **** "BBB@ HHJ*YN8+.V
MEN;F5(8(E+R22-A54<DD]A0!+14=O<0W5M%<6\BRPRH'CD0Y5E(R"#W!%)<7
M,%I T]S-'#"GWI)'"J.W)- $M%5UO[-M0;3UNH3>)&)6@#C>$)P&(ZXSWJQ0
M 4444 %%%17%Q#:6TMS<RI%!"ADDD<X5% R23V % $M%1V]Q#=VT5S;RI+!*
M@>.1&RK*1D$'N"*AO]1LM*M&N]0NX;6W4A3+,X102<#D^] %JBBB@ HHHH *
M*BCN()998HYHWDB($B*P)0D9 ([<5+0 445F7?B+1K&TN+NYU.UC@MIA!._F
M B.0X&UL=#R.* -.B@$$ @Y!HH **** "BBB@ HHHH **** "BBB@ HHI"0
M22 !U)H 6BN?\/>--$\4WM_:Z1</<-8L%ED\LA#DD?*3U^Z:Z"@ HHHH ***
MSM0US3]+O]/L;N8I<:A(8K90A.]@,D9 P./6@#1HHJK8ZE9:D)S97,<XMYF@
ME,9R%D7&5^HR* +5%%% !16?HNM6'B'2H=3TR?SK2;.Q]I7."0>" 1R#6A0
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MK>%+A9"CL1M#$=>A)/3D5;\.>"M:TS4? LUS!&$TBRN8KLK*#L9P=H'KU[4
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MBTN"ZTJ6QM=,CF$B^8ZD>8Y!(SV^A]N<F'PGXR32?"VJPZ?9P:YX<#6BVCW
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M+BV O+5&6.9&E&U@& *GA@:ZVY^'>N:5-HFK:#<:=/J-EIL6GW=M>H3#<*@
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M1V4+!KG9CYG;'7 .![F@#*TK7-7\'7?Q"UVYO+:YAMKWR_LXBV&:X8@(V<\
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M;NR?Q)\5=+MK>W*:1X6B+R/C"M.ZC8B^NT!3D>A'I0!Z/1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEVA+6D<ZAMP8CA2=W..E;VH:WI6D%!J6IV=F9/N"XG6/=VXR>:\(B\/Z%9?
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M4T)L7G&1'+M+#'IRJ<T >E2^(M$AU(:;+J]BE\>ENUPH?/IMSG-2ZIK6EZ)
MLVJ:A:V4;'"M<2A Q]!GK7S/9Z?)>>"-0N;Z_P#"=O)),[7<E\DO]HQR[SV
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M?3?"VIWUMI4SQWUQN5$B"MC(Z[NYQQ@<UTUEXWT_4=9T;3[:&9AJM@;Z&4X
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M:S;6=G$W@N^&L7\KK:6)G7YHU4'S&8#Y?O 8(]>: /0Z8D,4;NZ1(KO]YE4
MM]?6O*]<\<W6M>"?%^F7FF3Z-K6FVBF:(3!QA\8*NOM_/OS7=^#':3P+X?=V
M+.VFVQ9F.23Y2\F@#<HKS_7OB+J%EXDU+0-%\,SZI>V$232,)U1/+*AB>1G/
M( '?GTK)7XS22V-MK2>&+M?#QD2"XOI)E!CD/4*O\2@]^,^U 'JU%</K7CO4
M4U^ZT3PQH#:S=V,:R7C-<+"D6X9503]YB.<?S[59/BQ82>&["]L=/GN-5OKD
MV<6F%PK"=<;U9SP -R\]\CIV /05147:BA1UP!BEKS>W^(^J3C5M)O= %CX@
M@LGNK6 7:O'<*,@XD' (P>/8],5S'AK7;Z[\'^!9=9@O7>37!%;W(OOFG!+_
M #N""2H)*[21G;UQ0![?17EC_%77)TUBYTWP<UU8Z//+'>7!O54!4/)4%<D[
M1DCG%:-Y\2Y[N72;/PMH;ZO?W]F+UXFG6)8(CQ\S'C.>/_UT >@A0HPH &<\
M4M<?X'\;S>+;G6+2ZTA]-N=+E2&:-YA(2YW9' '0J?7-=A0 45X_JNO:[8_'
M#4HM$T4ZK/\ V5'%Y/V@1*JY#ER3QWQ^-;\/Q0BN= TO4(]-9;BYUF/2+JUD
MEP;:1LY.<?-C ],Y]J /0:*X_P 1>,;O2_%=EX=L-,2[NKRRFN8V>?RQN16*
MKT/7:>?I6/\ !35-7U7P09=4WRJ)W\FZDG\QYLL2V1U7!]?6@#TBBO,_C'J^
MLZ3I^A/IL),+:G$9'%QY>]QDI$1_=;!)/0;16!!K?B>S^,?B,:9H(U"]ELK5
MIK4W@CC@Q%&3AB,'EL#UYH ]KHKS8?%J%?!-MK,VENFIW%XUA'IYE _? XP7
M(&%'&21QG%2Z!\1-2D\26FA^)=(MK">_W_8Y;2\2=&*\E6VDX/OW]* /1***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \N\3:A;^%?C
M)8>(-<9DTF?2FLX+GRBRP2A]Q!P"1D$\_P"UZ UR:ZMIVN#XK:EI*;;*>Q@,
M9\O9OPC MCW()_&O>IH8KB)HIHDDC88*.H(/X&@0Q@$"-,$8(VCD4 >5>"X4
M?XF6DKH"Z>%+38Q[9*@XKBQ>#PWJ7BO3]<\6:CHDTM_//]EAL!*MXC]&5B.K
M#CD@=/>OHH(H((4 @8! [>E-DMX)G5Y88W9?NEE!(^E 'A=DEMX4'@#Q!<VN
MH)X?MX[I&>[0/);F4L4=@@/!SQCL.QXJSXOU^S\7^"_&UUH6B 6:K:C^U%AV
M->,LJELY )"@=^@^M>W,JNI5E#*>H(R#34BCCB$21JL8& BC  ],4 >.R>*M
M'TSXF6GC&_+MH.I:2+>SU 1LZQ2*WS*0!E3P1TSSZ$UA:O-#KWAWXF^([&!A
MI%ZUFMJ[QE?,>,J'< ^YSGWKW\PQF,1F-"@Z+M&/RI?+39LV+LZ;<<4 >7_$
MI-,AT'PU+J!U2P2!AY6J:>/^/$[ /F YP?;GC\"?"C5[[4=7UR+[9'K&G)Y?
MEZU]D,$EP^,;&R 6*CC)Y'T->HLJNI5@&!Z@C-(B*B[44*OH!@4 <%\7]/O+
MWPA;SVT#W,5C?PW5U;HNXR0KG<,=\9!^@KG=4\4:7X_\<>#X?#'FW,MA=_:K
MJX\ET$$0 W*21WQCTS@9YKV&F)%''G9&JYZ[1C- 'G7PK$BZIXX#!@G]OSE<
M],Y.<?I^E6OC*CM\-;YD1W"30.VU2<*)%)/TKO0 ,X &>300&!! (/!!H \M
MT/4;+7OC8-8T_=<64^@!H;@*0H_>X.<CKP17#>)=,NKAO$UW;1WBVMEXI2XN
M?LJ$2(FU@95&.H))S[YZ5]%JJHH50 !T %+@?G0!X;X2_L;6/B1H]UI.L^)/
M$+6D<CR7=[)^[M04("G<F3DGH".?6O8?$&EC6_#NHZ6SE!=V[P[AVW*1FKZ1
MI&"(T50>RC%.H \>\,?$ZP\'>&X/#WBFSOK+5=-4V_EI;EEF"\*4.<'(QST/
M4<52U35?$.IVWAKQMK>E21Z;8ZM),;6.-O,AMF"A)&'4D%6.<=QV->V-&CD%
MD5BIR,C.*=0!XIJ.K0>._%=[K.@6\SZ=IV@W<4]V\+)YSNC!47C)QG.#[TSQ
M.$M/V==!+P HGV5WB(QNYR0?KS^=>VJJHH55"J.@ P*P?&7A2W\9>'WTBZN)
M((VE23?& 3\ISCGUYH \ZU#6+?XF>,?#\?AR"ZC738[E[J\EA:/[/OC"B/KC
M.<9'Y<9K#L_$]MI?PHN? -UI-^_B,+-:+9BU+;G=R5<'N!N!'?(&.QKW]55<
M[5 R<G ZFC SG'/K0!YAX*TJZTOXD26UW'F:U\-V=N\H!(+*%#8;ORI_*N U
MK4[W4K7Q#9ZAJNL6NI_:+B.#0=,LC'')G^*0JN'4@9.>2._-?1]% 'AR7RZ7
MK'PKUF[BG73X=*-L\J0LVV0P[-I &>I'ZGUK/TA;O3=,TW7Y]*GFL=(\2WC7
M"I$2_ENJ@2A<<A6SSZJ/P^@:* /$-6OO^$UU_P 0>(-(L[Q=+M/#-U:&XE@*
M">1E<A5R,G&?KQ^>CJ5M,_P'\/1FU(E1K'Y%C((_>*,XZY([^_O7KU% !7@F
MIV%[?VOCK0+>SN'U--:.KK;%&"W%N&7HW0YR"!G)[5[W10!X_JWB"+XE:UX7
ML] L+]'L-02]NYYH#&+9$ZKN/5O8>@_#UNZ!:TF"PB8F-@(F. _'W2??I4M%
M 'S=87$^ES6D'A@>(;'7OMBB3P_<1&:T3YLD@D<*,D[NH]?XJM7^G6?A[Q3X
MCM_$T_BFV^UWLMU9-I4I$=TCDD X&-_0'\NW/T,S!5+,0% R23P!2"1"^P.I
M; ; /./6@#QGPKH-Q8Z]\/2=(N[2"*"_D*3GS##ORR[F"@ D$'& 1G%6_BII
MNL:?KL>J^'[.2>76[)]'NA&"=NXC8_ X.,C/M7KM% 'A_CGPA'X<OO"UXW]K
MG1+"Q-C<SZ4VV>)ADAS[,2<_3Z9V?A/9VDGB#6]6T^RUO['+%%%'?:O-NDN"
M.3@;1P,#G)XQ7J]% '#_ !;L;R_^'EY'8VLMS-'+#+Y42EF*K(I. .3Q7+'Q
M=-XN^)W@^\TS0]42PLS<I)<7%L47=(FUAGD?*%'?O7L-% 'CV@:7<)^SA>64
MMC*MT;>Z)@:(ARWF,1\N,YX&/PJ*WCN=(^(GA&ZNK&[\FY\-PV",D#-MFP<J
MW]W&1G/2O9J* /%?!^FW\5W\+6DLKE%MH-2$Y:)AY1(;&[CY<]LU[/*N^%UQ
MG*D8I]% 'SWH4-Y/X7\ Z<=(U*.ZTCQ"JW)DMV55#2M)D<<C'4]L<]179^./
M#^HZ[XWU"VLX91]H\+2P1RX(0R>>"$+= 3C\C7J--9T0J'=5+':N3C)]!0!\
MUV6@:;?:=I^D1^&/$\^O%XH;B&[D>*UCVGYWW=AC.../Y_2U%% 'D/AS2-1A
M^%OCRTDTZYBN9[N_,4;1L&FS& "HQR#C QUQ7(R>%VL'\-ZQKFE:S<Z3/HT5
MO+_9P<36TJXQN P0I&.OK[5]&44 >(: EWH7ACQ1J.B>$=3 U-XK:PBND>::
M<8<&25#G"#=G/0]/>M#P)X<UKP%?77ABYLFO+75K4SQWT$1VQ3B,AHI&[#CY
M23W]SCU^B@#A_A/<RMX$M-/N+"]L[G3B;:9+J$QY8'.5SU'-8GQ2;5?^$@TA
M9CK,7AH1,9YM&3,XFR<*Q'(4C;[9^G'J=% 'SKIOA_44TKQZEIX?URWM[VRA
M^Q1WL#M-* W()QRW? Z?A7HGB33=1FE^'C6]C/)]EO83<[8V/DKL );'W<<]
M:]&HH \O\$:1J5IX;\<PW-A<PRW6HWC0))$5,JLF 5SU![$=:PX5U;PI)X&U
M^;0=2NK6UTAK.ZBMH"TT+D<90X(YQUQWKV>YNK>RMWN+N>*"!,;I)7"JN3@9
M)X')J4$$ @Y![T >$2?\)G=6'C'5[#1-5TU]1O;5FA$9%PUL$=7\OC[_ -W.
M.1DU%X=T![?XD^&]3TOP[XGAT^%Y([BYU=#O+-&V"1_"HSUZ'Z]?>?-C\[R?
M,3S=N_9N&[;TSCTIK7,"3K TT:S,A<1EP&*CJ<=<#(Y]Z .%^$.E7^C^$;JU
MU&SFM9_[1G8)*I4E>!D>H.#@]ZI^-I+W0_B'HWB2PM#J;1V4MO/I]N^;DQDD
MB1(^I&3@D"O0+/5=.U!Y$LK^UN7C^^L,RN5^N#Q6/XG\$:/XLFM;B_%S%=6N
M1%<6LQBD4'J,CM0!XY-::S\0+[X@PQ:6UGJ$HL9A9RD9'E@X1C_?*\_7CCM<
MT'PQI]YXFT3^Q_ASJ.FO;SI/?76JO.D<04@_NLOASD<9![<8SCU[PSX2TCPE
M:2P:5 RF=]\TTCEY)6]68]>_MR?6KNGZWI6K2W$6G:E:7<EN=LRP3*YC//7!
MXZ'\J /.?#GA_5K#X8^.K&YL9UNKRYU![>,KEY@T052 .3D@X]:Y+5/!$D$O
MAW5]9\,:GJ^FMHMM:W%M9[A<6TZ*.=@(.,#&.F<YQQ7O5UJ%G902SW5W!!#"
M0)'DD"JF<8R3TSD?G5@$$ @Y![T ?/=WX*U.Y^'^MMI/@]],2\O;?[+9EI'N
MFC4D%I-[''+=!C'.>!FNR^*=GK%UK6D;[36;SPRBLUU!HPS.TO.,@<E>GZ]#
M7J5% 'S]I7@_5X;'QNEGX9U*RMM1TY/L4-RX>1B",@G.=Q.XX_\ K9]I\*6L
M]CX.T.TN8S%<0:?!%+&W566-00?H16Q10!P^CZ=J$/Q.\8W<EE*MG=V]H(;A
MCA'98R" .AY/7MCWKAY/"?B*3]GR'0VTR;^TDN]PMMH#A/.)R1^.?I[5[A10
M!X1XG\#C3_&^JZEJG@^\\1Z?J)62V:QF</!)@!E<(1P3W/& .>M0WWPXU1_!
M.AW)\,0_Z+?RW5SHMM/('>&0(,%V<G?B,=#W'&017NDVH6=O?6UE-=0QW5UN
M\B%G >7:,MM'4X')Q5F@#QGP/X5QXKGU#3O!+Z!806LD(>_GF:>21@1\@9MN
M/7@_6J_A[1_$$WAOP;I4^@7UM-H6NHUP\J@*T>7<NISRHW8STST)KVZB@#S3
M0M!U6#X>>-K&6QE2ZOKK46MHF&#*'3"$?4]*YO2H=?\ "6L:)?6FG0ZC?C08
M[6_TB.=4N844_*X7//09QGG/%>WUROB_P?X7UY%U/Q!"$^QQMFZ$[1%(^IR0
M1Q]: ///"7B;4],B^)'B:ZTU/MD,\3M:^:-BD;@5WC@E01G'7\:]CTV[.H:7
M:7IB:$W$*2^6W5-R@X/N,USWA#3?!LOAB6R\-Q6EUI#RE9E!,BR28&=^[))Q
MMZ^U=!J&I6.CV+WFH745K:QX#2RMM5<G Y^I% 'G>N3^*- ^)]]K>G^&Y]4T
MR;3HK=OL[*&+@L5/KP<@X[$'TK"D\#>*(?!G]JM8QR^(9/$"ZY<V2R#HN[Y%
MP2"<MG&>AQU&*]C@U&RN;NXM(+N"6XMPIFB1P6C##*[@.F1R/6K- 'DUG'XG
M\1_%31/$-[X:N-+TZ"TG@7SI%9@=C<N!]W+-@<<XS6M\'K#5M$\+7&AZMI4]
MG-97#[97(*3AB3E,=0,=>G(KT.B@#A?BMI>J:EX:L9=(LVO+FPU*"\,"\LZI
MN& ._+#\,U7\*Z9JK?%'Q%X@N]-GL[.^LK41><1G=Y:;EX/4$$&N\M;NVOH/
M/M+B*>+<5WQ.&7(.",CT((J:@#PK4_AYXDU7P]<$:9!+)9^(+F\BLIY-GVJ%
MV&><C&<<<CCOTJ[X2\+W-UXUT[4+?P#;^'=/LMS3R74C22R/@[=F2.AQSCUY
MZ"O:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M.\6_$"+POK-GH\>CW^IW]Y"TD$5H =Q!Q@\Y'0G.#C%4;?XIVHT?7+G4M'O+
M#4-&5&N=/D(+E7("E3P".1^GJ*EU;3-0F^,OA_4HK1VL8=/G2:<QDJA.<#=C
M 8Y'X9KE/$_A36]4\3_$(VNGS,E]IUL+60KA)F01DJIZ$_(1CUH ](U;Q/;Z
M3J.AV4D$KOJ\QBB9<83"[LM_]:N+7XU6KVYU%/#6K?V-#-Y%W?L%VPL3@8 )
MW=1GD8R/;.=-JVM^+?$W@QX_">KV<6FW6Z]ENHC&BL5 ;:>I48/)QG@<9JBO
MAS71^S_JVE-H]RM^]Z7CMEA/FR+YZ'<5')Z'\ .U '9:3\2?[4UR+2+S0K[2
MS?6\D^GSW##$Z*"<X_A.!G'/\JXKX?\ Q-N]%\$V;ZKHVJW6F0SM'<ZPTF]4
M9W..",E1N SGKQZ"NM\2:/J5W\2_!MY!82&VMK:Y6>2)28X28R ">W)P*XC2
MY?%"?"G_ (05?!NK+J$Y:%+F2#; L;N6+,Y/##)&#QT.>U 'I.M^/I+36I=(
MT'0+S7;RWC66Y^SN$2$,,J"Q!R2.<"LZ]^+NGVV@6%_!I5Y<7=U=M9/8*0)8
M9UZHWODC''?\*X_7_!<ND^,KZ\U'1==U:PO((1;S:(Y#HZ1A2LB@]"1G/\^<
M1Z9X+U:&'PM<0>'+BQ3_ (2);R2%I6EDB@&S#2D]#\I]/UH ]?TC7I+OPV=7
MU;3IM'V*[S07)RT:KG)..V!GI7(Q_%G"V^HWGAC4[3P]<2B.+5)"NWYCA69.
MH4^N?SKL_$VE2:YX7U32HI%CDN[62%'8< LI S7DVHR>)]>^']GX"/A'4K;4
M%\FUFO'C M4CC(^</GDD*./<X)Z4 6= %UXE^..K7.LZ+=JVF"/[,&N_DLOE
MX.T8W>9C/MGG-=QXH\:3Z'K%IH^F:%=ZSJ5Q$TYAA8(L<8.-S,01R>/_ -8S
M5\,Z/?6'Q)\6WD\$PM+B*R2"X<<2E(MK8/<@]:Y_XC6.LWOBVV6\M_$=SX:-
MMA8M!P7,^[GS!_=QW/X=Z -BW^*MA_PC6J:GJ&G7-E>Z;<"UETYB'D:4_<4$
M>IR/^ FL*/Q=JE_\5="75=)OM"CAL;J2:":;>DJ["0WR\'&WIC(KEM%\$^)+
M72=<FM-"N;6YM=4L]4L+2Z;>9EC,AV%\X+889[YXZUTEW'KGC[QG97$GAK4M
M(TY=+N[-IKQ-K"26(J>/0$@ ]_;I0!F_$#XAWWB#X=W[6OAO4+?2;N1$MM4,
M@VL%E!R5'*@[2/J0*T?&GB"YTN?QT=(74?M\5M9K+-]K CMT=/OQKC(/0'!)
MR<C&*Q]5?Q=<_"U? C>#=1-_"$B>YC1?(,:.&4JPX+' !'U.<UO^)/"^M7^H
M?$)K>PE=;^PM%M&XQ,R*-P7W&,4 3:?XMMK;Q!I%YK<>I6-VOAUKF>)[O?$J
M*Y^9DQ\SL%R#G/(!&:N67Q6G:33[K5?"U[INB:C*L=MJ,LJLOS#Y"R@?*#UZ
M]/6N7O/#'B#QAJ%I=_V7=:<)_#+6#?:H]GESH[?*P/(5CT/7!SBK-XWBOQ;X
M;TCP;)X4N]/E@>%;V_N.(%6+'*'^+./PZ<]: -V\^*.J&]U>WTCP=>7ZZ1</
M%=R^>$4*I/(&,DG!./2KM]\2_,L=(;P]H5WJ][JENUS';J?+$:*<$NQ&!\W'
M_P"L9/#&BZE:_P#"<^?9R1?;]0G>UWX_>J4P".>AKSZ;P[XEM]%\+V>KZ7KL
M^@PV31W%CI+8F$Y=C^\7NN-O_P!;N :?C?QS+XD^%^OP26,^E:KIUU;Q7=L9
M-VPF0%2&&,C*G\J]2UWQ#:^&/"DVM7^]X;>)6*KRSL<  ?4D"O#[?P)XC7PI
MXSL;3PW=6(OI+*2TMFF5RR([$KNSRP# G\?:O6/B)X7N_%/P^N-*L\?;5$<D
M2,P 9D(.TGW&1]<4 <?J/B?7=7\9>"H=7\-3:/OOC/#(;@2"1"A&TX VMSR#
MS4FG^/;?PSH072]&O;Z;4-<N[:."6[!;SMP/!V_=)8<=N>34TM]XL\5^*O"S
M7?@^ZTVVTZ[\ZZGDE5AN*$?+_L]>>>H'UHZ5X2UZ"[T%Y-+DVV_B6ZNI=Q7Y
M(6QA^O3@X_\ KT = WQ'UR:ZATBP\'RW&OI!Y]]9F\1%M5S\H+D88D8./<5,
M?BI9MX;6\ATRX?6'O3IRZ23B07(ZH6QC&.=W]:YSQKX,D;Q_>:Y=^$Y?$FG7
MT$:JEO<M%);RHH7H&&00O7W_ #KVG@[7K/P]I^KZ=X7MK"[T_5S?1:3'<,SR
M0%0"'=V/S_E].U %_P 7>./$3^"O$%E=^';O1]5@@1]\=SN3R68*SK*HP2,@
M%0<\^QQI1?$#5X++1M(L_#$U]X@GLTGEM1=KLAB^Z'>3H"V,X/3/)JIK3>.?
M&N@Z_ ^A#3-/>R\NVLYW4SSS;E;.>@& 1SWQ[XKVB^*-'UNP\5P>%KJX2XTM
M-/N]/\U5FA>-N''JI 'Y\XH U+KXM):>&)M0DT2<:I:WR6-WIC28:.1MV,-M
M(8';QQ_]=ES\2]>M[G3-);PALU^^#R"REOT15C!PIWD8))!X]O>N?E\%^)=4
MBO=>N=*^SW^IZY9W)L5E5C!!%N&YCG&?FZ=>/P'0_$W1[K4M2LC+X/CU_3/(
M9&>WE,=W;R9SD-G[N,<8/.>G< [/PSK4^O:*EY=:;<:;<AVBFMIQRCJ<'!_B
M7T-<7-\4]2EU#46TOPK-?Z7IMR;>ZFBND\\;6 9EA&6(YX/3W'.-/X6:/K>B
M^&9X-8\^-'NGDL[6XE\V2W@.-JLPXSU.!^F<#S_Q/X2U[4-7OC'X+,6MM=%[
M/6=*N_(B*YX:123AL9ST)/Z@&U/K.M:=\9?$"Z%H#:M<3V-L61KA8!&H4<DL
M,=^E;EM\39]0\*6>H:=X>N;O5;F[>R-A')\L4J<MODQ@#&#R._U-6/"V@ZUI
M_CW5M0U-/,2;3;.$W8(VS2HF'(&<CD'K7!77@7Q38^'38M87=UI_]NW4]W:6
M=RL<EU RHL; Y/'#':>>>G< '1WWCF\US0?&GA_6-&&EZI9:1-,8TN5G5D,9
M_B7@$;EX]_:JWP]_Y'O2O^Q,L_YI6)I?@?7;>Z\1R:?X/;2[+4M#EM+:"2]6
M5O,.,;B6)#-@\< <=.M=EX-\,:QI7B[3[R\M/+MXO#%M8N^]3B="NY, YXP>
M>GO0!<\4>.]6TKQA#X8T7P\-4OI[+[5&QN1$J_,P.<C&!M]1UQ5"/XKM!X?O
M9-1T.:'7K2]33SIB2;O,F?)3:V.A /KT[Y%:5SH&IR?&BSU];;.F1Z0;=I]Z
M\2;V.W&<]&';%<OK7@;Q'<ZOK^K6-M']HBUJTU/3XY9% N?*0@CKQRW?'2@#
M=M/'GB&#5DT77_#4>GZG>P22:8!=J\5Q(H)\MF&=IZ#/\LBCX-ZGK.J>"A)J
MT+;5GE\FZ>;S'N,R.6)'4;6^4>N*K6=OXH\9^,]%U/6= ;0=/T5I90CW"RO<
M2L-H P!@#&<_X\:/PLL];T;P_/H.LZ4UH;"=_)N!(K)<*[L^1@YX)_4=\T 4
MM?\ B#XCL[W4WTOPPC:9I;E)[K4+D6_G,.2(@<9X!(/.?R!Q-;\6:WK7BSX>
MW^DZ8S6=XDL\4#7)7>^W;)NQTV*20><AC[BLW5?!>OWFNZ\VJ>%)->O[N:3^
MSM1FOPD%O"<A<ID=,YQ[=NM7D\,^+=,T'X?7L>D/<7VARSQW5G'.B-LD8!?F
MSC&U1GZ\]Z /2O%FO7/A[1A=66E7.J7<DR00V\"GEFZ%B =J\=?7 [UR.G_$
MK4[;6[O1?$>DVD%]'92W<(LKL2JWEJS,CXSM/RGKZ=*U/BAHFM:]X;M[;2$:
MX1;I)+RS2?R6N81G*!SP.W7Z]L'@K+X?ZNOBJ*^T_P ()HFG-I]U:^6;Y9GW
MO$X#R$L3R6 XS@"@#8C^+>NKHEIXFO/"L<'AR64123"ZW2\G&]5P,KGCIVKK
M[#QQ%)?^)K/4;7[')H>93^\W>=;E=RR#@8R.W;(KDM0\':_-\ K7PW'8[M70
M)NMQ*HQ^^W=<[3@>]4?BIHT]UXRT:UTJ_P#)O-=A&FWL"#),"NKER!S@<Y/H
M,=,T >@:;KNJZS\.O[;73D@U&>UDFBM6E('\6SYL<94 _C7EW@_5W&A?#^+6
M])659=3D%C=BZ;<26;+LHZG>V.>P]Z]P:T5---G  BB'RHQV Q@5XWH?A'Q:
MUIX+L+W0Q:IX?U,O),;I&$D;-O+@ \8QC'.<C\ #0F^+7B"/3+S6U\+P'1=/
MO&M;F8W6'<[]HV#'NN>O)_+:TKQ]K2^([;3O$>AP:?;WMG)>6TD-QYC(B#<0
MX]<>G?\ 3%NO VOR?"+7="6T4ZC=:D]Q#%YJ_,AF5@<YP. >M;NM^%-5U#QA
MX;N(XT^P0:;<6=Y*'&8]\>T8'?G% '-'XVW:PIJYTS3/[&:79Y(U)#>!,[=Q
MBSGKSC'3VYKTWQ#XCM/#WA>[UZ;,EO!")%"G!D)P% SZD@?C7CUOX$\266FQ
M^'XO N@S7,3E%U^8QNK(6/SF,\DX/?/3I7JOC'PPWB;P-?:!'*D4LL*B)R,*
M'0AER!T&5 XZ"@#B=,^+E\=7TJ'5K+1UL]2E6%#8:DD\L#-C;YB@D]\'I_2K
ME]\4K[39]1T6YT4'Q-'=K!86<;$I=HQ^60-V7 )/X=.<8VE>$O$$^IZ/;OX$
MT'1Q931O=ZD!%+YRKC.Q0,@G'4]^XJ?4? WC#5M6O?&3W M/$-K<+_9-DLJM
M&L"D_([?[08]^YSUX -R[\9^*KS7+G1_#FAV5W/IL,9U":>8I&)F&3&G3)Z\
M_P"3G:K\6+^./2[*STBWL-8N[9Y[B+6IQ;1VP#%0"6*ELE21TXQZ\2-9>-O#
M7B#4=9T;0H-1CUR.*6XM7ND1K2X5<'YNC+GT_3OBZCX \5P7>F^(;^RL?%FH
M_96@O;*Z9 JDN60QD@ [0<<\]<<'@ U8?C+'#X:U*>^M+4ZQ8W$=L(K:Z5[>
M=I,E660$@+A6)STQUYX=H_Q7N(M<CT[Q&FCF.>"2>.YTF]6=8]B%V20 G! !
M&>A(XXY&-)\-/$.M>&]2DFTW1M(N9+N"ZL]+@ACV 1AP4D=1SN#]R1D=L\6]
M)\%:QK6JH+_P=H?AO35AFAN3;I')-/YD93Y&&2@&[.<C\: ,CQSXL\7>(_AM
M?Z@^@VD'AJ^*"*7S2;B-!*I5W&<8) ' [U[C'YG]GIY.WS?*&S?]W..,X[5X
MQJ'AKXC2>!I/ J:/I\UC%A$U 7*J9(U?<HVD\'('7M^=>V0H8X(T;JJ@'\J
M/)/!FGZQIWQLOUU[5$U#49M#\V5XT*I'F9 $0'^$ >@ZGO5VXTJ7QUXY\6PK
M?2VMM9V46E1SQ')!<B28 ?AM/UKHET+4D^+%SXA\N,V!T46D;;@"9?-#;2,Y
MZ#K[UE:7X0\01_#C4;9;S^S?$^HW,E[+/%)P)3)D*67/RE0!QZT <?9V^EZ'
M\6_#FFZ5HMWH<=LTUI)>W*,BZEA< #C#9/.>^1[5Z3XW\67/AN'3K73+..]U
M?4[C[/:022;%SC)8GT&1Z=:YF/0_&WBO6O#[^)["QT^ST>=;IY(9][W,JCC
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MI1TPZCH,=UYRSRMY;^:?NC R<J2.V#4T_P ,-6\1Z5XCO/$%U:1:[J[1&(0
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ME+,>?<\YKI=#\8:W<:7X7\/>$],TJ"]GTTWDYN/,^SV\08J  "6Y([D]1Z\
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M]_0]CFG:/X*\0W6KFZD\.Z%X;MXK26/RK>.*9KB5T90=VTE%&>Q]N<\>NT4
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MK&YT_4HWDMF9% \Q5 ZG'<>OK55/A;JEEX.TZRL-2LTUBSU8:L&:(BW\SIL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMB+4P_V5=_9MYDW>;\N=V,#'TYJ*[\71V_C/1] BMEGBU*&:1;M)AM0QC)7
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M=IFDD 2PP@S<YS(WS/\ ^/$UX]HWA'POJGA;QSK.J!#?V]]=A)C*5-OMR4(
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MDP6&C;;"86!<R"!CM)DSD'J2-O=NG-4/%EVTUK\4)2P9)KS3@&VCF/+%2/P
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MMJH6XCG!7S"Q'(R<\G@G![9'>^#;6W'Q4\?2>1%YB2V91M@RNZ)BV#VSW]:
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MX/?41=_V<ZH)!+]D69A 6]?+SC\.E=+:Z#I]GKM]K,,3+>WL<<<S;C@J@(7
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M0/#EQXIT2SL((HY574()ITD; ,2M\_Z'I5[0_!?ASPV9SI.D6]LTX*R,,LS
M]5RQ)Q[=*SM&UV>VU/Q#!K6MV<T>DP6S3*D3(UN3%N=G. #N() 7.!QQTI+#
MXI>#=32[:SUE9#:0M/*IAD5MBC+%0RC=@=AF@"[J'@'PMJFFVNGWFBV\EM:
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M[V1M/?3XKZV1S\L*J KX].22: .K'AW15ADA72+$12R++(@MT"LZXVL1CDC
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M#<XMQ]IMV+J,;2<<\C.?7Z5=USXJZ+HNMW>C"PU6]O[0KYT=I;;\*5#%LYZ
M$9^M '97MC::E:O:WUK#<V[_ 'HID#J?P-%O86=I(9+:T@A<HL9:.,*2J]%R
M!T'85SEQ\1?#D'A.#Q&+IY;.X<111Q)NE>0_\LPO][@\5'X<^(VC^(+N:R>W
MOM,OHH3.UOJ$/E,8QU8<X(% '3+IUBL,\*V=N(IV+3((EVR$]2PQR3[U%I^B
MZ5I)<Z=IMG9F3[YMX%0MSGG YY-<%/\ &W0889+O^RM;;30S)%?"UQ#,P[*2
M1^N*]%M+E+VR@NH@PCFC610PYP1D9_.@":BBB@ HHHH **** "BBB@ HHHH
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MDXKWG6/!WAS7[N.[U71[2[N(Q@22)SCT/J/8T^#PEX?M5V6^CV<2"Z6\"I&
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M+QYE2+<RC>><>W7\*V-7OX?%USXV\2:/:S#2QH(L_/:)D^TR[@VX CG"C;^
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M/C'P29K>3R(O#3-&[I\JN7(;''!P5[]"/7GVNHUGA:9H5E0RJ,E PR/PH \
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M8!" 00K,#R!CT'MBNZ&A:8-7M]5%H@O;>W^S0R9/[N/.=H&<#ZXS0!HT444
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MJ,ZV<K7H'F6\C?=;?SQWZ] <^M8US\6M2CT#QC-"EZUW!?-'82-8GR[:(LJ
M.<85AR<-SDCZ5<UOQ';?%77=%T#P];SW&EVUY'>W]\\3(J*F<*,]R"PY[XQT
M-8>JW4;>&OBCH8$G]I'4WOA!Y;9,'G1_.#C&._TYH ]$3XF:79Z5HXNX-3N-
M5OK82_8H+)C.<<,Q3C R&(]0,CBKFF?$OPWJT6GO!<3*U[=&S2.2(AHY@,['
M_NDYX['\#7FFJ^+K?4_$5C-'JS^'=)ETQ1#J-M8%[BZ*G:T6_&Y=IW# [@'G
M(K-T72Y=0\&>,IH/MYU#3-5CU:W-XA6=BH+!G&/O,N\\=S^8![=#XRT.?6-6
MTM;O%UI,7FW89" J8R2#WQQFL:;XJ^'TCL?L\.IWMQ>P_:(K6TM#)*(\D;F7
ML#C\J\:O=-UIK&P\065O(+SQE)=VMPA=B$$LHV#C'8$\YR,FNJ\1W2Z+XO\
M[)OM7NO#6FV.GPPVEQ86FZ>_55 YD49&TC&WI0!ZYX;\2:=XJT=-3TR1V@9B
MA$B%61AU4CUJSJ^HQ:/HM]J<P+16EN\[ =2%4MC]*\G^%.MVOA3P-J<FJI?1
MYUQHB)83YH,B1A2X/3/?_P"O7J7B+2_[;\-:GI8*AKNUDA5F&0K,I /X'!H
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M+S9"WEH-N%7/0#T%>0SJ;J\\-WMO<>+M6FM;^VFO&OHF$%N R_*JD?>SWSC
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M.>U2T4 1):V\=J+:.")+<+M$2H @'ICIBF6UA9V<2Q6MI!!&K%E2*,* 3U(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YNY3^SO$:2](;KJ1_>__ %UTE07%I#=(%GC#
M@$$#TH C65G *KD$]32@_-T/ SBJATN6%R;68!/^><@R*'AU-QM7RD4^C$_T
MH LSW4=M"22-Y'RKGFH]+@>*-Y9.'D.?PIMMI01Q)<.)7'3' %:0Z4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 44WYMY&/E]<TZ@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>oncolyticslogotaglinebluea.jpg
<TEXT>
begin 644 oncolyticslogotaglinebluea.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
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M9(2CU'7BI/_:  P# 0 "$0,1 #\ W^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                       "&H!$
M$JN0EVP"H"GTGF*:J 7!*KD*( *NV@VT*.HU0 J;9#:4I[:$-M +%7:4;2E+
M;\RD-I>SX 9M^+HJ[2D"GM+V? -I>SX +?BZ*@)-5[$([_,!;\71,"7?YB&_
MS 6_%T3D=5*6TO8-I>SX +?BZ*VTHVE*.TO9\!';[4 M^+HJ[2D=M2CMH-M
M+?BZ+C;&VA1VD&H,%='H3:EN "X!;DZ/\P!5!3Z3S$R/0 F!#4B
M
M
M
M
M
M
M
M
M
M
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MXR*A%'*4MI4XH11X%BNCR9'(40#!< H:J3(\ J@E1R*3
M
M
M
M
M
M
M
M
M
M
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M@JC4IZ*GG(H_M L5D>5$<A0U !< I(]2='H 3
M
M
M
M
M
M
M
M
M
M
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M)HOF([T\Z ^D8JW J(I51Y;H]"<'R+C4%!%)VO[0"H""*1
M
M
M
M
M
M
M
M
M
M
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MB]@,W_%BJC]2<I:HO'B-I?2@/I*ULK%9':%5':ENCM28'R+@%)'E1% (@
M
M
M
M
M
M
M
M
M
M
M   $%4 B2.>2J\D L152!*KD)=Z\=R RHD5=V$NFG$AM=GM)%<#Z;RMYB=7=
M742;2$BKJG8A+M>8'R)W=T)-KL*3G^LI*[M4 JND*:N*2O*3G@%;;0I.>4%?
MY]"DL@!75Y1<\HK)YRDZ3U %9S^_ IJ\MW/\Y163U@%RY_G^$HND+994]!3=
M)YP"Z63TE)TA9+-WU*2R^< OND])267NA8NE[\219/. 7KIN_P"@I+,62R>H
MDZ3S@%XLG=2FLOG+/I4[J2++Y_C +U9"17^HL5F[ZE-9=>L R.VO;\1)TOI,
M<LW?4E6;OJ 9)9"7;,9TQ!9?2 9/I=.)+TOG[^PQBS=]27IO/\(!E>E\_P '
MZ!TOG^#]!BNF7M^$=,O;\(!E>E\_P?H(=*8OIE[?A(]-Y_A ,ITOG^ F29#$
M=-Y_A(I-WU ,QTGF'2>8Q73=]Q'I@#*I)Z2HC_.8A)N_ GZ;OJ 95'KVDW2>
M8Q:2^<G2?OJ 91)?23I(8MLWG^<J)*@!E$F*C9N_ Q:2><J))ZP#+),3I)W0
MQ22>HG27S@&723S^TJ)(8A)>^I6;-WX &4;+W4K)(8MLI623S@&39)WZRJUY
MC&R?K*S) #)(_M*J/4QR2;^)523L^, R37]A51YCDD*J/\X!D&N["HC^TL6O
M]151X!?H[MX$6^;V*6B.[%*C7@%WM(3-=H6Z.]9,WS>P N-R^9?@(ZJG$HHY
M"HCNW>#-RMJ"DB=B^HF1W;N L5T?VE0MR9KM 8*P)4=J3
M
M
M
M
M
M
M
M
M
M                                             IN?U $SG:>DI*I
M@JZ $2FKM=R#37CU$JJG4#EDN_LX$>'G)5<2JY$)->M?8##9-M;]$)51$\ZD
MBN]2%!SM08*KI>_44574E5="@YX!55_847/*3G:E%S^P JN>45D*+I"B]_6
M5E>A1>\H+)QWE)7^H JND_44ED+=\GZRW=* 7;Y._46[YBV=(6ZR>L NG2E%
M9>Z%NY_:472H 72R%%7^LMG3%LZ8 OEE0D68QZRE-TO=0"^6;OQ*3I2Q67TE
M)9/. 7RR]T*2R%BLJ=OPE/IN^\ O^E)%D,>Z=.WV$G3^E0"_64=+WWF.61W9
M\1)TBKUIZC*0,CTOI)>E[ZF/V^U?B)=M.U?@%N_T.WIX R"R+V?"0Z7S?"GT
MF.Z1.M=299/9ZS%_Q8?C-V7IX%^LOH(=/YN_M,;MH3=*G8'ES]&8L9#I_-W]
MI'IC']*WL[^PE5Z!-/A?SJWSCT>DR72^CX/I(](O9\)C.E[ZJ1Z1.TRU8&3Z
M3OP)^F])BTD3M^!"*/UZ_B7XC'X_#,I&527SDW2^@Q72+V^TF1ZKOW+Y]P_'
M68,JDG="=)?.8I)53J4BD_G ,NDI5;*8=L_H[^@JME](!F&R]T*J3&&23S^T
MK-E ,PDV[NI424P[9>_ K)+W4 RR2%7I/08=LR%RR;O^@ R;9>ZE9LIBTE0K
M,D ,JV4KME[H8E)"JV3U@&8;)ZRLDOJ,0V4N&S &5:_VE='F)1_G*Z2)Z #*
M-D*S9#&,?W[2NV0 R2/*R2&.:XJM=V &012HC^TLFO*[7:@%ZBHOTH3*NA9H
M[0KM?^H N$=V$^NO$H<>!,CNKK *J:IZ"HBE%%)_.G !LJ%1KNTHHY%)@"X!
M1:XK(H
M
M
M
M
M
M
M
M
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MBZ%+AZ"=% :\Y<([4B4$70JM=J#!,
M
M
M
M
M
M
M
M
M
M              2N=H'.T*2J %4E52#G:$NFN]>H :JOF0@KNP@KM2DJ]2 $
M5=[2373CO7XAJB</:4'/ )GO**KVD'.*+G[@"97^HH.?^LIN?VE!S^T G=)^
MLMW/T*;WE!T@!.Z0MU?^LIO<6KY0"N^0MGR?K*#Y2W=( 572%!S^PH.D1"W?
M, 7+I"U?*6KY2V=( 73Y2V=*6[I"V?-IN[_& 72R>?0H.E0LW2_IT*+G)^L>
M9OL5K_+D+]R[\D7#Y^PHJ_5.)1V]=R)JO5V[N*Z<5T3T=6_J/E'E&<M[*C*>
M';Q]CFPV*J="LU/9Y*R.IO\ 5L1-=JEL5(L]SDC=N:DZTS*5KU1KYVJNB??#
M8:I6EN4J<ZDGDHQA)MOJ6[DSK8K&4:,7.K5ITJ<>,JDHQ7F;E'_4^KU>A(]Z
MZ.5?X+5<Y=WDHUJN555%T1&IO<O4B[^"Z:IG*5\)=M\"5%%E)@>6XSHKF0X@
MQHZ2CH&:(NS/'8K?,E=5;]E%IZBXVYV]?KB[FG@;RA><]SVS/DJ&XHS#O$5M
MG=JVP8=6/#5B@C379A916=M-+4-9JJ)-<:JNK'(NDE4]$:B2%HO9=I&O:5;H
ML)!_G')U+?!Q3S['./+@1CIG:_HS#-QH[^,FKI="K4[\O9)[MUVQ4NRYOE\H
M+G&,E,L&2)C+,2P4-7&W:2TT4[[W>Y$WHBPV:RLK[A(FWHQSFP*R-SDZ9T;?
M*/$O/+PFG"M*M139<9=7V]O9M-ANV,*NDL- ]Z:HCX[5:I[M<)J=[M-A:BKM
MTZM54?2L57(S3S>JN<][E5TDCE?)(Y5=)(]RZN?)(J[;WN<JN5SG*Y7*JJJZ
MZ$.^[=IZ-"2=%[*]'4;.NZF*FN4Y1A3\T(^%;ODR*]+;9=)U[K#1I8.#RO&#
MJ5?VYJR?=!6/8#/'GSN41C+I8:7%-)@RAD5R)381MU/25"1._P#4ON=8E;6J
MK>"30.I9D7>CD4\I\=XYOF*;@^[XGO5VQ)=7HJ.N=_N5;>:]6KOV$J[C/4U#
M8]>$3)&QHW1K6HB)I_+@WO Z&PN&CNT</1I=>Y"*;_6MO/SLCC2.GL9BWO8C
M$UZW5TE1M*_5&^ZO,D01$ZD3NNOQD0#TSR0 !Z?2/,O1\P  ]'H08
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MJM<BDQ23?O3BA.UVH,M?[%9KRH6Y4:_J!Q*@
M
M
M
M
M
M
M
M
M
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M[S;\[\Q#>E-.8S&U.DQ6(K5IO-=)*Z7<E:*[-V*RXL=_1NTW=F[< #T;GDV
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MW4 5
M
M
M
M
M
M
M
M
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M7:[4 N44J<?26R=O=2HUVH!7:[J4G*6NOI[29KNI0+%=KNTJ%N5&OZ@"H
M
M
M
M
M
M
M
M
M
M                        2N71"*KH454 @JDKG:$570I^=?4G &4/.O'J
M0D<[K"KVE)5]@,,CKUKPZOTE-[_T(0<[0H:@!5[2@Y^X.=["V<X BYY;/?\
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MT7=Y_F*B* 5FN)REQ37K0G:[4&;<RNUQ.6Z*5FNU!@F
M
M
M
M
M
M
M
M
M
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M% :\Y<(NI$HM70K P
M
M
M
M
M
M
M
M
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M=="DU>KK0JHNNY?4#*?H*I.UW446KU$X#5BX!(QVI.#
M
M
M
M
M
M
M
M
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MFE!SD_,F8LR@2Y8PP/)6XSRWB<^IE1(>DQ-A6E<[>R[PP)I=;?3JYJ>[5)'
MZ.!46X4,2Q2U,U@M4MH]#&[M#%)8?$^*I7?1U9=E\HR?N>%^#M8K-KKLKQ&
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M9%+=%U)VJ 5@
M
M
M
M
M
M
M
M
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MW %9NY="H4DW[NOJ)VNU!GM*[%)R@BZ%9%!@B
M
M
M
M
M
M
M
M
M                                         050"5[BD1521R^T!$J[
MU\R$CEU)N!1<H,OJ(<5\R%)[R95ZNI"W5=08)7*6CU^$JO=^@M'N^$ IO?["
MTD<57J64KMX!2D>6,KRI(\L'O *;W%K(_0F>[0L)9 "G))W[]1CWN]A/(_7O
M\!92R: 7*<\GZ"Q<_OZ>SS]?4FRBKKKHCII';^/'UZ+VZ:IJB<7:*B[*+O1=
MYY:<Z?SC-JY/V"?&*9U+78^Q)%5TV#+'/K(BR0M8RIOMQA:K'-M%J?-'M.>L
M;*ZLZ*AC<YWC"1]W1VCZN*K0HT8.<YR2BEP?-NZS223N[9'1TGI*CA*%3$5Y
MJ%.G&\I/MR25[7DVTHKFVK9'R)STW.KQY46:?+C =PB=F9?J/2MKX%;+^PFS
MU;-E:Q^J*UM]N%.Z1EIAD:K:5CO=">-S$ACDT;*BHDFEEFGDDGFFDDFFGFD?
M/-/-+(LDL\TTSGRS3S2.=)+-*]TDDCG2/<LCE<O]#C;&UVQ)>;IB&_7"INM[
MO=?47.Z7*KD=+45E;5O62:9[W*JZ:KT<<::1P1,9!"UD,<;&_P N6LU5U9I:
M+PRHT_RLK2K5;+>E-\4GRC'A%?)F4RUQUNK:7Q<JT[]##P,/1O:,(1;5Y9M2
MG+C*7<N"  -F2MD:BE8  R9 !^BY2Y38AQWB6T80PG:ZB\8AOM6RCMUOIFJY
MSWO75\TTFB,IJ*DB59ZZLGV8::FCEFE<Q$0^=2K&$7*32C%-MMV225VV^27-
MG.C2E4E&$(RE.348QBKR;;LDDN+>5K7?RECESEM?\7WNWX;PM:*Z_7Z[3I36
M^U6Z-):JIF=II]DK(X(&)M/GJZE\--31M66HDBC:YS=Z_FLN:)P_D=04>*,4
MQ6_$.:M33:U%T2/QB@PIXS$YLUMPTZH;MLFZ*26DK[TUE/4U\;IH8V4U'*L"
M_I_-E<UOA?D_V1:V5(KYF/>:2*/$>)Y-9(Z2+?(MCP]$]-*"V12.3QFH8UM9
M=98XI*Z5\4-%3TOJTUO9WZU^%2O&O.O\\7*>$PDG'#1=JDXY2K2ZKIY4^6[S
M6;SR+0[.]F=/ QAC<;!3Q<UO4Z4O"AAUR=FE>MSW^$>$5Q<H-9V?-\R)[2ZC
MC(QL[_,7;(]^B)P[[B*KY+\)=BZDOE)E;_U[7UOM?-DC&]2%Y'%KIJ3QQ:%X
MR/73L!@D8PO(XN_?XBHR+@7L<0!29'W^@NF1]_I*K8_UERR, I-C_47+8BLV
M(N6L *3(BX:SL*[(^_87",W@%!D2*5F,\W?XBNUG:5]A0"BV/]15:SU%9K.Q
M"JV/S %!(RJD?="X1A41J( 6Z1E5&=I51JJ3(P I;"$R)V%PV/NI.K>W< 6R
M,4FZ/SE?3S*OP$=_8@!12/UD_1>8J(B]?P$=E "FD?J([/G0GV$[".RG8 4]
ME.TAHG;\!6T\R>P %'1.WX!LIVE8AH 4]E.U!L>@J:)V$-A.P I='YOB)5C\
MQ7V4"IV %KT9+L*76B]B*-$ZT]@!:*WS$BM0O=E.WU$JLU0 L]@I+'YB\5G8
M2[*]@!8K&4G1]T,@J:E-6 &/<SUE%6&0='ZBFYG: 8QT91=%NU,FK"DYGFW@
M&)<PH/A[[C++'VEN^-0##/BTX%LYAFGQ]I:OA ,0YGJ+.2(S#XRW>SV &#?&
M6KV>;U&<?%UH63X@#"/B3J+&1O:9Q\99R1:]0!A7L+9[._?>99T:IWX%H^,
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MTLT4N&._2 7"*5.&_M*#=V[V%5%Z@$5B=CNHHM7J)P&7 )6KJA,
M
M
M
M
M
M
M
M
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M9?A?ZD-$[2&J)Y^_H)T:A,#-UU7^0I:^;X"._L0J "ZZOE*>B]B#1>Q/@*@
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MT(U*34J4XJ4))W3B^:*D8O#5*-6=*K%PJ4Y.$X25I1E')J2^;K68 !]CK@
M']+@[&-UP]=[9?[)73VR]6>NIKE:[C32.CJ*.NI9&RT\\;V^4BM>U-I/L7L5
MS'HK'.1>AOS6G.)VO/\ P&RMJ%AH<=8<Z&W8RLS5:W2H5G][7RW,1=9+3=HV
M](Q=&NHZUM502-V8(9ZGG1GT]R/>5GBG)7'=HQWA63;J*)Z076TR2/918ALL
MSV>/V>M1J.V4J(V[5+4I'(ZBK&0521RMCDIYM+UTU4AI+#6BDL32O*A/FV_&
MA)Y>#+CGDI9Y9F^Z@ZYST1BO";>$K6CB*>;2:RC5BL\X<TLW&Z=[1MU F/\
M;U&1ADU/G[D\9^X;S.P=8L<82K$K+)?J1M33;6RE333-\BKMU;&U7+%<*"='
MTU7#KJR5FJ)LN:J_ND3NOON*L5Z,J<Y0FG&492C*+R:E%V::>:S+C8>O"K3A
M5IR4H3C&49+-.,E=-/FFN#,W$XR$4AA(WZH7T4A\CZF=8[<BEY&\Q$3^'?U%
M\QWL ,Q&\OHWF'B=O+Z-WP &6C?J7;'&,C=V%ZQW6 9)CBNU=Y8,7J+MJ@%Z
MG#T%1%+9B]G$K\%UZE *RKNU3B5$4I,7>3-W+H#EQ\R*S5WE8MRLUVH.),
M
M
M
M
M
M
M
M
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MS#R]FKPOB)Q?Y*BWE!_I5,T^:CWHQ"K\&G'T(GMT1$U[$X(0 + _)W%9>_,
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M1T O^+(EV4(DZ,]1,C$!@I$^PI5 !31A'80G !+L)V#83L)@ 2["=@V$["8
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M*7+'?  7#7:E7BGG0H*O65F*#*94:NI4:NA23<NG:3@P7 )6KN)@
M
M
M
M
M
M
M
M
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MW[# (LC_ %E]''W[!%&7S&:( 1C9YB[C9^D@QA?1Q $8HR]9'YA&SS%VQOM
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M7109Y>C[2LQ2L6Y7:NX&"(
M
M
M
M
M
M
M
M
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MD)MG7C["9&^TF!EV\_6"9&ZD485$30'$@C="8
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M$JHI48I19UH3HH,%P B@
M
M
M
M
M
M
M
M
M         $KEW$Q2>O4 2%-=Z^@G5=Q3ZE7M!E?CSHE<N\I=JDSE^$I.=N]'
MT P47J6[U^ JJO6I:2.^$ HO<6DCBL]=Y82.W]^P HRN,?*XN9'=_,8^5P!;
M2*6,KMQ<O=UF,E> 6TK^)CY7%>1WZ3'3/U^+T!A%L]_6>='.B<LN'(_*&_XI
MA?&N)+EIAS!U*]6JL^(KI')'!4R1*YCGTEGIFU%WK4:]BNBI&T\4B5-3 CO1
M&1>_Q(OF7K-"#GVN6>W,S-R?"MGJUGPMEE)6V"G='(JP5V)>E2/$E8Q&N5KV
MTM3$EF:_K?156RLD#XGNW+4;0'J_'THR6]1HM5:W5NKA!^_:M;L-%VA:R?R;
MHZK.+2KU[T*"OGO33WIKG[&EO)]=EU)^)U?<)ZN>>KJIY:JJJIIJFJJIW])-
M4U-1(Z:>>5^[:DFE>^21=-5D<]RHFNB6@[]^_P .JJ+6J*2LDDEP2X6Y6\Q3
M)R;=W>[XW=W?G=]=^( !DP "#G(B*JKHB)JOH3CY_,FB*JJJ;A^/QW\!^.KS
M^;B?9'(*Y(=SSOS.P_@2A26&WU$BW'$]TC:JLL^&:!S'W.L<Y?)2>9'1VZW,
M7[9<*VFU3HFRR1=)?+_ EIPQ9;5AZQ4<5!9K)0TUMME%"B-CIZ2DA9!$Q-E&
MHKD8Q%>_9;MOU>J;>KCR7YE'D)?W(,K::]7NA\6QUF##17R_-EC1M5:K6YCY
MK#8)7*NVR6BI:CQNX0.1B4]QJZJFT>Z)SY/9QK?9WT^DK%M$UE]7XN5*$KX?
M#MPIV>4Y)^'4:3X-I1CV0OS+=;+M4OY.P2K55;&8M1G4DUG2I\84HWX-)[T^
MMSZDBI&TO&1[D)(F>WOWT+Z&/OV$>7?-W^SL).Z_QER_U*T3-"_B84HHS)11
M@%6&,OF-^ D8TNXF %:-OZ2_8SOV%.-FA>1L )V-X%XQOFWDC6%VQOM )F,+
MF-I!C2X:WJ (M34KL9N\P8SV%5$U]'4@!!$U]'8540@3::\.P&4B;S)P[2=$
MT((W0G1-09;ZN! JM;H3(FA$'$
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M#%+MJ[@"]3>GH*B*4(W%5J[] "NJ[T7M*A23@OM)V+N!FV5RNQ2<H-7>5P8
M
M
M
M
M
M
M
M
M                                               !052JY=Q1 )']
M2$CNPF3CJ2.7B#DUDBGKO]!;R*5M=WG4MG+O!Q*3UZBR>O$N)5XEF]0"@]Q9
M3*7#W=?L,>]W$ MYG<3'2.+F9WT%B]=X!:S.,7(XO9G]_C,7([X0"VE>8U[N
M*\.OU=1<SO,?(O?XA>W?P7G^[CZ0U?Y_1_H>?_.:\KJ/);)_$^+8)HV7ZIA]
MPL*1N5-N3$-U9+#221QJYJR>YT?2W.5&M78CI%DD3H44YL\DLCW.?*]\LLCW
MR2S2.5[Y97N59))'KY3WO?J][WZO>YSG.57:FP1X0[RLUQEFI;\NK94J^PY:
MT;FUS6/UCJ\7WB..:X2/:FJ:VFW>*6Z#:\ID\UT<U713M<FOH6>V::#]1Z/A
M5E&U;%>R3;6?1\*:]%Y<O&MRN5%VL:P^KM)3H0DW1P=Z,;/+I+IU)+M32A?/
M.%T\[  $@HC$  R$/AX[N&N[YOLMW8>R7,D\B-F;N;$=WO-'XQ@[+GQ#$%[2
M1J^+5UVEGF=ARSR;+D63QBIHZBX3QL31M-;7-G562MCE\=J*AGJIH::EA?45
M-3-#34U/$BNEGJ:B5L,$$3415=+-*]L<;=-[W(='OFQ>1O#DCE+8<*S00MQ'
M7I[OXQJ8T17U&(;C%$L\+Y$1'2,ME/'!;*=':]'#2HQ'.1%>[0MH>L/J' RA
M"5J^)O3I6:3C'+I)I9\$]U<,W>^1).R_5;^4<?&I5C?#86U6JGFIRSZ*'+C)
M*3X^"LUF>A+$TX;NI$W::(N[31$141----6JFBHNFB)>1MZB@Q-Y>L;\)5UO
MKMZ"W]O0LDNPKQ-U,C&W@A2B87\3.!@%>-ADHFZ(48H^_P Y?,;[$ )XV_"9
M&*,H1L,DQH!.QI>1,[26-O?T%VUOP $[&_H+IC?:2L:73$W $40N&,]I+&TK
M^9.'6H!%%1?5U%5K=?02HA/YD]8,I#CN0J(F@1-"9$ ;_'6$34K(F@1-"(,
M
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MT4NV;TT *S2=NY="BU=4*SEX*#**A71=2AJ5&+U P5
M
M
M
M
M
M
M
M
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MQO)=,;["_B9P+>)O?SF3A8@!<1M+V)G?SE&-/T&0B8 5HVE]&THQL[]I?QM
M*C&?H+MC/TDC$ZRZC8 5&)UE=J:DK4WZ<"Z:W=Z.H ::>GXBHU-$")UE5$TW
M_  .&[K)VIH2L3K*B RWR";]Q71-"#6Z$P,
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MHW%TQ=X!=)N70JIU^TH:\%[-Q78N\ J,7<5&KO*2;E5"<&6N'<7 ((NJ$08
M
M
M
M
M
M
M
M
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M$: %Q&W]!D8VEM&W]!?QH 5XFE\UO44(4W:EZQ "K&WX"[:FGK*;&^PN6)J
M3QL[^8K:;].I"")HGIW%1J:( 3-0GTU] TZNOK)T30&5^/E(E1C>LE:F\K P
M
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MB>8:-=WH,E"[=H5V+1&8B4R<;OI0PL;OA,I"[AWX@&6B7YC(QNU0P\;C)1.
M,HQ>_M+^->'G,9"[M+]B[@"_C7XR[12Q8I>,7< 7K=Z*A4:O MXW%9O6@!5<
MO7U[_@*Q1ZE\Q5:NX&?]/M*S%W$Y28N\J@P
M
M
M
M
M
M
M
M
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M$T?AJ/!JFI3Y7G+PIO\ :;*/:Y:6]6Z3Q>(O>,JLH0[*='V*"7ZL4^]OAP
M-@-9   /V/D[Y*W',?'F$,!VIKW5F+,0VZRI(U$<E)1U,[%NER>W<YT%JMC*
MRXSHGE]#12+%J](]>H3@_"E!8K5;;):H&TMLL]OH[7;J9FFD-'04[*2F9NW.
M<VGB:CW_ &3WZO?Y;C3;\&[Y.;;WF!BO,FLAVJ7!=JCLMJ>K46/W:Q"U75$J
M:M56S4UJIY6,=&Y-&U4S951LR--TAC>HKMM7TPZN,IX56Z/#4VIVYUJGA?\
M;#<3[;WX%HMBVA%0P-3&27AXR=H/JH4KJ+[I3WVGP:W2XB;P]I>1-U4H1IW\
MQD(&? I%!,Q=QM,E"TM(FF2B: 7D:;B^8W@6T;?@,A"T NHF[B]C9])1C3X"
M_C3X@"LQI>1H4&(7L;4]@!4:FXNHV_2I28F\N--$](!.F]=?456]I(B=1/IU
M=@,I$S6]?P$X*C$ZP)/,G1-"( ,
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M)%+K7=Z "X9Q(L7J*;5X%37?Z087WE5%WE<MRNBZ@R1
M
M
M
M
M
M
M
M
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M1-2LA(Q.LJ P
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M  $47JZS%_QWF+_C\=Q, #)D $BN7L,-@G!+KV_J)C*8
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MKH 1!(JJGSD6KJ84D"8 &0 "&H%R(((I$        $NJZ[N!AL$P(:]A$R
M  "!$           $ "(                  !*J^P F!+KN)D,7  !D
M        E<J]0N"8$NUWWDPN    "57>TCK^@Q<$0 9
M                 !+M(-3%_,$R8$NTA%%,@B"55[]_H)=OCU>I?H[[MQCS
M"Y4!+M=]4^D;7?=])DQ=$P*>VOF^'KX=7H3T^8F:NH,DP)5=H05W9\0!."3:
MW?H(HNH!,"":]9$                             E7J&O?NOT@$P)&JN
MOFZB;4Q<(B"15Z^/?OU!'=_4G?=N,W!."7:[ZI](VN_Z@8NB8$B.[[^^J#5>
MZ*8O^+,S<G!(CEZR"/X_ 9N"H"1'$=KUBX)@
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MT@RE<G:G63D$X%5@,-DZ$0
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M5->W?UG):JXT?%(U>#F.;V<6JG'J.HQR0\V?V=96Y?8O67II;_A&Q5U7*O\
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MZ(TA4I3G3J0H2E"=.3A.+33O&2S75D:PG[=ORK_PVXD_HC!W^[1+^W;<J_\
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M'A:]:G*E6JN,TJ-.+LJ<Y9-)-9Q1OP_#P]>[C["J2IW]JDQ *998  R
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MO>/9)Y$:[3M8\7HS!T:^$G&%2>(5.3E",UNNG)VM*ZXQZC98^JQLN/P28_\
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MX),?_P!)X9_/31T ]:[0_P"9J?OZGWCUW--_GZ7_ $]+^$WB_JL;+C\$F/\
M^D\,_GH^JQLN/P28_P#Z3PS^>FCH!ZUVA_S-3]_4^\>NYIO\_2_Z>E_";Q?U
M6-EQ^"3'_P#2>&?ST?58V7'X),?_ -)X9_/31T ]:[0_YFI^_J?>/7<TW^?I
M?]/2_A-XOZK&RX_!)C_^D\,_GH^JQLN/P28__I/#/YZ:.@'K7:'_ #-3]_4^
M\>NYIO\ /TO^GI?PF\7]5C9<?@DQ_P#TGAG\]'U6-EQ^"3'_ /2>&?STT= /
M6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28__ *3PS^>CZK&RX_!)C_\
MI/#/YZ:.@'K7:'_,U/W]3[QZ[FF_S]+_ *>E_";Q?U6-EQ^"3'_])X9_/1]5
MC9<?@DQ__2>&?STT= /6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28_\
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M._$Q\2?$92%O#OP +^-"^B3>6K$X>8OXD^D OHT^$OF-UTT]9;1MWIYC(1H
M7$:%[&G M&)N+YB %=J;RX37VE&-/H+GKT[ "HU."%3BOH)&]O83,3K!E,J%
M9J;BFWB5@8
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M/B^YOM/[2$474I,<BKU\._L[>!50A-/EZ?N+ )D0 9,@
M    &J?X6%]RS*K\9-3^2=[-%\WH/"PON695?C)J?R3O9HOEF]EWDFG\+6^F
MRI.V#RU5^ P_T&  2*1:#9J\%B^[GC'\6]7\O6@UE39J\%B^[GC'\6]7\O6@
MU+7OR1CO@E].!NNSGRWH[X:7U50WY$[^U28E3O[5)BI:^_YRZ8 !D
M            E5VA,2N (ZH05R%)7:>GON3OZ#X6Y=?.)Y9\GS#K;WCN\,9<
M*UD_['\+4#HY\18BGIVMZ1MNM^TCVTL#Y(FUESJ>BH*%)8O&)T?+!%+]\)A:
MM>I&C1A*K5D[1A"+<I/J[,LV^2XV5SJXW&TL-2G6KU(4J--7E4F[02[^>>22
MS;R69]L7W$%#:Z.JN%RK*:@H**"2IK*VLGCIJ2EIXF[4DU143.9%#&QJ:N>]
MS6HG%35LYP?PF#"6$9J["N2%L@QW?H$DIZG&EQ<Z#!EMG^N,5MK@CV:[$U7
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M*#\9?\2VZGPWF1KKEM)PFC-ZA3W<3C+/V&,TH0R_K9K*+7%T_&:ZD;%_+_\
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M!TM#V&?1UXI;^'J-*:X7<>52-VEO0O;@[/(_? 2)P[Z_#\_L)S5S<0
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M"V&R?6OU=@_4E:7\YP:4&F_"G0RC2GQN]VVY)VY1OQ/VG4B2H3$;(E@
M           $% /X/,S,>RX0P[?,58BKH;98<.VJOO5WN%0[9AI+?;::2KJI
MW*O'8BB<K6(BN>[98U'.<C5Y7W."<LV[Y]YJ8CS$N;9Z6DKI4H,.6J=VKK/A
MFA?(RTT+F-<^-E0^)SZVO2-SFK7U=2U'RM8R639:\)IYQ)D;*7D]85N*+-+X
MC>\RWT<WVF!4BN%@PO5.C71LU2UU-?JVCE152D=:99(EBJH7+II]GF33LW>A
M-WP;NKBI8799JST%&6/JQM6KQM03XQP_.2RXU7GUJ"33\)E8ML.MGJC$+1M"
M5Z.&:=9I^#.NN,7U]"LE^G*2:O%  $M]RLNI$*?/POU]_< "61[6(KG+LM:B
MJY>&RB<5X+[?9O,/AR7#C\OR<!\N5[?=^.!]F<@/D;WK/G-3#67%FVXHKA(^
MY8@N3$VF6;"UN?"^\721=4V%5DT-OHE77;N=?10HU72(=4#*7*VR8)PS8L(X
M;H8K;8<-VNCM%IHH4:UD%%10MAB14:B(LCD:KYGJFU+*Y\KE5SU/&'F%.;B_
MN)Y8,Q+B2W+39C9C4]#=[ZVJB6.MLME1JSV/#<D;_*II:6.H=77&!S63MN53
M+!4^52,B@]XFIH5@VBZT>K\9T5*3>&PTG"G;Q9RO:=3MO;=B_<JZ\9EN=E^J
M/\G8+IJT+8K%QC.I=>%3I\:=+LM?>FL_"=O:HBB$0"/R3P      >.W/[?>E
M9N?R3"WY<89/8D\=N?V^]*S<_DF%ORXPR>SJ[Y0P/QO#?70-?UK\F:0^)XCZ
MJ1S.  7&7!%%E]_S@ &3(                                   ,K[_
M )C?*\%4^XOCO\8]1\@68VAC5Y\%4^XOCO\ &/4?(%F-H8J3KOY6Q_P[^C$N
MIL\\BZ.^+Q^=@ &JFY@         _/,W?WJ8G][]Y^3JD_0S\\S=_>IB?WOW
MGY.J3Z4?'C[Z/SH^.(_)S]Y+Z+./O4?;)?XV7^T<4BK4?;)?XV7^T<4B[-/Q
M4?G_ #\:7OF  <SB6E?]HF_BI/ZBG7[Y/W[P\#^]##?R+1'($K_M$W\5)_44
MZ_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P  @LL0
M                 0U).D3AO[._Q^@MJ^NAIHI)ZB6."&&-\LTTSVQ0PPQM
M5TDLLCU:R-C&HKG/<Y&M:BJY40U*.=.\(XH;"^YX$Y/M31W>],Z2BN.93X8:
MVR6J=%<R=F%J>=DE+?*R#16-NE1'-963+K#'<4C1'^SH30.)TA65'#4W-^VG
MPA37NIRX)=F<GPBFSP=8-9,)HRBZV*J*"X0@FG4J2X[L8\7VMVBN+:69[T<N
M+G),J.3_ &9;CCR_-]TYHGOM.$[1T5?BF\R-3R64=LZ6-((7.5K'W"X2T=NA
MVT=/51,17&DKR[O"#<Y,V_';-A*63*K!LRRPLHL/UTC\35U*JN:Q;KB:-E//
M!+(Q462&RQ4+(51K&5,ZM=-)X@8YQW>\3W:MOV)+Q=+_ 'RY2NGN%WO-=4W*
MXUDSW*]TE1654LDTBJYSW(USECC5VD4;&HW9_E"P.K6SG!X%1J5MW%8E.]Y*
M]*'O:;R;6?A2WI=5BLFM>U+'Z0<Z="3P>%\7<I23J5/A*L4IJ_N8-0Z[A=[G
MO757R/?+(]RJKY)9'*^221ZJYSY)'JKY)'N<^1ZN>]5<Y0 2*E967#DK*R[E
M^+<B,'GQ;?%W>;=^-WSOSN  $K#\<%]@ !D               ?C@ON!5IYY
M(989X9'PU%--'44U1"]\4]/40N1\%1!-&YLD-1#(FW'-$YDD2HUT3VOU*0,-
M96>:YW2=^^Z,QDT[K)]:Y=W5YLS87Y!WA%6;65[Z*RYA-FS5P=$L4+UN-4D&
M,[=3,3962AOLVW'=GQLV7)37MCGU3V*Q]SI73.JV;LG(QY?N5V?-A;?<O,11
M5[HFM]U+#6M2AQ'8IU56NI[M:)7NFA<UWDLJ875%#4MV):2JG@DCD?RA#]JY
M.N+,P+/C;#<^5EROMLQ]67>WVS#+\.5+X+E5W2OJXZ2BM[6(O0UE-63RLBJ:
M.O9/;JBGEFCN$+Z.27:C76G9U@L6IUJ%L'B,Y2E&/L,K)MNK#Q:?"^_#=LKM
MIDJ:H;3\=@I0H5M[&X>ZC"$I>S1;:25*IQGF[;D]Z[LDT=>1'(3:GYME#;L1
MTF%\/TN+[C1W;%=/9K=%B.Y6^E;0T-=>64T;;A4TE*W1(8):I)%C:UL;-G16
M0P(O1,_1V_#UE:YJTFD[V;5UG%V=KI]_#L+84Y[T8RLX[RB]V64E=7LUUK@R
M8 &#F          "5W9V@-D=3^4QKC>SX<M=??+_ '.BL]GM=-+67"YW*HBI
M**BI86J^6:>HF<R-C6M[5U551&HKE1#'YDYDV+!UAO&*,3W.CLF'[!;ZFZ7>
M[7"=E/1T-!21NEGGFE>J(B-8U=EB:OD>K8XVN>]J+SC^=UYW[$O*+Q!)9;'4
MW*PY26>=[;-AQ)7TLF(YV2-5M_Q/#$_2JF7HVNM=MG5\%JC57L9X]/43+M6J
MFJ=?2M9PA>G0IM=/7:NH)\(Q3\>;7)<%=NQI6NFNF'T/04IVJ8BJFJ&'4MUS
M?.4GQC3CSE;.Z2S9][<Z-X1?B#&<MTP/D3+6X7PBCYJ*MQZY/%\28CB;(Z.5
M]A@<FWA^T5+$1L%;,K;W412N>L%K>U&FK945$DTLLTTDDT\\LD]1/+(^6:HG
MF<LDT\\TJNEFFFD<Y\LDKG2/<NV][G.<C:'Z=_6O5\7%.'8"SNA= 871])4L
M-34;*TJG&I-\'*<NWDN"6214G3VLF+TE6=;%592:;W8<*=-7X4X9Q75O9N7%
MR8 ![/X_#6?RG@M)\L[WOFFNZS0  ,@             #\<6OFL+=B]%_G"]
M]VOSIW[>!]K\C'G"<U<A;HZOR\Q)/16^HJ$GN6&+@KZ_#%V=JFV^KM4CTCAJ
MI&HC5N%$M+7*UL725$C8VL;\4 ZV*P=&O"5.M3A4IR33C**DK=W.SSOQ7%--
M)G:P>.K8>HJU"I.G4CFG"3B\NU9Y\+/P7P:LSI <V=SZ66V?3:+#=[;%E_F:
M]$B7#5RK62VN_3LC5SI\*W>5E.E:DK6/>MJK(J>Z4KM8&LKXFQUU3[F(]#C<
MT]1)#)'-%))#-#)'-!/$]T4L,T;D='+#*Q6R1S,>C71OB<V9KD1T:IHIT6/!
M[\[LZL>Y,RW;->I]U;-37-+7EYB"Y->F)[Y9:%CHZZHN\WVNXT-)6I[FVB[2
MHVX7%M'5OK'5:1P7&NK[K]J'2P$'C,-4M0<HQ="H_#4I7_)-YS3M?=;;BDW=
MJY9;9MM&K:1J+ XNFYUU!RCB*<?!<8K-5X1\&E)9)37@R;M9.U_?%%0B46Z;
MM-^[KX\/5\7J*Q%-^/83.F  9,@
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M#A^BT3A%;QX3J/M<ZLFGYU<IEM*QO3:9QDKW49TZ2[%3I137FD_3<  W$T0
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MX%JQ.LO "O'U=^LK,[21C=WHX%5J: %3J])41-"14X(5 9ZB=B=95)&<"<&
M
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M!KOO5,,>^O'OY57$]["G^M?E+'?&:OTF7CU,\E:/^*TOH@ &OFS
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MYVE\$\3A<1AU)1=:C4I;S5TNDA*-VN=KWM=''FU0:H=6M.;%Y-G_ $>\D/\
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MA_8JO[RG]P]8RO\ V^E^YE_&<I3:3M0(O?CU[^"*NY/-Z51-YU;$YL7DV?\
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M?\.I'>7:X>.EV-$:Z2T)B\')QQ6'J8=_\:$XQ?O:ENCEW)F. !WUZ>Z_VGF
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MTTO8J/ZL7O37NVT[V1#9)@#022P
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M G3[(J$C.LJ-XH#+XLK(1 !@
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M  -?-F                           !*Y-RZ:=_9\9,04-@\(.?GYN?\
MNV95SXCP]0NJ<P\N:>OO5B93QH^KO=G9&L][PW&C6]+45%5! E5:8&O3;N5/
M# B.=4'.+AE:]C'M5'->U'-<U45'([>BHJ<45%UU3<NNO'4[)ZMW::)V>;37
M?JG7JB\/B.=GX05S=ZY/YH-QQAZAZ' 69]777"G2GCTI;+BYKO&KW9W(U5;
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M/\7B#Y'J#I?)P0KEM;\HTOBL/K*I:;8IY,K_ !RI]"F1 !%A,0
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M5^/BQ648*_*$;)=?>2_H'0U+1^$HX2DK1HP2;]U-YSF^-W.6;SR[BH #S3V
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M35"LA(C?-U$Z$2+S][_'^Y-=_F5^_L["( ,F0
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M?67+ "LG%._G*[>OT%%$W^@K)P7OQ )V<"JSB4V<"JP&7Q95  ,
M
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M3;S;;>;=RV5"A3I0C3I0C"G!*,(12C&,5DDDK))  ' ^H
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MI3$1]DJK=PB:\2B_&JQ[:CRB^4(]4B"*NXJ$$0B0XE;TW)V0 !D
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M\X_DT_ZRJGXTGQIJW@Y2:WK;LC45J+W[^O\ 054(;),0PO23TE;(  R9
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M4*5MMW;=VVVV^-V[E^8P44HI622274EDD  #D
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MX)W[0"=G K1]92;P0JQ]8#94
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M?T3HRE@\-1PU".[2HP4(\+NW&4NN4I7E)OC)M@ '2/1
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M&-.$:<(J,(14(05DHQBK122X)))+L0 !P/J
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M^HIU^^3]^\/ _O0PW\BT1">V3Q-'^^Q7S4"P&PGQM)]V%_QC]@ !!98@
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M)/<
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M-Z_2I57[%._:4F\5*J_8IW[0"HG!"K'UE)."%6/K *@
M
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M]18'8AH6[Q6D)K-6H4F[9-VE4MS\7<2[')9IA$T7ON*@!!J5BPX !D
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MMMN]R\E&E&G"-."480BHQBE9*,59))<DLDN  !P/H
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M\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_P"*TOH@ &OFS
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M\U14U$TBMCB@@BC?)+*]S6,8QSG*B(IR\N=>Y?-;RA,V[SBB&:H;@ZS/FL.
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MNHJ,>1<K9[JI'16 A"27JFONU<3+FI6\&E?JI)[MN#EO2MFR8 &GF^
M                            U:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^
M,-OR#<C:M1O*^"^%_N3-+VB>1=(? KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P
M#)D]D>8'^^IRY_B\0?(]0=+Y."'-!Y@?[ZG+G^+Q!\CU!TODX(5RVM^4:7Q6
M'UE4M-L4\EU_CE3Z$"( (L)B                           !^>9N_O4Q
M/[W[S\G5)^AGYYF[^]3$_O?O/R=4GTH^/'WT?G1\<1^3G[R7T6<?>H^V2_QL
MO]HXI%6H^V2_QLO]HXI%V:?BH_/^?C2]\P #F<2TK_M$W\5)_44Z_?)^_>'@
M?WH8;^1:(Y E?]HF_BI/ZBG7[Y/W[P\#^]##?R+1$)[9/$T?[[%?-0+ ;"?&
MTGW87_&/V  $%EB             04B "DJ\$Z_H[H<POGKN40[,CE)YCU\4
MZ5%MPU<FX(M+FN58VP881U#<-&HJL1Z7M+DQ[F:](V-JN550Z2O*!S6I\"X$
MQEC2K1'083PKB#$DD;E^W)9;757!($1%:KGSN@;"QB.:Y[Y&L:NTJ'(:JKE5
MULTU;7SOJJZMFEK*ZJD762JK*J1T]54R*B)J^>>225ZZ)JYR[B9-C^CE*MB\
M4_ZN$:4'U.JVY-9<HP5N]D#[<=)[M'!X-->R5)UIKKC2M%)KME-^A6S*  )\
M_'R6*W_C\=W  $%7OWZOI0S;AVY+OX*_G,7^1-OT96/<CP?+DB+FARA+->;A
M2^,87RNIEQI=^D:CH)KPG2T>$;=(NTBHZ2[JZ](QS7PS18>GIIFZ3IKT@]=R
M=]QKC>#,<F]N%LAZC&M3 UERS(Q!77*.56(DBV6RR/L]N8DOV?1/J*:MFZ-$
M:QKWN>FUMJY=CM$^!"JFT32_JO2=9)WIX9^IX+EX%W.2[74OFN*27(N'LNT'
MZCT30;5JF+OBJE^-JBBJ<?U::CE[J[RX$Z*1 -))&
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MM545-%1="LU=33S>T[DP !D
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M67,?S@%RG%?45-=W?SE).*E5."^H J-7<A6CZRBS@5F*#+*@ !@
M
M                  E?P*)5>FXI %)J[E*+UW%7J]92?U R_N^8IR=?H^8M
M'\"YD7B6S^ ,%H_B6$B;B]D7B63UW>OY@"PDZNW]!CIEX^LR,J[S'3=?K ,<
M_B8V5>KL,D_B8R8 QTWSF+EX>PR4R_.8N7__ "3X@"RE7>6>[5N[5-I-W;YO
M7P4NYN*^OYS'S2[";:Z:,17KKV,3:T]>FF_=V[CG!7:7NFEY[IF).R;]S%OY
M#F*<MNXOJ\X\TIW[.T['N*&^1ILJV&[5-,U=RJFND'E=>O%#Y?/UKE 71M=F
M!CZN9L[-?CK&5:U6.5S%;58CN4[=AR[WL1LB(UR_P=GM4_)2Z.CH;N'H1]S1
MI+T02*#Z5GO8K$RX[V(K2_:J2;^5@ '<.@"*=7#U[N_T:H0'I^/37OQ]0!T%
M>87HF1<EC+B1NUM55?F#43;2JNLK<R<74C7-1>".IJ6G7=N<NKN+E/8YF[3T
MZ^P\M.9?MBTG)@RCB5S7+)9KO6:M16HB7'%-^N"-5%XO:E4C7N3<]R*]-SD/
M4MB[T0IWK-4WM(XY_P#W5>_FJR7V%ZM58[NC-'IJS6#PR[O8H9>8R,/5ZC*1
M=7K,9 G#OP0RD*;N_G/#/>,G'UF0B3?[#'Q\#(Q<?8 9"-?C,C&F]/1^DQ\?
MSF2C7AZ "[BX>POXOF+&--Q?1?, 7+.)<)_!]9;LXERW^#ZP"JGT_$:P7A4/
MW&,#_C!A^2*\V?4^GXC6"\*A^XQ@?\8,/R17&V:C>5L#\8A]IINT+R)I'XO(
MT.P 6TZNY?,BE"X(  &3:*\%5^[!F)[P*7Y:C-\7K]GSFAUX*K]V#,3W@4OR
MU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB4GMU7?\W'].[V(J:*A5)7*1
M^_Q8D\U\>?)YHZ#//#<V/,#V^)N;>%K<[Q:&'H8%QO9J-))_V-U4TCX85N<2
MK(^P5=7(R.&ID=22RP4U2Z>#GEW"W5%'43T=93ST=9232TU71U<$M-5TE3!(
MZ*>FJ:>9D<L%1!(QT<L$C&21O:]CVL<QS3L?:>;3?U:^8U$?"".9X6]1W'/K
M*^VJMXHZ=\^9&%Z&#:]V*.G1'?LMM<$2(]+I10(]M\I6(]+E1QT]= R&KHZO
MW2F#9OKMT$H:/Q4O8INU"I)W5.;X4Y-\*;Y/A&67!Y05M4U =>,])X.G>O"-
M\30@K=+%6]FAUU(+QTLYQ7-I)Z48#51414X*B*F]%UX(JHJ;M%7141-K<JKM
M*F@+ _C[OD*V?B_6^?=GE8#O\V_MXKNX+NU3< /QZ!^/2>]7,A<[759"XJ;@
MW&=PFERBQ15(E6D[W/9@F]SR1LCQ#1*YVS!::EJNCQ#2,C2%VD-TC6&>GJVU
M_12M-VIJZFIZRCGAJJ2K@BJJ:JIY&RT]33SQMEAG@E8JLDBEC>U\<C%5KV.1
MS55%..'W^/Z5-M;P?3G@6X;GM>0>9MSV;'6U3:/+;$5?.YR6BLJGIT.#ZZHE
M56QVVJF>B6"5ZQQ453+[EJY()Z%D<,[1]2NEC+2&%A[)!?SBG%?E(I-]+%+V
MT%XZ]M'PN6<Z[*]?N@E'1N,FU1D_YM6F\J4FTE1D_<2>4'>T)+=S4EN[O"+Q
MX$4*#':^;5-?1KU*G;Q[/-YJZ$")W^:S+)+S=:MU<GYR( ,F0     #5/\+"
M^Y9E5^,FI_).]FB^;T'A87W+,JOQDU/Y)WLT7RS>R[R33^%K?394G;!Y:J_
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MZ[OQ?22;B^+]HHV[+$0 :6;^
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MG$-?D,.DGU3K3W?3N4WZ>&=SZ= !7LLZ
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ME19<LJ6KB:J22KK%>\7-C57*U&(CK/99'M:JHMTJVM<Q;=.FN9S>G(FO6?\
MFGA_+VUNFI+?4RMN&*KS$Q'>X>%Z.6);K6LVVK$ZMEB<E':X9%5LU?4P[;?%
MHJAS.I[EQEW9L)V"SX8P]0PVRQV&W4EJM5# FD5+144+(((VJOE/=L,19)'J
MLDLBODD<Y[W.6(]J.M'04?4%*2Z7$1O6:;O3HJUH]2=65[_H)]:9-6R#5'U3
M7_E&O'V'"S]@3652NT[RSXJC'ARWVE[1I_VB,T[[N&GM\Y.A$%>RSP
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M5E]\-15*G3IQ5HTX1A%=D(J*^1  'S/N
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MHU'WQBU;G<DO1&U30^*<8NO+"S=ENXI*$;]E5.5+LSDG?E;,VA]2&UOX>L_
M\C.4_E]F;;DNF <8X?Q91;#9)'6:XT]544S7*K4\;HT<E92*KD5J)500[2M<
MB<#]Y:NO7KJF[=NX<4WKN7J\W6:/4I3@]V<7&2XJ2<6N]/-><D*C7A4CO4YQ
MG%\)1:DFNQK)KM*B*1((FA$X'V
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M2C7CH7C.!8QKP])>Q]8!D(^LN(^LM(UX%TSB 7"<?5\Q7;U^@MT3AWZRY9Q
M)F<"LSB4&=95:N] 9?%E<  P
M                                                   4W]127@5'
M\2D]=P.4>)3ZO647<4*[NHH]?H0&'Q*$CMQ;/4N'\"V?U P6;UXEA,7CU^$L
MY-_?S@%C)\QC9N_M,C(OP&-E7B 63^)BYU^ R,O7ZC&2K\_P &,E^8QLR\/3
M^A/B,E*O'T&,E3X-?I +&5=ZG\WB2LCI[?7SRO;%%!15DTDKW(UD<<5/(]\C
MW*BHUC&HKG*J:(U%5=Q_1R+Q/EWEI8T_8YD_FM?T=L/LN6^.+G&NNR[IJ/#5
MSG@:Q=IOUR29D<<34<USI7,:UR.5%3LX*EOUJ45[:K3BN^<U$ZV-K='0K3?"
M%*I)]T8N7V?<<Q&KN[[A-/<)=4EN$\]?(CM-KI*R5U2]';"-8JM=*J*K6M9J
MODHGE-;;E.&/88UF[R6M;NW:*U$3ANW;MVY.O1$X)4+K1C9)=67HR*!3E>4G
MUMOTY_:  9.()7+HFO4F]=Z)N3?JNNG#34F+:L<J0RJB:JD4BHB;U54:NB(B
M<55=R)UKHB(J[A:^769CQ.E_S9MC=;N3UDK2/1S9&Y:81FE:[9U9-5V>EJYH
M_)545&33O:BZ\$1.H^[H^._L73YC\3Y/&%_<3 6";.B(B6S"N'Z'1%:Y$\6M
M5)%IJQK6KHC4UV6M3_JH?MT:;_84LTG5W\17J>[K57Z9N7GXE^-%4>BPN'I_
MFZ%*'[$%'[#(P]_892'J,;#\QDH.HZ1WS)1I\9D8>/?SEA'U=^LR$/?V &0C
MZC(,;\'_ (>_K+"+J,A'Q7S:@%ZS@7T?'U%BS@7S% +F/K+E.*>@MH^LNNOU
M %5G6:P7A3_W&,#^_P#A]ON/7&SXWK]!K">%0?<8P/\ C A^1[@;9J/Y5P/Q
MB'VFG;0O(FDOB\C0X !;-<$4H  ,@VBO!5?NP9B>\"E^6HS?%Z_9\YH=>"J_
M=@S$]X%+\M1F^+U^SYRKVTWRO6^#I?01;G9%Y%H?#8CZ;(D-"(- )/!;RL8J
M.:K6N:YJM<U416JU=RHJ*FBM5%5%1=RHJ]I<%/9W+\&O48[ONN8:OE^/1S-!
MWG[>9\?E?=*W./+>UHW+B^U[Y\4V6ABTCP3>[A4*[QNFI8V(VFPM<ZF9611P
MZ4]EK)&4;8X*&:F2/65.Q/C/!UJQ!:+E8KY04MULUXH:FW72VUT+)Z2MH:N)
MT%335$4B*U\4T3W,>U4Z]45%1%.;7SR'-75_)PQI'5V1E77Y68LJ9G82NT[E
MF?:*W26IFPC<ZA=7.K**G8^:VU4ZK+=;9$LCG/JJ&O<MA=G&NOJF,<!BI?SB
M*W<-5;SK02SA-M^/"*\%\9)=:SK%M2U ]22GI+!P_F\FY8FDEX-"3=E.*2OT
M4Y/PE[278U;QL []_.G!4XHNY02Y?GP^;\/B0K;EY_QV=78"#DU3LX+JB[*H
MJ+M(Y%U145KO*145'(N]OE:$0++--73XKA?K3[UD+OEE;AV=5NXWT.8/YX5N
M9EMILFLR+BC<P[#;VIAB]ULFS^S>QT34C=32RO\ LL3VF'HUJ8G*DMVH4=<8
M&NDI;@D6SXSU]6NOH^CLW>O4XZV#\7W7#]UMU]L=PJ[3>;1607"V7.@F=!64
M-;3/22"HIY6[VOC>B+HNK'MU9(U\;G,=TB^9JYU2W\HK Z45]DHZ#-/"M-#!
MBVU0:0P72)J]#3XIM$#WOD;07/1KJRFVI%M=Q?-1])+!XM435WVB:D^I9/'8
M6/\ -ZCO6@E^1J/VZ7*G/GRA.ZX-6L[LMU_]5P6C\7/^<TU;#U)/\O37M9-\
M:M.UDN,X6>;4F>T0(:D2)[DU@     &J?X6%]RS*K\9-3^2=[-%\WH/"PON6
M95?C)J?R3O9HOEF]EWDFG\+6^FRI.V#RU5^ P_T&  2*1:#9J\%B^[GC'\6]
M7\O6@UE39J\%B^[GC'\6]7\O6@U+7OR1CO@E].!NNSGRWH[X:7U50WY$[^U2
M8E3O[5)BI:^_YRZ8 !D            %K65$<,4DLKVQQ1,?+)(]4:R..-JN
M>][G*C6M:U%<YSE1$:BKJ<;IUXFN+GW&HU\8N#WU]1J][UZ>L<M3-J^15D?]
M<E=Y4JK*[[*3RU<J]A+-.ZLH<,8BK96N='1V*[U4C6?9.93VZIF>UJ\$<YK%
M1%7K5#CNVENE+3(O%*>%%ZMZ1M0G'8U#RA+XM\G3?>5ZVZSST9'MQ//K]3WR
MX/@LWPY<67X )N17M<$"*+IWU^#K]";^P@._?<IR1DZ2/@[^%4MG)4P',C=G
MW7K\5755V7-VE?B&OH=K5SG([]P(B.;LM7339U1RK[?(AY,<QE;DIN2?DS&U
MRN1]ANM4Y5T14=68HOM6]B:?P8WSN8W_ *K4/6@IMK#/>Q^-;XO%XCY*LT7J
MU7IJ&C<!%</4>&?IHP8 !XY[P
M       /#WPB>_K1<DO,5C%<V2X77 5N8K6M<FS-CW#DE2V35=S7T<%0Q'-1
M[D>YGDM3:<WW"->_PF>=[>3!6M:]S6RX]P6R5J.T25B5E5*C'I_":DL<<J(O
M\.)B]2&P:J0WM)Z/7_W=!^BI%FM:Y3W=%:1?_P!GB/EIR1SOP 7 ^PHX   ?
MIN2>'W7;&F#K6QNVZY8KP[0(W1'*Y:J\4<*HC=VUY+W:IKN;O7>AU]Z6ECA9
M'#$U&10L;'&QO!D<;48UJ)V-:U&H<F?D)4L<^=^3L,S&212YGX%CEC>B.9(Q
M^);<U6O:NFTB\%35NFK=ZZ'6A;Q]J?"0+MCG[-@8_P##K/LS=/.WFL60V&P]
M@TA*W&M07HA-OZ2[K=Y. "&2>                               04B0
M5?TF)< :S'A3^#UKL@L(71C/KEAS7LE1(_=JVEN&&,6VN1F]4322KJZ!R[*.
M=K$U-S5<J:"YT5/"5:6.3DM7Y[XVN?!C# TL#U358I'7^"G<^/?Y+EAFEB5=
M^K)7IUJISJRRVRFI?1=O<8FM%=S4)_/-E3MLE+=TQO>[PM%^=.</E44  261
M0#[KYL&].MW*,R1K&[2=%F3AAC]A$5SHJBN2FE:FUY.KHI9&]3M'<3X4/I_D
M32*S.3*MS7*US<P<)*CFJJ*B^[-'O145JIINWHJ.UU37970\[2U/>PN*CREA
MJZ?<Z;1Z6A*FYC,+)<5BL.UV/IJ;^<ZV"$0"F!?8            $%ZN_4I$
M@O5WZE (=7J^8Y<G/,_?3YW^_"/Y LIU&^KU?,<N3GF?OI\[_?A'\@64EC8_
M_3L1\5_Q($,;;O)N&^-Q^JJ'F8 "Q!5X  /@N_[C#Y?CDSHR>#7?>J88]]>/
M?RJN)[V'@GX-=]ZIACWUX]_*JXGO84_UK\I8[XS5^DR\>IGDK1_Q6E]$  U\
MV8                                    $-"( /,/G:^0'1<H3**[88
MAC@BQ?97.Q#@2Y2IL>*XAHHGJV@FF9&^5MNOE/TELKXVHJ)TL%8UJU-%3.9S
M \08?K[17UMJNE)/;[G;*NHM]QH:IB1U%'74DKJ>II9V(JM;+#,QT;]ESFJY
M-ICE:J'8U<B[M._5Q]'?J71D\)9YN3]C&)H,^\*42LL.+9Z:W8]I86)T=NQ5
MIT=#?FM1J)%37^GCCI*]J<+O3LJM\ESG=',&RS6?HJLM'5I-4Z[WJ#]S5]M3
M3?!55FK>W77(@W;#JCTU%:3H0724%;$JWC44K1JV2S=+A+]!_HFJ:!WW</4O
M7Z>OCN!8"]RM/9\G,  ?C_5=JY#\?CLZSU8YM;G5L7<G&WYCVJRP27*@QM8I
M%M=))*SQ6PXWIH'4MJQ-'#*CV.3Q1_BMTBC9M5D=):G2I(RWQQGEI<KG55U3
M4UM=435E;75%165M74/=)45=75S.J*JJGD>KGR35,[WS32.<Y9)'JY7.UU+(
M'1P^CJ%*M6KTX)5<1N=-4YS=..[!]F7&UKNS9Z&(TIB*M&AAZM1RI8;I%0IY
MVIJH[S5^=WPZE=+)@ '>//!,UCG*C6,?(]SFM8R-JN?(Y5V6QL8F]\CW.:R.
M--%>YR(WRD0E[]^^Y-Z[C8>\'FYNA<U\RW9CXGH>EP#EG4PU,,<[$=!?\:_6
MY[7;48[5LM'9X5]U[BNFBSI:Z5O2,J*E8/*TUI:G@<-6Q-7)4H[R7YQO*$%U
M.4K1RSL[\CV- Z%JZ0Q=#"T5>=2:3E;*E36=2;[(QO)M\;**S9LQ\Q'S=3\C
M<J*>\8CH&09C9@L@O>)4>C75%EMJHY]BPTDJHCF/H:.1M3=(V*L:WFJJXV.E
M@IZ>9WN6B]7?J)6MW?-W]9-JO9Q*@Z4TA4Q>(JXFJ[SK3<FN44WE%7SW8JR2
MSLDB[FAM%4<#AJ.%H1M3HP48O*\G;PIRLEG)W;=EFRH #I'J
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MI71T%SQ=%_LS3_NG1^9P[]_,3$D?#OV)\Y.4_+Q@
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MC4IRC.$U>,HR4HR76G%M/S,F!#:0(NI\S[D0
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M"\8N\LF%X@!=IP]"E5O%"BU=RE1J\% *J+O4J%->*+VE0&65T4B2M7<3 P
M
M                       ""J 454I/ZBH2+Q0'*/$E>N\H=:^@JN7>4>KT
M@XE"3B6DB\?07+EWEI([B 6DG463UT]I>/+!_;J 64B\3&RK\9?2*8^5?B +
M*1>)BYE^(R,KC%RKQ]@!CY>LQLCM_P !?RK\.IC'KQ +21?A4\N^>7QBEEY,
M^:\R/5DEQLE!8HD17-61+[?;5;*F/5J+HCJ"IJW*U^C9&-=&NYV_U"?U&O\
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ML?L,JKH-(0Y]-1DEV.$U?_M+\ $,$\@
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MVC454\[3$]S"8J;Y8:N_-&G*_GR9ZFA*6_C<)#W6)PR7>ZU-(ZK " I@7T
M          !!>KOU*1(+U=^I0"'5ZOF.7)SS/WT^=_OPC^0+*=1OJ]7S'+DY
MYG[Z?._WX1_(%E)8V/\ ].Q'Q7_$@0QMN\FX;XW'ZJH>9@ +$%7@  ^"[_N,
M/E^.3.C)X-=]ZIACWUX]_*JXGO8>"?@UWWJF&/?7CW\JKB>]A3_6ORECOC-7
MZ3+QZF>2M'_%:7T0 #7S9@
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MM%^J,7&.Y?C2H+.-N:=7*4OT=Q=8;P)@"+R80
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M$K_M$W\5)_44Z_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P
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M--W?3LW>;L)R1B]G:OZOU>CJ)RGI>4
M                        %.3V=^_T%0@8!_ 9C978<QA:*JP8JL=IQ'9*
MU$2JM=YH*>XT,RIO8]U/51R,;+$[RX9FHV:%Z))"]CT14UV>5KX,;E)C!U5<
MLM;S<LK[M-MO9011NQ!A-TKG*NCK35U--7TD6S];2.WW2GB;OE?#,[R5V940
M*AZ^B].XS!2WL-B*E*_%*5X2]]!WA+SKSGAZ8U<P6/AN8O#4ZMN$MU1G'+VL
MU:4?,T<TCE+\PARD\M4FJ?V(T>.;/"CG>ZV7]?)>FMA;J[:J+364EJOE.YD:
M(LVEMEIV.U9%55"-VU\?\18>N%GKI;9=Z"NM-R@^WV^Z4=3;ZZ'CITM)5Q0U
M#-=%TVHTUV5ZD.QHL::Z]?;U]]Q^!9V\E/+;,BB?08]P-A;%M*Y5<C+[9*&O
MDC>J;*2PU$L*U,$[$^UU$$L<\:HCHY&N1%),T7M<KQM'&8:G57.I1\"??N3<
MH-VZG#/F1-IG8CAYWE@L54H/\U6M4I]V_%1G%+NGW'(QT[_HX^;LUZ]Z:P[^
ME.TZ".?'@Q')^Q(LU3@VLQ=EQ5R+JV"VW>;$5E8JZJ]4H,2OKKBQ7/5'-C@O
M4%/$U7LBIVM<FQXOY[>"X9Q619JC F+<)XUI6NE='1U[JK#5U6)J^0Q'2MKZ
M"HJ7<$:LU-$F]%EW)K(&CMI.BJ^732P\GDXXBGN6_6AO0],K$9:3V5:8PS;6
M'CB(+A/#5%4O^I)0J>B/R&L<#Z[Y0'($SKRL=*N/LK\8X?I(OLKPMHGNF'51
M%ZL1V9+C8VN<FCF0R7".H5J^5"QR.:WY#1R+KHJ+IJBZ;]-.U$U7S:\-===$
M34W;#XNE6BI4JD*L7FI4Y1G&W?%M&AXK!5J$G"M2J4IK+=J1<)=7"23?F(@=
M^^FJ>P':W7U/T'4N  <3-P  #Z-Y+'*QQ[DQBRCQGE[?:BRW>!T,=9"BK+;+
MY01S)(ZTWRWN7H;A;Y5VVHQR-GI5FDFH9Z:I5)CHL<UISLN">4E8)64K6X=S
M!L=+3R8HP=4S-<^-K]6>Z]AG5?\ A2QS2L<U)6(E302.;3W""!TE/)4<QKV^
MK<OM/U3)3.W%.7.*;1C3!EWJ+)B.QU3:NAKJ=55JZ*WI:2K@VD;5V^JC:L-=
M1O7HZFG<YB[+D:]NCZXZET=)TMZ,8T\7"/@5HJR=N$*J]M'J>;CRRNB0-2-?
M<3HFLE*4JV#DTJM"3O;_ (M)OQ9+BTK;]K/@F=??:[.KOW])413S3YKSG%\/
M\HS+BCQ-1LAMN*K6V"V8WPVV1'NM%\;"FW/2:N<^6S7+1:NU5+_*6G?T$Z-J
MH96GI6U=W#0J_B\'5P]6="M%QJTI.,XOK3]#36::R:S61;S 8^EBJ-*O1FIT
MJL(SA)<U+DUQ33NFGFGD^HF !USN
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M"HBE)%XH3L7<#/V?>7#%)RBSB5@8
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M0<\/)9-Q<)-Q3_4E#+_<B #1B1
M         ? G.DY?.Q3R=\YK'%$DU35Y?8C?1L5-K2NI*"2LH7Z;M>BJX(I4
M35-[#[[/Y;&.'H[O:+K:I-$CNENK[>]7)JB,K:62G<JIHNJ(DJJIV<'7=*M2
MJ+)TZD)IKENR3O\ (=32%!5:%:D^%2E4I]?CQ<>'G..K&_::UR<'(BIZTU)S
M^SS(P7-AK$>(,.SQOBEL-[NUF<R5KFR-]S+A443=M%W[2MA1RJO':3S'\874
MIU%)*4<XRC%Q?8XIKY&4%J4W"4H/C"4H-=3@]U_*@ #F<"257;+MA5:]$56.
M3BUZ;V.3SM=HJ>=#K0\A?,^/&N3F6&*H=.CO>",.5GV6UH];931O157^%MQO
MVT5$<UVK5374Y,1T,O!G\^6XKY.L>&IZA)+EEQBN]8<FC>]%F]RK@L.([)4;
M&JJVE;3W:>U4SU1$>^SSHFJL5RQ+M=P+G@L/B$K]#5:D_<QJK=S_ %HQ]*)H
MV)Z05/2&(P[?](H7@NN5'P[_ +$Y&PZ "O):
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M[XS5^DR\>IGDK1_Q6E]$  U\V8
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MJ(9<E30F*LW;S>;?'O+BI)*R5DLDEDDN278N0  ,@
M                    U:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^,-OR#<C:
MM1O*^"^%_N3-+VB>1=(? KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P #)D]D>8'
M^^IRY_B\0?(]0=+Y."'-!Y@?[ZG+G^+Q!\CU!TODX(5RVM^4:7Q6'UE4M-L4
M\EU_CE3Z$"( (L)B                           !^>9N_O4Q/[W[S\G5
M)^AGYYF[^]3$_O?O/R=4GTH^/'WT?G1\<1^3G[R7T6<?>H^V2_QLO]HXI%6H
M^V2_QLO]HXI%V:?BH_/^?C2]\P #F<2TK_M$W\5)_44Z_?)^_>'@?WH8;^1:
M(Y E?]HF_BI/ZBG7[Y/W[P\#^]##?R+1$)[9/$T?[[%?-0+ ;"?&TGW87_&/
MV  $%EB             0(D%4 UE/"F<!.N.1F%+XUODX;S"MTDC]WD)=K9<
MK2S5=4717U#=W!51%U:J(Y-!O7OU^OOKVHBG36Y];*U<5\EO-&%D3IJBR6VB
MQ12L:B+]<L-QI:R:147^##1I4S.7L9J<RE%UT7NG==Y8_9+BE/1LZ?.EB)^9
M5(QDOEWBJNVC".&E:=2UE6PM/SRISJ0D_1N  $HD0@_=>2[F3'@[,S+S%DTB
M0TV',;X7N];(YR,:VW4=YHY+EJ]R*C$6@\817JBHS[-45&Z'X44IX6R,?&]-
M6R-<QR=K7ILN1=Z)IHNN]4X(F_71?EB**J4YTWFIQ<'W23CZ/"N^P^V&KNG4
MIU%DX3C)=\7O?99<,^9V3Z>5'L:].#VH]/0Y$5/@4K'Q%S;F>3LR<ALI\9RU
M'C%==L$6%EYFW(KL06RC9:<0:HFFB+>J&N5NJ(JL5JZ:*?;2(NA2O%472JU*
M4N-.<X2[XMK["_&!Q*K4:56.<:E.G43ZU.*E]I.""$3X':
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M]15*Z*4"JQ0<2<
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MM)/M3R9>>A6C4A"I"2E"I%3A*+NI1DKQ:?4UFNPF !P/J
M         ""J1  /Q/E&9TVO+C F,<>WEVELPAAN[X@JF)(V)]2VV4,U3'10
M/<UZ>-5TS(Z.D:C'NDJ9X8VQO<K6N_:U=IW[]T-5KPH+EDQX=P#8,G+36HV\
M8]JH[SB*"";9E@PG9JEKH&5;8W*K8;O>HX(H63-:RI;;JQT3E\3EV?9U>T6\
M;C*&&BFU.I'?MRIQ:E4=^5H)_)UFOZTZ8A@,!B<3)I.G2ET?Z562<:<5VN;2
M-'O&V-;EB6]7C$=YE2HO&(+K<;Y=9TUV9;E=JR:X5KF-<YZLB6IGD6-NVY6,
M;&QJ(U#^9"=^KX.H%Q8P44HI64<EPX<EEU*R\S*-5)N4G*3O*7A2?6WQ=^+N
MT^( !R. [_#I\YO^^# 9'NP_D3=\6SQ[%1CS&%=6PN<Q4>ZVV2"&STRL>OV4
M$LT-3(Q$U1)'2]:Z)H#0TD\[XZ>D@EJJNHD9!2TL$:S35-5,YD5-3PQ,U>^:
M>5S8HV,3:D>Y&-17*B+UIN1/R?X\K,I,N\OF)'TN%<)V:V5[XEUCGN[:5DM[
MJF*B;VU5WEKJIO\ &H1+M<TBJ>!HX=/PL16WFN>[13^1RE'CU+SS/L4T8ZFD
M*^)E&ZPU#=C)\-ZL[*W:HJ:\[/J8 %>2T(            (+U=^I2)!>KOU*
M 0ZO5\QRY.>9^^GSO]^$?R!93J-]7J^8Y<G/,_?3YW^_"/Y LI+&Q_\ IV(^
M*_XD"&-MWDW#?&X_55#S, !8@J\  'P7?]QA\OQR9T9/!KOO5,,>^O'OY57$
M][#P3\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_XK2^B  :^;,
M                                       04_@\T/WM8BX_\17?T?\
M%]0?WI_"YH?O9Q%_,5W^3Z@^V'_*4_?P^DCK8Q>Q5?@Y_19QV+1^Y*7^3P?V
M33(F/LW[DI?Y-#_9-,@76I>+%=27T44$K>//WTOG8 !]#YEI7K]8G_B9/ZCC
MKY<G1O\ YOL"+_\ @;A?Y#H4.0;7_:)OXJ3^HIU]N3G]SW GO-PO\B4)"FV1
M7IX%?IUOHP)\V%KV72/P>'^E4?V'[&U-._?L)B1.*^CZ"<@E?/F6,  ,@
M                                    &K5X5A]Q[+S\8;?D&Y&TJ:M7
MA6'W'LO/QAM^0;D;5J-Y7P7PO]R9I>T3R+I#X%?60-$5?H^(@17Z/B(%M5P1
M2I??\X !DR>R/,#_ 'U.7/\ %X@^1Z@Z7R<$.:#S _WU.7/\7B#Y'J#I?)P0
MKEM;\HTOBL/K*I:;8IY+K_'*GT($0 183$
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MP<G0DGQW$DZ4NNVYX-^N$N1<@ CXE
M                                    $CM?.3@ H/:N_P!"IV:_I\_Q
M=7@-SSO,T6;/:QU6-L$T]'9LW;+3/J(9FQ,CH\<45-$[6Q7E6+'T=P5J)[CW
MI4D?33-2CJHY:2IZ6DV "W<W737U)W[=Z>C<J*BG?T7I6O@JT*^'G*%2#3R=
M]Z+XQE'VT)+C%Y><\G36A<-C\/4P^)IPG2FN#2O&?M:D7QC.+S4EP[CCEWNR
M5EMK:RVW&EFH;A;ZJ>AKZ*IC6*HHZREE=!4TL\;M5CF@E8YDC%5=E6_9.31R
MXLVF_":N07382QE:,Z\-T3:>T8]E]R,94]/&C(:?%U)3[=)>$CC9I&V_VV%T
M5>]=ECKI0-JG.DJKI5.75D^$MMJ_IF&/P='%1LND24H^XJ+P:D7SRGXO7%I\
MRE6LN@JFC<;6PE2[=.?@3]W3DMZG/AQ<+M]L6  >V>$#W#\'HY0<F!N4IANW
M22N9;LP+?<L'5K-I&QNGEA6Z6N21RKHB1UEO5$16JJND8U')MZ)X>'ZKD1F6
M[!>.<%XP;(L286Q9AW$$KT=L?WM:+Q1UU6QSMIB)'+2PS0RHKFHZ)[FN79WM
M\K3F"6)P>*H-752A4C;MW?!?FE:2[4CV=7M(O"8["XB+LZ5>DT^QS2FGV.#E
M%]C.OPFF[T?H)RTIY4EBCD;P?&QZ:=CT1R:>;>793-9774_Q\I>V+35UP>:[
MN7R  &3D                                       4G\2D[@5GE, I
M.X(4')O]/ZBNG!?,4E^= 9DLRWD3X%+5Y>R)Q]I:.3<#!8R=98RIW]!D)$^$
MLY$W>@ QLG$QTR<3*S)W^ QTH!BW\3&S(921/@+"9.KOP ,-*F_4QD^[U?J,
MO,WCWX&-J&[N_?L,,)F+?Q[]]>SS]O!><=SP.4:X-Y2&:-"V)8Z.\WJ'&%N7
M9V&34V+*&FO-4^)O!(X;S476B39T;M4CMEK4\E.CI-PW^A?BT]>XT[?":LE_
M%L39;YAPPZ,NMIN&$+A4:(FW46N;W6M,>TBZZ-@KKHYR/1/+?Y*JJN4DS9=I
M!4M)NFWEB:-2G>V2G%J<+]MH67>1/MCT9TNB>E4;RPE:G5W;N[A)2IS\V:?F
M-7,$5(%E;]EO],GZ65/_ -,^VV8   -FOP9_._Q'&^86751,K8<18=H\6VN-
MRZ1I<,.5T%LND<:?PJFMM][H9]E-=J"QR+NZ,UE#[MYLK/%,N\]\M<32RN@H
MDO\ '9+H]NTNMKQ'%)9:QCD3=LJVL:Y5=N:K&R::LVV:]K9H[U5H[%T;7?1.
M</A(>%%+MO%+MWK<S:=2M)K!Z4P==NT%6A3J/_AU7T<F^R*DV^2M<Z4C'</1
MWX[R]C7<8V-4TW*BIU*BZHJ=2HN_5%331>POXW%06K9<+96+OMF4@=\QDHEX
M&(B=O4R42_28!F8E,A&OTF*A=]!D6.W@&6A=W])?1J8F%W49*-> !DXUW%\Q
M?A,9$[J+Z-?I ,@Q2YC7X"RC<7+%W@%VW<OIX%9N]%+=%W>="LU>"@)E5B[O
M@)VKHI11=%])5!E_<7 )6KN)@8
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MPR:W9UE*O-9IJ563:7["@^K/@4VVFZ46*TQBG%[T*#CAH-<&J44I/]XZB\R
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MR'XN_P Y>QI\):QIUE[&G  NXT^ N&%%A=1)\(!5TWHG9O*["DG%?456[D4
MF8G7VFL%X5']QG _XP(OD>O-GYO!#6!\*C^XS@?\8$7R/7FUZD>5<#\8I_::
M=M#\BZ2^+5#0W !;7J[E\R*4]7XYL  &#:*\%5^[!F)[P*7Y:C-\7K]GSFAU
MX*K]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
M     04B0=P,,'YWFGEA8,9X>N^%<46NEO-@OU%-;;I;:R-LE/54D[5:YCFK
M]B]NY\4K%;+%*ULD3FR-:Y.9[SK?-F7[DVX]EMVE5<LO\03U55@;$<K%<LM(
MSZX^Q7:9K&Q-OMJ8Y(I516)<J5C;E!%&CIZ>GZ@:IJN_X%X'S!RPN27A'.O
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M-2U[\D8[X)?3@;KLY\MZ.^&E]54-^1._M4F)4[^U28J6OO\ G+I@ &0
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M*-G\G%,N_H#35'2&%I8JB_!J1SC?.$UE*$NIQE=?Z  'EGL@
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M.[(-;EB,/_)M>2Z?#QOA[V\/#>Y3YRI/)KW#C;Q6>A()$>G=%3X.HG(F)K
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MOZWT8$^["ORND?>8?Z50_8D^R7OV$Y(GV2]^PG((7!%BP #(
M                           !JU>%8?<>R\_&&WY!N1M*FK5X5A]Q[+S\
M8;?D&Y&U:C>5\%\+_<F:7M$\BZ0^!7UD#1%7Z/B($5^CXB!;5<$4J7W_ #@
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MSC*+X-/_ %L3  'T
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MCBY5>"@%9$U0G:NXIM7>3)N4 K-712L6Y68NX F
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M:'7@JOW8,Q/>!2_+49OB]?L^<J]M-\KUO@Z7T$6YV1>1:'PV(^FR( - )/
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MUDUFLBW6 Q]'$TH5J%2-2E-7A*+337V-<&GFGDR8$-4"*=8[A$
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M[5[N$O;0EU.+NL^J_!E'M.Z&JX#%UL)634Z4GG9VG!YQJ1ZXR6=UDG=<4T
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M^'TO05G&&+A%=/0OG=9.=.]MZFWFFK[M]V6?']F!#:3M0B:@;R
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MG@??UOHP)]V%?E=(^\P_TJA^Q)]DO?L)R1/LE[]A.00N"+%@ &0
M                              #5J\*P^X]EY^,-OR#<C:5-6KPK#[CV
M7GXPV_(-R-JU&\KX+X7^Y,TO:)Y%TA\"OK(&B*OT?$0(K]'Q$"VJX(I4OO\
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MJ.8]CE:Y%1454T,BBD$O)M/EQOR+&QDFDUFFKIKJ9$$-I"(,@
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M]' M]KK]6A61= +E5JZH3HNA1X+KU+W^ J@S+B7 *;'=14!@
M
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M]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
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M[BYVIVJU/1.#AAXN,JLFJF(JI6Z2I;.WZ,?%BK\,^;(M4B :Z;8
M      ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/WT
M^=_OPC^0+*2QL?\ Z=B/BO\ B0(8VW>3<-\;C]54/,P %B"KP  ?#N:^5HP^
MOJX^A_C(Z,G@UWWJF&/?7CW\JKB>]AX)>#7K_P"BIACWUX^_*JXGO9M(4_UK
M\I8[XS5^DR\>IGDK1_Q6E]$B"&T@VD-?-F(@AM(-I "((;2#:0 B"&T@VD (
M@AM(-I "((;2#:0 B"&T@VD (@AM(05WK%P3 EVMY,
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M"%<MK?E&E\5A]95+3;%/)=?XY4^A B "+"8@
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MZZN#NFDU8F'5O3M/2."HXNG9=)%;\4[]'55ND@^=T_2FFFT3  \@]T
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M\9I?#MQ;I89O$U';+P%[&G[ZHX6YV3MP9L1MZNO=W\WL*I+IP7S$Q5<N(E8
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M@!7!!%(@
M                 $%4H*NN\F<[7T$BKH 0<[0D7=N"=I(J@RU8D<O4A35V
M[S(5.":EL]>H&"FJ]9;2/*CW=1:/?^@ I/4LY'%5[BSE< 4)'F/F>7,KC'2.
MX@%![O@,?,[B7,CC&2N +:5QCYW]1<R/,7(_?Z-0"C(O5[2Q>[]'?X5TW]F\
MKR/,-=[K34-+4UM;/%245%3S5E95SO;%!2TM+$Z>HJ9I7^1%#!"Q\TLCO)C8
MQSW;FZ+F*;=DKMY66;SZES?4C$FDFWDDGFW9<.;Y+K-9+PDOE3>YN%<*90VN
MJ5E7BBOCQ1BB*)[5>M@LJR)9[=4)O=&ROO;H;I_ZM[ELE/HYT$LK'Z=Z^WS]
MOG]?$^M>7/RIJK.7-/%N/Y>E9;[I7NI</4LJ.:^DPS;]::RPR1.U=%--2M2N
MJHE5W15=7/&URQL8?));G5#0BP& H4+)3W5*KU]+/PI)];CE&_9ED4FUXT\]
M):2Q.(3;IJ2I4NKHZ=XQ:ZE.SDEE9-)JX !LQJ(  !)+(UC7O<NC6-5[EZD:
MU-5WKI]BB:NZD1S55=ZZ=)#FK^38[*W(S >'*FF=27JLM46),112,<RHCO>(
M4;<:FEJ&/\ME1;XIJ>WSQ.UZ*:ED1-E-6IH^<UIR7_[K6=V#,.54"3V.W5J8
MGQ(U[=J-;/87-K'TTC5:YCX[A6,I*&2%Z?7()JG91SM&KTD6-U7AU\-W'AU;
MO9N["$-KFEOZ/@8RROZHJI/FO!I)]_A/NL6$V(Z#_I6D91Y>IJ3:[I56O,H1
MRZFN*+B-N]/09*)-VA:1LU7X/5V>PR,:=9!Q80O(6]_092)-Q8Q-[^@R<:<
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M5M"JM2>!(G122V<U.UWH:3@J<FJ6+BO"HWRG[J=%OBN?1\8*_%+>*D:\;/\
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M"<D3[)>_83D$+@BQ8 !D
MU:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^,-OR#<C:M1O*^"^%_N3-+VB>1=(?
M KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P #)D]D>8'^^IRY_B\0?(]0=+Y."'-
M!Y@?[ZG+G^+Q!\CU!TODX(5RVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
M                       !^>9N_O4Q/[W[S\G5)^AGYYF[^]3$_O?O/R=4
MGTH^/'WT?G1\<1^3G[R7T6<?>H^V2_QLO]HXI%6H^V2_QLO]HXI%V:?BH_/^
M?C2]\P #F<2TK_M$W\5)_44Z_?)^_>'@?WH8;^1:(Y E?]HF_BI/ZBG7[Y/W
M[P\#^]##?R+1$)[9/$T?[[%?-0+ ;"?&TGW87_&/V  $%EB
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MJ&,>ZKW:IXB*2@^SI%:#[=SJ-[8%!J]JK^DJM77>5O[&OQYLD6JO]W-<.\F
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M#LWU2_DK!>RJV+Q.[5K\]S+P*2?5!-WMEO-D0 :,2(
M                           47IO*;N!7?P*0"915=40I.XHI61.*%-R
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M47V$Z+IZ.H'*W^Q68N\K%N3-=H#B5@
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M?R]:#4M>_)&.^"7TX&Z[.?+>COAI?55#?D3O[5)B5._M4F*EK[_G+I@ &0
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MV$":1T9B,)4=+$T:E"I')QJ1S[U;*2[8MJW,F [[]WP*#N'0
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M='A:5I.W25YVE6JOCX4[7W5[6*M&/)7S)--/@[\"H >$;*
M       ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/W
MT^=_OPC^0+*2QL?_ *=B/BO^) AC;=Y-PWQN/U50\S  6(*O
M                  SR]'VG4-YEG[UK)7WF4/\ :3'J&>7G,L_>M9*^\RA_
MM)CU#*::=_IN,^,U_K9%[]7OZ!@_BU'ZN( !Y1[                /X7-#
M][.(OYBN_P GU!_='\+FA^]G$7\Q7?Y/J#[8?\I3]_'Z2.OB_P E5^#G]%G'
M9LW[DI?Y-#_9-,@8^S?N2E_DT/\ 9-,@76I>*NY?,B@=7QY>^E\[  /H?,M*
M_P"T3?Q4G]13K[<G/[GN!/>;A?Y$H3D$U_VB;^*D_J*=?;DY_<]P)[S<+_(E
M"0KMC_)X'W];Z,"?=A7Y72/O,/\ 2J'[$GV2]^PG)$^R7OV$Y!"X(L6  9
M                                      -6KPK#[CV7GXPV_(-R-I4U
M:O"L/N/9>?C#;\@W(VK4;RO@OA?[DS2]HGD72'P*^L@:(J_1\1 BOT?$0+:K
M@BE2^_YP #)D]D>8'^^IRY_B\0?(]0=+Y."'-!Y@?[ZG+G^+Q!\CU!TODX(5
MRVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
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MLM3]&:B]9."NLG>3EDKW=EDLW?)<K<$N2+2PCNI1NWNI)-N[LDEF^;=KM\V
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MLZ>'OV/*=5<IK*.:C?BX-1=.SOW[->S30J-UZR8$7DP
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MJ
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M)63]XENI<%=OF4KUZUE>E,?5KQ;Z&F^CH)\%265[<+U))RD^-E%/@  ;4::
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M3CNSLI)Q23X.2^4G3470%71FCX82O*$ZD*E6=Z>]NVG-N/C)/)9$P -9-Q
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MDB"1Z:+KP^C3OZ5)]GAYB8&JV-R(:;@B$09
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MFVW6?,S ]S8FUT<=707JW3.T:]6[2HRJA9M.2-BKMJC5<KOL6GSW>_!D>4G
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MS!:.AT>$H0I)^-*UZD[>[J.\I>=V)=-Y%$(@\BQ[@ !D
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M$VNGG0')YY\.PK-=H544H:A%!Q+@$J.)@
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M"(                               (;*#0B  2JU%)@ 05"(
M                           (:$0 0V4&RA$ $-!HA$ $$1.'4-"( (:$
M-E.SOP]7I)@8L"&R@V4(@R"&R@T(@ AHA$
M         $$30B ""H1  (:(-"( (:!$(@ AH@1J=U]1$&+ @J$%:BDP,@AH
MA$  AH@1J$0                                  0T"(1
M                        !#0B                             ""(
M1                                              !!4"(1
M!#0B $@                                   $@     +
M                        $--^I$  @J:D08L"&R@V4[._'XR(,@EV$&PG
M'3>3 "Y#0:$08LNH$NPG8-E"8&1<ALIV)["&PA,#%@01"(!D$$30B
M                   "&A$ $- J:\2( (:#93L(@ AH$:B=^PB "&A#93AH
MFG9Z>/MZ^TF L"&B!$(@PU?B@0V4(@&0
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M7]I11VG$G 2+C4%!%*K7:@P3
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MIGQ%)B=97TW(G: 3M[>TJ\$])*B=1.G'T RB9J:(5&)O)2JQ-P,$X
M
M
M
M
M
M
M
M
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M279ZN^A51.H F;N15]1.U/A)535=$X(5 9N10KE-B=94!@
M
M
M
M
M
M
M
M
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MJ"EMJ2ZJ 5R&J%  %57D-LID%5 ";:4@2*_L&_T Y;K)]217DN[MU\PV^Q-
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MY8WV%)B%QYD]8!%O:56KHBD&IU$Z[UTZD!E*Y,U"=$(%1C>L&"H
M
M
M
M
M
M
M
M
M                                                   47(5B5R:@
M%!4U0IIO30JDCDZP<HJY1<FI35-=_7UE=W:4G;EU[>(.):.0MWM+U[?T%NJ
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M
M
M
M
M
M
M
M
M
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M:>PCJWL+1%([2@%WJG4NGJ(;7G^#]!;;2DVWY@"Y_P#>3X"&_M0M^D\PZ3S
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MI,U.L&5UDR)H3M3524K-3<#!,          0U (@               AJ1
M               !#4 B   "&I$7                      !#4B  -0
M!J  "&H!$                :@ #4
M                                               #4  $-2(  &H
M!#4B              !J     "&H!$             :@     AJ 1
M                               &H  U               (:@$00U(@
M              AJ 1    &H                    (:@$00U0B  "&H!$
M$-2(
M
M
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MX^U]_P",[<D51UWVB8G2TG3@Y4,'%^!1CDZG+?KN]I99QAXL6^;28 !O9'0
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M.NX CL]7M*B)U$&IH5.&[K4&5;F1TUW=2%0@U-"9$U ;^0F8G652")HA$&
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M+&$E9O)9R=^LE+9=KICM*U<9#%RIR5"%&4.CI*GG4<U)/-MVW4?48 (L)C
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M)::**-8-1<?H^]2=-5:"O[-1O**7Z<7:</UENWX29,VK.T;1VD[0A4="N_\
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MV(HTI[M%1ENSJ1B[.^63.FFUJ>TJDBKN]&A%O KNOQ\I: F !D
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MK#4+]%2FHPWI.3LX1EQ?'-LL=J9I:KCM&83%UW%U:T)2GNQW8W52<5:/+)(
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M
M
M
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M:SY#Q7O\/]?3-54 %I2GY2G^UR?Y#_ZJG6RY$/W',K?>#A3Y$HSDFS_:Y/\
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M;?-2#P33]YN<WOKPQ\AU9MOE3-?/*^-^$A]53+G;-/(>C_@I?6U  #43>@
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M;$? 5?JY')QI_M<?^0W^JA6*-/\ :X_\AO\ 50K%TEP104&XCX);^[<\OXG
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MYYO/F\_LX=R+I15E;JY=0 !R,@
M
M
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MV7(A^XYE;[P<*?(E&0YME_(8#X2M]"F3SL*_+Z2]Y0^G5/J, $!%CP
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M4)=GSK[1L^=?:3 6[?F^X$NSYU]I#9\Z^W]!.!;M^;[@2[/G7V_H)53Y^)4
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M?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
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MYB=)XE8?#1O:W25'XE&+\:4W]%*[D^'-KR=YO;F0\X,^DI;ZZC_8'E],J/\
MV88BI9$END2.<V1,,V/I(:ZZ;V*Q+C+XI9V.^U55;+%+3&X'R6_!_P#DXY<P
MP37/",69-Z8UJ2W/,"."]T;Y$T57PX=DC;8(VN5$722@J7,77HWM1SD/:R@H
MHJ>*.G@CC@@@C9%!!"QL<444;49''%&Q$9'&QB(UC&(C6M31$1-"^*YZ?U_Q
M^.E)*IZFHWRI4'N9<M^:M*3MQS4>J/,M)JWLST;H^,7*E'%8A+PJV(2J6?53
M@[PA%<LG+KER/YO#>%+99Z2GH+1;:"UT%)$D-+16VCIJ*DIH6Z[,5/34T<4,
M,;=5T9&QK4U71$U/Z+OH3 TB3;;<G>_&^?SW?RDA1@HJT4HKDDK)>;@2IZ-"
MA/ V1-E[&O;V/:UR>Q=2Y!A*W#+N,M)JSS7:><7*-YIOD]9HMJY,49789BNM
M6C^DQ'AZWPX;Q$LK]5Z>2ZV6.CFKI6ZKL^Z/CL;5551BNT-8KER># XKL$%;
M?\CK\N,:*)))UP3B&:DM^(DC;M/6.S7I[Z:UW.1K=EL=)<EMDDB(]4KI971T
M[MY(D<FO=/G1?1U=9M.A]<=(X%KHL3.=.ZO1K2=6DUU;LLXKWCB^TU'3FHNC
M,>GTN&A"I;*O02I54^3<HJTNU34EV7L<Q[FM.;@O^;&?U!@#%N'KI:+/@N1V
M(,S*"\T%1;ZFAM5MJ6PPV6KIJN.-Z55^NG0VZ*E>U'RT27.L9%)3V^I1O34H
M*&&D@AIJ:&."GIH8Z>"&)J,CA@B:D<44;6IHUD;&HUK4T1&HB)P,?2X;H(:V
MJN4-%217"LBIX*RNCIXF5=7#1]+XK%4U+6MFGCIEGF\79(YR1))(C%3I':Y]
MO!#.M>M=72M6G4G&-.%*&["G%N45)YU)-Y7E-]BLDER/GJ5J;1T-1J4X2=6I
M5J;]2JXJ,I12M3A:[M&"X9YMN7,E3C\/K12< U8W,
M
M
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MJ<7G"2>3BT5;TQH;%8"LZ&*HRHU%=V?BRC?*4)\))]:_T40 >B>8[<@  8
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MVJKY>O!S!SI\<R']ZEDM[VJKY>O!$6V#^AX7XS_A5":]AO\ 3\;\47UU(]6
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M^VG^2*OPM#Z9).R3RWAO@:_T)&WB "L!;\
M $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ=/KGM/O6<Y/>M)_K5*<P5>*
MEA]D']!Q/QG_  XE8MN'E#"?%?\ %F0 !+2^_P"8A1\/VOHF[CX)I^\W.;WU
MX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?54RYVS3R'H_X*7UM0
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M15;$2MX6]*\H0[%3C+=MU[SYDFG G -.2-^
M
M
M
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M.U4Z*K](Z.E8UF(XH6(J*^VPLKY&L1S;=*][T;/VK&TK"XS<I8FV%Q#LK/\
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MW_6[\F;<;8IJ=>"=_<[S;]_UN_)FW&V*5.U[\K8WX2/U<"Y^S7R)@/@Y_6S
M -1-Z               /Y?&W_$UW_FNO_U68XXUG_<E+_)X/[)IV.<;?\37
M?^:Z_P#U68XXUG_<E+_)X/[)I.6QKAI'OPGS8DKSMW_^F=^)_P $R( )N*^I
MG[?R?>4GCO*G$#\59=8EK,*8ADMM59WW6AIK;53NME;/25-71K%=:&X4O1SS
MT%'(YR0)*CJ=B,D:U7H[[:_;M.5?^&[$G]#8*_W7/+8'FXK0V$KSZ2OA:%:=
ME'?J4H3ENJ]E>46[*[LNT]7!Z<QF'AT=#%8BC"[EN4ZLX1N[7=HM*[LKL]2?
MV[3E8?ANQ)_0V"O]UQ^W:<K#\-V)/Z&P5_NN>6P.M_X:T=_8<)_T]+^ [7_B
MK2?]OQ?_ %%7^(]2?V[3E8?ANQ)_0V"O]UQ^W:<K#\-V)/Z&P5_NN>6P'_AK
M1W]APG_3TOX!_P"*M)_V_%_]15_B/4G]NTY6'X;L2?T-@K_=<?MVG*O_  W8
MD_H;!?\ NN>6P'_AK1W]APG_ $]+^ ?^*M)_V_%_]15_B-MOF(><KSXS2Y05
M#A+,+,N\XIPW+@[%-QDM-;;\.4T#JZA2W>*5*RVRR4%7M0=-+LL\8Z)VVNW&
MY4;L[N;>OTG.J\&D^^CMOO"QI\5I.BJWK])7K:5@Z-#26Y1I4Z4.@I2W*<(P
MC=N:;W8I*[LKNQ9S9-CJV(T2JE>K4K5/5%:._4DYRW5N66])MV5W9$P (_)-
M      )7*?/O*LQT_#66.8F(&2]#+9L$XHN,$F_R:FELU;)2Z*F_5:AL;47@
MBJB[1]!GG;SLM?)2\FW.>:%421N!+NUJN:CF[,C6Q.3975%79D<GF71>*';T
M?#>Q%"'NZU./IDD=#2E7<PV(G[FA6EZ*;?V'*]@^P9_D-UW\%5$U3MTU3AVH
MFI5)6?8IZ$^;Z$]A,75LEPY9+N*#7OGS:5^VP/8_F#,H8\7<J7+WIXVRTV%(
MKYC2>)S4<CGV:W/I*"1=Z;*TUVNMNJXW)M.Z6!C539<BGC@;*O@MULAES[Q-
M4O15FI<O*]D*Z[FMJ;M;DF];N@BT7JV5-;UPQ$J6B\=..36'FOV_ _O&TZD8
M:-;2VCZ<E=/$TW;D]SP\^SP?/P-_EJ=_0I,2\-WI)BH1=\  R
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M+T*P  ,@
M
M
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M5'35E9+)5UDSDW(Z6IG5\\BHFY%?(_<FNC2D >NDEDE9=AX<IR><G=L  R8
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M!PI\B49#FV7\A@/A*WT*9/.PK\OI+WE#Z=4^HP 0$6/      !!2)!>'=?@
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ML;\)'ZN!<_9KY$P'P<_K9@ &HF]               '\OC;_ (FN_P#-=?\
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M47>+G=6DD^:+!;-M!XG1VC5AL7!0K=/5G92C);LMW=SBVN7R$P -*-^
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M>'J-)<7N+?LN_=-GU+Q2HZ6T?4?!8FG']N\/[QT\T0B2M7OZU)BH*+P@ &0
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M&Z_X)A^]?.OWRX1^1[H1[M/\D5?A:'TR2MDGEO#? U_H2-O$ %8"WX
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M14U3RHY&KN54[%,X4O::;3XIM6ZK9%]8M-)KFD[]C28  .0
M
M
M
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M3G!KS22?GX+F1 !V%^.5^ZYU5^,U?OM>]@
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MU+PYVY[J@FG[Y+F27LHT.\5IBE-Q;IX2,L5)YVWX^QTT^5]Z2DD^.Z^H]YD
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M23K02IXB'MHUH*TG;CNS:WHOFGV%8$J.)C5S<        0U (@E1Q,
M    "5>KOUH3$J]7?K0 U6_"P/N296_C1=^1N)C15-ZKPL#[DF5OXT7?D;B8
MT52SNRWR/1^%K_3*C[8/+=7X##_0!%.OOUH0(IU]^M"0R+UQ7>=(GP<K[T?+
MO^>,Q_\ O)Q8>XQX<^#E?>CY=_SQF/\ ]Y.+#W&*=:R^4<=\;Q'ULR\^J7DS
M ?%:/T$  >(;"      #R9Y\C[U?-WWO1?*5">LQY,\^1]ZOF[[WHOE*A/7T
M!_3L'\9H?61/$UE\GXWXM6^KD<Q4 %RGQ91%<$#=?\$P_>OG7[Y<(_(]T-*
MW7_!,/WKYU^^7"/R/="/=I_DBK\+0^F25LD\MX;X&O\ 0D;>( *P%OP
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MF[M2@E>7NU+L/Z($B.4G-%)&       !  B"5%\Q,@
M
M
M
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MR:=CG&W_ !-=_P":Z_\ U68XXUG_ ')2_P G@_LFDY;&N&D>_"?-B2O.W?\
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M$=JJZZ:(F_4;KZGZ']PZ2/NH^E&0!1:N_=W^,JIYSBG_ *=QR3[NVV=GU$0
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MR<6'N,>'/@Y7WH^7?\\9C_\ >3BP]QBG6LOE''?&\1];,O/JEY,P'Q6C]!
M'B&P@      \F>?(^]7S=][T7RE0GK,>3//D?>KYN^]Z+Y2H3U] ?T[!_&:'
MUD3Q-9?)^-^+5OJY',5 !<I\6417! W7_!,/WKYU^^7"/R/=#2@-U_P3#]Z^
M=?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
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M!?U\4&B[2/)&)[Z7UD20=EWEO!_\WZJ9N=IQ3OU(5"FG%._4A4*L+[_G+C@
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M$G&<)*SC)9--$NX/%TZ].%:E)3IU(J<)Q=U)/A;\73R:31, #XG9
M
M
M
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M[@@ :G9Q[>I"9&^TBB:$^B=OJ (:$WHX=9%$U]'85 9_'XR)6MT)B*(54;H
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MT;Y5*BS3J+C&+\3B_"MNS(S<-%T[]^!.A$AU>GO)U_#((1 ,@
M    \@>?M^])SB_F[#/Y<88.9<O%3IH\_;]Z3G%_-V&?RXPP<RY>*EB-D'D_
M$?')?4T"KVW#RGA?B,/_ )&((  E=\OQR9"[^[YS>+\$[^YWFW[_ *W?DS;C
M;%-3KP3O[G>;?O\ K=^3-N-L4J=KWY6QOPD?JX%S]FOD3 ?!S^MF  :B;T
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M+>_SX_.0/4M+\W#]B/W#U;6_/5?WL_XC]&_NQXQ_QPQ9_G+>_P ^']V/&/\
MCABS_.6]_GQ^<@>I:7YN'[$?N'JVM^>J_O9_Q'Z-_=CQC_CABS_.6]_GQ]Z<
MUKFIBFJY1^2-+5XGQ)5TM1F/AV*>FJK]=ZFGFB6H55CF@FK'Q2QN5$U9(QS5
MW+IN/,4^_>:H^^6R,_&3AW_6''DZ?PM+U#C?8X?T3$>TCDU1G9K+BGFNT]K5
MS&5GI# IU:K7JS#73J3::Z:&36]FGS1U36,W:>O5-.OU)\14;P#?F3YPS@4[
M77YOE+RDP ,@      D5/,8J^6.CN5%56ZX4E/74%?3S4E=1U<3)Z6JI*B-T
M513U$$J.CFAFB>Z.2.1KF/8YS7(J+H9@E=P"=LU>ZLU9YW7-=IAQ3332::LT
MUDUU/K78<Z7GI>9MN&0-UGQS@BEK;ED_>:_1'Z.JI< U]=,_Q:R7.9%69UCE
MD5M)8[K4MT8YU+:KA5R7&:DEK_ M$W=6Y-?0G:O8U$_A+HFB:ZG8LQ1A>W7N
MW5UHN]#27.U7.DFHKC;JZGCJJ.LHZF-T5135-/,UT4T$T;W,DC>U6JU32'YU
M7P=:_88J;GCW(6EEO^%7=+773+[:=)?L/KKTDLN&E<CDO5I:FU(MMD>VZT*)
ML4ZW&F>D=#/NH^T:G4C'"8^:C65HT\3.5HU4LE&K)JT*BRM)NTTG>TK;U:MH
M&RZI2G/&:.@YT7=U,+"&].B\VYTTLZE-OVL5O0;LDX^+JE@N*REEIYIJ:HAF
MIJBFED@J*:HBDAJ:>>)=F2">"5K9H9XG^1+'*QKHU31^BJB+;DQK@FN?"2X-
M?H]G @Z2L[-9KBGQ3[> '?L]/;YM%T\E=Z;P [=2[S"RX9=WW\?->PA1(Y63
MQZQ3L75D\:[$S':ZHYDK4:]CDZE8K571%54755_3K9G=C:B;L46-,843=EK$
M;28HOE*U&MUT;LP5[6[+$55C:K7,155=-Y^8@^4Z$)>-",O?14OI7/O2Q-2'
MB3G'WLI1?IBT?I-VSFQE7II78QQ;7:M:U4K,2WNJ39:YST;_ 'Q72ZL1SE<U
MNB(UZN5K4U/S)86*]TJHBRNT5\BM1TCUTTU>]4VW+IHW>Y55$^SZEJ S"C"/
MBPC'WJ4?HV,5,14GX]2<O?2<OEDV15>_S>A.KK[54@ ?19</L=^^]^\^#65O
MQ]U^TG:]S5:K'/8]JHYCV.V7L>UR.8^-R(NPYK_*1VCEU3=IY*ITO.9)Y?;,
M]\G*":Z5<<F.L#^*X8QE"KTZ>::.G_X(ORQ.<Z5*>^T<+WMF=M))<*6Y0I(Z
M2EGTYH.GPZ^;AKV[^I.&JZ+JB*A[F^#UYI9@8;Y0=MBP9AZ\8EL6(*+W#S I
M+9&UU+;[%+(Z>AOMPGFE@H*9]HK8W3TJU-3%4RP/N,%$R=TTL,FA;1-!PQFC
MZM1N,:N%4J]*4G&,<MWI*;D[*U2*\%7SFHVOP)(V8:PSP6DZ5-*4J.,:H580
MC=YWZ.HHQ5[TY-7=G:GO7ZSH_M7AZ/A)RFUR*JZ=^K]!4*MQ[K=G&Q<!  &3
M(   )5ZN_6A,2KU=^M #5;\+ ^Y)E;^-%WY&XF-%4WJO"P/N296_C1=^1N)C
M15+.[+?(]'X6O],J/M@\MU?@,/\ 0!%.OOUH0(IU]^M"0R+UQ7>=(GP<K[T?
M+O\ GC,?_O)Q8>XQX<^#E?>CY=_SQF/_ -Y.+#W&*=:R^4<=\;Q'ULR\^J7D
MS ?%:/T$  >(;"      #R9Y\C[U?-WWO1?*5">LQY,\^1]ZOF[[WHOE*A/7
MT!_3L'\9H?61/$UE\GXWXM6^KD<Q4 %RGQ91%<$#=?\ !,/WKYU^^7"/R/=#
M2@-U_P $P_>OG7[Y<(_(]T(]VG^2*OPM#Z9)6R3RWAO@:_T)&WB "L!;\
M                        $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ
M=/KGM/O6<Y/>M)_K5*<P5>*EA]D']!Q/QG_#B5BVX>4,)\5_Q9D  2TOO^8A
M1\/VOHF[CX)I^\W.;WUX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?
M54RYVS3R'H_X*7UM0  U$WH         \1?"+/O0\S?YRRV_[TL%G-J7J[]:
MG25\(L^]#S-_G++;_O2P6<VI>KOUJ6*V1>3Z_P ;E]52*M;:_*='XK#Z<R
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MGQLLRT.Q+%59Z/Q%.;;ITL0NBO[53IJ4HK]:[:7-LF !%),X
M
M
M
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MXN5]U2G%Q3=L\F^1R#".[NGZ3I<LY@KDK]66<*?_ %8O"?\ V:I/^T$\E?\
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M>?.3;RO8LMJMJY1T5@Z>$I/>M>=2H^-2I*V]-]5\E&/",4DB( /#-C
M
M
M
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M2= G:9/HR78[[_H ,=T/?>.A[[S)=&.B3N@!C>A[[QT/?>9+HD[H.C[ #&]
MG:3=%WT+_8[[_H(I& 6/1+W0BD/?@7R1DW1^90"Q2'O^HF2)"^Z+S?"12+S
M%DD9/T?F+U(NZ(3I%Y@"R2/U$_1=]"];%YOG*J0^;X@"P;%YB=(B_2)"HV).
MI "Q;#VE5L)=I%YBJV/]0!:I%H56Q^;UERD:%5L0!:HPK)%H7+8RJUG8@!:I
M'YO@^<JI&7",[2HC>Q "@C.K3VE5(^Z%=K.TK-9Z@"W1JE5L>G:5T:B$Z-4
MIHPJ:$[6?J*VSIQW %%L?ZBMLHG'=YB9J=F[SDR-]8!+HJ\-R=A.UNA-LJ3)
MYMZ@RD$;V[B.O8GK&SKQ*@&7G)$83@J-9V@-DK6ZE5$T(@&
M                                         "&A$  AH1
M
M                (:$0
M                                  0T(@    AH1
M
M
M                 (:$0
M
M
M
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M
M
M
M
M
M
M
M
M
M
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MJ(3
M
M
M
M
M
M
M
M
M
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M(!D2;UX)IY]Q'8[5)P!?L((FA$F1BE1&Z P4D34F1G:50 01$0B
M
M
M
M
M
M
M
M
M
M
M                                      "56HI, "FK.PDV5["N "W(
M:%PK44E5B %#93L&SZ4*NPI!6J#-RBNO4-I>SX"H +]GSE+5.Q0B)YRJ05$
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MC.TCLH#!21J]A,C.TJ@ E1J(3
M
M
M
M
M
M
M
M
M
M
M                                 $-!HG81 !3Z/SCHRH "BK%(:+V*
M5P 4-%[!H5P 6X*RM0AL( 4@5=A!L( 4B&B=A6V$&P@!1T3L(E780;" %(%7
M80;" %(%780BC4 *)'1>PK@ H:+V*1V%*P *6P1Z/SE0 $J-0CHG81
M
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M.CL?5='"8N%>JH.;A&-2+4$TG+PJ<4[-I//*Z/N9%(D$(GA(V8  R
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M.K!/H5&$J<7&,\E-WG>\4XY/,]GT74F)6IYNLF-9CP^<VX  R
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MM'XO'>H,+5=>HH3G*<%>DE#=36^_&=Y>UNNT][D!+KV$QK!N(
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MGN6HK?IT\FVYU/%Y-6BY._&QM\*OGX?$3E!K>&O??H5D\YJR_'G-R_U(@ R
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M6I&K1DVHSBFDW%V=KI/)IIY<28 '3.^
M
M
M
M
M
M
M
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MY4C)FVN7_DRG?^V4[6ZNCKV((V+6_E:LU_8*J:XYJI0OZ38$ !6\M4
M "&\ B""*1       !KH>%!(B\FNBU373,W":IZ?<_$7L[-?CX+L7FNEX4!]
M[71_C-PG\GXA-BU12>E-'W5UZKH9=?LD35]=G_Y1I+XEB.'P<CGN]^_I75?7
MVZZ[\W@M'W"\4_C N'^H4!H,&_/X+/\ <+Q3^,"X?ZA0$Z[5%;1+7+U31\WC
ME==CC7\M*RM_-<1QS;_)YW-F5O'V?$I4*;>/L^)2H5G7/\<D6Q7!  &3(
M                     /YW$^)J.SVVX7:X2I!0VRCJKA63.5K6Q4U'"^HG
M>JO5K4V8XW+O<B:Z)JFI_1'A)X1!RJ/[F_)UOEHHJE8+_F;7T^!+6D:Z31V^
MLBGKL3U::*U\<<5@HJNA94L7^]Z^YV]=ZO:B^AHG1TL7BL/AH\:U6$.Y-J\N
MZ*O)]B9Y>FM)1P>$Q&*GXM"E.IRS<8MJ*OSE*T8];:1H*<KK/NJS2S0Q[F'5
MJJR8MQ-<;I"BN>Y([=MI2VBG9TFKTCI;534=-$QR_68HF1)N1I\Z]_F]/7IN
M5%\_4I$3J3S)YDW?0FOHU(([7AZ_-P7?_@KIOT=H[S;E+DT,-&E3A2IQM&G"
M,(1ZE"T8I>9?*42Q.)G6JU*LWO5*LYU)M<Y3E*4I>F7V'05\&9Y3RXNR)FP)
M75#IKIEA>ZNU4Z2.:Z5V'+S++>;2B:NZ1[**:HK[<Q>C;'#3T])3LU6-438X
MU3L]?H.<-X/'RIFY=<HBS6&OJ?%['FC2/P75K(_9@;?'=)6X4DE7_#J+HR2R
M4B(U5=67N#54:CG-Z/#4T\^_?ZRKNT;1#PNDZVZMVGB;8BF^5YOV1?MJ3MU-
M=9;S9?IOU9HF@I.]3"_S>I?C:FET<NW>A97[.?$J)P0B$!I!(B  !D
M @NHW@$3YKY97W(\SO>#BWBFO_L*NZCZ40^;.63]R/,[W@XM^0JX[6!_+T?A
M:?TT=+27]'K_  -7A[R1R.:-$Z&)$X)''IV(B,:B(B:*N[?_  M-Z^2BFR/X
M+.G_ *2V(U__ $(XP^''65WT&MS2?:HOXMG]5#9%\%H^^6Q'^)'&'Y=96EI]
M>$OY(QMLET$<N2\4ISL]\M:/XWZ9MW=V\JAT#^OO_A%0I]??_"*A4XNF
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M."$;[3?+&(^#H?5(EC9+Y#PWPF(^NF1 !H))0
M
M
M
M
M
M
M
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M>>1JQKS@]+3JPPL*WL,%*<JD%&"WK[L;J3SDDVNQ'U."DS7K]7GW%4U4W0
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MLJ&AITAMU^RSLL52Z-$=!)BG#K&4>)W-F:QC)99JJLIZMRM1=(:BGU75=_\
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M=D;/ZJ&R-X+/]\MB/\2.,/RZRM)KUX\D8WMH)^AQ1 .S[RW@.RLUW^#-_:=
M[K[_ .$5"GU]_P#"*A4TNF 0=P4_+LW,Z,)X!L57B7&F(K1ABQ4+=JINEYKH
M*&E8O!&-?.YO33/7<R&)'RR.71C'*<H0<I1C%.4I.T8K.3?))+-ON.%2K&$7
M*;48Q5Y2DTHQ2XMMY)'ZD#4>Y7?A36%[7/6VG);!]9BF2%SH(\78KZ6RV.9V
MG[IMEF:JWNJI]^U')=665[GL<CJ-8%9,_7\SLY\OE/XWEFZ?,NNPS12JO_!V
M"J*BP_ Q-5V5;7,BGO37,:J(NS=(HWN57*CW;.S(&BMF>D\2E*<88:#2?L\F
MIV^#BG*_9+=[;$9:8VMZ)PKE&G.IBYQ;3Z"/L=U?^MGNP:NK7C=<U=9G3@5R
MZZ)W[^KM&J[N/?U'(GQ+RH\T+U)TMYS,S&NTFTKT?=<=XJN#VN5$35KJN[SJ
MWR4:Q%1478:UNY$1$LK#RDLR+5/XU:LQLP;75::)4VS&^*+?4Z:HNB5%)=H)
M=-41?LT35$7J138_6<KVOZMI+OI2LNO^LOQ[/,:N]NN'WK?R?6MV5H-VZ[*%
MK^>QUZ0<S+D[<^SRELO:JG<['U5C>U1*WI+-CF*.]-FCW;;6W=60WR.1[-T<
MTMQJ4C<FUT#M7:[B/-@<]W@#E$2?L8K:1^!\R8(>F_8U754=30WZ&.-'5%;A
MBY(D2U;8=[JBV5<5/<:9CFR1MK:=LE2S4M/[/\?H^+JRC'$4$KNK0>^HKKG&
MRE%=;S2ZS==6MIFC=)2C2C*>&KR=E1Q"W7)]4)J\9/C99-\D>W@***OP[M_'
M]"<"JW@:.2&1 ,9=9GQTM1(Q='QP32-<J:HCF1N>U53K1%1-4UT7@.Q?+DO2
M8;LF^K,R8.<M<?".>5''45$;,083V(JB>)FN$J95V8IG,;KI6[UV43RD715/
MN[FMN?,SVS*S^RZP-C_$.%DP9?9,8/Q"Z&P4]J?'26/+S%^)*>;W16L<VD9#
M<;-133RN:YJT[)8W[+7J]LAXO9GI&C1J5Y/#RC2ISK24*CE)TX1WFXK<S?9>
M]R,<%M9T77KTL/%5XU*M14H[\(QBIMM9O?=HJV<N"-WLD<J]2=^_F-1CG"/"
M;K98ZVOPKD':Z/$M33=)33Y@WQDBX=\9:YS'KAZUQOCJ;S3Q.:B-N57)1T=2
MJN=1PU-*D5;-J^YR\YER@<?54M3B3-['KXY5>BV^S8@KL,6A(G*KDB]RL.36
MFCGCC1=ABU<-3-LHFW+(_:>[Z:%V8X_%0Z2JX86FTFE54I56GPM1CX2_6<7V
M'PT]M>T9@Y]'2W\9)/=E*BXJBFN*Z:7@R:_0WEVG5F1>Q%[--._T$Z:]^_T'
M(+MV?^/Z.5M11X]QS23QZK'44F,,1TT\>J;UCF@N+96+PWL5%W<>L]!.3SSV
MG*5RZJJ9]-F5=\66V#5)+-CN1,54]2UR(B[=SKWK?FRHU%2)WNQT;'NVY&2:
M(B>MBMC^*BFZ.+HU9K^KDI4V^R[<\^JYXF#VXX.4E&M@\13C?\I"5.JK=>ZM
MUNW.UW8Z>8-?KFSN?VR_SPJZ'!N+J9F7N9%4U64=#4U'38:Q-*UNTK,/W:16
MOAK]E'/2SW-D%3*QJNH9Z[9F;![_ +5T1.U>.O%._K3L54(STGHK$8.JZ.)I
M2I5%[62XKKB^$D^N+?5QR)=T1IK"XZBJ^%JQJTWE>/&+YQG%VE"2YJ276LLR
ML"BO7KJ'<%T[-./Q'G?C[CU'U<^157J[]2DOZ?ZR&L3S^W.>YMY 8GRUMF6U
MRLU#1XFL.)*Z[,NEFCNKY*FVW"TT](Z!\D\*P,2*LG21NCD>Y6*BILJKO 3Z
MH^Y4NJ?^4&$=/>C3]NG_ "Y%^9.LWO1&SO'XW#4\72=!4JF];>G)2M&<J;;2
M@^<7S(YT[M.T;H_$U<'75?IJ=D]RFG"\H1FEO.2Y27G/+#EC_=CS?_&OF5^6
MU\/ICF>?OH,D_?BGR-=CX#QSC*NQ'?+YB.Z/9)=,17F[8@N<D4:0Q27*]W"H
MNE?)'"BN;#&^JJI71Q-<YL;%1J.70_K,C<Y[_EUB_#^.<+S4]-B'#%?[I6F>
MKIDK*:.JZ":F5TU*JM2>-8:B1NPLC?*<CDT5"Q^*P<Y8&IAU9U)X65!6=UO2
MH]&I7LO!OGPO8JQA](TXZ1I8N5U3CC57?!O=5;I+9-J]LN-CK]@YQ?U1_P J
M7_&#"7^:-/\ GI'ZH_Y4O^,&$?\ -&G_ #T@/UIM*=>&_>R_RRR7KT:'ZL5^
MZ7\9T<P>4',O<J_&6=.1%EQ[CRJHJS$5=B#%5OJ)K?0MMU*M-:;U4T5&UE*R
M25K7-@C8DCD>[;?M.UTT0]7D4CO'82>'KUL//=<Z-2=*;B[QWH2<79V3:;3M
MEP)/T=CH8FA1Q%--0KTX58;RL]V<5)76=G9D0#2OYW+GJ<^LH,_\;9?8)O&'
MJ7#=CI\+R4$%?AZ"OJHW73#%INE6DE4^JC=(CJNLF<Q',:K6.1C=4:AZ.@-7
MZ^DJTJ&'<%.-.53PVTK*4(Y6C+.\UYCR=9M9\-HJA#$8I5.CE55*].*DU)PG
M--IM96@^!NGZ(1.;W=O"1N5/%2U,S,081VXJ>:1BKA"!4VF1N<W5$KF[M437
M>AT;K94/EIX)'KY3X8GNZDVGQM<JHF[=JO4NB</1VM8]4\5HKHEB73?3;SAT
M<M_Q-VZ:LFO&B=35C7/":657U*JJZ'=WNEBH>/>UG=]3R,L"CJJ[CX&YS?'N
M9&$\DL<XNRGK*.FQEA.@AQ'315]N;<Z>NM-JJ8I\0T?BBZ/EJ76-*^HM[(5;
M)+<*>E@UV)GH>#A*#K5:=*+495)Q@I3>[!.;25Y<E=I._#B;)C<4J%&K6<9S
MC2A*I)4X[TG&";>ZN;LGDLV??X.<3]4@\J141R8APCIIKNPC3*B]>Y4K4^/0
M]^>86YWS'.>N*,<X#S1KK34X@M]FH\486EMEL;:DJ;52UC+5B&GEC;+*U\M%
M4UUDJ(EVD?(RMJ=&)'2J]=TTOL[TA@L/4Q-7H94Z23GT<W*5FTKI;BNE>[?)
M9FA:%VH:,Q^)I86CTZJUFU#I*:A%R2<K-N>3:B[99O)9FSZ"33S^?CQ(LX&A
MWSMS^PD:_P"/,3 $FUQ,@G!XE\^7SB.(.3[EA:*_!53008WQ3B2EM=G?<*1M
M?3T]NH6.KKW5.I'2Q)([H(X*.)55&M=5OEVMJ)K7:H'U1]RI/\8,):>]&G^'
M^_47V&ZZ!U#QVD:"Q%#H8TY3<(]+-Q<G'BXI0E>-\K]:?4:%K%M&T?HS$O"X
MCII55"-27104U%2X)O>5G;.W4T^9T<P>+W,@<I7-_.#*NNS$S7N%MJEO%_JJ
M3"D-MM#+0QMGM;&TM35SL:^59WU=Q2HZ*5).BZ&!FRQKE>KO:!J[C5](X&6&
MKU</-QE.C-TYN#WH[T<I).RO9W3RXIFW:+TA#%X>CB:<9QIUX*I!5([L]V6<
M6XW=KJSM?@R(*6NGPA7]TZ^KT>O<GG0Z7<=\JD%/(7G&^>7RLY.S$M5RDJL7
M8]J8DEH\$X?DA6JIH7M<L==B&XS?WG8J%SFHQC)/&+I5*[;HK7401U513:>W
M*9\(7Y1V/JFHCL>(:3+:R3=(R.W81I('W!*>1%:K)[[=(*JNZ1&Z/2>@903Q
MN149(U=43=- Z@Z0TA%5*=/HJ+X5JMXQ?O$DY2[U'=_2-!UCVDZ,T;)TYU76
MKQXT*%ISB^J4K[D7V.6];/=L=(%5W]??U$NJKNT^ Y%F*>53FG?9NGO>9V8U
MXF5RO1]SQSBBN5JJB-^MI4761L2(U$:C8D8UK$1C41J(A'"7*KS2P_.E58LS
M\Q;-.CFO5]MQSBFBZ16*CD;.VGN:1SQKL)MQ5#)(9&:,?&XW)[&ZZ2OC*=VL
MO8*EK]2>]?\ [317MTPZDE_)]>W'\M2O;M6[;Y3KK(1.<IR7?"*>4/@*H@AQ
M-=Z',VQM>Q)J/%%-!37=(&HC.CI+Y:J:FF1R,U?TE?25TCI%:LLSDU0W)^;N
MYV?*WE&V]8\-5D]BQE1TZ2WG E]?#'>J/8:U)JNW2Q.6EOMH217)%<*%>D:Q
M&^Z%%;IU=3-TG6#4?'Z.BZE6FJE!6O6I7E&-^&_&RE"_6U:^5\T;]JWM#T=I
M.2I4IRI5WPHUDHRE[R2;C/N3N^K)V]1 2M7<3&GF]   %->KT+\1S.^?N^^H
MS*]-B^1Z4Z8B]7H7XCF=\_=]]1F5Z;%\CTI*6R+RE/XK/Z=(A_;5Y+I?&X?5
M53TG\%"^Z9FO[R[!\LUQO0FB]X*%]TS-?WEV#Y9KC>A/,VF^6,1[RA]3 ]?9
M-Y#PWOZ_UL@:;?A:GVK(C^/S"_U?"9N2&FWX6I]JR(_C\PO]7PF=79WY8PG_
M #_J*A]]J?D/&=^'_P#D4C343]?H/TO)C-^^9?8NPUCK#,[:>_X2O5!?;5(_
M;Z&2HH)VS+2U36.:^6AKX6RT-?"CF=/1U$\6TNUHGT1S<V5EIQQGCEI@V^T[
M*JSXGQ"EFN,#TVFNIZR@K8]K1%1=J.3HY6*U45KF(Y%:Y$5/PG/_ "5N^7&-
M\58#OL;H[KA.]U]EJMK369*29S::K;LJK-BLI%@JV*Q59LSILN<GE+9VIB:5
M2M5P<DI3="-7<E:TZ52<Z4EW7C:7+=DBI5/"5J=&GCH-QC'%.E&I&Z=.K3A3
MJQSZVI;T+>VBSK'Y YV6?,;!6%L=8?DZ2S8KLE#>Z%7*CGQQUL#97TLJIHWI
MZ.7I:6=$33IH9$1=$37]'Q%B"CM5OKKI<:F&CM]NHZJOKJRH>R*FI**CA?45
M53/*]6LC@@AC?++(]4:QC'.5R-34U-/!<.6DVZX?Q3D9>*I5N.&>EQCA%DCM
M5J<.5]5#37VCB7>Y76:]55'4*QSD3Q:]0,A8K*6=6_8/A(?+,;E[DH_ -MJE
MBQ%FR^HL"MBDV9H<*0-CDQ-.[22-Z4];#+#99=&R,DCN,D$D>Q*JMJWBM5:L
M=+?R;%/PJR4)6O[!+PU4[=VEG+M3+?837.C/0G\JR:6[0;G&Z_I$?8W37;*K
M9+*]FLC2:Y?G*TK<[\V\99CU+I$HKQ<G4^'::5'L=187MVU2V*F6*362&5]$
MQM950O5W15E751L=L1M1/CHRU@P_77:OH+3:Z26NN=SK*6VVVAAT6:LKZZ:.
MEHZ6+543;GGEBB:KE1J;2*Y4:BJGVGSC?)H@R=S1J,MHECDJ,,80R^BN]3$C
MT96XAN.#;/=L1US4D\ML=5>ZZNDIXG*JP4JP0:Z1M1+0X>5'#/#X*-HM4WT<
M%;*E1Z.&\^S>FDNMMO/,J'BU7Q*Q./GO24JJ52I*^=6MTD]U=O@R;7))+A8]
MO/!0_NK9I_B^MOY1P&]4G!#15\%#^ZMFG^+ZV_E' ;U2<$*W;3?+&(^#H?5(
MM7LE\AX;X3$?73(@ T$DH
M
M
M
M
M
M
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MJJ="'9(Z=>Y/1V$/8W:MCJ]&K0G0PNY5ISINT:EXJ<7%N-ZC5TG=732?(G#
M;&]'X:O1Q$,3B]ZC5A5BM^FHR<)QFE*U--IN*3SX97YD6KN0F((1(O)>/SO-
M3-"Q8*PW?,6XFN-/:</X=MM7=[M<*E^S%345#$Z:9^G&21R-Z.&"-'2U$SXX
M(8Y)9&,=S-.=)YSC%7*0QM/7U,]9;, 6:HEBP9A+I5;2TE,U71^[5RB;LMJ;
M]<H]9*B>7;=10O914BQQQJLFP-X4ARU):*@POD19ZE6.O44.,<:-AE<W6V4M
M6^+#MKJ6M1$DAK+E2U5P=$Y[F+[EPNDBUZ%YI<HNF_AIJO'M1-=Z\-R:*O\
M@[U3J)^V6ZJ4Z=%:1K0O5J[RP]U^3I\'-+W4WSX[CRXLK/M>UPJ5<0]&4)N-
M&CNO$[KMTE3BH2:XPA=)1X;ZSX(+KU\55$TTW[3D31NS]EM+JC4;IOT1$U74
M]?>2]S%O*-S3H:>\T>#H\(6&J9#-373'54ZP2UE-*FJ5%%:%@J+TZ-K%;+&^
MKH[?'4,>U]//*S>FP1S /,\6.S8;L&>^9-J@NF)L14D-XP#8[E DU'AFQU;6
MRV^_S4<\:1R7Z[4RLK*"61LC;9;IZ=U.C*R>=[=L1K%]'?\ 5YE[.M?CK7M1
M=&M/#Z/C";IO<J5ZD;Q4UQC3A=7<7E*4FU=-)6S?8U+V1+$4*>)TG.I"-6*E
M3PL'%2W'FI59M.V^K-0BHR2SD[Y+0QKO!6\YV4CIH,=X!J*M(VN;1JR\0M=(
MK45T:U3H9&-1KM6[:1>5IKHFNAX[<L?FSLZ,B'MDS"P?4P625Z,I\665[[UA
M225[FMC@?=J:)C;?4R.T;%!=Z:W3U*II2MJ$:YQU7#^:Q7A"VWRVUMHO-!1W
M:U7&"2DK[=<*>*KHJREF39D@J*:=CXI8W)Q:]CD]"HBIJVC]JVD*=1/$1I8B
MFWX<5!4IM?HSA;-+@I*2?"W,W#2NQG1E2DUA75PU5)[DG4E5I[W+>A4WLGSW
M7%\SCJ_.GM3M3M]2Z:[E73<;)?,.<[Q<<KL36K*/']VDGRRQ+6PV^PUUPJ=8
M\"WRLE2.D:R>=W][X9N=0]E/5Q.D936JIDBK8V14[ZU[/GGGQN:_IN3YCNAN
MV$H9&9;8Z?52V&G<^25</W>D;')<</++(KI'TR12-K;4Z21[TI5FIMM4H]&^
M'+V;37-553::Y%TUZT73MXKIOTW:IHO$FFI2PFF]'KA*E7C>,K)3I3BG:2X[
MDH2O%I<>=TR!*5;&Z TD\W3K4)6G&+>Y5IMIN#SM.,XV:;R5U9*2.R<WX]Y,
MJGD_S+?*ZGSBY/\ @^^W*H\9Q'88Y<(8ED?(CYY;G84931U=1IJK9;A;UHZ[
MZXKI)$GZ5ZJZ13U<:NNY>PJCC\'/#UJM"HK3HU)4Y=\9..78[778T7-T9I"&
M*P]'$4W>%:E"K'WLTLN]-V:Y-,JFNEX4!][71_C,PG\GXB-BTUTO"@/O:Z/\
M9F$_D_$1[.J'E71_QNA]9$\77;R1I+XEB/JY'/<-^?P6?[A>*?Q@7#_4* T&
M#?G\%G^X7BG\8%P_U"@)TVJ^2G\8H_WRNFQORTOBN(^>F;,K>/L^)1I\':&\
M?9\2E0K/U]_W%LEP7<:F7A3/)-2[8.P9G%;J76OPC7+A7$$L;$VY</7R5T]M
M?-LM<^1MMO2.2%5V8H&76O>Y465-='M41=>"Z[NU/5U*GP*G#?HK>N5RM.3_
M $&:F6F-\N[BK(Z?%V'+E9XZA[5>VBKIZ=SK9<-A-[UM]Q92UK6[]IU.C514
M547DIXIPK<K#=+G8;S2NHKQ8[C7V:[43U17T=SM57-0W"E<YJJURP5<$T:N8
MNPY6[;$1KD5;%[)],.M@IX2<KRPDO!3S?156Y1]%3>5[9)I<+%7-LV@?4^/A
MC*<7&.+I/?:;2Z:DE&7#A>FXNW-J_$Z*O@[O*F=F)R=+%9:^K2IO^6=74X)K
M]I^LRVBD<ZKPI*]%U5&LL$]+:D>]5?/):IJA=GI$1/=U.'T<#GM>#3\JE,%9
MYS8#KZGHK1FC:9K;3->Y>B9B>R1372U[MS&+6T$=SI.E<J*^=M%2LVI)V-7H
M0,7<BZ^C7CU\>^A%&O\ HAX/2=>*CNTJSZ>GU;M1MM+WLU-=B2)HV;Z;6-T3
MAVY;U2A%8:IGG>DDDW[Z#A+SE8 @[@:8;X?Q.8N.+?ABPWK$EWJ(J.U6"U7"
M\W*KGD;%#34-LHY:RJFED=Y+(V0PO5[U^Q1-==VJ<E3E)YYW#,W,#&.8%T=(
MM7BW$%QO.Q(C4?!2U,[O$*1R,^MM6DH6TU,Y(_(VXG.:B(NB;WWA*G*C_85D
M')@FAJ70WG-.[4F'G=&_9E9ANW307;$3M475(Z^*GI;)*U[=B:ENE6W7::B+
MST_;KZU7CIUZKYU\ZD^;(]$='AZV-G'PJ\NAI7Y4Z=G/S2J-+]1V96C;9ISI
M,3A\!"5XT(.M6BN#J54U375>---_KYJYZ1<T?R6US?Y0>7N%)J=\]GH[B_%F
M)5:B[$5@POL7&=9G(CMAE9<4MEHC>K58M1<H8I-6R:)U)HHFM8UC&HQK6HUK
M6HB-:UJ(C6HB:(C431$1$T1$T3<AJ:^"R<E%+5A#&N<-P@1*W%M:S"F'Y7M3
M;9A^QR>,7*2%SFM?&VXWJ1K)D17QS16FA?JCV*C=M)#1]IFEUB=)2I0:=/"0
M5!6X.=W*HUYVH_JDB;(]!>I-%1K2CNU<9+IWPOT:2A23R3SC%RL[YRNK$J)P
M\Q, 1V2F      "54^@F(.70 UR_"7N5)^PO(ZGP/15217?-&[LL[HFO8DJX
M>M/17*^3*QRH_P 7>Y*"@DDC7:CDKH&[D>NO/DX=7#J7=]"I\&A[K^$2<J!V
M8?*-N]GHZETMCRRM-'@NWQ->KH%NRODNV)JYK-7,943U]93VJ=S-6RTUAH'J
MB/:YIXDX1PE7W^[6JPVF+I[I>[C0VBVP^4J25UQJ8Z2E:[9:YR,Z:5JR.1J[
M,:.?HJ(6HU T6L%HJBYI1E6A+$U6\EX:3I[W5NT]WN=^LISM)TQZOTQ75.\X
MT9+"44L\Z>4]WC=SJ[W>K+B;R7@L_)E;9,K\59JUE/LUV/;_ #6:SS/8J.?A
MW"<LE#/)$]43:BJ,0K=('(J+LRVQ=A4:[939DS)P';L58>O>&KM$RHME^M==
M:*Z*1C9&OI;A324TJ*Q_DJK62*YNJ:(Y&\%X?F?)3R(MV6&7&",O[6W9I,)8
M;M=E1RHW;GGI:9B5E7,K$1KZBLK%GJZF5$^O3S22+O=J?0#V=FY>KOW^<KCK
M!I9XK'XG%IOPZKE3?-0@[4DNJT4NXM'JUH6.#T;AL&XI[E",:JY2G-7JWMQO
M*4K_ ''(/S\R@K\OL<XOP+<XW15V$,1W?#T[7[U=[F5LM/#*CN$C)Z=L51%*
MU59+'*R6-58YKE]'.8WY47]RWE&8+J:FI2FLV,GR8$O:O>K85AOTD"6M\J:I
MJL=[@MW1)KLK(]JN;HB*OVWX3GR6OV*9TVK,FAI]BV9GV2G2Y/9&]&,Q3A>G
MIK3,^1^B1M?7V)EGZ*)JJ]S[;6U#]5D536S@J9H)(YJ>:2FJ()&34U1"Y8YJ
M:>)[98*B&1JHK)H96,EB>U45CVHY/*1%2SF!K0TMHB&]PQ6%W*CY1J..Y*U\
M_ JJZOU)N_$J3I"C4T+IJ2C?>P>+<Z:X;U)2Z2.:MX])I-I+BUEP.R0CD(ZG
MQ/S=W*<CS@R4RYS!VF>.WS#5 V^Q,V=FEQ+;F^YF(J=K4>YS8&W>DK'4G2;,
MDM&^FF=&Q948GVQH5/Q-"5*I4I35I4JDZ<E^E!V=NPNA@\5"M2I5H-.%6G"I
M"WN9Q37GY$0 ?$[(**KQU7S[^I/9N3K_ %H5CQ$Y_;EC3939!WNDM52ZFQ+F
M+*_!%GEBDZ.>FIKC32NOM;"YOEMDI[.VJBBD;LN9+/&]DD<C8W)W=&X">*Q%
M'#T_'K5(P3ZKO.3[(J\GV)GFZ7TE3P>&K8JKXE"G*H^VRRBNMR=HI=;-7#GS
M^=EK,Z\6567V"KL],IL*5SX>DH952GQO?:1ZQRWJHEC<K:ZS4<C7Q6-G[DFT
MDN;6R=+22-U^25D:-1&MW(W1$1$3@B(B)NX(B(B(B=6]5T:C5]E^9BYKV;E&
M8_DGORSTN6F"Y:2MQ=/#M1SWN>5ROH<*T-0W3Q=UQ2-\MSJV*LU/;&21TR1U
M59!54EL84\'H7 <J-"A#-VO.<G;>S5KU*DFDFEQ:RW58IA*KCM.Z0B_RV*Q4
M]V/A;L(0C=VLVU"E3@KWXY.]V[OX@Y+/(2S<SIJ9H<M,"WK$E-2R-AKKTR..
M@P[;Y51KNCJK]<)*6V)5,C<V9:""HGN#H521M(]CV*[UDMO@R'*6FI4FEER[
MI9WLVTI'XGKI7HNRUS8I966-T3'ZJK']&V1C'MVD=*U=#?\ LOLO+'A6ST&'
ML-VJ@L=DM5,RDMUJMM-'2T5)3Q[FLB@A1C4U^R>]=9)'JZ21SGN<YW]MLH0K
MI#:SCIU&\/3HT*:>2E'I:C2R\.;DD[\<HJU[7=KD\Z+V*Z/A2CZJJUZU5I.6
MY)4J<9/CN147)+ME)WMO65['+JY3_,Z\HC*.BJ+MB;+ZLN5AHV[=5B'!]0S%
M%JI&(CE?+61T+&WBBIH6IMSUU7:J>@B:J=)5L^Q3S$:YKDU:J.3<J*BHO6FB
M[M>"]?4J;]%0[)BMX^Q-QJ0\_+S+5EK\/WS._*:SP6S$%D9+=L=85MD#8*+$
M-I:Y7W+$-LI8T;#37RU,5]=<((F1,NMNCK9&:W&"""OVC57:EZHK0PV.A"FZ
MCW85J2:BYMV49Q;DX;S]NI;K;LXI9FI:Y;(/4M"IB='5*E6%*\IX>HU*I&"S
ME.G-;JGNJ[<)1WMW-2;5C23[_I-C[P6?[Y;$?XD<8?EUE<:X"+KHJ<%1%1=V
M]%UX>SCPZM=38^\%H7_TEL1_B1QA^765IO&O,E_)&-^!LOVHF@;/%_YUH_X=
MMW[82[CH']??_"*A3Z^_^$5"I9=0E=P7T&I-X5?R?KC<<&Y;YE44M;+;\,7R
MLPUB"@2:9]!#%B2)DUDO3Z7:\7AEIKC03V=U5T?32NOU+!M)&Q4-MIW!?0?)
MO+?Y+E)G-E5C3+6LJ(*+]E%HDI**XST[JN.UW2&2.JM5T6G;)$Z5U!70P5+6
MMD8JNB16JU3W=6=*K!8_"XF6<*=5=)E=]'*\9M+KC%MKML:YK=H=Z0T;BL)'
MQJM*3AX6ZG4A:=--\E*22?9D<F'7>U.MRHUK4WN<Y=S6M:GE.<Y539:U%5VT
MW91=INOJ5R:N9@Y2&:4,-?8\NJ^PV>=J.@O6.7KA*BF8Y-IDE/27"%;Y402L
M5'0U<%H?13M5.BJG:J;QO-_<R]D_D+2T-=26N+%^.X49+4XXQ'2T]37Q5B+M
MJZQT2M=2V*FA>NS2)2(M;'$UO3UU3.Z6>3US:W?QXKW]&[=PW^TE'3>UUW=/
M 4(RBLE7KK)I<XTH[MEU.<G?FD0]J[L432J:1Q$HMYO#X=K)OVLZSWDVNJ$4
ME[KF:)&&/!3\W*NF;)<\R,!VBH5C5=31T-ZN;6.77::D\?BK7HW=Y21MVNQ#
M\PS?\& S[L--+4X:O6"L;+"QSUI*6LK+!6U"-9JC*9MRCDIGSN5K6-9/64T.
MJZND:B*XZ!;>!%>!J<-J&EE+>=6C./N)4*>Y_P!JC+_N-VGLBT*X;L:-:G+\
MY'$5-_\ [I2C_P!MCC[YKY/XKP)?JW#&-,.WC"^(;>[9K+3>J*6BJHVJYS65
M$>VG15='+L.6EKZ1\U%51_7:>HE9Y1_*X7Q5=+%<J"]6.X5EIO%JJH:ZV72W
MSOIJZWUT#NDIZJEFC<Q[)8WM16Z+HYJJU[7QN<UW24Y[_D"VG.C)C$5?2V^%
M<?8$MU7B;"%SCA:M;,MNC=57/#LDB(CY**^444U/'$YW1TUR6CKM/K#VR<TN
M.1'M:YJ[37)M-['-<B*BKUIM)V:;.Y$30F_5#6F&E\+*<X*%2G)4J]*RE'PD
MLXWSW*D7)).[5FKNUW7S775*IH7%PIQJ2G3J+I,/63M+)M.+:MX=-J+;5D[I
MI*^74JYJ+EQLS]R:P]C.K= F)J5'V'&-/3M9&R+$=M9&RKJ&0LT;!#<HG0W.
M")&L:R.K1D34C:P]*$-(#P4/.F>FQKFMES),Y]+=L,6O'%%3J[1D%5A^Z4V'
M[O4,CTT<ZMAQ#88Y7*OUIMO@8W:Z153=^;P*Z:X:(C@=(XBA!6I[V_37)0J)
M3279%MQ78BT6HFFY:0T7A<34=ZF[*E4?74HR<)2_6LI><F,/?&_WC6?R2HZO
M_N+S,&*OO[AK/Y+4?V+S6X>,N_[3:ZWB2]Z_F..I=_W96_RVK_UF4MZ:JEA<
MKX99(7+'/"Y\4CHGK!4P24U7#ML5%6*II)IZ>IC^QEI99X9$?%))&^XN_P"[
M*W^6UG^LRG][DMD[B#,'%N'<#X4H5N.(\4W2GM%II$56L?4S;3WS3O1%Z&CH
MJ:.>NKZE6JVEHJ:HJ7ZMB5%NPZD8TU*I)1IQ@W*4G>,8J-YMWX)1\W64"W9S
MJN$(RE.<MV,8I[UY2M%1W?"DY/P;+.Q_)84PC=K]<:2S6"TW2^WBNDZ&AM%D
MMU9=KI6S:*[HJ.W6^"HJZF3917='! Y=EJNV4:BZ>T>4G@[W*AQ31Q5]1A:Q
M80AE1CFP8MQ%34MRZ*1B/;(Z@M5/>'1:HJ;5/4STE3&[5M1%%*U\:;J?-J<U
MY@7DYX3IZ"T4M-=L:U]-$[%>-:BG9[I7.K5-J6DH9'M62WV2GD5S*2AA5B2-
M:V>K2:H57)Z:KZNI->_P:$%Z<VN5G-PP%*$:<6TJM6\I2M[91O%0B^*OO-I\
MN!875[8M1Z*,](UJDJDTFZ%&T8PNO%<VI.4EP;CNY\Y+,YS&9G@WW*=P_125
MU#9L*XJ2*-'>(X?Q-&ET>Y'2*K88+O1VNDD1K4:J:5T;G*[HVQ.5%5_B5CS
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MB #022@
M
M
M
M
M
M
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M &BDC@
M
M
M
M
M
M
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M,86IH/3DMRZ6&Q,*]*%K;U"<G-1NN3IWA+-VNUF=D!R_-Z34K\*AY5WN7A+
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MU$1$1$1$1$3@B(FY$3J1.!. +$-!H1 !!41>*!$(@
M
M
M
M
M
M
M
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M6.U0F-7-S!KI>% ?>UT?XS,)_)^(C8M-=+PH#[VNC_&9A/Y/Q$;'JAY5T?\
M&Z'UD35]=O)&DOB6(^KD<]PWY_!9_N%XI_&!</\ 4* T&#?G\%G^X7BG\8%P
M_P!0H"=-JODI_&*/]\KIL;\M+XKB/GIFS*WC[/B4J%-O'V?$I4*SKG^.2+9+
M@@ #)D\[N=8Y*;LY<ALP\%TE*RKOSK'47O"<3ME'.Q386/N5FIV/<YK8EN4\
M*VE\SE5L4-?+(K7;.B\K]'*J:JCFN_A->U6O:[K:YKD16N1=45JZ*U4T5$4[
M)KFZKOX+NTZNZ\.^AS#^>KY*+<H^4+C6UT=.ZGL.*:C]G%@U1R1+38AFGJ+A
M3PN5&M<VFO+;C%L1-;% Q60,1&QIK->R'3-IXC S>4ET])?I*T:B7>E!\O%D
MROVV_0=X8;2$(YQ<L/7?Z+O*E)]B;J1[Y1/M#FQN<UJLK.3#RB\(LN'B]]MM
M'35^7>U-T<\5VQX_]C-5+;VZ(^26S5#?V1S,16-:RG<UNBR*IKHQL:QC6-W-
M8U&IKO31-&[]?,B:N75RZ;U554JH]416HJHBZ:HBZ([373:1-$<J:KHJ\-VF
M]-]"65(V.>Y=&L:YRKOW(U-57T:)OX;NM.)+V!T-2PU;%5X+P\54C4J<,G&"
MCYU=.>=_#G)\"$=)::KXJC@\/4E>.#HRI4O>RGO6?7*UH*V6[&"XIFU[X+5R
M2O=C'.+\XKE2(^CP?;GX5PQ/-&QR)?K[$V2]5M/MIMQST=D:RW,J(M6+#>;C
M3;6BO1V\JU-/T<.!YD\T%R579/\ )]R_PS64JTM_K[3#BC%,+V;$T.(,21LN
M=913)_\ 3;5'-!:G[U17T;WHNCSTW:A5[7/3#QVDL16O>$9=%2MPW*?@IKWS
MWI]\BWNH.@UH_1>&HVM.<.GK=?2U4I-/MA'=AUVCV$0 :N;D      "#N U)
M)96L:Y[U1K6(KG.541&M:FJN55W(B(FJJNY$0!LT^?"J^5*E-;,O<F;?4*D]
MUFJ,>8GBCD5-FV6^22UX:I9XT54DBK[I[JUR;6RZ*6Q0N;KTB[.ERJ^;CQWH
MB?#HFY-W4JHFNFNIZ+\['RFW9MY_YB8KBGZ>U4UW?ABP*B:,99<,J^V4VQHY
MS7-FGCJJSI&+L3+5+,U/KBJOR#D+E!79@8WPE@:V[?CN+<16BP0+&J(]BW*L
MBIY9F[2*U%@@=-,U7:-1S&[2[.T6SU0T=#1VBZ$9^#*-#U16;]U43J2O:WBQ
M>Z^%E%=12S772DM)Z7Q$H^$I5_4^'BK9QIRZ&#C>^4Y7DNMNZR-]GP;/DKNP
M5R?8\67.D8R[YJ7RHQ6U9F-6:/#=)"RT89A5=%:L51!3UU]IW-<J]%?D:Y4<
MBL9L(^(0_P#TF'_X;/\ PG\AEAE_;L)X<L6&+3%'!;,/VBWV:@AC8D;(Z6W4
ML5+"C6-\EFK(D79;N371-VA_=Z%7M,Z2EB\7B,0[KIJLII>YBV]V/'VL;+S%
MN- :'A@L%AL+%*70TH0<FE>4DKSEPXRFY2\Y9^(0_P#TB'_X;?\ PCQ"'_Z1
M#_\ #;_X2\T[_ -._?T'F[S[?3_J>OT:]S'T+[BS\0@ZX(?5&S_PEG76*DJ8
MIJ>>DIIJ>>)\$T,D,;HYH96.CECD:K=',D8Y6.:J:*U7(O$RZH-GOO&]*Z:=
MK9\0Z46FG&.>3R7W')MY??)OJ,H\Y\R,O9HWLI[#BBX/LSWINJ,-W5WNSAJH
M1^RV-[Y+-743:I(5V(JQE53NT= Y"WY"G*:ER>S=P'F*DLT=%AZ_TC[XV';5
MTV&ZQ?$;\Q8HM'5&Q;)YZJ*EX2U5+ BKPTV/O"J.2\E+?,O\X*&!=FZ4LV",
M02,8JMZ>@6:YV&:5Z-V6:PS72F;MN<Z9R1MW-@1%U#%35%14U1475/-IO^#]
M2\"VFKN-AI/15)U%O=+0="LOTHITY_*E+N92W6C 5-$Z8K1IO=E2Q$<11GEG
M3<NFIKS-VN_<M'9"MM?!500U--)'-3U$4<\$T3FOCEAE8CXI(WM56O8^-S7-
M>U5:YJHJ;E+UIXU<PURG4S+Y.."TJ:E)[U@:G_8%=T<]'3Z8>9'3VB:9%U>B
MU%D\05'2.5\JL?*NBO5$]E4XKV%5])8"6&Q-?#S\:A5G2?;N2:WNZ7%=Y<71
M&D(XO"X?$PMNUZ5.JK<M^-W']5NS[B8TU/"N>3Q,]<K\U:2GUBIVW3 M\F;&
MYRM942>[.'W3/TV(88IVWJ!CGKI)47")C/*71VY6?&7+^Y)=OSORFQCES6NC
MAJ+S;9)+'72(BI;<142+562N7R7+T45='%'5(Q$D?12U+(WLD>R1OK:IZ8]0
MZ0PV(?B1GN5>KHJBW)MV]RGO=Z7,\?730?\ *.C<5ADKU'#?H]?2T_#A;AQ:
MW>-L\\CD^&[IX+[RX**OPI>,AKS6,CNV&ZJXXFP9!,Y4=66&[5CJZ_4-+M+H
MYUNO=7/<GQ-U=L7=\NKHT332WQY@2\X6O=WPUB.WU%IOU@N-5:+Q;:ENS+1W
M&BF=!4P.7[%[-IJ/AG8KH:F!\=13ODAFBD?E\I,U\0X%Q-8\883N=19\28=N
M$-SM%RIOME/50[6J/9HK:BGJHWR4M92SI)!5TLTU-*QT<KFK9G6?0<-*8&5!
M2CX5JM"I>ZZ2/B-/G&49.,K<8O+.Q4K5/6"IH?2$<3NMJG>EB:5[-TI-=+"2
MY3C**E&_"<;.R.P4Q4WZ$YKT<W;X0=E7FA;*&T9CW&W9:X_CBAIZV.[3I285
MO54U$8^LLEYJ'K!21S/VGOM]TE@J*16R-26I@;'42>[=HS2PU<*5E=08AL5;
M1/8Y[*RDN]OJ:5S&IJYS:B&H?"K6IO<Y'JU.*J58TAH7%82HZ5>A5A-/G!M/
MMC)*S74T[%Q-%ZPX+&4E6P^)I5(2S\9*2[)1=I1DN::^0_NE/AKG)LYL.X%R
M+S1OV)[@RWV[]B%YM4#G)MS5EVO=%+:;1;*.'5%FK+A<:RFI8(]6L1TBS3/B
MIXY9F?PG*CYV?(3*6WU%3B/,&QW"X1QO?!A[#5;38AOE7*Q-U.RDMLLS*9ZK
MHBNKI::.-J](]R,U<:%G.C\Z]C3E*XAB\;IW8:R_L=7)+A7!L50LSXW;"PMO
M.(:ENS#7WV>)9=EL$;*.U02NH*-U4K*BY5VT:G:EXO&XBG5E"5'#4IQG.K-.
M*ENR34:5[;TG:S:\%)YO@GJ.O6O6$P&&JTH3A7Q56$J=.C3DI.._%QWZMGX,
M$FVEXTFK)-7:\GX(U9&QBZ:M8UJ^E$1.Q.S7T=ALA^"S_?+8C_$CC#\NLK37
M"U_3V>G3M]9L>^"S_?+8C_$CC#\NLKB>->8K^2,;V4/[T2N>SWRU@'S==W_8
MF= [K[_X1%4[^PAU]_\ ")]"I37X[BZAX!^$JV::KY+UWDA:KFT.,L'UL^B:
M[,#*^>![UX:)M3LW]BIVG.L[]_.=6OG)N3E/FQD5F=@*B8C[K><*W"2PM56M
M1^(;6C;M8H'2.U2*.JNM#2TL\J;V4T\VB+O1>4JK'M56R1R0RL<Z.6*5CHY8
M98U5LL,L;T:^.6)Z*R2)[6R1O16N:BHI8?9#BXRP-:C=;U/$N;5\[5*44GW7
MA9=J?85@VW82<=(8:M9[E7"JG&26473J3?IM//L\YT#?!?\ ,"W5_)XN-B@F
M1;CAS'M_;<(-=7Q176&AKJ&5W8V:-)=GMZ)7:KM&Q\KMW6AR^N:CYRZ]<FO'
M_NPE-)>,$8B\5MV-[!&[2IEHHI'>+WFSN<YL3+S:%D?-%%*G07*F6>VS/IG3
M4U=0=%7DO\N#*S.*UP7/+[&=FOJRQ-FFM<=7%!?J#5K7.9<+).^.Y4KHE=L.
M?)3]"KVN1DK]ERI'>T'5S$8;'5\3T=2=#$U'556,6U&4\YQE;Q=V5[72NN!)
MFS'6K#8G1V'P?20IXK"THT>BE))SA3\&$X7?A;T4K[K;4LFED?6:!2FUZ\-%
M]>I\-\JKG),E\FJ.IFQUCJRT5PA8_8P]0545UQ+42M15;##9:%T]8R231=A:
MF.")=ER;?DJAHE#"U*LNCI4YU)OA&$7)Y]R9).*QM&C!U*U6G3II-N<Y*,4E
MVR:1]9Y@8QM5AL5WO5[N%):K1;+;5UMQN5=,RGHZ*DA@>^:HGGD5&1QL:FJJ
MJZJNB-155->0SF1=J:OQ'B.OHY4GHZ_$5]KJ2=&R,2:EK+K5U%/,C)6,D8DD
M,C'[$C&2-UT>QJ[CU^YU/GJL:<HN23#-KI9<&Y64U2R:GPVV=)+MB&6"1SZ>
MX8JJXGOII48J,DI++1I)0T4C5EGJ;A.V&:+Q-U[IW7AU>EVNNNZQ^SK52MHZ
ME6J8AQC5Q'1^Q)I]&H7=IR63J-.[2NH\&[Y*JNU#76AI2M1I817P^&5273NZ
MZ:<\FH)YJ$;>"VE*3ODHK/WZ\&C^^CH/Q?8U_K64Z*C.!SJ_!H_OHZ#\7V-?
MZUE.BHS@1IM6\J?_ (]#YZA+VQSR/_\ E5_[A,8J^_N&L_DM1_8O,J8J^_N&
ML_DM1_8O(VAQ7>OG)2J^)+WLOF9QU+O^[*W^6UG^LRGHQS.^<>'< <IS)_%N
M++C':</6Z]7^BK[E,CEIZ.3$N!\4X5MDU4YJ+T-)[KWR@;5U3](:.E6:KJ',
M@A>Y/.>[_NRM_EM9_K,ICG-145%35%TU3=HJ=BHNJ+ZT7T%S\9@UB<-4P\FU
M"K2E2G)<5&I#=;74^_*Q0S1^/EA<72Q,-USHU8U5&5]V;ISWDLK<5=99G9&@
MJHY8V2Q/;+'*ULD<D:H^-['IM,>Q[=6N:YNCFJU516JBHNBH7.UN- [FG_"!
M[WE12T.7V;\=?BO+^G;%3V7$=-MU6*<)0-T9XI41OD5<06*&-$6EA:D=VMR-
MDCBEN-*Z"DH=T#(GET9/YE4<-;@K,7"E[25FJ4<5YHH+I%HC5<V>U54L%QA<
MQ5V7J^F1J.1S4<NBE5M8-4,;HZJXU:4YTF_8Z\(N5.:Y>$KJ,K<8NS7:LW<;
M5C7C :3HQE2JPIUK7J8>I-1JP?/P7;>5^#C=/KO='UF4Y.'I/QW,'E$X"PG1
MNK\38TPK8*-C'2+/=K_:Z%CFL15<D25%2QTS]$71D+7O<NYK57<:K7.N^$7V
M22R7++_D^UK[C<KFR6BO&9'0RPV^U4$C594085BGCC?7W6K8Y8VW>5J4=LBZ
M1]/#55KXI:+IZ'U<QF.JJG0HSXI2J2@U3IJ^<IR:227I?),[NG]:<%H^A*KB
M*T+[LG"E&:=6H[91A%7=V^;LEQ;23/);PA7EH4V:^>\UCLE4VKPIE90282MT
M\3VR4]=B"HJ&U>+KE3O;]G#XU#06-BHKHI?<)]7!(Z.K15\(7R(UJO<J-:QJ
MN<JKN1&IJY57S)O55X)H5I)7R.<^1[GO>YSY))'.?)(][E<^21[M7OD>Y5?(
M]SE5RJYRGJUS,W(7J,]LZ[);*NDEEP=@]U-BO&U3L:TK:"EJ&NM5HED<QT2S
MWZY0I!#3O1ZU-#2721&.BI9UCM)2A0T3HY1;2I8.CW.4MV\FUSE4FVUQ\)M<
M"G]:I7TUI.4[.5?&UUNJ/"$;I16=DE2II1;ZH7YF]GS-O)OJLK>3?EAANXP.
MIKU5V:3%-]@E;LU$%UQ;6U.(9:*I1$1$GM5/<*:T/V=6_P#!Z:.DWR/]/RW@
MB2-C(XV-8R-C6,8U-&L:U$:UC43<C6M1$1.I$+@J3CL9+$5ZU>?C5JDZC_7D
MY6[E>R+KZ-P4,-AZ&'AXE"E"E'NA%1OY^-^T@O5WZE)?T_UD)E)-?C7YE.H^
M7XY,[C.1_P L;[L6;_XV,RORVOI]'\T+6Q4_*=R3EF>D<:8UACVG:Z;<]LN<
M$+=R*OUR:1D:+IHCG(BJFNI^$<N:R3VW/#.F@J6*R>ES=S,B>BHK4<W]FU\?
M%*Q'(BK%/"Z.>%RHFU%(QVF\_)LF,TJ_ V,,*8UM<:37'".)+)B6CIGR.ABK
M);)<::X>(32M1SV05R4[J.H<UKE2"HE5&N71I<B5!U]'.G#C5P?1KM=2BE#N
M3;X\%S*,>J%0TMTTEX-''NH\LFH8EREFN=DW;B^1V!1J?)_)HY;F66;6'+?B
M7!>+K+<*>MHH*N>WON5'#>;4^1C%EH[O;'S)54-52RNZ"9LL?1+(U5AEEC5C
MW?G_ "F.<RR/REH:BJQEF'AZGJJ=CW>XELKX+UB"=[$1>AAL]L?4UB2O1?(Z
M=D+':.V7KLKI4:.C,0ZG0JA6=6^[T:IR<K]5DKY%UY:8PD:73RQ-"-%K>Z1U
M8*-K7O=M'W<CM28^#.;RY<-+R@L#UF85JP[78>L$F([M9;'%<ZB*6XU]':'Q
MTTUPK(:=JT]$^:M\98RDBJ*OHX8V.DG25SX8OO)JZGPQ6&G1J3I58N%2G)QG
M%VO&4<FG:ZNGQ.Q@\73KTJ=:C)3I58J=.:O:49*\6K\FLT1.:AX0A]]MF=_)
M,#?D/83I7G-0\(0^^VS._DF!OR'L))>R3RE6^)U/K\.1)MN\E4/CL/\ X^(/
M$B_?N&M_DE3_ &+SLH6+]Q4?\E@_LV'&OOW[AK?Y)4_V+SLH6+]Q4?\ )8/[
M-A[>V3CH_P#_ "O\$\'89_\ 4/\ D?-(RC>OTJ3$K>OTJ3$)%@@05-Q$@J '
M.#\(=Y*S\NN45>K]24_18?S1HH,:6US6Z0QW?8BMV*Z-':(JS>ZE.R]S:ZM:
MV_PLC5=AS&>17)_SEN&7F.,(X[M:S>.X2Q!:[Y&R!=)9XZ*I8^JI6+JB(^LH
MO&J-%54TZ=RZIU[Y/A*G)9;C7(C]FU) C[QE==8;XLC43I'6"XNCMEZCVMES
MW11=-25SXT1&IXKTSU1L2J<]G=^E/.G'?VHO'35==VF[2T>H>DHZ0T53A4M*
M5*#PE6+YJ*M!RZU*FXE/=HNBGH[352=*\%6G'&T6K*SE)R:3X7A54EV)IOCG
MZJ<\[RP:7.G/W%&([/<&W#"EEHK1A7"DL+G.II*"V4,<]UJH-5Z.1E;B.LO+
MX:IC=*F@;1+K(QD;D_%^;/Y+#LY<\, 8%EI_&;357B*ZXDC5B/B7#=D5MPN\
M4[%W/@K8J=EOD;KJC*M7(NNA\)=_I[^U57>;E?@JG)8<V+,3.:Y0;II:7 6%
M72,3:V*9&7;%%='M-^PEEFLEM@FC5CMJCND+T5KD.WK#B:>B-#U%1\'H:4</
M03XN<UT4)*V6^DW5D_=1;.KJQA)Z:TU2E6\+IJ[Q.(ZMRFW4FG?VMXQI1Y)2
MC%<D;CE/3MB;'&QJ-CC8UC&IN1K6M1K6HGF1-$[$0N21-=Q.507V_P"_RERT
MK)+@EP75V>8  R9/@7G.^36[-S(C,K D,22W"Y6"6NLJ+NV;_8IX+[8W(J:*
MB)=+=3(]$5KI&*Z-%T>J+RJY89(WR131/AFB>^&>&5JLEAFC=L2PRL7RF2Q2
M(Z.1BHCF/:Y%1--_9(5$75>SX>_ZSG+\_P <WI4Y.YLU>,K+2*W+W,VNJKQ:
MY(VHV&R8EE9XS?\ #TJM9'&ULT_C%YM.FNU05$U*JN?;99I9EV2:>C3J5L!4
MDHJM:K1O^=7@SBNV<+2[=RW&Q VVK5V52E0TC3@Y="^AKI?FI>%";[(3NF^6
M_P!1B/!_^7#19.9V^YN(JY*+"&9UOI<*W:HD<K::BO=/6.GPI=:E=4:C(JFK
MN%J?([=%%>II55=A#H_P.14U:NJ+HJ*F]%33BBIN5%[ZG&U?'JFRY-SD5%33
M<O;HJIO375$7S+P-N_FC?"'Z;#5IM>6>?=3.^W6R&FMV&\QV1U%7/!0Q*D,%
MOQE&CIIYO%(UCBIK_31ZK20HRZ0NGC6MJ/6VDZEU<1-8[!P<Y[JA7HQ5YS4?
M%J4UQ;2RFE>Z2:YGB[*M?*.%B]'8R>Y2WM_#5G?<C*?C4IODF\X/@KM.V1NP
M@_)LJ<]\&8ZM[+I@S%-@Q10/8R1*FQ76CN36->BJU)VTLLDE,]=%UCJ&1R-5
M%1S45%/Z7&N8M@PU1/N6([W:,/V^+[977NY4=JHV?Y=57300-];T((=&:>ZX
M34EENN+4K^]M?EU%C%BJ3CO*I!Q]TIQ<?VKV^4_LG+N[Z$C':[]Z>9=W;WUX
M+Q153136IYPKPCW+? -OK;'D_)19D8VD9+!#<F=/^PRQSHO1I4U]<Q8)+S+$
M[;<RW6N1K9',9XQ74L,K)'^?_,R<_7B&?&,N7F?6(O=2BQC=JBIPSC:OZ&F]
MP[Y<JCI&8?N*11QT\-AKYY5BM$OD,M%5T="_6CJ(74NU4M1-)3P=3&>IW&--
M)JG--5:D/;2C"U]V"SS2;5]VYIM?:+HJ&-I8+U0ISJMQ=6+3H4I^UC.?#>F\
ME:Z3M>QNLIQ)BE&NO!=?TIJB_"5343>$P  9
M
M
M
M
M
M
M
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MJ8:IJTD]=07.EC>LD#$<Z6BF385R(U':.3PN^I7N3SK^^[.3S?\ E)@Y?_X
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M+@3#J-LJ6CZT,9BZW2XBF[TJ=)RC2@[6WIR=I5&N"64.;3Y0CX)W^GA[.PG
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MSY+)<BR%"C&G"%."M&$5"*NW:,59*[S>2Y@ 'S/J
M
M
M
M
M
M
M
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M1T[]T(@IZEDB[Q)KYE[^A""MWK]!4!RL"GO[./Q$S4)@82M_NW\YBP !DR
M 0(*3  IJWNI'3A[-Q. P4U[=^[J)F<"8  I-3J*H!AHIJW<15.Z(A.##5S)
M*U-/C)@#(2!!5(@ $JH3 Q;F"DJ*A43@1!DPE^.0  ,@   E=PW;B8 %-.W?
M\_ FZ^!,##0*:-[[R;90F L/QED0T(@"P  ,@
M
M
M
M
M
M
M
M
M
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M2'ZL;+S$NZ$T7'!83#X6%K4*4(-KVTU'PY?K2;?G)@ = ]4
M                                                  &'O3M:*L_D
MM1[.A=O[Z&8+.IIFS1R1.UV9&/C?IIKLO:K5T5=4U35=%5%ZET4RG;/JS]!P
MJ*Z:ZU;TY''@AL-?=;TZUVJBJ[I<Z^Y54%#;K=33UU?63.GE<D5)1TL<U342
M;*.5611.<B-<[393:-KCF0N9@SHPIFS@'.W'-OH,%V'"SL1U<6'[O,^3%=W2
M^X-Q'A>G1MOI$EI[7%"^^QU\C[A5-G=#3] RD5\RR0;2G),YNO)S)*"9N7N"
MK;;;E6;[EB.L:MUQ/<E5[I-*N^UZS5WBZ2/=(R@II*>W0R/>^&DB<YRK]L:)
MZ5]NOJ[\>KJE?63:?4Q5*IAL+15*C4IRIU)56I5)1DMV2BEE#+GX3YY$,ZI[
M(Z>$K4\7C,0ZU>E-3ITZ'@4HRB[WDY)RF[Y^TCV-%5KM4U)B5J:$Q$R)I  ,
M@
M
M
M
M
M
M
M
M
M
M                                     @J#93L(@   6
M                                                        (:$0
M 0T0:$0+
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
D                                             __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>oncyf-20211231_g1.jpg
<TEXT>
begin 644 oncyf-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (; I\# 2(  A$! Q$!_\0
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M%ZS.0*N^<95(]:I2V+>9\O/-!!>TFY9E^:K5U<;!4>E6+ #=UJQJ%IN@/;%
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MI7_@CQ!Y/_!0OP![_P!H_P#IMNZ^:K>;SACK7T]_P2(BV?\ !0GX?'_L(_\
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M%^R1^V3\+=+N_%GB6]^*FJ>';C6I[06,9T<Q2V\J-$L@(D1UPY!.X,(SG:6
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MB7-U<16)9,>J.W^KQV\K9S[U\NZ-XSUZ[^)]D_B-;(6<*E8RKMY0)^Z_))8
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MVM:M::;>V.GMI5GYXDN]P2ZN';9;V:8'^NG?*IGCY23P*XS23OB&ZO8/A_\
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M3TMMIYH-K!;VBQ**^D_^"2+@?\%"_A\O_81_]-MW7S=)/Y5?1/\ P2*DW_\
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MM@L6%<3\.?V4?^%@^'O!<[>,=$TK6/B))<V^@:7<6MP[3S0S-"5FE12D",P
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M-TO28E2)HN6VJN /K[^I-?F7'/%=+&91'#X;2<VN:Z?NVZ;:MO:W1:V/;R_
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M7P/^V-=?#H:;'IG@_0%M=!U:?5M+MGOK_P FU:?;YBR(LP%P?EPCS!FCW''
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MK;\;EO%.A72,TGEVL[S0D _.VT\'U')Y[5\Z-:"&:XFU76ETIKI\1G.UH6.
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MH^#^B1PR^/(;R\3QU\3]/O-,MUDTU]-UJXCT\6SB5(?[1S#+Y4@AAE:+<55
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MKN%^8G)SJ^)?VIM4U_Q%KE]J?A[PAJMKXJC@;6M-N+.4V>IW$))2\(64/'<
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M/6G@Y4DITW[OXO\ R\NI]R?"OPQ\._%-];S7G@'PO+JEQ)Y(E@.XN!@Y /
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M?LCW5C9W#:U,NB:I!;&^US49E#1^&[$9+1 GC[0R@[AV.%Z*^?F;XL^(]/\
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M[CPE+;Z=! VM7(L[9XWA=<>?(,,$))(.57GBOF,1M/(L:*TDDC!551EF)X
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M>I\X_"">\N_A_INE^'9O MI8ZA+=0^.'U@6YO6A,B&!0L[*K6;1@API)#*>
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M!LM/'9'V_*V/^>:80=RU9_B/X^R>/=$NM)\26[76CRNDD=K"Y@6 IG:$V\*
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MDS0L L4(^9BX[#MGKD@5[5JNL>#[SQ3<:+?W^GRR>&XT/]D6TJ.--! *RSQ
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M0K<Z)/M$LMM-;D,L9)'W&^8 'HW/%>OZ#^UK)X3M9KR9K>Y5GPT:JWES*/\
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M[ U\=I936S-'*C1RH2KHPP4(Z@UUG@;]HF3X52M%?:6TUY<I:V%C>6]P85A
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MJ1_,*DNAF(LOI3KCPYJNF^'+/6)M-OHM'U">2VM;YX66WN98\&1$?&&9=RY
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MIF>2,.[/R>%$6 !C.:\M^)]Q#?Q^'+W3+A6OK56T\J[*[,5!SYB8P 5QM4C
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MTKFIU2*?Y8UX.1QTHW+J4.:5V_Z_R_4CTR&2:[FFD6-7N)&D8)&(T!)).%4
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MHW>24=4X^JL^UC<\1ZQ9ZYXFNKJQMUM;60KL01+%DA5#/L7Y4WL"^U>%W8'
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M<JG*HSE?FIV=WR:V7-LW:]O)N_#^/+3PWXIT^WLM4TS3_#]NO""&R2T:!B,
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MO$$D>1UW]Z]NNOVB;GQ1\&]4\;:'XCUKQ)8:WJD&GVVC7D'EQ^%!%ES%L P
M(Y(XU:/.]5W-R,#ZS.,QKX_A_#8JA=RHWI5)*S2BK.%^JW:3_NGY-P_PQ3R7
MC3'97.M#EKN%:C!I_O)MVJJ*2Y;*RE)-K25EOI5U[]G+6O$OB_1[*TTFQT_5
M)+!)-:-FFS3[68N_W/F8 ^7L+*K,-V<>@FU7X2>#_AI?-#JVI-J%XH)D(.R,
M'T"CD_G3[GXB>,)?"JSWFO:+X4LK+#RS3W(V1%P652[<;BH)P V "3@"OGKX
MS#Q!JWBW4+)8;N.YM9#%=.TH=Y2>0Y<<%6!!&WY2"#S7Y[6SZIRJA3J6459O
MJWYL_:<MX/E7KRK8I1@I-NRTBM;V2OLKJRZ)J^ZOZKX@O/!=S;R&'^TEQE4>
MVA=PON00<XK@9HK7[0LEO=QWT); 9 5<>Q4\BO.-+^&6O:*6OH&FBCC4RM.C
MG&T?>8>H7N1TJW=>9#=-)#K"27$BY9R^ Q_E^-=5+-<;A6G7=XRVNGJNZT_'
MJ:UN$\GQ=25/!8A-QWM9V?9V>C\MSZM^%G[./_":Z:)M2O%M8MH(AA(,G/\
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M59$FG6\JPJ?:M?Q=\1)-;\.^%=+G@CMT\*VLUK!+&QWS"6YDN"S>A#2$#'8
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MB_M=.B\CWLRR'+,(U"CC%.,X*<>6-WS-V]G47-[CNI-N\M$G;73P?]G>XNO
M_A?&GZAJUPUU(98XIU7Y3RO'/!XZGUKMM)N+NYN;6^6XNHX)[D_:K>5%/F]
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M5IQ_9]Q$A93;1*(D)49*DA-V" ><TGBK7]"?P;))</Y&L!&:21Y"TDDA*[5
MR<KC<<@#@>HYXGPQK+:VBVLEPODR/\JNP!&?3=W]J^<Q<<3@Z,5)QDIVE:-]
M-+?+^O1?6Y=3PV8U:F*IJ5.='FIWE%*ZNI-KHUHM;K[FFZ/P%\0O\1/&-KX?
MTG[5;7EYF&?RV,1=.K;SQP/?H*]6\4>*-/\ $FKN\WF?\*W^'@QR<)JUT?\
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MT5;[1-#T^5U $(!W*?<@\5Q_ZQ8>^D7^'^9U+)L1'W9V3_KL?"^K>']0U.W
ML;&[O)&X AA9\G\!6Y\-/V4_B)XP9;AM'?2[64_(]^WDEA[*?F_2OO6VN=+\
M/> [>STF&PL[5?E M@J>8?KW_$UP-K<:EXR\3M$LW]EPK*(A/.K*SMQ@(O\
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MFI[@;R\GD_?L2,8)Q@+C[J+P/U/'VWB#P;:?#SP_JFC^9HEK>VJ1P70^_$5
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M#[_PW\(-=\O1+6'2]-,C"6Z<AYF/7!D;D*., '%9?C;]HR_2_P#,BN)&M6)
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M+O?M^GZC;[5+RIG*G+@@JN,@D$ \'V3X2_%^+5]?ACDL+.X\/JF(?(TW;]F
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M$?M?_'WQ%\3I(]8^#$GA[QQI5[:M(IT9H]3U**=2"8Y[(LLD< 3HP4G=P=@
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MOX<+-X=UQ6DP[07MQ"^1Z88Y!X[\USE_\-/%VF7;+J7AS4-,CP&#R0G:I(Z
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MI.T5TZWLTON=V[>1X1+^S#\5--U;^T;&WT:YE"^7Y1U) SJ>#UP/UKH_@/\
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M%23YBOL.X]ZU/A39W&N:M&MHUPUQNQY.TACCGI7+?\,X>-O"PGELM8;6-/\
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MJX^7(Z"O(?V+OA[X9\#_  _;P[JW@K3UD^(9<:AIVI6SQIJ2VK?N;6=)%)5
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MO+/'?A^+0EDN;F[?IMWMS@]B .^>,?SZUSUW^T>N@Z]Y<"-,PS%<1(<,!D9
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MI:='=G3=.O"+568.ZIYC(4B=/+9I2/NAV0#<<']OX7G0KY31JT=K:[_%K?\
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MC?X[0Z3JGAW1&M[C1]4UMIY#/-IR1I#!; $1AW3#-.#RP90"3G KT3]E^_\
M$'@W6?#^M6LC75M'._DJ05R0C$JV<A@1D5^5\:9/3P6-CAN=246GIL]G_7W'
MVG">98CB+)J>/]G*G&I=6;2::;2[VZ.]O.UF=7\5OV ]-N] \0:YIVN6UCI.
MDW\S:7I]FS:O<!';)\TX24(OJ4)"\\XJEX'_ &;?%'A6[CCOM(FAM9 K&XV@
MVMPN 5EBDZ'(Z$<D5N_LS^+_  5XU^)2Z?XGO/%7@/7E??INJVEZ)K6/!( =
M74,N/4-C!Z=J^\])_9=N_&NB1*NL:?XHMX4#*VG2X8+V9H6Q\Q]1C\:TPN%J
M37>QKF6(66UI*I/W;VNTUY6OM?U=^MK6O\Z_"WX%6< 6?:C3L>2BX 'XU]-_
M!+X:31^(M/DAM_+D@XWJ,<$$<_7-87Q!3P?^S5X'DUG7)KVQM-.8++N@8RW,
MC [((U;&Z1F!VJ.@#$D $U\/_M3?MV>*OCRDFGV5U<>#O"$.5BTJRN2LMW_M
MW,JX,C?[(P@[ ]3[&%H\KNSY7,<R]NN6EU[_ .74_13X@?#>&]E9UC8*Q,8V
MKSN7^+IC!QU]!7BOC/P9I/QQT-[?2]0\/:LME<MI@NK*Z%WY-PL32O$TT.Y8
MV"*Q.\JN<#J0#^>/@?\ :9\>_":3'A[QAXBTVTN%YA^UM+;SJ#CF-]R$ Y'3
MVKZ _9H_X*6Q?"_1;K3?$?@71]6M+IWF,N@>7HTTLS'+/+&JF*0DXR0%/'>L
M\1A%4GS1=F<\>>G'FFN:VUO^#IIU7XIF];_\$\;[QCKHM-->XDAN&=7FFE$<
M88#);.,G &<+DXZUG^+_ /@G1JGP_O\ 2X[A;.;[7,(HS#-YC ]3D8XKT;P5
M_P %6_ -[XJT>XU[PMKVD2:0\HL[Z6UAU :8)4V2&,(RN-R\' )[]:]:\9?M
M;>&=:^!LGBSP/'JWQ.GM;A;*'0M'VJZ3RRHWGW"R*'@**K .Q"[&888D$98B
M-2=-JHVWT/:P>>5L/6BJ459[Z==;6>VUGTUNME=\KXM^ >D_!S]D;Q1)<Z?I
M^LWEW<PZ/'!>P)+$8VVR2':X*Y!5/F/ Z^E?$-]\$=!^%WBN+6K'4-6\)^(I
M)A-$_A"1D@@93E797&P./6/;7UG^T5^T#J_Q2\SP['I=KJ6FKY:VFD6=FWG0
MMD^=,[JQ,FX[<9 V@ <YKBOC1X,LF\':?XA\-WTT=PMNTQMY)E8?NQA\(>QQ
MW[5Q8...I48K#QTU7,WHWN_\M>PZ/$F73IU,)FE)5JK?,[VT5DE9_$E;72RN
MWJS/U;2M!_:,T"UN-8UO1O#GQ1FXB\2WNGI:Z;XG?^%=2B0 6]PW3[6@",?]
M8O\ %7F-Q^T%X\_9Y\:7WA'QK)=>&=0TH;I[,:>(Y1$?NO$^YEDC(Y5T.UEY
M!-4?BEXHCUGP#IMU9ZK=S:UJ!\FXTYDWS6KYRIB()9XVR3@A>O2G:#\4[30_
M!5GX1^.^G7^N>%=/._0;Q9$77O#,AP3_ &>[G,L)X+VLA,77!C;&>C YAB,1
M&U9ZW_J]OS7S[D5>&\%&/URCAU&DU=J[O&W6+<M?\+W^RUI%^F#]J&S\4>$V
MT_PRT\RW48\^_G;=-.3Z>@KLOA!HEGI>C227&=L8\U@#\TKGW^IKP._^ &I?
ML[^'M+UJUU+3_%'@+6IF_LKQ3I(;^SYR3GR)5/SVTXR T,F"I'!8<GT;PE\1
M+/Q+X<:V2:-VQY<R!^H_G7L5J#C)<RTTO;L?F?UM5:N^G;^OZ6QZAXKU/_A'
M_(ECL_M"W$:REHG),>1D@@]<>U<?XB^,5JZ1B.1HW4X!Y!0YZ5A7'Q-N/#%F
MUG<21WVG$X#E_P!Y#SG##NH]1Z5YI\1_'%G8:H)-./VI9\J1CD_Y%>]F>499
M4PGUO!RLU:\;_H]4^OH=F*Q<'"\7J=9\2/A=HOBRVGUC2X8[?6)/WTJ(/DN2
M!R2O0-CN.O?GFO [WQM#8^(Y;=XE'4218P5P>#_7/K7OOP*GE\2ZU9VC+)NN
MF,8CW=21@*/KFL&__8YU37?$D:^)?#&I#4H4#O\ 8W6.9 >,.58K^O->)@Y*
M*:DSGQ&%GB:473MS?<_^"<1IOQ?FLM-FCM[N20-T1_G#>G/%5/"EO<:OK#,R
ML;RXD!SCU]J^F?!?[/VC?#ZUC^Q^#8X[I%^1KJ0.Q]QRW\ZUM.T*/6?$-I:S
M:'')JEQ<".TLK"$W&H7,H_@10.,XZFNS&8ZMB.6G4DY6VV_3\V8T\OJI>TJO
M;N9GA'X-ZIK?P]L\WD-A/<ZBEM;&ZSY9!!W[A@\=!TZUJVOP??PO=-9B^AN9
ME;(:VML1D]\9;UKB?VFO'GQ-^$_Q\\"IXN\#:]X3\&R7_DVC2O&UO=N =\?F
MQLRB1<Y*,0W!..M>N:#\9?#^O31[?+MY(E)+M(I\OTY_SFO/K>WI6A!].VM_
M0]"CC*$FU92\ULOFGKY].BON>>^+]!UCP@?,N/,6Q_Y:7%K:B:1!ZE=VX?7!
MQ7EO[8?Q9O\ 2O@C'8^!XYM0T&;"W]W#\TD&<;O,4<KD]R,5]!_$/QA:W>GS
M7$+3R,HRSE" !]/2OGK7-1M=/\2&]LWAM;B09FV,/)NE[AQT/'>KY,50L\5"
M4;]XM7^\K$8J,?=:M_GW\[=/,W/AA^U9;>'/#EA81RQQ_9XHPNT??PH'/K_]
M:O6M*^*7_"9^%9+VWNK>=5RLBR#9L('(/.>O2OE?XHZ/I.BZ"NMVD*QV-PVQ
MU'2UE'5..W<5E^%/B?IEKI\=Y:ZA):W4I"N8L.LX7@;AT('J.:];)O[/4W]>
MI\\9:7U]U_+]-3SI8CV-3EFKI]3W37]1AU">[CN,6\\&69&/&.FY6[UQ?BS1
ME\<>&)]/+1S7-OF;3I&/RK*.B$_W6Z$=.A[5ROB+XB7WCY57S/.C7Y6F5-OR
MCH/RXKMOV;?AOK'Q@\?6^@^'_LMY>7%O/=A)I_+39!&9)/FP?F"J<#N:PS&A
MA(8C_A/;<=+7[]M=;>IS4\1%S=_A/E"\^+U[X=\0SV=]9R6,L;G]T<HT9S_"
MW?%>R_#+]H.&7P]-'-<0S/Y1C42#YP&]1T)Z?3'O7TI\4?V(]-70[/Q)X@CT
MNZT3Q,9!IZ(BM,DL(59]Q[ 2' '?K7*^'OV*O!-M-]ML--#3<95Y0R(?H?\
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MHN1MD"GJ" PP#V(_2+2/^+K^'K.ZMY%\5>'=:3SM-O+><&50>-B,V3D'AHI
M2".QK\J?VI])T7X;?$VS3P_9V^D:A?6<-U?:7:3&2#2WV[3$X.0LCXW[48JJ
MLHX)KZ _X)@?&K5KC6_%WA*&^N+*UU326U(1([82XA=!O3!RK-&[!L=0J^E>
M#G66*G.IA*S3E#2ZU3M_7R\SP<ES#Z_A:.98:#C"LD[35G&[M?1W6OWKU/:O
MBM_P3"U;7?%ZWFDVWB+R&GC-U:W.GP31R)NR595E&0!VX)/I7;_L]?L3^-O!
M<=O:Z=\-M%T>UT,LNEZEJM^([RX5Y'9_,2,2%57<0J[L[2 >E?-?[0WC[6_#
M]Q<36?B"\:=R=["Y=9,C^\3@G\:^??%?[67Q*CL)&;Q-X@\J+]VGD:C*I.>G
M1J\=YYC*& EE<*D_8R?PJ23UMUY6];;+1W=TV?7XGPSH8_'PS[$3I/$PBHJ<
MJ;T2OVFDWK\4DY)))-+0_6_XP? #6[;2##JVIV=]:W8'G6RZJFCZ7:QCKN/,
MTG<X .<<D'BOF#]HSQU\(O"VIVW@OP/KFEW6M75KY3Q01,MFTQS\Q<DNX()7
M+[@"%;@9K\EOB9^T!XH\::PUTVJZK-(2=\\]S)-(V/<DX ]*XW4O&6I74UO>
M#4+E=2M6\R&Y\QED#>H;KFO'IY;A^7DC22YNK;G+Y-VM^/D?7Y+D$<N<98G$
M2J<NMHQ5.+?>2;E>W2RC?K<_2?0Y_P#A*?"/B+2_%WA*U\1>+O EL;=8?M4E
MMJ5[:X8B7;C;(T8.!G). /3/S9\8/@E-%X&B\1:/JEGJW@^XG-NM];$I=6TW
M5(;B-N8G(]RIQP2,5A_L]_M]ZMXP\9:3IOC:Y9M4MS!:VVLO(8;RT"G:'23(
MXQ@%6R",<<9K[F_:/_9ID^&6A-\7O#USX;U+0-2TWR=:T9,O9Z^-RKY_&55V
MR&Y7AT]6(JG3C0K<K]W3?HSZ269X>#BJ<[1K.R6MN:RO&S^%N[:VZIW5FOD;
M_@G;J"V7[<W@6.%FG:.UU?S,#.S&DW9Z_45Y=J_[14>KZ?;P^7*LT%L $A3&
M<*./;W)K["_9A_9NCT3]N[P'>VSZQJ%QXATW4+VV:&WCDL;>*73+I%4SQX4J
MI8#( ZCOFO%YOV!M'\$32:3XE\<6=O>Z;M34(-(TR2YDEB."8Q([(C,.F0#@
M]<U])0XE6 IPYXIZM*_R?ZGS4\'#$YI446TW"GLF_M5%TOY'D'@R37?C+J&H
M6MI/_9VDZ39/J&IWI.Y8( ,[1SR['Y0H.23V KT/P%^SC\1OVCM(TN3P[X;F
M.EZ>Z6T<K1?9X(-W/G2/@%CW+<\  =J]K^"7B'3_  GIEYX;\'_#M6@AN,VJ
MW,OG&Y0  2W11#N8D$\L ,X!&*]KTS]ISQII7AV30[B;0;>\GC,,ILK!56T4
MC'!#O@@<< FO#SS/*N*K1JQU?2RT7Z?B>R\CQF'A[.A23EUYGT]%K;[CY&\
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M,U[BO\D>;3PJY^6K)KU;_P _R*O[.EC\.=0NM3UU_AC-HS>'D:57;Q7=S*7
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MA/9RM:W#8^Q/?2Q*;3R\Y\@."4X+BOC?PI^QQKEG$LWVRTE7@22$-N"_3O\
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M]$UI:U^BO\KZ9;0ZSX;\(MJUWIVM:MX\N?*U:););B2UBCN$*Q,1(H:0,%9
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MI6-Y*$@EB#*;*1%1'C)R&R=V3U5F[5T&K^#)/#NIW%O<Q/#.&)96'6M7X?\
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M57AECC2>#@2H1E&!X(^A&>/>LZD*N%G['$Q^_P#X!RU(4ZDO9MV?1GSK>_M
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MXLM[Y>HMY[00D>P;D'\<5Z%:FOBN_DO^">!!Q<O=:^;_ $2?XG7_  F_9_\
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M"M9N_$?DP6-Q-'(0,%2=O_ZA7U6*XPC+%U*\E4JQ:CRJ5E9I:[:*[VT;L<7
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MGAB;:N'$; @[AN!(Q]WK6'??"'PYX@\&R7FK:;-X3UBX+7=C>Z?92/I^HQA
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MO,&[#IW/O7UF<\1SS' 0P:A^\33<NEDFO76_^6YS8C'*5-*70\B^%GP=BO\
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MG=7=O\V[]&K)>:;-[Q'+IOAO]G'7(M#N/#>DZI,/L^BW5[,BP+>W'EI',,Q
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MB\5CJLY5Y.\E:W1*][)=OZW/CW1? 7]I6ICDC#$]B.M>\_LX^#HOV,O#-O\
M%_4(4/B+4/,M_ FBR']W<RCY)=5N$[VT&2L:G_6S?[*$UU'[-_P"TJ\TR_\
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MN[--07[1:J/,GB896;:1@$<YQG=@\$@"O8_V(OB=:>/OVUO![*L?VD&]&YF
MD(^PW)P5]!@<5Z^0<+JIAWCZL[-7:2_NOKZV.?&VA@JOO?9?Y')_#GPFOB#4
MUCA7]WDM(Z]$QW)KMI/%UOH%O-I<,D2VLDF9]RAO.*\_D#WK0^(7Q3\+_L[_
M  :O-.TN:UFOI8\R3%E\V5O8=3_(5\=7WQ]F\0ZZ/)F.YC@(AY [U\K&G)N\
M;_UV/0E)1IM-??K_ %Y(^Q(_B/I=C9F>\:&88^5' 8?D:R_'!^'OQYM-!77K
M:8-X7NS>V"VEV8%CE)4G('4?(O%?)EW\1II=8$%U),T;1APK-A<DD8S]172S
MZU'X:TZ-5CBC>9C(A#G]VGY]SV/2OK\ER_%X3"O,J%7D<4VK73[;]WL?-YID
M^&S*C*GBXJI%VNI*ZT::T\FKKS/K+7OVK-1T[5?]%988V?.Y.5;-9/Q-_:MG
M^&MAI_B:3S;C19)C;Z@8^1IY(XEV]=AYSZ$9Q@\>*_"2VU;XAW"PK#FU8YW\
M[1[UZ-XV^'.AW?P]?P[J4TFV\F+R&,=4 (QS_>!(^E>2L;-5+MZ=3HIY;1]D
MZ=KRZ=_/Y'H'AWX[OXH$=[8ZK;W-M-A@R2^8A^C+G\C7HFC_ !=T_0[5;G6M
M<M;:W10Q::X6%1]237P:O[/^E?!F''A+P_I^K0J=Y2[DD64?BS;#^E<UKG[2
M<.FL^G:EX)TN-TR'AN;?Y1]!R"*Z%BJ,M5)_=_P3SZV4U*;][E7S_P" ?>_Q
M _X*9^ +8+H.@^(K75-4(X6S!EB&WE@T@^4< ],UY(G_  4+FUG5I(X[IF?<
M< -@5\@#Q3X<\:ZW;S0>%].TVZA.8WT]?)8?EC/T-7/ 7P0EN;J[FCU8^<P+
M0Q[,=^&S^A%<]62D_P!TWMU.RG@H4L/=I-M[KM]R/L[_ (;5N+>\6'49I8@P
MS'AN)..@QW!J;3?VLO[4N\QWLTUOC>1N.X=,CWZ]J^-[JVUA[U].U#3[V:Z7
MA,'<C^A%>B>&?@MKTFFPRS6LB A6PTAPA]<>M>_@,]PM&BJ>(HMR756U];Z_
MF%"&'DU&4#Z8M?VIY9[OR%EDFCS\DA;GISG]17H'@OXOOJ^CZ@TVH+;00PL7
M>1O]7QP?Q.*\G^$_[/=CI5E#=:]/YD$<9D>-&V[% R23Z 54\.>-=%\0&35(
M(UL[%;AQIE@#\I ^47$F>7<_P@\*#P,Y-?+8[,)NH\1;E3=TE^7_  ?P.[#X
M##UN94TM-WT7^?I^)Z3_ ,)W)?\ @W5(?$5E?7FG:M926U\+*39B.1"CGCYA
ME6ZXX-<K\,/CW\.?V<OA O@WPG;WEMHT,TMRJW%ZTTH>0Y;Y^#C/;M5:+Q1,
MNG32K)M1QG&>2/K7SY\7?#NG^-=5NX]!$AU)"7F>(JMO*2>F>F?=>/7->EEN
M<9CC8/"X=2:;3Y5M=;-]-+O4\_$<+8'ZPL5&DI3BFDW\5G9M75M&TG9=AGQ-
M\8Z#XZ^(#7VEW5TMXP>-U\TN&W \?-GCZ&H-#^(]TWA^&S\SRS9JB,0>5SQG
M]*\T\&?#G7-$\9M+-&8VAD^99#W'^/;'%>]>'/A_H=]I!,\.UKISYEP#A5)Y
M"[N@(]#UKS<=&LZSIXCXHZ:JUO(^BHQIK#<E"'*UNM7\SE+_ .*)\+VLT:O-
M<0S'S#P<!CRP/L3@].YJ'PU:V?C2+[=H[>5<S'S7"QE9';N#^??TKH;K]E[5
MO$.LVT,6K0+IBN#ETVN0.Q-?5/P/_9]\+^"+6,7 M[R9T (DP%7\/\:]ZCQ-
MB8X/ZC.FIZ<J;Z*UE=6UM\CB>9>SARU=3P7P9\/=6UC3%5MTC'YMA/S5!^V)
MXZMOV;-&\)V6FW=C8ZVS^;JGG#>9(2"1$$'5L\@D<9^M?5_C5_"_PL9;Q8;>
M&&QB,[HK<R-U5/Q..*^#?'?P\TW]I7QCK?BSQ,UQ(VI3L+0QS;3:Q D#'45\
MK1FHWG576UO/K]QUPK3K05.FK1M=WT]%\SNOAC^V!X+DM4O+[4UA>3EX([<%
MS]2K"MSQ'^W[X+TE&ALY]=\LKCY"%5OQ'S ?C7R3\0?V99OAOMN-'NO[4M9V
M^2$C;, .I]#C\#[5F6O@#6!9I-<6,L<>W>0IWL@]QU'Y5ZE#!XG$0]IAX.45
MV7Z=?D<%9<L^90_KY'OOCK]KG1OB3:KX?AFGTW3;XD21,[-YI]7)Z\UTFB:+
M=:1X;L;%6;['#'^Y=#NR.HQBOFNQ\ 7-W-O,4;*O0&OI;]G'Q$RZ2NCZE^^B
MC4+'N^]'Z8->;4IJ23['7&M[>EHK27FW?YMLEBO8;RY621HH;Z- )!,/E8+G
MD<9R02/\*P/$/Q-U*/Q.T<,,$L.YMJC)#9/''' 'YX!KJ/BYX1C_ +56.XAD
MC9UW0S <.#6]\$O@OI-O=Q7VI*UU(Q^17X4"O:P>?X["4/94)62\D_S1QQKU
M%I$YG1?ASKGC.W_M#^S[B:.0Y8Q18!/H !CV]:]'^&GPNO\ 0]5L9GLYH(VE
M789!M+$'ICK7N>AZC#IS0M'##';PIM"JN%C _3%>(_M@_'RZ\+V$\>FR-#?W
MD)2T*'F%&X,WL3R!7B5Y3Q-1U*S]Z3NWWON;4;N3D]$M;WZ]O4^<?BYXWA^%
M'[47C*Z61?%$.N7QFNK&+Y8+,(<)\_5I .HX'.*[[PY\?/#OB+1FA_L^&:&X
M.YX@,O&?Q(/Y9KQ/P)X/^UV\LTBF2:4DLY^]]2?4UG^(?"$_AZ]9X6:./.Y@
MAY%>GS<TM.AR2J0FN6JK^:T9[[.O@W5'61=-*S'LT+<?4$XKT/X:>,M!\&Z;
MY-JL=LN=SXC*JQ/>ODK3?%GB"(+':7LVWJ-W.VM?P/H/B#XC>,]/\-W6O6MK
M#KDWV=IK^X:&UML@G?(_.U1C^5:1I\UK_<<F(HX=0LI,^R]4_:$TBVTT0M>0
M('899G P.M><21Z%XYUNXO;?4_,F61]GE.K)(A_P/7'3%>#?M=?L@Z3^QT/!
M-UI?C'4O'$?C#3Y;\2S@):1E3'@P@<E#OXW$G '/-<'\(/%NJ>+?BWX0\*S7
M7V6P\1:U:Z8SP(%DM5GE6,NG;(#9P>#BJGAFY6DM>PZ-3#TZ-J-3YVM^'R/?
M?BAXOG\.>'Y]+N]/6XMO^6-POWE/8^V/UK)^&^I-^TQX7@\!:Q'''XBTU#'X
M4UNZSLG3D_V7=.>0A)/DR'_5L=I^5ACNK[]GOP9XL^/GB[X,^"?BQXH/Q4\+
M6KW,>F:]I4?]G:EMC20QQS+_ +,BY/;).T@&N(\#V]QXA_9M^'NM:7X.\0+X
MT\5>)YO#XO9-1MHM+U"=))T^SQ1^9O20&+&651F-^2"M=BHUH4_9)OE_EOI_
MPYY3Q2DM7_3ZZ]-"MHW[$>M?;F345M=.N(I#'/#*Q\R!@<%6 '!!XJ?XT?LY
M^'? W@&Z>ZU".[GM86EEVIMB@0#G))Y].W45W/C*Q^+'AN?0='U#P7K4>N>+
MKZXT_3;?[3')/>S0 M,W#$A H+&1L+CG.,&O#/VM? _Q:^'5YHN@^*/!NJ6L
M?BRY^S6)M98[U-5N,X6W1H7<%P3G83N)R>W'F?4:MFVF>ME^,HQJ1J3DE;7[
MCY\UGX$^"?#_ (+G\16OB#6['7K60PM8IIY:.)E; D^T X56P.H&.>H-9/AS
MQ;X]U6WADM/"^L:Q#%^[.HFWDF8AE"1X;^(*!\N,@=R*]^\0?L:?M.? KP[;
MVL/A6YL=/\67UMI^!-9W&+B1@L$4[JY,.6=0#(0N6&3DBKW[?'["7Q5_8Z;3
M]6O/%VM>)/"VHV=O;WVJB:.TCBO93+FT2!96<H%0'?C!SU'2M\MIX["TYP3T
M??;R=NY[4\]RJM75:IK/5)I)NW:__!.0_P""=GP0U2V_:AT?Q!JGDZ7<2QZJ
MD=MJ,HAOKECIMV"8X>6(&>2<# [UZK^ROI$W[,?[.FJ:S:R6O_"0>)-*?2X[
M<MNN$62/"R%3R,EM^3T" =3@>2_LF_L<?$#X\3W6M>"-#U35)-+;RI]06\2R
MCB=E_P!7Y[NF6*M]T$G#<\'GT[X.?!7XG77Q&USX?:?X"U/_ (2#0T5]7@N&
MC@CT^)QF-WF=A'M8<H0QW $C(!QY>.R.>*C"$F^7F<GI?FVT_#4/[=P/-4A!
M63BD[VZ.7W7NON\S \%6$/A32;73T"HL*J&9OX0.I-=?X,;5_B]XLFAM9$BM
M58XP=L80<#)Y_"NL_9U_8_O?$?QZ\7>!_BII6LZ3<:=X6NM=MXH+H0L2DB+&
MPD3<LD9RWW21D>H(J]\)- T'X>_L%_"[XB0R3PZYXROY[:^>6XS"PB,X7:G\
M/^K7]:^CA+&4Z3C3G9?UUWZGRKS.*ERQ?7\S<T/P;#X$U&&&[55:0C'&<GV]
M<UQ_QAM;CX[?'W0_ NCR6]GIV@6$FJ:S?S<6VDQ-AI;B8]E2/:,=69@HY(KU
M..^T+QC^RA\2?'FI73"]\"BW:VE6?;#&)&4'>O?J:^7]8_95^*MQ^T(FDS:/
M?2>(OB%:MJ&G6L%_"T6HV(RX8NK^64 C#8<CHIQTKSH8&2:G)-W.S"YI&$9-
M.SVU^^_W&_\ ''XHZ9XNN-/\/>&[6XL_!?A='BT>V8#S+AF/[R]G[>?,1D_W
M5"H.%KRV^03S@R1_(W5@.!7I'@C]D7XP?$#P%-K'AGP+>ZC;1W$L(F;4+:/[
M>869'^S*\@,N&5@&7*G!P34.K^#UO?V7OA[JVC^ ?&__  FWC+Q)<:!]HDGA
MDL]2FC>X0V\-N',R2*82"710/+DRQ!&/HL-EF&K4;S;4W^';3L<CQ6'2Y8O6
M_P#5SF;/1K?7;55B8QSQ_=8=<XJ_XB\ ^,%\'ZGK\.A^'[J:S3*:K(&:\M9Q
M&D2O$,8C/EJ#D$_-SQTK1\5?LD?%;]G;28=<\8>'9=+TR6<6ZSI=P721R'[L
M<GE.VQCV#8KVCX-3OXK^!'BRWD7(\E)0GH1D$U\W4H2C5Y)GT.39M.G2<:33
MC=?+57_ ^#Y/!.L2:K%K6J7]UJ%UD.S32M(1[?,37T]\"/VG;.STM;&\$5L2
MJI,CKF&<#@%AZX[CGZUY_JGAQ9I2OS%<=._I7)^(_":VFYHLAE/..U)I6TT,
M_P"TJD4X5O?B]T^_=/H?94/C[2]2T^,Z39QK\^YS;S*_Z-@UH:I\6K7PQI+B
M.VNH[J1?O2 (N/P)K\^[CQEKGA6]0Z??7,;9&-K'^5>T^"M8U/XU>&K.SFO5
MT_7(98V$N=J72!@3$Y_A##C=V[\4Z=.G=*LVH]U_P>A,7@Y*])-2[/\ *_\
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MJM(0P-=52:9/L</-<ZIM?._X:?F>M?$:^O-;\+7*7VFW:76/W<3H?]']2S=
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M0?&:PMO[8\/W&GWT2!M\J;89F]48\\]:^BM3\90:/8*6BMH_+^9U27S&(Z]
M*_.7X;>-=6LYO,COKA79L$AJ[K4O&NK7^F_O=0N6W'GYL9_*O1J5KR=H_C_P
M#GCE>'DTW)WZZ?\ VUOP/I7XG_MF:I>Z/?:/I_AE?[(FADMYM36?YXCL.,Q
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'[/\ %'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>oncyf-20211231_g2.jpg
<TEXT>
begin 644 oncyf-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" 00!@0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKXZ_P""R?[17C+]G;X,^ IO
M"=QJ&EP>(_&5II.JZE93+#):PM',ZIO;A1)(B*3D9&5S\U;O_!*_]HKQ/^TM
M\*?$.N:]J,VL6*ZJ\.G7DD:J2H+!XP5 !"E5^A)'6O8ADM666O,E)<JERM=>
MGEYGB3SRE',UE;B^9QYD]+=?GT['U11117CGMA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?*U__ ,%8
MOA]IWQWU/PA]CU2\T?2I_L<WB2S*7%@MP,>8A"DN C$J21R5; (&3VX++<5C
M'*.%@Y.*N[=OZV6[Z'#CLSPN"498J:BI.ROW_K=[+J?5-%0VUU'J%K'-"ZR1
M3*'1U.5=3R"/8CFOBO\ X*W?\%7[;]@>QT?PGH=D]YX[\61>9;W4T1.GZ' 7
M\L3SO@KO9LA(R#G:Q(( #1@L'5Q5=8>DO>??9>;]"L?CZ.#H2Q-9^ZNVK?9+
MNV?4/QH_:(\$_L\>'6U3QIXCTW0;4G$8GDS+,<,0$C7+L?E8_*#T/H:^!OVL
M?^"]=CX?^*&@Z=\(6T?Q)I,&@7?B/4)+N)R=55#MCMXBIS"/DG+.ZY)"!1@D
MGY3^$WB/XM?M/?$#XI>&?$PF\4?%2>PGTG1];BF@73;URJ. [2 %(X%=2L@1
M2N\JHR1CP_\ :-LM+L_"MGXYT7P&_AOQA\,;J#0O$<<MVRS3JTHAOW,;!OM$
M;HTI&'5XA\W*D@?J&5\&8.C[];]Y.*O);+EZM1W=M;/9M=#\ES3CK&5WR4K4
MH2?+%[RYMTG+X5?2ZW5^NQ^CG[0'[=NG_MX_L;ZAHOB7P>NB^&=<;2+J[O[>
M]34%C'VNWF5$ 7"R;TQ\Y V;F#$@@?27[*O[??@'XE>$DM_#^D+I=CI\\MK<
M)8!'BMYU8[P555)9C\_ RV[."<U^!OQ4T+3_ -DKXUZ];_\ "?\ Q$M;367E
M6QEL;1X\M$9$MK9XSN8Q)&R[9$W9PV.<Y^Z?V(=2^)?BO0O >DVMVNGZYHFH
MK=LMK=VQ;Q?8NCRPZC.(R0Y4D@$\%<JVQQD>EC.%<OEAGA^54Y1;E\6BT6^K
M>J2WVUMU/+P/&68K%*OS.I&24?@UD[_9T2T;>VKTOT/V'\%_$[1O'UA%/IUU
MN\[(6.9##)D=1M8 _EGBNBKX%^'GBY_@7XU\1^$[S0]1M[;2P=5T'5+R^+6U
MW)<L6DMK>60$B16/R0L<YP <$5](?LZ?M#1^)=-L=.UR]N5O[K<MM)J$(MIY
M&4?/$ZX \Q.X&3CD\$&OS?-.'YT$ZM'WH=.]GK?3LM_GV9^J95Q%3Q#5&O:,
M]GO:ZTMKW>W=>J/:J*AN[N*PM9)II$AAA4N\CMM5% R23V ZY/2OE?X+?\%=
M/AG\??CVO@WPV;JXT^0NEMKUQ)'!:7C+T,2,=Y0M\H8@$DCC!!KQ\)EV)Q49
MRP\')05W;HOZZ;GL8S,L+A)0CB)J+F[1OU?]==CZNHHHKC.X**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD;\>?A]X7^&_AOX;:WI_BS0)=5NY/$NGWMS-'*EPT0$9M[N !=H!P03GOVH
M_6VBOY^/VL/^#S?Q1X+^'_P]TWX6>!_ >N^-KKPSI6I^,=6U1;N31;;4[BSB
MFNK*SMHITEQ#*[(7DG8JRLF&*[S^A_[=?_!<GP[_ ,$Q_P!@WX7^.OBEI=OK
MWQ<^(GARSO;3PCH;M9PWE\;6&2[8/(96MK2.27;O?S7^90 YW$ 'WQ17\U5_
M_P 'H_[2%UXC?7;'X._"B+P%;ZA!;S12VFJ37*!E+FW-\MRL*S2+',4)@X"D
M['"'/Z\?\$7_ /@N#X"_X+#?#W6?[+TFZ\&_$+PBD+Z]X;NIQ<!8Y,A+JUF
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M'X>F[GM['4/&,%[=W>LI&4RZ_9YX(X6 ;+)F8KYB9/K^JG_!$_\ X++>&?\
M@L5\!];URRT&3P?XR\&745EXBT)[M;I(/.5F@N89 %+0R[)0-ZJRO#(N" '8
M ^TJ**^0_P#@L+_P6%\!_P#!('X$V'B3Q)I]QXF\5^)I9;;PUX:M;A;>75)(
ME4R222D-Y5O'OC#R!'(,B *2U 'UY17\T^I_\'H?[2ESK;Z]8?!_X2P>!8]0
MBMF2:RU2:=<C>;<WJW21><R+(5/D< 9V,%.?U@_X(C_\%Y/!O_!8?PYKNE_\
M(_+X$^)GA.!;O4] >\%Y!<VC/Y8N[6;:C.@<JKJR QM(@RX8,0#[XHK\0_\
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M/IOQ<M;S0_@CX%TOX=WB_:+2QUI[Z35]1MO,D02I=I)'"H8ICBWD561QN;L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS]D#XB^%?$FK6D-OJ$7A7X6Z[9VM_)$"!<2K,LSM.RE59]_(C3C@D^W>#?\
M@G[_ ,%&_P#@@O\ 'GQ!J'P=\*^*O$6DZM<P6<^H^$-%3Q1IGBBVC9Y(C-9J
MDL\( \U2SQQ/&9&"R 2*S^V_L1_LW?\ !5']O[]L;0?B)X\\=_%OX+Z'A;;5
M=9U4)X?BALHW=6@BT,(BRRL"Y0RVNS=MD9\[6(!SO_!W7XS\8:C\/?V/-+\4
M+J5E=-X&FU'4[.Y9E9=3>.Q6X$B, ?-0KM)8 C<PP.17ZD?\&O/PO\,>%?\
M@B5\*[C2;.QDE\6G5;_6YQ$NZ_N?[2NH&$O'S;(XDBP?X8P*TO\ @OQ_P1I/
M_!6[]E[1['P_J=EIGQ0^'\TMYX<OM0 6WOEE15N+2=T0E%E\N-@RC"O&O&TF
MOQ/^!4__  54_P""4OP]U7X0^!?AW\8=-\/W0DN(;?2O!$7BNUTR:293)-:W
M<$%S&CMY3J4$A7$S2! [)( #Y]T6QB_9Y_X.%!IO@&/^Q['PI^T ^F:);V!,
M20VL?B%H(X$"_P#+,Q 1E>A4E3D$BON3_@]S_P"3P?@O_P!B=<_^EKUW/_!
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M6EOI7Q&\?VD.G6NC1S1SR:'IRN)66:1,KYTL@C9D5B%$*9.XD+^LU 'X;_\
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MO^"9_A/X?_\ !*[4/V6?#-U-8^';GP1?>$8]2>)!,TUW!*LM\ZJ ID>>9YF
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M:UI/B">70]6NS\*T0W]NX6 V[7\=H+?[/N4O]I1@3O9C.R8P ?J9_P &Z?\
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MYR<'TH ^+O\ @K_X5M_'7_!>+XO:'>%Q::Q\2/L,Y0X8)+-$C8/KAC7[U?\
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M&;XE_#/X@_#M=:A\/#3CXF\.WFDB_,3:GYGE?:(T\S9YD>[;G;O7.,BOD?\
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M/#.I?#WPOHGB&'QQ>R:R(K75M?OUF^V)$EDGSP;I]C2>:D052RJ"P*K]3?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8(K["H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6UA<:UXDNVTK1O$D.GKIMW!J0RJV=[;H%CS(ZE%9$0K(55E(;*>O_P#!H?\
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MQQ3P3QQJL9=3+&RNBKD;PP) )_8^348(6VO/"C=PS@$5_+-_P9O_ /*7*_\
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MJG_!8*X*J%+^#-)+$#[QS.,_D /PK]C_ /@H?_RJ]ZQ_V1W1/_2:RH _GO\
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M^#-/3;>U_P""4&N3QPQI-=?$+4FF=5PTA%I8J"3WP  /:OQ9_P""7MG#<_\
M!PK\.8Y(HWC7XKSNJLN0&6ZF92!T!! (]" : /?OVN_^"T7_  4T_89^-NAZ
MS\6]2O\ P$WB2-M0TS0+WPYIQT>\@4@/$H1&?Y=RA@9?.7<I8@D$_N7^RI_P
M5\\)_&;_ ()#6G[5GBNU_P"$>TG3=#NK[Q!86Q,A@O+25[>6"#=RWFS(!$&.
M2)8P3G)K\XO^#XE%_P"%;?LZMM&X:GKH!QS@Q6.?Y"N!^$7@K6O'/_!E/XMM
M]$6:26QU:XU*[CC!)DM8/$$4LQ/LJ(7/H$)H \UM_P#@NC_P4._X*V?''7].
M_9LTNZ\/:1HZ_:_[&\-:;93'3[8MMC-U?7JD&1L'HT8<AMJ8&!W_ .P9_P '
M*'[2G[(7[;%A\%_VQ+%M0T^34H-&U:ZU'2X-.UGPT\VT17+&!4CGM\.CL2I+
M(=Z.< -\4?\ !#']F[XD?M6>+?&_A/X8_M4M^SKKD<-K?/IW]M7NF'Q1&OFJ
M70V\B+(UOD95LD"?*C&XCV;XW_\ !%_3?C#^U[>>#OB1_P %!/A+XC^+T26]
MO</XDN[^YN'RN(8/ML[&)Y N (1*77*C:,@$ _6+_@X__P""X.M_\$IOAIX7
M\*_#>WTNX^*?Q 26YM[J_A^T6^A6$1"M<&(D"2221MD8;*#9(S [0K?G!^QY
M_P %7/\ @I5;_"/4/CKXF\-^)?C%^S[-;W1UMKO1[&UC:S7?'<7%HT*1SJ(C
MO/F*KQ QL&!"DCGO^#RWP#K/A/\ ;M^$UU?22W6FR?#6UTZVN&!"RSVU[>>?
M[;OWL3'OAU]J_5W_ ()P?MN?!GPY_P &^W@G7K_QAX5M-#\'_#;^R==M9;V)
M98+N"U:&>W>$G=YLDH.U",R>:A (<$@'X5?\&MI7_A^)\(=N[;Y6M8SUQ_9%
MY7]>5?R%_P#!K3_RG!^$'_7'6O\ TT7E?UZ4 ?A/_P '</CC]JJQ@UG0_"=G
MK3_LLW7A/39?%MQ%I=G)9+J']IR;0]RR&X0[ULOE1@N2O!RV?RP_X(Y_$+]L
MKP!KWCR3]D&Q\07E]<6]DOB?^S-'L=1V1AIOLV\74;A<DS8VX)P<YP*_HR_X
M.;T:3_@A_P#'#:I;$&E$X&>/[7L<FOR__P"#)SXC>'_!GQA^/ECJ^N:3I5YJ
M.CZ/-:PWETD#W"1378E9 Q&X+YD>['3<OK0!Z;_P6&_X*L?MB?L"?L#?LDZI
M<>+KSP1\6/&^GZU_PG27>@:9+/<7-N]IY.Z)H'CB*I*QQ&%!W<Y(&/T,_P""
M ?[7'Q!_;7_X)5^#_B1\3->_X2+QEJMWJT5UJ'V."T\Q8+Z>*(>7"B1C:B*.
M%&<9.22:_-W_ (/;=:L_%O@3]F76-*O+75-)NY?$#07MI,LUO.K)II4JZDJP
M(!(()!Q7T=_P;9_MB_#'X(?\$%K#4O%'C?PWH\/@&ZUV37(KG4(HY[,FZGN$
M0QLVXM)&Z%% )<L N3Q0!\4?\$2?^"]G[5O[7/\ P5:^%WPU^(7Q0_M_P9XB
MO;^'4-/_ .$>TRV^T+%874J#S(;=)%P\:'(8$XP<@D'TO_@Y,_X+6_M+_L"_
M\%'8_ ?PI^(__"*^%6\*:?J1LO["TZ]_?RR7 =]]Q [\A%XW8&.@R:_._P#X
M-KYA<?\ !<;X(2+P)-0U-AGT.E7IKV;_ (/%?^4O,7_8C:5_Z-NJ /5OVW?^
M"U'_  4.^,'P>/QY^'OAWQ-\)OV=+=XX=.U:VT:RF>\0L(1=W,DR/(5DER T
M:+ "RJ"Q 8[G[)/_  <Z?M=?M9_ /_A3_P ._A[;?$+]I"^NRUEXFM--A%O%
MI2QYEGFMLK MPK[5$C!8,.-REL!OT#_;ITRWTS_@U9O+:WABAMX?@QH(2-%
M5<6UB> ..O/UYK\Z/^#(^TC;]L+XSS-&AFC\&VZ*Y'S*K7J%@#V!*J<=\#TH
M \U^"_\ P<C?MF?L"_MGR>&OVA=3OO$UCH^J1VGBSPMKFCVEK>6<3%2[VTMO
M&A601L'C.6B<%3@JP-?LO_P73_X+9Z9_P2>_9G\.ZQX>TVQ\4?$+XC&1/"UC
M=.RVD4*(C2WLX4AVC021 ("I=I%&0 Q'X-?\'6R*G_!;;XEE57YM,T0G ZG^
MS+8<_E7T%_P>">"]8M_$'[+OB"2.8^'[OX?G3K>3!\L743122C/0,4FA..I
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MC]S[.BB0?ZOYGRW3GFO[%*_G*_X/>U/_  TA\"6YP?#6H@''<74?^- '-_\
M!%OXP_\ !2'2],_9^T7P=IOBR3]F?^W-/@,T7AW2I+3^QFU$?;#]H>+S]H#3
MY;=N'.T\"M'_ (*7_P#!>W]J[]G_ /X+!^/?A;X1^*7]E>!]%\8VVE6>F_\
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M=_P5A^/WB32?V;=)OO#6DZ'FZ_L/P]I=E))IUL6*QF[O;Q3^]8@\!D#$-M3
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M#P7JNK7&J_8X(?,N86NQ$_E1HL0V^6G 0 XY!R<_EO\ \&[O_!<7]I_]N?\
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M1NFAEA!*QW")F0&/".BO\J%1O^3_ /@IC_P<(?M&?L:_\%I?&'@>W^(D]O\
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M_P &7'PS\:> _"%I\*?B1K/@K7=!L?L>L7FM6 U6/Q'(79S<LJ21>1(-Q4!
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MQ!^)7C>Z^+.N>&[A+[3-+&EKIVD6]RA#1RRH9)'N"C ,JED3(&Y6 Q7Z_44
M?*7_  5F_P""1_P[_P""N/P,L?"OC2XO]!UKP]</>>'_ !%IZ*]UI,K@+(I1
MOEDAD"J'C)&=B$,K*"/SB_9,_P"#+#PG\-/C9I^O?%3XM2_$#PKI-TMRN@:?
MH1TP:IM;*I<2M/(1$< ,B ,P) =>M?N510!^2_\ P3E_X-=+?_@GS_P4/T3X
M[6?QB37K/0[G4YH/#J>%!9*$N[:X@6,3?:W $8G!&(^=F,#/'ZT444 <)^TQ
M^SMX6_:V^ 7BSX:^-K*2_P#"_C+3I--U"*.3RY0C='C;'RR(P5U;!PRJ<'&*
M_#[Q/_P8]+-X_9M%_:&:W\+/+N6.]\)^;J$4>?NEEN5C=@,#=M0'KM'2OW\H
MH ^!/VB_^#?OX;_M*?\ !,7X>_LX:YXJ\1,_PKA7_A&O%QBB:_M)@'#%XAM1
MX65]ABR.$C(8,H:OB+]FC_@R@\/>"OB_I^K?$[XRR^,O">FW*3OHFE: =.DU
M15;/ERSM/)Y:-C#!%+$$@,IP:_=BB@#\D/V&O^#62Q_8B_X*0Z'\>M+^+T-_
MIOA_6-1U*T\+1>%/LL<,-U#<PI;K/]K? B6< 'R^0F,#/&W_ ,%B?^#:#_A[
M#^UXOQ4_X7)_P@NW0K31?[,_X1?^TO\ 4/*WF>;]KBZ^9C;LXQU.>/U4HH ^
M:?CY_P $]/\ A=__  2SN/V:?^$L_LWS_!EAX1_X2'^S?-Q]EC@3S_LWF+][
MR<[/,XW8W'&3\X_\$1O^#??_ (<Y_%WQKXJ_X6M_PL'_ (3#1XM*^S?\([_9
M?V39.)=^[[3-NSC&,#'7)Z5^DE% 'Y'_ /!5S_@UM_X><?MM>)?C%_PNS_A"
M_P#A(;6RMO[)_P"$3_M#[/\ 9K:.#/G?:X]V[9NQL&,XR<9K[G_;-_X)F?#3
M]O[]D6Q^$/Q.L9M3TW2[>W&GZK:$6]_I=U#%Y2W5NQ#!&(W J0RLK%6!!KZ)
MHH _G[\5?\&/-P_C!_[$_:(AC\/O)E1?>$#)>1+GD$I=JCD#'.%!/85^F7_!
M(_\ X(=?"?\ X)%>']4N/"LVI>*O'7B"%;;5?%&JHBW$D(8,+>"-!M@A+ ,5
M!9F(4L[!4"_:5% 'Y'_\%7/^#6W_ (><?MM>)?C%_P +L_X0O_A(;6RMO[)_
MX1/^T/L_V:VC@SYWVN/=NV;L;!C.,G&:_5KP-X:_X0OP5H^C^=]H_LFQ@L_-
MV;/-\N,)NQDXSMSC)QZFM:B@ HHHH **** "BBB@ HHHH **** "BBB@#%^(
MGA/_ (3WP!KNA>?]E_MK3[BP\[9O\KS8F3=MR,XW9QD9QU%?E3_P2C_X-;?^
M'8_[;7AKXQ?\+L_X33_A'K6]MO[)_P"$3_L_[1]IMI(,^=]KDV[=^[&PYQC(
MSFOUPHH *\U_:]_9;\,_MK_LU>,OA7XR6[;PWXUT]K"[>UD"3P'(>.6-B" \
M<BHZY!&5&01D'TJB@#\"-'_X,E-0T7X@7#6O[2=Q9^%[@M%(+?PLT>H36S8+
M1,1=^6<C@D@@X!V]J]!_:S_X,NOAWX]7PS)\'_B9JGP_ETG3(;#4XM9T\ZNN
MKS(6W7I=98C'*^1N104X&T(!@_MM10!^7/[<G_!MNO[9?[$W[/OP='QDNM#;
MX&6=U;RZU<>'CJ$FOR7"P^9*8S=(8OGC8X+OP^,\9/UA_P $F?\ @GM_PZ^_
M8KT/X0?\)9_PFO\ 8M]>WG]J_P!F_P!G^;]HG:;;Y7FR8V[L9WG.,X'2OI:B
M@#P__@H9^P1X)_X*5?LL:]\*?'GVZ'2=6:.YM;ZQ<)=Z7=Q$M%<1%@5+*205
M8$,K,IZY'XX:1_P8\E/'?^G_ +1 D\,+)G%OX1V7[IQ\N6NC&K=1NP1WV]J_
M?^B@#\L?^"LG_!M1'_P4W\;?#358?C-=^#X?ASX,M?!Z)=>'!JL^HK \C"YD
MD6X@ =M_S )C()R <#U;]HC_ ((,>#?VHO\ @E1\-OV:?%7B[4EO/A;9VB:)
MXLL;%8Y([N"%X3*ULSL&CD1W#1&3/W2&! -??%% 'X/? K_@RCM_#WBZ./X@
M?M :EK/@K[3'/=Z-H.A'3Y=3"'@-+)<2)&<<;A&Y&3@C@UO_ !L_X,P?#6N?
MM--XI^&OQCOO /@FYO\ [8-"DT=[N[TJ,MEH;:Z6X1BN"0I<;E! )<C)_<*B
M@#\V?^"UO_!NEX5_X*T^+/#?C+2_&DWPZ\=>'=+713='31J%EJ=FCL\22Q[X
MV5XVDDVR*QR&P5. 0W_@DW_P;I^%_P#@GC\ /C-X(\8>-&^)D?QRTN+1-<$>
ME?V;#:6:1W,9CA_>2,6;[4QWDC!1" ",G]*** /P-;_@R L8_BMYT?[0%U_P
MA:W D6WD\+!M3\K.?+,HN!'NQQY@0#/.SM7WQ_P5$_;E_9(^(/[!GQP^&?C+
MXP?#QDL-$U'0KS0;;6;9]:MM0M05BBALRWFM/'<QQ[ %QN0'.T$C[ZK\=/C3
M_P &:7P5^+/QDUGQ3;_%;XI:7;Z]J$NHWEG-]DO9?-ED,DFV=HPW+,2"X<C.
M230!^4W_  ; ?L+S_MD?\%2_"NL7M@UUX1^$>/%VK2O'NB\^(XL8B>FYKG8X
M4YRL$GH<?UR5X'_P3T_X)L_"G_@F+\$V\#_"O19K&UNIA=:IJ5[-]HU+69P-
MHEN)<*"0.%555%&=J@DD^^4 %%%% 'X\_MV?\&H__#:O[?7B[XX?\+R_X1W_
M (2G6+?5?[&_X1'[7]F\J*%-GG?;$W9\K.=@QGH<<_2G_!<+_@BA_P /E/#'
MPYTW_A8W_"O?^$!N;^X\S^PO[4^V_:5@7&//AV;?)SG)SNZ#'/WE10!\S_\
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M4-GI.O\ ]@A-/\,;;F&:26*T\_=-,Z1M%O:50JROA<G-?9W_  1"_P"",/\
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MCU_PO/\ MC^P?%<GB;^Q/^$1\CS]\DC^3Y_VQL8WXW>6<XZ#/'TI_P %P_\
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M_P OY_YGV@__  6X\9#IX#\-_P#@?/\ _$T1_P#!;GQDQY\!^&@/^O\ G_\
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M4N4/[/P_\OYGVF?^"VWBX?\ ,B^'/_ Z?_XFF_\ #[SQ9NQ_P@OAW_P.G_\
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M/&)/_(B>&_\ P.G_ /B:^+XTW4]XPE%D"R^@_L_G_F?:(_X+7^+O^A%\._\
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M%+,0: ^*?*@^HX?^7\S[7_X?8>+O^A%\._\ @=/_ /$TI_X+7^+O^A%\._\
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M[\*_AJ5Q_P#$U?@_X+[>,Y?^:>^%Q_W$;C_XFOS8TO4\@'=6[8:EC%'*=?\
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M(OAO_P #Y_\ XFD?_@MKXO7_ )D7PW_X'S__ !-?&14-]*0Q\9HY4']GX?\
ME_,^R#_P6^\8*?\ D0O#?_@?/_\ $TG_  ^_\8?]"'X;_P# ^?\ ^)KXSE@#
M=JB^RY[4<J#^S\/_ "_G_F?:/_#\#QA_T(?AO_P/G_\ B:>G_!;KQ>R_\B+X
M;_\  ^?_ .)KXGDAP>G%.@7;1RH/J&'_ )?S/MK_ (?;>+?^A%\._P#@=/\
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MI_\ XFFG_@MEXO"_\B+X=_\  Z;_ .)KXSV?+[U#(<*U&@?V?A_Y?S/M,?\
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M#O\ X'3_ /Q-*/\ @M=XN/\ S(OAW_P.G_\ B:^)U;FIHJ.5 LOP_P#+^?\
MF?:7_#Z_Q=_T(OAW_P #I_\ XFF-_P %L_%R_P#,B^&__ ^?_P")KXSD=<55
MN7PAHLAO+\/_ "_G_F?:+?\ !;SQ<I_Y$7PY_P"!\_\ \33E_P""V_BY_P#F
M1O#G_@=/_P#$U\.,Q+'FK%IG-*R$\OP_\OYGVQ+_ ,%NO&$9_P"1#\-'_M_F
M_P#B:6'_ (+=>,)&_P"1#\-C_M_F_P#B:^+6BSBK%G  0<46)_L_#_R_G_F?
M;UG_ ,%F_%MR!GP/X=7_ +?IO_B:U;3_ (*^^*;GKX,T ?2]E_\ B:^)M/.&
M'UK?TT]/PI\J)>!PZ^S^9]EP?\%8?$TH_P"1/T+_ ,#)?_B:O6?_  5+\1SD
M9\)Z(N?^GN3_  KY!MI]O>M;3I<,*7*8RPE'^7\SZYA_X*9>(9/^97T<?]O4
MG^%<_P#M<?\ !5_Q1^SIX<\):II_@_0=4M?$:2"4SWDL?DR*$8 87G(8]?2O
M![!MR+6#^WWI7_"2?L2:5J0&Z7PWK,88]PC[XS^'SI0]"8X6CSQO$ZE?^#@[
MQHW_ #3KPM_X,KC_ .)IR_\ !P5XU9A_Q;KPK_X,KC_XFOSDAU+<.#5FWU'&
M68X Y)]J?*=O]GX?^7\S](K'_@OAXSNOO?#WPNH_["-Q_P#$UI0_\%UO&$O_
M #(/AH?]Q"?_ .)KY'^+/[&GC3]GWX.>#_&VOG36TGQ@L9AAMI7>XTYWA6>.
M.Y4J C/&<@*3T.<<9X*QO>!S19$0P>%DKQBOQ_S/OV+_ (+C^,)!_P B'X:_
M\#Y__B:D'_!<+Q>3_P B'X;_ / ^?_XFOA6RN?,[\UU7PW^&^M?%OQ3#HGA^
MQ;4M4FCDF2!71/DC0N[$L0  H).32T*>!PR5W%?B?82?\%OO%['_ )$/PW_X
M'S__ !-2?\/M_&)_YD3PW_X'S_\ Q-?'?P^T;3=>\:Z19:QJ7]C:3>7D4-Y?
M^49?L4+. \NWOM&3BMCXI>&=#\*?$G6-,\-ZY_PDF@V4^RSU/R_+^UIM!)QT
MX)(R.#C/0T61/U'#WY>7\SZLC_X+:^,FZ^ _#8_[?Y__ (FI/^'VGBX_\R+X
M=_\  Z;_ .)KXWL-'NM7U*&SL;:XO+NY<1PP01F265CT554$DGT J/6=*NO#
MNJW%CJ%M<65[9RM#/;SQF.6!U.&1E8 @@\$$9!HLBO[/P_\ *OQ_S/LQ_P#@
MMCXO5<CP+X;/_;]/_P#$U1?_ (+B^,D;'_"!>&O_  /G_P#B:^.<[EJO<6H:
MGRH/[/P_\OY_YGVC!_P7"\8S'_D0_#0_[B$__P 34K_\%NO&"C_D0_#?_@?/
M_P#$U\4V]OY9ITRX%'*@^H8>_P /Y_YGVD/^"W_B_P#Z$/PW_P"!\_\ \337
M_P""X/BX=/ GAO\ \#Y__B:\!^&7[(%_\2?A)#XTN?&G@7PEHMQJ$NF0MKU]
M+;-+-&H9@NV-@<@Y'.< \"LGXQ_LJ>(/A%X.MO$R:GX9\6>%;JX%H-9\/:@+
MRUBF(R(Y?E5HV(Z9 !Z9R0"K(R^K83FY;*_S/I:+_@M]XPD/_(A^&_\ P/G_
M /B:E?\ X+;^+D'/@7PY_P"!\_\ \37Q!8<D^U371X'M3Y4:_4,/_+^9]K?\
M/O?%V?\ D1/#?_@?/_\ $U(G_!;/Q=(/^1%\.?\ @=/_ /$U\,^=\V:T+1U:
M('UHY4']GX?^7\S[8_X?8>,/^A%\.?\ @=/_ /$T'_@MEXO'_,B^&_\ P/G_
M /B:^+P=RXQ2[03CY=U%D-9?A_Y?S/LF3_@MQXQ3_F0_#?\ X'S_ /Q--/\
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M13U.10-(S]0M]@!JHGWJU[E-T1K,:':YH"2Z%VP&8\>E1WL=2V)VQTMQ%YE
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M[,'Q*^&W[5OQ=L?AC=?"'PKX9T'Q$D]OI&JZ;),=9TV58GDBDEG9\3$A,,"
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MO;^MA_B3P7X;^.G[27@[PWX9\,ZI\.[SQ!);V6N:7=*PBT^Z9CYKVZO\XCV
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M<DDU]!_LLWTG@S]C#X\>)M-9X=;:/3-$6YC)62VM;B8B;!Z@.#@GV'I7AGQ
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M[MG(6:)QT*NA((/?!Z@&O-SK(*&,IR<5:??OY-=;]_\ AAT\3.GL]#U;XH?
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MB=FU7Q1)-'@LJ6ECL<@''5F(!^@-<9X_T#P_\,K0?8_#5UJ,JXW3:E=.1R<
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MMH-@JPHP*6)0BDU!)+M(]ZH)#IDW#'K55[5E]ZL*^ZI%7=B@-BHELS8[5.L
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M./+(];_:J_95D^!=U8^(O#MZOB3X;^),2Z/K,3>8$#9(@F(& X&0&(&[!X#
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M .?6E<R=2*;3Z*[_ !_R.4^S[A5.]@P#Q6[XNTQ?#'B[6-,C=IDTV^GM%=@
MTBQR,@)'0$A<G%9$[^8#3-MUH8\L&U^M21/S]*F=02>*8D>!TH))X-Q^E.>7
M&:CB<K4R1EP=R]:"D);?,>M78-JU5BA\L^N:L1?)0/J6DZ5'<'-$3;CUJ1U^
M4FIMJ,IH3NQ5ZWCRE5XEPU6X?OTKB2L/2W]J;(F :L L=O%5[R;RNM/9#&J.
M.E.1#BJC7WS*!5F"X#BA(">&'-5M1A^4^U7(KI57'>J]XVXTM0,>.+9)CM7N
M_P"R?^U2GPD@O/"7BRR;Q%\-?$&8]2TV0;S:%L SPC.0PX)4$9P""& ->'_9
MV:2KMO&5--&=2G&I'ED>R?M3_LMR?!&>R\0>'[S_ (2+X>^(L2Z1J\1WA V2
M(92!@.!D!B!NP> P('C,TVTFO;OV6?VHU^$<%YX3\66?_"0?#?Q#F/4M-D&\
MVA; ,\(SD,."0",X!!# &J/[5W[*DGP3FL_$'A^\_P"$B^'GB'$ND:O$=X0-
MR(92!@.!D!B!NP> P(!Y,RIU)1E[*KOT??\ X/YGCD4VXYJ4/E*K)E<U*CY%
M2=*) H)YILT/R' Z4Z#EN:M"VWIZ570;U9CD;&/%!RR?2K$]O\U206N5QC.:
M.8CE,EHL,S?WJ(7P,=*O75IY8/'%9\R[&HB,N6TV!4WVG -9]LY!-27$F(_<
MU0#I+[<QI@42U2>0B2K6GG=^= HL=]FQ[U#LW-BM&6W^3BJ<EN5)-!0MO !4
MWD8%,B;Y:>\WEK4I&8;O*--GN-JBH9+C>.*8=TN*HKE)#*72JUZF^K5K#P<C
MFGW-MO7/<4D29MLK!OEK?TQF55K)MX-C8[5KZ9*1)CM0E81NV$V<5T6DRY K
MG=.A#<UN6&(R/:E$RD=-I[945I1+E161IDFY.*U[4X6J.=HZ'X=7W]E^-=+F
MZ 7"J?HQVG^=? G_  4J\&?\(+^V[XUC5-D6IRQ:G'Q@$31*S$?\"#?C7W78
M,8)$D7AHR&'X&OF;_@M3X86U^-7@OQ-&O[O7]!\IV ZO#(2,GUVR+4Q"CI47
MH?*>DR;L5UV@RXQ7 Z=?;378>'K[<%.:H]!,]$T.0E5K<4[XC[5S6@7(9%KH
MHI@83_M4MD45U?\ ?&MG07(EK'*?O.GO6UX>3+Y/:GTL9G26APO-5-6N/*@Z
MU;A'[O\ "L77)2QVT 5/.WG.:NZ<=Z5CE]K >IK;TI?W(]Z!(+ML?C4%O=8?
MGI5Z\@PIXK+F38=U S7A?<M#-NK*@O&C]<5I0/YD8)H'<CE+,:EM_O"E:W8C
MBI+6VVGGH*5Q&C;Q;DIES!M'M2QS>6*5I]U,HR;JWQG-1)\AQ5VYQOJ'9EZ!
M20Z$EB*F9C&!WJ '::GB#2'D4#B-5BTHJY"0,5"8,N&[BID4\&D$BTASBG.<
MBH0PS4P7*BEJ45)%*O5BU3YLTV1,/FI8]W%# L+!N[4YXL"G19*T7#;$ZYHV
M KA<-2JNX_PU6EO<$XZTZVN\_6B(7+D46YZOV'AB\U[*VL#.J\,[$+&GU8D
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MI2+J<_V+?/\ X!G^!OV<_$'C7XZ:%X"OK"^\/ZMK5U'"Z7]LT4MK$P+-*48
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MB.F06^UJD(P_I210YI@HH,F[%9NHWWES<&M+P7IEQXRUZUTRT7=<7;[5ST0
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MV^D_V='$F94A*!9$B7IEV=F8GDE0.P ^/R/(UF^9*C.HU!)R=MW:RM\[]?\
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MW(:I3V.Z7TP<UJ!&#<CBAK<$]*-B[%6PAV=JOKTJ!1L(JU"FZF,@E4AJB,@
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M_=*#'"C'3/..<=3VVD?'36H]5T^#2[S5+72K:'?$AD$4T[L5+.[1\;F/08(
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MS)N6)., @' "CJ?K4,^;S2NY5>1;(]A\9_&K6O[2FO6MKFZM0,&:(C,6<Y+
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MDKJCH@X"M'Y9 ' ' Z5U/Q@\4PV7BM=!O]1ALAI%XP6X#GRTCX#!MIR",+@
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M2"W?S4U.%W!C=" 0'C PP)! Y!.37,>&M+32ET;4-3V2V]Y@B$Y& I*D$<9
MQG@C(Z5^C973]V\NO^2/R3#\K?-36S:Z?*QW?PH_:"\=?#KQAH^K-K7]M:7,
M%=M+O"TEM*A.&&,$J?0H<@]B,@^]?'+QIXUL]>2\\%ZQJL=IK\,E[I<4!A:$
MJ$#"-A(" 5RQ(P<A3CMGY?\ #?@2;4OB:8=+ECOX8YA,B6[&**<C+!$W $,!
MG (R2 .>]KX@75QX?GU.QBU'4K#1-0FCD-A?D.;EU?Y2J'[@SPVTC!!R.M<^
M,X<P3KJI&$>;JG%6=^Z[KOZKJ>Q/&8_#T9T^>4HMI_$[Q?EKMW6RT?KYOX_\
M8>*OVEOB5I:ZT^CS7.G1.D<]G8+:$L2"PEV@*QRO!50.3@=SGJ]QI'B"72;^
M"2"Y@<*5(R"#T(]0>H/>O3O 6C?8_'2W6EO?&0(WF6]L$^<\$%MP(9<\8&">
MHZ$58^*'A"/Q5<V]XK7"WEM&#*@16\M01DMM!8L >1CW!KTHY7]6@J5**C%;
M)))+Y+8\_'Y-BZL?K%5N4F]?N6[WT/3/V4[>/Q#9RZ;/=V>E3VI*Q!Y@DY4D
MD,488;@8)&<#KC-;_P 0M,M=.@GUA))K";3E9Y;N2/,<2D!201@%B  ,<#L<
MUX1\._BUI_@?QM;R7%XC"XC-I+>0*)Y+?)Z, P*@@DYZ@#H<D54^)GQLL/B/
MXYU"QM9M4&AZ;8RQP#(8S.  &=<C^)F((!(  QR37++ ?O'=Z&U.-&.'=*>K
MOIKMUZ=OZ=S@OB/86?Q)\0W5AI<CBQOI\)+( CI&QRSA3C(!SP.3GVS7U]^Q
M,MMX<T4V&G-*8]*CC83A3B7!P7))XR3P*\3\"_ ?3?#_ (<EU*2UFBBEMI7\
MYQYC7*E0&(!&00,].!NR:]*_9Z^+>NZ[K%M8SW\EQ#:Q1+(HC""5$4JJ,5 #
M%5!'/UY))KR\4KQ<8]#Y_!15#$J4NK=CD?V\_"NG^#OVC=2_LV%+>'5;2WU*
M2-%VHLTJG>5'0!F4M@< L:\5NKC]U7I7[5?Q4M?C#\9M0U:Q\S[####8VY?^
M-8DVE@,# 9MQQZ'/>O+I#\QKY.7Q'](X)36'@I[V5_N(OL2W;;MM7K'3?+[=
M*CLSN.VM:V 5*GE.SE*[6FSDU7F9<U:NIBV1CBL>[F99>O&:-R63._G2[>U6
M+.T/F+[U6L#YLX'K6[:VOEJ.*;&M06%5'2BIFA.>**7,/0IZC;DUR?BFV$;'
MBNPOYP :Y7Q$=[47%(YV%?WG/05N:''D_*.*Q[F/:1[FNB\/1XB!ZDU1G$UX
M58**20L'J_;6^Z '%03VK%SZ5.VAL1Q3?,*DGDW$+1#!L'2CR\S4:$V*]S#D
M=>:J3#YL5IO;;FSVJG<1 MQQBCS&M"G/%YB&JL=CDU;/#>U2P6[,XXXHW(+&
ME6YC(%:RILQS4-A:MA>*N26K!=U&QH/@G"\&I7FR.M9LDK!CS5JPC:<^M2,9
M,07/%3V<@0CL:?<6.Q,XP:SI-R2>PJDKH-CH(+I3QTJ25RR\'FLG3I&DPO4U
MK+ V/F/-9\H]6RK+$SL,<FFM;LHJ_#&$-69+=6CZ=J2NMBC!)*FM"Q"E*KZA
M%Y3\#Y34-M=-OQTJMP-*:/>C#%9\EOY1-:EK"9U'\ZAU*R* CO2V8O0S7MO.
M0XYK-N]$;?N(SC-:D<AA:K+EIXQA:H5D8UE%Y7 '-:UH_P"[VTU+%AD[:EMK
M)FFVXYQFB4BMA;^+=:D>HKB]7T5FN"0&R3S7NG@OP_I\^G:&UQ#X7FLIKJY7
MQ!+J-]-#J%G $'D&SC0;68MG.[/.!C&2.$?0UGE(VL<$XR!G';-<U'$<\Y02
M:Y7NU9/T[G1B,*X4X5')/F3=D[M6;5I+H]+I/HT^IS&@:/Y:[F7 ]*U7\/K<
M#=LP16O%H_D=$JY#;CR\$<UO?0Y^4YO[ MAUXJ.6]6-"WI5[Q!:MN.VN1\0W
MS69"U70F6AM6VJ+.^.U:UFID(KA_#U\US=@$YR1BO1M.L-EJI/IS1+L$=2M/
M'O4C'-9LMMM+9K?DA7!Q69J46#]:%*R*E$I6LNP;>]:E@=X]:QHH6^T<>M=#
MID"QQ_,?NT$Q VN!G'%0W<>V+BM!IU4^HJ)XUG0]JE%&*&9'S6I;2[XA5&[B
MQ)CI5FT.(A1NP)I!FJ\Q5 1A:DN9-B9JC+-N>B-NH"-:+,3ZU4OK)2A&.:O1
M?)\S=ZBE;>Q]ZKJ3N8#:9^_W?PUJ6UL(XA_*K#6@89 6@1;>M K%&_BPN!WK
M-N$\I?F[UO3VXE6LN^L2YVU41.)BRC<WRU/9J4Y]:EN+':>G-36T&X 8Z4-B
M19@)* TCG&:D9/+2JK3;%/&[%&XI; L.]_3!KK/"D6'4^E<W8GSP#BNGT&46
MZB@AJYV^CME1QBMFVG##%<QINH^8@V]*W-.EWJ*>QC*)>E3*\58\/7C:;K-K
M<#@P3*_Y$$U'&FY*<(\,<_>-0821\H_\%<O!H\/_ +7QU*-/W7B+1[6[#?WV
M3,3'\D6OF^T3=UZ5]K?\%A=!_M+P9\+?%07EH9],E?W*I(N?Q#U\2VMQQ5<Q
MUX65Z2^[[B0?+-70:"PR,]\8K!B?,M;6BG-RHJAR/1?"X8(O%=?8LVSTKE?#
M/")Z<5V5K!^Z%!K'8FM796^]6I:39-9\%NU:$";4Q[5+8M1V[SF-5YH\-UJU
M;QY!]Z:UMM!SS4@9S'+U!=0>8*N3QX!:H%7<:K<)$-I8XD%;NF0MMJG96K%^
MG%;%I;, .*.4(CD^5NM6H;A<=>:KSPM#S559&W=:DHTII=WXU5'WJLV=JTT?
M3+4R[M3"#QBJTO8K4GM+A8Q^'2N[^)_@#6O _P 'AJ>G^%4UZ>:"2:9?MIAO
MS&$(=HH<CY(B 2P!8D] !7/? ;PW!XN^+NC6-[M:T\Q[B92,B18HVEV8[[B@
M&/>JW[:WB/4KWPKIL<-FUG.-T$]Q'\K22$!FS@DC);!((SMQT!KT,OH*<G)]
M#\]X\S:K0A##4I-<UV[.UU>R5^V]SFOV;?B9IVC_  \U&#3=(CTJXU"X\^]N
M$)/GHH!4%B22 =Q.",D]!UKK])BUZP\7V[7"267]J7\4;W]RBSRV:,/F$4.<
M(% Y)P23U.,'C/A_I=C)X'NK7[*MO%;QAI+QE$H0H0%B49P"Q4'@=6R2>@]=
MN;)=/:VN-0:.[BG"13VUM*5;<%&&(SN)!&2<#!XQDU]QA\-^[Y5O;YGR^#PL
ME0]FM[-VZWON_EJO\T=)<:E%K<=KHLGB*X\1ZI8Q^;<SR:*CQ[3\Q4%I Y"D
M+MSG')Q@U8\(:_J'B3X5ZEX?C\7>(OAS<WVKVNIR:]H822\DAMIR\T#1D@QQ
MRXV@D\A22,'!YM0OAVY>VA=;:%D5MTL2M*&(W*C-\I)&"Q Q@<Y.<5T6KV]Q
M8V]W=7E[]FTPJS2*J%./*()<Y.!D#(!R>_!JJV3TL50EAIMV>_3[K6/HLJC*
MAB8U\/)*I3UO)<ROTT>CMU3W]#W;X:ZS9:K\8[O5K&XMO(U&^8J! \:RQ<A6
M(+;=P;J5P#G!'//0ZSX)TCXKQ:IJ,,<=Q<+<&.%HB=F2"I4+G/)R#V(.!7E'
MP?TR3QU\*ECTJ>-G\MD:Z,$BSX96)D"*RL JX P"#A 2#@GL?AKJR^$?!&H:
M?>075OJM@&6<12 ;R$+),JL<*&ZD$9SGVKQZW*H25)OF5E\K[ORV_4Y88R-2
ME*"5WZ=WJ_)?UJCA/#4>@_#O4HK*_GO[&_F,YM)[=I4DMMC*3 XZ$* 7!Y.#
M@]*\A^.?P5FTPZEJT+;WM)U%_&(MJ 2'"31GH0QY8<$%@<$'CTCXIZ!?P>$U
MUV/[5>P6\R7R7DB;7B8XWJQZ$@. 2O' SCI5[QYK,>B^'M;O=4GL9H->TB:V
M<Q2>8=[)&\2$*2I82$D<Y P>H->5CJ,6G\_O1YN4XRI@<RC"DK1;2:[INWWI
M[,^39-'^SR%CW//\JNV8VXXX%7[F%IB,B@6#*.E>!S6/V2W8F@;S-M4?$-HU
MQ$1UK0L;)F7=AN"1^7!KN_&NA:;#IVN;8_"HM(YK4>'I=,NIY=0N(BG^D&]5
M_D4ANFT#' &:Y:M?DG&-F^9VT6WKV1UT<*ZL)SYDN57LW9O5*T5U>M[=DWT/
M!CH;"[&%;&>GO7U]_P $G(H4^->OZ3-(D;:UX>FAC!'+,LL;<>X&3]!7@$>@
M*[;MN:]+_9*\5K\+OVC?"&K2_);QWZVTS;L8CF!A))]!OR?I75S7/,Q5'FHR
MBNQ]1?M ?!!OB':6,<0FMFT4&>Y$:AWD+DJ57T 5<\]SCM4WPG^#5QX9OM$O
M[M)+:XU@M;7L*#F2':53T!("H<@<\@5]+1V&DZ1XENE=4CN;W$S!A_K!TR/8
M$XQ7G?QQO8[6\M;?1Y(Y-21UEM4,A"!P>!D<@$G/'ITKNP=::O2C]K]+_P"9
M\?1D[\BZGD/BK2=<\!ZE-8VY1Y-*NS P+X\L/AE=1W#*,8QUQCO7*Z]K]_\
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MQ"V"'@%G0$DG/T(QGTKL/"7Q2\-W-_\ 9[J&V.GV<(BAEDMXWFGWJRJZ'Y2
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M,=J?I\JRS 'L:J0M"U8Z=MCZ5>M5:,[3TJY:K&(_E&:)$52#C%+F(DC6T1\
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MS_9IE9"RNC!E8'!4@\$'J"#7T[\*/VN])^(&L6^G^*F;0I)(]D=[&H-L\IP
M)>I4$]'P<<AN.1T0J-.Z/E<?E<H2]K05UO;M_F>E:;H,_P 1 _VJZNHM<MRV
MXR$[9U7E3VY [YSWZ9J?P/XEM_"D5S#?,DEC>2+').(1(T4RGAWCX)7'!/!&
M!P37%>)/$6K6WCJ'2VA:+48B%A,39:Y!Y1A@E2"N""#@CG-;N@Z??>.('OK/
M4]-DG>1K>66UN4N89RA ="R,0KCH0?H:]JAFE-_N<0]'LMFK=OZTV],*-1SI
M-U$^565U?1O;5;/32_XB?'/4_#OB/;9Z+LN[V'=+*LMNRPR,0>5/&#U&003T
M(.:\9\6^'_.B2:[AAN[JV0B2.V A&T <-V89Q@D$C'8'GU3XKQ6/A32]TD$U
MX8E"1P0H968Y  !R#@'!P#VR:\CUWQFMML5M/\NZ20._"!QQWZ\8.,$5Z&%Q
MF&IT=7U>[;?372WY#A6H*&KUUMJVSHM/TN33M$\ZZEL],C6 !R1N,"D8 S@#
M+9P,<Y/ )XKP_P")'AEOBY\4-2\)Z'JWA[5(O#,1\_1H]0#ZA;C(#3318"#
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MU2SBN[4NHP'$<@(W ="!G%>S0?"S3=9D^V:BJ:A?2JH:>X48VJ!M"H,!5&
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M7W3:MJ<Y9^'=)L?!]UX@\1>(+;P[H5I=Q:?]IDMY+F26XE!*HL<8R1@$DG@
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M.^-\ICC49?! SR<9QUJJFEZ]H7B2)KC1;^,/;3O:-<6LL<5X[ (%5L '@D@
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M955:T')VC?1;:>FM[KS:6IW=YX8T_P )WR;=7U6&XN<QP*=5(DR 6(4E3D@
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MK,FX&53R&7N!G/;@UU1JTJT_91EK\]#:MEN)AA(XVK3]QR<5+HY*S:];._\
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M@SW,2X@LA!$H3  !=N69B.I/YUXO\3/$$U_IS7EK-=/J$TPW77EGRHMWMR,
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M-?:M<"8J/+7Y0D2] %7& !TKYW%X_$X=\E2SZIH^TP-3!XJG[6+:MHXO=/\
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MM;Q;R19KB7;.67?A<9Z8/)^GY5Z?\ _#?AS6]"_LJ\L;;5'UA60R&("X1N>
MR@$>@(P0>]>;7@E[JU.*5K66K74\A^"FIW6EZ)YC2-)!O/\ HTBB2.1,<YXX
M)_GWKV+P?\*]'\>^)],AN;*ZM=/OIA++<B0A4C# ,".<$?W<@C.1Q7J%U^SK
MX8\/^!I+2U1M$DO8A!!NQ))DGDA<EB#R,GL<@UY?J-SJGPW\;S>&S);.M],\
M<<,4Q8(L:J4D!QU8%@0<$ ?0GQ<=AY3@ZE-VDEWW\F>KD^92H5%0EK"3^YO2
MZ_7HRQ\*=0\5:EXI\96/BKPAHO@[PWH]F?LCVNGR6\]M<"X98XQ<,BK<"2(
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M. Q<Z"E&7*WMJM]M.O<^MX;SQYME=+'6<542?+)./1.Z3;T?1]5]Q]U_L^_
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M:7*K6?5WM'Q._CN-%TXS6DTGS_,L>XDGG!&.E7/!_P 9]?\ A_JT:R-,UNS
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M_A%(]'7QC)9+_8DNNP'^STD\U#)N8@*&,>\(6(7=CD"NBI3C1ESX5.W1;O\
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MW81H2RE04/ 9>Y!((SGIFN\\2:I#!X&DAMFLX#?1 I/>LS7+J7.0J[F0$@'
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M8,"",]P02*ZOX0_LO:+<>.M+U+XJ>/-'FMKU)+F4WM^\\LL87$3.B[I KG!
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M\(R+/<+IOB:!"^FWD0"DD=(I1W1B,,#T'(YZ^$Q^)K6W>W^SB219?G$C2B/
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M ?,@SG(YX))'8YY%>8^)=)O;S3+NWGF2SF6[DN5O)&8B=F0!E<LQ5%&T;0
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M)=W%U*=B@@ X4\#)XXZD#O7S9X3\"?\ "J]3U5M0=1%'JLEO9JH)S#@.A(Z
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MPD0(C07!FCCSQD#)  ]/SJA,MS9W.A^'X;C^S;+5KN*.YN-O5F8*">0/ES@
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M2NT#!(SG SR.O%?/XRI&NG&?O7Z6T^1PQQ]:G65>C-QFG=-:6?=/OYG@>O\
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MT^%E56(CV!4()7D?,<\8KR[Q1+<^#]5AUSPQJ5S%,ETZ+<VLA2:W#,0H# #
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MZ)N^SZ7I=FK  B*T1<@=,G';)Z^M0W?Q%TW6K-(;ZUTV_MAD^7<6J-LR,<'
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M,2"1>0#A6Z'KU[U\W_"'XR-/J4LECX6L]2;S8$9;F 3#R(E**)%)P=JC).<
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MQ8[,*6+K/$1BHWMHOZW)JTZW*KK\;G%_M&Z_')X=T+76G^S"9Y+)U7@R,H#
M@Y'0&LWX?>'?B%XLC#:'X;FNM/D4;Y]0 LT<C. &?!8$@C(YZ<CBOH34]#T?
MX>>$/#^FZAI=C?ZY#YE[%)-$)&L/, 7*YR Q5>N,C/!%0V?B6:ZDROF-$#W)
MXQVS_C583-*V#=\-I*W7L];?D'*IOFF[>GEIOZW.;\+?!;QII-I+<;?#\.I"
M$B*!;W=M8C)&[9R?X1S@#J><UGR?!CXD1K"U]I:W$* DO;3QSX!.>0ISG)/
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M)I?NT[ZI)-ZM[O7?J:NBZ;I?Q5NH/%*Z>NCZ=J5VTS*#O1"K!5!W''!R,@$
M,23WKZ"_8N\/1:T\&K6<%Y,-/O;NW:W8@I<^:Q82D\D@ #D<= .F#P7@[X'R
M:9X>BUCQM?75G"%:&UTNV !OVC#NX5>5.], J1SR0.,CU3X>>.-=\ :1''8Z
M1-X8T^[D_>/=.EQ,F 2HV* $4#H "1W//'H9ABYN+A'5=/ZZOT^1Y=2I)1Y8
M;6MV_I^2-C]K_P#:!\?? /X9Z;>>#_#]EK%U?7<\,L]S#)/;Z2J1[XD:./+L
M96RJC(Z8!!(KHM?\97VH^&M*O-7TI;:ZDL89-4L+=R?LEQ+'\\08@$;22%)
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ME0R#-PDH9$&>2>X&/6NN\5>*='A\5ZB=(TZUM2\@2:[BB"S7C(H169NI "#
MS@>E>?3K1@_:+^G_ , TI\UE"6G7:^B_S9X_X%^$_P 3M>2#[5H>EV%BK81K
MZZ2"6-,9SY:@D'/!!'X#K7H%U\%?'$&@06NE3Z).[R"2<K=>6=PY&-R@;1@
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M"9('!&"986.5R><CCGH*O_#TV_C#6]2US2]<TFU\,-(+5K,VKI<229&)1D<
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M-6G2551;AP1;Q>=^\V(!G)P,Y(')%>(_"SX,Z7XVM_$6OZUJL<6G6"QPBWC
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M;B*=K>X4E) CAL J0RMQP0<#]#E_$#XL:QK-Q!_I<D:/*\-C;RN76VA9BWE
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M%]>J]&S]+-%^)WPU\-_!AM<LU:S^'NA2O"L=I;,HO9%?84PV&8%V_P"!'/.
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MC. <#GVQ751RO,:,/KBIR4>_^:O>WJK'F8B4*T.2K35OR\UV.\M/#%SX8O\
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M#X3FT&37+BXM4O)9Y9GMX(YQ%(Q:.U5855?+A7*H6R2#DXR /A_5O#NDZO\
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MU;F18T^=O[V<_P"<U6-]A.TJ4>5]>QQ2Q5]$=]=3KXO\+2*H_P!,M%+PL.I
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MG QJ5YJ%2F[OFT=_+I)6T_%I,\V^ GPFL_BQX_T[1[K;I-O*QDDNKV%V@>
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M?H[GH?CNYD^'"K-$[RZ7<G$4H/*9Z(Q]>P/?ZUS.F>*]/U==[S2-=*,D,^<
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MW_71GU+S/ZS5EB'&*=EI!**TBDK)62O:_F[MN]S5N?&^K2:=%;QR_9X5)9Y
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M6/$7CV"\O+_4+1+BVB%I.D$8B,WF2-.AB3Y8Q*-KEP5)/!&:](_:5_X)X/\
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MQ)9FTCDC.PJ<Y5NX8,IR<Y!(&#QT7A+XSMX3^'5H+6WCNF2=7E+,2X0%64J
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M23(&YL'/%:WPR^&5EJ_AG6]:\5);Q>$M-MA/JLLF2MP.%6)!U,SL0%P1@G/
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MKK/BBPLI 64SKN&>P.<@^V*^2?VSO'<OB7]L7Q8H?SK;3Y8M.7'(Q%& 0/\
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M&K76E_&2;7TM6M$NI(TN?XHI;H1 NP'/$BD.![D=J^2J8-XCE=[2CI>U]/\
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MUY3A9"^ N"PR, $$9!\C\<?#;X?V5[YVG0MJ2Z;;0:?ID=XI^R1+&@1,Y"C
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M@#D#!/4 _'WP]_8"^*7CKPQ'K']E6UG;WJF>4W,QBD2$_<+A5+#(Q@$@XZ@
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M3[_6O=E3A&-FU?\ KL?*RITX1LWK_78@M/VE8==O(H;VPMA82Y^X"< <$$$
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MVR,'$L(C=0VW!P0ZY!< XX/@G[3,%_9?%"]O=?D;4-2U>7[3,ZVS6N<\ A6
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MU4$R*6?YMI&-I(SSGZV_9G^"EOX<@6]CO6UBXA9HVO5^2%&4D.$!^9B#D$G
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MP)2($J22KR%!QDG.!SQ7BP4^3VC6G?IW_(^C]FI5O8P?O/TOV_,^)?\ @O\
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M3WL[O5K3?6I6PTL<\,W&$M9:_9BE>4VNLFEU^%67Q;<O^U?^T]X6_9S\'?\
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M \$@>^>?I^/2O+5UY8KL*S(I<Y;)_+COQ70^$_$46KWLD4D4<LB$($+''?D
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MI)&X)Y+;"R[B1G)P>V,5K>%OVS;?X??$9=4T^+4+J.YD6YN$D=(8)I@"IDV
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M"BG['5A^P5^U+J7@C2?$5]XDT-K&WU6PN+RW$5S'#,6 BD( 5W0HP+* "-O
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MI5_J"A+NYU)A CP)<AC*ETH#;UC4@QC'W2#U)#O!/QSTJZ\1EKJ^U;3+*>W
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M^Z_AO^SY\-/V>K"QUZX$>D-:JSA+VZDGN+"<K@J48 LQP "JC)  '0U]0_\
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M[*UJ1;BT>-DD(W3+MGB(^Z3M. P&,X/TKTCX7>([;2KME01^5-\K X)4YSD
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MI2HQI+EBFH7LW%6<K-NSEN[65^AP7_"8<>OU-%<;JVM>7?R(K+ 8V*,D@Y#
MD'MTHKV?JYX#Q6I^D.D>#],\,V ;3[.."V,;*9E^Z,C'7L:\(^+%Z]QK$EM\
MT<</&/4^M?0'P^UB/6-.N-)U2)'@NEV-@?*3V..W->/_ !RT".T\0S:>HV7D
M2%H2W_+PHZX/<KW'I@UY-.E[:/M.J>Q[];$<D_9OX6E9^?F>>W>D27FF1_NU
M= 00W.X'U![4[3-5U![673YI%E21AABN)$4<8ST(_"H9/$&H^'+9+>XLVA@<
M;E=T)!!]#@C-;?PZ\%77CK5HI+/SE6-\R7!0B)%'7J!FNNCBL31@Z=.32?\
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M?4=LCD>XKTWQ)XBD\8>(+O7KTPK>7D@18D4(MLL>4$*@YQ@!>"1D<$=:\_\
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M8'\ZW/"?A>U\+P'4+A8Q& /)MT/#GL2>_-.\4?%'RM>TNQDE66XF??(!@!%
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M%SI?PT7Q/K*QFTM9YWE.CW#LI+&56()>/Y0$8A3P02>3]AD,O90=)='IZ/\
MR9^-^(&%]I6CC%IS))[Z./R>ZV]&>(? OP;%XW6]T^X:VVV]N9)>2T\>X8&!
MT*XYR 2._'7T[P3J%UIGPZTQ8SJJ16JO;QNTQ5, G:<8QLSG&2>O  XKS/\
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M\PWL2!P!@\_J?[*7AOXE?&#4]#\,65]_9=I>%+AIOGMX%Y#[FR05C((WDY.
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MP1@$XR"#DUL_M%_!C0?VD["W\(F/5;>72+E;.TG60R&PO!"98I-V/F4 E6!
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MQAR078# !)XQ7*^+O'4WC_0(-WG+&$&0\A<Q\DDJS9(//(Z9Y&*V7TWPW8^
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MMW0G#  @$[F!(X' Q]>:L>!?A-=ZEK6I:]XHO?#-A\2M<\0QZGI5_!91:F-
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M_B;:=LWP7T*\LLB>N,X/4=0:Z#P9\,=0\:7,2Z=:75U*2"6C0_NQ[GH!]:]
ML?#T^E^('\*Z/;)J?B?4K>2-D>0".T4C:997.555SU.23@ $D _$UHTW"\]N
MO8ZL'>'O?@>O?LA_%GX,_M):8WB+09=%T7Q.]LHG6Z"F9$7_ )YNV-R*3C'!
M4X! X%>N:KIGA&WL5O+[4GUN&S)5':0RQ*W?_9SGCU[5\:_!'_@F7\,_@"\T
MFL:]X@\2ZO?$R7D<=X+'3O,).[8,&0CD@G*Y'4#I7T%\-['1=!C72=%L_!]G
MIJC;LNKO[=+(/?S)#^@!KYW%5\'']U2M)+K:3_"ZB_R.F.!K2O7YIQCOJTOD
MGK+\!_BOQ+'XBU;3YO"MUI>F:;:WB2ZI&;8^=<1(P9XW+#A2H/ '/K7Q]\6-
M?\0:_P",=3OKRUNM*CU&>6Y@@N('\UHF<L&;@8R#D^G>OT2^'O@$6VMV<UC8
M>&9+)'#2K;VT<;KCH003^5>F>)/"UOJL?F-;V<K*I ,D"N0#Z&NK*<CJUZ,J
MO1/1.-ONL[?U8X,5Q!0PU14E&]UOS7:];J_](_$_7]-O=?NUM_D8J<KGD'\,
MYK0M_B-JG@'2+NQT73+/5=0>1+"&[6V=[W2+R4D>A4J4VE<Y&.200:_3+QU^
MQ'X-\<WDET=#MH+L982V'[AL]\JORG/T%>(>._\ @GDME!?3:/=:I9W<FUXD
MO( 5=E8;<L"5('. 2""?<U]=PIFF$RO$N684N9-65XIV=U=W?339>?FG\OQE
MA<3G>$C0RZO[-IWE[S5TD]$E=7;=[O:R\FOE+XF6MYI/AC4K2*\U*\U:&53,
M;HMYCNHV2J 68!>XVG!/?)IW[.&E23Q?VC>2V^GZ3;2$W]U=RA7M8TB+F14^
M\X!VK\H^\Z@X&<>]7W[%7C+5K^,0PM>P2R$L975'#$Y+-R<\\DU8US]@3Q(F
ML0Z:D%B/M5C*9[YO-$5K%)B-@CJ"/.S@A"#P"< \U[7#N;9?7S2I+'WA2J<T
MNDDKIZ/9I+2UKV:2VVX>(L)F66Y)"EE$XSKPY5ORMV:U2=U*3U;4K)W;W/)=
M1^*%TUC#=6ME-<0>([>.ZTN.-$'E0 #YB%R=S[@Q#'Y00!R":<GAC6/$PGFC
ML+J2ZO<?N8266/ P![D#J?7I7T%\ ?V+K'PMHUFOB#1H4\5Z###:3WMQ:^3!
MJ'!=)E96)?&\[N!A]P(. :]HTKX<Z-X?9I;J:6^DC3>(H(MD>?08YY__ %UY
M?%TL)+&3H8!_NDU;ST5K.[O&VS>KW=VSU.$:^.JY92J9HOWKU:5WK=WOHK/R
M6BV5DCY6_9V_9#UI]<7Q)KU@$LM%D$PCF4!IY,C;D=2JDAB3UP!TS7L?CW5T
MM;)(?LTUPZ$L^TY=LG)('<]]O4GBNZ^.WQ)UWX+?"#4=2\(>%8?&7BJ> -IG
MA>.X$*7@=E1@6Y8D!B2< 84@8ZUQ?C;P%KOA/3+1?$%G;V&KW5G%-<0VLIF@
MMI64%T1R 6".2 2.<9[U\/BL Y-5'JEI;_ANY]?1Q4YIP3Y;WM9J^F^GE?>U
MM>MCXMN?B+>?$#XFZSHECX4\1#29K6'4;B6V@,CVC.2)%4JW*L/G8C!3DXYK
M8U'Q;YFEQ+'-(RAL$@$9P<$8^M>E>,?AS-!''<:?)-93V\QN)I8AM^V%E*R!
ME! &\$YQ@ \X->6^*;!M-N@2'.2<KM/;G@>U?0\1XW+L6J2P-)P<59_\'371
M+WFTVMT>/P?E>:8%5O[3K*IS-<OEZ?RZM^ZE9?99-\-O%T-A\5IUO;A8;>[B
M5XM[  G !..O!]/SKN/&OQGT+PZDD8O(99$<IB$[BX!!SC .1DCWKQ7Q5<6L
MUG^_56';(P03Z'J,^U<#_8=HFI&:)I;=XG5AOF9L$'@@=3C\:C+<=1BHQQ$7
M[METM;YV_P F?1RG.-YTK=;7OO\ *Y]-6GQ)U3Q%H<"C1KJVM[R+[5#=R8!D
MM2_EF54^\REL*"."W%;G[0M\]O\ !Z[O8+C7)M0F%O!#8V-UME=5< RPQ$%3
M,F\,< D@ 8)P#QWPCO=3\6S:>E_JFJ/;V=L;;3&L9/(MK9@QE+R1;"&\P\.&
M?!P-N"37T3X:UZ/2M/BA?R6GMT4;P H=@!DX[9(SC-?>9AB\ORW&X;&8&?M%
M&TG%-J^JMK9I7:U6K35ET9^74:V:Y[@,9@LTI>Q<FXQ;L[)JSTNFVD_=>BDK
M-]4?._[+FA>,;_XVW?BWQ,L/B>;P_):Z+9YE)/V<I(6F/RB,$9 ^?+ G)*'-
M?1W[17B74OBY\++KP+X3F\*V7Q3\3:0VI^'[#Q-!'<Q6Z1RQQSS%<.IDC60[
M2 0&Y.0#7E7P/^&N@_!OQ5XJ7P_>:K.GBK6)-8OHKN^-PGVF0DL8@0-H.<$9
M/ '/%?0;ZSX<^'$^G>+M0TO2[OQ9:6<EIH]S+$K3V4+D&0ANH0D#C.#C)XZ_
M/\9<9QS;%0J*"A9)*UW9;M=%NW;1=-3T^!^"5P]@Y4H595>:3E[R23>B3:NW
MJDN;WGI?J9?[8UA\2OAUX(^$^@_#^:.::/Q%H<7B9+:**"#3].AWO>RM]TLD
MS",, "0%7 Y->5_\%3/"VL?'C]E35;7PEI5SK?B;2+V*]TR&UDVW !W0S;!D
M;\PR.#'G##L2!5GQK\:]4\3:E?#^U4N[VXNHD18CNDC5PQ=G&,878<8R3GH
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MQ['#G"A0<DCVS@"JOPRGC,37$ENCQE@(PV2,=SCTKG?&'Q G^)^JP1L/*M
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M:YDDF.Q"-C1H1&> "%3DG-9WC_X\^'_A?'J6@^ UTNSGU*8W6K:K#&J&[NF
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M-K))!"5,C2R@D \#L" >W6OLG]E#]I#PYI,3>']2^&MKXBL2IGFE@GE>:V4
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MG:>AS7E_BKQIKGB.U;4M>6.*\OG)2$$DQA1R"['D#@#@9)QUXK*_:'\9ZOX
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MX<^ ^@V))OI-5O"Y!;=,=KG/<<"N@U;PMI]KHU_K&N:TN@Z5IJ*]W?7%W)%
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MLK,&*/6-0MC))<+D$F* D*B\<%\D]2!TKB_A/_P6Q^)'@6Y6/Q%H/A'Q59G
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M9!(R",$')W]5^ GAWXNZ#;GPYJEKK=YYKW-O9ZE"6M(V,3IEP&5@"'. #@G
M.!S76>%_@WJGP]^$[Z1)<27EYK&IWNIJTP+)L>3)5@V<K@D8Z<9Q4'P;TWP1
MK>NO&;[5?!NN6LK1;K8)+ITY4XRJ'E03R0& YX%=63YG5P&/ABL-[LX:Z[/K
M9K1V\CZ/BKAR.:93+ YA:I3J)IV2YX]+Q;NKK:Z5]['9_ ;]F-M%\,1^'[Z2
MXTRZLHH'OK&U<OIOFE6)D@8(I 8Y!!+[0B X!!/L>@?!5?"]S;16L\=RLJDM
MEP2F.I [ <<FL_PWKGB;PX$61H;^UBP5NX$WQ.O8LO5#]<>Q-1_M/_M*?\*)
M_9XU?QE%'"VJK(EEI\4B_+<7;YV!NA** 7(SR%/M7L9UG&)S;$?6,5K)I;:)
M;7M;];OI=V/A>'^',-P_A%E^7*T$WO>[NW:]^U^EE>[25S<^,W[07@_]EGP>
M+[7+]4NID;[-8VY#:AJ##C$:=$3/5VP .IS@5\&_%?\ X*N?%+Q!XE-UHJ:+
MX;T]7+):):+=L^3_ ,M)).23WVA1[5\[^+/BGJWQ#\4WVOZ_J5QJNJ:A*9)[
MJ=LM*WL.BJ.BJ  !P!1X$\/2?%_QS8Z%;W]CICW;G==7A*PV\:J6>5CV554D
M]SVR:YZ-)U&J5-7D]$N[/:E"&&C+$XE^[%7;>R2W?^?8^OO#G_!;+5]7BN;'
MQ9X%TNZTZZA6+?I%ZUG=0D+@NI964G/(& !QUQFO6OV'/CQ\+OB!X,O/#.I_
M$K5M3O+^[2\^P>/8[>9XMC[X8HIF!218F 926+ @$ =!^<OC7P+8_#+XBV$.
MI7JWNC27R)<&V&YHXTD GB)R<NJD$8R&# Y'2O4OCWX^\/ZUX+U"SAUCP;K'
MFZQ$_AR#1[$0OI>GA&#).VQ3DYC&&))*D\5RYC&>%Q2P6)IMO9];:=7Y_D=6
M5T,-C\OEF&7UE&-HRCNG)\R7N*S5XO5ZJUG9W5C].O$EQXF.J:/9_#W4?!<B
MW>IS0^)M1NKR)M1M+-XR$GM>2#*&8N!@Y*J. 2:TO"GPNL]-L[?3=7N;CQ#J
M$MI]AU#6KTXO-14.[*Q=6++L# +AR0%7)R!C\63H^V9-K-9W!'R#.&<C^Z0>
M?PKJO"'[6OQ0_9PTA;C0?%>L1:;!(&^R3R?:K0G/(*." #W"X_.G1=6A-U*,
MVKZ;NUKIVT\TGZF.)R_ZUAHX6<8-1=[\BYF_>5Y2U>BDXI*RY;*S:3/V4\">
M$;"W\5ZK:WEI:Z5$^I2P:>L&HK<K>VJX,<[':OENY+9BY*A<Y)->#_M8_$/2
M/%=[XPT;4KJ\CFT5HHOLZVCI:".1,($G8;9'  W;"=I(!Y.!X/IWQ+\*_M_?
M"G0/B]XLO9/"$OPMO@C0_P!JB#1S>E0RW9W .9#TP6.W&!D$YN:AX53XI3ZE
M:W^JS2VEMILFHVL$+[GU5T"NL2RD[8R=R'<>H/&><3@,GK8[$?4L)!N4]6TM
MDNKV22VN]%?N>3F6?4>'J<LVKS47&RL[[W6D;N3E)K6RU?=*Y<7X)>(/!/P1
M6?1K>VBM+J)G40R!9 &.2692#D_GZ"N)^#;ZXFC:I<:?]LGAT6$RW\#RQS>4
MI)4N Q+$ X) S@'.,<UVGP_^+EQ=WQ\&^$[=O%]]K9AM["RDN?+EL(V4N@E$
MFV,,2)07!((B )(Q67\7/@5XX^$/QKBTO2[6VM];\16X21;5O.MXD<9F5I64
M JG)8C  Z'D5R<2<.RRR<L)C;JK=6W]Y/U;37FNUM]#UN%>/ZO$,85L'73A*
M^BMHD[:I:I^3_%:GAZP7W[0/QNT/PIYKZ?=:K?+:_:@04B4Y+E1P"0H) [G
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M8*&$6) >A)*'! ST_P"S;\</#?A#X=Z+#_PE,?AJYLM7EO/$%L^E&[?Q#:G
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MC!JFJ:[XS.K7L]Y<F9%C"RRM*+= #M1,\JBYX'0<]\U<\$:LUQ"_*@0J&.6
M)!. 0.IY]/?TKM-:BA\6^+M/L]/U"UTZ1 ;B_>:Z-NC6P(5D+;2 7#E2"" ,
MG!'7ZW^)W@CP;XS\%7FCZ%X<T32?#+^';?4H;R[5(K7PXT Q,D=P@#&1U).&
M#?.1W8@S_JO5SBO6Q\)*#2;=[).6KWZ=6W;I9:[>+Q)QUE_##PV30I.46XQB
MHMMQBK*R3W=K**YNMWMKP'_!/?\ X*$:Q^Q+\1%%P;C4_ FM2!=8TL$MY?\
MT\PC.!(HZC@..#S@C]AO#?BCPK\7O =CXJ\)W%KK6@ZM$)K>XMOFC<=P1U#
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M 2H',@(&TD$<X R":POBE\,19Z4FH_V7)HTFI*MQ)!)$QCGD()!A<LQV\,&
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M@# Y.!DU[0^H"QTJUN$5A:RA$CF?&!D<@OT!R.<D?3O7#^,=4TOQAKMAIO\
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M<9.,U][_ +&%]HVI?!_0-)\$PZ'!HBZW;7'B3[>PCU*./>48WLRA5DMP69B
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MYT]!<0O;S)("TB8VCD$D-@G)(P?4<5Y-8_#M?$LL^O>?#<6LLQ5 P#>4F2%
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MBP#*.Q&!DYKT+2OAM!\2/A?\%KS7+RZ2\LO%]KH9NTF=)[FSF;)MVD4ABK$
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M  !_9CT'X77/A?2-/UGP_P"#[OQQI\^NZMHE\HN/$&L&5%D)CED82+#!EQ@
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M R\Y^AKN_A3%9?"[2_)+Y3.21DLY]AS6]<SO\4-1A$VS3-)A):2:4@2.HY(
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M.=LJQN5=5/7!/5\ X.1DXQEV7Q[F^%.JZ!-I-C;_ /"1:Q=VL%C>W:B5[(J
MA.QE(8  ,"",'ICG/1^,O@]#IOA6XU6:"%IM166X=TCP&=R79CUY+$FOT7,,
M\RZC&$L-'FEKK]V]T[_YWW/RKAO*LZQ&*JK,Y>Y%1T_\"LE9JW?57M;OI]4_
ML_\ BW3/BK\%++2?#NF2?V/I\&_7-.M]'>YGN%6"1K5YUW9N TV\*8B"05R#
MC(^)_ '@/5/C=\<[[PYX?L6B>UT&;6]0_M*X2W33-KA0ID<@*JDXPQ).<'D$
MU]$?L,:/9+\"='A\1:C?:6VI^+C+X>^RW#I)J=Q%%&OE2%5;RXE8  GIEL
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MYYM]SJN]?,8(1C>6!(()4C@5E:=8?V5XBDEF^SQF%LA9&VYY['&*]K\'>--
MU_0@9;=8'E'D7>7RDBDX!4@ @CU!KX["\4?V%F<,;6P_M::W3MUZZI[=M+[.
MVYZGB5D5;,,L^KX"M.E)V]]2DWHM%\2=M%9_9W2[_!_[0?[/.G^%/&6I)IL&
M=+69HK.,X=T120%)488 Y(89R,$FO.],^%.N?$K4X-#L],U"2\6".VMK=4\B
M*5-^%#ME54 N27D./4Y(K[TUCX7:?XNU'4_$FEW2R0QW+((FR61%8+@<?C@#
MZ\4V?X>VHT\7$$TDLEW&]N5BROVB-D*LK!>=H!R?3 ((XK])X5IT,PQ$*N83
M=.-5WDHMJ,+ZI:WT5]V[*W7KX>?<08K!\/\ /@*2Q%>C#W%)+FDXKKIO)+51
M2<F[)J]U^?\ \2OV9M8TG6Y-/OM/:VO)'D$ODPK]GWJ2K*A7*L 1C*\9]:D^
M$OP?UKX6ZQ%JMC)<6TUL?,Q&[1R #DD'CCZ5^@LG@O18O#NEV+1S;K>RC:8M
M<E[=W*_O6@1OFBC9TWX).2Q).>!YW\;O"*:OH=S!I5HR_P !=< AL' )[#H?
M:NCBC+*,L;/#Y=4<H/[3U];]7]YAP?FV98O*Z%?,L/&CB$K.*T4;/2R226EK
M+73JR[X"_P""IEK\1?#">#_BAX3MO&FEIA7N6C,>I1*!@,DR $L!TW CL0:]
M(\.?"+_A/M$BN/@5XUUCQ/INCQ^8?#\TB1:QH:DY($,BGS4&>3&<@?P@5\1_
M#[3TTC79M.NMLM\\I65]O&P]"/7TKZ^_X)]^)=&^!?Q<U'Q-J=S<)IV@:+J%
M[/*B[I"HMF41@9 .XLJJ"<9*@5\70INEC/J=96>U_P#@]?G?3:Q^BX/"U(X*
MMC,/!)PBY*/+>$WV<-DV]+PY7??FV<>M?L_Z/XZ\4QS>.OC=X1TW5X4\L65Y
MJ+3-;$=(SY"&&,YZY)(/6NH\/?!CP+^SYJ:2>,O&7PZM+9XS(LBWB:\]VIY4
MQPP@LIQSEV7)]@*_..;QO>:EKUW=2!9%N9WE*2C+(&8D#((S@''X5V7ACQ8=
M:N+>S@L+>6>0DCJ6<@$X&2.<=!G)Z#FNJI%4YKDI\TO*^OE;=_*QZT\;)4I1
M==PIV=[1@K)=8NUDNKYN?U6Y]O)_P4*^%/PAE_L_0_A[>>.F25W6XU&_73K(
M \Y6W16X] S'\*S]0_X+!WVBB9O#_P (?AKI9NH3!))-8M*\X]&&0I4>X(KR
M/Q-^RAKG@'P[9:UJ46EPM=61O&@M)?M4UM$&V-+(%4JH$GR$;B000<CFOGWQ
M_P"*]8T2X?9<MM7(#&)&Z<X!*G\JUQ_U_!UHT,33=)M72:2;7?:]KW5WU36Z
M9\QD^:\*9TYU,')U^5VD^=RC?M;GY+];);-.UFK_ %@O_!6;XK>)[F[6ZT/X
M>PZ5?)]FN8T\.PH#$!@ /]X8'3DCVKT7Q/XV\8?&O]D#2M)\ VJ6;Z7<7%YJ
M,2H8S>S,0RSN6.6)7Y.#@!.!7Y_?#76+CQ'KHAU+4)F2;);<053@D''0<X'%
M??7_  3,^+-IINKW&DZLRBT>S>%=\7F1[@0RDC!((.2#C@9[5HJDN:*E+26C
M^?\ P3WZV%PV%PD\1@\.E*F^=))*[2<=H]5&3MU3L[Z'R+?>!=>\327NJ:I9
MW$ TE!]NEMU7R(&))^=B1EFP<=>01Q7=^#(H_#D3?:+K)@)B*JA5T<'HRD @
M_6O9/VDOAKH&H_%75)+6[2TT*YNHKG4KG3,N)"""A"J"H*GAL#&22.I%>0?$
M/4[7XG_'6XM;.>WO+2>0 WMC#]GBOQ'DGY5R0X!568  D$@<@G[V>0X:>"C5
MPL_?3U3VMNW?^[>STUTT3>OX?A^)\UGGDL/CZ-H3CS)[-/HFGNYI<Z2;LN;=
M*Z]B\&_$K5+KPO9:3ILEO:J+B2<W0C1YXXWC"S0C=@A90J@L"2I&0*^A/@M'
M:W.BJWV%;21HV9;:>[DD@BD"$H"V2PC+XRPYP2>M?,K?"W3-*,$EB%MY'RR?
MO"9  0#SDYP>,GFOH'X:ZWI_AZ^T;18;G5-5N-0(1G>':\9V@CGJ03E5..N
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M!]C73P_6IX3&PJU/AU3^:W.NIB)0K:G9>(O#']HZ4[2?NY3.%0%B3Q@Y'3C
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MI)IL @LN % &/4GDG-=5\??VB;K0=372M.O([^.ZM8KFVN;7_CWE@E4-&Z#
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M& "2,8_/->::7XIU#P>PTG6TV/L*K*#NBN%/0@X_2KNHZX\%H_EW6^.50N6
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M-<0ZG,K#S':7@0LZ/$R0G!() R017TGXJ\,Z1XA^"5CXLT^_VRZM%C:D?W'
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MO$.LB>1?5(U9OKC<Z?C7Q)X6TV2Z*LQPV/Y>W6OI[_@K#\08?^$Q\$>&K/;
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M5K$4&0CL&P>QV@XS]37ROXU^+/@.?Q]?ZZL=[J>N7Y/F7-S,7!!&-H' "@=
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M>H_%2X36O$^DW'B+1;=I;?4B+.*]O8RJ';N.!,JDD8DR>._!%>=>,OA1X/\
M"/BB/5H+2ZUS08+=W-K,9(Y[978;!(>,E"&^900"R[B<C-G2/BA>?"+XEW&D
M^+(=4\)ZOI,C6]PUDVV:.0'(.[.UE[C!&00<BK$/Q>L[[5Y7AU5+BS1S)',8
MBL^[DDD*202>,@X.>>,U>49QC<LKK$8=6>SZZ.VU[K6W^0\\P. XBPOU+&7<
M;WM=JS2T>EGI?:YY)^T7\:(_B'XDL+6U6_ETGPYIL>DZ1]LO1-+;*C%V,K8
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MN)%BW$;B2Q ! ]>>E?*,'QST&^U.*3[))IZ ;8KB(%_+ & '7J1[CGV->M>
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M+2:VE6.4&*0LLT3*[OYA(8L&# './,]&_:\G\0^$Y/%?AO45MKRVM+4W,"Q
MKJ$3&12=C @A2%.#@C>PR,5[/XK_ ."@.K?'']I+X:_#.Q\(Z?J+ZKHMOJWC
M6^U&%S;V<,ML)I!:.NU0$R2SD#+$#'6O!-?_ &?=2^(7Q7N)/!\VGZ;:V"R2
MW4]\XM[*"R5\9E*@X'*@  G)  Y-<?MH5Z<N65^3K:R?7\CZ:I]8RJ=*.(I6
MCB4Y0CSJ<E%R<5S62][F3ULKK=7O;EO$_P 1=#^/?B:TD\2^&M#NYYIX[:2X
MMY9-/= Q RQRR9 .<G''4XK$^-?[--G\/=.N-5TO5+?Q'X8U M;0,+@2RZ>
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M!1[Y)["OCO6-&\5?%F"WCOK^YN/#VBA+6!O,"V VX BC7),S@<$G'O@5[G\
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M[J?<?K5[0OA5;V%Y"LZQRK&0W(!Y'2L>?XA+XA\;:A>:AJ#6\$LA$;VK[&8
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M;CPW=()PN^2U#9$RGH\9[@^W2O-=<O?$&GHUO);S(R'T.,CV]:;X,^,FB>
MNEZA>7C^2Y=)?,(DMV)R=I'0$]NE>C6GQ<T+Q#M\O6+&Z#8'^E( P]RR]?RI
MU$N:\7=#K937O;=];?\  N>4^&O .O>)Y;B8HL:,,-NRI/&,>A&*[+PA\![R
MV=3=2-(@^ZF<+G&#DXR?IG%=II4MU-*6LY]#N5<Y5&OQ&/8?=_G5K7/$OB?0
M],>:6#P]'%&I.8[DSMCV ')KUZ.:8NG3Y*;T7D<RP^(3Y'^:+7AWX>V-E#-Y
MEG;[MN"6 R#CCGK5/1="=]4D2T2&*",AI)FXCB7/4GH![=37G+_'R2&VO;JZ
MN)KHP8\R**$Q[,G &6Z9]<5K>&/B3>>+].&T);P+\RPIG8GN>[,?4_ABO.KU
M*CESSW?<Z*.%C\55I(Z[QWK,=M9G3[63%MGYV'#7C#H3Z*#T'XFLK1OAS=ZM
M:+<LTT2.<JW(_*M#P/X277KU[B1I)B#U<]_I7M7AOP_"^FK#M^5$"C\*E2Y5
M<QQ.,<[4Z>D4>)2Z#J6C &&>8[>AWDUK^!/%^I7?C;2K&XWL)+F,'=SP#DD?
M@*] \6^$H8!^["AO2J7PN\*I<^/;>61% LT>4GTP, _K6]&49M'EU,15A=J3
M/CK]OT2>/_VR_$5U#&WV>QBM[", 9 *Q OCZL[5;^%/PGF@MTFD88"AM@!W'
MVIOC#Q%!X@^)&O:K(RA+S49IM[_*,%CCEL # JKX@^/>EVGA74;+2K^UNK]8
MPCI;L9#&K'!);IGM@9ZUC4BYR<GL>]2E*$(Q6^AZ/8>)%U)VCM9%%AI[>3&
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MS;KWP^O-;OWO%3;@D!6.#MSQV[U]-F>5X?!TE%/79+R/+Q4G3GSQD[O4\O\
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MU3"3ISC"I'5]#Y#GJTYJ%_Q/ECPE'H?@GP^NE:"8[3RYFBM[2*W3,"@#)"J
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M>/)X[?6FN;/S'@Y1(W;< N<[2,>O.?6O>Y?BA%XDTYH]4TRWN(V_B@;:2/4
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M";X.MH]K,;>Z^T8?S8P5P0>X!SR#7*^.O%]G<: ]C?63QSP9V2<A@XR 0<8
M /3D5#X._:*DGA\FSN[:5<_+#<K^\0>F,C(^AK<UWQAI?BBW7^UM*RV/]9;O
MR/P;!Q[9-.G)TY*<&XR1R5J-=/WM5W1\[W=[+I-[+&D;7"2$M\Y+$D]2#ZGO
M6EH7PCU+QYF2QTN9\'+;%R >N2>E>P:=X>\*B96M6C=F;[EPA7'XX(_6O8O
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M"2<D\]ZJZOX7QX@>V:-E123NQQ@>]<.48)8&DZ47=MMM^9YF:M5;58*R>O\
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M8O\ 9M/F@BMI81YCQ>7$JLH';)W9]ZY7X8>)=/\ AD1#&VJ2S*</]IN7./\
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M2B\7-25&FJ4=$K15VEHE?5O5W=NIY;\??&6I1:?_ &4MLEW=BWD@\Z3 D.<
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MGE:C05*2NDTEY)M+]3\W-)^ E_KA&I:U--<3-SAY68*/3))))ZDGDGDU[_\
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MJJ=WLU:UO4XZ$:%*K>I[R2OH]]B;X@_$J_\ %NJ/!#,MS<L/*\T\+$H_A4=
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M*O?8_P"R?B;8ZS-$%CO@4GR./, X./<>G/7%:GBSXBQ7\TT*Q0ID@;QP#M
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MCQK7@^T#+=[GXP6&['M7"XRY5S:L]_%4Z<I2M*W;S7Z'WYIWQ#^P'$ENT(3
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M2KRJ8:'+%]//KZ>AG[-1]]:(YWX1-<V;*GS%<C+<_J*ZSQSX*.ML)[&94NE
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ME;L<7XUTK_A((MT;K'*X.[:WRGWQD$'L3W&0<YKSW4O!$D-WYDK/@-G!/R<
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MS_+%=<*BO?J<M;+:\7IJNZU.HT'PQ9>']/>Y\L23MC;N Y;USUP/3IQ7BO\
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M!,06 #8/" 9!W9YY%</JGPZN/'FMS76G1.T:$-)YXV_OBHWJO^RI! / .,@
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M4X\"^*HGSDYMXV'ORKFG:]\*/'TL6VQ^'WBAGQSFW1 3]=_%?H)11_9\>[_
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M5"'_ )-_F?G?-^SO\1VMEAO_  #JUT@_BMGC/Z,PY_&M33_@]XRTV$*OP_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%1W%S';+F21(U]6.*YW6_C)X1\+JYU/Q5X<T\1
M??\ M.I0Q;?KN88I2DEN7"G.;M!-^ATU%>*^+O\ @HS\!O JG^U/B]\/[7'4
M#6H9"/KM8UYGXK_X+F?LK^$BZR?%O1+YD_AL8)[G=]"J$'\ZPEC*$?BFE\T>
MKA^'LUK_ ,'#5)>D)/\ 0^MJ*^ ?%'_!R;^S/H:M]CU#QGK3+VM-!D /XR%:
M\X\3_P#!TW\)].:1=(^'/Q"U9>=C2BWM=WUW.<?K7++-\''>HOS_ "/:H>'W
M$=7X<'/YKE_]*L?J+17XY>*O^#K.=E(T/X*R ]FU#7EP?P2/C\Z\V\6_\'3'
MQBOV8:/\-_ .EJ1A?/N;FY8>^<J,_A7/+B#!+[5_DSUZ/A+Q-4WH*/K./Z-G
M[K45_.WXJ_X.0_VH=>1EM-0\$Z*K'@VVAB1A]#(S?RKSOQ-_P6\_:I\7%FE^
M+6I6&[J-/T^VM@/IA#BN>7$V%6R;^2_5GK4?!7/)?Q)TX_\ ;TG^43^FBH;B
M^ALEW331QKUR[!:_E/\ %O\ P42^/OC0.NJ?&/XC74;YR@UB2)>?9< 5YWKG
MQ:\8^,I2VK^+_%NI$]3=:Q<R_P#H3FL9<44_LP?WGITO!'$_\OL5%>D6_P W
M$_K,U_X\^!_"<+OJGC'PKIZQ_>-SJL$6/^^FKSGQ9_P4R_9]\#;EU3XQ?#^W
M9>H76(I<?]\$U_*O?67VZ0M(SS/_ 'I7+G\V.:;!91V2_P"JC'N%%<\N)JC^
M&"^\]&GX+X2/\7$R?I%+\VS^E[Q7_P %X_V5/":ON^*NFZ@\?\%C9W%P6^A6
M/!_.O-?%?_!S'^S1X?4_8I_'.M'_ *==!=1^!D9:_GUCG1T_A%5[NY+C:HS6
M7^L&)>R2^3_S.^GX39)#XY5)>LDORB?N-XF_X.M?A7:F1=%^&?C[5&'W&GDM
MK53]?F8C\C7G/BO_ (.P[^0'^PO@K&GH=0UX'/\ W[CK\>8?,@_AZU,)"_5:
MR>=8N7VK?)'=3\.\@I_\N.;UE+]&C],/%W_!U5\:=2D>/2? 'P\TD-G:TKW-
MRR?^/*#^5>:>,/\ @Y+_ &I-;0_9=;\&Z,K=/L>@H[#\9&;/Y5\)3Z=YS[JD
M&G*1\W-92S'$RWF_Z]#LI\*9-2^#"P^<;_\ I5SZAUS_ (+<?M4>-C(9OB]K
M=BLF<K86EO;#W VID?@:\R\:_M_?'CQO)LU3XQ?$>[1OX3K<T:\^@4C%>7A4
MM5]*"$EYZUE*O5EO)_>SLIY=A*7\*C"/I"*_)&EK_P 0/%7BUV?5/%OBC4F;
MEC=:M<2D_7<YS7.WUE&T<C.&FD*\M(2YZ=R2:OEE7O45ZI:W?;Z'^59^IU1E
M):)G]/G_  1;&W_@FK\,,<?\2X\ ?[9HI?\ @BZ,?\$UOAC_ -@\_P#H;45^
M@8/^!#T7Y'\J\0_\C3$?XY?^E,ROB4FL-^U3XP.BFS:Z6"W+0W3,(9E* $.5
M!/N,=P:Q=1^'%]KD[>9HOAM_L9+72B[N88[?(W$(D> PQD_,#D\8 K4^+&E0
M:Q^T[XRAN+C4K3-M#)&]G>26SNRQ [24P2,<X) X[FM"'X):/>:?9S74NH2R
M0()/,:]<G)&<LV<MSW;/'M7/S)-^OZGVV$DEAZ=_Y8_DC#O[+4-'L+4^=X;D
ML9@&MHY+=SYA(P?.?YLI@XP%!'K5>]\&_8;ZV75?!>EZL\:%H(-&5,VF#PZ>
M:R$ D\C/!P0#S6H/AW /#HU*VEN[E;@LK1R7+RQ;2Q&(5/"@GD@ 9ZXINO>#
M?#_A,R0ZCXDURQCCA%R_FZM<^=""P4%6SD*3QM!Y..,"CF6R.KVBZ;AH?BZW
MTB^>Z71?$4BI'Y(@CMA=W%HV26#&-BN#V^8XZ<<BD.O7>IZ+)80:3JOVB_G,
MZ7"VWDV\8)!4;F)^;(P0,G.<\4RV\/>']:FCMK'7+IXYH1)9M;ZH8&O7.249
M@P,A/4@\\G([U9T_P1I&O:!=:@NJZY&(E:*:&?491%9R(,%=F0J%2!@J 1U!
MYH]W<.:*U]"76=2\336"MJ6CZ+I]O%(LGF_VB]RI?. '00KA23R03CL*AN9?
M%WAR]@N)O^$?U"Z:-E%M!)+90&( $DEBXRIY!QR,]*HNEYX6M;6WN'FU*UMW
M%[";G54+R;EXC)E(<+G)#.2,G&>!4>I^*+S4-2>[DOM+T2:[41M$98KZ>*W7
MABI5@H4DDLYR .!DBA1?E_7X@ETT-2STGQ=>:<UQ;WVDPQ:@#-<;XR\AR/\
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M;*X162>VTU9'W'G!0E#@^QS_ +..:JS_  \"Z,NH3:E?Z9MROV5[MXK>X Y
M$>=I)QZ9..N*;<:E=>((5@U!M*M++3X&,+66K!KBX8* !NPHC8]@<D'G/'+U
MZ/\ ,YY83#3WA%_)'3:-^TS\4[;Y=0T7PHLWEF86\D[K<&,=3M4D ^PS]36I
MI7[8GBN_L1=6_@S3]>M]_EM)I6K(WEGN&#8(([@X(]*\]\'>&M0N5A>SFO\
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M@YJ2J,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **:\BQ)N9E51U).!6/K'Q&\/^&Q_Q,-<
MT:Q[_P"D7L<?_H3"DVEN5&$I.T5<VJ*\I\5?MQ_!OP0K'5/BEX#LS']Y7UNW
M+#\ Q/Z5YMXI_P""RO[,OA$D7'Q>\,SLO5;3S;DC_OA#6$\71A\4TOFCU,/D
M.9U_X&'J2](2?Y(^GZ*^'?$?_!PS^S1HGF+:^(/$FL,G06.@SN'^A8*/SQ7G
M_B7_ (.8_A%8JW]D^!_B-JV.[VD%J#^+2&N6IG&"A\56/WGN8;P[XFK_ ,/
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M/#>O:?J/V.*#P>]XL>TK;PO;Q6L9))*Q[F D);.20".>:D3Q+XTL$DMX]/\
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M./%LC?VQXZ\<ZFK\N+C7KEE/U&\#]*Y'6;*+4YMUP]S=D]3<7$DN?KN8UO7
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MK7':W_P7S^#MLQ72]!^(^M<<&'0C$I_&1U_E7)4S?!0^*K'[T>[A^!.(Z_\
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M;&%FEB8]%157YE[8 !'4Y'-,U6]U#65N[F+28;>WDV"4:CM$L '1@@# N<Y
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MA8[AMZF<GC,Q4$@YX&,CZ5M?\(U)JVI0V]WJEQ>+YS&0+;HL<DB@8<X)QC(
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M5 "@'IUZ>QIUYX)U#3IHXX==U*4R(Q=[LI(95'5"=O YSD8(/>C38GVD=O\
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MN);HQ"WVSPF)3(#]YN!P!TQ@'IG-"01E\S,,/AJ73/*#Z:-65?+V,$6XXX*
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MV$L.E0LL<$*-C *H!C]*XY<=5;VC32]6W_D>M1\%<#%?O<1.7I9?HSZ:OO\
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MTQX)DN%L[4< B=G+L3U&!T7T)ZD5)%<R)<"XN9MI#;G9<A5'< <G&*M>7<+
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MC5 =AA2+:<#WR3CWJ6;2'CMPZW5TS-C8&8?NR?3CBD+KJ0RPZA<3_O+?3&F
MW*I)*=>I.,DCM2"*^ D;R[/'(E&XG:<<[>,\CUJ::2[D.YE6S90$:1F#$#U
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M?_$4_P"SL5_(_N#_ %TR/_H*A_X$C!HK=_X9,_:&_P"B>^%?_"H3_P"(I/\
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M5D^8.DJ5"E)+Y?YG'A^..'E4<ZV+IM^IYVQW'ZU);V<EP_R(S9]*[^+]@_\
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M4B?_ !-7+/\ 8%_:"@_UO@3PK)Z >)4 _P#0*I<-YDW_  G^ ?\ $1>&TO\
M?(?>>8:19M+,JMW//TKM;:^MK2%8]Z]*WKO]A#]H:1<0^!?"<([_ /%2IG_T
M"J3?\$_OVC&/_(E^$O\ PI%_^)KLP^2YGAV^2BVWU.>MQYPW6MS8V"^9QOB>
MQ6\F\R.16SP1FN=FTI8/F ;(KU4?\$_OVBQ_S)GA/_PI$_\ B:=_PP#^T0WW
M_!/A-A_V,B?_ !-<U7A_,YS<E1:N=%/Q"X;A%1>-@_F>0+>SK)MV\9J2\LFO
M$!)QZUZW_P .^OV@MV?^$'\+_P#A2Q__ !%7;7]@[X^VJX_X5_X5;W/B6/\
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M[-^5?O5SC>-V,F/.7->N:Q_P3D_:*U:1V_X0_P )KNX_Y&)/_B:P_P#AU?\
MM%?:-_\ PBOA+KG_ )&!/_B:FMDF:U)M^SDET_JY='Q$X5C%7QE._77_ (!Y
MSJ=_->QE]VYL<5RVH6%UJ+G<OXU]!P?\$U?VB(HPI\(^$3C_ *F%/_B:D/\
MP37_ &@MO'@WPON]?^$B3_XFN6/#N:IW]B[_ ".M^)G"MK?78?>_\CYOM=%N
M+6<-C:/6KVL79GM5C63YN_->\7__  3*_:*NHBJ^$_"2?]S A_\ 9:R8O^"4
M?[1*3[W\,^$V[X_X2!/_ (FJ_P!7<SEK*D_P#_B)G"R5EC8?>_\ (\1TK09O
M,#L[ ?6MJ9&$!53\V*]J3_@F1^T1%"%7PCX3X_ZF%/\ XFJ[?\$P/VD"^?\
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M_'_(^<O$.KR6(_=C-<O?7UQJ<BJV[FOIR_\ ^"17[1U[(6_X1_PF!Z?VZO\
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MCH/YO_(^>GTV&5MVU2:N6*Q6RGG# <5[Y!_P1C_:3@7 TCPB?^XVO^%3V_\
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M*'##=UCH?>_\CX3V[C392!VK[M7_ (-V?VBB?^/?PC_X-5I6_P"#=;]HD_\
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MY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?'.C*P1[S0]4AOXHG(SL<QLVUL?PM@^U5[C]J?X9VGQBG^'<OQ"\$Q>/K:
MW4WAM];MEU:*(1><9&MM_F!1%^\)*X"?-TYH [ZBOGC4O^"JO[.K^#O%6K:;
M\<?A+>1^$R+>]D_X2FS$$-RZ2M#"TF_;ND,,@4 DG8V,X-? W_!$#_@Y!7]M
MO7OBWJ'[17C?X-_">QT632T\+:;-J,6D+,L@NS<D27<Y>X(V09(("Y' W4 ?
ML!15#P[XBL/%WA^QU;2;ZTU/2]4MTN[.\M95F@NX9%#)(CJ2&1E((()!!!'!
MJ_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !17Y:_\'2O_!13XQ?\$YOV=/AAKWP=\7?\(CJGB+Q'
M<6&H3?V;:7WVB%;8NJ;;B*15PPSE0#[XK[>^#_[4.B>$?V'/AK\2?BMXR\.^
M&H=:\+:->ZKK>MWMOIEF]W=6D+L2[%(D+R.<*,#)P!T% 'ME%>*_$[_@HS\
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M4@XP:\X^&W_!3_\ 9S^,?Q!3PIX5^.7PKU[Q'+)Y,.GV7B:TEGN7SC9$H?\
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M^"3GBCX"^/OV?],U'X>ZIJ5U>I*MMJ=S<>7<V/V26WNXWF=W24&1MQ#8)"G
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M^-7Q>^*7BC4;F:;4M/G_ -#LX&V[71Q?P227#OO=Y) >2 .A+?L5_P $$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /Q(_X/=?\ DT7X*_\ 8WW7_I$U=;_P7A_Y5<O G_8$
M\$_^BK:O0/\ @Z5_X)U_&+_@HS^SI\,-!^#OA'_A+M4\.^([B_U"'^TK2Q^S
MPM;%%;=<2QJV6.,*2?;%=#_P5F_8&^+'[3'_  06\)_!?P3X5_MGXD:;I7A>
MVN=(_M&U@\N2SC@%P/.ED6$["C#(<@X^7/% 'R)_P2X_X()?!/\ :Y_X(MV7
MQ2^*=OKWBSXC>+O#-]-I6LRZQ<H?"UM9M<064%K$KB/8@@5B)%8$LR\+Q7SW
M_P &M_\ P39\"?\ !3C0?B GQLEUSQEX#^$]Q;CP]X/DU6YM],M[W4EE-S=E
M870AMMI$  0"22P) K]I/^"5W[+?CK]G#_@C9X%^%7C+1/['\>:/X8U'3KO3
M/M<,_E3RSW31KYL;M$<B1#D.0,]1@X^6?^#5K_@F?\:_^"<'@?XSV?QD\&_\
M(?<>++[29M*3^U+.^^TK#'=K*?\ 1Y9 N#(GWB"<\9P: /CC_@DE\++7_@G[
M_P '5GCKX*_#V^U2R\ S1ZMIK6$URTHDM1IXOX(Y"23(89 JJ[9; .22S9XC
MQQ^R1I_[<_\ P=C?%#X6Z]JVL:7X1\3ZM='Q'%IEVUK-JMA!IL5T]F74@B.6
M2&)6QSC)&" 1]O\ P4_X):?'3PC_ ,'0_BC]HG4/!/D_!_49KY[?7O[6LF\P
M2:,+9#]G68SC,WR\QC'4X'-+^S[_ ,$MOCIX(_X.>O&/[0VJ>"?LWPAU6;46
MM=>_M:R?S!+I0@C_ -'68SC,@V\QC'7@<T ? O\ P<<?\$\O 7_!*W]MCX&Z
MI^SM'JOPQO/%EI+,GV'5+F0Z=>6]Q%$MS#+)(TJ%EF 8!\?)D ;CGZ"_X+\_
M\$#_ -G_ /80_P""4"^// VC:M!\0O".IZ=!?^(;K5+FYG\1FYE$,[7$<CM$
M"S/Y@,:+M(P."0?>/^#F3_@EM\=/^"@G[1?P%U[X2>"?^$KTKP7#=KK$W]K6
M5E]C+W-LZC;<31LV5C<_(#C&.I /U1_P<+_LA_$+]N/_ ()?^*OAW\+_  __
M ,)+XPU+5-+N+>P^VP6GF1PW:22'S)W2,852<%@3VR>* /B?X\?$W6OC!_P9
M<6^N>(M0N=5U9_#6F64EU<.9)94MO$4%M$68\L1'"@R22<9Y-?3G_!J(,?\
M!$KX:_\ 83UO_P!.=S5#X+?\$IO'GQ)_X-NK']EWQE!;>"_B)<>'KBV:*XN8
M[J"RO4U62^MA)) SJ8V*Q!BA8@,>"1BOC3_@G'\"_P#@J5^Q5\$+K]FOPG\,
M_ ?AWPO)?W/V/QQK5];7 \-QW+EIIX&ANCYH#,TB*8'<,QRI'"@&/_P9Z_\
M*0#]J;_KUC_].,]>#?\ !&W_ ()]>%/^"CO_  6._:&\&_$6ZUBZ^'.@:KJ_
MB+5?#]G?RV</B"XBU=H;:.=HV5C'&;B5\*0<@#(!-?>__!M5_P $B_CA_P $
MT?VL/CM??$_PZUGX=UVTBT[0];.I6EP=<$5Y*PG\J*:22/?&5?$@!&[!Y!JQ
M_P $%/\ @EK\=/V,/^"I'[1/Q&^)/@G_ (1WP;XZAU)=$O\ ^UK*Z^V&75UN
M(_W<,SR)F(%OG48Z'!XH ^*_VJ_V5?"W_!);_@YZ_9]T+X(QWWA3P[XJU3P]
M=2:<M[+.EM'J%_)8W=LKR,SM#)&C':['!D('  &K_P '2W[5MCX\_P""O/@#
MX4_%"\\7?\**^'MCIVHZQI'AS8;W4'N=TUQ+$LCK&9FA\N%&<XC <CEF!^N?
M^"K_ /P2Q^.W[2G_  7U_9^^-7@OP/\ VS\-/!,WAAM:U?\ M>R@^QBSU>:Y
MN#Y,LRS/LB96^1#NS@9.179?\%V_^",?Q6_:-_::^'_[3O[->I:;:?&;X?I;
MQ3:9>31P+J@MI6EMIHGE_<^8I=XWCE(22,J,C:0X!^,/_!1#]H/]C'7O"?@_
M7OV1?AW\:O@Y\4O">J03K>WLO^B7,"*Q$OF?;KB6.Y218V5T !&\-D[2/ZG/
MV!/CAJ7[2O[#_P (_B#K47DZUXR\(:9J^H+Y?EC[3-:QO*0O8%RQ ]"*_+,>
M+_\ @KE^V1XQ\)^'?^$(^'_[..GZ-?13ZMXGMELY$NPNY6\R&2XNFFC();R8
MXPK,%W,!@C]F?"VFW>C>%]-L]0OO[4O[6UBAN;WR%@^URJH#R^6ORIN8%MJ\
M#.!P* /B3_@Y>'_&D7XZ?]>6F_\ IULZ_.'_ ((!_P#!!+X3_P#!1C]@71?B
MM\<;_P 6>+KJYGN]"\,Z=!JTEG:^'+"UN9!M0)RSO<-</AB4 <?(223^K'_!
M<;]FGQK^V!_P2S^+'PY^'>C_ /"0>,O$MM91Z=8?:H;7[08]0MIG_>3.D:XC
MC<_,PSC'4@5R_P#P;X?LD_$#]B#_ ()=^#/AU\3M!_X1OQAI6HZI/=6'VR"[
M\M)KV:6,^9 [QG<C*<!B1G!P>* /QE_X."_VL?"_Q3_X+MVO@'XX-XWO_@%\
M'(K*SD\.^&=GVNY\RPCNY6B1Y(T5YI98XWDW!A"@VG(%?.?[?'[4?[*^E>-_
MAW\0OV*_ _Q?^"_Q"\&:FES<G4F!LI5108IXV-Y<2+,KJ%9>$D21]P)'/[%?
M\%FO^"-/QN\0_M\>%OVOOV4[S29OBGHB0)J^@:A-%!_:#PQ&!9HFF*PNLEL?
M(EBD=,JH*L22!S?@_6O^"L7[:WQL\&V^I^'? O[+_A+0KM9=9U2T@L[M=07
M$F^VEGNGN/EW%(P$0,06<$!@ >4_\'3G@;XU_M6_L]?LV_$S1_"_B;Q)\(QH
M46N>*='T196&GWUS';S"2X1 S*IA9XTF*,(CO!(+@-\X^#K_ /X)8_MKV?@_
MP_I%K\3/V1_'EC?VO_$]N;J>^M92DBEXWN6GF2-FY"W#I#Y;[6;*KL/[%?\
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MQGRH$=@9&Z#"@\LHZL 6M^T9X!C^.2?#-O&7AD?$.33SJJ^&_P"T8O[3-J"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU\&Z3:>*[/1%MR#"EG'J]LL*H>Z! H4CJ #7T[\.?^#3OQK\ ?B!KVF_#/\
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M,;LY.,$ _'7X*>*O$>C_ /!E%XPDT.6X\X7EW8SM&3NCL9?$,:W(_P!UHY)
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M!_P7?_:(U3QEX?TWQ(W@:;7-4TBWU"W2XM[>[?6%A$Y1@5+I&\@4D'!;<,$
MC]@O^"17_!&'X;_\$AOAMJ^G^%;S4/%/B[Q2T;:]XFU*-8[B]$>2D,4:Y$,*
MEF8)EB2Q+,V%"^>_\$M_^"%G_#MG]MSXN?&+_A9O_"8_\+2CO(_[)_L#[!_9
MOGWXO/\ 7?:)/,V[=GW%SUXZ4 ?=^D^!=#T+3C9V.CZ79V9N?MA@@M(XXC/N
M#^;M  W[@#NQG(!SD5>FTRWN;V&XDMX9+BU#"&5D!>(-C=M;J,X ..N*LT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 QXUDQN56VG(R,X/K08E9U;:NY<X..
M1FGT4 ?SM_\ !TQX'TWXG?\ !<S]F/PWK$*W6D>(=*T/3+Z$])8)M>N8Y%]>
M58BOK3_@[T^$_A?1_P#@D%HK6?A_1['_ (13Q?IEOHWV:SCA&F1-%<1M%"%
M"1LH *+@':O&0,>T?\%+/^"%/_#PW_@H-\(_CK_PL[_A$_\ A5J::G]B_P!@
M?;?[1^R:C)>Y\_[1'Y>[?L^XV,9YSBO8/^"P?_!-3_AZY^Q\_P *?^$Q_P"$
M&W:U::Q_:?\ 9?\ :/\ J!(/+\KS8OO;_O;N,=#F@#\O_P!N'Q1X@TO_ (,U
M_A2-+N+I;>_L="LM5=&.?L0O'(5C_<\Q(%QT(P.AQ7W)_P &ZWP9^'$O_!$3
MX6V>GZ)X?U#2_%VE7<WB=9;:.9-4NWN9H[E;H,,2;=OEX?.$15Z 5[=\#/\
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M_9O_  C$&G0_\)1_87F_:?LD_FY^R^>NW?TQYIQUYZ4 ><?\$+?V;O ^F_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>oncyf-20211231_g3.jpg
<TEXT>
begin 644 oncyf-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !) .(# 2(  A$! Q$!_\0
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M/%,OC7Q)KFJ-?:/H7GG3K"UDEN 9+J<L[>;(D32 #Y>_WNE?J%10!\D>#?V
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M0(/4@,>!C! 8=Y\?]'^*OPN_;DT'QUX.^#-]\1/#VE^$%T+PS#ISB*SL)F+
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D5& L:X   P. !D'  P!V=% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>eyheadera.jpg
<TEXT>
begin 644 eyheadera.jpg
M_]C_X  02D9)1@ ! 0$ 40!1  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !: $X# 2(  A$! Q$!_\0
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1#9YSG.<\YKI** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>34
<FILENAME>oncyf-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:04d38e4b-b411-4668-8f8c-e4013a42568d,g:242f92a0-4583-4d5d-9e63-4960e9cee1a1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:oncyf="http://www.oncolyticsbiotech.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.oncolyticsbiotech.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.oncolyticsbiotech.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.oncolyticsbiotech.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION">
        <link:definition>1001003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical">
        <link:definition>1002004 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS">
        <link:definition>1003005 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT">
        <link:definition>1004006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncorporationandNatureofOperations" roleURI="http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations">
        <link:definition>2101101 - Disclosure - Incorporation and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofFinancialStatementPresentation" roleURI="http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation">
        <link:definition>2102102 - Disclosure - Basis of Financial Statement Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103103 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails">
        <link:definition>2406401 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantJudgmentsEstimatesandAssumptions" roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions">
        <link:definition>2108104 - Disclosure - Significant Judgments, Estimates and Assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalents" roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalents">
        <link:definition>2109105 - Disclosure - Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsDetails">
        <link:definition>2410403 - Disclosure - Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment">
        <link:definition>2111106 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables">
        <link:definition>2312302 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails">
        <link:definition>2413404 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.oncolyticsbiotech.com/role/Leases">
        <link:definition>2114107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables">
        <link:definition>2315303 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails">
        <link:definition>2416405 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRightofuseAssetsandLeaseLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails">
        <link:definition>2417406 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTotalUndiscountedLeaseLiabilityDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails">
        <link:definition>2418407 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivative" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative">
        <link:definition>2119108 - Disclosure - Warrant Derivative</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeTables" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables">
        <link:definition>2320304 - Disclosure - Warrant Derivative (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails">
        <link:definition>2421408 - Disclosure - Warrant Derivative - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails">
        <link:definition>2422409 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails">
        <link:definition>2423410 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapital" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital">
        <link:definition>2124109 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables">
        <link:definition>2325305 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleofShareCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails">
        <link:definition>2426411 - Disclosure - Share Capital - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleofShareCapitalFootnotesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails">
        <link:definition>2427412 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalEquityWarrantsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails">
        <link:definition>2428413 - Disclosure - Share Capital - Equity Warrants Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalSummaryofOutstandingWarrantsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails">
        <link:definition>2429414 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation">
        <link:definition>2130110 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables">
        <link:definition>2331306 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails">
        <link:definition>2432415 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails">
        <link:definition>2433416 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2434417 - Disclosure - Share-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails">
        <link:definition>2435418 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails">
        <link:definition>2436419 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare">
        <link:definition>2137111 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareDetails" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails">
        <link:definition>2438420 - Disclosure - Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiability" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiability">
        <link:definition>2139112 - Disclosure - Contract Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityTables" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables">
        <link:definition>2340307 - Disclosure - Contract Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails">
        <link:definition>2441421 - Disclosure - Contract Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails">
        <link:definition>2442422 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://www.oncolyticsbiotech.com/role/Commitments">
        <link:definition>2143113 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails">
        <link:definition>2444423 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.oncolyticsbiotech.com/role/Contingencies">
        <link:definition>2145114 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails">
        <link:definition>2446424 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes">
        <link:definition>2147115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables">
        <link:definition>2348308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>2449425 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails">
        <link:definition>2450426 - Disclosure - Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofNoncapitalLossesDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails">
        <link:definition>2451427 - Disclosure - Income Taxes - Summary of Non-capital Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails">
        <link:definition>2452428 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures">
        <link:definition>2153116 - Disclosure - Capital Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables">
        <link:definition>2354309 - Disclosure - Capital Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails">
        <link:definition>2455429 - Disclosure - Capital Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments">
        <link:definition>2156117 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables">
        <link:definition>2357310 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2458430 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails">
        <link:definition>2459431 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures">
        <link:definition>2160118 - Disclosure - Additional Cash Flow Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables">
        <link:definition>2361311 - Disclosure - Additional Cash Flow Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails">
        <link:definition>2462432 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails">
        <link:definition>2463433 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndemnificationofOfficersandDirectors" roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors">
        <link:definition>2164119 - Disclosure - Indemnification of Officers and Directors</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependence" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence">
        <link:definition>2165120 - Disclosure - Economic Dependence</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependenceDetails" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails">
        <link:definition>2466434 - Disclosure - Economic Dependence (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenses" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpenses">
        <link:definition>2167121 - Disclosure - Other Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpensesTables" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesTables">
        <link:definition>2368312 - Disclosure - Other Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpensesDetails" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesDetails">
        <link:definition>2469435 - Disclosure - Other Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions">
        <link:definition>2170122 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables">
        <link:definition>2371313 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2472436 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents">
        <link:definition>2173123 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails">
        <link:definition>2474437 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="oncyf_TwentyThirtyMember" abstract="true" name="TwentyThirtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" abstract="true" name="WarrantDerivativeAndSharesUnderWarrantAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharesIssuedFairValueOfCommonShare" abstract="false" name="SharesIssuedFairValueOfCommonShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_TwentyThirtyFiveMember" abstract="true" name="TwentyThirtyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" abstract="false" name="ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_TwentyTwentyEightMember" abstract="true" name="TwentyTwentyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_PurchaseObligationCommitmentTerm" abstract="false" name="PurchaseObligationCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ProceedsfromInterestReceived" abstract="false" name="ProceedsfromInterestReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" abstract="false" name="TaxEffectOfChangeinFairValueOfWarrantDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_StockholdersEquityNoteStockSplitConversionRatio" abstract="false" name="StockholdersEquityNoteStockSplitConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="oncyf_InvestmentTaxCreditsMember" abstract="true" name="InvestmentTaxCreditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_CommitmentSharesMember" abstract="true" name="CommitmentSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharePurchaseAgreementAmount" abstract="false" name="SharePurchaseAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_WarrantsAndRightsOutstanding1" abstract="false" name="WarrantsAndRightsOutstanding1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_PurchaseObligation1" abstract="false" name="PurchaseObligation1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureofrelatedpartyAbstract" abstract="true" name="DisclosureofrelatedpartyAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_PerformanceShareUnitsMember" abstract="true" name="PerformanceShareUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ShareCapitalNumberSharesAbstract" abstract="true" name="ShareCapitalNumberSharesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TaxEffectOfStockBasedCompensation" abstract="false" name="TaxEffectOfStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_EquityAuthorized" abstract="false" name="EquityAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_NumberOfStockOptionPlans" abstract="false" name="NumberOfStockOptionPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" abstract="true" name="CorporateInformationAndStatementOfIFRSComplianceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" abstract="false" name="ClassofWarrantorRightExercisePriceofWarrantsorRights2" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="oncyf_OverheadRepayment" abstract="false" name="OverheadRepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TwentyThirtyOneMember" abstract="true" name="TwentyThirtyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_StockOptionsOutstandingAbstract" abstract="true" name="StockOptionsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyThirtySixMember" abstract="true" name="TwentyThirtySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SupplierConcentrationRisk1Member" abstract="true" name="SupplierConcentrationRisk1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_DisclosureofeventsafterreportingperiodAbstract" abstract="true" name="DisclosureofeventsafterreportingperiodAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyTwentyFiveMember" abstract="true" name="TwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ShareIssueCostsMember" abstract="true" name="ShareIssueCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_WarrantsandRightsOutstanding" abstract="false" name="WarrantsandRightsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_RestrictedShareUnitsMember" abstract="true" name="RestrictedShareUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_OperatingExpensesMember" abstract="true" name="OperatingExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_OperatingLeaseRemainingLeaseTerm" abstract="false" name="OperatingLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_CommonSharePurchaseWarrantPerUnit" abstract="false" name="CommonSharePurchaseWarrantPerUnit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_UnusedNetOperatingLossCarryForwardsMember" abstract="true" name="UnusedNetOperatingLossCarryForwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_AdjustmentsForDepreciationRightOfUseAssets" abstract="false" name="AdjustmentsForDepreciationRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_CashEquivalentsInterestRate" abstract="false" name="CashEquivalentsInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_SharesUnderStockOptionPlanMember" abstract="true" name="SharesUnderStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharesUnderIncentiveAwardPlanMember" abstract="true" name="SharesUnderIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_WeightedAverageExercisePriceOutstandingAbstract" abstract="true" name="WeightedAverageExercisePriceOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfCapitalComponentsTableTextBlock" abstract="false" name="DisclosureOfCapitalComponentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_SharesUnderSharePurchaseAgreementMember" abstract="true" name="SharesUnderSharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" abstract="false" name="ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" abstract="true" name="DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyFortyMember" abstract="true" name="TwentyFortyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_Statement1LineItems" abstract="true" name="Statement1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_Statement1Table" abstract="true" name="Statement1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyFortyOneMember" abstract="true" name="TwentyFortyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureofsharebasedpaymentarrangementAbstract" abstract="true" name="DisclosureofsharebasedpaymentarrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_LeaseModificationRightOfUseAssets" abstract="false" name="LeaseModificationRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" abstract="true" name="DisclosureOfShareBasedPaymentArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_AgreementDomain" abstract="true" name="AgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_TwentyTwentyThreeMember" abstract="true" name="TwentyTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" abstract="true" name="DisclosureofrevenuefromcontractswithcustomersAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ForeignExchangeImpactRightofUseAssets" abstract="false" name="ForeignExchangeImpactRightofUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SYNSORBMember" abstract="true" name="SYNSORBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_Currency1LineItems" abstract="true" name="Currency1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SharesUnderAtthemarketAgreementMember" abstract="true" name="SharesUnderAtthemarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" abstract="false" name="ContingentRoyaltyPaymentPercentOfSalesRevenue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" abstract="false" name="PropertyPlantandEquipmentAnnualDepreciationRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" abstract="false" name="IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ConcentrationRisk1Table" abstract="true" name="ConcentrationRisk1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingWarrantDerivativesMember" abstract="true" name="SharesPublicOfferingWarrantDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_WarrantsMember" abstract="true" name="WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_CashFlowOperatingCapital1TableTextBlock" abstract="false" name="CashFlowOperatingCapital1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingEquityWarrantsMember" abstract="true" name="SharesPublicOfferingEquityWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TwentyThirtyEightMember" abstract="true" name="TwentyThirtyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TaxEffectOfExpirationOfTaxBenefits" abstract="false" name="TaxEffectOfExpirationOfTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharesUnderCommonStockPurchaseAgreementMember" abstract="true" name="SharesUnderCommonStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TaxEffectOfTaxPools" abstract="false" name="TaxEffectOfTaxPools" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightNumberofWarrantsExercised" abstract="false" name="ClassofWarrantorRightNumberofWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_UnusedCapitalLossCarryForwardNetMember" abstract="true" name="UnusedCapitalLossCarryForwardNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_GainsLossesFromForeignExchangeImpact" abstract="false" name="GainsLossesFromForeignExchangeImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_CommitmentsAndContingencies1" abstract="false" name="CommitmentsAndContingencies1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_IssueOfEquityShares" abstract="false" name="IssueOfEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DividendYieldPercent" abstract="false" name="DividendYieldPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" abstract="true" name="DisclosureOfNotesAndOtherExplanatoryInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" abstract="true" name="SignificantJudgmentsEstimatesAndAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsTableTextBlock" abstract="false" name="OtherExpensesAndAdjustmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_ShareIssueRelatedCostCommissions" abstract="false" name="ShareIssueRelatedCostCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1Domain" abstract="true" name="ConcentrationRiskType1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsLineItems" abstract="true" name="OtherExpensesAndAdjustmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyTwentyTwoMember" abstract="true" name="TwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_OfficeEquipmentAndFurnitureMember" abstract="true" name="OfficeEquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ContractLiabilityRecognitionPeriod" abstract="false" name="ContractLiabilityRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" abstract="false" name="ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1LineItems" abstract="true" name="ConcentrationRiskType1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_AnnualContingentPaymentGrossSalesPercent" abstract="false" name="AnnualContingentPaymentGrossSalesPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_BalanceHeldInForeignCurrencyNet" abstract="false" name="BalanceHeldInForeignCurrencyNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ProductionServiceAgreementMember" abstract="true" name="ProductionServiceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_AnnualContingentPayment" abstract="false" name="AnnualContingentPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SaleOfStockDomain" abstract="true" name="SaleOfStockDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_WarrantIssuedUnderlyingSharePrice" abstract="false" name="WarrantIssuedUnderlyingSharePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="oncyf_ContingentRoyaltyPaymentAnnualMaximum" abstract="false" name="ContingentRoyaltyPaymentAnnualMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ConcentrationRiskNumber" abstract="false" name="ConcentrationRiskNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" abstract="false" name="CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_TwentyTwentyFourMember" abstract="true" name="TwentyTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TwentyThirtyThreeMember" abstract="true" name="TwentyThirtyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightWarrantsExercised" abstract="false" name="ClassofWarrantorRightWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ShareCapitalAmountAbstract" abstract="true" name="ShareCapitalAmountAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" abstract="true" name="PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_MedicalEquipmentMember" abstract="true" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_CommonSharesPerUnit" abstract="false" name="CommonSharesPerUnit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1Axis" abstract="true" name="ConcentrationRiskType1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_AgreementAxis" abstract="true" name="AgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" abstract="false" name="ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_FundedandRoyaltyRepayment" abstract="false" name="FundedandRoyaltyRepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ContingenciesAbstract" abstract="true" name="ContingenciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfEconomicDependenceAbstract" abstract="true" name="DisclosureOfEconomicDependenceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyThirtyFourMember" abstract="true" name="TwentyThirtyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" abstract="true" name="SharesUnderAtthemarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_IssuedCapitalExcludingCommitmentSharesMember" abstract="true" name="IssuedCapitalExcludingCommitmentSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TwentyTwentySevenMember" abstract="true" name="TwentyTwentySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_CommitmentsAbstract" abstract="true" name="CommitmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_GrossProceedsFromIssueOfOrdinaryShares" abstract="false" name="GrossProceedsFromIssueOfOrdinaryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_IncomeStatementLocation1Axis" abstract="true" name="IncomeStatementLocation1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_PaymentsForExecutoryContracts" abstract="false" name="PaymentsForExecutoryContracts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_Currency1Table" abstract="true" name="Currency1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingMember" abstract="true" name="SharesPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TwentyTwentySixMember" abstract="true" name="TwentyTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TwentyThirtySevenMember" abstract="true" name="TwentyThirtySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharesIssuedPricePerShare1" abstract="false" name="SharesIssuedPricePerShare1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="oncyf_SaleOfStockAxis" abstract="true" name="SaleOfStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_FairValueofWarrantIssuedPerWarrant" abstract="false" name="FairValueofWarrantIssuedPerWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" abstract="false" name="DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_IncomeStatementLocation1Domain" abstract="true" name="IncomeStatementLocation1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TwentyThirtyNineMember" abstract="true" name="TwentyThirtyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ClassOfWarrantOrRightOutstanding1" abstract="false" name="ClassOfWarrantOrRightOutstanding1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ChangeInFairValueWarrantDerivativeRollForward" abstract="true" name="ChangeInFairValueWarrantDerivativeRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsTable" abstract="true" name="OtherExpensesAndAdjustmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" abstract="false" name="IncreaseDecreaseThroughIncentiveShareAwardsEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" abstract="false" name="MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" abstract="false" name="DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_SharePurchaseAgreementTerm" abstract="false" name="SharePurchaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" abstract="false" name="CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_AdditionalCashFlowDisclosuresAbstract" abstract="true" name="AdditionalCashFlowDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_NumberOfWarrantsOutstandingRollForward" abstract="true" name="NumberOfWarrantsOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_RightOfUseAssetsAbstract" abstract="true" name="RightOfUseAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" abstract="false" name="CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" abstract="true" name="UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharesIssuedWarrantPricePerShare" abstract="false" name="SharesIssuedWarrantPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="oncyf_TwentyThirtyTwoMember" abstract="true" name="TwentyThirtyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" abstract="false" name="ScheduleOfForeignCurrencyHeldTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_ProceedsfromWarrantExercises1" abstract="false" name="ProceedsfromWarrantExercises1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_DisclosureofincometaxAbstract" abstract="true" name="DisclosureofincometaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfEconomicDependenceTextBlock" abstract="false" name="DisclosureOfEconomicDependenceTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_TwentyTwentyNineMember" abstract="true" name="TwentyTwentyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_EffectOfLeaseModificationOnLeaseLiabilities" abstract="false" name="EffectOfLeaseModificationOnLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>35
<FILENAME>oncyf-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:04d38e4b-b411-4668-8f8c-e4013a42568d,g:242f92a0-4583-4d5d-9e63-4960e9cee1a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_447d5a34-150a-4fb8-8c55-d6fd0ad39d8c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_9caaedcf-427d-4c20-ac61-932e0474f7d6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_447d5a34-150a-4fb8-8c55-d6fd0ad39d8c" xlink:to="loc_ifrs-full_Liabilities_9caaedcf-427d-4c20-ac61-932e0474f7d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1_991f15e9-d6ad-4e32-8ebe-8bff137b625b" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_447d5a34-150a-4fb8-8c55-d6fd0ad39d8c" xlink:to="loc_oncyf_CommitmentsAndContingencies1_991f15e9-d6ad-4e32-8ebe-8bff137b625b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_7cd17efd-b1bc-43b8-bd1e-cfcba831e41a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_447d5a34-150a-4fb8-8c55-d6fd0ad39d8c" xlink:to="loc_ifrs-full_Equity_7cd17efd-b1bc-43b8-bd1e-cfcba831e41a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_cb8f9ef1-a710-4064-ac81-820cc05f881c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_831b8a57-5fa6-4db9-ad22-ab17d739080b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_cb8f9ef1-a710-4064-ac81-820cc05f881c" xlink:to="loc_ifrs-full_CurrentAssets_831b8a57-5fa6-4db9-ad22-ab17d739080b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_05a8413d-c1ec-4eeb-8693-f4f0dcccde6b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_cb8f9ef1-a710-4064-ac81-820cc05f881c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_05a8413d-c1ec-4eeb-8693-f4f0dcccde6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_c3643ca7-9830-498a-9a98-25977dcac3d3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_cb8f9ef1-a710-4064-ac81-820cc05f881c" xlink:to="loc_ifrs-full_RightofuseAssets_c3643ca7-9830-498a-9a98-25977dcac3d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_9136c808-c0b8-46ab-888f-408a11f71027" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_84ddb4d7-9d00-481d-8213-6bb83d66310e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_9136c808-c0b8-46ab-888f-408a11f71027" xlink:to="loc_ifrs-full_IssuedCapital_84ddb4d7-9d00-481d-8213-6bb83d66310e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_fc2e383f-d651-4e99-98a7-b33d30661b0e" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsandRightsOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_9136c808-c0b8-46ab-888f-408a11f71027" xlink:to="loc_oncyf_WarrantsandRightsOutstanding_fc2e383f-d651-4e99-98a7-b33d30661b0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_d0ae34b6-6aa9-428b-9e10-0a3209ebfbd5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_9136c808-c0b8-46ab-888f-408a11f71027" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_d0ae34b6-6aa9-428b-9e10-0a3209ebfbd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_a6a8dd56-ef11-4d32-804c-5199811abace" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_9136c808-c0b8-46ab-888f-408a11f71027" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_a6a8dd56-ef11-4d32-804c-5199811abace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_933e0799-e0a7-4a71-bb40-de67c8c58935" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_9136c808-c0b8-46ab-888f-408a11f71027" xlink:to="loc_ifrs-full_RetainedEarnings_933e0799-e0a7-4a71-bb40-de67c8c58935" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_490a9578-bc93-421d-b9a9-969d11687feb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_17486b78-71d4-45cc-a241-22dc57f485d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_490a9578-bc93-421d-b9a9-969d11687feb" xlink:to="loc_ifrs-full_CashAndCashEquivalents_17486b78-71d4-45cc-a241-22dc57f485d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_13d2f406-e226-490b-b2b6-689d7bceb9a4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_490a9578-bc93-421d-b9a9-969d11687feb" xlink:to="loc_ifrs-full_OtherCurrentReceivables_13d2f406-e226-490b-b2b6-689d7bceb9a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_3a0171b3-1ca3-43df-9dda-ab2040e7a8de" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_490a9578-bc93-421d-b9a9-969d11687feb" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_3a0171b3-1ca3-43df-9dda-ab2040e7a8de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_66dc5fee-111b-4084-93e3-362bbc2e3db8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_3ef3c638-8693-40d3-8c56-bc45fd908d17" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_66dc5fee-111b-4084-93e3-362bbc2e3db8" xlink:to="loc_ifrs-full_CurrentLiabilities_3ef3c638-8693-40d3-8c56-bc45fd908d17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_20200bb0-019c-4eee-b23c-031d04553411" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_66dc5fee-111b-4084-93e3-362bbc2e3db8" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_20200bb0-019c-4eee-b23c-031d04553411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_22e4a943-8be9-451a-91e6-c86ade76091c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_66dc5fee-111b-4084-93e3-362bbc2e3db8" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_22e4a943-8be9-451a-91e6-c86ade76091c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_aafaaab4-92a9-4be1-96be-aafa649fec82" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_ab0bda3f-8f86-494b-b7e0-cc11f5982810" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_aafaaab4-92a9-4be1-96be-aafa649fec82" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_ab0bda3f-8f86-494b-b7e0-cc11f5982810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_9a111ad2-f9b0-40aa-a564-4d179d1b1331" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_aafaaab4-92a9-4be1-96be-aafa649fec82" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_9a111ad2-f9b0-40aa-a564-4d179d1b1331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_4a301027-b03e-4ad4-8c29-57ccdfd31f99" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_aafaaab4-92a9-4be1-96be-aafa649fec82" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_4a301027-b03e-4ad4-8c29-57ccdfd31f99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_05908c74-d56b-492a-b50d-6427fca045cf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_aafaaab4-92a9-4be1-96be-aafa649fec82" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_05908c74-d56b-492a-b50d-6427fca045cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_ec6db81f-59aa-4eb9-b58c-79c97c224d9e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_54084b05-f2f7-4cb7-9c6b-e83b4866ba26" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_ec6db81f-59aa-4eb9-b58c-79c97c224d9e" xlink:to="loc_ifrs-full_ProfitLoss_54084b05-f2f7-4cb7-9c6b-e83b4866ba26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d12012a3-4b6b-4eae-a2fb-7fc42eca06d2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_ec6db81f-59aa-4eb9-b58c-79c97c224d9e" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d12012a3-4b6b-4eae-a2fb-7fc42eca06d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_7295324b-1f2a-4425-8d6b-67da35c8b0c6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_6298b0dc-27fb-4806-bbb7-9c8894addc7a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_7295324b-1f2a-4425-8d6b-67da35c8b0c6" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_6298b0dc-27fb-4806-bbb7-9c8894addc7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_2ba9c03d-ebde-402b-8c5f-a8ccf53b42af" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_7295324b-1f2a-4425-8d6b-67da35c8b0c6" xlink:to="loc_ifrs-full_OperatingExpense_2ba9c03d-ebde-402b-8c5f-a8ccf53b42af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_0752e23a-d45e-487a-b8ae-9c3b8e501433" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_0d48409a-9cd0-453d-9801-71eaaec0317f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0752e23a-d45e-487a-b8ae-9c3b8e501433" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_0d48409a-9cd0-453d-9801-71eaaec0317f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_841a6590-92d4-4b79-b8c4-19316287cc13" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0752e23a-d45e-487a-b8ae-9c3b8e501433" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_841a6590-92d4-4b79-b8c4-19316287cc13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_49efa72a-fd70-4582-a36c-0249552cd920" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_7d415092-9e50-4e94-9211-4bc28180db7d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_49efa72a-fd70-4582-a36c-0249552cd920" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_7d415092-9e50-4e94-9211-4bc28180db7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_7f76b8bc-cdda-43cc-b025-9475e6b26788" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_49efa72a-fd70-4582-a36c-0249552cd920" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_7f76b8bc-cdda-43cc-b025-9475e6b26788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_4f71d2f3-0c47-41b9-861d-5d0d75398e75" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_49efa72a-fd70-4582-a36c-0249552cd920" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_4f71d2f3-0c47-41b9-861d-5d0d75398e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_41cae741-fab5-47b2-b7f4-e63c38f02fe7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_49efa72a-fd70-4582-a36c-0249552cd920" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_41cae741-fab5-47b2-b7f4-e63c38f02fe7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_a48c3f6e-82e8-4fcc-890a-1921af61885f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_a0da32a5-88e4-458c-9273-388139e0a653" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_a48c3f6e-82e8-4fcc-890a-1921af61885f" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_a0da32a5-88e4-458c-9273-388139e0a653" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_e6bf9b77-446f-4b5a-8467-66a33c475a1f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_7ea8a4cd-a39c-4e78-bf17-ec51bbf253ab" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_e6bf9b77-446f-4b5a-8467-66a33c475a1f" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_7ea8a4cd-a39c-4e78-bf17-ec51bbf253ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_0bf8d08f-811d-4d31-ad61-22f924133157" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_e6bf9b77-446f-4b5a-8467-66a33c475a1f" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_0bf8d08f-811d-4d31-ad61-22f924133157" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_62e4fcde-3227-41db-a5e7-f160f2c89abe" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_e6bf9b77-446f-4b5a-8467-66a33c475a1f" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_62e4fcde-3227-41db-a5e7-f160f2c89abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_59a0d682-b6ff-43bc-9fa9-865df14d3532" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_bb805c4e-8a77-438f-a0d0-75a023952180" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_59a0d682-b6ff-43bc-9fa9-865df14d3532" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_bb805c4e-8a77-438f-a0d0-75a023952180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_6ea7e947-d13d-4dec-9ada-83f75b361fa9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_59a0d682-b6ff-43bc-9fa9-865df14d3532" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_6ea7e947-d13d-4dec-9ada-83f75b361fa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_571af95c-f335-4017-8681-14aa07a6707b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_59a0d682-b6ff-43bc-9fa9-865df14d3532" xlink:to="loc_ifrs-full_CashOutflowForLeases_571af95c-f335-4017-8681-14aa07a6707b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_457bf507-e7e7-43e6-9648-24734e33365e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_3f32c4c7-6231-4182-9768-18d838e409ab" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_457bf507-e7e7-43e6-9648-24734e33365e" xlink:to="loc_ifrs-full_ProfitLoss_3f32c4c7-6231-4182-9768-18d838e409ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_cfb63fb7-8b1e-4e9a-a5f0-465e1cb1627f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_457bf507-e7e7-43e6-9648-24734e33365e" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_cfb63fb7-8b1e-4e9a-a5f0-465e1cb1627f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_863f87ca-4d11-4f16-ae00-9d40efec2463" xlink:href="oncyf-20211231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_457bf507-e7e7-43e6-9648-24734e33365e" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_863f87ca-4d11-4f16-ae00-9d40efec2463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_34db2f03-a8af-4d97-ac3e-1324895cf8c4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_457bf507-e7e7-43e6-9648-24734e33365e" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_34db2f03-a8af-4d97-ac3e-1324895cf8c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_e029d0b9-9f66-40f1-a907-46b589a7f788" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_457bf507-e7e7-43e6-9648-24734e33365e" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_e029d0b9-9f66-40f1-a907-46b589a7f788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_362a2850-516d-4edf-a9da-904feed7a091" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_457bf507-e7e7-43e6-9648-24734e33365e" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_362a2850-516d-4edf-a9da-904feed7a091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_7dbd245d-6ed3-4752-830d-ef0a6a219741" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_457bf507-e7e7-43e6-9648-24734e33365e" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_7dbd245d-6ed3-4752-830d-ef0a6a219741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_dd3a2b6d-d141-42fc-93dd-12a29fa2f7ba" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_457bf507-e7e7-43e6-9648-24734e33365e" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_dd3a2b6d-d141-42fc-93dd-12a29fa2f7ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_02fe8514-cfaa-4528-a9c6-7dbba336498e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_23b6a9f8-90ec-476d-990d-bddfbd12710c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ContractLiabilities_02fe8514-cfaa-4528-a9c6-7dbba336498e" xlink:to="loc_ifrs-full_CurrentContractLiabilities_23b6a9f8-90ec-476d-990d-bddfbd12710c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_46b5d43f-e1ee-41c5-b65d-dbad23bbc469" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ContractLiabilities_02fe8514-cfaa-4528-a9c6-7dbba336498e" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_46b5d43f-e1ee-41c5-b65d-dbad23bbc469" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_da8a93d2-4cb0-4da8-a6e6-f16e3a240037" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_fdd26f56-6895-4e31-a96a-89cce5219bcd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_da8a93d2-4cb0-4da8-a6e6-f16e3a240037" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_fdd26f56-6895-4e31-a96a-89cce5219bcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_7ff5b793-6c3a-4f60-998b-e423a1193337" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_da8a93d2-4cb0-4da8-a6e6-f16e3a240037" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_7ff5b793-6c3a-4f60-998b-e423a1193337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_7fa14eb4-e0e5-4287-999e-31f973c87a17" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_da8a93d2-4cb0-4da8-a6e6-f16e3a240037" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_7fa14eb4-e0e5-4287-999e-31f973c87a17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_c5cb1ce0-e151-4582-87f4-b279495d48d4" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_da8a93d2-4cb0-4da8-a6e6-f16e3a240037" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_c5cb1ce0-e151-4582-87f4-b279495d48d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_2327f2ac-6d98-4cd9-b5ea-ee016dd4c252" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_da8a93d2-4cb0-4da8-a6e6-f16e3a240037" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_2327f2ac-6d98-4cd9-b5ea-ee016dd4c252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools_6f163e64-77b8-4da4-aa06-053d3ecdc185" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_da8a93d2-4cb0-4da8-a6e6-f16e3a240037" xlink:to="loc_oncyf_TaxEffectOfTaxPools_6f163e64-77b8-4da4-aa06-053d3ecdc185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_3fadb04e-2adf-464f-8398-f967bcb2ccc7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_da8a93d2-4cb0-4da8-a6e6-f16e3a240037" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_3fadb04e-2adf-464f-8398-f967bcb2ccc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_3ea86d80-3595-490f-b1f6-25267cbe5380" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_da8a93d2-4cb0-4da8-a6e6-f16e3a240037" xlink:to="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_3ea86d80-3595-490f-b1f6-25267cbe5380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_ee53a5db-ff7e-4228-a090-bbb62e75322e" xlink:href="oncyf-20211231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_da8a93d2-4cb0-4da8-a6e6-f16e3a240037" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_ee53a5db-ff7e-4228-a090-bbb62e75322e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_c49f3a53-f8dc-4ce2-b8fb-1c9560565756" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_6b5f2197-40a9-480a-a896-237d927f7782" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_c49f3a53-f8dc-4ce2-b8fb-1c9560565756" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_6b5f2197-40a9-480a-a896-237d927f7782" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_cb43d02c-e8a0-45cc-bdd7-dcb740dbfcf2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_c49f3a53-f8dc-4ce2-b8fb-1c9560565756" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_cb43d02c-e8a0-45cc-bdd7-dcb740dbfcf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_c4af017e-dada-4aaa-81b0-2be1dcc7554d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_c49f3a53-f8dc-4ce2-b8fb-1c9560565756" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_c4af017e-dada-4aaa-81b0-2be1dcc7554d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_d0473652-da80-4520-af08-60c3278effc5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_c49f3a53-f8dc-4ce2-b8fb-1c9560565756" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_d0473652-da80-4520-af08-60c3278effc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_8cffe5f8-898b-47cc-b1e6-3d9c3fcf77aa" xlink:href="oncyf-20211231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_c49f3a53-f8dc-4ce2-b8fb-1c9560565756" xlink:to="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_8cffe5f8-898b-47cc-b1e6-3d9c3fcf77aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_c2b0f9f6-4a9e-4d55-803b-6cb45ac0da73" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_d87ea194-27b8-4b3e-9eb6-9d4787842ba3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_c2b0f9f6-4a9e-4d55-803b-6cb45ac0da73" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_d87ea194-27b8-4b3e-9eb6-9d4787842ba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_e430a116-aeb6-4ef1-a1a1-48182c9e542b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_c2b0f9f6-4a9e-4d55-803b-6cb45ac0da73" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_e430a116-aeb6-4ef1-a1a1-48182c9e542b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_24ba06b4-1915-472f-b4fa-d30af4f2f773" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_c2b0f9f6-4a9e-4d55-803b-6cb45ac0da73" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_24ba06b4-1915-472f-b4fa-d30af4f2f773" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>36
<FILENAME>oncyf-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:04d38e4b-b411-4668-8f8c-e4013a42568d,g:242f92a0-4583-4d5d-9e63-4960e9cee1a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="simple" xlink:href="oncyf-20211231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="extended" id="i2ddf91247d3a45c69095e0473287dfae_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_036402fa-cc65-47a8-8240-d4083768906b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentType_036402fa-cc65-47a8-8240-d4083768906b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_592b42f1-e0e4-4492-ad03-f58a182389bf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentRegistrationStatement_592b42f1-e0e4-4492-ad03-f58a182389bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_672eb85d-d8ea-4a0b-8404-af62f03c1081" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentAnnualReport_672eb85d-d8ea-4a0b-8404-af62f03c1081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_829e8a6f-cc7d-4e3f-96f2-3ec97d3a569d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentPeriodEndDate_829e8a6f-cc7d-4e3f-96f2-3ec97d3a569d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1dbf57ca-8bbf-424b-8ea6-8f433e3c0746" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_CurrentFiscalYearEndDate_1dbf57ca-8bbf-424b-8ea6-8f433e3c0746" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6024c2a4-945c-48e8-9b4f-2a4a1949af5f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentTransitionReport_6024c2a4-945c-48e8-9b4f-2a4a1949af5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_e3834ffa-3182-4a49-972f-460bc851f5d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentShellCompanyReport_e3834ffa-3182-4a49-972f-460bc851f5d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f0e5355f-7252-4f26-a266-8f9e3e8c2d9a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityFileNumber_f0e5355f-7252-4f26-a266-8f9e3e8c2d9a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_db486f6b-f65b-403b-8571-433cabccef4b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityRegistrantName_db486f6b-f65b-403b-8571-433cabccef4b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_45a1fd4d-e595-47b2-bbaa-ff27d0f114fa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityIncorporationStateCountryCode_45a1fd4d-e595-47b2-bbaa-ff27d0f114fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_60182e5c-fcdd-4620-98b8-3b681bd23cdf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityAddressAddressLine1_60182e5c-fcdd-4620-98b8-3b681bd23cdf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_23a36cb1-a873-4885-975c-bed2b5d1ee93" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityAddressCityOrTown_23a36cb1-a873-4885-975c-bed2b5d1ee93" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_54bebb91-ff0b-4f1e-8745-3f9610fd8bc0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityAddressStateOrProvince_54bebb91-ff0b-4f1e-8745-3f9610fd8bc0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_c1db54db-0dc7-4f16-8b14-57d93feecafc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityAddressCountry_c1db54db-0dc7-4f16-8b14-57d93feecafc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bf3ba5c8-2acd-4800-950e-08a551fdeb5a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityAddressPostalZipCode_bf3ba5c8-2acd-4800-950e-08a551fdeb5a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_a2ae6077-60ea-4dbb-9a5e-9790e59db303" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_ContactPersonnelName_a2ae6077-60ea-4dbb-9a5e-9790e59db303" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_151d2c4a-c3b1-4510-b478-a96eeffba35b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_CityAreaCode_151d2c4a-c3b1-4510-b478-a96eeffba35b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fc6aa4eb-793b-4910-b3fa-c7181805d014" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_LocalPhoneNumber_fc6aa4eb-793b-4910-b3fa-c7181805d014" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress_5358b5f7-104f-49d1-ad8f-8a53ad27a95d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_ContactPersonnelEmailAddress_5358b5f7-104f-49d1-ad8f-8a53ad27a95d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1a0a34a6-343d-43c7-94d3-22646401eed5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_Security12bTitle_1a0a34a6-343d-43c7-94d3-22646401eed5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0f3aa367-3586-42f6-97c4-3caa9f0a9414" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_TradingSymbol_0f3aa367-3586-42f6-97c4-3caa9f0a9414" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_63fb135e-61ac-47c2-9bc6-ad8128b71cb4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_SecurityExchangeName_63fb135e-61ac-47c2-9bc6-ad8128b71cb4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8fa4baae-387f-4947-945b-e5d5dfb37adb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8fa4baae-387f-4947-945b-e5d5dfb37adb" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_11066c8b-15f0-4e79-af8f-b88fb27131f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_11066c8b-15f0-4e79-af8f-b88fb27131f5" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_69e8dabf-9aef-41e5-9dae-3ce32f34a6a1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityVoluntaryFilers_69e8dabf-9aef-41e5-9dae-3ce32f34a6a1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8c12856c-1b6a-45e3-a2c4-e4adf49c94d8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityCurrentReportingStatus_8c12856c-1b6a-45e3-a2c4-e4adf49c94d8" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_66d111af-2bd0-4029-b714-fb541bb387a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityInteractiveDataCurrent_66d111af-2bd0-4029-b714-fb541bb387a8" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_da9d4ef4-ac2c-46fa-ba48-01c8b98fa729" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityFilerCategory_da9d4ef4-ac2c-46fa-ba48-01c8b98fa729" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e92d106c-b61d-4d1f-b093-7f31c15fc39d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityEmergingGrowthCompany_e92d106c-b61d-4d1f-b093-7f31c15fc39d" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_e4ef8e56-0906-4982-ab16-44e8c21cbdac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_IcfrAuditorAttestationFlag_e4ef8e56-0906-4982-ab16-44e8c21cbdac" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_8d49a2c7-6fe2-437e-b6f7-f000d538b0ef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentAccountingStandard_8d49a2c7-6fe2-437e-b6f7-f000d538b0ef" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2cd04d47-8569-401a-993a-100020a747e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityShellCompany_2cd04d47-8569-401a-993a-100020a747e3" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3c126ef3-a211-413a-af74-e97232d99579" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityCentralIndexKey_3c126ef3-a211-413a-af74-e97232d99579" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a9d3cd9e-3496-4ff7-ac3e-7e6f4b4f4be0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentFiscalYearFocus_a9d3cd9e-3496-4ff7-ac3e-7e6f4b4f4be0" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_630bd552-1621-4182-9102-2ec872a50d35" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentFiscalPeriodFocus_630bd552-1621-4182-9102-2ec872a50d35" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9e8b3ba5-5268-4ba1-b4ee-af2135a4322e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_AmendmentFlag_9e8b3ba5-5268-4ba1-b4ee-af2135a4322e" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_808aaf8f-ff34-4e84-9072-2da57dfde0eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityPublicFloat_808aaf8f-ff34-4e84-9072-2da57dfde0eb" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_3353e99b-29da-4ed9-bc94-20f95ff07af7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentInformationTable_3353e99b-29da-4ed9-bc94-20f95ff07af7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_a5c969fb-f62e-4241-ad12-631cd6640e8e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3353e99b-29da-4ed9-bc94-20f95ff07af7" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_a5c969fb-f62e-4241-ad12-631cd6640e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_a5c969fb-f62e-4241-ad12-631cd6640e8e_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_a5c969fb-f62e-4241-ad12-631cd6640e8e" xlink:to="loc_dei_AddressTypeDomain_a5c969fb-f62e-4241-ad12-631cd6640e8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_f4f2d953-fb38-4721-9161-e6c21229c5fe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_a5c969fb-f62e-4241-ad12-631cd6640e8e" xlink:to="loc_dei_AddressTypeDomain_f4f2d953-fb38-4721-9161-e6c21229c5fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_c826ecc9-6995-418d-8bb7-e1a9b03cef32" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_f4f2d953-fb38-4721-9161-e6c21229c5fe" xlink:to="loc_dei_BusinessContactMember_c826ecc9-6995-418d-8bb7-e1a9b03cef32" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="extended" id="i98a8c663ca5240cba436aa5f7229aa30_CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5970ccd6-5f0f-4643-899a-3fa65e336419" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_Equity_5970ccd6-5f0f-4643-899a-3fa65e336419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_cf639a48-bb57-48de-af9c-3aa699b63946" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_ComprehensiveIncome_cf639a48-bb57-48de-af9c-3aa699b63946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_336c9677-9fd9-45ab-978d-e62128caf927" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_336c9677-9fd9-45ab-978d-e62128caf927" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_78e68c01-92aa-4ff4-919b-aef34ede6002" xlink:href="oncyf-20211231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_78e68c01-92aa-4ff4-919b-aef34ede6002" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_15ed5ff6-b2d9-4bf3-b458-bd41ae6c47a2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_IssueOfEquity_15ed5ff6-b2d9-4bf3-b458-bd41ae6c47a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_4d6d72f5-b2d2-45c1-a1bf-b098df24230d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_4d6d72f5-b2d2-45c1-a1bf-b098df24230d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_cf91f06f-7b70-4dd4-9757-c448f1bb25ff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_cf91f06f-7b70-4dd4-9757-c448f1bb25ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_fc77d74e-930e-4eec-bb4a-fbcdafc5f224" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_fc77d74e-930e-4eec-bb4a-fbcdafc5f224" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_1daa9202-5693-4938-9e7b-25f6e40ddad5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_0e6c5fbf-9e35-4efc-bf29-f197e9155f5d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_0e6c5fbf-9e35-4efc-bf29-f197e9155f5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_e424dc73-ce18-4f17-9509-6f44b6309ff9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0e6c5fbf-9e35-4efc-bf29-f197e9155f5d" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_e424dc73-ce18-4f17-9509-6f44b6309ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_e424dc73-ce18-4f17-9509-6f44b6309ff9_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_e424dc73-ce18-4f17-9509-6f44b6309ff9" xlink:to="loc_ifrs-full_EquityMember_e424dc73-ce18-4f17-9509-6f44b6309ff9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_e424dc73-ce18-4f17-9509-6f44b6309ff9" xlink:to="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_4b41f092-61a2-4029-98b7-940bebcd1fd9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:to="loc_ifrs-full_IssuedCapitalMember_4b41f092-61a2-4029-98b7-940bebcd1fd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_a6ab1982-2c7a-43e9-a515-9ff92e977dbf" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:to="loc_oncyf_WarrantsMember_a6ab1982-2c7a-43e9-a515-9ff92e977dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_d775b379-b62f-492a-9813-9e3af1201ede" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:to="loc_ifrs-full_SharePremiumMember_d775b379-b62f-492a-9813-9e3af1201ede" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_c6845257-7088-4ab8-b5f8-0a421005a87b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_c6845257-7088-4ab8-b5f8-0a421005a87b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_a41ef9ca-ed18-4c1d-b87d-7619bbd08b96" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:to="loc_ifrs-full_RetainedEarningsMember_a41ef9ca-ed18-4c1d-b87d-7619bbd08b96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_914b8985-2b7f-4004-8fbf-28e0ebadcbf1" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0e6c5fbf-9e35-4efc-bf29-f197e9155f5d" xlink:to="loc_oncyf_SaleOfStockAxis_914b8985-2b7f-4004-8fbf-28e0ebadcbf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_914b8985-2b7f-4004-8fbf-28e0ebadcbf1_default" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_914b8985-2b7f-4004-8fbf-28e0ebadcbf1" xlink:to="loc_oncyf_SaleOfStockDomain_914b8985-2b7f-4004-8fbf-28e0ebadcbf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_f7f49220-7368-4bfe-b142-0018a2ae4f0c" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_914b8985-2b7f-4004-8fbf-28e0ebadcbf1" xlink:to="loc_oncyf_SaleOfStockDomain_f7f49220-7368-4bfe-b142-0018a2ae4f0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_4b81ab7e-35b5-4d8d-9ab3-cb6632b31bf6" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_f7f49220-7368-4bfe-b142-0018a2ae4f0c" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_4b81ab7e-35b5-4d8d-9ab3-cb6632b31bf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_8d0ad350-d389-4621-9cba-11447302ac5f" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_f7f49220-7368-4bfe-b142-0018a2ae4f0c" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_8d0ad350-d389-4621-9cba-11447302ac5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_d3921540-806d-4eb8-846e-abbcb7599b14" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_f7f49220-7368-4bfe-b142-0018a2ae4f0c" xlink:to="loc_oncyf_SharesPublicOfferingMember_d3921540-806d-4eb8-846e-abbcb7599b14" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ie0d41eb710ff4519854730d4ac02a21b_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:href="oncyf-20211231.xsd#oncyf_Statement1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_4d1eb062-09ca-4b73-80bf-d62a94592d6b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_ProfitLoss_4d1eb062-09ca-4b73-80bf-d62a94592d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_4fef8432-f8c6-43e8-a135-3e067ac772e5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_4fef8432-f8c6-43e8-a135-3e067ac772e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_a137fed0-3726-4cf9-bb0f-1b8492cad762" xlink:href="oncyf-20211231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_a137fed0-3726-4cf9-bb0f-1b8492cad762" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_f7aa7cba-43e2-4db3-b508-1541442840d4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_f7aa7cba-43e2-4db3-b508-1541442840d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_44c6a6c9-efbb-4309-bc3e-a01e219a3ce6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_44c6a6c9-efbb-4309-bc3e-a01e219a3ce6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_bced4724-490e-4806-ac88-26dba94f5ee0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_bced4724-490e-4806-ac88-26dba94f5ee0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_63e5a1b4-fde1-40d4-b4a8-7af3f0c41c3b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_63e5a1b4-fde1-40d4-b4a8-7af3f0c41c3b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_0b9c91aa-d35f-43b5-9bd0-f6c8ffe87583" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_0b9c91aa-d35f-43b5-9bd0-f6c8ffe87583" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_4f873683-0cc5-46d2-8f04-93493fb3a94e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_4f873683-0cc5-46d2-8f04-93493fb3a94e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_dc9c31d3-7d00-48cb-8c4d-fd568e476fa6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_dc9c31d3-7d00-48cb-8c4d-fd568e476fa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_8a5df9a7-e6d6-40c8-a7f9-ef2c9596621a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_dc9c31d3-7d00-48cb-8c4d-fd568e476fa6" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_8a5df9a7-e6d6-40c8-a7f9-ef2c9596621a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_df6aac6e-1c77-4ed2-b408-debfd431f27e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_dc9c31d3-7d00-48cb-8c4d-fd568e476fa6" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_df6aac6e-1c77-4ed2-b408-debfd431f27e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_0a05ae6e-c892-4c8e-8a3f-219152db3fc4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_0a05ae6e-c892-4c8e-8a3f-219152db3fc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_bd9eeee4-cc83-45d0-9577-a8a5e641fc95" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_bd9eeee4-cc83-45d0-9577-a8a5e641fc95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_60489474-a777-40b0-8cf7-ca602d0cced2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:to="loc_ifrs-full_CashOutflowForLeases_60489474-a777-40b0-8cf7-ca602d0cced2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a171734d-b6cb-489a-8216-b1d6d2b591cc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a171734d-b6cb-489a-8216-b1d6d2b591cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_dd513533-0b96-4ac8-b71f-177f8c1fd138" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_dd513533-0b96-4ac8-b71f-177f8c1fd138" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_a77ddb12-cc04-47ef-84bb-66939ec9a5e6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_CashAndCashEquivalents_a77ddb12-cc04-47ef-84bb-66939ec9a5e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_953611b0-c22a-4ffe-9e45-0290722375fe" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_953611b0-c22a-4ffe-9e45-0290722375fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_22ca9004-205f-47bb-80e9-93b45de5f123" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table_0aad9327-39ba-439b-a626-0cb93ebfc32a" xlink:href="oncyf-20211231.xsd#oncyf_Statement1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_oncyf_Statement1Table_0aad9327-39ba-439b-a626-0cb93ebfc32a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_822990fc-7bb8-4ab5-b2c8-49bc62e044f3" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Statement1Table_0aad9327-39ba-439b-a626-0cb93ebfc32a" xlink:to="loc_oncyf_SaleOfStockAxis_822990fc-7bb8-4ab5-b2c8-49bc62e044f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_822990fc-7bb8-4ab5-b2c8-49bc62e044f3_default" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_822990fc-7bb8-4ab5-b2c8-49bc62e044f3" xlink:to="loc_oncyf_SaleOfStockDomain_822990fc-7bb8-4ab5-b2c8-49bc62e044f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_822990fc-7bb8-4ab5-b2c8-49bc62e044f3" xlink:to="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_b3195fa1-e6ab-4fd6-a6b0-1d949d37712c" xlink:href="oncyf-20211231.xsd#oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:to="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_b3195fa1-e6ab-4fd6-a6b0-1d949d37712c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_074452a4-15a2-476d-a230-78abdf7e21d2" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_074452a4-15a2-476d-a230-78abdf7e21d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_982ab64c-4381-4d72-ab90-469c39d0bcaa" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_982ab64c-4381-4d72-ab90-469c39d0bcaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_4a4cad95-990d-49e9-a0d3-d2c30fb1c89b" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:to="loc_oncyf_SharesPublicOfferingMember_4a4cad95-990d-49e9-a0d3-d2c30fb1c89b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="extended" id="ib7c9e8b03f704972801c49462051f721_SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ffb255ab-edd8-4aa8-b4fe-4087aeed8811" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_84d0b64e-3952-45ef-95a6-d5d0fadb80ae" xlink:href="oncyf-20211231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ffb255ab-edd8-4aa8-b4fe-4087aeed8811" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_84d0b64e-3952-45ef-95a6-d5d0fadb80ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2cf7a6b3-fcd6-45f4-91cb-d966132033db" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ffb255ab-edd8-4aa8-b4fe-4087aeed8811" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2cf7a6b3-fcd6-45f4-91cb-d966132033db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_0146ec71-ad3d-4b27-ad57-9f070bf53287" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2cf7a6b3-fcd6-45f4-91cb-d966132033db" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_0146ec71-ad3d-4b27-ad57-9f070bf53287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_0146ec71-ad3d-4b27-ad57-9f070bf53287_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_0146ec71-ad3d-4b27-ad57-9f070bf53287" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_0146ec71-ad3d-4b27-ad57-9f070bf53287_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_31f23cea-e520-4619-90dc-a19220256b20" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_0146ec71-ad3d-4b27-ad57-9f070bf53287" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_31f23cea-e520-4619-90dc-a19220256b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_6aa11733-2dd9-4635-934a-2118fea9d406" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_31f23cea-e520-4619-90dc-a19220256b20" xlink:to="loc_ifrs-full_OfficeEquipmentMember_6aa11733-2dd9-4635-934a-2118fea9d406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_d33e2696-78ef-4fd0-80ce-b487d0aae9e3" xlink:href="oncyf-20211231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_31f23cea-e520-4619-90dc-a19220256b20" xlink:to="loc_oncyf_MedicalEquipmentMember_d33e2696-78ef-4fd0-80ce-b487d0aae9e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_4175ddb5-aa07-4be4-b113-78ad4a359a84" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_31f23cea-e520-4619-90dc-a19220256b20" xlink:to="loc_ifrs-full_ComputerEquipmentMember_4175ddb5-aa07-4be4-b113-78ad4a359a84" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="ife2cdbcfdeaa4733b931bd32e3877cd8_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b2a5762b-6d13-4992-8913-c5c4ff7b7e56" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b2a5762b-6d13-4992-8913-c5c4ff7b7e56" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_dc8a5a6c-38e9-4ce1-88a2-c086ef0599b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_dc8a5a6c-38e9-4ce1-88a2-c086ef0599b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_eda3c94c-e57e-4c52-b110-9769b75bd5f6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_eda3c94c-e57e-4c52-b110-9769b75bd5f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_a7ac1d75-63ce-419a-972f-3ace9393c76b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_a7ac1d75-63ce-419a-972f-3ace9393c76b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_4ca0752c-a0eb-43b5-a3be-fcfa245036d9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_4ca0752c-a0eb-43b5-a3be-fcfa245036d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_42a93dda-2ac6-41ba-8f05-23fbef8d64d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2393f9df-82b0-4482-ae60-d2883c1572fd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b2a5762b-6d13-4992-8913-c5c4ff7b7e56" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2393f9df-82b0-4482-ae60-d2883c1572fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4dbb3db-bfcc-4df6-9201-1e9cdd404243" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2393f9df-82b0-4482-ae60-d2883c1572fd" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4dbb3db-bfcc-4df6-9201-1e9cdd404243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_b4dbb3db-bfcc-4df6-9201-1e9cdd404243_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4dbb3db-bfcc-4df6-9201-1e9cdd404243" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_b4dbb3db-bfcc-4df6-9201-1e9cdd404243_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4dbb3db-bfcc-4df6-9201-1e9cdd404243" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_d015d0bf-20ee-410c-b4f0-8088cc059c24" xlink:href="oncyf-20211231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:to="loc_oncyf_MedicalEquipmentMember_d015d0bf-20ee-410c-b4f0-8088cc059c24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_58b10751-3e08-4d2c-9314-754a61775514" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:to="loc_ifrs-full_ComputerEquipmentMember_58b10751-3e08-4d2c-9314-754a61775514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember_1d2cf5ab-32d2-4d8f-9408-39a4744d2cb5" xlink:href="oncyf-20211231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:to="loc_oncyf_OfficeEquipmentAndFurnitureMember_1d2cf5ab-32d2-4d8f-9408-39a4744d2cb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_fe70fe1f-f0d9-4dea-b07f-c90bca1396ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_fe70fe1f-f0d9-4dea-b07f-c90bca1396ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1b22826d-d526-430d-8096-f566e93807da" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2393f9df-82b0-4482-ae60-d2883c1572fd" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1b22826d-d526-430d-8096-f566e93807da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_1b22826d-d526-430d-8096-f566e93807da_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1b22826d-d526-430d-8096-f566e93807da" xlink:to="loc_ifrs-full_CarryingAmountMember_1b22826d-d526-430d-8096-f566e93807da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_31c541d4-a124-4e2c-aa49-b6d871e3d924" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1b22826d-d526-430d-8096-f566e93807da" xlink:to="loc_ifrs-full_CarryingAmountMember_31c541d4-a124-4e2c-aa49-b6d871e3d924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_68331997-40e3-4cfa-bc7c-c589d802ef5e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_31c541d4-a124-4e2c-aa49-b6d871e3d924" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_68331997-40e3-4cfa-bc7c-c589d802ef5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_be95d3be-1a87-4062-b2ae-923606f69bac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_31c541d4-a124-4e2c-aa49-b6d871e3d924" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_be95d3be-1a87-4062-b2ae-923606f69bac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ic43b1bb590014c51b3d8fbbdb1f0fd90_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_d0991e37-3d96-4079-ba50-b196825c3ced" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm_718fa832-99e6-44a6-831a-8f4e632577fe" xlink:href="oncyf-20211231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_d0991e37-3d96-4079-ba50-b196825c3ced" xlink:to="loc_oncyf_OperatingLeaseRemainingLeaseTerm_718fa832-99e6-44a6-831a-8f4e632577fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_7027044a-bc6b-4fa0-a202-738f476254ba" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_d0991e37-3d96-4079-ba50-b196825c3ced" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_7027044a-bc6b-4fa0-a202-738f476254ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_dcf59cf0-e269-4e60-9d00-f80bb689f625" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_d0991e37-3d96-4079-ba50-b196825c3ced" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_dcf59cf0-e269-4e60-9d00-f80bb689f625" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_36e20e5e-f4e0-4616-97e3-1f25edb866b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_dcf59cf0-e269-4e60-9d00-f80bb689f625" xlink:to="loc_srt_RangeAxis_36e20e5e-f4e0-4616-97e3-1f25edb866b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36e20e5e-f4e0-4616-97e3-1f25edb866b2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_36e20e5e-f4e0-4616-97e3-1f25edb866b2" xlink:to="loc_srt_RangeMember_36e20e5e-f4e0-4616-97e3-1f25edb866b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6c24378-e062-4cb8-98e5-26e7bbfdb106" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_36e20e5e-f4e0-4616-97e3-1f25edb866b2" xlink:to="loc_srt_RangeMember_b6c24378-e062-4cb8-98e5-26e7bbfdb106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d8a38308-781a-4ad6-b7f2-81de735ccb30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b6c24378-e062-4cb8-98e5-26e7bbfdb106" xlink:to="loc_srt_MinimumMember_d8a38308-781a-4ad6-b7f2-81de735ccb30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0098b653-aa24-442d-b5ea-dc93069cb76d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b6c24378-e062-4cb8-98e5-26e7bbfdb106" xlink:to="loc_srt_MaximumMember_0098b653-aa24-442d-b5ea-dc93069cb76d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended" id="ifc632042c1f74f609adfe2daca8ff93e_LeasesTotalUndiscountedLeaseLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_32a12544-8fda-41c7-95fa-853be2a3523e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_e91232ed-f7ca-4ad4-b37e-831b4d68aa25" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_32a12544-8fda-41c7-95fa-853be2a3523e" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_e91232ed-f7ca-4ad4-b37e-831b4d68aa25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_94539a1b-ae42-4539-8628-abff395dab99" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_32a12544-8fda-41c7-95fa-853be2a3523e" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_94539a1b-ae42-4539-8628-abff395dab99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_3629b37d-75ff-4a05-aed5-9834f506b93f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_94539a1b-ae42-4539-8628-abff395dab99" xlink:to="loc_ifrs-full_MaturityAxis_3629b37d-75ff-4a05-aed5-9834f506b93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_3629b37d-75ff-4a05-aed5-9834f506b93f_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_3629b37d-75ff-4a05-aed5-9834f506b93f" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_3629b37d-75ff-4a05-aed5-9834f506b93f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1c7fa407-3d0a-4a4b-99dd-d000c4152c94" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_3629b37d-75ff-4a05-aed5-9834f506b93f" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1c7fa407-3d0a-4a4b-99dd-d000c4152c94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_24b88176-e96d-46cb-a73a-3b3b5d5a342e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1c7fa407-3d0a-4a4b-99dd-d000c4152c94" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_24b88176-e96d-46cb-a73a-3b3b5d5a342e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_6bc69343-4277-4098-8d37-6d2cef5ddea6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1c7fa407-3d0a-4a4b-99dd-d000c4152c94" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_6bc69343-4277-4098-8d37-6d2cef5ddea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_8d5e0e45-cfe3-4fa3-9767-c98289f79267" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1c7fa407-3d0a-4a4b-99dd-d000c4152c94" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_8d5e0e45-cfe3-4fa3-9767-c98289f79267" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#WarrantDerivativeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended" id="i7dc8d30b82904910bab04575fdbacec2_WarrantDerivativeNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_31b6018e-3548-4d26-acb8-f1b0be979265" xlink:href="oncyf-20211231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_IssueOfEquityShares_31b6018e-3548-4d26-acb8-f1b0be979265" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_698b867b-2b33-405a-8e85-a5367fc0667d" xlink:href="oncyf-20211231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_698b867b-2b33-405a-8e85-a5367fc0667d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_8a77d21b-69b9-4e42-b8f9-2e5da8065c78" xlink:href="oncyf-20211231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_8a77d21b-69b9-4e42-b8f9-2e5da8065c78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_166572c8-764f-45a1-bb3a-efe840bbf405" xlink:href="oncyf-20211231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_CommonSharesPerUnit_166572c8-764f-45a1-bb3a-efe840bbf405" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_6e7baeec-7fca-401c-a402-747c390307a5" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_6e7baeec-7fca-401c-a402-747c390307a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_236c61cd-164e-447e-a16d-9e8701ac89b8" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_236c61cd-164e-447e-a16d-9e8701ac89b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_f210215a-8336-406d-a0f7-e091854dfed3" xlink:href="oncyf-20211231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_f210215a-8336-406d-a0f7-e091854dfed3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_c183e0bb-21d8-4356-ba17-50d78902b251" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_c183e0bb-21d8-4356-ba17-50d78902b251" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e5f7af88-9ab8-4b6c-955b-cb42c0605443" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_c183e0bb-21d8-4356-ba17-50d78902b251" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e5f7af88-9ab8-4b6c-955b-cb42c0605443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_e5f7af88-9ab8-4b6c-955b-cb42c0605443_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e5f7af88-9ab8-4b6c-955b-cb42c0605443" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_e5f7af88-9ab8-4b6c-955b-cb42c0605443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_06d916cf-fc3f-46d3-87fa-af0bad1a9282" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e5f7af88-9ab8-4b6c-955b-cb42c0605443" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_06d916cf-fc3f-46d3-87fa-af0bad1a9282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_2c0098e4-7a0e-4000-b05a-a82247526b1e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_06d916cf-fc3f-46d3-87fa-af0bad1a9282" xlink:to="loc_ifrs-full_IssuedCapitalMember_2c0098e4-7a0e-4000-b05a-a82247526b1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_09bb1c51-3769-4289-a005-61edca1ac9b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_c183e0bb-21d8-4356-ba17-50d78902b251" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_09bb1c51-3769-4289-a005-61edca1ac9b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_09bb1c51-3769-4289-a005-61edca1ac9b5_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_09bb1c51-3769-4289-a005-61edca1ac9b5" xlink:to="loc_ifrs-full_LiabilitiesMember_09bb1c51-3769-4289-a005-61edca1ac9b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_c8af01e6-efae-4368-a366-2faed66ee812" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_09bb1c51-3769-4289-a005-61edca1ac9b5" xlink:to="loc_ifrs-full_LiabilitiesMember_c8af01e6-efae-4368-a366-2faed66ee812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_798e9730-487e-46e9-8402-fb477ac1e466" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_c8af01e6-efae-4368-a366-2faed66ee812" xlink:to="loc_oncyf_WarrantsMember_798e9730-487e-46e9-8402-fb477ac1e466" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_ae993ff3-3dac-4206-89a0-9d244bfee72e" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_c183e0bb-21d8-4356-ba17-50d78902b251" xlink:to="loc_oncyf_SaleOfStockAxis_ae993ff3-3dac-4206-89a0-9d244bfee72e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_ae993ff3-3dac-4206-89a0-9d244bfee72e_default" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_ae993ff3-3dac-4206-89a0-9d244bfee72e" xlink:to="loc_oncyf_SaleOfStockDomain_ae993ff3-3dac-4206-89a0-9d244bfee72e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_a16f35de-5190-4f9e-b843-019c1fa625bc" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_ae993ff3-3dac-4206-89a0-9d244bfee72e" xlink:to="loc_oncyf_SaleOfStockDomain_a16f35de-5190-4f9e-b843-019c1fa625bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_fd2b2ea0-53cb-4c99-a4b9-4dfb15167adb" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_a16f35de-5190-4f9e-b843-019c1fa625bc" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_fd2b2ea0-53cb-4c99-a4b9-4dfb15167adb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="extended" id="ia1a48c43310e477dabc4937c10296322_WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_93530283-8bb7-40a9-acc8-a5c4f5032795" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward_bd74537d-5cc8-4b4c-b918-941044fd3878" xlink:href="oncyf-20211231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_93530283-8bb7-40a9-acc8-a5c4f5032795" xlink:to="loc_oncyf_NumberOfWarrantsOutstandingRollForward_bd74537d-5cc8-4b4c-b918-941044fd3878" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_c3d2753f-0d30-47b8-afc6-0834f78b45e4" xlink:href="oncyf-20211231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_bd74537d-5cc8-4b4c-b918-941044fd3878" xlink:to="loc_oncyf_ClassOfWarrantOrRightOutstanding1_c3d2753f-0d30-47b8-afc6-0834f78b45e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_560b4630-a811-4121-9e99-7afe41dd6bf2" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_bd74537d-5cc8-4b4c-b918-941044fd3878" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_560b4630-a811-4121-9e99-7afe41dd6bf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_17d24c49-b1d0-4f38-ac4b-433238e139ab" xlink:href="oncyf-20211231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:href="oncyf-20211231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_93530283-8bb7-40a9-acc8-a5c4f5032795" xlink:to="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_06ea002f-b3f6-455f-8701-98097de807ad" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_06ea002f-b3f6-455f-8701-98097de807ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_762a3431-8efa-4b10-bd4a-d20305e43cc4" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_762a3431-8efa-4b10-bd4a-d20305e43cc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_68b5c476-249f-4ad9-8909-4153c7b82847" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_68b5c476-249f-4ad9-8909-4153c7b82847" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact_69f0528a-1d6f-4277-a6e3-545b3574bf2d" xlink:href="oncyf-20211231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:to="loc_oncyf_GainsLossesFromForeignExchangeImpact_69f0528a-1d6f-4277-a6e3-545b3574bf2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_b1260dda-cec4-4904-8128-f831b47ea16a" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_18711cd9-ca2b-4e15-ab9b-d7847e93d96f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_93530283-8bb7-40a9-acc8-a5c4f5032795" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_18711cd9-ca2b-4e15-ab9b-d7847e93d96f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_a00a8961-7d51-484f-b5b3-eb1a44ee4d3e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_18711cd9-ca2b-4e15-ab9b-d7847e93d96f" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_a00a8961-7d51-484f-b5b3-eb1a44ee4d3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_a00a8961-7d51-484f-b5b3-eb1a44ee4d3e_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_a00a8961-7d51-484f-b5b3-eb1a44ee4d3e" xlink:to="loc_ifrs-full_LiabilitiesMember_a00a8961-7d51-484f-b5b3-eb1a44ee4d3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_882bc8f8-372b-4222-9db1-d79ca67ea778" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_a00a8961-7d51-484f-b5b3-eb1a44ee4d3e" xlink:to="loc_ifrs-full_LiabilitiesMember_882bc8f8-372b-4222-9db1-d79ca67ea778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_28ba617b-82da-4bd2-9cab-95489785eac9" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_882bc8f8-372b-4222-9db1-d79ca67ea778" xlink:to="loc_oncyf_WarrantsMember_28ba617b-82da-4bd2-9cab-95489785eac9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="extended" id="ie79cc578ea424c99a6d0dafa48548dd0_WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueofWarrantIssuedPerWarrant_59f8520d-217d-4b78-ad94-2a0d6f8b9001" xlink:href="oncyf-20211231.xsd#oncyf_FairValueofWarrantIssuedPerWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_oncyf_FairValueofWarrantIssuedPerWarrant_59f8520d-217d-4b78-ad94-2a0d6f8b9001" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantIssuedUnderlyingSharePrice_3bf04928-adf0-4ebf-82a0-458e82df4b53" xlink:href="oncyf-20211231.xsd#oncyf_WarrantIssuedUnderlyingSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_oncyf_WarrantIssuedUnderlyingSharePrice_3bf04928-adf0-4ebf-82a0-458e82df4b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_ad3d6ac9-f6e0-435f-a6a1-44eb5aae3812" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_ad3d6ac9-f6e0-435f-a6a1-44eb5aae3812" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_5e0b796b-210d-41ec-b47a-6739714b6fe5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_5e0b796b-210d-41ec-b47a-6739714b6fe5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_73a67052-2612-4987-8dd6-9b37814446ca" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_73a67052-2612-4987-8dd6-9b37814446ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DividendYieldPercent_fcfa0090-d4a2-4fca-81a2-3ff2c86c758f" xlink:href="oncyf-20211231.xsd#oncyf_DividendYieldPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_oncyf_DividendYieldPercent_fcfa0090-d4a2-4fca-81a2-3ff2c86c758f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_16055177-5abe-4064-ae9a-cdf1350509c2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_16055177-5abe-4064-ae9a-cdf1350509c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_06b6eff1-f85e-4f50-ad1b-e32ee06eaaea" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_16055177-5abe-4064-ae9a-cdf1350509c2" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_06b6eff1-f85e-4f50-ad1b-e32ee06eaaea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_06b6eff1-f85e-4f50-ad1b-e32ee06eaaea_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_06b6eff1-f85e-4f50-ad1b-e32ee06eaaea" xlink:to="loc_ifrs-full_LiabilitiesMember_06b6eff1-f85e-4f50-ad1b-e32ee06eaaea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_363c8a63-b6d2-4a14-8506-5a1e518faf9a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_06b6eff1-f85e-4f50-ad1b-e32ee06eaaea" xlink:to="loc_ifrs-full_LiabilitiesMember_363c8a63-b6d2-4a14-8506-5a1e518faf9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_6da01ca2-a9de-43f1-b0da-b76f751ac6f6" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_363c8a63-b6d2-4a14-8506-5a1e518faf9a" xlink:to="loc_oncyf_WarrantsMember_6da01ca2-a9de-43f1-b0da-b76f751ac6f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareCapitalScheduleofShareCapitalDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="extended" id="ibff01f3867ed49b69ac884aa988c9458_ShareCapitalScheduleofShareCapitalDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_359ca975-a7ac-4960-a3f1-c9c979c39ba6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract_2bc3eb25-ed3f-4953-994c-de5d60ab9851" xlink:href="oncyf-20211231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_359ca975-a7ac-4960-a3f1-c9c979c39ba6" xlink:to="loc_oncyf_ShareCapitalNumberSharesAbstract_2bc3eb25-ed3f-4953-994c-de5d60ab9851" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_b0e516a6-e3d3-4d77-ab76-11945bd74928" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_2bc3eb25-ed3f-4953-994c-de5d60ab9851" xlink:to="loc_ifrs-full_NumberOfSharesIssued_b0e516a6-e3d3-4d77-ab76-11945bd74928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_142ea693-faf7-4afb-9bbc-a1fb2465363e" xlink:href="oncyf-20211231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_2bc3eb25-ed3f-4953-994c-de5d60ab9851" xlink:to="loc_oncyf_IssueOfEquityShares_142ea693-faf7-4afb-9bbc-a1fb2465363e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_350a2d8f-4795-4e59-ac4f-483899aeaa3c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract_9dafea75-fa8f-4fd8-b96f-aca58624edf8" xlink:href="oncyf-20211231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_359ca975-a7ac-4960-a3f1-c9c979c39ba6" xlink:to="loc_oncyf_ShareCapitalAmountAbstract_9dafea75-fa8f-4fd8-b96f-aca58624edf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_c8dfdd65-77e8-4dab-bba3-d75dd86a8f78" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_9dafea75-fa8f-4fd8-b96f-aca58624edf8" xlink:to="loc_ifrs-full_Equity_c8dfdd65-77e8-4dab-bba3-d75dd86a8f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_2edfdf4f-c13c-4a5e-90ea-7fe2a9ba66d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_9dafea75-fa8f-4fd8-b96f-aca58624edf8" xlink:to="loc_ifrs-full_IssueOfEquity_2edfdf4f-c13c-4a5e-90ea-7fe2a9ba66d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_e44fdbc9-c27f-43b4-a09b-3c89354b7d0d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_9dafea75-fa8f-4fd8-b96f-aca58624edf8" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_e44fdbc9-c27f-43b4-a09b-3c89354b7d0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_e160dddc-450f-4ecf-9697-8b6e7cbc2a79" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2603ed61-2017-456e-bd2e-7978679fc2c8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_359ca975-a7ac-4960-a3f1-c9c979c39ba6" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2603ed61-2017-456e-bd2e-7978679fc2c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_638e93de-3682-4f37-a938-bdc78af8de01" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2603ed61-2017-456e-bd2e-7978679fc2c8" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_638e93de-3682-4f37-a938-bdc78af8de01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_638e93de-3682-4f37-a938-bdc78af8de01_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_638e93de-3682-4f37-a938-bdc78af8de01" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_638e93de-3682-4f37-a938-bdc78af8de01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_deb8fa62-9513-45dd-ae7b-bf08d4de8329" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_638e93de-3682-4f37-a938-bdc78af8de01" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_deb8fa62-9513-45dd-ae7b-bf08d4de8329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_6c9be3ba-e7d6-438d-8c93-17f8af9b09d8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_deb8fa62-9513-45dd-ae7b-bf08d4de8329" xlink:to="loc_ifrs-full_IssuedCapitalMember_6c9be3ba-e7d6-438d-8c93-17f8af9b09d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_01e1672b-3077-4cbf-b2d1-01f0e8ee7b0a" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2603ed61-2017-456e-bd2e-7978679fc2c8" xlink:to="loc_oncyf_SaleOfStockAxis_01e1672b-3077-4cbf-b2d1-01f0e8ee7b0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_01e1672b-3077-4cbf-b2d1-01f0e8ee7b0a_default" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_01e1672b-3077-4cbf-b2d1-01f0e8ee7b0a" xlink:to="loc_oncyf_SaleOfStockDomain_01e1672b-3077-4cbf-b2d1-01f0e8ee7b0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_01e1672b-3077-4cbf-b2d1-01f0e8ee7b0a" xlink:to="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_b0fecd2a-3a6a-4915-80e7-80f8c1fb3dbf" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_b0fecd2a-3a6a-4915-80e7-80f8c1fb3dbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_29225585-76ec-4c73-b9bc-6123e53a0c44" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_29225585-76ec-4c73-b9bc-6123e53a0c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_db84a673-d9d3-43b6-81aa-a03be8636bb7" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_db84a673-d9d3-43b6-81aa-a03be8636bb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_a6b2b4c0-e23f-4ac3-9457-44578b524d70" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:to="loc_oncyf_SharesPublicOfferingMember_a6b2b4c0-e23f-4ac3-9457-44578b524d70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_e284f57d-b875-4019-b86b-0e3c31f3ffd9" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SharesPublicOfferingMember_a6b2b4c0-e23f-4ac3-9457-44578b524d70" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_e284f57d-b875-4019-b86b-0e3c31f3ffd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_7668c660-ecc2-40b1-a70f-f61963311b59" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_7668c660-ecc2-40b1-a70f-f61963311b59" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareCapitalScheduleofShareCapitalFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="extended" id="i42cd33b3310f488db65bdb930cba9b68_ShareCapitalScheduleofShareCapitalFootnotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_09068e96-8dc5-47a7-bd72-6f5a45b148e7" xlink:href="oncyf-20211231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_09068e96-8dc5-47a7-bd72-6f5a45b148e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_628b320c-9f00-4201-8dfa-1e71bc1620c5" xlink:href="oncyf-20211231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_628b320c-9f00-4201-8dfa-1e71bc1620c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_396178b7-ec58-4459-ab41-a27a5a6c2adf" xlink:href="oncyf-20211231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_IssueOfEquityShares_396178b7-ec58-4459-ab41-a27a5a6c2adf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_9c1c5313-e6d7-4e0a-80c7-ec9b207ed866" xlink:href="oncyf-20211231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_9c1c5313-e6d7-4e0a-80c7-ec9b207ed866" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_85819205-2f5b-4de7-bbf0-37a4abbf5da6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_85819205-2f5b-4de7-bbf0-37a4abbf5da6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_2cb5fe58-b596-4a3a-9a1c-cf4ed4795960" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_2cb5fe58-b596-4a3a-9a1c-cf4ed4795960" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_07618e90-cf67-4e72-96d2-6676790ec717" xlink:href="oncyf-20211231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_07618e90-cf67-4e72-96d2-6676790ec717" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_dff99c9f-34f1-4ed1-86db-67da47b45e7a" xlink:href="oncyf-20211231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_dff99c9f-34f1-4ed1-86db-67da47b45e7a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_ff87cbdd-a5f7-472e-b0e9-b6aeefa9de86" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_ff87cbdd-a5f7-472e-b0e9-b6aeefa9de86" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_3db6e1c5-fb41-4f2b-99e9-ce2185ed8d27" xlink:href="oncyf-20211231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_CommonSharesPerUnit_3db6e1c5-fb41-4f2b-99e9-ce2185ed8d27" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedFairValueOfCommonShare_569a6531-742a-414f-a5ef-31d97d94d86b" xlink:href="oncyf-20211231.xsd#oncyf_SharesIssuedFairValueOfCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_SharesIssuedFairValueOfCommonShare_569a6531-742a-414f-a5ef-31d97d94d86b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_270ae9f8-fa93-4e7f-a73a-93359792bbcf" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_270ae9f8-fa93-4e7f-a73a-93359792bbcf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_aaa81a66-7d4a-4717-9d16-de059bc83cde" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_aaa81a66-7d4a-4717-9d16-de059bc83cde" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_754c60fd-0474-4fd1-99ac-e30c9b5e2d64" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_754c60fd-0474-4fd1-99ac-e30c9b5e2d64" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_90488778-6c5f-438b-b26c-b8003dcff6bd" xlink:href="oncyf-20211231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_90488778-6c5f-438b-b26c-b8003dcff6bd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_dadea136-b3bb-48d5-8ba2-bf881b84acea" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_dadea136-b3bb-48d5-8ba2-bf881b84acea" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_eb2855c1-089f-493c-9991-8fa543efb243" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_eb2855c1-089f-493c-9991-8fa543efb243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_eb2855c1-089f-493c-9991-8fa543efb243_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_eb2855c1-089f-493c-9991-8fa543efb243" xlink:to="loc_ifrs-full_LiabilitiesMember_eb2855c1-089f-493c-9991-8fa543efb243_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_714bf32a-a734-4ad7-80af-9bc80d5e2a22" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_eb2855c1-089f-493c-9991-8fa543efb243" xlink:to="loc_ifrs-full_LiabilitiesMember_714bf32a-a734-4ad7-80af-9bc80d5e2a22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_005d80d7-910f-4585-b577-c57e14d2f34d" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_714bf32a-a734-4ad7-80af-9bc80d5e2a22" xlink:to="loc_oncyf_WarrantsMember_005d80d7-910f-4585-b577-c57e14d2f34d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_470f76fd-b46f-404b-862a-a3c1cc99bcf4" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:to="loc_oncyf_SaleOfStockAxis_470f76fd-b46f-404b-862a-a3c1cc99bcf4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_470f76fd-b46f-404b-862a-a3c1cc99bcf4_default" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_470f76fd-b46f-404b-862a-a3c1cc99bcf4" xlink:to="loc_oncyf_SaleOfStockDomain_470f76fd-b46f-404b-862a-a3c1cc99bcf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_470f76fd-b46f-404b-862a-a3c1cc99bcf4" xlink:to="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_e319b972-97bf-4e4a-8b51-aebc9fed3f4e" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_e319b972-97bf-4e4a-8b51-aebc9fed3f4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_fca4edfb-99cc-49e0-a6e5-85c384ddeaf3" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_fca4edfb-99cc-49e0-a6e5-85c384ddeaf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_2a2e2ecf-7624-48e6-aa28-42f13aab033c" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_2a2e2ecf-7624-48e6-aa28-42f13aab033c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_57d497c2-5a61-4942-ae23-72f030835a6f" xlink:href="oncyf-20211231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:to="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_57d497c2-5a61-4942-ae23-72f030835a6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_ee22ea75-a327-4d3b-baf5-d9ce4be43a5f" xlink:href="oncyf-20211231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:to="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_ee22ea75-a327-4d3b-baf5-d9ce4be43a5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_b184ba74-e648-4ba7-9416-70a601930a2c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_b184ba74-e648-4ba7-9416-70a601930a2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_b184ba74-e648-4ba7-9416-70a601930a2c_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_b184ba74-e648-4ba7-9416-70a601930a2c" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_b184ba74-e648-4ba7-9416-70a601930a2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_dd54564e-10db-400f-9ab3-65edb2777a00" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_b184ba74-e648-4ba7-9416-70a601930a2c" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_dd54564e-10db-400f-9ab3-65edb2777a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_1991b8c4-9b76-4d87-8f52-c565858876f2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_dd54564e-10db-400f-9ab3-65edb2777a00" xlink:to="loc_ifrs-full_IssuedCapitalMember_1991b8c4-9b76-4d87-8f52-c565858876f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember_ca3086ec-c2c4-4e86-8069-87ca5ebd1f74" xlink:href="oncyf-20211231.xsd#oncyf_IssuedCapitalExcludingCommitmentSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IssuedCapitalMember_1991b8c4-9b76-4d87-8f52-c565858876f2" xlink:to="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember_ca3086ec-c2c4-4e86-8069-87ca5ebd1f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentSharesMember_d6cbe656-08a2-4790-b92e-43aabea623be" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IssuedCapitalMember_1991b8c4-9b76-4d87-8f52-c565858876f2" xlink:to="loc_oncyf_CommitmentSharesMember_d6cbe656-08a2-4790-b92e-43aabea623be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_8f3bd97b-315e-45a0-9f70-3faec4ba87d8" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_dd54564e-10db-400f-9ab3-65edb2777a00" xlink:to="loc_oncyf_WarrantsMember_8f3bd97b-315e-45a0-9f70-3faec4ba87d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_e8654333-cc95-4b59-b903-113ded661029" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_e8654333-cc95-4b59-b903-113ded661029" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_e8654333-cc95-4b59-b903-113ded661029_default" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_e8654333-cc95-4b59-b903-113ded661029" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_e8654333-cc95-4b59-b903-113ded661029_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_a8c46342-7d54-4c60-9657-0a9948e5401f" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_e8654333-cc95-4b59-b903-113ded661029" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_a8c46342-7d54-4c60-9657-0a9948e5401f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingExpensesMember_6eaf2a22-9f90-4542-92de-bf3f40188add" xlink:href="oncyf-20211231.xsd#oncyf_OperatingExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_a8c46342-7d54-4c60-9657-0a9948e5401f" xlink:to="loc_oncyf_OperatingExpensesMember_6eaf2a22-9f90-4542-92de-bf3f40188add" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareCapitalEquityWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="extended" id="i9485ad136a8345a49d0dd94fb65a9386_ShareCapitalEquityWarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_adf7d535-4378-4865-948d-622e50aeec53" xlink:href="oncyf-20211231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_IssueOfEquityShares_adf7d535-4378-4865-948d-622e50aeec53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_b87f4219-0c56-4c3f-8e71-313d09818864" xlink:href="oncyf-20211231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_b87f4219-0c56-4c3f-8e71-313d09818864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_71eb242d-5331-47f2-859e-58200a6dec40" xlink:href="oncyf-20211231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_CommonSharesPerUnit_71eb242d-5331-47f2-859e-58200a6dec40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_3ecac747-9820-4450-8703-eb404d612379" xlink:href="oncyf-20211231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_CommonSharePurchaseWarrantPerUnit_3ecac747-9820-4450-8703-eb404d612379" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_041253d7-8851-4b6b-b0a4-40ccc9e27ce5" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_041253d7-8851-4b6b-b0a4-40ccc9e27ce5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_61153b2f-f988-42f8-b718-e0a03636756c" xlink:href="oncyf-20211231.xsd#oncyf_StockholdersEquityNoteStockSplitConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_61153b2f-f988-42f8-b718-e0a03636756c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_99357631-f94c-449f-8203-40a6bdc4fdd9" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_99357631-f94c-449f-8203-40a6bdc4fdd9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_1a61de2b-40ea-45e1-8eb3-884e60b5d2a7" xlink:href="oncyf-20211231.xsd#oncyf_SharesIssuedWarrantPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_SharesIssuedWarrantPricePerShare_1a61de2b-40ea-45e1-8eb3-884e60b5d2a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e86a8835-766b-4e3b-894d-76c3696e5885" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e86a8835-766b-4e3b-894d-76c3696e5885" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_d96f0340-2519-44a3-8253-b9f98dbb0a82" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e86a8835-766b-4e3b-894d-76c3696e5885" xlink:to="loc_oncyf_SaleOfStockAxis_d96f0340-2519-44a3-8253-b9f98dbb0a82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_d96f0340-2519-44a3-8253-b9f98dbb0a82_default" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_d96f0340-2519-44a3-8253-b9f98dbb0a82" xlink:to="loc_oncyf_SaleOfStockDomain_d96f0340-2519-44a3-8253-b9f98dbb0a82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_034ab60c-7ecd-4926-ba50-814607cebc5f" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_d96f0340-2519-44a3-8253-b9f98dbb0a82" xlink:to="loc_oncyf_SaleOfStockDomain_034ab60c-7ecd-4926-ba50-814607cebc5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_a6c81f90-ceea-4ff0-a650-3ee9adf1b695" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingEquityWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_034ab60c-7ecd-4926-ba50-814607cebc5f" xlink:to="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_a6c81f90-ceea-4ff0-a650-3ee9adf1b695" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareCapitalSummaryofOutstandingWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="extended" id="ie5033a1fc7d84fb09e92114bd14c3b64_ShareCapitalSummaryofOutstandingWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1d66d01e-724e-4c25-b443-4c39cedefd53" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_46484311-2ca8-4ff6-9742-28b925520e28" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1d66d01e-724e-4c25-b443-4c39cedefd53" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_46484311-2ca8-4ff6-9742-28b925520e28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_b013c52d-01f7-438f-8988-56a755a458e4" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1d66d01e-724e-4c25-b443-4c39cedefd53" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_b013c52d-01f7-438f-8988-56a755a458e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_ac73bab1-3c2e-4bcb-9b8f-08b4b6e74f04" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1d66d01e-724e-4c25-b443-4c39cedefd53" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_ac73bab1-3c2e-4bcb-9b8f-08b4b6e74f04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_fbe7f314-7ca0-4994-a9d7-ff4eefcb75ab" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1d66d01e-724e-4c25-b443-4c39cedefd53" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_fbe7f314-7ca0-4994-a9d7-ff4eefcb75ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_cec7742f-92da-4837-a2f2-f1fb5afb3ef7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_fbe7f314-7ca0-4994-a9d7-ff4eefcb75ab" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_cec7742f-92da-4837-a2f2-f1fb5afb3ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_cec7742f-92da-4837-a2f2-f1fb5afb3ef7_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cec7742f-92da-4837-a2f2-f1fb5afb3ef7" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_cec7742f-92da-4837-a2f2-f1fb5afb3ef7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_7f647896-867a-432c-a380-5144ed784b90" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cec7742f-92da-4837-a2f2-f1fb5afb3ef7" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_7f647896-867a-432c-a380-5144ed784b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_01c2340a-92e3-49ad-b9df-e647624807df" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_7f647896-867a-432c-a380-5144ed784b90" xlink:to="loc_oncyf_WarrantsMember_01c2340a-92e3-49ad-b9df-e647624807df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="extended" id="i21c5858089a74c42a192dd0905ffbf06_ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_376b9692-68fa-4fe6-acf3-eb04c47c77f6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_376b9692-68fa-4fe6-acf3-eb04c47c77f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_ddf4007e-da69-476b-9c75-16c4403b7f0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_ddf4007e-da69-476b-9c75-16c4403b7f0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_ef0585be-1884-4a6f-898c-36f0ae82e5d6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_ef0585be-1884-4a6f-898c-36f0ae82e5d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_5dd0e0d8-1060-45b2-a580-c404ebc2ea91" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_5dd0e0d8-1060-45b2-a580-c404ebc2ea91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_b25f0188-655e-4ad1-b891-8be70a349723" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_b25f0188-655e-4ad1-b891-8be70a349723" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_d4210900-de64-434f-aabe-2700428dce61" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_d4210900-de64-434f-aabe-2700428dce61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_a9e14a32-4028-4214-9157-7d85daab3f04" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_a9e14a32-4028-4214-9157-7d85daab3f04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1c856d97-8b0b-40a5-8353-b699250bb100" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_a9e14a32-4028-4214-9157-7d85daab3f04" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1c856d97-8b0b-40a5-8353-b699250bb100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_1c856d97-8b0b-40a5-8353-b699250bb100_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1c856d97-8b0b-40a5-8353-b699250bb100" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_1c856d97-8b0b-40a5-8353-b699250bb100_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1c856d97-8b0b-40a5-8353-b699250bb100" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_0518ecb1-20df-4a09-ba99-ae9250e850f3" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_0518ecb1-20df-4a09-ba99-ae9250e850f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_868de419-ccb1-4781-a513-f3f99a4e530a" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_868de419-ccb1-4781-a513-f3f99a4e530a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_5388d1b8-dafc-4791-b6a1-7c09e91a339f" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_5388d1b8-dafc-4791-b6a1-7c09e91a339f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_f76cba78-d0d7-4025-90ea-b72139e8269f" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_f76cba78-d0d7-4025-90ea-b72139e8269f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_dac6865c-1a22-425e-98a7-d5235ce39b93" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_dac6865c-1a22-425e-98a7-d5235ce39b93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_093d4115-a617-4d69-9910-43c05e7c253e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_a9e14a32-4028-4214-9157-7d85daab3f04" xlink:to="loc_ifrs-full_RangeAxis_093d4115-a617-4d69-9910-43c05e7c253e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_093d4115-a617-4d69-9910-43c05e7c253e_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_093d4115-a617-4d69-9910-43c05e7c253e" xlink:to="loc_ifrs-full_RangesMember_093d4115-a617-4d69-9910-43c05e7c253e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_bc991ad7-9a70-47ed-afdd-af411ecc3719" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_093d4115-a617-4d69-9910-43c05e7c253e" xlink:to="loc_ifrs-full_RangesMember_bc991ad7-9a70-47ed-afdd-af411ecc3719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_fe643339-49ec-4da2-8362-c2934bc21ef1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_bc991ad7-9a70-47ed-afdd-af411ecc3719" xlink:to="loc_ifrs-full_BottomOfRangeMember_fe643339-49ec-4da2-8362-c2934bc21ef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_300e1c73-a18e-43a0-8b1e-4cb6ba950987" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_bc991ad7-9a70-47ed-afdd-af411ecc3719" xlink:to="loc_ifrs-full_TopOfRangeMember_300e1c73-a18e-43a0-8b1e-4cb6ba950987" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="ibd4dfea0f6894e1e8e9c59ba35ebb194_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_38ccb631-8ea8-4675-9f1e-96cc5e6f4a4a" xlink:href="oncyf-20211231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_38ccb631-8ea8-4675-9f1e-96cc5e6f4a4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod_be28f160-2267-4f3a-a773-bbcf01a370c4" xlink:href="oncyf-20211231.xsd#oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:to="loc_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod_be28f160-2267-4f3a-a773-bbcf01a370c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9ba87a49-821d-4c3f-bb1c-54cd97b48b64" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9ba87a49-821d-4c3f-bb1c-54cd97b48b64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7dfeb586-5676-401a-b30e-9300f2972cf7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7dfeb586-5676-401a-b30e-9300f2972cf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_fe90ed0a-9ed5-44cf-bc77-32b8f2d9c5a9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_fe90ed0a-9ed5-44cf-bc77-32b8f2d9c5a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_20430f7e-8e29-482e-b8c4-59317c005d5c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_fe90ed0a-9ed5-44cf-bc77-32b8f2d9c5a9" xlink:to="loc_ifrs-full_RangeAxis_20430f7e-8e29-482e-b8c4-59317c005d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_20430f7e-8e29-482e-b8c4-59317c005d5c_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_20430f7e-8e29-482e-b8c4-59317c005d5c" xlink:to="loc_ifrs-full_RangesMember_20430f7e-8e29-482e-b8c4-59317c005d5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_5e621a52-607f-4167-b1af-fdc83d0c66dc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_20430f7e-8e29-482e-b8c4-59317c005d5c" xlink:to="loc_ifrs-full_RangesMember_5e621a52-607f-4167-b1af-fdc83d0c66dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_b65a719c-ab05-4eb3-8c24-44b356777fe6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_5e621a52-607f-4167-b1af-fdc83d0c66dc" xlink:to="loc_ifrs-full_BottomOfRangeMember_b65a719c-ab05-4eb3-8c24-44b356777fe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_fd01e0ff-220c-41b4-b086-6cbe86c54c48" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_5e621a52-607f-4167-b1af-fdc83d0c66dc" xlink:to="loc_ifrs-full_TopOfRangeMember_fd01e0ff-220c-41b4-b086-6cbe86c54c48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_510d753a-d386-47a6-800d-f23529de0745" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_fe90ed0a-9ed5-44cf-bc77-32b8f2d9c5a9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_510d753a-d386-47a6-800d-f23529de0745" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_510d753a-d386-47a6-800d-f23529de0745_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_510d753a-d386-47a6-800d-f23529de0745" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_510d753a-d386-47a6-800d-f23529de0745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_5ea6e772-89c4-4b76-81f8-8e621bbad808" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_510d753a-d386-47a6-800d-f23529de0745" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_5ea6e772-89c4-4b76-81f8-8e621bbad808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_198e42c6-8323-40b8-b1a9-bc772b06aa94" xlink:href="oncyf-20211231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5ea6e772-89c4-4b76-81f8-8e621bbad808" xlink:to="loc_oncyf_RestrictedShareUnitsMember_198e42c6-8323-40b8-b1a9-bc772b06aa94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PerformanceShareUnitsMember_6e1530d4-fa39-4e01-8676-2af558214fc3" xlink:href="oncyf-20211231.xsd#oncyf_PerformanceShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5ea6e772-89c4-4b76-81f8-8e621bbad808" xlink:to="loc_oncyf_PerformanceShareUnitsMember_6e1530d4-fa39-4e01-8676-2af558214fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_bd36daa2-1a61-4113-b203-23a60a715d20" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5ea6e772-89c4-4b76-81f8-8e621bbad808" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_bd36daa2-1a61-4113-b203-23a60a715d20" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="extended" id="i482aca2279e741d69990e3c504c0b0b8_ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7d25f7a9-5fb7-4f49-96fa-d181c64a0752" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7d25f7a9-5fb7-4f49-96fa-d181c64a0752" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_a191de7c-8daf-4208-8705-a0fed2b3d2f5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_a191de7c-8daf-4208-8705-a0fed2b3d2f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_587cc2a9-cf4f-4edc-893c-d965d05296d9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_587cc2a9-cf4f-4edc-893c-d965d05296d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_9ee79110-4593-40ec-9c85-c77b586b5c6c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_2e21395e-99e7-4679-91c8-4e8d507ba9da" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_2e21395e-99e7-4679-91c8-4e8d507ba9da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a4caca5b-3e10-4206-8188-870484514429" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a4caca5b-3e10-4206-8188-870484514429" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0f2cde5-7804-422f-b079-c8437d219a53" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a4caca5b-3e10-4206-8188-870484514429" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0f2cde5-7804-422f-b079-c8437d219a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0f2cde5-7804-422f-b079-c8437d219a53_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0f2cde5-7804-422f-b079-c8437d219a53" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0f2cde5-7804-422f-b079-c8437d219a53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_7298f6ce-5e9c-4246-a808-9db28c245e96" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0f2cde5-7804-422f-b079-c8437d219a53" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_7298f6ce-5e9c-4246-a808-9db28c245e96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_6de02edb-fde2-497b-bcb4-3f53fc68fc45" xlink:href="oncyf-20211231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7298f6ce-5e9c-4246-a808-9db28c245e96" xlink:to="loc_oncyf_RestrictedShareUnitsMember_6de02edb-fde2-497b-bcb4-3f53fc68fc45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PerformanceShareUnitsMember_451059fa-bea2-4f2a-abb8-e9ee5e6ae80a" xlink:href="oncyf-20211231.xsd#oncyf_PerformanceShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7298f6ce-5e9c-4246-a808-9db28c245e96" xlink:to="loc_oncyf_PerformanceShareUnitsMember_451059fa-bea2-4f2a-abb8-e9ee5e6ae80a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="extended" id="i57f2bc66c4b44dcd8acc5a9998e03038_CommitmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1_dd9ce963-4d71-46f4-82cd-c5bd9f7e026f" xlink:href="oncyf-20211231.xsd#oncyf_PurchaseObligation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_PurchaseObligation1_dd9ce963-4d71-46f4-82cd-c5bd9f7e026f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm_8978a28d-b243-421d-b6c8-4490b99d9be1" xlink:href="oncyf-20211231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_PurchaseObligationCommitmentTerm_8978a28d-b243-421d-b6c8-4490b99d9be1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_3ae111ae-c490-40ec-8880-b79021a8bad4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_ifrs-full_OtherReceivables_3ae111ae-c490-40ec-8880-b79021a8bad4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_65013b26-e117-4f17-8529-8dcbca9031a2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_65013b26-e117-4f17-8529-8dcbca9031a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FundedandRoyaltyRepayment_3424c76e-6822-4185-8654-2bd9c02b1fba" xlink:href="oncyf-20211231.xsd#oncyf_FundedandRoyaltyRepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_FundedandRoyaltyRepayment_3424c76e-6822-4185-8654-2bd9c02b1fba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OverheadRepayment_299e1d02-7be2-43ac-a78b-bdd48e20d85f" xlink:href="oncyf-20211231.xsd#oncyf_OverheadRepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_OverheadRepayment_299e1d02-7be2-43ac-a78b-bdd48e20d85f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_48b11829-21de-4736-89af-09cae5829afb" xlink:href="oncyf-20211231.xsd#oncyf_AnnualContingentPaymentGrossSalesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_48b11829-21de-4736-89af-09cae5829afb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPayment_f159137d-5455-47b3-81bd-15395ea059ff" xlink:href="oncyf-20211231.xsd#oncyf_AnnualContingentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_AnnualContingentPayment_f159137d-5455-47b3-81bd-15395ea059ff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_7f8644b9-b223-4bc8-a89f-f7efc9dea409" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_7f8644b9-b223-4bc8-a89f-f7efc9dea409" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_c945a36f-1e07-4cc9-918f-ef8ac35a6018" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_7f8644b9-b223-4bc8-a89f-f7efc9dea409" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_c945a36f-1e07-4cc9-918f-ef8ac35a6018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_c945a36f-1e07-4cc9-918f-ef8ac35a6018_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_c945a36f-1e07-4cc9-918f-ef8ac35a6018" xlink:to="loc_ifrs-full_OtherProvisionsMember_c945a36f-1e07-4cc9-918f-ef8ac35a6018_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_4f9aa728-0cf0-4ffb-ad3a-93b571e7fcae" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_c945a36f-1e07-4cc9-918f-ef8ac35a6018" xlink:to="loc_ifrs-full_OtherProvisionsMember_4f9aa728-0cf0-4ffb-ad3a-93b571e7fcae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember_52f8c7ff-feb5-4d8a-bfa6-e5821ab21a82" xlink:href="oncyf-20211231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_4f9aa728-0cf0-4ffb-ad3a-93b571e7fcae" xlink:to="loc_oncyf_CollaborationAgreementMember_52f8c7ff-feb5-4d8a-bfa6-e5821ab21a82" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="extended" id="ib1325dd34daa4c11a6bf3af302e3b1e1_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_bdf24789-c4f0-4b94-b5a5-95ee112c30a0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_bdf24789-c4f0-4b94-b5a5-95ee112c30a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_b43ee526-4ac3-4ef0-a012-478b739db354" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_b43ee526-4ac3-4ef0-a012-478b739db354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_3e6b0391-6a0c-489c-ad80-e60ca572ed88" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_3e6b0391-6a0c-489c-ad80-e60ca572ed88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_236ad5b8-a890-4145-8141-9a9f009999ca" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_236ad5b8-a890-4145-8141-9a9f009999ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_5ca53a6f-94e8-440e-bb34-1e4135ca53aa" xlink:href="oncyf-20211231.xsd#oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_5ca53a6f-94e8-440e-bb34-1e4135ca53aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_bc71b2dd-a48f-48bc-9818-5531262b539f" xlink:href="oncyf-20211231.xsd#oncyf_ContingentRoyaltyPaymentAnnualMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_bc71b2dd-a48f-48bc-9818-5531262b539f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_af6ff71e-db52-4ed1-82a1-ad8ca3f2a4b2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_af6ff71e-db52-4ed1-82a1-ad8ca3f2a4b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_9f7e4515-a98c-4171-9997-3b9a1d47486f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_af6ff71e-db52-4ed1-82a1-ad8ca3f2a4b2" xlink:to="loc_ifrs-full_CounterpartiesAxis_9f7e4515-a98c-4171-9997-3b9a1d47486f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_9f7e4515-a98c-4171-9997-3b9a1d47486f_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_9f7e4515-a98c-4171-9997-3b9a1d47486f" xlink:to="loc_ifrs-full_CounterpartiesMember_9f7e4515-a98c-4171-9997-3b9a1d47486f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_8438e582-72bb-48dd-86d7-1fdf05b0f882" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_9f7e4515-a98c-4171-9997-3b9a1d47486f" xlink:to="loc_ifrs-full_CounterpartiesMember_8438e582-72bb-48dd-86d7-1fdf05b0f882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SYNSORBMember_44f16eaa-51f7-4291-b63d-96a16e621e78" xlink:href="oncyf-20211231.xsd#oncyf_SYNSORBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_8438e582-72bb-48dd-86d7-1fdf05b0f882" xlink:to="loc_oncyf_SYNSORBMember_44f16eaa-51f7-4291-b63d-96a16e621e78" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" xlink:type="extended" id="i0eed0d7c67754324bc394d644a902cfa_IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_024299ae-bbe1-49f4-8da3-2a39f552cedb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_96899278-e419-41a6-a9d3-9e582f5f1bdb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_024299ae-bbe1-49f4-8da3-2a39f552cedb" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_96899278-e419-41a6-a9d3-9e582f5f1bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e950bf1e-b031-4e7b-a674-5ca6c2adc74a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_024299ae-bbe1-49f4-8da3-2a39f552cedb" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e950bf1e-b031-4e7b-a674-5ca6c2adc74a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_f809f1c2-5ae2-4754-8a7c-3cd52806ac09" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e950bf1e-b031-4e7b-a674-5ca6c2adc74a" xlink:to="loc_ifrs-full_MaturityAxis_f809f1c2-5ae2-4754-8a7c-3cd52806ac09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_f809f1c2-5ae2-4754-8a7c-3cd52806ac09_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_f809f1c2-5ae2-4754-8a7c-3cd52806ac09" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_f809f1c2-5ae2-4754-8a7c-3cd52806ac09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_f809f1c2-5ae2-4754-8a7c-3cd52806ac09" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyTwoMember_83bc2f8e-e6ce-4ecd-af62-daa9f91d5e76" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyTwoMember_83bc2f8e-e6ce-4ecd-af62-daa9f91d5e76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyThreeMember_ff61a3e0-1e7d-4023-a65c-6b86f4f490ff" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyThreeMember_ff61a3e0-1e7d-4023-a65c-6b86f4f490ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFourMember_1fd2d65e-bf2f-4870-9a73-2769ef50476e" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyFourMember_1fd2d65e-bf2f-4870-9a73-2769ef50476e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFiveMember_e5b39677-e559-496f-a050-7e738313cd4d" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyFiveMember_e5b39677-e559-496f-a050-7e738313cd4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySixMember_eac49de7-9cdb-4a11-9fa7-126e02097786" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentySixMember_eac49de7-9cdb-4a11-9fa7-126e02097786" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySevenMember_8f92b2fa-27a5-45f8-998b-abd0a284de00" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentySevenMember_8f92b2fa-27a5-45f8-998b-abd0a284de00" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyEightMember_5420fe9a-e5dd-4e62-b3ce-d263700f6358" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyEightMember_5420fe9a-e5dd-4e62-b3ce-d263700f6358" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyNineMember_6ace93f7-e591-4c2a-bae1-b909085bab17" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyNineMember_6ace93f7-e591-4c2a-bae1-b909085bab17" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyMember_89b807fb-2f67-4289-be52-0c267d4a7d29" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyMember_89b807fb-2f67-4289-be52-0c267d4a7d29" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyOneMember_95754c95-f3df-4039-885b-7fdd1198ff28" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyOneMember_95754c95-f3df-4039-885b-7fdd1198ff28" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyTwoMember_952e1077-9470-4ecd-86e1-98c2f886d71d" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyTwoMember_952e1077-9470-4ecd-86e1-98c2f886d71d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyThreeMember_a7b33f43-9d1d-42af-97b2-3551cbe00998" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyThreeMember_a7b33f43-9d1d-42af-97b2-3551cbe00998" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFourMember_af14fc43-2660-4085-a6ef-e08ca89e8a02" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyFourMember_af14fc43-2660-4085-a6ef-e08ca89e8a02" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFiveMember_2a5672ba-dcb3-464b-964f-1048451318ad" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyFiveMember_2a5672ba-dcb3-464b-964f-1048451318ad" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySixMember_2d37f023-638c-4e13-ab5c-5e07362511a1" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtySixMember_2d37f023-638c-4e13-ab5c-5e07362511a1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySevenMember_d4b7634a-84ed-43ef-bc24-6d0fa3d1736b" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtySevenMember_d4b7634a-84ed-43ef-bc24-6d0fa3d1736b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyEightMember_49bfd524-4cbe-4eaa-a74c-4f3e47200880" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyEightMember_49bfd524-4cbe-4eaa-a74c-4f3e47200880" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyNineMember_ef5b0010-3167-4ca3-8bf3-594525ccca0e" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyNineMember_ef5b0010-3167-4ca3-8bf3-594525ccca0e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_731fff24-2d5a-47c5-8657-c89c7c9e09e0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e950bf1e-b031-4e7b-a674-5ca6c2adc74a" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_731fff24-2d5a-47c5-8657-c89c7c9e09e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_731fff24-2d5a-47c5-8657-c89c7c9e09e0_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_731fff24-2d5a-47c5-8657-c89c7c9e09e0" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_731fff24-2d5a-47c5-8657-c89c7c9e09e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_37ac1b73-a3e0-49fb-a539-c868419de852" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_731fff24-2d5a-47c5-8657-c89c7c9e09e0" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_37ac1b73-a3e0-49fb-a539-c868419de852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_0a7e4528-9c4b-460c-b140-699f93f9e352" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_37ac1b73-a3e0-49fb-a539-c868419de852" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_0a7e4528-9c4b-460c-b140-699f93f9e352" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_8eff933b-ee42-4a61-b5ca-15a8d11c2469" xlink:href="oncyf-20211231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_37ac1b73-a3e0-49fb-a539-c868419de852" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_8eff933b-ee42-4a61-b5ca-15a8d11c2469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_25fb6160-7ddf-475a-8616-0a117ba76248" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e950bf1e-b031-4e7b-a674-5ca6c2adc74a" xlink:to="loc_srt_StatementGeographicalAxis_25fb6160-7ddf-475a-8616-0a117ba76248" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_25fb6160-7ddf-475a-8616-0a117ba76248_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_25fb6160-7ddf-475a-8616-0a117ba76248" xlink:to="loc_srt_SegmentGeographicalDomain_25fb6160-7ddf-475a-8616-0a117ba76248_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f55a474f-d395-4b2a-bd60-fba1deb92254" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_25fb6160-7ddf-475a-8616-0a117ba76248" xlink:to="loc_srt_SegmentGeographicalDomain_f55a474f-d395-4b2a-bd60-fba1deb92254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_0fdd66d3-14eb-4271-b684-5f52a86a1c37" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f55a474f-d395-4b2a-bd60-fba1deb92254" xlink:to="loc_country_CA_0fdd66d3-14eb-4271-b684-5f52a86a1c37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d483dd11-4f2f-44ba-adb4-c7311e0af567" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f55a474f-d395-4b2a-bd60-fba1deb92254" xlink:to="loc_country_US_d483dd11-4f2f-44ba-adb4-c7311e0af567" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IncomeTaxesSummaryofNoncapitalLossesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails" xlink:type="extended" id="i3850302d91e5414c9f8117353fd241ae_IncomeTaxesSummaryofNoncapitalLossesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_96c4afa1-247c-453d-b95c-ca294578e14a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_b90d33c7-498c-4b43-a747-90d621aa8f05" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_96c4afa1-247c-453d-b95c-ca294578e14a" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_b90d33c7-498c-4b43-a747-90d621aa8f05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_c8f47eb9-7fab-4650-a754-3d1aa894b685" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_96c4afa1-247c-453d-b95c-ca294578e14a" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_c8f47eb9-7fab-4650-a754-3d1aa894b685" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_9e646d6a-4499-475e-b7cc-b24677569223" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_c8f47eb9-7fab-4650-a754-3d1aa894b685" xlink:to="loc_ifrs-full_MaturityAxis_9e646d6a-4499-475e-b7cc-b24677569223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_9e646d6a-4499-475e-b7cc-b24677569223_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_9e646d6a-4499-475e-b7cc-b24677569223" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_9e646d6a-4499-475e-b7cc-b24677569223_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_9e646d6a-4499-475e-b7cc-b24677569223" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyTwoMember_378b54bb-b765-447f-a356-c532789527d2" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyTwoMember_378b54bb-b765-447f-a356-c532789527d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyThreeMember_6404696e-adcf-4098-9bb9-0011e116c0e4" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyThreeMember_6404696e-adcf-4098-9bb9-0011e116c0e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFourMember_029c9376-0e8e-4dc5-b235-e18007a7976a" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyFourMember_029c9376-0e8e-4dc5-b235-e18007a7976a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFiveMember_69f348da-100a-4336-a0c5-0bb454c3f3eb" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyFiveMember_69f348da-100a-4336-a0c5-0bb454c3f3eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySixMember_aa721ebe-146f-4db3-adbf-f5620be60fa2" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentySixMember_aa721ebe-146f-4db3-adbf-f5620be60fa2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySevenMember_2d2f6d5f-d2d5-4e98-bfdd-4a34f2b37e28" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentySevenMember_2d2f6d5f-d2d5-4e98-bfdd-4a34f2b37e28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyEightMember_5b366e05-f14b-45db-99e6-f689b3231ea1" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyEightMember_5b366e05-f14b-45db-99e6-f689b3231ea1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyNineMember_3497590f-94db-405e-b336-d8a272d48ca6" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyNineMember_3497590f-94db-405e-b336-d8a272d48ca6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyMember_ef844ddb-51c4-47d7-b6fe-401dc774e825" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyMember_ef844ddb-51c4-47d7-b6fe-401dc774e825" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyOneMember_8bd2d8b6-f5c3-4079-a92f-72d3f60d9953" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyOneMember_8bd2d8b6-f5c3-4079-a92f-72d3f60d9953" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyTwoMember_400f7f9c-543e-4069-bb71-cd22db03a937" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyTwoMember_400f7f9c-543e-4069-bb71-cd22db03a937" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyThreeMember_6249d46c-8a79-4cc8-96f5-f94e193eadcf" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyThreeMember_6249d46c-8a79-4cc8-96f5-f94e193eadcf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFourMember_1402d7c4-ef29-4f38-a39d-43ee4c37a6ee" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyFourMember_1402d7c4-ef29-4f38-a39d-43ee4c37a6ee" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFiveMember_76ded99d-61d4-48dc-a338-df8e139fb52b" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyFiveMember_76ded99d-61d4-48dc-a338-df8e139fb52b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySixMember_0865930e-ecd2-4055-b570-de80ce586f5a" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtySixMember_0865930e-ecd2-4055-b570-de80ce586f5a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySevenMember_6b0a2287-b1b7-4983-9f57-f47e44b29b9e" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtySevenMember_6b0a2287-b1b7-4983-9f57-f47e44b29b9e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyEightMember_76259c1a-558e-4efe-b520-173a9601fccf" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyEightMember_76259c1a-558e-4efe-b520-173a9601fccf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyNineMember_03bba763-01a7-43ab-872d-eb43619cdc8e" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyNineMember_03bba763-01a7-43ab-872d-eb43619cdc8e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyFortyMember_c2c57e92-75af-4db6-86a9-7b3216d50ba9" xlink:href="oncyf-20211231.xsd#oncyf_TwentyFortyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyFortyMember_c2c57e92-75af-4db6-86a9-7b3216d50ba9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyFortyOneMember_83af93fd-c018-46b5-8957-47bab00161d6" xlink:href="oncyf-20211231.xsd#oncyf_TwentyFortyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyFortyOneMember_83af93fd-c018-46b5-8957-47bab00161d6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_677cfe47-e212-4b61-8e9c-8976f7fa53fa" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_c8f47eb9-7fab-4650-a754-3d1aa894b685" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_677cfe47-e212-4b61-8e9c-8976f7fa53fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_677cfe47-e212-4b61-8e9c-8976f7fa53fa_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_677cfe47-e212-4b61-8e9c-8976f7fa53fa" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_677cfe47-e212-4b61-8e9c-8976f7fa53fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e84ce20-00b5-4fb5-a2a4-65baf8ffdd82" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_677cfe47-e212-4b61-8e9c-8976f7fa53fa" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e84ce20-00b5-4fb5-a2a4-65baf8ffdd82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_038fe3d8-5599-4cac-8f0a-a50e9ac3ea59" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e84ce20-00b5-4fb5-a2a4-65baf8ffdd82" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_038fe3d8-5599-4cac-8f0a-a50e9ac3ea59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_edb880b6-38ca-4daa-82f8-10860d31aa3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_c8f47eb9-7fab-4650-a754-3d1aa894b685" xlink:to="loc_srt_StatementGeographicalAxis_edb880b6-38ca-4daa-82f8-10860d31aa3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_edb880b6-38ca-4daa-82f8-10860d31aa3a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_edb880b6-38ca-4daa-82f8-10860d31aa3a" xlink:to="loc_srt_SegmentGeographicalDomain_edb880b6-38ca-4daa-82f8-10860d31aa3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_36000d76-fd20-4cfa-86c7-73adc24434a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_edb880b6-38ca-4daa-82f8-10860d31aa3a" xlink:to="loc_srt_SegmentGeographicalDomain_36000d76-fd20-4cfa-86c7-73adc24434a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_1d66d58e-c28e-4c20-be35-a7f87a3aa3ad" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_36000d76-fd20-4cfa-86c7-73adc24434a5" xlink:to="loc_country_CA_1d66d58e-c28e-4c20-be35-a7f87a3aa3ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB_66c39984-dd01-4362-b4d5-d3098f7ce44c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_36000d76-fd20-4cfa-86c7-73adc24434a5" xlink:to="loc_country_BB_66c39984-dd01-4362-b4d5-d3098f7ce44c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended" id="i540a122c922049a09efc2e24173b6477_IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b2a907b1-e904-4303-ae0f-6c978f8a99a6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_8936b59c-14bb-4ffb-9ea2-18a685049ab8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b2a907b1-e904-4303-ae0f-6c978f8a99a6" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_8936b59c-14bb-4ffb-9ea2-18a685049ab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_b59fcbb5-7b66-4fdf-a928-df150dfccb4a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b2a907b1-e904-4303-ae0f-6c978f8a99a6" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_b59fcbb5-7b66-4fdf-a928-df150dfccb4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ed85fa1c-779c-45da-a0df-ef00cb753b35" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_b59fcbb5-7b66-4fdf-a928-df150dfccb4a" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ed85fa1c-779c-45da-a0df-ef00cb753b35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ed85fa1c-779c-45da-a0df-ef00cb753b35_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ed85fa1c-779c-45da-a0df-ef00cb753b35" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ed85fa1c-779c-45da-a0df-ef00cb753b35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ed85fa1c-779c-45da-a0df-ef00cb753b35" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_ae54d31a-c581-4241-b7ac-c170cc5f17a9" xlink:href="oncyf-20211231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_ae54d31a-c581-4241-b7ac-c170cc5f17a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_22f309fc-d77f-4780-ae24-e2bb4486b595" xlink:href="oncyf-20211231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_22f309fc-d77f-4780-ae24-e2bb4486b595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_598f19b9-cd83-4e95-ba63-fb73f8a3adce" xlink:href="oncyf-20211231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_598f19b9-cd83-4e95-ba63-fb73f8a3adce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_dd184c1d-60b5-4ec4-8fe5-1c63ae881489" xlink:href="oncyf-20211231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_dd184c1d-60b5-4ec4-8fe5-1c63ae881489" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember_a492f1fc-b60f-44e7-9153-45bfff9ae3bf" xlink:href="oncyf-20211231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_ShareIssueCostsMember_a492f1fc-b60f-44e7-9153-45bfff9ae3bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_b430b138-fbef-4c81-9b74-82c2f23b9ee9" xlink:href="oncyf-20211231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_b430b138-fbef-4c81-9b74-82c2f23b9ee9" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i3f99f45918444eac8ce694103e2ca5fe_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_351d910b-f2dd-476d-86c6-ae84a62e30c6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_bcd3d3ac-5331-4507-b5d8-ed977578dad4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_351d910b-f2dd-476d-86c6-ae84a62e30c6" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_bcd3d3ac-5331-4507-b5d8-ed977578dad4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_c048826d-6f65-4d7d-9f8b-6372602af4d3" xlink:href="oncyf-20211231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_351d910b-f2dd-476d-86c6-ae84a62e30c6" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_c048826d-6f65-4d7d-9f8b-6372602af4d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_fc9959ef-2ba6-4570-93fa-beb143ae3972" xlink:href="oncyf-20211231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_351d910b-f2dd-476d-86c6-ae84a62e30c6" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_fc9959ef-2ba6-4570-93fa-beb143ae3972" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5033a6eb-9118-4deb-8dd9-392b9f00dc3a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_351d910b-f2dd-476d-86c6-ae84a62e30c6" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5033a6eb-9118-4deb-8dd9-392b9f00dc3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_26499c4b-d53f-4542-8f9a-2ac48cf5f520" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5033a6eb-9118-4deb-8dd9-392b9f00dc3a" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_26499c4b-d53f-4542-8f9a-2ac48cf5f520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26499c4b-d53f-4542-8f9a-2ac48cf5f520_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_26499c4b-d53f-4542-8f9a-2ac48cf5f520" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26499c4b-d53f-4542-8f9a-2ac48cf5f520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9a07f1b0-c5b9-40bf-84d3-7a222a5aecaf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_26499c4b-d53f-4542-8f9a-2ac48cf5f520" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9a07f1b0-c5b9-40bf-84d3-7a222a5aecaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_b7c5f09e-03ac-454e-ae86-22896f009afc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9a07f1b0-c5b9-40bf-84d3-7a222a5aecaf" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_b7c5f09e-03ac-454e-ae86-22896f009afc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_270ff4d3-2c3a-48a6-a5f8-99b268b6f9b2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5033a6eb-9118-4deb-8dd9-392b9f00dc3a" xlink:to="loc_ifrs-full_TypesOfRisksAxis_270ff4d3-2c3a-48a6-a5f8-99b268b6f9b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_270ff4d3-2c3a-48a6-a5f8-99b268b6f9b2_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_270ff4d3-2c3a-48a6-a5f8-99b268b6f9b2" xlink:to="loc_ifrs-full_TypesOfRisksMember_270ff4d3-2c3a-48a6-a5f8-99b268b6f9b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_331a5972-26e6-433d-9057-a1040476be00" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_270ff4d3-2c3a-48a6-a5f8-99b268b6f9b2" xlink:to="loc_ifrs-full_TypesOfRisksMember_331a5972-26e6-433d-9057-a1040476be00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_87725029-42f0-4216-afef-4bfe97871fc3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_331a5972-26e6-433d-9057-a1040476be00" xlink:to="loc_ifrs-full_CurrencyRiskMember_87725029-42f0-4216-afef-4bfe97871fc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_609a9639-d9dd-41e5-a19f-1c4d2be1046b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5033a6eb-9118-4deb-8dd9-392b9f00dc3a" xlink:to="loc_srt_CurrencyAxis_609a9639-d9dd-41e5-a19f-1c4d2be1046b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_609a9639-d9dd-41e5-a19f-1c4d2be1046b_default" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_609a9639-d9dd-41e5-a19f-1c4d2be1046b" xlink:to="loc_currency_AllCurrenciesDomain_609a9639-d9dd-41e5-a19f-1c4d2be1046b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_4db02993-6cd2-496e-a309-29bf8e361670" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_609a9639-d9dd-41e5-a19f-1c4d2be1046b" xlink:to="loc_currency_AllCurrenciesDomain_4db02993-6cd2-496e-a309-29bf8e361670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_d0893571-e246-4ccf-90f1-fe658d8539f8" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_4db02993-6cd2-496e-a309-29bf8e361670" xlink:to="loc_currency_USD_d0893571-e246-4ccf-90f1-fe658d8539f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="extended" id="i019c167478d14776b60cf1837dbcb900_FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:href="oncyf-20211231.xsd#oncyf_Currency1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_aba9cbd2-af30-478a-9bc8-82897a8952f0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:to="loc_ifrs-full_CashAndCashEquivalents_aba9cbd2-af30-478a-9bc8-82897a8952f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_1d654250-aa23-48f9-b801-d56b85058c66" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:to="loc_ifrs-full_OtherReceivables_1d654250-aa23-48f9-b801-d56b85058c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_fb9e023e-7c18-4aa6-a288-80612d40c580" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_fb9e023e-7c18-4aa6-a288-80612d40c580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_0dcbb025-fe1b-4305-b015-c206556de365" xlink:href="oncyf-20211231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_0dcbb025-fe1b-4305-b015-c206556de365" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_82ecdd2a-6b1a-4b54-912c-a4a1198e485c" xlink:href="oncyf-20211231.xsd#oncyf_Currency1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:to="loc_oncyf_Currency1Table_82ecdd2a-6b1a-4b54-912c-a4a1198e485c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_cf9d0d43-0a67-46a8-92a8-c7aaef13dcec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Currency1Table_82ecdd2a-6b1a-4b54-912c-a4a1198e485c" xlink:to="loc_srt_CurrencyAxis_cf9d0d43-0a67-46a8-92a8-c7aaef13dcec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_cf9d0d43-0a67-46a8-92a8-c7aaef13dcec_default" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_cf9d0d43-0a67-46a8-92a8-c7aaef13dcec" xlink:to="loc_currency_AllCurrenciesDomain_cf9d0d43-0a67-46a8-92a8-c7aaef13dcec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_e0c01f6c-b615-44a4-bb74-72923d7641bd" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_cf9d0d43-0a67-46a8-92a8-c7aaef13dcec" xlink:to="loc_currency_AllCurrenciesDomain_e0c01f6c-b615-44a4-bb74-72923d7641bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_60ab1a1c-044e-4b2c-be8c-3de67ce67d3f" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_e0c01f6c-b615-44a4-bb74-72923d7641bd" xlink:to="loc_currency_USD_60ab1a1c-044e-4b2c-be8c-3de67ce67d3f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#EconomicDependenceDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended" id="ie67fc7c2f3454150880daac1f2f9238d_EconomicDependenceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_583fa144-c928-4eb5-8226-8370b6c1cbc9" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber_f2ca9d40-dda7-49a1-838a-fd829a5fa7e2" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_583fa144-c928-4eb5-8226-8370b6c1cbc9" xlink:to="loc_oncyf_ConcentrationRiskNumber_f2ca9d40-dda7-49a1-838a-fd829a5fa7e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table_2b3d2fa3-5f25-4e57-9a93-90e3e042e0ef" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_583fa144-c928-4eb5-8226-8370b6c1cbc9" xlink:to="loc_oncyf_ConcentrationRisk1Table_2b3d2fa3-5f25-4e57-9a93-90e3e042e0ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_4e6ef920-94e1-44c0-a10f-69c38c05dc44" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_ConcentrationRisk1Table_2b3d2fa3-5f25-4e57-9a93-90e3e042e0ef" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_4e6ef920-94e1-44c0-a10f-69c38c05dc44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_4e6ef920-94e1-44c0-a10f-69c38c05dc44_default" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_4e6ef920-94e1-44c0-a10f-69c38c05dc44" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_4e6ef920-94e1-44c0-a10f-69c38c05dc44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_6f59c35f-cede-4eb9-af6d-ce03cfdbb89b" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_4e6ef920-94e1-44c0-a10f-69c38c05dc44" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_6f59c35f-cede-4eb9-af6d-ce03cfdbb89b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_f81d78b7-b2ef-412f-85fc-a3c23bbcf6ea" xlink:href="oncyf-20211231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_6f59c35f-cede-4eb9-af6d-ce03cfdbb89b" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_f81d78b7-b2ef-412f-85fc-a3c23bbcf6ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#OtherExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesDetails" xlink:type="extended" id="ib66d1a953fdd48c2b7d9754a1641b5f0_OtherExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:href="oncyf-20211231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_d09de8a2-531f-475e-89bb-03e2e0fbe19c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_d09de8a2-531f-475e-89bb-03e2e0fbe19c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_b199dea3-601d-41e8-87f3-691360c9e8ab" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_b199dea3-601d-41e8-87f3-691360c9e8ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_f1f7c30b-68bf-415c-9402-0b9e252a5d8b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:to="loc_ifrs-full_AmortisationExpense_f1f7c30b-68bf-415c-9402-0b9e252a5d8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_f28acd38-3db2-4761-81be-792806996cae" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_f28acd38-3db2-4761-81be-792806996cae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_8a54f527-c588-44bb-89d2-fb37e73a28e7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_8a54f527-c588-44bb-89d2-fb37e73a28e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_c0326f8b-8e78-4d72-90d4-5886d3c93872" xlink:href="oncyf-20211231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_c0326f8b-8e78-4d72-90d4-5886d3c93872" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_12705a66-5a95-453a-86ed-0469c2a6b3b1" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_c0326f8b-8e78-4d72-90d4-5886d3c93872" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_12705a66-5a95-453a-86ed-0469c2a6b3b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_12705a66-5a95-453a-86ed-0469c2a6b3b1_default" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_12705a66-5a95-453a-86ed-0469c2a6b3b1" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_12705a66-5a95-453a-86ed-0469c2a6b3b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_9c00e6fa-edfe-4b33-a5ae-cd402a2bd280" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_12705a66-5a95-453a-86ed-0469c2a6b3b1" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_9c00e6fa-edfe-4b33-a5ae-cd402a2bd280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentMember_35a1dfe5-1a30-40a9-9c58-075573c810b2" xlink:href="oncyf-20211231.xsd#oncyf_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_9c00e6fa-edfe-4b33-a5ae-cd402a2bd280" xlink:to="loc_oncyf_ResearchAndDevelopmentMember_35a1dfe5-1a30-40a9-9c58-075573c810b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingExpensesMember_8c1d9e6f-210c-4901-b7c8-3c21c90f297d" xlink:href="oncyf-20211231.xsd#oncyf_OperatingExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_9c00e6fa-edfe-4b33-a5ae-cd402a2bd280" xlink:to="loc_oncyf_OperatingExpensesMember_8c1d9e6f-210c-4901-b7c8-3c21c90f297d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_5b0da493-7ccf-43c4-a2b4-c98dc49ca013" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_c0326f8b-8e78-4d72-90d4-5886d3c93872" xlink:to="loc_oncyf_SaleOfStockAxis_5b0da493-7ccf-43c4-a2b4-c98dc49ca013" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_5b0da493-7ccf-43c4-a2b4-c98dc49ca013_default" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_5b0da493-7ccf-43c4-a2b4-c98dc49ca013" xlink:to="loc_oncyf_SaleOfStockDomain_5b0da493-7ccf-43c4-a2b4-c98dc49ca013_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_0da715d5-d2b0-4810-b44f-8cb9983df640" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_5b0da493-7ccf-43c4-a2b4-c98dc49ca013" xlink:to="loc_oncyf_SaleOfStockDomain_0da715d5-d2b0-4810-b44f-8cb9983df640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_c470fb59-8f58-42ef-8b13-0e255a47c087" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_0da715d5-d2b0-4810-b44f-8cb9983df640" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_c470fb59-8f58-42ef-8b13-0e255a47c087" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended" id="i39e02ce4a2c3454089fb42f44c343235_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_b3e9a7d9-63e4-4237-b405-b2d459cbc725" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_a4f2d1d1-55c2-48f9-b07d-96cb85ac8c87" xlink:href="oncyf-20211231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_b3e9a7d9-63e4-4237-b405-b2d459cbc725" xlink:to="loc_oncyf_IssueOfEquityShares_a4f2d1d1-55c2-48f9-b07d-96cb85ac8c87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_080acb99-e93d-4cdb-83b5-b55dab0bfe58" xlink:href="oncyf-20211231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_b3e9a7d9-63e4-4237-b405-b2d459cbc725" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_080acb99-e93d-4cdb-83b5-b55dab0bfe58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PaymentsForExecutoryContracts_db097ff2-0877-44a1-9c3c-4b0d77e8d880" xlink:href="oncyf-20211231.xsd#oncyf_PaymentsForExecutoryContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_b3e9a7d9-63e4-4237-b405-b2d459cbc725" xlink:to="loc_oncyf_PaymentsForExecutoryContracts_db097ff2-0877-44a1-9c3c-4b0d77e8d880" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6c68cc85-cef4-4cfa-a19e-81760b9e5362" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_b3e9a7d9-63e4-4237-b405-b2d459cbc725" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6c68cc85-cef4-4cfa-a19e-81760b9e5362" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ed136fa0-117a-4019-9b03-e866f5b1b38f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6c68cc85-cef4-4cfa-a19e-81760b9e5362" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ed136fa0-117a-4019-9b03-e866f5b1b38f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_ed136fa0-117a-4019-9b03-e866f5b1b38f_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ed136fa0-117a-4019-9b03-e866f5b1b38f" xlink:to="loc_ifrs-full_NonadjustingEventsMember_ed136fa0-117a-4019-9b03-e866f5b1b38f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_d9b7f88e-67fb-4eaf-b2bd-00b7dd749272" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ed136fa0-117a-4019-9b03-e866f5b1b38f" xlink:to="loc_ifrs-full_NonadjustingEventsMember_d9b7f88e-67fb-4eaf-b2bd-00b7dd749272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_861cebae-64dc-48ed-b1e6-12ed7ab5ac92" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_d9b7f88e-67fb-4eaf-b2bd-00b7dd749272" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_861cebae-64dc-48ed-b1e6-12ed7ab5ac92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_dfe3208b-7c8b-4a54-bea4-05e46ee5d4d6" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6c68cc85-cef4-4cfa-a19e-81760b9e5362" xlink:to="loc_oncyf_SaleOfStockAxis_dfe3208b-7c8b-4a54-bea4-05e46ee5d4d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_dfe3208b-7c8b-4a54-bea4-05e46ee5d4d6_default" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_dfe3208b-7c8b-4a54-bea4-05e46ee5d4d6" xlink:to="loc_oncyf_SaleOfStockDomain_dfe3208b-7c8b-4a54-bea4-05e46ee5d4d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_091076ab-07e3-4fd0-a6b0-ebc5532a86f6" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_dfe3208b-7c8b-4a54-bea4-05e46ee5d4d6" xlink:to="loc_oncyf_SaleOfStockDomain_091076ab-07e3-4fd0-a6b0-ebc5532a86f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_145330aa-f855-495c-a2c8-bb53debddb28" xlink:href="oncyf-20211231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_091076ab-07e3-4fd0-a6b0-ebc5532a86f6" xlink:to="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_145330aa-f855-495c-a2c8-bb53debddb28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AgreementAxis_24a13491-81d0-4cf3-99b0-3ad9670f77ad" xlink:href="oncyf-20211231.xsd#oncyf_AgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6c68cc85-cef4-4cfa-a19e-81760b9e5362" xlink:to="loc_oncyf_AgreementAxis_24a13491-81d0-4cf3-99b0-3ad9670f77ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AgreementDomain_24a13491-81d0-4cf3-99b0-3ad9670f77ad_default" xlink:href="oncyf-20211231.xsd#oncyf_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_AgreementAxis_24a13491-81d0-4cf3-99b0-3ad9670f77ad" xlink:to="loc_oncyf_AgreementDomain_24a13491-81d0-4cf3-99b0-3ad9670f77ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AgreementDomain_620592d7-7f9f-408b-97bd-067740ebfa62" xlink:href="oncyf-20211231.xsd#oncyf_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_AgreementAxis_24a13491-81d0-4cf3-99b0-3ad9670f77ad" xlink:to="loc_oncyf_AgreementDomain_620592d7-7f9f-408b-97bd-067740ebfa62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProductionServiceAgreementMember_cadea876-0400-49e8-b160-cc102fa28080" xlink:href="oncyf-20211231.xsd#oncyf_ProductionServiceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_AgreementDomain_620592d7-7f9f-408b-97bd-067740ebfa62" xlink:to="loc_oncyf_ProductionServiceAgreementMember_cadea876-0400-49e8-b160-cc102fa28080" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>37
<FILENAME>oncyf-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:04d38e4b-b411-4668-8f8c-e4013a42568d,g:242f92a0-4583-4d5d-9e63-4960e9cee1a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_9bfa2f66-3fb8-4b59-8571-bdf985df7e9d_terseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of increase in value of currency, amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:href="oncyf-20211231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_f0afffe4-1b0d-46f4-9ff8-2ad6d4358dae_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesMember_ee21cd2e-4205-4c7f-9741-66ac39552fd0_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesMember" xlink:to="lab_ifrs-full_LiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_12217b8d-0bdb-4adc-987a-397f8510303b_terseLabel_en-US" xlink:label="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivative and Shares Under Warrant Agreement</link:label>
    <link:label id="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_label_en-US" xlink:label="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivative And Shares Under Warrant Agreement [Member]</link:label>
    <link:label id="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_documentation_en-US" xlink:label="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivative And Shares Under Warrant Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:href="oncyf-20211231.xsd#oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:to="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_b3f1b2b6-c822-49a6-986d-806e35ebf11f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_96c41a71-fc83-4994-a4a2-959b1f8f2b14_terseLabel_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum option expiration term</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_label_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_documentation_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:href="oncyf-20211231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:to="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_2cc7a629-3457-4e1c-a9ec-6e48c08acc72_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued pursuant to incentive share award plan (note 10)</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:href="oncyf-20211231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:to="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_88c38d42-fb05-4257-a674-6c7fda6dfe01_periodStartLabel_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued, beginning balance</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_3c08fe69-3d19-4b67-bc3a-d7cf75da65bd_periodEndLabel_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued, ending balance</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_1a42bc02-c155-4cec-bb37-283a1db840b0_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_label_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding1</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_documentation_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsAndRightsOutstanding1" xlink:to="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_ffdecf6f-7408-4772-9319-0445a35ed11b_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_927468d3-c89b-4b04-8612-f3c4cae8607e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_0f85ed41-6652-401f-85fc-4ea650f81ed8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_1189f4aa-c47f-4964-80bc-54f652e1757a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of number of other equity instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b8ca0ca6-9414-44fa-b32b-e4b73a109436_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8192db1d-b597-45d6-b4e7-0aa69a20db38_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_477f4ff0-2eb1-4e03-a71c-6a5bdcc46696_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (cad and usd per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_label_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1" xlink:href="oncyf-20211231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedPricePerShare1" xlink:to="lab_oncyf_SharesIssuedPricePerShare1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7d162c90-475c-4c64-8e09-fe5c64ed2b15_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_4134cf59-e389-4b1f-ae5e-ddbe499151ab_terseLabel_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment tax credits</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_label_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_documentation_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember" xlink:href="oncyf-20211231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_InvestmentTaxCreditsMember" xlink:to="lab_oncyf_InvestmentTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProductionServiceAgreementMember_ceb762ae-34c4-45ce-ae4d-2be75ecea0d9_terseLabel_en-US" xlink:label="lab_oncyf_ProductionServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Service Agreement</link:label>
    <link:label id="lab_oncyf_ProductionServiceAgreementMember_label_en-US" xlink:label="lab_oncyf_ProductionServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Service Agreement [Member]</link:label>
    <link:label id="lab_oncyf_ProductionServiceAgreementMember_documentation_en-US" xlink:label="lab_oncyf_ProductionServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Service Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProductionServiceAgreementMember" xlink:href="oncyf-20211231.xsd#oncyf_ProductionServiceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProductionServiceAgreementMember" xlink:to="lab_oncyf_ProductionServiceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_5bac05f3-17d4-494b-a189-11832605b9d1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationExpense_c31082fc-78d2-4c74-b3a2-f19a47a9e004_terseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation - property and equipment</link:label>
    <link:label id="lab_ifrs-full_AmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense" xlink:to="lab_ifrs-full_AmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_3e2c44dd-cb35-4b08-b694-12ca5b588af7_periodStartLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued, beginning balance (shares)</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_8dff416d-1ad8-4317-88e1-afe15ef13c7f_periodEndLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued, ending balance (shares)</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_label_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding1</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_documentation_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:href="oncyf-20211231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:to="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_d1a3b4b3-3429-4eee-a855-4df03f4a6629_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of lease liabilities (note 7)</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_6596a9a5-d59d-48cd-8289-d8ec1374e303_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_b4eb42cc-abfb-43b4-a2ff-b83ba40957df_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_2f455b18-edd0-4a18-a76e-ba32caa23367_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_a0c7545c-3097-4d64-909c-5104c22db496_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_ba77d439-e765-4ee2-a907-545aa1572010_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_da17ffde-5d36-4d68-9d4a-d64c6f139fbe_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_a295ecde-b266-45ec-a61f-15c26f080a53_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AgreementAxis_e23ffed8-8ad5-40d2-a533-d294c6f6d436_terseLabel_en-US" xlink:label="lab_oncyf_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement [Axis]</link:label>
    <link:label id="lab_oncyf_AgreementAxis_label_en-US" xlink:label="lab_oncyf_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement [Axis]</link:label>
    <link:label id="lab_oncyf_AgreementAxis_documentation_en-US" xlink:label="lab_oncyf_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AgreementAxis" xlink:href="oncyf-20211231.xsd#oncyf_AgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AgreementAxis" xlink:to="lab_oncyf_AgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_68a65ea4-22e5-4aef-854b-821981fef961_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_01ec5ca9-7e1c-4b53-bfec-a3bfb542ef85_verboseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingMember" xlink:to="lab_oncyf_SharesPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_efa4cadd-1597-4979-8ba1-9bff5ad492b8_terseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease through performance obligation being satisfied, contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:to="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fd9cd8b1-f38e-437f-8215-8ae70c59c6a6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_0f70ffdc-e88f-46bb-97ae-dab8bb68009a_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_e97bad6e-fafb-466d-92d6-d33d4cf8b3a2_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions, net of foreign exchange impact</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_09f4a535-5c49-4b9b-b9eb-db8ad159f322_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributed surplus (note 10)</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapital" xlink:to="lab_ifrs-full_AdditionalPaidinCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_cd83cbe7-7390-4298-9664-37d0e4c5c8d5_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant derivative (note 8)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_f5db308c-fc88-4927-8f95-65cdea165e90_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant derivative (note 8)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_3d5911dd-7af9-4ae5-89b7-5cdeeeed533a_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_dbf6de47-1cf3-4aae-a58d-89d05ac7fdb2_terseLabel_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_label_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Amount [Abstract]</link:label>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_documentation_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract" xlink:href="oncyf-20211231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareCapitalAmountAbstract" xlink:to="lab_oncyf_ShareCapitalAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OperatingExpensesMember_a4c16a4d-a12a-4d12-b1e2-7ac00c51ee30_terseLabel_en-US" xlink:label="lab_oncyf_OperatingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Included in operating expenses</link:label>
    <link:label id="lab_oncyf_OperatingExpensesMember_label_en-US" xlink:label="lab_oncyf_OperatingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Member]</link:label>
    <link:label id="lab_oncyf_OperatingExpensesMember_documentation_en-US" xlink:label="lab_oncyf_OperatingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingExpensesMember" xlink:href="oncyf-20211231.xsd#oncyf_OperatingExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OperatingExpensesMember" xlink:to="lab_oncyf_OperatingExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_18101ec9-975c-43ec-967d-1888d647495a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incorporation and Nature of Operations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_f1432226-d768-4b90-9ec3-bf47840c699e_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_fbf262f6-10ad-44df-8a5e-12d62b7e8a6f_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (cad per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_label_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Warrant Price Per Share</link:label>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Warrant Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare" xlink:href="oncyf-20211231.xsd#oncyf_SharesIssuedWarrantPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedWarrantPricePerShare" xlink:to="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_e6b43dc3-5621-4809-96af-5bef768789d9_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseholdImprovementsMember" xlink:to="lab_ifrs-full_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_b6c60bb3-e6d9-4fe3-9f87-2bc4afc583bb_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_a457e669-d318-49da-94d8-d61e28fd7128_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_57575a6b-9241-4170-9ccd-8b56c379d1d7_terseLabel_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 United States ATM</link:label>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20211231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_9b03be8f-e9e8-40d3-872d-86ff30d1e37d_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants (note 9)</link:label>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_label_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_documentation_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsandRightsOutstanding" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsandRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsandRightsOutstanding" xlink:to="lab_oncyf_WarrantsandRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_6c4f7f74-3d38-4d6f-8c1d-156c86aa4731_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in non-cash working capital (note 18)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_32113611-6341-4959-a7a4-34efb3522511_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-cash working capital related to operating activities</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_6b9ea772-615d-41dc-9c50-ac8b45e9b13d_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_84902dec-4488-47c8-a211-859feb4f5ee5_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_label_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:to="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_eb86d184-7b4d-49a9-93f3-eeb542935e09_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of depreciation rates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_1dee4fbc-a2db-4bd4-82aa-e072f5082297_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_646dc6d4-1275-4e9b-84ac-654491e9449e_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_6fbf4495-2c7e-450c-b1f2-bfb83ee366e0_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital (note 9) &#160;&#160;Authorized: unlimited &#160;&#160;Issued: December&#160;31, 2021 &#8211; 55,043,789 December&#160;31, 2020 &#8211; 46,166,980</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_3c7b9ebd-88d1-465a-a95f-a46e2253dcca_terseLabel_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_documentation_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="oncyf-20211231.xsd#oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_9bd25077-f0fa-47b0-a4ed-112c362709da_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign exchange on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_35b30360-1324-494a-a876-ac6e93e530c9_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_8a970100-9942-4d38-b09c-dec90f6ad3b7_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_610975c3-7133-4fa9-bf3e-c0946644b4cb_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected share price volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_75e5b592-2a8d-44a4-ad82-d5787600b89c_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected share price volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_150350fa-55fb-4451-9051-2c4715fda269_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_2942ee57-64f4-41cf-9c24-762e2ea6d5c8_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e0f8456-a34b-4237-9d2d-a7a28cc53b49_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_e97d7591-9b60-46f6-a9f6-bbba1b8a9051_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect of expense not deductible in determining taxable profit (tax loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_c1b97545-c628-4f55-9acb-6aa4eb10566c_terseLabel_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 United States ATM</link:label>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20211231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_3a36aef1-f59f-4a67-af66-0a11e000e1e9_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities (note 13)</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_8b29b858-de4c-46c0-9ae9-c9c086e25282_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyFortyOneMember_314e7d67-10a5-4928-b31b-3b7eba25b327_terseLabel_en-US" xlink:label="lab_oncyf_TwentyFortyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2041</link:label>
    <link:label id="lab_oncyf_TwentyFortyOneMember_label_en-US" xlink:label="lab_oncyf_TwentyFortyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Forty One [Member]</link:label>
    <link:label id="lab_oncyf_TwentyFortyOneMember_documentation_en-US" xlink:label="lab_oncyf_TwentyFortyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Forty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyFortyOneMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyFortyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyFortyOneMember" xlink:to="lab_oncyf_TwentyFortyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_5175d360-3cc3-4673-a655-41c94fcda703_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_9ffbd4ff-08f9-44ab-88ec-08f3b198f12a_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_f54cf18b-4f01-4cb4-848b-10242da0b097_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:to="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentySevenMember_7c6de01a-f3a2-437e-910a-976991ddc335_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_oncyf_TwentyTwentySevenMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Seven [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentySevenMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySevenMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentySevenMember" xlink:to="lab_oncyf_TwentyTwentySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_cc7b0b78-cd06-4bf0-af9d-c1597a859dfc_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States ATM</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_8044d7ec-c475-46e0-9efe-f63bfbee0020_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_aaa7b669-c97c-4ffd-bda0-080e001fd412_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_505e14ce-2fb2-48e0-ae19-269344c7d188_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash impact of foreign exchange</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:href="oncyf-20211231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:to="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_c64a9b20-dd8f-44bc-97f0-f5af9bed95fb_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementMember" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SaleOfStockAxis_bd854746-6416-40c5-b34a-0bbdb804afc6_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_label_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockAxis" xlink:to="lab_oncyf_SaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_c1923f20-f083-4096-adf8-a7c55bca89a4_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities (note 7)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_cbc8ec19-7d3c-435f-8dbc-4e0de860d2e8_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_37d05353-4aca-482e-8152-f8c55ef9e0eb_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Currency1Table_a67d6e6f-c020-4bb3-9ef4-96418e6f8338_terseLabel_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_label_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_documentation_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table" xlink:href="oncyf-20211231.xsd#oncyf_Currency1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1Table" xlink:to="lab_oncyf_Currency1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantIssuedUnderlyingSharePrice_b3f20ed2-c2e1-47f4-a987-cbab0217e194_terseLabel_en-US" xlink:label="lab_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying share price (usd per share)</link:label>
    <link:label id="lab_oncyf_WarrantIssuedUnderlyingSharePrice_label_en-US" xlink:label="lab_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued, Underlying Share Price</link:label>
    <link:label id="lab_oncyf_WarrantIssuedUnderlyingSharePrice_documentation_en-US" xlink:label="lab_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued, Underlying Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:href="oncyf-20211231.xsd#oncyf_WarrantIssuedUnderlyingSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:to="lab_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_68204f27-bcee-4385-8a52-b133f69d1552_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated tax recovery</link:label>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income) at applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AdditionalCashFlowDisclosuresAbstract_label_en-US" xlink:label="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Disclosures [Abstract]</link:label>
    <link:label id="lab_oncyf_AdditionalCashFlowDisclosuresAbstract_documentation_en-US" xlink:label="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:href="oncyf-20211231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:to="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_ad228bbc-79b2-4edd-b72f-b7c7f0cedb9c_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Alberta rate change</link:label>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect from change in tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:to="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_d8db1510-4c7d-4c87-b6cb-079768bf1d6a_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_969dba4d-7c3d-4e53-a908-28a65b339b20_terseLabel_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_label_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_documentation_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:href="oncyf-20211231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:to="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_ecdd502e-5f50-40ed-90c0-dfa8dbd57a80_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_44e70371-3e66-4684-a3e6-785f7cdb2cd8_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_d944cc92-b367-45c6-aabf-c6bdf5238133_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities (note 7)</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_1259b11a-f143-476a-9a72-0151cfba2b07_verboseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_8eb158c0-c28b-41fd-b4c8-2ae8be31ab39_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from warrant exercises</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_label_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1" xlink:href="oncyf-20211231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromWarrantExercises1" xlink:to="lab_oncyf_ProceedsfromWarrantExercises1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_fa176182-2dc2-4da9-a89f-604d98cb36d1_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_bcdc9787-2dbe-4c8b-a516-e758c3bfec76_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_c1fa0b30-c56d-464e-8bd6-c8774fe98db4_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_91f3160e-99d9-4b72-bda0-4466236860cb_terseLabel_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_label_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Outstanding [Abstract]</link:label>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_documentation_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockOptionsOutstandingAbstract" xlink:href="oncyf-20211231.xsd#oncyf_StockOptionsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract" xlink:to="lab_oncyf_StockOptionsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_61e7d1a7-b752-4f2a-9518-04bfd348bfd5_negatedTerseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_5b4ed576-8b51-4624-a24c-55729c7315af_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_982be826-3c17-45c9-a7eb-27f4a623da60_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_0b2bc59e-ed4a-4ec2-ac80-8da32df20d07_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities (note 7)</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_7c47a1d2-a5ce-485f-a03d-0558928b2f9c_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_0727dc33-a69c-4dce-ae03-61c1ba2434dc_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_81271f3b-83bc-406e-9667-113fb3bf96fd_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Outstanding (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_2984b4a6-60c8-4f0c-a823-857e482a7e4b_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_b1fef1cd-07e6-4c43-b902-377b6a1bccd3_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_6a1b8f9f-e1a9-4dc3-a31d-1acba66fc6a0_terseLabel_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares reserved for issuance (shares)</link:label>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_label_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_c6e5dc34-7d37-464a-a257-496b38a486e0_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_a7ec89b4-500b-4526-8463-9ddd8f2d19f3_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_6caad290-79a5-4af0-90f9-481ffb1114e3_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_bbf9aca8-d410-4f4c-be4e-c131965b7e06_terseLabel_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets [Abstract]</link:label>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_label_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets [Abstract]</link:label>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_documentation_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RightOfUseAssetsAbstract" xlink:href="oncyf-20211231.xsd#oncyf_RightOfUseAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RightOfUseAssetsAbstract" xlink:to="lab_oncyf_RightOfUseAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4e2fec3a-f6ec-4ccd-9ee3-cae301db6c2e_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment (note 6)</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_404242dd-4a4c-4c78-a1b4-998baef2d405_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BB_780f0fc8-4950-4a41-9e55-e5570a90ef05_terseLabel_en-US" xlink:label="lab_country_BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARBADOS</link:label>
    <link:label id="lab_country_BB_label_en-US" xlink:label="lab_country_BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARBADOS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BB" xlink:to="lab_country_BB" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_ad0c4496-2430-4245-bd7a-7e32bef0c7ec_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsAbstract_fdcb675f-14fc-4d43-b5f9-e2b8dc686fb1_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:label id="lab_oncyf_CommitmentsAbstract_label_en-US" xlink:label="lab_oncyf_CommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:label id="lab_oncyf_CommitmentsAbstract_documentation_en-US" xlink:label="lab_oncyf_CommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAbstract" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsAbstract" xlink:to="lab_oncyf_CommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_2e392ed9-6f69-420d-91f9-26fa00740b89_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_b2b946cd-1fa5-49e0-bbca-e4259fb08173_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax credits for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_5ec407d3-1e52-49e4-90cc-fa2345065dce_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_6c0b1ee0-c902-444e-b219-16094272d468_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_0d36c850-e352-4540-9a3b-f352690cc37c_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per common share (cad per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_596f3eef-8b03-42d6-9aab-ee6ba160073e_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2032</link:label>
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Two [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyTwoMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyTwoMember" xlink:to="lab_oncyf_TwentyThirtyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyFourMember_0c4a7d06-5748-4fee-86d8-47aee0023b85_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFourMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Four [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFourMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFourMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyFourMember" xlink:to="lab_oncyf_TwentyTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_2c4ea159-232f-449b-a71d-9bbd2c623c30_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:to="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyMember_3544cd21-e19a-4650-9794-a45259218199_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2030</link:label>
    <link:label id="lab_oncyf_TwentyThirtyMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyMember" xlink:to="lab_oncyf_TwentyThirtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_ff4b29fe-d983-42c3-85c4-8343ef6baa67_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember" xlink:to="lab_ifrs-full_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_5ce2f2ab-604f-447d-b5bf-682224edf3c7_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before the following</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_8b73aa07-7e60-4a2b-998a-b3c010f3f497_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation of key management personnel</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_9889aa78-af0f-41f0-ae2e-40d6aa314237_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_2c7dfb5b-42a9-4a89-a5fd-bc709ca9c1f8_terseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development (note 10, 21, 22)</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_93643bb8-dcc7-48e3-94b1-cad66793f276_terseLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_98e4b269-9505-4f64-8167-dc6281ce8e4a_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other cash flow disclosures</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:href="oncyf-20211231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:to="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_57c68ade-1c78-452b-a1d1-b500a0549e92_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable into common shares (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DividendYieldPercent_96ac03df-7450-4943-9514-82c6a517651d_verboseLabel_en-US" xlink:label="lab_oncyf_DividendYieldPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_oncyf_DividendYieldPercent_label_en-US" xlink:label="lab_oncyf_DividendYieldPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield, Percent</link:label>
    <link:label id="lab_oncyf_DividendYieldPercent_documentation_en-US" xlink:label="lab_oncyf_DividendYieldPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DividendYieldPercent" xlink:href="oncyf-20211231.xsd#oncyf_DividendYieldPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DividendYieldPercent" xlink:to="lab_oncyf_DividendYieldPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_LeaseModificationRightOfUseAssets_e0424721-8919-4872-bdaa-22b315112c6b_terseLabel_en-US" xlink:label="lab_oncyf_LeaseModificationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease modification</link:label>
    <link:label id="lab_oncyf_LeaseModificationRightOfUseAssets_label_en-US" xlink:label="lab_oncyf_LeaseModificationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Modification, Right-Of-Use Assets</link:label>
    <link:label id="lab_oncyf_LeaseModificationRightOfUseAssets_documentation_en-US" xlink:label="lab_oncyf_LeaseModificationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Modification, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_LeaseModificationRightOfUseAssets" xlink:href="oncyf-20211231.xsd#oncyf_LeaseModificationRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_LeaseModificationRightOfUseAssets" xlink:to="lab_oncyf_LeaseModificationRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_c12c78e8-03d0-477e-8f91-0275fb785b97_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure weighted average assumptions and fair value of options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e021de5d-ab51-454f-9c64-7959ccb8a267_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CollaborationAgreementMember_0a839d5c-32f1-444b-9b82-315d552be9e3_terseLabel_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRACELET-1 collaboration agreement</link:label>
    <link:label id="lab_oncyf_CollaborationAgreementMember_label_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_oncyf_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember" xlink:href="oncyf-20211231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CollaborationAgreementMember" xlink:to="lab_oncyf_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SaleOfStockDomain_e7ce1c2c-ab70-461c-8ae2-0c20aca06b7d_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_label_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Sale Of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockDomain" xlink:to="lab_oncyf_SaleOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_880f0121-e964-4dc8-851e-4d78b1f33866_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share transactions</link:label>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_label_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_7921c082-1619-4daf-a3b5-e650d158d10e_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (note 10)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_db006ebd-7a46-4e5a-9e5c-9174ead70695_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$3.02 - $3.90</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeThreeMember" xlink:to="lab_oncyf_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_ad1a444a-28a3-4be9-a328-4113b8397075_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:href="oncyf-20211231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_e451d901-fc88-44cd-ba49-930d1bb0f325_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8126658c-0127-4bc8-8de1-66375c40d10d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_94b1eda7-fbd4-4f45-943a-d6b1e6cea8e6_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3a83e1d4-325d-4362-a55f-2d6734d96a0c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_527b30eb-f00e-4b86-81e0-02b835c46ea2_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_c4529739-703a-476b-ad9b-a21b6d3cf203_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_d40b77d7-c46e-4b6e-83dd-8fef9b3662fb_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued shares</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_bf75ffb4-4502-4356-82ac-53f795b5538c_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_fc4900ef-ef7c-41a0-801b-0edac444e427_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in other operating payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsMember_91eabdec-9f38-4c03-9a2e-ff4dea45b496_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_oncyf_WarrantsMember_1fc7cd5f-51ad-4fc1-b127-1fcb54999eb3_verboseLabel_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_oncyf_WarrantsMember_label_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Member]</link:label>
    <link:label id="lab_oncyf_WarrantsMember_documentation_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsMember" xlink:to="lab_oncyf_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_062065d7-4154-46a8-895f-719fa9270d30_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ccc88f0f-d852-4f87-aa07-96ea490b8f4f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8fa88109-1bd6-46d1-a0a4-d9d061d3c3bf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_1338c99e-3b5a-4a1a-9822-3b473a06f19b_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment due period</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Period Due</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Period Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_c0a35aa1-29b0-498f-aff8-9932ce1e55ef_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_e4cfc084-fe12-4179-b0c4-3ab536de323c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options and weighted average exercise prices of share options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_5340925f-1866-4842-97f5-37e6d1aeefbc_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_462bafe4-c517-4987-9e08-1bef4c850387_terseLabel_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:href="oncyf-20211231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_2aeab875-35e7-4b8b-9e2e-16acbb1f6e3a_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Domain" xlink:to="lab_oncyf_IncomeStatementLocation1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_a2c0147a-9d36-4e3e-9269-cdfd0eea12b3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_8f1cc79b-5b59-41d1-a18d-6956ac5b14ca_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2033</link:label>
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Three [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyThreeMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyThreeMember" xlink:to="lab_oncyf_TwentyThirtyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_ec1415d2-9b15-4273-8405-d73964d02ac7_terseLabel_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net capital losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_label_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_documentation_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:href="oncyf-20211231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:to="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_bbd2438b-d09c-4e9f-bbf8-9cf8abec986d_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_label_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses by nature [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_1e5ffba1-f732-425f-97f2-ff9fd7a9bcb7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue costs (note 9)</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_da820c80-eece-4ce3-b3de-9edfe3f9b386_negatedLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_2565a4b8-0f88-4259-bba5-2a34d50f0a77_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue related cost</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_4ea98e9e-f6ff-4088-a3ab-1e87447264a5_verboseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost, warrant derivative</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_43a1bfb0-9604-485f-8f27-1778071ef14a_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_26fef451-b08c-454e-98fd-6b70caf5d237_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssueOfEquityShares_60d4fb48-ef97-4fbe-b90c-09c194c1dc66_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_label_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares" xlink:href="oncyf-20211231.xsd#oncyf_IssueOfEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquityShares" xlink:to="lab_oncyf_IssueOfEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1a984a7b-ef22-4489-a731-fbfc1bc59c36_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_798efb30-c360-4960-8ff6-8cb9dbb27c38_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets (note 7)</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_fd694cc1-1a29-44b2-a68f-373850d60054_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, beginning balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_799c8ec4-de86-483f-9560-f6a31678e144_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, ending balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_05caa2a0-fe58-42ed-b74d-1c18c9b0f743_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Domain" xlink:to="lab_oncyf_ConcentrationRiskType1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_7aa751b5-c24a-4366-9e11-80abd0a69c8b_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to opening tax pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_label_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfTaxPools" xlink:to="lab_oncyf_TaxEffectOfTaxPools" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_33534032-05ee-4211-9588-7bdb41faaade_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_eb09f60b-6eec-4bf9-9112-255c98e4949b_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration, number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskNumber" xlink:to="lab_oncyf_ConcentrationRiskNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_ac5146b2-5457-4ac2-b684-090689dd50bc_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common share purchase warrant per unit (shares)</link:label>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_label_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Share Purchase Warrant Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_documentation_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Share Purchase Warrant Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:href="oncyf-20211231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:to="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_6941ee56-4799-44fe-83d9-492076124b2c_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:to="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_cd631bbd-0ad9-41ea-8001-413b6a853b97_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (note 15)</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_d1acd85a-401c-4c66-a01b-a98d5105ab28_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_34cf5b8c-a825-4a7c-8e09-7603a78c5255_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification of Officers and Directors</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_7a1244b8-cbb1-45b0-858f-7b6a07c7b8d8_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5286e926-3ee9-4420-8eee-d1f3a3092ab5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a671bd8b-1606-4fea-9576-9ee2ddc5eab4_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_efcbe137-9691-48f4-9f65-307336058f17_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue related cost, commissions</link:label>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_label_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Related Cost, Commissions</link:label>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_documentation_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Related Cost, Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions" xlink:href="oncyf-20211231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueRelatedCostCommissions" xlink:to="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_41766472-2666-4ea4-accb-54ddf8b48d38_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:href="oncyf-20211231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:to="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReceivables_1e09107a-5810-4794-b660-30be28c781e4_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReceivables" xlink:to="lab_ifrs-full_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyFourMember_f817e975-173c-4766-8ea4-87d8f496cb25_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2034</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFourMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Four [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFourMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFourMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyFourMember" xlink:to="lab_oncyf_TwentyThirtyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_206a208d-3296-416f-a52d-7feb2eeea833_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_a5114cd2-4696-4661-8c20-a1de94e0e7c6_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$0.54 - $1.79</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeOneMember" xlink:to="lab_oncyf_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyNineMember_e8c2dc75-e877-4902-adf3-2f4bf34461c6_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2029</link:label>
    <link:label id="lab_oncyf_TwentyTwentyNineMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Nine [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyNineMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyNineMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyNineMember" xlink:to="lab_oncyf_TwentyTwentyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_d1d7c3fe-a72d-4e8c-9f8b-4dfda7b4bc87_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_78bcf6bf-9d8f-4cef-bd4f-7a52a7d06918_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_d0439c9a-1743-4ef0-bb6a-36e9421f6aae_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_0d180cda-d876-4a1d-b0f8-bbcbab0aca76_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_6e4d64f2-a3cd-488d-a202-e58da17ec372_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_35e375ee-e6e7-44c7-b45a-83396ba55d77_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_32c40eae-c0f2-4c38-b668-5cfc1c4d58ad_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$7.42 - $52.63</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFiveMember" xlink:to="lab_oncyf_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_e3c86768-372a-4b47-9ad7-bc93842c5e61_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Three [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyThreeMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyThreeMember" xlink:to="lab_oncyf_TwentyTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_f61f0d22-bb96-47e8-9724-7ad8ba0236a6_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_42b16e14-6193-4478-9475-3889df801d11_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued pursuant to warrant derivative exercised (note 8, 9)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_71b8bea7-9e08-492b-abfe-733a137a4bb9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_FairValueofWarrantIssuedPerWarrant_cfa1ad50-ce37-4f88-9aef-86e2300d88d1_terseLabel_en-US" xlink:label="lab_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per warrant (usd per share)</link:label>
    <link:label id="lab_oncyf_FairValueofWarrantIssuedPerWarrant_label_en-US" xlink:label="lab_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrant Issued, Per Warrant</link:label>
    <link:label id="lab_oncyf_FairValueofWarrantIssuedPerWarrant_documentation_en-US" xlink:label="lab_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrant Issued, Per Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:href="oncyf-20211231.xsd#oncyf_FairValueofWarrantIssuedPerWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:to="lab_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_f7c4701c-a750-463f-bb76-b782fb65423e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_9abca296-fdef-4663-ab6e-b00f575d1ed3_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_71dfd669-537f-4af7-b78f-7931c8fe56ac_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other operating expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_bccb8fb7-ce37-4d47-bf14-e292da904cb9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_effea02d-5d75-4b07-ac11-9963260bbcf9_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of options (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_8a7208fe-61e3-4b29-8ec1-bd7a7b2030c2_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_label_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_documentation_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfStockOptionPlans" xlink:href="oncyf-20211231.xsd#oncyf_NumberOfStockOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfStockOptionPlans" xlink:to="lab_oncyf_NumberOfStockOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_eb6de574-e7f1-401a-9cc6-4bd45eba376d_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation - property and equipment (note 6, 21)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_6e628eff-28d9-49fa-b420-6d277a631e25_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_749927e8-78b4-405e-ba1c-5d15614899fe_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_da0e0f52-db6d-46a5-a279-c99aedf35be2_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per common share (cad per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_12c20824-1e98-4693-b9e1-408a16e0b5fa_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_abf046b2-2844-478e-ac01-2964ea0e7bb5_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant derivative (note 8)</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_40c42574-f2cf-4673-a1e1-22be57847cdb_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant derivative</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_a2fc8239-1ef1-46c0-aa21-86334ae90612_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign jurisdiction tax rate difference</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_28598c81-11c1-4255-bd9c-9eb3513c0c4e_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued pursuant to stock option plan (note 10)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_6dddc2d5-f1b8-4c11-8347-9fbfd7cae53a_terseLabel_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember_4ca197c2-928b-4b50-a9ff-71182539ebe4_terseLabel_en-US" xlink:label="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued Capital, Excluding Commitment Shares</link:label>
    <link:label id="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember_label_en-US" xlink:label="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued Capital, Excluding Commitment Shares [Member]</link:label>
    <link:label id="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember_documentation_en-US" xlink:label="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued Capital, Excluding Commitment Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:href="oncyf-20211231.xsd#oncyf_IssuedCapitalExcludingCommitmentSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:to="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_7321d3ad-1393-4664-9580-121925b13f88_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_152c4dc1-f305-44be-8762-b4189d93bb3e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_ece83840-ac92-467e-b967-3a717a13bd9c_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1.80 - $3.01</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeTwoMember" xlink:to="lab_oncyf_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_816d2db8-2c7b-453e-8b0f-1d68a0e44cb1_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_04959590-133d-415c-b23d-7353f3595b82_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_ba6e0b13-5e3b-4d16-ba4b-44b3fc7de2c4_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_b5c38d14-9983-4272-aa73-f27ab74172f9_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:to="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_7e49d6c6-d928-4e89-a19f-f4eca4dec9be_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (note 5)</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_f9e355ed-db33-4b3d-9d96-9cbf9665b580_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_18ab0eee-9037-4a08-ae6f-a73e39625889_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_7b0e12c0-dcd8-41d0-8698-31713ef7e28f_verboseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_08abd8ae-73df-4c38-87c3-e329e1c1badc_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:to="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarnings_99cb8309-272c-46d9-97a6-48abf69b5913_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_7dae7f53-05df-4b05-af94-677f1732e4c2_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected hold period to exercise</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_3c91dcab-c92d-4c42-9ea3-d0fd1ff8d8aa_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected hold period to exercise</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_6b817d4c-27a7-47b5-b12d-d2826145434d_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment (note 6)</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_cbe87b92-0a1e-42f8-bbc2-10e143124c6d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment (amortization), beginning balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_2babe2a6-5d3c-486c-8593-3c5dced95cab_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment (amortization), ending balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_21fd3287-612d-498f-9123-634a681aff44_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_label_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRisk1Table" xlink:to="lab_oncyf_ConcentrationRisk1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_8cfe11e2-1a9b-4adc-9094-9cb4bd9a24ff_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b6f0ff20-73a0-4a7d-835d-1631a23e10d8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_35cea436-99cb-4445-aaf6-5b71a031d4f1_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares (diluted) (shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_42034637-359f-40b6-95bd-ef3abfb274f6_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_258a18b1-dd65-482a-a6df-fa4be354b52b_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash taxes paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid (refund)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_370d8147-5f15-48bc-9928-82f6ab021872_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_label_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Share Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:to="lab_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_4cd86f62-b1bc-43f0-8e6e-8e4cce5941a1_terseLabel_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current annual interest rate</link:label>
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_label_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Interest Rate</link:label>
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_documentation_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashEquivalentsInterestRate" xlink:href="oncyf-20211231.xsd#oncyf_CashEquivalentsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashEquivalentsInterestRate" xlink:to="lab_oncyf_CashEquivalentsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_f4321541-440d-43ff-ac29-3d4343939c55_terseLabel_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment maximum</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_label_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Payment, Annual Maximum</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_documentation_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Payment, Annual Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:href="oncyf-20211231.xsd#oncyf_ContingentRoyaltyPaymentAnnualMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:to="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_5f9fdc91-4d66-4485-910a-dc89c365830b_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_778bdb0c-f45a-42b7-83ee-1b6c867b3d33_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses and adjustments</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:href="oncyf-20211231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_b1aa0d59-fafb-429a-bb7a-1f61de93b7bb_terseLabel_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized deferred tax asset</link:label>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_label_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_eec87f35-40b8-4e30-b032-5ae5d1f70400_terseLabel_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation - right-of-use assets (note 7, 21)</link:label>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_label_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Depreciation, Right-of Use Assets</link:label>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_documentation_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Depreciation, Right-of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:href="oncyf-20211231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:to="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_578a6397-a1b5-4c76-9cb7-d4143b5f79fd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_535bdad7-70c3-43f7-aefd-97f461da942d_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment due to founding shareholders, percent</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Received,Percentage</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Received, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0dd239cd-333e-44d3-9a94-5b2999ed2a25_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_7cdecd55-1b1b-43cb-952a-3b175c5f8663_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions</link:label>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember" xlink:to="lab_ifrs-full_OtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_965da2bb-5d3d-4227-a72b-a54faca97911_terseLabel_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_label_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_documentation_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:href="oncyf-20211231.xsd#oncyf_StockholdersEquityNoteStockSplitConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:to="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_afe7aeef-b2de-4b00-83c4-e556fa5253b6_terseLabel_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy</link:label>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_305dd68f-4144-4df0-a0d9-f75bb28fc36b_terseLabel_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_label_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_documentation_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:href="oncyf-20211231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:to="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesIssuedFairValueOfCommonShare_04c59518-5f8f-42f0-8317-82a40eeb4b22_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedFairValueOfCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, fair value of common share (usd per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedFairValueOfCommonShare_label_en-US" xlink:label="lab_oncyf_SharesIssuedFairValueOfCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Fair Value Of Common Share</link:label>
    <link:label id="lab_oncyf_SharesIssuedFairValueOfCommonShare_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedFairValueOfCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Fair Value Of Common Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedFairValueOfCommonShare" xlink:href="oncyf-20211231.xsd#oncyf_SharesIssuedFairValueOfCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedFairValueOfCommonShare" xlink:to="lab_oncyf_SharesIssuedFairValueOfCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_9c0da2e2-cd5d-4b75-b0e5-fe6015626405_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_48cad1ff-cca9-4428-a519-3ba2ef58fee5_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Statement1LineItems_529156e0-609e-4cac-924f-5911ac2746f2_terseLabel_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_label_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_documentation_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Statement1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems" xlink:href="oncyf-20211231.xsd#oncyf_Statement1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1LineItems" xlink:to="lab_oncyf_Statement1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AgreementDomain_d0ffc1e5-c5b6-4b38-aab6-057473022440_terseLabel_en-US" xlink:label="lab_oncyf_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:label id="lab_oncyf_AgreementDomain_label_en-US" xlink:label="lab_oncyf_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:label id="lab_oncyf_AgreementDomain_documentation_en-US" xlink:label="lab_oncyf_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AgreementDomain" xlink:href="oncyf-20211231.xsd#oncyf_AgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AgreementDomain" xlink:to="lab_oncyf_AgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_dfc95a23-143b-443d-84d1-81775b41d635_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_6353045f-b029-4167-90e0-9669c7e4de1a_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, end of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_480a454c-bde5-4fe6-ab90-09805fdbe1f7_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_9a658467-9cab-498a-8688-eca645a575d1_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyTwoMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyTwoMember" xlink:to="lab_oncyf_TwentyTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_86876788-7620-443c-98e5-f8d0bd6f7376_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for impairment of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_69f9e585-6b0c-4d9c-b41b-9aad30634223_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_9b234f2d-63b1-46cb-85ae-b453e8ba0223_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss for the year</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesMember_56a556b6-6cca-4e60-b3b3-e15be14d296a_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesMember_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesMember" xlink:to="lab_ifrs-full_CounterpartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_cc219a07-dad1-46f5-9656-b1b2105f9bc1_terseLabel_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_label_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment and furniture [Member]</link:label>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_documentation_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember" xlink:href="oncyf-20211231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OfficeEquipmentAndFurnitureMember" xlink:to="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_1430370c-a685-4008-a3c6-1adc6cf6c869_verboseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of capital components</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:to="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_53714295-1f1a-40c1-adc9-11233211cab2_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment on net sales due to founding shareholders, percent</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_7d1762ca-bab7-4398-b2ce-5b2e76e88ae4_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:href="oncyf-20211231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:to="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_10ff17ac-4bf4-43f2-a3ec-8da9e1ba1ddb_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_d0143c03-bbb8-44f1-bbf7-b97cbaf31928_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Concentration Risk Type1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems" xlink:to="lab_oncyf_ConcentrationRiskType1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b02d1449-554f-4bce-a79e-3a7daff9bbc1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_ca1a5c2b-bf18-45c4-8159-cfef92372f7d_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_0fc3a398-43de-4334-96ca-7b751c76f6d0_negatedLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_dbb3c6bc-ba8a-487f-aed0-83204a17713f_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:to="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContingenciesAbstract_ef056215-8966-4406-914e-563a527a3416_terseLabel_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_label_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_documentation_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract" xlink:href="oncyf-20211231.xsd#oncyf_ContingenciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingenciesAbstract" xlink:to="lab_oncyf_ContingenciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2ac0f570-0479-42f7-8d48-4ddecfd63660_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentSharesMember_d6fadb23-a33a-4d33-a61b-0e68d8f8bc93_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Shares</link:label>
    <link:label id="lab_oncyf_CommitmentSharesMember_label_en-US" xlink:label="lab_oncyf_CommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Shares [Member]</link:label>
    <link:label id="lab_oncyf_CommitmentSharesMember_documentation_en-US" xlink:label="lab_oncyf_CommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentSharesMember" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentSharesMember" xlink:to="lab_oncyf_CommitmentSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyNineMember_d88c2822-8b32-4189-aff6-c747dc6ff12d_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2039</link:label>
    <link:label id="lab_oncyf_TwentyThirtyNineMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Nine [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyNineMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyNineMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyNineMember" xlink:to="lab_oncyf_TwentyThirtyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyEightMember_64a60396-0997-4765-95e3-463e7d749c1c_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_oncyf_TwentyTwentyEightMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Eight [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyEightMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Eight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyEightMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyEightMember" xlink:to="lab_oncyf_TwentyTwentyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_5b7607fa-e466-4c15-9273-431073521f6e_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm" xlink:href="oncyf-20211231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementTerm" xlink:to="lab_oncyf_SharePurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_f0963f3a-48e6-4ad0-bafb-696d0a66f803_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_a62126bb-d343-49c4-ab28-bb0e73613aa0_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_53e73209-a062-46b5-8eba-5e7aa8d443d5_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_4dd845b8-5205-40b3-b26d-b8eaf3db1d90_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derecognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for derecognition of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_7530d5ff-69e6-4964-8512-b7f981ee754a_terseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed scientific research and experimental development expenditures</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_8031c343-2e85-43c7-b006-33e3f55aa981_verboseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific research and experimental development</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_label_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_documentation_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:href="oncyf-20211231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:to="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_be715618-d858-40b8-bfb2-7b31b77c7ce2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_a1535fb4-d438-4d21-8b10-67584d95be6b_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Warrants Outstanding</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_label_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Outstanding [Roll Forward]</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_documentation_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:href="oncyf-20211231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:to="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_EquityAuthorized_6bfbce5b-1ddf-47a3-ae23-9b14e58511df_terseLabel_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Shelf securities authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_label_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_documentation_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EquityAuthorized" xlink:href="oncyf-20211231.xsd#oncyf_EquityAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_EquityAuthorized" xlink:to="lab_oncyf_EquityAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_065c55df-2e1f-4a60-9481-3b79f4e45af5_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual depreciation rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_label_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:href="oncyf-20211231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:to="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_bc24f8e6-e51d-4f3c-8566-1238a39f1d27_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_91a9e4c3-f90a-40f3-a7ac-1cc63ae3b42c_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_a921c47e-e650-41b1-bd07-39f4621c4b17_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of outstanding warrants</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_0c64a6cc-53cc-4f01-a455-bfa3468ad9f6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_2d679779-dc0f-488d-8376-92a17f5653ce_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_5c5b066a-d75f-43a9-9828-9c60d337f154_verboseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation - right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_5762a0dc-2e9c-4e8a-80b1-fe2878a125f5_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Axis" xlink:to="lab_oncyf_ConcentrationRiskType1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_1cc5ae6a-1cd9-4756-bef9-4515f30ef28a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_3b13284b-5150-4e2a-bf5a-d94100eab2ce_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_3461397c-1f25-4996-80c9-bcd66ce2c86f_terseLabel_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share units</link:label>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_label_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units [Member]</link:label>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_documentation_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember" xlink:href="oncyf-20211231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RestrictedShareUnitsMember" xlink:to="lab_oncyf_RestrictedShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PaymentsForExecutoryContracts_251dcee5-8054-41b3-93d5-aa0fc3f051b8_terseLabel_en-US" xlink:label="lab_oncyf_PaymentsForExecutoryContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for executory contracts</link:label>
    <link:label id="lab_oncyf_PaymentsForExecutoryContracts_label_en-US" xlink:label="lab_oncyf_PaymentsForExecutoryContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Executory Contracts</link:label>
    <link:label id="lab_oncyf_PaymentsForExecutoryContracts_documentation_en-US" xlink:label="lab_oncyf_PaymentsForExecutoryContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Executory Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PaymentsForExecutoryContracts" xlink:href="oncyf-20211231.xsd#oncyf_PaymentsForExecutoryContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PaymentsForExecutoryContracts" xlink:to="lab_oncyf_PaymentsForExecutoryContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyOneMember_4e6e05f7-d69d-48e4-9df8-ac4c7eebd851_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2031</link:label>
    <link:label id="lab_oncyf_TwentyThirtyOneMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty One [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyOneMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyOneMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyOneMember" xlink:to="lab_oncyf_TwentyThirtyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_b7889cfa-8ca0-4d01-b25b-373560becb82_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_c6d52f10-ac30-4e98-94cd-46957863174c_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights2</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:to="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_4bc41736-2a50-40b8-b22a-7655cbf6de55_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_ad53b4e8-1669-47ee-89a7-c8af52e24d34_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability (note 12)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_9c5687c2-1362-4218-9df2-a93aeddcad85_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability - non-current</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_a9f67b67-5d5d-4569-90a5-ea852ce4bcdc_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_14c9d3e3-cc6a-422b-a422-33986960dad1_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities_6d5d86d1-9c7a-4997-9f17-d5838dff648d_terseLabel_en-US" xlink:label="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease modification</link:label>
    <link:label id="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities_label_en-US" xlink:label="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Lease Modification on Lease Liabilities</link:label>
    <link:label id="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities_documentation_en-US" xlink:label="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Lease Modification on Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:href="oncyf-20211231.xsd#oncyf_EffectOfLeaseModificationOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:to="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_65648384-02df-40ba-9c30-a22b1404303a_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital issued (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_dd70fb8f-9736-40ac-895c-5b1b95650770_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital issued, beginning (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_9a731627-f657-459d-b392-b0d2ab63cfd8_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital issued ending (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_c2ab2855-0151-483f-8da4-dd5f20a6fe4e_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:to="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_4a6b0253-7316-4edd-a35f-931c0c0bef82_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term employee compensation and benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_ba0c46ad-17da-439d-98df-6eeb01e4d723_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributed Surplus</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_8f5285b3-5da5-49ad-93e0-f1e1cfea55a5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates and Assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_95097777-766f-48ad-9cb6-4428ff49a81a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_f4d4937c-31c0-44c7-bf9a-18445a177935_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyEightMember_8c1bb6a3-5a37-4bcd-a10d-53d90d40c4d4_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2038</link:label>
    <link:label id="lab_oncyf_TwentyThirtyEightMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Eight [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyEightMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyEightMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyEightMember" xlink:to="lab_oncyf_TwentyThirtyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_ff6890eb-a92a-474e-bce8-66d51fa588d0_terseLabel_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment, maximum</link:label>
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_label_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded and Royalty Repayment</link:label>
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_documentation_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded and Royalty Repayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FundedandRoyaltyRepayment" xlink:href="oncyf-20211231.xsd#oncyf_FundedandRoyaltyRepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_FundedandRoyaltyRepayment" xlink:to="lab_oncyf_FundedandRoyaltyRepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_bf1a7455-54e3-427e-9daa-c2e7c1365a36_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_310df32a-3c63-4d95-821e-411163f217f5_terseLabel_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance share units</link:label>
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_label_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units [Member]</link:label>
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_documentation_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PerformanceShareUnitsMember" xlink:href="oncyf-20211231.xsd#oncyf_PerformanceShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PerformanceShareUnitsMember" xlink:to="lab_oncyf_PerformanceShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_bfd8e16c-cb9a-43b5-8545-f6978f79e8cd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccountingProfit_c7aad608-9a4a-4415-9f9b-59c5e1b17826_terseLabel_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_AccountingProfit_label_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccountingProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit" xlink:to="lab_ifrs-full_AccountingProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_0fc2c1a4-98f2-4f26-8ebf-6069c9b27395_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of related party transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Currency1LineItems_3a3f4d42-9127-48b7-bc54-b2f54d3ddeee_terseLabel_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_label_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_documentation_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Currency1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems" xlink:href="oncyf-20211231.xsd#oncyf_Currency1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1LineItems" xlink:to="lab_oncyf_Currency1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_706c9ac3-074c-413b-aabb-bb4fb29d8d29_terseLabel_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from common shares</link:label>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Issue Of Ordinary Shares</link:label>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_documentation_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Issue Of Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:href="oncyf-20211231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:to="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_091c82b5-72cf-40a1-b71b-3bce426c06f9_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One to five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_570c0c3c-7096-4a86-83a2-d60d16ae7f3f_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_9f869a55-8081-4361-9d89-f4085f36160c_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_341f9dd3-4008-4022-9baf-36f37bb8bf50_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_c7837f36-81e9-42f2-8a22-0c36acd85dcc_terseLabel_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_label_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) From Foreign Exchange Impact</link:label>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_documentation_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) From Foreign Exchange Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact" xlink:href="oncyf-20211231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GainsLossesFromForeignExchangeImpact" xlink:to="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_b5a399dc-644c-4d19-a628-fd7471f91f22_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average rate</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_0f3a1f49-e031-4c7c-a4e6-364e4b8d63a1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_0ddec177-95ff-4dde-9f5d-efa9a05fa753_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_63e1c7b8-671f-42ff-9dd0-1b3867fc7382_terseLabel_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual installment of gross sales of product, percent</link:label>
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_label_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Contingent Payment, Gross Sales, Percent</link:label>
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_documentation_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Contingent Payment, Gross Sales, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:href="oncyf-20211231.xsd#oncyf_AnnualContingentPaymentGrossSalesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:to="lab_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_563f55d6-e423-41f0-911a-564f37bc4d38_terseLabel_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number</link:label>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_label_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Number, Shares [Abstract]</link:label>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_documentation_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Number, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract" xlink:href="oncyf-20211231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract" xlink:to="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c2144f73-3467-4888-a41e-ccf3e8eb990b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_db1a2d41-544b-43d8-908d-2a772e0dd60b_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss items that may be reclassified to net loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_f9a08b87-dac4-4704-b7aa-6edd4ac5a1c8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommonSharesPerUnit_3d9486a7-0711-4b52-be0a-c920990f21e0_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares per unit (shares)</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_label_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_documentation_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit" xlink:href="oncyf-20211231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharesPerUnit" xlink:to="lab_oncyf_CommonSharesPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_4528d248-2063-47ac-93b0-1608e3773ce6_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_ab7161fe-d6cb-4f2a-96bf-d0ce01ab19af_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_Equity_0f0fcb14-9b1b-4aaa-bbcf-bb13e655034d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity balance at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Equity_9a67bb00-aa14-4c9b-9293-0941a12d15fb_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity balance at end of period</link:label>
    <link:label id="lab_ifrs-full_Equity_823a8cb3-a118-4d98-86d5-4adc025305a9_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b203e70a-9999-4d16-b3ef-f76e1f6df58c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_2377c717-85f6-44e4-bd97-ce1323b12569_terseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember" xlink:to="lab_ifrs-full_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_77b9636a-d871-4158-abfa-c005367eeb70_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_5a809bf6-5288-44cc-9ef4-d6bb7797368f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentySixMember_6f92a14a-d5d5-43a4-8b2f-6aa1b19d591e_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_oncyf_TwentyTwentySixMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Six [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentySixMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySixMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentySixMember" xlink:to="lab_oncyf_TwentyTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b3a538fb-751e-459e-ac22-ca3488463493_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_6c8e770d-63db-46d1-80c6-1c75d25cb581_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_0f1a5177-3f85-4501-8afc-3318ad464938_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_3de6e4bc-ea30-49e5-9ad6-e01adbb1cd94_terseLabel_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment on sales revenue, percent</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_label_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Payment, Percent Of Sales Revenue</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_documentation_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Payment, Percent Of Sales Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:href="oncyf-20211231.xsd#oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:to="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_5e1977df-6743-4e70-9bd3-c104070f8aea_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_ee204f75-2a62-4043-86d3-57370861a66c_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_d902e85c-3d88-4556-a3c8-7167196e6000_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of share-based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_6c1c98a3-2b83-4d66-b6dc-ad446036ce73_negatedTerseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in net loss due to change in currency value</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:href="oncyf-20211231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_84d799a3-cb83-4ae0-a583-eb7fc82bf755_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_390d71f7-e756-48cc-8a2b-e9b9ebf5aa12_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares issuable per warrant (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_MedicalEquipmentMember_f81aa081-5fd6-42f5-a24a-88785467a798_terseLabel_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical equipment</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_label_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_documentation_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember" xlink:href="oncyf-20211231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MedicalEquipmentMember" xlink:to="lab_oncyf_MedicalEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_939733a0-98f5-4080-aeab-d54c765951a8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_bf293ef4-d037-48d7-86f7-1bccf1c9b509_terseLabel_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_label_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelEmailAddress_3df671d6-6f48-4378-b243-238d3a10cbbc_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelEmailAddress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Email Address</link:label>
    <link:label id="lab_dei_ContactPersonnelEmailAddress_label_en-US" xlink:label="lab_dei_ContactPersonnelEmailAddress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Email Address</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress" xlink:to="lab_dei_ContactPersonnelEmailAddress" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_0ac46547-b875-40b8-ae8f-78a86f2f8e8c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_3d2829f7-a68f-40ba-8278-22bab5e7fe62_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable" xlink:href="oncyf-20211231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_911092c0-ede6-4d5e-bd2c-9d409f38d309_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_c1be21f0-e05b-4694-a3a7-bc158231a223_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_43bb1641-ee53-489c-87b8-9e011a71f5e5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_090efddc-a377-48c2-8f0d-a7b32a1e0f26_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_cbd916f5-3dbe-40de-b7d2-c61d9edcc7b1_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities And Shareholders&#8217; Equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_c0223060-facc-4da3-a8cd-05631fe4b932_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashEquivalentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalentsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_ce0542e5-9b80-4170-a6b7-cdbc66d9639a_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables (note 13)</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_05ea06d3-9bd2-4a13-86b2-117e8de1cc9f_terseLabel_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_1de7442c-f542-4e8f-8f68-46c7ae45fedc_verboseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease liability</link:label>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities" xlink:to="lab_ifrs-full_GrossLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_b4e3e240-6782-4421-af6f-6e9c8b336c16_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_e0b4dfbf-ed6f-43a3-933c-5c70fbb91331_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_e53dab5d-e4d0-4672-95f1-4aba2ea861ac_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_19dacbad-786a-438f-837e-109d4f859a9a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign exchange loss</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Statement1Table_cbcc0e7e-ee77-4d12-979b-8785caeb26f1_terseLabel_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_label_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_documentation_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table" xlink:href="oncyf-20211231.xsd#oncyf_Statement1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1Table" xlink:to="lab_oncyf_Statement1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_c468c625-fad3-4e9c-a379-0049c6d03df9_terseLabel_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected recognition period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_label_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_documentation_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod" xlink:href="oncyf-20211231.xsd#oncyf_ContractLiabilityRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContractLiabilityRecognitionPeriod" xlink:to="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_a79c5522-d4c6-43bc-9ef4-70d64c39cda4_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract" xlink:to="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_adb2376a-8bac-4211-9b41-fac7e463aa64_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Financial Statement Presentation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_7dbdb964-f197-4295-86d9-de637f746f1f_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from share issuance</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e57b2409-12b9-40f0-b8d0-86c34098ce8f_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SYNSORBMember_56fd3d93-cdd0-4c7e-aef7-67c34c13b770_terseLabel_en-US" xlink:label="lab_oncyf_SYNSORBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SYNSORB</link:label>
    <link:label id="lab_oncyf_SYNSORBMember_label_en-US" xlink:label="lab_oncyf_SYNSORBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SYNSORB [Member]</link:label>
    <link:label id="lab_oncyf_SYNSORBMember_documentation_en-US" xlink:label="lab_oncyf_SYNSORBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SYNSORB [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SYNSORBMember" xlink:href="oncyf-20211231.xsd#oncyf_SYNSORBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SYNSORBMember" xlink:to="lab_oncyf_SYNSORBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_362535f5-e47f-40f8-b4a6-a08e368aa85a_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability balances</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Explanation of significant changes in contract assets and contract liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_c102bfdf-6126-4764-8f61-130a205d50bf_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_959551a2-3e4e-4009-8516-7d671829d42a_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_ca89bc61-31ad-4f33-a675-20ba5ed585af_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_d70b34ac-8bdb-49e1-ab82-79a90052ee80_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_5d6a6fa9-e90a-42e6-8451-e531bd8e9dd4_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_626d2dac-ae6a-4d4c-b138-6b8c1b54da9b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_d4186b7f-db35-48c4-8772-217a8fa8bab2_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_label_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_10d25330-1724-4015-a775-d3fa257bcdd3_verboseLabel_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period, if not immediately vested</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_documentation_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:href="oncyf-20211231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_feb9221a-1733-4acb-857b-508b84708f17_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_26112f40-9985-4c42-8b37-5e3a91983f1c_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, beginning balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_b290400f-0545-427b-a5a2-9c9484525cfb_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, ending balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_dc936344-6d7c-4f31-a76e-8c0a597bcb32_terseLabel_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_label_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_documentation_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:href="oncyf-20211231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:to="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_9b93bc3d-5fa6-40ad-9aea-3faac32c583a_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiry of tax benefits</link:label>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_label_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Expiration Of Tax Benefits</link:label>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Expiration Of Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:to="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_cee47f19-91c3-48d4-a931-56920ef9c1d5_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_ef86ccc1-fc11-4d42-bee4-d8c985d31e5f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_4df35618-bac8-4bfa-a92d-ee4de2939d6e_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtySixMember_d43bbfd0-7d6a-4a8a-8318-633561ba8e05_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2036</link:label>
    <link:label id="lab_oncyf_TwentyThirtySixMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Six [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtySixMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySixMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtySixMember" xlink:to="lab_oncyf_TwentyThirtySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_997f38d6-a3c1-4af4-8ef0-7d0bda9554fc_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Canadian corporate tax rate</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_5cecb397-87d7-4361-8fdd-08d462d9c197_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regional licensing agreement</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d3465310-198a-4c35-a907-ef2c0f76e2f1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_9e3b3695-e9a3-4da8-97c5-c0a1d3578d60_terseLabel_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:href="oncyf-20211231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:to="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_53ac2c77-6280-442c-a9f1-630fffd05cb0_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount" xlink:href="oncyf-20211231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementAmount" xlink:to="lab_oncyf_SharePurchaseAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_822ae60b-53fc-4c2c-ac15-555e1ee8d422_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_738e31cc-e06a-4a85-9957-baa740ca9e48_terseLabel_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrant Derivative</link:label>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_label_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Warrant Derivative [Roll Forward]</link:label>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_documentation_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Warrant Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:href="oncyf-20211231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:to="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_c3fe7716-7805-4af1-bf0a-b944c527f93a_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_980f93f6-ce27-4062-bb1e-a600ae56d3c4_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability - current</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_f11f03de-e337-4190-b3fd-cfd996b41a01_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AuditorInformationAbstract_label_en-US" xlink:label="lab_oncyf_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_oncyf_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_oncyf_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AuditorInformationAbstract" xlink:href="oncyf-20211231.xsd#oncyf_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AuditorInformationAbstract" xlink:to="lab_oncyf_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_9bd44d07-5dd5-4ff5-a87b-6f2331699e89_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_bf6e53f8-6145-44df-a2f3-c94418009479_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_816e57e4-132d-4b0c-9dc3-30758253ad2d_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_c938b970-4e4e-483b-80ed-1cfe63a11cad_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, termination benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_c8c7788c-3939-4127-8b5a-ef44aba4a400_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_a21ad736-8ad8-46bf-9578-013c30794651_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease liability</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_85fc7545-248f-47ab-802f-35c5751d9a1a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyFortyMember_d0cc3eec-c3e9-4f4f-ba38-289c07d12f3f_terseLabel_en-US" xlink:label="lab_oncyf_TwentyFortyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2040</link:label>
    <link:label id="lab_oncyf_TwentyFortyMember_label_en-US" xlink:label="lab_oncyf_TwentyFortyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Forty [Member]</link:label>
    <link:label id="lab_oncyf_TwentyFortyMember_documentation_en-US" xlink:label="lab_oncyf_TwentyFortyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Forty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyFortyMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyFortyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyFortyMember" xlink:to="lab_oncyf_TwentyFortyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_9bb4064f-4c75-4af6-9415-9188a73bf451_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PurchaseObligation1_5f1aa7cf-7a33-462c-912c-bb6723944f50_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment for payment</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_label_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1" xlink:href="oncyf-20211231.xsd#oncyf_PurchaseObligation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligation1" xlink:to="lab_oncyf_PurchaseObligation1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod_bfac2551-c8da-422e-82ec-234dcdb11c16_terseLabel_en-US" xlink:label="lab_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cliff vesting period</link:label>
    <link:label id="lab_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod_label_en-US" xlink:label="lab_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Cliff Award Vesting Period</link:label>
    <link:label id="lab_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod_documentation_en-US" xlink:label="lab_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Cliff Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod" xlink:href="oncyf-20211231.xsd#oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod" xlink:to="lab_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_a56c127b-2cfb-4ad4-b2d5-c52d11202dee_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_ccde1152-08ae-47ac-a197-863b55aa1697_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:to="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_0a923297-67e1-4b5b-9112-1726288ac72e_negatedTerseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_label_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfStockBasedCompensation" xlink:to="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_45ffc918-b3fb-4b88-aa89-e659e2e064ac_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_1adbcd55-7f5b-49a1-b0d1-e95d4948c148_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_1a39ee29-d474-461b-bec9-8ddaa64c1643_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (note 10, 21, 22)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_d1d734ec-7c01-48df-88bb-927e47dc2f5a_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_e2a1c252-760d-4e25-9716-e627d0432c48_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_05d2387c-8b9b-475e-81dc-fac68fdae701_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_9edb89b6-2459-4f91-9af1-b1d229208d65_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (note 13, 14, 19)</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_label_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_documentation_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsAndContingencies1" xlink:to="lab_oncyf_CommitmentsAndContingencies1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_4d0ba9b8-d022-43c1-95ce-edc8c690391a_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Economic Dependence</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_47f197d0-3596-4974-9afc-1d68ca4454f5_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for deferred income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_dcf971bc-b306-4f2e-bd0c-e4ca4e870d17_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_88ebd7e7-9b0e-45e6-ba58-1f3fd4d51509_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$3.91 - $7.41</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFourMember" xlink:to="lab_oncyf_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_cc2f83a4-e62b-43dd-9f45-d969e6994df8_terseLabel_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toll manufacturer</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_label_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_documentation_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member" xlink:href="oncyf-20211231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SupplierConcentrationRisk1Member" xlink:to="lab_oncyf_SupplierConcentrationRisk1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingExpense_48bdb6c2-578f-4a47-90f6-ac576945ebe9_terseLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating (note 10, 21, 22)</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_b3a56e75-0653-4fac-804b-fdeacbf6c69e_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_58cc7f8c-77bf-4b08-bf56-f6c88c6c072f_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_4c5f2e8a-503e-4370-8fef-0900b2765190_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_8414852c-8106-40a6-8383-8f6414ce23bc_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_b5b3bbb9-bdfa-4943-8e01-12a7455ffa72_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards and Interpretations Issued but Not Yet Effective</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_8870cc21-00fd-4ee5-8270-84ad0fd41678_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2035</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Five [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFiveMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyFiveMember" xlink:to="lab_oncyf_TwentyThirtyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f7d13df2-e11f-4c70-a18a-f26a9b232843_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_92d5684f-6c55-46e3-b45b-4502edf611b7_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofincometaxAbstract" xlink:to="lab_oncyf_DisclosureofincometaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_6119a05c-7542-4d56-a136-0847072c00b2_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_9bdb4fcb-382e-461e-a45c-8e9c1e4e5656_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of change in fair value of warrant derivative</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_75fe1336-95db-418c-92cf-8d4ee8473b57_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_c678d0c7-353d-4781-88ee-550b7a602450_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment term</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_label_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Commitment Term</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Commitment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm" xlink:href="oncyf-20211231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligationCommitmentTerm" xlink:to="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_99c2e0bf-5384-4ba2-9fe7-4f3b9895547c_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive award plan</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_label_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:to="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019f7f4a-9ebe-4811-b658-5a41e5569868_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_d9422696-4915-408a-8cc8-e8b5c88f66fb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_8546126c-5cad-4f26-ad26-76d9e94d4513_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_1f85d25a-c075-466f-ba25-9428719c1bea_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_ca1f0449-d63c-4be0-9791-267934c9c3a7_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_0214c2dc-58dc-4281-8335-b3dae02df16c_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Exercisable (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_ad67b705-0d60-45c9-b768-87d5e6002f70_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_9ce23e51-5f56-4c29-a76d-286288af5da6_terseLabel_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in non-cash working capital</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_label_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:href="oncyf-20211231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:to="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_5285a02b-0eff-4a67-ae10-7967dec3a5ef_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options (note 10)</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_0bdf39ed-f096-4aaf-b2b5-050a262f7b5b_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issue of ordinary shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_27d93406-e286-4f79-8675-3fa3e647cf1c_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_27bc2b54-1d3f-4b99-812d-97276654afce_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares (basic) (shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_46eac441-07ce-45f2-b584-12cf11881e3c_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding (shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtySevenMember_4ada51b2-3c86-4a47-94c6-147b50f0a3db_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2037</link:label>
    <link:label id="lab_oncyf_TwentyThirtySevenMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Seven [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtySevenMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySevenMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtySevenMember" xlink:to="lab_oncyf_TwentyThirtySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_6cb500e5-eba8-467e-945c-6daec58f8816_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_d840f0c1-60ff-4c55-b3b7-a78681b4f122_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange loss (note 21)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_f547dfc0-b81a-48eb-9f84-ae633e7c5b2f_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash interest received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_label_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromInterestReceived" xlink:href="oncyf-20211231.xsd#oncyf_ProceedsfromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromInterestReceived" xlink:to="lab_oncyf_ProceedsfromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_8c0e010f-d32d-41d4-b296-62a6b88187c3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0303e7cc-2310-4172-9a2e-fb360430298f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_02d051b2-aa8a-4ac3-9805-75ffbd471d77_terseLabel_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Included in research and development expenses:</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentMember" xlink:href="oncyf-20211231.xsd#oncyf_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ResearchAndDevelopmentMember" xlink:to="lab_oncyf_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_5a0a87b8-c910-4a7a-97bc-d6211afbedd6_terseLabel_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_label_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Outstanding [Abstract]</link:label>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_documentation_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:href="oncyf-20211231.xsd#oncyf_WeightedAverageExercisePriceOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:to="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f505100e-f9d5-4973-9184-b438b843901f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OverheadRepayment_622ef911-0d74-432f-99f4-f5422f6345e6_terseLabel_en-US" xlink:label="lab_oncyf_OverheadRepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overhead repayment</link:label>
    <link:label id="lab_oncyf_OverheadRepayment_label_en-US" xlink:label="lab_oncyf_OverheadRepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overhead Repayment</link:label>
    <link:label id="lab_oncyf_OverheadRepayment_documentation_en-US" xlink:label="lab_oncyf_OverheadRepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overhead Repayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OverheadRepayment" xlink:href="oncyf-20211231.xsd#oncyf_OverheadRepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OverheadRepayment" xlink:to="lab_oncyf_OverheadRepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_7f7806f4-4158-4315-87d4-2fe8dfd71081_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options outstanding and exercisable by range of exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_9cd20939-a548-4f9f-8e28-66c75ec870a6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_2a967047-d714-48a6-a1de-840972dc3fae_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:href="oncyf-20211231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:to="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingEquityWarrantsMember_254d34d7-de03-4bd8-b770-760cc04551bb_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Equity Warrants</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingEquityWarrantsMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Equity Warrants [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingEquityWarrantsMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Equity Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingEquityWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:to="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_754896ee-e25d-4b31-958f-6ec644fbc566_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-capital losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_8572f9a6-1d87-43d0-9a3c-f69cffac6d85_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFiveMember" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyFiveMember" xlink:to="lab_oncyf_TwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_18031708-2184-43d8-b47f-be21054483b8_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_e3410a1d-c7c2-48c9-b61c-2a95a332e4da_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ea0b404f-61fa-4ac7-8ea5-99b37e6ed918_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractLiabilities_5bc1708a-f0cd-402b-a216-0d48d055b983_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_d907d10c-2d30-4374-8a22-044bc9355e5b_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_ab36bc5a-c84f-4bd9-86a7-48cf4eaa7c5d_totalLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_855276ac-4fae-4b6c-ac73-cd6f59bb2cdc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_da63745e-7075-4549-8876-2b6568318ddf_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable federal investment tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsMember" xlink:to="lab_ifrs-full_UnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_e7f55370-3f21-493d-be09-7fa1dc9f78aa_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_279a3f0f-37d5-481a-ae04-162d3b7146e9_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_444a8e09-587b-496a-a872-f08b0a753a88_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustment</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_9c8fd508-aa12-4267-a6e9-867981213dc7_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_0e837ed9-ad23-4227-b16f-56752482c33b_terseLabel_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_label_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_documentation_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet" xlink:href="oncyf-20211231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_BalanceHeldInForeignCurrencyNet" xlink:to="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ec9319ec-9d3c-4dbb-806d-10f8d45d34c7_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_45aba207-2840-45ee-8efe-ddf6bc5b0c19_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_22ef52f9-cb11-45b4-b43f-9448714a6435_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashEquivalents_31472173-7ffd-4b53-ad5d-9951b4c0dec2_terseLabel_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalents" xlink:to="lab_ifrs-full_CashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_76239e6d-af34-4fd2-b76d-083782992b43_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of commitments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_61ba7bce-be69-44f6-9bd2-c3916e1a68c5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivative</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_757ca870-b929-4f2a-85ed-20dba5f9be23_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Warrant Derivative Agreement</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_e0e5efff-1420-49b8-8dff-29f684297f46_verboseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivatives</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Warrant Derivatives [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Warrant Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:to="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_2ceba1fa-94fb-4bee-b2e6-4eefc7866642_terseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_ee3a534c-43ef-4a50-839c-3e7e3b380a17_terseLabel_en-US" xlink:label="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment in connection with share purchase agreement</link:label>
    <link:label id="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments made by entity, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:to="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_59eba676-147f-474c-adc9-0f9fa17a21f9_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareIssueCostsMember_9a3e40d7-20da-4b47-80dd-ce323713f33d_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_label_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_documentation_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember" xlink:href="oncyf-20211231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueCostsMember" xlink:to="lab_oncyf_ShareIssueCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_4914a791-f4aa-4b01-b069-9420ce634fd0_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. dollars</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_6adb6d3b-b6f6-4945-9672-e0b130a98ee8_verboseLabel_en-US" xlink:label="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_label_en-US" xlink:label="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Common Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:to="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_25354956-54df-46cd-8320-92ecf2af1edd_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_130d52a5-4cfc-4d35-8d62-4841225c4dc1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_5c5a39e7-48d9-4977-b61d-d2685b1852a8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AnnualContingentPayment_711e1358-cdb8-4ba8-85f8-9ccbfc2115a6_terseLabel_en-US" xlink:label="lab_oncyf_AnnualContingentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual installment of annual product sales</link:label>
    <link:label id="lab_oncyf_AnnualContingentPayment_label_en-US" xlink:label="lab_oncyf_AnnualContingentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Contingent Payment</link:label>
    <link:label id="lab_oncyf_AnnualContingentPayment_documentation_en-US" xlink:label="lab_oncyf_AnnualContingentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Contingent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPayment" xlink:href="oncyf-20211231.xsd#oncyf_AnnualContingentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AnnualContingentPayment" xlink:to="lab_oncyf_AnnualContingentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_1cca010b-89ac-42df-87bf-0ecb74f1ca47_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_817c59d9-bbe9-4eba-923d-5fdfcece475f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_c96c57c9-40bf-4043-af2e-a323b17d4888_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Axis" xlink:to="lab_oncyf_IncomeStatementLocation1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_286d61a5-f2fe-4776-8970-bce27cfbde35_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_a9a97577-b2f0-4bdc-9443-d79ad81faf1d_negatedTerseLabel_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred tax benefits deemed not probable to be recovered</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_label_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_documentation_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:href="oncyf-20211231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:to="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_b7d3b76c-351c-4405-a103-6a2f175eabea_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option plan</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_label_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderStockOptionPlanMember" xlink:to="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>38
<FILENAME>oncyf-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:04d38e4b-b411-4668-8f8c-e4013a42568d,g:242f92a0-4583-4d5d-9e63-4960e9cee1a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="simple" xlink:href="oncyf-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e94971c0-c04d-4133-85d1-caad97f0c69f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_3353e99b-29da-4ed9-bc94-20f95ff07af7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e94971c0-c04d-4133-85d1-caad97f0c69f" xlink:to="loc_dei_DocumentInformationTable_3353e99b-29da-4ed9-bc94-20f95ff07af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_a5c969fb-f62e-4241-ad12-631cd6640e8e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3353e99b-29da-4ed9-bc94-20f95ff07af7" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_a5c969fb-f62e-4241-ad12-631cd6640e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_f4f2d953-fb38-4721-9161-e6c21229c5fe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_a5c969fb-f62e-4241-ad12-631cd6640e8e" xlink:to="loc_dei_AddressTypeDomain_f4f2d953-fb38-4721-9161-e6c21229c5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_c826ecc9-6995-418d-8bb7-e1a9b03cef32" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_f4f2d953-fb38-4721-9161-e6c21229c5fe" xlink:to="loc_dei_BusinessContactMember_c826ecc9-6995-418d-8bb7-e1a9b03cef32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3353e99b-29da-4ed9-bc94-20f95ff07af7" xlink:to="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_036402fa-cc65-47a8-8240-d4083768906b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentType_036402fa-cc65-47a8-8240-d4083768906b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_592b42f1-e0e4-4492-ad03-f58a182389bf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentRegistrationStatement_592b42f1-e0e4-4492-ad03-f58a182389bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_672eb85d-d8ea-4a0b-8404-af62f03c1081" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentAnnualReport_672eb85d-d8ea-4a0b-8404-af62f03c1081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_829e8a6f-cc7d-4e3f-96f2-3ec97d3a569d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentPeriodEndDate_829e8a6f-cc7d-4e3f-96f2-3ec97d3a569d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1dbf57ca-8bbf-424b-8ea6-8f433e3c0746" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_CurrentFiscalYearEndDate_1dbf57ca-8bbf-424b-8ea6-8f433e3c0746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6024c2a4-945c-48e8-9b4f-2a4a1949af5f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentTransitionReport_6024c2a4-945c-48e8-9b4f-2a4a1949af5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_e3834ffa-3182-4a49-972f-460bc851f5d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentShellCompanyReport_e3834ffa-3182-4a49-972f-460bc851f5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f0e5355f-7252-4f26-a266-8f9e3e8c2d9a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityFileNumber_f0e5355f-7252-4f26-a266-8f9e3e8c2d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_db486f6b-f65b-403b-8571-433cabccef4b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityRegistrantName_db486f6b-f65b-403b-8571-433cabccef4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_45a1fd4d-e595-47b2-bbaa-ff27d0f114fa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityIncorporationStateCountryCode_45a1fd4d-e595-47b2-bbaa-ff27d0f114fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_60182e5c-fcdd-4620-98b8-3b681bd23cdf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityAddressAddressLine1_60182e5c-fcdd-4620-98b8-3b681bd23cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_23a36cb1-a873-4885-975c-bed2b5d1ee93" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityAddressCityOrTown_23a36cb1-a873-4885-975c-bed2b5d1ee93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_54bebb91-ff0b-4f1e-8745-3f9610fd8bc0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityAddressStateOrProvince_54bebb91-ff0b-4f1e-8745-3f9610fd8bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_c1db54db-0dc7-4f16-8b14-57d93feecafc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityAddressCountry_c1db54db-0dc7-4f16-8b14-57d93feecafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bf3ba5c8-2acd-4800-950e-08a551fdeb5a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityAddressPostalZipCode_bf3ba5c8-2acd-4800-950e-08a551fdeb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_a2ae6077-60ea-4dbb-9a5e-9790e59db303" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_ContactPersonnelName_a2ae6077-60ea-4dbb-9a5e-9790e59db303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_151d2c4a-c3b1-4510-b478-a96eeffba35b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_CityAreaCode_151d2c4a-c3b1-4510-b478-a96eeffba35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fc6aa4eb-793b-4910-b3fa-c7181805d014" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_LocalPhoneNumber_fc6aa4eb-793b-4910-b3fa-c7181805d014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress_5358b5f7-104f-49d1-ad8f-8a53ad27a95d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_ContactPersonnelEmailAddress_5358b5f7-104f-49d1-ad8f-8a53ad27a95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1a0a34a6-343d-43c7-94d3-22646401eed5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_Security12bTitle_1a0a34a6-343d-43c7-94d3-22646401eed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0f3aa367-3586-42f6-97c4-3caa9f0a9414" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_TradingSymbol_0f3aa367-3586-42f6-97c4-3caa9f0a9414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_63fb135e-61ac-47c2-9bc6-ad8128b71cb4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_SecurityExchangeName_63fb135e-61ac-47c2-9bc6-ad8128b71cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8fa4baae-387f-4947-945b-e5d5dfb37adb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8fa4baae-387f-4947-945b-e5d5dfb37adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_11066c8b-15f0-4e79-af8f-b88fb27131f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_11066c8b-15f0-4e79-af8f-b88fb27131f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_69e8dabf-9aef-41e5-9dae-3ce32f34a6a1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityVoluntaryFilers_69e8dabf-9aef-41e5-9dae-3ce32f34a6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8c12856c-1b6a-45e3-a2c4-e4adf49c94d8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityCurrentReportingStatus_8c12856c-1b6a-45e3-a2c4-e4adf49c94d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_66d111af-2bd0-4029-b714-fb541bb387a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityInteractiveDataCurrent_66d111af-2bd0-4029-b714-fb541bb387a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_da9d4ef4-ac2c-46fa-ba48-01c8b98fa729" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityFilerCategory_da9d4ef4-ac2c-46fa-ba48-01c8b98fa729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e92d106c-b61d-4d1f-b093-7f31c15fc39d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityEmergingGrowthCompany_e92d106c-b61d-4d1f-b093-7f31c15fc39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_e4ef8e56-0906-4982-ab16-44e8c21cbdac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_IcfrAuditorAttestationFlag_e4ef8e56-0906-4982-ab16-44e8c21cbdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_8d49a2c7-6fe2-437e-b6f7-f000d538b0ef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentAccountingStandard_8d49a2c7-6fe2-437e-b6f7-f000d538b0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2cd04d47-8569-401a-993a-100020a747e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityShellCompany_2cd04d47-8569-401a-993a-100020a747e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3c126ef3-a211-413a-af74-e97232d99579" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityCentralIndexKey_3c126ef3-a211-413a-af74-e97232d99579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a9d3cd9e-3496-4ff7-ac3e-7e6f4b4f4be0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentFiscalYearFocus_a9d3cd9e-3496-4ff7-ac3e-7e6f4b4f4be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_630bd552-1621-4182-9102-2ec872a50d35" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_DocumentFiscalPeriodFocus_630bd552-1621-4182-9102-2ec872a50d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9e8b3ba5-5268-4ba1-b4ee-af2135a4322e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_AmendmentFlag_9e8b3ba5-5268-4ba1-b4ee-af2135a4322e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_808aaf8f-ff34-4e84-9072-2da57dfde0eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_f9a0b1d0-0133-4efc-ae1f-66fed7e50617" xlink:to="loc_dei_EntityPublicFloat_808aaf8f-ff34-4e84-9072-2da57dfde0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AuditInformation" xlink:type="simple" xlink:href="oncyf-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AuditorInformationAbstract_afdf2ed0-5a2e-4a49-a9dd-be393f848e06" xlink:href="oncyf-20211231.xsd#oncyf_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_5fb05355-a4c6-483b-9c1f-5c41da93ad6a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_afdf2ed0-5a2e-4a49-a9dd-be393f848e06" xlink:to="loc_dei_AuditorFirmId_5fb05355-a4c6-483b-9c1f-5c41da93ad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_6ad9f48e-49c1-4e28-a0ca-57939a071894" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_afdf2ed0-5a2e-4a49-a9dd-be393f848e06" xlink:to="loc_dei_AuditorName_6ad9f48e-49c1-4e28-a0ca-57939a071894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_2f102a3c-d9a5-4104-9cb0-791e3319c9e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_afdf2ed0-5a2e-4a49-a9dd-be393f848e06" xlink:to="loc_dei_AuditorLocation_2f102a3c-d9a5-4104-9cb0-791e3319c9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_d6c08488-0059-467f-9e29-7f6e6fab6795" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_2e926613-7126-4906-b1aa-a3390aa06620" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_d6c08488-0059-467f-9e29-7f6e6fab6795" xlink:to="loc_ifrs-full_AssetsAbstract_2e926613-7126-4906-b1aa-a3390aa06620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_d6628bfb-4809-451e-9b74-ec6bbc90957c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_2e926613-7126-4906-b1aa-a3390aa06620" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_d6628bfb-4809-451e-9b74-ec6bbc90957c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_37a0288d-2d77-4554-bacd-9ac250e83bcb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_d6628bfb-4809-451e-9b74-ec6bbc90957c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_37a0288d-2d77-4554-bacd-9ac250e83bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_4e110115-37bd-4942-be92-925aa452958d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_d6628bfb-4809-451e-9b74-ec6bbc90957c" xlink:to="loc_ifrs-full_OtherCurrentReceivables_4e110115-37bd-4942-be92-925aa452958d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_b7cc3edd-df40-43f9-9894-690ad3f0e09b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_d6628bfb-4809-451e-9b74-ec6bbc90957c" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_b7cc3edd-df40-43f9-9894-690ad3f0e09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_59b3d49b-531b-4035-90b6-12f9d6e7ee08" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_d6628bfb-4809-451e-9b74-ec6bbc90957c" xlink:to="loc_ifrs-full_CurrentAssets_59b3d49b-531b-4035-90b6-12f9d6e7ee08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_b003ca1a-70e6-44a6-b0d3-4a6dd2c5f74d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_2e926613-7126-4906-b1aa-a3390aa06620" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_b003ca1a-70e6-44a6-b0d3-4a6dd2c5f74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_e62b20e4-6cd7-4e5f-9669-8bcff8b377d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_2e926613-7126-4906-b1aa-a3390aa06620" xlink:to="loc_ifrs-full_RightofuseAssets_e62b20e4-6cd7-4e5f-9669-8bcff8b377d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_94990041-c969-41b0-816f-a966c8045db6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_2e926613-7126-4906-b1aa-a3390aa06620" xlink:to="loc_ifrs-full_Assets_94990041-c969-41b0-816f-a966c8045db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_c51030e1-6244-4c18-bf0e-1ce8001dbbff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_d6c08488-0059-467f-9e29-7f6e6fab6795" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_c51030e1-6244-4c18-bf0e-1ce8001dbbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_a5fbb1ee-c661-41ae-8225-64f8b0130fa0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_c51030e1-6244-4c18-bf0e-1ce8001dbbff" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_a5fbb1ee-c661-41ae-8225-64f8b0130fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_2b897d32-ff6d-45c4-a8d1-e35768f48e69" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_a5fbb1ee-c661-41ae-8225-64f8b0130fa0" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_2b897d32-ff6d-45c4-a8d1-e35768f48e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_c18ab96c-214c-4a27-ae1b-5c83acb44d1e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_a5fbb1ee-c661-41ae-8225-64f8b0130fa0" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_c18ab96c-214c-4a27-ae1b-5c83acb44d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_dfbd879b-4155-4159-9502-7224e3f66d69" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_a5fbb1ee-c661-41ae-8225-64f8b0130fa0" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_dfbd879b-4155-4159-9502-7224e3f66d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_fc389a40-0b9d-4d3c-bbe6-433aa7a66825" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_a5fbb1ee-c661-41ae-8225-64f8b0130fa0" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_fc389a40-0b9d-4d3c-bbe6-433aa7a66825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_bd20e0d6-0170-4093-95cb-673a3d14f9b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_a5fbb1ee-c661-41ae-8225-64f8b0130fa0" xlink:to="loc_ifrs-full_CurrentLiabilities_bd20e0d6-0170-4093-95cb-673a3d14f9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_2069568b-e82e-47fc-8962-f13633450535" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_c51030e1-6244-4c18-bf0e-1ce8001dbbff" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_2069568b-e82e-47fc-8962-f13633450535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_5550ad76-fbc4-4b4f-a76e-75d1be492946" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_c51030e1-6244-4c18-bf0e-1ce8001dbbff" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_5550ad76-fbc4-4b4f-a76e-75d1be492946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_dfc81bd1-c361-427d-a549-2f0dc6e01d1b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_c51030e1-6244-4c18-bf0e-1ce8001dbbff" xlink:to="loc_ifrs-full_Liabilities_dfc81bd1-c361-427d-a549-2f0dc6e01d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1_ff37dfe3-3aa4-4a07-9b15-31c78315c235" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_c51030e1-6244-4c18-bf0e-1ce8001dbbff" xlink:to="loc_oncyf_CommitmentsAndContingencies1_ff37dfe3-3aa4-4a07-9b15-31c78315c235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_54dd0c74-2540-4881-8cc4-808afb8c0d39" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_c51030e1-6244-4c18-bf0e-1ce8001dbbff" xlink:to="loc_ifrs-full_EquityAbstract_54dd0c74-2540-4881-8cc4-808afb8c0d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_af254c5b-a90c-45fd-a66c-1ab6f925ac56" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_54dd0c74-2540-4881-8cc4-808afb8c0d39" xlink:to="loc_ifrs-full_IssuedCapital_af254c5b-a90c-45fd-a66c-1ab6f925ac56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_8ba3fb7c-926d-4c52-acd7-1833e452e12a" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsandRightsOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_54dd0c74-2540-4881-8cc4-808afb8c0d39" xlink:to="loc_oncyf_WarrantsandRightsOutstanding_8ba3fb7c-926d-4c52-acd7-1833e452e12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_1aba3d7e-f0e7-4935-834e-5824367bfbf3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_54dd0c74-2540-4881-8cc4-808afb8c0d39" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_1aba3d7e-f0e7-4935-834e-5824367bfbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6f381601-c7c7-42d8-aa52-d631c801def9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_54dd0c74-2540-4881-8cc4-808afb8c0d39" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6f381601-c7c7-42d8-aa52-d631c801def9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_2b5a81fc-86c1-4f16-b63e-9571d91cbcef" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_54dd0c74-2540-4881-8cc4-808afb8c0d39" xlink:to="loc_ifrs-full_RetainedEarnings_2b5a81fc-86c1-4f16-b63e-9571d91cbcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_df77ee28-f25b-4a17-958b-77f9c917a5a6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_54dd0c74-2540-4881-8cc4-808afb8c0d39" xlink:to="loc_ifrs-full_Equity_df77ee28-f25b-4a17-958b-77f9c917a5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_7bf1fb65-2e5b-4fad-b992-1042d988ae6c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_c51030e1-6244-4c18-bf0e-1ce8001dbbff" xlink:to="loc_ifrs-full_EquityAndLiabilities_7bf1fb65-2e5b-4fad-b992-1042d988ae6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_e308d99c-d5ad-4a12-a944-88f3069b55c0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_e052e58c-9032-4c9e-b767-0ee71bd79655" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_e308d99c-d5ad-4a12-a944-88f3069b55c0" xlink:to="loc_ifrs-full_EquityAbstract_e052e58c-9032-4c9e-b767-0ee71bd79655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_4cee00a1-dcde-49d0-a92c-cc7766a039d6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_e052e58c-9032-4c9e-b767-0ee71bd79655" xlink:to="loc_ifrs-full_NumberOfSharesIssued_4cee00a1-dcde-49d0-a92c-cc7766a039d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_6a006de3-a1da-4113-aaa8-50bc86c846e5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_ExpenseByNatureAbstract_6a006de3-a1da-4113-aaa8-50bc86c846e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_bccd83e4-6563-472f-ac70-c505b3525de9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_6a006de3-a1da-4113-aaa8-50bc86c846e5" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_bccd83e4-6563-472f-ac70-c505b3525de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_60aec698-9e75-405b-a530-dc672dbde737" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_6a006de3-a1da-4113-aaa8-50bc86c846e5" xlink:to="loc_ifrs-full_OperatingExpense_60aec698-9e75-405b-a530-dc672dbde737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_31527ba6-3fda-4585-aee8-b661702f4a9e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_31527ba6-3fda-4585-aee8-b661702f4a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_5a8ecc5d-7575-4ff0-b372-9390c3be1211" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_5a8ecc5d-7575-4ff0-b372-9390c3be1211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_16bc5a05-4513-4fbc-8215-5df42935cdac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_16bc5a05-4513-4fbc-8215-5df42935cdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_0a279d41-e47b-4277-a25e-0ff5edcbe600" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_0a279d41-e47b-4277-a25e-0ff5edcbe600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_350c7f0f-e022-4ae4-996a-bf6dbd8c4bd2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_350c7f0f-e022-4ae4-996a-bf6dbd8c4bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_706fe4dc-1559-42f3-accc-7b2955639b01" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_706fe4dc-1559-42f3-accc-7b2955639b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_d1c06deb-071e-483a-823c-2cfee44af252" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_ProfitLoss_d1c06deb-071e-483a-823c-2cfee44af252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_123e40ae-41da-4f7d-9af9-cbb4f8824ddd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_123e40ae-41da-4f7d-9af9-cbb4f8824ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ceb6d8c6-9535-4011-89c8-e5b24c052958" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_123e40ae-41da-4f7d-9af9-cbb4f8824ddd" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ceb6d8c6-9535-4011-89c8-e5b24c052958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_584ff016-b40d-4250-bacc-2729785359b8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_ComprehensiveIncome_584ff016-b40d-4250-bacc-2729785359b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_e582c6c5-a532-4d4a-9e9a-781d5d3189ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_e582c6c5-a532-4d4a-9e9a-781d5d3189ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_61e2e6d0-b6d5-4348-8d13-27230d527deb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_61e2e6d0-b6d5-4348-8d13-27230d527deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_5c72a350-e9b0-4951-84e4-65397f7bb3f7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_WeightedAverageShares_5c72a350-e9b0-4951-84e4-65397f7bb3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_cba60129-8765-49bd-80fe-b2343e4a766c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_75e456ea-3eea-4c3e-8b26-42562aa525cd" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_cba60129-8765-49bd-80fe-b2343e4a766c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_794b6d36-e95f-4830-8785-7da5840c1486" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_0e6c5fbf-9e35-4efc-bf29-f197e9155f5d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_794b6d36-e95f-4830-8785-7da5840c1486" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_0e6c5fbf-9e35-4efc-bf29-f197e9155f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_e424dc73-ce18-4f17-9509-6f44b6309ff9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0e6c5fbf-9e35-4efc-bf29-f197e9155f5d" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_e424dc73-ce18-4f17-9509-6f44b6309ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_e424dc73-ce18-4f17-9509-6f44b6309ff9" xlink:to="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_4b41f092-61a2-4029-98b7-940bebcd1fd9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:to="loc_ifrs-full_IssuedCapitalMember_4b41f092-61a2-4029-98b7-940bebcd1fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_a6ab1982-2c7a-43e9-a515-9ff92e977dbf" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:to="loc_oncyf_WarrantsMember_a6ab1982-2c7a-43e9-a515-9ff92e977dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_d775b379-b62f-492a-9813-9e3af1201ede" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:to="loc_ifrs-full_SharePremiumMember_d775b379-b62f-492a-9813-9e3af1201ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_c6845257-7088-4ab8-b5f8-0a421005a87b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_c6845257-7088-4ab8-b5f8-0a421005a87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_a41ef9ca-ed18-4c1d-b87d-7619bbd08b96" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_6525545b-aaeb-4163-a428-bdf192f7f158" xlink:to="loc_ifrs-full_RetainedEarningsMember_a41ef9ca-ed18-4c1d-b87d-7619bbd08b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_914b8985-2b7f-4004-8fbf-28e0ebadcbf1" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0e6c5fbf-9e35-4efc-bf29-f197e9155f5d" xlink:to="loc_oncyf_SaleOfStockAxis_914b8985-2b7f-4004-8fbf-28e0ebadcbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_f7f49220-7368-4bfe-b142-0018a2ae4f0c" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_914b8985-2b7f-4004-8fbf-28e0ebadcbf1" xlink:to="loc_oncyf_SaleOfStockDomain_f7f49220-7368-4bfe-b142-0018a2ae4f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_4b81ab7e-35b5-4d8d-9ab3-cb6632b31bf6" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_f7f49220-7368-4bfe-b142-0018a2ae4f0c" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_4b81ab7e-35b5-4d8d-9ab3-cb6632b31bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_8d0ad350-d389-4621-9cba-11447302ac5f" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_f7f49220-7368-4bfe-b142-0018a2ae4f0c" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_8d0ad350-d389-4621-9cba-11447302ac5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_d3921540-806d-4eb8-846e-abbcb7599b14" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_f7f49220-7368-4bfe-b142-0018a2ae4f0c" xlink:to="loc_oncyf_SharesPublicOfferingMember_d3921540-806d-4eb8-846e-abbcb7599b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0e6c5fbf-9e35-4efc-bf29-f197e9155f5d" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5970ccd6-5f0f-4643-899a-3fa65e336419" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_Equity_5970ccd6-5f0f-4643-899a-3fa65e336419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_cf639a48-bb57-48de-af9c-3aa699b63946" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_ComprehensiveIncome_cf639a48-bb57-48de-af9c-3aa699b63946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_336c9677-9fd9-45ab-978d-e62128caf927" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_336c9677-9fd9-45ab-978d-e62128caf927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_78e68c01-92aa-4ff4-919b-aef34ede6002" xlink:href="oncyf-20211231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_78e68c01-92aa-4ff4-919b-aef34ede6002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_15ed5ff6-b2d9-4bf3-b458-bd41ae6c47a2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_IssueOfEquity_15ed5ff6-b2d9-4bf3-b458-bd41ae6c47a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_4d6d72f5-b2d2-45c1-a1bf-b098df24230d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_4d6d72f5-b2d2-45c1-a1bf-b098df24230d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_cf91f06f-7b70-4dd4-9757-c448f1bb25ff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_cf91f06f-7b70-4dd4-9757-c448f1bb25ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_fc77d74e-930e-4eec-bb4a-fbcdafc5f224" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_fc77d74e-930e-4eec-bb4a-fbcdafc5f224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_1daa9202-5693-4938-9e7b-25f6e40ddad5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_3a87f6c4-bda3-49f1-b2a7-f89b0b57ccad" xlink:to="loc_ifrs-full_Equity_1daa9202-5693-4938-9e7b-25f6e40ddad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_788cb986-cbbc-42cb-bad2-795f45102f41" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table_0aad9327-39ba-439b-a626-0cb93ebfc32a" xlink:href="oncyf-20211231.xsd#oncyf_Statement1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_788cb986-cbbc-42cb-bad2-795f45102f41" xlink:to="loc_oncyf_Statement1Table_0aad9327-39ba-439b-a626-0cb93ebfc32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_822990fc-7bb8-4ab5-b2c8-49bc62e044f3" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_0aad9327-39ba-439b-a626-0cb93ebfc32a" xlink:to="loc_oncyf_SaleOfStockAxis_822990fc-7bb8-4ab5-b2c8-49bc62e044f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_822990fc-7bb8-4ab5-b2c8-49bc62e044f3" xlink:to="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_b3195fa1-e6ab-4fd6-a6b0-1d949d37712c" xlink:href="oncyf-20211231.xsd#oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:to="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_b3195fa1-e6ab-4fd6-a6b0-1d949d37712c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_074452a4-15a2-476d-a230-78abdf7e21d2" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_074452a4-15a2-476d-a230-78abdf7e21d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_982ab64c-4381-4d72-ab90-469c39d0bcaa" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_982ab64c-4381-4d72-ab90-469c39d0bcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_4a4cad95-990d-49e9-a0d3-d2c30fb1c89b" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_b5a6b650-b99f-4577-9550-e9191592af73" xlink:to="loc_oncyf_SharesPublicOfferingMember_4a4cad95-990d-49e9-a0d3-d2c30fb1c89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:href="oncyf-20211231.xsd#oncyf_Statement1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_0aad9327-39ba-439b-a626-0cb93ebfc32a" xlink:to="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_4d1eb062-09ca-4b73-80bf-d62a94592d6b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_ProfitLoss_4d1eb062-09ca-4b73-80bf-d62a94592d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_4fef8432-f8c6-43e8-a135-3e067ac772e5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_4fef8432-f8c6-43e8-a135-3e067ac772e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_a137fed0-3726-4cf9-bb0f-1b8492cad762" xlink:href="oncyf-20211231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_a137fed0-3726-4cf9-bb0f-1b8492cad762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_f7aa7cba-43e2-4db3-b508-1541442840d4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_f7aa7cba-43e2-4db3-b508-1541442840d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_44c6a6c9-efbb-4309-bc3e-a01e219a3ce6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_44c6a6c9-efbb-4309-bc3e-a01e219a3ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_bced4724-490e-4806-ac88-26dba94f5ee0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_bced4724-490e-4806-ac88-26dba94f5ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_63e5a1b4-fde1-40d4-b4a8-7af3f0c41c3b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_63e5a1b4-fde1-40d4-b4a8-7af3f0c41c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_0b9c91aa-d35f-43b5-9bd0-f6c8ffe87583" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_0b9c91aa-d35f-43b5-9bd0-f6c8ffe87583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_4f873683-0cc5-46d2-8f04-93493fb3a94e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_d4cb7b20-e90d-485b-a9f6-1907efef4135" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_4f873683-0cc5-46d2-8f04-93493fb3a94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_dc9c31d3-7d00-48cb-8c4d-fd568e476fa6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_dc9c31d3-7d00-48cb-8c4d-fd568e476fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_8a5df9a7-e6d6-40c8-a7f9-ef2c9596621a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_dc9c31d3-7d00-48cb-8c4d-fd568e476fa6" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_8a5df9a7-e6d6-40c8-a7f9-ef2c9596621a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_df6aac6e-1c77-4ed2-b408-debfd431f27e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_dc9c31d3-7d00-48cb-8c4d-fd568e476fa6" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_df6aac6e-1c77-4ed2-b408-debfd431f27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_0a05ae6e-c892-4c8e-8a3f-219152db3fc4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_0a05ae6e-c892-4c8e-8a3f-219152db3fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_bd9eeee4-cc83-45d0-9577-a8a5e641fc95" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_bd9eeee4-cc83-45d0-9577-a8a5e641fc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_60489474-a777-40b0-8cf7-ca602d0cced2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:to="loc_ifrs-full_CashOutflowForLeases_60489474-a777-40b0-8cf7-ca602d0cced2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a171734d-b6cb-489a-8216-b1d6d2b591cc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_4f26632d-3f49-4017-b656-ebf7ddc6c624" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a171734d-b6cb-489a-8216-b1d6d2b591cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_dd513533-0b96-4ac8-b71f-177f8c1fd138" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_dd513533-0b96-4ac8-b71f-177f8c1fd138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_a77ddb12-cc04-47ef-84bb-66939ec9a5e6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_CashAndCashEquivalents_a77ddb12-cc04-47ef-84bb-66939ec9a5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_953611b0-c22a-4ffe-9e45-0290722375fe" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_953611b0-c22a-4ffe-9e45-0290722375fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_22ca9004-205f-47bb-80e9-93b45de5f123" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_ffa24b0d-c284-44d1-8464-1f95fe5e0fee" xlink:to="loc_ifrs-full_CashAndCashEquivalents_22ca9004-205f-47bb-80e9-93b45de5f123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IncorporationandNatureofOperations"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_fb5a2435-ea06-447e-b94c-ff31c6f4ab6a" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_57f29d33-ff99-499a-9628-3e18988350e5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_fb5a2435-ea06-447e-b94c-ff31c6f4ab6a" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_57f29d33-ff99-499a-9628-3e18988350e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation" xlink:type="simple" xlink:href="oncyf-20211231.xsd#BasisofFinancialStatementPresentation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_af17c63e-53fd-4d9c-baf7-e3930d3247e2" xlink:href="oncyf-20211231.xsd#oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_493d4553-a039-40ce-b955-c8a47e5ecb4f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_af17c63e-53fd-4d9c-baf7-e3930d3247e2" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_493d4553-a039-40ce-b955-c8a47e5ecb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="oncyf-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9a48ed6b-76b7-450e-bd1c-e19515641c97" xlink:href="oncyf-20211231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_0bba9fd8-c7b4-4a88-add0-867946d98633" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9a48ed6b-76b7-450e-bd1c-e19515641c97" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_0bba9fd8-c7b4-4a88-add0-867946d98633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="oncyf-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:href="oncyf-20211231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_28300b73-d227-44b6-97e7-9ca17c79cc38" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_28300b73-d227-44b6-97e7-9ca17c79cc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_5fd39eff-bb63-44d0-a658-8cc3b2f3cc25" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_5fd39eff-bb63-44d0-a658-8cc3b2f3cc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_c5cacd19-c52d-44ef-bb1d-7dfdac98296e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_c5cacd19-c52d-44ef-bb1d-7dfdac98296e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_c5bb1628-ac9c-4086-b74f-d1ef8cd31c8d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_c5bb1628-ac9c-4086-b74f-d1ef8cd31c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_20825f3a-e708-44a9-9c01-4fbfd5a3628f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_20825f3a-e708-44a9-9c01-4fbfd5a3628f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_353c6f65-20d6-464f-946e-f987f086454c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_353c6f65-20d6-464f-946e-f987f086454c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_9ba5f00e-7126-4514-80fb-442f57178c85" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_9ba5f00e-7126-4514-80fb-442f57178c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_0aef48b0-bf73-4ede-a048-468bf2ea1d71" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_0aef48b0-bf73-4ede-a048-468bf2ea1d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_9d3b415e-6023-4c5f-a1c8-7a29b5537f94" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_9d3b415e-6023-4c5f-a1c8-7a29b5537f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_d50499bf-8ea3-421a-9551-470e9b8562d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_d50499bf-8ea3-421a-9551-470e9b8562d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_487a251f-17db-4d61-a102-d32fc98c929b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_487a251f-17db-4d61-a102-d32fc98c929b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_5d01f621-8b6b-4a04-8116-4be809fc3017" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_5d01f621-8b6b-4a04-8116-4be809fc3017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_43a2e97d-c31a-477d-b89a-22477c18a64e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_43a2e97d-c31a-477d-b89a-22477c18a64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_9e7ec43b-85d7-4b6f-9ff0-988d9454fbd8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fa41263b-b003-4612-a05e-a904d4e137e6" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_9e7ec43b-85d7-4b6f-9ff0-988d9454fbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_ca39ad44-8bbc-4026-81ff-fbe73657b799" xlink:href="oncyf-20211231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_1fff9757-7070-4180-bec4-388ad79b4bde" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_ca39ad44-8bbc-4026-81ff-fbe73657b799" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_1fff9757-7070-4180-bec4-388ad79b4bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_0948591d-7752-45ce-b8ec-f4a950c3b487" xlink:href="oncyf-20211231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2cf7a6b3-fcd6-45f4-91cb-d966132033db" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_0948591d-7752-45ce-b8ec-f4a950c3b487" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2cf7a6b3-fcd6-45f4-91cb-d966132033db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_0146ec71-ad3d-4b27-ad57-9f070bf53287" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2cf7a6b3-fcd6-45f4-91cb-d966132033db" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_0146ec71-ad3d-4b27-ad57-9f070bf53287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_31f23cea-e520-4619-90dc-a19220256b20" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_0146ec71-ad3d-4b27-ad57-9f070bf53287" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_31f23cea-e520-4619-90dc-a19220256b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_6aa11733-2dd9-4635-934a-2118fea9d406" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_31f23cea-e520-4619-90dc-a19220256b20" xlink:to="loc_ifrs-full_OfficeEquipmentMember_6aa11733-2dd9-4635-934a-2118fea9d406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_d33e2696-78ef-4fd0-80ce-b487d0aae9e3" xlink:href="oncyf-20211231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_31f23cea-e520-4619-90dc-a19220256b20" xlink:to="loc_oncyf_MedicalEquipmentMember_d33e2696-78ef-4fd0-80ce-b487d0aae9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_4175ddb5-aa07-4be4-b113-78ad4a359a84" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_31f23cea-e520-4619-90dc-a19220256b20" xlink:to="loc_ifrs-full_ComputerEquipmentMember_4175ddb5-aa07-4be4-b113-78ad4a359a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ffb255ab-edd8-4aa8-b4fe-4087aeed8811" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2cf7a6b3-fcd6-45f4-91cb-d966132033db" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ffb255ab-edd8-4aa8-b4fe-4087aeed8811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_84d0b64e-3952-45ef-95a6-d5d0fadb80ae" xlink:href="oncyf-20211231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ffb255ab-edd8-4aa8-b4fe-4087aeed8811" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_84d0b64e-3952-45ef-95a6-d5d0fadb80ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_c222bfc4-40cf-4e51-a2f5-b76b1c05e416" xlink:href="oncyf-20211231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfStockOptionPlans_e7b3c118-cf4f-4dbf-9fd6-98556569b391" xlink:href="oncyf-20211231.xsd#oncyf_NumberOfStockOptionPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_c222bfc4-40cf-4e51-a2f5-b76b1c05e416" xlink:to="loc_oncyf_NumberOfStockOptionPlans_e7b3c118-cf4f-4dbf-9fd6-98556569b391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_ea21b6c2-1653-4691-9e51-2babe06f0302" xlink:href="oncyf-20211231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_c222bfc4-40cf-4e51-a2f5-b76b1c05e416" xlink:to="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_ea21b6c2-1653-4691-9e51-2babe06f0302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="simple" xlink:href="oncyf-20211231.xsd#SignificantJudgmentsEstimatesandAssumptions"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_8e75ec10-637e-4499-935b-af5e413dbedc" xlink:href="oncyf-20211231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_9ddcd4de-8c07-436e-821d-7128f1448865" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_8e75ec10-637e-4499-935b-af5e413dbedc" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_9ddcd4de-8c07-436e-821d-7128f1448865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CashEquivalents"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalentsAbstract_5e9c236c-5839-4b89-a7aa-64fcaad996fe" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_87111618-0a8e-40b6-8bfa-a8a1da504a2b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashEquivalentsAbstract_5e9c236c-5839-4b89-a7aa-64fcaad996fe" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_87111618-0a8e-40b6-8bfa-a8a1da504a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalentsAbstract_5ee01937-a9a2-4ee5-8bff-12e187547f11" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_0e729886-3726-4d92-a0ed-b8c1122a04c9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashEquivalentsAbstract_5ee01937-a9a2-4ee5-8bff-12e187547f11" xlink:to="loc_ifrs-full_CashEquivalents_0e729886-3726-4d92-a0ed-b8c1122a04c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashEquivalentsInterestRate_d5eeafd8-ccc7-4f4d-9f30-83734949e721" xlink:href="oncyf-20211231.xsd#oncyf_CashEquivalentsInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashEquivalentsAbstract_5ee01937-a9a2-4ee5-8bff-12e187547f11" xlink:to="loc_oncyf_CashEquivalentsInterestRate_d5eeafd8-ccc7-4f4d-9f30-83734949e721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="oncyf-20211231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_b2b90f99-fc93-4f8e-9347-089e71090dd0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_c8f0a91e-e7dc-4437-919f-754bbdc76c61" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_b2b90f99-fc93-4f8e-9347-089e71090dd0" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_c8f0a91e-e7dc-4437-919f-754bbdc76c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_3a3646f2-c5a5-4f55-b3ca-76b6207061d2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_d9cc97dc-2f6e-4edf-b1e3-b539c98fbe3b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_3a3646f2-c5a5-4f55-b3ca-76b6207061d2" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_d9cc97dc-2f6e-4edf-b1e3-b539c98fbe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_9d8ccaf7-642f-4c65-ae97-0aceccafdcd2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2393f9df-82b0-4482-ae60-d2883c1572fd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_9d8ccaf7-642f-4c65-ae97-0aceccafdcd2" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2393f9df-82b0-4482-ae60-d2883c1572fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4dbb3db-bfcc-4df6-9201-1e9cdd404243" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2393f9df-82b0-4482-ae60-d2883c1572fd" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4dbb3db-bfcc-4df6-9201-1e9cdd404243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4dbb3db-bfcc-4df6-9201-1e9cdd404243" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_d015d0bf-20ee-410c-b4f0-8088cc059c24" xlink:href="oncyf-20211231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:to="loc_oncyf_MedicalEquipmentMember_d015d0bf-20ee-410c-b4f0-8088cc059c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_58b10751-3e08-4d2c-9314-754a61775514" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:to="loc_ifrs-full_ComputerEquipmentMember_58b10751-3e08-4d2c-9314-754a61775514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember_1d2cf5ab-32d2-4d8f-9408-39a4744d2cb5" xlink:href="oncyf-20211231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:to="loc_oncyf_OfficeEquipmentAndFurnitureMember_1d2cf5ab-32d2-4d8f-9408-39a4744d2cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_fe70fe1f-f0d9-4dea-b07f-c90bca1396ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_d85a6ce4-2176-4eec-a01a-9c873d7e70d0" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_fe70fe1f-f0d9-4dea-b07f-c90bca1396ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1b22826d-d526-430d-8096-f566e93807da" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2393f9df-82b0-4482-ae60-d2883c1572fd" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1b22826d-d526-430d-8096-f566e93807da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_31c541d4-a124-4e2c-aa49-b6d871e3d924" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1b22826d-d526-430d-8096-f566e93807da" xlink:to="loc_ifrs-full_CarryingAmountMember_31c541d4-a124-4e2c-aa49-b6d871e3d924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_68331997-40e3-4cfa-bc7c-c589d802ef5e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_31c541d4-a124-4e2c-aa49-b6d871e3d924" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_68331997-40e3-4cfa-bc7c-c589d802ef5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_be95d3be-1a87-4062-b2ae-923606f69bac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_31c541d4-a124-4e2c-aa49-b6d871e3d924" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_be95d3be-1a87-4062-b2ae-923606f69bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b2a5762b-6d13-4992-8913-c5c4ff7b7e56" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2393f9df-82b0-4482-ae60-d2883c1572fd" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b2a5762b-6d13-4992-8913-c5c4ff7b7e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b2a5762b-6d13-4992-8913-c5c4ff7b7e56" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_dc8a5a6c-38e9-4ce1-88a2-c086ef0599b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_dc8a5a6c-38e9-4ce1-88a2-c086ef0599b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_eda3c94c-e57e-4c52-b110-9769b75bd5f6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_eda3c94c-e57e-4c52-b110-9769b75bd5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_a7ac1d75-63ce-419a-972f-3ace9393c76b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_a7ac1d75-63ce-419a-972f-3ace9393c76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_4ca0752c-a0eb-43b5-a3be-fcfa245036d9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_4ca0752c-a0eb-43b5-a3be-fcfa245036d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_42a93dda-2ac6-41ba-8f05-23fbef8d64d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_c3308f34-79d8-4a56-89fe-9077ce8cf7ee" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_42a93dda-2ac6-41ba-8f05-23fbef8d64d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="simple" xlink:href="oncyf-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_b822f05f-59be-4911-9fda-79ffbc552e03" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_5e5441a3-c9cb-4f8d-9df6-400e5e56c170" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_b822f05f-59be-4911-9fda-79ffbc552e03" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_5e5441a3-c9cb-4f8d-9df6-400e5e56c170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_e8ac73a9-aa69-4998-939b-ee62c82c1e05" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_a939cd37-4e93-4f45-ba08-1a2b08039118" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_e8ac73a9-aa69-4998-939b-ee62c82c1e05" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_a939cd37-4e93-4f45-ba08-1a2b08039118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_1e73e752-e46d-430c-9f71-78cf076d9ab7" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_e8ac73a9-aa69-4998-939b-ee62c82c1e05" xlink:to="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_1e73e752-e46d-430c-9f71-78cf076d9ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_ad001a15-e410-4732-8867-acdb183ced79" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_e8ac73a9-aa69-4998-939b-ee62c82c1e05" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_ad001a15-e410-4732-8867-acdb183ced79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_43450ace-6ed8-45e8-869f-8ede5f40e0e8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_dcf59cf0-e269-4e60-9d00-f80bb689f625" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_43450ace-6ed8-45e8-869f-8ede5f40e0e8" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_dcf59cf0-e269-4e60-9d00-f80bb689f625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_36e20e5e-f4e0-4616-97e3-1f25edb866b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_dcf59cf0-e269-4e60-9d00-f80bb689f625" xlink:to="loc_srt_RangeAxis_36e20e5e-f4e0-4616-97e3-1f25edb866b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6c24378-e062-4cb8-98e5-26e7bbfdb106" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_36e20e5e-f4e0-4616-97e3-1f25edb866b2" xlink:to="loc_srt_RangeMember_b6c24378-e062-4cb8-98e5-26e7bbfdb106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d8a38308-781a-4ad6-b7f2-81de735ccb30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b6c24378-e062-4cb8-98e5-26e7bbfdb106" xlink:to="loc_srt_MinimumMember_d8a38308-781a-4ad6-b7f2-81de735ccb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0098b653-aa24-442d-b5ea-dc93069cb76d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b6c24378-e062-4cb8-98e5-26e7bbfdb106" xlink:to="loc_srt_MaximumMember_0098b653-aa24-442d-b5ea-dc93069cb76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_d0991e37-3d96-4079-ba50-b196825c3ced" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_dcf59cf0-e269-4e60-9d00-f80bb689f625" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_d0991e37-3d96-4079-ba50-b196825c3ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm_718fa832-99e6-44a6-831a-8f4e632577fe" xlink:href="oncyf-20211231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_d0991e37-3d96-4079-ba50-b196825c3ced" xlink:to="loc_oncyf_OperatingLeaseRemainingLeaseTerm_718fa832-99e6-44a6-831a-8f4e632577fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_7027044a-bc6b-4fa0-a202-738f476254ba" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_d0991e37-3d96-4079-ba50-b196825c3ced" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_7027044a-bc6b-4fa0-a202-738f476254ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#LeasesRightofuseAssetsandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_f81cf649-65c0-45e9-93b6-263d9a71358b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RightOfUseAssetsAbstract_1aac11ff-12cf-4797-957c-2903171a07a7" xlink:href="oncyf-20211231.xsd#oncyf_RightOfUseAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_f81cf649-65c0-45e9-93b6-263d9a71358b" xlink:to="loc_oncyf_RightOfUseAssetsAbstract_1aac11ff-12cf-4797-957c-2903171a07a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_d5e8b790-7d60-41f4-b0fd-15a4c25d8791" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_1aac11ff-12cf-4797-957c-2903171a07a7" xlink:to="loc_ifrs-full_RightofuseAssets_d5e8b790-7d60-41f4-b0fd-15a4c25d8791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_9d924e6c-5985-4a57-aeaf-cb6beb012963" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_1aac11ff-12cf-4797-957c-2903171a07a7" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_9d924e6c-5985-4a57-aeaf-cb6beb012963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_LeaseModificationRightOfUseAssets_85337f90-0f0b-4e24-9a43-1a3df48d7779" xlink:href="oncyf-20211231.xsd#oncyf_LeaseModificationRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_1aac11ff-12cf-4797-957c-2903171a07a7" xlink:to="loc_oncyf_LeaseModificationRightOfUseAssets_85337f90-0f0b-4e24-9a43-1a3df48d7779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_2b449cc4-9ea8-4446-9a66-181b59de9c33" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_1aac11ff-12cf-4797-957c-2903171a07a7" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_2b449cc4-9ea8-4446-9a66-181b59de9c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets_02a537f6-3532-4938-8a88-89febbdf46c7" xlink:href="oncyf-20211231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_1aac11ff-12cf-4797-957c-2903171a07a7" xlink:to="loc_oncyf_ForeignExchangeImpactRightofUseAssets_02a537f6-3532-4938-8a88-89febbdf46c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_3da13e7e-2897-4a02-8b39-60ee849d95ea" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_1aac11ff-12cf-4797-957c-2903171a07a7" xlink:to="loc_ifrs-full_RightofuseAssets_3da13e7e-2897-4a02-8b39-60ee849d95ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_eea3e784-2cd6-4dc6-995d-fdce88af6073" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_f81cf649-65c0-45e9-93b6-263d9a71358b" xlink:to="loc_ifrs-full_LeaseLiabilitiesAbstract_eea3e784-2cd6-4dc6-995d-fdce88af6073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_2bd9fc06-7dc8-4dee-b669-f77f87b12bc1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_eea3e784-2cd6-4dc6-995d-fdce88af6073" xlink:to="loc_ifrs-full_LeaseLiabilities_2bd9fc06-7dc8-4dee-b669-f77f87b12bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_d65eda32-e404-413b-9c7b-4264827c924a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_eea3e784-2cd6-4dc6-995d-fdce88af6073" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_d65eda32-e404-413b-9c7b-4264827c924a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EffectOfLeaseModificationOnLeaseLiabilities_2b2d6e62-fd2c-4a92-9207-b5dc18cf75b5" xlink:href="oncyf-20211231.xsd#oncyf_EffectOfLeaseModificationOnLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_eea3e784-2cd6-4dc6-995d-fdce88af6073" xlink:to="loc_oncyf_EffectOfLeaseModificationOnLeaseLiabilities_2b2d6e62-fd2c-4a92-9207-b5dc18cf75b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_9adcf488-b4cc-4fde-b154-54136fa2445c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_eea3e784-2cd6-4dc6-995d-fdce88af6073" xlink:to="loc_ifrs-full_CashOutflowForLeases_9adcf488-b4cc-4fde-b154-54136fa2445c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_17d42e87-25d8-4ed9-9b90-67e4ad0d1362" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_eea3e784-2cd6-4dc6-995d-fdce88af6073" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_17d42e87-25d8-4ed9-9b90-67e4ad0d1362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact_aa42b382-8c4b-42e7-a4c5-0eafaedfdba6" xlink:href="oncyf-20211231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_eea3e784-2cd6-4dc6-995d-fdce88af6073" xlink:to="loc_oncyf_GainsLossesFromForeignExchangeImpact_aa42b382-8c4b-42e7-a4c5-0eafaedfdba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_90247534-3eed-4291-b372-c5dba8648ee1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_eea3e784-2cd6-4dc6-995d-fdce88af6073" xlink:to="loc_ifrs-full_LeaseLiabilities_90247534-3eed-4291-b372-c5dba8648ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_74f8a696-3be9-4d8f-b9d7-6d5ca6538fe6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_94539a1b-ae42-4539-8628-abff395dab99" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_74f8a696-3be9-4d8f-b9d7-6d5ca6538fe6" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_94539a1b-ae42-4539-8628-abff395dab99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_3629b37d-75ff-4a05-aed5-9834f506b93f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_94539a1b-ae42-4539-8628-abff395dab99" xlink:to="loc_ifrs-full_MaturityAxis_3629b37d-75ff-4a05-aed5-9834f506b93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1c7fa407-3d0a-4a4b-99dd-d000c4152c94" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_3629b37d-75ff-4a05-aed5-9834f506b93f" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1c7fa407-3d0a-4a4b-99dd-d000c4152c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_24b88176-e96d-46cb-a73a-3b3b5d5a342e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1c7fa407-3d0a-4a4b-99dd-d000c4152c94" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_24b88176-e96d-46cb-a73a-3b3b5d5a342e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_6bc69343-4277-4098-8d37-6d2cef5ddea6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1c7fa407-3d0a-4a4b-99dd-d000c4152c94" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_6bc69343-4277-4098-8d37-6d2cef5ddea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_8d5e0e45-cfe3-4fa3-9767-c98289f79267" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_1c7fa407-3d0a-4a4b-99dd-d000c4152c94" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_8d5e0e45-cfe3-4fa3-9767-c98289f79267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_32a12544-8fda-41c7-95fa-853be2a3523e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_94539a1b-ae42-4539-8628-abff395dab99" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_32a12544-8fda-41c7-95fa-853be2a3523e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_e91232ed-f7ca-4ad4-b37e-831b4d68aa25" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_32a12544-8fda-41c7-95fa-853be2a3523e" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_e91232ed-f7ca-4ad4-b37e-831b4d68aa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="simple" xlink:href="oncyf-20211231.xsd#WarrantDerivative"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_2b1fe2e0-bd95-4432-8ae7-38ba93146b54" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_d7461078-8976-412c-a2af-7ac9c43b2eff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_2b1fe2e0-bd95-4432-8ae7-38ba93146b54" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_d7461078-8976-412c-a2af-7ac9c43b2eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#WarrantDerivativeTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_9c4221ce-0742-432c-a898-6b74553f8735" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_468e0db9-402c-4a6f-a89f-d416589302a1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_9c4221ce-0742-432c-a898-6b74553f8735" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_468e0db9-402c-4a6f-a89f-d416589302a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#WarrantDerivativeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_f28413d1-f013-47b3-aab3-2a2716e0b1be" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_c183e0bb-21d8-4356-ba17-50d78902b251" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_f28413d1-f013-47b3-aab3-2a2716e0b1be" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_c183e0bb-21d8-4356-ba17-50d78902b251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e5f7af88-9ab8-4b6c-955b-cb42c0605443" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_c183e0bb-21d8-4356-ba17-50d78902b251" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e5f7af88-9ab8-4b6c-955b-cb42c0605443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_06d916cf-fc3f-46d3-87fa-af0bad1a9282" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e5f7af88-9ab8-4b6c-955b-cb42c0605443" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_06d916cf-fc3f-46d3-87fa-af0bad1a9282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_2c0098e4-7a0e-4000-b05a-a82247526b1e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_06d916cf-fc3f-46d3-87fa-af0bad1a9282" xlink:to="loc_ifrs-full_IssuedCapitalMember_2c0098e4-7a0e-4000-b05a-a82247526b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_09bb1c51-3769-4289-a005-61edca1ac9b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_c183e0bb-21d8-4356-ba17-50d78902b251" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_09bb1c51-3769-4289-a005-61edca1ac9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_c8af01e6-efae-4368-a366-2faed66ee812" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_09bb1c51-3769-4289-a005-61edca1ac9b5" xlink:to="loc_ifrs-full_LiabilitiesMember_c8af01e6-efae-4368-a366-2faed66ee812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_798e9730-487e-46e9-8402-fb477ac1e466" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_c8af01e6-efae-4368-a366-2faed66ee812" xlink:to="loc_oncyf_WarrantsMember_798e9730-487e-46e9-8402-fb477ac1e466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_ae993ff3-3dac-4206-89a0-9d244bfee72e" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_c183e0bb-21d8-4356-ba17-50d78902b251" xlink:to="loc_oncyf_SaleOfStockAxis_ae993ff3-3dac-4206-89a0-9d244bfee72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_a16f35de-5190-4f9e-b843-019c1fa625bc" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_ae993ff3-3dac-4206-89a0-9d244bfee72e" xlink:to="loc_oncyf_SaleOfStockDomain_a16f35de-5190-4f9e-b843-019c1fa625bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_fd2b2ea0-53cb-4c99-a4b9-4dfb15167adb" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_a16f35de-5190-4f9e-b843-019c1fa625bc" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_fd2b2ea0-53cb-4c99-a4b9-4dfb15167adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_c183e0bb-21d8-4356-ba17-50d78902b251" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_31b6018e-3548-4d26-acb8-f1b0be979265" xlink:href="oncyf-20211231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_IssueOfEquityShares_31b6018e-3548-4d26-acb8-f1b0be979265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_698b867b-2b33-405a-8e85-a5367fc0667d" xlink:href="oncyf-20211231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_698b867b-2b33-405a-8e85-a5367fc0667d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_8a77d21b-69b9-4e42-b8f9-2e5da8065c78" xlink:href="oncyf-20211231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_8a77d21b-69b9-4e42-b8f9-2e5da8065c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_166572c8-764f-45a1-bb3a-efe840bbf405" xlink:href="oncyf-20211231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_CommonSharesPerUnit_166572c8-764f-45a1-bb3a-efe840bbf405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_6e7baeec-7fca-401c-a402-747c390307a5" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_6e7baeec-7fca-401c-a402-747c390307a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_236c61cd-164e-447e-a16d-9e8701ac89b8" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_236c61cd-164e-447e-a16d-9e8701ac89b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_f210215a-8336-406d-a0f7-e091854dfed3" xlink:href="oncyf-20211231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_420b6a9b-34da-4a37-bafe-228e95e8cfe8" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_f210215a-8336-406d-a0f7-e091854dfed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_5d76ee98-1a25-4c1d-8d8b-64e5062f1578" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_18711cd9-ca2b-4e15-ab9b-d7847e93d96f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_5d76ee98-1a25-4c1d-8d8b-64e5062f1578" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_18711cd9-ca2b-4e15-ab9b-d7847e93d96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_a00a8961-7d51-484f-b5b3-eb1a44ee4d3e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_18711cd9-ca2b-4e15-ab9b-d7847e93d96f" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_a00a8961-7d51-484f-b5b3-eb1a44ee4d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_882bc8f8-372b-4222-9db1-d79ca67ea778" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_a00a8961-7d51-484f-b5b3-eb1a44ee4d3e" xlink:to="loc_ifrs-full_LiabilitiesMember_882bc8f8-372b-4222-9db1-d79ca67ea778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_28ba617b-82da-4bd2-9cab-95489785eac9" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_882bc8f8-372b-4222-9db1-d79ca67ea778" xlink:to="loc_oncyf_WarrantsMember_28ba617b-82da-4bd2-9cab-95489785eac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_93530283-8bb7-40a9-acc8-a5c4f5032795" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_18711cd9-ca2b-4e15-ab9b-d7847e93d96f" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_93530283-8bb7-40a9-acc8-a5c4f5032795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward_bd74537d-5cc8-4b4c-b918-941044fd3878" xlink:href="oncyf-20211231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_93530283-8bb7-40a9-acc8-a5c4f5032795" xlink:to="loc_oncyf_NumberOfWarrantsOutstandingRollForward_bd74537d-5cc8-4b4c-b918-941044fd3878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_c3d2753f-0d30-47b8-afc6-0834f78b45e4" xlink:href="oncyf-20211231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_bd74537d-5cc8-4b4c-b918-941044fd3878" xlink:to="loc_oncyf_ClassOfWarrantOrRightOutstanding1_c3d2753f-0d30-47b8-afc6-0834f78b45e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_560b4630-a811-4121-9e99-7afe41dd6bf2" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_bd74537d-5cc8-4b4c-b918-941044fd3878" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_560b4630-a811-4121-9e99-7afe41dd6bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_17d24c49-b1d0-4f38-ac4b-433238e139ab" xlink:href="oncyf-20211231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_bd74537d-5cc8-4b4c-b918-941044fd3878" xlink:to="loc_oncyf_ClassOfWarrantOrRightOutstanding1_17d24c49-b1d0-4f38-ac4b-433238e139ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:href="oncyf-20211231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_93530283-8bb7-40a9-acc8-a5c4f5032795" xlink:to="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_06ea002f-b3f6-455f-8701-98097de807ad" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_06ea002f-b3f6-455f-8701-98097de807ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_762a3431-8efa-4b10-bd4a-d20305e43cc4" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_762a3431-8efa-4b10-bd4a-d20305e43cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_68b5c476-249f-4ad9-8909-4153c7b82847" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_68b5c476-249f-4ad9-8909-4153c7b82847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact_69f0528a-1d6f-4277-a6e3-545b3574bf2d" xlink:href="oncyf-20211231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:to="loc_oncyf_GainsLossesFromForeignExchangeImpact_69f0528a-1d6f-4277-a6e3-545b3574bf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_b1260dda-cec4-4904-8128-f831b47ea16a" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_5921867b-9ec9-46a4-8ba6-91ea9a276a1d" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_b1260dda-cec4-4904-8128-f831b47ea16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_403047a4-668b-420c-8fb5-369c1f13d262" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_16055177-5abe-4064-ae9a-cdf1350509c2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_403047a4-668b-420c-8fb5-369c1f13d262" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_16055177-5abe-4064-ae9a-cdf1350509c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_06b6eff1-f85e-4f50-ad1b-e32ee06eaaea" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_16055177-5abe-4064-ae9a-cdf1350509c2" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_06b6eff1-f85e-4f50-ad1b-e32ee06eaaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_363c8a63-b6d2-4a14-8506-5a1e518faf9a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_06b6eff1-f85e-4f50-ad1b-e32ee06eaaea" xlink:to="loc_ifrs-full_LiabilitiesMember_363c8a63-b6d2-4a14-8506-5a1e518faf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_6da01ca2-a9de-43f1-b0da-b76f751ac6f6" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_363c8a63-b6d2-4a14-8506-5a1e518faf9a" xlink:to="loc_oncyf_WarrantsMember_6da01ca2-a9de-43f1-b0da-b76f751ac6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_16055177-5abe-4064-ae9a-cdf1350509c2" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueofWarrantIssuedPerWarrant_59f8520d-217d-4b78-ad94-2a0d6f8b9001" xlink:href="oncyf-20211231.xsd#oncyf_FairValueofWarrantIssuedPerWarrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_oncyf_FairValueofWarrantIssuedPerWarrant_59f8520d-217d-4b78-ad94-2a0d6f8b9001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantIssuedUnderlyingSharePrice_3bf04928-adf0-4ebf-82a0-458e82df4b53" xlink:href="oncyf-20211231.xsd#oncyf_WarrantIssuedUnderlyingSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_oncyf_WarrantIssuedUnderlyingSharePrice_3bf04928-adf0-4ebf-82a0-458e82df4b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_ad3d6ac9-f6e0-435f-a6a1-44eb5aae3812" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_ad3d6ac9-f6e0-435f-a6a1-44eb5aae3812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_5e0b796b-210d-41ec-b47a-6739714b6fe5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_5e0b796b-210d-41ec-b47a-6739714b6fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_73a67052-2612-4987-8dd6-9b37814446ca" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_73a67052-2612-4987-8dd6-9b37814446ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DividendYieldPercent_fcfa0090-d4a2-4fca-81a2-3ff2c86c758f" xlink:href="oncyf-20211231.xsd#oncyf_DividendYieldPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_89508916-9321-4c96-8abc-face0cc82c61" xlink:to="loc_oncyf_DividendYieldPercent_fcfa0090-d4a2-4fca-81a2-3ff2c86c758f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareCapital"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_05f3eeb9-ba54-4610-ac1c-7d1d0499f825" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_5b54e88a-7a2d-4016-9c10-fdeaf06c7ecf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_05f3eeb9-ba54-4610-ac1c-7d1d0499f825" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_5b54e88a-7a2d-4016-9c10-fdeaf06c7ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareCapitalTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_24012516-cc7d-48b2-a478-53c1d962492d" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_2d2fba33-bb36-47dd-b9aa-70f8b6cc30ea" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_24012516-cc7d-48b2-a478-53c1d962492d" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_2d2fba33-bb36-47dd-b9aa-70f8b6cc30ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_a68b26ef-8be7-496e-8e39-18c576615a20" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_24012516-cc7d-48b2-a478-53c1d962492d" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_a68b26ef-8be7-496e-8e39-18c576615a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareCapitalScheduleofShareCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_823d13e3-c63f-4673-a87c-5ec0519d8c2f" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2603ed61-2017-456e-bd2e-7978679fc2c8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_823d13e3-c63f-4673-a87c-5ec0519d8c2f" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2603ed61-2017-456e-bd2e-7978679fc2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_638e93de-3682-4f37-a938-bdc78af8de01" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2603ed61-2017-456e-bd2e-7978679fc2c8" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_638e93de-3682-4f37-a938-bdc78af8de01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_deb8fa62-9513-45dd-ae7b-bf08d4de8329" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_638e93de-3682-4f37-a938-bdc78af8de01" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_deb8fa62-9513-45dd-ae7b-bf08d4de8329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_6c9be3ba-e7d6-438d-8c93-17f8af9b09d8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_deb8fa62-9513-45dd-ae7b-bf08d4de8329" xlink:to="loc_ifrs-full_IssuedCapitalMember_6c9be3ba-e7d6-438d-8c93-17f8af9b09d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_01e1672b-3077-4cbf-b2d1-01f0e8ee7b0a" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2603ed61-2017-456e-bd2e-7978679fc2c8" xlink:to="loc_oncyf_SaleOfStockAxis_01e1672b-3077-4cbf-b2d1-01f0e8ee7b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_01e1672b-3077-4cbf-b2d1-01f0e8ee7b0a" xlink:to="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_b0fecd2a-3a6a-4915-80e7-80f8c1fb3dbf" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_b0fecd2a-3a6a-4915-80e7-80f8c1fb3dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_29225585-76ec-4c73-b9bc-6123e53a0c44" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_29225585-76ec-4c73-b9bc-6123e53a0c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_db84a673-d9d3-43b6-81aa-a03be8636bb7" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_db84a673-d9d3-43b6-81aa-a03be8636bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_a6b2b4c0-e23f-4ac3-9457-44578b524d70" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:to="loc_oncyf_SharesPublicOfferingMember_a6b2b4c0-e23f-4ac3-9457-44578b524d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_e284f57d-b875-4019-b86b-0e3c31f3ffd9" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SharesPublicOfferingMember_a6b2b4c0-e23f-4ac3-9457-44578b524d70" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_e284f57d-b875-4019-b86b-0e3c31f3ffd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_7668c660-ecc2-40b1-a70f-f61963311b59" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_c36274c8-80da-42d1-9873-a31d9aca303d" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_7668c660-ecc2-40b1-a70f-f61963311b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_359ca975-a7ac-4960-a3f1-c9c979c39ba6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2603ed61-2017-456e-bd2e-7978679fc2c8" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_359ca975-a7ac-4960-a3f1-c9c979c39ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract_2bc3eb25-ed3f-4953-994c-de5d60ab9851" xlink:href="oncyf-20211231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_359ca975-a7ac-4960-a3f1-c9c979c39ba6" xlink:to="loc_oncyf_ShareCapitalNumberSharesAbstract_2bc3eb25-ed3f-4953-994c-de5d60ab9851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_b0e516a6-e3d3-4d77-ab76-11945bd74928" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_2bc3eb25-ed3f-4953-994c-de5d60ab9851" xlink:to="loc_ifrs-full_NumberOfSharesIssued_b0e516a6-e3d3-4d77-ab76-11945bd74928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_142ea693-faf7-4afb-9bbc-a1fb2465363e" xlink:href="oncyf-20211231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_2bc3eb25-ed3f-4953-994c-de5d60ab9851" xlink:to="loc_oncyf_IssueOfEquityShares_142ea693-faf7-4afb-9bbc-a1fb2465363e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_350a2d8f-4795-4e59-ac4f-483899aeaa3c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_2bc3eb25-ed3f-4953-994c-de5d60ab9851" xlink:to="loc_ifrs-full_NumberOfSharesIssued_350a2d8f-4795-4e59-ac4f-483899aeaa3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract_9dafea75-fa8f-4fd8-b96f-aca58624edf8" xlink:href="oncyf-20211231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_359ca975-a7ac-4960-a3f1-c9c979c39ba6" xlink:to="loc_oncyf_ShareCapitalAmountAbstract_9dafea75-fa8f-4fd8-b96f-aca58624edf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_c8dfdd65-77e8-4dab-bba3-d75dd86a8f78" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_9dafea75-fa8f-4fd8-b96f-aca58624edf8" xlink:to="loc_ifrs-full_Equity_c8dfdd65-77e8-4dab-bba3-d75dd86a8f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_2edfdf4f-c13c-4a5e-90ea-7fe2a9ba66d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_9dafea75-fa8f-4fd8-b96f-aca58624edf8" xlink:to="loc_ifrs-full_IssueOfEquity_2edfdf4f-c13c-4a5e-90ea-7fe2a9ba66d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_e44fdbc9-c27f-43b4-a09b-3c89354b7d0d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_9dafea75-fa8f-4fd8-b96f-aca58624edf8" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_e44fdbc9-c27f-43b4-a09b-3c89354b7d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_e160dddc-450f-4ecf-9697-8b6e7cbc2a79" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_9dafea75-fa8f-4fd8-b96f-aca58624edf8" xlink:to="loc_ifrs-full_Equity_e160dddc-450f-4ecf-9697-8b6e7cbc2a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareCapitalScheduleofShareCapitalFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_eac8f5b1-682f-4503-83b8-19705611c2b6" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_eac8f5b1-682f-4503-83b8-19705611c2b6" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_eb2855c1-089f-493c-9991-8fa543efb243" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_eb2855c1-089f-493c-9991-8fa543efb243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_714bf32a-a734-4ad7-80af-9bc80d5e2a22" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_eb2855c1-089f-493c-9991-8fa543efb243" xlink:to="loc_ifrs-full_LiabilitiesMember_714bf32a-a734-4ad7-80af-9bc80d5e2a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_005d80d7-910f-4585-b577-c57e14d2f34d" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_714bf32a-a734-4ad7-80af-9bc80d5e2a22" xlink:to="loc_oncyf_WarrantsMember_005d80d7-910f-4585-b577-c57e14d2f34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_470f76fd-b46f-404b-862a-a3c1cc99bcf4" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:to="loc_oncyf_SaleOfStockAxis_470f76fd-b46f-404b-862a-a3c1cc99bcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_470f76fd-b46f-404b-862a-a3c1cc99bcf4" xlink:to="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_e319b972-97bf-4e4a-8b51-aebc9fed3f4e" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_e319b972-97bf-4e4a-8b51-aebc9fed3f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_fca4edfb-99cc-49e0-a6e5-85c384ddeaf3" xlink:href="oncyf-20211231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_fca4edfb-99cc-49e0-a6e5-85c384ddeaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_2a2e2ecf-7624-48e6-aa28-42f13aab033c" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_2a2e2ecf-7624-48e6-aa28-42f13aab033c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_57d497c2-5a61-4942-ae23-72f030835a6f" xlink:href="oncyf-20211231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:to="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_57d497c2-5a61-4942-ae23-72f030835a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_ee22ea75-a327-4d3b-baf5-d9ce4be43a5f" xlink:href="oncyf-20211231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_a9914669-4505-4c69-9178-6547216fc65a" xlink:to="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_ee22ea75-a327-4d3b-baf5-d9ce4be43a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_b184ba74-e648-4ba7-9416-70a601930a2c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_b184ba74-e648-4ba7-9416-70a601930a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_dd54564e-10db-400f-9ab3-65edb2777a00" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_b184ba74-e648-4ba7-9416-70a601930a2c" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_dd54564e-10db-400f-9ab3-65edb2777a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_1991b8c4-9b76-4d87-8f52-c565858876f2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_dd54564e-10db-400f-9ab3-65edb2777a00" xlink:to="loc_ifrs-full_IssuedCapitalMember_1991b8c4-9b76-4d87-8f52-c565858876f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember_ca3086ec-c2c4-4e86-8069-87ca5ebd1f74" xlink:href="oncyf-20211231.xsd#oncyf_IssuedCapitalExcludingCommitmentSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IssuedCapitalMember_1991b8c4-9b76-4d87-8f52-c565858876f2" xlink:to="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember_ca3086ec-c2c4-4e86-8069-87ca5ebd1f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentSharesMember_d6cbe656-08a2-4790-b92e-43aabea623be" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IssuedCapitalMember_1991b8c4-9b76-4d87-8f52-c565858876f2" xlink:to="loc_oncyf_CommitmentSharesMember_d6cbe656-08a2-4790-b92e-43aabea623be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_8f3bd97b-315e-45a0-9f70-3faec4ba87d8" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_dd54564e-10db-400f-9ab3-65edb2777a00" xlink:to="loc_oncyf_WarrantsMember_8f3bd97b-315e-45a0-9f70-3faec4ba87d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_e8654333-cc95-4b59-b903-113ded661029" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_e8654333-cc95-4b59-b903-113ded661029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_a8c46342-7d54-4c60-9657-0a9948e5401f" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_e8654333-cc95-4b59-b903-113ded661029" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_a8c46342-7d54-4c60-9657-0a9948e5401f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingExpensesMember_6eaf2a22-9f90-4542-92de-bf3f40188add" xlink:href="oncyf-20211231.xsd#oncyf_OperatingExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_a8c46342-7d54-4c60-9657-0a9948e5401f" xlink:to="loc_oncyf_OperatingExpensesMember_6eaf2a22-9f90-4542-92de-bf3f40188add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7d3b7603-4019-4f83-89e1-c36647f02886" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_09068e96-8dc5-47a7-bd72-6f5a45b148e7" xlink:href="oncyf-20211231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_09068e96-8dc5-47a7-bd72-6f5a45b148e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_628b320c-9f00-4201-8dfa-1e71bc1620c5" xlink:href="oncyf-20211231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_628b320c-9f00-4201-8dfa-1e71bc1620c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_396178b7-ec58-4459-ab41-a27a5a6c2adf" xlink:href="oncyf-20211231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_IssueOfEquityShares_396178b7-ec58-4459-ab41-a27a5a6c2adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_9c1c5313-e6d7-4e0a-80c7-ec9b207ed866" xlink:href="oncyf-20211231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_9c1c5313-e6d7-4e0a-80c7-ec9b207ed866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_85819205-2f5b-4de7-bbf0-37a4abbf5da6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_85819205-2f5b-4de7-bbf0-37a4abbf5da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_2cb5fe58-b596-4a3a-9a1c-cf4ed4795960" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_2cb5fe58-b596-4a3a-9a1c-cf4ed4795960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_07618e90-cf67-4e72-96d2-6676790ec717" xlink:href="oncyf-20211231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_07618e90-cf67-4e72-96d2-6676790ec717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_dff99c9f-34f1-4ed1-86db-67da47b45e7a" xlink:href="oncyf-20211231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_dff99c9f-34f1-4ed1-86db-67da47b45e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_ff87cbdd-a5f7-472e-b0e9-b6aeefa9de86" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_ff87cbdd-a5f7-472e-b0e9-b6aeefa9de86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_3db6e1c5-fb41-4f2b-99e9-ce2185ed8d27" xlink:href="oncyf-20211231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_CommonSharesPerUnit_3db6e1c5-fb41-4f2b-99e9-ce2185ed8d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedFairValueOfCommonShare_569a6531-742a-414f-a5ef-31d97d94d86b" xlink:href="oncyf-20211231.xsd#oncyf_SharesIssuedFairValueOfCommonShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_SharesIssuedFairValueOfCommonShare_569a6531-742a-414f-a5ef-31d97d94d86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_270ae9f8-fa93-4e7f-a73a-93359792bbcf" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_270ae9f8-fa93-4e7f-a73a-93359792bbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_aaa81a66-7d4a-4717-9d16-de059bc83cde" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_aaa81a66-7d4a-4717-9d16-de059bc83cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_754c60fd-0474-4fd1-99ac-e30c9b5e2d64" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_754c60fd-0474-4fd1-99ac-e30c9b5e2d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_90488778-6c5f-438b-b26c-b8003dcff6bd" xlink:href="oncyf-20211231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_90488778-6c5f-438b-b26c-b8003dcff6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_dadea136-b3bb-48d5-8ba2-bf881b84acea" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_d69d3cee-aae8-4f56-9acf-75187448eb5f" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_dadea136-b3bb-48d5-8ba2-bf881b84acea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareCapitalEquityWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e86a8835-766b-4e3b-894d-76c3696e5885" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_d96f0340-2519-44a3-8253-b9f98dbb0a82" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e86a8835-766b-4e3b-894d-76c3696e5885" xlink:to="loc_oncyf_SaleOfStockAxis_d96f0340-2519-44a3-8253-b9f98dbb0a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_034ab60c-7ecd-4926-ba50-814607cebc5f" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_d96f0340-2519-44a3-8253-b9f98dbb0a82" xlink:to="loc_oncyf_SaleOfStockDomain_034ab60c-7ecd-4926-ba50-814607cebc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_a6c81f90-ceea-4ff0-a650-3ee9adf1b695" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingEquityWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_034ab60c-7ecd-4926-ba50-814607cebc5f" xlink:to="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_a6c81f90-ceea-4ff0-a650-3ee9adf1b695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e86a8835-766b-4e3b-894d-76c3696e5885" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_adf7d535-4378-4865-948d-622e50aeec53" xlink:href="oncyf-20211231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_IssueOfEquityShares_adf7d535-4378-4865-948d-622e50aeec53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_b87f4219-0c56-4c3f-8e71-313d09818864" xlink:href="oncyf-20211231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_b87f4219-0c56-4c3f-8e71-313d09818864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_71eb242d-5331-47f2-859e-58200a6dec40" xlink:href="oncyf-20211231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_CommonSharesPerUnit_71eb242d-5331-47f2-859e-58200a6dec40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_3ecac747-9820-4450-8703-eb404d612379" xlink:href="oncyf-20211231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_CommonSharePurchaseWarrantPerUnit_3ecac747-9820-4450-8703-eb404d612379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_041253d7-8851-4b6b-b0a4-40ccc9e27ce5" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_041253d7-8851-4b6b-b0a4-40ccc9e27ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_61153b2f-f988-42f8-b718-e0a03636756c" xlink:href="oncyf-20211231.xsd#oncyf_StockholdersEquityNoteStockSplitConversionRatio"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_61153b2f-f988-42f8-b718-e0a03636756c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_99357631-f94c-449f-8203-40a6bdc4fdd9" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_99357631-f94c-449f-8203-40a6bdc4fdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_1a61de2b-40ea-45e1-8eb3-884e60b5d2a7" xlink:href="oncyf-20211231.xsd#oncyf_SharesIssuedWarrantPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_c8948d1d-53f0-4f98-9216-b52bae62bcac" xlink:to="loc_oncyf_SharesIssuedWarrantPricePerShare_1a61de2b-40ea-45e1-8eb3-884e60b5d2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareCapitalSummaryofOutstandingWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_317f9ed0-01f6-404c-9e13-be1cef572fc7" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_fbe7f314-7ca0-4994-a9d7-ff4eefcb75ab" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_317f9ed0-01f6-404c-9e13-be1cef572fc7" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_fbe7f314-7ca0-4994-a9d7-ff4eefcb75ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_cec7742f-92da-4837-a2f2-f1fb5afb3ef7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_fbe7f314-7ca0-4994-a9d7-ff4eefcb75ab" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_cec7742f-92da-4837-a2f2-f1fb5afb3ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_7f647896-867a-432c-a380-5144ed784b90" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cec7742f-92da-4837-a2f2-f1fb5afb3ef7" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_7f647896-867a-432c-a380-5144ed784b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_01c2340a-92e3-49ad-b9df-e647624807df" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_7f647896-867a-432c-a380-5144ed784b90" xlink:to="loc_oncyf_WarrantsMember_01c2340a-92e3-49ad-b9df-e647624807df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1d66d01e-724e-4c25-b443-4c39cedefd53" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_fbe7f314-7ca0-4994-a9d7-ff4eefcb75ab" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1d66d01e-724e-4c25-b443-4c39cedefd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_46484311-2ca8-4ff6-9742-28b925520e28" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1d66d01e-724e-4c25-b443-4c39cedefd53" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_46484311-2ca8-4ff6-9742-28b925520e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_b013c52d-01f7-438f-8988-56a755a458e4" xlink:href="oncyf-20211231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1d66d01e-724e-4c25-b443-4c39cedefd53" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_b013c52d-01f7-438f-8988-56a755a458e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_ac73bab1-3c2e-4bcb-9b8f-08b4b6e74f04" xlink:href="oncyf-20211231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1d66d01e-724e-4c25-b443-4c39cedefd53" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_ac73bab1-3c2e-4bcb-9b8f-08b4b6e74f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_4bf79e7a-4fa3-4416-ad37-9e0b29b88657" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_3e97a97f-539c-4480-afd4-347c7e00b010" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_4bf79e7a-4fa3-4416-ad37-9e0b29b88657" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_3e97a97f-539c-4480-afd4-347c7e00b010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_04508ae6-68ac-4990-a42c-9e83cbe94f92" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_12fcfaae-bf34-4c8b-8013-171e6164ce30" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_04508ae6-68ac-4990-a42c-9e83cbe94f92" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_12fcfaae-bf34-4c8b-8013-171e6164ce30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_1c8e7040-c1e7-4a90-a040-f65f7f138920" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_04508ae6-68ac-4990-a42c-9e83cbe94f92" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_1c8e7040-c1e7-4a90-a040-f65f7f138920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_9b53cd46-ccfb-41a8-8c6a-babd09ab56e5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_04508ae6-68ac-4990-a42c-9e83cbe94f92" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_9b53cd46-ccfb-41a8-8c6a-babd09ab56e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_2a1de82c-921d-4583-8bf0-b2217d1e5c2f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_04508ae6-68ac-4990-a42c-9e83cbe94f92" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_2a1de82c-921d-4583-8bf0-b2217d1e5c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_8538ea3b-f599-4d03-adf5-c841592546b6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_04508ae6-68ac-4990-a42c-9e83cbe94f92" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_8538ea3b-f599-4d03-adf5-c841592546b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_e4e3ce65-0606-4325-97f2-57e774d1b470" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockOptionsOutstandingAbstract_8283d709-2486-46bd-a71a-7cf3ac25b4c1" xlink:href="oncyf-20211231.xsd#oncyf_StockOptionsOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_e4e3ce65-0606-4325-97f2-57e774d1b470" xlink:to="loc_oncyf_StockOptionsOutstandingAbstract_8283d709-2486-46bd-a71a-7cf3ac25b4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_d88c1d08-c530-4110-bb5d-9aa3eab59350" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_8283d709-2486-46bd-a71a-7cf3ac25b4c1" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_d88c1d08-c530-4110-bb5d-9aa3eab59350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_d631f026-5b3d-4486-8343-b014df2284fc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_8283d709-2486-46bd-a71a-7cf3ac25b4c1" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_d631f026-5b3d-4486-8343-b014df2284fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_f1718eb9-9de7-484b-9a47-54c19bfe0d00" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_8283d709-2486-46bd-a71a-7cf3ac25b4c1" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_f1718eb9-9de7-484b-9a47-54c19bfe0d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_0b8f9ef2-ce08-4bb5-8e2b-d8747026ecd6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_8283d709-2486-46bd-a71a-7cf3ac25b4c1" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_0b8f9ef2-ce08-4bb5-8e2b-d8747026ecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_2bacd77e-a3d4-44da-a4d8-63f9eb53ad7a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_8283d709-2486-46bd-a71a-7cf3ac25b4c1" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_2bacd77e-a3d4-44da-a4d8-63f9eb53ad7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_3432b662-aa6b-4f44-84ba-b92e250e3227" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_8283d709-2486-46bd-a71a-7cf3ac25b4c1" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_3432b662-aa6b-4f44-84ba-b92e250e3227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_27039758-b7a1-479d-a61c-c93dfa63a943" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_8283d709-2486-46bd-a71a-7cf3ac25b4c1" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_27039758-b7a1-479d-a61c-c93dfa63a943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_e8590e06-5a53-4789-9958-4ebd8d16c252" xlink:href="oncyf-20211231.xsd#oncyf_WeightedAverageExercisePriceOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_e4e3ce65-0606-4325-97f2-57e774d1b470" xlink:to="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_e8590e06-5a53-4789-9958-4ebd8d16c252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_6c2c99f8-5f17-4d6a-9161-eb1c41cf2252" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_e8590e06-5a53-4789-9958-4ebd8d16c252" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_6c2c99f8-5f17-4d6a-9161-eb1c41cf2252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_07099e68-146c-4842-a924-c3baa194e895" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_e8590e06-5a53-4789-9958-4ebd8d16c252" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_07099e68-146c-4842-a924-c3baa194e895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_4d600237-e842-49c1-9e60-6b4edeed3bd7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_e8590e06-5a53-4789-9958-4ebd8d16c252" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_4d600237-e842-49c1-9e60-6b4edeed3bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_3a45ecec-d174-4402-8419-37a755ad7285" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_e8590e06-5a53-4789-9958-4ebd8d16c252" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_3a45ecec-d174-4402-8419-37a755ad7285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_15231bfe-a67c-4d7f-b57b-4fab8969c721" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_e8590e06-5a53-4789-9958-4ebd8d16c252" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_15231bfe-a67c-4d7f-b57b-4fab8969c721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_8ec44a51-fdcd-4d5c-9c4c-80aa8a312c00" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_e8590e06-5a53-4789-9958-4ebd8d16c252" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_8ec44a51-fdcd-4d5c-9c4c-80aa8a312c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_ad462c45-281c-4548-80f2-471f2349c190" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_e8590e06-5a53-4789-9958-4ebd8d16c252" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_ad462c45-281c-4548-80f2-471f2349c190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_764684b3-e96e-496a-94ea-bce395f70361" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_a9e14a32-4028-4214-9157-7d85daab3f04" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_764684b3-e96e-496a-94ea-bce395f70361" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_a9e14a32-4028-4214-9157-7d85daab3f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1c856d97-8b0b-40a5-8353-b699250bb100" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_a9e14a32-4028-4214-9157-7d85daab3f04" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1c856d97-8b0b-40a5-8353-b699250bb100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1c856d97-8b0b-40a5-8353-b699250bb100" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_0518ecb1-20df-4a09-ba99-ae9250e850f3" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_0518ecb1-20df-4a09-ba99-ae9250e850f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_868de419-ccb1-4781-a513-f3f99a4e530a" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_868de419-ccb1-4781-a513-f3f99a4e530a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_5388d1b8-dafc-4791-b6a1-7c09e91a339f" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_5388d1b8-dafc-4791-b6a1-7c09e91a339f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_f76cba78-d0d7-4025-90ea-b72139e8269f" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_f76cba78-d0d7-4025-90ea-b72139e8269f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_dac6865c-1a22-425e-98a7-d5235ce39b93" xlink:href="oncyf-20211231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4ae8bbb7-5866-46c1-9c6d-7de700f5ed60" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_dac6865c-1a22-425e-98a7-d5235ce39b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_093d4115-a617-4d69-9910-43c05e7c253e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_a9e14a32-4028-4214-9157-7d85daab3f04" xlink:to="loc_ifrs-full_RangeAxis_093d4115-a617-4d69-9910-43c05e7c253e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_bc991ad7-9a70-47ed-afdd-af411ecc3719" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_093d4115-a617-4d69-9910-43c05e7c253e" xlink:to="loc_ifrs-full_RangesMember_bc991ad7-9a70-47ed-afdd-af411ecc3719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_fe643339-49ec-4da2-8362-c2934bc21ef1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_bc991ad7-9a70-47ed-afdd-af411ecc3719" xlink:to="loc_ifrs-full_BottomOfRangeMember_fe643339-49ec-4da2-8362-c2934bc21ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_300e1c73-a18e-43a0-8b1e-4cb6ba950987" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_bc991ad7-9a70-47ed-afdd-af411ecc3719" xlink:to="loc_ifrs-full_TopOfRangeMember_300e1c73-a18e-43a0-8b1e-4cb6ba950987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_a9e14a32-4028-4214-9157-7d85daab3f04" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_376b9692-68fa-4fe6-acf3-eb04c47c77f6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_376b9692-68fa-4fe6-acf3-eb04c47c77f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_ddf4007e-da69-476b-9c75-16c4403b7f0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_ddf4007e-da69-476b-9c75-16c4403b7f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_ef0585be-1884-4a6f-898c-36f0ae82e5d6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_ef0585be-1884-4a6f-898c-36f0ae82e5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_5dd0e0d8-1060-45b2-a580-c404ebc2ea91" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_5dd0e0d8-1060-45b2-a580-c404ebc2ea91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_b25f0188-655e-4ad1-b891-8be70a349723" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_b25f0188-655e-4ad1-b891-8be70a349723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_d4210900-de64-434f-aabe-2700428dce61" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_faaa5bd4-fade-41f3-b58f-6521b7e1d22b" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_d4210900-de64-434f-aabe-2700428dce61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_bac537b8-883f-498e-8acd-ca540d2622fe" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_fe90ed0a-9ed5-44cf-bc77-32b8f2d9c5a9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_bac537b8-883f-498e-8acd-ca540d2622fe" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_fe90ed0a-9ed5-44cf-bc77-32b8f2d9c5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_20430f7e-8e29-482e-b8c4-59317c005d5c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_fe90ed0a-9ed5-44cf-bc77-32b8f2d9c5a9" xlink:to="loc_ifrs-full_RangeAxis_20430f7e-8e29-482e-b8c4-59317c005d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_5e621a52-607f-4167-b1af-fdc83d0c66dc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_20430f7e-8e29-482e-b8c4-59317c005d5c" xlink:to="loc_ifrs-full_RangesMember_5e621a52-607f-4167-b1af-fdc83d0c66dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_b65a719c-ab05-4eb3-8c24-44b356777fe6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_5e621a52-607f-4167-b1af-fdc83d0c66dc" xlink:to="loc_ifrs-full_BottomOfRangeMember_b65a719c-ab05-4eb3-8c24-44b356777fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_fd01e0ff-220c-41b4-b086-6cbe86c54c48" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_5e621a52-607f-4167-b1af-fdc83d0c66dc" xlink:to="loc_ifrs-full_TopOfRangeMember_fd01e0ff-220c-41b4-b086-6cbe86c54c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_510d753a-d386-47a6-800d-f23529de0745" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_fe90ed0a-9ed5-44cf-bc77-32b8f2d9c5a9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_510d753a-d386-47a6-800d-f23529de0745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_5ea6e772-89c4-4b76-81f8-8e621bbad808" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_510d753a-d386-47a6-800d-f23529de0745" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_5ea6e772-89c4-4b76-81f8-8e621bbad808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_198e42c6-8323-40b8-b1a9-bc772b06aa94" xlink:href="oncyf-20211231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5ea6e772-89c4-4b76-81f8-8e621bbad808" xlink:to="loc_oncyf_RestrictedShareUnitsMember_198e42c6-8323-40b8-b1a9-bc772b06aa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PerformanceShareUnitsMember_6e1530d4-fa39-4e01-8676-2af558214fc3" xlink:href="oncyf-20211231.xsd#oncyf_PerformanceShareUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5ea6e772-89c4-4b76-81f8-8e621bbad808" xlink:to="loc_oncyf_PerformanceShareUnitsMember_6e1530d4-fa39-4e01-8676-2af558214fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_bd36daa2-1a61-4113-b203-23a60a715d20" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5ea6e772-89c4-4b76-81f8-8e621bbad808" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_bd36daa2-1a61-4113-b203-23a60a715d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_fe90ed0a-9ed5-44cf-bc77-32b8f2d9c5a9" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_38ccb631-8ea8-4675-9f1e-96cc5e6f4a4a" xlink:href="oncyf-20211231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_38ccb631-8ea8-4675-9f1e-96cc5e6f4a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod_be28f160-2267-4f3a-a773-bbcf01a370c4" xlink:href="oncyf-20211231.xsd#oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:to="loc_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod_be28f160-2267-4f3a-a773-bbcf01a370c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9ba87a49-821d-4c3f-bb1c-54cd97b48b64" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9ba87a49-821d-4c3f-bb1c-54cd97b48b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7dfeb586-5676-401a-b30e-9300f2972cf7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f984004b-6059-4639-b608-d9dec147f34e" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7dfeb586-5676-401a-b30e-9300f2972cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_90dfc3b1-d568-4461-a1f6-690babe43684" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_6656284e-f1c5-40bc-ab7a-a9feb8ca5ac2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_90dfc3b1-d568-4461-a1f6-690babe43684" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_6656284e-f1c5-40bc-ab7a-a9feb8ca5ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_d9ffc1d0-2359-4630-9f0e-30c9eac9893a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_90dfc3b1-d568-4461-a1f6-690babe43684" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_d9ffc1d0-2359-4630-9f0e-30c9eac9893a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_152b690e-c361-4215-85ac-9bdce2035edd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_90dfc3b1-d568-4461-a1f6-690babe43684" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_152b690e-c361-4215-85ac-9bdce2035edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_f0516879-8661-4701-b202-fbc2673e6b3c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_90dfc3b1-d568-4461-a1f6-690babe43684" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_f0516879-8661-4701-b202-fbc2673e6b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_710d7326-8899-4dad-aba4-0cacd7a1087e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_90dfc3b1-d568-4461-a1f6-690babe43684" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_710d7326-8899-4dad-aba4-0cacd7a1087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_ced0c89d-2fe9-4f7a-8254-bd89cff311a0" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a4caca5b-3e10-4206-8188-870484514429" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_ced0c89d-2fe9-4f7a-8254-bd89cff311a0" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a4caca5b-3e10-4206-8188-870484514429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0f2cde5-7804-422f-b079-c8437d219a53" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a4caca5b-3e10-4206-8188-870484514429" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0f2cde5-7804-422f-b079-c8437d219a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_7298f6ce-5e9c-4246-a808-9db28c245e96" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0f2cde5-7804-422f-b079-c8437d219a53" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_7298f6ce-5e9c-4246-a808-9db28c245e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_6de02edb-fde2-497b-bcb4-3f53fc68fc45" xlink:href="oncyf-20211231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7298f6ce-5e9c-4246-a808-9db28c245e96" xlink:to="loc_oncyf_RestrictedShareUnitsMember_6de02edb-fde2-497b-bcb4-3f53fc68fc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PerformanceShareUnitsMember_451059fa-bea2-4f2a-abb8-e9ee5e6ae80a" xlink:href="oncyf-20211231.xsd#oncyf_PerformanceShareUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7298f6ce-5e9c-4246-a808-9db28c245e96" xlink:to="loc_oncyf_PerformanceShareUnitsMember_451059fa-bea2-4f2a-abb8-e9ee5e6ae80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a4caca5b-3e10-4206-8188-870484514429" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7d25f7a9-5fb7-4f49-96fa-d181c64a0752" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7d25f7a9-5fb7-4f49-96fa-d181c64a0752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_a191de7c-8daf-4208-8705-a0fed2b3d2f5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_a191de7c-8daf-4208-8705-a0fed2b3d2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_587cc2a9-cf4f-4edc-893c-d965d05296d9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_587cc2a9-cf4f-4edc-893c-d965d05296d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_9ee79110-4593-40ec-9c85-c77b586b5c6c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_9ee79110-4593-40ec-9c85-c77b586b5c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_2e21395e-99e7-4679-91c8-4e8d507ba9da" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_54ae9894-8f11-4a44-afc3-47338fc7028f" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_2e21395e-99e7-4679-91c8-4e8d507ba9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="oncyf-20211231.xsd#LossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_4a816dc6-53cf-479a-a267-8d53f88b239e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_77e8ed16-02c8-4b7f-8fc6-066fa26a98bf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_4a816dc6-53cf-479a-a267-8d53f88b239e" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_77e8ed16-02c8-4b7f-8fc6-066fa26a98bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#LossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_9b15332b-6464-45eb-bb9a-2dbbaa51bd7a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_1c26500f-e047-422d-96c8-8a87c7f08d60" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_9b15332b-6464-45eb-bb9a-2dbbaa51bd7a" xlink:to="loc_ifrs-full_WeightedAverageShares_1c26500f-e047-422d-96c8-8a87c7f08d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiability" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ContractLiability"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_f89bef29-98cd-406d-89ca-956fde8a6961" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_f5b27649-1476-439e-a57f-7f05e844767b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_f89bef29-98cd-406d-89ca-956fde8a6961" xlink:to="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_f5b27649-1476-439e-a57f-7f05e844767b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ContractLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_12fdc264-03dc-40a5-b23d-411cb7c9a9a6" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_0e8c6ef7-aa27-454a-886d-5bb563206690" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_12fdc264-03dc-40a5-b23d-411cb7c9a9a6" xlink:to="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_0e8c6ef7-aa27-454a-886d-5bb563206690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ContractLiabilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_ded2993e-e9b2-4489-bd69-fc58b3f487b6" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod_fc2b637a-d546-40be-955b-52f32cf4a2f7" xlink:href="oncyf-20211231.xsd#oncyf_ContractLiabilityRecognitionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_ded2993e-e9b2-4489-bd69-fc58b3f487b6" xlink:to="loc_oncyf_ContractLiabilityRecognitionPeriod_fc2b637a-d546-40be-955b-52f32cf4a2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_bb0e0a01-9b9d-4c81-9ae7-6c679d243440" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_378e33cd-df20-46ab-90a7-49f36ae5553b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_bb0e0a01-9b9d-4c81-9ae7-6c679d243440" xlink:to="loc_ifrs-full_ContractLiabilities_378e33cd-df20-46ab-90a7-49f36ae5553b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_8e13951e-94a7-46c4-86fb-85184a29b14f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_bb0e0a01-9b9d-4c81-9ae7-6c679d243440" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_8e13951e-94a7-46c4-86fb-85184a29b14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_7660e39b-803d-44d4-82da-7c0ba6bfc5ad" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_bb0e0a01-9b9d-4c81-9ae7-6c679d243440" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_7660e39b-803d-44d4-82da-7c0ba6bfc5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_14d8eb00-f6d9-4db3-a994-7ec7a33e4b88" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_bb0e0a01-9b9d-4c81-9ae7-6c679d243440" xlink:to="loc_ifrs-full_ContractLiabilities_14d8eb00-f6d9-4db3-a994-7ec7a33e4b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_7ac3fb71-ca1b-4fe6-8ccc-668aedbb551a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_bb0e0a01-9b9d-4c81-9ae7-6c679d243440" xlink:to="loc_ifrs-full_CurrentContractLiabilities_7ac3fb71-ca1b-4fe6-8ccc-668aedbb551a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_2dfe3abb-533b-40d0-96ac-12f35fc8ff9b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_bb0e0a01-9b9d-4c81-9ae7-6c679d243440" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_2dfe3abb-533b-40d0-96ac-12f35fc8ff9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_3ccf99bb-0233-4512-bde3-49ddcee979e8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_bb0e0a01-9b9d-4c81-9ae7-6c679d243440" xlink:to="loc_ifrs-full_ContractLiabilities_3ccf99bb-0233-4512-bde3-49ddcee979e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="simple" xlink:href="oncyf-20211231.xsd#Commitments"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAbstract_430f2035-b0b8-4565-927e-ca70aa73c70b" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_70a41f87-e96a-4850-8097-26a38a3242be" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_430f2035-b0b8-4565-927e-ca70aa73c70b" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_70a41f87-e96a-4850-8097-26a38a3242be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAbstract_c5bf6076-d69f-4cc0-bd7f-35ccd42da9df" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_7f8644b9-b223-4bc8-a89f-f7efc9dea409" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_c5bf6076-d69f-4cc0-bd7f-35ccd42da9df" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_7f8644b9-b223-4bc8-a89f-f7efc9dea409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_c945a36f-1e07-4cc9-918f-ef8ac35a6018" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_7f8644b9-b223-4bc8-a89f-f7efc9dea409" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_c945a36f-1e07-4cc9-918f-ef8ac35a6018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_4f9aa728-0cf0-4ffb-ad3a-93b571e7fcae" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_c945a36f-1e07-4cc9-918f-ef8ac35a6018" xlink:to="loc_ifrs-full_OtherProvisionsMember_4f9aa728-0cf0-4ffb-ad3a-93b571e7fcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember_52f8c7ff-feb5-4d8a-bfa6-e5821ab21a82" xlink:href="oncyf-20211231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_4f9aa728-0cf0-4ffb-ad3a-93b571e7fcae" xlink:to="loc_oncyf_CollaborationAgreementMember_52f8c7ff-feb5-4d8a-bfa6-e5821ab21a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_7f8644b9-b223-4bc8-a89f-f7efc9dea409" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1_dd9ce963-4d71-46f4-82cd-c5bd9f7e026f" xlink:href="oncyf-20211231.xsd#oncyf_PurchaseObligation1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_PurchaseObligation1_dd9ce963-4d71-46f4-82cd-c5bd9f7e026f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm_8978a28d-b243-421d-b6c8-4490b99d9be1" xlink:href="oncyf-20211231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_PurchaseObligationCommitmentTerm_8978a28d-b243-421d-b6c8-4490b99d9be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_3ae111ae-c490-40ec-8880-b79021a8bad4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_ifrs-full_OtherReceivables_3ae111ae-c490-40ec-8880-b79021a8bad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_65013b26-e117-4f17-8529-8dcbca9031a2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_65013b26-e117-4f17-8529-8dcbca9031a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FundedandRoyaltyRepayment_3424c76e-6822-4185-8654-2bd9c02b1fba" xlink:href="oncyf-20211231.xsd#oncyf_FundedandRoyaltyRepayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_FundedandRoyaltyRepayment_3424c76e-6822-4185-8654-2bd9c02b1fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OverheadRepayment_299e1d02-7be2-43ac-a78b-bdd48e20d85f" xlink:href="oncyf-20211231.xsd#oncyf_OverheadRepayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_OverheadRepayment_299e1d02-7be2-43ac-a78b-bdd48e20d85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_48b11829-21de-4736-89af-09cae5829afb" xlink:href="oncyf-20211231.xsd#oncyf_AnnualContingentPaymentGrossSalesPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_48b11829-21de-4736-89af-09cae5829afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPayment_f159137d-5455-47b3-81bd-15395ea059ff" xlink:href="oncyf-20211231.xsd#oncyf_AnnualContingentPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1c85196d-485b-483f-99b0-1f21e9799ca7" xlink:to="loc_oncyf_AnnualContingentPayment_f159137d-5455-47b3-81bd-15395ea059ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="simple" xlink:href="oncyf-20211231.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract_5ce53c2a-87ce-485c-93a0-2f4a07d8a66d" xlink:href="oncyf-20211231.xsd#oncyf_ContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_bc0ec8c9-348b-4aa9-ac4f-09d208859fba" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_5ce53c2a-87ce-485c-93a0-2f4a07d8a66d" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_bc0ec8c9-348b-4aa9-ac4f-09d208859fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract_4bd6ad45-e96b-4367-90bd-88359e307fe4" xlink:href="oncyf-20211231.xsd#oncyf_ContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_af6ff71e-db52-4ed1-82a1-ad8ca3f2a4b2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_4bd6ad45-e96b-4367-90bd-88359e307fe4" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_af6ff71e-db52-4ed1-82a1-ad8ca3f2a4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_9f7e4515-a98c-4171-9997-3b9a1d47486f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_af6ff71e-db52-4ed1-82a1-ad8ca3f2a4b2" xlink:to="loc_ifrs-full_CounterpartiesAxis_9f7e4515-a98c-4171-9997-3b9a1d47486f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_8438e582-72bb-48dd-86d7-1fdf05b0f882" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_9f7e4515-a98c-4171-9997-3b9a1d47486f" xlink:to="loc_ifrs-full_CounterpartiesMember_8438e582-72bb-48dd-86d7-1fdf05b0f882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SYNSORBMember_44f16eaa-51f7-4291-b63d-96a16e621e78" xlink:href="oncyf-20211231.xsd#oncyf_SYNSORBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_8438e582-72bb-48dd-86d7-1fdf05b0f882" xlink:to="loc_oncyf_SYNSORBMember_44f16eaa-51f7-4291-b63d-96a16e621e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_af6ff71e-db52-4ed1-82a1-ad8ca3f2a4b2" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_bdf24789-c4f0-4b94-b5a5-95ee112c30a0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_bdf24789-c4f0-4b94-b5a5-95ee112c30a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_b43ee526-4ac3-4ef0-a012-478b739db354" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_b43ee526-4ac3-4ef0-a012-478b739db354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_3e6b0391-6a0c-489c-ad80-e60ca572ed88" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_3e6b0391-6a0c-489c-ad80-e60ca572ed88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_236ad5b8-a890-4145-8141-9a9f009999ca" xlink:href="oncyf-20211231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_236ad5b8-a890-4145-8141-9a9f009999ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_5ca53a6f-94e8-440e-bb34-1e4135ca53aa" xlink:href="oncyf-20211231.xsd#oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_5ca53a6f-94e8-440e-bb34-1e4135ca53aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_bc71b2dd-a48f-48bc-9818-5531262b539f" xlink:href="oncyf-20211231.xsd#oncyf_ContingentRoyaltyPaymentAnnualMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_099d3dc8-6f5b-4b71-bd12-ec32ec73d464" xlink:to="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_bc71b2dd-a48f-48bc-9818-5531262b539f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_08487782-9215-46e8-9e63-1c2d306b2d68" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_6c46a44d-1516-4211-82d1-8856d01ad8dc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_08487782-9215-46e8-9e63-1c2d306b2d68" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_6c46a44d-1516-4211-82d1-8856d01ad8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_cc102fcc-6f22-4297-b3a6-068528a7fcb6" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_4e1fb677-ef3d-4294-9a93-3b53bf4f1680" xlink:href="oncyf-20211231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_cc102fcc-6f22-4297-b3a6-068528a7fcb6" xlink:to="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_4e1fb677-ef3d-4294-9a93-3b53bf4f1680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_fa6c846d-6cc9-46a2-a207-aae4b1a10166" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_cc102fcc-6f22-4297-b3a6-068528a7fcb6" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_fa6c846d-6cc9-46a2-a207-aae4b1a10166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit_559746e9-6722-41cc-aea8-abc6cead8a9b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccountingProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_ifrs-full_AccountingProfit_559746e9-6722-41cc-aea8-abc6cead8a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_a0cafa20-16af-46b5-8db7-6ed895401df3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_ifrs-full_ApplicableTaxRate_a0cafa20-16af-46b5-8db7-6ed895401df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6fd8c9aa-f5d7-4bda-9669-a34bc5915153" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6fd8c9aa-f5d7-4bda-9669-a34bc5915153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_3d43531d-7b50-4a22-bf87-b572a92c991a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_3d43531d-7b50-4a22-bf87-b572a92c991a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_e14e7d78-2977-48a3-a758-887c4e90f030" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_e14e7d78-2977-48a3-a758-887c4e90f030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_8c36b7e2-86e6-4dc5-866f-21b08cc3bc20" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_8c36b7e2-86e6-4dc5-866f-21b08cc3bc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_30f16fa8-1d6c-4cee-a0c9-cf1e716177f3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_30f16fa8-1d6c-4cee-a0c9-cf1e716177f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools_b0f568ac-e9a8-4ed7-83c3-3a0a35935859" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_oncyf_TaxEffectOfTaxPools_b0f568ac-e9a8-4ed7-83c3-3a0a35935859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_747e7841-a1dd-4ea0-bc12-572bb21daa15" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_747e7841-a1dd-4ea0-bc12-572bb21daa15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_893c2667-fac5-490e-866f-eb45a51f94ea" xlink:href="oncyf-20211231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_893c2667-fac5-490e-866f-eb45a51f94ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_1bbdfde6-0069-4e64-9952-0d10df10ac40" xlink:href="oncyf-20211231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_1bbdfde6-0069-4e64-9952-0d10df10ac40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_d1f7df18-d5c7-48ea-998d-2d74bb421154" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_63ec8630-f0c1-4c04-a1bb-1a0c41a32c63" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_d1f7df18-d5c7-48ea-998d-2d74bb421154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_8c8c84fe-c558-493b-b1df-51aa03c2c10b" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e950bf1e-b031-4e7b-a674-5ca6c2adc74a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_8c8c84fe-c558-493b-b1df-51aa03c2c10b" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e950bf1e-b031-4e7b-a674-5ca6c2adc74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_f809f1c2-5ae2-4754-8a7c-3cd52806ac09" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e950bf1e-b031-4e7b-a674-5ca6c2adc74a" xlink:to="loc_ifrs-full_MaturityAxis_f809f1c2-5ae2-4754-8a7c-3cd52806ac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_f809f1c2-5ae2-4754-8a7c-3cd52806ac09" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyTwoMember_83bc2f8e-e6ce-4ecd-af62-daa9f91d5e76" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyTwoMember_83bc2f8e-e6ce-4ecd-af62-daa9f91d5e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyThreeMember_ff61a3e0-1e7d-4023-a65c-6b86f4f490ff" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyThreeMember_ff61a3e0-1e7d-4023-a65c-6b86f4f490ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFourMember_1fd2d65e-bf2f-4870-9a73-2769ef50476e" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyFourMember_1fd2d65e-bf2f-4870-9a73-2769ef50476e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFiveMember_e5b39677-e559-496f-a050-7e738313cd4d" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyFiveMember_e5b39677-e559-496f-a050-7e738313cd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySixMember_eac49de7-9cdb-4a11-9fa7-126e02097786" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentySixMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentySixMember_eac49de7-9cdb-4a11-9fa7-126e02097786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySevenMember_8f92b2fa-27a5-45f8-998b-abd0a284de00" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentySevenMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentySevenMember_8f92b2fa-27a5-45f8-998b-abd0a284de00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyEightMember_5420fe9a-e5dd-4e62-b3ce-d263700f6358" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyEightMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyEightMember_5420fe9a-e5dd-4e62-b3ce-d263700f6358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyNineMember_6ace93f7-e591-4c2a-bae1-b909085bab17" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyNineMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyTwentyNineMember_6ace93f7-e591-4c2a-bae1-b909085bab17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyMember_89b807fb-2f67-4289-be52-0c267d4a7d29" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyMember_89b807fb-2f67-4289-be52-0c267d4a7d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyOneMember_95754c95-f3df-4039-885b-7fdd1198ff28" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyOneMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyOneMember_95754c95-f3df-4039-885b-7fdd1198ff28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyTwoMember_952e1077-9470-4ecd-86e1-98c2f886d71d" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyTwoMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyTwoMember_952e1077-9470-4ecd-86e1-98c2f886d71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyThreeMember_a7b33f43-9d1d-42af-97b2-3551cbe00998" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyThreeMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyThreeMember_a7b33f43-9d1d-42af-97b2-3551cbe00998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFourMember_af14fc43-2660-4085-a6ef-e08ca89e8a02" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyFourMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyFourMember_af14fc43-2660-4085-a6ef-e08ca89e8a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFiveMember_2a5672ba-dcb3-464b-964f-1048451318ad" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyFiveMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyFiveMember_2a5672ba-dcb3-464b-964f-1048451318ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySixMember_2d37f023-638c-4e13-ab5c-5e07362511a1" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtySixMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtySixMember_2d37f023-638c-4e13-ab5c-5e07362511a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySevenMember_d4b7634a-84ed-43ef-bc24-6d0fa3d1736b" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtySevenMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtySevenMember_d4b7634a-84ed-43ef-bc24-6d0fa3d1736b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyEightMember_49bfd524-4cbe-4eaa-a74c-4f3e47200880" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyEightMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyEightMember_49bfd524-4cbe-4eaa-a74c-4f3e47200880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyNineMember_ef5b0010-3167-4ca3-8bf3-594525ccca0e" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyNineMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_98709665-c0eb-408e-94eb-495b87e88e02" xlink:to="loc_oncyf_TwentyThirtyNineMember_ef5b0010-3167-4ca3-8bf3-594525ccca0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_731fff24-2d5a-47c5-8657-c89c7c9e09e0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e950bf1e-b031-4e7b-a674-5ca6c2adc74a" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_731fff24-2d5a-47c5-8657-c89c7c9e09e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_37ac1b73-a3e0-49fb-a539-c868419de852" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_731fff24-2d5a-47c5-8657-c89c7c9e09e0" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_37ac1b73-a3e0-49fb-a539-c868419de852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_0a7e4528-9c4b-460c-b140-699f93f9e352" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_37ac1b73-a3e0-49fb-a539-c868419de852" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_0a7e4528-9c4b-460c-b140-699f93f9e352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_8eff933b-ee42-4a61-b5ca-15a8d11c2469" xlink:href="oncyf-20211231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_37ac1b73-a3e0-49fb-a539-c868419de852" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_8eff933b-ee42-4a61-b5ca-15a8d11c2469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_25fb6160-7ddf-475a-8616-0a117ba76248" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e950bf1e-b031-4e7b-a674-5ca6c2adc74a" xlink:to="loc_srt_StatementGeographicalAxis_25fb6160-7ddf-475a-8616-0a117ba76248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f55a474f-d395-4b2a-bd60-fba1deb92254" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_25fb6160-7ddf-475a-8616-0a117ba76248" xlink:to="loc_srt_SegmentGeographicalDomain_f55a474f-d395-4b2a-bd60-fba1deb92254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_0fdd66d3-14eb-4271-b684-5f52a86a1c37" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f55a474f-d395-4b2a-bd60-fba1deb92254" xlink:to="loc_country_CA_0fdd66d3-14eb-4271-b684-5f52a86a1c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d483dd11-4f2f-44ba-adb4-c7311e0af567" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f55a474f-d395-4b2a-bd60-fba1deb92254" xlink:to="loc_country_US_d483dd11-4f2f-44ba-adb4-c7311e0af567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_024299ae-bbe1-49f4-8da3-2a39f552cedb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e950bf1e-b031-4e7b-a674-5ca6c2adc74a" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_024299ae-bbe1-49f4-8da3-2a39f552cedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_96899278-e419-41a6-a9d3-9e582f5f1bdb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_024299ae-bbe1-49f4-8da3-2a39f552cedb" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_96899278-e419-41a6-a9d3-9e582f5f1bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IncomeTaxesSummaryofNoncapitalLossesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_941cd009-c810-4da0-8e40-92df10aaaf48" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_c8f47eb9-7fab-4650-a754-3d1aa894b685" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_941cd009-c810-4da0-8e40-92df10aaaf48" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_c8f47eb9-7fab-4650-a754-3d1aa894b685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_9e646d6a-4499-475e-b7cc-b24677569223" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_c8f47eb9-7fab-4650-a754-3d1aa894b685" xlink:to="loc_ifrs-full_MaturityAxis_9e646d6a-4499-475e-b7cc-b24677569223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_9e646d6a-4499-475e-b7cc-b24677569223" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyTwoMember_378b54bb-b765-447f-a356-c532789527d2" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyTwoMember_378b54bb-b765-447f-a356-c532789527d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyThreeMember_6404696e-adcf-4098-9bb9-0011e116c0e4" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyThreeMember_6404696e-adcf-4098-9bb9-0011e116c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFourMember_029c9376-0e8e-4dc5-b235-e18007a7976a" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyFourMember_029c9376-0e8e-4dc5-b235-e18007a7976a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFiveMember_69f348da-100a-4336-a0c5-0bb454c3f3eb" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyFiveMember_69f348da-100a-4336-a0c5-0bb454c3f3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySixMember_aa721ebe-146f-4db3-adbf-f5620be60fa2" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentySixMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentySixMember_aa721ebe-146f-4db3-adbf-f5620be60fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySevenMember_2d2f6d5f-d2d5-4e98-bfdd-4a34f2b37e28" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentySevenMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentySevenMember_2d2f6d5f-d2d5-4e98-bfdd-4a34f2b37e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyEightMember_5b366e05-f14b-45db-99e6-f689b3231ea1" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyEightMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyEightMember_5b366e05-f14b-45db-99e6-f689b3231ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyNineMember_3497590f-94db-405e-b336-d8a272d48ca6" xlink:href="oncyf-20211231.xsd#oncyf_TwentyTwentyNineMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyTwentyNineMember_3497590f-94db-405e-b336-d8a272d48ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyMember_ef844ddb-51c4-47d7-b6fe-401dc774e825" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyMember_ef844ddb-51c4-47d7-b6fe-401dc774e825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyOneMember_8bd2d8b6-f5c3-4079-a92f-72d3f60d9953" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyOneMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyOneMember_8bd2d8b6-f5c3-4079-a92f-72d3f60d9953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyTwoMember_400f7f9c-543e-4069-bb71-cd22db03a937" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyTwoMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyTwoMember_400f7f9c-543e-4069-bb71-cd22db03a937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyThreeMember_6249d46c-8a79-4cc8-96f5-f94e193eadcf" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyThreeMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyThreeMember_6249d46c-8a79-4cc8-96f5-f94e193eadcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFourMember_1402d7c4-ef29-4f38-a39d-43ee4c37a6ee" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyFourMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyFourMember_1402d7c4-ef29-4f38-a39d-43ee4c37a6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFiveMember_76ded99d-61d4-48dc-a338-df8e139fb52b" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyFiveMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyFiveMember_76ded99d-61d4-48dc-a338-df8e139fb52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySixMember_0865930e-ecd2-4055-b570-de80ce586f5a" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtySixMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtySixMember_0865930e-ecd2-4055-b570-de80ce586f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySevenMember_6b0a2287-b1b7-4983-9f57-f47e44b29b9e" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtySevenMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtySevenMember_6b0a2287-b1b7-4983-9f57-f47e44b29b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyEightMember_76259c1a-558e-4efe-b520-173a9601fccf" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyEightMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyEightMember_76259c1a-558e-4efe-b520-173a9601fccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyNineMember_03bba763-01a7-43ab-872d-eb43619cdc8e" xlink:href="oncyf-20211231.xsd#oncyf_TwentyThirtyNineMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyThirtyNineMember_03bba763-01a7-43ab-872d-eb43619cdc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyFortyMember_c2c57e92-75af-4db6-86a9-7b3216d50ba9" xlink:href="oncyf-20211231.xsd#oncyf_TwentyFortyMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyFortyMember_c2c57e92-75af-4db6-86a9-7b3216d50ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyFortyOneMember_83af93fd-c018-46b5-8957-47bab00161d6" xlink:href="oncyf-20211231.xsd#oncyf_TwentyFortyOneMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9cc03c4d-fc60-462e-806f-16e776d47da3" xlink:to="loc_oncyf_TwentyFortyOneMember_83af93fd-c018-46b5-8957-47bab00161d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_677cfe47-e212-4b61-8e9c-8976f7fa53fa" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_c8f47eb9-7fab-4650-a754-3d1aa894b685" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_677cfe47-e212-4b61-8e9c-8976f7fa53fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e84ce20-00b5-4fb5-a2a4-65baf8ffdd82" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_677cfe47-e212-4b61-8e9c-8976f7fa53fa" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e84ce20-00b5-4fb5-a2a4-65baf8ffdd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_038fe3d8-5599-4cac-8f0a-a50e9ac3ea59" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e84ce20-00b5-4fb5-a2a4-65baf8ffdd82" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_038fe3d8-5599-4cac-8f0a-a50e9ac3ea59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_edb880b6-38ca-4daa-82f8-10860d31aa3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_c8f47eb9-7fab-4650-a754-3d1aa894b685" xlink:to="loc_srt_StatementGeographicalAxis_edb880b6-38ca-4daa-82f8-10860d31aa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_36000d76-fd20-4cfa-86c7-73adc24434a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_edb880b6-38ca-4daa-82f8-10860d31aa3a" xlink:to="loc_srt_SegmentGeographicalDomain_36000d76-fd20-4cfa-86c7-73adc24434a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_1d66d58e-c28e-4c20-be35-a7f87a3aa3ad" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_36000d76-fd20-4cfa-86c7-73adc24434a5" xlink:to="loc_country_CA_1d66d58e-c28e-4c20-be35-a7f87a3aa3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB_66c39984-dd01-4362-b4d5-d3098f7ce44c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BB"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_36000d76-fd20-4cfa-86c7-73adc24434a5" xlink:to="loc_country_BB_66c39984-dd01-4362-b4d5-d3098f7ce44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_96c4afa1-247c-453d-b95c-ca294578e14a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_c8f47eb9-7fab-4650-a754-3d1aa894b685" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_96c4afa1-247c-453d-b95c-ca294578e14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_b90d33c7-498c-4b43-a747-90d621aa8f05" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_96c4afa1-247c-453d-b95c-ca294578e14a" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_b90d33c7-498c-4b43-a747-90d621aa8f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_7f6722ff-d5e2-48a2-9f1c-1b6357536ddd" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_b59fcbb5-7b66-4fdf-a928-df150dfccb4a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_7f6722ff-d5e2-48a2-9f1c-1b6357536ddd" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_b59fcbb5-7b66-4fdf-a928-df150dfccb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ed85fa1c-779c-45da-a0df-ef00cb753b35" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_b59fcbb5-7b66-4fdf-a928-df150dfccb4a" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ed85fa1c-779c-45da-a0df-ef00cb753b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ed85fa1c-779c-45da-a0df-ef00cb753b35" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_ae54d31a-c581-4241-b7ac-c170cc5f17a9" xlink:href="oncyf-20211231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_ae54d31a-c581-4241-b7ac-c170cc5f17a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_22f309fc-d77f-4780-ae24-e2bb4486b595" xlink:href="oncyf-20211231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_22f309fc-d77f-4780-ae24-e2bb4486b595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_598f19b9-cd83-4e95-ba63-fb73f8a3adce" xlink:href="oncyf-20211231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_598f19b9-cd83-4e95-ba63-fb73f8a3adce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_dd184c1d-60b5-4ec4-8fe5-1c63ae881489" xlink:href="oncyf-20211231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_dd184c1d-60b5-4ec4-8fe5-1c63ae881489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember_a492f1fc-b60f-44e7-9153-45bfff9ae3bf" xlink:href="oncyf-20211231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_ShareIssueCostsMember_a492f1fc-b60f-44e7-9153-45bfff9ae3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_b430b138-fbef-4c81-9b74-82c2f23b9ee9" xlink:href="oncyf-20211231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3a10c183-31a3-4d52-9144-3d20f0e21583" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_b430b138-fbef-4c81-9b74-82c2f23b9ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b2a907b1-e904-4303-ae0f-6c978f8a99a6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_b59fcbb5-7b66-4fdf-a928-df150dfccb4a" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b2a907b1-e904-4303-ae0f-6c978f8a99a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_8936b59c-14bb-4ffb-9ea2-18a685049ab8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b2a907b1-e904-4303-ae0f-6c978f8a99a6" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_8936b59c-14bb-4ffb-9ea2-18a685049ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CapitalDisclosures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_77ccc6a8-f274-4743-a90d-207b8f0e806e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_a4240d6a-ec7c-4187-ae93-5043775eef01" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_77ccc6a8-f274-4743-a90d-207b8f0e806e" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_a4240d6a-ec7c-4187-ae93-5043775eef01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CapitalDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_4c52decf-4a8f-4766-af6c-9d957e1737ae" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_25570ece-26c2-4093-aa76-bf3abc5afe09" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_4c52decf-4a8f-4766-af6c-9d957e1737ae" xlink:to="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_25570ece-26c2-4093-aa76-bf3abc5afe09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#CapitalDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_767fdc85-fcfd-42f5-a358-8edb1eef0fa4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_a73dab11-0fd7-4815-a089-f6ee0682ba4c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_767fdc85-fcfd-42f5-a358-8edb1eef0fa4" xlink:to="loc_ifrs-full_CashAndCashEquivalents_a73dab11-0fd7-4815-a089-f6ee0682ba4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_e390bbb0-2868-48f5-bece-59a45348b261" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_767fdc85-fcfd-42f5-a358-8edb1eef0fa4" xlink:to="loc_ifrs-full_Equity_e390bbb0-2868-48f5-bece-59a45348b261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EquityAuthorized_ffd7141e-b578-480a-8a31-1dc29137bb73" xlink:href="oncyf-20211231.xsd#oncyf_EquityAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_767fdc85-fcfd-42f5-a358-8edb1eef0fa4" xlink:to="loc_oncyf_EquityAuthorized_ffd7141e-b578-480a-8a31-1dc29137bb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="simple" xlink:href="oncyf-20211231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1c3a175a-f978-41b0-833e-6f056de70525" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_0812613f-a5f7-4181-b170-6608d9599d02" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1c3a175a-f978-41b0-833e-6f056de70525" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_0812613f-a5f7-4181-b170-6608d9599d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1ba6895c-acee-46f7-b4f6-ae6ef44340c7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_678c0b7f-6cb5-4664-aec9-25ef75e1b4ff" xlink:href="oncyf-20211231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1ba6895c-acee-46f7-b4f6-ae6ef44340c7" xlink:to="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_678c0b7f-6cb5-4664-aec9-25ef75e1b4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_44564245-235b-4025-aea5-1a01edde8b8d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5033a6eb-9118-4deb-8dd9-392b9f00dc3a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_44564245-235b-4025-aea5-1a01edde8b8d" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5033a6eb-9118-4deb-8dd9-392b9f00dc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_26499c4b-d53f-4542-8f9a-2ac48cf5f520" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5033a6eb-9118-4deb-8dd9-392b9f00dc3a" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_26499c4b-d53f-4542-8f9a-2ac48cf5f520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9a07f1b0-c5b9-40bf-84d3-7a222a5aecaf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_26499c4b-d53f-4542-8f9a-2ac48cf5f520" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9a07f1b0-c5b9-40bf-84d3-7a222a5aecaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_b7c5f09e-03ac-454e-ae86-22896f009afc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9a07f1b0-c5b9-40bf-84d3-7a222a5aecaf" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_b7c5f09e-03ac-454e-ae86-22896f009afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_270ff4d3-2c3a-48a6-a5f8-99b268b6f9b2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5033a6eb-9118-4deb-8dd9-392b9f00dc3a" xlink:to="loc_ifrs-full_TypesOfRisksAxis_270ff4d3-2c3a-48a6-a5f8-99b268b6f9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_331a5972-26e6-433d-9057-a1040476be00" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_270ff4d3-2c3a-48a6-a5f8-99b268b6f9b2" xlink:to="loc_ifrs-full_TypesOfRisksMember_331a5972-26e6-433d-9057-a1040476be00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_87725029-42f0-4216-afef-4bfe97871fc3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_331a5972-26e6-433d-9057-a1040476be00" xlink:to="loc_ifrs-full_CurrencyRiskMember_87725029-42f0-4216-afef-4bfe97871fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_609a9639-d9dd-41e5-a19f-1c4d2be1046b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5033a6eb-9118-4deb-8dd9-392b9f00dc3a" xlink:to="loc_srt_CurrencyAxis_609a9639-d9dd-41e5-a19f-1c4d2be1046b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_4db02993-6cd2-496e-a309-29bf8e361670" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_609a9639-d9dd-41e5-a19f-1c4d2be1046b" xlink:to="loc_currency_AllCurrenciesDomain_4db02993-6cd2-496e-a309-29bf8e361670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_d0893571-e246-4ccf-90f1-fe658d8539f8" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_4db02993-6cd2-496e-a309-29bf8e361670" xlink:to="loc_currency_USD_d0893571-e246-4ccf-90f1-fe658d8539f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_351d910b-f2dd-476d-86c6-ae84a62e30c6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5033a6eb-9118-4deb-8dd9-392b9f00dc3a" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_351d910b-f2dd-476d-86c6-ae84a62e30c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_bcd3d3ac-5331-4507-b5d8-ed977578dad4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_351d910b-f2dd-476d-86c6-ae84a62e30c6" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_bcd3d3ac-5331-4507-b5d8-ed977578dad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_c048826d-6f65-4d7d-9f8b-6372602af4d3" xlink:href="oncyf-20211231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_351d910b-f2dd-476d-86c6-ae84a62e30c6" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_c048826d-6f65-4d7d-9f8b-6372602af4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_fc9959ef-2ba6-4570-93fa-beb143ae3972" xlink:href="oncyf-20211231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_351d910b-f2dd-476d-86c6-ae84a62e30c6" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_fc9959ef-2ba6-4570-93fa-beb143ae3972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_ab109491-fb99-4ea8-900e-babcd31bd0ec" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_82ecdd2a-6b1a-4b54-912c-a4a1198e485c" xlink:href="oncyf-20211231.xsd#oncyf_Currency1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_ab109491-fb99-4ea8-900e-babcd31bd0ec" xlink:to="loc_oncyf_Currency1Table_82ecdd2a-6b1a-4b54-912c-a4a1198e485c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_cf9d0d43-0a67-46a8-92a8-c7aaef13dcec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_82ecdd2a-6b1a-4b54-912c-a4a1198e485c" xlink:to="loc_srt_CurrencyAxis_cf9d0d43-0a67-46a8-92a8-c7aaef13dcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_e0c01f6c-b615-44a4-bb74-72923d7641bd" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_cf9d0d43-0a67-46a8-92a8-c7aaef13dcec" xlink:to="loc_currency_AllCurrenciesDomain_e0c01f6c-b615-44a4-bb74-72923d7641bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_60ab1a1c-044e-4b2c-be8c-3de67ce67d3f" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_e0c01f6c-b615-44a4-bb74-72923d7641bd" xlink:to="loc_currency_USD_60ab1a1c-044e-4b2c-be8c-3de67ce67d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:href="oncyf-20211231.xsd#oncyf_Currency1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_82ecdd2a-6b1a-4b54-912c-a4a1198e485c" xlink:to="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_aba9cbd2-af30-478a-9bc8-82897a8952f0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:to="loc_ifrs-full_CashAndCashEquivalents_aba9cbd2-af30-478a-9bc8-82897a8952f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_1d654250-aa23-48f9-b801-d56b85058c66" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:to="loc_ifrs-full_OtherReceivables_1d654250-aa23-48f9-b801-d56b85058c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_fb9e023e-7c18-4aa6-a288-80612d40c580" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_fb9e023e-7c18-4aa6-a288-80612d40c580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_0dcbb025-fe1b-4305-b015-c206556de365" xlink:href="oncyf-20211231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_dc09f286-b7a8-4a38-b045-d53d1d69c4e6" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_0dcbb025-fe1b-4305-b015-c206556de365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="simple" xlink:href="oncyf-20211231.xsd#AdditionalCashFlowDisclosures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_16453414-7009-4e6e-b7db-3ce002e675ab" xlink:href="oncyf-20211231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_5c876b0b-d2e4-4455-9e9a-bbffe0543978" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_16453414-7009-4e6e-b7db-3ce002e675ab" xlink:to="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_5c876b0b-d2e4-4455-9e9a-bbffe0543978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#AdditionalCashFlowDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_adfe7ebf-8c39-4b31-b254-0e819eb07bfb" xlink:href="oncyf-20211231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_c4704450-e3e0-4989-94b4-d4a7ce32b0f0" xlink:href="oncyf-20211231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_adfe7ebf-8c39-4b31-b254-0e819eb07bfb" xlink:to="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_c4704450-e3e0-4989-94b4-d4a7ce32b0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_d5fbce64-6893-464e-813b-5cd84758f8bd" xlink:href="oncyf-20211231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_adfe7ebf-8c39-4b31-b254-0e819eb07bfb" xlink:to="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_d5fbce64-6893-464e-813b-5cd84758f8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_cc929b9e-574d-4f49-bc52-7b0b2233f495" xlink:href="oncyf-20211231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_62accdfc-b6af-489e-8170-f4a1047fec1b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_cc929b9e-574d-4f49-bc52-7b0b2233f495" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_62accdfc-b6af-489e-8170-f4a1047fec1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_6cae5bfa-9247-40b1-816a-45675a17749a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_cc929b9e-574d-4f49-bc52-7b0b2233f495" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_6cae5bfa-9247-40b1-816a-45675a17749a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_b6efba0e-7122-48c3-8318-8c1c69f442fd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_cc929b9e-574d-4f49-bc52-7b0b2233f495" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_b6efba0e-7122-48c3-8318-8c1c69f442fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_c4598746-ed89-48de-bc85-f98f070e5277" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_cc929b9e-574d-4f49-bc52-7b0b2233f495" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_c4598746-ed89-48de-bc85-f98f070e5277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_2330469e-509b-4ec7-8cbc-c6f25fc0a5a2" xlink:href="oncyf-20211231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_cc929b9e-574d-4f49-bc52-7b0b2233f495" xlink:to="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_2330469e-509b-4ec7-8cbc-c6f25fc0a5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_57c6cf55-b59a-4415-8bdb-84d577d2cac3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_cc929b9e-574d-4f49-bc52-7b0b2233f495" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_57c6cf55-b59a-4415-8bdb-84d577d2cac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_35068f91-58af-4f4a-a0af-ca26c2662347" xlink:href="oncyf-20211231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromInterestReceived_8fe04fbf-e5b9-4d55-8fb1-685f8532720d" xlink:href="oncyf-20211231.xsd#oncyf_ProceedsfromInterestReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_35068f91-58af-4f4a-a0af-ca26c2662347" xlink:to="loc_oncyf_ProceedsfromInterestReceived_8fe04fbf-e5b9-4d55-8fb1-685f8532720d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_17b2ddfc-9bcb-4139-bc1d-6f7a41b61f1d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_35068f91-58af-4f4a-a0af-ca26c2662347" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefund_17b2ddfc-9bcb-4139-bc1d-6f7a41b61f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="simple" xlink:href="oncyf-20211231.xsd#IndemnificationofOfficersandDirectors"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_621a1154-69a6-4698-a646-14481f1704fe" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_52910ecc-8a04-4702-bd40-b6c70de78efd" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_621a1154-69a6-4698-a646-14481f1704fe" xlink:to="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_52910ecc-8a04-4702-bd40-b6c70de78efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="simple" xlink:href="oncyf-20211231.xsd#EconomicDependence"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_fb3e9987-6362-4701-a13a-d1fe0a80f12e" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_baba470a-b0a0-49fb-8a06-d71c96d01c46" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_fb3e9987-6362-4701-a13a-d1fe0a80f12e" xlink:to="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_baba470a-b0a0-49fb-8a06-d71c96d01c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#EconomicDependenceDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_8faff02d-0062-44d5-99d4-6e1a6521abe1" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table_2b3d2fa3-5f25-4e57-9a93-90e3e042e0ef" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_8faff02d-0062-44d5-99d4-6e1a6521abe1" xlink:to="loc_oncyf_ConcentrationRisk1Table_2b3d2fa3-5f25-4e57-9a93-90e3e042e0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_4e6ef920-94e1-44c0-a10f-69c38c05dc44" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_2b3d2fa3-5f25-4e57-9a93-90e3e042e0ef" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_4e6ef920-94e1-44c0-a10f-69c38c05dc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_6f59c35f-cede-4eb9-af6d-ce03cfdbb89b" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_4e6ef920-94e1-44c0-a10f-69c38c05dc44" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_6f59c35f-cede-4eb9-af6d-ce03cfdbb89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_f81d78b7-b2ef-412f-85fc-a3c23bbcf6ea" xlink:href="oncyf-20211231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_6f59c35f-cede-4eb9-af6d-ce03cfdbb89b" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_f81d78b7-b2ef-412f-85fc-a3c23bbcf6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_583fa144-c928-4eb5-8226-8370b6c1cbc9" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_2b3d2fa3-5f25-4e57-9a93-90e3e042e0ef" xlink:to="loc_oncyf_ConcentrationRiskType1LineItems_583fa144-c928-4eb5-8226-8370b6c1cbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber_f2ca9d40-dda7-49a1-838a-fd829a5fa7e2" xlink:href="oncyf-20211231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_583fa144-c928-4eb5-8226-8370b6c1cbc9" xlink:to="loc_oncyf_ConcentrationRiskNumber_f2ca9d40-dda7-49a1-838a-fd829a5fa7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpenses" xlink:type="simple" xlink:href="oncyf-20211231.xsd#OtherExpenses"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c7cde73a-0cbd-4f9c-9994-19d0b6b0d90c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_f2c56510-f4a9-4616-843e-a1715b47bebc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c7cde73a-0cbd-4f9c-9994-19d0b6b0d90c" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_f2c56510-f4a9-4616-843e-a1715b47bebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#OtherExpensesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ad47a43c-339c-427a-9ff0-c4e5d0356e1a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_ce75d1c0-6d93-4fbe-9470-d202024f3c3e" xlink:href="oncyf-20211231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ad47a43c-339c-427a-9ff0-c4e5d0356e1a" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_ce75d1c0-6d93-4fbe-9470-d202024f3c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#OtherExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4ce36e1c-972b-4c6e-9252-88b46c743b40" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_c0326f8b-8e78-4d72-90d4-5886d3c93872" xlink:href="oncyf-20211231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4ce36e1c-972b-4c6e-9252-88b46c743b40" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_c0326f8b-8e78-4d72-90d4-5886d3c93872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_12705a66-5a95-453a-86ed-0469c2a6b3b1" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_c0326f8b-8e78-4d72-90d4-5886d3c93872" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_12705a66-5a95-453a-86ed-0469c2a6b3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_9c00e6fa-edfe-4b33-a5ae-cd402a2bd280" xlink:href="oncyf-20211231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_12705a66-5a95-453a-86ed-0469c2a6b3b1" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_9c00e6fa-edfe-4b33-a5ae-cd402a2bd280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentMember_35a1dfe5-1a30-40a9-9c58-075573c810b2" xlink:href="oncyf-20211231.xsd#oncyf_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_9c00e6fa-edfe-4b33-a5ae-cd402a2bd280" xlink:to="loc_oncyf_ResearchAndDevelopmentMember_35a1dfe5-1a30-40a9-9c58-075573c810b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingExpensesMember_8c1d9e6f-210c-4901-b7c8-3c21c90f297d" xlink:href="oncyf-20211231.xsd#oncyf_OperatingExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_9c00e6fa-edfe-4b33-a5ae-cd402a2bd280" xlink:to="loc_oncyf_OperatingExpensesMember_8c1d9e6f-210c-4901-b7c8-3c21c90f297d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_5b0da493-7ccf-43c4-a2b4-c98dc49ca013" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_c0326f8b-8e78-4d72-90d4-5886d3c93872" xlink:to="loc_oncyf_SaleOfStockAxis_5b0da493-7ccf-43c4-a2b4-c98dc49ca013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_0da715d5-d2b0-4810-b44f-8cb9983df640" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_5b0da493-7ccf-43c4-a2b4-c98dc49ca013" xlink:to="loc_oncyf_SaleOfStockDomain_0da715d5-d2b0-4810-b44f-8cb9983df640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_c470fb59-8f58-42ef-8b13-0e255a47c087" xlink:href="oncyf-20211231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_0da715d5-d2b0-4810-b44f-8cb9983df640" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_c470fb59-8f58-42ef-8b13-0e255a47c087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:href="oncyf-20211231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_c0326f8b-8e78-4d72-90d4-5886d3c93872" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_d09de8a2-531f-475e-89bb-03e2e0fbe19c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_d09de8a2-531f-475e-89bb-03e2e0fbe19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_b199dea3-601d-41e8-87f3-691360c9e8ab" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_b199dea3-601d-41e8-87f3-691360c9e8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_f1f7c30b-68bf-415c-9402-0b9e252a5d8b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:to="loc_ifrs-full_AmortisationExpense_f1f7c30b-68bf-415c-9402-0b9e252a5d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_f28acd38-3db2-4761-81be-792806996cae" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_f28acd38-3db2-4761-81be-792806996cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_8a54f527-c588-44bb-89d2-fb37e73a28e7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_de172b8b-9b18-4b48-acf4-f33d56f26406" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_8a54f527-c588-44bb-89d2-fb37e73a28e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="oncyf-20211231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_0ae248e1-06f7-4079-a842-20a59d99df82" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_2706721a-28ba-4f8c-b867-0d3719cbcf3b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_0ae248e1-06f7-4079-a842-20a59d99df82" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_2706721a-28ba-4f8c-b867-0d3719cbcf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="oncyf-20211231.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_7499e6c1-4ad4-492c-b106-a60091c4829a" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_7e5a3ee2-fe11-458b-89b7-5ee891d1b5df" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_7499e6c1-4ad4-492c-b106-a60091c4829a" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_7e5a3ee2-fe11-458b-89b7-5ee891d1b5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_5f7df7ae-eea3-48a6-b029-168bd95dac3e" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_93a2fae1-9eda-4fd5-9ffc-393ca2db97b7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_5f7df7ae-eea3-48a6-b029-168bd95dac3e" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_93a2fae1-9eda-4fd5-9ffc-393ca2db97b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_e27644da-ca16-4497-9869-9857cc6f545b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_5f7df7ae-eea3-48a6-b029-168bd95dac3e" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_e27644da-ca16-4497-9869-9857cc6f545b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_b8f21424-c22e-4ced-bd57-7c1ad7bd088e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_5f7df7ae-eea3-48a6-b029-168bd95dac3e" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_b8f21424-c22e-4ced-bd57-7c1ad7bd088e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_be94e117-bbc7-4413-b0a0-4b7f4e847d42" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_5f7df7ae-eea3-48a6-b029-168bd95dac3e" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_be94e117-bbc7-4413-b0a0-4b7f4e847d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="simple" xlink:href="oncyf-20211231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_8a8c034a-a181-4d3d-9a1b-ddd873d6fda4" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_76347032-6742-4748-afa1-e36d9094a3f7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_8a8c034a-a181-4d3d-9a1b-ddd873d6fda4" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_76347032-6742-4748-afa1-e36d9094a3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="oncyf-20211231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_d6671faa-fbcf-4526-a5f2-4843fab1ce4e" xlink:href="oncyf-20211231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6c68cc85-cef4-4cfa-a19e-81760b9e5362" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_d6671faa-fbcf-4526-a5f2-4843fab1ce4e" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6c68cc85-cef4-4cfa-a19e-81760b9e5362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ed136fa0-117a-4019-9b03-e866f5b1b38f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6c68cc85-cef4-4cfa-a19e-81760b9e5362" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ed136fa0-117a-4019-9b03-e866f5b1b38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_d9b7f88e-67fb-4eaf-b2bd-00b7dd749272" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ed136fa0-117a-4019-9b03-e866f5b1b38f" xlink:to="loc_ifrs-full_NonadjustingEventsMember_d9b7f88e-67fb-4eaf-b2bd-00b7dd749272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_861cebae-64dc-48ed-b1e6-12ed7ab5ac92" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_d9b7f88e-67fb-4eaf-b2bd-00b7dd749272" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_861cebae-64dc-48ed-b1e6-12ed7ab5ac92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_dfe3208b-7c8b-4a54-bea4-05e46ee5d4d6" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6c68cc85-cef4-4cfa-a19e-81760b9e5362" xlink:to="loc_oncyf_SaleOfStockAxis_dfe3208b-7c8b-4a54-bea4-05e46ee5d4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_091076ab-07e3-4fd0-a6b0-ebc5532a86f6" xlink:href="oncyf-20211231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_dfe3208b-7c8b-4a54-bea4-05e46ee5d4d6" xlink:to="loc_oncyf_SaleOfStockDomain_091076ab-07e3-4fd0-a6b0-ebc5532a86f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_145330aa-f855-495c-a2c8-bb53debddb28" xlink:href="oncyf-20211231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_091076ab-07e3-4fd0-a6b0-ebc5532a86f6" xlink:to="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_145330aa-f855-495c-a2c8-bb53debddb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AgreementAxis_24a13491-81d0-4cf3-99b0-3ad9670f77ad" xlink:href="oncyf-20211231.xsd#oncyf_AgreementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6c68cc85-cef4-4cfa-a19e-81760b9e5362" xlink:to="loc_oncyf_AgreementAxis_24a13491-81d0-4cf3-99b0-3ad9670f77ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AgreementDomain_620592d7-7f9f-408b-97bd-067740ebfa62" xlink:href="oncyf-20211231.xsd#oncyf_AgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AgreementAxis_24a13491-81d0-4cf3-99b0-3ad9670f77ad" xlink:to="loc_oncyf_AgreementDomain_620592d7-7f9f-408b-97bd-067740ebfa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProductionServiceAgreementMember_cadea876-0400-49e8-b160-cc102fa28080" xlink:href="oncyf-20211231.xsd#oncyf_ProductionServiceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AgreementDomain_620592d7-7f9f-408b-97bd-067740ebfa62" xlink:to="loc_oncyf_ProductionServiceAgreementMember_cadea876-0400-49e8-b160-cc102fa28080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_b3e9a7d9-63e4-4237-b405-b2d459cbc725" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6c68cc85-cef4-4cfa-a19e-81760b9e5362" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_b3e9a7d9-63e4-4237-b405-b2d459cbc725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_a4f2d1d1-55c2-48f9-b07d-96cb85ac8c87" xlink:href="oncyf-20211231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_b3e9a7d9-63e4-4237-b405-b2d459cbc725" xlink:to="loc_oncyf_IssueOfEquityShares_a4f2d1d1-55c2-48f9-b07d-96cb85ac8c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_080acb99-e93d-4cdb-83b5-b55dab0bfe58" xlink:href="oncyf-20211231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_b3e9a7d9-63e4-4237-b405-b2d459cbc725" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_080acb99-e93d-4cdb-83b5-b55dab0bfe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PaymentsForExecutoryContracts_db097ff2-0877-44a1-9c3c-4b0d77e8d880" xlink:href="oncyf-20211231.xsd#oncyf_PaymentsForExecutoryContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_b3e9a7d9-63e4-4237-b405-b2d459cbc725" xlink:to="loc_oncyf_PaymentsForExecutoryContracts_db097ff2-0877-44a1-9c3c-4b0d77e8d880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144099512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ONCOLYTICS BIOTECH INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">804, 322 11th Avenue SW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Calgary<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">T2R 0C5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">no<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ONCY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">55,043,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001129928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">804, 322 11th Avenue SW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Calgary<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">T2R 0C5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Kirk Look<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">670-7377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">info@oncolytics.ca<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144469672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Calgary, Canada<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144686504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents (note 5)</a></td>
<td class="nump">$ 41,262,044<span></span>
</td>
<td class="nump">$ 31,219,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables (note 13)</a></td>
<td class="nump">866,055<span></span>
</td>
<td class="nump">89,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">2,775,800<span></span>
</td>
<td class="nump">2,427,200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">44,903,899<span></span>
</td>
<td class="nump">33,736,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (note 6)</a></td>
<td class="nump">392,041<span></span>
</td>
<td class="nump">236,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets (note 7)</a></td>
<td class="nump">584,251<span></span>
</td>
<td class="nump">372,468<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">45,880,191<span></span>
</td>
<td class="nump">34,345,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,987,870<span></span>
</td>
<td class="nump">1,805,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities (note 13)</a></td>
<td class="nump">352,279<span></span>
</td>
<td class="nump">123,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities (note 7)</a></td>
<td class="nump">293,672<span></span>
</td>
<td class="nump">248,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative (note 8)</a></td>
<td class="nump">56,017<span></span>
</td>
<td class="nump">531,228<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">2,689,838<span></span>
</td>
<td class="nump">2,709,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability (note 12)</a></td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities (note 7)</a></td>
<td class="nump">361,081<span></span>
</td>
<td class="nump">153,174<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,781,206<span></span>
</td>
<td class="nump">9,592,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAndContingencies1', window );">Commitments and contingencies (note 13, 14, 19)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital (note 9) &#160;&#160;Authorized: unlimited &#160;&#160;Issued: December&#160;31, 2021 &#8211; 55,043,789 December&#160;31, 2020 &#8211; 46,166,980</a></td>
<td class="nump">391,348,183<span></span>
</td>
<td class="nump">356,824,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsandRightsOutstanding', window );">Warrants (note 9)</a></td>
<td class="nump">3,617,570<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalPaidinCapital', window );">Contributed surplus (note 10)</a></td>
<td class="nump">34,161,103<span></span>
</td>
<td class="nump">31,022,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">387,738<span></span>
</td>
<td class="nump">400,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(393,415,609)<span></span>
</td>
<td class="num">(367,111,330)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">36,098,985<span></span>
</td>
<td class="nump">24,752,993<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 45,880,191<span></span>
</td>
<td class="nump">$ 34,345,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAndContingencies1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAndContingencies1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsandRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsandRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144332456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued (shares)</a></td>
<td class="nump">55,043,789<span></span>
</td>
<td class="nump">46,166,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163152026936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development (note 10, 21, 22)</a></td>
<td class="nump">$ 12,920,371<span></span>
</td>
<td class="nump">$ 12,944,510<span></span>
</td>
<td class="nump">$ 10,817,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating (note 10, 21, 22)</a></td>
<td class="nump">13,314,574<span></span>
</td>
<td class="nump">12,514,496<span></span>
</td>
<td class="nump">9,558,641<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss before the following</a></td>
<td class="num">(26,234,945)<span></span>
</td>
<td class="num">(25,459,006)<span></span>
</td>
<td class="num">(20,376,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative (note 8)</a></td>
<td class="nump">17,117<span></span>
</td>
<td class="nump">3,491,928<span></span>
</td>
<td class="num">(12,608,808)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange loss (note 21)</a></td>
<td class="num">(135,636)<span></span>
</td>
<td class="num">(659,173)<span></span>
</td>
<td class="num">(316,719)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents', window );">Interest income, net</a></td>
<td class="nump">98,612<span></span>
</td>
<td class="nump">121,194<span></span>
</td>
<td class="nump">179,277<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="num">(26,254,852)<span></span>
</td>
<td class="num">(22,505,057)<span></span>
</td>
<td class="num">(33,122,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense (note 15)</a></td>
<td class="num">(49,427)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">(26,304,279)<span></span>
</td>
<td class="num">(22,505,057)<span></span>
</td>
<td class="num">(33,122,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive loss items that may be reclassified to net loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Translation adjustment</a></td>
<td class="num">(12,487)<span></span>
</td>
<td class="num">(63,876)<span></span>
</td>
<td class="num">(143,403)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net comprehensive loss</a></td>
<td class="num">$ (26,316,766)<span></span>
</td>
<td class="num">$ (22,568,933)<span></span>
</td>
<td class="num">$ (33,266,291)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per common share (cad per share)</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (1.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per common share (cad per share)</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (1.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares (basic) (shares)</a></td>
<td class="nump">53,513,225<span></span>
</td>
<td class="nump">40,338,789<span></span>
</td>
<td class="nump">22,137,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares (diluted) (shares)</a></td>
<td class="nump">53,513,225<span></span>
</td>
<td class="nump">40,338,789<span></span>
</td>
<td class="nump">22,137,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2021-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141007384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT) - CAD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share Purchase Agreement</div></th>
<th class="th"><div>At-the-market agreement</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>Share Capital</div></th>
<th class="th">
<div>Share Capital </div>
<div>Share Purchase Agreement</div>
</th>
<th class="th">
<div>Share Capital </div>
<div>At-the-market agreement</div>
</th>
<th class="th">
<div>Share Capital </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Contributed Surplus</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period at Dec. 31, 2018</a></td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,193,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 28,260,613<span></span>
</td>
<td class="nump">$ 607,504<span></span>
</td>
<td class="num">$ (311,483,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(33,266,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,403)<span></span>
</td>
<td class="num">(33,122,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan (note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(391,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,403,385<span></span>
</td>
<td class="nump">$ 8,476,454<span></span>
</td>
<td class="nump">$ 3,314,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,403,385<span></span>
</td>
<td class="nump">$ 8,476,454<span></span>
</td>
<td class="nump">$ 3,314,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant derivative exercised (note 8, 9)</a></td>
<td class="nump">9,152,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,152,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation (note 10)</a></td>
<td class="nump">1,470,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 9)</a></td>
<td class="num">(854,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(854,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2019</a></td>
<td class="num">(107,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,077,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
<td class="nump">29,338,849<span></span>
</td>
<td class="nump">464,101<span></span>
</td>
<td class="num">(344,606,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(22,568,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,876)<span></span>
</td>
<td class="num">(22,505,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan (note 10)</a></td>
<td class="nump">241,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan (note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">732,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(732,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,037,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,037,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant derivative exercised (note 8, 9)</a></td>
<td class="nump">6,332,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,332,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation (note 10)</a></td>
<td class="nump">2,558,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,558,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 9)</a></td>
<td class="num">(1,741,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,741,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">24,752,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,824,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
<td class="nump">31,022,356<span></span>
</td>
<td class="nump">400,225<span></span>
</td>
<td class="num">(367,111,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(26,316,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,487)<span></span>
</td>
<td class="num">(26,304,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan (note 10)</a></td>
<td class="nump">238,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan (note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(543,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,168,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,168,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant derivative exercised (note 8, 9)</a></td>
<td class="nump">686,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation (note 10)</a></td>
<td class="nump">3,825,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,825,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 9)</a></td>
<td class="num">(1,256,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,256,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 36,098,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,348,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 34,161,103<span></span>
</td>
<td class="nump">$ 387,738<span></span>
</td>
<td class="num">$ (393,415,609)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Incentive Share Awards, Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141646088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (26,304,279)<span></span>
</td>
<td class="num">$ (22,505,057)<span></span>
</td>
<td class="num">$ (33,122,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation - property and equipment (note 6, 21)</a></td>
<td class="nump">130,243<span></span>
</td>
<td class="nump">88,957<span></span>
</td>
<td class="nump">122,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdjustmentsForDepreciationRightOfUseAssets', window );">Depreciation - right-of-use assets (note 7, 21)</a></td>
<td class="nump">321,822<span></span>
</td>
<td class="nump">357,230<span></span>
</td>
<td class="nump">362,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation (note 10, 21, 22)</a></td>
<td class="nump">3,825,901<span></span>
</td>
<td class="nump">2,558,974<span></span>
</td>
<td class="nump">1,470,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities (note 7)</a></td>
<td class="nump">91,727<span></span>
</td>
<td class="nump">68,526<span></span>
</td>
<td class="nump">94,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized foreign exchange loss</a></td>
<td class="nump">425,681<span></span>
</td>
<td class="nump">645,078<span></span>
</td>
<td class="nump">353,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative (note 8)</a></td>
<td class="num">(17,117)<span></span>
</td>
<td class="num">(3,491,928)<span></span>
</td>
<td class="nump">12,608,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Net change in non-cash working capital (note 18)</a></td>
<td class="num">(907,987)<span></span>
</td>
<td class="nump">209,779<span></span>
</td>
<td class="num">(1,795,777)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operating activities</a></td>
<td class="num">(22,434,009)<span></span>
</td>
<td class="num">(22,068,441)<span></span>
</td>
<td class="num">(19,906,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property and equipment (note 6)</a></td>
<td class="num">(285,948)<span></span>
</td>
<td class="num">(29,305)<span></span>
</td>
<td class="num">(10,905)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(285,948)<span></span>
</td>
<td class="num">(29,305)<span></span>
</td>
<td class="num">(10,905)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of stock options (note 10)</a></td>
<td class="nump">238,450<span></span>
</td>
<td class="nump">241,922<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities (note 7)</a></td>
<td class="num">(365,510)<span></span>
</td>
<td class="num">(460,724)<span></span>
</td>
<td class="num">(447,497)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">33,015,677<span></span>
</td>
<td class="nump">39,773,804<span></span>
</td>
<td class="nump">21,015,596<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Increase in cash</a></td>
<td class="nump">10,295,720<span></span>
</td>
<td class="nump">17,676,058<span></span>
</td>
<td class="nump">1,098,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">31,219,574<span></span>
</td>
<td class="nump">14,148,021<span></span>
</td>
<td class="nump">13,699,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Impact of foreign exchange on cash and cash equivalents</a></td>
<td class="num">(253,250)<span></span>
</td>
<td class="num">(604,505)<span></span>
</td>
<td class="num">(650,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">41,262,044<span></span>
</td>
<td class="nump">31,219,574<span></span>
</td>
<td class="nump">14,148,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember', window );">Warrant Derivative and Shares Under Warrant Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">230,946<span></span>
</td>
<td class="nump">1,696,460<span></span>
</td>
<td class="nump">3,465,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,360,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">32,911,791<span></span>
</td>
<td class="nump">38,296,146<span></span>
</td>
<td class="nump">8,131,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,505,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsForDepreciationRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Depreciation, Right-of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsForDepreciationRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144334792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Incorporation and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract', window );"><strong>Disclosure Of Notes And Other Explanatory Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Incorporation and Nature of Operations</a></td>
<td class="text">Incorporation and Nature of Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2021, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;2, 2022. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development-stage biopharmaceutical company that focuses on the discovery and development of immunotherapeutic products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is an intravenously delivered immunotherapeutic agent that may be a novel treatment for certain types of cancer and may be an alternative to or used in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and/or targeted therapies.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Notes And Other Explanatory Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163145049512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Financial Statement Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate Information And Statement Of IFRS Compliance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Financial Statement Presentation</a></td>
<td class="text">Basis of Financial Statement Presentation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc. and are presented in Canadian dollars, our functional currency.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of consolidation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries. Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern. Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Information And Statement Of IFRS Compliance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144924392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Deferred income taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification and measurement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"IFRS 9"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent &#8216;solely payments of principal and interest&#8217; on the principal amount outstanding (the &#8216;SPPI criterion&#8217;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derecognition</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contractual rights to the cash flows from the financial asset expire, or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign currency translation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Loss per common share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units, and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property and equipment </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share-based compensation </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees, and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive share award plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incentive share award plan (the "Share Plan") is available to directors, officers, and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and example to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduces a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the IASB issued amendments to IAS 12, which narrows the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. We are assessing the impact of adopting this standard on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144009880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Judgments, Estimates and Assumptions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract', window );"><strong>Significant Judgments, Estimates And Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Judgments, Estimates and Assumptions</a></td>
<td class="text">Significant Judgments, Estimates and Assumptions<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full extent to which the coronavirus infectious disease 2019 ("COVID-19") pandemic may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. We considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to our consolidated financial statements as of and for the year ended December 31, 2021, our future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Judgments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and assumptions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses represent a significant component of our research and development expenses and we outsource a significant portion of these activities to third-party contract research organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that have been performed by the contract research organizations. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted are disclosed in Note 10. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of the warrant derivative are disclosed in Note 8.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Judgments, Estimates And Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163145045080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalentsAbstract', window );"><strong>Cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash Equivalents</a></td>
<td class="text">Cash Equivalents <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of interest bearing deposits with our bank totaling $39,901,509 (December&#160;31, 2020 &#8211; $30,361,591).&#160;&#160;The current annual interest rate earned on these deposits is 0.45% (December&#160;31, 2020 &#8211; 0.36%).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163151870056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,512&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913,003&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,419&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,358</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159,034</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">392,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144952072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees, or leases not yet commenced to which we are committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we recorded a lease modification and an addition related to the office lease extension for one of our subsidiaries and a new office space lease for our Canadian head office, respectively. The weighted-average rate applied was 15%. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets outstanding at December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">372,468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208,976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323,782</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(321,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">847</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">584,251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,468&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities outstanding at December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">402,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">203,868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323,782</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(365,510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91,727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">654,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2021 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807,643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144858584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Warrant Derivative</a></td>
<td class="text">Warrant Derivative<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share and one common share purchase warrant (see Note 9). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IAS 32 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments: Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of US$0.90 meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in fair value of the warrant derivative is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,508,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,418,369)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,636,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,491,928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455,670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,017</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we received cash proceeds of US$181,550 (2020 - US$1,276,532; 2019 - US$2,642,082) with respect to the warrants exercised. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative at December&#160;31 was determined using the following assumptions: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$0.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$1.57</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$1.39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.38</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.39%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163145103976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share Capital</a></td>
<td class="text">Share Capital<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,399,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,193,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,425,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,619,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,935,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,152,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(854,256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,198,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,077,859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)(d)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,182,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,037,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,741,640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,166,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,824,172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,401,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,256,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55,043,789</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">391,348,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. This agreement expired in 2021, and no common shares were issued during 2021 and 2020. In 2019, we sold 2,477,665 common shares for gross proceeds of US$4,055,725 and issued 17,278 commitment shares. The commitment shares were fair valued at US$29,758 and were recorded as share issue costs in addition to cash share issue costs of $3,757.  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement expired on June 4, 2020 and no common shares were issued during 2021. In 2020, we sold 6,741,518 (2019 - 4,425,040) common shares for gross proceeds of  US$17,538,342 (2019 - US$6,390,691) at an average price of US$2.42 (2019 - US$1.70). We received, net of commissions of US$526,150 (2019 - US$191,721), proceeds of US$17,012,192 (2019 - US$6,198,970). In total, we incurred share issue costs (including commissions) of $856,754 (2019 - $344,834). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. In 2021, our share capital included fair value of $455,670 (2020 - $4,636,317; 2019 - $5,687,003) in addition to gross proceeds of US$181,550 (2020 </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- US$1,276,532; 2019 - US$2,642,082) for the 201,722 (2020 - 1,418,369; 2019 - 2,935,647) warrants that were exercised (see Note 8). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market price, with an aggregate offering value of up US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2021, we sold 5,685,097 (2020 - 5,441,014) common shares for gross proceeds of US$18,503,188 (2020 - US$12,628,775) at an average price of US$3.25 (2020 - US$2.11). We received, net of commissions of US$555,096 (2020 - US$378,863), proceeds of US$17,948,092 (2020 - US$12,249,911). In total, we incurred share issue costs (including commissions) of $707,421 (2020 - $884,886). On March 4, 2021, we terminated the June 15, 2020 ATM equity distribution agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. In 2021, we sold 2,715,932 common shares for gross proceeds of US$8,654,892 at an average price of US$3.19. We received, net of commissions of US$259,647, proceeds of US$8,395,245. In total, we incurred share issue costs (including commissions) of $548,859. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold for gross proceeds of $11,511,500. Each unit included one common share and one common share purchase warrant. Following the 2018 share consolidation, 9.5 common share purchase warrants entitled the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. These warrants were classified as equity. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,443,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617,570</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Exercisable into 1,730,894 common shares.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144034168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract', window );"><strong>Disclosure of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Option Plan </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted stock options to acquire common stock through our stock option plan of which the following are outstanding at December&#160;31:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,764,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,832,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(110,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(123,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,334,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,165,679</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164,551&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327,845&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.54 - $1.79</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.80 - $3.01</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.02 - $3.90</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,982,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.91 - $7.41</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.42 - $40.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,165,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82</span></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants vest either immediately or annually over periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzM1OA_3e8a9208-2071-47f7-9434-36998b16603e">one</span> to three years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the year was determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.90%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incentive Share Award Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Units</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also granted RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a three-year period. The following RSUs are outstanding at December&#160;31:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(94,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,560</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSUs granted was nil in 2021 (2020 - $2.41 ; 2019 - $0.80).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Share Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also granted PSUs to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after 3 years or vest over a three-year period, depending on the grant. The following PSUs are outstanding at December&#160;31:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>We have reserved 5,504,379 common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs for the year ended December&#160;31, 2021 was $3,825,901 (2020 - $2,558,974; 2019 - $1,470,153).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144938824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss Per Common Share</a></td>
<td class="text">Loss Per Common Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended December&#160;31, 2021 of 53,513,225 (2020 - 40,338,789; 2019 - 22,137,990). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144939976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Contract Liability</a></td>
<td class="text">Contract Liability<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regional licensing agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract liability</span></div><div style="text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regional licensing agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163142802344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Commitments</a></td>
<td class="text">Commitments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments totaling $21,516,576 for activities related to our clinical trial, manufacturing, and translational science programs which are expected to occur over the next three years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include the committed payments related to our co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1, as this phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2021, we recorded US$616,855 ($782,049) (December&#160;31, 2020 - nil) in other receivables related to BRACELET-1 cost from Pfizer per the terms of the collaboration agreement and US$277,866 ($352,279) (December&#160;31, 2020 - US$97,381 ($123,985)) in other liabilities representing future trial costs to be incurred.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product.&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) 5% of gross sales of a specified product; or (b) $100,000 per annum once sales of a specified product commence.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144083560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingenciesAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumption Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1999, we entered into an agreement that assumed certain obligations (the &#8220;Assumption Agreement&#8221;) in connection with a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, a milestone payment was still outstanding for $1.0 million, due within 90 days of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell pelareorep to the public or the approval of a new drug application for pelareorep. This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the milestone payment, payments may become due and payable in accordance with the Share Purchase Agreement upon realization of sales of pelareorep.&#160;If we receive royalty payments or other payments as a result of entering into </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders 10.75% (2020 - 10.75%) of the royalty payments and other payments received.&#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of 2.15% (2020 - 2.15%) of Net Sales received for such products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRI &#8220;Work in Kind&#8221; Contribution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&#8220;BRI&#8221;).&#160;The terms of this agreement include a &#8220;work in kind&#8221; contribution from BRI.&#160;In exchange for this &#8220;work in kind&#8221; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue at the lesser of 0.5% of Sales Revenue or $20,000 per year until December 31, 2028.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 86<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_86&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141518184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31, </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,254,852)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,505,057)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,122,888)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.50%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,038,616)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,401,214)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,777,565)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdiction tax rate difference</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,716,319</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,237,898</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,088,811</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">879,957</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614,154</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,591</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,937)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(838,063)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,341,334</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Alberta rate change</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,758,175</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to opening tax pools</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(552,079)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,711</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,973</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,290</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,945</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,294</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,661,187</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax benefits deemed not probable to be recovered</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,342,306</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161,541</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,961,613)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,427</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2021, we have the following approximate non-refundable federal investment tax credits and non-capital losses for income tax purposes in Canada, as well as non-capital losses in Barbados that are expected to expire in the following years, if not utilized:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Barbados</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment tax credits</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-capital losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-capital losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,826,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,063,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,990,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,138,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,809,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,575,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,280,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,009,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,774,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,343,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,056,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,864,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,724,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,619,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,833,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89,537,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">162,986,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of approximately $27,663,000.&#160;We also have unclaimed U.S. credits for increasing research activities available to reduce future years' taxable income of approximately $1,343,000 expiring between 2031 and 2041. We have not recorded the potential benefits of these tax pools in these consolidated financial statements.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,157,950</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,487,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,625,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,705,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,338,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,715,652</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,068,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,222,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">350,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,927,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">647,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,583,775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,541,435&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,712,066&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any other material income tax examination currently in progress by any taxing jurisdiction.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144923576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory', window );">Capital Disclosures</a></td>
<td class="text">Capital Disclosures<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;We include shareholders' equity and cash and cash equivalents in the definition of capital.  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:63.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,262,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,219,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36,098,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,752,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 12, 2020, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries, and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreement in June 2020 and March 2021 (see Note 9). We use these equity arrangements to assist us in achieving our capital objective. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 134<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144695800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, accounts payable and accrued liabilities, and warrant derivative.&#160;As at December&#160;31, 2021, the carrying amount of our cash and cash equivalents,&#160;other receivables, and accounts payable and accrued liabilities approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December 31, 2021, the fair value of our warrant derivative was $56,017 (December&#160;31, 2020 - $531,228).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents and other receivables from Pfizer in connection with the BRACELET-1 study (see Note 13) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our Pfizer other receivable by entering into collaborations with global biopharmaceutical companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar as a portion of our financial assets and liabilities are denominated in such currency. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2021 by approximately $240,000.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable and accrued liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies at December&#160;31, 2021 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,102,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(886,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,837,699&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 16. Accounts payable and accrued liabilities are all due within the current operating period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163140988952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Additional Cash Flow Disclosures</a></td>
<td class="text">Additional Cash Flow Disclosures<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(776,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,017,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(348,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,012,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,368,203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228,294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(723,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(194,142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(907,987)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,779&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,795,777)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190,339</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,959</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section Presentation of a statement of cash flows<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144325352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indemnification of Officers and Directors<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract', window );"><strong>Disclosure Of Indemnification Of Officers and Directors [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock', window );">Indemnification of Officers and Directors</a></td>
<td class="text">Indemnification of Officers and Directors<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Indemnification Of Officers and Directors [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Indemnification Of Officers and Directors [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163145152888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceAbstract', window );"><strong>Disclosure Of Economic Dependence [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceTextBlock', window );">Economic Dependence</a></td>
<td class="text">Economic Dependence<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163145152760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory', window );">Other Expenses</a></td>
<td class="text">Other Expenses<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details highlight certain components of the research and development and operating expenses classified by nature. The foreign exchange loss as presented separately on the face of the consolidated statement of loss and comprehensive loss is also classified as a research and development expense. Remaining research and development and operating expenses include expenses paid to third parties.  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,645,264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,775,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,086,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,542,210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,739,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction cost, warrant derivative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144067192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation of Key Management Personnel</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain employees of the Company.   </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,918,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,514,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,786,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,703,256</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,757,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,621,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,767,425&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,910,075&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141669000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofeventsafterreportingperiodAbstract', window );"><strong>Disclosure of events after reporting period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Between January 1, 2022 to March 2, 2022, we issued 2,050,240 common shares for gross proceeds of US$3,560,397 through our March 2021 ATM equity offering sales agreement. </span>(b)In February 2022, we paid a non-refundable deposit of US$1,368,000 related to a production service agreement (the &#8220;Agreement&#8221;) entered on December 23, 2021 with our primary toll manufacturer. Under IFRS, the Agreement was deemed an executory contract at signing. As a result, the contractual obligation to pay the deposit was not recorded in our December 31, 2021, consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofeventsafterreportingperiodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of events after reporting period [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofeventsafterreportingperiodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144726568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory', window );">Deferred income taxes</a></td>
<td class="text">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"IFRS 9"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent &#8216;solely payments of principal and interest&#8217; on the principal amount outstanding (the &#8216;SPPI criterion&#8217;). </span></div>Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities</a></td>
<td class="text">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory', window );">Impairment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory', window );">Derecognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contractual rights to the cash flows from the financial asset expire, or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div>A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per common share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units, and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div>We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development costs</a></td>
<td class="text">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees, and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive share award plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incentive share award plan (the "Share Plan") is available to directors, officers, and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </span></div>We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Accounting Standards and Interpretations Issued but Not Yet Effective</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and example to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduces a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the IASB issued amendments to IAS 12, which narrows the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. We are assessing the impact of adopting this standard on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the derecognition of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the impairment of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144049976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of depreciation rates</a></td>
<td class="text">Depreciation is recorded using the declining balance method at the following annual rates:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,512&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913,003&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,419&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,358</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159,034</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">392,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141487208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of property and equipment</a></td>
<td class="text">Depreciation is recorded using the declining balance method at the following annual rates:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,512&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913,003&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,419&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,358</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159,034</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">392,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163140869304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Right-of-use assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets outstanding at December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">372,468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208,976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323,782</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(321,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">847</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">584,251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,468&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock', window );">Lease liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities outstanding at December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">402,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">203,868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323,782</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(365,510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91,727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">654,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Total undiscounted lease liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2021 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807,643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 97<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Quantitative Information About Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144012520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Reconciliation of change in fair value of warrant derivative</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in fair value of the warrant derivative is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,508,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,418,369)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,636,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,491,928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455,670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,017</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative at December&#160;31 was determined using the following assumptions: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$0.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$1.57</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$1.39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.38</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.39%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163151884312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of share capital</a></td>
<td class="text"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,399,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,193,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,425,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,619,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,935,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,152,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(854,256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,198,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,077,859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)(d)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,182,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,037,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,741,640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,166,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,824,172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,401,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,256,280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55,043,789</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">391,348,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. This agreement expired in 2021, and no common shares were issued during 2021 and 2020. In 2019, we sold 2,477,665 common shares for gross proceeds of US$4,055,725 and issued 17,278 commitment shares. The commitment shares were fair valued at US$29,758 and were recorded as share issue costs in addition to cash share issue costs of $3,757.  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement expired on June 4, 2020 and no common shares were issued during 2021. In 2020, we sold 6,741,518 (2019 - 4,425,040) common shares for gross proceeds of  US$17,538,342 (2019 - US$6,390,691) at an average price of US$2.42 (2019 - US$1.70). We received, net of commissions of US$526,150 (2019 - US$191,721), proceeds of US$17,012,192 (2019 - US$6,198,970). In total, we incurred share issue costs (including commissions) of $856,754 (2019 - $344,834). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. In 2021, our share capital included fair value of $455,670 (2020 - $4,636,317; 2019 - $5,687,003) in addition to gross proceeds of US$181,550 (2020 </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- US$1,276,532; 2019 - US$2,642,082) for the 201,722 (2020 - 1,418,369; 2019 - 2,935,647) warrants that were exercised (see Note 8). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market price, with an aggregate offering value of up US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2021, we sold 5,685,097 (2020 - 5,441,014) common shares for gross proceeds of US$18,503,188 (2020 - US$12,628,775) at an average price of US$3.25 (2020 - US$2.11). We received, net of commissions of US$555,096 (2020 - US$378,863), proceeds of US$17,948,092 (2020 - US$12,249,911). In total, we incurred share issue costs (including commissions) of $707,421 (2020 - $884,886). On March 4, 2021, we terminated the June 15, 2020 ATM equity distribution agreement.</span></div>(e)On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. In 2021, we sold 2,715,932 common shares for gross proceeds of US$8,654,892 at an average price of US$3.19. We received, net of commissions of US$259,647, proceeds of US$8,395,245. In total, we incurred share issue costs (including commissions) of $548,859.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Summary of outstanding warrants</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,443,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617,570</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Exercisable into 1,730,894 common shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.54 - $1.79</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.80 - $3.01</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.02 - $3.90</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,982,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.91 - $7.41</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.42 - $40.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,165,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141563528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract', window );"><strong>Disclosure of share-based payment arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of stock options and weighted average exercise prices of share options</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted stock options to acquire common stock through our stock option plan of which the following are outstanding at December&#160;31:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,764,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,832,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(110,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(123,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,334,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,165,679</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164,551&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327,845&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Schedule of stock options outstanding and exercisable by range of exercise price</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.54 - $1.79</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.80 - $3.01</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.02 - $3.90</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,982,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.91 - $7.41</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.42 - $40.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,165,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,443,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617,570</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Exercisable into 1,730,894 common shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.54 - $1.79</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.80 - $3.01</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.02 - $3.90</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,982,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.91 - $7.41</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.42 - $40.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,165,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Disclosure weighted average assumptions and fair value of options</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the year was determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.90%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of number of other equity instruments</a></td>
<td class="text">The following RSUs are outstanding at December&#160;31:<div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(94,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,560</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSUs granted was nil in 2021 (2020 - $2.41 ; 2019 - $0.80).</span></div>The following PSUs are outstanding at December&#160;31:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share-based payment arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofsharebasedpaymentarrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163152025544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Contract liability balances</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regional licensing agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163143854776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock', window );">Provision for income taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31, </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,254,852)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,505,057)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,122,888)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.50%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,038,616)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,401,214)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,777,565)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdiction tax rate difference</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,716,319</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,237,898</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,088,811</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">879,957</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614,154</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,591</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,937)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(838,063)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,341,334</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Alberta rate change</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,758,175</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to opening tax pools</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(552,079)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,711</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,973</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,290</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,945</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,294</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,661,187</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax benefits deemed not probable to be recovered</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,342,306</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161,541</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,961,613)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,427</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2021, we have the following approximate non-refundable federal investment tax credits and non-capital losses for income tax purposes in Canada, as well as non-capital losses in Barbados that are expected to expire in the following years, if not utilized:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Barbados</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment tax credits</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-capital losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-capital losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,826,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,063,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,990,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,138,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,809,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,575,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,280,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,009,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,774,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,343,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,056,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,864,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,724,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,619,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,833,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89,537,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">162,986,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,157,950</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,487,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,625,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,705,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,338,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,715,652</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,068,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,222,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">350,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,927,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">647,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,583,775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,541,435&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,712,066&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144789992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock', window );">Schedule of capital components</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:63.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,262,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,219,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36,098,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,752,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Capital Components [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfCapitalComponentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144926024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock', window );">Schedule of balances in foreign currencies</a></td>
<td class="text">alances in foreign currencies at December&#160;31, 2021 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,102,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(886,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,837,699&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Foreign Currency Held [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163145152888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashFlowOperatingCapital1TableTextBlock', window );">Net change in non-cash working capital</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(776,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,017,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(348,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,012,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,368,203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228,294</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(723,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(194,142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(907,987)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,779&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,795,777)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock', window );">Other cash flow disclosures</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190,339</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,959</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashFlowOperatingCapital1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Operating Capital1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashFlowOperatingCapital1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144926024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock', window );">Other expenses and adjustments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,645,264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,775,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,086,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,542,210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,739,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction cost, warrant derivative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Expenses And Adjustments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherExpensesAndAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144961688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of related party transactions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,918,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,514,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,786,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,703,256</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,757,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,621,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,767,425&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,910,075&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163140901336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Annual Depreciation Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PropertyPlantandEquipmentAnnualDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144014920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>plan</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberOfStockOptionPlans', window );">Number of plans</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement', window );">Maximum option expiration term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Term Of Options Granted For Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Stock Option Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163142802760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalentsAbstract', window );"><strong>Cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">$ 39,901,509<span></span>
</td>
<td class="nump">$ 30,361,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsInterestRate', window );">Current annual interest rate</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="nump">0.36%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163140068456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">$ 236,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">392,041<span></span>
</td>
<td class="nump">$ 236,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">1,278,083<span></span>
</td>
<td class="nump">1,264,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">285,620<span></span>
</td>
<td class="nump">28,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">650,700<span></span>
</td>
<td class="nump">15,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">913,003<span></span>
</td>
<td class="nump">1,278,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="num">(1,041,419)<span></span>
</td>
<td class="num">(967,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">130,243<span></span>
</td>
<td class="nump">88,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(650,700)<span></span>
</td>
<td class="num">(15,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="num">(520,962)<span></span>
</td>
<td class="num">(1,041,419)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">13,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">11,358<span></span>
</td>
<td class="nump">13,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">61,512<span></span>
</td>
<td class="nump">60,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">61,512<span></span>
</td>
<td class="nump">61,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="num">(47,650)<span></span>
</td>
<td class="num">(44,708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">2,504<span></span>
</td>
<td class="nump">2,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="num">(50,154)<span></span>
</td>
<td class="num">(47,650)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">116,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">120,986<span></span>
</td>
<td class="nump">116,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">365,537<span></span>
</td>
<td class="nump">352,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">40,338<span></span>
</td>
<td class="nump">27,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">405,875<span></span>
</td>
<td class="nump">365,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="num">(248,933)<span></span>
</td>
<td class="num">(224,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">35,956<span></span>
</td>
<td class="nump">40,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="num">(284,889)<span></span>
</td>
<td class="num">(248,933)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">89,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">159,034<span></span>
</td>
<td class="nump">89,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office equipment and furniture | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">352,667<span></span>
</td>
<td class="nump">352,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">141,305<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">276,789<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">217,183<span></span>
</td>
<td class="nump">352,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office equipment and furniture | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="num">(262,895)<span></span>
</td>
<td class="num">(250,587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">72,043<span></span>
</td>
<td class="nump">12,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(276,789)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="num">(58,149)<span></span>
</td>
<td class="num">(262,895)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">16,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">100,663<span></span>
</td>
<td class="nump">16,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">498,367<span></span>
</td>
<td class="nump">498,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">103,977<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">373,911<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">228,433<span></span>
</td>
<td class="nump">498,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="num">(481,941)<span></span>
</td>
<td class="num">(448,258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">19,740<span></span>
</td>
<td class="nump">33,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(373,911)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="num">$ (127,770)<span></span>
</td>
<td class="num">$ (481,941)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141659928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16', window );">Weighted average rate</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph C12<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_C12_a&amp;doctype=Appendix&amp;subtype=C<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144350872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Right-of-use Assets and Lease Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_RightOfUseAssetsAbstract', window );"><strong>Right-Of-Use Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, beginning balance</a></td>
<td class="nump">$ 372,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_LeaseModificationRightOfUseAssets', window );">Lease modification</a></td>
<td class="nump">323,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation expense</a></td>
<td class="num">(321,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(357,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ForeignExchangeImpactRightofUseAssets', window );">Foreign exchange impact</a></td>
<td class="nump">847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, ending balance</a></td>
<td class="nump">584,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, beginning balance</a></td>
<td class="nump">402,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_EffectOfLeaseModificationOnLeaseLiabilities', window );">Lease modification</a></td>
<td class="nump">323,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities</a></td>
<td class="num">(365,510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(460,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(447,497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">91,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GainsLossesFromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="num">(1,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, ending balance</a></td>
<td class="nump">$ 654,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 506,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 44B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_EffectOfLeaseModificationOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of Lease Modification on Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_EffectOfLeaseModificationOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ForeignExchangeImpactRightofUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Exchange Impact, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ForeignExchangeImpactRightofUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GainsLossesFromForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) From Foreign Exchange Impact</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GainsLossesFromForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_LeaseModificationRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Modification, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_LeaseModificationRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_RightOfUseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_RightOfUseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141469176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Total Undiscounted Lease Liability (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">$ 807,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than one year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">372,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">One to five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">434,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 58<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144418072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 16, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ProceedsfromWarrantExercises1', window );">Gross proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,550<span></span>
</td>
<td class="nump">$ 1,276,532<span></span>
</td>
<td class="nump">$ 2,642,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share)</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="nump">$ 3,742,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants | Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromWarrantExercises1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Warrant Exercises1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromWarrantExercises1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144195368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward', window );"><strong>Fair Value of Warrant Derivative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Issued, beginning balance</a></td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="nump">17,117<span></span>
</td>
<td class="nump">3,491,928<span></span>
</td>
<td class="num">$ (12,608,808)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GainsLossesFromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="num">(1,173)<span></span>
</td>
<td class="num">(9,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Issued, ending balance</a></td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstandingRollForward', window );"><strong>Number of Warrants Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightOutstanding1', window );">Issued, beginning balance (shares)</a></td>
<td class="nump">265,757<span></span>
</td>
<td class="nump">1,684,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised', window );">Exercised (shares)</a></td>
<td class="num">(201,722)<span></span>
</td>
<td class="num">(1,418,369)<span></span>
</td>
<td class="num">(2,935,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightOutstanding1', window );">Issued, ending balance (shares)</a></td>
<td class="nump">64,035<span></span>
</td>
<td class="nump">265,757<span></span>
</td>
<td class="nump">1,684,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward', window );"><strong>Fair Value of Warrant Derivative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Issued, beginning balance</a></td>
<td class="nump">$ 531,228<span></span>
</td>
<td class="nump">$ 8,508,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightWarrantsExercised', window );">Exercised</a></td>
<td class="num">(455,670)<span></span>
</td>
<td class="num">(4,636,317)<span></span>
</td>
<td class="num">$ (5,687,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="num">(17,117)<span></span>
</td>
<td class="num">(3,491,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GainsLossesFromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="num">(2,424)<span></span>
</td>
<td class="nump">150,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Issued, ending balance</a></td>
<td class="nump">$ 56,017<span></span>
</td>
<td class="nump">$ 531,228<span></span>
</td>
<td class="nump">$ 8,508,764<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Warrant Derivative</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ChangeInFairValueWarrantDerivativeRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassOfWarrantOrRightOutstanding1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Outstanding1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassOfWarrantOrRightOutstanding1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GainsLossesFromForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) From Foreign Exchange Impact</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GainsLossesFromForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsAndRightsOutstanding1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsAndRightsOutstanding1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144395896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>year</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">0.66%<span></span>
</td>
<td class="nump">0.34%<span></span>
</td>
<td class="nump">1.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected hold period to exercise | year</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected share price volatility</a></td>
<td class="nump">110.45%<span></span>
</td>
<td class="nump">110.82%<span></span>
</td>
<td class="nump">97.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_FairValueofWarrantIssuedPerWarrant', window );">Fair value per warrant (usd per share) | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantIssuedUnderlyingSharePrice', window );">Underlying share price (usd per share) | $ / shares</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">0.39%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected hold period to exercise | year</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected share price volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DividendYieldPercent', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DividendYieldPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend Yield, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DividendYieldPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_FairValueofWarrantIssuedPerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Issued, Per Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_FairValueofWarrantIssuedPerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantIssuedUnderlyingSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued, Underlying Share Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantIssuedUnderlyingSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163140295096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 16, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,166,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,043,789<span></span>
</td>
<td class="nump">46,166,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,752,993<span></span>
</td>
<td class="num">$ (107,894)<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,256,280)<span></span>
</td>
<td class="num">(1,741,640)<span></span>
</td>
<td class="num">(854,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,098,985<span></span>
</td>
<td class="nump">24,752,993<span></span>
</td>
<td class="num">(107,894)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,168,071<span></span>
</td>
<td class="nump">$ 40,037,786<span></span>
</td>
<td class="nump">8,476,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,314,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">$ (699,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,166,980<span></span>
</td>
<td class="nump">32,198,453<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,043,789<span></span>
</td>
<td class="nump">46,166,980<span></span>
</td>
<td class="nump">32,198,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,824,172<span></span>
</td>
<td class="nump">$ 311,077,859<span></span>
</td>
<td class="nump">$ 285,193,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,256,280)<span></span>
</td>
<td class="num">(1,741,640)<span></span>
</td>
<td class="num">(854,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,348,183<span></span>
</td>
<td class="nump">$ 356,824,172<span></span>
</td>
<td class="nump">$ 311,077,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Incentive award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,899<span></span>
</td>
<td class="nump">234,172<span></span>
</td>
<td class="nump">323,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 543,833<span></span>
</td>
<td class="nump">$ 732,367<span></span>
</td>
<td class="nump">$ 391,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,494,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,403,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,401,029<span></span>
</td>
<td class="nump">12,182,532<span></span>
</td>
<td class="nump">4,425,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,168,071<span></span>
</td>
<td class="nump">$ 40,037,786<span></span>
</td>
<td class="nump">$ 8,476,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,314,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 686,616<span></span>
</td>
<td class="nump">$ 6,332,778<span></span>
</td>
<td class="nump">$ 9,152,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,159<span></span>
</td>
<td class="nump">133,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,771<span></span>
</td>
<td class="nump">$ 385,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareCapitalAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareCapitalAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareCapitalNumberSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Number, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareCapitalNumberSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163136843160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital Footnotes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 27, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,256,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,741,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 854,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ProceedsfromWarrantExercises1', window );">Gross proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,276,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,642,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,256,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,741,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 854,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,494,943<span></span>
</td>
<td class="nump">2,494,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement | Issued Capital, Excluding Commitment Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,477,665<span></span>
</td>
<td class="nump">2,477,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,055,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement | Commitment Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,278<span></span>
</td>
<td class="nump">17,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember', window );">United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">19 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,741,518<span></span>
</td>
<td class="nump">6,741,518<span></span>
</td>
<td class="nump">4,425,040<span></span>
</td>
<td class="nump">4,425,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,538,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,390,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 856,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,012,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,198,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,742,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 699,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Warrant Derivatives | Included in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Warrant Derivatives | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedFairValueOfCommonShare', window );">Shares issued, fair value of common share (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2020 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,685,097<span></span>
</td>
<td class="nump">5,685,097<span></span>
</td>
<td class="nump">5,441,014<span></span>
</td>
<td class="nump">5,441,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,503,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,628,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 707,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 884,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,948,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,249,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2021 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">16 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,715,932<span></span>
</td>
<td class="nump">2,715,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,654,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 548,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,395,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,636,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,687,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised', window );">Warrants exercised (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants | Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 466,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedFairValueOfCommonShare', window );">Shares issued, fair value of common share (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromWarrantExercises1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Warrant Exercises1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromWarrantExercises1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareIssueRelatedCostCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Issue Related Cost, Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareIssueRelatedCostCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedFairValueOfCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Fair Value Of Common Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedFairValueOfCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_IssuedCapitalExcludingCommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_IssuedCapitalExcludingCommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_CommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_CommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144381800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Equity Warrants Narrative (Details)<br></strong></div></th>
<th class="th"><div>May 22, 2018</div></th>
<th class="th">
<div>Jun. 01, 2017 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1', window );">Warrants exercisable into common shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_StockholdersEquityNoteStockSplitConversionRatio', window );">Stock conversion ratio</a></td>
<td class="nump">0.105263157894737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember', window );">Shares Public Offering, Equity Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,511,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharePurchaseWarrantPerUnit', window );">Common share purchase warrant per unit (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1', window );">Warrants exercisable into common shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedWarrantPricePerShare', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharePurchaseWarrantPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Share Purchase Warrant Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharePurchaseWarrantPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedWarrantPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Warrant Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedWarrantPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_StockholdersEquityNoteStockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity Note, Stock Split, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_StockholdersEquityNoteStockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141592376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Summary of Outstanding Warrants (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Warrants issued</a></td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1', window );">Warrants exercisable into common shares (shares)</a></td>
<td class="nump">1,730,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsAndRightsOutstanding1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsAndRightsOutstanding1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144303352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_StockOptionsOutstandingAbstract', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, beginning of the year (shares) | shares</a></td>
<td class="nump">3,764,055<span></span>
</td>
<td class="nump">2,246,947<span></span>
</td>
<td class="nump">1,249,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the year (shares) | shares</a></td>
<td class="nump">1,832,500<span></span>
</td>
<td class="nump">1,817,500<span></span>
</td>
<td class="nump">1,020,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares) | shares</a></td>
<td class="num">(110,612)<span></span>
</td>
<td class="num">(141,418)<span></span>
</td>
<td class="num">(12,839)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the year (shares) | shares</a></td>
<td class="num">(28,364)<span></span>
</td>
<td class="num">(25,520)<span></span>
</td>
<td class="num">(9,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year (shares) | shares</a></td>
<td class="num">(123,159)<span></span>
</td>
<td class="num">(133,454)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, end of the year (shares) | shares</a></td>
<td class="nump">5,334,420<span></span>
</td>
<td class="nump">3,764,055<span></span>
</td>
<td class="nump">2,246,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options exercisable, end of the year (shares) | shares</a></td>
<td class="nump">3,165,679<span></span>
</td>
<td class="nump">2,164,551<span></span>
</td>
<td class="nump">1,327,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WeightedAverageExercisePriceOutstandingAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="nump">$ 5.31<span></span>
</td>
<td class="nump">$ 8.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the year (cad per share) | $ / shares</a></td>
<td class="nump">2.99<span></span>
</td>
<td class="nump">3.19<span></span>
</td>
<td class="nump">1.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited during the year (cad per share) | $ / shares</a></td>
<td class="nump">6.21<span></span>
</td>
<td class="nump">3.84<span></span>
</td>
<td class="nump">11.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Expired during the year (cad per share) | $ / shares</a></td>
<td class="nump">37.63<span></span>
</td>
<td class="nump">62.49<span></span>
</td>
<td class="nump">29.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercised during the year (cad per share) | $ / shares</a></td>
<td class="nump">1.94<span></span>
</td>
<td class="nump">1.81<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">3.53<span></span>
</td>
<td class="nump">4.08<span></span>
</td>
<td class="nump">5.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Options exercisable, end of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 3.82<span></span>
</td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_StockOptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_StockOptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageExercisePriceOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageExercisePriceOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163140659416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">5,334,420<span></span>
</td>
<td class="nump">3,764,055<span></span>
</td>
<td class="nump">2,246,947<span></span>
</td>
<td class="nump">1,249,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="nump">$ 5.31<span></span>
</td>
<td class="nump">$ 8.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">3,165,679<span></span>
</td>
<td class="nump">2,164,551<span></span>
</td>
<td class="nump">1,327,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.82<span></span>
</td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">718,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">718,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">1,026,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">531,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">2,982,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">1,329,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">3.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 3.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">478,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">1 year 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 6.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">458,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 7.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">128,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">1 year 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 20.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">128,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 20.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">7.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144244680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Narrative (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation</a></td>
<td class="nump">$ 3,825,901<span></span>
</td>
<td class="nump">$ 2,558,974<span></span>
</td>
<td class="nump">$ 1,470,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember', window );">Restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod', window );">Cliff vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember', window );">Reserve of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Common shares reserved for issuance (shares)</a></td>
<td class="nump">5,504,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Cliff Award Vesting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144459928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract', window );"><strong>Disclosure of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">0.66%<span></span>
</td>
<td class="nump">0.34%<span></span>
</td>
<td class="nump">1.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected hold period to exercise | year</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected share price volatility</a></td>
<td class="nump">110.45%<span></span>
</td>
<td class="nump">110.82%<span></span>
</td>
<td class="nump">97.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value of options (cad per share) | $</a></td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144720312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember', window );">Restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (shares)</a></td>
<td class="nump">134,618<span></span>
</td>
<td class="nump">209,657<span></span>
</td>
<td class="nump">260,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">154,923<span></span>
</td>
<td class="nump">270,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year (shares)</a></td>
<td class="num">(94,058)<span></span>
</td>
<td class="num">(229,962)<span></span>
</td>
<td class="num">(321,196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (shares)</a></td>
<td class="nump">40,560<span></span>
</td>
<td class="nump">134,618<span></span>
</td>
<td class="nump">209,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Weighted average fair value at measurement date, other equity instruments granted | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (shares)</a></td>
<td class="nump">56,841<span></span>
</td>
<td class="nump">61,051<span></span>
</td>
<td class="nump">63,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year (shares)</a></td>
<td class="num">(56,841)<span></span>
</td>
<td class="num">(4,210)<span></span>
</td>
<td class="num">(2,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,841<span></span>
</td>
<td class="nump">61,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141586824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of common shares outstanding (shares)</a></td>
<td class="nump">53,513,225<span></span>
</td>
<td class="nump">40,338,789<span></span>
</td>
<td class="nump">22,137,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144915736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContractLiabilityRecognitionPeriod', window );">Expected recognition period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContractLiabilityRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Liability, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContractLiabilityRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144423032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability - Schedule of Contract Revenues and Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, beginning of year</a></td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Regional licensing agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, end of year</a></td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liability - current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability - non-current</a></td>
<td class="nump">6,730,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163136763832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PurchaseObligation1', window );">Commitment for payment</a></td>
<td class="nump">$ 21,516,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PurchaseObligationCommitmentTerm', window );">Commitment term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities (note 13)</a></td>
<td class="nump">$ 352,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_FundedandRoyaltyRepayment', window );">Repayment, maximum</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OverheadRepayment', window );">Overhead repayment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AnnualContingentPaymentGrossSalesPercent', window );">Annual installment of gross sales of product, percent</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AnnualContingentPayment', window );">Annual installment of annual product sales</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember', window );">BRACELET-1 collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">782,049<span></span>
</td>
<td class="nump">$ 616,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities (note 13)</a></td>
<td class="nump">$ 352,279<span></span>
</td>
<td class="nump">$ 277,866<span></span>
</td>
<td class="nump">$ 123,985<span></span>
</td>
<td class="nump">$ 97,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AnnualContingentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Contingent Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AnnualContingentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AnnualContingentPaymentGrossSalesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Contingent Payment, Gross Sales, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AnnualContingentPaymentGrossSalesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_FundedandRoyaltyRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funded and Royalty Repayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_FundedandRoyaltyRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OverheadRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Overhead Repayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OverheadRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligationCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Commitment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligationCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163152342360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue', window );">Royalty payment on sales revenue, percent</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingentRoyaltyPaymentAnnualMaximum', window );">Royalty payment maximum</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember', window );">SYNSORB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions', window );">Milestone payment in connection with share purchase agreement</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue', window );">Payment due period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage', window );">Royalty payment due to founding shareholders, percent</a></td>
<td class="nump">10.75%<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage', window );">Royalty payment on net sales due to founding shareholders, percent</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 21<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_21_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Period Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Royalty Payment Received, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingentRoyaltyPaymentAnnualMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Payment, Annual Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingentRoyaltyPaymentAnnualMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Payment, Percent Of Sales Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144513320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss before income taxes</a></td>
<td class="num">$ (26,254,852)<span></span>
</td>
<td class="num">$ (22,505,057)<span></span>
</td>
<td class="num">$ (33,122,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory Canadian corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Anticipated tax recovery</a></td>
<td class="num">$ (6,038,616)<span></span>
</td>
<td class="num">$ (5,401,214)<span></span>
</td>
<td class="num">$ (8,777,565)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Foreign jurisdiction tax rate difference</a></td>
<td class="nump">2,716,319<span></span>
</td>
<td class="nump">3,237,898<span></span>
</td>
<td class="nump">3,088,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfStockBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">879,957<span></span>
</td>
<td class="nump">614,154<span></span>
</td>
<td class="nump">389,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative', window );">Change in fair value of warrant derivative</a></td>
<td class="num">(3,937)<span></span>
</td>
<td class="num">(838,063)<span></span>
</td>
<td class="nump">3,341,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectFromChangeInTaxRate', window );">Impact of Alberta rate change</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96,028<span></span>
</td>
<td class="nump">3,758,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfTaxPools', window );">Adjustment to opening tax pools</a></td>
<td class="num">(552,079)<span></span>
</td>
<td class="nump">20,711<span></span>
</td>
<td class="nump">11,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Other permanent differences</a></td>
<td class="nump">44,290<span></span>
</td>
<td class="nump">108,945<span></span>
</td>
<td class="nump">149,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfExpirationOfTaxBenefits', window );">Expiry of tax benefits</a></td>
<td class="nump">1,661,187<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1', window );">Change in deferred tax benefits deemed not probable to be recovered</a></td>
<td class="nump">1,342,306<span></span>
</td>
<td class="nump">2,161,541<span></span>
</td>
<td class="num">(1,961,613)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current income taxes</a></td>
<td class="nump">$ 49,427<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Change in Fair Value Of Warrant Derivative</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfExpirationOfTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Expiration Of Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfExpirationOfTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Stock Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfTaxPools">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Tax Pools</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfTaxPools</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163140219544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember', window );">Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">$ 4,833,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Unclaimed scientific research and experimental development expenditures | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">27,663,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Unclaimed scientific research and experimental development expenditures | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">1,343,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember', window );">2022 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">465,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember', window );">2023 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">361,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember', window );">2024 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">228,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember', window );">2025 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">271,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember', window );">2026 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">520,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember', window );">2027 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">596,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember', window );">2028 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">622,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember', window );">2029 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">173,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember', window );">2030 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember', window );">2031 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">114,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember', window );">2032 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">381,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember', window );">2033 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">487,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember', window );">2034 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">270,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember', window );">2035 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">183,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember', window );">2036 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember', window );">2037 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember', window );">2038 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember', window );">2039 | Non-refundable federal investment tax credits | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141033160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Non-capital Losses (Details) - Non-capital losses<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">$ 89,537,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">BARBADOS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">162,986,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember', window );">2022 | BARBADOS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">42,826,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember', window );">2023 | BARBADOS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">33,063,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember', window );">2024 | BARBADOS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">15,990,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember', window );">2025 | BARBADOS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">15,138,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember', window );">2026 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">9,809,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember', window );">2026 | BARBADOS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">16,575,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember', window );">2027 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">12,170,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember', window );">2027 | BARBADOS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">26,114,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember', window );">2028 | BARBADOS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">13,280,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember', window );">2029 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,009,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember', window );">2030 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,774,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember', window );">2031 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,343,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember', window );">2032 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,873,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember', window );">2033 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,457,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember', window );">2034 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,472,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember', window );">2035 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">3,125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember', window );">2036 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">6,430,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember', window );">2037 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,812,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember', window );">2038 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">5,056,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember', window );">2039 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">6,864,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyFortyMember', window );">2040 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">9,724,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyFortyOneMember', window );">2041 | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">$ 10,619,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyFortyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyFortyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyFortyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyFortyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144204728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 37,583,775<span></span>
</td>
<td class="nump">$ 34,541,435<span></span>
</td>
<td class="nump">$ 32,712,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember', window );">Net operating losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">25,157,950<span></span>
</td>
<td class="nump">21,487,804<span></span>
</td>
<td class="nump">19,625,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Scientific research and experimental development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">7,705,028<span></span>
</td>
<td class="nump">6,362,152<span></span>
</td>
<td class="nump">6,338,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember', window );">Investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">3,715,652<span></span>
</td>
<td class="nump">4,068,105<span></span>
</td>
<td class="nump">4,222,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember', window );">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">350,695<span></span>
</td>
<td class="nump">1,927,709<span></span>
</td>
<td class="nump">1,908,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">647,978<span></span>
</td>
<td class="nump">689,193<span></span>
</td>
<td class="nump">611,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember', window );">Net capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 6,472<span></span>
</td>
<td class="nump">$ 6,472<span></span>
</td>
<td class="nump">$ 6,474<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144172952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Disclosures (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 12, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 41,262,044<span></span>
</td>
<td class="nump">$ 31,219,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,148,021<span></span>
</td>
<td class="nump">$ 13,699,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders' equity</a></td>
<td class="nump">$ 36,098,985<span></span>
</td>
<td class="nump">$ 24,752,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (107,894)<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_EquityAuthorized', window );">Base Shelf securities authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_EquityAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_EquityAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163141659400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">$ 56,017<span></span>
</td>
<td class="nump">$ 531,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">(Increase) decrease in net loss due to change in currency value</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">$ 56,017<span></span>
</td>
<td class="nump">$ 531,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144145464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 41,262,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,219,574<span></span>
</td>
<td class="nump">$ 14,148,021<span></span>
</td>
<td class="nump">$ 13,699,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(1,987,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,805,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,102,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">$ 621,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(886,891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,837,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_BalanceHeldInForeignCurrencyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Held In Foreign Currency, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_BalanceHeldInForeignCurrencyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Currency1 [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163145085864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Other receivables</a></td>
<td class="num">$ (776,394)<span></span>
</td>
<td class="nump">$ 1,979,111<span></span>
</td>
<td class="num">$ (2,017,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(348,600)<span></span>
</td>
<td class="nump">286,391<span></span>
</td>
<td class="num">(2,012,605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">182,855<span></span>
</td>
<td class="num">(1,368,203)<span></span>
</td>
<td class="nump">1,347,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables', window );">Other liabilities</a></td>
<td class="nump">228,294<span></span>
</td>
<td class="num">(723,230)<span></span>
</td>
<td class="nump">807,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet', window );">Non-cash impact of foreign exchange</a></td>
<td class="num">(194,142)<span></span>
</td>
<td class="nump">35,710<span></span>
</td>
<td class="nump">78,708<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Change in non-cash working capital related to operating activities</a></td>
<td class="num">$ (907,987)<span></span>
</td>
<td class="nump">$ 209,779<span></span>
</td>
<td class="num">$ (1,795,777)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163143994888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ProceedsfromInterestReceived', window );">Cash interest received</a></td>
<td class="nump">$ 190,339<span></span>
</td>
<td class="nump">$ 189,720<span></span>
</td>
<td class="nump">$ 274,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Cash taxes paid</a></td>
<td class="nump">$ 34,959<span></span>
</td>
<td class="nump">$ 12,080<span></span>
</td>
<td class="nump">$ 5,448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Interest Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163143970008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>manufacturer</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member', window );">Toll manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1LineItems', window );"><strong>Concentration Risk Type1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskNumber', window );">Concentration, number</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Concentration Risk Type1 [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163136711720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,825,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,558,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,470,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction cost, warrant derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,256,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction cost, warrant derivative</a></td>
<td class="nump">$ 699,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember', window );">Included in research and development expenses:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,645,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,775,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,096,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,086,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,043,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember', window );">Included in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,542,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,635,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,555,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,515,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Depreciation - property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember', window );">Included in operating expenses | Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction cost, warrant derivative</a></td>
<td class="nump">$ 233,143<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherExpensesAndAdjustmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Other Expenses And Adjustments [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherExpensesAndAdjustmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163144099976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee compensation and benefits</a></td>
<td class="nump">$ 3,918,564<span></span>
</td>
<td class="nump">$ 3,514,527<span></span>
</td>
<td class="nump">$ 3,786,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">495,175<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation</a></td>
<td class="nump">2,703,256<span></span>
</td>
<td class="nump">1,757,723<span></span>
</td>
<td class="nump">1,123,408<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Compensation of key management personnel</a></td>
<td class="nump">$ 6,621,820<span></span>
</td>
<td class="nump">$ 5,767,425<span></span>
</td>
<td class="nump">$ 4,910,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140163136672024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 02, 2022 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2021 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,715,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,654,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Share transactions | Production Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PaymentsForExecutoryContracts', window );">Payments for executory contracts</a></td>
<td class="nump">$ 1,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Share transactions | 2021 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,050,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,560,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PaymentsForExecutoryContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Executory Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PaymentsForExecutoryContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AgreementAxis=oncyf_ProductionServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AgreementAxis=oncyf_ProductionServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>oncyf-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:oncyf="http://www.oncolyticsbiotech.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="oncyf-20211231.xsd" xlink:type="simple"/>
    <context id="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibe633dda267842029258e53a782fe561_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i113d492fc4cf424c8489d5302adf402d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i21ac1e8adaee40f6b58f4f0a7d541a1a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2fca816bbeb24d2f9554e7f82f33d0aa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9a4b3d20c0e34a60b680edd8e972dcfc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaefbcea0de304b2694dda77f60ddb9c8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6f8ab54803934f9ba120d4a3bc5e6154_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i762faf08df5c4521a4f2689a278651e0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7497baf23598431f909bb5527274fe07_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idb855524d3594b9281f4a4752081bdde_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1259d944f2ca4e288ad6295bde8a4c8d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icb74087cec10424881ec8739a53a5f47_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i77cf8a24c33d40808c7ac3ad20112a31_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7dae23e4a8384544b5f5e4a7c1153719_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia3c73cf11c2d41678a6efb1f84d128a2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib500d93c61d242cda9af6cc3f32d688c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea11c29de32043f3b1182fba91ce8ff8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaca09b43294947cdbd585359e3ccaae8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i304f57b073284387a43a1c3c507589e0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ebb4717b09f4ceb9bf3bf6ef866ac14_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3e0d0525ecbf4dbabb9d6b81ca747d24_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4f455a49c64e4496ab595aaa0cba3f3e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2f790228dc448d9936518bb5cf5c8a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if543a2c06c834e58a4a76a3dab2778ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i560a323e55304acfbf5998d3542ba7c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9dc054b35a584c518e17f16ec259dee3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida3a1ebaced94f77b77c50976f1eb191_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8c0d97615104d688ed55dd772c5d7cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6f313c8714fa4ba0957f98a3704b93ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09fddfef79174f75b8bff1cf359841fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94a1d5d3239c42da9c1871d21717c343_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied32f90a78ea42c7b0c30d1104a4a175_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i477bd6213b6949fc9c3b06ce5e97889c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c09166535004a96a1e9ce08bb6369e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcaaf6e1542d40d79d27fe0f2a8794c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9aafba09422b4432b91193f442b37784_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i97be07f487294e63a92bac56d0415c91_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89d130fa6b8345b9bb8639ac65bf6959_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20441217b630482b9af70e8a326d5e57_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69f83b81a5514d5f825fc606476e7579_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d63c24097454dbdb7cd6dea53770f97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01941d662103459ba01338223c19f6f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2dbea1a75bc4a34b367005fb0c6ff02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d1d3557b69d4abb86a20c233c6f1c42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i928abeb5cacb4a81b5b6294857079d2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11d9fb4cd4024c309548c1bf2a5386e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic6a4fa14d2b2483c8f5abacada092873_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c799a9f2ad149fd871347906998cdbb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iee32e2321a294a0d825d8564edea4786_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i963faf8316e44553ac2c61cbab41d123_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i982cf0e1d89f41ceba66f2d117947048_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2da45bc703e4440590e52cbb6c0cae23_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32242ff3d2e742fe9c6db2f637808bec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f3e572ad5cd4feea41d839ed408d512_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd1040437dbe4ddfa654981a27937d0a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9862680256f347348f49335ecd9cb274_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i800ff2f75db84660ab49b5fd43edd4c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic58c717a06a14201a8ec51df519af985_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if7d43a48ed72460b82de5da9f8bc806c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb4dd3dcb3854bb3a98aeec910cf0b0b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e928b35b509443e9b3f89941d035b11_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if68c471b3ecb4bdeb645af1dc5364be4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifeb2f08e8214484fbe8e7de1348ff6e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7007c392b1ea42b7bfa5f63652da1152_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ee8f344469f41d9b0a08a69b6edeba2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie86e21b5f131400fa46a3e0b45cf078a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2584f9ecb64b45a3b52d3a4ad2b34c59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6dbbc452c8f400f9ca5600d1ea5533a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e58c6e381b84e12b2792dec22095ada_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i301c21dc622442aca90541862f62c6d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9a9ad61b7c34714ab9be21ec4261caf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieae72557ba464b78b3c52ff1fde0c3e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icca0c7d56dcc43cdbb15d5b8cc79a270_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief8ec86040be42ba9d536b3bf953a071_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib5302452976149d498ed33786d7128b5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d04cbd5984d4fffa8e832079f479563_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c331b0bbafb4b2680c749659e1c82b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27b25b30c9fd4ba59fc2eafb50014834_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i204bc52fd44a4d0c816c0a2181824b55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c201bd2cec84413bbbc206341b41448_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7b48fc3177846248e8e650003e9519e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb14eb0dd43c4a709e096b2d83073f70_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3b342b88388a4129a9cc8369e81686ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0edeeed139064a33990a9c7ee6e5964b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2a981d61c5eb439da38fb12362dd8fad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i480c049e5a834c568af08f9e90655523_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i82a3d365592c40cb897ba384875fc12d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad6b64867bef4fc0afcde57faf6fa67b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05109703e464417fa841f9c540f3678f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b165e9375644237b4496e8ca868e02d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icfedcf2862364d49b2a7c3a1f4e8dfcf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa6646a5d6c34f7abe7a9ae44f606c91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f033263dc0240bd861510077d28d05f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f8794d0236d482997b1f6aa91113f6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i939b5018129e4e1e8aa83500cd6fa35a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c9a6b3f743d4662992a44369b2b7a76_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf250eba9f184833af1a42fc1ec5cb78_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81d59e90707242a995284a6cface9df4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6004ba24adf34129bfd6da674261a96d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie411180fd99f4e5790c4b079d04b0000_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f0874df70594af896849c68995cffcc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69e2f780ec994d4a9364ffcb20e6ff20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i680a4d77ca0147b2aae6c2c4160d7120_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifac774375ae04e15b64aebbe75cc3267_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb2705498f8a4d26910dc44f4ac0e29d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8f1299e30cf4e0c90e275bafdaaf57b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9240fcdbfad4d159109b9211c4a25dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i604b72e2ed1e45c0986b519ae61b7407_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71b8d6a28ae24cd8a53aac765710b347_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia96d51ce70dc4c5196635b560cc91d6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93dfc0b8bdb64273a5af3bd7e762ee6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i245cb0b82ebe4888bdb55d9598677214_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79bab5333acc4486b6de092783d41a58_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife652053dd47472d83f53067d84eaef0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8237782881b84c70a77a2cf4a54d5e61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76fe8a9f3db24be59863f170633d5a51_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88fbac179750483d8af64e04435a79bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7dc0ed2ed7547d89fd4e3e287348bd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22879de6b8fa44818a5c41e8a35f3c84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32540143275947cf9a999007e5c89d46_D20190816-20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-16</startDate>
            <endDate>2019-08-16</endDate>
        </period>
    </context>
    <context id="i60804d42d4e24611b5b61485d0a443bf_I20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="i3d6b7c66a4fc4f108fb4d53193ce2035_I20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="i29a8a4e95e79475ba60e7ba7d35e2cf9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76b8dc9ee72c4d6e999cf36c6458c7f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idfae6e354e8248509fd71f314f2f7bb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedc65d68837a4eacac34675a1cd9779e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i830cca3a0f664a4d8b3b50a1c284e3b4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7bed414ac6874a10b56efb160637b31e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie3a11c0f144e4ff3a325f5a105f0f4d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83e860d0f0a34191b33af656961cbc19_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idae5479b6b654d84bb1c05fde1394dd8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7e5a099158d84fb599da0d92dcc26605_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i11b4be78aa4f47c695bf177fab865a55_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ab215a79e4441f2b018c7706826735d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ce569aab88d48369c11f14c0bf78a25_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7c46f6b7f524d1387c1a6b6fe9dfa39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78884fc7ad21406cb0e0bd491aad0b54_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6968307567a4ac88a5fbac883bf6779_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7204566da8c8413784114e3a0277f22b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i313db08027ee47b8a313714b551d5295_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie790de8f351b420c97389308ec3102f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d55af5d6889492ba6feaef6f3089cbb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1068e88a4ef24a30afc676a512075718_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id057bd4ec78a491094f4618144a1c09d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3a75af6263f486894cd6657c4bd2464_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2902b2520fea41089f98be9b8eace36f_I20180927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-27</instant>
        </period>
    </context>
    <context id="ifdc041cff18445c2bf6a95ff95de581f_D20180927-20180927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-27</startDate>
            <endDate>2018-09-27</endDate>
        </period>
    </context>
    <context id="i67283f9ed1904a3db011f7a4a67ddd74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5f476ff70c064f36b090da63b6c25511_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i070d85f1ae5c470e839378eff83c30b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifb21fdd6d32d40719bcec4f80757184e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:CommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieef3c4b044f443248ece0ef8dc3ac073_I20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-24</instant>
        </period>
    </context>
    <context id="i8604cae19b054cb08c0871ae11d35ebd_D20181024-20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-24</startDate>
            <endDate>2018-10-24</endDate>
        </period>
    </context>
    <context id="ie179742cb9f841999fd8416ad5ecaf64_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e6b52351e9440c6a782ff3ab4b4b8f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32cccb978d9e4fdbb89e459a307b27ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8764aff5c6754164b0bd8ea7f5a1155f_D20190816-20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-16</startDate>
            <endDate>2019-08-16</endDate>
        </period>
    </context>
    <context id="i249c2d938ccb432fbaf49910859f86b3_D20190816-20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-16</startDate>
            <endDate>2019-08-16</endDate>
        </period>
    </context>
    <context id="icc5c0ca931d74739a3b6246850a2c5de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i445f25b6895b4f3a9e8820470f449122_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="i6952840e54e1456a84822c9606b3c424_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie82286507f1648e4b150250e27787981_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id09b9d3dab2a4150999c1ca5b995feac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f6e4d5e9ea74cf5ab41ddd51549cf33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6dd8b35d2c3f4ace9728ec15e62387d6_I20210305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-05</instant>
        </period>
    </context>
    <context id="if6351d06a26d494f80f99bf946853adb_D20210305-20210305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-05</startDate>
            <endDate>2021-03-05</endDate>
        </period>
    </context>
    <context id="i4ede084a4122418cb65982299416868e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0bd694e01e0d4b7bb354e73aa065b8bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12d8b8a2f06d4c838611847df4e4d947_D20170601-20170601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-01</endDate>
        </period>
    </context>
    <context id="i1104cc6b33de4026a773d0273129e2f2_I20170601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-01</instant>
        </period>
    </context>
    <context id="ie6f80ce545f5419fa462f45df6c010da_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9eb1111616934aec84de469599269b27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i886943a54e40452081d9137b1996e966_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i511314b0c0694411a575ec0eca0098cb_D20180522-20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="i320159cd827547e58721ba67d7836f34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74c3e389b53640549c1c373710f94064_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b105f49e63542228ae11b453f0ca87e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c605804bd334ec1907207bb23e349c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d0c21adfb3d488cb2fc325f543e0e92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83fe2b09673c484791ef8bd4e2f7f518_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88ca0ee1c2a247149de0db08710d0a11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4cfd0864279f4fb89386b82c0e907044_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia23c9e23b2584b9cb0a3b24d1c38da91_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7d59de09bb940c189e78dc90d63966d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5662aedb669484599906207af734e31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2aacc6b616f41dd8d5b26d42c3e9a80_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i550a47322a8b427e8965901e54efbac0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifeabe67f4cdc4d9593317276ede6b031_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06a718d83ebe46fda6f2392bc946d68c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i165f5ef5cadc4c27bc78cb9fa65a9ebb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if96dbdc3a85a498cb7c50c2c3fcc5136_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f3a94bc480946578503b6bc026df946_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e6af5d5c037483e9cf8a1e5b633bf9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a76d437dabc4644966186d4b447fc15_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5803ba163d63468d93a4dcc9c0042c33_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie946e9ce17b442b0a2db67f95b9168ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id035d2b8dd6d43178b57bd66e4788c61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8bdb149a74484759861585dd847d705c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56539f49321e44d8a1eef4fc8f086d52_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ef39cf43fa64dfbbfb9e8655e1baa24_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4b715806bf704ad08871493d7b3a4e1c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i982e2e082ae5410dbcf107355f007a0d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4fc7bd5d5a9e465d989e66ae6a3abb49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i814af0580d834778b5cede92893765d0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica2719d210fc449890e82fdb8d83507c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb01c95903d246608417f9782e2afe30_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic87ace5c41714cf3b1812237cd1344ef_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib775f5c95fa8484385ae22162e973750_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70523a9ebf4444508afc8076e91b525e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i127a482ddc3e443f908cd8d6e513e1e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie486096482ef4dbdbfc5aac0d2ef7dbd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f73e01a75a540b3bd81d5cbc09e5ef3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1358bb7098240d2b664975d761c15b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icca82039f3674df999dc93b86acdc4b5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7062d63d6b934781a4bc28b162213372_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d3bff3314ec4be6ba448395655d2141_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if548fffce7f84aaeac70a8fdef2ff771_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1da936afae14dc49119ba8ffe8ecd44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0136e4da0fc41549105d0be0238fef9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia63919fb6b0447f6a8378922a57a0e56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5017b3339eec4bedacd81c4e5981b39a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6f9bf167d3e4703927ae2652aa85037_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if88b7239836e47ee87d1993c2c69f365_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3821df9c92a94be4821466bf971f7738_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6b5060463694393849921c58686af13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i754d4b44f8894e0bbeddfd1cbb8a2e24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78b655fa2c2545fcbf00fef881bf589b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa114dbc78574101a453118abbe69a95_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ca59ee964074feca5cc2d804c6f3e05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7be63a4d7e934a779ffa098a8c199bbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2b331eb2ec14c0e884108fdc1e52785_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f9f805b162c4a61970dee91fe9b7b6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e1e786a729e443ba51a570b25e7dfb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c684f104e0f40f7a2835b480bb00c0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a91cd1ffa8b427ea4ede5259eb7c307_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief9049c105f7454c87536a38658d6c0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1eb2c5a4d51543949a0ffbdf4ec7a8bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82c158562bdf41e7a6759b2f5d325150_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib10f6659cd90429fb750eb8ed77dc3e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66ea19593d434f9b8f9057991c2ee87e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i522e5807f7804127b24ef62fe2d3d449_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c3f0b5419c0434c83941543d561ae09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i841d852358ae4ecda2e98b20193fcc61_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifdea1c38e3904299ae54711a02c93657_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib45ee033334041378788db209329639e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4449dd50bc6407d98849bb27aa044d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc931101e8f347f9916d973a1aeea8a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if376893af6704869aa4000196dff2a9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b10f7069e464035b0d01d42a3daefe9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68fe7581765a490288f89d0a93ec69f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccd6471f6d9042109c8c9ea4e5b721a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i551872a26867455eaad5a877c53f122a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8acbc8f07e144d19384899f34b15b1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb56d715075745efb29466f96d59e553_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyFortyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c59a90a0dc54356b24f4e161e4d58b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyFortyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie39699155be34d93b5eee0afd15baccc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafea390033d44f86b623be26aa1611fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaaf0f7affb224fd0a519419d263a370f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i691c2aef708c40e4959eda123656f876_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id89944ab2f3648f88d0e3371530558e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i569c7f4341664d4b8664d09e7fff7d81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f423bf1a59c47c5a5c56ae5a92be8fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86190dfcd5e447cd8e04730476245e4e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5d5cda63e0542bfb6b7cdd527ea542d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8aefcdf933a04c1591bc48676eeb3311_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id63e281c95ed4160b4cfa6e9d2499567_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibbdf50475dc0456b9d7a6b17c5375332_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib796065ed9ef4953ab1452c82a71d086_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a94de62f7e941fd85969fb9eeb33c7a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i974cc837b3484870886ee47cd5811453_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbae27b666e24aa78eafbec4c720309d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75b7f989f0c7451bad6b8015dcb583ef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib599fad21e614582ad5c64473790e8e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c2429705a0742a9958a515cdbca5c9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08b1e6664397457eb8e8ce0dfdc08ea1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8d66e5ff5ff48138f1c4239fa19d36a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i118bcfe7943a4062a9525f725b80591f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia79a3437f60544f18719723caeb2aefd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i921a0b76be5e4a5192afdce2bfa1f576_I20200612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2020-06-12</instant>
        </period>
    </context>
    <context id="if9c241e91c964c239ec005ab7fd76cda_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13e8c5af4bf84a0ba2e3af4a542a05f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72934bebe99040b6b7e0c0c2f19de911_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i06647bdfde1c470b8b4d0a645c9ba2d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd70dd98103f43b6af3a92c583cabdb7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86f880390f904058bf8a9cf3258849d0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i631df61a67ec41a593216ea67df15be1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e7344f3cdea473fa96384f7743d95b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieb584ab1725b4b40910af903b876e75c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i95d0e74b706c4b069c1415f031d34f1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida85ff23b9654045a8551b3d03eece63_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd23113a5fc540bf93ca41f097c068f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic461088cc874441196432eb9bafe69bc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i803b09a886c44d92b85f0e3efad65433_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i89a71f2e8ff5408fba66dd7456a26ab8_D20220101-20220302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-02</endDate>
        </period>
    </context>
    <context id="i9757885e4d9e44f386e37be5103b4760_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:AgreementAxis">oncyf:ProductionServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="cadPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>oncyf:plan</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="year">
        <measure>oncyf:year</measure>
    </unit>
    <unit id="manufacturer">
        <measure>oncyf:manufacturer</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV8yLTEtMS0xLTgxMjE_35140406-bf6e-4b13-bd45-7e19f409ce0d">0001129928</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV83LTEtMS0xLTgxMjE_3f7605ac-7635-4dca-bc45-aebf9c1ba795">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV84LTEtMS0xLTgxMjE_04e1c0c8-7c86-407c-9ef7-9dbd16b69cf8">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV85LTEtMS0xLTgxMjE_7ae27411-bacb-443e-b0a1-5b64569fb105">false</dei:AmendmentFlag>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV81LTEtMS0xLTE4NDI0_fe829cd6-ccbf-44aa-aff0-713996434c09">A0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl80L2ZyYWc6MTUyYjdjZDM0ZDFkNDkyY2E0MDBkMGRiNzljYTgyMTYvdGFibGU6N2RkOTY5NzM2NmY5NGFmZmIxYjU4NDQzYjcwN2JjZTEvdGFibGVyYW5nZTo3ZGQ5Njk3MzY2Zjk0YWZmYjFiNTg0NDNiNzA3YmNlMV81LTEtMS0xLTE4NDAx_7b0a861b-1ab0-456f-ac62-cbdc21743c1f">false</dei:EntityEmergingGrowthCompany>
    <oncyf:StockholdersEquityNoteStockSplitConversionRatio
      contextRef="i511314b0c0694411a575ec0eca0098cb_D20180522-20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjMvZnJhZzo0YzZjZTA0ZGJmMzg0MmRhYmY2NGE1NzE3ZGEwZGRiYS90YWJsZTo1NWZhZWRlYjBhNDA0ZGJhODc4NWJmNzdmN2JiODZjYy90YWJsZXJhbmdlOjU1ZmFlZGViMGE0MDRkYmE4Nzg1YmY3N2Y3YmI4NmNjXzEtMS0xLTEtODEyMQ_f20641f7-aa1e-4e44-9b78-13d0372954df"
      unitRef="number">0.105263157894737</oncyf:StockholdersEquityNoteStockSplitConversionRatio>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="i5803ba163d63468d93a4dcc9c0042c33_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzM1OA_3e8a9208-2071-47f7-9434-36998b16603e">P1Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzg2_a1756c80-8c70-4127-a140-bbc1741196ca">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl8wLTAtMS0xLTE4MTU3_9d111858-ed3f-49b9-b817-864c37867313">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl8yLTAtMS0xLTE4MTU5_965d7fe6-f0a2-4dc6-9fdf-437b37fe42c6">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl81LTAtMS0xLTgxMjEvdGV4dHJlZ2lvbjo1MTY0YzNhZTYyZjM0N2M5OGQ4ODQ5MTA3OTI1ZmFjZV80_57a33e3c-83d0-4a22-841f-20e7e5d9f1e2">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl81LTAtMS0xLTgxMjEvdGV4dHJlZ2lvbjo1MTY0YzNhZTYyZjM0N2M5OGQ4ODQ5MTA3OTI1ZmFjZV80_de394497-f149-4a44-b37c-b47a3537b29a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl84LTAtMS0xLTE4MTYx_b49d9e17-8d3e-4e9a-b439-4037c846013e">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6N2I1MTFhMDIyZDkyNDEyMTgxZDFlMDUzN2I5YmQzYmIvdGFibGVyYW5nZTo3YjUxMWEwMjJkOTI0MTIxODFkMWUwNTM3YjliZDNiYl8xMS0wLTEtMS0xODE2Mw_1b24b76b-d0c2-4705-83f2-2d677d5085e6">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzg3_5ae9c739-2a33-4627-a674-682cf3210822">001-38512</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzg4_44cd7744-b8e0-4ffe-bc49-c7dbf7db47bc">ONCOLYTICS BIOTECH INC.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzky_9fa280db-d597-4356-81e3-32169eb9de55">804, 322 11th Avenue SW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzkz_4a678b43-6e45-42eb-afc0-77de9c35e44a">Calgary</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzk0_85ec8638-c0d1-4abc-b4a4-f0757cf798e6">AB</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzk1_39687dc0-ab8f-4d0e-b22e-6cca8a510c2e">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzk2_13d24091-0aa7-4f30-9225-09f8ad1f4a08">T2R 0C5</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName
      contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczMzk5_faf2cee8-87bc-4d45-923c-84ddd690f82b">Kirk Look</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDAx_fdf2f067-c67e-4331-9f99-f28be33c23c0">804, 322 11th Avenue SW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDAy_e091cc78-beb7-4cd4-b97f-cbd306dc33b5">Calgary</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDAz_03a0acdd-1b98-4d57-b98d-7d484b927930">AB</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDA0_914d5dc0-bee2-4ab1-b49b-07d5bf32ad0b">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDA1_e54e1b2d-c112-408e-80a1-3681f3379492">T2R 0C5</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDA3_98a8a159-9247-4457-93a5-df5d1af1519a">403</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDEx_6e2e15fe-6115-4240-980c-23e0369fba68">670-7377</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress
      contextRef="ibf1fff5c23b247aeaaf2be68a7ff281e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDEy_2b5eb5cd-b265-4565-afe1-1f1420ddc17c">info@oncolytics.ca</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6YjQwMTg4ODQ2NzA3NDgyNjk5NTMxMWZhZGRlZGQ1Y2EvdGFibGVyYW5nZTpiNDAxODg4NDY3MDc0ODI2OTk1MzExZmFkZGVkZDVjYV8xLTAtMS0xLTE4MjYyL3RleHRyZWdpb246NTUyNTJlNDkxMDBhNGQwZThiZDRjYTFiOWE0YjYzZTVfMjc0ODc3OTA2OTQ3Mw_4c908c49-163b-4cf7-ae7f-dfd5fd527c1d">no</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6YjQwMTg4ODQ2NzA3NDgyNjk5NTMxMWZhZGRlZGQ1Y2EvdGFibGVyYW5nZTpiNDAxODg4NDY3MDc0ODI2OTk1MzExZmFkZGVkZDVjYV8xLTEtMS0xLTE4MjYy_e3a12d32-06bb-42fb-84cc-85826e98e815">ONCY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6YjQwMTg4ODQ2NzA3NDgyNjk5NTMxMWZhZGRlZGQ1Y2EvdGFibGVyYW5nZTpiNDAxODg4NDY3MDc0ODI2OTk1MzExZmFkZGVkZDVjYV8xLTItMS0xLTE4MjYyL3RleHRyZWdpb246MmViMjgyMTYyZDJjNDkzY2JlNjk3MmNmNTQ3M2Y1MDVfNzE0NjgyNTU4MDU3NQ_4dbeac9f-257e-4665-ad21-e112e918c50d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8xMDk5NTExNjMxNzU5_94f3616e-fa03-478d-8ca7-4367d7552353"
      unitRef="shares">55043789</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDE4_40f224fb-4ae5-4ab2-bdaf-40f7d47bad2b">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDE0_84d93e9f-bffb-48d8-845a-cfb39520bf3d">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDE1_20fd70cd-b1c7-45ee-a27e-b93624a272c4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDE2_0b8d30e9-ebe9-4120-9e9a-06c2f49c64a2">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6ZGM2Yzc4OTBmYTA0NDkzODgxZmIxNGYyOWQzNTYyOGIvdGFibGVyYW5nZTpkYzZjNzg5MGZhMDQ0OTM4ODFmYjE0ZjI5ZDM1NjI4Yl8wLTEtMS0xLTE4MzM1L3RleHRyZWdpb246MmVmMTAxMDA1NTY0NGFmZGE0ZTA0Mzg5ZGVmMzhmMDZfMjc0ODc3OTA2OTQ4MA_8c8c41b6-b98c-4a67-b3c0-0fd07b3c4eaf">Accelerated Filer</dei:EntityFilerCategory>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV83MTQ2ODI1NTg0NTIz_5a491399-381e-446e-9100-2fe44895b02b">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGFibGU6NmRkY2I0ZmNiZGZiNDk3NGI1YmEzYjIyNzE2MzE1MzEvdGFibGVyYW5nZTo2ZGRjYjRmY2JkZmI0OTc0YjViYTNiMjI3MTYzMTUzMV8wLTEtMS0xLTE4Mzk2L3RleHRyZWdpb246NDEwMjhhZjUxZjg0NDJhOTk0NmFhNGIyOGUyM2Q1YmZfNzE0NjgyNTU4MDY5Mw_a48f2c6a-cfa7-41b2-8363-d45b6874527f">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xL2ZyYWc6MDBjYjU3YzhjMmQ0NGMzMGE3OWZiMTUxOWZmNmJjMGEvdGV4dHJlZ2lvbjowMGNiNTdjOGMyZDQ0YzMwYTc5ZmIxNTE5ZmY2YmMwYV8yNzQ4Nzc5MDczNDE3_fc9e5d51-be87-419b-9089-e11a0c8f1e95">false</dei:EntityShellCompany>
    <dei:DocumentPeriodEndDate
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8zNC9mcmFnOjhhNWI2MmRlYjU5NDQ5ZGM4MGE1NjQyYzNjODAzZmNlL3RleHRyZWdpb246OGE1YjYyZGViNTk0NDlkYzgwYTU2NDJjM2M4MDNmY2VfMjA2_57a33e3c-83d0-4a22-841f-20e7e5d9f1e2">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8zNC9mcmFnOjhhNWI2MmRlYjU5NDQ5ZGM4MGE1NjQyYzNjODAzZmNlL3RleHRyZWdpb246OGE1YjYyZGViNTk0NDlkYzgwYTU2NDJjM2M4MDNmY2VfMjA2_de394497-f149-4a44-b37c-b47a3537b29a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AuditorFirmId
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl82NC9mcmFnOjAxNjg5NDI5NDY4ZDQxNGZiNDM3ODQ0MTUyZWJhN2Y2L3RleHRyZWdpb246MDE2ODk0Mjk0NjhkNDE0ZmI0Mzc4NDQxNTJlYmE3ZjZfMTA5OTUxMTYzMTc3NQ_ead20a24-c7db-4a0b-b27f-c7542031f4f4">1263</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTIvZnJhZzo2M2EzYjlmNDg0NDU0MzdjOTgxZTgzMGNlNWEzNzFhYy90ZXh0cmVnaW9uOjYzYTNiOWY0ODQ0NTQzN2M5ODFlODMwY2U1YTM3MWFjXzI3NDg3NzkwNzQyMjc_15d04121-f32c-4e71-8723-28ffcb0ae84d">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTUvZnJhZzo1M2I4NjZhMzliZWU0NThhOGM2OTdlY2RlZjNjYWUzZi90YWJsZTo4YWZlNmFjNzZlOGE0YmE4YjU0NTVlMjRkMTM4MmJjMi90YWJsZXJhbmdlOjhhZmU2YWM3NmU4YTRiYThiNTQ1NWUyNGQxMzgyYmMyXzMtMC0xLTEtMTkyNDc_c60c66c8-9ed3-4b0c-b4f9-916b55699d81">Calgary, Canada</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMtMi0xLTEtODEyMQ_cb9f27a7-7caf-4c03-8e13-6d1482f894f4"
      unitRef="cad">41262044</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMtMy0xLTEtODEyMQ_11999d6a-d2a2-4473-9522-9a9b21d34877"
      unitRef="cad">31219574</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:OtherCurrentReceivables
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzQtMi0xLTEtODEyMQ_c882404a-1902-4e46-a751-6381feef376f"
      unitRef="cad">866055</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzQtMy0xLTEtODEyMQ_78a2515c-0236-4b72-92d2-14362b6414a2"
      unitRef="cad">89661</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzUtMi0xLTEtODEyMQ_1527e32f-098a-42bd-a0c0-2e51ed80f642"
      unitRef="cad">2775800</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzUtMy0xLTEtODEyMQ_0aa15a6e-e39c-4dd6-b1b4-6a717ee8e547"
      unitRef="cad">2427200</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentAssets
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzYtMi0xLTEtODEyMQ_563d5d2a-22ab-4964-9cb8-c2da8630295a"
      unitRef="cad">44903899</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzYtMy0xLTEtODEyMQ_fc9cd2c7-7de3-4b84-8560-486c0d1a7854"
      unitRef="cad">33736435</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzgtMi0xLTEtODEyMQ_588d0be7-d798-4219-8e02-67f9dc509f83"
      unitRef="cad">392041</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzgtMy0xLTEtODEyMQ_f2545cdd-84aa-4187-a76e-5283d91f03d5"
      unitRef="cad">236664</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzktMi0xLTEtODEyMQ_8602f071-323a-4c2f-a39c-598bfec20759"
      unitRef="cad">584251</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzktMy0xLTEtODEyMQ_ae0d3c56-0b74-4bf2-a300-ac1c19c2d902"
      unitRef="cad">372468</ifrs-full:RightofuseAssets>
    <ifrs-full:Assets
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzEyLTItMS0xLTgxMjE_d8e08a2f-2b9b-498c-aaf9-fa30feb7d125"
      unitRef="cad">45880191</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzEyLTMtMS0xLTgxMjE_d31fbf65-5051-4c9a-abf7-0bc97b7764c2"
      unitRef="cad">34345567</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE1LTItMS0xLTgxMjE_9847beeb-024e-4e47-8407-19bbc3001d92"
      unitRef="cad">1987870</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE1LTMtMS0xLTgxMjE_bc7bd0ab-a782-4cf8-889d-c6f05b8e5b2f"
      unitRef="cad">1805015</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE2LTItMS0xLTgxMjE_d0b1e0d7-87e8-4486-8352-59d925381fb3"
      unitRef="cad">352279</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE2LTMtMS0xLTgxMjE_a83757c6-c524-4390-9ea0-623571976693"
      unitRef="cad">123985</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE3LTItMS0xLTgxMjE_52dacd4a-36a4-45f8-ba1d-384fab932133"
      unitRef="cad">293672</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE3LTMtMS0xLTgxMjE_2a9f4832-f957-4a16-8656-98193f33edf4"
      unitRef="cad">248885</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE4LTItMS0xLTgxMjE_858eb712-3e8e-4a3e-b756-9e2f6a82bf7b"
      unitRef="cad">56017</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE4LTMtMS0xLTgxMjE_ffa58a32-01ae-4bd0-a2e8-511c7cb85eaf"
      unitRef="cad">531228</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE5LTItMS0xLTgxMjE_900b56db-ec56-4721-a8c8-8b90a2057ef3"
      unitRef="cad">2689838</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzE5LTMtMS0xLTgxMjE_caf5da95-a0f5-4213-8894-36d32dcffec6"
      unitRef="cad">2709113</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzIxLTItMS0xLTgxMjE_4fa4b602-bc8f-486d-ae83-777a178fa650"
      unitRef="cad">6730287</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzIxLTMtMS0xLTgxMjE_326f308f-7c8e-4a7d-8e28-836012cce9dd"
      unitRef="cad">6730287</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzIyLTItMS0xLTgxMjE_32451b5d-4b1c-4de3-ac3d-8a9eff0bf9a9"
      unitRef="cad">361081</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzIyLTMtMS0xLTgxMjE_9b73093b-dcc2-49a1-b2c9-1b020eea0b57"
      unitRef="cad">153174</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:Liabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI1LTItMS0xLTgxMjE_06c5d819-b279-4581-822f-7e19f7d03fa4"
      unitRef="cad">9781206</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI1LTMtMS0xLTgxMjE_938bbb1b-ae56-4fb1-a3af-5c2777c5d53f"
      unitRef="cad">9592574</ifrs-full:Liabilities>
    <oncyf:CommitmentsAndContingencies1
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzIwLTEtMS0xLTE4NDQx_7b5b5997-66b7-42da-b522-37f0a9b5c2ae"
      unitRef="cad"
      xsi:nil="true"/>
    <oncyf:CommitmentsAndContingencies1
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI2LTMtMS0xLTgxMjE_be71b6e1-a6e5-4d3c-9f91-43f0f5c869c8"
      unitRef="cad"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI4LTAtMS0xLTgxMjEvdGV4dHJlZ2lvbjo3Y2FjYzI5NDI1OTU0NGEwODY5YzQwOTA5MjViODc0OF8xNjQ5MjY3NDQxNzUz_59ffdc92-ff32-4ad5-a452-d5c5a79035c0"
      unitRef="shares">55043789</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI4LTAtMS0xLTgxMjEvdGV4dHJlZ2lvbjo3Y2FjYzI5NDI1OTU0NGEwODY5YzQwOTA5MjViODc0OF8xNjQ5MjY3NDQxNzQ2_707e7a50-8e3e-4c6a-8a00-0f4024e494d0"
      unitRef="shares">46166980</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapital
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI4LTItMS0xLTgxMjE_63c084a1-3539-49d0-9ce4-8366fddd6cc9"
      unitRef="cad">391348183</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI4LTMtMS0xLTgxMjE_f93e9a4f-5e0a-4457-9947-3bbfae53ad1f"
      unitRef="cad">356824172</ifrs-full:IssuedCapital>
    <oncyf:WarrantsandRightsOutstanding
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI5LTItMS0xLTgxMjE_e65d6dac-ee74-41bb-b1bc-14633a8fa4de"
      unitRef="cad">3617570</oncyf:WarrantsandRightsOutstanding>
    <oncyf:WarrantsandRightsOutstanding
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzI5LTMtMS0xLTgxMjE_6d805283-705f-436c-8d0b-71e3ccddc204"
      unitRef="cad">3617570</oncyf:WarrantsandRightsOutstanding>
    <ifrs-full:AdditionalPaidinCapital
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMwLTItMS0xLTgxMjE_93c5e739-a73d-47fc-822c-c3fa2da0ad58"
      unitRef="cad">34161103</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AdditionalPaidinCapital
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMwLTMtMS0xLTgxMjE_fde5b282-e66c-4a59-a982-7496614df75c"
      unitRef="cad">31022356</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMxLTItMS0xLTgxMjE_708e59e0-c515-48a4-9b57-23a99bef3bff"
      unitRef="cad">387738</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMxLTMtMS0xLTgxMjE_86ada7e8-6b4d-436a-a899-b941ee096b7a"
      unitRef="cad">400225</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:RetainedEarnings
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMyLTItMS0xLTgxMjE_5d413079-d245-48ac-b255-f435b94ad970"
      unitRef="cad">-393415609</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMyLTMtMS0xLTgxMjE_14f8ab86-cea9-4c4d-afb4-5912e0e1c257"
      unitRef="cad">-367111330</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMzLTItMS0xLTgxMjE_9c5d799e-dfca-4411-8701-f0f7b4fc07b8"
      unitRef="cad">36098985</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzMzLTMtMS0xLTgxMjE_366e67f7-7d90-4764-861f-b671a084a357"
      unitRef="cad">24752993</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzM0LTItMS0xLTgxMjE_64183d42-8f96-423c-b155-10e1abc321a5"
      unitRef="cad">45880191</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMTgvZnJhZzpjYTc1MDk2ZTQ5OTk0ODg4OTIzYzYzNTVhZThlN2UxOS90YWJsZTo4ZDM0YTk3NDQyYjg0OGQwYTZjYTQ2ZDI0YzJiMGFlZi90YWJsZXJhbmdlOjhkMzRhOTc0NDJiODQ4ZDBhNmNhNDZkMjRjMmIwYWVmXzM0LTMtMS0xLTgxMjE_33f6974d-08ea-4521-9862-102eaaa06d01"
      unitRef="cad">34345567</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzMtMi0xLTEtODEyMQ_efcd0a92-f945-4298-be1e-1584d2c55e66"
      unitRef="cad">12920371</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzMtMy0xLTEtODEyMQ_b9018e41-5e6b-42f9-bbe0-db17ca11dea8"
      unitRef="cad">12944510</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzMtNC0xLTEtODEyMQ_4e708f2a-630d-4809-ba66-f6a3a6db9522"
      unitRef="cad">10817997</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OperatingExpense
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzQtMi0xLTEtODEyMQ_8a3a7809-2d49-46ff-a02b-66509e0008c7"
      unitRef="cad">13314574</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzQtMy0xLTEtODEyMQ_c65371a8-933a-4faf-9bf6-376eff9a5b74"
      unitRef="cad">12514496</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzQtNC0xLTEtODEyMQ_67caa2c5-c491-44c8-91ff-c29bf8511761"
      unitRef="cad">9558641</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzUtMi0xLTEtODEyMQ_fd264b0f-66a3-4f19-a111-77e7b6bf24dd"
      unitRef="cad">-26234945</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzUtMy0xLTEtODEyMQ_2490f1bf-8a29-430d-af9c-f56d9f22c258"
      unitRef="cad">-25459006</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzUtNC0xLTEtODEyMQ_6c2c82b1-a8e8-40ac-ad21-9ff7d4c68d69"
      unitRef="cad">-20376638</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzYtMi0xLTEtODEyMQ_b86717f9-d5c8-4de9-a770-e77d9eb5131a"
      unitRef="cad">17117</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzYtMy0xLTEtODEyMQ_c77823ae-065e-4f86-aa72-747d519f6d0a"
      unitRef="cad">3491928</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzYtNC0xLTEtODEyMQ_a0556003-0f91-4c35-9e04-3c6b7e7bd4d4"
      unitRef="cad">-12608808</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzctMi0xLTEtODEyMQ_0eb62dc6-6db4-4c83-bea9-88ac2efe0947"
      unitRef="cad">-135636</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzctMy0xLTEtODEyMQ_352b693a-8824-4377-913e-f91b31962d35"
      unitRef="cad">-659173</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzctNC0xLTEtODEyMQ_3e834915-6019-4928-a577-fbaed2271817"
      unitRef="cad">-316719</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzgtMi0xLTEtODEyMQ_7997f237-c73b-4809-8c83-c4c814ea2506"
      unitRef="cad">98612</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzgtMy0xLTEtODEyMQ_2e510d65-a7c8-46bb-b0a3-df1b994cc239"
      unitRef="cad">121194</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzgtNC0xLTEtODEyMQ_52c523f5-a0b3-439f-b9dc-106268beffd4"
      unitRef="cad">179277</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzktMi0xLTEtODEyMQ_683612eb-d0ed-47b0-872e-71d018bbd3e5"
      unitRef="cad">-26254852</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzktMy0xLTEtODEyMQ_e200952b-578f-4759-9781-1a1d4109dfa4"
      unitRef="cad">-22505057</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzktNC0xLTEtODEyMQ_0da66875-0549-4274-8a84-6b183e403141"
      unitRef="cad">-33122888</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEwLTItMS0xLTgxMjE_134d13b5-da99-4001-88f0-dd5163657853"
      unitRef="cad">49427</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEwLTMtMS0xLTgxMjE_0e609e41-72ca-4236-ad79-85c01bff12f9"
      unitRef="cad">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEwLTQtMS0xLTgxMjE_a479da37-b884-49c0-9fb9-4d5603b45c5b"
      unitRef="cad">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzExLTItMS0xLTgxMjE_bb9f64d1-8cc4-4991-b8b6-b7c2dfd40876"
      unitRef="cad">-26304279</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzExLTMtMS0xLTgxMjE_e6eb68e0-d4fa-4914-9b0c-e1c8e25573dc"
      unitRef="cad">-22505057</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzExLTQtMS0xLTgxMjE_230252b6-5cb0-42a8-b853-71ef43f3af34"
      unitRef="cad">-33122888</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEzLTItMS0xLTgxMjE_4e0ecfcc-e019-4581-9e9d-ec264f75f7f7"
      unitRef="cad">-12487</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEzLTMtMS0xLTgxMjE_4fd59385-888c-4fa8-b380-83ea3b7ac2c6"
      unitRef="cad">-63876</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzEzLTQtMS0xLTgxMjE_cd89aa9c-130e-4c15-81bf-7615ec241e32"
      unitRef="cad">-143403</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE0LTItMS0xLTgxMjE_1f90e530-8b9d-4a05-930d-6212d8cfd280"
      unitRef="cad">-26316766</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE0LTMtMS0xLTgxMjE_e1ace500-eee7-4742-a195-d3e204745dcf"
      unitRef="cad">-22568933</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE0LTQtMS0xLTgxMjE_e2b8a897-5bf9-4693-ac0a-ddcf49ba71cc"
      unitRef="cad">-33266291</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTItMS0xLTgxMjE_752f4e6f-6e1e-4aaf-8673-687fc2de6d4e"
      unitRef="cadPerShare">-0.49</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTItMS0xLTgxMjE_aad3b9af-7725-4789-9641-ac4a9a6b3ae7"
      unitRef="cadPerShare">-0.49</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTMtMS0xLTgxMjE_82ea75c3-a8ae-4c7c-aecb-87dd0b4af04f"
      unitRef="cadPerShare">-0.56</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTMtMS0xLTgxMjE_ee52cbdf-1577-41f4-8af2-241829c2f228"
      unitRef="cadPerShare">-0.56</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTQtMS0xLTgxMjE_329f3733-b527-4646-9681-630e5366fd1b"
      unitRef="cadPerShare">-1.50</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE1LTQtMS0xLTgxMjE_3c9e3f19-42ae-4ed8-b8ca-24f001d89068"
      unitRef="cadPerShare">-1.50</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTItMS0xLTgxMjE_0656803f-7a88-4c46-8ab7-555d1ee032c2"
      unitRef="shares">53513225</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTItMS0xLTgxMjE_79006d47-f35a-4f3e-aa15-82bb970331e9"
      unitRef="shares">53513225</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTMtMS0xLTgxMjE_3e9ac702-d7ec-41c4-a78b-640317b2a3f7"
      unitRef="shares">40338789</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTMtMS0xLTgxMjE_4b6d1af4-1745-4234-82ab-9be837eaeda3"
      unitRef="shares">40338789</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTQtMS0xLTgxMjE_032279d3-cdab-438b-befd-39d2f10df08d"
      unitRef="shares">22137990</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjQvZnJhZzo1ODkxMGI2ZjJmZDc0NDkyYmQxYmRmNzc1ZGEwMWZjYS90YWJsZTpmNjEyOWU5NjgxMTg0NTIzOTQwYzFmMjM1ZjU4YzZlYy90YWJsZXJhbmdlOmY2MTI5ZTk2ODExODQ1MjM5NDBjMWYyMzVmNThjNmVjXzE2LTQtMS0xLTgxMjE_555bae2e-527e-4714-99c5-933a600a7e0c"
      unitRef="shares">22137990</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:Equity
      contextRef="i21ac1e8adaee40f6b58f4f0a7d541a1a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTItMS0xLTgxMjE_f148fb07-fa76-47e7-82d5-917c2e49e8cc"
      unitRef="cad">285193061</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i2fca816bbeb24d2f9554e7f82f33d0aa_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTMtMS0xLTgxMjE_45c4384f-8a9f-41e4-8c82-1cda41663959"
      unitRef="cad">3617570</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i9a4b3d20c0e34a60b680edd8e972dcfc_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTQtMS0xLTgxMjE_a1cd0783-dee1-4484-bffe-04dd86a0fee5"
      unitRef="cad">28260613</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="iaefbcea0de304b2694dda77f60ddb9c8_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTUtMS0xLTgxMjE_ae0baa1b-5e4a-4f88-8fc7-c53c8b6212b6"
      unitRef="cad">607504</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i6f8ab54803934f9ba120d4a3bc5e6154_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTYtMS0xLTgxMjE_7d136457-eedc-4b26-9ac6-04b6f92df1ed"
      unitRef="cad">-311483385</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i762faf08df5c4521a4f2689a278651e0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzExLTctMS0xLTgxMjE_fc4f1467-fad7-4c35-a1c0-06c9413b6f09"
      unitRef="cad">6195363</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome
      contextRef="i7497baf23598431f909bb5527274fe07_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEyLTUtMS0xLTgxMjE_9c36bee8-89c2-44be-808a-36e64e10889f"
      unitRef="cad">-143403</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="idb855524d3594b9281f4a4752081bdde_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEyLTYtMS0xLTgxMjE_7009753a-9ad0-4adc-9cb6-c9744f9e85e7"
      unitRef="cad">-33122888</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEyLTctMS0xLTgxMjE_edcac7b9-7657-40b4-853b-f448c14690a8"
      unitRef="cad">-33266291</ifrs-full:ComprehensiveIncome>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i1259d944f2ca4e288ad6295bde8a4c8d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEzLTItMS0xLTgxMjE_7104c13b-fc3d-4820-b095-9fb75d76220a"
      unitRef="cad">391917</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="icb74087cec10424881ec8739a53a5f47_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEzLTQtMS0xLTgxMjE_4ff35fff-1825-4364-a5f4-5c1b6c2d59b7"
      unitRef="cad">-391917</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzEzLTctMS0xLTgxMjE_daa36371-0b0c-4287-b241-77969cc2cc52"
      unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i77cf8a24c33d40808c7ac3ad20112a31_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE0LTItMS0xLTgxMjE_bc7cb5f6-1cf6-4693-8d8d-cbae396c9f7d"
      unitRef="cad">5403385</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i7dae23e4a8384544b5f5e4a7c1153719_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE0LTctMS0xLTgxMjE_78db193a-e9fb-401d-8907-0feb7a8e2210"
      unitRef="cad">5403385</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="ia3c73cf11c2d41678a6efb1f84d128a2_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE1LTItMS0xLTgxMjE_b89001ae-49a3-48f0-a02a-964c213b0df9"
      unitRef="cad">8476454</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="ib500d93c61d242cda9af6cc3f32d688c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE1LTctMS0xLTgxMjE_a40406a9-cc48-42f4-9db1-4f9a1872bb7d"
      unitRef="cad">8476454</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="iea11c29de32043f3b1182fba91ce8ff8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE2LTItMS0xLTgxMjE_918a5266-96e8-47ea-8589-9e6ffc835d22"
      unitRef="cad">3314429</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="iaca09b43294947cdbd585359e3ccaae8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE2LTctMS0xLTgxMjE_158a2777-8d78-4bc8-a3b7-17cbab057055"
      unitRef="cad">3314429</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i1259d944f2ca4e288ad6295bde8a4c8d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE3LTItMS0xLTgxMjE_e8f8815c-c692-4dc2-b95d-61baa78562e8"
      unitRef="cad">9152869</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE3LTctMS0xLTgxMjE_1c99ecf7-a11d-4c65-97e9-0682d1651064"
      unitRef="cad">9152869</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="icb74087cec10424881ec8739a53a5f47_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE4LTQtMS0xLTgxMjE_31b9cc3c-20c9-4941-bf26-af6134eae92e"
      unitRef="cad">1470153</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE4LTctMS0xLTgxMjE_44d3f85e-8e9b-4053-a283-7e8e70e77d13"
      unitRef="cad">1470153</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i1259d944f2ca4e288ad6295bde8a4c8d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE5LTItMS0xLTgxMjE_98c80540-bff6-4f1e-b9ab-039740959fce"
      unitRef="cad">854256</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE5LTctMS0xLTgxMjE_40f2266b-521e-4141-a709-9d4e2fce5eba"
      unitRef="cad">854256</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="i304f57b073284387a43a1c3c507589e0_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTItMS0xLTgxMjE_c70cadf1-4835-4110-9c1f-0f7c100059be"
      unitRef="cad">311077859</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i1ebb4717b09f4ceb9bf3bf6ef866ac14_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTMtMS0xLTgxMjE_1c568bf6-6f77-4e20-a2a7-6bfe3cfd1688"
      unitRef="cad">3617570</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i3e0d0525ecbf4dbabb9d6b81ca747d24_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTQtMS0xLTgxMjE_42db4858-16b6-4ba9-8b47-4e1b8b28dcd0"
      unitRef="cad">29338849</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i4f455a49c64e4496ab595aaa0cba3f3e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTUtMS0xLTgxMjE_d9a11102-7ca6-4ce2-b97f-57557d680092"
      unitRef="cad">464101</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ib2f790228dc448d9936518bb5cf5c8a5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTYtMS0xLTgxMjE_fb6da0f4-1cbd-4eff-a80a-8eb0aa84a926"
      unitRef="cad">-344606273</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTctMS0xLTgxMjE_a37d139a-d014-4ada-91ca-6deeabc4d69c"
      unitRef="cad">-107894</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome
      contextRef="if543a2c06c834e58a4a76a3dab2778ee_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTUtMS0xLTgxMjE_331033bd-993b-41b9-829f-8f7392c3ed11"
      unitRef="cad">-63876</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i560a323e55304acfbf5998d3542ba7c4_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTYtMS0xLTgxMjE_8c848dd4-5cde-4eac-8f0b-73568a5524e0"
      unitRef="cad">-22505057</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTctMS0xLTgxMjE_308cae7e-4da4-47c7-8367-1f21861c0f2c"
      unitRef="cad">-22568933</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i9dc054b35a584c518e17f16ec259dee3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIyLTItMS0xLTgxMjE_75d8f2a1-3c69-40ed-b44d-fb47edeb114f"
      unitRef="cad">385022</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="ida3a1ebaced94f77b77c50976f1eb191_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIyLTQtMS0xLTgxMjE_d2e49c15-bb48-4ad3-a685-adc923d2c9ea"
      unitRef="cad">-143100</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIyLTctMS0xLTgxMjE_a820e258-322b-4013-9f93-d98ae73ebcd6"
      unitRef="cad">241922</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i9dc054b35a584c518e17f16ec259dee3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIzLTItMS0xLTgxMjE_3c8447b2-21a8-42fd-a799-c305629944fe"
      unitRef="cad">732367</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="ida3a1ebaced94f77b77c50976f1eb191_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIzLTQtMS0xLTgxMjE_6a4de44e-c651-48c7-8acd-49440268f945"
      unitRef="cad">-732367</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIzLTctMS0xLTgxMjE_4fe6ccad-7709-4b9a-8ff7-f7c94a41db69"
      unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <ifrs-full:IssueOfEquity
      contextRef="ia8c0d97615104d688ed55dd772c5d7cb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI0LTItMS0xLTgxMjE_428f7c70-fc39-4aca-aed4-5d5c408edd94"
      unitRef="cad">40037786</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i6f313c8714fa4ba0957f98a3704b93ec_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI0LTctMS0xLTgxMjE_552a4c6b-7b79-4eff-8189-679e70b3e5da"
      unitRef="cad">40037786</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i9dc054b35a584c518e17f16ec259dee3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI1LTItMS0xLTgxMjE_3247fcf3-fc07-41bd-be0c-00dfc64fbb40"
      unitRef="cad">6332778</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI1LTctMS0xLTgxMjE_c8b20cc7-6c6b-4918-9be1-ba1c37a244f5"
      unitRef="cad">6332778</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="ida3a1ebaced94f77b77c50976f1eb191_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTQtMS0xLTgxMjE_709db0f4-5ee2-4962-a29c-a40c374e4107"
      unitRef="cad">2558974</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTctMS0xLTgxMjE_c9854550-86e2-44e9-b1ae-5e5a7428b53e"
      unitRef="cad">2558974</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i9dc054b35a584c518e17f16ec259dee3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI3LTItMS0xLTgxMjE_c8512ace-31a8-4383-8075-bc40afb6ec4e"
      unitRef="cad">1741640</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI3LTctMS0xLTgxMjE_c5c6461e-297d-4b25-af67-648d3411abab"
      unitRef="cad">1741640</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="i09fddfef79174f75b8bff1cf359841fc_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTItMS0xLTgxMjE_132a69cf-3501-4007-8902-2b4f65e07fc3"
      unitRef="cad">356824172</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i94a1d5d3239c42da9c1871d21717c343_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTMtMS0xLTgxMjE_726b9426-1450-4a9e-829a-ce87ed8ff82d"
      unitRef="cad">3617570</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ied32f90a78ea42c7b0c30d1104a4a175_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTQtMS0xLTgxMjE_3ebc4b09-44f8-4530-a339-a93eea80b5f6"
      unitRef="cad">31022356</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i477bd6213b6949fc9c3b06ce5e97889c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTUtMS0xLTgxMjE_942433bb-379f-4781-a914-80868b0a1ab8"
      unitRef="cad">400225</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i2c09166535004a96a1e9ce08bb6369e6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTYtMS0xLTgxMjE_0a69ec7a-3d36-422d-a313-9f2a3b872680"
      unitRef="cad">-367111330</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI4LTctMS0xLTgxMjE_464274c5-86da-49bc-a887-e7b4943b7851"
      unitRef="cad">24752993</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome
      contextRef="idcaaf6e1542d40d79d27fe0f2a8794c7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE5LTctMS0xLTg2NzA_212c71bd-4168-4ee4-a16b-c2bc568f8801"
      unitRef="cad">-12487</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i9aafba09422b4432b91193f442b37784_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE5LTktMS0xLTg2Nzc_60df7a77-41cf-4244-a980-53564b60267e"
      unitRef="cad">-26304279</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzE5LTExLTEtMS04Njg0_a92bc63c-e45b-4fab-b9da-2019096b8836"
      unitRef="cad">-26316766</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i97be07f487294e63a92bac56d0415c91_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTEtMS0xLTg2NDg_1862a7d8-879a-44f4-b54c-0169733f14b3"
      unitRef="cad">381771</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i89d130fa6b8345b9bb8639ac65bf6959_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTUtMS0xLTg2NjI_82ac633d-57cf-482e-96fa-0cfd57290c4f"
      unitRef="cad">-143321</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIwLTExLTEtMS04Njg0_96e62b77-9776-4c88-9449-854b685a465b"
      unitRef="cad">238450</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i97be07f487294e63a92bac56d0415c91_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTEtMS0xLTg2NDg_5d326c88-02ed-4efe-aeb2-0835640a5cec"
      unitRef="cad">543833</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i89d130fa6b8345b9bb8639ac65bf6959_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTUtMS0xLTg2NjI_e99cc139-220b-4573-929b-a98e4e1157ae"
      unitRef="cad">-543833</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIxLTExLTEtMS04Njg0_9151c07a-0a47-48fa-97a4-770e63147906"
      unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i20441217b630482b9af70e8a326d5e57_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIyLTEtMS0xLTg2NDg_89333daa-397e-4963-a4e9-6f9860a95068"
      unitRef="cad">34168071</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i69f83b81a5514d5f825fc606476e7579_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIyLTExLTEtMS04Njg0_693edc19-4a52-4f2d-b6ce-bf56106db54a"
      unitRef="cad">34168071</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i97be07f487294e63a92bac56d0415c91_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIzLTEtMS0xLTg2NDg_429c7a04-28a3-48ab-b505-058d41762269"
      unitRef="cad">686616</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzIzLTExLTEtMS04Njg0_2c6ca41b-5472-477f-80e0-08ef007fa75d"
      unitRef="cad">686616</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i89d130fa6b8345b9bb8639ac65bf6959_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI0LTUtMS0xLTg2NjI_dcb1a7c2-d0c0-4aba-91a6-23caa9a03c35"
      unitRef="cad">3825901</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI0LTExLTEtMS04Njg0_5dea2fed-3c45-4934-b6c1-b8b7c31b1a04"
      unitRef="cad">3825901</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i97be07f487294e63a92bac56d0415c91_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI1LTEtMS0xLTg2NDg_db58d175-eeec-4b14-bb54-ff89cd58419e"
      unitRef="cad">1256280</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI1LTExLTEtMS04Njg0_7a6e35ef-1cbd-4ab1-8a81-0f28d1004d57"
      unitRef="cad">1256280</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="i2d63c24097454dbdb7cd6dea53770f97_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTEtMS0xLTg2NDg_ef57de22-c16e-42e1-ad9e-d1c0a6b58e52"
      unitRef="cad">391348183</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i01941d662103459ba01338223c19f6f2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTMtMS0xLTg2NTU_a4464a1f-fc04-4dfb-a40b-14c55469b87c"
      unitRef="cad">3617570</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ia2dbea1a75bc4a34b367005fb0c6ff02_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTUtMS0xLTg2NjI_f016f5f5-659c-4062-94dd-4e70c6325fb0"
      unitRef="cad">34161103</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i2d1d3557b69d4abb86a20c233c6f1c42_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTctMS0xLTg2NzA_0329245f-b719-4f1a-a80d-7c2767e1c2a1"
      unitRef="cad">387738</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i928abeb5cacb4a81b5b6294857079d2f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTktMS0xLTg2Nzc_4c421f57-94dc-4112-8edc-af1203c1d28a"
      unitRef="cad">-393415609</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMjcvZnJhZzpkNTcyZDdlNThhMjM0Mjc5OTNkYTI5ZDJkMTRiYmJiYS90YWJsZToyOGE3YWNlMjAwYWI0MzU2ODIxZmQ0OTY4M2FjYzZjNi90YWJsZXJhbmdlOjI4YTdhY2UyMDBhYjQzNTY4MjFmZDQ5NjgzYWNjNmM2XzI2LTExLTEtMS04Njg0_929722ff-7721-40b5-80ab-f32c6730eae8"
      unitRef="cad">36098985</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzMtMi0xLTEtODEyMQ_c3b9250d-c4f1-4a15-88ef-1078182c065e"
      unitRef="cad">-26304279</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzMtMy0xLTEtODEyMQ_693ac9af-a78e-4bd5-b66e-b58394f62ae2"
      unitRef="cad">-22505057</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzMtNC0xLTEtODEyMQ_e90cfd86-e9fc-4430-864f-08d9358b6cb0"
      unitRef="cad">-33122888</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzQtMi0xLTEtODEyMQ_7a1bc6ec-f340-401f-b0f3-3d8b9ebdc791"
      unitRef="cad">130243</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzQtMy0xLTEtODEyMQ_3ab9210d-834b-4642-9995-a8989271c568"
      unitRef="cad">88957</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzQtNC0xLTEtODEyMQ_b4a60ea5-d153-4f6e-911e-50625443f4ec"
      unitRef="cad">122982</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzUtMi0xLTEtODEyMQ_9598d829-e9c0-40c6-994f-10ad0ddac2c6"
      unitRef="cad">321822</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzUtMy0xLTEtODEyMQ_02bf2f9f-3858-4c90-9ddd-45269d257eeb"
      unitRef="cad">357230</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzUtNC0xLTEtODEyMQ_23c72328-c0b5-4d56-8a61-96f4fd2b82b3"
      unitRef="cad">362592</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzYtMi0xLTEtODEyMQ_04f6ca49-7e6a-4ef4-b4c5-98eb0c846e85"
      unitRef="cad">3825901</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzYtMy0xLTEtODEyMQ_3b9ce78f-d1a0-4be8-afa1-722b721f569e"
      unitRef="cad">2558974</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzYtNC0xLTEtODEyMQ_405938ec-34ba-4472-b4c2-a6a0737fc11a"
      unitRef="cad">1470153</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzctMi0xLTEtODEyMQ_84b85855-1ada-48a3-9d45-1d502719f62f"
      unitRef="cad">91727</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzctMy0xLTEtODEyMQ_cb8e6db0-0911-43fc-840e-0cb28f12e4e1"
      unitRef="cad">68526</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzctNC0xLTEtODEyMQ_102f2f3c-7611-4bdd-b2ea-8183f5c55c9e"
      unitRef="cad">94817</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzgtMi0xLTEtODEyMQ_0464f8d6-1859-4f72-b0f6-701184203990"
      unitRef="cad">425681</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzgtMy0xLTEtODEyMQ_e30d2821-b5f6-4b5d-aa9f-490ccb14e12c"
      unitRef="cad">645078</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzgtNC0xLTEtODEyMQ_aa437245-d6cf-4f26-b678-95950858b70f"
      unitRef="cad">353189</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzExLTItMS0xLTgxMjE_1936badf-f694-4955-be8f-6d320cfb6fe3"
      unitRef="cad">17117</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzExLTMtMS0xLTgxMjE_c04c5c4d-9349-45ac-85ff-4de7c88345d8"
      unitRef="cad">3491928</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzExLTQtMS0xLTgxMjE_dd20865a-79c6-4705-b603-d2d66cb8e2fa"
      unitRef="cad">-12608808</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEyLTItMS0xLTgxMjE_394ab962-cb0c-49fa-b85e-f47bf89a825d"
      unitRef="cad">907987</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEyLTMtMS0xLTgxMjE_74b5075c-516c-4cfb-a110-5ff8803d118f"
      unitRef="cad">-209779</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEyLTQtMS0xLTgxMjE_3e019c69-f0a5-4da3-8102-038be47f3b81"
      unitRef="cad">1795777</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEzLTItMS0xLTgxMjE_78e9ecfd-9896-4397-8c2c-5cc223117e77"
      unitRef="cad">-22434009</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEzLTMtMS0xLTgxMjE_5db55b34-2762-4a5c-800d-623187e73d50"
      unitRef="cad">-22068441</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzEzLTQtMS0xLTgxMjE_365157ea-20d8-430b-85be-052dcd3bb49f"
      unitRef="cad">-19906124</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE1LTItMS0xLTgxMjE_b5b188b4-1dcd-4826-a033-f3aceed3d836"
      unitRef="cad">285948</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE1LTMtMS0xLTgxMjE_cad4d9a2-b8fc-4713-a768-7b01536725df"
      unitRef="cad">29305</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE1LTQtMS0xLTgxMjE_ffef095e-4932-4511-b5a1-43f47177f2dc"
      unitRef="cad">10905</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE2LTItMS0xLTgxMjE_31b40aba-cdd2-45e5-8b7d-68ce9c170577"
      unitRef="cad">-285948</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE2LTMtMS0xLTgxMjE_9ea04b3a-e326-4433-b0b7-a82ea7120138"
      unitRef="cad">-29305</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE2LTQtMS0xLTgxMjE_24ef3131-cc26-4ade-9140-ba751ba2b010"
      unitRef="cad">-10905</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE4LTItMS0xLTgxMjE_cd96589a-2164-4b1c-a198-fd40e6fb4cb6"
      unitRef="cad">238450</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE4LTMtMS0xLTgxMjE_73b93e2d-3b01-4b27-b9b8-92b91502f481"
      unitRef="cad">241922</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE4LTQtMS0xLTgxMjE_dcf967b6-5ef8-4071-b866-47d21902fa90"
      unitRef="cad">0</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i11d9fb4cd4024c309548c1bf2a5386e4_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE5LTItMS0xLTgxMjE_64de583a-b973-4879-b1c9-50509b78bdc4"
      unitRef="cad">230946</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="ic6a4fa14d2b2483c8f5abacada092873_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE5LTMtMS0xLTgxMjE_a8f84b91-2c29-42d1-96bd-1799ff160e0f"
      unitRef="cad">1696460</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i2c799a9f2ad149fd871347906998cdbb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzE5LTQtMS0xLTgxMjE_fa3fa259-e1a0-42e6-9544-3e844812711c"
      unitRef="cad">3465867</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="iee32e2321a294a0d825d8564edea4786_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIwLTItMS0xLTgxMjE_7b525bc8-34ec-483d-bd70-fa087f64e03f"
      unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i963faf8316e44553ac2c61cbab41d123_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIwLTMtMS0xLTgxMjE_4af0bb69-71af-47c0-ab34-8acacc5d3afc"
      unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i982cf0e1d89f41ceba66f2d117947048_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIwLTQtMS0xLTgxMjE_77548975-e19d-4254-9f77-0f726061803c"
      unitRef="cad">5360247</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i69f83b81a5514d5f825fc606476e7579_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIxLTItMS0xLTgxMjE_81331afc-1a62-41fd-b922-c6b5fa11f5a1"
      unitRef="cad">32911791</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i6f313c8714fa4ba0957f98a3704b93ec_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIxLTMtMS0xLTgxMjE_a4551616-9bef-42a0-b361-eb0d930fc7af"
      unitRef="cad">38296146</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="ib500d93c61d242cda9af6cc3f32d688c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIxLTQtMS0xLTgxMjE_88ddf200-6735-400b-92be-6d2a713a7f84"
      unitRef="cad">8131620</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i2da45bc703e4440590e52cbb6c0cae23_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIyLTItMS0xLTgxMjE_034c021b-11ec-4653-bb9e-01029f61a920"
      unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i32242ff3d2e742fe9c6db2f637808bec_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIyLTMtMS0xLTgxMjE_8fe64c7d-410a-493b-92b9-f6ed301dff52"
      unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="iaca09b43294947cdbd585359e3ccaae8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIyLTQtMS0xLTgxMjE_5b0ae327-66a3-40ec-b92f-88463f511367"
      unitRef="cad">4505359</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:CashOutflowForLeases
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIzLTItMS0xLTgxMjE_6d036133-3c2a-466d-97a5-10a55c89756c"
      unitRef="cad">365510</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIzLTMtMS0xLTgxMjE_9136257f-d458-4f4c-8f37-69a46faea6a8"
      unitRef="cad">460724</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzIzLTQtMS0xLTgxMjE_8607b7a8-21a4-43ea-bcd7-650cfd58c757"
      unitRef="cad">447497</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI0LTItMS0xLTgxMjE_7c7c77aa-e334-4d9e-a817-48302d859ae5"
      unitRef="cad">33015677</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI0LTMtMS0xLTgxMjE_50a77096-d46a-45fc-9d17-e011a6b9a3eb"
      unitRef="cad">39773804</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI0LTQtMS0xLTgxMjE_a68031bf-dbf6-4486-aea1-4d5676c97771"
      unitRef="cad">21015596</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI1LTItMS0xLTgxMjE_4ee6194b-b42c-4487-af3a-618db26ba812"
      unitRef="cad">10295720</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI1LTMtMS0xLTgxMjE_41b4283f-cf09-4c0f-9e27-dc322feaed3e"
      unitRef="cad">17676058</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI1LTQtMS0xLTgxMjE_b2e5d938-fcd5-4ace-97c6-50c8b4e4376a"
      unitRef="cad">1098567</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI2LTItMS0xLTgxMjE_55e6c3cb-cbd2-4df1-b5a0-1ea8826bdf61"
      unitRef="cad">31219574</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI2LTMtMS0xLTgxMjE_94bcd93b-b6c3-4411-81f2-b48cbab50264"
      unitRef="cad">14148021</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i762faf08df5c4521a4f2689a278651e0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI2LTQtMS0xLTgxMjE_4564fa7f-7c71-4b3f-8d88-7332849a1b2f"
      unitRef="cad">13699881</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI3LTItMS0xLTgxMjE_27eeba02-baa0-4ada-96ec-a64f7b073559"
      unitRef="cad">-253250</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI3LTMtMS0xLTgxMjE_2ac1d4dd-057e-46a0-97ad-ad2d00aee224"
      unitRef="cad">-604505</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI3LTQtMS0xLTgxMjE_59a2bf5d-151c-4805-bb5b-9acf599444c5"
      unitRef="cad">-650427</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI4LTItMS0xLTgxMjE_6c2b6ef3-31c5-4d34-959f-07b9339054e6"
      unitRef="cad">41262044</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI4LTMtMS0xLTgxMjE_23d6c048-1bf4-4374-94fd-c4a87e1d9dbf"
      unitRef="cad">31219574</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzAvZnJhZzozZWU1NTlhZDM3ZjU0YjhhYTM3NjVkYTkwZTIzZGJiZi90YWJsZTowMmY3YzlkNGEyNDk0MmIxOTMwNzlhYjQxNDYwZGI0NC90YWJsZXJhbmdlOjAyZjdjOWQ0YTI0OTQyYjE5MzA3OWFiNDE0NjBkYjQ0XzI4LTQtMS0xLTgxMjE_c3e691e4-2165-41bf-99a6-8541715ce0e8"
      unitRef="cad">14148021</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzYvZnJhZzo2YmEwOTUwNjMzNjA0MTFiYWJjMDNlMTBlMzliM2Y4ZS90ZXh0cmVnaW9uOjZiYTA5NTA2MzM2MDQxMWJhYmMwM2UxMGUzOWIzZjhlXzE0NTY_7b180c82-61de-489c-88af-e7e626456917">Incorporation and Nature of Operations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements for the year ended December&#160;31, 2021, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;2, 2022. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Avenue SW, Calgary, Alberta, Canada.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a development-stage biopharmaceutical company that focuses on the discovery and development of immunotherapeutic products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is an intravenously delivered immunotherapeutic agent that may be a novel treatment for certain types of cancer and may be an alternative to or used in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and/or targeted therapies.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xMzkvZnJhZzpmZTVmY2ZmMWMxYTk0MGM2YjQ2YTkwODE5YzA5NzU4OC90ZXh0cmVnaW9uOmZlNWZjZmYxYzFhOTQwYzZiNDZhOTA4MTljMDk3NTg4XzEzODU_cd222d95-c74d-418f-b5d0-dfd0d92534b2">Basis of Financial Statement Presentation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc. and are presented in Canadian dollars, our functional currency.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries. Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern. Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MTk5_eeabb164-ea96-4217-bb75-f9f771722a8f">Summary of Significant Accounting Policies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Classification and measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under IFRS 9 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"IFRS 9"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#x2019;s business model for managing the assets; and whether the financial asset&#x2019;s contractual cash flows represent &#x2018;solely payments of principal and interest&#x2019; on the principal amount outstanding (the &#x2018;SPPI criterion&#x2019;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#x2019;s original effective interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derecognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial asset is derecognized when:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contractual rights to the cash flows from the financial asset expire, or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Loss per common share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#x201c;in the money&#x201d; options, restricted share units, performance share units, and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Property and equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the identified asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Share-based compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one stock option plan (the &#x201c;Option Plan&#x201d;) available to officers, directors, employees, and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#x201c;Board&#x201d;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of options that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive share award plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our incentive share award plan (the "Share Plan") is available to directors, officers, and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt;Accounting Standards and Interpretations Issued but Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Presentation of Financial Statements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and IFRS Practice Statement 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Making Materiality Judgements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in which it provides guidance and example to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 8 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies, Changes in Accounting Estimates and Errors&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 8, in which it introduces a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 12 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the IASB issued amendments to IAS 12, which narrows the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. We are assessing the impact of adopting this standard on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjAz_7f07697a-9c3c-47fb-a6b4-42680e6002f2">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.</ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjM1_92a0be00-7504-4c44-987f-6f6f29c43b40">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under IFRS 9 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"IFRS 9"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#x2019;s business model for managing the assets; and whether the financial asset&#x2019;s contractual cash flows represent &#x2018;solely payments of principal and interest&#x2019; on the principal amount outstanding (the &#x2018;SPPI criterion&#x2019;). &lt;/span&gt;&lt;/div&gt;Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjA5_410c8e1a-7dec-4036-bee3-2a63a904b68d">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjI0_b2e47ca1-502c-4e24-94d9-7ed8c225982f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#x2019;s original effective interest rate.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjI1_c06aff08-841a-4104-b58e-846e09ceee9e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial asset is derecognized when:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contractual rights to the cash flows from the financial asset expire, or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. &lt;/span&gt;&lt;/div&gt;A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired.</ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjI2_9251559e-874a-4dca-b6d2-07756c643b17">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjEw_85e61bcf-85b2-430a-98d1-3d29de3253b4">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjI3_32f018ea-3264-4687-9a14-06446e30dbca">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#x201c;in the money&#x201d; options, restricted share units, performance share units, and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjQw_9ffab46e-42c2-4322-82d0-33ab4b0af846">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjEx_b94cf91f-c715-4607-bc65-c9bac25bf1ff">Depreciation is recorded using the declining balance method at the following annual rates:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Equipment and Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(650,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(650,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,358&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159,034&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100,663&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;392,041&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="i2f3e572ad5cd4feea41d839ed408d512_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90YWJsZTo0OTc2ODllMjM3YjQ0MWU3YjBmZDY4MDhhOTE2ZjZiNi90YWJsZXJhbmdlOjQ5NzY4OWUyMzdiNDQxZTdiMGZkNjgwOGE5MTZmNmI2XzAtMS0xLTEtODEyMQ_0451d70d-9414-4c9e-a5b4-ae9af74ecbc0"
      unitRef="number">0.20</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="ifd1040437dbe4ddfa654981a27937d0a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90YWJsZTo0OTc2ODllMjM3YjQ0MWU3YjBmZDY4MDhhOTE2ZjZiNi90YWJsZXJhbmdlOjQ5NzY4OWUyMzdiNDQxZTdiMGZkNjgwOGE5MTZmNmI2XzEtMS0xLTEtODEyMQ_6652aadd-7b8f-48d7-a154-1b700789ffa0"
      unitRef="number">0.20</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="i9862680256f347348f49335ecd9cb274_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90YWJsZTo0OTc2ODllMjM3YjQ0MWU3YjBmZDY4MDhhOTE2ZjZiNi90YWJsZXJhbmdlOjQ5NzY4OWUyMzdiNDQxZTdiMGZkNjgwOGE5MTZmNmI2XzItMS0xLTEtODEyMQ_7db138b3-8c40-4ed0-9f04-fa246ef58269"
      unitRef="number">0.30</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjE5_3daaa352-7105-4e10-92e8-4e815d586bc5">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the identified asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/span&gt;&lt;/div&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjQ0_a7617c73-e6ba-45c0-942a-42866e7b2d2c">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed.</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjAx_81b52a0a-eace-4e5c-ae55-d35e9638de28">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE3MjA2_cc2819ac-9883-4f1b-9f87-0dc5e0ddd8fc">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one stock option plan (the &#x201c;Option Plan&#x201d;) available to officers, directors, employees, and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#x201c;Board&#x201d;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of options that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive share award plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our incentive share award plan (the "Share Plan") is available to directors, officers, and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  &lt;/span&gt;&lt;/div&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change.</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <oncyf:NumberOfStockOptionPlans
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE1MDIw_58a7be8d-cbbf-46d9-857b-4cc11fcbc9f1"
      unitRef="plan">1</oncyf:NumberOfStockOptionPlans>
    <oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzE1NTMw_fd4b1538-ed6b-4fb4-841e-1c76aa78f9ff">P10Y</oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDIvZnJhZzoxZDk2ZDA1ODZkMGM0ZTBlOTE3YzgzNzY4YTU2NjU2Yy90ZXh0cmVnaW9uOjFkOTZkMDU4NmQwYzRlMGU5MTdjODM3NjhhNTY2NTZjXzI3NDg3NzkwODg0NTM_332e65db-7380-47f0-a063-f5f2bb5c53cf">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Presentation of Financial Statements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and IFRS Practice Statement 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Making Materiality Judgements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in which it provides guidance and example to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 8 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies, Changes in Accounting Estimates and Errors&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 8, in which it introduces a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 12 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the IASB issued amendments to IAS 12, which narrows the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. We are assessing the impact of adopting this standard on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDUvZnJhZzo2YmJjMThmMmFlNTU0Mjc5OTQ4ZGE5MmFhOTBlM2I4ZS90ZXh0cmVnaW9uOjZiYmMxOGYyYWU1NTQyNzk5NDhkYTkyYWE5MGUzYjhlXzc4ODQ_b6f19668-3b3b-4013-891e-76f8b4418f07">Significant Judgments, Estimates and Assumptions&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The full extent to which the coronavirus infectious disease 2019 ("COVID-19") pandemic may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. We considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to our consolidated financial statements as of and for the year ended December 31, 2021, our future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Judgments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Estimates and assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses represent a significant component of our research and development expenses and we outsource a significant portion of these activities to third-party contract research organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that have been performed by the contract research organizations. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of share-based compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted are disclosed in Note 10. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of warrant derivative &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of the warrant derivative are disclosed in Note 8.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDgvZnJhZzplZGU1NjBhZmQzMGE0MWNkOWNiOTQwNmY2OTMzNDFkZi90ZXh0cmVnaW9uOmVkZTU2MGFmZDMwYTQxY2Q5Y2I5NDA2ZjY5MzM0MWRmXzIxNw_673c81d4-5866-4440-b796-0926a5beecb8">Cash Equivalents &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of interest bearing deposits with our bank totaling $39,901,509 (December&#160;31, 2020 &#x2013; $30,361,591).&#160;&#160;The current annual interest rate earned on these deposits is 0.45% (December&#160;31, 2020 &#x2013; 0.36%).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <ifrs-full:CashEquivalents
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDgvZnJhZzplZGU1NjBhZmQzMGE0MWNkOWNiOTQwNmY2OTMzNDFkZi90ZXh0cmVnaW9uOmVkZTU2MGFmZDMwYTQxY2Q5Y2I5NDA2ZjY5MzM0MWRmXzEyOA_e4bb9306-a88b-48bc-a43f-32156e9d3c8e"
      unitRef="cad">39901509</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDgvZnJhZzplZGU1NjBhZmQzMGE0MWNkOWNiOTQwNmY2OTMzNDFkZi90ZXh0cmVnaW9uOmVkZTU2MGFmZDMwYTQxY2Q5Y2I5NDA2ZjY5MzM0MWRmXzEzNw_2ab7cc09-fe2f-4f54-9ff8-1e9421fae062"
      unitRef="cad">30361591</ifrs-full:CashEquivalents>
    <oncyf:CashEquivalentsInterestRate
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDgvZnJhZzplZGU1NjBhZmQzMGE0MWNkOWNiOTQwNmY2OTMzNDFkZi90ZXh0cmVnaW9uOmVkZTU2MGFmZDMwYTQxY2Q5Y2I5NDA2ZjY5MzM0MWRmXzIwNA_e2c1f902-537d-41b4-bc67-6c8ebfb598a7"
      unitRef="number">0.0045</oncyf:CashEquivalentsInterestRate>
    <oncyf:CashEquivalentsInterestRate
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNDgvZnJhZzplZGU1NjBhZmQzMGE0MWNkOWNiOTQwNmY2OTMzNDFkZi90ZXh0cmVnaW9uOmVkZTU2MGFmZDMwYTQxY2Q5Y2I5NDA2ZjY5MzM0MWRmXzIxMw_99fb10ce-a40e-489e-b456-f92f5edf3fe4"
      unitRef="number">0.0036</oncyf:CashEquivalentsInterestRate>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90ZXh0cmVnaW9uOmNkZDkzM2ZkNWM5NDRiMWM5NjMzOTY0YTE3NTJlYTM0XzU0_be120e77-8ea0-4db8-9eef-1624fde1b66b">Property and Equipment&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Equipment and Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(650,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(650,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,358&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159,034&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100,663&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;392,041&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i800ff2f75db84660ab49b5fd43edd4c1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzUtMS0xLTEtODEyMQ_49ea23c1-d482-4093-b4e1-eba8054eefe0"
      unitRef="cad">60378</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ic58c717a06a14201a8ec51df519af985_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzUtMi0xLTEtODEyMQ_376a78c4-85e4-4274-b36e-c992ea9b25db"
      unitRef="cad">352955</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="if7d43a48ed72460b82de5da9f8bc806c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzUtMy0xLTEtODEyMQ_cae34088-ba1e-4a87-ad79-ec0f003f7ae3"
      unitRef="cad">352667</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icb4dd3dcb3854bb3a98aeec910cf0b0b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzUtNS0xLTEtODEyMQ_86a5c9a0-9baa-4a2b-8383-a180888b00bf"
      unitRef="cad">498367</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i2e928b35b509443e9b3f89941d035b11_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzUtNi0xLTEtODEyMQ_b33966f8-b5ce-4c83-ac70-a4753d82a76c"
      unitRef="cad">1264367</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="if68c471b3ecb4bdeb645af1dc5364be4_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzYtMS0xLTEtODEyMQ_ce4ef2f0-d245-4799-a91d-96eefe0c5e80"
      unitRef="cad">1134</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ifeb2f08e8214484fbe8e7de1348ff6e3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzYtMi0xLTEtODEyMQ_2db425a2-1539-4eeb-84f8-3b19ff1629c4"
      unitRef="cad">27719</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i7007c392b1ea42b7bfa5f63652da1152_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzYtMy0xLTEtODEyMQ_e7efcbee-abb5-4fb4-8058-0138501622a7"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i6ee8f344469f41d9b0a08a69b6edeba2_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzYtNS0xLTEtODEyMQ_5b7be15e-c70b-46ee-bb28-c540ef36294c"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ie86e21b5f131400fa46a3e0b45cf078a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzYtNi0xLTEtODEyMQ_9e061b5d-16e4-4db6-9f6f-83cb9946733b"
      unitRef="cad">28853</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="if68c471b3ecb4bdeb645af1dc5364be4_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzctMS0xLTEtODEyMQ_818ea86d-4a3c-457c-8eb1-e84a1154c5f6"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ifeb2f08e8214484fbe8e7de1348ff6e3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzctMi0xLTEtODEyMQ_93f10e45-8832-4ae4-b70e-584f935e2469"
      unitRef="cad">15137</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i7007c392b1ea42b7bfa5f63652da1152_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzctMy0xLTEtODEyMQ_57aff3e2-c11e-4287-b0db-ce424a63a03f"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i6ee8f344469f41d9b0a08a69b6edeba2_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzctNS0xLTEtODEyMQ_748bd45a-447d-44ba-a92d-02086a86de58"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ie86e21b5f131400fa46a3e0b45cf078a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzctNi0xLTEtODEyMQ_f3acbb89-3257-4c06-8627-4141948971ef"
      unitRef="cad">15137</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i2584f9ecb64b45a3b52d3a4ad2b34c59_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzgtMS0xLTEtODEyMQ_17b01519-1e57-47b2-8f63-e29aaaa932e7"
      unitRef="cad">61512</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia6dbbc452c8f400f9ca5600d1ea5533a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzgtMi0xLTEtODEyMQ_2284c2fc-8daa-4e91-8c72-3a39b2652150"
      unitRef="cad">365537</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i9e58c6e381b84e12b2792dec22095ada_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzgtMy0xLTEtODEyMQ_0bfd9e80-1f1c-4b69-ae6f-15b075a94bda"
      unitRef="cad">352667</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i301c21dc622442aca90541862f62c6d2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzgtNS0xLTEtODEyMQ_da6ee6a3-960c-4e97-bb55-1bab4201430f"
      unitRef="cad">498367</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia9a9ad61b7c34714ab9be21ec4261caf_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzgtNi0xLTEtODEyMQ_73641c16-bd9f-41d6-8374-87e056b834c5"
      unitRef="cad">1278083</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ieae72557ba464b78b3c52ff1fde0c3e8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzktMS0xLTEtODEyMQ_57165c1f-a71a-483d-b3a8-38003041af44"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="icca0c7d56dcc43cdbb15d5b8cc79a270_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzktMi0xLTEtODEyMQ_56d2fa08-6720-4825-ab9f-67004051e1b7"
      unitRef="cad">40338</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ief8ec86040be42ba9d536b3bf953a071_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzktMy0xLTEtODEyMQ_a5512f6d-b0ec-481b-8c1e-b2951dba7d85"
      unitRef="cad">141305</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ib5302452976149d498ed33786d7128b5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzktNS0xLTEtODEyMQ_de18938d-64e1-45fe-b2cf-b395efe0b054"
      unitRef="cad">103977</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i5d04cbd5984d4fffa8e832079f479563_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzktNi0xLTEtODEyMQ_c76d99c7-71f4-43b9-a307-d065d5307182"
      unitRef="cad">285620</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ieae72557ba464b78b3c52ff1fde0c3e8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzEwLTEtMS0xLTgxMjE_9358fb52-f05a-45a9-bd32-9048e3fbc05f"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="icca0c7d56dcc43cdbb15d5b8cc79a270_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzEwLTItMS0xLTgxMjE_6eb91384-3f2e-499b-bdfa-f5e6cf0c92e6"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ief8ec86040be42ba9d536b3bf953a071_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzEwLTMtMS0xLTgxMjE_d6d1b3ce-4042-4b6f-b840-1bc48a4669b8"
      unitRef="cad">276789</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ib5302452976149d498ed33786d7128b5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzEwLTUtMS0xLTgxMjE_04f31fee-93b8-4dd6-a68c-1059703b4cc6"
      unitRef="cad">373911</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i5d04cbd5984d4fffa8e832079f479563_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzEwLTYtMS0xLTgxMjE_fdb72d85-14db-4a7b-a70f-4dec65920aca"
      unitRef="cad">650700</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i6c331b0bbafb4b2680c749659e1c82b1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzExLTEtMS0xLTgxMjE_ff7af24a-5c56-4095-b9e5-88b10a3e6b01"
      unitRef="cad">61512</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i27b25b30c9fd4ba59fc2eafb50014834_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzExLTItMS0xLTgxMjE_3f7b73e9-f63a-4c2b-8c6b-a7f911d721d2"
      unitRef="cad">405875</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i204bc52fd44a4d0c816c0a2181824b55_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzExLTMtMS0xLTgxMjE_376a478f-dab0-4428-b31d-1a0aefb15221"
      unitRef="cad">217183</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i5c201bd2cec84413bbbc206341b41448_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzExLTUtMS0xLTgxMjE_b26848b9-e284-47e8-87fa-39e6e50b325f"
      unitRef="cad">228433</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ib7b48fc3177846248e8e650003e9519e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzExLTYtMS0xLTgxMjE_07893b27-70cd-4053-a765-851a572492ca"
      unitRef="cad">913003</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icb14eb0dd43c4a709e096b2d83073f70_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE3LTEtMS0xLTgxMjE_67b5872c-a428-4034-ae3b-191146640355"
      unitRef="cad">-44708</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i3b342b88388a4129a9cc8369e81686ea_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE3LTItMS0xLTgxMjE_d4fc6812-c6a1-4e4a-8bcd-24ccd7f7668e"
      unitRef="cad">-224046</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i0edeeed139064a33990a9c7ee6e5964b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE3LTMtMS0xLTgxMjE_5ace7aa3-9fe2-45dd-8126-da278380b11f"
      unitRef="cad">-250587</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i2a981d61c5eb439da38fb12362dd8fad_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE3LTUtMS0xLTgxMjE_dd22837a-948c-41f4-bc43-046baffaac53"
      unitRef="cad">-448258</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i480c049e5a834c568af08f9e90655523_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE3LTYtMS0xLTgxMjE_875e6718-d389-4682-92c3-db80222f36a7"
      unitRef="cad">-967599</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i82a3d365592c40cb897ba384875fc12d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE4LTEtMS0xLTgxMjE_feb247c1-7c9e-4500-998b-f16830aac3f7"
      unitRef="cad">2942</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="iad6b64867bef4fc0afcde57faf6fa67b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE4LTItMS0xLTgxMjE_4be5a47a-e6d5-4d58-9ab4-bed12fb75f4b"
      unitRef="cad">40024</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i05109703e464417fa841f9c540f3678f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE4LTMtMS0xLTgxMjE_bfa122dc-0ff9-4323-9790-9dfc49a252e3"
      unitRef="cad">12308</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i9b165e9375644237b4496e8ca868e02d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE4LTUtMS0xLTgxMjE_8ef9aaf0-b695-4c72-962c-4d52ba80b596"
      unitRef="cad">33683</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="icfedcf2862364d49b2a7c3a1f4e8dfcf_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE4LTYtMS0xLTgxMjE_112ba700-3daa-4c50-93ab-3ede5ab586fa"
      unitRef="cad">88957</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i82a3d365592c40cb897ba384875fc12d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE5LTEtMS0xLTgxMjE_9187f8eb-9a52-4cc5-94ac-10a07e598bd3"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="iad6b64867bef4fc0afcde57faf6fa67b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE5LTItMS0xLTgxMjE_1b6a5403-4578-4fb6-9f9d-06c0b4449059"
      unitRef="cad">-15137</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i05109703e464417fa841f9c540f3678f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE5LTMtMS0xLTgxMjE_8d985857-7c57-43aa-a6fe-e5a43d547434"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i9b165e9375644237b4496e8ca868e02d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE5LTUtMS0xLTgxMjE_edc20040-e93e-4934-a4b3-8035f8cc434d"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="icfedcf2862364d49b2a7c3a1f4e8dfcf_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzE5LTYtMS0xLTgxMjE_8ad84dd5-5dd2-45b5-83f2-d6d090bc8a55"
      unitRef="cad">-15137</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ifa6646a5d6c34f7abe7a9ae44f606c91_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTEtMS0xLTgxMjE_9dc70de7-f369-470d-949b-f267e59f74af"
      unitRef="cad">-47650</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i6f033263dc0240bd861510077d28d05f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTItMS0xLTgxMjE_3f2aaf5e-2820-4b6c-9af6-638d4a16474a"
      unitRef="cad">-248933</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i0f8794d0236d482997b1f6aa91113f6f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTMtMS0xLTgxMjE_10e82511-5cb2-45aa-ae68-6fb87b6e93bb"
      unitRef="cad">-262895</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i939b5018129e4e1e8aa83500cd6fa35a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTUtMS0xLTgxMjE_b33b9edc-2578-4988-be47-fe4868e75f1e"
      unitRef="cad">-481941</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i4c9a6b3f743d4662992a44369b2b7a76_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTYtMS0xLTgxMjE_b409786d-b403-406c-8535-6729d36806b8"
      unitRef="cad">-1041419</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="iaf250eba9f184833af1a42fc1ec5cb78_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIxLTEtMS0xLTgxMjE_7f203152-a91b-402e-a135-39c50fa7b38d"
      unitRef="cad">2504</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i81d59e90707242a995284a6cface9df4_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIxLTItMS0xLTgxMjE_862d51d6-2d7c-4285-ade8-eacbcb680421"
      unitRef="cad">35956</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i6004ba24adf34129bfd6da674261a96d_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIxLTMtMS0xLTgxMjE_e5e720f6-69a8-44d8-a5ce-b27eb9dc415d"
      unitRef="cad">72043</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="ie411180fd99f4e5790c4b079d04b0000_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIxLTUtMS0xLTgxMjE_3191a161-61f2-4dd7-ace5-e6953725f5d2"
      unitRef="cad">19740</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i9f0874df70594af896849c68995cffcc_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIxLTYtMS0xLTgxMjE_7d96b96b-9cb1-40e9-a57b-ac731eff6014"
      unitRef="cad">130243</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="iaf250eba9f184833af1a42fc1ec5cb78_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIyLTEtMS0xLTgxMjE_1dd6daea-1365-4429-87b5-9ef37812e48f"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i81d59e90707242a995284a6cface9df4_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIyLTItMS0xLTgxMjE_ae88eb67-3b26-433c-a4e2-6636e3005819"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i6004ba24adf34129bfd6da674261a96d_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIyLTMtMS0xLTgxMjE_6b38fa4b-11a5-447a-8022-e90ff406fda8"
      unitRef="cad">-276789</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ie411180fd99f4e5790c4b079d04b0000_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIyLTUtMS0xLTgxMjE_4ca606f8-6354-42b5-a1ae-d14383702e69"
      unitRef="cad">-373911</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i9f0874df70594af896849c68995cffcc_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIyLTYtMS0xLTgxMjE_07deb0b5-c066-4594-acda-2c1f33d81e63"
      unitRef="cad">-650700</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i69e2f780ec994d4a9364ffcb20e6ff20_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIzLTEtMS0xLTgxMjE_e2bbf86f-26ed-40c0-966f-9e374912bd16"
      unitRef="cad">-50154</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i680a4d77ca0147b2aae6c2c4160d7120_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIzLTItMS0xLTgxMjE_19d288d4-9132-4054-9e03-5e8b0ce730a2"
      unitRef="cad">-284889</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ifac774375ae04e15b64aebbe75cc3267_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIzLTMtMS0xLTgxMjE_685e8753-a890-4e9f-98b4-feccc2ec6862"
      unitRef="cad">-58149</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icb2705498f8a4d26910dc44f4ac0e29d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIzLTUtMS0xLTgxMjE_dec1d4d0-3f53-43ba-9f36-f88d1cf6e396"
      unitRef="cad">-127770</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ie8f1299e30cf4e0c90e275bafdaaf57b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIzLTYtMS0xLTgxMjE_a8c5e73c-fc10-4eba-9a80-dd02f62cb3a6"
      unitRef="cad">-520962</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="if9240fcdbfad4d159109b9211c4a25dc_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTEtMS0xLTE0NTE0_a9554dcc-9fec-455e-87e3-e969c807e8b1"
      unitRef="cad">13862</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i604b72e2ed1e45c0986b519ae61b7407_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTMtMS0xLTE0NTE0_c18e4e10-942b-4890-81cf-6a59e6cbf1d9"
      unitRef="cad">116604</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i71b8d6a28ae24cd8a53aac765710b347_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTUtMS0xLTE0NTE0_e12dbdd1-6542-4fc8-87d3-676920cf33e1"
      unitRef="cad">89772</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia96d51ce70dc4c5196635b560cc91d6f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTctMS0xLTE0NTE0_3c0d3334-0430-4853-9e29-8c8becb0a9bb"
      unitRef="cad">16426</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzIwLTktMS0xLTE0NTE0_897ab224-730c-4f4b-b181-45b1e36bbcf1"
      unitRef="cad">236664</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i93dfc0b8bdb64273a5af3bd7e762ee6a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzI2LTEtMS0xLTgxMjE_8e4030dc-d985-4728-abfd-b75c95f1c06a"
      unitRef="cad">11358</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i245cb0b82ebe4888bdb55d9598677214_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzI2LTItMS0xLTgxMjE_609e0e97-32bf-4243-b7b5-d382ab3db917"
      unitRef="cad">120986</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i79bab5333acc4486b6de092783d41a58_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzI2LTMtMS0xLTgxMjE_08bd3e6c-83d4-45c2-9c53-d0ad1db08dc7"
      unitRef="cad">159034</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ife652053dd47472d83f53067d84eaef0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzI2LTUtMS0xLTgxMjE_e3c82fca-e775-4c4c-9eda-564295fcafa6"
      unitRef="cad">100663</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTEvZnJhZzpjZGQ5MzNmZDVjOTQ0YjFjOTYzMzk2NGExNzUyZWEzNC90YWJsZTpiNTY0NTBiNzE3ZDk0YmI0YjVhMmQzNmFkY2NiMDJiNS90YWJsZXJhbmdlOmI1NjQ1MGI3MTdkOTRiYjRiNWEyZDM2YWRjY2IwMmI1XzI2LTYtMS0xLTgxMjE_702aa4cf-6047-464c-a26f-ddda24a596aa"
      unitRef="cad">392041</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzkyMw_424279d8-fa3a-41c9-848f-83c5b3e71dd8">Leases&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of leases consists of office spaces with lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees, or leases not yet commenced to which we are committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, we recorded a lease modification and an addition related to the office lease extension for one of our subsidiaries and a new office space lease for our Canadian head office, respectively. The weighted-average rate applied was 15%. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our right-of-use assets outstanding at December&#160;31:      &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;         &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;372,468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;208,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease modification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;323,782&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(321,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;584,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our lease liabilities outstanding at December&#160;31:    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;              &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;402,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;203,868&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease modification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;323,782&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(365,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;91,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;654,753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our total undiscounted lease liability as at December&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More than five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liability &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <oncyf:OperatingLeaseRemainingLeaseTerm
      contextRef="i8237782881b84c70a77a2cf4a54d5e61_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzEwNg_f1ad92df-0a26-433f-9417-279ba9121d81">P3Y</oncyf:OperatingLeaseRemainingLeaseTerm>
    <oncyf:OperatingLeaseRemainingLeaseTerm
      contextRef="i76fe8a9f3db24be59863f170633d5a51_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzExMg_1a06a400-8d45-43e6-bcf0-6716ec26894a">P6Y</oncyf:OperatingLeaseRemainingLeaseTerm>
    <ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzEwOTk1MTE2Mjk1MjQ_e97f0c17-87ee-432d-9154-4cc3bf4ba7d4"
      unitRef="number">0.15</ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzkyNA_73e47e65-c6c4-4470-8a8b-95ae01a32dac">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our right-of-use assets outstanding at December&#160;31:      &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;         &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;372,468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;208,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease modification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;323,782&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(321,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;584,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzEtMS0xLTEtMTcyNTY_8b648257-f42b-40a0-bc7c-c52b33cfb916"
      unitRef="cad">372468</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzEtMS0xLTEtODEyMQ_5ed3d6d0-b852-406f-834a-3320b65d0c81"
      unitRef="cad">430713</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzItMS0xLTEtMTcyMjk_ec795a22-b4d1-4852-8c8c-d846d9f5d26d"
      unitRef="usd">208976</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzItMS0xLTEtMTQzODM_d8060513-3bce-4f74-a320-3560eefef746"
      unitRef="usd">297373</ifrs-full:AdditionsToRightofuseAssets>
    <oncyf:LeaseModificationRightOfUseAssets
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzMtMS0xLTEtMTc1MDA_32841e40-9bb8-4adc-a3ea-61b526ece10e"
      unitRef="cad">323782</oncyf:LeaseModificationRightOfUseAssets>
    <oncyf:LeaseModificationRightOfUseAssets
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzMtMy0xLTEtMTc1MTE_9a0b3e52-ca68-4165-95c7-7150a4d41782"
      unitRef="cad">0</oncyf:LeaseModificationRightOfUseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzMtMS0xLTEtMTcyMjk_aefcd452-f1d2-496c-ac00-a885a44402d0"
      unitRef="cad">321822</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzItMS0xLTEtODEyMQ_f119a12d-b0b9-4ee3-b50f-1f2640465528"
      unitRef="cad">357230</ifrs-full:DepreciationRightofuseAssets>
    <oncyf:ForeignExchangeImpactRightofUseAssets
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzQtMS0xLTEtMTcyMjk_ec2e6baf-f79a-451a-aec9-f473b2c01ce5"
      unitRef="cad">847</oncyf:ForeignExchangeImpactRightofUseAssets>
    <oncyf:ForeignExchangeImpactRightofUseAssets
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzMtMS0xLTEtODEyMQ_081652f8-cbf3-4709-a05c-fb3349513df9"
      unitRef="cad">1612</oncyf:ForeignExchangeImpactRightofUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzUtMS0xLTEtMTcyMjk_a4befef9-5107-4b90-a8df-5e96f13594e1"
      unitRef="cad">584251</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1OTk2OTg3OTMyMjM0YWI1OWIxMGI1OGJkZmZlZTljYS90YWJsZXJhbmdlOjU5OTY5ODc5MzIyMzRhYjU5YjEwYjU4YmRmZmVlOWNhXzQtMS0xLTEtODEyMQ_a9d658f1-5784-4f8d-9b96-897a166d1896"
      unitRef="cad">372468</ifrs-full:RightofuseAssets>
    <oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzkyMQ_ac908eb0-d266-427b-825d-fa774a960a53">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our lease liabilities outstanding at December&#160;31:    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;              &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;402,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;203,868&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease modification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;323,782&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(365,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;91,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;654,753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock>
    <ifrs-full:LeaseLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzEtMS0xLTEtMTcyOTk_0412ebdd-2d40-4519-b47b-424a5b0aa767"
      unitRef="cad">402059</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzEtMS0xLTEtODEyMQ_53f76508-9d47-4686-80c3-3c474fc4b5ae"
      unitRef="cad">506275</ifrs-full:LeaseLiabilities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzItMS0xLTEtMTcyNzE_1caead2c-b63c-42b9-b2d8-67eac8cddd1b"
      unitRef="usd">203868</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzItMS0xLTEtMTQzOTE_4bbe44dc-8c7f-4897-add1-4e9e754bb9f1"
      unitRef="usd">297373</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <oncyf:EffectOfLeaseModificationOnLeaseLiabilities
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzMtMS0xLTEtMTc1Mjc_56b11131-a69d-4934-a2c3-b3b4a390895d"
      unitRef="cad">323782</oncyf:EffectOfLeaseModificationOnLeaseLiabilities>
    <oncyf:EffectOfLeaseModificationOnLeaseLiabilities
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzMtMy0xLTEtMTc1Mzk_ac77f12f-c192-4777-94a3-8190e517d1b0"
      unitRef="cad">0</oncyf:EffectOfLeaseModificationOnLeaseLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzMtMS0xLTEtMTcyNzE_ce7ba941-0e43-4177-ae85-eb18cb3a4596"
      unitRef="cad">365510</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzItMS0xLTEtODEyMQ_1ef04030-0569-430c-9f3a-888c8cf4e452"
      unitRef="cad">460724</ifrs-full:CashOutflowForLeases>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzQtMS0xLTEtMTcyNzE_4c905472-7372-4ecb-acfa-16f5f5e4a7fc"
      unitRef="cad">91727</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzMtMS0xLTEtODEyMQ_3edb7fe8-55db-40f1-8c56-e355d7f64330"
      unitRef="cad">68526</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <oncyf:GainsLossesFromForeignExchangeImpact
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzUtMS0xLTEtMTcyNzE_ba7b60d5-4457-4e8c-97b1-c99b1af2c75c"
      unitRef="cad">-1173</oncyf:GainsLossesFromForeignExchangeImpact>
    <oncyf:GainsLossesFromForeignExchangeImpact
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzQtMS0xLTEtODEyMQ_fb344277-1d0e-4558-a67b-bce496240dc0"
      unitRef="cad">-9391</oncyf:GainsLossesFromForeignExchangeImpact>
    <ifrs-full:LeaseLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzYtMS0xLTEtMTcyNzE_cdabf258-25de-40ed-b712-1aa5e66dd115"
      unitRef="cad">654753</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTo1ZTE2MGQ3ODFlN2I0MDYyOTI3ZmNiMzBiOTdjYTg5ZC90YWJsZXJhbmdlOjVlMTYwZDc4MWU3YjQwNjI5MjdmY2IzMGI5N2NhODlkXzUtMS0xLTEtODEyMQ_fb15907d-8403-451f-b5f5-3e56171bd310"
      unitRef="cad">402059</ifrs-full:LeaseLiabilities>
    <ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90ZXh0cmVnaW9uOjdjNTU3MGFlZmMwNDQ5Y2NhMmRhMGFhMTc0ZjZhNDI0XzkyMg_993bbb70-d753-4d2c-be20-60d0312ddc7e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our total undiscounted lease liability as at December&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More than five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liability &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i88fbac179750483d8af64e04435a79bf_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTowYTBhMjkxYmJlNDk0OWFhYWNjMTcyMTQzYTkwOWU4Ni90YWJsZXJhbmdlOjBhMGEyOTFiYmU0OTQ5YWFhY2MxNzIxNDNhOTA5ZTg2XzItMS0xLTEtODEyMQ_011eaa78-d940-458c-a964-9cb22a2f4e37"
      unitRef="cad">372707</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="ic7dc0ed2ed7547d89fd4e3e287348bd7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTowYTBhMjkxYmJlNDk0OWFhYWNjMTcyMTQzYTkwOWU4Ni90YWJsZXJhbmdlOjBhMGEyOTFiYmU0OTQ5YWFhY2MxNzIxNDNhOTA5ZTg2XzMtMS0xLTEtODEyMQ_6c4788dc-c352-4777-89f0-3b2320909516"
      unitRef="cad">434936</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i22879de6b8fa44818a5c41e8a35f3c84_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTowYTBhMjkxYmJlNDk0OWFhYWNjMTcyMTQzYTkwOWU4Ni90YWJsZXJhbmdlOjBhMGEyOTFiYmU0OTQ5YWFhY2MxNzIxNDNhOTA5ZTg2XzQtMS0xLTEtODEyMQ_b13c15d3-e91a-4819-adff-60f46063b5d1"
      unitRef="cad">0</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTQvZnJhZzo3YzU1NzBhZWZjMDQ0OWNjYTJkYTBhYTE3NGY2YTQyNC90YWJsZTowYTBhMjkxYmJlNDk0OWFhYWNjMTcyMTQzYTkwOWU4Ni90YWJsZXJhbmdlOjBhMGEyOTFiYmU0OTQ5YWFhY2MxNzIxNDNhOTA5ZTg2XzUtMS0xLTEtODEyMQ_c2691731-59e0-472f-831d-c105f8a2aca3"
      unitRef="cad">807643</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzIxODQ_9bea491c-7baa-4c9a-ab86-dcee6ee25b8d">Warrant Derivative&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share and one common share purchase warrant (see Note 9). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under IFRS 9 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and IAS 32 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments: Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of US$0.90 meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the change in fair value of the warrant derivative is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of Warrant Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,508,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,418,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,636,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,491,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(455,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56,017&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we received cash proceeds of US$181,550 (2020 - US$1,276,532; 2019 - US$2,642,082) with respect to the warrants exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the warrant derivative at December&#160;31 was determined using the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$1.57&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underlying share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.38&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.39%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected hold period to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <oncyf:IssueOfEquityShares
      contextRef="i32540143275947cf9a999007e5c89d46_D20190816-20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzk4_752bd731-7085-469b-bb55-f286d7ebdd23"
      unitRef="shares">4619773</oncyf:IssueOfEquityShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i60804d42d4e24611b5b61485d0a443bf_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzE0MA_03112f2f-64f7-443d-be2e-914aca8de56d"
      unitRef="usdPerShare">0.81</oncyf:SharesIssuedPricePerShare1>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i32540143275947cf9a999007e5c89d46_D20190816-20190816"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzE3NA_b99e54ce-b39b-4ff9-b3ef-e1296d070792"
      unitRef="usd">3742016</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:CommonSharesPerUnit
      contextRef="i3d6b7c66a4fc4f108fb4d53193ce2035_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzE5Nw_8c980f64-1e9e-4e4a-9831-40c8773b392f"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:CommonSharesPerUnit
      contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzIxNw_e61658fd-b24d-4b50-8362-bb8508737b26"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1
      contextRef="i60804d42d4e24611b5b61485d0a443bf_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzMzMQ_147ad134-6f61-4741-a532-32e9bd482763"
      unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
    <oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2
      contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzM3MQ_ca6ec6d7-d600-4866-ac8e-ac18b3acb7e8"
      unitRef="usdPerShare">0.90</oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2>
    <oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2
      contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzc1Nw_8028c35e-6583-4d04-b514-a9da3473be3d"
      unitRef="usdPerShare">0.90</oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzIxODU_5b40a2d2-2403-4bcd-a1a6-3b6e6c4feba4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the change in fair value of the warrant derivative is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of Warrant Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,508,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,418,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,636,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,491,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(455,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56,017&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the warrant derivative at December&#160;31 was determined using the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$1.57&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underlying share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.38&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.39%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected hold period to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <oncyf:ClassOfWarrantOrRightOutstanding1
      contextRef="i29a8a4e95e79475ba60e7ba7d35e2cf9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzEtMS0xLTEtODEyMQ_a0644d1d-1168-45b6-9742-32aa760174d2"
      unitRef="shares">1684126</oncyf:ClassOfWarrantOrRightOutstanding1>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="i29a8a4e95e79475ba60e7ba7d35e2cf9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzEtMi0xLTEtODEyMQ_6e09538b-42c8-4f9d-909f-1577df72dd6d"
      unitRef="cad">8508764</oncyf:WarrantsAndRightsOutstanding1>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzItMS0xLTEtODEyMQ_9b4c7e52-2566-4190-a98b-173f5dabc7cb"
      unitRef="shares">1418369</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:ClassofWarrantorRightWarrantsExercised
      contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzItMi0xLTEtODEyMQ_1a11a720-c0e7-4d92-a4bd-fca5b874ac07"
      unitRef="cad">4636317</oncyf:ClassofWarrantorRightWarrantsExercised>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzMtMi0xLTEtODEyMQ_619645ba-ea0e-4666-9e32-2d6bf1206fbb"
      unitRef="cad">-3491928</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <oncyf:GainsLossesFromForeignExchangeImpact
      contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzQtMi0xLTEtODEyMQ_6ec76adf-3198-42d2-b032-1998a880c794"
      unitRef="cad">150709</oncyf:GainsLossesFromForeignExchangeImpact>
    <oncyf:ClassOfWarrantOrRightOutstanding1
      contextRef="i76b8dc9ee72c4d6e999cf36c6458c7f1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzUtMS0xLTEtODEyMQ_488db619-e75c-471e-b90c-12560393fdf3"
      unitRef="shares">265757</oncyf:ClassOfWarrantOrRightOutstanding1>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="i76b8dc9ee72c4d6e999cf36c6458c7f1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzUtMi0xLTEtODEyMQ_8e99c2eb-3881-4a4b-9e9a-e435349db3e5"
      unitRef="cad">531228</oncyf:WarrantsAndRightsOutstanding1>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzYtMS0xLTEtODEyMQ_85e5ffbe-bfb1-499e-83ff-051c61eddea4"
      unitRef="shares">201722</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:ClassofWarrantorRightWarrantsExercised
      contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzYtMi0xLTEtODEyMQ_94e44db9-ae86-4d41-afa7-3a4f1cd78c98"
      unitRef="cad">455670</oncyf:ClassofWarrantorRightWarrantsExercised>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzctMi0xLTEtODEyMQ_7cb86b39-394f-4e92-bde6-9bdd58088559"
      unitRef="cad">-17117</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <oncyf:GainsLossesFromForeignExchangeImpact
      contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzgtMi0xLTEtODEyMQ_f878f762-7aa4-4db0-aab1-a5c712c168ab"
      unitRef="cad">-2424</oncyf:GainsLossesFromForeignExchangeImpact>
    <oncyf:ClassOfWarrantOrRightOutstanding1
      contextRef="idfae6e354e8248509fd71f314f2f7bb7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzktMS0xLTEtODEyMQ_ecbc3782-4bdd-461f-9815-2432bc8ff87b"
      unitRef="shares">64035</oncyf:ClassOfWarrantOrRightOutstanding1>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="idfae6e354e8248509fd71f314f2f7bb7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo0ZDM1ZmZlZDZiNzA0Y2U4YmVhZmU5ZGU5YzJlYzY0YS90YWJsZXJhbmdlOjRkMzVmZmVkNmI3MDRjZThiZWFmZTlkZTljMmVjNjRhXzktMi0xLTEtODEyMQ_c8d54944-f9b9-4651-9c24-9ddc74074be1"
      unitRef="cad">56017</oncyf:WarrantsAndRightsOutstanding1>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzE1MzA_04c5be87-7b02-4519-9303-284428809dd0"
      unitRef="usd">181550</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzE1Mzk_2c1bfaca-83f3-45fb-a9aa-a22dc5b972e7"
      unitRef="usd">1276532</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90ZXh0cmVnaW9uOjRmNTA0MGJiMmZjOTQ5N2I4MGZkZTAzYWRmNTRlNWMxXzEwOTk1MTE2Mjk5OTA_9f6477fd-4397-46fb-bace-012e7cee1ef4"
      unitRef="usd">2642082</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:FairValueofWarrantIssuedPerWarrant
      contextRef="idfae6e354e8248509fd71f314f2f7bb7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzEtMS0xLTEtODEyMQ_c3ef961a-b1ad-49a8-8a4b-fe7366f0b77a"
      unitRef="usdPerShare">0.69</oncyf:FairValueofWarrantIssuedPerWarrant>
    <oncyf:FairValueofWarrantIssuedPerWarrant
      contextRef="i76b8dc9ee72c4d6e999cf36c6458c7f1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzEtMi0xLTEtODEyMQ_e5768764-0c31-4315-b12b-f5429288d899"
      unitRef="usdPerShare">1.57</oncyf:FairValueofWarrantIssuedPerWarrant>
    <oncyf:WarrantIssuedUnderlyingSharePrice
      contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzItMS0xLTEtODEyMQ_47d8466a-d80c-44d6-bf71-71830db5186c"
      unitRef="usdPerShare">1.39</oncyf:WarrantIssuedUnderlyingSharePrice>
    <oncyf:WarrantIssuedUnderlyingSharePrice
      contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzItMi0xLTEtODEyMQ_1f3dbe19-1d97-4dd9-be22-b7f8d7f390cd"
      unitRef="usdPerShare">2.38</oncyf:WarrantIssuedUnderlyingSharePrice>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzMtMS0xLTEtODEyMQ_bff97ea4-7084-4df0-a27a-6a40fe6f8220"
      unitRef="number">0.0039</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzMtMi0xLTEtODEyMQ_5eaa8ac6-f79f-42a7-97c0-b93ad14c769b"
      unitRef="number">0.0010</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzQtMS0xLTEtODEyMQ_65d87719-4063-42b5-9835-dfa38fe1dada"
      unitRef="year">1.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzQtMi0xLTEtODEyMQ_35946c4c-5c55-4bcb-a27b-6149a43d9324"
      unitRef="year">1.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzUtMS0xLTEtODEyMQ_ed700f6b-2aba-4a35-a09b-ee1ddd191923"
      unitRef="number">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzUtMi0xLTEtODEyMQ_fed9dc02-5ccb-4fa4-83ea-52b30d2cadc4"
      unitRef="number">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <oncyf:DividendYieldPercent
      contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzYtMS0xLTEtODEyMQ_0fc6ba14-9e8a-4c7f-bd4e-11fabc1d94d6"
      unitRef="number">0</oncyf:DividendYieldPercent>
    <oncyf:DividendYieldPercent
      contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNTcvZnJhZzo0ZjUwNDBiYjJmYzk0OTdiODBmZGUwM2FkZjU0ZTVjMS90YWJsZTo3MDhjN2EzZDBhNzc0NjUxODVmNWRmZjY2ZGRiYjU5Yy90YWJsZXJhbmdlOjcwOGM3YTNkMGE3NzQ2NTE4NWY1ZGZmNjZkZGJiNTljXzYtMi0xLTEtODEyMQ_91d5e331-ac3e-4074-b8d2-81393d2aa8ab"
      unitRef="number">0</oncyf:DividendYieldPercent>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzYwMDQ_1744418e-7399-48e5-8f95-3698530e0f62">Share Capital&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Authorized:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unlimited number of no par value common shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,399,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,193,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to Common Stock Purchase Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,425,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,476,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,619,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,935,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,152,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(854,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,198,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,077,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,182,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,037,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,332,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,741,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,166,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,824,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,401,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,168,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,256,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;55,043,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;391,348,183&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. This agreement expired in 2021, and no common shares were issued during 2021 and 2020. In 2019, we sold 2,477,665 common shares for gross proceeds of US$4,055,725 and issued 17,278 commitment shares. The commitment shares were fair valued at US$29,758 and were recorded as share issue costs in addition to cash share issue costs of $3,757.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement expired on June 4, 2020 and no common shares were issued during 2021. In 2020, we sold 6,741,518 (2019 - 4,425,040) common shares for gross proceeds of  US$17,538,342 (2019 - US$6,390,691) at an average price of US$2.42 (2019 - US$1.70). We received, net of commissions of US$526,150 (2019 - US$191,721), proceeds of US$17,012,192 (2019 - US$6,198,970). In total, we incurred share issue costs (including commissions) of $856,754 (2019 - $344,834). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. In 2021, our share capital included fair value of $455,670 (2020 - $4,636,317; 2019 - $5,687,003) in addition to gross proceeds of US$181,550 (2020 &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- US$1,276,532; 2019 - US$2,642,082) for the 201,722 (2020 - 1,418,369; 2019 - 2,935,647) warrants that were exercised (see Note 8). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market price, with an aggregate offering value of up US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2021, we sold 5,685,097 (2020 - 5,441,014) common shares for gross proceeds of US$18,503,188 (2020 - US$12,628,775) at an average price of US$3.25 (2020 - US$2.11). We received, net of commissions of US$555,096 (2020 - US$378,863), proceeds of US$17,948,092 (2020 - US$12,249,911). In total, we incurred share issue costs (including commissions) of $707,421 (2020 - $884,886). On March 4, 2021, we terminated the June 15, 2020 ATM equity distribution agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. In 2021, we sold 2,715,932 common shares for gross proceeds of US$8,654,892 at an average price of US$3.19. We received, net of commissions of US$259,647, proceeds of US$8,395,245. In total, we incurred share issue costs (including commissions) of $548,859. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold for gross proceeds of $11,511,500. Each unit included one common share and one common share purchase warrant. Following the 2018 share consolidation, 9.5 common share purchase warrants entitled the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. These warrants were classified as equity. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our outstanding equity warrants: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,443,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,617,570&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Exercisable into 1,730,894 common shares.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzYwMTc_12e6ab12-c4f9-49d0-97f2-36dab8146fdd">&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,399,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,193,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to Common Stock Purchase Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,425,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,476,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,619,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,935,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,152,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(854,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,198,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,077,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,182,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,037,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,332,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,741,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,166,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,824,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,401,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,168,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,256,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;55,043,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;391,348,183&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. This agreement expired in 2021, and no common shares were issued during 2021 and 2020. In 2019, we sold 2,477,665 common shares for gross proceeds of US$4,055,725 and issued 17,278 commitment shares. The commitment shares were fair valued at US$29,758 and were recorded as share issue costs in addition to cash share issue costs of $3,757.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement expired on June 4, 2020 and no common shares were issued during 2021. In 2020, we sold 6,741,518 (2019 - 4,425,040) common shares for gross proceeds of  US$17,538,342 (2019 - US$6,390,691) at an average price of US$2.42 (2019 - US$1.70). We received, net of commissions of US$526,150 (2019 - US$191,721), proceeds of US$17,012,192 (2019 - US$6,198,970). In total, we incurred share issue costs (including commissions) of $856,754 (2019 - $344,834). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. In 2021, our share capital included fair value of $455,670 (2020 - $4,636,317; 2019 - $5,687,003) in addition to gross proceeds of US$181,550 (2020 &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- US$1,276,532; 2019 - US$2,642,082) for the 201,722 (2020 - 1,418,369; 2019 - 2,935,647) warrants that were exercised (see Note 8). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market price, with an aggregate offering value of up US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2021, we sold 5,685,097 (2020 - 5,441,014) common shares for gross proceeds of US$18,503,188 (2020 - US$12,628,775) at an average price of US$3.25 (2020 - US$2.11). We received, net of commissions of US$555,096 (2020 - US$378,863), proceeds of US$17,948,092 (2020 - US$12,249,911). In total, we incurred share issue costs (including commissions) of $707,421 (2020 - $884,886). On March 4, 2021, we terminated the June 15, 2020 ATM equity distribution agreement.&lt;/span&gt;&lt;/div&gt;(e)On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. In 2021, we sold 2,715,932 common shares for gross proceeds of US$8,654,892 at an average price of US$3.19. We received, net of commissions of US$259,647, proceeds of US$8,395,245. In total, we incurred share issue costs (including commissions) of $548,859.</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="iedc65d68837a4eacac34675a1cd9779e_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE1LTEtMS0xLTgxMjE_e264a366-3fc8-437f-acf5-6ddf874d1285"
      unitRef="shares">17399749</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="iedc65d68837a4eacac34675a1cd9779e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE1LTItMS0xLTgxMjE_101d1cef-d9d7-4903-b4f1-86a872c22b46"
      unitRef="cad">285193061</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="i830cca3a0f664a4d8b3b50a1c284e3b4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE2LTEtMS0xLTgxMjE_857fd0d1-4891-4419-a4d0-a69803fe1ee5"
      unitRef="shares">323301</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i830cca3a0f664a4d8b3b50a1c284e3b4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE2LTItMS0xLTgxMjE_773ffe3e-9350-4128-85bb-112008f00d46"
      unitRef="cad">391917</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i7bed414ac6874a10b56efb160637b31e_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE3LTEtMS0xLTgxMjE_1720b9ba-ea0b-409a-ae34-f925ed27866c"
      unitRef="shares">2494943</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i7bed414ac6874a10b56efb160637b31e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE3LTItMS0xLTgxMjE_f045447c-e61b-4de5-aaa5-27915180ba0f"
      unitRef="cad">5403385</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="ie3a11c0f144e4ff3a325f5a105f0f4d1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE4LTEtMS0xLTgxMjE_b55659c4-dc30-4be6-83fe-99e57a19fa40"
      unitRef="shares">4425040</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="ie3a11c0f144e4ff3a325f5a105f0f4d1_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE4LTItMS0xLTgxMjE_f6651f5d-a84e-4fcc-b89a-db46b7347f35"
      unitRef="cad">8476454</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i83e860d0f0a34191b33af656961cbc19_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE5LTEtMS0xLTgxMjE_86865673-015c-438c-97d6-5a21168c6cfe"
      unitRef="shares">4619773</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i83e860d0f0a34191b33af656961cbc19_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE5LTItMS0xLTgxMjE_d19e500e-9195-4d17-9746-6751e01435cc"
      unitRef="cad">3314429</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="idae5479b6b654d84bb1c05fde1394dd8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIwLTEtMS0xLTgxMjE_f3ff2a24-8c8e-40b4-a0f3-3fb52b221268"
      unitRef="shares">2935647</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="idae5479b6b654d84bb1c05fde1394dd8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIwLTItMS0xLTgxMjE_5e0a4166-95ae-41d2-9272-512b20a1b72d"
      unitRef="cad">9152869</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i7e5a099158d84fb599da0d92dcc26605_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIxLTItMS0xLTgxMjE_e4d16255-d401-4798-a8e0-d7f35449a17f"
      unitRef="cad">854256</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued
      contextRef="i11b4be78aa4f47c695bf177fab865a55_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIyLTEtMS0xLTgxMjE_6b57ed1e-ae15-4997-bef8-dd210c958cf6"
      unitRef="shares">32198453</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="i11b4be78aa4f47c695bf177fab865a55_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIyLTItMS0xLTgxMjE_1073ead0-39b6-4913-98de-a9c6d0c20b4c"
      unitRef="cad">311077859</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="i1ab215a79e4441f2b018c7706826735d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIzLTEtMS0xLTgxMjE_fd025f5f-3e66-4041-9ee1-7d805142c33f"
      unitRef="shares">133454</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i1ab215a79e4441f2b018c7706826735d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIzLTItMS0xLTgxMjE_644c7cd5-2d41-477a-865b-51ff11b5a14f"
      unitRef="cad">385022</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i7ce569aab88d48369c11f14c0bf78a25_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI0LTEtMS0xLTgxMjE_96714005-030d-4eed-8144-5ae824ec90f8"
      unitRef="shares">234172</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i7ce569aab88d48369c11f14c0bf78a25_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI0LTItMS0xLTgxMjE_7d676b63-2777-43be-a7b4-feccdc42d321"
      unitRef="cad">732367</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="ia7c46f6b7f524d1387c1a6b6fe9dfa39_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI1LTEtMS0xLTgxMjE_729b3303-62e7-4fd7-88a6-a5e5e259a528"
      unitRef="shares">12182532</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="ia7c46f6b7f524d1387c1a6b6fe9dfa39_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI1LTItMS0xLTgxMjE_1a106cf3-83ff-4a88-9bd8-f0a9d8d49dbc"
      unitRef="cad">40037786</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i78884fc7ad21406cb0e0bd491aad0b54_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI2LTEtMS0xLTgxMjE_a7bc3c3a-2422-4604-b5b4-ddaa04780ce0"
      unitRef="shares">1418369</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i78884fc7ad21406cb0e0bd491aad0b54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI2LTItMS0xLTgxMjE_963d3b57-c126-433a-ba96-07d9d8359175"
      unitRef="cad">6332778</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ib6968307567a4ac88a5fbac883bf6779_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI3LTItMS0xLTgxMjE_3b98a8e1-1fe0-4549-a2af-2d1db4eff2d9"
      unitRef="cad">1741640</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued
      contextRef="i7204566da8c8413784114e3a0277f22b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI4LTEtMS0xLTgxMjE_f13fe8ec-5ec1-44eb-a310-77a2d562d93e"
      unitRef="shares">46166980</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="i7204566da8c8413784114e3a0277f22b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzI4LTItMS0xLTgxMjE_73779a5a-d97a-429a-b0d4-190ece368db9"
      unitRef="cad">356824172</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="i313db08027ee47b8a313714b551d5295_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE2LTEtMS0xLTkzODE_9582d844-4c6b-4197-a789-0b99854f7ae6"
      unitRef="shares">123159</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i313db08027ee47b8a313714b551d5295_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE2LTItMS0xLTkzODE_f914cc54-ebcd-4e70-baea-657b333742c4"
      unitRef="cad">381771</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="ie790de8f351b420c97389308ec3102f1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE3LTEtMS0xLTkzODE_c028e1f5-050f-4989-b282-da8ae21a4c63"
      unitRef="shares">150899</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="ie790de8f351b420c97389308ec3102f1_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE3LTItMS0xLTkzODE_b9b22efd-d86f-48e2-8333-bd2421548b90"
      unitRef="cad">543833</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i8d55af5d6889492ba6feaef6f3089cbb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE4LTEtMS0xLTkzODE_3a310245-f232-45c0-aa94-6d0ee2d7bebb"
      unitRef="shares">8401029</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i8d55af5d6889492ba6feaef6f3089cbb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE4LTItMS0xLTkzODE_fc843aca-51f3-4c7a-82f6-672f8a0a6104"
      unitRef="cad">34168071</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i1068e88a4ef24a30afc676a512075718_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE5LTEtMS0xLTkzODE_1c0e9605-4821-414f-9fd8-9206ebbfbe43"
      unitRef="shares">201722</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i1068e88a4ef24a30afc676a512075718_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzE5LTItMS0xLTkzODE_7587ac2e-bd1d-42f5-ba24-891782661329"
      unitRef="cad">686616</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="id057bd4ec78a491094f4618144a1c09d_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIwLTItMS0xLTkzODE_af91e879-f79b-41b4-bce9-e770c097dadd"
      unitRef="cad">1256280</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued
      contextRef="ic3a75af6263f486894cd6657c4bd2464_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIxLTEtMS0xLTkzODg_5902aae4-4def-423e-a578-b8f32e92eb02"
      unitRef="shares">55043789</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="ic3a75af6263f486894cd6657c4bd2464_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTo1NWMwMjFlOWJiNDE0NDc1YTEyODEzNjk4ZTZkODZhZC90YWJsZXJhbmdlOjU1YzAyMWU5YmI0MTQ0NzVhMTI4MTM2OThlNmQ4NmFkXzIxLTItMS0xLTkzODg_84ff7785-022a-4788-9617-1d39292d636a"
      unitRef="cad">391348183</ifrs-full:Equity>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="i2902b2520fea41089f98be9b8eace36f_I20180927"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzE2OTE_a6de4b64-ef55-4c78-9525-1d147f5cf3a7"
      unitRef="usd">26000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm
      contextRef="ifdc041cff18445c2bf6a95ff95de581f_D20180927-20180927"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzI3NDg3NzkwNzk1NDM_190ff63d-5ecf-4409-9a69-daff4925bd4e">P30M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="i67283f9ed1904a3db011f7a4a67ddd74_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2Mzc4MjI_c1845e2c-ff55-4de0-ba69-c795c83b3660"
      unitRef="shares">0</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="i5f476ff70c064f36b090da63b6c25511_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2Mzc4MjI_e16bbac7-5e2d-4ed1-8ae2-58948598c09a"
      unitRef="shares">0</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="i070d85f1ae5c470e839378eff83c30b7_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzMwODk_eb006432-7d98-4304-a689-624287a9b24d"
      unitRef="shares">2477665</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i070d85f1ae5c470e839378eff83c30b7_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzMxNDg_e00eeaf7-1f39-4fe2-ba78-04cb7b5aeace"
      unitRef="usd">4055725</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:IssueOfEquityShares
      contextRef="ifb21fdd6d32d40719bcec4f80757184e_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzMxODE_7880fbc9-c1e4-4569-9094-b27f298fd76f"
      unitRef="shares">17278</oncyf:IssueOfEquityShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ifb21fdd6d32d40719bcec4f80757184e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzMyNjQ_36de5375-d241-41fd-b246-0a6eeebb4fbe"
      unitRef="usd">29758</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="ifb21fdd6d32d40719bcec4f80757184e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzMzNjY_b4157130-22f2-4ea0-aee5-957180ed2558"
      unitRef="cad">3757</ifrs-full:PaymentsForShareIssueCosts>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="ieef3c4b044f443248ece0ef8dc3ac073_I20181024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM2MTY_23a633a3-8d3d-4f16-bee4-8af9993655ef"
      unitRef="usd">30000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm
      contextRef="i8604cae19b054cb08c0871ae11d35ebd_D20181024-20181024"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzYwMTg_dc2f3775-9542-4cbb-a3d1-2cf1e257ad02">P19M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="ie179742cb9f841999fd8416ad5ecaf64_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2Mzc4MzY_4e24b14c-335a-49b1-8eed-a3f4102705a5"
      unitRef="shares">0</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM3NDA_ab5ab52e-8eeb-475b-80ff-16e2f1b65b99"
      unitRef="shares">6741518</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM3NDk_6775977d-60b7-4353-9746-94fca4a31977"
      unitRef="shares">4425040</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM3OTg_4418bf5b-0e2a-4858-9e3b-2f5bd19129ba"
      unitRef="usd">17538342</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM4MDc_549e7e69-ebd6-400c-9673-c4665688e4a1"
      unitRef="usd">6390691</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i3e6b52351e9440c6a782ff3ab4b4b8f5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM4NDM_b5c60d0a-4e21-491f-a52a-79f5e20d0974"
      unitRef="usdPerShare">2.42</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i32cccb978d9e4fdbb89e459a307b27ea_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM4NTI_dced3bc1-a6df-4013-9979-bdc8937e5d7a"
      unitRef="usdPerShare">1.70</oncyf:SharesIssuedPricePerShare1>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM5MDE_7f8d2015-d573-45f9-ad07-fb5d85342116"
      unitRef="usd">526150</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM5MTA_85761219-0120-4b6b-b9bd-06cad9c95907"
      unitRef="usd">191721</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM5MzY_251bf632-ec83-42e4-8dc7-1a82785fabfb"
      unitRef="usd">17012192</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzM5NDU_0c3715c6-3465-46bc-8656-0d66360c5d38"
      unitRef="usd">6198970</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i4699adcc4bda418995f52f8cc778b12c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQwMjY_d9e309aa-1d8d-4e82-807f-f28141547342"
      unitRef="cad">856754</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ie4ab3b17c515463fa8c3e3e1f68b2516_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQwMzU_5ff451d0-accb-45dd-a8ae-445f1cbe7a68"
      unitRef="cad">344834</ifrs-full:ShareIssueRelatedCost>
    <oncyf:IssueOfEquityShares
      contextRef="i32540143275947cf9a999007e5c89d46_D20190816-20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQxNTM_906d2534-3524-4285-b9eb-8cde4ec8cfa7"
      unitRef="shares">4619773</oncyf:IssueOfEquityShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i60804d42d4e24611b5b61485d0a443bf_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQxOTU_3b960002-0751-4dc8-b8e7-241bd569dd8c"
      unitRef="usdPerShare">0.81</oncyf:SharesIssuedPricePerShare1>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i32540143275947cf9a999007e5c89d46_D20190816-20190816"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQyMjk_736a6b81-2abd-4720-9a9e-2538d1cc6bc7"
      unitRef="usd">3742016</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:CommonSharesPerUnit
      contextRef="i3d6b7c66a4fc4f108fb4d53193ce2035_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQyNTI_1d5b2ae3-1094-4a61-b4a6-721a99ba04af"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:SharesIssuedFairValueOfCommonShare
      contextRef="i3d6b7c66a4fc4f108fb4d53193ce2035_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQyODk_dacf456e-d277-48bd-a60f-2af80f3d6b9a"
      unitRef="usdPerShare">0.54</oncyf:SharesIssuedFairValueOfCommonShare>
    <oncyf:CommonSharesPerUnit
      contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQyOTY_e985ef04-67fb-4ae5-90a4-1ca5615890d2"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:SharesIssuedFairValueOfCommonShare
      contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQzNTA_4293b5f4-6895-42a3-b0e5-113d5ac38d18"
      unitRef="usdPerShare">0.27</oncyf:SharesIssuedFairValueOfCommonShare>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1
      contextRef="i60804d42d4e24611b5b61485d0a443bf_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ0OTE_c8f5e5c1-001b-4fb9-a634-f21c85d5fe43"
      unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
    <oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2
      contextRef="ibf3fe505e96845b69a4d9d88e6f269eb_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ1MzE_2298fbde-28b7-4b2a-bc2d-b435cff02a63"
      unitRef="usdPerShare">0.90</oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i32540143275947cf9a999007e5c89d46_D20190816-20190816"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ1OTA_79d8a1bd-4282-4515-a1fe-cdfa3e3caeeb"
      unitRef="cad">699427</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i8764aff5c6754164b0bd8ea7f5a1155f_D20190816-20190816"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ2MDI_06008078-ee99-4b1b-8b13-ea1ebada89c9"
      unitRef="cad">466284</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i249c2d938ccb432fbaf49910859f86b3_D20190816-20190816"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ2NDU_0f729046-37b8-41f8-b803-68721eee5d14"
      unitRef="cad">233143</ifrs-full:ShareIssueRelatedCost>
    <oncyf:ClassofWarrantorRightWarrantsExercised
      contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ3NzE_867e333e-67d6-4948-bce5-aa2196a1a7a5"
      unitRef="cad">455670</oncyf:ClassofWarrantorRightWarrantsExercised>
    <oncyf:ClassofWarrantorRightWarrantsExercised
      contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ3ODA_1a11a720-c0e7-4d92-a4bd-fca5b874ac07"
      unitRef="cad">4636317</oncyf:ClassofWarrantorRightWarrantsExercised>
    <oncyf:ClassofWarrantorRightWarrantsExercised
      contextRef="icc5c0ca931d74739a3b6246850a2c5de_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU4MzI_819d5e88-aadb-4959-a74a-a30dc6c9128e"
      unitRef="cad">5687003</oncyf:ClassofWarrantorRightWarrantsExercised>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ4MTc_04c5be87-7b02-4519-9303-284428809dd0"
      unitRef="usd">181550</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ4MjY_2c1bfaca-83f3-45fb-a9aa-a22dc5b972e7"
      unitRef="usd">1276532</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU4NjY_9f6477fd-4397-46fb-bace-012e7cee1ef4"
      unitRef="usd">2642082</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="i8b523b39298241d5a55a5bd6358d49b7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ4Mzg_0201cc2e-0602-4942-9ec0-80022e7e836c"
      unitRef="shares">201722</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="i64412a8e195c453b95c3f5b28fd12bf9_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzQ4NDc_9b4c7e52-2566-4190-a98b-173f5dabc7cb"
      unitRef="shares">1418369</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="icc5c0ca931d74739a3b6246850a2c5de_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU4NzE_42f80d48-c695-4a6c-8d64-a2d81eb7805c"
      unitRef="shares">2935647</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="i445f25b6895b4f3a9e8820470f449122_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUxMjk_1472a87a-48f5-40fa-9056-676656a9ebb8"
      unitRef="usd">40000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm
      contextRef="i6952840e54e1456a84822c9606b3c424_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzYwMDk_157f660c-9ec9-4024-89bb-e8296318013c">P25M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5Mjc_f0bc472d-9d20-4322-8d35-40cc3afaed05"
      unitRef="shares">5685097</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="ie82286507f1648e4b150250e27787981_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUyNDQ_2f07a4fd-062f-4f3c-82bc-09fb92235413"
      unitRef="shares">5441014</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5MzE_36308bdd-6962-4a0b-a663-300329cbe30a"
      unitRef="usd">18503188</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="ie82286507f1648e4b150250e27787981_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUyODM_5daec418-0eef-44e5-9b50-c736dec87191"
      unitRef="usd">12628775</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="id09b9d3dab2a4150999c1ca5b995feac_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5MzY_0ec3c687-c6af-4933-954b-52f69a8050d0"
      unitRef="usdPerShare">3.25</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i4f6e4d5e9ea74cf5ab41ddd51549cf33_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUzMDk_9b852b18-f08b-4345-b12d-fd66f7cd2682"
      unitRef="usdPerShare">2.11</oncyf:SharesIssuedPricePerShare1>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5NDE_f1cb7dc5-a524-45e4-a3e6-2f7080d4af06"
      unitRef="usd">555096</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="ie82286507f1648e4b150250e27787981_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUzNDg_a8a07f38-7438-4d37-bd9d-295d1d861670"
      unitRef="usd">378863</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5NDY_d75aaa44-bf05-46da-a1c6-c0e88070dc54"
      unitRef="usd">17948092</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="ie82286507f1648e4b150250e27787981_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzUzNjQ_a3ac1c3e-5018-48f7-b6ae-32c712f61dab"
      unitRef="usd">12249911</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i96d9ad21766c47d3b0ffa7740fa1df30_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzU5NTE_a93fcc92-23af-4a87-b61a-39f4cb8c6dae"
      unitRef="cad">707421</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ie82286507f1648e4b150250e27787981_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU0MzU_4f9b7451-47fa-49ed-b22c-976cc79181db"
      unitRef="cad">884886</ifrs-full:ShareIssueRelatedCost>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="i6dd8b35d2c3f4ace9728ec15e62387d6_I20210305"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzYzMDE_bc2730e6-85da-41e8-93cf-75ddd363c682"
      unitRef="usd">80000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm
      contextRef="if6351d06a26d494f80f99bf946853adb_D20210305-20210305"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzI3NDg3NzkwNzk1NDI_62125743-17c9-4e82-b238-1f913580fd09">P16M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="i4ede084a4122418cb65982299416868e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY0ODM_addfe673-6f89-4c2c-abb1-5a9c13f07de3"
      unitRef="shares">2715932</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i4ede084a4122418cb65982299416868e_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY1Mjc_c951ad36-695c-49f0-aee4-f763ee3bf08f"
      unitRef="usd">8654892</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i0bd694e01e0d4b7bb354e73aa065b8bb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY1NTc_5adfa366-5ca2-4210-88b7-ec4811a86bd5"
      unitRef="usdPerShare">3.19</oncyf:SharesIssuedPricePerShare1>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="i4ede084a4122418cb65982299416868e_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY1OTk_9b54025e-93ee-4e74-941a-9bc1f296c6a1"
      unitRef="usd">259647</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i4ede084a4122418cb65982299416868e_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY2Mjk_3407dce9-03b7-49b6-bddb-3e117dc7223d"
      unitRef="usd">8395245</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i4ede084a4122418cb65982299416868e_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzEwOTk1MTE2MzY3MDg_7c4570e5-7fa2-40c4-8b13-2ade38d15d4d"
      unitRef="cad">548859</ifrs-full:ShareIssueRelatedCost>
    <oncyf:IssueOfEquityShares
      contextRef="i12d8b8a2f06d4c838611847df4e4d947_D20170601-20170601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU1MjY_a89d81fb-5996-4946-a768-d952abfc7c6a"
      unitRef="shares">16445000</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i12d8b8a2f06d4c838611847df4e4d947_D20170601-20170601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU1Njc_3500f0bd-63fd-4459-a52e-87531b8a070c"
      unitRef="cad">11511500</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:CommonSharesPerUnit
      contextRef="i1104cc6b33de4026a773d0273129e2f2_I20170601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU1OTA_500c36f3-bd1e-4544-b5f4-3506597fe9a4"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:CommonSharePurchaseWarrantPerUnit
      contextRef="i1104cc6b33de4026a773d0273129e2f2_I20170601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU2MTA_379de6b1-c0e7-424d-8a95-d142e90292ec"
      unitRef="shares">1</oncyf:CommonSharePurchaseWarrantPerUnit>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1
      contextRef="i1104cc6b33de4026a773d0273129e2f2_I20170601"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU2Nzk_24922ab0-5eaa-4457-bd21-29cc9865335e"
      unitRef="shares">9.5</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1
      contextRef="i1104cc6b33de4026a773d0273129e2f2_I20170601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU3NDU_f7ac3300-a755-4628-b0c5-36bca177ebda"
      unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
    <oncyf:SharesIssuedWarrantPricePerShare
      contextRef="i1104cc6b33de4026a773d0273129e2f2_I20170601"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU4NDk_70076025-7deb-4a30-ae2f-4ebdcfa9125b"
      unitRef="cadPerShare">9.025</oncyf:SharesIssuedWarrantPricePerShare>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzYwMTE_f0fce19a-a735-40b7-aec5-b5bbdb7538d3">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our outstanding equity warrants: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,443,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,617,570&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Exercisable into 1,730,894 common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.54 - $1.79&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.80 - $3.01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.02 - $3.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,982,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.91 - $7.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.42 - $40.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,334,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,165,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="ie6f80ce545f5419fa462f45df6c010da_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzQtMS0xLTEtODEyMQ_3ae5f00d-9fef-4e3a-b09f-ebc9398b1fee"
      unitRef="shares">16443500</ifrs-full:NumberOfSharesOutstanding>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzQtMi0xLTEtODEyMQ_e31d0b8f-e576-463b-bd71-ca7494e467b7"
      unitRef="cad">3617570</oncyf:WarrantsAndRightsOutstanding1>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i9eb1111616934aec84de469599269b27_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzUtMS0xLTEtODEyMQ_3e98c4af-88b9-47b6-b95d-1fcf264d681b"
      unitRef="shares">16443500</ifrs-full:NumberOfSharesOutstanding>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzUtMi0xLTEtODEyMQ_395c0baa-7b3d-41a3-894d-a50fa549eb21"
      unitRef="cad">3617570</oncyf:WarrantsAndRightsOutstanding1>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i886943a54e40452081d9137b1996e966_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzMtMS0xLTEtOTQzNg_b881adf0-77bb-4bb1-be71-1a32f5a1f4f2"
      unitRef="shares">16443500</ifrs-full:NumberOfSharesOutstanding>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90YWJsZTowYTg0YmY2ZWMzMTE0YjMwYTMxYjQwNzNmOWYwZDYzNS90YWJsZXJhbmdlOjBhODRiZjZlYzMxMTRiMzBhMzFiNDA3M2Y5ZjBkNjM1XzMtMi0xLTEtOTQzNg_f9e52150-5a0a-4458-af7e-aab08f3636ea"
      unitRef="cad">3617570</oncyf:WarrantsAndRightsOutstanding1>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjAvZnJhZzozOWZiY2QyMGNkOWE0NmNlOWFlMTIyNDU4ODQxNDk2ZC90ZXh0cmVnaW9uOjM5ZmJjZDIwY2Q5YTQ2Y2U5YWUxMjI0NTg4NDE0OTZkXzU5ODc_9399d050-3793-4f2a-b5bb-3d292b9a14ca"
      unitRef="shares">1730894</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNzA_3fcc5e31-f533-4f1f-80d7-9fb72385f39e">Share-Based Compensation&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Stock Option Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted stock options to acquire common stock through our stock option plan of which the following are outstanding at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,764,055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,832,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,817,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(110,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(123,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,334,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,764,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,165,679&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,164,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.54 - $1.79&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.80 - $3.01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.02 - $3.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,982,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.91 - $7.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.42 - $40.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,334,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,165,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option grants vest either immediately or annually over periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzM1OA_3e8a9208-2071-47f7-9434-36998b16603e"&gt;one&lt;/span&gt; to three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options granted during the year was determined using the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.66%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.34%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected hold period to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.90%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$1.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Incentive Share Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also granted RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a three-year period. The following RSUs are outstanding at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;134,618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(94,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,560&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; (1) The weighted average fair value of the RSUs granted was nil in 2021 (2020 - $2.41 ; 2019 - $0.80).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also granted PSUs to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after 3 years or vest over a three-year period, depending on the grant. The following PSUs are outstanding at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(56,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We have reserved 5,504,379 common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs for the year ended December&#160;31, 2021 was $3,825,901 (2020 - $2,558,974; 2019 - $1,470,153).</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNjY_b39e53bd-7b73-448a-8e9a-c26a922e0b4c">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted stock options to acquire common stock through our stock option plan of which the following are outstanding at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,764,055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,832,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,817,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(110,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(123,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,334,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,764,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,165,679&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,164,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItMS0xLTEtODEyMQ_0624f6b3-2a1f-4d4a-86bf-e5e843becf13"
      unitRef="shares">3764055</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItMi0xLTEtODEyMQ_5051117e-b379-4df1-af2f-28ff457ca826"
      unitRef="cadPerShare">4.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItMy0xLTEtODEyMQ_c7df73b5-2cf7-4934-bf3a-d4caa31df89d"
      unitRef="shares">2246947</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItNC0xLTEtODEyMQ_75eda1cb-924f-4623-8c50-db6849a0cf48"
      unitRef="cadPerShare">5.31</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i762faf08df5c4521a4f2689a278651e0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItNS0xLTEtODEyMQ_4414a2bd-a605-4a83-bfc6-342f64614877"
      unitRef="shares">1249361</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i762faf08df5c4521a4f2689a278651e0_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzItNi0xLTEtODEyMQ_c197562b-3f29-46d8-9618-2ff87c30fcc8"
      unitRef="cadPerShare">8.73</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtMS0xLTEtODEyMQ_59d573df-97d4-4cbc-8b96-b89893d61f48"
      unitRef="shares">1832500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtMi0xLTEtODEyMQ_84ab4ba9-2f98-4977-ad1c-19da105a1fea"
      unitRef="cadPerShare">2.99</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtMy0xLTEtODEyMQ_c6cfd6a8-e1ba-4f81-8d96-5548f9df8fd9"
      unitRef="shares">1817500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtNC0xLTEtODEyMQ_11d4d3bf-53fc-442f-bea8-2e4f2eaa0bb9"
      unitRef="cadPerShare">3.19</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtNS0xLTEtODEyMQ_ff5fe4d4-184b-4fa9-9e34-e08400ac9b6c"
      unitRef="shares">1020000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzMtNi0xLTEtODEyMQ_5bc93a50-e932-40cb-8231-720289dc9fa3"
      unitRef="cadPerShare">1.42</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtMS0xLTEtODEyMQ_7fca74ec-b663-47c8-875c-fee0b437d562"
      unitRef="shares">110612</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtMi0xLTEtODEyMQ_adddf394-a3a6-4ba9-a92e-a907e8d24b81"
      unitRef="cadPerShare">6.21</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtMy0xLTEtODEyMQ_48453b98-5cdb-4939-8de4-b559039ebc3e"
      unitRef="shares">141418</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtNC0xLTEtODEyMQ_5f19a641-e15c-446c-aa8a-2db224df4dfe"
      unitRef="cadPerShare">3.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtNS0xLTEtODEyMQ_b3ad978a-4b11-45c0-aad2-da20fd4ac22a"
      unitRef="shares">12839</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzQtNi0xLTEtODEyMQ_8296cce0-2214-4d88-8208-05a899c247e7"
      unitRef="cadPerShare">11.35</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtMS0xLTEtODEyMQ_21002b59-3dff-4153-a237-ebc5b11e834a"
      unitRef="shares">28364</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtMi0xLTEtODEyMQ_67902d3d-309c-47d7-9ab8-b1abeb56f642"
      unitRef="cadPerShare">37.63</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtMy0xLTEtODEyMQ_13d437b9-dda9-459a-97ba-fef62d02aed9"
      unitRef="shares">25520</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtNC0xLTEtODEyMQ_ac4e4ba9-f1da-4976-9a49-2b6b3b0b91d4"
      unitRef="cadPerShare">62.49</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtNS0xLTEtODEyMQ_e12ab46d-295c-4b5d-ad25-c7f13b99c487"
      unitRef="shares">9575</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzUtNi0xLTEtODEyMQ_fbacac00-6952-44ea-8b65-8004a157a6d6"
      unitRef="cadPerShare">29.07</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtMS0xLTEtODEyMQ_40a797f7-c519-4e22-ad4b-7ab39c8ee26b"
      unitRef="shares">123159</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtMi0xLTEtODEyMQ_e1adfb0c-51ea-4c09-815c-c0848f2bfd33"
      unitRef="cadPerShare">1.94</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtMy0xLTEtODEyMQ_6385555c-8178-424e-88f0-f5844c1083ab"
      unitRef="shares">133454</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtNC0xLTEtODEyMQ_fa0d4a5e-eb4a-4ed5-88e4-29aeaef2a85b"
      unitRef="cadPerShare">1.81</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtNS0xLTEtODEyMQ_3cfafdba-c6d0-4cad-a507-5e6d02ccaf80"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzYtNi0xLTEtODEyMQ_5c9e6b62-a890-4217-80a3-388d05b01bed"
      unitRef="cadPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctMS0xLTEtODEyMQ_093f89cd-4fcf-4336-9e13-ffab2eac2b57"
      unitRef="shares">5334420</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctMi0xLTEtODEyMQ_9cf5e5e9-da12-46a4-82d1-289731de461d"
      unitRef="cadPerShare">3.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctMy0xLTEtODEyMQ_dcf0d639-50a1-462a-b7ea-294ca7fc52e4"
      unitRef="shares">3764055</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctNC0xLTEtODEyMQ_711400fb-aaca-43d3-9460-08fdfc3b1502"
      unitRef="cadPerShare">4.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctNS0xLTEtODEyMQ_6848ef13-375f-41f1-91ba-af52eec1a285"
      unitRef="shares">2246947</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzctNi0xLTEtODEyMQ_c18f2c1b-c757-4ca1-bb76-7e772bcd0d8f"
      unitRef="cadPerShare">5.31</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtMS0xLTEtODEyMQ_0bb1ff71-c3f2-4b71-8f7e-6e88d096c09d"
      unitRef="shares">3165679</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtMi0xLTEtODEyMQ_4876e14d-8247-4271-aa0e-b4bc2cc821fd"
      unitRef="cadPerShare">3.82</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtMy0xLTEtODEyMQ_3be85da8-ae46-47bb-aaff-aa125da2fe3b"
      unitRef="shares">2164551</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtNC0xLTEtODEyMQ_64da7d7c-c60f-4231-8b56-f154a4d45f76"
      unitRef="cadPerShare">4.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtNS0xLTEtODEyMQ_c6447d41-c49d-46de-8520-3aa6369fc27d"
      unitRef="shares">1327845</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiYjQ2MzQxNjAxOTI0MTdjYWE1YTM3NWZmNGRhMDE4ZS90YWJsZXJhbmdlOmJiNDYzNDE2MDE5MjQxN2NhYTVhMzc1ZmY0ZGEwMThlXzgtNi0xLTEtODEyMQ_7b3cf49f-521f-4dbc-ad3e-1e99145c49a8"
      unitRef="cadPerShare">7.22</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNzI_aa232481-3229-4b1a-89dd-70cd43ff3fe9">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.54 - $1.79&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.80 - $3.01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.02 - $3.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,982,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.91 - $7.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.42 - $40.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,334,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,165,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i320159cd827547e58721ba67d7836f34_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtMC0xLTEtODEyMS90ZXh0cmVnaW9uOjAzNTcyNzg4NjA2NDQ2OTk5OThkZDU4ZmQ1YjRmMjQxXzQ_aaecebf1-aabe-4d71-8416-ee646f08449b"
      unitRef="cadPerShare">0.54</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i74c3e389b53640549c1c373710f94064_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtMC0xLTEtODEyMS90ZXh0cmVnaW9uOjAzNTcyNzg4NjA2NDQ2OTk5OThkZDU4ZmQ1YjRmMjQxXzk_d03460ad-085e-4389-98cd-f6fa8a63d08c"
      unitRef="cadPerShare">1.79</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i0b105f49e63542228ae11b453f0ca87e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtMS0xLTEtODEyMQ_1dd1f1b6-dbdb-4342-9fd9-1615d6df357d"
      unitRef="shares">718331</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i7c605804bd334ec1907207bb23e349c3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtMi0xLTEtODEyMQ_46b90a56-7e85-4dd9-b690-8931d298a931">P2Y3D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i0b105f49e63542228ae11b453f0ca87e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtMy0xLTEtODEyMQ_2b65b9f7-5ae5-4b4d-a042-888eba1c8460"
      unitRef="cadPerShare">1.39</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i0b105f49e63542228ae11b453f0ca87e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtNC0xLTEtODEyMQ_29237dd3-bf1c-4852-91f5-ae2aa3b3baa8"
      unitRef="shares">718331</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i0b105f49e63542228ae11b453f0ca87e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzEtNS0xLTEtODEyMQ_a14d9c1f-a246-4263-9599-967bddd66772"
      unitRef="cadPerShare">1.39</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i5d0c21adfb3d488cb2fc325f543e0e92_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItMC0xLTEtODEyMS90ZXh0cmVnaW9uOjAzYjUwYWIwYzU2ZjQyODg4YjQ1ODVjNGIzZDc2N2Y2XzQ_31ac6d00-6ef4-4f15-a609-1f7bd02cc2f2"
      unitRef="cadPerShare">1.80</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i83fe2b09673c484791ef8bd4e2f7f518_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItMC0xLTEtODEyMS90ZXh0cmVnaW9uOjAzYjUwYWIwYzU2ZjQyODg4YjQ1ODVjNGIzZDc2N2Y2Xzk_099cd1a3-3b08-4141-ac69-02a733ffa816"
      unitRef="cadPerShare">3.01</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i88ca0ee1c2a247149de0db08710d0a11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItMS0xLTEtODEyMQ_616b967b-e83c-4c16-971b-27c1044deef3"
      unitRef="shares">1026573</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i4cfd0864279f4fb89386b82c0e907044_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItMi0xLTEtODEyMQ_394bc648-a649-48e6-801a-1f73ad8b3118">P3Y10M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i88ca0ee1c2a247149de0db08710d0a11_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItMy0xLTEtODEyMQ_ba67a297-bbdb-47a4-8292-7166a7b8205b"
      unitRef="cadPerShare">2.36</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i88ca0ee1c2a247149de0db08710d0a11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItNC0xLTEtODEyMQ_cda9c7ef-30d6-4398-b107-31836b322116"
      unitRef="shares">531173</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i88ca0ee1c2a247149de0db08710d0a11_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzItNS0xLTEtODEyMQ_cb188104-59ec-4e75-983e-755de07d1435"
      unitRef="cadPerShare">2.47</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="ia23c9e23b2584b9cb0a3b24d1c38da91_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtMC0xLTEtODEyMS90ZXh0cmVnaW9uOjNjNjVlNDA4OGI3MjQ2Y2M4ZDRhMzgxZmMxMTQ1ZGU2XzQ_713c07c9-c3eb-4220-9563-6fb866a20b51"
      unitRef="cadPerShare">3.02</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="ib7d59de09bb940c189e78dc90d63966d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtMC0xLTEtODEyMS90ZXh0cmVnaW9uOjNjNjVlNDA4OGI3MjQ2Y2M4ZDRhMzgxZmMxMTQ1ZGU2Xzk_e3f4bc1a-0478-4d5b-bdd2-9ce9a6a1e19c"
      unitRef="cadPerShare">3.90</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ie5662aedb669484599906207af734e31_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtMS0xLTEtODEyMQ_510576d8-0926-4479-8b25-fa27933ef800"
      unitRef="shares">2982382</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="ib2aacc6b616f41dd8d5b26d42c3e9a80_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtMi0xLTEtODEyMQ_1189e82b-4148-40f5-9834-8de6d1ac44b2">P3Y4M9D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="ie5662aedb669484599906207af734e31_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtMy0xLTEtODEyMQ_cf9ca7eb-0a01-4114-aaca-94b9818ab391"
      unitRef="cadPerShare">3.29</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ie5662aedb669484599906207af734e31_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtNC0xLTEtODEyMQ_34794b8c-e3d3-4ff7-bc5a-4610d6c4b423"
      unitRef="shares">1329041</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="ie5662aedb669484599906207af734e31_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzMtNS0xLTEtODEyMQ_1e824e7a-dc90-43aa-9a69-0fd80fc81029"
      unitRef="cadPerShare">3.24</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i550a47322a8b427e8965901e54efbac0_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtMC0xLTEtODEyMS90ZXh0cmVnaW9uOmFkNDBmOTYwOTIzNDQ4MTdiZjcxMDAwNTkzMzlkNTEyXzQ_0d08ab51-1dd4-4e47-8d4d-49e5833639ce"
      unitRef="cadPerShare">3.91</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="ifeabe67f4cdc4d9593317276ede6b031_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtMC0xLTEtODEyMS90ZXh0cmVnaW9uOmFkNDBmOTYwOTIzNDQ4MTdiZjcxMDAwNTkzMzlkNTEyXzk_8a943b3c-9974-4708-9cd5-7667865835cc"
      unitRef="cadPerShare">7.41</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i06a718d83ebe46fda6f2392bc946d68c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtMS0xLTEtODEyMQ_01c994a0-430d-4806-b4a8-949c39aa2917"
      unitRef="shares">478516</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i165f5ef5cadc4c27bc78cb9fa65a9ebb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtMi0xLTEtODEyMQ_c8b31429-ca3d-4a50-b9b0-6ac178b7ebcd">P1Y8M19D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i06a718d83ebe46fda6f2392bc946d68c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtMy0xLTEtODEyMQ_d5ad0a50-6b1a-4231-baf0-a65b27f76803"
      unitRef="cadPerShare">6.09</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i06a718d83ebe46fda6f2392bc946d68c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtNC0xLTEtODEyMQ_8f80b672-f132-487d-b86b-05629a6316bf"
      unitRef="shares">458516</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i06a718d83ebe46fda6f2392bc946d68c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzQtNS0xLTEtODEyMQ_a7794173-4564-4033-a93b-0631e03ed347"
      unitRef="cadPerShare">6.13</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="if96dbdc3a85a498cb7c50c2c3fcc5136_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtMC0xLTEtODEyMS90ZXh0cmVnaW9uOmUyOWNhNzU0ZWZjZTQxY2Q5MzNmNmE3MGZmOWFjNGM4XzQ_b170a160-38e4-41ca-8a4d-b1dabab9fa25"
      unitRef="cadPerShare">7.42</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i9f3a94bc480946578503b6bc026df946_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtMC0xLTEtODEyMS90ZXh0cmVnaW9uOmUyOWNhNzU0ZWZjZTQxY2Q5MzNmNmE3MGZmOWFjNGM4Xzk_5607e316-ee36-4207-8461-af928c2577eb"
      unitRef="cadPerShare">40.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i3e6af5d5c037483e9cf8a1e5b633bf9b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtMS0xLTEtODEyMQ_034ac8a8-b698-4bb6-b985-2fa95928362b"
      unitRef="shares">128618</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i0a76d437dabc4644966186d4b447fc15_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtMi0xLTEtODEyMQ_422d7a9c-a743-4ea1-8e70-ba78e1b02c34">P1Y6M18D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i3e6af5d5c037483e9cf8a1e5b633bf9b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtMy0xLTEtODEyMQ_5d983498-9eec-48b8-bde6-0808bf88e4ae"
      unitRef="cadPerShare">20.80</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i3e6af5d5c037483e9cf8a1e5b633bf9b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtNC0xLTEtODEyMQ_310e0543-b7f7-4e47-a240-d81435cc0bd0"
      unitRef="shares">128618</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i3e6af5d5c037483e9cf8a1e5b633bf9b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzUtNS0xLTEtODEyMQ_b80b76ad-92cd-4a1d-9dca-c7f143cd8944"
      unitRef="cadPerShare">20.80</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzYtMS0xLTEtODEyMQ_f788bf9f-d996-4bc8-b313-2a418933a3c9"
      unitRef="shares">5334420</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzYtMi0xLTEtODEyMQ_690a539e-4f74-42d6-a719-51555801bf53">P3Y29D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzYtMy0xLTEtODEyMQ_11fb52b0-5749-4e99-8efe-3752edd29e80"
      unitRef="cadPerShare">3.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzYtNC0xLTEtODEyMQ_f662ee17-3ac0-4f16-bdb0-92f77476b24d"
      unitRef="shares">3165679</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTplY2MzYjViMWRhMDE0NjFkYTE2YTNmNTE4Y2NiZjBmNS90YWJsZXJhbmdlOmVjYzNiNWIxZGEwMTQ2MWRhMTZhM2Y1MThjY2JmMGY1XzYtNS0xLTEtODEyMQ_801de565-4895-4b02-a400-5f0210a05e57"
      unitRef="cadPerShare">3.82</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="ie946e9ce17b442b0a2db67f95b9168ec_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzM2NA_f13b2db4-40f2-43bd-b186-e75a60480c17">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNTQ_38833b30-5143-4a78-8501-6d5da1e31069">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options granted during the year was determined using the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.66%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.34%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected hold period to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.90%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$1.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzEtMS0xLTEtODEyMQ_1098f1f3-0670-4a3b-9db7-4e757e6cd308"
      unitRef="number">0.0066</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzEtMi0xLTEtODEyMQ_0d3ea3cf-18db-4331-9163-18a1a9aa30d2"
      unitRef="number">0.0034</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzEtMy0xLTEtODEyMQ_f9135d3a-7cea-4ca7-a846-fe301a9ed7cc"
      unitRef="number">0.0162</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzItMS0xLTEtODEyMQ_81ab0fb8-76f3-4e63-9d44-2bf8b4a2ba7d"
      unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzItMi0xLTEtODEyMQ_fbd5e3ab-83be-41f1-ac92-67250ceb71a7"
      unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzItMy0xLTEtODEyMQ_44694ee2-c1e3-41ca-82df-2b4e806526dc"
      unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzMtMS0xLTEtODEyMQ_5c4c6f04-d460-4081-9725-4272f149af3c"
      unitRef="number">1.1045</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzMtMi0xLTEtODEyMQ_57fb7d7d-bddf-4fd5-8597-66f555e9c192"
      unitRef="number">1.1082</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzMtMy0xLTEtODEyMQ_0dcef66f-ef63-4828-ac0a-57dc0110c5d5"
      unitRef="number">0.9790</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzUtMS0xLTEtODEyMQ_f2e683bc-197d-4e88-aa02-f42765fba238"
      unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzUtMi0xLTEtODEyMQ_5c967231-ac01-4138-a9e6-03557edb5a3c"
      unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzUtMy0xLTEtODEyMQ_05649f5b-2898-494b-b61e-37cdb7bf11a0"
      unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzYtMS0xLTEtODEyMQ_24ec8364-3197-4098-9319-d9dc952df243"
      unitRef="cad">1.99</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzYtMi0xLTEtODEyMQ_7609e8eb-3d0d-44c8-9c7d-5ddebff27e31"
      unitRef="cad">2.12</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo2MTkxZDQ4NjJjNjE0ZWIwOTk5Y2Q5YTM5MDUxNWM4ZC90YWJsZXJhbmdlOjYxOTFkNDg2MmM2MTRlYjA5OTljZDlhMzkwNTE1YzhkXzYtMy0xLTEtODEyMQ_33496737-58d5-4380-9009-291251b035ec"
      unitRef="cad">0.87</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="id035d2b8dd6d43178b57bd66e4788c61_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzI3NDg3NzkwNzI0MDE_29dd16e8-80d4-4833-8652-e64e77e387b5">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNzM_1fea5ad0-f862-4912-8ec7-a0506db50fd0">The following RSUs are outstanding at December&#160;31:&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;134,618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(94,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,560&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; (1) The weighted average fair value of the RSUs granted was nil in 2021 (2020 - $2.41 ; 2019 - $0.80).&lt;/span&gt;&lt;/div&gt;The following PSUs are outstanding at December&#160;31:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(56,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i8bdb149a74484759861585dd847d705c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzEtMS0xLTEtODEyMQ_c23e2f02-fdd3-49c9-8396-f624f87c19a7"
      unitRef="shares">134618</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i56539f49321e44d8a1eef4fc8f086d52_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzEtMi0xLTEtODEyMQ_79583214-0aaf-450b-a67b-b5af5385ef0d"
      unitRef="shares">209657</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i0ef39cf43fa64dfbbfb9e8655e1baa24_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzEtMy0xLTEtODEyMQ_5082719a-fca1-4380-88b5-ad0130188d99"
      unitRef="shares">260755</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="id035d2b8dd6d43178b57bd66e4788c61_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzItMS0xLTEtODEyMQ_7f57c2f6-e66e-4379-acf4-ecc9bf325dcc"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i4b715806bf704ad08871493d7b3a4e1c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzItMi0xLTEtODEyMQ_f90baa02-c12a-4350-a8a0-a7943d7de44a"
      unitRef="shares">154923</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i982e2e082ae5410dbcf107355f007a0d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzItMy0xLTEtODEyMQ_e5bc63d3-9171-4e70-a0df-fd0940c24973"
      unitRef="shares">270098</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="id035d2b8dd6d43178b57bd66e4788c61_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzQtMS0xLTEtODEyMQ_f05b1d37-be4b-46bd-8e23-8ffe8dfd7a2c"
      unitRef="shares">94058</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i4b715806bf704ad08871493d7b3a4e1c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzQtMi0xLTEtODEyMQ_2a284a4b-8ea5-4311-aebb-6489e2b17b59"
      unitRef="shares">229962</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i982e2e082ae5410dbcf107355f007a0d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzQtMy0xLTEtODEyMQ_687c86fa-ac19-4f7e-8787-94e0617fd54b"
      unitRef="shares">321196</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i4fc7bd5d5a9e465d989e66ae6a3abb49_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzUtMS0xLTEtODEyMQ_25d106f3-22d2-441c-8400-3220a846ee70"
      unitRef="shares">40560</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i8bdb149a74484759861585dd847d705c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzUtMi0xLTEtODEyMQ_f49966a4-0ebc-48d7-9e27-b6d3f46b3730"
      unitRef="shares">134618</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i56539f49321e44d8a1eef4fc8f086d52_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTo4ODM4NTNhNWE4ZjQ0MjAxOTQ3OGIyMWY2NmU3Y2FiMC90YWJsZXJhbmdlOjg4Mzg1M2E1YThmNDQyMDE5NDc4YjIxZjY2ZTdjYWIwXzUtMy0xLTEtODEyMQ_01fba76a-1963-4175-8a53-5cf809adbb56"
      unitRef="shares">209657</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="i4fc7bd5d5a9e465d989e66ae6a3abb49_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzE1NTk_1e2234d4-de46-4bba-9869-1886299a069d"
      unitRef="cad">0</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="i8bdb149a74484759861585dd847d705c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzE1NzQ_0bdfe54e-315e-4d5d-aee0-6c26383f5d08"
      unitRef="cad">2.41</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="i56539f49321e44d8a1eef4fc8f086d52_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzE1ODQ_c8c0940d-23b0-4483-a8f7-68cd2339e464"
      unitRef="cad">0.80</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <oncyf:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod
      contextRef="i814af0580d834778b5cede92893765d0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzE3NzU_a439180a-ed5c-4433-ba09-bc041e6e7174">P3Y</oncyf:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="i814af0580d834778b5cede92893765d0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzI3NDg3NzkwNzI0MDA_1cb774e0-aac4-4e7f-a523-e2671cbbe059">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ica2719d210fc449890e82fdb8d83507c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzEtMS0xLTEtODEyMQ_7de60f5a-3aa1-491a-ab29-6be4e3330261"
      unitRef="shares">56841</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ibb01c95903d246608417f9782e2afe30_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzEtMi0xLTEtODEyMQ_8c196552-9664-41c0-a8d0-72e1f153cff4"
      unitRef="shares">61051</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic87ace5c41714cf3b1812237cd1344ef_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzEtMy0xLTEtODEyMQ_77f0ed52-3180-4b90-9a76-6f6fad2927e0"
      unitRef="shares">63156</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i814af0580d834778b5cede92893765d0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzMtMS0xLTEtODEyMQ_49dc523f-2b2f-49ca-a728-202f9ceb303e"
      unitRef="shares">56841</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ib775f5c95fa8484385ae22162e973750_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzMtMi0xLTEtODEyMQ_416fdf6e-24e4-49e2-bc33-962a9714f646"
      unitRef="shares">4210</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i70523a9ebf4444508afc8076e91b525e_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzMtMy0xLTEtODEyMQ_8f604d72-bd9d-477e-a2de-0ad80f03f406"
      unitRef="shares">2105</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i127a482ddc3e443f908cd8d6e513e1e6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzQtMS0xLTEtODEyMQ_2dac8f2d-f6ce-4b61-bffc-c8a032a43efe"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ica2719d210fc449890e82fdb8d83507c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzQtMi0xLTEtODEyMQ_401b5e16-95cb-4c93-aed8-a45f3c2ca77c"
      unitRef="shares">56841</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ibb01c95903d246608417f9782e2afe30_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90YWJsZTpiODZmMGRiZGVkYTc0MmE4ODBhZjZjNGE1MmJiMTNlMi90YWJsZXJhbmdlOmI4NmYwZGJkZWRhNzQyYTg4MGFmNmM0YTUyYmIxM2UyXzQtMy0xLTEtODEyMQ_336fcc14-3534-41dd-993d-3f27328009da"
      unitRef="shares">61051</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="ie486096482ef4dbdbfc5aac0d2ef7dbd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIxNTc_109e7e40-86d9-4b28-9d3b-7be262bf5faa"
      unitRef="shares">5504379</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzMjk_106f9d6b-48da-4b4d-8693-1ffdca2a19ae"
      unitRef="cad">3825901</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzMzg_e6475d9a-4db0-42f9-82f0-2db2795612c1"
      unitRef="cad">2558974</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjYvZnJhZzplODA0MDBkNDYxYTA0ZTMzYWFjNDI3MzAzMmJhODI5NC90ZXh0cmVnaW9uOmU4MDQwMGQ0NjFhMDRlMzNhYWM0MjczMDMyYmE4Mjk0XzIzNDc_e8c0bdf2-b6b8-497f-8b21-ddf54d736fa9"
      unitRef="cad">1470153</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzQxMg_4c6e64eb-43a4-4e30-af3d-59a5e328dda8">Loss Per Common Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended December&#160;31, 2021 of 53,513,225 (2020 - 40,338,789; 2019 - 22,137,990). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzE4OA_0656803f-7a88-4c46-8ab7-555d1ee032c2"
      unitRef="shares">53513225</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzE4OA_79006d47-f35a-4f3e-aa15-82bb970331e9"
      unitRef="shares">53513225</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzE5Nw_3e9ac702-d7ec-41c4-a78b-640317b2a3f7"
      unitRef="shares">40338789</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzE5Nw_4b6d1af4-1745-4234-82ab-9be837eaeda3"
      unitRef="shares">40338789</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzIwNg_032279d3-cdab-438b-befd-39d2f10df08d"
      unitRef="shares">22137990</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNjkvZnJhZzo1YzU1YTlkN2IzMGE0ZTMxYjc2NDY2MjY4OTE4NzM0Zi90ZXh0cmVnaW9uOjVjNTVhOWQ3YjMwYTRlMzFiNzY0NjYyNjg5MTg3MzRmXzIwNg_555bae2e-527e-4714-99c5-933a600a7e0c"
      unitRef="shares">22137990</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90ZXh0cmVnaW9uOmJiYTc0OWYwNzVlYjQyZGU4N2RiMDA1MDU0YzYzZWU3XzY5NA_373d9a63-5539-46f7-977a-413a45253d1a">Contract Liability&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regional licensing agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liability balance at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31&lt;/span&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e expect to record in revenue over the next five years, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regional licensing agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90ZXh0cmVnaW9uOmJiYTc0OWYwNzVlYjQyZGU4N2RiMDA1MDU0YzYzZWU3XzY5MA_26046e97-2742-48e8-9c9c-9d2cd62df121">&lt;div style="text-align:justify"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liability balance at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31&lt;/span&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e expect to record in revenue over the next five years, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regional licensing agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <oncyf:ContractLiabilityRecognitionPeriod
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90ZXh0cmVnaW9uOmJiYTc0OWYwNzVlYjQyZGU4N2RiMDA1MDU0YzYzZWU3XzY2OA_dfb12821-4563-4a40-bdb7-f58a1fd71963">P5Y</oncyf:ContractLiabilityRecognitionPeriod>
    <ifrs-full:ContractLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzEtMS0xLTEtODEyMQ_5696d381-127d-40fd-bbe0-b960b4a1a358"
      unitRef="usd">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzEtMi0xLTEtODEyMQ_8710e12b-7c5f-4707-9200-893f8c672768"
      unitRef="usd">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzItMS0xLTEtODEyMQ_aa0fa4b6-2b10-41d6-9e52-c4fce656bdd2"
      unitRef="cad">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzItMi0xLTEtODEyMQ_2fa0cbbc-9027-4be5-bc5d-8426c55bbac7"
      unitRef="cad">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzMtMS0xLTEtODEyMQ_1554eb47-1d2e-41b3-8420-f0311a8852e1"
      unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzMtMi0xLTEtODEyMQ_34f14b63-1d18-4a36-ab1a-b44a28cfeb80"
      unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzQtMS0xLTEtODEyMQ_6a3202bd-8fd0-4dde-93f2-399ad54aa1dc"
      unitRef="usd">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzQtMi0xLTEtODEyMQ_7d926808-9d2d-45a2-9425-daf5e911aa01"
      unitRef="usd">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzYtMS0xLTEtODEyMQ_5ed4d79c-887e-43c5-bcae-c3089037a055"
      unitRef="cad">0</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzYtMi0xLTEtODEyMQ_96e3960f-cd0e-40fa-b3fd-4e970c4ad77e"
      unitRef="cad">0</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzctMS0xLTEtODEyMQ_b55793c8-be8b-4246-a14c-f432838cfee2"
      unitRef="cad">6730287</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzctMi0xLTEtODEyMQ_a5488ca5-e1c9-417f-b86a-f473759a0b05"
      unitRef="cad">6730287</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzgtMS0xLTEtODEyMQ_54d5b406-c793-4947-9471-666a83db091a"
      unitRef="cad">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzIvZnJhZzpiYmE3NDlmMDc1ZWI0MmRlODdkYjAwNTA1NGM2M2VlNy90YWJsZTplYmExN2RiOGVjYjI0ZTY0YjU1ZjVlNjAzYjc1ZGNhNi90YWJsZXJhbmdlOmViYTE3ZGI4ZWNiMjRlNjRiNTVmNWU2MDNiNzVkY2E2XzgtMi0xLTEtODEyMQ_4a8dc3b8-8302-4d7c-bc69-0b22c45a72f9"
      unitRef="cad">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfCommitmentsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzExNTg_640ca6c0-02df-4c17-81ec-cbc0b5f1fe3d">Commitments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are committed to payments totaling $21,516,576 for activities related to our clinical trial, manufacturing, and translational science programs which are expected to occur over the next three years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our commitments include the committed payments related to our co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1, as this phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2021, we recorded US$616,855 ($782,049) (December&#160;31, 2020 - nil) in other receivables related to BRACELET-1 cost from Pfizer per the terms of the collaboration agreement and US$277,866 ($352,279) (December&#160;31, 2020 - US$97,381 ($123,985)) in other liabilities representing future trial costs to be incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under a clinical trial agreement entered into with the Alberta Cancer Board (&#x201c;ACB&#x201d;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product.&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) 5% of gross sales of a specified product; or (b) $100,000 per annum once sales of a specified product commence.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <oncyf:PurchaseObligation1
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzY2_5fc6b087-f226-4049-a4b2-353eb3dcd902"
      unitRef="cad">21516576</oncyf:PurchaseObligation1>
    <oncyf:PurchaseObligationCommitmentTerm
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzE5OA_27abfb41-0a2e-4ea8-a2f5-66dd4e73fef6">P3Y</oncyf:PurchaseObligationCommitmentTerm>
    <ifrs-full:OtherReceivables
      contextRef="i7f73e01a75a540b3bd81d5cbc09e5ef3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzAyNjQ_59e5cf69-94a8-4b67-9f20-6e39c64215dc"
      unitRef="usd">616855</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="i7f73e01a75a540b3bd81d5cbc09e5ef3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzI0NzQ_744e6045-f93c-4ade-a000-b466423b135f"
      unitRef="cad">782049</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="if1358bb7098240d2b664975d761c15b0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzAyNTQ_e23dc5b1-6052-4739-8393-9e8c7ade88df"
      unitRef="usd">0</ifrs-full:OtherReceivables>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i7f73e01a75a540b3bd81d5cbc09e5ef3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzAzMjg_a7144bb4-00dc-47b0-b4d0-628230a593ca"
      unitRef="usd">277866</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i7f73e01a75a540b3bd81d5cbc09e5ef3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzI0OTQ_35f658a3-ffa8-418d-aa9e-d86082d11fa9"
      unitRef="cad">352279</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="if1358bb7098240d2b664975d761c15b0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzAyODg_8f944ac2-45e7-4871-af2f-25b8c1568532"
      unitRef="usd">97381</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="if1358bb7098240d2b664975d761c15b0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwOTk1MTE2MzI1MTY_5ad02b35-ff3a-42fa-b200-f29363c14093"
      unitRef="cad">123985</ifrs-full:OtherCurrentLiabilities>
    <oncyf:FundedandRoyaltyRepayment
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzg4OQ_08d43094-686b-45e8-8c36-c4b56551e39c"
      unitRef="cad">400000</oncyf:FundedandRoyaltyRepayment>
    <oncyf:OverheadRepayment
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzkyMg_984664e8-8bc7-4e25-b33e-affbc7945e12"
      unitRef="cad">100000</oncyf:OverheadRepayment>
    <oncyf:AnnualContingentPaymentGrossSalesPercent
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzEwNTM_9ecc7caf-b0d0-4b21-bff7-e66b74612eb6"
      unitRef="number">0.05</oncyf:AnnualContingentPaymentGrossSalesPercent>
    <oncyf:AnnualContingentPayment
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzUvZnJhZzo4N2Y5MmUzNmIxY2Y0N2EyOGJhMGMzYmNmZDM1MzIwYi90ZXh0cmVnaW9uOjg3ZjkyZTM2YjFjZjQ3YTI4YmEwYzNiY2ZkMzUzMjBiXzExMDI_7b7ebb6a-e737-4183-90e5-c9f5369961dc"
      unitRef="cad">100000</oncyf:AnnualContingentPayment>
    <ifrs-full:DisclosureOfContingentLiabilitiesExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzE4ODQ_d60c7e02-9b0a-44b9-bdae-94a6c1146978">Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assumption Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 1999, we entered into an agreement that assumed certain obligations (the &#x201c;Assumption Agreement&#x201d;) in connection with a Share Purchase Agreement (the &#x201c;Share Purchase Agreement&#x201d;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, a milestone payment was still outstanding for $1.0 million, due within 90 days of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell pelareorep to the public or the approval of a new drug application for pelareorep. This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the milestone payment, payments may become due and payable in accordance with the Share Purchase Agreement upon realization of sales of pelareorep.&#160;If we receive royalty payments or other payments as a result of entering into &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders 10.75% (2020 - 10.75%) of the royalty payments and other payments received.&#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of 2.15% (2020 - 2.15%) of Net Sales received for such products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BRI &#x201c;Work in Kind&#x201d; Contribution&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&#x201c;BRI&#x201d;).&#160;The terms of this agreement include a &#x201c;work in kind&#x201d; contribution from BRI.&#160;In exchange for this &#x201c;work in kind&#x201d; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue at the lesser of 0.5% of Sales Revenue or $20,000 per year until December 31, 2028.</ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
    <ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions
      contextRef="icca82039f3674df999dc93b86acdc4b5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzM4MA_e5f4101c-0586-4f7c-9ae6-66abd5afe18c"
      unitRef="cad">1000000</ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions>
    <oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue
      contextRef="icca82039f3674df999dc93b86acdc4b5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzM5NQ_8763e198-fcfd-414f-a219-0f054dfe4725">P90D</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue>
    <oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage
      contextRef="icca82039f3674df999dc93b86acdc4b5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzExMDQ_8307a9a7-f616-4236-b7d3-85f0b1f1bdbc"
      unitRef="number">0.1075</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage>
    <oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage
      contextRef="i7062d63d6b934781a4bc28b162213372_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzExMTM_1c472250-ebdc-42ef-afd3-73cb6a17f2d9"
      unitRef="number">0.1075</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage>
    <oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage
      contextRef="icca82039f3674df999dc93b86acdc4b5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzEzNzQ_4717f163-af6e-4644-863a-d146691f8122"
      unitRef="number">0.0215</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage>
    <oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage
      contextRef="i7062d63d6b934781a4bc28b162213372_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzEzODM_aa5eeeb3-7ced-47b0-9cb2-1cc1ae868a7d"
      unitRef="number">0.0215</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage>
    <oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzE4Mzc_734325ac-22f1-4614-b1b7-dc13c9db8fa4"
      unitRef="number">0.005</oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue>
    <oncyf:ContingentRoyaltyPaymentAnnualMaximum
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xNzgvZnJhZzoyOWIxNGRhMDg2MzM0NzVmOThlMGI1N2ExODMwZDk5My90ZXh0cmVnaW9uOjI5YjE0ZGEwODYzMzQ3NWY5OGUwYjU3YTE4MzBkOTkzXzE4NjA_0ca5f860-90d3-4c7f-9bd1-ba6f2f40184b"
      unitRef="cad">20000</oncyf:ContingentRoyaltyPaymentAnnualMaximum>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90ZXh0cmVnaW9uOjJkNjJhMjYwZTAzZTQ3NTM4NmM4MzM2YmIzYTk1Y2EwXzEwNDY_ead3a7ac-0d05-463b-b2f3-96fe57bc6518">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(26,254,852)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,505,057)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,122,888)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory Canadian corporate tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anticipated tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,038,616)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,401,214)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,777,565)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign jurisdiction tax rate difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,716,319&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,237,898&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,088,811&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;879,957&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614,154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,591&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,937)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(838,063)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,341,334&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of Alberta rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,758,175&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment to opening tax pools&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(552,079)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,711&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,973&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,290&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,945&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,294&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiry of tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,661,187&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax benefits deemed not probable to be recovered&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,342,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161,541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,961,613)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49,427&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As at December&#160;31, 2021, we have the following approximate non-refundable federal investment tax credits and non-capital losses for income tax purposes in Canada, as well as non-capital losses in Barbados that are expected to expire in the following years, if not utilized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Barbados&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-capital losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-capital losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,826,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,990,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,138,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,809,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,280,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,009,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,774,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,343,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,873,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,472,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,812,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,056,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,864,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,724,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,619,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,833,980&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89,537,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;162,986,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years&#x2019; taxable income of approximately $27,663,000.&#160;We also have unclaimed U.S. credits for increasing research activities available to reduce future years' taxable income of approximately $1,343,000 expiring between 2031 and 2041. We have not recorded the potential benefits of these tax pools in these consolidated financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,157,950&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,487,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,625,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific research and experimental development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,705,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,362,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,338,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,715,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,068,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,222,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undepreciated capital costs in excess of book value of property and equipment and intellectual property&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;350,695&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,927,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;647,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37,583,775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,541,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,712,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any other material income tax examination currently in progress by any taxing jurisdiction.</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90ZXh0cmVnaW9uOjJkNjJhMjYwZTAzZTQ3NTM4NmM4MzM2YmIzYTk1Y2EwXzEwNDQ_4be389fc-9119-4b2c-867f-80ecc8b651f4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(26,254,852)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,505,057)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,122,888)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory Canadian corporate tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anticipated tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,038,616)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,401,214)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,777,565)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign jurisdiction tax rate difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,716,319&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,237,898&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,088,811&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;879,957&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614,154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,591&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,937)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(838,063)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,341,334&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of Alberta rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,758,175&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment to opening tax pools&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(552,079)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,711&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,973&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,290&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,945&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,294&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiry of tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,661,187&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax benefits deemed not probable to be recovered&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,342,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161,541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,961,613)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49,427&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock>
    <ifrs-full:AccountingProfit
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEtMS0xLTEtODEyMQ_7f630683-1338-4b60-ad38-a1827841f1d3"
      unitRef="cad">-26254852</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEtMi0xLTEtODEyMQ_a30edeaf-f17a-4247-850c-cd147c65d894"
      unitRef="cad">-22505057</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEtMy0xLTEtODEyMQ_5059b69e-2c0e-4df8-97de-929833a3ad0d"
      unitRef="cad">-33122888</ifrs-full:AccountingProfit>
    <ifrs-full:ApplicableTaxRate
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzItMS0xLTEtODEyMQ_ed32e57c-b45e-4433-b291-bd87fbc7a935"
      unitRef="number">0.2300</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzItMi0xLTEtODEyMQ_d746a181-7167-42cf-ba62-7b1dd2a9db16"
      unitRef="number">0.2400</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzItMy0xLTEtODEyMQ_fd998ee8-37ed-41e3-a371-567f04f5f180"
      unitRef="number">0.2650</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzMtMS0xLTEtODEyMQ_ad6e5df0-2135-4db4-aa73-865f8cc1978b"
      unitRef="cad">-6038616</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzMtMi0xLTEtODEyMQ_222f5a61-7ff4-498f-bb2c-aaaa09b5d417"
      unitRef="cad">-5401214</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzMtMy0xLTEtODEyMQ_79d8c4f5-0460-487b-b0ad-bdffa77dcf1c"
      unitRef="cad">-8777565</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzQtMS0xLTEtODEyMQ_22b36d60-cc0f-4e6a-a263-e4c033f76f67"
      unitRef="cad">2716319</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzQtMi0xLTEtODEyMQ_91452b40-d1e7-4af6-809b-6811dd7ea03e"
      unitRef="cad">3237898</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzQtMy0xLTEtODEyMQ_ab2860d8-d920-4fd8-9d29-7f1f5268f51e"
      unitRef="cad">3088811</ifrs-full:TaxEffectOfForeignTaxRates>
    <oncyf:TaxEffectOfStockBasedCompensation
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzUtMS0xLTEtODEyMQ_06bc898d-6310-475f-8785-0e67a3adebd1"
      unitRef="cad">-879957</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfStockBasedCompensation
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzUtMi0xLTEtODEyMQ_4c321405-10b0-47ca-94bc-f912429c0451"
      unitRef="cad">-614154</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfStockBasedCompensation
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzUtMy0xLTEtODEyMQ_94595bde-47ef-4152-9440-0f73d32a6f0d"
      unitRef="cad">-389591</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzYtMS0xLTEtODEyMQ_509f87bf-25d7-4e6a-9b86-7897e4439395"
      unitRef="cad">-3937</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzYtMi0xLTEtODEyMQ_91c86422-c9da-48c0-85a2-ddf9300bbd35"
      unitRef="cad">-838063</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzYtMy0xLTEtODEyMQ_1912abce-d765-48e0-8b66-777ea6e6277b"
      unitRef="cad">3341334</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzctMS0xLTEtODEyMQ_18c6889b-40d4-4c0b-84e1-389b31d642fc"
      unitRef="cad">0</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzctMi0xLTEtODEyMQ_7f313ddb-aa81-4415-97a7-2dc6191117e4"
      unitRef="cad">96028</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzctMy0xLTEtODEyMQ_84d52337-62dd-456a-a3e5-0e54d7093c2f"
      unitRef="cad">3758175</ifrs-full:TaxEffectFromChangeInTaxRate>
    <oncyf:TaxEffectOfTaxPools
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzgtMS0xLTEtODEyMQ_e5288ced-fc62-4e54-9212-06106699a31c"
      unitRef="cad">-552079</oncyf:TaxEffectOfTaxPools>
    <oncyf:TaxEffectOfTaxPools
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzgtMi0xLTEtODEyMQ_fab821ca-d77c-4007-92ce-aaf5aa87134d"
      unitRef="cad">20711</oncyf:TaxEffectOfTaxPools>
    <oncyf:TaxEffectOfTaxPools
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzgtMy0xLTEtODEyMQ_f22356fa-ea44-4c20-b335-cb70bd539b57"
      unitRef="cad">11973</oncyf:TaxEffectOfTaxPools>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzktMS0xLTEtODEyMQ_e3d38d5d-a637-43a1-8295-7b232bcf33b8"
      unitRef="cad">44290</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzktMi0xLTEtODEyMQ_94e57548-65b4-47cb-90c0-9fb553dc4a32"
      unitRef="cad">108945</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzktMy0xLTEtODEyMQ_bc53a886-c948-42e5-936e-45745ecc94fa"
      unitRef="cad">149294</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTEtMS0xLTIwNzkz_61e4dfbd-9ee2-455d-ad39-77e7df516a3f"
      unitRef="cad">1661187</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTMtMS0xLTIwODAw_a8ee25cd-4ca0-45be-923c-6b0c434b87b5"
      unitRef="cad">0</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTUtMS0xLTIwODA3_174ffd20-23a6-4396-bf62-d8a4cdcfb07e"
      unitRef="cad">0</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTEtMS0xLTgxMjE_9be77e46-8fff-4fb8-a202-331e83d923a2"
      unitRef="cad">-1342306</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTItMS0xLTgxMjE_99226cbe-71c5-4062-8349-62ef885e1308"
      unitRef="cad">-2161541</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzEwLTMtMS0xLTgxMjE_68fd0951-d2c2-4b00-a85a-c3d1e610694c"
      unitRef="cad">1961613</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzExLTEtMS0xLTgxMjE_6276b391-ca0e-4d2f-bb1d-49e616c995fe"
      unitRef="cad">49427</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzExLTItMS0xLTgxMjE_56f99be0-4c7b-4582-a221-dd75efc44ebb"
      unitRef="cad">0</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZToyMDI1ZjJiYzExMWY0NmVlYjkwNzdiMDlkODBkNjUwZC90YWJsZXJhbmdlOjIwMjVmMmJjMTExZjQ2ZWViOTA3N2IwOWQ4MGQ2NTBkXzExLTMtMS0xLTgxMjE_20943784-5728-444a-bf4e-ea7b6a09927d"
      unitRef="cad">0</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90ZXh0cmVnaW9uOjJkNjJhMjYwZTAzZTQ3NTM4NmM4MzM2YmIzYTk1Y2EwXzEwNjA_7af8a186-7252-4ba7-b27a-5f054b5098b6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As at December&#160;31, 2021, we have the following approximate non-refundable federal investment tax credits and non-capital losses for income tax purposes in Canada, as well as non-capital losses in Barbados that are expected to expire in the following years, if not utilized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Barbados&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-capital losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-capital losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,826,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,990,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,138,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,809,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,280,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,009,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,774,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,343,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,873,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,472,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,812,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,056,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,864,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,724,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,619,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,833,980&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89,537,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;162,986,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,157,950&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,487,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,625,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific research and experimental development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,705,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,362,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,338,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,715,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,068,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,222,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undepreciated capital costs in excess of book value of property and equipment and intellectual property&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;350,695&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,927,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;647,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37,583,775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,541,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,712,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i4d3bff3314ec4be6ba448395655d2141_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEtMS0xLTEtMTcxMDU_ab70b674-79eb-46a8-9715-51e1c31c1c93"
      unitRef="cad">465000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="if548fffce7f84aaeac70a8fdef2ff771_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzItNS0xLTEtMjA2NzY_8ced7e92-bf83-44d7-a465-4d491c73172a"
      unitRef="cad">42826000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ic1da936afae14dc49119ba8ffe8ecd44_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzItMS0xLTEtMTcxMDU_95633b6b-464e-4a6b-a74c-c325d2d828a0"
      unitRef="cad">361000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="ib0136e4da0fc41549105d0be0238fef9_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzMtNS0xLTEtMjA2NzY_a9bcd54c-1b78-4c47-bd25-5483236166e9"
      unitRef="cad">33063000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ia63919fb6b0447f6a8378922a57a0e56_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzMtMS0xLTEtMTcxMDU_bfb46cca-e072-4868-971a-025aee329b65"
      unitRef="cad">228000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i5017b3339eec4bedacd81c4e5981b39a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzQtNS0xLTEtMjA2NzY_f8376c93-0bc7-4245-b8a6-6b8299edec4e"
      unitRef="cad">15990000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ie6f9bf167d3e4703927ae2652aa85037_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzQtMS0xLTEtMTcxMDU_7c090577-94c7-4f13-aa23-3331100caed5"
      unitRef="cad">271000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="if88b7239836e47ee87d1993c2c69f365_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzUtNS0xLTEtMjA2NzY_1fe5948f-2f50-4208-a4c4-89521ab8dd2b"
      unitRef="cad">15138000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i3821df9c92a94be4821466bf971f7738_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzUtMS0xLTEtMTcxMDU_40110da6-0348-4972-9958-748614e8206e"
      unitRef="cad">520000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="id6b5060463694393849921c58686af13_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEtMS0xLTEtODEyMQ_ea1598df-8c1c-498b-a279-1e447a1a0055"
      unitRef="cad">9809000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i754d4b44f8894e0bbeddfd1cbb8a2e24_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzYtNS0xLTEtMjA2NzY_d68cbc6d-e1ff-451a-8fde-90cbcb3c2916"
      unitRef="cad">16575000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i78b655fa2c2545fcbf00fef881bf589b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzYtMS0xLTEtMTcxMDU_6ffced95-9c96-4e4b-81b3-bd375df13740"
      unitRef="cad">596000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="ifa114dbc78574101a453118abbe69a95_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzItMS0xLTEtODEyMQ_d7fad3f3-4511-489a-8c14-4c88c6709e3f"
      unitRef="cad">12170000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i2ca59ee964074feca5cc2d804c6f3e05_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzctNS0xLTEtMjA2NzY_7f2e6de3-bde2-48ec-a15a-38c1ee125894"
      unitRef="cad">26114000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i7be63a4d7e934a779ffa098a8c199bbb_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzgtMS0xLTEtMjA2OTI_e7c6ef45-f926-4b70-8837-44388492f4f6"
      unitRef="cad">622000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="ie2b331eb2ec14c0e884108fdc1e52785_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzgtNS0xLTEtMjA2OTk_bf1197ca-43db-40f7-8bda-167051ce7a35"
      unitRef="cad">13280000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i1f9f805b162c4a61970dee91fe9b7b6e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzctMS0xLTEtMTcxMDU_7216df11-9d72-44ed-94f0-391f70716db1"
      unitRef="cad">173000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i1e1e786a729e443ba51a570b25e7dfb0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzMtMS0xLTEtODEyMQ_2272fcf5-9ac4-410c-95a9-233d00927df6"
      unitRef="cad">4009000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i7c684f104e0f40f7a2835b480bb00c0d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzgtMS0xLTEtMTcxMDU_502abad9-044b-4251-a068-4b5aafbe396c"
      unitRef="cad">91000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i4a91cd1ffa8b427ea4ede5259eb7c307_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzQtMS0xLTEtODEyMQ_4039c1fe-c607-46d7-9fd7-a8e0210ac672"
      unitRef="cad">4774000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ief9049c105f7454c87536a38658d6c0f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzktMS0xLTEtMTcxMDU_62440da8-52c9-4d0a-bf0c-e906d7086fa3"
      unitRef="cad">114000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i1eb2c5a4d51543949a0ffbdf4ec7a8bd_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzUtMS0xLTEtODEyMQ_f9de1cde-3c52-4712-9f3f-74b940369389"
      unitRef="cad">4343000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i82c158562bdf41e7a6759b2f5d325150_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEwLTEtMS0xLTE3MTA1_56c91623-12b3-49e4-aad8-b5941e3b51da"
      unitRef="cad">381000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="ib10f6659cd90429fb750eb8ed77dc3e5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzYtMS0xLTEtODEyMQ_c077049c-5818-4bbc-9d66-d2169c92d466"
      unitRef="cad">2873000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i66ea19593d434f9b8f9057991c2ee87e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzExLTEtMS0xLTE3MTA1_adbc185e-d294-4db1-a06d-1a96461b302a"
      unitRef="cad">487000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i522e5807f7804127b24ef62fe2d3d449_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzctMS0xLTEtODEyMQ_700bfd10-a1cb-42f5-890e-8dfa764e753d"
      unitRef="cad">2457000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i2c3f0b5419c0434c83941543d561ae09_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEyLTEtMS0xLTE3MTA1_d9d2e145-7ac3-4ec9-894a-78c90be8e4ed"
      unitRef="cad">270000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i841d852358ae4ecda2e98b20193fcc61_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzgtMS0xLTEtODEyMQ_2ebee092-2169-49d7-bb3d-b64c997351c6"
      unitRef="cad">2472000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ifdea1c38e3904299ae54711a02c93657_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEzLTEtMS0xLTE3MTMw_fa747028-7372-4c4b-9273-fca0ff4020ed"
      unitRef="cad">183000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="ib45ee033334041378788db209329639e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzktMS0xLTEtODEyMQ_f243d1e7-acb1-4cd6-bd1b-f4ddaad57b46"
      unitRef="cad">3125000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ie4449dd50bc6407d98849bb27aa044d1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE0LTEtMS0xLTE3MTMw_1f04afc8-0b4e-4551-954c-fe870ef84b6e"
      unitRef="cad">41000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="icc931101e8f347f9916d973a1aeea8a2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEwLTEtMS0xLTgxMjE_923d67d0-96e2-4f14-b72d-2bb29ff39360"
      unitRef="cad">6430000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="if376893af6704869aa4000196dff2a9d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE1LTEtMS0xLTE3MTMw_5731f2bc-b838-479b-8254-d362bbfb42c1"
      unitRef="cad">980</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i4b10f7069e464035b0d01d42a3daefe9_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzExLTEtMS0xLTgxMjE_1c7cc94f-da1a-4508-988d-9b8ad32e7d87"
      unitRef="cad">4812000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i68fe7581765a490288f89d0a93ec69f4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE2LTEtMS0xLTE3MTMw_e6eb1acf-6b0d-453b-954f-40ba28215f1e"
      unitRef="cad">22000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="iccd6471f6d9042109c8c9ea4e5b721a1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEyLTEtMS0xLTgxMjE_5ec9fd2e-f54b-49c6-bedf-4e223e19551f"
      unitRef="cad">5056000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i551872a26867455eaad5a877c53f122a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE3LTEtMS0xLTE3MTMw_eef2d424-5761-4a97-af3e-dd6f5a6c0a05"
      unitRef="cad">8000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="if8acbc8f07e144d19384899f34b15b1b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzEzLTEtMS0xLTgxMjE_21c84c7d-c585-4f94-b3a2-942a33fffa14"
      unitRef="cad">6864000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="icb56d715075745efb29466f96d59e553_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE0LTEtMS0xLTgxMjE_2be5f470-bd03-4772-97e0-8f16be739641"
      unitRef="cad">9724000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i6c59a90a0dc54356b24f4e161e4d58b8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE1LTItMS0xLTE1ODQz_8974a1a6-c95e-43e8-8303-610a3d49a3fa"
      unitRef="cad">10619000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ie39699155be34d93b5eee0afd15baccc_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzIwLTEtMS0xLTE3MTUy_da843ece-c5f6-4a46-8131-8cb688680a7a"
      unitRef="cad">4833980</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="iafea390033d44f86b623be26aa1611fc_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzE1LTEtMS0xLTgxMjE_53eb658b-4108-487c-88ec-d22ce0128393"
      unitRef="cad">89537000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="iaaf0f7affb224fd0a519419d263a370f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTo0NDU2YWE4ZWI4MjM0NDVmODk0YTEwMTk2NDMwMDM1Mi90YWJsZXJhbmdlOjQ0NTZhYThlYjgyMzQ0NWY4OTRhMTAxOTY0MzAwMzUyXzIyLTUtMS0xLTIwNzYy_fa6cbb54-b00e-4a2d-9fae-67338a3d8964"
      unitRef="cad">162986000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i691c2aef708c40e4959eda123656f876_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90ZXh0cmVnaW9uOjJkNjJhMjYwZTAzZTQ3NTM4NmM4MzM2YmIzYTk1Y2EwXzYxNw_b4926c8b-d655-4dc9-8e44-60172268dad8"
      unitRef="cad">27663000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="id89944ab2f3648f88d0e3371530558e0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90ZXh0cmVnaW9uOjJkNjJhMjYwZTAzZTQ3NTM4NmM4MzM2YmIzYTk1Y2EwXzEwOTk1MTE2MzE5NjE_6650b9d4-dae0-44ce-9ecc-4c5f33608e49"
      unitRef="cad">1343000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i569c7f4341664d4b8664d09e7fff7d81_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzEtMS0xLTEtODEyMQ_77cbdce6-4c49-43e1-8588-1101b21f52a1"
      unitRef="cad">25157950</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i9f423bf1a59c47c5a5c56ae5a92be8fc_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzEtMi0xLTEtODEyMQ_404318da-fa4a-463e-a2d1-4843198ca40b"
      unitRef="cad">21487804</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i86190dfcd5e447cd8e04730476245e4e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzEtMy0xLTEtODEyMQ_74b0758f-ea20-4db3-93cf-e72ee3b0a864"
      unitRef="cad">19625642</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ib5d5cda63e0542bfb6b7cdd527ea542d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzItMS0xLTEtODEyMQ_7d32473e-2050-4f2c-87dd-a1eb1c8b81fc"
      unitRef="cad">7705028</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i8aefcdf933a04c1591bc48676eeb3311_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzItMi0xLTEtODEyMQ_542884bb-823c-497e-abb0-749c5324c9cc"
      unitRef="cad">6362152</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="id63e281c95ed4160b4cfa6e9d2499567_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzItMy0xLTEtODEyMQ_795b3dad-fa35-432c-b176-6c33264d4d32"
      unitRef="cad">6338542</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ibbdf50475dc0456b9d7a6b17c5375332_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzMtMS0xLTEtODEyMQ_726014d0-6749-475f-8a34-b57e141342ad"
      unitRef="cad">3715652</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ib796065ed9ef4953ab1452c82a71d086_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzMtMi0xLTEtODEyMQ_7134cd93-07a3-4fe1-bff4-3119014490e9"
      unitRef="cad">4068105</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i6a94de62f7e941fd85969fb9eeb33c7a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzMtMy0xLTEtODEyMQ_d7dbd68c-6ec4-40b7-8721-33e8b9d60e3f"
      unitRef="cad">4222016</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i974cc837b3484870886ee47cd5811453_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzQtMS0xLTEtODEyMQ_8adae837-8819-4495-a91a-8cdd38d90a01"
      unitRef="cad">350695</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ibbae27b666e24aa78eafbec4c720309d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzQtMi0xLTEtODEyMQ_550c922c-9cf9-4baf-93c2-7a04a3437ee8"
      unitRef="cad">1927709</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i75b7f989f0c7451bad6b8015dcb583ef_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzQtMy0xLTEtODEyMQ_4a4d5c17-b2ea-41ba-900a-e194b6c26f42"
      unitRef="cad">1908320</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ib599fad21e614582ad5c64473790e8e8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzUtMS0xLTEtODEyMQ_ced9671a-2fe9-4c25-8a8c-6d9562c3d95c"
      unitRef="cad">647978</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i1c2429705a0742a9958a515cdbca5c9e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzUtMi0xLTEtODEyMQ_8b524baf-1cb3-4992-89e2-d3d06eada751"
      unitRef="cad">689193</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i08b1e6664397457eb8e8ce0dfdc08ea1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzUtMy0xLTEtODEyMQ_6816077b-3a1d-4e65-8c81-56527253e030"
      unitRef="cad">611072</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="id8d66e5ff5ff48138f1c4239fa19d36a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzYtMS0xLTEtODEyMQ_02a95613-7577-4259-9f67-09e1d1e1b8de"
      unitRef="cad">6472</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i118bcfe7943a4062a9525f725b80591f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzYtMi0xLTEtODEyMQ_3dc6bae1-fc74-4121-8b9f-ac8b00c3dfe6"
      unitRef="cad">6472</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ia79a3437f60544f18719723caeb2aefd_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzYtMy0xLTEtODEyMQ_a6f5a41f-570b-4a18-9296-d87922b2e0c8"
      unitRef="cad">6474</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzctMS0xLTEtODEyMQ_3f2d4390-e14b-4797-a559-eb085fd7120d"
      unitRef="cad">37583775</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzctMi0xLTEtODEyMQ_10ed8192-2947-4256-bae5-24bf104b52f7"
      unitRef="cad">34541435</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i64f58da6cebe4bf3ae5166d65f25cf87_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODEvZnJhZzoyZDYyYTI2MGUwM2U0NzUzODZjODMzNmJiM2E5NWNhMC90YWJsZTpjZGNlODBjODUwMjQ0YmQ3YWI1MGE3ZDZmNWVmNDQwMS90YWJsZXJhbmdlOmNkY2U4MGM4NTAyNDRiZDdhYjUwYTdkNmY1ZWY0NDAxXzctMy0xLTEtODEyMQ_32b70c14-4d63-47ee-8d81-192161d20635"
      unitRef="cad">32712066</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90ZXh0cmVnaW9uOjBhYWViYjc4MmYyMzQzY2NiYjcxMWI2YTgyMzkyZTAzXzM1OTM_8eaf1905-ea27-4dcd-a9e3-5f0b66ca4fab">Capital Disclosures&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;We include shareholders' equity and cash and cash equivalents in the definition of capital.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,262,044&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,219,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36,098,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,752,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not have any debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#x2019;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 12, 2020, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries, and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Base Shelf allowed us to enter into our ATM equity distribution agreement in June 2020 and March 2021 (see Note 9). We use these equity arrangements to assist us in achieving our capital objective. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2021.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory>
    <oncyf:DisclosureOfCapitalComponentsTableTextBlock
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90ZXh0cmVnaW9uOjBhYWViYjc4MmYyMzQzY2NiYjcxMWI2YTgyMzkyZTAzXzM1ODk_2e8f4e7e-4324-4771-9a41-22455d2b1ea3">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,262,044&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,219,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36,098,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,752,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</oncyf:DisclosureOfCapitalComponentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90YWJsZTpkN2NlYzVlMTk3YjE0OGY5YTY1YTVhZjc3OWE2YzljZi90YWJsZXJhbmdlOmQ3Y2VjNWUxOTdiMTQ4ZjlhNjVhNWFmNzc5YTZjOWNmXzEtMS0xLTEtODEyMQ_cb9f27a7-7caf-4c03-8e13-6d1482f894f4"
      unitRef="cad">41262044</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90YWJsZTpkN2NlYzVlMTk3YjE0OGY5YTY1YTVhZjc3OWE2YzljZi90YWJsZXJhbmdlOmQ3Y2VjNWUxOTdiMTQ4ZjlhNjVhNWFmNzc5YTZjOWNmXzEtMi0xLTEtODEyMQ_11999d6a-d2a2-4473-9522-9a9b21d34877"
      unitRef="cad">31219574</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Equity
      contextRef="ibe633dda267842029258e53a782fe561_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90YWJsZTpkN2NlYzVlMTk3YjE0OGY5YTY1YTVhZjc3OWE2YzljZi90YWJsZXJhbmdlOmQ3Y2VjNWUxOTdiMTQ4ZjlhNjVhNWFmNzc5YTZjOWNmXzItMS0xLTEtODEyMQ_9c5d799e-dfca-4411-8701-f0f7b4fc07b8"
      unitRef="cad">36098985</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i113d492fc4cf424c8489d5302adf402d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90YWJsZTpkN2NlYzVlMTk3YjE0OGY5YTY1YTVhZjc3OWE2YzljZi90YWJsZXJhbmdlOmQ3Y2VjNWUxOTdiMTQ4ZjlhNjVhNWFmNzc5YTZjOWNmXzItMi0xLTEtODEyMQ_366e67f7-7d90-4764-861f-b671a084a357"
      unitRef="cad">24752993</ifrs-full:Equity>
    <oncyf:EquityAuthorized
      contextRef="i921a0b76be5e4a5192afdce2bfa1f576_I20200612"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODQvZnJhZzowYWFlYmI3ODJmMjM0M2NjYmI3MTFiNmE4MjM5MmUwMy90ZXh0cmVnaW9uOjBhYWViYjc4MmYyMzQzY2NiYjcxMWI2YTgyMzkyZTAzXzE4NzU_105f1560-192d-46e7-bf4e-6154fae03afe"
      unitRef="cad">150000000</oncyf:EquityAuthorized>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzM0ODg_a1c07a24-4ba2-4608-b893-750ca5c9d837">Financial Instruments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist of cash and cash equivalents,&#160;other receivables, accounts payable and accrued liabilities, and warrant derivative.&#160;As at December&#160;31, 2021, the carrying amount of our cash and cash equivalents,&#160;other receivables, and accounts payable and accrued liabilities approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December 31, 2021, the fair value of our warrant derivative was $56,017 (December&#160;31, 2020 - $531,228).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial risk management&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents and other receivables from Pfizer in connection with the BRACELET-1 study (see Note 13) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate our exposure to credit risk connected to our Pfizer other receivable by entering into collaborations with global biopharmaceutical companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest rate risk &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign exchange risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar as a portion of our financial assets and liabilities are denominated in such currency. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2021 by approximately $240,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable and accrued liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant balances in foreign currencies at December&#160;31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,102,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(886,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,837,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 16. Accounts payable and accrued liabilities are all due within the current operating period.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="if9c241e91c964c239ec005ab7fd76cda_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzU1NQ_a3c0c87c-4eb0-4887-bd86-c37055480cd8"
      unitRef="cad">56017</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="i13e8c5af4bf84a0ba2e3af4a542a05f4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzU2NA_be94304f-33a5-4585-8ac2-426dbbf0228a"
      unitRef="cad">531228</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount
      contextRef="i72934bebe99040b6b7e0c0c2f19de911_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzI0Mjc_53f82ff4-e72b-43f7-bf49-dd9844a19e2b"
      unitRef="cad">0.01</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings
      contextRef="i72934bebe99040b6b7e0c0c2f19de911_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzI1NzA_057a333f-4300-44f9-bfd5-eac777e005d5"
      unitRef="cad">-240000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90ZXh0cmVnaW9uOjI3NTE2NWIyNjJhMzRkNDJhN2U0OGQ5MDk0OGMwOTMyXzM0ODQ_dd555179-2b00-4e82-bbdc-c1dba263def5">alances in foreign currencies at December&#160;31, 2021 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,102,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(886,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,837,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i06647bdfde1c470b8b4d0a645c9ba2d5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90YWJsZTpjOGYzOTM0Yjk0OTY0MzRjYmI2NmVmM2Q4OWQ2NGQ5MS90YWJsZXJhbmdlOmM4ZjM5MzRiOTQ5NjQzNGNiYjY2ZWYzZDg5ZDY0ZDkxXzEtMS0xLTEtODEyMQ_e3ed7700-6622-4e07-bb69-759a59c2a242"
      unitRef="usd">31102844</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:OtherReceivables
      contextRef="i06647bdfde1c470b8b4d0a645c9ba2d5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90YWJsZTpjOGYzOTM0Yjk0OTY0MzRjYmI2NmVmM2Q4OWQ2NGQ5MS90YWJsZXJhbmdlOmM4ZjM5MzRiOTQ5NjQzNGNiYjY2ZWYzZDg5ZDY0ZDkxXzItMS0xLTEtMTc1ODM_8298b758-47ea-4002-a6e7-c09176d294e5"
      unitRef="cad">621746</ifrs-full:OtherReceivables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i06647bdfde1c470b8b4d0a645c9ba2d5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90YWJsZTpjOGYzOTM0Yjk0OTY0MzRjYmI2NmVmM2Q4OWQ2NGQ5MS90YWJsZXJhbmdlOmM4ZjM5MzRiOTQ5NjQzNGNiYjY2ZWYzZDg5ZDY0ZDkxXzItMS0xLTEtODEyMQ_41b1eabb-7610-41d6-b875-a0497cfdb551"
      unitRef="usd">886891</ifrs-full:TradeAndOtherCurrentPayables>
    <oncyf:BalanceHeldInForeignCurrencyNet
      contextRef="i06647bdfde1c470b8b4d0a645c9ba2d5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xODcvZnJhZzoyNzUxNjViMjYyYTM0ZDQyYTdlNDhkOTA5NDhjMDkzMi90YWJsZTpjOGYzOTM0Yjk0OTY0MzRjYmI2NmVmM2Q4OWQ2NGQ5MS90YWJsZXJhbmdlOmM4ZjM5MzRiOTQ5NjQzNGNiYjY2ZWYzZDg5ZDY0ZDkxXzQtMS0xLTEtODEyMQ_b5ed30eb-5c8e-4bb7-ada9-86f94faa373b"
      unitRef="usd">30837699</oncyf:BalanceHeldInForeignCurrencyNet>
    <ifrs-full:DisclosureOfCashFlowStatementExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90ZXh0cmVnaW9uOjhmMGNhZGVkYjc4NDQwY2FhNGFiYjMzMGQ0YTI0NmI4XzEyNg_1f42e88c-bcac-4e45-8ff6-56a7cb4df0f9">Additional Cash Flow Disclosures&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Change In Non-Cash Working Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Change in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(776,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,017,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(348,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,012,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,368,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;228,294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(723,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(194,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in non-cash working capital related to operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(907,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,795,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Cash Flow Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest received&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;190,339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34,959&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
    <oncyf:CashFlowOperatingCapital1TableTextBlock
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90ZXh0cmVnaW9uOjhmMGNhZGVkYjc4NDQwY2FhNGFiYjMzMGQ0YTI0NmI4XzEyOQ_9c23c108-3da6-4aa7-ba0b-8721d9079ea6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Change In Non-Cash Working Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Change in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(776,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,017,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(348,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,012,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,368,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;228,294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(723,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(194,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in non-cash working capital related to operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(907,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,795,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:CashFlowOperatingCapital1TableTextBlock>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzMtMS0xLTEtODEyMQ_7583abf8-a3cc-4fae-9d5d-6aa0da968ae0"
      unitRef="cad">-776394</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzMtMi0xLTEtODEyMQ_7ea274b0-269a-4610-9001-66303ee0b6c3"
      unitRef="cad">1979111</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzMtMy0xLTEtODEyMQ_5125b395-c765-4578-be9a-a0071959677e"
      unitRef="cad">-2017122</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzQtMS0xLTEtODEyMQ_d93b4001-81fb-47c6-a141-4e4387226845"
      unitRef="cad">-348600</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzQtMi0xLTEtODEyMQ_0ca166d4-8b83-443a-a24b-99ee092cd4c2"
      unitRef="cad">286391</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzQtMy0xLTEtODEyMQ_e05b0752-d274-4e44-8fee-98aff06de5c8"
      unitRef="cad">-2012605</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzUtMS0xLTEtODEyMQ_730fb7ab-99a4-49a9-b4e1-eb27554b643e"
      unitRef="cad">182855</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzUtMi0xLTEtODEyMQ_6d10b628-499f-485e-9963-7ab8736c3316"
      unitRef="cad">-1368203</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzUtMy0xLTEtODEyMQ_12e0e6e4-848e-4278-9661-5ae85b2d218e"
      unitRef="cad">1347365</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzctMS0xLTEtODEyMQ_8f6cea8e-bf45-4b5e-9336-4007c71e2fb2"
      unitRef="cad">228294</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzctMi0xLTEtODEyMQ_a4c804e2-30b9-4154-bc8d-77eeac40c246"
      unitRef="cad">-723230</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzctMy0xLTEtODEyMQ_76dcf91f-152f-4d93-a4f6-e3ff2a254650"
      unitRef="cad">807877</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzgtMS0xLTEtODEyMQ_bb1efe4b-d854-45b3-bcd7-d7400c3d9b47"
      unitRef="cad">-194142</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzgtMi0xLTEtODEyMQ_83de442b-7dcb-4ac1-a985-480f9443223d"
      unitRef="cad">35710</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzgtMy0xLTEtODEyMQ_b75db14b-922b-4bd1-a94c-e68674cf2575"
      unitRef="cad">78708</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzktMS0xLTEtODEyMQ_37095d1e-acb9-4f77-bdfc-ba30a7abe0fb"
      unitRef="cad">907987</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzktMi0xLTEtODEyMQ_21c5ea62-7b8a-4269-b73f-8edcba3d54d3"
      unitRef="cad">-209779</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjMjJiNGI1MmNjMzM0ZjM4OWUwNWEzMjczNjczYWQyMS90YWJsZXJhbmdlOmMyMmI0YjUyY2MzMzRmMzg5ZTA1YTMyNzM2NzNhZDIxXzktMy0xLTEtODEyMQ_76b8e23b-237f-4905-8885-efb8e6c4163b"
      unitRef="cad">1795777</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90ZXh0cmVnaW9uOjhmMGNhZGVkYjc4NDQwY2FhNGFiYjMzMGQ0YTI0NmI4XzEzMA_32b90788-a524-4df1-8c15-fa0a26223c18">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Cash Flow Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest received&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;190,339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34,959&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock>
    <oncyf:ProceedsfromInterestReceived
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzEtMS0xLTEtODEyMQ_49f61256-b996-41f4-9358-5f0c4782e198"
      unitRef="cad">190339</oncyf:ProceedsfromInterestReceived>
    <oncyf:ProceedsfromInterestReceived
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzEtMi0xLTEtODEyMQ_285cbd19-27a2-4dfe-ba73-3abf8cb45a55"
      unitRef="cad">189720</oncyf:ProceedsfromInterestReceived>
    <oncyf:ProceedsfromInterestReceived
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzEtMy0xLTEtODEyMQ_208b1c68-f187-41a2-baed-4fedd233c0e6"
      unitRef="cad">274094</oncyf:ProceedsfromInterestReceived>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzItMS0xLTEtODEyMQ_6186bfc6-7372-4fb5-af2f-3ab2e92f1a35"
      unitRef="cad">34959</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzItMi0xLTEtODEyMQ_06072600-d724-43c1-ad40-87a9d38d5c03"
      unitRef="cad">12080</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTAvZnJhZzo4ZjBjYWRlZGI3ODQ0MGNhYTRhYmIzMzBkNGEyNDZiOC90YWJsZTpjZTczMjY4MzhmYWQ0YjI4YWFiMGNjZWIyNDg5MTU4YS90YWJsZXJhbmdlOmNlNzMyNjgzOGZhZDRiMjhhYWIwY2NlYjI0ODkxNThhXzItMy0xLTEtODEyMQ_542e77b5-25ae-4107-b891-417ae694a1fd"
      unitRef="cad">5448</ifrs-full:IncomeTaxesPaidRefund>
    <oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTMvZnJhZzoxOGExNjM2ZTA3ZTY0NGRlYmU4NDkyZTkxYWZmNjFmZC90ZXh0cmVnaW9uOjE4YTE2MzZlMDdlNjQ0ZGViZTg0OTJlOTFhZmY2MWZkXzExNjI_63c56d54-e3eb-4dae-b61c-2a02ff4cdac6">Indemnification of Officers and Directors&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#x2019; and officers&#x2019; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.&lt;/span&gt;&lt;/div&gt;</oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock>
    <oncyf:DisclosureOfEconomicDependenceTextBlock
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTYvZnJhZzpkYzI5ZjViNTY3ZmI0NGUxOTYwNmE4YThjZWJhN2UzMS90ZXh0cmVnaW9uOmRjMjlmNWI1NjdmYjQ0ZTE5NjA2YThhOGNlYmE3ZTMxXzY0MQ_bf71a362-4fc1-4352-8706-6d1784a97324">Economic Dependence&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.&lt;/span&gt;&lt;/div&gt;</oncyf:DisclosureOfEconomicDependenceTextBlock>
    <oncyf:ConcentrationRiskNumber
      contextRef="ifd70dd98103f43b6af3a92c583cabdb7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTYvZnJhZzpkYzI5ZjViNTY3ZmI0NGUxOTYwNmE4YThjZWJhN2UzMS90ZXh0cmVnaW9uOmRjMjlmNWI1NjdmYjQ0ZTE5NjA2YThhOGNlYmE3ZTMxXzI3NDg3NzkwNzQyNjE_70343940-0cb0-480d-a6ca-40410574d448"
      unitRef="manufacturer">1</oncyf:ConcentrationRiskNumber>
    <ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90ZXh0cmVnaW9uOjIxMTI4MjQ1ZGJiNzQ5ZTA5NGQ1OTQ3MmUzNTQ5MzM5XzQ4Ng_0cacb5d0-2abc-4f35-8d61-200a43b8dd9f">Other Expenses&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details highlight certain components of the research and development and operating expenses classified by nature. The foreign exchange loss as presented separately on the face of the consolidated statement of loss and comprehensive loss is also classified as a research and development expense. Remaining research and development and operating expenses include expenses paid to third parties.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Included in research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,645,264&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,775,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,096,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,086,608&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;130,243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;321,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,542,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,635,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,739,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction cost, warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory>
    <oncyf:OtherExpensesAndAdjustmentsTableTextBlock
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90ZXh0cmVnaW9uOjIxMTI4MjQ1ZGJiNzQ5ZTA5NGQ1OTQ3MmUzNTQ5MzM5XzQ4NA_24bfd618-94ac-4e37-be7f-3f5c6ab7f3d5">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Included in research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,645,264&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,775,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,096,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,086,608&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;130,243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;321,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,542,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,635,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,739,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction cost, warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</oncyf:OtherExpensesAndAdjustmentsTableTextBlock>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i86f880390f904058bf8a9cf3258849d0_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItMS0xLTEtMTAxNDU_abefe488-9a10-4d42-bd2f-7343ff1a2654"
      unitRef="cad">4645264</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i631df61a67ec41a593216ea67df15be1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItMy0xLTEtMTAxNTk_82befe56-f786-4159-ba2b-ce5ad3ab4a00"
      unitRef="cad">3775263</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i7e7344f3cdea473fa96384f7743d95b9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItNS0xLTEtMTAxNjk_7d8784ac-22e9-4e71-a121-24c7d6d5fe43"
      unitRef="cad">3096231</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i86f880390f904058bf8a9cf3258849d0_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItMS0xLTEtODEyMQ_d25b213b-11f8-4778-aeee-88d127fcf387"
      unitRef="cad">2086608</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i631df61a67ec41a593216ea67df15be1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItMi0xLTEtODEyMQ_d00a2ded-f4d2-4b13-a5ca-48f08cb3f3e9"
      unitRef="cad">1043373</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i7e7344f3cdea473fa96384f7743d95b9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzItMy0xLTEtODEyMQ_8130ad36-6f65-4ba8-992b-f592256b4542"
      unitRef="cad">561420</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:AmortisationExpense
      contextRef="ieb584ab1725b4b40910af903b876e75c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzUtMS0xLTEtODEyMQ_5cd8b3f4-07f8-43b0-aaab-95595b9a50e2"
      unitRef="cad">130243</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="i95d0e74b706c4b069c1415f031d34f1d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzUtMi0xLTEtODEyMQ_351c669b-26da-4dcc-8670-b43afe43372e"
      unitRef="cad">88957</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="ida85ff23b9654045a8551b3d03eece63_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzUtMy0xLTEtODEyMQ_b296ff87-2ff9-4baa-bce0-72d90c67e841"
      unitRef="cad">122982</ifrs-full:AmortisationExpense>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="ieb584ab1725b4b40910af903b876e75c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzYtMS0xLTEtODEyMQ_4f8d9119-8876-4c2d-a993-fcaa958048b7"
      unitRef="usd">321822</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i95d0e74b706c4b069c1415f031d34f1d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzYtMi0xLTEtODEyMQ_195fe771-c885-4150-a290-71100af87624"
      unitRef="usd">357230</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="ida85ff23b9654045a8551b3d03eece63_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzYtMy0xLTEtODEyMQ_93399fb8-a024-4feb-a728-91bb1c45eff5"
      unitRef="usd">362592</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="ieb584ab1725b4b40910af903b876e75c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtMS0xLTEtMTAxNTI_7c1e8bb6-c3e3-4508-8417-3d491634c769"
      unitRef="cad">2542210</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i95d0e74b706c4b069c1415f031d34f1d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtMy0xLTEtMTAxNzY_4a0bdc91-c910-4f19-aa0b-12341d8b7c56"
      unitRef="cad">2635170</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="ida85ff23b9654045a8551b3d03eece63_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtNS0xLTEtMTAxODM_060c7867-13a1-4f80-a828-79a2fb12bbc4"
      unitRef="cad">2555274</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="ieb584ab1725b4b40910af903b876e75c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzctMS0xLTEtODEyMQ_70ce1893-1c20-432c-b5e1-e0a2f6f17b50"
      unitRef="cad">1739293</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i95d0e74b706c4b069c1415f031d34f1d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzctMi0xLTEtODEyMQ_8d03ad21-6af6-45ca-b3a2-92b84928f0c9"
      unitRef="cad">1515601</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="ida85ff23b9654045a8551b3d03eece63_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzctMy0xLTEtODEyMQ_935176eb-a771-4311-b648-601d22ad9ce8"
      unitRef="cad">908733</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ifd23113a5fc540bf93ca41f097c068f4_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtMS0xLTEtODEyMQ_76be7371-c385-4350-bd52-5cc07087b23c"
      unitRef="cad">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ic461088cc874441196432eb9bafe69bc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtMi0xLTEtODEyMQ_7ebdbee6-9b0e-4c62-bfb6-f659422734c8"
      unitRef="cad">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i803b09a886c44d92b85f0e3efad65433_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8xOTkvZnJhZzoyMTEyODI0NWRiYjc0OWUwOTRkNTk0NzJlMzU0OTMzOS90YWJsZTphOWI5MzEyZTcxNDc0ZjFkOGU5YjI1ZDk4N2QwNjk2ZC90YWJsZXJhbmdlOmE5YjkzMTJlNzE0NzRmMWQ4ZTliMjVkOTg3ZDA2OTZkXzgtMy0xLTEtODEyMQ_ee3ae8a4-0c0d-409a-8aa0-149216ba6bd1"
      unitRef="cad">233143</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90ZXh0cmVnaW9uOjdmYzhkMDI1YWYyNTQwNTRhMGQxZmVkOWEyMDdlNjY1XzM4NA_a45e5f53-9503-422f-b76c-cb2af7a97f9c">Related Party Transactions&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation of Key Management Personnel&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain employees of the Company.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,918,564&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,514,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,786,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,703,256&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,757,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,621,820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,767,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,910,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90ZXh0cmVnaW9uOjdmYzhkMDI1YWYyNTQwNTRhMGQxZmVkOWEyMDdlNjY1XzM4Mw_49883845-78fc-45cc-a20b-a788c8e48064">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,918,564&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,514,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,786,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,703,256&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,757,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,621,820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,767,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,910,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzEtMS0xLTEtODEyMQ_7bf30857-5217-44bc-b4be-ddcee07ddd91"
      unitRef="cad">3918564</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzEtMi0xLTEtODEyMQ_a3106044-5410-4d76-ae4c-221cc914de30"
      unitRef="cad">3514527</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzEtMy0xLTEtODEyMQ_f3846c98-7a75-47a5-91cc-26388411ecd8"
      unitRef="cad">3786667</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzItMS0xLTEtODEyMQ_e60bf551-9c32-4a19-ae83-d63ac3cb018b"
      unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzItMi0xLTEtODEyMQ_083785e6-596c-4a73-aaaf-23ca1e8e33b7"
      unitRef="cad">495175</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzItMy0xLTEtODEyMQ_49ab5616-9508-470f-afbf-c0ea367132b6"
      unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzMtMS0xLTEtODEyMQ_069fbe01-06ad-47ce-8795-e19bf8b72610"
      unitRef="cad">2703256</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzMtMi0xLTEtODEyMQ_4eca9962-d4de-4664-9bc9-d4d263a8a6e3"
      unitRef="cad">1757723</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzMtMy0xLTEtODEyMQ_6400eb2d-3dbe-41ed-923d-c3ad7c88b756"
      unitRef="cad">1123408</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzQtMS0xLTEtODEyMQ_6b9db147-65ce-4087-b1d2-f45253c6bfc1"
      unitRef="cad">6621820</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="i5b8d28a2413a458b9d2c643f62f8631f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzQtMi0xLTEtODEyMQ_678ce893-2617-4410-833c-d2315c2c03f5"
      unitRef="cad">5767425</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="if9aa41e1e91645baa74e4bd98de71a44_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDIvZnJhZzo3ZmM4ZDAyNWFmMjU0MDU0YTBkMWZlZDlhMjA3ZTY2NS90YWJsZToxZGExOTUxNjhhNjI0ZTM3Yjg2YzU4M2M4MzIyMzFhMC90YWJsZXJhbmdlOjFkYTE5NTE2OGE2MjRlMzdiODZjNTgzYzgzMjIzMWEwXzQtMy0xLTEtODEyMQ_5ce2e1d2-4160-41e9-b21b-cf536661bbba"
      unitRef="cad">4910075</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDUvZnJhZzo0NGNiYTc1NjVlMzQ0MWZhYmNjOTY5MWQwMmJhOWZmNy90ZXh0cmVnaW9uOjQ0Y2JhNzU2NWUzNDQxZmFiY2M5NjkxZDAyYmE5ZmY3XzI3Mg_99124db6-ad71-4577-9ccf-18f1131e5b75">Subsequent Events&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Between January 1, 2022 to March 2, 2022, we issued 2,050,240 common shares for gross proceeds of US$3,560,397 through our March 2021 ATM equity offering sales agreement. &lt;/span&gt;(b)In February 2022, we paid a non-refundable deposit of US$1,368,000 related to a production service agreement (the &#x201c;Agreement&#x201d;) entered on December 23, 2021 with our primary toll manufacturer. Under IFRS, the Agreement was deemed an executory contract at signing. As a result, the contractual obligation to pay the deposit was not recorded in our December 31, 2021, consolidated financial statements.</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <oncyf:IssueOfEquityShares
      contextRef="i89a71f2e8ff5408fba66dd7456a26ab8_D20220101-20220302"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDUvZnJhZzo0NGNiYTc1NjVlMzQ0MWZhYmNjOTY5MWQwMmJhOWZmNy90ZXh0cmVnaW9uOjQ0Y2JhNzU2NWUzNDQxZmFiY2M5NjkxZDAyYmE5ZmY3XzEwOTk1MTE2Mjg2MzA_c1196702-1c28-456c-bf41-2abbf67ed244"
      unitRef="shares">2050240</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i89a71f2e8ff5408fba66dd7456a26ab8_D20220101-20220302"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDUvZnJhZzo0NGNiYTc1NjVlMzQ0MWZhYmNjOTY5MWQwMmJhOWZmNy90ZXh0cmVnaW9uOjQ0Y2JhNzU2NWUzNDQxZmFiY2M5NjkxZDAyYmE5ZmY3XzEwOTk1MTE2Mjg2NDI_c30243e6-941f-4a70-b2b5-c536b39f2134"
      unitRef="cad">3560397</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:PaymentsForExecutoryContracts
      contextRef="i9757885e4d9e44f386e37be5103b4760_D20220201-20220228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNlZGIxYzljNmVlNzRmMzE5OWQ2ODUyYmE5MmJjNTliL3NlYzpjZWRiMWM5YzZlZTc0ZjMxOTlkNjg1MmJhOTJiYzU5Yl8yMDUvZnJhZzo0NGNiYTc1NjVlMzQ0MWZhYmNjOTY5MWQwMmJhOWZmNy90ZXh0cmVnaW9uOjQ0Y2JhNzU2NWUzNDQxZmFiY2M5NjkxZDAyYmE5ZmY3XzEwOTk1MTE2MjkwMzU_b9079984-1a2b-4f5f-95c8-aacf7c8bcbf2"
      unitRef="usd">1368000</oncyf:PaymentsForExecutoryContracts>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>121
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M%EGU->8,6FPE@-_7!;0!S85Z0'OH=/,?4$L#!!0    ( -N&8U2VGU-HK08
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MIC\^S=#\!WQ\_?3MQQQ=7Z*+Z?PSNOQR_6N.QG Q0^_^^OMD4L%#;=-)LG_
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MOIU]@5WT2!QO4/?;WSW1-[B,RI:U9$ES4[.\U<25;4/R0D;(>38(?5R\7RS
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M16L)9)AMX@'33518;CMVZ*6CBN<A+?68:1B19,M(,BW!LZG"U&8TA\&GGOK
MX*.',GL55!KA6O8.%:T&#N)7Q&/I=20#X\1-QT-=*-L1NA<>1<_(0^@IW,>I
M&:>^ M/"E)'P: F?Z_RA?GZ9?/SH#!@SBW,IN?IH_5*^N92C[0_9A#X)5F>?
M1@-1V82WHM-CG^*.U-9('A63Y4F]VJMTCRPD51:!0_9ZS , 2.56-^?Q*:*>
M.[%)._9.$+]6'G$HT9A2R)>U*3\_N"Y7GOTHO:IU0_ZLB^LVX[9V+*;?J$YH
M72X-& Z? ^NFISP5<G!:5 'R]F06_D0#P_@+[_3UR7ZK:1BO\OE ^/['N: 7
MQ4KM_.KL$\M.',][:?4=NRWE-79S+-&3^WR$W!ME/FAP3)S[18\4_0&L=%CJ
MZ%"68L2I0:Y89+W;7R5;/"VNCFQQ[^3J^I= I^'SJC:SLFF_.!YE?)(!4HR-
MC/XG$$>M30PI"]]I"':#1BVS+C]]+-QRAV;JW/=./OPA>A5"HO@8+PX"^]K3
M'/D^:Q#E/\G.M7Z=+%TB?4YY-KD_>/]1@!_L!@IP!JX>&,QLTO3S^:RQ&_CG
MV?I \QW6_G&U-_\<[+#AR*V-LZ8X1<V/GN:_5'&-$4QV]Y#B)?KS!+8[S2 N
M5>?[KO@KI5+_22+Z.37S+U]<%^?%5?ZE!^TS?*EZ/<R37S;%&SMO>^1S^&$1
MP0NTP,NHB-R33GGA-RS-9..#R"N@0H"&=+.X*-Y)[>I=]G,8?^FKI;[KLNF:
M5 \"3DAIM+TUR+7XVU];;Z0 PM"6?UPA_YF-WX9UI50[^B&-'8.*V@.F:STJ
M.[*LQE_8R>#BWH!GR(=3N?UO%H 7?S$-\U1^K^713"P8>:?#/()X)(&B*%%T
M79SK,)7?#/@&T$SU(&;-N>YI[SL>-I84?1,!^=T_;W+*XOQIZO=19L6KP5RR
M^S^GT@N$\'/;PJ7]$27Z:382LL-<(6:,,%#0V"U^NL(UZ5N,[S*II>K/=P?2
MHGRD13JB4)$>'W\ F+F J04%Q$\^DWYS)2)-=JIEI,\R(\A^Z^!G6B<[H&KE
MMX.: @GFWQ!*R_#W^'LG^L5;]I7:%,'_']7U_ +0"O65C_Q;,Z1\[\PW.*^+
M.-K8& Q621DCE'Z3%3QDVC#OI-KX@92"[KA4\%J;PZ]^<&LU\DN R^C+,WYR
M5"364&MNT]?S%2;M.L<X;^JG8/X/B'Q_;W+0$8D+)8>'Y@K3:'MIH^S-]<ON
M0;HXF'0"KS12ZJB?EK@9DG'=-1O',Q)]12?Y<JZ07ZUF4S]R=9;]S-C:MDO^
M,35TM,@DY1?'TM7T>VTOY&?*AL?EQ][>F7:)R?#:+NC5AZ=_^N%$&HGQC\YO
M^$?+YK[K_)K_N;*&M X/T/V%]UW\ QND7[%[_G=02P,$%     @ VX9C5)AJ
M#1\4#   OB(  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL[5I=C]LV
M%OTKQ#SM H[G(^DGD@"3I$6S:+9!TC8/BWV@)=IF1A)5DK+C_OH]YY*49&<F
MF0:[;_N2C&7R\GZ>>R[EQWOG;\+6F*@^M$T7GIQM8^R_/S\/U=:T.BQ=;SI\
MLW:^U1$?_>8\]-[H6C:US?G5Q<77YZVVW=G3Q_+LM7_ZV VQL9UY[548VE;[
MPS/3N/V3L\NS\N"-W6PC'YP_?=SKC7EKXF_]:X]/YZ.4VK:F"]9URIOUD[/K
MR^^?/>)Z6?"[-?LP^UO1DI5S-_SPLGYR=D&%3&.J2 D:_^W,<],T% 0U_L@R
MS\8CN7'^=Y'^H]@.6U8ZF.>N>6?KN'UR]NV9JLU:#TU\X_8_F6S/5Y17N2;(
MOVJ?UGY]<::J(437YLW0H+5=^E]_R'Z8;?CVK@U7><.5Z)T.$BU?Z*B?/O9N
MKSQ70QK_$%-E-Y2S'8/R-GI\:[$O/GUK-YU=VTIW4?UCJ#?P=PP+]4.(%B:;
MH'17J^N F/7T8GA\'G$J]YY7^81GZ82K.TZXO%*O7!>W0?W0U:8^%G .=4>=
MKXK.SZX^*?&%J9;JX>5"75U<77Y"WL/1!P]%WL,O]<'UL0_4OZY7(7HDU+\_
M<?JC\?1'<OJC_V$$_KLGJ%^W1JV'IE'F0\1:%9W:;VVU51%?5,Z[3N^L'X*R
MW5JJ"W_6-AA4!V)R^9WZV]GS7WY_^>+!Y7=G?U<]Q)O65DC; Y9Y[&@.RGGL
M'C_9MH<[E1M08T. _@$*>A-06T&YM0((>9V4H[)KV^FNLKJ!-A#"+Q805S5#
M;;N-B-$KV]AXH.YIM9''DZ %K .T!8._*K@,_FE4]!"*!SP$QQOM834_U&8'
M .OI.IP9Z+^]A8=J QFU KZLASAX,U\8X"\=E<93LW/-CJI1UA9( 9L'Z.0C
M<',!2.0Q0?Q;#TE!61H@S=,,^F"(*^#N39B;VCM&B)[(Y^_U#A&%=ZM#U9AL
M"N6:M<1J9^A<RM-5<FC4-Z:CG^!+JI-VX*2H2A27ZAT##RBNC3=)WG1R"=YZ
M7(]T@<A6WU#%;*4R1_GVOB0B_-S 8"R$"B+8FUYG'T F'H5TN&MLC?WS\(>(
M!R(&*FYM8[A<O!!4YQ2/\S,5<0*3X+/"& MZB*D&5U*K W)!&2*8 OZ8=F7\
MB$$+D9H#H -2*DBB).VA!>HO#K5)F31,MA5_+7C@'JU)#J8):@U]G6=NNJ&I
M<RTH1N?+K;)CEL+%SHO340_6U7#?B Q2_B=!N)]\;_X84-%! 0\BO7]CIC@O
M3A) SP GU8DDJ'@LJ8=C=.N&Y,BI6.E@BFMLJG$[SW+ 4-6X0!NQB1D-(QF+
MX]7I&*G<]>S$R2%+]9/;L_@64YVB#/4*59A3<FX CY_,.PT9]E2N-=G.[*5Y
M('7]'JV^S5@K**N]/PA@C![@8[&=U5W,.62WP5=3=,>8_G"GQY^92@\T@I&N
M@-T +B@#AC'&O-7=(3M;ML\\J&S(R$>5AWZ"/[A,8GU+(=^5D@@2R25MV=NX
M52]_?/-V2B5H 7)87",I]<5YE(KZ=HL^FT!W[4LGL2I*D.X!+_FPV_0KB4Z@
M$%2\)3L1VNLJ#A!:>F1*N=K"=F"'=RWVN7#J*^DS:9%!5I=M*Z/"Q!&6:DX8
M)@&M!H*M#O.()%>7EGL? &+?,M^K-\R3@895CN#(%'G'@HS27U!K#JGYLZU(
M_R'^>N--.C(1D=Z['7H12[EU/%XPL]>'##5$[:&''Z3R*06,QAC)-_.AVFK$
M5!9IJ+#!Z="SK,MP"AT R":Y&>?!\_&P5*\FZP=&R<*L@G$"SWW?'$K<;-<#
M+EJ#6-2I)Y8J*RLRPT+<<02,#$3.O?8U8]/VC9FU009?QC A,ZO&;J2VEK=Z
M<RR@NV$*EN.@U'DCC"S?U(7AI&2F%A\R!^$3CEETTFI4R-03 #>FVZ"(N1;#
M6Z(58H?YA G'8=QI@.(*Y&6IGA\1LZDV[GJ.0B%M8VK.4UIT<%WV-*-[)[D;
M1?&+/4EC#-A0F1.)4I!SAB+S9<($P7#KZP> /_B-(,)I83H40[3N[)^)B"X3
MWQ[KA0D29G)+Z@=ADF%8O3>IZ7=FXT# D@/AM$,J_/&X3.GD;UI#_CTUI:%C
MUI2:46N,YUESGGJBX>M<6=@%!EA03D2'.0=.I.6(S^IJ:W%2(40C&\R- DL!
M1 'C!JK?NZ8I"WN<G990]^-B*$*.>?LL!,#'H.C]5%GL0Z7B/HM2"X:]U$(N
MTKX@0RZQ/XW<!8C1P?B=K4IWWX)_HS3HV5(<!,VYQ^[,@W<SUIS",!:K*,6&
M/0XPM%<<DX02I6R7;FGHI=P#IBS,:A;H)+6<RX(_=-I$X/-\A&^#ZSK3E! D
M_L_2'"%/)@.Z0JIJPA9H0)-7>'*DEMYIVXB$W#B)$C.RI>LTSIU8P]1=&9*H
MF02$ T0S-00NT UR>,X]P; <B595D7//@GH+57I)A4%K)"_%V^G, J1UB;ZO
M9W0MI*>?PY*/SDO-()6'A*[AMC*5[8BVR=R03,@)C];,RD(;]1RV9<ZK3?D@
M7"JD@1.4!9%JFL/1V":@G;I?:H5'[$ &6K%XW8R4\E[&962'9<J2$@(D#2CT
M[[H91OH7MM#K0:H:5C,VI^\R2672K[4E_#=#:LXANNH&69J:U\8#=TT]=;;3
M7MJ*\3U[->  8=Z-Y[>NAGM3JAQQUYRG"7-SEJ<,+!"<SB5(,SM*!NDFN+^@
MB1"! J\?Z36-\P5MQ/N-79M%\ANJEK6[<QR52?M32=:6I8P_#M8TN0EG_#AJ
M^V5J:5.O.:4$6;N!H:'?S5^,"!7,O#DES3\=;+Z\.,D T!IN@+>\W6E>1=P1
M^T(T/EZOB296;AU:)#TJJI5RQ7.#1@/?&9^F&0D2QX/\S2F%_O(T^G\J?"I
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MOB':]@[9OGA3AWO;RGC< L-C@6NWM+P!W]<&9]_NA17T%_FSOP!02P,$%
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MWVSV<PSFP3#<J*1+Z(L1S<"C4B(4#*> <2*G#NJ4T_6TM18=1]Y1;CQX3#>
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M@/O7#0:AX0=M,+Y.._LO4$L#!!0    ( -N&8U2@D$!\?P<  %\2   9
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MC'T'\)6:$HS)XM:UH;SML(^Q>">BA%=]1:'G?0[X>RA#N[7JU<8-6*F0>MZ
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M0:/>=!R KM_I>F)5Z=_&C;+TTOJA.QO4SH#V,Z7L8>(<M!]+BW\ 4$L#!!0
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MFDZJ,@(S'-2!<;H/1VRC'9W$0+;T#4+C#4B_U=J=&1]@_*HMOP%02P,$%
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M,"F%37%,B-W/B[_Z+9VRG>7%C/PQR&1NN2X[K$!2Z(-&)KB!)QOP58>VV"?
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M1M_YR][3FR+X_Z.Z7E[!_:,<\0O_L@\IWSOS%>!U%<?]&H-A(\GZ0^DW67U
M)O"R5J6^'\ M!'G+7Y<*7DM9^$$4[D1&?HES';T%QW>.:JH:]IF[]),)%:;/
M.L>QR-0/[_P?$/G^W@30,5H42@X/S069T?;2==@;]I?=@S0],/T#7FDY3L??
MM"+,80.7*;,1-2,O0HE.\M>Y0GZQFDWY_H?9;Y:M;;OD7V9# XA,4GZ^+'V;
M?OWMI?SFV7"[_'3<.],N,2U=VP4]>G'^^-LSZ;O%#YW?\"^@S7W7^37_N;*&
MM XWT/6%]UW\@ W2;^+]\$]02P,$%     @ VX9C5#Z^PNEL!   ( H  !D
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M.>.B ^ZOK V[AUA@OB">_0U02P,$%     @ VX9C5$OD2\VB P  .PD  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULI5;;CMLV$/T50BT*&V!6$JF;
M7=O ;M*@ 1+$2#;M0]$'6AK;1"31)>EXMU_?(64KWHVMH.V+37)FSMS.D)H=
ME/YLM@"6/#1U:^;!UMK=- Q-N85&F!NU@Q8E:Z4;87&K-Z'9:1"5-VKJD$51
M%C9"ML%BYL^6>C%3>UO+%I::F'W3"/UX![4ZS(,X.!U\D)NM=0?A8K83&_@(
M]M-NJ7$7]BB5;* U4K5$PWH>W,;3N\SI>X7?)!S,V9JX3%9*?7:;-]4\B%Q
M4$-I'8+ OR_P$NK: 6$8?QTQ@]ZE,SQ?G]!?^]PQEY4P\%+5O\O*;N=!$9 *
MUF)?VP_J\"L<\TD=7JEJXW_)H=--TH"4>V-5<S3&"!K9=O_BX5B',X,BNF+
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M&=QV#^)7]>ZSXIW0. (& UBC:723XYCJ[JGN-E;M_/.X4A8?6[_<XM<-:*>
M\K52]K1Q#OKOI<4_4$L#!!0    ( -N&8U3?I1CEJ@,   8(   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;(U5VW+;-A#]E1TUZ=@SK$B %"6YLF;D
MVR0/23QVG#QT^@"1*Q%CD&  4++_O@M2HI76<OH@$9?=LV<OV)UMM7FT!:*#
MIU)5]GQ0.%>?A:'-"BR%'>H:*[I9:5,*1UNS#FUM4.2M4JE"'D5I6 I9#>:S
M]NS6S&>Z<4I6>&O -F4IS/,%*KT]'[#!_N!.K@OG#\+YK!9KO$?W4-\:VH4]
M2BY+K*S4%1A<G0\6[.PB\?*MP#>)6WNP!N_)4NM'O_F8GP\B3P@59LXC"/IL
M\!*5\D!$X\<.<]";](J'ZSWZ3>L[^;(4%B^U^BYS5YP/)@/(<24:Y>[T]@/N
M_!EYO$PKV_[#MI,=CP:0-=;I<J=,#$I9=5_QM(O#@<(D.J+ =PJ\Y=T9:EE>
M"2?F,Z.W8+PTH?E%ZVJK3>1DY9-R[PS=2M)S\^_"&%$YN$(C-\)'"$Z^BJ5"
M>SH+'1GP8F&V [OHP/@1,,;ADZY<8>&ZRC'_&2 D9CT]OJ=WP=]$O,)L"#$+
M@$><O8$7]^[&+5Y\#$_:3&G;& 2]@OM"T.)2U-()%< =6C0;M+"H<OCB"C1P
M_:.1[AD^5@X-6@=_+9;6&2JEO]\@D_1DDI9,<H3,'6:ZRJ22HBU0(I05HEHC
MR I60AK8"-6T1+>[+.5]EEY+SMO6%O2&_FV/?#QJT]_]URY("\+"2BMZSO8,
M/C?EDN)$\KM*LO"E<=:)*I?5&FX\Y+<]Y"O%MB X?Y!AB].EFDV!!>DD"1A/
MX1U,@E$T"<9I M=/:#)I,8<3%B1L$L3I]!1.DB"-TR!FXU.X?,V;WW^;<,;_
MA),X2*8LF/+)*=";IA=; 3[M U#6E-=>EHVB8!Q-7R?((^#I*!B/QD1O1&><
M3P[)D0O!F'-/;30*TG'T*V)L'#!/_U>L3GB0\.3T""L&:1)$\<B32H.(C>$K
M)9'J5E+[(E[_*\$_XY*$I5LJ?VH^!-%8GU:OVI6 WPE++;WV-44%T=)H(W3S
M8JTFK+VIA_MWT3"=^B\;4@ ?J%48]>R!;/L>:R,S[*[C5HP/XPG<2?OXQ\J@
M#^'N,1IR"B(2>D__+'I/&:BIV1/+0JO<&Y4Z!Z<IFEUF@ TC>$9A7A:]RJ'M
MC584"^5?_C0:1H2\^_32N=S('*E-/$LD4Y^E\K_7>D)XT)M+-.MV EG(=%.Y
MKDWWI_V06W2]_46\FY"?A%G+RH+"%:E&0S]33#=UNHW3==OIE]K1W&B7!0UJ
M-%Z [E=:N_W&&^A'__P?4$L#!!0    ( -N&8U14@6AOI@D  ,@9   9
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M]+8NXUO#]B+-R7>,W_>J*&F3M:MY/"DRS;LM%-4Y=ETJJW?6N,B1>P/H?&\
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M*ZTPO]$"O%_4:-7]%]I@^/'FZO]02P,$%     @ VX9C5)0D366*!@  DA,
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M#8,,W;WI7H"Z@=-;_^HRT\[IC?]<JW*A#!%@?:FUZP>D8'B&N_H/4$L#!!0
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MR76!T33C9!@W3@^A&^^TP]X>EBT.4V&\ -[OM7;GC3<PC^?UWU!+ P04
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M2VE(P<XLZ<E$90/H?B6E.3B6H'^$I_\ 4$L#!!0    ( -N&8U0?-%(MGP(
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M! &''!T"M;\]W /G#LC*^#M@!B.E2SRUC^A??.VVEATU<*_X+U9@O0AN U)
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MY,W:OEN@78#=+Y7"H^,(QI<P>P502P,$%     @ VX9C5*I).M)* @  Q@4
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MU6H\W?9]L^F;]/2-2? I2\M%$7Q(9WK6[F!L%-UI2UZTO2'>'F_U]%U \5E
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MCDG4$\X40$+](#FTP*,V  A'K*NF0RID/0Y&@1+43PEO\&[;^H+7*]+6J?'
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MH1=9,JLR>YX]ZLJ2PA<U0!-QVKM5 O @AKM=)1S7I@0C/5LT :00 Y%"V 3
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M+C6YUAN&C7OLT'@'MUYK33O#;Q"?S_D?4$L#!!0    ( -N&8U1H3* <" 0
M )0/   9    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;*U7WX^;.!#^5ZSH
M'GI2LV#SNTHB93<;7:56M^IJ[QZJ/CC@)%8!Y["SV?[W9QL"! R;G.XEP3#S
MS>=A_ TS.['B)]\3(L!;EN9\/MD+<?AD63S>DPSS.W8@N7RR946&A5P6.XL?
M"H(3[92E%K)MW\HPS2>+F;[W5"QF["A2FI.G O!CEN'BUSU)V6D^@9/SC6]T
MMQ?JAK68'?"./!/Q<G@JY,JJ41*:D9Q3EH.";.>3)?RTAH%RT!9_47+BK6N@
MMK)A[*=:?$[F$ULQ(BF)A8+ \N^5/) T54B2QS\5Z*2.J1S;UV?TM=Z\W,P&
M<_+ TK]I(O;S23@!"=GB8RJ^L=,?I-J0I_!BEG+]"TZEK2\CQD<N6%8YRW5&
M\_(?OU6):#F@(0=4.:!K'9S*P;G6P:T<W&L=O,K!N];!KQQ\G?LR63K3*RSP
M8E:P$RB4M413%_IU:6^98)JKRGH6A7Q*I9]8?"'RM7 P!;JFIFP[/7("EIP3
MP0'.$Z -P!>*-S2E@DK;#RLB,$WY[S-+2 8*QXJK:/=E-#00#2+PE>5BS\%C
MGI#D$L"2U&O^Z,S_'HTBKDA\!QSX$2 ;P8?E"GSXS<3KX0:4E^<AE-7U*/8P
ME\<;4(:YK*]&@9&1RT6ZG;I<' WK#,"65?+G=OK25,GWY8:+0DK$CY$ ;AW
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MM0GYSK]]KK68$X=I/Z#';!HDDU&<^H][N(QZ+J.C7*Y :X(5%40:B5N@ZHC
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M?B'2G&8%*KHV(>%=8O(LCWW8<:#%KNE,5D*;/J=YW9K>E4IK8+ZOA="O [M
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MRY<(KMP_;&O;T(-DK;3(:[#Q(&=%]:0O]40< :+1!4!4 Z+7 N(:$)\!R"5
MKP:XJ0XJ*6X>%E33V42*+4AK;=CLBYM,AS;R66'C_J"E^<H,3L^^4REIH6&!
MDFVHC0%\A(<J"4 LX4:9C"AMB!0\*DR!%: SA#FGR3,\))G@J.!W9P%WDB6L
M6,$WD2('DY10TRMXOT!-&5<?)H$V;MO!@Z1V<5ZY&%UPD42&L-"9@L]%BNDI
M06#T-J*CO>AYU,FXP,2'F/P*41B1'5+Y"P2@,BI1M;AW^WJR\"K9XM5D9&S)
M.M3&38ACQQE?XF0JX4*M)=J +BF3L*%\C9 CM;UF%6O[A3/ZQ#C3S 3T3TL"
M3&.N_NIPH=>XT',N]"ZX<,_4\\>E1$-9:#0SHT%2C6VYT$T4^H/!N[8878/%
MO3;8HAM&_$'TKD-^OY'?[^3Y_%*:,F<6CUDM*91FJ8D4M !\09DPA? /_!CK
M:CHJXKXCMC5\,XLGP>98^56+19?%B9Y!HV?P.CTNS:$TRQYA([BI'R9_=FTZ
MN@D)"?U>OS6PUX&C\QA5JKN!XZ$_#KMB.VSF8MA)M*]P'52CAFKT?RW4<>/"
MN%/-E\.@)DUA6^\.[]?*Y6T5\ \F7SN+W+P:9'B4<6;ACL8GO[,T_A%"_/ZP
M/4])>-C=PDX]CV;'D'QG-Z7C7'VKGGJ44^_B<PDM5I$?CRYH.-JAR<\JGE>8
M3!D<MRZRJSC2N59(=- 2_5>5L&8^+F/D/ !=)J<>'S9/$O_L6G>%<1SZX?ET
MUOZ_'7BJZK ?D^Z=K5&5L@U+L4AAQY"GK6JN;:V7Q+P95VD)C@ZS.<J5NQ0H
M2,2ZT-41K^EM+AXW[KA]UC^W%Q)W2#[05+>9;U2NF#G0<EP:RM ?FHR1U06A
M:FA1NB/SD]#F .Y>,W.I0FD-S/>E$'K?L ,TU[39OU!+ P04    " #;AF-4
M.9?A+CL&  !=(   &0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6REFMMN
MXS80AE^%,'J1!3:Q>)+$16(@L5TT%VV##=J]9FS:%B*)7HF.=X$^?*E#3%FB
M:&6% (D/_XPX0_*;H93;H\Q>\YT0"OQ(XC2_F^R4VG^93O/53B0\OY%[D>IO
M-C)+N-)OL^TTWV>"KTNC))XBS_.G"8_2R>RV_.PIF]W*@XJC5#QE(#\D"<]^
M/HA8'N\F</+^P==HNU/%!]/9[9YOQ;-0_^R?,OUN>O*RCA*1YI%,028V=Y-[
M^&5)@\*@5/P;B6/>> V*4%ZD?"W>/*[O)EXQ(A&+E2I<</WG3<Q%'!>>]#B^
MUTXGIVL6ALW7[]Y_+X/7P;SP7,QE_"U:J]W=))R M=CP0ZR^RN,?H@Z(%OY6
M,L[+W^!8:7TT :M#KF12&^L1)%%:_>4_ZD0T#"#I,4"U 1IJ@&L#/-2 U 9D
MJ &M#<K0IU7L9>(67/'9;2:/("O4VEOQHLQ^::WS%:7%0GE6F?XVTG9J]KSC
MF0!SOH\4C\$U>-8K<7V(!9 ;</[=U4(H'L7Y)ZV:WR_ U6^?;J=*#Z%P-%W5
MEWNH+H=Z+G=_V-X Z'\&R(/,8CYWFR_$Z@9@6)@C:#%?##?W+.;+P>;MP4]U
MVD^Y1Z?<H](?[O'WUR%Y$9G#$3XYPJ4CXIS$53U149X?Q/HS>!';*$VC= NN
M\D*0V^9K7GFFI>>"*F\SXD/?9Z%.T)ME3.0T)O+A,0&1KB^-AW3&0ZE'<!"R
MTWBJJ>X*W0.GIX%3YZS<)_*0*L>L^"='OC,#R^^'2/W4&(MYNA* J\:,Z-VU
M%UDDU[845&[]1F2(!!0QAELIZ JOH:<S1<YURZ[.AXQB']LS%9P"# 9,<3FU
M8"5SE=N""3K3= T1]5%CFJI@;,* 0)^TA$N+,*1$^[1'$YZB"3\X77JUNB<J
M[(P$^QX+64A;L76%]AE==H7M&3V+C9UB8\[8[M6UVHEKW0J\ZMZ#;S,A=+%W
M+7+HF0+BC=LOL%&+H'.8CQ4E*CI8JP/LK&2LETCH!;"5<8N2>!X.@M!OI;Q6
M-G,>DL GM"?GT. =(F<X3X>7.%J!OS<;O8+2K2M%AO00C\RV 31T$_I2MI>U
M_5FV,20$L9[,&,1"ZKST-YYE/%5@H1/SQHM6,7>%9(@+_7$5%1JV03?<ZNPX
M2M4#[))(ER 6!#U<A09%,!PYRV;G0_?6'P+IA]K'627Q&2,HL$>"#!V0=_GR
MKLE%A@X(CIM<U&B\W#MS3,-4NW8V'A6#+$J,( L);6/?HH0!9BP@/5L-&6"@
MC_>&0_HPU&T,>QHQB]*>D*5%V4G(>9@&9HB,VS'(P FYX?3+?5OM]XR7U \1
M@0%JY\PBA;K2!R%E[:1UI2BDD&'/ASU9,[Q$[A9U4 =7^QC0PEF5UA[.IG0U
M<<AP&[FY_0MM7.WQ;#(8Q"2$8;OCMDGM4[RT23M3?!ZDJ0_(W:M65 7_@4<=
M8UK43\"//%N#O8[:M0E,V4!LY-G4E #L+@&7*^F\]G#&/^J%K(T:BPYA2^XM
M.HPP]GHV##8U"+MKT$7,8%.#L+L&76QV:_OF J($A[B])BVZ0$?K!^VD='5Z
MF3/84^-QX^[#@!)3K,:Y3!*9@F<E5Z_@Z9"M=CP7X'[ <0,;T&,WZ"\O3 -Z
M[ ;]Y86YK#V<G]R8_NDI6-B@%[M;U<LKR2 /#VI5^QMYW$41)1[&C7/J^:4-
MB/! $'W\A(D-B_!(%A'#(C*:1:3+CI!XT$.=&U 6:"$8(HK;.+(H]2E*=U-]
M]]@,C\A('A'#(S*21\3"#_OAVZ+L.7Q;E,[#-S%0(@.A-/P43AKW-D="B!@(
MD=$0(ET(.<^9Q$"(C(00,1 B(R%$+/V0ZVX",1 B R'TL=L*Q "(C 00-0"B
MHP%$+4V.IWN<]AG"HH-$MZQ^^P1A<\ATVTIZ*C\U^*$C\4,-?NA(_- N*OS0
MUP?-=EHL.HR1AD\[+5TA@Q2%?L^"I(8]="![JDY([LMGHA=Z<VKH0T?2AS:>
M=8RESYQVZ0,1ANUSZL*FP[B7Y-1 BHZ$%#60HN,@-:<62(4PZ%0XJXYZC3U:
MC7#:>#);/'C_DV?;*,U!+#;:T+L)=+JRZEEV]4;)??FP]D4J)9/RY4[PM<@*
M@?Y^(Z5Z?U,\_SW]1\'L?U!+ P04    " #;AF-4-WC0"R()   L-P  &0
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MSCFK(54!4!MYBAV(3NT&5!<Z:=(A TAG"YEB^04\^&$*GOUH6T95814<CJ0
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M+Y^$OQ1I(2"_?TB2_.U-\?C,[@&YD_\#4$L#!!0    ( -N&8U3:<S\D5@,
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MLCR)JLYJ!E$0E__]URH0C0ZTJP.I.I"^'6C5@?;MP*H.K&\'7G4H7+=+WXO
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MN^H9-8:JAP>6O0-"Q8>$"@H;-E>V#2:HX'Q5F1>M(E."0+G [DCH "4 FVM
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M;S36/HGZ4E!/%-_:8_***WWHML-,7Z1 &(!^ON9<O4[,"]JKV?QO4$L#!!0
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M(.AT\F$1,.PGOS>L;ORT';2EEOEE18\%H N@_4)K>S9<@O'Y2?\"4$L#!!0
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M[Y PUAK-#&STK;>.%V$F459*Z%VB_=1XQID2^K;0#X+7A!+UBKZ@E4['.*>
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MH.'5B<Y['XAZQRGV*XK],Q2+JQ80\821?^__=D4<^^>(+9HL:L3"BEC8+B%
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MG+H ?A,>WL+#[4UV)QYP*^EWJ\4S'P4/Z)7,IX<'U$M.7?*^"4_0QK,0W7C
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M<%%UPPUG.5<6 .]74IKCQ-Y6VW]GS/\%4$L#!!0    ( -N&8U37M>Z%M (
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M=@;T?J&4W77<!/67SNPW4$L#!!0    ( -N&8U37C-RK$@,  ,L)   9
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M.P()4>W%I&T8V;A2O9,&"K][+.$NQY0-@.][*<VY83OH;X>K_P%02P,$%
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M;L&U<]/KD*O79]O)=QJOV^8#SV]4+)-<@I0MM*%[;+Z(B-TWD]U \77Q!O[
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M;N(-/9+ AA6IN9:']U YU+-\L4RU>Y)#N7: %N-"&YE58!QG7)1O=EL%X@A
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ VX9C5*1AGS,,!@  YS0   \
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M>\:+[$XS]]$L[@NBV"WP6]5%,8)M\^I6\?SU=SJOOS&Z_@]02P,$%     @
MVX9C5*N<,4MN @  VB\  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<\W:2VZC0!2%X:U8+""X;MT':<49]2335C: G/)#L8T%M#K9?5O.P#ZH!SV)
M."-4("Z_&'Q"P-.O<FC'?7<:=OOSL/@X'D[#JMJ-X_E'70_K73FVPT-W+J?+
MD4W7']OQLNRW];E=O[?;4LMRZ75_/Z-Z?KJ?N7C]/)?_F=AM-OMU^=FM?Q_+
M:?S'X/I/U[\/NU+&:O':]MLRKJKZXW#;/=3737JX3*X6+V^KJG]Y2U4]=Y!
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MWLUWZCV,GX<RW'J^UGC][Z1ZO)Q;;I>_+K]V3F["%>?ZOF)X_@M02P,$%
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M2P$"% ,4    " #;AF-4!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -N&8U1,71P<[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M -N&8U297)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ VX9C5"'<NWHB!@  _1P  !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M -N&8U1B,M&C( (  &X%   8              " @68.  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " #;AF-4X# _XZX%   F%0  &
M            @(&\$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ VX9C5#L=9E4@ @  @@0  !@              ("!H!8  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( -N&8U16BHN;* 4  ( 2
M   8              " @?88  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " #;AF-4MI]3:*T&  !Y'@  &               @(%4'@
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ VX9C5+#%5@WE
M!@  ^1L  !@              ("!-R4  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( -N&8U1N1N>ANP0  $8*   8              "
M@5(L  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #;AF-4
M" M_=0 $  !."0  &               @(%#,0  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ VX9C5 ".F;4 &0  T4X  !D
M     ("!>34  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -N&8U1K\9C=V08  -0/   9              "
M@<9F  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ VX9C
M5-K63T]="0  6AL  !D              ("!UFT  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " #;AF-4H)! ?'\'  !?$@  &0
M        @(%J=P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( -N&8U1ZG8/HO@(    &   9              " @2!_  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ VX9C5":3D5&E P  2 @
M !D              ("!%8(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " #;AF-4.0$("U8$   X"0  &0              @('QA0
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( -N&8U3&><*W
MEP0  #P*   9              " @7Z*  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ VX9C5$-?.EFQ!P  >Q$  !D
M ("!3(\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #;
MAF-495KD&#\(  #=$@  &0              @($TEP  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( -N&8U3B,""P)P<   83   9
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M970R."YX;6Q02P$"% ,4    " #;AF-4&,"*2SL#  #A!@  &0
M    @($GM@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M -N&8U0*P^I7<P(  # %   9              " @9FY  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ VX9C5'A)+G&C&   'T\  !D
M             ("!0[P  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " #;AF-4/K["Z6P$   @"@  &0              @($=U0  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( -N&8U0Y^D$U=P0
M "P*   9              " @<#9  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ VX9C5$OD2\VB P  .PD  !D              ("!
M;MX  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #;AF-4
MWZ48Y:H#   &"   &0              @(%'X@  >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( -N&8U14@6AOI@D  ,@9   9
M      " @2CF  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ VX9C5)0D366*!@  DA,  !D              ("!!?   'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #;AF-4MM-G2;L"   ^!@
M&0              @('&]@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( -N&8U1*=A%!00<  'X0   9              " @;CY  !X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ VX9C5.%'(:=E
M @  ^@0  !D              ("!, $! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " #;AF-4Q(>$[9D"  !X!0  &0
M@(', P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -N&
M8U3Q[L!_= ,  *H'   9              " @9P& 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ VX9C5'TFI)LM P  H 8  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( -N&8U3T43_SKP<  "HU   9
M  " @5$8 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
MVX9C5(O&;Z)H @  2@<  !D              ("!-R ! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " #;AF-4:$R@' @$  "4#P  &0
M            @('6(@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( -N&8U2:*G//CP(  %@(   9              " @14G 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ VX9C5(BBL%:& P
M*PT  !D              ("!VRD! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " #;AF-4"<7#^^4#   9#P  &0              @(&8
M+0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( -N&8U2U
MF0[[P0,  +(-   9              " @;0Q 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ VX9C5#F7X2X[!@  72   !D
M     ("!K#4! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -N&8U0DVGQ]W08   ,O   9              "
M@5)0 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ VX9C
M5!;R>SE[ P  2@X  !D              ("!9E<! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    " #;AF-43][HM$@#   +"@  &0
M        @($86P$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( -N&8U1J'\_HY@,  *8-   9              " @9=> 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ VX9C5*C\0TAC @  Q04
M !D              ("!M&(! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    " #;AF-483TFBAL"  "*!   &0              @(%.90$
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( -N&8U0'T)\'
M&P,  *4*   9              " @:!G 0!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ VX9C5$+V\,>$ P  'PP  !D
M ("!\FH! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #;
MAF-4]UQF9_H"  !B"0  &0              @(&M;@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( -N&8U1(:4I,FP0  %8/   9
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M970W,RYX;6Q02P$"% ,4    " #;AF-43#WQ<OP"  #U"   &0
M    @(%>B $ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M -N&8U37C-RK$@,  ,L)   9              " @9&+ 0!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ VX9C5/<HA<ER P  *0H  !D
M             ("!VHX! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    " #;AF-4W>7XK'<"  "3!@  &0              @(&#D@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( -N&8U0C)]1M& (
M *D$   9              " @3&5 0!X;"]W;W)K<VAE971S+W-H965T-S@N
M>&UL4$L! A0#%     @ VX9C5+3T;PYJ!   Q1(  !D              ("!
M@)<! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " #;AF-4
MI;; 9_,"   Y"   &0              @($AG $ >&PO=V]R:W-H965T<R]S
M:&5E=#@P+GAM;%!+ 0(4 Q0    ( -N&8U2*'UO>/0,  ' *   9
M      " @4N? 0!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%
M  @ VX9C5 >KM<(L P  "!,   T              ( !OZ(! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #;AF-4EXJ[',     3 @  "P
M@ $6I@$ 7W)E;',O+G)E;'-02P$"% ,4    " #;AF-4I&&?,PP&  #G-
M#P              @ '_I@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MVX9C5*N<,4MN @  VB\  !H              ( !.*T! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ VX9C5$3DWU@> @  ERX  !,
M             ( !WJ\! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %D
,60!F&   +;(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>306</ContextCount>
  <ElementCount>363</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>86</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Incorporation and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations</Role>
      <ShortName>Incorporation and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Basis of Financial Statement Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation</Role>
      <ShortName>Basis of Financial Statement Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103103 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - Significant Judgments, Estimates and Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions</Role>
      <ShortName>Significant Judgments, Estimates and Assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109105 - Disclosure - Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CashEquivalents</Role>
      <ShortName>Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2111106 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2114107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2119108 - Disclosure - Warrant Derivative</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivative</Role>
      <ShortName>Warrant Derivative</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2124109 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2130110 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2137111 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2139112 - Disclosure - Contract Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiability</Role>
      <ShortName>Contract Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2143113 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2145114 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2147115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2153116 - Disclosure - Capital Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</Role>
      <ShortName>Capital Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2156117 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2160118 - Disclosure - Additional Cash Flow Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</Role>
      <ShortName>Additional Cash Flow Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2164119 - Disclosure - Indemnification of Officers and Directors</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors</Role>
      <ShortName>Indemnification of Officers and Directors</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2165120 - Disclosure - Economic Dependence</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependence</Role>
      <ShortName>Economic Dependence</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2167121 - Disclosure - Other Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpenses</Role>
      <ShortName>Other Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2170122 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2173123 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyandEquipment</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Warrant Derivative (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables</Role>
      <ShortName>Warrant Derivative (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/WarrantDerivative</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareCapital</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareBasedCompensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2340307 - Disclosure - Contract Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityTables</Role>
      <ShortName>Contract Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ContractLiability</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2348308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2354309 - Disclosure - Capital Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</Role>
      <ShortName>Capital Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2357310 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/FinancialInstruments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2361311 - Disclosure - Additional Cash Flow Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables</Role>
      <ShortName>Additional Cash Flow Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2368312 - Disclosure - Other Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpensesTables</Role>
      <ShortName>Other Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/OtherExpenses</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2371313 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CashEquivalentsDetails</Role>
      <ShortName>Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CashEquivalents</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2417406 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Right-of-use Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails</Role>
      <ShortName>Leases - Total Undiscounted Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2421408 - Disclosure - Warrant Derivative - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails</Role>
      <ShortName>Warrant Derivative - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails</Role>
      <ShortName>Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails</Role>
      <ShortName>Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2426411 - Disclosure - Share Capital - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Share Capital - Equity Warrants Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails</Role>
      <ShortName>Share Capital - Equity Warrants Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails</Role>
      <ShortName>Share Capital - Summary of Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Share-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails</Role>
      <ShortName>Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Contract Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails</Role>
      <ShortName>Contract Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails</Role>
      <ShortName>Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Commitments</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Contingencies</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails</Role>
      <ShortName>Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2451427 - Disclosure - Income Taxes - Summary of Non-capital Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails</Role>
      <ShortName>Income Taxes - Summary of Non-capital Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2455429 - Disclosure - Capital Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails</Role>
      <ShortName>Capital Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2458430 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2459431 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails</Role>
      <ShortName>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2462432 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2463433 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2466434 - Disclosure - Economic Dependence (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails</Role>
      <ShortName>Economic Dependence (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/EconomicDependence</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2469435 - Disclosure - Other Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpensesDetails</Role>
      <ShortName>Other Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/OtherExpensesTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2472436 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="oncyf-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2474437 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SubsequentEvents</ParentRole>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="oncyf-20211231.htm">oncyf-20211231.htm</File>
    <File>articles.htm</File>
    <File>ex121ceocertification2021.htm</File>
    <File>ex122cfocertification2021.htm</File>
    <File>ex12onc-2017byxlaws1636459.htm</File>
    <File>ex131ceocertification2021.htm</File>
    <File>ex132cfocertification2021.htm</File>
    <File>ex151-2021mda.htm</File>
    <File>ex152ey2021consent.htm</File>
    <File>ex21exdescriptionofsecurit.htm</File>
    <File>ex418mattcoffeyamendment3-.htm</File>
    <File>ex419kirklookamendment3-em.htm</File>
    <File>ex420allisonhagermanamendm.htm</File>
    <File>ex421andrewdeguttadauroame.htm</File>
    <File>ex422thomasheinemanamendme.htm</File>
    <File>ex80subsidiaries2021.htm</File>
    <File>oncyf-20211231.xsd</File>
    <File>oncyf-20211231_cal.xml</File>
    <File>oncyf-20211231_def.xml</File>
    <File>oncyf-20211231_lab.xml</File>
    <File>oncyf-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>oncyf-20211231_g1.jpg</File>
    <File>oncyf-20211231_g2.jpg</File>
    <File>oncyf-20211231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="722">http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>127
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "oncyf-20211231.htm": {
   "axisCustom": 4,
   "axisStandard": 19,
   "contextCount": 306,
   "dts": {
    "calculationLink": {
     "local": [
      "oncyf-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "oncyf-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "oncyf-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "oncyf-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "oncyf-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "oncyf-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 492,
   "entityCount": 1,
   "hidden": {
    "http://www.oncolyticsbiotech.com/20211231": 2,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 8
   },
   "keyCustom": 71,
   "keyStandard": 292,
   "memberCustom": 56,
   "memberStandard": 27,
   "nsprefix": "oncyf",
   "nsuri": "http://www.oncolyticsbiotech.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.oncolyticsbiotech.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103103 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - Significant Judgments, Estimates and Assumptions",
     "role": "http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions",
     "shortName": "Significant Judgments, Estimates and Assumptions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109105 - Disclosure - Cash Equivalents",
     "role": "http://www.oncolyticsbiotech.com/role/CashEquivalents",
     "shortName": "Cash Equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111106 - Disclosure - Property and Equipment",
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114107 - Disclosure - Leases",
     "role": "http://www.oncolyticsbiotech.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119108 - Disclosure - Warrant Derivative",
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivative",
     "shortName": "Warrant Derivative",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124109 - Disclosure - Share Capital",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapital",
     "shortName": "Share Capital",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130110 - Disclosure - Share-Based Compensation",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137111 - Disclosure - Loss Per Common Share",
     "role": "http://www.oncolyticsbiotech.com/role/LossPerCommonShare",
     "shortName": "Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139112 - Disclosure - Contract Liability",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiability",
     "shortName": "Contract Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.oncolyticsbiotech.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143113 - Disclosure - Commitments",
     "role": "http://www.oncolyticsbiotech.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145114 - Disclosure - Contingencies",
     "role": "http://www.oncolyticsbiotech.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147115 - Disclosure - Income Taxes",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153116 - Disclosure - Capital Disclosures",
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosures",
     "shortName": "Capital Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156117 - Disclosure - Financial Instruments",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160118 - Disclosure - Additional Cash Flow Disclosures",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures",
     "shortName": "Additional Cash Flow Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164119 - Disclosure - Indemnification of Officers and Directors",
     "role": "http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors",
     "shortName": "Indemnification of Officers and Directors",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfEconomicDependenceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165120 - Disclosure - Economic Dependence",
     "role": "http://www.oncolyticsbiotech.com/role/EconomicDependence",
     "shortName": "Economic Dependence",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfEconomicDependenceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167121 - Disclosure - Other Expenses",
     "role": "http://www.oncolyticsbiotech.com/role/OtherExpenses",
     "shortName": "Other Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170122 - Disclosure - Related Party Transactions",
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
     "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:OtherCurrentReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2173123 - Disclosure - Subsequent Events",
     "role": "http://www.oncolyticsbiotech.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Leases (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Warrant Derivative (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables",
     "shortName": "Warrant Derivative (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Share Capital (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalTables",
     "shortName": "Share Capital (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340307 - Disclosure - Contract Liability (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityTables",
     "shortName": "Contract Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2354309 - Disclosure - Capital Disclosures (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables",
     "shortName": "Capital Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357310 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:CashFlowOperatingCapital1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361311 - Disclosure - Additional Cash Flow Disclosures (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables",
     "shortName": "Additional Cash Flow Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:CashFlowOperatingCapital1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2368312 - Disclosure - Other Expenses (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/OtherExpensesTables",
     "shortName": "Other Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2371313 - Disclosure - Related Party Transactions (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2f3e572ad5cd4feea41d839ed408d512_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:PropertyPlantandEquipmentAnnualDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2f3e572ad5cd4feea41d839ed408d512_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:PropertyPlantandEquipmentAnnualDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:NumberOfStockOptionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:NumberOfStockOptionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Cash Equivalents (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/CashEquivalentsDetails",
     "shortName": "Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i113d492fc4cf424c8489d5302adf402d_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413404 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2e928b35b509443e9b3f89941d035b11_I20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416405 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i113d492fc4cf424c8489d5302adf402d_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417406 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
     "shortName": "Leases - Right-of-use Assets and Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails",
     "shortName": "Leases - Total Undiscounted Lease Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ProceedsfromWarrantExercises1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421408 - Disclosure - Warrant Derivative - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
     "shortName": "Warrant Derivative - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i113d492fc4cf424c8489d5302adf402d_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:WarrantsAndRightsOutstanding1",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
     "shortName": "Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "idfae6e354e8248509fd71f314f2f7bb7_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "oncyf:ClassOfWarrantOrRightOutstanding1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails",
     "shortName": "Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "idfae6e354e8248509fd71f314f2f7bb7_I20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "oncyf:FairValueofWarrantIssuedPerWarrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i113d492fc4cf424c8489d5302adf402d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426411 - Disclosure - Share Capital - Schedule of Share Capital (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
     "shortName": "Share Capital - Schedule of Share Capital (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "iedc65d68837a4eacac34675a1cd9779e_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ShareIssueRelatedCost",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
     "shortName": "Share Capital - Schedule of Share Capital Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2902b2520fea41089f98be9b8eace36f_I20180927",
      "decimals": "INF",
      "lang": "en-US",
      "name": "oncyf:SharePurchaseAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Share Capital - Equity Warrants Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
     "shortName": "Share Capital - Equity Warrants Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i12d8b8a2f06d4c838611847df4e4d947_D20170601-20170601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "oncyf:IssueOfEquityShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:WarrantsAndRightsOutstanding1",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails",
     "shortName": "Share Capital - Summary of Outstanding Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i886943a54e40452081d9137b1996e966_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i113d492fc4cf424c8489d5302adf402d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails",
     "shortName": "Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i762faf08df5c4521a4f2689a278651e0_I20181231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i21ac1e8adaee40f6b58f4f0a7d541a1a_I20181231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
     "shortName": "Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Share-Based Compensation - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "id035d2b8dd6d43178b57bd66e4788c61_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails",
     "shortName": "Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i8bdb149a74484759861585dd847d705c_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails",
     "shortName": "Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i0ef39cf43fa64dfbbfb9e8655e1baa24_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Loss Per Common Share (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails",
     "shortName": "Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ContractLiabilityRecognitionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Contract Liability - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails",
     "shortName": "Contract Liability - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ContractLiabilityRecognitionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i113d492fc4cf424c8489d5302adf402d_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ContractLiabilities",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails",
     "shortName": "Contract Liability - Schedule of Contract Revenues and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i64f58da6cebe4bf3ae5166d65f25cf87_I20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:ContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:PurchaseObligation1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - Commitments (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/CommitmentsDetails",
     "shortName": "Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:PurchaseObligation1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Contingencies (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AccountingProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AccountingProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ie39699155be34d93b5eee0afd15baccc_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails",
     "shortName": "Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ie39699155be34d93b5eee0afd15baccc_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "iafea390033d44f86b623be26aa1611fc_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451427 - Disclosure - Income Taxes - Summary of Non-capital Losses (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
     "shortName": "Income Taxes - Summary of Non-capital Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "iafea390033d44f86b623be26aa1611fc_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455429 - Disclosure - Capital Disclosures (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
     "shortName": "Capital Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i921a0b76be5e4a5192afdce2bfa1f576_I20200612",
      "decimals": "INF",
      "lang": "en-US",
      "name": "oncyf:EquityAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentDerivativeFinancialLiabilities",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458430 - Disclosure - Financial Instruments - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i72934bebe99040b6b7e0c0c2f19de911_D20210101-20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ibe633dda267842029258e53a782fe561_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459431 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
     "shortName": "Financial Instruments - Schedule of Balances in Foreign Currencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i06647bdfde1c470b8b4d0a645c9ba2d5_I20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:CashFlowOperatingCapital1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462432 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails",
     "shortName": "Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:CashFlowOperatingCapital1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ProceedsfromInterestReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463433 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails",
     "shortName": "Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ProceedsfromInterestReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ifd70dd98103f43b6af3a92c583cabdb7_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ConcentrationRiskNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "manufacturer",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466434 - Disclosure - Economic Dependence (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails",
     "shortName": "Economic Dependence (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "ifd70dd98103f43b6af3a92c583cabdb7_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ConcentrationRiskNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "manufacturer",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469435 - Disclosure - Other Expenses (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails",
     "shortName": "Other Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i86f880390f904058bf8a9cf3258849d0_D20210101-20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Incorporation and Nature of Operations",
     "role": "http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations",
     "shortName": "Incorporation and Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472436 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i4ede084a4122418cb65982299416868e_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:IssueOfEquityShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474437 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i9757885e4d9e44f386e37be5103b4760_D20220201-20220228",
      "decimals": "0",
      "lang": "en-US",
      "name": "oncyf:PaymentsForExecutoryContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Basis of Financial Statement Presentation",
     "role": "http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation",
     "shortName": "Basis of Financial Statement Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20211231.htm",
      "contextRef": "i2810b19dc2f24df9b90352c780bea9ee_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 86,
   "tag": {
    "country_BB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BARBADOS",
        "terseLabel": "BARBADOS"
       }
      }
     },
     "localname": "BB",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "CANADA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "U.S. dollars"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r200",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r200",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r200",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address",
        "terseLabel": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r200",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r200",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccountingProfit": {
     "auth_ref": [
      "r43",
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accounting profit",
        "terseLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "AccountingProfit",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "auth_ref": [
      "r50",
      "r57",
      "r78",
      "r82",
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and amortisation [member]",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income [member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AdditionalPaidinCapital": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      },
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "terseLabel": "Contributed surplus (note 10)"
       }
      }
     },
     "localname": "AdditionalPaidinCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions, net of foreign exchange impact"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share",
        "terseLabel": "Weighted average number of shares (diluted) (shares)"
       }
      }
     },
     "localname": "AdjustedWeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other operating receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in prepaid expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense",
        "terseLabel": "Depreciation - property and equipment (note 6, 21)"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in other operating payables",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based compensation (note 10, 21, 22)"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "auth_ref": [
      "r92",
      "r100"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for unrealised foreign exchange losses (gains)",
        "terseLabel": "Unrealized foreign exchange loss"
       }
      }
     },
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r21",
      "r60",
      "r126",
      "r137",
      "r138",
      "r159",
      "r169",
      "r172",
      "r182",
      "r183",
      "r185",
      "r191"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]",
        "terseLabel": "Aggregated time bands"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "auth_ref": [
      "r59",
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]",
        "terseLabel": "All levels of fair value hierarchy"
       }
      }
     },
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationExpense": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation expense",
        "terseLabel": "Depreciation - property and equipment"
       }
      }
     },
     "localname": "AmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of income and expense [abstract]",
        "terseLabel": "Analysis of income and expense [abstract]"
       }
      }
     },
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Statutory Canadian corporate tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r19",
      "r113",
      "r114",
      "r115",
      "r178",
      "r180"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r71",
      "r72"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic loss per common share (cad per share)"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r151",
      "r167",
      "r185"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "auth_ref": [
      "r50",
      "r54",
      "r78",
      "r79",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r156",
      "r162",
      "r163",
      "r193",
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountMember": {
     "auth_ref": [
      "r54",
      "r79",
      "r81",
      "r83",
      "r84",
      "r156",
      "r162",
      "r163",
      "r193",
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount [member]",
        "terseLabel": "Carrying amount"
       }
      }
     },
     "localname": "CarryingAmountMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r17",
      "r98",
      "r111"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "terseLabel": "Cash and cash equivalents (note 5)",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashEquivalents": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents [abstract]"
       }
      }
     },
     "localname": "CashEquivalentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r86",
      "r99"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r86",
      "r99"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "auth_ref": [
      "r93",
      "r100"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operations",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashOutflowForLeases": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash outflow for leases",
        "negatedLabel": "Payment of lease liabilities (note 7)",
        "negatedTerseLabel": "Payment of lease liabilities"
       }
      }
     },
     "localname": "CashOutflowForLeases",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]",
        "terseLabel": "Classes of liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]",
        "terseLabel": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]",
        "terseLabel": "Classes of other provisions [axis]"
       }
      }
     },
     "localname": "ClassesOfProvisionsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]",
        "terseLabel": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Commitments made by entity, related party transactions",
        "terseLabel": "Milestone payment in connection with share purchase agreement"
       }
      }
     },
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]",
        "terseLabel": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r4",
      "r32",
      "r104",
      "r106",
      "r107",
      "r110"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Net loss and other comprehensive income",
        "totalLabel": "Net comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComputerEquipmentMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer equipment [member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContractLiabilities": {
     "auth_ref": [
      "r120",
      "r123"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      },
      "en-us": {
       "role": {
        "label": "Contract liabilities",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year",
        "totalLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CounterpartiesAxis": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [axis]",
        "terseLabel": "Counterparties [axis]"
       }
      }
     },
     "localname": "CounterpartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CounterpartiesMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [member]",
        "terseLabel": "Counterparties"
       }
      }
     },
     "localname": "CounterpartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r175",
      "r186",
      "r187",
      "r188",
      "r189"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency risk [member]",
        "terseLabel": "Currency risk"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r22",
      "r107",
      "r108"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentContractLiabilities": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_ContractLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current contract liabilities",
        "verboseLabel": "Contract liability - current"
       }
      }
     },
     "localname": "CurrentContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current derivative financial liabilities",
        "terseLabel": "Warrant derivative (note 8)",
        "verboseLabel": "Warrant derivative"
       }
      }
     },
     "localname": "CurrentDerivativeFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities (note 7)"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r23",
      "r107",
      "r109"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepaid expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "CurrentPrepaidExpenses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "totalLabel": "Current income taxes"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through performance obligation being satisfied, contract liabilities",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deductible temporary differences for which no deferred tax asset is recognised",
        "terseLabel": "Unrecognized deferred tax asset"
       }
      }
     },
     "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r53",
      "r56"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "negatedLabel": "Depreciation expense",
        "verboseLabel": "Depreciation - right-of-use assets"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for deferred income tax [text block]",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for the derecognition of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for derecognition of financial instruments [text block]",
        "terseLabel": "Derecognition"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for earnings per share [text block]",
        "terseLabel": "Loss per common share"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for fair value measurement [text block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets [text block]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial liabilities [text block]",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for the impairment of financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for impairment of financial assets [text block]",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]",
        "terseLabel": "Accounting Standards and Interpretations Issued but Not Yet Effective"
       }
      }
     },
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Expected share price volatility",
        "verboseLabel": "Expected share price volatility"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Option life, share options granted",
        "terseLabel": "Expected hold period to exercise",
        "verboseLabel": "Expected hold period to exercise"
       }
      }
     },
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r71",
      "r72"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted loss per common share (cad per share)"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "Significant Judgments, Estimates and Assumptions"
       }
      }
     },
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "verboseLabel": "Basis of Financial Statement Presentation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of cash and cash equivalents [text block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CashEquivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCashFlowStatementExplanatory": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for a statement of cash flows."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of cash flow statement [text block]",
        "terseLabel": "Additional Cash Flow Disclosures"
       }
      }
     },
     "localname": "DisclosureOfCashFlowStatementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "terseLabel": "Schedule of share capital"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]",
        "terseLabel": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of commitments [text block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [text block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [line items]",
        "terseLabel": "Disclosure of contingent liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesTable": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to contingent liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [table]",
        "terseLabel": "Disclosure of contingent liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "terseLabel": "Schedule of depreciation rates",
        "verboseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [text block]",
        "terseLabel": "Reconciliation of change in fair value of warrant derivative"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [line items]",
        "terseLabel": "Disclosure of fair value measurement of liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [table]",
        "terseLabel": "Disclosure of fair value measurement of liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]",
        "terseLabel": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [text block]",
        "terseLabel": "Warrant Derivative"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivative"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of general information about financial statements [text block]",
        "terseLabel": "Incorporation and Nature of Operations"
       }
      }
     },
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Disclosure weighted average assumptions and fair value of options"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [text block]",
        "terseLabel": "Total undiscounted lease liability"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [line items]",
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [line items]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [table]",
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [table]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]",
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]",
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]",
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]",
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "terseLabel": "Schedule of number of other equity instruments"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Schedule of stock options and weighted average exercise prices of share options"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]",
        "terseLabel": "Schedule of weighted average remaining contractual life and outstanding stock options by exercise price",
        "verboseLabel": "Summary of outstanding warrants"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of objectives, policies and processes for managing capital [text block]",
        "terseLabel": "Capital Disclosures"
       }
      }
     },
     "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating expense [text block]",
        "terseLabel": "Other Expenses"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [line items]",
        "terseLabel": "Disclosure of other provisions [line items]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsTable": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to other provisions."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [table]",
        "terseLabel": "Disclosure of other provisions [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [text block]",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]",
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]",
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the range of exercise prices for outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of range of exercise prices of outstanding share options [text block]",
        "terseLabel": "Schedule of stock options outstanding and exercisable by range of exercise price"
       }
      }
     },
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue from contracts with customers [text block]",
        "terseLabel": "Contract Liability"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "terseLabel": "Share Capital"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapital"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]",
        "terseLabel": "Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [text block]",
        "terseLabel": "Schedule of related party transactions"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "terseLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]",
        "terseLabel": "Earnings per share [abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Impact of foreign exchange on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r1",
      "r3",
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Employee benefits expense",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r19",
      "r26",
      "r103",
      "r105",
      "r113",
      "r114",
      "r115"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Equity balance at end of period",
        "periodStartLabel": "Equity balance at beginning of period",
        "terseLabel": "Shareholders' equity",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "terseLabel": "Liabilities And Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options",
        "terseLabel": "Exercise price (cad per share)"
       }
      }
     },
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected dividend as percentage, share options granted",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses by nature [abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "ExpenseByNatureAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]",
        "terseLabel": "Contract liability balances"
       }
      }
     },
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on change in fair value of derivatives",
        "negatedTerseLabel": "Change in fair value of warrant derivative (note 8)",
        "terseLabel": "Change in fair value of warrant derivative (note 8)",
        "verboseLabel": "Change in fair value"
       }
      }
     },
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r14",
      "r61"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "verboseLabel": "Foreign exchange loss (note 21)"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r50",
      "r78",
      "r82",
      "r85",
      "r156",
      "r163",
      "r164",
      "r165",
      "r193",
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "auth_ref": [
      "r136",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross lease liabilities",
        "verboseLabel": "Total undiscounted lease liability"
       }
      }
     },
     "localname": "GrossLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]",
        "terseLabel": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r33",
      "r41",
      "r43",
      "r44",
      "r69",
      "r112",
      "r177"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedTerseLabel": "Income tax expense (note 15)"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund)",
        "terseLabel": "Cash taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefund",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes",
        "totalLabel": "Increase in cash"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in working capital",
        "negatedTerseLabel": "Net change in non-cash working capital (note 18)",
        "negatedTotalLabel": "Change in non-cash working capital related to operating activities"
       }
      }
     },
     "localname": "IncreaseDecreaseInWorkingCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of options, equity",
        "terseLabel": "Issued pursuant to stock option plan (note 10)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of warrants, equity",
        "terseLabel": "Issued pursuant to warrant derivative exercised (note 8, 9)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based compensation (note 10)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r97",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase through new leases, liabilities arising from financing activities",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "terseLabel": "Interest expense on lease liabilities (note 7)",
        "verboseLabel": "Interest expense on lease liabilities"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestIncomeOnCashAndCashEquivalents": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income on cash and cash equivalents",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Issued",
        "verboseLabel": "Issued shares"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital (note 9) \u00a0\u00a0Authorized: unlimited \u00a0\u00a0Issued: December\u00a031, 2021 \u2013 55,043,789 December\u00a031, 2020 \u2013 46,166,980"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share Capital",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Compensation of key management personnel"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Short-term employee compensation and benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, termination benefits",
        "terseLabel": "Termination benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationTerminationBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "auth_ref": [
      "r137",
      "r138",
      "r169",
      "r171",
      "r174",
      "r191"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years [member]",
        "terseLabel": "More than five years"
       }
      }
     },
     "localname": "LaterThanFiveYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r168",
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than five years [member]",
        "terseLabel": "One to five years"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "periodEndLabel": "Lease liabilities, ending balance",
        "periodStartLabel": "Lease liabilities, beginning balance"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities [abstract]",
        "terseLabel": "Lease Liabilities [Abstract]"
       }
      }
     },
     "localname": "LeaseLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      },
      "en-us": {
       "role": {
        "label": "Leasehold improvements [member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 2 of fair value hierarchy [member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "Level2OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "auth_ref": [
      "r59",
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]",
        "terseLabel": "Levels of fair value hierarchy [axis]"
       }
      }
     },
     "localname": "LevelsOfFairValueHierarchyAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r19",
      "r113",
      "r114",
      "r115",
      "r178",
      "r181"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities [member]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Major ordinary share transactions [member]",
        "terseLabel": "Share transactions"
       }
      }
     },
     "localname": "MajorOrdinaryShareTransactionsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r21",
      "r60",
      "r126",
      "r137",
      "r138",
      "r159",
      "r166",
      "r169",
      "r182",
      "r183",
      "r185",
      "r191"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]",
        "terseLabel": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]",
        "terseLabel": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]",
        "terseLabel": "Non-adjusting events after reporting period"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      },
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_ContractLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current contract liabilities",
        "terseLabel": "Contract liability (note 12)",
        "verboseLabel": "Contract liability - non-current"
       }
      }
     },
     "localname": "NoncurrentContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities (note 7)"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r20",
      "r137",
      "r138",
      "r169",
      "r174",
      "r191"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r152",
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Granted during the year (shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "negatedTerseLabel": "Vested during the year (shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding, end of the year (shares)",
        "periodStartLabel": "Outstanding, beginning of the year (shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r143",
      "r148",
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding, end of the year (shares)",
        "periodStartLabel": "Outstanding, beginning of the year (shares)",
        "terseLabel": "Number Outstanding (shares)"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercisable in share-based payment arrangement",
        "terseLabel": "Options exercisable, end of the year (shares)",
        "verboseLabel": "Number Exercisable (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "negatedTerseLabel": "Exercised during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options expired in share-based payment arrangement",
        "negatedTerseLabel": "Expired during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "negatedTerseLabel": "Forfeited during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Granted during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "periodEndLabel": "Share capital issued ending (shares)",
        "periodStartLabel": "Share capital issued, beginning (shares)",
        "terseLabel": "Share capital issued (shares)"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "terseLabel": "Number of shares outstanding"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OfficeEquipmentMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Office equipment [member]",
        "terseLabel": "Office equipment and furniture"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OperatingExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Operating expense",
        "terseLabel": "Operating (note 10, 21, 22)"
       }
      }
     },
     "localname": "OperatingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive loss items that may be reclassified to net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r24",
      "r35"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "terseLabel": "Translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other liabilities (note 13)"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentReceivables": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "terseLabel": "Other receivables (note 13)"
       }
      }
     },
     "localname": "OtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherProvisionsMember": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other provisions [member]",
        "terseLabel": "Other provisions"
       }
      }
     },
     "localname": "OtherProvisionsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherReceivables": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments for share issue costs",
        "terseLabel": "Payments for share issue costs"
       }
      }
     },
     "localname": "PaymentsForShareIssueCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Presentation of leases for lessee [abstract]",
        "terseLabel": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "terseLabel": "Proceeds from exercise of stock options (note 10)"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of ordinary shares",
        "terseLabel": "Net proceeds from issue of ordinary shares"
       }
      }
     },
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Proceeds from share issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r31",
      "r90",
      "r104",
      "r106",
      "r107",
      "r178",
      "r179",
      "r184",
      "r192"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net loss for the year",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r157",
      "r178",
      "r179"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r34",
      "r70"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Loss before the following"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r16",
      "r54"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Property and equipment (amortization), ending balance",
        "periodStartLabel": "Property and equipment (amortization), beginning balance",
        "terseLabel": "Property and equipment (note 6)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r55",
      "r75",
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Acquisition of property and equipment (note 6)"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r151",
      "r167",
      "r185"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]",
        "terseLabel": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r151",
      "r167",
      "r185"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "terseLabel": "Ranges"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [axis]",
        "terseLabel": "Ranges of exercise prices for outstanding share options [axis]"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [member]",
        "terseLabel": "Ranges of exercise prices for outstanding share options"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in property, plant and equipment [abstract]",
        "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "terseLabel": "Research and development (note 10, 21, 22)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve of share-based payments [member]",
        "terseLabel": "Reserve of share-based payments"
       }
      }
     },
     "localname": "ReserveOfSharebasedPaymentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r26",
      "r37"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 5.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r8",
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Regional licensing agreement"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "periodEndLabel": "Right-of-use assets, ending balance",
        "periodStartLabel": "Right-of-use assets, beginning balance",
        "terseLabel": "Right-of-use assets (note 7)"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "negatedLabel": "Share issue costs",
        "negatedTerseLabel": "Share issue costs (note 9)",
        "terseLabel": "Share issue related cost",
        "verboseLabel": "Transaction cost, warrant derivative"
       }
      }
     },
     "localname": "ShareIssueRelatedCost",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremiumMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium [member]",
        "terseLabel": "Contributed Surplus"
       }
      }
     },
     "localname": "SharePremiumMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]",
        "terseLabel": "Share-based payment arrangements"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares reserved for issue under options and contracts for sale of shares",
        "terseLabel": "Common shares reserved for issuance (shares)"
       }
      }
     },
     "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]",
        "terseLabel": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]",
        "terseLabel": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]",
        "terseLabel": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]",
        "terseLabel": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TaxEffectFromChangeInTaxRate": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect from change in tax rate",
        "terseLabel": "Impact of Alberta rate change"
       }
      }
     },
     "localname": "TaxEffectFromChangeInTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect of foreign tax rates",
        "terseLabel": "Foreign jurisdiction tax rate difference"
       }
      }
     },
     "localname": "TaxEffectOfForeignTaxRates",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "terseLabel": "Anticipated tax recovery"
       }
      }
     },
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r151",
      "r167",
      "r185"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "negatedTerseLabel": "Accounts payable and accrued liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r158",
      "r160",
      "r161",
      "r186",
      "r187",
      "r188",
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]",
        "terseLabel": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r158",
      "r160",
      "r161",
      "r186",
      "r187",
      "r188",
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]",
        "terseLabel": "Risks"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]",
        "terseLabel": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax credits for which no deferred tax asset recognised",
        "terseLabel": "Unused tax credits"
       }
      }
     },
     "localname": "UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UnusedTaxCreditsMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for tax credits that have been received and are carried forward for use against future taxable profit."
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax credits [member]",
        "terseLabel": "Non-refundable federal investment tax credits"
       }
      }
     },
     "localname": "UnusedTaxCreditsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses for which no deferred tax asset recognised",
        "terseLabel": "Unused tax losses"
       }
      }
     },
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses [member]",
        "terseLabel": "Non-capital losses"
       }
      }
     },
     "localname": "UnusedTaxLossesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement",
        "terseLabel": "Options exercisable, end of the year (cad per share)",
        "verboseLabel": "Weighted Average Exercise Price (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "terseLabel": "Exercised during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement",
        "terseLabel": "Expired during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement",
        "terseLabel": "Forfeited during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement",
        "terseLabel": "Granted during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r143",
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding, beginning of the year (cad per share)",
        "periodStartLabel": "Outstanding, beginning of the year (cad per share)",
        "terseLabel": "Weighted Average Exercise Price (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average fair value at measurement date, other equity instruments granted",
        "terseLabel": "Weighted average fair value at measurement date, other equity instruments granted"
       }
      }
     },
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average fair value at measurement date, share options granted",
        "terseLabel": "Weighted average fair value of options (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16",
        "terseLabel": "Weighted average rate"
       }
      }
     },
     "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options",
        "verboseLabel": "Weighted Average Remaining Contractual Life (years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "terseLabel": "Weighted average number of shares (basic) (shares)",
        "verboseLabel": "Weighted average number of common shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Shares Under At-the-market Agreement, United States",
        "label": "2020 Shares Under At-the-market Agreement, United States [Member]",
        "terseLabel": "2020 United States ATM"
       }
      }
     },
     "localname": "A2020SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Shares Under At-the-market Agreement, United States",
        "label": "2021 Shares Under At-the-market Agreement, United States [Member]",
        "terseLabel": "2021 United States ATM"
       }
      }
     },
     "localname": "A2021SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_AdditionalCashFlowDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Cash Flow Disclosures",
        "label": "Additional Cash Flow Disclosures [Abstract]"
       }
      }
     },
     "localname": "AdditionalCashFlowDisclosuresAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_AdjustmentsForDepreciationRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments For Depreciation, Right-of Use Assets",
        "label": "Adjustments For Depreciation, Right-of Use Assets",
        "terseLabel": "Depreciation - right-of-use assets (note 7, 21)"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationRightOfUseAssets",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement",
        "label": "Agreement [Axis]",
        "terseLabel": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement [Domain]",
        "label": "Agreement [Domain]",
        "terseLabel": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_AnnualContingentPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Contingent Payment",
        "label": "Annual Contingent Payment",
        "terseLabel": "Annual installment of annual product sales"
       }
      }
     },
     "localname": "AnnualContingentPayment",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_AnnualContingentPaymentGrossSalesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Contingent Payment, Gross Sales, Percent",
        "label": "Annual Contingent Payment, Gross Sales, Percent",
        "terseLabel": "Annual installment of gross sales of product, percent"
       }
      }
     },
     "localname": "AnnualContingentPaymentGrossSalesPercent",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_BalanceHeldInForeignCurrencyNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Held In Foreign Currency, Net",
        "label": "Balance Held In Foreign Currency, Net",
        "terseLabel": "Balances in foreign currencies"
       }
      }
     },
     "localname": "BalanceHeldInForeignCurrencyNet",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_CashEquivalentsInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents, Interest Rate",
        "label": "Cash Equivalents, Interest Rate",
        "terseLabel": "Current annual interest rate"
       }
      }
     },
     "localname": "CashEquivalentsInterestRate",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CashEquivalentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_CashFlowOperatingCapital1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Operating Capital1 [Table Text Block]",
        "label": "Cash Flow, Operating Capital1 [Table Text Block]",
        "terseLabel": "Net change in non-cash working capital"
       }
      }
     },
     "localname": "CashFlowOperatingCapital1TableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_ChangeInFairValueWarrantDerivativeRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Fair Value Warrant Derivative",
        "label": "Change In Fair Value Warrant Derivative [Roll Forward]",
        "terseLabel": "Fair Value of Warrant Derivative"
       }
      }
     },
     "localname": "ChangeInFairValueWarrantDerivativeRollForward",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ClassOfWarrantOrRightOutstanding1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Outstanding1",
        "label": "Class Of Warrant Or Right, Outstanding1",
        "periodEndLabel": "Issued, ending balance (shares)",
        "periodStartLabel": "Issued, beginning balance (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding1",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price of Warrants or Rights2",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights2",
        "terseLabel": "Exercise price (usd per share)"
       }
      }
     },
     "localname": "ClassofWarrantorRightExercisePriceofWarrantsorRights2",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1",
        "terseLabel": "Number of common shares issuable per warrant (shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights1",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights1",
        "terseLabel": "Warrants exercisable into common shares (shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightNumberofWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Warrants Exercised",
        "label": "Class of Warrant or Right, Number of Warrants Exercised",
        "negatedTerseLabel": "Exercised (shares)",
        "terseLabel": "Warrants exercised (shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightNumberofWarrantsExercised",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightWarrantsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Warrants Exercised",
        "label": "Class of Warrant or Right, Warrants Exercised",
        "negatedLabel": "Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassofWarrantorRightWarrantsExercised",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "BRACELET-1 collaboration agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_CommitmentSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment Shares",
        "label": "Commitment Shares [Member]",
        "terseLabel": "Commitment Shares"
       }
      }
     },
     "localname": "CommitmentSharesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_CommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments [Abstract]",
        "label": "Commitments [Abstract]",
        "terseLabel": "Commitments [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_CommitmentsAndContingencies1": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies1",
        "label": "Commitments And Contingencies1",
        "terseLabel": "Commitments and contingencies (note 13, 14, 19)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies1",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments Made By Entity, Related Party Transactions, Period Due",
        "label": "Commitments Made By Entity, Related Party Transactions, Period Due",
        "terseLabel": "Payment due period"
       }
      }
     },
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage",
        "label": "Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage",
        "terseLabel": "Royalty payment on net sales due to founding shareholders, percent"
       }
      }
     },
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments Made By Entity, Related Party Transactions, Royalty Payment Received, Percentage",
        "label": "Commitments Made By Entity, Related Party Transactions, Royalty Payment Received,Percentage",
        "terseLabel": "Royalty payment due to founding shareholders, percent"
       }
      }
     },
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_CommonSharePurchaseWarrantPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Share Purchase Warrant Per Unit",
        "label": "Common Share Purchase Warrant Per Unit",
        "terseLabel": "Common share purchase warrant per unit (shares)"
       }
      }
     },
     "localname": "CommonSharePurchaseWarrantPerUnit",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_CommonSharesPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Shares Per Unit",
        "label": "Common Shares Per Unit",
        "terseLabel": "Common shares per unit (shares)"
       }
      }
     },
     "localname": "CommonSharesPerUnit",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ConcentrationRisk1Table": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk1 [Table]",
        "label": "Concentration Risk1 [Table]",
        "terseLabel": "Concentration Risk1 [Table]"
       }
      }
     },
     "localname": "ConcentrationRisk1Table",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ConcentrationRiskNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number",
        "label": "Concentration Risk, Number",
        "terseLabel": "Concentration, number"
       }
      }
     },
     "localname": "ConcentrationRiskNumber",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oncyf_ConcentrationRiskType1Axis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk Type1 [Axis]",
        "label": "Concentration Risk Type1 [Axis]",
        "terseLabel": "Concentration Risk Type1 [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskType1Axis",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ConcentrationRiskType1Domain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Concentration Risk Type1 [Axis]",
        "label": "Concentration Risk Type1 [Domain]",
        "terseLabel": "Concentration Risk Type1 [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskType1Domain",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ConcentrationRiskType1LineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Concentration Risk Type1 [Table]",
        "label": "Concentration Risk Type1 [Line Items]",
        "terseLabel": "Concentration Risk Type1 [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskType1LineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ContingenciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingencies [Abstract]",
        "label": "Contingencies [Abstract]",
        "terseLabel": "Contingencies [Abstract]"
       }
      }
     },
     "localname": "ContingenciesAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_ContingentRoyaltyPaymentAnnualMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Royalty Payment, Annual Maximum",
        "label": "Contingent Royalty Payment, Annual Maximum",
        "terseLabel": "Royalty payment maximum"
       }
      }
     },
     "localname": "ContingentRoyaltyPaymentAnnualMaximum",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Royalty Payment, Percent Of Sales Revenue",
        "label": "Contingent Royalty Payment, Percent Of Sales Revenue",
        "terseLabel": "Royalty payment on sales revenue, percent"
       }
      }
     },
     "localname": "ContingentRoyaltyPaymentPercentOfSalesRevenue",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_ContractLiabilityRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Liability, Recognition Period",
        "label": "Contract Liability, Recognition Period",
        "terseLabel": "Expected recognition period"
       }
      }
     },
     "localname": "ContractLiabilityRecognitionPeriod",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "label": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]"
       }
      }
     },
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_Currency1LineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Currency1 [Table]",
        "label": "Currency1 [Line Items]",
        "terseLabel": "Currency1 [Line Items]"
       }
      }
     },
     "localname": "Currency1LineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_Currency1Table": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency1 [Table]",
        "label": "Currency1 [Table]",
        "terseLabel": "Currency1 [Table]"
       }
      }
     },
     "localname": "Currency1Table",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureOfCapitalComponentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Capital Components [Table Text Block]",
        "label": "Disclosure Of Capital Components [Table Text Block]",
        "verboseLabel": "Schedule of capital components"
       }
      }
     },
     "localname": "DisclosureOfCapitalComponentsTableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfEconomicDependenceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Economic Dependence [Abstract]",
        "label": "Disclosure Of Economic Dependence [Abstract]",
        "terseLabel": "Disclosure Of Economic Dependence [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfEconomicDependenceAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureOfEconomicDependenceTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Economic Dependence [Text Block]",
        "label": "Disclosure Of Economic Dependence [Text Block]",
        "terseLabel": "Economic Dependence"
       }
      }
     },
     "localname": "DisclosureOfEconomicDependenceTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependence"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Indemnification Of Officers and Directors [Abstract]",
        "label": "Disclosure Of Indemnification Of Officers and Directors [Abstract]",
        "terseLabel": "Disclosure Of Indemnification Of Officers and Directors [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfIndemnificationOfOfficersandDirectorsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Indemnification Of Officers and Directors [Text Block]",
        "label": "Disclosure Of Indemnification Of Officers and Directors [Text Block]",
        "terseLabel": "Indemnification of Officers and Directors"
       }
      }
     },
     "localname": "DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Notes And Other Explanatory Information [Abstract]",
        "label": "Disclosure Of Notes And Other Explanatory Information [Abstract]",
        "terseLabel": "Disclosure Of Notes And Other Explanatory Information [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Quantitative Information About Lease Liabilities",
        "label": "Disclosure Of Quantitative Information About Lease Liabilities [Text Block]",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Share-based Payment Arrangements [Abstract]",
        "label": "Disclosure of Share-based Payment Arrangements [Abstract]",
        "terseLabel": "Disclosure Of Share-based Payment Arrangements [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfShareBasedPaymentArrangementsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "label": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "terseLabel": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]"
       }
      }
     },
     "localname": "DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofeventsafterreportingperiodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of events after reporting period [Abstract]",
        "label": "Disclosure of events after reporting period [Abstract]",
        "terseLabel": "Disclosure of events after reporting period [Abstract]"
       }
      }
     },
     "localname": "DisclosureofeventsafterreportingperiodAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofincometaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of income tax [Abstract]",
        "label": "Disclosure of income tax [Abstract]",
        "terseLabel": "Disclosure of income tax [Abstract]"
       }
      }
     },
     "localname": "DisclosureofincometaxAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofrelatedpartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of related party [Abstract]",
        "label": "Disclosure of related party [Abstract]",
        "terseLabel": "Disclosure of related party [Abstract]"
       }
      }
     },
     "localname": "DisclosureofrelatedpartyAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of revenue from contracts with customers [Abstract]",
        "label": "Disclosure of revenue from contracts with customers [Abstract]",
        "terseLabel": "Disclosure of revenue from contracts with customers [Abstract]"
       }
      }
     },
     "localname": "DisclosureofrevenuefromcontractswithcustomersAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofsharebasedpaymentarrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of share-based payment arrangement [Abstract]",
        "label": "Disclosure of share-based payment arrangement [Abstract]",
        "terseLabel": "Disclosure of share-based payment arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureofsharebasedpaymentarrangementAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DividendYieldPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend Yield, Percent",
        "label": "Dividend Yield, Percent",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "DividendYieldPercent",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_EffectOfLeaseModificationOnLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of Lease Modification on Lease Liabilities",
        "label": "Effect of Lease Modification on Lease Liabilities",
        "terseLabel": "Lease modification"
       }
      }
     },
     "localname": "EffectOfLeaseModificationOnLeaseLiabilities",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_EquityAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Authorized",
        "label": "Equity Authorized",
        "terseLabel": "Base Shelf securities authorized"
       }
      }
     },
     "localname": "EquityAuthorized",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Five [Member]",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$7.42 - $52.63"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Four [Member]",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$3.91 - $7.41"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range One [Member]",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$0.54 - $1.79"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Three [Member]",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$3.02 - $3.90"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Two [Member]",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$1.80 - $3.01"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_FairValueofWarrantIssuedPerWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value of Warrant Issued, Per Warrant",
        "label": "Fair Value of Warrant Issued, Per Warrant",
        "terseLabel": "Fair value per warrant (usd per share)"
       }
      }
     },
     "localname": "FairValueofWarrantIssuedPerWarrant",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_ForeignExchangeImpactRightofUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Exchange Impact, Right-of-Use Assets",
        "label": "Foreign Exchange Impact, Right-of-Use Assets",
        "terseLabel": "Foreign exchange impact"
       }
      }
     },
     "localname": "ForeignExchangeImpactRightofUseAssets",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_FundedandRoyaltyRepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funded and Royalty Repayment",
        "label": "Funded and Royalty Repayment",
        "terseLabel": "Repayment, maximum"
       }
      }
     },
     "localname": "FundedandRoyaltyRepayment",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_GainsLossesFromForeignExchangeImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains (Losses) From Foreign Exchange Impact",
        "label": "Gains (Losses) From Foreign Exchange Impact",
        "terseLabel": "Foreign exchange impact"
       }
      }
     },
     "localname": "GainsLossesFromForeignExchangeImpact",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_GrossProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Proceeds From Issue Of Ordinary Shares",
        "label": "Gross Proceeds From Issue Of Ordinary Shares",
        "terseLabel": "Gross proceeds from common shares"
       }
      }
     },
     "localname": "GrossProceedsFromIssueOfOrdinaryShares",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_IncomeStatementLocation1Axis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Statement Location1 [Axis]",
        "label": "Income Statement Location1 [Axis]",
        "terseLabel": "Income Statement Location1 [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocation1Axis",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_IncomeStatementLocation1Domain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Income Statement Location1 [Axis]",
        "label": "Income Statement Location1 [Domain]",
        "terseLabel": "Income Statement Location1 [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocation1Domain",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net",
        "label": "Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net",
        "terseLabel": "Non-cash impact of foreign exchange"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Incentive Share Awards, Equity",
        "label": "Increase (Decrease) Through Incentive Share Awards, Equity",
        "terseLabel": "Issued pursuant to incentive share award plan (note 10)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughIncentiveShareAwardsEquity",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_InvestmentTaxCreditsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Tax Credits [Member]",
        "label": "Investment Tax Credits [Member]",
        "terseLabel": "Investment tax credits"
       }
      }
     },
     "localname": "InvestmentTaxCreditsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_IssueOfEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue Of Equity, Shares",
        "label": "Issue Of Equity, Shares",
        "terseLabel": "Issued (shares)"
       }
      }
     },
     "localname": "IssueOfEquityShares",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_IssuedCapitalExcludingCommitmentSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued Capital, Excluding Commitment Shares",
        "label": "Issued Capital, Excluding Commitment Shares [Member]",
        "terseLabel": "Issued Capital, Excluding Commitment Shares"
       }
      }
     },
     "localname": "IssuedCapitalExcludingCommitmentSharesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_LeaseModificationRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Modification, Right-Of-Use Assets",
        "label": "Lease Modification, Right-Of-Use Assets",
        "terseLabel": "Lease modification"
       }
      }
     },
     "localname": "LeaseModificationRightOfUseAssets",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Term Of Options Granted For Share-based Payment Arrangement",
        "label": "Maximum Term Of Options Granted For Share-based Payment Arrangement",
        "terseLabel": "Maximum option expiration term"
       }
      }
     },
     "localname": "MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_MedicalEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Equipment [Member]",
        "label": "Medical Equipment [Member]",
        "terseLabel": "Medical equipment"
       }
      }
     },
     "localname": "MedicalEquipmentMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_NumberOfStockOptionPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Stock Option Plans",
        "label": "Number Of Stock Option Plans",
        "terseLabel": "Number of plans"
       }
      }
     },
     "localname": "NumberOfStockOptionPlans",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oncyf_NumberOfWarrantsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Warrants Outstanding",
        "label": "Number Of Warrants Outstanding [Roll Forward]",
        "terseLabel": "Number of Warrants Outstanding"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstandingRollForward",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_OfficeEquipmentAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office equipment and furniture",
        "label": "Office equipment and furniture [Member]",
        "terseLabel": "Office equipment and furniture"
       }
      }
     },
     "localname": "OfficeEquipmentAndFurnitureMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_OperatingExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Expenses [Member]",
        "label": "Operating Expenses [Member]",
        "terseLabel": "Included in operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_OperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Remaining Lease Term",
        "label": "Operating Lease, Remaining Lease Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "OperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_OtherExpensesAndAdjustmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Other Expenses And Adjustments [Table]",
        "label": "Other Expenses And Adjustments [Line Items]",
        "terseLabel": "Other Expenses And Adjustments [Line Items]"
       }
      }
     },
     "localname": "OtherExpensesAndAdjustmentsLineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_OtherExpensesAndAdjustmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Expenses And Adjustments [Table]",
        "label": "Other Expenses And Adjustments [Table]",
        "terseLabel": "Other Expenses And Adjustments [Table]"
       }
      }
     },
     "localname": "OtherExpensesAndAdjustmentsTable",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_OtherExpensesAndAdjustmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Expenses And Adjustments [Table Text Block]",
        "label": "Other Expenses And Adjustments [Table Text Block]",
        "terseLabel": "Other expenses and adjustments"
       }
      }
     },
     "localname": "OtherExpensesAndAdjustmentsTableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_OverheadRepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overhead Repayment",
        "label": "Overhead Repayment",
        "terseLabel": "Overhead repayment"
       }
      }
     },
     "localname": "OverheadRepayment",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_PaymentsForExecutoryContracts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Executory Contracts",
        "label": "Payments For Executory Contracts",
        "terseLabel": "Payments for executory contracts"
       }
      }
     },
     "localname": "PaymentsForExecutoryContracts",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_PerformanceShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share Units [Member]",
        "label": "Performance Share Units [Member]",
        "terseLabel": "Performance share units"
       }
      }
     },
     "localname": "PerformanceShareUnitsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ProceedsfromInterestReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Interest Received",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Cash interest received"
       }
      }
     },
     "localname": "ProceedsfromInterestReceived",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ProceedsfromWarrantExercises1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Warrant Exercises1",
        "label": "Proceeds from Warrant Exercises1",
        "terseLabel": "Gross proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsfromWarrantExercises1",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ProductionServiceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Production Service Agreement",
        "label": "Production Service Agreement [Member]",
        "terseLabel": "Production Service Agreement"
       }
      }
     },
     "localname": "ProductionServiceAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]",
        "label": "Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]",
        "terseLabel": "Undepreciated capital costs in excess of book value of property and equipment and intellectual property"
       }
      }
     },
     "localname": "PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_PropertyPlantandEquipmentAnnualDepreciationRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant and Equipment, Annual Depreciation Rate",
        "label": "Property, Plant and Equipment, Annual Depreciation Rate",
        "terseLabel": "Annual depreciation rate"
       }
      }
     },
     "localname": "PropertyPlantandEquipmentAnnualDepreciationRate",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_PurchaseObligation1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation1",
        "label": "Purchase Obligation1",
        "terseLabel": "Commitment for payment"
       }
      }
     },
     "localname": "PurchaseObligation1",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_PurchaseObligationCommitmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Commitment Term",
        "label": "Purchase Obligation, Commitment Term",
        "terseLabel": "Commitment term"
       }
      }
     },
     "localname": "PurchaseObligationCommitmentTerm",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development [Member]",
        "label": "Research And Development [Member]",
        "terseLabel": "Included in research and development expenses:"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_RestrictedShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Share Units [Member]",
        "label": "Restricted Share Units [Member]",
        "terseLabel": "Restricted share units"
       }
      }
     },
     "localname": "RestrictedShareUnitsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_RightOfUseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Assets",
        "label": "Right-Of-Use Assets [Abstract]",
        "terseLabel": "Right-Of-Use Assets [Abstract]"
       }
      }
     },
     "localname": "RightOfUseAssetsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_SYNSORBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SYNSORB [Member]",
        "label": "SYNSORB [Member]",
        "terseLabel": "SYNSORB"
       }
      }
     },
     "localname": "SYNSORBMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Axis]",
        "terseLabel": "Sale Of Stock [Axis]"
       }
      }
     },
     "localname": "SaleOfStockAxis",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_SaleOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Domain]",
        "terseLabel": "Sale Of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockDomain",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Foreign Currency Held [Table Text Block]",
        "label": "Schedule Of Foreign Currency Held [Table Text Block]",
        "terseLabel": "Schedule of balances in foreign currencies"
       }
      }
     },
     "localname": "ScheduleOfForeignCurrencyHeldTableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]",
        "label": "Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]",
        "terseLabel": "Other cash flow disclosures"
       }
      }
     },
     "localname": "ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]",
        "label": "Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount",
        "terseLabel": "Impact of increase in value of currency, amount"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings",
        "negatedTerseLabel": "(Increase) decrease in net loss due to change in currency value"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Cliff Award Vesting Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Cliff Award Vesting Period",
        "terseLabel": "Cliff vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffAwardVestingPeriod",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_ShareCapitalAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Capital, Amount",
        "label": "Share Capital, Amount [Abstract]",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "ShareCapitalAmountAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ShareCapitalNumberSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Capital, Number, Shares",
        "label": "Share Capital, Number, Shares [Abstract]",
        "terseLabel": "Number"
       }
      }
     },
     "localname": "ShareCapitalNumberSharesAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ShareIssueCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Issue Costs [Member]",
        "label": "Share Issue Costs [Member]",
        "terseLabel": "Share issue costs"
       }
      }
     },
     "localname": "ShareIssueCostsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ShareIssueRelatedCostCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Issue Related Cost, Commissions",
        "label": "Share Issue Related Cost, Commissions",
        "terseLabel": "Share issue related cost, commissions"
       }
      }
     },
     "localname": "ShareIssueRelatedCostCommissions",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_SharePurchaseAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Amount",
        "label": "Share Purchase Agreement, Amount",
        "terseLabel": "Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementAmount",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_SharePurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Term",
        "label": "Share Purchase Agreement, Term",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "SharePurchaseAgreementTerm",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1",
        "verboseLabel": "Vesting period, if not immediately vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_SharesIssuedFairValueOfCommonShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Fair Value Of Common Share",
        "label": "Shares Issued, Fair Value Of Common Share",
        "terseLabel": "Shares issued, fair value of common share (usd per share)"
       }
      }
     },
     "localname": "SharesIssuedFairValueOfCommonShare",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_SharesIssuedPricePerShare1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Price Per Share1",
        "label": "Shares Issued, Price Per Share1",
        "terseLabel": "Purchase price (cad and usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare1",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_SharesIssuedWarrantPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Warrant Price Per Share",
        "label": "Shares Issued, Warrant Price Per Share",
        "terseLabel": "Purchase price (cad per share)"
       }
      }
     },
     "localname": "SharesIssuedWarrantPricePerShare",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_SharesPublicOfferingEquityWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Public Offering, Equity Warrants",
        "label": "Shares Public Offering, Equity Warrants [Member]",
        "terseLabel": "Shares Public Offering, Equity Warrants"
       }
      }
     },
     "localname": "SharesPublicOfferingEquityWarrantsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Public Offering [Member]",
        "label": "Shares Public Offering [Member]",
        "terseLabel": "Public Offering",
        "verboseLabel": "Public offering"
       }
      }
     },
     "localname": "SharesPublicOfferingMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesPublicOfferingWarrantDerivativesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Public Offering, Warrant Derivatives",
        "label": "Shares Public Offering, Warrant Derivatives [Member]",
        "terseLabel": "Shares Under Warrant Derivative Agreement",
        "verboseLabel": "Warrant Derivatives"
       }
      }
     },
     "localname": "SharesPublicOfferingWarrantDerivativesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderAtthemarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under At-the-market Agreement [Member]",
        "label": "Shares Under At-the-market Agreement [Member]",
        "terseLabel": "At-the-market agreement"
       }
      }
     },
     "localname": "SharesUnderAtthemarketAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under At-the-market Agreement, United States [Member]",
        "label": "Shares Under At-the-market Agreement, United States [Member]",
        "terseLabel": "United States ATM"
       }
      }
     },
     "localname": "SharesUnderAtthemarketAgreementUnitedStatesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderCommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under Common Stock Purchase Agreement [Member]",
        "label": "Shares Under Common Stock Purchase Agreement [Member]",
        "verboseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "SharesUnderCommonStockPurchaseAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under Incentive Award Plan [Member]",
        "label": "Shares Under Incentive Award Plan [Member]",
        "terseLabel": "Incentive award plan"
       }
      }
     },
     "localname": "SharesUnderIncentiveAwardPlanMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderSharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under Share Purchase Agreement [Member]",
        "label": "Shares Under Share Purchase Agreement [Member]",
        "terseLabel": "Share Purchase Agreement"
       }
      }
     },
     "localname": "SharesUnderSharePurchaseAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under Stock Option Plan [Member]",
        "label": "Shares Under Stock Option Plan [Member]",
        "terseLabel": "Stock option plan"
       }
      }
     },
     "localname": "SharesUnderStockOptionPlanMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Judgments, Estimates And Assumptions [Abstract]",
        "label": "Significant Judgments, Estimates And Assumptions [Abstract]",
        "terseLabel": "Significant Judgments, Estimates And Assumptions [Abstract]"
       }
      }
     },
     "localname": "SignificantJudgmentsEstimatesAndAssumptionsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_Statement1LineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Statement1 [Table]",
        "label": "Statement1 [Line Items]",
        "terseLabel": "Statement1 [Line Items]"
       }
      }
     },
     "localname": "Statement1LineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_Statement1Table": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement1 [Table]",
        "label": "Statement1 [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "Statement1Table",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_StockOptionsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, Outstanding",
        "label": "Stock Options, Outstanding [Abstract]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "StockOptionsOutstandingAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_StockholdersEquityNoteStockSplitConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "oncyf_SummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Abstract]",
        "label": "Summary Of Significant Accounting Policies [Abstract]",
        "terseLabel": "Summary Of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "oncyf_SupplierConcentrationRisk1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier Concentration Risk1 [Member]",
        "label": "Supplier Concentration Risk1 [Member]",
        "terseLabel": "Toll manufacturer"
       }
      }
     },
     "localname": "SupplierConcentrationRisk1Member",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Change in Fair Value Of Warrant Derivative",
        "label": "Tax Effect Of Change in Fair Value Of Warrant Derivative",
        "terseLabel": "Change in fair value of warrant derivative"
       }
      }
     },
     "localname": "TaxEffectOfChangeinFairValueOfWarrantDerivative",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_TaxEffectOfExpirationOfTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Expiration Of Tax Benefits",
        "label": "Tax Effect Of Expiration Of Tax Benefits",
        "terseLabel": "Expiry of tax benefits"
       }
      }
     },
     "localname": "TaxEffectOfExpirationOfTaxBenefits",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_TaxEffectOfStockBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Stock Based Compensation",
        "label": "Tax Effect Of Stock Based Compensation",
        "negatedTerseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "TaxEffectOfStockBasedCompensation",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_TaxEffectOfTaxPools": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Tax Pools",
        "label": "Tax Effect Of Tax Pools",
        "terseLabel": "Adjustment to opening tax pools"
       }
      }
     },
     "localname": "TaxEffectOfTaxPools",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_TwentyFortyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Forty",
        "label": "Twenty Forty [Member]",
        "terseLabel": "2040"
       }
      }
     },
     "localname": "TwentyFortyMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyFortyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Forty One",
        "label": "Twenty Forty One [Member]",
        "terseLabel": "2041"
       }
      }
     },
     "localname": "TwentyFortyOneMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Eight [Member]",
        "label": "Twenty Thirty Eight [Member]",
        "terseLabel": "2038"
       }
      }
     },
     "localname": "TwentyThirtyEightMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Five [Member]",
        "label": "Twenty Thirty Five [Member]",
        "terseLabel": "2035"
       }
      }
     },
     "localname": "TwentyThirtyFiveMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Four [Member]",
        "label": "Twenty Thirty Four [Member]",
        "terseLabel": "2034"
       }
      }
     },
     "localname": "TwentyThirtyFourMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty [Member]",
        "label": "Twenty Thirty [Member]",
        "terseLabel": "2030"
       }
      }
     },
     "localname": "TwentyThirtyMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Nine [Member]",
        "label": "Twenty Thirty Nine [Member]",
        "terseLabel": "2039"
       }
      }
     },
     "localname": "TwentyThirtyNineMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty One [Member]",
        "label": "Twenty Thirty One [Member]",
        "terseLabel": "2031"
       }
      }
     },
     "localname": "TwentyThirtyOneMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Seven [Member]",
        "label": "Twenty Thirty Seven [Member]",
        "terseLabel": "2037"
       }
      }
     },
     "localname": "TwentyThirtySevenMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Six [Member]",
        "label": "Twenty Thirty Six [Member]",
        "terseLabel": "2036"
       }
      }
     },
     "localname": "TwentyThirtySixMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Three [Member]",
        "label": "Twenty Thirty Three [Member]",
        "terseLabel": "2033"
       }
      }
     },
     "localname": "TwentyThirtyThreeMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Two [Member]",
        "label": "Twenty Thirty Two [Member]",
        "terseLabel": "2032"
       }
      }
     },
     "localname": "TwentyThirtyTwoMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Eight",
        "label": "Twenty Twenty Eight [Member]",
        "terseLabel": "2028"
       }
      }
     },
     "localname": "TwentyTwentyEightMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Five [Member]",
        "label": "Twenty Twenty Five [Member]",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "TwentyTwentyFiveMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Four [Member]",
        "label": "Twenty Twenty Four [Member]",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "TwentyTwentyFourMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Nine [Member]",
        "label": "Twenty Twenty Nine [Member]",
        "terseLabel": "2029"
       }
      }
     },
     "localname": "TwentyTwentyNineMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Seven [Member]",
        "label": "Twenty Twenty Seven [Member]",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "TwentyTwentySevenMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Six [Member]",
        "label": "Twenty Twenty Six [Member]",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "TwentyTwentySixMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Three [Member]",
        "label": "Twenty Twenty Three [Member]",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "TwentyTwentyThreeMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Two [Member]",
        "label": "Twenty Twenty Two [Member]",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "TwentyTwentyTwoMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unclaimed Scientific Research And Experimental Development Expenditures [Member]",
        "label": "Unclaimed Scientific Research And Experimental Development Expenditures [Member]",
        "terseLabel": "Unclaimed scientific research and experimental development expenditures",
        "verboseLabel": "Scientific research and experimental development"
       }
      }
     },
     "localname": "UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_UnusedCapitalLossCarryForwardNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unused Capital Loss Carry Forward, Net [Member]",
        "label": "Unused Capital Loss Carry Forward, Net [Member]",
        "terseLabel": "Net capital losses carried forward"
       }
      }
     },
     "localname": "UnusedCapitalLossCarryForwardNetMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_UnusedNetOperatingLossCarryForwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unused Net Operating Loss Carry Forwards [Member]",
        "label": "Unused Net Operating Loss Carry Forwards [Member]",
        "terseLabel": "Net operating losses carried forward"
       }
      }
     },
     "localname": "UnusedNetOperatingLossCarryForwardsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1",
        "negatedTerseLabel": "Change in deferred tax benefits deemed not probable to be recovered"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Derivative And Shares Under Warrant Agreement",
        "label": "Warrant Derivative And Shares Under Warrant Agreement [Member]",
        "terseLabel": "Warrant Derivative and Shares Under Warrant Agreement"
       }
      }
     },
     "localname": "WarrantDerivativeAndSharesUnderWarrantAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_WarrantIssuedUnderlyingSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Issued, Underlying Share Price",
        "label": "Warrant Issued, Underlying Share Price",
        "terseLabel": "Underlying share price (usd per share)"
       }
      }
     },
     "localname": "WarrantIssuedUnderlyingSharePrice",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_WarrantsAndRightsOutstanding1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants And Rights Outstanding1",
        "label": "Warrants And Rights Outstanding1",
        "periodEndLabel": "Issued, ending balance",
        "periodStartLabel": "Issued, beginning balance",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding1",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants [Member]",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_WarrantsandRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and Rights Outstanding",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants (note 9)"
       }
      }
     },
     "localname": "WarrantsandRightsOutstanding",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_WeightedAverageExercisePriceOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Outstanding",
        "label": "Weighted Average Exercise Price, Outstanding [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOutstandingAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20211231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r1": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r10": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r100": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI",
   "URIDate": "2021-03-24"
  },
  "r101": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Section": "Presentation of a statement of cash flows",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI",
   "URIDate": "2021-03-24"
  },
  "r102": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r103": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r104": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r105": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r106": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r107": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r108": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r109": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r11": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r110": {
   "Clause": "ix",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r111": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r112": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r113": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r114": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r115": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r116": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r117": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r118": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r119": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r12": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r120": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "105",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r121": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r122": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r123": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r124": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r125": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "118",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r126": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r127": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI",
   "URIDate": "2021-03-24"
  },
  "r128": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI",
   "URIDate": "2021-03-24"
  },
  "r129": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r13": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "134",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_134&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r130": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r131": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r132": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r133": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r134": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r135": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r136": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "58",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r137": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r138": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r139": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "C12",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C",
   "URIDate": "2021-03-24"
  },
  "r14": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r140": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2021-03-24"
  },
  "r141": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2021-03-24"
  },
  "r142": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r143": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r144": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r145": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r146": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r147": {
   "Clause": "v",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r148": {
   "Clause": "vi",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r149": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r15": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "51",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r150": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r151": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r152": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r153": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r154": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r155": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r156": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r157": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r158": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r159": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r16": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r160": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r161": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r162": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r163": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r164": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r165": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r166": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r167": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r168": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r169": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r17": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r170": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r171": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r172": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r173": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B52",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r174": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r175": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2021-03-24"
  },
  "r176": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2021-03-24"
  },
  "r177": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r178": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r179": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r18": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r180": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r181": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r182": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r183": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r184": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r185": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r186": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r187": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r188": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r189": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r19": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r190": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r191": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r192": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r193": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r194": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r195": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r196": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r197": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r198": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r199": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r20": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r200": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r201": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r202": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r203": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r204": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r205": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r21": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r22": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r23": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r24": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r25": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r26": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r27": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r28": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_vii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r29": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r3": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r30": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r31": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r32": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r33": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r34": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r35": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r36": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r37": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r38": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r39": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r4": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r40": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2021-03-24"
  },
  "r41": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r42": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r43": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r44": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r45": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r46": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r47": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2021-03-24"
  },
  "r48": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r49": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r5": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r50": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r51": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r52": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r53": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r54": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r55": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r56": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r57": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r58": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2021-03-24"
  },
  "r59": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r6": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r60": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r61": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r62": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r63": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r64": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r65": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r66": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r67": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r68": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2021-03-24"
  },
  "r69": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r7": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r70": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r71": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r72": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r73": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r74": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2021-03-24"
  },
  "r75": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r76": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r77": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r78": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r79": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r8": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r80": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r81": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r82": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r83": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r84": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r85": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r86": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r87": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r88": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r89": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r9": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r90": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r91": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r92": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r93": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r94": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r95": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r96": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r97": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r98": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r99": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2021-03-24"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>128
<FILENAME>0001129928-22-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001129928-22-000017-xbrl.zip
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M&TG>RR N?.+(J9G24L+W"]1Z=>"9%3?<Z WNA'VE@B/.XU)QR@8X)N_!@W#
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MR3<^\"FO\7.C\.'3^?\ 4$L#!!0    ( -N&8U3A^C#YEAT  (.N   >
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M^;PRKU6$O+*]B6U4U>U8"$4K@0Y*W8X9P2<E0?>/S@?+@H'PLX1R#;ZD1-,
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M9DK$F5Y?\HL;HN6SN*_*;\ZZ_P!02P,$%     @ VX9C5#+.,]^&!   *1(
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MH.F"2O-".-VZ6S4%WP6BT#;!\3M0<QKD$EL01D]X"./;(";\BF*G2%.FE D
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M-R39)9Z%]2!V)V7H0 @:I8N,R<.+<0EZ2Z8K.6$$D)9:OJ;4*N:QRL18_S"
M@#P0>2NJ#^DJ48AZ=(&-@TBQEPPLL+#5GDR#5"'T[P'XI@@[,DIXG7CF+1;2
M)I>_D)^GB0L7 %9<OETR3_B(2)_3$ 180*^6ZI#Z]8)L"OHG&.RH#L=@?%T
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MXXM@BG;'A'"QD'JP&=PF>L*00BFO!B/YR.#NXIYX"C]#+KTQ<4*R C9U'E8
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M)Z<1 B;\1&LD@-1^EDZ! _-7\CY@8X+F3Y[$0AB?0N O(RHQA\?MU/6X^4)
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M<*<$S)=9N/366SO:!-*5@*6&?EK6*./BB?BA6EEMRB\]-0':<(C":*TP2AH
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M+M=7O6JR+/IO8J+HW"R+P<BB#R9Z:,;7;!(SJ5IA3/I?74IH3; /U0"V&U\
M23B=Y^0QN6,EMFG%TIQH;3"FG6?HL76G%L>@XA "-/S:6U#V.'SH)%MAK\0E
M&SC#PG_F4-Z\D_U%D#R'Q[FJ.@H6"MSP*DN1+20-T-K1,69$EYEYSXM/!ZH<
M^1A]9N>:>!]/V3]UC]E:.,>D&7:(=-'8C4UBX0+BN64G/C/L<<?]D,M@4"4
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M%_.I /H(&IZWC3N)1=K;\45'.*Q+  ;<LBQ=H05TCAL9O\#6 YR)//EZW2(
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MM^/+(A1KLASTY./:O3$\T_1>LUUC(!WR<9YBY)R4BY5[+NUQN3O(7^$@(_%
MRAP'&==J\"6O91:52FRE">*U1D@X51;^RK7DC<2"U"Y[[U.K@G:4?&A*LJ-'
M?LQP+M!!\P=Q 5+6)$C)PM*B/$?:0"R;H\[TPQ'=T? !:2B"-92F6KU*=$S8
MB0G*HJ9D,DL5JYG]<=0N]Y!(9Z%;]Z2P65/K($[I;#;.!KKRS(X?(8M"^:%E
M4%%U^]Q#?N^#.)P6W8<.DTR;XH0^UW#ZK=2I4QNU"[?J">"B5/=:EX@*GJWE
M#0U'FCB3^,\69I$DC(D'L-+>8S9#R/MHPC7MC'71(3=1[/)RX7&W\+\4[7;"
M0@C^=#FI(_<YPT!V/NF*)NL"&$M@S@6.-@/9=WFTUO3Y:%:G,B</$E4W1O<M
M#=$)V_)4(YG,J6ESOQ:>D3&G_<VXM-%,H!#$&MC7]H7^9%X;3OB3/NO3J,+8
M@E(2T#UTYZ^?T+OTN7H4=//!LR2[*U@0RB<I'<TF"^H^78WR^__[TP][HW,R
M7^BL+/+I,RAK^$&8W\^>J\J+2DSNNBJ3R[QN<7S8;D;LA$0VPX%CMFCTRK[X
MM?MDWKY5U6*J4)05VJ^AY]Z=Q[#\R)X1$@M0)Y?$V EW/$E_.*+-\,3\84A<
MK>CF'.D.1G20\Z>WLM-?PK%SN7HV7O@.S<0BXW+A!VYT)06J[(C\M!*<^ _0
MDM8?YA?'B]:&.N2F%WB@J]<I+YK8%D-B=%Y5C:8<TJQ(UCZVCC(@^S"L$K.<
MFV4F>#.2L- OI9NRQ;*J&78^CDC4I=I*&=8-(:T\F\D@AN3"!C#6R95O)U!H
MEV552J\-%@2T)YY+(O*I_YWL,2,SSN)7.S#\0&K7[1;0Y HM"@4GC%8;@AN!
M'#2B^8.,G4G0T G^<K,8@W ACU2\RHJB\^@N-KYKM(D]8I5L ,@-##5,IM L
M _%R*"+J#"W9#&) CN.G_>@_JBLHZ=@?>Q,4G"#281F3NDI2DQG!5^*;=2@2
MV5EEM0 =:X#?+R31SSE]4T7SQ%*L"MT?A$DOL%FE%B+I($M+V7%_Y4(:);6&
M$"7F/(ICB28)8UP^Y^%!(=4/%!_L?HPOQLA,PRN2;D5:ED_,S-L5]WFBX9:I
MP#&98)5:NR159?;EGC(2UWW>0Z!NZE20B@7.$8I![!AG@0MA%;'4"6)7DG'L
M!,7SIFZU8531T1P51&&Y+@-CMJV#61(-?IO(Y\K, M5C0<#+*D78;$FS)4\
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MPZ'#I/N&&RN"@E1NEK#\UU![JD<))HHF!?[09/F_= \]'EI'5'1+ATET 9"
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M\E@'U0$N'964&MV2&KY+S0VR=.JGJ=T'D/"SCPMF,_1X8A; A :1C":<K\.
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M*\\%(BB-09T:,'4XT5ET -,LKZ?M0B3E[78OS6#+H^^WOX&LU>W[G_G9[E1
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M?CD09&_SX/YS*[6S(1=-)=J@:3-%=&:[>G^E7(*5CJ2 K(E'S%2S^!>[;S*
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MSHHGZ%^TYY V6IU^#\ LG>:JQZ=.I?(6?!*;G#T&CPO'^U1AY&NB D8A* B
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M#&28$#%QZ9@&+Z5SC$AH$#4JIV&IYG[^K!V\XN'=\5!X9WG2/"H,(%WRTN9
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M*_DX#SXF'133#+0LB]<X:8'XPJ.RVFJ?>87'=>^5C_46P=_O+56AHU$P*3!
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MZ*@U>EZ6"DP@(;M@R9I4QI%[(TIF[BKN>$O 5S,,YS9_1@A4EIEL+ ,N3!"
M68N,(A%)JURQ=B4@Y]I?JD+(LM0>"PJXBXR$9+3DU!37)BG-/;(5(6\'^6J&
MX=Q<&N#)*B&5]4A>=?("G0VEBE]9$U)7N$C%2D+.L[M4A8\YD0T9I44Y<6E<
M64_ <.Z9B$YJM8J&WQ+QU0S#>?G8H!"9I#] )J0TUEB;2$ Z*9R6;N74+(6
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MJS^F[*3T#")7CH<(5AN-6,I0\@<BBJL,]OP$=:(^+2R/3F$B4XH%B-EK=$F
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M^7=QG8M]%WBDSX=>(<CYGK_BGY%K9@*Y8TC&O6'!!DC,:R"WFOIVJGC]][_
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MF>3X8B]4>29^BLBQ^L13[()DK8Z+J,K>. CP](M*OIU+%)1Y5__MLR=D[K-
MKI_'4Y\WG4S.Z< ;PHI<^M*_8U#!$H.R33[J"IX9 HH"N\'F52TN-+P9NEUX
M/WBW5>' U%%$J$?*7/OFZ^E=L2>7./63C (%=B_)NYFCWEJ!\XF"-_"H06>+
MBTR1T9HNLLS0T<?O7O2E 8.7:E)H= <2U:UF&/WA_;;9N;EHD\$SD5:UST0?
M< S7TTEZ#*E["73DAZE;X9.!C/ZKRVOV"K,51$A33'LF17;Q"9)W]<S!5TV@
MO?WMQ0O,GKUZGKPY??N?R?.3)^]>O1GFR&Y-IH35,=L#<5262U3F.,W/)PI
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M3 FMNKY"IM3M@P7EG8)XJ*1Z-I=53"U<^173<"W+Y^3#H0R60../N+S8(^7
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M"(NL4SR2H)"CQVP@DVSZ'LF5-ZZ1[VDQ8PU\T\SM,:P;-T@=(5S<K&BJ2+7
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M!47<VX,BKJFZ"$Y-X9C^#6(9QO_Q/T@/<V_ -*^GW1(KZ-*LX)U4T<_::DK
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M7:U_^,R?HZKV*#!C!@,;8[C!7-O+U2-1[JWV5K"BA[D9OA@W3IH3N+.5<8A
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M@ \OEE+7+#YP*E+5WW%NYUV.^DE]ZQ!#[6B.YV3-$2$/LN6T3&1DC#'6)%K
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M(W5T4"4G94<(.YR[86"VNFWP0VXG]2=/]9A^0RZ%.CCPK'(G1W*'P&D';77
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M#G_Z!ER.2E[CA#$V1X\?W4=^J+FK!>HD].B1S)UXF6//9L,?B<$A;P/\K_?
M<+]NQ2AH,)P\E(XJDOI]+XXHYWZ.IU+P-YSN*1LCW3UP/M^QP,&G,S]*892%
M6&DT(D)2'$D6O%!?HS=U56F!QP<,[\5I!R64S%9*SY:7ECIDYK(9L9NFO:_Z
ME*W[L,IK[]DA:=\YM=Z)A&B6C.JP>@D>;+7>-$[)9K6HJ0L\]W:A:C>\@D=\
M4':( *D7?"60F?$*;.1,#;:ZCO2-#TO-HC6C]Q*"&R(.U3WTJ%_$0WC_S'?+
M^*Z+F,?*=YM#+$UX,*%/R67F5I/V\[&TR\ROJ,VR>E29>V@I1 ,#86*"E<F:
M3Q+22$HNVW.PL&\?9D 250NY?EE7\KRB,(P&U'%=Y'2XX8V7^'I1"9XM/KBB
MW^Z\@GT]_"/JX0_V]?#K8>IY1<'%S^H8C5/T[%*@]=&M3J[776_1[O#<:(:*
M=52GT:"[IWMM_;<_"\!'09S%4://9)4UT7O@\H>J"NG-&(,3>; C $<.YV[!
MJ"W?5#.EJDIP!_.M,[ 2PCGQ$.>X/<%>@YM-J/YYF+R20JDFTK+ ,AG7G>G&
M85 %$RIP9;U$?!HW:&<KR4TO(3C%7Z\J0F$;H"$'\R7X,T@YYK+6E]6C&^BL
M#/\5&JN,$!7M?^*ZTCA@ZQ#G(ZQ-XM%(:1#"D$J$&!?<BWDNPV$UB5ABR@M)
MV<_*X(Y?I3-HT,E"QRN?\E\DSF"^W[@!AF[0+7F 9MQ;U"L9+C>^(#^@A:/[
M!T1Q@*"]9 )#BC[ 6;([G6X<<\V/-3+9FH;BC8\83\=G#X;Q>B-4ZG:^2#3M
MM[\"Q)["I4)A8*CZTFP1T20CW@^UTC,?J03A\?%B-K*B$]>VDI>6%'5OPR@O
M<)A$'<MCSBJ5.;G@/UB(OU'C6]R"$::KH S#@<EG!;6">YU*/1U1K\+'%-%3
MT]_F@V1JEJ%D/@^4])T<M[C>]':)59+:U/?0I5^#?<6@(@B9IYJG8)=Q.W%!
MR,)%0L*]6'O$+;R2<#63=:WK3'I=1&I)PCAS.%;^&.]BC'0CMYG#R:Z[W+.
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M3WW6!2X(*WOT>#)PE7C.5=7X6C%Z!HWC<JW@#H4<EVC4*3M>UP(#"\SLRB;
M?R7G;8G55[0@1>[.N>BCH^.Y,<*6E8G4C\=U7&WUE&'=#1:0<6GR_KM^L ?N
M(7)-]*AC&,$<GWX^VLTE9SN #G3H#^Y>1#8S<LPE[X'GNZMQ/,.E3H%Z+",4
M6$8<2#R;\1,9;N[M*MD_7 U]]?'P'@=S(_A] ,\)ET1SZQU&Y&>&HY'[5GRA
M@@B%$44RJYH*G8B;S(L$N7FYR"=Y:Z>7<K=!W_B')>BY2YU41BN(;,Y\HR#2
M1HSO&:/*JWAN5AAV_MEB[]2.S?$DA]^40_)<9@81:RN9&X<IE3#%1I% 7*:$
M19P):6C8+@2#,='-IBY.D9<57H(T,!8D1W(A'#I_6\F0$;!T"&(Q33IC.@_&
MVV5<8SW/0)]TC;+M3CTUHTZ%\AMI^X?@7#6-CEI4R#_$#F& :*#?8O990=&&
M4S)*)1(_A70PX"]3U23,]AB0@&R&P[P1YPTO4LJR,/EF:,/.HGT-)"%ZXIFQ
M&?/2FE#QXS^"J7A/U.QSR^2>!N4Q(O^!$(J"*V+?1+@6,UZ:-P[U$B5JNJ8&
MB!LGNJC3S7'U7L]\DU()C*72L*,!HO=L>VG=P'(:/"?EB6;D@:>[5]?Q(DS5
M\[1MY.J=J]>&O31DS;P%+"KT:I5E]3!Y0U/@*$T#[X4HVC:U=%9*,% AT'8X
MNF66-W7']1HTP</A[ASMV4RF!,[R<Y1KL:B6C;!MF2F5<F3[(KXMXC_<%_&O
M9V4#"!.=/PR\0;MM.N#6=&&>3TZW%70<X$QI9G49B R=":)HB@K$7?,!JQ]5
M L9(JK?75C;Z$ZDJJ[4!:GZ"IO[Z#EQ,JK1+3_[2IE<M&QR1BH7I>3H@#@..
MKA2'4]H>ZT_Q#+\N[]7-?4Y.3N;+3.9QGTOD21R0V*DS<:X<Y27P6+\+&894
M5KV">*@[;RF\4G1/(;<?K;:!'$$J #&(!</W)8.Y.7^T]HC4L0JY5IH^[B9Q
MZ.O''6D&Q[.&^VD^?DR?[6JC_&"4V3<#"(4.@(>_>N_]QT_+":TP$5.>'11N
MWOYX[R$(PE#>^*.<N(9^/#AZM&J_VDEY='S\\+HIXK8\PD_1<AW=/WR :]&K
M4;$CQ4D,.T4^8&YLT.70"\4DGYDQPYDP&K.IGVW6#_L=_.L["*I(IK/IJ'=P
MP/=+?IU+3@EN+L#F2CSF@S0"O>3+"5*WD_$@6Q](7%;9NJKW9^):-RC4DYB,
M2@>?FVX=CF7;.I]0YRY8L]6JJMN?+)/H?F^N86^B56?B&G2\X#--S84)T]:W
M"=P(MSCM%#7M;"O@K!;K)@<WK>2^^-S 84>B"CN V/A\J6=/R;GVR\XA^G;9
M7*!COM%*.&Y\>]:<4IAZGF"S_NZ0Z3.:248SF@UIR^AN)B<$%:#Q694A<*$
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M:UCTTJ(ONYKK_3Y?YSYG$4@-2]GI*)( 62=PVU:>^@9WLQ+G<[0MUHQ.(0A
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MW@1K\%5-GCCVO@8]%8=0&XT8'H9,VM0D1/.DUU=1;DHBHF^@5(]_?9KWM4O
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MX4/H;JV%ZZT _C/@_PSY/R-.WG9WO,/4>P$WE>^,1=CMM3<7?DM4%G"<6_4
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MB71E%+"M0"\33N_P51G5A149?EU2&BBDUE20E6<"2,Z9X2?M5;_A]HRC?[R
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M#+PO.+U&>CIU\X*"TGCAES  ZK[\N? S-)X/+-B"SI>FV9[2?CIX=/OI$OL
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M4^:OC9,%(V>5C6.J^+]J]WH=!I0_!$Q_K?M0"9L>^CGNV'0W.KM;.! 6"]*
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M,/7$#Q&/?<131.HBLMF*X'<RX!])0PETY%)<V6?,J@5L>P3D#7$;%7"Q\.+
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MC_@Z"/P$6/YWL-CC7>'9FYLQLAL\>RV31MI3&MY<=CH;U*1(L6WY1X.3WM-
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MROU6EL?$>2JT.IDN)&/)B&9">-'6.^0C=+S)G0P9P/,Z$XH"Y%*YM]*B" ,
M70V$H(C^'&-FB7-4 U[_<G-=&Q@DH9PS&I3*=3*PL0RS2LD3"]6\1C3]6@^:
M(IW<'!(!;K=;,QE;!UH1_^6=@X_$X,M?;_N#X"NDU3T[!M]!:4-&;I9*[E/A
M[@H@$RNIL)0QEB%%5K.4QPK8'=<6=W9,I71TRH%4-<Z%$F,SY=DJ,(;[%&&W
MY,)<KET&R<9IG48Q(!K\]$_V'#O392R+%=CDRHJCHE"P=6%R$V(%9JEN$]Q9
MLF3Q!:IIQ\1BC#J!=H#GX9C(1;/Y4H?9S)=!ZB\"/]LGHU%.'6ZC_R=9\XN>
M5BWD;0[G 2\F(V6/F)8E(Z&_<5"87:YPPF:^N-.@392[E^E8KQA #+0VX25+
MZ5P:@ZC%',!BU7RFY9DJG:G%<9C9R-.K-'B,69! ]V()+8/&ODR(7$@>]*BB
M8>J'\#2",:0@\+"[B<H"+AL_,:*R,+MEW& HLS(8L K@'M,U8\'%R"Q-X)?'
MW*;KKL<G0_%R-E]S#F_JD<M;!]GR?"LOW$I*+MOU\.E&1-H!)N[11"R0ZNQQ
M*E1KD=^^&:&\J@TT40LK-[.\[L<Z&FAHK5-]0#GH_R7;3JNFTM@9$[3"1)1T
MCBIVQG4";DSZ*&XE?T,Y6D^6?KZ5L9!5G#)/,DR0 CR=,KV,<U+^\3&\EO&Y
M)U_7"$8:A.@H(P(Y33@8;M1#E@[?8+8N\%<IF <[?<S<5O.]/)I' 8:#\M=R
MXR#G$$7-D3*)1&,:M:(=',?SPW'0]K0"B.//#2W12GV9%';/>:NKKM[*BL$'
MRP/SK02X.E!#65B6KRJP!ED( F@)=/12"<HE'S_*E8"R[TM&5Z656#2.J+SZ
MY 3TE@IMU*XI*9T3R^%2[!Q7J0=F'ALJ'9EGWRQ@U#%F6@BFTPHS4=<,<O.!
MOS>0015=BSLAO0U*V^2/8 H-J=>E+HS-6]ZT@KGI$LX]*WXL@+!8 H9Y22"4
MTQE1RZ)-!ET 0D"#WV;(RTM,3K!NA-B"/N +DVU;A?N0C7F+J0XA7QVE=?84
MCTC*(#K\Y\3TP+D7/G@7!7!)>3%LZX,?KX;=*9D6U>6[%8 '9"K+9/)2T)T\
M6(AUI*\5Z96BR<?,>H8RS.P*LA)$B"[%S$PQNVA9BEF=A5X)ZHWT[FY]>.P#
M?91#PT)O^"K_1E@2USM^X-255_+O@$MDH9[R)>K'X^4</XN)=+IPS!N!9.59
M63/)VS3E1<(/+(0;F)-/LQ+J"*O3L7)&R5;C'JA+7L1;/;]W,.,Z>)'=+>(F
MU6!,%4!,ZZHUQ#_1L)9Z6:Z/03XV8T<(/&<:2XWMZ/I8O8].X8B&L.RV;&3"
M;K3+$34D;2JAW>1T[&VB,+!S],NQ/.QA1"*@Y&-Y/Q9]TBJ@+-B@]YAUG8QG
M8K*4Q",F)PM 1I$^R,0*Z]QQ0D:)\FTKUQ04*&M$D9T=>[$-R8$I#PW;GH*]
MXBS8Z37)YE@3'7C!CN %^1W?%KO XHP.P.#)  S650<WC4+/4@L,EX59_VLR
M]K,5 >\,<?,\%<&21&NRH3?AK-KF1^\,)%<0@E3U8?X5[Q,)C2GO.'VKF+%O
M?3&E46O*AZLKZ%3]\%J%M+3+3:59LE%OFF81L)I^JD1]?17(FCAB:TBTKM)Z
MH>RC,4C#VRCV62AGC450[8A(H,IKM6C6J\13]:!^HJ)HN[5T?JBD/5<-:U^C
M1DVL>H13T_GL:I?%5 >*LQ1#W$1L*.*G%GI'>PG]4-E[%B:9,OX,MY=0.J(I
M%775)$,'X,M>]BJY\'D9SER@$';)MX6.@Y4"%@PRG4%>5<4=D,6.^:'0IHJE
MSPUW5A;?8SU]J("4*NOQ6U25YO_81)!GBGX)5LW&D:H6JF$?0JWA4TM#JS2T
M4@FK<CUDRH0,#IH BTHSX] D QZRP[>8*&'XW!"2.\5*&A$GU+@ 30XZ%/Y\
MX?DQ.Z,R:,:"V]4VC//2<T-\[NK;_@ESV?W)__G)'XO)J#^^&I\+<7$Z'?:O
MKB;GEV>#D7<U&(W/KD;_W_#BIWIP5+G7]\.W]Q^=BY[S\?H_/W]U;GZ__OK^
M]\]_O'O_]<:Y_O3.^?K^C^MO[]\Y7ZZ_?OL?Y]O7ZT\WUV^_??C\Z:;^AX7%
MRK;B04G)_N4S2,GR/;GNO5P<P$9(N^P-B P?O7_88*W)%M&T.O+&WX7N4,6I
M:]S5#?5A]:_[D#VO]N7OA:I9@TX?/4J.\3GZD7KVP8="&<M'V=QSOK%P_AY&
M]S ,)VM$R]C(>Z2,$A'ZY+C7E7!DRGWTXO&,>7F(M:"#@>O<9]-'O5'GHIEF
M-*KI(Q$*&(W1<6%%,&CY<EV&<F1 @21# 5=S))?1':HR..\Q&Z<2W6'LQ3%Y
M1C-\]2Q]]BXB+RD+_)[C%+TF&\1H]\ =-.)K/P5F'&]:T)8XOR,\I;1O_@RI
M-<A-2OW,&WX>OEDEX*E,A9H@!HA@3H3]_%6,XJ47KY@9!V>*&\O"2S:+E"=-
MNUEQ\ ]_3AB<N5%4!VG"V,"LI<+0;LYO\O ;[-;[LW?3TP"8F/>CALKUS#&=
M+/8P"JHT&ZGP;2,L:66@;3T0IMEC',_&,U4;9!QS$EMQ,O,7V7=XS&2S'JN8
MM'E&-Q]_3">CQ#"C5\".@;=(Q&OU'V\F?@)&S.JU'Q)3T4MO['2)D@10XGO^
M669S7%WU+L^&F-"1QO#_)^K#,M>C1[D>/Z>3XF^GP][IR57ESR>]?N5OZX;M
M#WJ7^QBVW[NX/&W,;(>]\\O-AOV9]HWW#K@#N>S__#3\*:=MO1XL?CA]VQ3C
M7)U"CC!QQ_-K8)15].TA.:2/D21+ZU:\B?QN'1$^Z>6OD<4M7O76]U+K:/'E
M<?=TSN3<0"Z.O/'WVSA:AI-7<HWCL1#3Z1MYX^)]#&1S"!S-4038FJ@PS/-K
MED31_M79!ES2>C*<7;C]_L ==-0@:EQ64F'PA%0X<4IH0:9H?4AQ>NE>]OON
MV?E9B?#(%*XG80DBQ\F&Q#CXG;D\ZYU>U&Q37H(.?RG>9S^3G;>MM^,@2R$N
M;7(TMA2B+IZX0KE;31R*:[G@6L+Y%3VY%'KC3&N,YYE !>@NUDV1WR+@"!:2
M*;@2@KE#H,81Y[6EE#;N&L6!:]LZTFA%;U CG+&JSA%T\<](ORV#$2_D8>5]
M'!%>D[4+NKQ/QP=<:\ME:Z1'QRG<BOB$JX+$_ :ET#)^32!NX3^XT8+K)-A#
MF",)L?./R _A\UMR4/UC;[_4*/9V>8ID^"H!C[YX<;IROF4UP46VKUU8X8$0
M;&WF^7?!^?9T55+).J*_935:=+: ZC)X0/AD,H8GHW8P!8\%MTSZ29RC1 CG
M0RKFSOEQS\QT:0.,<@5VGA]*</*1N/5E:A,+NZF?@#++"$6<^_M.C(E2SK!/
MMV'?62[PNJL(>$Y A2;D$MPCWJ%,:"E4L 4=$J-PGD.K^'K$#>9PF_&](/)"
M&RB&<]AQ2([ NAEH"FWP/ZCKN ZP-J :J;$9$&]K)(4Y ^(#28:$DY;>_\#J
M?V:MMV#^):*HA3:-&6HSST]P2J]U)<FSYVN=GM0_7^NRY_SZX=/UI[<?KO]P
M/GSZ]?/7C]>8E%7_S6VL1*I?3M9;W3%%9:&PV8A"B<PBYU<-/YG]7"<6*:=T
MC>34EG9IW>G=['OAFTQ$UCR?H:LF&?=/_8 KR%$3U 5[$BHO%IC=0ZES_!SG
M"9..WK]\>ICK&O/J'V3:?XDCA $$V;(#H]9H\0\RCIUIF1**I3;8;'>,LA30
M&Z/R*C$Y+09.<QV/X3TBA%F526S22Y*1TO%N/3],*'=^_@;[+2H0!NW2H995
MS*@>5H'XB" \):^=\3EC4..+3N"G_BVY='9TOS1V:]2>H*LTOQ&E.P O(10F
M0Y+BAS5ML38AJU(@W!;N.LYZ_H.>TB8=CRUEPSL%A?X%9.UXU>BE;]"QAED+
MN]!0]W+/9[2.B:1"@A7H"(5H98-(AXXY E;/++R'7E3IP],E(A7(>IE;$6)A
M/D,63>$=.?PUSD.,N2\7E5GFAE\WM.HF1^4\LFYMQ/!W4^/42: HPKY57"\\
M@J%+7..2M0KV*1-,.IAU/:+XX3/DB]F IU9NDITTSOH:)?5S5M_ ;E+K2)#=
M'*GK-. G](PXB4%?!=-#+DU""4;7=:)=L I&"KW44@$N59DEQ(\L;"AHRR ?
M?HWBN3,X>?5KK0[S=INYH?=G6'_OSU7/^?;[>^?SK[^^_TI%>G]\N/GVX=-O
M[;VGT25H@,L8[6_)=+OJ7?=.Z4J2_WS;;'5M+2T^PVFVP$&H$!BL7<9P=QD4
M)X8[?_+S/Y>1[$" \N"3ETR\?VHM^]O-?QMULLEJ/HJ"1*$_?/[T]G]^HD>S
M/TC\!U?5YX+ZO7, ^"!3@:ZJ4X&VD%#G6D(U*G^HGK*T?R(U;>?ZW;L/Z$/O
M/.H'ZU%GK("WW@(MY<;O?&WFN;> 7NU9O'[VV4<QCV*XUI=SNMRO,<58 O1=
M)TD$I@'>J?7GJ1KQ?J5SK2(5U" Y)C+Z(;4,:K@C5^(I<%(A9R"2V:EZA!N+
M1HA%H]DI*I\_*:+\=&RHI+^HWBQ&JZ[$N69@F.M@A T8+/1L^$DW($3NEI,8
MK5X%WGU"CS+?_/0+_^FGXYZ#^K0:3$T,FQ BQJ6JAP2;>'!R<7%U,;P<R#?4
M@B1>EVYP%BMD!M22J8<Q@Q=))YM:TKT@=R%!)^"/U+%2UI_?8_*8?$!!,O2D
ME]$G+Y^>I]D:% FC0"$TR"]U_."VAJBSH^O B0@/F#!Y%,*4]!SZL;%3FG#U
M,/JW/&;OE'^SX0?+Z$8[YHXCTOQ%MC(;:-NX21)V(PHEYC.92-*)S/B: O/#
M(TYK9.[E'#ID:7_.;3QD[KGR%?\5VYW-EZ%0^<29$UE!>\)W";$U^V)B?U*'
MMO2W*;=._M'L>",;;ND</#^1W0%6&O+)',-XE9L2&G&E. \!GRT"(W 2QC_?
M]CB'2FXWD)DZFL,X<9!.O/:0<X<3!PSP>#F72(L" U7<@D&^F9\H>?(($T-V
M:+!/-^:D2GG @BV*8P;L(*&1871[2_C?V/^7!?5KI"[*#^.8#(5G-1]-F$8L
MO:1'D =$TL_B:'D[(^:AL,=?DS*9X1P1S*]Z%K%X_7FTM)N<ZL8WQRY(QA1)
M2-MJ24[</.#M1>"-N57:,LF)8!3U4J"KV*W<"8.TL"3\JHJ4X$ (\D^^U/)(
M:I,\1EL*QZ_XWR ]OL1B"C<682(C%=_IT-)UFF(?7FYNQ'ZFA@O2;QJU,2DI
M[58'CTKOS#816;0-&QYA*C'B34_$.,#VOSWG/::"9VB0.6R:K).!!*,AG[QN
M^P7B4 ANP V'S!117DI HA+0>NQ1DV_!XI7P(ST2?]G'N#K=RS#US ^J>)QT
M[,.H/V,N,RH$\,]L#OHRR>/74TPP4#A0F&[]*OOGU!1HQGU5Q!='H25/*C=C
ML2X0%TD,+ )_ET=3HOMA@TUJ[:R>=AU*VB9*&%-AJ<8Z6_:]HKS.M"22*A.B
M3^K=WJK<?_@@(N*B3&*@6WB1X"^0?#O[/&MS%#YC;=C$1R$[6JH]])($&U13
M<[][GS(J7BT7>,<G6GG0+<NX/34Q/'M+K,[J147EV !-+3E^? %S:G[Q"+)B
MNF=+>DL)"GS-I@1H$=Y+]LJ1IU^=>G-7Z3AD]@A8'M0F8+H,)WR&)V).VV.>
M4EN-9/!/,^V!KEY+69"-*IS 5UH+[)UJ *W8 ULW)I3MA*V:UX'*<'8>M522
MJ1@3:C6+_)DDY1ZD9AV_3Y%*G0AH4;1Y64,#BN-B;9W4S5*AFQ,0P1JP_&U=
M(GR1?#+[2KS-T(!96\DWMJD_%1Y41R0*KF?J6FSR3$DM2TLX1$+TWH&!QC:)
MNL4-&V^!+TVX/EA>[GR8/3GB7VU]OX4<I14=YT;2YR,3HFU\]*?M_R%9:BA9
M$BC4] ?-/1\HXWR*P'RBBT-2AE[^F*5>?@A!O9JS"?D6VWMA:U.ZEF^Q/PKE
MFICW &I4LF<XD&'0Y_N1VHRQ#$]-@- 3;D!F=<!5"2N4 \J3DAVIE(, ^!^H
MC0> \[?'49B)2]VNQ4@5D*W5T6T&\X8E@ *XTN8L>].<M[#HB:<#XXCO)*."
M)=Z7(B)YIM$:]GYZ'Y%G U=LD0F'D-T+\0[&GK,BE&V]$ AS16J2S/C5O^._
M]0,VI:>H(QV=_>58@4SJ=JXY2+>*^U8*%A'^(R(45PNQ59L.2H[XB<5,,"'X
M:D 0^7 ,TF4J;*%CR1FS"-8\@XKTH.9-EIB.NUA@>3DU+XY^^$)U/E#>64T6
MRA4H.GBPP<PDNSJ-!*ARTZ>%$O /W:9-.Y_E/0H$^7P?ML>HUWX@Z?M!IZ G
M$^F#(A5B305$UU!:[7M.*4(C4R1CT*#Q0(H@NE<(';9F1NIN-K0_1R\Z'6&2
M)3X>2U"O)8P"B0Q.NR,GE3T32F</7\$T_(GL"ZTP&AC,E2)%:M@NH\;8_K.3
MEH#KU.Y@&?>F\IP"7Y+[B7S)V<_H=S(M3;BD(^W)K3@DJ7EL3?=MWN^4@8VO
M!S&NG=3:.EJ5C(,H6;(ESWDHGQ62<_U7^U#/$BYO"%S54WF=?D:A'Z63H4Z5
M:4MCC8&T%;*]5&B,3W$?$]*'"-L!!]P _'Z#D2@L,J+>H.Q6 ^DZ<\L@\OLG
MY1CYTAR4;N @X,YF](&_VG@5Q=E0[K9N@X8'"]5EC@OY^$E#)\>YB3&V"[XU
M7G))L9; Z"H#7):5:+T/[0*CU76FNIN=&N6VP3>\N3"^P$Y:.3)I\Q-F?B&K
M;F+! 3VUA57HYJX!>E36J,#>I51_E+58I&?/N9;-=)"+W(>84<7Z.7K$F":!
M5',UK0AZ26^!\4OV662W1"@U/Y%Y_*ZDG4D9;>?(#3PS]L_H%KVR*:\:*7G?
M,9B+'NX&",R'G2742%3U7@ 332:;J&Z4&6ND,[@CZ,JBMN^JN[41>,R>5616
M/#BA.XRMMA1[8U-O)3RO*6T:/K=D[PJ.#>:IY+G^4''9>]6X% UROO02@P?L
MOJ?*&)3M]\8<MBSE^".,5%-5%;:-\U%3G5)@&FCR%8@#4YB\&AHA8W,BQSB[
M?'\.C[U!4HCAO-*5.@0KT\[G,?52!V5+E<:=*>VY+9-<'U$:N;E<')%F)J-4
M2(5$-KG2!XOD50E9M-5_\_ZMTOT53_B&"P,M1J78KZ0X4&<\L5?(TRK?4=F)
MP1P9I2XJ/:9=/,*K+6O+I2Z(:5Y[D@$^"N?ICK?WI$SEGXRE6.;<_@8<Z2UU
M(,:L^&*Y5\J4Q/HO_"%9EL5D[,"+I19'VHM7;(+;F+38JN3-R\'@_,W+A<WL
MW-C^:8\ZGDS 4E8=WF%C9O[(9[^HNE']T,31E+8)::3D6D=/&*M!RAEI=H!W
MYB*^I5Z0F7AC#2;S:L&5LQRG2[QWZIW1WZQ]]5'PSTDIQ^W,H &RBF7><E76
M9"1TJ,!<0C<10:NJ6&M.HV!603S6%!N/FZY7TWCM-O;)-I8O7*3[Q+*?94A<
MJ0B[M$_MB%Y%]$SK5O7'*!8YS.]*U845O^QN6Z]3:[UI)#N+P:77.ES9^B$:
M?E1)MV]E%FU7J?_T>+(;0<BJCH^4B[R<8_+UO]BN8_387WH2T$T>&I&4CTSA
M7IF.D]I8MAE2:I8SG0TI=<\H!B[!_(LQS"HA4:H+%LC_A0\%F(N(T4U$<L6.
MCG7:C9;A>[RKG=#0IK#$8"]I?%F[P]@4H:&]C!3:#A0DD9.L$A0#<!JUAT":
M(4DNQ4]'"<MJCV*Q\."/VC.M4O,HFYCA?M@II$=9+$=@NF=&3F0'*OWP#CZC
MRABR65 D)_.:4F-9.6\[LY\]R-)7$PL,V&,I'&<4R[1K5R$BN1J:RW7B:.4%
MVG_"@FSAK=BGEI^FD77*>-W*I>(J( E*+59^/8KZXO25N^N]6[/<TV_>#ZM*
M\R5XM7WNIZ^Y(Y,+PJ'3\!.PE3H<K7)#F6':S'_,N0I3XQS#J2!]);[U0O]?
M9'A%XZ5V96<%%/"6S&$0<3&";$=F##^*/I&JFK)F)^\#23Q2NB11KL?IBV9_
M8SJH*G:*Q9T/PZ)(Y'H[+U"N[H]^2+Y\I/>'< *<!UK>$:^!0@,JN\UP3M'F
MR,I:>=_(ZMJ\]PMC7NK)T#@C\G&.^&51&2J-RWU'^=7\1(4/@I4.<(!\'@DN
M9Q2OTID?3W1JG1U!E<Z:+'$=I]=34_M4G)KQL;GP0AD^I<L'L\4P)B.[KQC7
MXABF_2\1NBK>:S18P?)$*3!<)XTQY*%ZI3AWP#;+6%8*PZA+N,$PKY&3YXS6
M+28)=RF^W54$'?A[!YE U6]9 E5];;GW-;+E& M$Z9&;F?";;-3+L7<YS3]>
M?WO_%7LDO+W^=/WNP_4GY]?W[]Y_)8BGMY\_OG>^7?^W\_;SIYL/^%?$>[II
MOEH']VL0<%FX;Y6@9NGU>8Q'EP(7Z'A:J8<7,6:L+M ]F,]H1?P)K)+W?E#6
M-R:Z%'3'NNEM-&-@^!=7V+32=22UDI>3"B0!7IH@%F!+/BN#4J^9J4R<EY<D
MV==L>K4@6Z; &EF5Y/#5_ADSM2AA9=K.H['Q)&65>^3J-#>-$B-E@V0;O64&
M3=CZ2"EQ$10G<8= M2FM?"*P?@=_B^>ZY6$@PMMTEB7Q&% _>OCK6VI2J!3Q
M*6;=$?9-Z5MRSO9+X@>6NLJ<.9@]\Q1VU',^Y%;EJO4;)(,_H.6B,?Q-\$V@
MI_*D<3%,"I:55P=6_9T<7W7@TI[SFV)3MTA##52N;A.=0E4@+"52\+I4-N8D
M<Q;('R:1X%TG:[/X.1GMR((<.CN7BM]UR,-H(@*DPV8!;,!QVBE8S#IP0BTS
M^6[%Y*P&.,<>4"+\1.L#ED6>DS&*XB0M2D\]"Y$* ?+:.?*/Y1'E8Z=:G2(L
MC&0"@IM5#F?E=GE(,LF&IL9T#:4E!4LF7<EMQ$T%L?&&/G_DPWPT^Y <0-;$
M?RP3VGAD*6NJUD,$&*2FSH^6LA]\-Y3>99)A%0R8K;<> @4=*%_59M1)NC3\
MO*D294IQ5GG@"J0DBTPH>'9Y,EUR_B&+K\SZ5(WA-/-2"9Z$>3%Q8G-9R'^G
M>$L)PR%;BR 1E,\ABW!_ER,GLV@94.TMI4-QW2:UJH;#!6+23S0HEID IQ22
MN3K*YJEHF\@<>;ACRX7TBLO*P9+BX76Z%! )!-U8;&3#R1)9:D:IU2O2<W3!
MB/*+RLE@B2RZA6-R;SD+;/:B8FJ,ML%==1!4;9S)6,DA7P6(SB4K6N-5;?3S
MMU^OZR"3.'::S/C8WL>^JN F"GZ]KBI\S^^J3#=7G,4U'9S1,<;-YCM70SNB
MHA0EJ&?C$PB^^2"3<9 7[_8PA ''$KR3\"A'8N8%4[7Q9A"!6]V)S)S=<#VU
MX1,DR1=%K5IPC#QV2QQ;J[36-+6B+$*/ *E4OQ^LQ^*M%ZB=!(@">$N0A#@@
M"_FQA_OIW,)1#[<;'Z2[$AGT)52NB.\:?_':654V,5SKLLVT0LHVN$<(1CR,
M]EDDM1.$I;\@U#700(T<R<"[I_Q(^B8<L0#K:SBTX,I:)KP:J<F<+9DQA+2<
ML,&NNT%1$(VC3MA@CN;GI^634H8532FK1G>QE A$4T1I@$;=>:6'3RDG.;_?
MG-I2(6B-V: &9(HN4MO"B5BI\.1D(=7<Z&TIKCLCOSHG51<>DG+-???UNCG:
M286PRVDGE.8CK3IMO(9HG&M_R<S#&=^1&,<K!@Y%XJ,AM<5.&F82YNX0$K2T
MZ4+JI4YZI)\JVS^-E]D3W%41[Q2I58ZE7VM%5KG/>#2LD_8>J9OR8\:P8\2[
MF2>4CM0@W;1")2+A7=+'KZ[+*!?6OU8[$AA,TIOCN4\8Q]B T[+J"0UP'1 T
M*F)K='LT+/6C#!#3R$?S)D@' A_"VE&/"I<GJOMDPMEK>N1C68*M0#1_I'B/
M<IVCG*^R])3UA8=K$@7 A_ U/AIP.:0JE3?_C+0UV*C+,NWP!C+0BRFW Q%!
M21G0GE-)P*:S^#NU/8U91Q4.A$*;)>Q#O+IC,?&IB5-LN<5*'@A+6)B\="5^
M&VV*F/YVJMS0@%>:SY!9U+$A,<JJ8RR5_ $6$_.W;^,(_:9SUCL4?C<O"<$?
M"+2*T6GQ9<*2FBS'64DNLJNJ1S9]C=IKU\->=,#EWGR!E<19P)'MD%=_AKYN
MAYX0=[_5/C[GJ']U>7),+GO5F, T1[[1%Y0^[EJ+S-, 1IM4[Q51O93L,J/(
M*\9@S*17'8+P9=F91 9BBMIK+/6OLH?3&,5$Q\(G^/-I_@W;VTMI@?Q._TRC
M5:S;Y-Z^ [_;^B=9NB[C6U[& WH!/*%%IGQ&$FXNB[GA;O'%5.&8A&L]S,T7
MJOH6D]U*#,G2F+55P"8N(@F"K%6 (TKGDS+6NL$Y*]Y8/3QK6(Y109)*20?'
M$FYC _/(?$;5W"S ' >]_+O0."NP.!0(?F@B5R@U(9[3T;2&IN;#0L'\<5R$
M,O>+WT#I5RJ8LE-/3@!@X #(B?F-,@:'5;.21NI/ 0B"8\2-P,X-4M=BL3!:
M&7@D7<:=F7$W:%G&76V.=(4"KLNU\TTSA8SL8@*UET0A"7'4Z?,C<$O-6Y3I
MF(B"1P#^C2?\./,=E5@%91]6YZ3D"#;GNJC W-U$KL@HJ:%F9ND8IJ?:AB'/
M22$IG+3*:^UV7"+"BQ)<:Z-YE=D ,M7-4&&*GN7Z4/D(*HO<<'2H5T@#> 4/
MIMP[(/_*$16 >AF*3X$&QTJ8EY%5ZN#4IL;FUJ:ST9<LK2-OS-"Q\Q-I[.B0
M^$2@TY$R@I(T&G_71K!N6.M98$DFGQU)?Z9&]I3=LI@Q/EW?O+O^O[2]WV[^
M^]A=0_:R2'\)[QLPN95<Q=Q:N>L>IU9H#O;8U4ESFA!V"$WE_,2!J:0$P.1'
ML/ Y' J?ZPT6V%IAHIXT#TIJY8]BF2_,>.)GK7CF(K50ESF' WN3R)R+'/[=
MD7=<Q<2N<S0ZSO"OT"4!ULJ\DN<G_D1FAR"0;UD>&6=F'(V/S4*,)-.DJD8F
MK48"UCW%/&0S%JF44?F8*EZL0"ET5*\D24DJ;C$7X9*9.&%KVRY^D;C.6?$+
M;0,C>V&]8RP+K>SJ&$,7-9)?3(1N;?%-/3]6.BHUF;8A4&#OZ(#%H+)-JM9'
MD8#U;()BG=Z",W1'1T.?".#.I2<C4@H9$IE'2@"S[C5:8L1<O@DKUP*W4@C
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M;!^ I3>T>J-KEP%X7Y9XGTMEP&YYV'R:3&]83JJR&=5*S=9?5!B68AL(% A
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M2KN^Y13L/J/OE'+%HYF@K/(.-*+0">P-1EPQ4FMJ6YD+!@,[K>",<D_B=1:
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M"1)-#&6,Y$1IRYD)7#%U VNQX/"/Q.'7"QS^L/].XBA"0AQ@(I%!B3U0/&@
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M7_;(X9\O!B^?/8<O/_SZ,=X#_N^7@]G! &8_^N&SYQ<'?[RSQ"C,8%RO-"!
M-6) RG3<$0J))+:0,Q\M'%X32&LL;B'B>(\BAWT&INUX_#" Z>:'KYF1*5B.
M*2*:,FF4PY93$C@.DA,4,C#!#IA@ :8> -/%"C!Q1;15.@ MI ?4. 8,YQX8
M)HFB49#:XPA,N&:0U9") DP%F.X!, 6E-44>>84X949K07U<W$HZ+Y"F- $3
M4BTP(56 Z>Z!Z>73%6#R"MK@) =>!0LH)1!(3@. TBD2MQIN\QD(4J,(3E)N
MIM;>"3 ]+)?4=CU\YD\G<8TWC0- =3H9G\;1751ZY"K_[[/!Z5(_>EY7&#W<
MXH@W3_6_]>HU>^[#V7261#!],9XLRVIOY/9.QG&:FIX/SS^G]@^^@-CM@=@?
MZ[1/:&0L]Q8$0B&@$ 5@8"" N&@K>^.L4&AG%Q%88WJO3W&5$ED_6#X_E*05
MC.D5QJPR.**-BEN$ Y)0 RBG&"BE&-!2284%LHS+G5TI:[6%O14U?S!J?G/*
M4]2\3VJ^QH<,U1QZS8!#C  :N <*(0\8Y)A%>A2HM]&4B&1(2=PC/7\,X;DU
M1I1G!8P#.)OZ2D^G?EXG7OQU.G15EU2A0_'5QB-[$;Z"7_],PSL,KZ=^+XNG
M(-?M(=?K=1*D6-R#)%; J]00"EH>#12:8E_:0>>TC>;HSB[!J)9X$[GN$0GJ
MGX/[P2!+;TA0098[1995Z@.Q"3BH (AD$E"K(% NU<EAF$<!,^&]B<C"1(W)
M9D&SHMT/1KMOB_L4[;Y+[5YC/)A8@0F6P*9#I]0Q#J3F""@>:'#82&Q(.GF*
M:Z9NS'A*#.AV&TDGHA/_'Y?8SYW%?C;:^!6XND6X>K-.<R -J?&] L)S#:@/
M%!AJ&5#2&V@EY5Y^M>_M/2(ZQ0W<7U/H>T=["JI\9U19B^X89;V0 3BD(:#&
M2Z"#1D!@;$2J8L13![YH C%9*T%[Y/@MFMU3DE,T^VXT>XW>4,@4D=X"0DVT
M%ZC R5[ 0',-!1'!(J13RR,J8(W89G9(">E\3[W<3\=?_716^2:V647='*8>
MV=5PH,U@F ]B=E&=$M'YH4W+&\FT0>?#T6])++\MI%)0Z_90RZZS'$F-9)(Q
M@+2+J"4U <K1^$_'(!:I[0<..[L*U0)O9IO<(XI3O+W]-81NG^(43/FQF++*
M<:R1GCL# 50(@2A("R2%'D!KL P(>^K1SBZ7-<.\1W[>HM>])SA%KW^H7J\Q
M' 2CT1>(!8(GO3;. 8.]!A))$IAES";?A:*U1#?.3"WQFVMIY>O1Q,=A?/$N
M*4#\9!2)CCW6H_<^%YHH49N[BMJTDIEZ]Z(1S/-6+NG$H9_^0P]&!;5N$;7>
M;\9Q. W2<8 D2PT]DE\&!@X$1"C5JR9*P9U=BEG-98GB%%_O/:$X!67N&&56
M.8\G, H8(V!8Q!9JF -:JP"H@M8:%!D/MI'S4%9#L7FVN6CZ@]'T[QW5*9K^
MHS5]C05%\1*!*0..VZC? 7-@N)! ,<6@C-@N8$A)JJ1&<K/N4XGR?$\]?=HP
MGL&H"GHPJ3[IX9FOQJ$ZUY.)'LVBGDT&GW(?@#;4(Q];J.?'EJE;A[*,3@U0
M'8X:8>V/7D11_2M)ZC \F\NG8-@M8EAJ ;/?M<SZ?/#A^3ND"#?:!1"XHM%(
M80P8+P/@CF!H@^'!DYU=)&JTQ95SGTM$/1CU[D.QMZ+>O5'O@Q7UMI!:9JD#
MBE %*-,62!:BM1*-4"LEH<RE)D\U5:A6N">UEHJ&]XZ*7%HTK6CZG6GZ'RN:
M[AR&DC,-A+(<4 %3O4=(@,..\Q2(Q2%EG>&:0UE+>&/70XG+7+O0MYV3DCCO
MP.KI<74^GGQ,/0"L/DU=T+I3-G^1C=P'OTH?V<C^R$Y2_/B9;W[NC_YLY/*T
M$4M!KEM$KHMU"D(4U49Q#*R!-E*0H(&1S(- A0E2:8F9V]E54-1*WH2#%&=I
M?RV4[UAONBCWCU7N50(BJ&%0, L8XE&Y;3! (P1!)"%20N(0DB%U %*UV%(<
MOX1#^JWA/[9R<]'LN]7L5<)!?)22Y0H$J-,I?DU -,PP@$0:3T4@1J82J+50
M+.IV3S;NAQ7[V&Y+/TW$XBP=X(],8SQO,Z:_W6;L"HZ2*[?%ZAV"]8%X7&JD
M))F]&([/IR\FXY/747;[H[9!W+A$<6\5Q[ZLTP\AO?(V.*"DXH 2)8"T.!HL
MUN(H022\$+E1!B6TAO 6.OA<I[7<?7&@WE]<Z$/\I.!"'W!AE;DP9Q@SA (L
M. 941PXC(72 1_')" K$,9AQ 7)94[J9,5IPX9'CPG<,NQ1<^(&XL,9[.$-,
M>!UEYF2T%Z !DAD/(,/..F(,52'R'E4KR&N$-RMW] \7'E8 9KNAOS_ZY*>/
MO-_R]IFY1_V!>S:?I=]R?WTCVV6S9_]]-I@.\LX]#M]H<5520G]D$/;WLXD]
MUE-_&'YOI?+[4(]F>R/WO!/,TZ&>3@=AX-W>=([G"S@O=L\MVCUHW4]BF$%2
M&@I0-', E9@##0D!@>B(.(XX27CD0Y+5BI9$LEZJ?1]<'47M^Z[V:QFDVE&G
M- 9&IG:= A&@!9= &(@8X0(SEP*XJB:0%:U_F%I_^Z';HO5]T_I5)T<(/D#%
M/*"*8$ 92N=9=:[A$R% B(!=:DH%:]47K7\,/HR5R.Y@[M"X863WN@2\=P#7
M!S9S'4]M0;/OBV9X(\,4&0JUT< ZE]#,,R"-<(!+ZY5% K(<XKTQ=?D+KJS[
MDIQV?]&A#Z2GH$.OT&&5X2BO(35$ T\P!Y02 @PT FB)O18H"I3(6V X!1P>
M)#C\V"!O 8?O#@ZK1 A3'P@B"%B;P$&[U)V70F"T8,AH;*)D;X$(_2AP>%@Q
MGNV&_XO!2(_L+41ZOQ5^[VM8\M;#O%?UE#W$R;SU&.\/G<R;!7A[[2+9+IC?
M)^,4C9I6(>Z9E?_L)W8PS:5_IK.Q_5B-3W.*U+R=W6,[:'NW(=Y6.,F>>=Z*
MYC <GI:LM=NV8^BZ"\0ZQ9E4&N!HI@)JD 4:*0F"H]#S8*@U*7I+9$W99D?=
M4ORTG 'LQ2G?@BAWB"AK)WN)4<1C!TCD0!%1L !&&0D4-@HQB --Y_^BK&N%
M;]S%MVAU?[7Z.T2'KZ[58?#9._#%3\9%H:^MT&L5A&Q07!@.F \24"@0,)*G
M6D(.1_GAH%-]]/_\#XD1_J5'"OVP?!K7I35M1=..T<BZ4H\M;_4:6(604\G8
MC58OII9 Q:BTR 2L&9'<TYMQFOWI]"S.7>ZW6:R/VP0KMLYG.'6>2:*CS2$(
MH%(H$#F- @PRJ(R0QEF:^ RL%=WL+76/^$Q)C.NOY6.YID$CZK#!5!(K ]-Q
M*K334&$IR,WX3$&3[X@FJUQ&RR!II"T 6ZP Q0X!Q8T#2"@50M17GTJYHYHK
M7E.^Z1\I.OU@=!K;*'.MHD7@$%7!28$(%0IRI:1UQMR,S12=_HXZO9;"JDG0
MF"G@D891IST'T=JC@'A)J418(&1SZ6/.:LE+G[J[)#1/QR<G42U?Y1!-EQM>
M[;V?>+]T(.\O$IO[X(2Y,;'QGF"/"48:*ZJA2T4S)>/4.Z^ID/R[$9OB@/F+
MB+5_OE&)R##,C)6 4&\CIR$.&"=@7%M0BA!E"4FXW %SCSA-\>;VU_Y1/&Z;
M01+$/:6,$6VQY<@:;2AR$3:^&Z<I0'(#(%FE,U0': Q70" = !46 ITJ&<G(
M3:UECNA@^^C)+<I\V\HLL0W0(R=5H,AZHSD/D=U&7DL%I+*0F=YJ]"J9$8)1
MJ02+9$:Y2&88!2H( 6 0F$..)"11HUE-.*PQO3&9Z5]T)C^;/6%;:$W^]V#D
M(E'X&=#\E3ZIZRK3V=F;5;-C7QWHR4<_V\E%1V87E1M,9Y.!.<L*K6^']]P'
M=\V->0]7T58Q$FG&$'4L1-X3;-0(*K@73*@2T.DGPFTTHI.(D&BM6(!T*K>(
M0B0_"F-@N6%!(Q281CN[!-<*I9K2][I!=_'_]M=DXNFXAY4"T:"IT5 Q$934
M))I+*=_)EIA.;P%E+:83V2OBB -E?"1!6$-@"$? &^@4@<$*G=KSRAHK7J,M
M0>*BU ]&J0V#2>B6(X<IMDXK';BU)!#LN)2V\*#>*O4J#Y+2N1#A%W!!&(CK
MPJ1\4P^XPUH@HD60=&=7UHB@FN,^!6H?7U#G],P,![8:AQ#O-GI?@CC?CCV[
MN&D9*R#QE%+(%/0,6V.XA5;[UO=:@CA]0JB-;G:04!ME8P!"*8C#&0'&* ^B
MU+ *'&F%OY)%>X](3/'[]M?>(3B:.2$0A[V(OWAEN3,X<"(DE.8[DI@")#<
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M>*XOICM_7YF*D\&H&Y-*@[[NE.W^EYG\??=2D7[_F<;?<I;DF3Y\^?3PMXA
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MW;E+K5CZ4C;OJ_'9++F$TD'3)KF[?<"KWW_?[]Y]/&KOLA&&7P]R/"0 O.2
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M7B=#8,-^L\5/;Y76?]=M/^G5SEMTX=M>WLA3>.F5 T,)=FJA8N4=NYFS4D[
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M]D3WBMR]!H7N %5W6*(6-H\M]!OG6VO?(G?.,"R1U=HAKIU'EK.$&"5"1A,
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M,9P$#!^2VK6T;+ T:<0YQHR4";0EX4%;\AF1O,+(<B58T-0JZ5=629-*OF3
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MM4(.!X=\Y)1;R2QFJ3ZI7X%0+]Y56 OUHPGUE!M0<>T"6$^(\TRZQYU%UM"
M8-VTS'IY%+H6ZN<JU+=1OQ?O!ZS5[T<6[4GU.S'KG=,&,2H4XAY+I"6%_R*<
M&*Z-(C$ME_K]*I(3YY$*4'R?5,0KV1N>(V3=)HFZ,"2C=Y(#2EGFP*I@EMM
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M.B9C;<+(20,G=VYA;B3U^0RGSFKLA,GD7JPI%U:N6 OW$@JW3S'X1+6D3/+
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MO$:[&NU>)]J!T:I $3 Z:5#RJ#0$!\]YXM;C2$VHT6YIT6ZJ!7ST)/" $4L
M>9PYBTQB$B70^(A/,K+<+(E0U51J43G$-=S5<+<$;WV;^*E.A!H3&?:)1^P-
M@)P2SJ:0*;Z4J^%N:>%N,IIBM1=@L7J4/,G*788[JS$* =,DJ7?,9L\=Q4TC
M[]VS^5'@K@JV#$<QW.&\ +-%1UIO<(^QMV7P2J%[Z@[CY.O>Y_;U$.LA/M@0
M7T/@LAT'#=?M'C1^V,/3JVE,%E&75=^COL>]1>P95@<] "7Z,\Q?NHWOU%".
MDP\N6;!%B3 $&V= H?;<4A'\E0QGM5;]Q'SG&_"\#?S-&B%X\!Z9%#WB0D2D
M560H&FF\QBIJ1W*M8E/?7ZNN$Q&75Y EYD[12&,@D0N/C99.$&.C)$YQK&I!
M7C9!;DT*LB<Z,\UB9#AUB.<(B"8^(6F%B=*[1$)N=TAD4]Z?Z:N6Y.659$6<
M#M)2;2/E/F@KF+5>2:$(=HS7DKQTDOQE4I(CH<&%0) 4G"*>O(8C.3 DE304
M^\18A"-9FZ92]9'\@@4YE^\)XJ/* 3H/A[&43#@AL?>&A%]T$J@%^8D$V4\*
M,O,X,,8XPIQA.)(%0R;F GRO7?0.6Y,[",")S.F]Z?EJ05Y>02:$!6YH BE.
M',YD#=I9$ Q3&Q+/#4MK05XR03Z8%&1ME'64<J08!B,Y<8<<T21W,B212>=\
M@A.9,M"MY3+IUJ_!*[[8<I[R569B#C<(1RQCSL#\&;MKSL ]YV99X'S^I-RJ
MMTM('COM@I.<*F:%3<P%%96D,4I[94I!#>=/ >=TN@9(1XX9Z-0H-Y1'7%&-
MK$L!.26\$8EX+&WVE#29T#-@/I2=IU Y[I7$<#_I?1XI735ZU^A]'7I3+L#T
M<II&%[G6&<6%"$88+96BA-?HO6SH/5G3)+&).!J%&'4)@3G% +B=0(%I:AT+
MSA"5TUYQ$U:TAN\:OI<+J6KXOF=TPSCK!&/,>L^YEDZ&B U5F@5.K- U?"\;
M?$_6:&$X<%G,_=-@P1"<Q109+Q@*V 82'-;!9_@6IHG9K"NEAN\:OFOX?L;P
MG:(4% L6 E=@>0>=BY>P5$'S:&.ZFEJ@AN\G@N_)HK/(O*;)6Q25$HA[[I&)
MP2(A.34"ODBY"@.V15/*66K[&KYK^*[A^QG#MXN2 79;*I7F@-2&"AT%LPI
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MM>W&Y&?_M#_HI/.5J[?ZE&"4:WC] "=?R @;.&42OG(\:N."B$(E&2G5&AL
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MQ6.+I_RPO4[63BK<.+'G60/OPQ,/[:"\Q3C(5#_K#K<(W#)#T6#/#HHGY#'
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MH@99;$7:RZ &61X.I]HN7#14[\Q&KX)U"18(41$ JW$,R"E"$;%61"E#($2
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MP&FP6A@KJ$E!,,HSJ\'&:IDI,0XV N4FL2P)E303L(@S/#><8*3K$F<.,8A
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M4R!1O30DC%^LB4DS!S!?*%&O_YTCB$)79[,"K7,D("P&E0IEP;N02FM7TOB
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M"I4#7[>3\X3OM?+DJ3OL903KTIO(C>/ A .)%CSRH$!D!/Y&"98K!:27"K@
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MQ#GC"(^>%ZB$_Z6243:37-NUR[QOE_E0*>7:93Z&(HY&F5ZX:#5J'GC&",A
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M,,X4WF]#P'M%O#62\.RL1&43BJ.F,6Z:BIFZPNG)!4-3L_K4:15!:'37 12
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M&5I5[_(_0F*+&T8]0U? ,X>(CMY2(7G0Z"Z2P\BL3FP]%3,PFMA294JEL(E
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MB3/L7;""1A>!86N5\F&:RR-= !FQ_RWW<KD3KD2N)382S#2X07#!)2^L]3C
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M#YP5Q J%'151A>1P13U60\7KTQYH2A5-/@EDK.<(^*1'1EB#*&,!X]P5*]N
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M(H-1S!(;H]665OQP153\6I[QP??ZT<Z^H2Q(%3 R,A=@3H0CIVA %!#<I,3
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MJPLWDV:1=H*6QA#QCB%N#$7:1(H""UA&&ZP2!.!&FQHQ;(D\V)7*+UCEL79
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M+$5=C%@<]KPK /%]A4Y!;+WN90[ Q([+2W&&Z "Z<Q.8C3\7I#\7K@E2]EP
M/N!^K]S#<-T#FE<QE8/^@LQ12C/+##@W+9PJX*#/\U****6'HA>P,/P+FSX
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MD-TR"3%UJ.M=2NL%B$ZC2@P*E!G(]E( #D/@-P([X&I*XG@5O0GR1$"RH)?
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M(1N4K9/?L.;I!^;IA]=>:IY^,IY>5&,RQK(L-XKH&'M&Y=X0+:DB66),8KD
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M)CF<09X+'JO<Z#1U<!HBU3351@4(H3,(H3&+Z;S\L=]Z,T.40=].\]]"Z48
MDG\FQ7CZH7KC9H@;3PTK>^<'[=.DV481XY@V+W8^6ZR$*V.*[6@48$QJB<DY
M[+PV)D^E=Y2'%EJQB!N4KUK7,$"H!T=>GG2HZ072PF@4G0T'UGL7:F1]_/ ?
M=ZGP>3_ZB!>IXRW.YL]J,MBMH"*7@R'0/A!X33"W)YC6[OYG"]O-&1;BY4F.
M ;HQ")M&$ NRIF%93A/&0[)G&C=8MIK1%(T[($T>=T)9MPI10%"(=MK-R <6
M!HK) <_ZQ]$(=GT4Z>.A#YK%JZOJ:BO"W?U%M8>_N9[C1KG^NOSN];=T7<:*
MIQFSBGOKN64\LTK$6:*,%JED>,"_F%^O.X5UN<L8OUEV^/[B]OO1&V^&X?Z[
MO.O.-&@P.@):)D.?@SX4BK\YD%E'Q?A[*#<9K31@DD(J)3QWF>>@%:C4,PG'
MD<3,<)G&%<K1&<I1JKZ!<I6S?O1F,-S[ZNT$A>;7\#J<2 UNMP"WT_/FQ<?/
MH,W(+%.<))H:PG.1DTQ81;2VN;3*6)-3],>S5#6 G%?!;5@5005I2>,5Z"8E
M(0!1?P$]\ K+HE^PT!G&-]/X7SNS3\/OR;]^C4*I*A@''KTL@$99HX3*4(P2
MX?-L""<(-#H>=+M8[W*2PSQ JQJ^BCX"% VC_3?O/S1"2;7+5T3G>@1T!#\#
M-?<C/Z.6LN0F/!]I4-<!VH";7D4[6&P3[L=)=UR.,_O61'>C@0$(+!D+UGNF
MI^$;,X[ ]_0'8WC:HBW 144_3'J^H%M83R-4Y40#0=BZ'*[EOBU@_-$8/@AD
M_6H5:Z+H%M4VYU#\X>Z#YQ^I CZ.92/#9L.&_!9(K_CBKZI%_N?6PE/5B^.K
M1[2!;9^,;W[DIH+53WVKO2$T6]R-A?^;@9O"/YUQK[O]_P%02P,$%     @
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M#VG+]0+[\.,*8(A<.KA/1VZ,D^)U(:%)!*.8_O4+1O'JTQ%O#B.P/#(BUCQ
M01 O/[IH:<-@2GZ@6(Z.R\<O%>6>!"Z[GQY^([9I6F1[\H0!@U1/L2&R]E>!
M#W(:AC'(BK+,O%P]AVS*GNV'VSGK@%9/$ :T@%.D.S\R.0+-L.M,;S(:CDR!
M$)/H\1E\M?$/D!'C&]DVP)U'])%9-96;8CLXF=T(#^BGL :EQ5UX0SA4?\^*
MK=OGV$O?#L/MFPL(L[>?TN(P<^#$F%V[O;1]'[B+;8'9I&%HEO+S_H@/S>W\
MFY#O,WT2L_]>TT%IT5ANW@E^O8^Q\VR'8+;PX1/K++M<^@CPLI2.U8 'GQ__
M)@72FAU&#@!NZ&&TG 81(!2.'H #R%9SRV>F!*HS*_[;@F>(D!_  M9C2B+B
MB5J$-UIL::^O/0\XT4Q^/&4F/YY2.OW:>#J[(JR(X3/RR1D2\D)2=T2C9=_.
M5SZ,+E'P0GXBG3[0X94?P77QO!'GKV*]X[CHSI):1JD@.G 6;04+UPK4<REK
MW?X\V'A2N;E5929+^M">6O\K!:IQ%NYL/8=1^<WV7JY<*2L0^OA,QJXF7050
M^Q1,M1%B=W!U1*B,6J[R5$!UEH;R$5\^Q\*VG9U9YHQ 'N;.NA7UU4V2R94Q
M:#7<&XE^@IXPBQ;1 /807M)E9**#6DH5$E,)TOZF$]\\X(8"%^Q5Q*J&:YU8
M@J[%U(F"-P6JM;0RR#WTLK<^')@2-8FC9X3I%<C26<H-.RM2'D (;"(#B9"_
M B_ 1ZMJ?Y8:IOV=QW?-3*Q4?D]6,RRE5SG VQCMD)AG3P#K*9%XA<AR@6G
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M3J*?C\E*A Y-(/O\T_\#4$L#!!0    ( -R&8U2^DA^81Q,  '.Q   6
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M'!"9E"*6BD TAF?*1YJ\Z:TGZ=-PUW>V3S_C^*1I9V7I^RW2J+D N%[K3-:
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M':"8[C;JS=&/@.Q.!'N;;-,%V>\^XF3R8G;V":9?+U"A\DH7,A@5F0BTI^C
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MKT,D:Q2YUD4UY?>P!1(Z8.C>8@B[2&J &_1-X!Q#,82=Q/[ 5?I]9#8 E=&
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M 9^=9NPO[@[/VG>0Q<6ENF)+<0)9CD;6R@2">0FB;KP)5)&@XV#95<T@'^8
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M<MIFMFC&[]-OM+'8?@;,>8O[1RN&7(CHA6#*(_.Y1)&%XE8&HZR].'[8DS.
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M/ C:Q4$YBGI0%P?>!V%<,(5^3E:$MR7<"_><!F$U#N?3/8ENM]H.,DU>A/Q
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MTMK6US\P.#0\,CHV/3.+F)M?^+VXL;FUO;.[]V?_X.SO^<7EU37JYM]_N-
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M<85NN/;LNR$AX[,5T6P8[Z<&<D9>\1]CLQGL/^4OBMIEU*:Y%E_,B[!.DB]
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MD9_ ?-F?VP3)'RME7(!J4#]C_Z29$>?Z?-\D]+./)]-[LC&$T;+[.P7AZEX
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MP:IZ+X 5GZ@:0*P,R";,)DQ5/0#1^%=['TCSUJP\.&0Q;83"=-=#KQ=K1CI
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M=;7_W-K@8O%U@A11@;]VGT3S%4L74^KQ2>.]TM'Q#6^\FGK9:JO-1[QA%KJ
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MT=W<K!E)9!93QMKM R=/1L- (Y5:__U[ /MTR>(6][>:!ZY!QJQ#M 5+;O\
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M^S9L]PV/?0X=NL)MS[ U%J6R+*<_/K$E5LGW*I/0L[;Q*>N;5-:3K;BD%-J
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M#PR+SL4[\J3EB(:6S B]25/A^I-US)T$:EW1%B-P^2GQD/\]M,J8[UN79O(
MN*,P<V(TS0Q+5'&W_PM+^@+]DUL5>)Y"H!M.;CQK/.9P7:3%T&_BY2WU")7;
MR<C7N4*&OHR&OSEO,J'NBI?2G-]_U@:NA80[90]02#DGLS[4T6<<4%!0W< N
M5]CG/*E/DA(L6MR3J$QK94KO9K9.=:ZL2/+FQCO=%.3VC9,1?;R^TJ+78T8:
MP'>CDR6XMOJ-CB%9OVO<_HZIL5:5%IJ:L*7_6TS!QEF%ZQU'F_*.C(B=WVRG
M"I#.&))K/,47(%IFU]/Y'NT^+P4J?!=/J3D[>-(7*2_ C;QDS'MPR@^+[?V"
MJ1<;Z]P28M@S,RJ&5EX734*3O8&& X+-6:*EL3U6D/KQ_$$.FE-Q<0Z7Y671
M\H/%TY;* +]@[SW%0?@&6?MCSU=-P$AFRB,ITG5!V))]ID\TPBZ@P?%(.(.C
M'OQV_<OX2/UW%^N7YE9+48^X3$2R;\1VKEL.VR(M,:I3N63LD^F:@0(\/)D]
M0U)/W2@$C6TYC^GSB"C^V #6&&9_VI.P?^._>TGL8^XV]8Y$.0XV<'"K9NS]
M.:9#(:M[TDWG51']>>P\C-VKE0 -BY5A@62BU$D6P'Z5?T67U873[@'2/BFM
M"EZLSB@U$"M;DH%?XD5)I'7;^#&]UN2R];R_)2N(RLIT0L&5D/0BPK.5"$.2
M&(Q>U47G(%#$P1UIE]>IM26W^44*$[%5%.X],SYO*BK'ZE-\!H).3O@A19AC
M%&\N1A#UL>[ZDZBF?>V,]T)@S3+#DC$;&;>%@3B'AV4^VU>*%TKLU27?NJ2,
M_PQDYZ5.-;6NYBYO.1D1A"7@4R(-SXTS73>#]HQ4LFR#>EF\W 2E'%,^P9YT
M.58_'S^_*9'RDI96A^K$++SW3784"&<=$N.4X#,-^[O#Z7I%>#<KMW]66O#M
M.?U9Y>G0IGPV[QVJ8X\6U=@0B5ID^E0UU,^FOXL(&;BCE'"XG/$Y]'4)#'3Q
M93^\)#.6^'33>F',V"M]XELQR:J FYQP6H<^?/%1\S^-XE?ZZDU:9;/D3+G4
M)[9K#;QR_79##_DPD!,]WE8V9RH%A5 /C8[D()_PM_*Q?.]NPX3>5]_C5'@D
M!U-*E*<3&(J,3,3?[U]K<>L[:@C%-1R>2F#:OY!NFZD'39@]#@"B+Y6PZ6[
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MPKD8QNKP^?\ 9P\46OQ#/AJ:R2QOE$DDLM[(+>WMHHU+22R2-PJ*H))-</\
M96)RR,H8YRN_>O+2R:Z/MYK2_8]O#\39?GW+4RM0]U*#4'>\EHVUOS-_IZOU
M7Q[KNKWW@[Q_/XS\1^$=0\'30/%X)T[1UM_+7]\3:/$JN9HY4CVB4E$&W<K9
M(!/SE&Y?:M;WCCX5ZAX&UFPM6:QU1=8A6XTZ[TR7[3;ZE&S% 8F !8[U*E2
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M=+BADD*7-Q;Q/#M(6S95B1\PA-S\MD<5XU\0/V??%WPSL(;K7M!N["*YNC9
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M.>WR,T>HRW;W)[=#2,GF/5>!65>:FCX>D!.++*;CTKZ'_P""2J!?^"@_P_\
M^XC_ .FVZKY^5LVWTKW_ /X)+DG_ (*%?#_Y3C_B8\^G_$MNJ#GQG\"?H_R/
MF.^<@UGG4&205:DN/,4AJI&,L_%,U+HN#<BI;:UW/2:?9L8^E:$4*Q)0-=R&
M2WVCVJE,P67VK1FG#H16=-"78X[_ *4 RWI\H8[:T$M5D[UFV<31+4\5YL?_
M #S1<HL7NGY2NU^"'Q<M_"TZ^'_$4C?V'</_ */=$9;3)#W_ .N1/4=NH[UR
M4-TDT>UNM5-4LUD:I(G34E9GU5<>!)+"X\MU5E8!T=#N253R&4]P>N:O67A
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M#^02LH?Y6;!7H29M ^$4FC_'SQ-X]F\7>)=2B\0:7#IEOX=N&QIVD*BQ@^4
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MUS*Y\[G]I'Q)=:E87$=UHME'I+SRQ6=EI-I;V1DG01SO) L8CD:1 %8NIRH
MX%:5S\6/'%AXLU>XN+S0]#O/"&F2:=/HMS:VMI:BV>4>;8I8E?+E+2/YC1[2
MQ(+]5R-KQM\;9O$W@7Q7J$][HJ:KX9\;6S^&OLMI;0R6-FWVP2) J*-T \N
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MTTV#S4VF9Y(P[L_)X418 &,YKRWXGW$-_'X<O=,N%:^M5;3RKLKLQ4'/F)C
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M*5)W7>]_Q.'$4\9@,7*GB(.G43]Z+7*U?6SC96T=UIML?CGXTT_P]IFGVO\
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MF498D)@!1R20/>L[Q=\-K'1-&TO6M#U236M!UEYXK:YDLGLY1)"P$BM&Q/\
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M^7IX;$0O&-]'V_NO\OP//]5\'6-P(UO-<BTG6/,\F&Q2%?-MTW8VKR#O (Y
MP 21[=1%X1B\'_#J^TVZ\)36KI*ME8G17 GN]_+RAY!\OS?[Q(;OSC'^*F@>
M(_"ECX=M_P"T9[>ZN9RES:W?E3R6;\8DC&"?49!X. ,<UTR^ /&'A+3[K3=?
MUS3[IC,8[>&\N)9)]BK\K@0,PY;'#@,#ST%=6/S%5W&:;]/3T.?%8]8BIS)2
M36FRLKKU>OW?@=-\/?V6K/QEX5N[&\L;71;29(5.J7DVZ2[3.5"8VAFR3D#
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M1=-KON[L_:+]EW]HCX8?M&>'F3X<3Z?H]]-(;R[\-S6\=C?I*0 SA1\LP
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MKOGUW^QM+O+B:ZDM+&UMY;NZ=<G9%'&SNV!R2$5N!R>E5B.;D]R7+YVOIU_
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MZ)IG[,'C"7;&VFK#YBY"M("R^Q S@UZ7\ /CWH=CX9N-0L[>TF9CYC.BJ9&
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MR;>XDBT_1U;Y--L@4@'^^>LA]V_(5RUI;R&9<#C//M6W'I2%254<=,"KFDZ
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M]FALTC1Z<UL)96A9_-,9<["^,;MO3=@D9ZXKV?\ X)@!HOV[/ JXPK?;\_\
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M07**R)/<22QJ5!XX8'MBNC^*?CW4/#\,.F-"\"Y>5I ,K=.^%9L]"%"JBX/
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MW Y4$_>&173E_$$*<HT:SUV36WS?Z[=SS\W\+<TK49YC@H7^UR?::M=N*_\
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MC!V$L%VB-&BW" C<B;B-O&"%/H*7X5^*]=/BY[[0[;R+?5-1C>[MTNBL5C"
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MC$8;6$6TDTEVS#.PDKD<=> #GD]2#Q=\*O%5E<7'EP1WDFU6:,$*KCD_,4R
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MZI%K@.C;P7#<*#N;:C*TMO!?H51[*MP,DF"-E^FSY^N(0;TP#IZ9D9&XM)N
M)W57,V^S72!\!U#/MX=^6(64[GLSNI>BA9N23F9&+@\1E3U?'0NFW5&K/A\*
MBD"'<Y<_D#2S;\V73&::4 +=F<D#L:+Y-1JM82IH, Q*,%"G:*N#@\.DWB3:
MSG51PCJ:S10=QJASUVF)Z"S>F,7[\%;PL.FK"<>O.6(<;0-PG6;F'J+V6.<C
MN6O 7*.E;)CUL#0+AJIT<6C,V>96/M%BQ.'O.,Q:JMHTDV:'$-J6G]681^D^
M@-P%/JV?"I>=WW;^W$8^<C-:^,XEV@![:'4-^'#V6& FM*7Q97/ZJ-W<,?%Q
MOH^:SO.CI0^IX$4U=%E*;P#OF_>]06CCM2_OJ?<O8G1* ZP+>IO]P0M-N /+
M*7ZO;B2_KB+@]IY(@W3W"A8^,;2CY-\!<[WRKU=RFPF>]IE$1)C.J$HM1]"%
M:DS(40WSC+!W3KW[ZKEY[.S6\B",R<F1]P6Z %J]VI$QGZ95X=:J>G;,W68]
M_S#UU-;B"W3MK"1=!YG=O<IM,L'IW; 163RX)221^/J2UMV.M1>CT;OKY.99
M_OC^W"WOF[YCQ]NC//#=R95Y+6L)R5YT?$#'?$[8N5UHQNRTJK^&ZQ 5<.-R
M)T YL =YFVC3'#,Q?B@K\BG@B<<6B(GWG%<M+"D@G_TJSY\NMH!.CJ!W2J,\
M$]"J][ ED>6XB.K=\V0=4Q3,83M@!DGEM]$X2<S$W5K"'2M>=/Y&'@_++!&&
MT8FTRNOXK+61CI4!AF&(X[&](,.Z:S!C7OED.7JBO6+3*OEQF+:<@(E$,1H7
MO+U5Q''F!=<CU%O_-<.Y=OTY32(' _$&5NPY/NE.VI-S^#8><$HG7@*GHOM
M]#2)L3?;Q#E?WV/(9VC'T1-/VJZZ+$\6$] 3+'C5F#2_\6;Q5=WHPNBDD/KT
M#A#0+G<6 @W5JS8<!Q'.K'XV>!)LDK__(=VX2+>KJ_SJ=)@Q('C:E$)B_])B
MFMY&F+P&R"1-R_*RTU& 6H'11*F*$81664OFH] ?([1,#*@;_XVR[QC8M>#U
M<-:06Y4)>@UVFA\?<^Z\+-;*O:D["G2_I.M'\C8F:- :.$(GVR<%\:I%3&2Y
M/M(:#^RI%)(/!:;9B\$?T=[++4"9[?R,+>TR<9A.\EGHX+E'V?1AF(?S$5<I
MNWM!%I%WMW+C<BN&Z+\L,@6Y!S)U^UM_&_'I=C:[32>WQD?"I5\-LC]?N!-[
M%9-04O\+;?$2MO;PL<_!PAWC4;+$,/!?B2@>:8^G3[[ZMRG6R+85;Z"X>F5L
M>:*S)B'G;1R[1)W*O\H\D0I9_T1_T3I%F(_KO\'M/T&QN0275M\7!/H4T!L%
M&X&BTYF#P\UG#HI[)\' !E*'@OHSG'SI*F2/,R1$@Q+__BCLB=D3Q[J,_Q*X
MB%V&-Q0O)U75/4\K)F:N ?HV8D\H>G^,LENQ<@&J(R,/1WSMHT-PG*^P2Q]+
M4P]*"*IIKIZ&%D21!74&Z/NAU0]29:4@EK+[B7G']Z^ZSU5&^7A:8)*AFDD_
MQS(H61*=9P8OSP)(K:RJJA,=<PA_QZYV<%7?"B_M7WGI @F/EB_]$?$6CFEA
M^)OM-FLI_9RCE+OWX'GM/B!C;8"7Q4W3<P39B/=DXNO37>#KT/_P'LN''+LU
M]3;S[AJSA R![*=<NC*Y#D%$/>9?N^HW\![>Y?+I8<LPP57!Y;HFT>%K !E_
M+B'*UI)KX#6.$BXW+' %:NI['JVG?;X18D.Z>7B>?P/[U&**)(V/UVAZ<'26
M*&O0V"V3F^OE/4K>4;N*[&,+?5S,3NQ9GYU+@)+)RQ?54."O#()UNHVB[1FP
M%I&'K#W!MBR2%:XM08;;8L5= S13D9<6HTC.:X!S[<<E3KD<RQ/_^@;L',WJ
M&2GB(>O RCO"*.H;3 H:_V5GE-EJVS_@9+M\I3"K\<S;*]#W;]LY8GG_SS+Q
M <Y>?S=D6[#=O(<Y6>T"<".]WTL:.AJZVI8R.]J='9'H/[<08AX2W3#YJSE-
M\"*P3O$5Q1)RS214_!KPWF\[@NXTI0D:U6^\2_E'>NY/]WB-MJ2TH2ZOT?.S
M0U8\KT'L2F-F)V-]_(B*O!6_FE/+?9YOQ_-K?,Q_792FI*#6EEP/$0_1PZ7C
M-M-$TD7Q$YA2?]EC:Y&(_.PS4?P:2FK[:&FI1/E$W3^YP"U\7%[6]>-=9U.7
MKZCL%A&9UZ\S>."_@.'C]V9[@OP=:;-<?6M4*8S;DZ6=IIY)L16*^B(V-!L=
MN?S9-]MY4;RLKDUIJR@3]5>)M2VZ)-[GQ\,0V_9F[-^,DL[<086G-^79==Y&
M#NQC6J A=%DFN54NQKY@RVI08 <!::>2[:*4NV/V^8%?BR-Y>G!%Q5]B+3-_
MDX'(VQ1??"E.Q22VJ[I&O^*I0'L\CZQN2B;3X!N,T\BMMDB(!/OLL2O<FW03
MG\525VB+K[9M.3JI9A^&Y^5*AQ^;Y+UBU=CK;_O,<BH$2 5*#6 /4?;\TQP[
M:+UV.-Q\'B).-XN>K$YMPY)W#/4N 4X/;Y,&>>AQ-'NN>X*DH_Y-Z!^V&L%/
M%[@]U/T/XIQ>O%[T/93'#55^KB,_A@6$0L36>.:0V_F'E*^KC=@-8=;2Y33I
M@0T9.:T>8A,>8@%2<".681QCW[YWD!RLW4?I3Y7\TYOIXSK WO7\T_!='3B.
MO/ L3)PS3ZMXOA2VXKKBW?*+*YJ=*]46$:4J(-]28].]M+/A?R,.4\Y/2^<[
M^OQ2-E2IX2J[L</$[7!_,V8E*6ECW5M%BWK'[%-6=_/+G^OBOKG+D?H/?H'6
M<"(8H[3/@9EQXLB9A8,P'5YH(CZ0NOA#"KQ7+^3S:LU&E9W\T?@2V-T'217A
M9L1!&@Y^-M/)C40@)[8"/VVW?J 1J$<"!MC,=9)& "JZMV@U%2O\KP'XQPI]
M=*P&-!W)I;P?:D[FZL)8ST3)Y=/^:_,9?N#S\^AY_EW5K9NM!H&]UD+]BA#_
M.=;F?"4!_N^EUJZ.76_^ V;=WV?[94MK"!XB@E>&;&B><QL9-H!*HC8*[E>@
M(K"UKDK%>Y6ONI:=!9=/0)BSF;F]2[EF? 1%U.]'DR/'HOQFH)+U4F;!'.N%
MYNH!_]:#VJE+LA56(I/%ZH=P@0D/HH'C"J'B4'PM8E][/$TEJ3"&]"IZ@"MF
M[A/XVU69.A-0X;VX[)Q^93&5MVA6/?6OHPK^]325+944ZXOS_@@&UF[YIF&N
MF70=Y<<?4DDE]%-ARBX=OFN'^[S?=X WB )K8*6UM,VSP3#.E^8/,O5SG+2M
MV*$;*_>/IZI]@?$NS+@+F*)93EO90<V<^>SA- A? (SZ]=@4]J33++;<*-]
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MQ?C0WV4E):YJN;:)T2&[=C@2*"&M6#'3%M^FOHJ7\^6-5>7SK79/U>(2OO6
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MJ/\#RQ)9BX^R;IT\K4Z A:RXARKE#+9RFCQ@N/\@^,;1%E]^L 5-=:C+I(=
M-EC1L0$4&3L217D F_*=LOA,M,!/5D!ISV;A9#1G616NOYH=IL[-N;^\,D49
M6NOH1/0@5H?R;;2$).)L:L/D"&G H/WLP#[(^TX>O-@JA/RO.LW4":<&$SYX
M2:_E+LCEH.$_L]3UW"BU[H:*T2]XK967 5LD!>@U8&6K'YGR"3\S:M ,GQ87
MV^\[6B@)U:=^?(^^/M_4G:YC=*(3.!,N+(K!9][-5.LJH1KLO=#P<ZWE6O:3
M2Q!*$I?8<TH&3;N:28O670-8+[:!>HF#4L;=WTW2O$!J' &GDR,8-N.>\4(!
M$Q&@_=DU@.] (BFB"1FE:ES3!*]VZQ1OP#E/=U1I,2QJMRJKWM8(;@L/,FM*
M66CNSCVV"!?^_^K9B<;'IJR"/ZV><(] &'!VR5U2'^)(4_6=0;14]>_:\:;H
MP%$6'R3T1(,!U"F<OBKQP67<L]35.;H$_CEQ@"G^KCDPO#>0O!,\'@'2H'<+
M?Y#&"0Z)*\MKS]0VOTCVQEN0FQHFXEC[0EG/8>APS.[41*FR2&HC9M8?#BLO
MBT?M6/0;S:&[2/QC)$$0;KM3%)[0G]5TV9%3A^!U:M<*P^G*I/ ?F+;H^49-
MQE] >H#LUP X7$]40BK"T?M+>=+EE>9>R'MECF.F!MQYDI]S<VS7Y4RW?C_+
MPL?M]T%;Q',8750!5;O!:BT+QEH]/0Q2(5MX2[IWO-,W>34_D.M6-;(J]+'U
M^<)AF/_N^0?05+$<K17_60=! #WPD/<CD$$.^;Y3/'M&977,8PDLTZ0^3N:W
MV$*D:Y;C3MG7@:S:J7;T-; 7*I$_:#E2I$@)5SL"_XU( /ZH224\(3KHI]PS
MJ'3K9,+>_J"L/^3>)8B[11QX;$I\Q!U_R,<OP>VC1K=2$$-D7;XS@^JQYX+'
M3 R$5F1X1#WWOMKF%$7-9[\<K7[]N$K*%FU=7H^\R)N2%"]Q%1#1/K.#S..S
M_L/O0ZJA,#,%&UM7MZ0N^Q L&!WJ^_\D0G>JX!.T<;Z[J7B(9N=DWTPU'ZIE
M0WB.==#^2)+;B,NELZH#"XE5C9"%5$ MM J&'F3K>9BYF)(&=O'9!;TD)01B
M@E.G13<4*?AH%=CZH_\K)G]V%&@/7^GAOBWTJ"RO0X>K@[]0OJ0FY^\>TJ)N
MI9/ZZE,G.YZA7YXTW#XCF%*@3EK)"6PQNV\QP8LU+'A'NC&.!!O=W<U6B'F[
M=QJFNJ@:^$E?:*!S<%6>3>P]91LU_2&F/;8_@KE=!>2\OGWI.GM0^(2?H<Z%
MYF3_'[(1&67ZLV/*"79X!B5^2-V2P%H5EW/$F#B=XOXG+_#8P-&\O=A@.\_G
MO86YN3#6H;%$I[_MS&9L @=#17M#$63MP J=FFN ZQ"U#PHAI+CN+Z3V[E0.
MN!;8;2"TZE++:0>VCOVSM_XVX3'K%LW<;^=EVB\OP^$C&'Q\S\]*@8*Y.SD@
M\&Q#9FJ;ML8L<"L[MD>#)W(J?V;V31[$\0$K9#@293];2W$W!F9>6]?=-] !
M0Y]<Y*]7:2N/6DED;BK$J0.(4DT(EC001];PT5>:^;Z!TQ'O2PN5E=$_Y3U;
MO4G^*X0%0^[YU$#"NB9I8 6IBJZ20WYQL$C6]_^J_UCL$R_['TV>W'7OB5:)
MV$66YI8IRM+?GT++S /9DN[Y"UT&SS3OL/V^#72(-Y2&[V&"U5O=-$"Q%5/.
M3)WF$9&H4!-$ UYB63#:-:EF82UNG>SU,R65EKWGR>"M*XO^_(>XJ]\_\/I&
M,W!.2)L(QGI >B#YVSVIOC!4I5LV,'$U>;@Q3,/\U1/5?4V%XM=;*NJ'%*FY
MJ\U&W- :0I=%T;0X7T,,5T7,G5YO<;6;R^%F QQ39XF>UX";(J9)>B$"(G+G
M2 V^#0U:(/Z\9U.?!=M9Z<C#OGBT.CY68R24.K!U6OL<JQXM$4.4\UZEL5ZZ
M]^>=@Q[%Y8 EUJ8.)<3STZ($= U@^-@*JN71DVRQL!4NL"^K((TO\DVI2X:/
M(%@Z>> $;9BCLF0T@,?=*5EQ?;,C?G9$@IW-85=AL,E._FAWYPVVAGZS8^+?
MI-;*#+;KXTB<8L)A#6UZDGQ*%R6^\V'*TY#;^$M4K]=!<RN(W>:-Y]L#Q:XU
MY$5?D&O4-<#)*-%><CI[S71L?7+/+"#ND,VFCVTWFF)3XQT1;#^Y;%CY+50;
M<NL/OHTD4OUQ?\- G4I(_AJP3:\O:_QU8+!-AY$K^CX+&5]N2*Y4=%&=3SO7
M!EN+M;R'-3H87G^Q X5^7\VGS95B0P;DEA3E[#Y^VQEV=A"B_O$ASKZL*:!-
M?>C&Q:+,^9=K . :H 9&J],1Y6-[K+_-U/(E'3"WP^2GD\UEB*;-)%$?)AZ9
M]#^O>.M=]WK"RO^:(SH?M<A;Z/V*= 1$HD6-0J\!ESLI\9VBO-3X-9-C,LZ/
MSFX>,#/?'V3OO%0<CVO)%/O,^]YL68GX6@] /+*6$1?YO5*RI>S/2]*,E^J/
M.A>16*/_<.>))W.F02R%_K)9MV\*.O5OJ2ZGK%Y:C"X^QAW.RH4UB=8A^,LF
M5/M.N5-6]+]OJS_ :7Q\,V7^^#.%ZZ?A^Q_5-^[G!ZVI 4Z9X;Q=FSC$Q[>J
MNW_%O 8_%+'TZ[*+>DG>.+D"+P[A#?/>=J KYMUWW=H$C@WLEI 7/+1\"4<8
M$PAFX41/ 0_38%CJ2F%UYY"(*VQ!@)QLFHX6%RB&! ^D4JSW2 ]#&<9=)T]I
M]/MF#E?[)F$'$GN-C3VV+_CB<OOO[O32?*,CP<VPZN7+!;1_6YNJ_2MV.5YD
M4_[R%)73D#":4BV)D/@=\[#'1R6T[?CH]0&*_0B2S-M$#HO 3L/I[L[:_ TV
MV"" 9$J>_IZN>>U6X)<ZR/]F</#GO?:8+M&"@([YXI[?(Z7V5H.221,9!^@0
M^X']:;\YTU690S;I;+:0B0_EZA9#V/)9%95JH?%#M'[^TDH8H_9X^X-O.QPZ
ML3 _3K4G_2)_3A (K>Q9)\X,&_<C[ZC4J7ON9RFK(5"XQP]0O76?5&^,8FB]
MT=2RZV*G]57.-<"--XZ'2G=?G*A%V_$M2&JNJWSAN=6W]_Q_*Q^]>=[?%FY0
M[N=9?+!^);*2POPW7'P";J!7LW_"B]?9(JC#P1$2GYKH\MK0O[LP-ANS0^0/
M@O@IOQ-Z_O7?2K#(DS^+"HSW')"=]!"<Z)@+,_1DQ[UGARN^MBLT$[$'61N(
M68,JRB9\X&EVU!(8BI49V.K9*T2R2HA;Q'3[L;CK"_\'OC%<N$GFGU;AH_<B
MG&S5RU?%.(U2#*,]:^\>4VF24<=0_G<L\TDRYX<E>3]X_GO-/DDIE&T2#F/W
M]^!1DBA#Q,%#GH*\$N@Q3D<Y>25GJE?+7IJUC%>M,)@'D68922L[@\#85T?X
MJ_9O^H(Y%YZE?G^4]JY?VMI$FYQ*^N 6K7*](?>0E.7INVH*CNP%7Y4:LT#X
MY+A&7D%J5V^N59Z#-"I[HGK8P'K"V-S=<,@ONP&\X;_90F.S.AH;S@B-,L N
M1J\L@'NM/8:KAP,%9KZ)<D /*&^G/?KYJ$SC<3+_$)V,(IE@9RQVJ5>-CG3O
M FZC]AK4:A_%H'954WB/$;3S<T_ XFO@_GVFVU]CI')=C[<,Q]J]UU3R* RG
M^)K3COH#4SQ.=@6ZZ9%#3<=?&>0?!#SV:!&96J8.>TJ@(S[$I<3 .R1>X?I.
MEN9,=8) (*:#6N\S8W;R9QDV8-%P%_JB?J:MI/[.XX_-K(\JH_1,&[?+!R]R
M/"2"^H[M1!9V/7@Z1,,=N\,%77&_\W9]M1O3TNK-/<=-#%5ALX^V(X)$W##@
MOVK@;B]\O5;,3HA+YMM'20[/0'?9-8^Y:.9]_O0';0,%B,XS)%8HL%]&,+T8
MLP,[ZY^$)SU]V1*BIYIV9X':&ULU<M?*AY!(5I5]*=&E0(T.4$Y$^[Z87230
MWG!66O_DW9S(X)NX!8=JUQ)$A\M#S<;;81(&.)<<_UI8WL;@E_&B24L5\L\R
M-/4Z+*<7GR%W\Y84>%6Z;86R3'PKLTUC%G<ZDV0OTH,%)^"=D+*";_B,')P@
M>09'D+-[DAYAV&ZV+/<MO-[SZDR_IB;]##3IOT0YB_]'M\%7ZZW/#<6RE0J3
M7W*V'FC/[]PP9]@W<[A/MDE-'M&')-_FX:C+TL,%)L#XIOV=XE98O#P2#"QT
MW,J:I9D'N1YU>]Z7#U[F?8,SNTKI":/0C^UAQ;Q=PB;-/Y_YM-WC4?)#DNK,
MW/RVDY8N6E0?XJ)ZLS YY1_L;&O (U)DD9Q4-G;*9OE20:5A>1"/@Q5=>QFF
MM\M!1@4BPK-=_\VO1RUO2*_,"[I:T)E5K$Q?*-GF=":C;3$0U[(F]>PRA12!
MU/$^9X]!9-O^J^);1;5@C%Z0_?"L0HA;J!FV>"4B3IV:-,TAGN,U<]E?&#K>
M$^A1]HL2:&W8UK^\XM46\(OMW:MHN3/$?AM.I[?@MCH-5,?DB]AF2Z4(1M-;
M.,9R.2&2/U$QKU78-]%G]C[EJ1C5F4/[%-'\$AVK*N3*TX@;H)EI"'L(1V56
M;U0XO+.,-E-]1.'IG09>*YB3656'EQ"=D-@<4>4HZ/-Q#SEV)Y_7F6N!.<))
M/;<8!I7(4N>8+UB\'U^YE&S;]9L$0 PD_!:SVX+<(BR]DJ!KSM$Q$ADCGU]5
M:<HN7+R=: #I9,^TM:=93)K^/-UW[.41B#< 6K>GUL#O&LYD/VUIRS=: $3<
M^=DO*;SUX01Z^+:(8%:+85^B] H./OMY>5KK@_>GB%%_&*HQZ=@.'_LN)J9)
M0C=GD[>U-AWS_M8V^X5A';HC8&CA2W:XW&K12XX56^A;*PG^@/Y/#^0YV,WI
MA1KO?-.SFW@Y[:U#^>:(>)OZE;NVR?>6%M-I.R'D*+HC!?B^W;:\MWD>)=ZS
MXFY\F3NOE-WH?*@GP.E1 JE)V9O?Z[R_&XSJO@;4;6,,6E%R4T]>'<6!7-?R
MPSID+#HY\:,HCJR/)_YHOBG'\:3!KWQZ]%]T1K ]AY$_">_21R2]C8E:.*X(
M^H-&]F2Q4XI&VIV[NL5JE-'<M)+>2]G[H<QET BI86\!% :]>9&!O+'=]DYD
M9.5MK40,3[Z,9*S<LT-^8O[<TN6?S>'C 72W1=>T>Y)V*;.($#\&I <\!$ZJ
M$DB4O"L:=/-NUN*51>(Y;]%4HFAO2Z$"6@Y%580X*CCK >D:,$*96WL?/5)P
MJY-)(?FT+<0F0L@([B+F7_&B +<-V"CY'P!#0+R_;UP.%7^)BH[U]U_$3P;8
M>*/ MY&MG9PM>*CE&1A)/(H/.!ZY &>3BL'P%^R1>Z9IVDPW4,T,-\RWMX6&
M-Q*@H.@^5$/?NS&MLXXDPU7$5J^'I*$;I12VTBEZ:6>UKG#X>X2.!RNE@\=B
M95)0<_?G\4KR<KZW?79N5MKM(X.?4X_$:PV.C6L^DZ)IEJ+/3X7YD6&/.))3
M_%([99B, ESCC%=/X4T^\L/#T(R=SDD[F^8FNA_:/\*6/@73UM_#[+M,2K-<
M@?ZS&#M'I_.O%+_Q[XBT2"%F6:.UW'_2<?NKC:<$(_W6QTPI/0^E?*T98S'0
M]IAT[;O?3?5]C].JX^C7H4XTI1A%Z14G9O9==6[M=WJKZL^BOAI:W6M:A'"9
MUFD7!\E>&09XR3]T>]>F:MJL%EI&H:7JMCI-U:ZM;+::DJQX:^B6-HECE<$%
M@J.RC&."?K7@O[-_Q'_X2'3M:FFE\F:W8GE]K;,<G/T%:^C_ !)M;KXBQV]O
M(VN-;N)GM$C>8.B$%M^W^$]"<CKUZ5]ED65XFM*,97GHM.S:V7WV[MGYWF,:
M=.5>OBI*G&-^;9;:ZOY)ZZ*U^A],:@MEX_\ V<M<\-Z3:_Z'J.A3Z7;65NXC
M7:86B$ (^ZN/ER.@KR']B[X>^&? _P /V\.ZMX*T]9/B&7&H:=J5L\::DMJW
M[FUG21250*&?:^%)YXKTGX(^/%U<0EHY[5HTDC.]8VN58E\.X6-(]Z;@ "F,
M1J&SR3Z'H?C+2+JVFM][ZK+9W"Z/JEU.+>"1SY'^D74@^56R0H=(!DM)@#"F
MOK,JS"&"A.%6E>_7JGM;3?\ K4_&^+N%IYI7A/#5W%+HGHUO=:*ST6K=^G+?
M;\J/^"JOA7P/^SS^VYJS>"+RQTF;5H+749?#>E67D6OAMFB4,F\,5/F;?,$:
M@;0^3U KPY?C!KGC(/);OJ5U!;G)CM 5C0^Y'?VK]0KW]@CX0?M _M+^(OB)
MKO@&PUS1[BS9;C4I?$DRVE[KD4B0?97M8W!010H7=L8)"C'7.A:ZS)XM_8AU
M[3+'P?;> =2EL[Y;+1=)LUM946">3[.@5=K9ECCC##<"1(>>17DUJU.<O,^H
MRJGBJ,/807,HV5V[_ENUU_S//?\ @GMX<\9>#/%OP'^*6F:-9O=WGA[7M#U?
MS(1,\EM'#<36,A4G._*"(LO.V-!R&-?"OP!U>?X]?M(>'/#5]IWFZCXGUM#=
MV9M_)^9Y-\H*8^1!\V1C"K]*_2W_ ()Q?M&ZA>_&CX6^ ];L[JX\2+X4O;_6
M+N[_ -%N+!Q SPP^23N;]TR*SE1G:G4[L=W\2_B;'H.DK=:3IMO-K%U+%"L\
M$2+/EF"MN8 -@J2,[@<D=0"*]*EA*6.K4,)AWK)VULE?3\+?/R/G,;F&)RJE
MCLPS**Y:<5*\$W+D3FU\[WMT2M=HX?X@_ =/#/QQD^-OBNT\*VOAOQ1H<W@7
MQ_HUG#.(=,9T-DSV<JQJ[N L,'[M0S;LH2"2.QL/%/A?Q1\#O#\^@WMJ=/L8
M5@LI]+N)WLXEMV>)(D^T9EB=5"(Y)\Q60]N*XKX]^*)_B/\ "8WVO6+?9=2L
MR=7UA]3D8^%],P;@2V\4<A62>"5(L*%W-M<$'<<0^%OA_H/P%_9%\/:+I%_8
MZMHEMI:7MOJ2^9%=:G=SRM++*T!RJ1%'##YBV< ]\3B*V*R?%2C=<\7:ZU3?
M7]?ZT*R_+\JXFRJE4G&7LJJ349>ZTOL[/5K1KNME97/*_P!H+P!J=_:OJ<EG
MMM(RB2/;RM.L?R<$L<M@XQN;&2>>M>&?!2UAU_6-<NVB:Y6&(H3(@(0$X&#V
M^HKT/XC?''4Y;N4Z?;KI\Q9</;ROYD@')8R;R,$\[.BX&*CM=(NM?^$%_P"*
M]'T'^T-8TLO/J,2,8SJUL/F?*K@[UY.5ZCG&17)4S;!T<=[6<E+VO79<TM_3
M\=>K1^@\.93CL)EL:5=.$:;Y8Q>KY4O==TW?LGIT7*K,\E\5^&4\(W<>M6+?
M9X5EPX&3N/\ =!_+FK?@#QQJ_CJ*\L+'2[74/MBE+J-T63S$7G)4D;< ]>F>
MG-<G\7/BUH^N6-O_ &#I^M6%O=GSI$U.82*O1ML;* 3SQE@.E=)\&=(N]6\*
MWS:1KFAZ3)J#K#/'<74:3LJL)%:)63Y-KJ#DN-W(Q@T9AEV6X_,8JI+DBU9R
M\^FU_)>6]]#HSC-L5A\IJXC#T%6J1LU';3J[MK97>E[VLEJ>G_!W]HKQ!^S7
MXAE\.R3:A;>'+Z/R[W2Y(]JR1MSL((((;H&]*]G_ &\_BSX@_:>\(Z'J5C<?
M9/#EC"/[.M+2,PP6JA=H0ID\KC;R3T-?,R:1-XO\2Z=;1V*S1Z,OE2,X._4)
M6):69SN(Y; &#C '%?8'[,_AS[5X9N/#>N:?)>:?)&98%B.UXG"]C@\'C/'\
M->-6R^%'$.&$GS0=M>_7]?GO8G),RE*E3QF.H*%>*DGW3>C:;ZV2]$VKL_/O
MX:?!74?$'QHL4D/F73>8VZ0@@G@'GIWKU3XB?LMW%O9W-Q=6D;Y4#8B\@?WC
MZ5]*>(_V8Y[GQ#;W5E):Z5-9RXA<*<-D\AA_M#OU'%;?BOPCH]]X>G1[VZTW
M5+$!'@GGPV[^\0>JG Y[U]%@\Z5+EHQW6Z^>_P"GD>#5QBH8J]2\K]3\TKKX
M77W@7QG',)I[6./B!UYPQ(XVGKGIC_&O:OA/\=O"L'QH\.W'Q*\-7EYX#^T^
M7KUMIKD3ZA&(F1&"[@0=^QF0-G 8*1FMCXEW%AXOU(Z?>V\=U:6\RO)Y3B(,
M00<9XQG!SSR/3.:X7XW:KHGC*UMS8QE7,I2WECM_(%O$J(JQ,,DGD/UR> =Q
MS75F5"<:$Z].HHQDTW!K>W;];?.R)<J&)S;#T9X><G:252+MR)JVKOZN-]FK
MQO+;TKX_?"2U\(:M)\0OA3<-J7P7UF\VVEU;R/+-X=9@";"_C?\ >02C) +Y
M5P!M9J]B^ 7Q=LH/!=KNOFW;-IVOCBO)/V8_%MU^RY\"O&GC*26;]S9RK<Z;
M);K<6>MQ>66%K<PO\DD3N44AN0&RI!P:ZGX">"O"/Q]\ -XC^$5N;/5$B^UZ
MMX%DN'N)K$J,ROIKM\]Q;CD^2W[^(<?O%&ZO P>#A7A.K15G>SMUZZ>6O_#F
MGB-CIX)X; U9<RBFU)WNT[)*?1M6^)/7=J/7T[QEXZO/$CFWM&DF68']Z[$E
M  22?P_7 KRSQWX?BT)9+FYNWZ;=[<X/8@#OGC'\^M<]=_M'KH.O>7 C3,,Q
M7$2'# 9&0/0@@'ZCFM[PVNL?&"%?L^G:A=6\?SN3!A5Y&% '!)]OZU]ODV$R
MJEE52KB;.KKH]_+E7GW7GV/SU8Z,J?F:WP5\:WVH1S6-TS20R@1+&_S!E/!Z
M]0:^;OC%JM[X+^,^LV=C;S"+3[][>"58RN]5;'0CD5]=^#_A5=KJ:SW$ L5L
M6$K*Z[6PIR>.W%.T.VL/&_B[4&U&$74/G-([O$I8,3TSZU\S@\4J4G4O9K:Q
M,\&ZU%23Y=3PGP'\/]:^.FF(]O:W-Q%:@">:09CB]!N/ ^E>Z_ _]G>QT66.
M[U61EL;%U$C ;EE/9$[LQ/I7JFDV6@Z3X<_L[3;-H85.\CA5)/<@8!-<3\6_
M$>N:)I$E]I\+7]GI%L\JP0)^^$@7A@G\7KQ53Q<<16<ZLV[[WO=_>:4<OJTH
M\RUE\M//<Z?PEX=\.V?Q#\3:CI\,5QJMU,$W38F%IA1D(#TP,#BKT]Y+>7K1
M-(TDBG[Q8[<U\4_!O]I6]L-$N+J2YFCNKR_FD:7^-22!7L7@7X[0>(;H0WVI
M?9@XPKN>6D[9/TS^.*A9;/&8E4XV3EHM;)'5'$1C:FI:=WNWU?S/7->UJWTM
MV\QS),@X(7(3\\UYG\9[+6O$VJZ3XL74FO+/1XY8[ZVQA@'P%F '7'(([9!]
M:D\4>+KB R?9YDO[>3#%AC<??T/7I7':=\:8-'UQ8=PF@NCY5Q$1]Y2"#D?F
M*UQ63XO >Y56CV:=T_Z\S.IC%[10J;='U7I^OD7M7_:;NO#UB((-0D&T8PK>
MW%5+3QW-K5CNFOI+RXN%)"1."N2I.,]#VZ_I7FGQC\#CP#YNIR))=:7<,9;:
M>,%@!_=;'0]J\U\'^++K5;[[59Z??M#N(^2-PLA_#@UZF3U,-A6ZE:ESW6CW
MM\GW/-GB50J.FU?S/5O%_P 5(]&_T.8/]JR#E?N_A5^^N[WXL_#J]TF2,371
MA-U:^HD09'XD<>^:\YU[PQK'BF2.9='OHP@Q_J&X'TZU]#?LY_#E]#\#ZOJU
M]/\ 8_(LFBAN&0$VY93E@#QD+DC/?%>9B*<)UG*C'ENVTNVM_P  P<G.4I3V
MMJ?%-S\9"/\ B5S6TUS,K @HI5HF'Z_B*O7'Q&F2W6*-KAI,;?+>,[@#UZ"O
MOKP7^SIH,WAK3[CP[I&E><MHAEOIXEDN+AB,DER..N..*P/%'P2OM$=M02SC
MA9SAVA1?F^N/_P!5)YM%)THW47TOO\C3$94X*SG=];;+R^1\T?L^ZQ(_B[38
MY0RYG4.>XR?2OK#X0_";2/"FGPW$>EZ9=ZK<W<^VYNH5^T$+(0,$CY?PQ7)Z
M7:Z78:M93WVG0&XLYDE$NP*[;3G!/H:YW5OBQK'A[Q5.VM,R,US+-"5?Y7A+
MEE92/7\Q7+5J2J*U+0Z\#:C1DG9OIY;'TE%87WB.+=*D=DD+%2RY!X]J<GB"
M'PG,NV],T\(+)*>'0X[>E>)Z)^TU;ZSJ-K'?77E6=PWE-AMH5B#@G'I[X[9-
M7O%7B[9:^=:R--:M\P9R&95..^>1SSZ&O1P_#F(Q&$>*HM.S?N];+KZ];:>5
MWH:_6VX.UC<^)WQ$UZVTVZN]#E.H1JZR7$./WD:*H&0O\2]2<<C/I65HO[2E
MU=^'86DBM;<,X$C6Z;2F?XN^!Z^F?2O/[?XL-I'C-%L[II%5AO'ITY'TZ5RG
M[3?B)?A7KT.HVNVVL=>B::*-5)_>J?W@7MW!Q_M>U<F$FZ=>,Y14G>^NM[=&
M<];$*=)2@E:.R\OZW/?;_P =7=OI:ZE;:BM]"WS;0?N@\C!&#TSZBO.?B!\4
M)'"WS32%V88R0<#T(]*^?/ G[0K2330K?21QY)"8X&>N!CBJ^M?$>ZUCQ L4
M.^XCS\S*<@9/Z5[F=5,!B7"KAJ7LY_:Z+[EI?Y+S//J8SF:<$_Z['JWQX\3M
M-\*KSQ9"S*VB)']I:%O]9&S!!GZ$C'L372?\$-?CC?>-O^"D?PYT[-X;68:H
MS#),8QI=XP)[#) _&MKX6?#&V\1_LZZA#J6(;;Q'?VUBT3#B>,.&< ]N=HR*
M^Q/^"=W[/GAGX+?M)^&8_#/A#1]!M\W6ZXA!DGE_T28?-(Q+$GZXKS<+C/8R
MC"-TY.W;2]OF5C,+*>%J8B<K+E?S=F_RM<_-G5/CU-JWB>XM9#=+,LA\T$?.
M3W&.M=_X3\4V_F0W$LEYI]Y&?W<J?(4YSR",$=^:^U="_9U\">!GDU6UT>UC
MU"\8F6]>%7N+CMC?U'T7 K+USX9Z#>-))9Q)&) =Z31!@WYUXM/-(4:EZ%TU
MLUH>U/!^TDY.KKVM?\;G&_"C1]2\?Z?"T.H3Z@D"!8XD&YVQW('Y9]..E=/)
M\0GL[I=!CEW-N"W$@Z,W]T?[*CCZYKLO@S=6_P /#,NEQ6T:7@,=PL:!"">X
MQTKXK^-WQLNOA+\3]:TA6D\SSV*7+ Y5&)^Z#W]S6U:K6QTO;U).3VUW7;Y$
MU(/#7=?LFGW[^C6GWGO_ ,4?CW'X5U1K2PDVK:QA';^$R$X _,BLY?$,&NF>
M74)/M8$*O(23M3(Y(&<;<_0\]J\$TCXD0>)_#2MNDCG#+,)64-A@<\^M=M\(
M]0F\;:G]A6-9+5G#",(1YAXP,]>#BOJN'\;EV58>I6JQ4JW32[VT2?2[WUV[
MF-'%<TW.4=>FAWO@SP _BRSMV:U"FX<A!NQ'&O4N_H .?PKVOPIK/ASP#IOV
M'08I)YL9FO"!NE(X.T?PKZ8YKA/CU!XI^!G@+0+'PSHVE:[JFO721ZC#)F3[
M+9$,"44,"Q$@CW8W84YP!EAPWB/]IKPS\*?!^K:LM[::-XDTVXATJ;1M9LKJ
M&33;J4E4<H8W+PO@-$X$B-O&3\I%>?@>%LQS*C3Q&'Y7[235D]8]>:2M[L>M
MUY=U?Y[,^.,MRNO5HXWF3IP4KM>[._V8._O2OI;39OH[>[2^#]8\3"&YO+A8
M8[DEXX[A9&D=>Q")ECG/!; )/!KYU^)/[2_@'X:_M4^#_$"Z?-J?E:+J6FZA
M?%8;2ZM[N&XMHK1_+D8L&MXY=0PS#F.1@H)V$>7^#/C3:_M$KXAU+XES>';S
MPK=?:[JVUN[,]EI-B<A1-;@70^T7F'"JK1IRHR[;1&?&?#EE-X@L(]%UZ$1Z
M"R/%#*M[,N^=PS0B</!L6&1XSM".R+N*B0D8/[)PWX<Y;@YOV\I2J./+=-Q3
M4E:2TV36FK;ZK8_GKB[Q<S7'J+HQA&G&7-9Q4FG%WB_>ZIZV22MH]S]'?@_^
MU!X/^-.C2QW&K:MX?GB9(E@OX3(JR,I8"*>(;9@%&3M!P/6L+XQ?#77-2\1Q
MR^'(;>_AFRWVZWD5K>Y7&X'S5.-W/0\\]*^5?A9X;T?X?ZAHL&FZWJ?AJ>X:
M>:YTY8EMH3?PAI%MFC=Y $9 5 "'YFM<*I8$?3'@#XV:A\'O$VCVOB*UOFT7
MQ%:6UVS22QO#);-(\<DIE!R\@<I&(OO)Y6[D$@&:>'N'I0D\G;C*WNP;NGI=
M)-VET[OT%DGBE7KU81SY*<-I32M):I-V3<=VM++U,VQ\$^.E$B3Z;$/+'43J
MRO\ 0@UZ#X$^&^K:<RS:E/:I @S((I Q'XUG?M _&2S^'USJ&G>'[1_&GB\6
M(U#2O#MD9))[B%N5NKI5YMK8+N.Z4J79=B!F.*YWP;\2]:O?!7AS4M8M[?2/
M$5_$TE[91P&W"KN!1C$WS1D@D;7 8[=Q5<XK\]P]3'PP+QF)@HI/EY6[2?FH
MO=75K^O9GZK7P^45<='!8*4I-QYN9+FBMM').R;3NEVMU:3XW_@H_P"+-)\<
M:KX9\#^(1>G0],TQ]=DGM(VGO%>5S&!MW "!%C21QD9VDYX%?(_A#X^WDWAO
M6M'7Q1-XMT#3[B"/3);;2!IEW(7"+(B%H\O&S<M" $9<G.>#]:?\%"_#FN:-
M9>#_ (H^';B&UNH_*T>Y28!9%96>5)T!4[T\MGB; (5FC)X:OG_QSI&EZ/HD
MNJ1Z?<6]MJ6G1W9TW3KPBU5F#NJ>8R%(G3RV:4C[H=D W'!_;^%YT*^4T:M'
M:VN_Q:W_ !=^I_-_'%.OAL\Q&'Q"UYM-OA=N7\%;IUN>:^'?B%KOA3PA'?>'
M_P"RM'US4-69-)MUBAN)(VCGBW(C2H4!)9Y. %\M>H_B^ROV/_#^M7?BCP1X
M_P!2T/4U<7337(UA75;A?+:.VF5W8EYBBR;7P=I(<EMRN>;_ &._AQHO[0/A
MK4HYM,\+ZYHT=KFY^UVD2M;P,7C2%?.RD+.96 "N)CL4LC!AGV[PWXOTVU^)
MGA;POIVFKX?T.WN[K1XDU:-H_M1BN74&*62<E)'57'E;?-<*&*X95/3C*D;3
MHNS7+[U[?#RN_56NOPL<.6QFJE.LKJ7,G&U[\W,N6VCOKO?K<]@^)%W'-XEN
M]/NKZ1I(RV^>:3+'!..2?QKR7XS_  ST7XR_#J\\+ZA=+ OF)<Z=<B'=)97B
M(P$TQ8-NC.XKLC"_*Q)W,JT>.?B';ZAXJUK4+Y9[=;BY:81-&1*J9X^3KC&/
M05D^,-;U'7]/^U:3Y=O'$NYL%7N608R/[JG&<#D\5^%<'Y35A"6.P\K3B_=N
MDWT=]>KVOZ]S^NN),+4SBF\!"#FK>\D[1VLTWHO-*^Z32T/'?B!^S)\1O^%N
M>";KP[H4QNVGW7KQ7 N]-N$65'E1#P%5XBV .08W( "@#Z-_:-TF+X=^);[4
MK5;RSU[4(#&ZI&;NSTB(P+"1,BX#A]N=L)1D#$JXY#>?^!KC?+]JM'6[OO-6
MYB:Y7S9(90K(KJ<_?"R..<@!C7T9XXM?$6J^#/"M_%#I\4GV>6VU$7$9+3JH
M7R_F^Z,<@[@<Y&.E=^;>(V)QD8T</%4Y6?,VMU=75FVK-;W\U>S/D>'?!^AE
M\WB,1)U/>7*D[6=G9W44[I[6ZV=KH^1KSQ=<>(=7N8+74)K?258"W2280*1V
MXSZY/S$XXR<U1\/:=J[:TMEI]PUW'J0\AULI/,=O52!S[?C7O5Y\._#:W*W,
MWA>TNIV^^]K9JRANX^\!U]JO7/Q2L?AWH4S:7H\EK<0QMA4LXXY(NV<\Y'TS
M]*^#Q>+Q&+:]K7YO+FT7HMON/U*GEOLES1H27=N/YMZ_>>/^)?AC?_#5[&SO
M$V7FI3*L-C'.&D0=W8<A<#))/3TKC]<_:>NOA_>:G:^%[RX\.:3JDHDN8]*E
M6&;465=@>:3)>7(&,G"X/RJ!7*ZS\6?MECXPU*YEFD\7>(+?RI)GNC,FGV.5
M_=Q,<8:3YMQ&.'QUZ>0Z)IMUXX\5BQCNE3<GF-(%X8D<(O;'^%?-4/:8C&.G
M%O31+;U;?8_;N',/A,!A/K&(@IRZ75[>:3OKV?37N>T^#_VB+JUU>/5IOMUQ
M]@D!!%ZR.K'IED VCT/>OJGPEJ?PA_:AL+>7XB?#W4O!NHZ\ 8];266>/477
M;AY"P#DL%!ZG(/0@YKYU^&OB=OAC\)6T+5M):^@3[1=%=/L(S)J,DD8C59FD
MX555?F4 A@01AEYQ8_B/XL^(0UH>#/A_'<^(M1>RO;^WW2K_ &FT,9B1TDE)
MAC$:;LK'@9Z]A7KYOE-3+E1KTZD:BJ+WETC;97[_ #37H>;EO%D\]Q6*P^.P
M]3#>P?+3J*5N=-J[2NERVNU>,TVE&R=W'[9UW_@D/X1FU2S\5:(M\+!8Q)%%
M9W!GB>(GE DBEE7'.%Z$D8%>3>.O^"7>A-=MJ%K<>(M*O$ES!;7=CNC09.._
M*?[IR/2M[X;_ /!1>]_8?\$Z?I_B32+S5M>U&V\YO#6G7(*60R<RO*XPGS[@
M,+\V#Q@9KE=6_P"#DG7X-:F$/PJT==/5L!;G6G>4CW*QA<_05R_5Z59J<I./
M=6O]SN> \TXBP.)E2H6JP6TKQBVNB:=[M==_)[CO!/[ 7BFX\37$C:;:LMIM
M G,JK#< ]-F?XO7.,=Z]0^'G[%[>([5;W[*H^QW<]N1;:<\4KO YC>,M*J'!
M92%=0RL/F!(YKSV]_P"#D=)-$;R_A':Q7\B<&35R\1/T$(./QKY3_:4_X+"?
M&C]HF>:U/BBZ\*:#*"O]FZ 38(RGL\JDS/QQ@OCVKGJ91@U+VKES>5O^#_F)
M9GGN.J?OJ$8/^9M/3KHD[M]-4E^7Z9VGP\A^$]LVH>(/^$:\)V:+N2W,L23$
M] &EE(RQXZ#.?:O.OB5J,/Q6\1:;<?#_ ,5^"O$4/A-+I/&D,-X;O4H(CM6T
M,07",N]I%>095=JCN*_'U_&=W?7;23W,\[R'YI)9"[M]6)S7J7[,_P >]4^
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MI6J9O9^;1AVBT,B?)\ "$[@;6YV&E_@$=O6T66X@9:DL)YCX;'-^XK5U].<
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MVPIWN^9B6/97=M6CK0QD5P[#IEEEEV_13">;F06GF% 7@">BQJ03KI;HYM,
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M^D'$%F!S@_W-L9"K(/TE!IKU<]&F(0F9"\!U<LQ*2=6.DP5I>NZ__###J0N
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MD^7W/RN5NH#STR7@WL=*V(:0[M#*.60[Y,,T*9]PT)GA\0$M@BL54&Y(C,Y
M[,JVP;H#0 TN1KGA,W\/##& )%V:V94_*@ZMD,OG'&1OS,0\VZC;WMV#Q?ZY
M?OS\IJY8GJ6L;$!>;=2&K:D)?]BM!IIQ=LR-O1 6%_.0VX3L= ?56-C54S<8
MJ<]6QHGYRN.DP>ZO+JH'6;_I&H@QZWV/I3K&4V6';=54TJ+@?R?N%&#3MN8J
MK#Q\IEU)E>.R>]"[3A!7LR;FB@A#K&QQ#A-8(-&CP+7F6&S%:HM)NTZO"!;U
MT G6D@PXL2BZSP.:62H)A+1#/I+\>8"HH1(9SF#I;;'7&>8IGEQ=O;<(Y7[[
M]_\AZI8CCKO!%P[-)1<1:FR(O_)S78WMU%GF@QN_L?DKBYF;-L"ZWM1P#C]O
M8(>I"=&-F;-]AWMUM9..[[BRQ=7,NUB,YR&",<+F*QZ2&?J_7U386U3K7'(]
MN&$O9/S>H7\G=6PBS=IJPF/US&VG^ 0$).5@BT>+>HZ<J7+( *^%C%U=I5!A
M'9]A><<?%&V]WW#CNS6C[X(ON^G5"P8/T?@A/@_\7>D^N+PGS*K3<KE)F5Q<
MM@!5:M=:U1&KKQXRD3UDV)$FRMN07?"EPCI(L9<C\[TJA-DZRRO^-]E6N1SN
MQWP/$2>SV8PNH=%-4 X6FK>DJQB&\I9!+*OJP V(1C LI&2S**I8L-CCY_!V
ME1FJ%U*YMIU90*YI(;IFQ,^M-!YV=']477:H]IX]ZH=29<E #U_\21E2@%>?
M0 V'9GX/];O\+5)L5'!TOOQH(3$0\4?#8RE+G0(!)X7/9OKO/U=7..F:[VK6
MQ:L^.A_.^)#H0T,8B'46R/INT21^2U*JM#T'Y[2Y8#+QY[/87FBK3 )P4GU:
M9^;T8(OLK_J!K$-1)3MCS.7GA1HG/*YARCWYAJNTFY72%-0>\_)$<%]3QB%;
M+P ,D.F^:V7EN#?4\F/[QJFJ8-8G):6<77(A; 2>' _1A?5JN?)V%B,AFO^$
M+FG5=2&Y)OSCD$?<RGK6G;:JG0*V;6SU$G(JI^)!!%?"B;O#%WDE>4\(7\)O
M!?C^ C)]<Y";'$W87WLV^KI&Z7,(_X@33D_%[OZ VMPGKX*AA-3E$(E:(KB-
M#KBC?\W#W8?3=TZE)(8GZ)K*OD(2[7%]PM$6CQ3Y?36^;RPO2F7GRYP.GURP
MLFD6T/*#*=PQ02;[]M5"3:.PQ<0?'/CYRJ*;M984KO]"+@!D6C%MDR()I[D<
M3<16$.6)6KS?7P$/Q70>M_\</&RX_ 8=S'VV@M5Q9ODLWOJKG&^!]"UT5ME"
M9]]DY,DS/C(!$C)SL@7*WQ_?C6<_:/?IFFC*)AM1I-=5[Q!F$Y*#?^RF'(_J
MC24^[;JR83M2:BS3^$W@1!D"KCT(CG=WYBAMP@^&7.^>.(W/_^9"P7S6V#]6
M[&+="Y$E^R\ELB!TD\3MD\JJ]*64%:;G'3@OVS3L\>XQ=X5-FJ?!-PZ!4TB;
M"+MJ-,4!T[R>EA!H VSHV:0U.2Q%3J5W])?,;EKE'[5D6\_J\%;ZK@GF8- +
MD8IB$F-'?X@DS[CLTXU3*DH.%1IALE$=XAN_,B:WUQU?+G1E]A[N:"N4^8VF
M)-0S#T-H.O1]-]--7N-LLC^]>1QLW>&WII^@W=^N7AF""&?ZH#(H6+!AQTJD
MZPPE)&UB&6?*5CXH7ED1"LG2@!JG.7S0-5WB9ZMT0?9SLT=[%1^J0LDK2\![
M+@LL;E1'T@;/IDY'4O=:(,9[:S3NW'0S].8_B:.W[KP+N_T#F%XX':?;/,_;
M)/*#D$>R>PC9YC8YT\<\=WIZ_LO@K?>Y%SU\KU-,G/(OG'94Q><]+GZNJ[ A
MY5RH.B=B3;'P:AQ>PQ5LE]JE+/B>(EM(J^2*Z;(4GAQE+2YOS:?/+E>4KRDW
M?/MVT*5+A,3-R]+!JV_>$7ST@.O@:./$7,VW&$+^25(LG<.]\\[V) <';PV#
M^"GBFU8?WN<257^\3:3'V/+:4_XZ1VQ,-V7*] N]>CP40\8NEM:L.,2RQI!Z
M^.277HFX;%P;>[8ZL+6<)L@Q6W":T#6-#L5_:%.Q7CJ.^U4WDJ&WH[CZMN*)
MOP[3H#!Y5X4^6(/@L(2''W=65Q.$VX%?6,*H]WU5:S>A*>3<0OFH$$DHT<7?
ML)*S.FGYM1D&?)-&$J.4E'&"EG77.[A7<A.IM9 N(5YSC@*!6TA*QPEBZ> H
M#'0J#Z^LNE8G&)88>*C&<#[0)$#8:?XJ994'GWW6>Z/LN#V4#:V5_[1J>J/&
M4CGS\<F#QH2_YH8A$A#7"34T8>!SY?(=/F_EQSQAD!49W2J>HK/ET78-M4#S
MD]"L:!#3HEXH X(5Z[OC8*@79/,\242P=^0&Z[NK1R FR M+ZPW/-V98N8,9
MZZJDDOP7\>5EE[@56$^**2X(4R(R[F?%:$N]/O-0!(MD6:<Y]U.C=PP'2!<R
M-T4#(ACET]BFT1 U+WB](VN;Y1;//Y0CO<\,6!UO!UC*.U$$)JKW5?+C2/KV
M>V_6]X8O !""DNT9I!#^F]M1($&NQO']K?J:ORHJ6Z$D86S)$7":TDILE\\2
MV/J[$@@LM_%24>B'0Z)#Q";):]H?#..M1BCVB6^5^;BN1"1A%=E!(9HHM<5O
M0!:QE0M ^#LRK0:LV#_P].,#:\6I MOR"\ 0=!SSMJ-B\W!S-$=64=9]8^\L
MU!P_4+R_M)HV(+'_,+;-"QYK@*J9@_I6&S^-Y7]E&+!6IXJ.<PZSFUL"OS=Q
M.;TE[[&\0=RY-=#?)_A?V-:Z\CCX74[E;EZY.D_MG_6ACBMWG6XMWYZD;6ZT
M#YD.K5HI> <"TT9MFVDO5<9;N"_EPYKAB4^SK\&G2/;1?SWIF(3VIRPE)/I/
M*H=:<:DN!_+59\D7 +4MAZ NI;.RE-*3-#6'*!R[F4"#9%'6NW6Z([Q*0P8>
M;8XKE;+>.RS>$%]-Y(SIKW5"&^_AN0?*G?[V'FBV>TZ'''N3L8Z$H)8%0EH>
ML_Y5:9D?V4_P= R*@X;*MQLKMV)&A99.R22LO+#9^'GLJ?9Z@J+\&[W44.L4
M^.D%X"D1H7<K[95.Y7XO5TG$4!37*G)]H7(GIQ-X9=9JWD9'H(BUP7IZOILA
M!R HPI6S\"30^1>T<EB51C1$*'E368XB7+,;X65= #J\>I PA7Q#"&T5*>[K
MX^S.E2-R7*X3J7+;](+VEQKDWZSXH7_@55U6[7?&\5[2Y[<=*T_6!<#D0$N/
M? ,GQOQVPDP:T@]].]1=O9@6'[:KLC6!OD11AO=ACM,P^CQ05H]&4;S[-$48
M.%FMC8 &E\Q [+I6;?ME=-XTV0C(K?.SG_P)V.G_Y[]9F^Y1#0EB,W*QN+Z@
ME4VQM2K&I&W.3Z%<YC^L,LAEYWKG-Q:?=O;-05<O ,]S<+X7@!O-SA> FSE7
M+@"OR#\59?5,C?O=>X?S&*H2Y>2ORGB$:QXY*@@TR9"G* \0=PEL.S=4L!_R
MT/4C1W=1=#]GOO@*N><G/+I_;5= O"RGD4]$A$E@.UF!)QIG"^[,89&9 DGC
M@P6"8CEN<VZ/]D$?J/[(55!+T/ .+-A6#UYB8'C3MY2&SIB8\(*-F'4,.=:\
M ZM'?+M'DIK=>MRWL?\2VOOH+"W%:G?$W_SP !0W&+G_K3<7F9C+T6"U476(
M2H&FF>T'VF&0K1ZQV8PC"$G<!8 9KJ57US3FT%1;V6!=')70M[WE"?([9OP9
MG__Z9L?._8+>@CAS=6?BF@FQUWIRB^V3Y4;Y54CES/VHD?N_62[3BD7:T$^U
M='HKY;3/6;?7RTS;-D4X_)J:!1Z^KXD>_Z4\=R+:1=<X&6ES.QA0 KR$N#GA
M3M5:;G7PE/%B?/PBJ_G\!\0T!G^]C\T8G:I;[@KZ;6;F JV.V8-QEG>V3/$
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M-J^+Y WXO'T^5/<Y:?7VJBR'1=>QUYR%0R(YR',I='(UV+K33BI9@(B-$7O
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M0,L^^B5 1S7O".E&B)P:4F6"-^"NK:;?VWR,R8!%\Q4FKWJB0B D<W'/N,5
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M41< YQTUPRB<VAV+R:Z  -BMI/J__5Q)>^RB"<U2NHKMM[5DUWKV"_A=] K
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MMV*GGTF7KE?D-;DQJPH/C=^3BUV.J?BH;[]54C8; K/MB06DG\0/F(5K71>
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MX/OC8[C,1"G1R//34&Q4-T="7L1:!ZZT7EMSV[>6,J'@0^A745J_W4Z #%^
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MVSSR+L_QQH(TT?O;/%DIA'[+0*/AX/T!&^HM(-[[8DG]W#BUNM909"%/)S;
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MLZY1ZW.?F=6(LB!$1=F/'PTZLFS+6W;YI S =KP"=&;93NAB3Y+"##IB+V]
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M.?!JJQD+R]NO4-G>'M4%'Y_S[NU9Z<@G'OVC(/L G"Y#@O[HY)S [RO XRN
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M/SQX3U]LKLPDF?(KMY@\]3&=VLEI;9T]6)C219J"H8YY\!0E2P:O64<O,$Y
MA?';/?[9P65F<PMF0J\W=/=OO]&0DQV3ZJ$S6PG.4US#=*:=&?38K$:7?=.>
M&6Y?+!W3.Q@S*=]<)!P>*B<2BTA6@\L7FE.*]?5Q(1DV\^E=2RE[SXR.&"C!
MS;!/7.(HB2ZWW57E[B&UA?5%2D5T')EMXMVTU ^>+?%G[Y"_@M"SP.ON:_D'
MHX+)==ZF&;Z@WK<?.Y+YC$4>,F2/!X&(E&\]&;8./[]'<(>4H-<@;>WQ4G%.
MQ:E+%V63=Q^X-P8,H+ZM7 %2#"5%V>L6^%,Q]I'@Z$&:^_,"US:HEM';EE>
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M=XWHEPA."!)&QMKB]W=&<#3"^OW:!MH-!U72#!TWW/SD*-IOJR0J@5<1-ZX
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M'RA6OU?4^'!E4-KA7[-1LX*Q02UD5?/@VZ$(4C@=7]Z)IG>!(PPMIW[5?IG
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MP/XW]MX[J*DX^A<,TGOO)511JDI30&*EB(B5*D1%I E! 8D2B-([(@(*2FR
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M+[FS!Y=RN*.-!,]\L;(-5.08Z/CL;,_!_OC!^&KAZD%@O./!%DOD;5>>: 4
MU831>HF1TJ9GY72D#O6\[\,&&\>[ZM9_2"\XA(L\T%!W)YE^#!F% F[]+B$
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MLD@2D]6O)DOB0HSK9TP?.<]]2OE3F>*_EU5LV2YZ+=G_<)<V<Q]Q@0#QM\(
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MA+O9S#,'-,,.OLR0819#@O=A 1?#G=U^:!Y&PZ0@94M> _V)1GVRC:@WH'_
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MB;':"L\\=20R]1NX95"<$;UTB(P$ @H[]&6N>I,XUO.'6#8<W([UC4!CGO(
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M$<0^$KA/>"5HCCA!9GB.-=H4>4]UIGQ]$.UPS]%%LE&J_E8ZH^'CZNI5<Z=
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M,BSL+'E<_?KY3 *_L4FRJO"MN3N(C6QM>"XB(?;;^RJ)Y2A*.0JX';K*R8S
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M\?)YP4.E)I:\&\#]L?%C4PD6WZESA&*##72YBH+TBRN&.;(@3@TQ81"A_-;
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MQNS\Q@QAZ105&"^*V>8C*I9(OAC*ST>A@F0,9BRD,]\80T3?,B-,*:!=-KF
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MP* \F@=P!_6*OQY"T:S1MS]C=6/\>1]2VI22936=&IK66@YS+W8B"AHP.^&
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ME3E"(%U0=&ET_R 1$J3,G-A, UE;A*0'S\Z@XN:@J^#9U^FC%([?K V\-S5
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MEY?CD?P&H+N#*,X3YU*_F*@MQW'V>$7>VF-YAJPR9Z=*N]YZVIZBZ,Q"*ZP
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MTXF%X]>5%W5'"30- $,A,[MRHYG9UIM:'0X7Q+<U+%P6,@+=/@DNA7@_AVC
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M[!&T>IKU4)W<^P"['!V'M%^YTF_X+GXL=UF7@P\4PRR)AX$M7W"A%66KY]&
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M4?G2>ZV'R@[&>X+3UWV>,!IV/[83W)6AG]/\'K413F(DAJ;!,UL>OO 3 ,)
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M1E6YV4>\%QF"L\+EYG1"NR1%796\Z]J9YQ@T0Q9?5?>30(GF/H((\9/\L@J
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MTX>*&AA*+9B3F')__J@B/TS7S,3^4B3.8B>!Y^ME4P'2:=U)269*^VV@A#]
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M)(B:)$3C.G)=PR+$]CEU5J_&XW'FK"@F5$]8=?/(O[.DWI?_I8!O$@<<[49
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M+.]>CL]8:NM5#^.\S?J*_VF^*Z"'GP/"2PU//M%-YY]SRL,!.3\DC]86 S\
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MT)^$1J2%%3JQOZ<+&E;&J6TL[6?Q1VVE.;;OBD=0,TJ@)13'=9\E0HV:_)9
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M)"5AHFY\=+ZE-=V@K,Y)!VN$705:\(WQ8*OH9B<H''++^%@*P\+[*:DVU[3
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M50O*Y<X7MF"/C52]<ZEU;\M+P7@"7Y<+CVB'4_'94F7"YH013$1QY69ZO%(
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M9!Z^2-(% RI9:=]5X!IX%?"9+B+%%^']/EDH%O_"/*H=*N>$'@!*F\-:*,A
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M /F)YQV!QBO,S;"Q6$Y8+6._]>K-J/-+"+F^);GT!XWU[P7>Z>UHL4-QHNN
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M&&0K=0;OH5&?I3O'.I_8/@=X3T^W3RK2_N)]2D /^L<*J@GUQO<C_>K\ZSC
MQQ?$%/#S7NR49/SY5)V^=K'J86RRZM/JO=7_ &\XW_"YY?XDEGU.^N+FXE::
MZNG:::5N3([$LS'W))->U?L7?M8S?"/2!X4U>_>QTQKE[BROBAD6Q:4J)D8#
M)V,%# @':XST)(\6O)EE8CUJ.QM5,FZOT#&X2&)HRH5+VEVT:\TSPHRY9J22
MT[JZ^X^H_C1^S'H_Q?\ $FN>)_ OB*.[:[E:Y-M<7,4\<I(!(21#N4>@=3@=
M2.M<%X/^$\WCWP!X8\/J_EG5+J;4KQI0?)MX8I<,&'1]P0 8/5P!G)(\KAME
M524^5L8)7@_B:]\^'_Q?A^'?A[P5<:PGG>'+C26TZ]E@\M9;/%V<N=Q!)50F
M2,X';%;Y#AL10J2C.ISJWN^ZDUY::/RT3\WT^,X\E#^SHQEI%RBGN^CWOY[L
MR?BGX3_L3P]XNA4VUE=NMOY:QY$NT>8REL?*BX/3J3CC&:\A\-7.FI+)<W N
MH;^ZLEN_.B"E3<KE=@YXC8'.3DY &,5O?M"?$9=;\7^*H](\6Z3>M.422"W?
MS4U.%W!C=" 0'C PP)! Y!.37,>&M+32ET;4-3V2V]Y@B$Y& I*D$<9 QG@C
M(Z5^C973]V\NO^2/R3#\K?-36S:Z?*QW?PH_:"\=?#KQAH^K-K7]M:7,%=M+
MO"TEM*A.&&,$J?0H<@]B,@^]?'+QIXUL]>2\\%ZQJL=IK\,E[I<4!A:$J$#"
M-A(" 5RQ(P<A3CMGY?\ #?@2;4OB:8=+ECOX8YA,B6[&**<C+!$W $,!G (R
M2 .>]KX@75QX?GU.QBU'4K#1-0FCD-A?D.;EU?Y2J'[@SPVTC!!R.M<^,X<P
M3KJI&$>;JG%6=^Z[KOZKJ>Q/&8_#T9T^>4HMI_$[Q?EKMW6RT?KYOX_\8>*O
MVEOB5I:ZT^CS7.G1.D<]G8+:$L2"PEV@*QRO!50.3@=SGJ]QI'B"72;^"2"Y
M@<*5(R"#T(]0>H/>O3O 6C?8_'2W6EO?&0(WF6]L$^<\$%MP(9<\8&">HZ$5
M8^*'A"/Q5<V]XK7"WEM&#*@16\M01DMM!8L >1CW!KTHY7]6@J5**C%;)))+
MY+8\_'Y-BZL?K%5N4F]?N6[WT/3/V4[>/Q#9RZ;/=V>E3VI*Q!Y@DY4DD,48
M8;@8)&<#KC-;_P 0M,M=.@GUA))K";3E9Y;N2/,<2D!201@%B  ,<#L<UX1\
M._BUI_@?QM;R7%XC"XC-I+>0*)Y+?)Z, P*@@DYZ@#H<D54^)GQLL/B/XYU"
MQM9M4&AZ;8RQP#(8S.  &=<C^)F((!(  QR37++ ?O'=Z&U.-&.'=*>KOIKM
MUZ=OZ=S@OB/86?Q)\0W5AI<CBQOI\)+( CI&QRSA3C(!SP.3GVS7U]^Q,MMX
M<T4V&G-*8]*CC83A3B7!P7))XR3P*\3\"_ ?3?#_ (<EU*2UFBBEMI7\YQYC
M7*E0&(!&00,].!NR:]*_9Z^+>NZ[K%M8SW\EQ#:Q1+(HC""5$4JJ,5 #%5!'
M/UY))KR\4KQ<8]#Y_!15#$J4NK=CD?V\_"NG^#OVC=2_LV%+>'5;2WU*2-%V
MHLTJG>5'0!F4M@< L:\5NKC]U7I7[5?Q4M?C#\9M0U:Q\S[####8VY?^-8DV
ME@,# 9MQQZ'/>O+I#\QKY.7Q'](X)36'@I[V5_N(OL2W;;MM7K'3?+[=*CLS
MN.VM:V 5*GE.SE*[6FSDU7F9<U:NIBV1CBL>[F99>O&:-R63._G2[>U6+.T/
MF+[U6L#YLX'K6[:VOEJ.*;&M06%5'2BIFA.>**7,/0IZC;DUR?BFV$;'BNPO
MYP :Y7Q$=[47%(YV%?WG/05N:''D_*.*Q[F/:1[FNB\/1XB!ZDU1G$UX58**
M20L'J_;6^Z '%03VK%SZ5.VAL1Q3?,*DGDW$+1#!L'2CR\S4:$V*]S#D=>:J
M3#YL5IO;;FSVJG<1 MQQBCS&M"G/%YB&JL=CDU;/#>U2P6[,XXXHW(+&E6YC
M(%:RILQS4-A:MA>*N26K!=U&QH/@G"\&I7FR.M9LDK!CS5JPC:<^M2,9,07/
M%3V<@0CL:?<6.Q,XP:SI-R2>PJDKH-CH(+I3QTJ25RR\'FLG3I&DPO4UK+ V
M/F/-9\H]6RK+$SL,<FFM;LHJ_#&$-69+=6CZ=J2NMBC!)*FM"Q"E*KZA%Y3\
M#Y34-M=-OQTJMP-*:/>C#%9\EOY1-:EK"9U'\ZAU*R* CO2V8O0S7MO.0XYK
M-N]$;?N(SC-:D<AA:K+EIXQA:H5D8UE%Y7 '-:UH_P"[VTU+%AD[:EMK)FFV
MXYQFB4BMA;^+=:D>HKB]7T5FN"0&R3S7NG@OP_I\^G:&UQ#X7FLIKJY7Q!+J
M-]-#J%G $'D&SC0;68MG.[/.!C&2.$?0UGE(VL<$XR!G';-<U'$<\Y02:Y7N
MU9/T[G1B,*X4X5')/F3=D[M6;5I+H]+I/HT^IS&@:/Y:[F7 ]*U7\/K<#=LP
M16O%H_D=$JY#;CR\$<UO?0Y^4YO[ MAUXJ.6]6-"WI5[Q!:MN.VN1\0WS69"
MU70F6AM6VJ+.^.U:UFID(KA_#U\US=@$YR1BO1M.L-EJI/IS1+L$=2M/'O4C
M'-9LMMM+9K?DA7!Q69J46#]:%*R*E$I6LNP;>]:E@=X]:QHH6^T<>M=#ID"Q
MQ_,?NT$Q VN!G'%0W<>V+BM!IU4^HJ)XUG0]JE%&*&9'S6I;2[XA5&[BQ)CI
M5FT.(A1NP)I!FJ\Q5 1A:DN9-B9JC+-N>B-NH"-:+,3ZU4OK)2A&.:O1?)\S
M=ZBE;>Q]ZKJ3N8#:9^_W?PUJ6UL(XA_*K#6@89 6@1;>M K%&_BPN!WK-N$\
MI?F[UO3VXE6LN^L2YVU41.)BRC<WRU/9J4Y]:EN+':>G-36T&X 8Z4-B19@)
M* TCG&:D9/+2JK3;%/&[%&XI; L.]_3!KK/"D6'4^E<W8GSP#BNGT&46ZB@A
MJYV^CME1QBMFVG##%<QINH^8@V]*W-.EWJ*>QC*)>E3*\58\/7C:;K-K<#@P
M3*_Y$$U'&FY*<(\,<_>-0821\H_\%<O!H\/_ +7QU*-/W7B+1[6[#?WV3,3'
M\D6OF^T3=UZ5]K?\%A=!_M+P9\+?%07EH9],E?W*I(N?Q#U\2VMQQ5<QUX65
MZ2^[[B0?+-70:"PR,]\8K!B?,M;6BG-RHJAR/1?"X8(O%=?8LVSTKE?#/")Z
M<5V5K!^Z%!K'8FM796^]6I:39-9\%NU:$";4Q[5+8M1V[SF-5YH\-UJU;QY!
M]Z:UMM!SS4@9S'+U!=0>8*N3QX!:H%7<:K<)$-I8XD%;NF0MMJG96K%^G%;%
MI;, .*.4(CD^5NM6H;A<=>:KSPM#S559&W=:DHTII=WXU5'WJLV=JTT?3+4R
M[M3"#QBJTO8K4GM+A8Q^'2N[^)_@#6O _P 'AJ>G^%4UZ>:"2:9?MIAOS&$(
M=HH<CY(B 2P!8D] !7/? ;PW!XN^+NC6-[M:T\Q[B92,B18HVEV8[[B@&/>J
MW[:WB/4KWPKIL<-FUG.-T$]Q'\K22$!FS@DC);!((SMQT!KT,OH*<G)]#\]X
M\S:K0A##4I-<UV[.UU>R5^V]SFOV;?B9IVC_  \U&#3=(CTJXU"X\^]N$)/G
MHH!4%B22 =Q.",D]!UKK])BUZP\7V[7"267]J7\4;W]RBSRV:,/F$4.<(% Y
M)P23U.,'C/A_I=C)X'NK7[*MO%;QAI+QE$H0H0%B49P"Q4'@=6R2>@]=N;)=
M/:VN-0:.[BG"13VUM*5;<%&&(SN)!&2<#!XQDU]QA\-^[Y5O;YGR^#PLE0]F
MM[-VZWON_EJO\T=)<:E%K<=KHLGB*X\1ZI8Q^;<SR:*CQ[3\Q4%I Y"D+MSG
M')Q@U8\(:_J'B3X5ZEX?C\7>(OAS<WVKVNIR:]H822\DAMIR\T#1D@QQRXV@
MD\A22,'!YM0OAVY>VA=;:%D5MTL2M*&(W*C-\I)&"Q Q@<Y.<5T6KV]Q8V]W
M=7E[]FTPJS2*J%./*()<Y.!D#(!R>_!JJV3TL50EAIMV>_3[K6/HLJC*AB8U
M\/)*I3UO)<ROTT>CMU3W]#W;X:ZS9:K\8[O5K&XMO(U&^8J! \:RQ<A6(+;=
MP;J5P#G!'//0ZSX)TCXKQ:IJ,,<=Q<+<&.%HB=F2"I4+G/)R#V(.!7E'P?TR
M3QU\*ECTJ>-G\MD:Z,$BSX96)D"*RL JX P"#A 2#@GL?AKJR^$?!&H:?>07
M5OJM@&6<12 ;R$+),JL<*&ZD$9SGVKQZW*H25)OF5E\K[ORV_4Y88R-2E*"5
MWZ=WJ_)?UJCA/#4>@_#O4HK*_GO[&_F,YM)[=I4DMMC*3 XZ$* 7!Y.#@]*\
MA^.?P5FTPZEJT+;WM)U%_&(MJ 2'"31GH0QY8<$%@<$'CTCXIZ!?P>$UUV/[
M5>P6\R7R7DB;7B8XWJQZ$@. 2O' SCI5[QYK,>B^'M;O=4GL9H->TB:V<Q2>
M8=[)&\2$*2I82$D<Y P>H->5CJ,6G\_O1YN4XRI@<RC"DK1;2:[INWWI[,^3
M9-'^SR%CW//\JNV8VXXX%7[F%IB,B@6#*.E>!S6/V2W8F@;S-M4?$-HUQ$1U
MK0L;)F7=AN"1^7!KN_&NA:;#IVN;8_"HM(YK4>'I=,NIY=0N(BG^D&]5_D4A
MNFT#' &:Y:M?DG&-F^9VT6WKV1UT<*ZL)SYDN57LW9O5*T5U>M[=DWT/!CH;
M"[&%;&>GO7U]_P $G(H4^->OZ3-(D;:UX>FAC!'+,LL;<>X&3]!7@$>@*[;M
MN:]+_9*\5K\+OVC?"&K2_);QWZVTS;L8CF!A))]!OR?I75S7/,Q5'FHRBNQ]
M1?M ?!!OB':6,<0FMFT4&>Y$:AWD+DJ57T 5<\]SCM4WPG^#5QX9OM$O[M)+
M:XU@M;7L*#F2':53T!("H<@<\@5]+1V&DZ1XENE=4CN;W$S!A_K!TR/8$XQ7
MG?QQO8[6\M;?1Y(Y-21UEM4,A"!P>!D<@$G/'ITKNP=::O2C]K]+_P"9\?1D
M[\BZGD/BK2=<\!ZE-8VY1Y-*NS P+X\L/AE=1W#*,8QUQCO7*Z]K]_\ #;4+
M.^FET\:9J-R/,8S'=;7"XP7!4A003GJ.W!KL=4UOQ-#XCUC5]<G33[J*<17B
MM&)5C0#=& ,#<%8 9SG!^AJ]=_$KP_\ $+P8-+U+14DOK@ 2ZG);AK2*5B<8
M."5!!('9>F1D&OL:=.$8)QAS;7:W3M>]G:]GMUMZGL2H0]G9QO?=KN>2?%'3
MK+Q[IS?94FCF+F1Y'&1&!@MA3D$D@,&!'<@8-<_X-\,_:+&;>\F^("02'*+&
MI#)N4G.22.<Y )X(&:]QTWP7X?CLO*M;BW=SO189?E215(W 9 R0#GV],=/,
MOB]X.M[35!'H,D-K;Z=9D7LL5^)0$/S 2* %W YX!SCMU-++,?)U/93D]-K_
M /!.&G-NI&FGK%Z7_+YGEGAW2YM4LK>21(V&F7Z/]H,;$E1AF16Y!) ^7L,D
M'GBN_P#!6JZ7IWB#6;G4#LL3H\\&HG>5"Y=6@!/7).X<9R"1[5A_#3Q7<W$L
M=J"]],P)@6VB)613T);A1@@$GGD=,]:/B^XB\(>!]2U:1HVCTR=[N??*-MQ-
MD!4/=F+[2 ,@8R<8KLS6I%1G*2T:M^&[]+Z"JJ7M9-KEBMO-O=OT_P CYU^,
M#R^('U:\M[>X>^DOY)%,Q)DG4D"/<.H( P?S&*](\2^&=4\-^"?#-GK!5KZR
MM3%+AB2A?$H1AV*A\9'!'<D5R?PD:+Q9KEKYDJSO/.TUR6)R@4[B6.#C<>!C
M/7\*]R_:GU6(V_AFSFMTCU46K7%WE0)/+9L0!^/O!,Y]>*_-ZDN9N1>5MO%)
MKS_(\/U 8(]*AM)/*F%:=W;JT>ZLT)B;CUK-GUS-,-E14;KNZT(Q J&ZF\L8
M]:.4".X96&,57>Q1UW=:%DWOBI"WEQX[U3\@,G4;%7'RKBJMEIOER].M;102
M-TXIK6FTY7;S02T0B':GK5"^AW/CTK5"5#=6F<GO03:YS]YM0;:IA<O_ +U:
M]QIY>0M546NR7[M5L%A]D3&-HZUHK]WYJ@M8,\U+<MMP:.87F)-\RX%6-,@S
M.K?I5/[05(XSFM;3$W,IQBC8RD=IX73R85XY-==8/A17&Z-?"!%^[VKH[.\:
M3'/%%M#.2-W>'6H)X\&EMCO2IWAS4G/)'FG_  4S\.'Q;^PGH6K*N^;POKD:
ML>X20/$?U*5^>FE?>%?J=\;O#'_"P/V'OBAHP7?-:6!U"%>^Z+$N1_W[-?EE
MHI\S:>QQ0;83X6NS.S\-/N9:ZZT0LJ]L5R7A]EB -=/9W? JI'83Z@@4#UHT
M_P"5QGC%-NIMP!-.A;@?44T[F,NYUOAQ/,(*CBNMLXVV"N9\*KB)<=379:?!
MN@''04-7-([%=P0XYJ>.0[Q3Y+8NU.B@V8I7#J$\N2%J&YC!4C-3&+=-G%*U
MKO.ZAL-3,FSFH9%5UJ]=1AFZ8JFPPWM23L$C>\+_  8U+Q3I]A<0W.BVAU>:
M2WTVWO-0CM[C4Y$^\L*,<L<\=LGBL^PL7MI3&RLK(2K ]00<$'W!K>\-^.+6
MP@T*2Z\+Z'J^K^%999M#U.Z5S-IC2'<Q"@A7 ?Y@&& >>:I6\,D\CR.=\DC%
MV8]2Q.23]2:Y,/\ 674G[9+EO[MM[>9Z&*C@E1I/#.3G9^TYDK*5W;EL[M<M
MKWL[WZ$@0)4T$_EUZ''X76)+"&/P_P"';CP;-X;EO;_Q%)J _M&WU0*2L"Q[
MP0 P0!=A!!))XS7E\C,",^E&&Q<:[FHIKE=M5:_IW16.R^>%5*4IQE[2*DN6
M2E9-M6E;X9::Q>J33ZF9\2M";QFVCZ1YOEQ:I>QQ+(6"K&X8$%B2 !R!S[\9
MKR#XD_"/6/A)X^OX]0B>WO+&6*&X92)O,9D#@[L<$+@G(X'O7TO\,]:L=$\0
MP7&I6":E:Q.)1&RAMD@!VN 002IP0"",@'M61^T9HE[X%^)GB'Q#I=GIOBW2
M/%CB2;68-,F1[91\PCG5@44J .4;)*\G&175S<K3/B,SHS5=R>SV/(_#7A>^
MU%(YIH52$N@/F,%D ;D8QG=T&!UQ7OOP&\1ZMX7@ATOPUHT=W=3S%Y=Y*.-I
M.2J@@@$< 9'')S@U-;?!35O&W@#3=9^W6LMMJ$;&&&%-D44H)"ECC<I.,%>0
M<XSQ6!'JNH^"/%4.L:;#:Z/=6SM;W'V0-G: 5)96RFYUY!  .3QG)KZZG7G[
M'VE"7_ _K\S@IQFI^TA/Y>I]2Z9X$U.'Q%8:Q>^&8[:RL1)<JUH$EG\Q8E!E
M2+),@0[3\H/S#!P <\=I^L:AKVBZ9I^I:]?>--9TBW9Y?$%WIT5G-JLQEW1A
MPH 6.)6 !P2=IX K!\*_$#6O%EI8S:A]C2\M[2XAM=:NH7EO=,@NO]="K;@!
MYH &2"0,#'4UWG@3PU=>,;J:/PE8*FG7'F1W%U=3?+$D;A2R\;BQ884+U!.<
M=L:<,14K1Q525N6\4^9VY79WDMK[Z:_B?3?7>7"*AAY<RDU*?-&-XRCS)*,M
M9*/*U=>[=[I\J9[;^SQ\.-9UZXU>[MY+/[+ D6G2S&(J% 0,[(F1DLSYR<\
M9)Z5[+:?#&Y\,I:?:-0_M2W@>)3$J*J%%R S=\XZG/)Q@=:K^%/!OA_P5X-L
M;>XU%M.N;F.+:BR^7.\I +%ARQ9CU)'49[U>\7W@TB V%O))<RS2C*F8%^>0
M3QTQQFO.Q>,C*H_9I6VVWTM?_AK'C5L3'GO3L_E_7Z'D/PY_9YTG]F+P9_PB
MOAV[\0^)K./6KK5ICK-X;ZZ>:Z?S3&'P,(,84>HR>2:[[XAW6L:#X=TB_P!)
MM5N+*\F=+V%B0Z(5&  .O&[Z"J%YX?UK0'2>QOVAN;V39/" 2TYR0%7@@@#!
M)/()QWKT+PI#<'0F6Z2&.:5Y9$@#AG\QOE(49Z*O&<YR2< "O)ITXTZ:A#8P
MQ6*JXB3K5Y<TI;O^O0^/O^"@'P.TG2/A#H_C6.5_[6DU"/36R,>9&8Y&V$?[
M!3(/HQ_#Y#$ G!K[(_X*O^.K277?#_@O3]B_V;YFK7P0\"64;8P?0A0Y^C+7
MRG\-/AYJGQ2\;6N@Z/$LVH78=T4G "HI9B?H!26KL?0Y?)PPBG5>F_HB]\!-
M.^Q_$R.:%K&/5OL-XNBO>X%O'J)@<6I<D$ "4K@G@'%=M^PG\ _CI\5==\40
M_&&76]-CU'3#;ZG;WVFS1::)C$! \1D8![F.8 [X>'4L2<8SZ]\.?V7+7X5^
M%'O#Y.M>.)F9$DEAVVFC*O)>+=D-)QQ(1@'[HSS6IX6\,:Q=W-C_ &MJ6JW2
M3W"H8I+AY7G8G@ $],\\5QXCAU8O$0Q,YM<G3O;4Z,+XH2RW!XK*\%AHU?;Q
M4?:22O'TNG?NKZIV:U1UMW^P)\)?!/PZMVD_M#6-0D3;]MFU"2(2N."0L9"J
M">@P?3)/-?.WQ#^ G@WP5\5U\26=C8+X^TO23X?LM6NYY>+$AP@95!5V59'
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M1L5NQ.<<5/,=B#)KMOAWX!A\2:?:R-I>O:J+S5$TR233?*$>D(T9<W=P7/\
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M=UI7B>";29IA?VER&M)K8'S"ZM\K*!SDXSC\*^K?#GQ[\/\ Q!L+&+7-4O\
MP?XDT]_W]E/(UO;.XQ\Q9QAE(!(0@%#T)'->EB/:8BE'#JIRJZ;TOS1ZQL^Y
M\;3PN&RK'5,VCA?;2<&H6E*#I5?LU8N.K<=TMKKLS%L[[3XO VC>$]#\%-:0
MZ5$MII \/L)XDM2Y+%DD+;P3DL^=V3DXP:P?$^B&#6+[P_KSV.@:HID2#365
M2"ZKN7)=E#JP8G(R#T'.*]'\4VFB:]%;_P#".ZQ;7>OVT2J(X)HXY(\$$B/R
MVW,Y#  =#N))&!7)?&-O$OA_PGH5I>;M:@OIB)[#6+=)EM)D *D%L2+SDC!
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M]EG5OBQX3U/QEK7QX\4.;>;3I(1&6$>G7EUM_P!'>U;>VZ82 -YD:@%&;.,
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MSSUJS\4_C'%^SUXKTOPOX;^&MSXS\4306$MWJM\%CTVW>\@DFBB220B"-@$
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MB:5?F4OLZZ$<00P>.RBCEM7!PC*FVW57QSNW:[L[6O:U[:*R3O?Z+\<?ML>
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M9IY%P&9F"(A/ !;IDGH!DGTK)O1#HVBW.J7DRQ6=H1N&[#..2<<'@#J<'J
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MLZ=XZT*6))+>"W:XD0[8V;.Z3'RY'7&<9_E6QX@\3Q>)O$B:7I7A:^U"'6+
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M:=U=/VG]ISQ=-\9OC-X@UC35N)=,U&Z:2 LA177 !?;P 7(+'ZUPL?@'5FE
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M4GWP0,BL:V Q*C[24&EW<7;[[%>V5U9'K#?$S7%MH=UO?3O,WEJD:ELL/?H
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M;<0.H%?D%\)-(;QU\4+6PU*9[&QN&:W 1$EDD8H2$5<[E)QPX!QU'-?:>O\
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MQJ.1NP0"20<Y/UK<^/O@R[\&7=K.]QI]]87;;Q):D2P2G )&<?> *D@@$9Y
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M&P+G+]YHCQ?7_P!E>;2/"EOI6CZ=I7AO33?3ZE+:"]DNI)+F;&]R[=L  *.
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MM*ISM)/ R 0JY (KO/ _[)6K^-F@N-)\1:L_@30(9;V]LAC&F0Q1F4><,!9
M[HJ*[!LLPR 3S2\/VMPET8;>U18B26"#"H3W)QR1[U^H9QQAEF*HTY82C[.4
M8\K>JO>SE=IW=Y7\VM7+4_". ?"W-L!5Q<,^QCK1=122=I*#5U&R:25H<MK-
M1C>T8I:ODO#WP,UC7M1:;Q/J%M8(6);[/()KBX).2S-R%)/4DDGT'6O6-)^$
M_@GP1HZM)IL>J3%0R)*@R_;);)8Y]B*NZ%X*76;K;+>6T*(HWY0X'^)%1:GX
M!FO/%$>EZ?-)<S3,L41F& 2Q &.#USP/2ORW&RK8_%<L*CO)[*_YMMZ^;;/V
MS"_V9@:'LH^[3IQU;2227G9))+^5+0]V^!O[5WA_X8^$_#,VG^)9O"-KX=BN
M/[2\-VEL[-K$K>;\ZMM8-OWQ@EG!3RLCDY'R_P#$+3/#_P 5Y3J$]HUO?X*R
M&.4J\@)+99L'<V3R3S^%=!\=O@?<_"_1FU1=134(8(X'GD2(P(C2@A  S%FP
M?OC *DCL>.)^%TMGXD\8:/I+3FV.K7T-H)5(<1&1PN2.!QG(S6V;Y+BLL:IU
ME)2M>U[Z/K\[==>YR\-YCD&=8:IC\MDJM.]F[6UBW)I^ZG)KFW=W9JSL<+>?
M#R^\+ZO;W^A:DLEY8R":*"_;*%E.5^9<'@@'H.>]>Q:;\:?$WQ4\ ZQ;>)+3
M1-.U#5O+759K.R2WN-453E1+(N=ZD\D C)Y((XKV?QC\*?"WC^ZU3POH?@S4
MK._TW2[Z\M-:EFWSSR6LLL1,T R#'*T+ ;0&0LO!!S7S9\(]"7XK>)K#P_<%
MM.^UO)YZE',L"QHSL5488MA" H().!6V1YY[.//BJ-XQ:?-9-K3=/S2V_+4R
MSC(L/4YE2YJ51Q5X\UTX)W3:BVTKKU3M=?"9_P -OV<+7QAXRO+G[7J3:+HM
MC/J5W!81B:[N!$!B*$$$%F+=<' !/->L:A\2H?@=;>&[&SCUI]$OK&'6H+/4
MY(K6]MB7E(MIG5260-EE88?GJ 1C@_&7P-_LKPWH7B[P/XF\0Z3IFKRRPP_V
MM$]M=VCPL%=SY9SL8,"",]P02*ZOX0_LO:+<>.M+U+XJ>/-'FMKU)+F4WM^\
M\LL87$3.B[I KG! P.!R03@>Q_K-[+&+'995M&4>5QY4NJWOI?SZ6/E\^X+H
MYE@YY;F]!MPGS)\TM)13BXJ*LV[WTW>UK:GE/Q2^**WFF>=<1QRSN6<88DEB
M222<Y!).:]X^"_[2$/ASQKH.N6?Q&\,VW@"ST&&V_P"$:M4 U26],&V17&T/
MO,QW"0D  9)(QG&\<>$/@?HOC*;^Q=3MM0TZ*17B*6-U-#P1D$2*&P<=L]<
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MRMXALU_>>=!<&2=.C%F3:K'!SR"2.>@)KW<'6R=UI3FW*#2M&UFGU?-=7O\
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M?DV>J1VSF:6^(CP%E"RMY;# *KY17!PX<M@ 8JC\1-5UJ]G9KZ\S&,XC0%0
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M"5:F&;:AT:=]5HWTO>_7IJ>+^/?#[W/B?5)%LV:[NKR5@K*/E!8L">W0_C7
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M,JE2FZLITX)I[)O9=F_(\,\"7,SZ?&L<4>H+#<CRBTP1KQ>,@'&552.IQDY
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MCI@Z7\+9=.1K?3;99=H^>0J,GOP>PK[XT?PC8Z5\!]-A7$4EU<+*^U1N*HI
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M6FZ'I.@PZG=?:[W^S=.^S&]GQ@22D ECR<9. 2>]<W9^(6UN8M#)YLB'ATZ
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M_56?W/5/3O?T/MR/5M LM.TAM>2XN;R[TTW,PCF6);.9G(0OR,*1M(<DCDC
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M/3F_V7]6TSXJ?&76OAMXFUB_M?B)I>C6]YJNDZ8\8L]*,9"O;;E!5CF:.0@
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M?&7P?_P45^&VI>,/A7#I^E>-M'O;>WU0>)+8W$VG1/O<HI4E67&XQL <!9
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MI/FBK.3][16;CRI6TDT[V/1?@-=2>*]=6UELTBL8,DRL/]6">A.<X)->E/\
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M.Q< # R 5X'W0#X[/\?I/@WH'A/PKX=T;Q1X,TWP6DCZ?/?2[KPRR2;VD+J
M  <  9'!/<U]QE^,Q.#QBH5-8M6=]+[:6[VM]_F?GG%'#. S;)Y9A1O& #M
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M4@(A]\+G\>:[C3_%\&CZ6UQ-<9N6&$A+9 SW/:JOAGQ#9VFLOJTEO;2:E,#
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M%I_B+Q'=W-FT;%TG@60Q12HQ^\'6,,".,D@8  KI/ +/HGEM$[/M .QCM)]
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M:<9-W3337A?PJ\/>+OCQ?ZXNL^&T\.^&[34FBT^8K^_U.U !5^IP&.?FP.^
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M#M6TMI7AC<Y&<Y&2!P.!@DD5T4&NS:A(6C#;.K\Y'K^9JU<_$%;.%4*2*YR
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M=:.(A>C+FC_=:>ROYGTIJGB;P3^SWKGA'3_$'B32=$U'QS?'3-%M+EG'VVY
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M/BS\-=0?4O"^G/'X O+(RZ+K?AJW36FO)U(,GVPJD@MUVG]V N'Y._((%?\
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M9^(&)8F\YEQ@]>?SKZZ.)PCBE*DEZ)?GN<=3'-^ZSUS0T:T=UDD?S&!4KM(
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M<5\BK_P4OOO"OQ)*Z;HNDWNAI(H>W3S8PZJ-@$>]F.T+_>'S$ D8XKU;2/\
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MN:VNMOD];=-SZ'^!6L>$]'^+MQ\/M'CTV[\26UM!JEQ8W3>=-;V\F K*<
MG!()(."0 17M7A+XG^!;_P"->N^"[76M-U#QE\/;87FI0/;$WVCVTZ LR.RC
M*E6 ;RV( 8 XSS\K?#?XX:;XK\=ZMI]K+H>M^([F_CT7PU<:3*NG:Q!&Q,=V
M?/ND$<@@D7D1,Y8%L)D5#^V-^W/X@^&O[*K6_B#X=CX??%SQ<UUHBS7*H]X=
M)CVH]P'V*X$K%D4$8^1F7@H:]6@O=O-;'Q.84:E7$\M&]YZ)72=WN[/5QM=-
M)>MUH_B+X:_M;:Y^SK^WYXB^*7A=4OGU'5KU[BVN<LNH6MQ,7>)B#D$C:01R
MK*IY (/JG[:WQ;TO]H7]IC5?'5C)<OINO:;I]Q%:E<26!-K&&MG;)#.C @E<
M@D\ '(KYBT>.'3;<W4Q19IWQYCGHI.#CODG.?\,UM^,_BU)\,M*;2[4/#XHO
M5B>-XR ND0,0P+'D^;(H&  "J-DG) KCE3GB)JA'9M?TCZC%93AL,HXA+WDN
M7>U]G\O7I^!])?!_]E]?'GP_N/%=G-ILD%O=Q0VD$K$7%YO&&"HP 4J3EF))
M &0,$5N^//V-)O#'A>]FU#7]/D\3:?I+:U=Z%#!(TD%J K$F?&PR!'5MHQP1
MR3D5R7[/7Q&O?#5T-1LI+?5(5N8]4L;75;B6>6VN&!$ZL?E)#JQZ ;2%X&2:
MK_'G]JCXA77AS4=%MY+.UT.=&LXK6&T036UGN!6R6=LRF%<+@$DD<$D"ON>+
M."L(\OPZRB7[[>2=XMII7WUT:]V[>C=VVKO\M\/<SS^OGN-CGM-PPZLJ<E)/
M9NVL4T[Q^.RC[R5N5/E7SU\:?@OXG\=>-M.O/!EK>>($O+:.WM;&QB:6:-E&
M'0HN3R>2<8YR376^#?V+/B=>WZ6VI6#^$6T:S^TZF=;=+4Q2@G=%;!2S,X(P
M1D$$'( (SS/PY^,?B/P+\5M.NK:WL(]+MTN$OXKT&5=52: Q/;;%*E$(<@L&
M#CJ.PKW2W_:?3]H#P-'K5Y%<6:?VB;NT@%RD-K:0VPCMYGC=G'RJ$0*&/)(S
MDDD3PGDM/$3E0S"T>1+>34M'UTM9JVM[[Z;'9XE<08O*G&>3.<E-R7P*46^7
MIKS73;TY>5K7F:NCP[QS\2_$WP[\0W6GR1WTOF01^?#JI-PF&4'>BMD!6[$Y
M...N:N_ 7]N'X@_LC^._[<\#WEC8VU_(HN;1;4"QU2,'/E7"# + D@,"&&<J
M0":W/VD-0T_Q_KPC\/WFH7>E(FV.\N2 ;B/=N6/:/E98S@*W4X)(&<5Y;=Z$
MWAVS,AC\R-_DFC<?(^.1D=!]:\#./94,7.C0ES1OI_DNZM;7KZ:GVG#]\9EE
M*MCZ2A*25UH[M)*[71WOHVW'9ZW2_8;]FO\ X*0_#O\ ;6\!QV[3:9X7^("Q
ME)/#^IW@@2XF X\B9@!)&QQ_M@9R#C)^/OCOXT_:.T#XSZ=X??0=5C\37NK&
MT&FV6B_;/#E^K-F%8+E8R7A9"NZ4S!@2Q(!&!X5^RS_P3*\>_MS:M$_A'4?#
M.@Z'>S,MK>:WJ0A>XV!3*+> !II_*+A6*+C/&[.<?I5_P3:^#O@S]C;X$ZA9
MR?$?5KS4-4OKB]O)O$Y&D16ZV31Q/);P22,(H%:5 79MS.<$ @ <$HQWJ6_X
M;?\ ,XZE&&&G-8:/M$FERV;Y7*_*KZVO9Z;NVYC^'_V#/#7@;Q/XGUR\\77^
ML7_BN1'0+&+BQT^*)F!@@VL0Q63<AD)!P@!4')/JGPT^'=M\._"LMOIOAW4K
MJ&\D#W5Y(A@2=.!Y8?&0G!!P1DGV%>C3?#S3?#UBEK#INGZ7I]B))4@LX4AM
MX][F5W"J OS,[.2.I8FO,?BK\2_#/@C4[R;04SXD\:V]BMU*MQ<%+FWMXW%L
M\:LWDH ,YV@;NI!J:>!Q&)J1IT8<TNT4WT;[>76QXN(SO"8:,JE:I9:<KDTD
M_>C%<WO)1]UWNN;5)6U<ES/QL\>W6@^$YM!DURXN+5+R6>69[>".<12,6CM5
M6%57RX5RJ%LD@Y.,@#X?U;P[I.K_ !EGUBXDC,K32WH6\=K5/+0A4A6Z)!'R
M;<J, DECG)%?26J>.[7QA:2J\UO,!(4D?(.6ZX4XYZ\G) ((//%>)_&#X,KJ
M<<UQ$L@D1?," ;N".3CICIUZ_A7U/#E.KE=:3KP]ZUM5JOO5_EMZ!Q%DM+/L
M#"FJJBKN5X_"_E&T;W^TEIM9K1>8^)K[0/'>N730W$,,*7#A';+;U)RN. 3Q
MCDC.<]14%O\ #AK-Y9+"ZCOH8TW2K C.(U/!W<8 ]C_*N2UOP#<:'>JWF31E
MG#(TB;XPP/0D#E2>_;G->W?!Z]\86>F>&=+TFXT#0)+%9-/O[K49Y+>._6^.
MZ5;@@$JJ[%"2*,C<%W8!%=^1>'KS3$5)0K*G&S=K;/I97U6_7H>'QQXE3X3P
M%*I"BZUY1CONM;W:6CM9)VM=GC\GPW\/7NIM']C_ +(OFP[/:CRO,4X.?+Y3
M)'0@#U.:^J/AW\%_"OBK0M M=-34FL[.(3S0I<E(XE )WRM@MD'( ! R20,G
M-?/_ (T32;WXC:Q-H-S:C2-/NVLH9(Y#(KK$ IE#$#<KD,01R1R>35.\O]26
MQ=K'4+B&UN#B6*-SM<X(#D9P>,]1QVK\_P VPWLJ\Z-.=^5M)WNFNCNNZ^X_
M3.'L=A*F&CF"H*-6<%>+3C9O=-/JGI?KWL?<6B^*OAE\&M FN3IV@/J"_P#'
MH)CY\V01ME,2'CGE0W)P"<9Q7HWB;]HSP#^S[X7EU:[L?$#?$#4)I-)CU**2
M*%K6;<&E>%0P 5?E#,0,YVG )!^'_P!ESPW>>,?'UWX@U;4-,M?#W@^!=2U+
M4+R3%K:0Q@B%2.I+3",!0"6PP )X/S[^TE^UE_PGOQ+3^R+FYET720]M:BYS
MYLNYRSRN<G,CL2[<G!;:. *Y<##%4JBJPM=:K1:6[73U\[:';FWU?%X>='$3
M;<K)KFE9IKX79I\MM7%-7OV/M3Q?^UO9?%31;W4M8UBP:YCL([!;=[:2>^U5
MXY79I))MP5"K2;HV(Y7(8DX Y1/CSX9NO#0TG5M*AOHI<[FF&5/H0>=I]Q7@
M'P1^&NO?'6PO;C0Y+/9;VCW,[23>6D3(1B-N,L2"& &>HP<Y%3:_\.O$>FZG
M)87"7$+&,3Q)*WSF(C(?H.#SVX, -T#(O\$5]CQ91QW$%.EF&(HJG"G%*\4]
M?GKI=:)[/1>7P?AQA<AX:>(R;#8F5:I4FYN,Y*ZT72RUL]7]I)2>ZO[IXK_8
M,\$^./$2Z%X=\87FE?$"\T?^W$T?[')+9V\1B$RI)<# 5VC.5R".Q(.*^>?$
MV@>)/@=*T>M6;7%LN"MW; R*>.-PQD''K^%?3/[+OQ#\:>/]'/AW4O$6CZ'9
M:=I4]M+K5YIH-_!:  +$DX(9HS]TDC(X&2 <8?C;PU)X;U.UM=8:,074,9=H
MW#_9P0,!@"=I((.",$'(KSL+E&>X# _VA57-05MW=VUUZ-+2UN^F[.?,,VX5
MS#.7DRFXXFVME]I/5:12LTTTG=I)OF:.-\%?\%!=$T#X8Z?I&O>'8/%$EEF*
MPD74I].N8(?-$Q@D:+!DA$JAPAP0>A&37TUX,U/1_C1XP\&_VYHWB+4/$?Q,
MTVWO4U'3Y(X=)T&%TD$$$2,2TPC6+YP"2 220>#\M?%/]BG1]?@35-,%G]J(
MWHT3;8Y.^UMOW2>S 8SC/!R/5/V6/C])\$/A\N@QZMJ5@UJ\D7V">0/]F#<N
M(L@L@8G) (!ZUY?M</BH^TP+Y*E]>[7E\]>GF>G]4Q&$M1S&^(PT8R4%S2BH
M2DK*5N][:;/0^OO#_P )?#>G_L_^(/"?B6&ZO;;Q;82:;J;65T;>=48\^5(.
MA! .>AZ$$$BN8T_Q5:_![X>:'X+\)K>6/ACPU;&SM$N;G[3<2*7+EG? Y+,<
M   # '%>;0_M6_VK:BWC^S[/N@MAL+_C_6J'BSXPZ7X"^%?B7QMJ&C>(/%,.
M@M;Q_P!F:/@3W#3N5#,V#MC7;DD#N*UQ%.,/W]=;+70\W XC%8B4<HP;;C4F
MG&%]'.W*GJTD[-I/31GH_P#PG]RSF4*LAZ%B_K7.Z[\0UW2&:ZCC*GG:V3GT
MQZ^U8OB"ZM1>:1-:M?:;8Z]I<&JQV>H8%Q:>:N[R7((R1@X. ",9ZUSOB:P_
MM&)8XY4$1QSD<\8/US[=.E?29/D4<7A_K$9V3V5OS['CXJ-6A6G3J:2BVFNS
M3LT=CI'QJATJ>!+9G;+CS9&.2>>@]!ZU;U5[?XB1-=6ZQP:LF7R/E6Y'=6'3
M/H?SKQ.23^PE,:[&&XC<&)R.QK=\(^,I(KV'8[*20O7H:Y)X1P;B]T['"L7*
M6C-^[^(.VY^R7$LUM)"Q24$ &/@@Y[@#V_"MO2IK9 GEW,C1N0=P<@_0'D=>
MU<I\:O"S:CH1\2>6T4MGMBE8'"RJ3@$^X/Z5YWH?CAX) K;T48QM<X_G7NY7
M6H4Z7+.FF[[V3^6ISUL3*EHSWB>TDGC7R)Y)8P3T8,?P]ZTK&[^Q6J;'>0Q-
MG)&.N.W7C'>O,_"/CT"3'VAE#X'48Q]*[*QUU;F18T^=O[V<_P"<U6-]A.TJ
M4>5]>QQ2Q5]$=]=3KXO\+2*H_P!,M%+PL.I &2OT(_6I/V??%DUUXXA_>L;>
MSADG97.<8&!],9J;X.^'IM<UP1LK+"J%Y".@4#)Y]ZO6/PH'P?\ @-\1_'6J
M7.S[-I%R]C IP4&&V;F[DL5X%<N%DZ=VG8BI)RM&.[/@GQ?\4CXO^*7B'6;F
M9G:\U.>Y10?X3(2!^6*?K^O6VI1I=0A;>1QN:('D8ZD>Q].HKR+4?$"Z!X=>
M\ 4R,0A8\[,\9/X]/>CPY\55@.V!%9SCG;G.!G).<G//XG\G@<MCB$ZE:5E^
M/_ /KI8B*2B^Q[3X3U6WG*X9B_!R0?TKZ<^"3_8/#5O+J#1I%<Y-O!(/F=1Q
MO;T![#O]*^6/@SIK>++V%F>2W;?ND&3L"YS@=@<?A7N>H^*=ER;F1V"H B '
M 10,  5XN)C&$G&#OV_S^XTIR;CH]#W.;XD6.AZ-O@F4,<HD42@J,#NO4 #N
M*X*Y^*<FH:T(Q:O-)*X55 .23P .,Y)[>M>+:)XPU#Q)XQ:WLEN959GE?RL_
M=!P"QZ!?4DXKV7PKJ=E\&? 7B_XE>(=#OO%0\ V5K?1Z#IQWS2M<SK"DLG3"
M(KF0C(RHR<#FO3PN2T%@IXW%3:T;5M=NK^9PO$1G6A@:3BZM22C"+:3E)Z):
M[*^[>B]#M_#?A/5O$TTTS64DBV2;Y8H6R /]J3&P9]B2?0<D<SXR_:$_L:)M
M-MK2VL[J"4@RS%IA;*.RCC<3UZXST.*]O^$?[4,WQ_\ V5U\3:KX?MO"=Q+>
M/8Q6=M<"2"X 0,C Y.QE!V.A)VE>"017R1\1_#%QKGCN[:V>.!F/^D$N73>>
M@3:,8QV%>[D.!P.(HQQ%.%UNF[W_ $_*WJ?E?'N*XBRO'U<KQ$^6<+QG&%N5
M>C3>OG>^^VJ/2O"O[=*Z/H__ !/;^VN;M_WDC-8P0&1E& [;5)=L8 +$G'H*
MH?$?_@H3(WAN&>SL_MMU=93RUCC!3'JV!C/Z#I7CVM?!/7+W39+RWCMKJ"$X
M=R2I0^I!&0/?I7E_B>SUCPA.TBV'[Q<X?@QHWJ3TP/?%?11RW"_R+[D?F=;.
MLVCI.I/UN_SN?1OP^^+_ (M^)>F:UIOBN>XT?1_$]BUB#IM\;;4+96=6#Q?*
M6S\N"6P""0*]^U;Q=-X/\,^,M)\2>';S2=-\#V%C8Z)KUWJ8N9/%, 7:S%<9
M+*!DMDGL>>*^'OV<K/4=?\9P76KW2AI,R(XD+&3 R3C)P!SSW/3UKVC]I3PC
MJ'Q=6+^Q4N(+ZXT?=9VR*4-V('.8U+$ M(K$ YQG&3CFOG<\R2G*?UO#JTXK
M9+XDEI'RZ[6NS]#X#X[K4*#RC,7S4)S5I-N]*4G&]16:YFTE%J=THMM*Z3/!
M?B3^T+XD?Q-JEUX?UBYT;2V0Q.D01C=KG(#!PR[01W!/ISQ7GOA3]KCX@_#+
MXE#Q9:>)]2:==JW5M+*\MOJD*D?Z-*A.WR2., #'48->=6/Q9F\6Z]/936;Z
M:+:=HFLW!$L+J=K"3/.\8P00,= !7=W?PUCD\/K<72I$+C_5Y(#'WQ7YO''*
MA/GFK2?9*]NUS^Q:.2X/$8)0T:DE?K?;Y?<?H?\ L>_M0?"/]K.\G7PWIEYH
M/B>STR5;WPYJD@G$2RD+)):%?FFA!;YAG>@((& :3X]?M'>&_P!@^7P[X1A\
M,7OCS7?B5')?V 5GCM+>&&X2$1R31YVD%LECD [#CGC\S]"^'NH:7X@BU'0[
MVXT_4-,<317EK*T<MLP( 974@C![@^U>T7?[=_Q@TJP6S\7S^&?B9IUNPGLX
MO$VBP7;Z=,2"7A=51@S!<,"2K<$@U]-*6(QN'Y,*^6;V?]7_ "9^?X7@O+\!
MG$<16I^WP\?BIMM/Y--7MOK)>K/UZ^$GB"Y\/>#K?4=/TMI])U33H-0ETN\7
M%Y9QS(&V,V-KE<D'!)Q@]"*Y?XA>(&^(%Y!H]CHS6=H4PH9RLEV^0J0!\$J"
M<98@XQ@=L?#OCK]OBQUWPUXCU2^U_4(_%D$-Y;1Z9YY2^TRXEMU2)[-HL*L$
M;;1@GY5+@ G!'S-_PWO\<M0T9=*D^)/C2'03&8I+=-0,DKHR!'#3E?-8-@D
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M/'09Q7NWQ'^*=SXO\207$TZ?\3*#[7#'%+N41L21(0,X4L#R<@D\$UYW\0O
M-GXIT:9FW397YVP0<D'D#K]!T]Z^GRG(L7D^.C5Q%-IK6S5O+^FCKIXC!\0Y
M!.G2Q$9QJK>#4TG?F:=G9[M-/OZ'SC\>;WPKHNGZ58Z4]A<7VGP,SSZ?OC\U
M7VL#+N4 NK!P0O9@<Y!%<=X9U^'QSJMII*Z9#=7%ZQCC,89I3@$DX7); !)
M&>*]$\?_ +/6H:3>6\<LUK/:ME(23\VT@D8/&,].3G-2_L^:1<>"-;U0^3I5
MFNHV3>'VNKR!6@CANGQ."^1ABH.TG)!'3&2/H*?#='/<V4Z\N1MIOI=*U_>O
MV5K^FBZ>5FO$F(X.X1J0R^#K>RC+E5VY*4F[6C9Z*33<5;2^KLK^H?\ !*K2
MK?X=?&KXH^%]6T/4+'Q'XG\/6D>CV=\B6EQ+<178F"1"<#)>,,0X!(57(Y(K
MZ0^+_P $XK^]_M*>=],>>3=//*0+<$@EE\PG /*@#&#@DD' /Q+^V5XML5\
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M:C44VKJ44]4TVG>VUVFE??=;,](_:;\,1^#?']UIL=O8PVL\"W5HUQR'C?)
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M?"3"&:99GC5\%MKD;SU&><'!Z9KU_P 7>&+?4_!&K-(J27A3RH(0-SRR$@*
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MC8I&/+9LH"6)(QQ[^E2ISEK=EU/9KX2U;_"GP=I<>V/2;=&.#F-R#^')KH_
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MOX:O?%@\ Z>WC9?$S6ADEUD(!HT%U]FBG$2KMRT9$J LC$@D$C!K $5 NK_
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MEN?-\2<21RK#VY>:3^'IM:^NNFJL8NEZ^/A1\.XK675H;K4-2?SI+2V3(3H
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M!E"%VP5*G+)D*P(7 .=P&<' YA^._P ,-<O+V]U:>TCT]9V-S!:J6FE$+8P
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MU[+ \W^C0E@SR2D!G Y.T8!/Y8]ZX?2?'%CI:G[/%&CHRJ[-)YLB;N0S$X
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M 4@$GKU!SFKG@R_\+Z/\-4\)7-O?PZ/93BYM%>[,AMY\C>D1;#",DL>3CDX
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M3;F+4+88MICB7;TC8]#]#7(?\)W<:B([56<PP'.-QV(>Y S@$CJ<5W6A6_\
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M F/VD?@MW PIY)%?$XK%*E3Y%MVZ?=L?>8;#\U3VKWZ/]>_]6W9C_'#]H/\
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M.ZO;?96-%\"6+?V+X)\*:3\.;+X4WJ70\5Z*^G[I=1#!=BQ(I"?,P_>/("V
MN,GI%_P5NFTT_P#!++XFV*V%N]GI&F6DEA;B,;+)XKF!8GC'12@X!'0<5SVI
M:K)X6U""^MT5?L[ALH0.??N<BO4OB/X"TW]HWX(^)_ NMR2)I7B_2Y=/EECP
M7@$B_+(HZ$HVU@#P2M<&(PLL/)6=TSZ&LG*I&4]XM/\ &]_4_,'_ ((*_P#!
M/K3?VSOC!XF\7>-M%L-4\">%;62SLUO)-T,FLL8GA#Q*P9ECC+.0WR-D YY
MXO\ X*&_\$N_'W_!+S3/#'B_7/&NF>)H_%.KW%L]QIMJ]JEC/@RI]XX(<;\
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MM[>>&Y4AD:,,O3'(QC':O#?BC^Q-;ZKX6N]-TVXN(+*< M;I*?+?&,97/;
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M#U[7;70FE+S:>[ML0^XZ%>W(_*O%? 6E+JGCBWL[RXL+6&^E6/S[V4QQP!W
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M'>'O?@>O?LA_%GX,_M):8WB+09=%T7Q.]LHG6Z"F9$7_ )YNV-R*3C'!4X!
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M"D22SO?6PECDLKD*2C*5(#JY?# 9*G# <$CZQN_ 7V"YT^1D8-+; $,/X0S
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MP='==MT?$/B[]G'Q!XI\3M]H2YT72[K5K:WF:)6QJ-B)"PWHSA5D4OY9R-I
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M"#R3].E>S?'SX'?#/0?AYK-Q\0O#/]LVBVABLUEE,:V:*@+2PX(Q*TCDAB,
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MK7SC\/+IKK38]SK.$78%+@=>F!W.*^DR^M2<YUDE?OV5DSV,KFG2YN]V>L>
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M@<8)YQ7SWXR_9;\5Q? K4Y]>\3_\(QX;O!%;C3XG^V1:JL0*VKSW$;$R!,\
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M:LK)>ZK;I<K5TM&?:WQ#^$NJ3^'/"NL:M'I=CK^K:6DVL+;1?9DGF#,%G$)
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M<<U\K7'CR^\8XN9=/N3IHE/,*!5P.I"]\>I)YZFM7XI76J>*?"Z133PR7\<
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MD;L D#FL/PK^QUXLT?Q1I-WK&GW.F2+"9-RWICN=.@VL0#!&2Y+.(MQ(PJ9
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M*ZKJBLEPJN0)(P#@'N,$Y!'((!!KB?B=\2-6\2^-Q<S31RS:D1%$[$NR*J!
M,DDG"J,9/7)ZDUQNO^.I+/7OL-LCB!055ARHSV)]?:JGABY&J?$2W\QE!MV
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MI.F]6'0X;)9"?KCMS7O\GB/PKXZT*.X\/Q3Z9=286>&*X\I8B3][&"" .<@
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M 96'1@01P0037)Z]K^GZ=X=TK1-'M6L-%T2%H;6.9Q+-(S'+R2, H+,0.@
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ML<6%0*,<]SCVIGB+6+31$:WE210@PV>5/N#VKL/$ETVE:4)85Q@'<I)&\9/
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M^SHO5ZM_I]Y[%X1O+>TL9HY)%AMT!^=L9./\:XGQMX>\"^-O$_A_7O$GA_\
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M+:*BU=)I6C%=EW?Y>9Y1X8_9Z729)-8UN5]5\0ZD?-N[R<!I)&/8#HJCH%&
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M)-1M!IL+9YS*RQD#WP[5BU[R5C*I)U/=O_3?]6/S%/B.:]DDO)2S37LC3/\
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M=B1DENYR1D]LC.!7>ZGK&N^!?!5W?>']&_X2#684W6>GO<K;+<2$@8:1LA0
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MEW(0&4$A%)P./:O:/@P=+\)P:=:_VG"VORW$]M>::L9CALQ&AP2[DD@G)R0
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M77534X/++':1%,K!21@YXQZ9K4T3QW\7/VMM9308_$WB#4[.Z!1=,M9TL-.
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M.Q_<Y)13P6?>>5&>?_;A^+GCKQ?XJNM0C\.:C%LG\R%[R9401 $@J=Q!(QG
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M+&""HV@G.TD\GCQ+X@>/[S6;]XO-D7!X'^!KWCQEH-CXMUVZA4S:7J5NQCG
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MMMKFE)6A:,G+P/\ 93_9DL/"J>(KVSCD6.YEEQ>384_8]P,2!>Q(4DC/)89
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MXPRG!!R"*P_V9OAKXJ^(7PGN--'A?Q/<:2H:ULKJ+2KF^BN\*2D2M&K$,,;
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M=9(;#.=S+@E<\ =LG\A7J9?FE;"^Y#6+Z?UL>?6Q=EJ=/HUHNNZBOV)/-?:
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ML?IU-?FEX]\7^(_VN-)NO"NF6=YJ-U%+%=QM#(%-@Z./)N"[$(H5RH^8@$L
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MU:^75/ ?BZ;2-!E:W;6%TF>.T=%X$F[:0%.1UX!SS7'+%*IB)0C\2M<^FRW
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M5FD]UY23_%._8]@U/[-\7/!\LU];WDUQH%L;2WCGN//,\@=B\H;Y5)8D$JH
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MBU\4>&KR/[)<VUYIJ117"G*L'3<P.]=N5)P,9SD\>?\ [;/_  3NT#X]^*]
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M%*:C'&UO=.2DN  ,D] ,#@'/3I7N_C.VM]"_9ZTRUA29=7\6W<DT\V,*+*V
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M7;D8)& <$5X3:ZSJOP[UO4+6\MXX(]0 ='BQMW*< KMZ9#$X_&O4X@S# 8S
M4<OP=!1E124IIWYG9)M--W3Y8O6[6J5K:^SX=9=F>79MB\USC'2J4L3?EI-6
M=-7<E%II6:<Y)J-DW:3O?3[+_;4\/6_@8I)I<L<FGZQ M[&5Y01L20/0X*].
ME?'_ (5\?3_"[QU%*PVRR'SG.,^4I&1@5['X>^-<^J?#:UM=8EM[NWCM19P_
M:83(L:%R1M8996'S8(&">O%:?PP\*_#6[^TR76C7-SO<,T^H,2;@9!(5@"%X
MXY ![5YN73=*NI3:Y7IJ]%>US['/,T^L48J*<IP3NTM96O;IO;UUN:/PIU"'
MXC^(;1[/4V2W?,TI<#S,<9VKD @G(!' YZUZ-^TCX;UO2_"NAW7A'6)8]7.I
MP&*Z1O*GT\+*BB4%23(BHY#@\CY6"\$58F_9ITV_UVU\4:38QZ7)N;8EH3'!
M<J264CDJ 0V !C)!R3FO)M>\;ZWXO^+$FCW$=UIUGI<J">,[G@T]#@/*3T /
M7GDYQFOMJ/$4<KQ\*M&U3E3_ !35KVNM];?B?EN>\/RXLR26$KMT>=I;W:Y9
M)WLFD]M+^ME<]\_9OTJ7X?>&;?1O^$KOKC5+6]G?5R+:)(#*) PP[[G<LC %
ML %0I&3S7O?B+X0>&OC1\+O&NEZU80Z?9^)+%'O;^R@1+L^408IF?'S&-E7;
MN)XR!Q7A^A>'/#>H:[I'ASP;IZWMWJ\J->7H)-Q<[0%&0.%R  ..!SP!7=?M
MW?M&0_LP_ "XT72FAEUS5)X[*XEZL[!"<(/[JXP!CDC)YKY?/,VJ9OCYXZ:4
M6[7276R5K[O;=OY*]CT^$^#:.1971RBE)R:;U;VBI.3E;:.CO9+?36UU\Y>/
MO^">/P7\*>"-0;Q7\2O&EREC UQ-/;Q00QV"#!+LBH[.1D#!/?@#BN-U3_@G
M;X-\6?"N+6/A9XGL/&\C/@7=U(VF:SI\R8XC=6$98?Q13(A/4,#BN>_9>_:8
M\5>,?$VN>&]&T=_$FIZDB:I*&OGLS'%;;C(9Y0"#: /F2-@ ^% .< \1;0^,
M?V*/B5J\>N1W$,NJ1V\5U]FE$EO<RKDF<.I92Q' .02,D@<5PQP>+5.6(E3_
M ':LN9;7ZKR:\^_I?V99I@HXQ8*.(_>O7D=K\NEGW:?EIHUKK;] OV+?CS\0
MO@=\&=0TKXT^(M+M6 2R\-:O>MF:>0JRA9RI8%$)B^8G!WXW$UZ;\ M4\=6W
MP/A;XAVEUXB\96]W);7$-B+:&YN[=[PQQRD%EBVI"1(X!R5' SG'R#\%OVF[
M?5Y+'^T[:VU;1=0N$0V]W"+B"5U&\$H<D$%<D@8R 37U?J5Q\8[I_A_'\,KR
MQOO"=P9;GQ+J&II#=7PNFNF?RI@Y4"U$+* 5&0 0/F SC.J_8>TBF^FFKO\
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MC[:*O%[7?_#'I7P1_98U#^T()-2NO+C3&(E'^L'7DU[U\2_&L?@_0@OG+M@
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MI*\7=,\Q_9W_ &K[5/ ]U\+M=UB:;31'_:?@S5GF+&)0 PM0_!PI.^,YR 6
MZ 54^(?QPUOQK;Q:?XH2QUV&V("QZE;*T@ /(6=-K@GIDD_C7AGQL\#0:G:Q
MQV2QV'V *+80#RQ;[>%V@=,8 &.E<WHG[1FM>#K9;/Q);M=PH-JWRINR!TW
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M]QFNRT?P[)KZ")@G'J@+#Z_6OFJE3V4W3GNG;T:/+NN>\?\ @/U/4;C0=/\
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MK5M-T:&YM_M,6J6Z9Y3R!,=@9.@*Y.<C/?)S7JX[+X3@U-:?E;JC\\P6-Q6
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M_(^!\KK8N&;3@G7A'D<^MEHW965]KNU[)*]D?2[^ M$^'MQK=KK7P\\9>"M
M\ ZS;VFFZIILQU&[UR"9Q&9Q&04VLI$A*]!U /%>D_%/XW7GP)N[.SB2'3M1
M\^57T^'43?,+0+&8)Y&_A=]S_+QD*#M4'!^?_P!GGQ'XG^)/Q-\7>/K?Q#)X
M3TXDS7-Y>ZB;:UL+=F"Q([$E<\*  "20<5T?C+PDWA;Q/+_:FW4)[M5NQ>I,
M+B*\64%DE63)#AQD@Y[$=17BY3E>(A55'VCDTK\JWU[OLKFG$&?0Q%%O#87E
MC=1]HW)Q?*HJT4W9.5G*2;>DDE:UWZ?;_MMWGCZ%M+;2=2U&1ERZV43O(B]R
M0H) ]ZX_5/%4U[>WTFAZMB:ZA:SO=-U>W6:"XC)&8I8Y%*D94'##@@'@UI:%
M=Z!XQ^"U[X/L]=U[P)?7P62YOM*T])9;N=;F.6*4SAUF39$KQ>4#L;>6/-7-
M<^%2?$SX]W&HLNJS:>UHTQCC*_;M1%M;< '&WSI2GH1EJ[*V(Q%*K.EB*;C!
M*_O6:EWT/$E&A3PU&O1J1=:4FG&*E%PM;EES:1NWVO:V_;F];^)&O>"?B%/H
MVN)INMPZY8(VI6MW;K)9ZHL@!(90 ,*0H&W&-H P!BNR\)?$5O#YW7.BPV]H
MHMXK6+2XHH(8+6,N6L61D?\ T>4ON?:0Y*CGTR;?PO'\:OA%X;\61>#]>\%Z
MDTUQ9KI&J2^=<)'%@K*"P# $DJ01C(.#BNPT/QKX#'Q%A^$-QXFMW^)<-OYL
M^FI:.;:"0Q^:(&F4\3%#D<%2>,UPU*^#K05::2YM.SWV.^MD^?8?%5,%1C*;
MHWG.*M.,>56E)I<T797][7J:GPGBM[>W3[J*,?3&.E;/B/6(UN=RNP3U)X/-
M4] O=-\/:9-@[V W+NQT(X!/3([@XKSSQ]\3C=WBVMK;OYW/7[J <DD_3@>]
M=E+"5*U7DI:MGS4,4DK1-KQ#\2M#M(M8T?58+C4M-\1:;-I&H6UO,T,SPS+M
M;:Z@E&'7-<7I&L^'_"G@?0/"/A6PFT;P[X;A>.SM[B<S7!:1]SO(Y !9CR
M !6=HPM;BX>1SN*L09'.=[$YSG )/;H?YUS7B/19%U$"U1PS.<%<G //7 Z@
M\_A7TV(X5P]*B\2Y-SBM^GHD;U<QQ4<(\&IOV;DI./1R2:3MW2;/3-'\>MIU
MR%4K(PZ9_+CZCK7H6BOH_P 3]&N+2-+=+PH3)9M_JKCW7^ZP[ =.WI7B/ACP
MQ/>6^T;S+T);C\?P[UUO@OP7?:9KD4T<ZQ,&WDAL$ <DGL ,<DD#%?.TZC@_
MZU//C>LE2G\NZ(M3^ T?VN3[!<X@W8:&7[T9[J?<?K5[0OA5;V%Y"LZQRK&0
MW(!Y'2L>?XA+XA\;:A>:AJ#6\$LA$;VK[&8 X&X'(/'(..:[KP99:#JH;R?%
M%_;[S_RWBBP3Z ^OX5T2MO%K[T56R?$4M7%V]'^ESHM/TJ;[*OER($Z#=167
MJ_AD6MX4BU34+I,#$BS(H/X45G[_ /31FL/+M^#_ ,CZ$N]1$URCF94QPJ9P
M$ Z<>WI7+_$?2K7Q)ITEK)LEBE7;(K'OZCT([4175K:-').SLSL$4D_?9CA0
M.W)-8?CK4;CP_#),\+BU48:0,' R<=!R1GTZ=2!7FX/+<773K48.26[7?]?D
M?25GS[;?H>#^-_!EU\.M=!MV:>SD/RR'^ ^C'''L>]>J?!MH?$J6\<DFRX"%
M27SLD Y SV/7':LS0-4A\17LT<QCN+>9MO4%<>A!]1VKL?#_ (,M_!\WF6#?
MNVR<%LE1Z?@:JI*27+-:]3RZ<'&IR1=DR]XH\'3Z9"7B#1D,,#KD'WZ?C7&:
MYX[N+)6T^X3CE2K\!P1C\>*]1T3QG;V\_DW15D !)/*IVS],]1VZCCISOQ:^
M'UMX@U-+F*W7RD&YPO49[@>E9TXQC+F1G6IU:<[3_P" <CX:\3VNB7-M9^:M
MQLPZR9 ' . S=<C'3'/X5Z#X?\)R>*]7\Y8H]J1*@*#<3@$Y)QSDG\.GUP/
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M!@>HKX$^.O\ P5VOOVC+:\\/_#>^M]1OUGMX[:2'S=/A56DQ-*^YBTBHG)Y
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M&]FP29ESQ$3R2.X'?T&?4YU?%7P0M+Z]N+B-FELXK07T2)@L\1(R%/\ %M#
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M=T_2=-O?$%TU[JL]E:QPO=S,/GEE*@;G(&-QR3W-,U35[73=*+-,BHBY)9@
M !U)KP/P1XSNIO$LUU.))))8R58Y.22"?TKJ+GQ1;>(-.FCN;NWC$1#LLK;1
M)M.=G0\GMGC.,T2E[:K&FWRQNM>R[G)3BH[OU?\ 7X'/_$?XD6>O7%VEC.BQ
M644EQ<7,C"*"TBC4L\KRMA550"2<\5XU\1_$-_?ZE$+BUMS:W&-2CFL(8?L]
MZ;E%<W(>( 2-*H0F0Y)P,GBNYUCXIVLVIW#6T<=J1N@=+A0T9#@@Q[>5D4@L
M#D$$$YJQX=\*ZO\ %K5"\,*7,<(2)611'$FT87 4!5 4 !1C    KZA<-X*E
M)5IU$X6WNKW[WVM;UU/:C*DJ#BI--O77W;=-.]^M_D'PGTMM/GL]9N=$6WNK
MC3ET:/5F28--:+.9Q",MY9Q(2<A0Q P3@5YS\$?V;?A[\:/B'J/Q=\5>$+SP
MG\1[+5[^6Q\-WVHEH+@1O&@UI;9U#F1OE4NN8MZY ) :OIJS_9SOHKO4=45'
M&I:U!907W^G32V^VU0I$8H6.R(D,2Y4?,>>.<U/&/@?3_#FGPZI/I]A)KJ12
MV$=\;=?M45N2&:(28W"-F 8J#@D XS7R$.6+E9*UW\_/IJ]SI6,YI*-*K*?N
MQC=NS22U@ES/W4[Q6UTKI1;L>>MX!L?%3W-U=1)<&-MJ*XR,D9)(Z$_6N2^-
MO[//@+XI?\(CJ7C!M2L;KP*LMM9BU@6XM[NWDE$S1F%F51(2& <AAM8@@D C
MM/!FM/! 0V[RWG8$'Z  U7\4O'_PEP:^$BVT"H5902 IR"Q' ()ZC.>!SCBM
M<+E/]HXE8>3]W?[B<HS+%9=B8XK!SY)J]FK=59[W6Q\>_M66#?%;XIZW?3:.
M\=O>.HLPPSLA1%1%)ZE@JC)]>>E?..J?"K4=(U1QIM]=6;+R(RY*\_CTK]!O
MC%H]CJ5BD=N\(NHOWB!?N."#G+'&2 .0  #7S;KWP^O-;OWO%3;@D!6.#MSQ
MV[U]-F>5X?!TE%/79+R/+Q4G3GSQD[O4\O\ AQ\4OB%\(];CN([R^DCX5WMW
MV.5]#MVDC\:]4UK]KJ\\(_"F&'P?X8N!?6(D8O+(XD+.26(8DL!DDD@Y/ X
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M4\"W=O9S:QIYO+A@D<,+>?*['@#"Y"Y/<G@5Y5:-2M*^K_KN=TJDH1LM/4]
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M2:)HU])?SW$\,4$L\A0HA58PJJD:D@$9)&,G@"OD7QA\-/$W@NX::&22XA?
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MZ2[CK)*8SYERW;)(  ..237P[^USXY\3^-_C;KVJZQK5]J=WJ;>9-,\I.?,
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MOB._N=#>[UJ9;)88X8P6FE; 2)1U)/88_$US_P 5O$5OIVDMI]I<;K>7!FF
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M1XG\>_AC\4O&'AQ6\4:@MKI>EW)CM+>T0*KAU!>4O@%MV<$GG[V<Y-<3X?\
MAFOA&*%K>WV%<$MW)]<]37WM\7M.7Q3^SW92;,F$&//TY%?,.H:5M01^7QQ@
M?A5THQA%*"W2.G&5I3::TLVK=.COZV:.H^"_QGCT^*WM+QFCE@<213 _-&XX
M)!]QP0>#7NVF^,=*\3HLE_;I</P?/MS\S_[R]1^HKY!OO#LMI)YD>Y"#G(J7
M3_B'JWAM_P!W.YV=L_RJ)1[%RQU'$*V*5I=U^I]=WWB;3HM51(9DBBQRLB%3
M_*M0>-=*T2Q:2.\C><CA8SG'X5\M>'?VN+BRG2'4(VD7."W!(^H-=OXS^*AF
M\'/KEC#]M@B0;HX8P)$SQD_[([GG%:4:*JR5.4E'S:T_ B6$HJ//3E=>6_W.
MQUGBWXHP":5KAO-E(_<V^<Y(Z&0]@/0<FO$OB+\1=0\;:I-#;O\ :;J0"-IN
M L:CC"#H /05%XYMM1_MQ8VW0QWEM%,NS/(90Q /U-2>'?A_>V,XFCB8H5!)
M S@'O7-4IJ,G<[I9C2PU)0PZ]YK5^JZ''VWP!BNIC=:A/L9OO$M3=:^%VAZ7
M8,T5\P<#C:U>@:M9QS6\AFFFCDA)!7&0",Y!XP00"<$Y[>]<A>:?;ZG/N>=#
MA2Y0L =H& 5& ,$#H>G<G-?5X7ARI5IQJU)6NM$CRO9M^\>;/I>N:86;2K^X
M*@\88DU>\._$KQAH%VD=Q/+*HZHX/(KOM+T"2&[66.)A"7R0!G*]L'KBIOB-
MI=LIBN(PBG@'_P"O7D8RA"C6=%-2M_5O4'B,1#6-1_>SN/AM#9_&;X?:I8SV
MR0WKPF2-PH!=@,X/<^U9/PIT:ZGTG[';*QGC<QLF.2P./Z4? K4VTR\D:W#"
M0%6^HS@_7K7I'@2PC\-?$6XE:)4@OHS,@.0 Q/S#UZUP-W?*7B93JT56;UZF
MI\-9I=!5H;B-T8D'!&*]#U+Q<UK;P6=K(L,MP"2X/S!0<<?4\$]JY/4_%5OJ
M<KB*!$;>6!/J21C_ #^%4-9\231:E9LBKMP0Y&,@$8)![' _6N_+:4)8F"JK
M2_\ 7XGEQGW-Z[GNM-431RO*NW>VY]X?'/\ G%3:=X^B\._#7QMXF=?*BT72
MI7+$XP=C$#V.0!6)?ZY)?W/E0KO)(&=N9#D9.1T'<?\ Z^<C]JG2+SPQ^P9X
MLMT'V>\\27,5G&K_ "L5:121[95&'TKZ#.J-*$8U(V4O+M;]/U,:L>:<4NK1
M\#ZYIWA[QV'FN1=&:?#.[73]>W&<<>F*C\'_  _M?#,EY]AFD,,\>=C8;=CD
M8;VKD9M+NM(9H9(Y(W7@JV1_^L>]=O\ "%_-OHXY?N/\IR#WXKYBIB*C@TWH
M?387ZKSVY6GTUZGK/A#Q3)_8\47S?ND&1W'&,UVFA:NUBT-XTZMCY'&2/D/<
MG.>#S7,^"/AC<36S7'F[!)F)5(]#W-:T^DW'AH-'>VLQVYV,BDAQZ5AAZ\\-
M6C6IK5/^E\T&(J3C*Z.OA\5V7BF9;6ZDA8S$L0^"LA R0/7D=L'FMW3O#]QI
MDD4MO^ZA(V[$)P6')([#KTSTQ7(_"7X67'Q%U02K:3(L;Y3:"C>F?KBOK?X6
M_LMJ=%_TB5()G&=I4L1Z9.>/>O=S+B2C6PTJ#IMS:\K+SO\ \ J6,CR_O#SC
MPSH5]>Z<@978/Z\G\O;TKT2+PC8^%_@SJNM7T;"X\LFS3)1S* 2N".1R*]"T
MWX.#PS=V\)D2224!<#[HSW ^E>&_MS>+M0\5:]9^!_#-PMO'!'B>13@#CDD]
MJ^2P\HS;<]EO_D:?6FHJE1UYORZG+_"SX\W/B.UAL]?.GV^HL>4QO&WKEB.A
M]C7MGA_QQH5E:!;[6-/C_NB.4D@?3%?!_BGX)>+?A].9FBN&B3DS0.9 ?<D<
MC\15>PUFZV#S)W![Y)_4UTRJ)J\+'%6]G:TD[_)?H?>&M?M#>&=.WQQ^)I O
M3"*$8^H+')Q7#^(OVD-'LK*9=%NY(Y9?OSO,6<Y]#7R>X;4&R=S9[@G'YT76
ME+,!&QD!SD8)X([@UGS>E_G^K%A\53IRMK;M=*_K:*N?0'@_26LM?FU>WD:?
M[8AS(.=^2#G\^U= +Z:VD6Z9L^8V'4\<?2O-O@!XOF\-79L[B1KFSE &&_Y9
M^IQVKW>Z\)VEU8"Z@VRP2#<?5,US3HVE='1B=/?CLSF8K-?M!FM4CN$9O-=6
M*KL!()!)(&/<<^QQ6+XM^)-Q8:LT:P.$$W7*A0H.  ,<D#@G\NM,\1:=>Z/<
MR-9RL86SE<9'/'%0>&_A]JGCW4TW+M3(+NPZ^OYU]'A.),5AZ7)"SZ7:U_/]
M#FCB)Q6C)U\17'BZ-56W2-%YVH"26[G=VZXQCI6AI/ACS)QYFY9/3'\AWKV_
MX;_!?2?"=BLUPJ7=V0,;E^1/H.Y]2:[Z#PKHK6#7$MK:^9&-Q;RP,>_X5X^-
MQU7&U?:UWKMV)E57Q25SR/X1:+)::_:MY;X5P&R,=>XKYW\7:A<?![XY>(=4
MUJ:.:UUZYD_XED+;Y1&'^5V;H"0,X'8U]#_&GXWP_#31;O4;6&,Z@X,-C&P^
M4,01O/L!S7R-8V5UXUUJ;5-1E>YN)6+,\G=CVQV ]!2PD>2$GWT^1O6E*DTI
M+Y?U_7XGTA\.?B[X;U".*ZL;;9'& /+8EBGL1U'Y5U37O@WQ9=,SI8I))]X&
M0KS^-?)%S:7/AC4O.A9T7.?E) 'M["NG\-_%FZA0&Z@2X1>0&Y/TSU%:--;*
MYBZ.'JOXG%GTE;_#OPFESMMX['>Q^ZS[@,]<<XYKUSX>:?I.@:3##9_9UB0#
MY5( 'K^M?(>C_'S3[*/]WIS[B!@;C][W'<5U'ACX]7&N026]M9065Q("L<S*
MWR-V)&<&LI0N[R_K\":V 7+RJ:^]?YGV WB*TM+<NSH  3@&O*?BBL/B/3%;
MS%56F._;_P LU8@ U\J^(?V@OB=;>+Y=#E>V//RS+%@;?7\JD;XD7VD7T$^J
M:OJ%\\3!GBA8+&?4$=Q5?%*^RM8Z*&52PJ4IO5V:U/<)O@ZVCVLQM[K[1A_-
MC!7!![@'/(-<KXZ\7V=QH#V-]9/'/!G9)R&#C(!!Q@  ].14/@[]HJ2>'R;.
M[MI5S\L-RO[Q!Z8R,CZ&MS7?&&E^*+=?[6TK+8_UEN_(_!L''MDTZ<G3DIP;
MC)')6HUT_>U7='SO=WLNDWLL:1M<)(2WSDL23U(/J>]:6A?"/4O'F9+'2YGP
M<ML7(!ZY)Z5[!IWA[PJ)E:U:-V9ON7"%<?C@C]:]B\ 6EE#8J(3;%0!@1L,<
M^U+%XBI4ES3DY/N]3*7>1X;X6_8@T?7OVHH_C'=?VQ'XB989I](N07MQ=0Q1
M1HT,GF[8H\PJQ C+<L,X/%CXA_ 2QTC1=4EU&YM9YW26YN/*SY<"\EB3TP,X
M  KV;QOXY;P^76%HXQ@*,<N6/0 >M?/OQV^(,FL:3=^'H)HV-ZH;4)%8[@ >
M(0>_JWOQ7#A\-"C?E6KW/IIYECLR=%8RIS1I148Z)6BMEHE?U=V^^A\7^&_@
M3X)^(^F:;>>(-9NO#2^?=V5MJ*V?VI'6!\X9,Y^[)&,@$@E>" 2,3P1X?DA\
M;:UH_A?4M2\9>'=/B:\CGNV%E:1E5$8FD,Q58PI(7<3D@X'."/6;J;5O"?@]
MO#L7AK1];L;?59-5LI;H.&M))$1)!A2 ZL(XR58D @\$$UCS?$;Q]?VNI:;J
MFG>&]0T/6(A%>:7?6@:SG <.I,:E0"K("#U&.*TP-;'X2I-X?:2V;T>SUL^Z
M];'14EE>)KPJ8ZUHO?EO)+9V\W%O1M*_WGF?Q)\(_$;2K'^P[SPMK6D[=L-P
M\ML#!/NP^]9-Q0HP*_O V"!UP3CJ?!/P6U#Q&==UW5$U+XG7/A2S@DCT;0-2
M,K7L\T@C*%L;42)5!?RP<^I-7_&7A/Q5\8/$CZEKVKM))*$B2"% L-O&@"I&
MBDG"J  !S^==5\/_ -G&/3Y!.U[?6Y'5XIC&Y!Y(#+@@?0BNK'RS#%T94Y5.
M522NDWRZ.^W>]]=]7W,J6,R6ABX8R5+VLXN^JY;IVNN9-2M)*SM;H]TCW/XS
MV/\ PC'[/>G?#/P_&T-OK"VNJW^FO()9]#8J9'MYF7CS/,<<$ @1#CFN(\)^
M$%\.0!,*SC )QZ5ZQ\#O#VC^'?#T]NRY:Y)5G=MS;CT))R3SWJKJ_A?'B![9
MHV5%).['&![UPY1@E@:3I1=VVVWYGF9JU5M5@K)Z_P!;[;',_P!JS>'O#T\L
M<2^9=2"&/D @ 9/&,$?K]:TO G@O6O%\PN(TN)(87#ETR/*8'(P>Q'MZ5!;V
MC>)/&"VJKB*'[J]L],XKZC^&GA6UT'18(8U411H-P Y=CR2??->]6S;%2AR.
M5EY:'CRJ-:'GBZEK5] UKJ=U'(DSJ\I\I(VN&484RLH#.1T!8DBN0_:G\50^
M!_A(;2W*BYUZ=8!SSY28+'Z$X%>V?%#PU;HT=Y&FQ-PS@'&0>XKY5_:M-]XV
M^*-EI]M$QM=*@5!Q\I9B6;CH,DBO+HTXIZ'=A*NOM9?UV^XXO1[9#8K(RYX]
M/6DF@C3+1C>QSP%SCM72Z%X)O;IX['"!F &YC@>G&2,\UL7?A"VM9I+5A#%)
M$!Y@S_JSC&">22<'IT-?097@88EM3>W1=3&K%59W9Y?+IZW%P59?F8X.:WM'
MTN.1%7.6  ;Z]\5U+^%K.]M3DJ7VY!!&?0<]L8'7K]:YBW6:UOF78VY#AAC]
M?QI9EE[PWPN\7^9RNBXR.?\ %G[/FM:SKKZGX3F6+4)82DL+XV7.T$J,8(+
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M^>U>P_#AO[8\&&P9&>UNHO+<'G# \''J#@UXLVHV<36A6JUKTJLF]-+B>']
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M>"2*^KOV6_A#I?Q>_8MT^3Q%;7UMXA34IXG?3 BK$%F+^:T2;5)V,HY )"@
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M/7')P:6!QS4N1)7>M_\ -];#CCJ[7LZ>_=_UL=7\-OAEI?BC]KO3/BE;>/\
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M)/5K9V\_<YOC#X'\+Z+H3>//%>DZ9/XD"MID$\;274D3.4663;RL996&_!
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MF>"M/UOP;H>N:3;)';66+2YMURWV< =!WP,Y'MQVJEH_B=-#TTV+1(%5< J
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MA79Z]IX\Z)(I0 BROD%#CGGICCGDU9\+^&+71[@*L/F9[CI[<=LUM:=?2>+
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MR7;K3&1S@1R7Z(Y!J& FD&9HPP,*G$=;VUJCZC+NU5B*9^;08_'R#NRWU]<
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M[)NMN':5NV>Z2LWGY1S9G5^\M9)]IU>YRG?W3.(:4/Y29:^8\>1(4O7SOM2
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M"%YPQ=PZ;'C?!^".3%0^!HU?*I])K+7CGMLS-#L2[AV_A50'?=,6,[%EG'$
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M4.LWP$#OXN-0[?3($1'1HR 4!/N$L\K6SMF7K?L&:%UYVN6&_\#K^6+H!76
M"5="DZ]I3D%AU.@+[=LUS111(6=Q^3(G^HE0Q6Z)ZVOX[S= _,6/%PHHI.<&
M<^)$B/.U];6TH >Y4^X-@$;H/_]I+9JM9]OHL.)O;[BLU[@?5JRW3^3-!6%
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MNBGR<[PI15_-'LL%F475T]NFI+=UEDJ<E6G/B?,ML?Z.E:>C+4?.R>Z4$_!
M_R8H<IQJ=LCZMJ[09<1G*]R6"K+J?<MR^R"]P)D.KA:*M99H]']PMY9O3"F2
M?]".(C M+Q#6^[) F,H1#Y[\^-NWID]#*YRM0(%/?B>CT#&!X+F;5::L;-RV
M)#O6Z^M,;+\5)6^SDF,#/?:TO_I+Q4++T-07MGX=&H<'E>M*WKU%>&[/5E3/
M=8Q#F,0]KL03A:K,"YX/7+7V<@3>=_ &^&+->HM%<_G?80_=HTI$P*Y5Q!N
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M&OL,I(P\I.NX(HD^:&UO;EDXK2[^0C#DTK7LXY*%KSQ;&YV%%93UWCL<\PV
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M415I&"-%D'Y'J(_L:,K&P-*C$LJ\DRLS=U;JBNF O-(P.1^]PQ.J2EY)W9N
MJ\RK9@-![2II&8(OVX2I-KL.MF3(0F>8L88TF)D T8(JU:R<1U'9'B^*:9RB
M'^U<B(;N8VJ-UO*GLD!V_%.#LM(8[C]IN<[EUD/6-+S]DRT<1-WOM;KY>(AY
M2(FM2)3H$SQ1ZN0H[2B1QI#(:H*J[]@Y%8%+L_GM01')Y/<GMO/XZ.A]FDDX
M>V'2GGV42R57Z_<]I9#5@>TNDV4;"QF/F,)G/MO27S*V&$@X:.. BQ"9TGWJ
MN=N7:>D#I?HE3M.;%Z9*ZWM/8SOS;O?%#_;/X>D-DBK?C8(6Z(+*2PPLN\G
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MY5NE&GYH5?"Y(!APPAFR9$]8)J7'#I;<2AB2'"$=*9;R*O[[U]IDO=/.CW]
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M<@8"D]"0<#& !CBO&;G_ (*:?!'P+KJ-;>/+SQ%&L96X^QV,]T\YYP?E0*S
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M(OR-9_ZP9Q5A[2,]/)+_ "/2I>'?#%&?*Z%WYRF__;C-N_VV_C=J48MH]4\
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M98;7#(H=NRE<8([8Q^-,NXK7[7Y*K:H^&3RTMF,H&>,,,A5QT''UIXO;B?\
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M/_RZ6-'CU3>A/X=E]GN0VA(9):]C6Q^+]?]:?OKPF3-VF[P(E)4QW04,;U=
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MXU!!,-#%D0\H3)*U7:5<?<BG A\BVNHMQ#<<])! JDK<XZS7$Y!.*&50Y,Q
ME?PS,J4C[F(Z#D,1SI^-3>GV%$TS[G3*;\FXZ4O-7W;\+$1%_9!K'!..3XPY
MWCBBK<E?2Z<><N:[U]\[^I=>WOV"-$0MUS=*\JZZ-^^0F,SK@G?%T"^\62',
M[C,8\%2%0JWU^!3]+W?-Q9;X2Z@'PK$_+3?J9?U'67X,CXV9GXI(/OOS%8QQ
M&P?K9OLY=HRB$F3?6UOW6>OU@X-$A_UH8/GR77E,WN*H-"$$I&;T[JKB 57\
MS]65"S^$%Y+[?<JX5/-;_GRE7E>58HT><7U\JE=MIO&NI$;@ _NG9:N8%;D*
MD0M[?453HU\V IN_7QF9^:S@]B=QV&T.I"2D+5!W[=B"5SIY\DW\KH5PU>4'
M9,7#UU:^;_LL1X=,W)GH84-$>W9/J3(-7O;DL&+QUTO&N"W(E6):PA]!)A4D
MJ.+FW.6WI:P=_1\[,K];OO\QIIKW+\,P.0FD_<B+>D/7%,ZK<C_._C,5F^R5
MC0*FCX]WI;;T!6LE&C/VQL5.+%L.;(1%A-ZJ!3=2=L9-^GLF: Y.FP08DL6'
MS.4K%P^KGES->-78JLJP*P!C8DDB+S9O)'/#'V*UW0J=HW8P _Y2"'I40.AI
MWH7TR[@83Q:829IJG6RV@(WIY9M/[JDR"2JS-UR:2AN;5V6=:HY]P1)&&VW_
M\Z1/ZJ389HQ5]NV.E^?@GS\,X;M]1RM1BCO%-[]OWZ4A'BP^MW\_5Z+*,UTL
MU<=>=R\*>YUIH*:'3;LQLY 9M2(''&(ON"J;:C#T^;(]0_!M^4=;(W"U>[6?
M?PYA9NA\YRY^I<[P&A8=J><)[1X^^US_38,U2Z!WM;3*Z=U/]G)=XG#WMP^U
MI0S?5A)YR(-GWL7_W&L')K660(F++N+IVK0^5BR_XGF>^Z]2P0*F19<MXH)N
MC"V[HK3HL7<H@B]KE':7QL$7AAU\/WO;?-X:]GLLN9DZ+9%'2(+R9$F^Z'1R
M^QDZ<.L'[5LM<ZA,1;F;E/Z=6 6C[PG*5 E:LBKM[(MCK3!C0JL"A8^&.4\;
M-U9M_K?UU/#2/+4\W7NK[.&F3%LB>2C:H(,&0TGG$ZP?%)7,J#38>-S^X*K6
M5%6R2(AW&FYT2[O7@Q?>T3ET_JIU$HA]LW!R%2HT_+TU2L74@[< /4<5:NE+
MD-KF+1])*E)E3K3O_51S*3J2EH<!-_>&,F?'0F2>!&K7P;/VN*0BH=&, U2?
MH-67U:3^OF'?2I QD,@'KO!2TY4YUF/$V]C<%:S>MG?]IP<6BGG<X-#7A_S\
M00B\\9;V4NLN]!:C^M3 H=W9P8A!N.9'E5V.6#UPTN?@==LXVDOO9=RZ'M]+
M6$>(2Y"/=MR:C32[*$H8[<.@+!C-H>V/B (.U+Q;BQ1XX7Q%LAM>%<G,9Q'C
M4IAA/L83S _"5Z_864$BZ^9F3XBI[^Y;61#]!Z,!Z8[R=%PV_M)8/G+8F]O[
M6L^4&X%)8:%AU#KLF?:5:CFH--6<FL])7]](H1H\?Z>/WL@EYG;OZK5?CZ,>
MRKUUFYX6/R5X[%>NK'_?G@;3H6KQ!&3AYL-B_%Q69F-9RX\GR^]J*\0I8Q84
MXM](6]<F,"EQP\F;P!_*.+-?;*;C4K;]]/""@QMXD^\6TA!"+8%:8D@^YN/%
MEKPO_;K>E]^-2/>,E6P3I;XWJ"!,!\1O?^!H:HY5_$YDK@'=\MOX6CE4KKRT
MA^>@X4^#1[<&EJG\V/7::B*!VE1ZD/HI&">THZC8F=ETV5RBE[_<+X*W]- K
M?B+$!ARY.88N<,4V)AU$0S/BSR@J@\:(E.BAGRDZ^[;!3M;Z[/TI%B$7V[YM
M%!WUK)AI5@&Y8\0^0;[<X?XE=&VX-'. 8G:(A[M"@OT2S*5N'P7_"2>S=R.!
M\K 6BL]8Z!'LX*$/7#5K:$\9Z]G 1(V:][8PKGG=TPOF+I)1#J.&L7SX&=12
M*_O/B7>E$2E]G*=S9]6N6#[*#ED&=E/3Q=N./+<4,V65FY*RY3S?:/=4B:<L
M"V'Y&H)1%7DRKA\4N+:#S)<ARSH"DP</I=_UXDL[4,?/?A]U'09AI"Y%]4W(
MJ1.^07WIV7?,Z"L$RNEQK24ORQ:W_?Y87*\.YQO)4L>K!FDKUVH!/ME/><DK
MI2MA)9?OV-]]G?G$H*'!XI>@EDDA%/CR.K:K],G:;( T6B&=L7)WM74J/_4W
M[M3APIEA.M9\8>K-(;O%@O>0R;[X ,)^</2XFT=WI*HBN-S <37EE&5QG]+]
MFK[>UF\2Z&<^-PG4P)@E0&@A@>QN],1)5;0Q;7&:NAWP<S>QCW/^N71F* 3%
MZ>&#IABU9)>3RC_VJ[XJQ 9=[E9^_2L^:F,U*3-:8EGCVF/(W^G!J67^CF\5
M);4M[-O?YRCCM:/4;US%+V=ON#7#8HD/=H ;8*V",/[1Y[Z!:,<O*#TBP+5,
M2W,LVZ%IRKOB91(([%#(I(4(>/SV,6L('V5_<WJB*^/[])H=S7'.>FI4JLQ)
MA;15E3[G@,S(GFVY,L_ 9O?1]WW8-S8XQUN/@.OHLAB-[A3.K6'UER\UI"$O
M!QW6T]'9'6>.P63AGG:8(\@;1:@(A9=, K^ASA6PH$]).Z;.;=C#9<PY*U^J
M2WG>0*)V7G!JMM/V;[W$VVK8J?7%RH.+U>H/7=6:"AQAEOF&-\/K3,)U:K("
MQSH;T!4E":'63/U#? X>BH*)*2V>Q[]?LNTN4XC8G$;%I99%5ABO\OMR-=O+
M*5G1LIH4Z,6]U[_&S^\E332<R9K,=^!5$T.*L_'HK;EGY(YR!U>N23Z36Q/.
MSG?<7N",?NY<N.[Z6,?>C]G$"=JR[3\ML.PO;06/_R+!E%.IJ%,9TI$_?2#]
MBA&8[H_P R?F@F'[Y+5RC!N[-B\V8B[ZT-%'CM:DQ=D'LR8M3_W2K&F=V=;)
M(_=[%"^HGU;OJ7%!/$+=Y?Z',D<??9AF8\7XDSH-)HV;?W^(:+BF(%<,*MM^
M3#8EB]2$R,\O=/DZW4</%2<R?4.9M966$.K?V3,EGI'/[0O^N)5/F9RQ=(PR
M6\6H"^]HL1@P+PPGGAA:MH^G",EK151\*AOJ-'R"I!!>V!DDTN.FK,,B.1(H
M(N9.Y/GJ?M>20']QG!;#E8(=S4EZ6;W"?T*ON9?/>,8\J(!TO]-LL":!0L-$
M7P:Z*PA-&LU] 3[Y39>FN^-8O-O"KYKDHSRE:ZRX2* ?.JIN&"/T7-I=G3EL
ME[H(?Y4M0V7*L<+':9&*/_.J!U$-A7]"F>H/M?-$U&,S]!J\19[FV94$?GHZ
M5S/NS%$':65U8Q$U2LL,"<7L6K/EUC0GK:Y:+;3(DP_+*VL:I%Y8*7^GG7<<
MWD>;:!$YHI.7V[2ZF]H!?=,+C:IKE<]7.=%&S1]D))IDW<]:U$@<B!,?T0GD
MXUKLHK@4&P=/LMGJSM0T;IFMROU<>*/=A##<:9A:+C;%-R'@.]P0R 89:.%.
M</S>L/_4&QC!T2KXG?0V(^-96;_]M*U!OHYO>0]:*KI]&$4^NB5,=-5.6!_^
MY/_%^-+ZFPW]?-1H')^74P4B7(]"#-*RL67N+;(^RAI:*R*PGG9U3E+_BQ=?
M),<EQ]?IKJ^DH2U1">NGJ%N_,^*.W2?NA#_.:6?YB^1:>5M>U H&(68@F6XF
M+J4<8W$,;@O-\Y)=T:YV=RQGP.5>2_F/_9/&CJ7WM<L(VUJK&I7&)B;&SI:E
M<5EU?4/.M#%!^ESU<LHE%24#:QF&<O4T@7FRLPQ;1BN\BE[R0]02';J?[7&X
MI$K/XBP=;71=/I(@:.NEE=K$<&:P$)G??5_$++;M_>1^L='6*/X;9;Z]\HW!
MSR5]'+Q?HB7IN6:4==$^&2X:/Z0ONYD1CM.V!-N3G@CENUA@9^UE+Q8=<U6Y
M5J3HO^/O5_?3LU*H)($$7<\87^F[GOIXI 1Q?7JN&$<[4;_PX$WWTL^SR79D
MXY/=+AE3/B.W3U^CUM<+1UG>V61%5ZK+67L+W[HE.O4=_RCE<K;0.W</4W.6
M9'K7N[M+:+Z@D\[?%IE_VN6[O+0[)\IO="W,,X2J_<Z7%7<\EFM;Z-_V[?DB
MTG8\;I?%@#.ZHJ]WJY#N=P^27KN!57FJUK(^;NIA">V%EV+5I_V&I;E_([)D
M>(+V/**GC\*K^^,>,S.NWTKUQ<!^=#N.!2B)"2,:OMSE_EH!UIM:&8]C*G=_
MS<.K+_VJG 2Z5$JI/1$N%IGS+ [$E-QEN6.0XIU(=VFU_ 8E54^@X$)8I0;O
MLY9TF-]J2_#$WS&5U75TV>\.YD"D8:WJ+JVONR!HSV31-<RJ5B3QN'B,"5J3
M;-/IIW_85/IP37N2WJ2@@3.CQ4""+8)\YVT01DX_\]GNPJ2W:NVD+)1JMC6J
MM$O-?*\Y:J>4*[B#_-9:9,1QE[)OH6DNG9=V'(53982)K#Q<4'BJ"7S'X7U!
MES3W6&UUHII B$OBNDHJOU/NI^JDWC(-O^.TI1(95('=5(*Y&3+ZO0.F&"EW
MWYJS5(.=3_5C:UZNL/78FX>GZ8WBD/"RNZA'M9FRND'MGBO]]S^NUP(Z<>,+
MAX'@S%%)L:Z&D:*D'[NR=DO<U.*&%'V%MT2-F3!EF,)Q5:7=4)$BG::P$;4/
M%"<>/,!]L3I_P/E8(G.O*K6T5&#FM%I6OUP(91#O$FL4K&T^Q'S"/L!0D?V4
MZ>^$B%74PK=3JRJQ%5\ZL7'.[>Q:Y?&IW);)<:WLUUVGY!/-K6$#LE'EAA=O
M_%8+M3++F/9V?)*7DFO%].+0Z7FZ1X_:JKA_<K+[@H'T4;F J5YC=2-OZ8&?
MMK,7H?3Z$U;FDRY/71AWJRV/!ZY :F)*Y9>[$)V8.;/CY"&;U-6\"3$&I\AW
MFSP">%7QW"N:5USYZOQLW*K?I;H2J7C2L8C/6/'AN1:#M@_^XD>/>F6F'Q>;
M=KI:*NA3&/'HV;?\]70?-SB48E%^%#9)ELHMAF+A+X_S%MQN6C8U<KU 6&?V
MGU+(1/9Q-0Y[<^I9#U'Z)CZH@WBQ@#$Q-\-O-5;HOJS%O40^&.@K/Y63R*4)
MLYP<V4:8VJ.2$CET<OJS8DKFIDX^$2 =Y2+)B?D&+:FU0_M?7^G\V3'45BD-
M8VN^,OYJ@LV8XW%C5+&>6Q#Q5P>Y^MS<>FTLJ\:+Y+F.\I<^_"&<IES--TR-
MG,+NVAV72M9T6UVY2\\\Y4K%M1M+=RW?GIEI=L$^[MWNSU(#R7$'ZH@UV-OR
M&XNW>4>^=_54\*FK?93]'JIMZ%UGSQM;;O"M(ZTM!AC>C[ROBFGO18VE*%(]
MTG3O*,C"R L*1$YXE<W(Z4@N-6L[N!EDSN*C6F=;/9^!(W(S4Z@JIX"9LTK,
M4+;B[HV7OVIZ/"5?N0?R<1OA^#O?A#XN*C19V.;-Y\,-=C1-)XROA1K2QF/#
M-%K2^(ET>> P@=U;:T[EYC#5,'H,ZC)YDUY!,Q6C/M/<NN"Q:?2' SY>F$,N
MHFPT><[CI<'7J>^* TT7*JS_YJ5MD!,TG-6T'?6L=2CD!])85A.&%91ZRIT<
MFC^-ES<$-)6UO+RZO'A58FG2V6]X26B/Z9Z!3@RW>$58?$8.1810P-/I%7NS
M]9Q L0$["WJVU,+92U*">A>T)@3I>_7!:Q59>MG\M_SKFPIL/NIH[Z3-!O*J
MSRI9NTQ^^B[Z7+;.^;E+^5]:MK&R^<D&WB@#;^'=(^G<1/IY$X-1P72KIG&.
M27_'V8*F"TD1>VD+#VI,\>U:+'R\XP[]SVHMTUVXQ-N*67ZUR+7:(@HUR"72
MO8>RU4K]BY5>>83"XG6-?1*DC2X=U#W/$U@VXV3Y-B1192?00 5SZ)STDG::
MPS>9;-[5.12(^C[L/Z7Y%7/(8\B7EC00*"Z6(AJ'D6XA/$&%^C/6Y",&KSDO
M"G#EY+-1C&9.LM0V/)"H^&NH7A.;Z]:];1@O3ZS_W39?I^F(W7C9)=*=Z64K
MW[- =_.=2#OW?#Y]^_U^79?Y:\ T24<;VRA6[Y<HU^+6J=?@]NO+W$.'1"JF
M=6'#_C3.)J7DO3T&)I?!J#!VYBCCE*L?BG<5Z3WT3)ZE]I*5/[=O,6K2F]K1
M;J@)2UP#/RC(;Q[.?&O/^>'SQ&LNBSV#>H-JZ;V*_ BQ==WIJ,JB]M7LSP:A
MB>M"Z>7\Z-);AN+ALCH3VWKC<6&L&P7/C7N&3!H>ACRI%7146)?H8:N+2;25
MVVK,9?*1U'7)>Q'(4_(WK  AJ"SOD.^Y2U5C5I0[)\X1,UCG59XDJMT<4)OY
M].QB;K\XBU&&QXO&]3J=IIC<<3:;H?M;FD&U/;A:]ZU7'L9S5C>C7)GL?UF.
MOREF:OEC14!$SJ:EY7F5;&J.:+>*BW^YI&G=,<&!<O$M=/=UD<[O$LM68[@<
M''7;J8#Q@AFY'9.&//'XZ;:ZU]>+I?."R)]#1FX?7LC%,FRE77R@8OC:X\6<
MF1.]>9VUZ:!)E*F7O!UW19YS)]UIRT1Z4]&"9?0'_=$WOAZ(C\9R@S]C<S^S
M2G]M&]6W;K(-+'TL]RV%>F--=TB"UAK7G<G2MOCEP)XK>P!E0LV?4'(I46\]
M]1OTD^YCTR9**3J'!W+?OD8^=;HU#']8?!WQH*1A696LW^TQ=:3H7-%R_!N*
M&,8<UDSV>N.T<B7[M1B;HI$D&M;/W4P:]Q/[Z5WL:"X^6!?U[*[K*$7M:31%
MVD162Y%#DPR;;XY_S"V3''"9V0%:!F^N-.76!O':K_,_O\[\_W]^I26!L&PD
M$#[/"@DC!(\0PR8,=WP@)SY^0KTD$*0QD?CL3_;9*83 DQGV<3"[UAL6D6:G
MUV-'F9P##VZ\1WS=$G&$74L3J.KDX'WX^-$OR8"L'D2K[8IY]/[X3Q*(Y7C(
M% G_& !>=F8W^7C5,5/76**2IF2I,*7GN:WTO6!$8Z#C"T+-WK=W-6CNCDRI
M!J])%N#<WF!(1%FFBVF%X<%SS(.E%9/;">6:?,D0VN6L2 ']W<"GGK->=8>M
MGZDE%RP?NF6 QW)4G ^>OYU3V(U;JN+PE);[$'>\7]& %)J%&VE4-;P_.NZ[
MA^ASH@^\<8>H/^P K1E!=56.M.&ZJ 4?7W'RFI5]'/S'.6*Y*EE$W4$7RDFT
MS5>^WSF _;)-!=P#9_&Y@0@QG#1DHHM\4$707.XS:^//87G[Z?$_FU7?DQV-
MU@(R6BZO3!Q(L1; 98\I_[!C<J97^$HU*AVB?B54!SQY4"COHW>Q>I%XW77?
M;ZW!/$!F7)QKUU7.FW_F;'5:KNI/W&<./\]&VP?0KB&>RJ>+ZZ,GZPW[-3]9
MF1ML?NPKAZ(DLA=275\__S#!')^V(KXXV[GD&F[3-?)+B+RCM,_(1:Z;;)KJ
MH^/J#0B6BZSKQJ4OQ)MXB,UQXB^J7JB$KFDR^#ND^P>WZTP;#?;JHJN6D.D'
M%?Q3KYBJ/XLUR@ 'WOOI^;B&3N][B!&D#==G=A&5>+I+2V943>%=C&'Y_&]"
M35E$MMV5<=R6(/\WY'W-)-#'L@!9FN "K/(R5UT2#KUY56!CA_UFC.&7+AQK
MT.\7-[D[%Z]_)8%L?U7!" G?P-5@%"4)I$@92@*A"[6(;%7)0J+^N@U]YW\=
M&.W%\D)8A0>FW"P^:P[H K;S5'U:Q+(_M@EFTF8$UN\B)BESNE7!H1YG*7C:
M)\L&13N$;'1BI\0#N#?NB?DA>1!5(5T:](T6@HD8"5R)H/].@&&!A;O_9Z$J
MR6GR".I. K&/Y@4OF4 /#BBGOL&?A<T'(199O>Y^FIT)>#CJ39$3(BFI&?R;
M^A% OUAE3#"6!%I^,.D2Q&F'<+>Z(D8"43Z5.FOB%J^&O+% T%.><A/I2*".
M3 @VRALO(GGNY5/@,QRK6T@"41FI2:<O?CDJ6I;BRN[8Q/\E@60SE!9*]V6-
MYS%[,>8B#T[[9WJN%&U4SNOXED4#4%/23@TF6]WV:0R JU[6V='7H MNL(X?
MLD0&,":,C*BZ]]\  NZY(L#_U[WDNRQ"D:J$C7SU""F3%'2)-BPW"A^_"D4/
M95&F67%.97L5J?C5K>?(=<&*YX[]M;#7ES)%6;5":Q\IOZLWA*2_F2Z$=K('
M_5X\TL+S 69EH/NT<#10B;42D-5L'T,2B-P3B 6?T-^_N@N4N[)6W;ZTGG&\
M8"Q5CY'/$^6Q7IQ@4OXLU<^#<FW()[H\1GZ^.GT]OP<_*\*)#-R8,!(H-Q!I
M@><9)X$B\H@,?/]6_/]W!2=+@X^!3#^'$3_FD$ ?V"^YY;@M-)! R 2XG>L9
M=]M_@PSY?Q9J]B&]7<3F-] C.DK\=7I/@SV\B"WJIDR /+J22+M% OW2(8$Z
MN8B_2: CK=;_>D8"U519]!*72*"7(I S\G#BY1A&/F\B@^C_XN*E 7!](X'"
M- @ HLTL['D$0L[90!SN@K+C@@F>0' V@0!0/]PLW\.^63SGW][_I"/Q_S$%
MN$B'A^U2'H^SDT!?BZ!+*ATETPT/$8K&]=//H6]&$/2P4\ M\(GH/^8@&OYJ
MX92VW7=)H!!P1PE\'GBF OZN_[)TJX+M;DD,V>W'/>;QQS9R;K^56?B.R"#&
M5S[61Z'2=JUCKQJ7M@+(*0FYUTF@>*:.;*S.N5$#H G\@6'"QF<]@RZB"U.W
M YYGXY4"]LY:4B>*APS2#^4KCTF@\/LW=+LZ]X0]!;AQC).I<:;%9?+^OT3,
M!_=OL5^..KJ$8R6.468N7$%'LF:C$\[M&C> OV>C*.1:PC\$\#:MPK"J0!5'
M5/PUT/HBHY9$KJ.^1K1E!<=)^>IYE$<7+!9O.'F#RU5=;3D[\1' %+6W3 @F
M@>ST X>6+,CC-^74 %#.,\2>[%JZSX]UD8NA/B10<1:$R-;X'2\$2R3\9=:>
M-OVE"8XZ$7X!%>W?]72,:#MRQ6I;Y6EY2?R.N>K+85@.^1N/4Y2T" ^B@?PG
MH(K$<RHS4J8 ]H 4P<X!+AYKPL7_HC8]H+]4^IR)^S> 1:2K'%N#1"GBD<P4
MYV*8H//(V8^?WG3;/9CGA!SX_V$!;WTA[E[0J'>\,^RG.2UL#IM*2>PS76YT
M^)8WQ.@.CX^EO.WNTR)G)K#!WFM=;S?+<BWG1;>O^"8,1QXTJB.QCH:$_,D"
MBOE? #6@?R"8"#<2B$TR%(+.!_C3JG7L*$H"90NAS]_#9G[_[8;9&X7#8<XO
MN\5_8\+>S+:\>\;7"ODNA+JMA8\@4@/%D 20HZJ0V+%8*Y_4+^MSM\/I;@.>
MHQC@O[YR6 U?Y3SDI\[^C7"! D&P+T7R7C77;F.AEBU+[^FT^)C0WT3<DPLD
M$,?)?Y5+&2]BB*( Q.Q_5RR,F2MI!OJ7B"L;\&FSA!.C<PHO'8_<Z!1H$;,:
ML&98;KJ1\52+A<+_>7:U)(J"#:C0T/\M^3*6)YC;A*^[:[9:%[ &\O./]WG!
MA(36YSWAPNX.GCP0A?#2#_N7V*+62J/#%WP#O-.UGNMO3*XU-1P@%*U82NM=
ML=PD$.IF#_$IE)P2EPKP*[*P"W>!.$IU2XX2J87G.5^IE"6\'*(>2R2VV7KL
M7PK+PO8& A&FE,SD$&I?SKPAIGIH^"W[#Q\F G+(CM4"$JEWGDAI8 X20G"]
MZ<'?5Z#!!ZADXS6TSAI2?VS"?^8OWP5B\!N(?+ 6E2HY\DVW?,ENRO)I@G93
M0['<V;1.-EK+%7$O<.\R5H4$FNL%MFJXXD!!OT>!J8$6$K*_R,JA1>2JCU-.
M;U\06[45E$/Z\LF]A,")H%G[MG'R[YM*5MCP3D5LZMVP'O$%$V*/1:UXV0UZ
M+!1I)D1X?BY>NJY0*SB";7<F/N 2TJAOCP2Z+@)$[L?9C )7N:#)YUEH\<K8
M2ED<3:O;6]P(4UJ7Y9=BA,I1R<F8G..!X;<1 ,VH>YS<7:1<]EDJH$.1!<K
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M7D''FD[QHJZ6LZLN5P*UBZ#MG("]V:&N %DDA\VNURIDK&H/NA0'K@T]^(0
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MSVD <?:5U93G<^>XE2?K6UE6 5T*AM3JC;G --$)0H68CHED.%I1""$Q%X"
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M/@2>S1:UAOC]\\S>R:A^[H%(IPUXCK1ND_A/%L7/)ESX]IX N#:(H\I$H_]
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MWJ$":V+GL>:TWW9XX<#PE4]<35>//'JQ]V!,Y*SBW^"W%Z\(Q:DRVA&$PID
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M?KXP>E>[#\_O,7%C8K=Q]+:/'.[BD.1#^475EMB#=])H0/WD!&HS>51HG-:
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M&# \X-HXT*<FC.)1/'0PX_^; %!+ P04    " #<AF-4]/\&\\H8  "A&0
M%0   &]N8WEF+3(P,C$Q,C,Q7V<S+FIP9YV7=U333=BF?R% I :0WB*"@A11
MNO0B300""DB-@@**%*4%#56E5WT!02E2!*7W*@%"$^F=("6)@ *!1!&B">'C
M_<[N?F?W[)ZSN_?,\]>4,]>9F7N>.5XX7@.XKIF8FP @$ BX?5* XR7 "  S
M,/Q;3\1X4IE.,3$Q,C*Q0B#,I]A9V=G96-G8.#AYN#@XN3G9V+CXN;A/\_+Q
M\;%#!03Y>05Y>/EX_YT$!#X9P\C$PL3$PLO!QL'[_ZSC;H#[%& .X,&@LP #
M-PC,#3KN V   &("_:> _R80P\D:F2&G6%C93CHT<0$,(#"8@1'\[ZI/6L-/
MV@%&;B8>B<L&S*=M[D#./N)5BLYX=TK2L*Z'SW:2)*7L_CB&A95?0%!(^-QY
M:9D+LBJJ:NH:5S2-KAJ;F)J97[MQT\[>X9:CD\?=>YY>WO<?! 8%AX0BPYX\
M>_XB-BX^(?'EJW\RL[)?Y^06%9>4OB\K__"QOJ&QJ;FEM:V]%]/7/S X]'EX
M:GIF=FY^81&+PQ.^K6]L?O^Q1?[Y:__WP2'ES]]_N4  &/3?];_EXC[A8F!D
M!#-"_N4",83^VX&;D4GB,C./@0WDSJ/39Y6B3_$:9KRKZV&15+8E\;D_GF3E
MEU+!G2/_B_:?9/]W8#'_7V3_ ^R_N+  .QATLGE@;D /.+I1+4<P[4\16?/O
M7>5!;B/<54;Y)ZO%5<]HC_<.\FQ2\H8+#^^X5J$LCP$F(4HV+@_:#P.CQ @B
ME$J41#DEI8D8,#IL[G-',-V00,DRE[)I:8/+@(=T@06:)R6!&H92(X?VY?FM
M68;BDE;Y86R&8UE8CG]ZG9V]M>L#Q%J*1:,&\_K2??;Q78^.4O8M3?NQ5F@R
MNF_B%,J4?-:LQE<AE)D^-EELV\S?G:I<FW,KM4I1\FQ7:B%#HLS_$G)?NN3H
M,S!67<B( NT1X1-,_Y,<>D=I=&/9=P?U&F.>%MX(VE)QR$5!CXKI8O3)=K>R
M<I0.6?3)4?,;I:5E/,MM9$[VX_5S=@^Y.#DOA108N67K,_':_!]#W(YJ$C&1
MJ[ZSMX;\_73;L:DJU+;55<N01,Q6=ZK:?FO*[L%(D/)[*,K9EPGY=:/O&*AW
M&( N$0@%\=4T!\*R$HQB@K/0,?&Q"'ES?7+O]9ZO[(1<M'+?B^OU8$Q>20OC
M#N40+Y"FYP-=FN['PC 58<RE..0WTFX<7LA9+4(XZDH:?*8NU4^LQ?0T Z?0
MHU^R]?1LU&F*7B$-0O$JHLAA,BY-[R_4'O+\4IT9";70+NOHX.FCK@4 A9PP
M#%UD&NV^NL@?KLMA^=O"&OQ=P$'N:<0EOW,V4E_+M9DSFC^"NR4"!QZ@=XS(
MAW9'I6@O/2B%X!8[L.K:FKN%/5"X(B3AD.AEAZT<,8%+:.=;ABD2[]2XTF<1
M/(U[BS4]#HKG7_'U"6?W63Z818>6+4K&62@0TC3MX2&_11RT_9<&(GMT:,$X
M_\5#W#% Y'BW+?PM1)R%))#B;\]&752.UYO]> PT;PX)PI5&%L#GH_0,RFLP
MBB(14PB8K@K*D))$-4%";LYTRJWMG3K*G]2;BNGAJ+C.P^89ORZ=D9SO\8&1
MX1M)C95*Q1\2+?'^?$@(+AOC'^N4F8P6Z9+T/@A]['(5,SQ!O-OL6*UX=R!$
MK.- 4?H#D X&P@L0ZI$]!ETZJ_2Q8Z !&D\S*')+@O*LFO-GEHSW>&]D=GG!
M(Q/<'6\]+:_)T7-?5NPO8#P&_!1A*+4V2MX'E"%I+AM7T$*)@\^4!?HST>^X
M1X3!?!1?#YL_)(3L.J3E*79*XJRQTW161W\<$=HO/)C2"0JO'/WH9E%^;=3/
M]M(O%R._T$"_:V'7NA4AJ8 [Z"\'"7Q H@3CK5EH%TE=:,*;2&X4?%YE26;/
MM]%9:+<.2:X^!E3?)9?<O?RG7O_&JVZ^WREALP-MI(XUUX&XPCC2WC._IC!"
M[=1^A89[2^ZNR>V/&4:"7S$:W]@YOSD433!#TCH#BVG*)*LV/)K+Y2C->+)*
MZE/'&Y'$@43S[MU!07#;&8?^U48!XKIB&MH3#5FEL6G&(/?PYVN#%/CG\+P"
MS56GHP/6'P^=&O'ID )=\KL\.'L,P.C011J*HH6/!!!;#L+&U2U^M4V_ZV.1
MUX;JY7RUN?\1$KW+HZ0Y_RV2=KKFX'([99D,[?O[;45[7D61 WG^P()-S +C
M<'YN:RM,O4+PG%9GYN7D9F:S3),GN<!1;&LMV0,EGS4L9C)"^?Y]@'?&3:=Y
M%:MKPEBJKV&MOM$MIN40$_%%K];K>030'XA'\(["^F )N:]$4BSZ_O9%/#*5
MEC_#<[=P+%#BSU(;F%5G$Q?:>\2V=@P\(Z)4<=\Z^+DZAJ=6ES\'/U))#=5^
M:2$A/V+=!=$' (>H8Z#')$)F.X*=(EV&U.M]V2@N1TFJ6*+8#MR34I&[<M:!
M,>A<Q/54TYR,J2B-FH7S?.3!06NL'O[@==T24LYM#C?5F" )SW!5*&KOW-+T
ME4A_MK7W57A/[][>TE/KHW)==905Z?V+TB(* G,!?#^WMTT1I=[Y> A3:'_[
MO79@(T^8AOA3<H?S-%V4=F[B&+@'BQ&P/Q17Z9I&-_CO%J6?:A13A_UH.:Q7
MY-:*#7SVR]/05 L<@"!9B$EW(P Z"V5PX.]A<I!/6*=!>."YSFSUR_TJN??B
M7A?9L/@2%#;;X"P#*XV@OP;RGQG]I:KK!HH#M40!'?/25.-<U:![0;>%'*T,
M(.^8T9+!"/YM! F> B,H]NT)40INDLIZK$&W7,1@&.'@[CAB"QM;ITE@C- 8
M5[/!E4R[4\"K[[IGC][3)6@7CN(CO2+!2 [/ OQJ:B-%?G^.6[[!>?$]GY1=
M@$.@G.''D4L"3R,YO<'[8XE_'NAAZ3" %D2Y0]7=:CX45Z:\*+\_H1C?U*&4
M871?HTE))?82^K+OB^&4=S8SOPX?K!)-J4BDUH$7.2ZV4^S<B\%$%*+*Q;#,
MHB['@RK%8\9E(9<>8&4U U9(#4GF >W/\GU;;1PD7CCQHU!<YXH<^4+6EJ,4
M?WO(*Y^TQ@<"4CQU9W280?*#+\!MW;I@ZB7Z\HH.I8-J:$UJ&42S.G=G_[QO
M6>F\L8[UEL FQ]P-AH6Y!/Y,#V#]"X37N$3VKR:)BU%@I&TG<DOB;NZXX90[
MCQ6Y^H]@ ^-5X_&1D9&/D _5O5VPHT\J2VE81?QA+V)QVB*OO[HX!&6-SXZN
M]6U<4$IJ37WS^9^+D<FF^K [2.@ UJ$OC>E[A.S$^LMPF&-#XM\I\R+OO*(,
MHPNRW5P!3^=6\V!O[_P2&%U"?QE:;M$8TU&&_V@/KDXKPRXX&HA5959:,')=
M;34CP/EN<G8#$!SBY)W-W6VC7HOL,=(]2[.?]DI'72'YO:5SU;;9Z]KM1$?+
MYN6$_FGPJO7^9 R$'[HYD@\/<BFA5&5*R*H]>;>]W7WYLH66C,?]ZNH%CX!4
MU6_1&5D:-ADOE63GB1#R(0;6@,!HK8H@&Y?5<OS/ZJ<O&F]8:H_G990/ 6_%
MS8%0U3^/(W2_1S;VHY-I1M#8ZJYS$1/B:K&^4(RN<$S/9CW)[_52D8/24-'E
MBW-A3C9OE3GA_(70&00G?4J/O=,&=Z3L6$^N3I?_+7*K>NWTLKQMV.,SP5^3
M#>Q[A"#I2!6'P17H,1!C0+&"LGAG;'=)SS@X6PCRTQSK+B5%"__)=Y02ZVCQ
MB!Z0*>2 +7KU' /<:'<1:V'OB',4@RJ4P:?YI@^JR@0HX[A/X,',;093>>4O
MO!D[NAZ!&3G.6^&O[&<CO:&IDWF*9A/N%&Y<&-TY+]"^/0X^7Y+\V]D'Z5C4
MXJZD_EE2:5/B,5.X@C$0@&"B0R@6:]+/!3 K/+4^2''[ULY/;>FCH9$!JQ%/
M$ZR5S 8_:'-&@:(1!8C3Z+57$6?]V6BF,SO:-Q134.;5#U+"B[^[A4U7*MS-
M6A.Z6"9/W!C*4(F"9J-7?B#*;\(AG\4YCJ+VJQ0/)-ZL*= ;Y[)S"YU';SA/
MXZ'MU+%4]ZVJE*&NFX^2U_XQF-@G%\0C2*:^K-/=3V0H"(*.D1$ENDQ+=:#M
MX_CY40-'?>Q5Q)8:85T&RAB[W ,K;H1#-@5V?A\#C*7S-.GW6[E>?04)CU>0
M_O:M%GD.F"X^)?W<BO/$BN"0GGO('D_=6\"]A"'M^2[:M:,H&@P_+HK4ZX_@
M)#,WD=[8D^9>8W4:\SF]B8=.ZXEELOJ2(]D*GWUIFPQ=A451V@)KJSN.I%]K
M>\DEY**N!H*>V- +:**V:[GJT<^84[[/H\K-I.[=%.51CC%^.LL+9WI*E6F2
M$WECCA&\*.E=PMIO-<<HRCVT]KM&ZRC_&/ J@-!'T- ;/2ML+:UIEM3KV:]<
MW(;/M;;FD-B&N@$S.V-!, @R\_<>+^#P/&)>#X@0I3TD&<>^(\NYSF@K%R.M
MO&:S[:?WLB:6N%H]O>[Z:0@.7AFX4A-:DW ,/-P.T]6*F$8P17I1*^+B>IWB
M\O %W$O%F53?3UV_V"&B1 7>J#1[^ZVB*%T+2D+X!\7>9>4>=$-VM"?)%(..
MS_VJ*W8,/,>X9*);M%VE2EN4("-)WH#O6,"IAZB.'.N%; 3IVFH,'"4VBY(N
M];: )%S<N7Z94O\[?V-++J_X-)-"DPEN6,8FQO038H*H$*$<L<+#IG$6P4SC
MG>3OG1*$R[-5K!2R<T&SN9T+KX-^UHK);><"M"8*V\E&9E)>O&M:>48^C;?L
MA'$J*DITS'0JX][D+ 9[/M^X?"%(_]E,U&!T,I=@: %L/S(1S8;VLX0,NG%2
ME,/)IS%8Q',!0]*(9F!\Y<YY]^Z&5MNS6*%YB)]=K*##]V!>T!]K4MF!UU$M
MBH-JCLS&WR$-QNQV.N*3[FOO<?DX]/I8RH\,.[JG7E&/,[81!+F&)#,8?/ZS
MVJM77T!4)OO@YYK(5HILKL@"ETEM4[&9EH@S]^J$\_J4F<6=K#R6N;C+>]=D
MTXO?0_:8D)M$.ZJQ4\2H'ANB#[$XY=-U!MV>=FVBT<Q\-3+\XM5'Y+')F$%1
M7,"5LU%Z%R+]H;"(25O40XHS'IT@SMI RJ2_)8_B\F0'[G4U/HW?Y5YHG@^8
M4CYE=-'DIK38^ ^]G6=4U6T81\D<_1S-;!:2H*N$_&SW^PWM0VJO1$HSW'=-
MUA>^A#S'R\EUFJQ'?$%2)F2GT?1(S8I)JSQ5_BAK@B(?]L=?_^C]<$V5IJG.
MOCM21;=#+R<X&@5@-JG$.;3=R8$_DCO)B)_OIW%\#ZFX5W+?O@[KU(W&",N
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M?/PS2$H 7M5'K)73&6LW])E0"J-$0$1%!G&$4IAE$D&J)(JE0A%/E5N&@A&
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M=N."SC[7,^5"&UNT"!6.8X8R*(4((*;Z)YHF)E=S%')*PRA*4J]$"VT'<YO
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MUP[LJG!/]]![Z&QWUY,.R,ATOE_PXJ;11J^!6W4 -?H M5$(5%N-QLL/,13
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M9PFE.(V0U\7AKIZMOO;I;PO_IDV2IQN3Q:J W-3J_M;(OLF(L,DCX7Y5N'-
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M(3&'..&!-F E@9SP($MD&(=9Z)]3RDNFN;'0?L:;O^^H="3K36FT@BL%M5Z
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M"8Y(&"EM5ZH@BS1KD012H3)(4Q['C-.,4.SFL#W=V=Q(K);O2%*/U#FGQQF
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M^9)71AJS_UJIUG^S*C_F-[?KAN^W_UIMW#IBD2"9"D13R-(XA%B%%)(893#
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M%%) EF(!$4<9)RQ0*;:Z&-C=U=S6L3U9@1$6U-)Z73,^B[&-&V(HY$9FANE
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M8(R%4!G#F;#+^N/<\^R8N17=G#BT"50JD!?F9KM1!/!&D]PM9:'+4%@Q]3@
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M6H] Q@MH!$0R'C_]2J&,%Q2X'LMXZ<,]#Y]WFXW>;F:&0I.KH@!"N/R64E>
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MV9TXD/"OZV<<=@4Z'9 #3Q<?3;%XLD*]XVMW=[7YN-IL/NEU/>U,\5SGAA1
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MFQ45896L((!06JHI" %",0F8%HA )*VI%'@1XSOUU(CG0KG(31VYU3CEZ\C
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M5D&S3HTR:EFSG;#97MJ0ZQ9?P'WNJ!+ F)A7VNXAM<C9-3BCRK3ZXAIRK94
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MGFX ,0.,WCCB5[W]C2_TYJ1Q1 EQP0B !MKC?"XAL!L% V[=D%T]R45 6MS
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M0Y-B?'#I2H&Y.<:8"2\^RKQ(;_%ZI&^OSOM],T6LJ<Z)*8&B3+D6)!@P92K
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M>?U#4>T-C-%R>V\^:K[1?UTIUY:J/EG?+^L?'1\-J+5[*JH@8++D+GR[!,S
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M*1L1V'4F<X2,.6J:1X2R+Q- 8H:(M3G=\=/N/Y_GFW]L:C.(:,C*4AE 2XP
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M7@I4<*AS4] P2]%CUJF9CT<BM[0ACX5N.W&%$KL/_+YT/3"HB4FX)YX1C!J
M3VJ>]!%E9/8+0.><TT(>[GE\7:J/<R[FBSIYX'"8%8I!:@A 2FB <V5WZ5(5
M0%*HF%92EL*K 8'?=%/CIB,1:T_KI:-N1ROP&- ##[Z]H1SG&.RB/Q='@"8]
M%M_$9*1#\F497N?(?!./JP?HVT\-$4=?L]JG]>K[?.,"-YLK')D7!<II#@R7
M$F#%$>"55" G%$&CL6#(Z];1?\JI$<]I]'2SC3_N1<[^V ;<FP4 [TL\0\*9
MF'QZ(MDSMOP6.&.&C5^4XQ4CPF_A<CO8^^:3T0U;3GO !F_$5YZ?T&OP]D7S
MXD2[;P<0R5N(7)E^[ 8BMU&XT#ZDXX'8[W5S9JAK9VP_:ZGM!/9UV<RDS@DN
M7(,04>4 PS('G(H22"4DI8I1Q )KPU^9:6K[:A,]L3X(F/VT7&UU!E&PZ_@:
MMKZ<,0!BB3FC :LIP[(]!FU(QNB (35C7)M^9,;H0.&<,;H>B'9;MI6Y[DWC
M7;!'@#;J9;\IYD3SW-619T(5 '/HRLJ+ D!8ZDII*"7S:F8>,NG4>&1?3\_:
ME(U#K3[>ZD;J'HE,'OA[NRT'136UU[(WH#&.2V^$DOLMNR49VVWIC<T%KZ7_
ML[$\]:_KU693)T0=>2AF4.D2XT("8\T;@%UV0F5H!3"5)=>8&*WD[+M>BY4_
M.5V<*>3-.9XOW0OT9>7: CXME3TKK9Z6SOM?IP'N76[!+LK+$/NR3V_8$A-.
M+=\+B.;#FC8W(4C-*)<G'YE$;B)PSANW/SZ$N_'0D^MH!LM-]JOAEO-Y)K!&
MNL YH&5E&01;=+FA!E#-9"40HA(&7LF&3#\U,V<OK[SU:@R!>XSG<4@T1_5"
MRD,7OY,+D:W^L<V$?87^D<PAZ8O9F,[)3IE>T5'IB]=MIZ7W*+T[3A\\HW6>
MH<X%5D88H)4E,8RX/;4A) &196Z$8!"AP.O;*S--CKD.C9//??[]&DZ_@-C;
M1]P?N-0^XGC,^O2;OHS':-VF7TS_6KVF+Z-PH]/TE0=B&637->3+M_7JZ>NW
M7_6?3;F)XPO@M9UO^?6]5>/]?,FM4;#\>B?KBN[N9* )4EP0!316N3URE05@
MQ$" N>"%YJ[AH%=^^( R38V5[E1;H"B4?/JOCB]-C8IY8D+;Z9)M&V6RI?ZS
M+8[SYL3RXHU&F7M#,[/3*>-[I88DOL$03DV1_04=F4P'0_:<=H<;.MHS?\@X
M?;]:_[ZTXBQ</+/]AYY_7;[[T71T^KARV\._\OER,X-,<2FX F5%N;7^G#L,
ME1K G"EL*L)XZ#5?N!!3H^!6YO_2RM7'<D)GNI6Z[H\5[+ /7Q9O!WY2L%,[
M](^2TETALJ>]^)=Q=U>Q7YT.UR]B8SS\T1 F]_B'2S;V#4 T=A=N!.+'BFI;
MN*N6 MN 0B%EKBWS:>T2+12TIFG)!'"UR277HJ#&ZQA\<?2I,=Q>O)CR&B^1
MN\U5O?%(3$('R8; (JCE7#PF8[6'\\<FM'7;9=V[VJR]>&K,EFB7!7[1ONS*
MAZ(Z$*V6]37HSGI\_JSEZNNR/AM^TNOY2LTDII6D!0&&*P2P9G66& -YCIFD
M*D?*>)4 \9UP:BSF+HREN\5<'R1U78.LJ$%]9[J1]J&X8?%+[<=KA<WVTKKN
MC@<4/Z5 ,:@[SZ!HCM5]IQ^JH3UUO"'JZIG3/="8/7&\U7K1\\;_N1@^/MS5
MK,Q:U^EVCWQ]5(J$ETP24A1 84GM25I(P%Q%[S)7%$O$I.+8GXV[IIL:%Y_>
M7K829[7(V1]W8:%NGH#[D/*0,(YZ_SL*@B&$/"22(]%Q3T0#Z=@7H XR[AQF
M1"KV5>F4B+V?&B):YV=>!Q%^6FL[1UL$O76M\L7>'C^)(^%*%*BD'%2"2X#M
M"@ F,'29A*7&%'%.<6@$8#^10MZ=<4(%:QW<6[,7/#OX#(Y+SO>)^(E8.U^_
MZ'CK,>JN(';+\GA0QOW3[%=IL]=GE%BA>&S'C!Z*D/(5XXGB,;T=8=1CW/CF
M-RNIM=JX"Z\/F\W3?/FUKH^PF95**,$H!@:RTI(P(Z"BB@&E*2I-B:F!@1DB
M5^>:FJF\$[2Y2J[+6C5-C^UW);RIS36 ?9ER$-@2D^ I8O-&RK9?]+#-:CJP
M2-^@YIH HS>EZ4#B4B.:KD?ZI%Z_7ZS^K(?^?>/J<MT_:D=AQ[?G^U.-)J4H
M<,X + 0#.#<Y$)7*+;](9']<25T%4DN8 %/CF[VHV5UWL,HP2^!+/NF 3>T_
M=;GRQDG><-)/3YNZ2N%?LM4>[4-H4,),^G#TQDBP#Y#J%?+NPS&[G(X?,4[4
M3?5__/K;_>>?VS+FA!J%%$- *A=":8^L@&M3 EI:=I,0B;+, ^ZIC\>>&G&U
MP@7=QYY@Y74S'8M ZGOI1JZHKMBG* 3=2<>B,=:-M"\JH??1E_3NNHT^>6;,
MN^A+PKZXB;[XD>CR?^V1L#XR_C;_NIR;N>3+[=LZ(F?S8;F[>[G;;/2V[;-Z
M<AGS(I4+T8(@8@C0N'0]@TP%!.84\+S2B%:<5R0PZG!H$:?&A?NKQ7VN;B;X
MPAT9@VVYP5?3U]I[S35*S-9'JM4]JP_*94W8VL:5L):[1>2U@KMFUZ<+FS+-
M+]4*)*^6.+3<8U=83(3[A:J,J68:(NW0&LC;YT]VZ*TK]_"?3_/'NJ2V2Y&3
M,"^$40906%" 2XI=608((,IYD1-%<A%Z:/>:>'(\?TBP>VSE?I.YU=@VQ4YV
ML@^0H7AC-;S/[X-CG/K</A"\/9,9N[$:,[?QAC2OF.K8C='MS$>/YV,Y[:/^
MKA=VEO=\OOYWOGC2_S:W1_^U_/9<OSV,,$(@+P#2V!7$SAFH"*2@5+2$5<$4
M+@*MV]L33HW#&FGK>TDK;_;="9Q]VTD<R5P=F/LRUG!()F:J?B!&\),?,JEY
MJ4.*D?G(#Y-S'O)\;H@ F/T-[E$CDT-I?EXQ(:EK:\P5P 8AP&E)0)$+3K0B
M]I@=:%7Y3CTU3CJ-HU!ZR^>+VF-O5NN'YMS&Q>II>Q1*<=R3*+Y:G_=:^3)8
MBA5(S&7IP>\9QN*#XY@!*S?E><70%!^<;@>A>(T0?=:\T,%'E;E F$M0"24
M9AH"+JH"E(RS/">%UE4^V[K*>-X'RYX-D_9SI7OA?M7;%RU]8O*6+\%)%.74
M< 8TRSG A::@P@0"31 4JM),*:\H]^'@'&'S<' Z .LSXG -J/HTG)IV@ZFW
MB=M)O6+[J FTBPIJ#Y6B'=0QH?_*M_:_=?G6K27S>_-YOOG'A4(7)XS_<;[4
M'[;Z83.C!56%LO3,M:L_H; $ J(*4%%)* A6G(EX"[6?<%.CH5,S:EGKUI9
M=MK520Y.OXNU:E[:5%9&^V8Z-7N9M#V7/\;H'6]11S6+1UC/GE;R,,"/:4?W
ME/@5+>UAL+YMBP\T1W1P>--1U57[J -%7="H?KO:;#<SA6%%16F $HBXKJ<8
M5&59@ *6O#*\$EP$=O>Z/MG46'XG:5T2YQ =KJW)::4-#A"_#K(O]PX#76(N
MC40M)DB\$X[D4>+7)1@[3+P3BPMQXMW/1$5)[CLU.XO7FKNU7^FH7;-X/F_F
M_"=?J_H/U^_9DEZ3)PYG,%<%02@'L"PPP#DD@)<E 0H97I!22*607XK@\,*%
MO'3C) NV\K6E-]YD<VO,K+;9_.%!JSG?ZL5SV\8]*(9QR/6\376ONT:)B;&6
M&=1"9\>*94>:9>(Y._Y<JUU6:_:F^4^V6^56Q5=;RZ!PUE=:T[&B8<=>V]"H
MV@3P=P7E#CGEF#&]":!Z$1*<8H9H#Y+>R/7\L0E3NY-U.QHW_&HQE\_6,CBJ
MW6*/)?J[7C[IF=&"%07D=E=&"& N!:CL9@Q(7HD*EWEE8!GH*XH08VKGA5:L
MXR)8P0Z=F-7P=MTDQCBUD^8@OG/(\+T"V6.M07W@."Y 5I<::98D609^#TB3
MNU]B9!O;T=(#OPLNE3ZCQ8>@O6BZ55"[%1J< _N%)@!+7(!*H!(0C3B#K$(&
MREECH?^VY>NM+T7VZ<_U<KJ4T5(OFG2]R83^.E\NW8O:)DJ$1YR]@%@4+,=Y
M;D!.L(6XL%L/)[P 3#)<85(0:40+\;NE&@_@W62CPJN7:DAL?7>3";>+.P-I
MV.B\U^D1]]KMX?P[PPW4%*XUE@^9$__K27UM"J-8"_B!;[5+FKC;;)X>:LH_
M!' IR1!%& .J2NF"[2#@)=6@DCDGK!12("^G=;0$4[-,CU3(]CJ\R?9:9%:-
M[$B/R#)W,6OEY1!*NP*I_3[3!3_(@Y-V$<9RU"18C%!?3#R072Z7B)'']*S$
M*_["@=)CH)@]Z O_\<X8+;?WYMV/Q_FN9)?]\<]ZJ<U\NYDQP9"02 %B. 4X
MYPHPKCE AG.)"DDJY)5IXCOAU':86LQG=^2VQHZU^!LI0_C+ V2?O6)8Z!)O
M#5:JK)$VNS?905[W+_>[G]/@&$+[P^(Y$LOWQC60TOU!ZF!PCX%&)&Q_M4[Y
M.>"Y5&[K,P?ZES5?;EPA*+LI')=,D-I5OH ,,"@1P)7"@#-[8""4%;DV3$)%
MAG5E^XHV-8H_OKN21Q<70_NXO9=N*+]WB@69@B]\<[1@C^UEX_9(M5?SBH<"
M_MJ><F]Y)^8]#\4YW*,>/,,0@>X7&W0W79^TJ:B4$@(C(71![ 40EN"!JB2K
MB$)0DQYIEM<GGAI7>[:P#^BR%;P4WNP\.,"IN7<(;'L&@'<#-69P]PUI7C%P
MNQNCVT'9'L^GLE[;3HMOG]9K;2WJFE07M;%U;/]@91"AL+);O*P %H9;T[50
MP!*>T@5#3%$]K.GJ)=?4N+ 5.I.MU(T-M$ABN_HMW%"&Z^#+,06KU=Q8KE>S
M6(.0?FUSU4_8B=FJ00B'&ZIAPT<YB?^T.\7SEV_S]?;YM_F/7<E7C(0P*G<E
MASC O.*@0I:R*7+4+7BE<R_WPHTYIL:W18YHD,/R(G!>OMZ^<*1V[];R98V
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M\[6><6[\?Q"WBGT_-M25E<B^*05]L-O>;XX(YM3^]# </:XW+;&9^G*S3XS
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M_R%??J-K6CN/G_2[N%FOY>JTJ93Q0)?KZJ^'ZJ^\R @K< R@A!) DC% 8BE
MPI7,,YHDG#IRB9<<<^.9$Q$=ZQ</71!;3IH<YHGY2LL?/1P4,$TJ:PW.JHF^
MJ4[@K!?"@\P&P3@UT?D)%Y@$!R%X29##AAOC.N3]LYZYO%/ZJ_=9/FZVQP9[
M9Z6""<>8$ ZR(BL 3%(,"$,42 4A9112&%NE1@R086ZD^>6)E?*_G\SK7,L_
MY,K";A5\KBA&QS;HE82LI(^H$3_:[N5OFOQ.5Q+-%[^0MPUV@MWP=L$)N>[;
M!+>AQJ#%W^CN:;O<O=RMZ>JE7);WZCPO;=] _/3UI&E"!<YR0*@@ .9,@0)A
M N(DX]I;+6".!MP1>T@T-\K\NMG15?2T%EHMXPN8T[*S?F66R13C+9D/HTZ\
M$$'Y]:'1):*-,N:7FT/>:[TZS9WOA$73QT$W)/OZB'E#+AZ :C<S#QG8/17-
M'$'JD;^\/+#-:D&0XMATP4PA40!B:KSY5($,<811(@J:6$4D7XP\.]ZLA8MJ
MZ>P3SL[AZN:Z02 $N"NPT-\IK:Q55^]TLO/1@J61M2IQFC[6_@'_&J\?M.WU
MLB_#&7.>2<F!_E/[A HJP&A&0$H*'F.1I"JS:CAP9?RYO81I#&/WVJ6G@'6_
M@"/ ,/5K6-<HK80;4,[U[#OD7,K5$YJP95PK(<<MW-JBMU71UM/G@A=L;1&Z
MK5AKV\?&<.(^RY4)"?A$]?"G5G_!&(QSS5=0VP\FE2D'!4P0*!)"*,Z8@D,<
MM2NSSHW/&C&C2L[HM'G-$"?L&N0^CM8(0 9UIK8-HH\5HB&<I1Z$0CI$UT2Y
MH=/3@TZW8]/WL(\-M:_-<<]6RV_53I0LD$HHQ5P!3+,,P#SEFH;T'XSE.,T*
M"!5R*#K4,L/<>.?MYN%AN:NNP4S/B^9PP<6,:(/1QK8:",[$7'(HCG,BWE!4
M7,RK@>@$,K"<4'(TM#H0Z#&UVIX,:&QU"'YN;G5]T+N<VB\FHO_TRO(DK/^7
ME^-']D'_)EO][6JI5/6WO\OR>)J_8(KR%*$$<"(H@&DJ 4FUBYEF4'#!DH0G
MN6,)MA'%FQV5&C&CYUK$YE+,N1K9F,MGP\*W7)2)*?RT3>RI<M&)=A%[B4X_
MUV@858J]B>HEK7Z(&C6;$KXW75CGTG0W6N"0Y>R"+[1/+;P)UL&F?MZ8TX:N
MN3<!9"UU^J:898PSD]\W:RK^\50-?_W:_=?E6G[<R8=R05'.DQ0SD'+% *0"
M I8*!#A*A?YJQ*F0KIT8_:69VP9]?CZPWJS!09N^T!8MD8R61JE!N="NR^ES
M3C/A(@4]OQE]?0:>[GCB&O+4QU7$&YX&>:+9?4KD.ZB/LW6<=Z/J+V?UW3Q\
M->MOYB&-EW,ADP2E("94FMMQ#FAB&A/E&4.(TB2WZT3D,_F\>;CGS?;*IW9<
M'!M':3K(@[+J#-!V\5ZF0SV0;S(R^HY.AQ]\/2Z%XZ !'08_=<_= <\QO((X
MZ(_W2DF^NU=?=AO^SPLG9!'3(LU2O4WD6"8 ,L1 H9<#)#C-4T(HQZET2/.V
MG-;J-0J?YWWJOI\FZCC%//1";A46,@J"@<)$Z(^H%C:Z5U$E;O3+Q5')N!@Z
MQ9&,B66HN))AF+I&G-@BU!>!TCM.R(@46Z5>1:A8/^;=5+0JH7FOWO^06[XL
MY:?MDLORPV9[_[0K=W1=!? 9)KJO>KR7=S^6Y0(BI7B1$%.%CFF>)@102@H@
M<U3(5,8YI([=AWW$F)N=7^M0V3V-%M%CI49UU;PY*E+7-(LVM2K1GU0KXWS.
MXK5PM@<L4R_'Q)O 1"OAT]MT )"3MSOUD2UT!]0!^+4T11TRFB_#OJ=;TT*L
M_"2WU=@'QS"A@G&!$,!*&[JPH E@L4B +)" !20\L>MNT3_5W)AR+Z?Q!)M7
M\$_JYHI;X&M+=F.@-C&A^0'FP5=]6$S-25?G#\P[?3A<<DOO$[[\<5<=\59Y
M3)JI+LI8EII'LD+*M  "8@A@GC# )"\ $8+2'/(DAYD;C_1-.3<^N>8J1S^M
M-SL9)?&;*$WT_].?7<FE%WQ;DAD3THG)YD34REYJJ< [:ET06VBFYIY>.0)S
MD"TNEUQD_:3WG;TL^799&4GWJBE(:"Z<-JLE-PD5GV4I];#?[];BG7R6J\VC
MF??]#_-FRM/(?)$(G$') >9Q B 1"A#"&"A2+"$6/%7(L:_+6*+-C>/V<E=5
M"\51<DUXI4?YC[$6T/K*_@;+,O5-TU$EXVK2@U+18Z5519[;:\LF:]6FR]08
M&?#)+_;'DC?T+?_(.+=<^8\]@[<G6[79T=.<=FN1*4UXBE* \U@ *%,$"M.H
M2^8I%C',4FZ\6%-[P]J+;9G&B8T/DTUX)%X5$SFIMEN]WY6E]'VSTJ"6_Z-I
M*>7LSK:!;.W*#H1N:C>V;K)EH)JH#4X7 )/[KFUSA_9;._1O\5F[/CU*/*<I
MT&'*]K[_L9.F9=?G9?G/\FZ[+#6!?=#R?UBNZ9HO37=9[2Y7EUEEW1$E1B+-
M".: L((!B)$$)!$<*,ISH@25>$C/&W_!YF87OHHBK/2JWC!9:5:EAAK=(EHK
M%YFO3:3VZD7+HWYCM+\9L.+6IF3P=9S:D RXA$.C0@?C'31 U%_:6\:*#L:X
M)VQT^/A>K;\/J;=-:QYCQ$H]CRR312$%(P7+]7HB4\ZE2$!1-7E-1)H6:4Q$
MCAPZ?7=,-3?^/I%UW_WJ*.W^ #-[$R50_[^P/,"T0+R;;<?%<6+^/(50RQF=
M"SH:8D[-N4="+E0O;C\$75MP6X#2UW&[:XB0#;8M5'G53]OFB6&1^??J/3<;
MZ)*_D]KY%WIT^57;$+^8PZ4%%#&C!2- Q&D*8,8UQ2(N@12<\+R(L\*N8)W3
MK'-CV[VHT5%6O]#O;JQMR'4"!,/9J?<J:H$R^M.('?W2?9@Y %>_6/K1\ T?
M1#\$9^_@>2N\K*/FNT>[2;B\E8+7XN3M'I[J9NV=5"8Z7WQ<\\V#-/&A)Y<Q
M$*NDP"(&&2IR  L,C17-02)RPBF$""HK*WH<<>;&_7M9M;]LA(VTN^G>)6W0
M^HQU6386ZG.X(!.7JW*S.S$;7&]]#]8IX\SNOFSP=+_OLAK5O;SS>SW+[J5I
M+7?(H?VB-_NG<B&X*G#".&!9K)E5I1(P$7,@H>9527 L$JM\UKZ)YL:9M:Q1
M(VQTD#:JQ;6O!MV);C<OCHG9U!=<GG Y%8^VP<*[EG3GX,%*2]NH>%IIVNKS
M/L[U6:1X%3[^07]9]LTAB60"2PP*%DL D<P!HXB 1&5*0($2%%LU NZ?:FZT
M\*_9WXHD M&_XK]!IP.V3CQMO.:Q4)J:"/9Y)Y6<425H9"3U*EW=B9J+3SP6
M>H$<X0$H.CJ_-L#T>+R=0P1T<VU4.?=MK9[PJM#X]/BX6LKM6R/W>K>MOB[F
MMBEIOKN<IXID%)IH(09@)@0H%$1 %'DA\Z* 0EFEP-A--S<6_;I9K4QCQB=%
MN;F2VSI5V>O#UH9-QT1L8D;=BQJ=R1I5PGJ1:B^ 3F4'1P0R5!G!08"ZE@.T
MQ*>OO%_?,"'+]5FJ]*K\GNU3O@>(APY(30#H A(F6,Y3@+!I5$2AME=CE0/*
M$<X+;;4R:66E7I]B;KQZD&]X_L\%FK9'>$,PFIA)C_ T,>AC'K%=TWOJ8[.+
M>0,?A5W3^_)XZ^HG?=]XX^96E3OOU5M:?O^PVOQ5'I)@6491+C$"<8XR +6E
M 4@,&5!"4LY4SK6AY?;V=TTW-R8XR&K.G[F6-E)&W '9QIU@VY+#6!!.;7+Y
MH^?!'#:@3,TBG3($9A0;/"[9Q>HI]\/Q=XU->CR._V+J)="M6"#".5:$ XR9
MMB]83 !3* >:6PCA.8]Q:M6)K7N:N3'+7M+H*&JTE]7^5+P#UOXS\7' FOH.
MT <GI^/P?AB\#\,[A@YV%-ZOWNE!N,6G?<V,KYO'>U6=#C7^,>1(I9)0@.),
M ICA&! E%8B+.&8ISE%26#4/NC[%W%[ZW^B/Y</3@ZO-<(&<K9TP!(^)WVLM
M6I674!W)_ODPUFE!O^Y3FP 7\P;>]J_I?;G57_VD[QM^,!A,$L ?I;EA_[AN
M&KS<\=WRN4Y&)#"!!*7:D4C,77A,<T RDNF7/]?_PF6:,>Z6\6DWL1,;!,@!
M-5)'3V45NJ+_M^^$0P\"N_*$)?ZV[#$^JA-SRMNCBU%E./W4@/NS&[H>9.,&
MU=049"E-8&)RP^B2KAR?'R6 TARQ\)V>ZD%_Y;1+]'&M)Z&K.W,&RVG]F=_E
M7WL;J;S??EQK0^)Q*^O3]W+!$,L88P5@0E$ "ZAY3L8)2%**(4)*49P."*D<
M+.#<3*06,[_.:WHE=_2Q+)_TV\V>=M'OFUWT7W+7U)A=/EN&Y$^VYK8$>[N5
MG-II.Z_BWF@6+2O5S*^6M7(1/6I7I:[*OZ+RL.J;K?[<^:('">P<;26"AGH.
ME_J6P9^C8=X3#CK>/%X5[*N&X5^_+[>[EP^:IPYQ8#CFW"QRK$P)%(D 28TW
M#*G0OX%)CAVB&-HGF1O/IW&&G*JHMT/73;5C 3*U+UP)&-421D9$KX"$*Q Y
M59<?#%6HDO(>D+G6D>_$HJ]X?/O#(2O&=XK_JDQ\]V?=J*ZRW[8OBS^^+!06
M2294"F22* "YYC2:$ I4FM."I5E*["J+'H><&XW]\?O'K^_?15^^WGU]_\7N
M93W!IYN]_+2>F*OL%+9^U2YU[#AL;SY<V4S['ZJ7KWKQ3H8*\II=BKY_J5K^
M96C+M#JY25N-A[OB(A4H)U"!G",$8"XSP*"I X[B5 J5)PGS[)!V,=?<7KIS
M]^(T[VMP/ZY+G&TLC-'0"^J730R<;]^R00#>I$V9&Y #>I)=A<:A!=GE&#?J
M.'95F>L-QJX_XG]EL=V^F /$!\/9C<6LN;.@,>( (Y@"J'E6FRU9#F("<8Q3
M;JXGW<[LVJ:9&ZON98QH):3[Y4,+DO97#</PF?QBX0R:2>XKNR"8_L*@9>[@
MUP/7]6^[#.CX]!B5)S_0Y?;O=/6D?2%J?E.'1)W4N3S-RR^88%!Q!C*22M-!
M00(*-7\06?!$0HERE/O7FG0196ZD\EF:+X"6\W#&R[]75_[+=:2T7M&S4<S\
M_B]J6LCO(KU@RV?J=8KONWS6Y_4!%B6H!7BR @]'-<R_G%8FGNS0?2"<(2M!
M.LEWP]J//CAV5WOT&G&<7C7O)-_J2>7']?Z_][OO<GL(@-?D(C57L)4L%Q@I
MF63:2"N0T$YP0C@H4JX $5!*;;=E#%FYPR/(,C<.K@2-MD<!AS6Q<5D56V8-
M@O7$U/JZ[8UHM(A^6C9ZF#B4:%.MQN:00V.S+H.;XG@@&K9;CHN -VVCXX%D
M7W\=GR%]SA,_Z6_Z=SW^/5LMOU7VV+&FY%>Y?5CP'!,1<PPRE D ,4D (5("
MA&*&:1ZG$%D%Y-I--S>:/$H7Z>DL@W0MD;4Y1!P3KXFI;B]J=)3U372"W]>Q
M\7,Y2QP3QT#'B8/P=#Q/M(6GYTBQ=YB IXJV*IT?+%H_Y56YPG1R*?]8Z\]_
MK!*UM3][IUU<\4DO?',X5A0\E3%3 &4$ LAH"@HE,8 J8P4I$(+8J@NV]8QS
M8]R#G!$U@D;&CW"JP& !L@WSC@S=Q.1;2QM5XD9'""N!(R.Q7S4+"RR="EJ,
MBVFHFA;#L74M;&&/4U]M"XN10I:WL%?L584+AP=]JS3>":'G*#]MRAU=_9_E
MX]N-D(LX*116D()",@D@21+ <D0 HC"1".4%R:W"\+JGF1L)-R4'&U'?1+6P
MD98V,N*Z5FAL1;:;A,?#:V+F]87*HSIC%Q(#:S.V#AVX,F.7>I=U&3L_/<9E
MSZ>M.8_9O1B&V9G&-O_]M-PW03RVFBU@FN957>P$ 1@3"@CG!$C"$"=$Y;EB
M_I<\-B+,C3KV,E?Y&0>!AUS;6"V$SW7-V/ &O:9Y;(1_4UG(N[JUUUZ!(-<S
M+O"%O):QDNN&US$NN'5?PSB-Y,N)OS\9Z^I>52;8?94R4?Z[N94UR787;<#O
MME7VMOGK@B"8)VG. >)4F/K6.:!"_X%S4<@""H@2JTC?$629&TLV0D?B:6O.
M^W??9?0BZ3;ZJ>KV6CJ7%/-?)%OB# +]Q Q:ZV#8LX(YVM1J1-^:U5BNZW\
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M@A8T''H2G#Y]HZ8$+0I<[TK0]F'WY.^[)VTP;[8?EMN'CV*1<\UHL41 ,DH
MS+'45(<XR 65'!&E#2ZK:_:+D>=&;XUPD9$N^OC./J7['*]N=AN$PL2,9@N
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M"T)S0!,A 8%Q@5/!,T6MZD=,(=S<]A'3\/9Q*_G2B+TO;QOQ3:E99%GEC)B
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MN=J5YB=0O[ ):'R5\Q&#O*"M2NQ?R/9_],X@I.5W4]WBF:[,CK[($HC3!&<
M*V4J]Z$,4($$* J4,,AC(7GJ6+/F?(:YO9A&O*KP2B.?<P;6*P!MM]X!L$S\
MBEHCXI-UU:[UY!E7KZ8-G6W5KG5+IM65#XZ19?5V\_"PK*Z/SSNVY6E6R%P
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M5>655\E?=P]RJW?0-]&['B"LW\ VS3L:Q.P_7D=O[W^J7LSJI3P;+LA;V*;
M_K5K_3?_>(/JWMSXYYOUE]V&__-3<_YUN#9O=H&<"I:+C &6JQS  B)0Y#@%
M,F9)%M."2$G<+[DM9Y_?+7<M<U0)'>VE'A)K8+L.]E?>$V ;YLZ[#N7H07C
MI;<MU.ZWWA- 'O;:>R3HO2[ '<&SN@&W'3/X%;BCLFUWX*Y##"P>\'E9_G/O
M$J0H0[! .4!0* !S+@#)TA@4J>0JI2J1PLKQ[)ID;K9:)9IGEO\I=K;7/<,0
MF9BI*ZDF2:.]KG:@#/S3F6^3:]^B^]6L^K;/CA%<WYFM?QKJK8T_@5** .3*
M5 S)$" B-[VC89*FB$/!$_\H>ULQYD86E=S@EZJ@A:G-)]=EM8$/";JW7A);
MAID:Z'#W(%8E1 )$Y+NB&#(TWUJV&\;HN^+7':SO/-HHR9&T_/YAM?GK4#?O
M],U$'-&LD*8=I2BT$XVQ=J<3 42:$\02HHG4L4RQ[=1S(\@[(9:&$.DJJK*$
MC=S149EAV9-=2^!#CF,!&Y00N8%5&5C+O=AA,BHMP J:5]DESRVS*RUPZLFQ
MM!G!YV3P;KU^HBO3K'.IZ7*]:^AS@9-$)ADB@ M& &24 ((4 07G3''M@B.:
MV]\W7IEE=DQ5B1DMU_HU6JVJUTB_7;3^[>-V(Y[X+BKIRBW-Y1K$-L=[(P W
M,1,UF!U%C!H9QX#(Y5AN!*@"'<"Y0^9XR-8#1<]QVK6G QZ<]2AP?D36]^$A
M56X,YY8?M'1_E*8[QOVA$/\BX9S&2<P *4QCX50H0#!3():<8:@23B%V[#[>
M-9\358;H0VY,CJJ#X_+0GV#]+3)1G<]^3<D[T;8UY4;#<&+6?+NWV,K(?/>C
MGQHH?YZHUX,5+B$*ZEP7X@;E=7H1:2^VT__8&-[E/?N'25EXEN6GS6IIRH+?
MK<6G[8;+LI2F9<]OVO[[IE^ZM_1QJ5_X4\^'))BC0ON=C$GM?&K/&!1I)@!2
M0G'))<3(L2/O2)+-S>)K)!S+'1VR9C[>:J"5".K,;@XZO8D>&ZVJ\-G'O5ZF
M8G[TT&BFG=]Z"4,XO"/@'=(?'B+N#=WE$5#N]J;'F,#'V7[59N/731U,G%2E
M.7F1<X2YINM8FY$PAAF@*I6 9FG&$BP@L>MKUC_5W$BXEC4Z"!L=I'6J=&J!
ML8W+/19R$Y-F.-!<G/"QP ODB?N#Z.B1V^#2XY9W#A'0-[=1Y=Q!MWK"UV0V
MJ=>[EWVP"LE%GE $5*HD@!CGVCTWE9.X3#%73$B[JM#MP\^--VO97.W5,\!L
MC4Y?&"8FP5JL28)3VC2>VG8[FS.P =:F[Z45U?HI'U/H[W3U5+' W4I[TZ8C
MSCNIY'8KQ5?ZXTZ;83O-&EM)2_W[^K]W#YNG]2Y9T((6&)GKU%3% #+!3='W
M# A<4$$2154B%FOYS:0;?[4UE[S%L7H9BOIEN!!J0K^V;B^Z7$>BT<,T'HV8
M7$NUW)7ZMYJ*1;3>[(Q;Q2A;R6BWT?\>;27?/$O]@(O]X+^:-A;9M(L3AJD.
M.D0')=Y$>S4BK4=4*?(FVJL2_;17YN<W4:-/F"5QL?>"+$T@8W#:)7(T& <#
MVV--^H\?T-0<#,*Y'3I\N(&Y-U7L=MUSW50.:FPPAD7&<,Y!AA(.((P1H(DV
M#W*:J@0CJ<>DKO4]KT\W-R.VSCS85%)6=;$\DSS:L;797L9$;.)=Y"QUHT:N
MEC8RX@[-DVF'T#,U9C"4M\B&\8#4/_^E$R'[E)?V86Z3Y=*ITM7$ENZGKG'N
MZ8K\JO_V;_^R_XW^PX2"_MN__%]02P,$%     @ W(9C5.6PI<'OE0  --P&
M !8   !O;F-Y9BTR,#(Q,3(S,5]P<F4N>&UL[+W9=IM)DB9X7T\1DWT[EN'[
M4J>J^C"T9&E:$51+BLRNOL'QQ5S"! BH 3!">OLQ!TB*"TC^ /X-D9/GI((B
M*;B;V>?F9N:V_-M__WHQ^^%W7*ZFB_F__X7_E?WE!YRG19[./_W[7W[]^!K<
M7_[[?_S+O_S;_P7POWYZ__:'EXMT>8'S]0\OEAC6F'_X8[K^_,,_,JY^^Z$L
M%Q<__&.Q_&WZ>P#XC\T_>K'X\FTY_?1Y_8-@0MS_Z?)?F<K2H8H0%>>@C''@
MBDN BG$9E-#&Y?_[T[\*)8H7@8'23H+*.H-'0U]YP] G1![XYD-GT_EO_UK_
MB&&%/Q!Q\]7FK__^E\_K]9=__?''/_[XXZ]?XW+VU\7RTX^",?GC]6__Y>K7
MOS[X_3_DYK>Y]_['S4]O?G4UW?6+]+'\Q__U\]L/Z3->!)C.5^LP3W6!U?1?
M5YMOOEVDL-[P_-E]_?#H;]2_P?6O0?T6< &2__7K*O_E/_[EAQ^V[%@N9O@>
MRP_UO[^^?W-GR04)>_9M/4VK.%VL,7W^:UI<_%A_\\<7"\(%[7GS&>MO7_#?
M_[*:7GR9X?7W/B^Q_/M?Z!.^%5I<<"ZV2_^W[;_\\?L.OBQQ1:#94/R6OG'U
M 769(W:#7]<XS[@E]7JIV2+=^:599?3BYE_.0L39YKN3C-/)YE//XFJ]#&D]
M0:^\Y8E!(EB"XE*"TYE#"B%[6U@ROMPEONY]19O?R&6%Z:^?%K__2!_\8^7'
M_U'U2]A^N6',@R6W3#IL[]='\<V\+)87&]Y^#'&&$RFU1.\C")\#*,P>8O**
M-E*\+H794.S19#RV^EV*;@O^;)E^6"PS+DG/7"\?END!".YB_.HW?OP2EO1!
MD#Y/9_GZ7U>%TX8LUXN6N;H5'VW]+S\0!PHNEYC?;J7W**$;*M>DB7'SF\<@
MX]5\/5U_.\N9N+_"U=47'^E?GGV=KB9!)T_41RA&("BA.(1,BL-(GK(QBJ'#
MH_'Q]!Z&0TD[\EUTPNR!87-KZR\7%V$ZGQ151/9:0HG2@;*"@^>& YHDN! ^
MZ7(\4AXL.QPXVI3EHBW&#HR*GRY7TSGM_L6"A)#6/^-%Q.4D.6$P)0_&>TWJ
MU65P,5H@0\Q')A,6*8Y&QLZEAT/'D6)<M,G3@4&Q0XN278=OUGBQFA0?6.29
M :NWKL*2(" O8$S!;%$SPSNQ/VYVT @BXB1NE]88/1+ U,,S89)TI2@!4C($
M=!O(Z1.*05;,26N<9R:V!I"ZXJC,C0/EMP,4>S-S)"!XCY^FU4ROW/A <L#Z
MS8GV(I*;3]J3H0*EO*#;E5S:HEW@3DCGX_'>UY-;&)7>: \FQ[-[)+@YF\\O
MP^P]?EDLUQ-C!49RZ2 [)(U*+ *GF() QEFAVY(SQUN#R^V5&Z%$GAQ*#F;N
M2,#Q#I?317XUSR\)X1,G/+I@"FE%2^X_R@+>% $2D[=9!FU\;@T==Y9N! ]U
M<O XG+T#X^/%Y;(R[O5TE<+LOS LKVG@.19M4ZA&=JG>'&$<@P%7E)0H$[/*
M'!_M>V3U1BC1)X.25I@\$D7R<1GFJVGER[4R9$(E$11XI1,HAPY\5 7H6X%[
MY4/1[1DF]U=O!!1S,D!IA<DC <J'SSB;O5A<? GS;U=4H'12%3+&)9E0=&\J
M#]X* KYA,3G-B\[M&24/UV\$%GMR8#F2T:.(QK^>SO"7RTV<IS#44NL"5FC:
M>Q$&@C!5)WJ4Z)+(/K04?_^^:B-HN).!QE%,'04@KKVR^?J7<(&3')4SQ=38
MLHZ@F*2+4EL.=$VF$%/"HHZ/B>Q:N1$P_(D!XPCFC@(<;^9IL21%]]UG?[&X
MG*^7WUXL,DZ4#KQDE0%U#13;*"#&$* 483,KG*O2E@)Y<B/-PFKLQ+#3'N]'
M :6K5XNK_U0F<3*VZ-9$LK-*RN2^&<' N^A 1N-XS$*F?+Q%^^CRS6!S.N'8
M=O@\)K"\H"_/EQ\7?\PG0@9I4N00G"6F.*?)T"**(F81R<A"]+)=J'Q?O!E0
M3B<@VP:/QP23C7(\7[Y;+GZ?SA-.M(H8H^>D#!E=LX4C.*LTR.(-9R6[F%B[
M6+FW@V: .9W8;&O<'A-JKF[32>(Y:I4CL)QLW3\9ZY$KT#9[61!3**EES;)=
MN1E*3B=$>S1WQX2.=XO5.LS^]_3+QMJ*1<:@DP,1$EV@CM$%JAD"<T&3DY\Q
MZK8LW5WK-T/*Z81I6^+TT!'];=;,._JPQ7R.LXV+%T1 PZP%P^J+58X1?-!(
M%ZEG9*KG*-GQ=LJNE9MAY'0BM$=S=VAT5(0O,6Q0S37/(JD 29)YI31G$)5U
M$+Q!+"4&J8^/JMQ>L1D:3B<$>S W!T9!K:^8O?N\F-_$!Y,)06$$ZR592[[N
M7=:L&<L==TQG]OW&/Q@)]U=MAH;3B;H>Q=6A]<(]O?;J(DQG5U?A1$OMHBX6
M.%.%Z,@UL]<5H,M/ABQL\/KX=(&G=M ,*:<3AFV-VP.CY@.FRR7I0"[BQ^EZ
M1CHPL"!5,""5)#M)DG'M598@A%%&,?+5LSX:*?=7;9:8=CJ!UJ.X.C B/BY#
MK8[\\.TB+F835F0(TE@@2!M0HABRB9("F4+PA06O6KA6[BS9# NG$ST]G)\C
M40VOOJ;/8?X)-X:RD25R29:QX2&!LDF C\E4_<:%BY:G>#P>=JW<#!:G$RL]
MFKNC"&J\6%Q<U$>D1?KMPV=BY.K\<EV+@2OB)ZX$%4- D,[6:U!5I:<CH,XZ
MERAMR&T]^3ZUCV;(.;6@:6N<'P6._H&SV?^8+_Z8?\! !A7F-ZO5)=G?G#-C
MDHO =6'$(^LA%+*DHG,E"LLE+\=;(T]NH1EZ3BV8V@:_1P&<OR]FER2/Y295
M9KF:&(\NAUC !R3D<]3@<ST(":4HU00+QR>H[5RZ&5!.+99Z#']' 9"KS-UM
M6EVUPT@FEZN)2W2A:I. 1Q- :900!-EAJ$(NRB>RSEU;=]/.'32#R^F$55OC
M]BA0\V9.GT;^_?1W?!G6X8JLB3&9<QX*B$@<4DQX(*-,08E:\1CIM@UMH6;W
M#IJAYG3"KZUQ>Q2HV>C(%V&-GQ;+;Y,<?"9.* A)D#%O2H 8E",6T07KR42S
MPK<$ECL+-\/(Z01EC^7M**#QZ@*7GT@A_FVY^&/]^2K7>X)>9+*X$D3#,ZA,
MW(C,2[!%\D0F6)(M5'$]L8%F4#F=J&Q;O!X8,F]269Y=YBG]QMEZC:NM2%[/
MPJ<)$C,<:@/,,T.>G1,0(J>O5,T!YRGF<'Q2R>/K-ZL-/9U ;4N<'DG!SEE*
M-3MF:W?-<UCFB<O*DZEE@1@A0$F+A/]BH3#&LI8N,FROMNOA^LWP<CK!W)8X
M/8HKZ7;5T42DS%16%LA,]V1K\0#>RP"<=B]8L,IB6VFPM]=MAH_3B>H>R=E1
MX.(%,6499F_F&;_^#_PVD>2\&2S59:LM+#GM/11+SINW0HKLO;9MV;'WEFZ&
MCI.+W![!WY%<--_KH%_3=U83LL9ERAY!*D\W9"&U%Y)$L&B*BHK^C\<G1C^R
M>#.0G$Z M@T>CPHFV\X*6R*,9#%K+8 ;4;%.1I7G3(# Y*P(FF5Y?#S_T>6;
M0>5T0K3M\'GHKHQ$0=Y04:UNCR[61%W0PCA0,7"("I$THN!2!R6%:*$CX^TE
MFX'B= *QA_-S%-;'N\LXFZ;7LT583QQS8?/\5(I4Q *GP#-+*,Y!VUPR,FSK
M ?G6LLT <6HQUD/YVAHH_NW'!_PDVGX[NHWWQGV_Q;"[&V_8T?O!A[3;W/OI
M/1[9YWM#SN0JBG%KD9M6T:'D(I" HT-MZUI[29 QD2&B]+(XY9"99SGTW"I'
M70';3WT]75Z\R1-=(JNM#B"H1(:.DQ%\(ISKI'@.Y#IE<WQ-S)TEAVF?V*K<
M[MP ![-S:%-@N_%M*E3(OA")H&BWI*.$@\!2 '*&)"E"RYT_/M'LUH+#]$;L
M&@-[LW(<"'A[-3UB(@I9K4$FR#[4EL&,;JH4&5C/44KNDV\A+'5OT6'Z'W:-
MA(-8.OK+_\7Y+Q_.W[YY>?;QU<L/'^G/GU_]\O'#^>O7;WXY^^7%F[.W[\X_
MO/GXYOR7@ZR"YI_>\BR0PZ@ZTHZ8EN4*RN5L-KEIHGI>7D_G89ZFY%TNMNW,
M;O"836*$.@>,:0_*V (>A0=;#)H2HK%^ARM_?3+K8AO,K,/7Q7QQ\6US/H%)
M$.K'S2;J;WS_"M)B.?G^*QOQ[+?A0]72]U7.5BM<KVX8(- +8[@$RT5](&(&
M(@\!@I2>A<",$3N"7MTPX.[6AK%G.L3/M3YK118#7G'?]W^5XW*/C$S[=+'$
M6I_L:P$B@H\U%)Q,C,DSK^V.U]UN(+5SAT,CZQBQ/\#0\3(8!Y3"ZO/9/-?_
MO/H_E]/?PXR(6DVD#4PXE\FKMY;HT IB+7WW(0G-D/R M"-XTA&6=FYQ:#"U
M(/^'F#I>&*, U?GZ,RYOLCD3$B5QAJN)0LX9YQJDC;E6%@@R0+T +W0(2@NO
MW8Z,I6Y0]<@>A_'DNH55&^(8!:ZN:'BWQ"]AFE]]_8+S%=$1;4H2R9O)13%0
MLGCPY)6"(36>96'(?'_*:N<6A_$*.U96QPMC3*#:\F:B?919^0A:\DTS3 V>
M10-<%)\-6D2V(TF[!R-JF,[YO4#H -8?CIS%.LQ:0LZ[Y>(++M??WLU"G1"1
MZYW]93,^)-)Z*?  EF%-^@MD6K(L@;[(621=K.KMHGMTET-?=:V:X^W(8A0*
MZ7V="+PHERN\.AAH1!1U#HU)F>P_U'6>A/'@8BK%16EM[BU6<']S0]]LK8+H
M*,Z/ CM7^_;*>\84ASJ2$12/#!PWI?8B,LDQI7/<,;VCR^C2T-=7JS@Y@,NC
MN+"J4EQ_(^WX=AKB=#9=3_$[2Y+F3#+D8(12H!)W$,E< Y[0,<9SC&5'LG<W
MF'EJHT-?6SW$)UN3TRATTI65MXN6H$N,'!$2'48Z00'!":'!*-*NC$M60F\W
MV^/;'#K4U!X<'K/ CY7-*'!6>^4@<>EVN.-=^+:-=8CHZNPM :683(Y*4A!<
MYH!26^/J [?9D8?>#=*>VNC06&L+$ ^0UIIT1H&UVU3<XM6$CE^(WB007"5R
M,82M:7;DTB8G0XI*9;XC [7[".>M/0Y]?W:&L#9D,@IP7=. @3[R%B&YQ.RL
MC\0979,OR++PF@FP0M0A@\;D_G38(WL<VAWL#%QMR&1,X'J)R^GOH39-N#%B
M;Y-5DG0^* 8L^EKO+!/$6,,G4H9@@S%.]):?T6C'0_N770.O17F-"8:W:8A9
M,&39 ..V=NSPDHY2BF"L##)S57SL7;WM";#6JW]ZU&P'2F(4@8U?%O.T):.V
MUJU,N4V.8,9KXR*@J\F/MB1PWI"QR:614NF:X=P7L)[<Z="F68>.9GL2&H7Z
M^D[. XM :\U"M@9*)#>F%E="L ;!ZLPC*B_\KLG)7:-M;(9:+U [2C:CP-E=
M4S/5N6@<DJQJ7M@,02L/HK"<#!)?>&]I#B.RO#I$TJ'<'_!.W%8"U/ZNTW4-
M4J]J/MEBTVP$R6K$%9^4(FTN*(%,0^))8!9\K%E /%DGN4[B_G7X:$774^L,
M;3"UCHN663L*_7+%I&NV:)4S2U:!T#5YQSD.+I&FK#6?);K$LNS-!+^[M6$F
MO?>B98Z0P2@PM.G^FU^$+U-27I-0:-])1PB>)5"ZD)XTM7EGB*;4S,*D>S-_
M[NQLZ,CZ,6)^@)G#>3X@9+8*]!]A64=/K\(\;_(M[O8>CT&6:!-X41\"DA80
M:NH%=U*BT@*Y" WOIJ?6&8FC=0P66F;F*#3)6<Z;9_0P>Q>F1,(UO@G'06:+
M0$K5@O)2@Y,*03NAI+&QQ+*CD+.C=);=>QR)/]6.=FE##N, 5$J7%Y>SL,:K
M=\?%!6WF,\Y7T]^QCC*O!<Y%.FX8&?:VS@(5V4$(=%2R(:O-T>V-I3>;I\%^
M1^)NM02TEN4S"M"]QW68SC&_"LLYJ>'ZNJV#XS6F96H)?9TV&XU$\-KR['F*
M:5<;S8[R-^]M;B1>6CMP.HKSH\#.EAV37*S%VFJ!#+M(?B0G/U*["-86GSRW
M08?>C.CMED;B?[6#DP.X/(IGCEU.Z(2N75ZBT2"P4E%"ANB]J.,#1?;.!32]
ME?WNVF CY+3>$*M/S_UP>;2&JL%;9+S;2.,STJ>0,7R'O+;[9=Q=:J#F&4_0
MVV\G#93,9>\39$U((R5&3IXG+#M7)#,^:IUZ2Z'MIY/&O:L &7FRVI&7RZ2@
M(^P1HC46&*+E,5MO=&^ONP?$+(?NI+$/?IZ-7>XCBU'86]M)S>=E.P5O&U6;
MJ(3(6."04ZY]KS(CEH@$*5EK3&#2Y_Y><'=L<&A<'2/TAZ^UQTK@9-M,O3W_
M\.'LEY<OSG]^]_[5?[[ZY<.;O[^JWVOU]GQTD7[NS68TMG9C;D,&-WKO!J)6
MH](& TBD/U3M?.UB+?P2VH@:3="IMWK<1_;8PKVX+<'_Z=LO87VYQ!OBZ;PP
MD^O4-)Z)>,[IJQ <:!83^<5.&>SO@MR]QZ$U6ANXV7$YMB"04=R2[TD>M(7:
MF^8E_HZSQ::R^HJ\24PI.UF+9+61H*PH$))ED#3341*/,O860'URIT.CK!4\
M[ AZM26<46#M_ LN0\VIN*; L(#)> <>K0;%ZC.GEHQ, V-%CAGM]W;:G9?4
MW-O<X.^(G2#J*!&, D3OEHLR7;]=K%:OB6LW])S5*9';*(WD6M@8#,A2.:2=
MAH#H(!K#+1-%!=];H=:SNQT:9MU<C^T*:10!VK^%Z7Q5*<+5^?S%YS#_A&_F
MK\-T^?<PN\3S\KV*8S71P6%*.H/5]5"5PB!**\!+SY*,R,FZ[PN!>^Q[Z(?N
M;K#8E>!&H0WO$/?J:]J0]W)::#LX3_6;'Y=AOIIMI/@>T^+3?+K"_&:^/:'G
MR_IO)]S$I /3M<L361(E)G"":]"Y*.$EL7?7\,@>\'HH14._I/> Y%Z$?3#&
M?\=E7+27AECG0.-JO64KG>+=S319$-9GQ0&5C36/VT(0&H&5HC&GB(;U%B]O
MMN6AG^B[P6D'XAJ%LOUNU?R$9;'$C^'K1&J6;&$%D D!*I [YKT)$(LAZ]DE
M%;/HW]B\V=_0;_M=FY>'"6(4!N66-;3U*U=L6V]P26;RE;V\F*\FEIF"*B?@
MNC8;$G4:9$H);!1>D]OO(^O-DFRRX:$S KI2:"V+:G\ ^BT Y_BI9M1][$2K
M33)/-;80@5F.=210(-- )A"I("I5<]$'4&:-,.5.#5,'LGT4JNNQA,X;UG A
M4;% Q&R"5,76CN;%0XI1%>>$RKGG;N"/;[81O/RIP:M5$8W"^GJ,HE]P?5XV
MNOEIAVB2,!HR! QX+6NHDW-P/CE '85*;-,4?6A0-B5FZ/>.=N'5&+V=R'H4
MZ-Z5'J]=C4#5Q&;%<CWWK Z'H'O!"F\=$>9C?PW+#RQ7X.S4-.>QDAC%#?U3
M6$W3=:Y\-3+>X7*3AC-![40R2==G'O*3L@K@T0>PCF>=)7<>>WL=>727S:!U
M<ED#[4AE%/KJY71VN?Y>CG&'&,-1H,ET1DPFY2N5 Y>YK*=%LJR%S;O&,W<#
ML2?VV0QD)_?VUI9D1@&S?V M?<5\]COYV9]PFTDXT<F*($D)(SG5H+RFVUUM
M$B&DM\7&*$MO>0,[=]@,6B?WE':\-$8!JK/\_UZNB(S=Y*08#./"@[.&SHB/
M&1PK"%%(139ML*:_HILG=]H,9"?WRM6>=$XV??C%?Y[]\K=7'][\\NI__OKF
MXW^]?/7ZS8LW'UM-'GYDB7Y2AYO0UT6IS?;U?_5F?B_-W7I%%Z(TI,%TJ0$X
M1O!R&FP.9/FSQ)7KK2K@^>T>KP ?7^-C;=H]84BF:(EUL$'UGK$DB(7.7.'>
MHN=:%]U;^.Z9O0X="&D970_589NR&L7M6_WKQ;R^ )^7*TY]G:XFJ(3*R4I(
MR%VMYZX5N\R#*8K8)YDO_?5JV+W%\4+M "3L#'L<*991P&N[]Y^QEAY-#-D:
M6M6<UH"UC[>1$)1P$#,Q111;>'\AW]L;&QI*;0C[D8+! S@_"MS<:;MU182*
MBA?F!1@>!"@FZL#+2$Q1+&),F9?<FT[:L;^A472XP)]N>G8 ]T?3^NQJ[\&$
MR+T3()(E%TBBAZ"YAGJ"!'IK<RS/VNZ[/GGH?/&C97XTNT:A+3;>Z+LE7DPO
M+ZYHR-;J**V': 29>5X$@BN7]38.A0O&,?<66'^XO:%SNUO4%4?R?A3X:= =
MZXJT9)PB=EFPS-&='"*Q21<'C#C&&=/!V=Z"Z8UW/73^=8MHZT92HP#A_9Y:
MU\I8<2P^!<!<K<#$,T1G,UC#?8R9N>A[BX;LWN+0:=,MPJL%&0QN^WP(,SPO
M']:+]-O&C?!<1>>=!A$M:6/&%+CJEPJ'#&/(*1;>T/BY]]%#6S]=N.#'\W!,
M 'BYN" \3PCV= L+!E8:PF^L$7JN!##&71 !56%I?PAL/WP8MZ<%,3TF\ -X
M-KS(-\\QO\[SU=/RN\ME^AQ6>/9IB9L3<N/$.1ZB19 ZTHG(KN:!10DI&B-%
ME#P6TQ0(S98<"3P.$>JB:PZ/"39G:S*G+L+R-US?)\EE%G)]4<[2U1'+9!SX
M% -PKI253 12LON#YO$%A[E6.H5,2]P="6#>7<;9-)W79$\RDJZ=/ND%KSU"
M':L]T)'L[=K] $*,*5KM??S^^-T();M6&<9O[@H:1_-Q%'[+XU;86S*EW]#/
M5A-)WE8Q29$9'B0H7SA$$2P4YR.+VJ841O"$>;/?H<,SW;XMM2VP4:#PJM.P
M]I:EE WH6GRHC)+@O \@2S :I32*]SQ79^AG@=:E_5B3YWU8?S!DOI"J7&2B
M:;GN,-4_%2-]4 XB$0_*95*_Y/_785.&%##]L+_)@H>F^@_B=[<%J6.%,@J5
M1/M>UKF(+W'[WX^?EXO+3Y]??<5EFJ[(ECC_LJU5I;.1O+$6?,ED NH0P5MR
M')",0>$242EZ2Z!MNNGQ7I%M8; 3\0UNP3]"%7V;>$F';6.9GOT1EGEUI=>M
M0^,2([=$A%H[5A1X[B,$+%)AKGTA1$/#?N_%AWZYZ IE?<AB'#JP9A)<9[5,
MN,:L2S'$H'I28I$0E:[!^3I+FWAH0V\5[7=V-O031@_:[&!!C -'SRGCZQ2&
M*P)5-MF*HBN!@G1RXA X.4R1>9>+4+7 9C17ZMV]#]TD9@0WZQ'"'#-:-_H\
MTM_SN_"M<GA3(QW2UHQ(Q?/"3 $;+0.5,^EV2Y9N4LH5'J/0I;?A58<0,'2S
MF<%PVYY81P'>#3F;Z^(];A(M7BQ6ZTE)UF:K$+QD" HQD1^F0IWOGD-)N@BA
M^D+GSAT.W9>F>_@=+Y@Q-3JZMD1R")XD#=KXRA*YZ7T<@8Z%0<5R#KGGH3)#
M=Z#I+6"W#^N/#-B]FN<A"_C./OSGZ[?G_VAWX,?W3^VI3&\W%9U4YH75Y]>S
MQ1_?Q[=9YU+TSM2.,0F42!%B(&/,>EV4YK5%=&^=[Y[:Z)'/F]>?S*_>64+(
M7@H+TL>:"%T];2,,,.*%Q%B2;#PD^]Y'C^E5X"AAWWO7/(*!@X?&[F<3.2&\
M9Z7V#(R;#-+J@"17RYR3$<B4NC\,N]7$N:Z28HX1T9-)<OOP:TS"OGK-CSJ8
M:&HO(>\+>9DUH*LW?12XY]J+4.P!XAY?DMQ>8GHF26X?G@TN\JNHPO<.\V?S
M?"M'Y^K']_-SHN2D]@('-*%.&<V&SD=DP+-7/DMKN6B:.WG0!D8"G4,$OJO&
MJ$/N#PZP6^2\6%Q<+.8;SCV6*<BL4EH$!5S7@CIK,@0A&5@78BX6!;_?J[I)
M6MWS"X\KO>YP0'7'[4'[[.^3.^B="-$HLM&DXZ"R%1"B9Z",3])G%E-H;)^V
MEIG96_I=*]!IB;LCT3T[,PI54(EL/ UT[6>ZYFLY)\L2LDB2E<B3\W$OE!R<
MF=GZ2VU7T#B:CV-0(3>&_O>X42E!J$B[3\(I4"K7YF"&E&*A6Q8ULG*_W60#
MA_;M7FF37=TL[;DU1_)M%$'\&Z>^3OSZ=3-V9L?<KQN//ZL4;13U@%1HNUH_
MYXL![IDE$LC?E[U%8??;^CA<Z0.1\C#OK3NQC0*6M]KL$V<P,B. U<)*%:T$
MQV*!;$3PBG1T-KU54N\YW:#+5C = N"IH0?[2&,42-KV):R';_5ZL7R)M),T
MW0IJGL\N%LOU=+7YZ_5H347L<$H**+41N9+H(!!W0"(S-B1K17_#F??=_- )
MO[VBLE/)#FZG/T[=^]I@\[P0>\]6*URO)D2$+9@92%O;=:;B(496@$>GO"!3
MU)JF 8+FJPZ=U]L#U#H5Q B5XX/\%+)2; @V;0QCK W.HX2HF0.N%5>*+!>6
M>\OF>&ZS0^< #ZC\CI3<*+!X/7[P2EN?S]_6U*FWTQ"GL^WP8:62"29YP!(C
MT<7H>-4NQ8%Q%-P'F;"W:IMG=SMTIG"O:&Q7=J. X]T#]NM\B6%6Q[+27W#Z
MZ6:.ZW:NZV;$ZR0FS,H*\N9\S;!RS$!(SH$P.9)Q7#1B;X-,]]_^T.G$ ZK/
MUJ4["@3O,T';2-2!1P4E(X=Z-T!4P8$-11:6%$^R-R>[[='G':82]XK9KN0Y
MIF3/^YG3;^;_6"Q_(VY>]1B=L.B3YR% EK4KMXP:?"2+NYCD2D%GM9/]V0!/
M;W;H3..>38 6)3<F2#[.Q9JUKXJK33TDL)0T*),%N,(4>*F\+%'2S=!;^] G
M=SITMG*O8&Q/9J,8"[>#G#=S4O./\2[Y)'F68#-CQ+L4P265Z2[0QJ&RIH3^
MNA+LM?5Q/ QV^$C3EMA&86!>I]"<EW?+!1VO];=WLYJ:-<^U<.!+Y>6+65BM
MIF6*^6RU@_:)"SH7'RR@R8;LE.0@V%*]1)&\]L8('OJ"ZO'DC/!1J#7 /7P4
MZE?Z(S<)=I&7BPDA&02>K 6%=,]$Q1QDC"4KR8NP0]H&AP*XW_>C[@#<@13'
M:BV\GL[#/.UFHBJB=IS,((OR=>:RA6BT 2+/YIQ,,OT5;.ZW]4&S#/NP%MH2
MVSBLA>4B(>8->0][X[# =$ Z9<EY 2HY!!=D 5'S\$2.LJ3>4/CD3D=XQ[<&
MDUV)'RW);'00K/71Q+*K^90Q>Z3_*4B)_$*E,P-?DT$#F2AH%"]DCPP!OSN[
M'.'MW _T#I?5*&!7^79^N2[$NM>+Y>9I;#4Q3#FOK"*+MYH5+#*R78J%% P3
MF:6$]ZLZNKUV[V]PA/D=W8'M: D=ZYWT:OI- K?<2C*4HR&3F:@,X 0W$'DV
M643M>>IM5G*S+8\PMZ-;-+8LQ5$X)@^?""JE9_-<_U.#!K^'V29W)6?-I982
M6/0&5$@.HN4%N+7%)5XRE[W-?VRZZ4'K6EIW1CH1U2A ^ @=I.-SCER04<&(
M718+L2M&,,9+C\E7TZ)/E7@@P%I/*.K2VSU2#"/J#?VJ%$SK\W*=-_*>V'75
MD^?\L9/CM32<DU&1A-BTZ$3PJ#0PX9D50EKB8E^(.V#_PZ0+=07'K@4X&C]D
M!QU"I.#K""3!ZL.\I>/F&'KP,I)SA;IPT5M*Q1%8:SW-IV?5MX\83J++5FW'
MOORRV+ZZAWG^):POE[@HMW(2[I#3L,U6@X]MM\_6OG0<V6AK"[N7TU6:+5:T
MT'GYA3:T(L1L!EF^^OIE%N;UWWY[,R^+Y<7V'%Q['B5JPJ;4@(&1/48W*$2O
M$I0B>3)%A6B:5OH?N(7C]=3MA?^&<^+R[,XZB\OUE3\49C?'<W5K5Q-MB_"9
MK-)2//E?=;J$-\*!1.Z\<U*S_FJXCJ9FR,K5/F#X4$/V"X#6[N:N%.E/835=
M+<I#DM_=6ND@7=KLD]M5IP=0TXI&?7&EQ/$VE.;Y5H.[-Z_??Z@#1693VAG>
M8#D4;I.1"%J6#"K[!#$4"RB]9%D* G?3\KI#]]"N3MU(H*9M(*F S1[.=XCC
MSGE27F:EM83 9 UHI7J>M8;D I&O,4756\_IXT@94IOV L&GU6G'LF^QG4E7
MVO3#Y<5%6'Y;E _33_-IF:::M)32XG)>$S_>+6;35 /.AZC3AA_=KCX]A)Y6
M%.K5PN=/+WR#X3J2";.)8$VTH.@&AIAY N1><VT43]XV5*/[K=RN\FRV]NWS
MPV(,OF0'R4;R%H-S$')FX(SURF3OC.S-OSZ*DD%;J'0'MJ<59K?R'KWMV4R[
M]* U!]6>X]&B)2@NC(P0"0J@#!=T+6N$X)G*"KFT]]\IQJ-%<966TR];F^/>
M0M\VK16V^-^.\?L8OMX^5,))QFJWF2P$'6@5#7B+%GP*9!I9GU)_3X+'$')"
M.G0?J.W0H7U)>Q2A]>>HO3&QMYU"[H0J2I8>2X$8C:S!9 ;!: >.B(RBR)1$
M?[&J@\D8M')G3+AN2=*GA>I;G1YN$YQT"BES#TD+<EL55M)Y!IM+#LD[X4UO
M3YQ'TC)HKODH\=V"S$\"Y&\NOH3I<AN>>>)P)TUDUA S$9E ,6<@6E4@<RPN
M9<F3ZVV08#LD#9K1-";(=X" DT#^2UQB6A#_[X4)W\R)[9</XH2".:&+#("6
M.3KYP9.]QCBH$DO601)K^HL1MTK:H*E78SH)'2+B)$[$3;>5GS'4\%"E^#;!
M4LMDBM'D;M>"5D.GWRN#4+RSA12"TJJWQ.HC:1DTOVM,F&]3YJ<!\FT/K!>7
MM#L2QV9(Z>RZD>H-V3X&71A#L+SVNM1<@6,ETBD715MN77+C<5N;4#1HDMFH
M -^Z_$\"]J_"<DY_7[W#;3O-.R']@$6YR" 6*VL->&U<J.A*,RX6@8%GV]M4
MPR/H&*8AU0@AWI:L3P+8C[;GN'.<LXR*$X,-$T1UT@4".2Q@@_!1:VF+[ZW^
MN@V"AFEW-4*HMR[]D\#\MH3S-HE9,^5]+."P3D(6/-1)/^2+6(8^.FU$[JTY
MZ]Z[;_9JQ/X)X'R<8$\"N^])NK3%6B/P$G_'V>+ZN-;6RG<2LQR=3[TIMLMD
M>&7#Z=0R 5F*DKQ+7MR?US4<I)L2U0SI_PP/I)W X$0.P*T8TWNB?7Z)$YT9
M+X;0YZ(A*LDD \<Y>1X1'?,E2<;M>,#^D(!FP/YG>"$]6KPG >('(QDV?C1Q
MMQ8,W3F^,@CT-D.2='4I2U_%6LLO!'V=N NFOPZR;1'5#.S_#,^EG<!@? >@
M7DMIC;D^E=4ZVC?U?(?9V9<OQ(>K-/-?\(\/ZS#/89E7Y\O-R C:_?JJ*:]'
MBTF1&)S.EHZ]*>!+8>"=RUYI56(>)L'K:-*:'88_W4-JOY#XDR32;F:2=IE&
M>[7 $$FTNV@;(H4V!>E#5F1@Q%C?Z84A4Z,4*!&M--I&Z_VSW!Z^$.$EG9/I
MK"90WJV,;!3P(7J+M]J"99:!XHY!I+,&TKF0K8\JYOZ,CI:(.J'4VGT@^'1Y
M0F\H^),HV _I,^;+&2[*G4E^88VK+2N[5+X-%A]",>_+DR&4-O/*:5_S"*T6
MH'0M0G28H*C@-4LR*G<*U6./'LOM,'*1B@TF2BBIYA+HHL#S%"%[8[@43,K<
M7T2O\;9/2/'N Z.G%6^+DAR%.[?IU8^K)P@[^SI=31A7!I/E$++,9),+2U_1
M#>(+72&Q:"GNG\,.FP4UVO+0#9N[ LW#OD+M2W 4R'R4G)_Q(N)R4EOPRX0!
M4 M6?58/GN4$@7M!V-$FBMY>]I[9Z]!8[ (BNSHWMR:O40#PO-"]@O?),"%P
M;B6!(&=/9$A=!T@%('O#%0P^*]9;Q\B=.QP:;*WBX '*CA?*X"/>?\9,]LKL
M/@U92A3&&[ ."ZA22\<W33?(-LDL!/0H&YJZNU<8NH]\%\!HC:.CT#BU!<PE
M?>!]0A2W.N>H(016(Z*H('(NB:Z059#:!]??K);=>QRZ;WRW6J<-P8P"88VL
MTK>W.EY&H76(@#D[4"$X.CP%:Y63#8C9.=Y? NQ>6Q]:V?5F_G<HT<%ORCOT
MA-OFZGQ^&6;WPU83IS*+1B%(OW'S2>M['0QDG5D).3H6GH_I';3TT$97ERA8
M]"62/TFL^9>P7&[F<7<?67ZPU!!QY*?I'>2I3P@12U*U:QT9?JC)I15%0[0F
M\L0T*CZN;CG;M7ZYK$8%+;5>I-^VT[;J,5M-T$:9R)6!5!31DV-]$:>[PCNM
MC38^2L\;TO/8&B<4S-U'NG>55RL,'OQ6_#E\G5Y<7GS$Y<7-4+:_+8EGF'=E
M'IW1Z9Q_VM0O3C ('DT2P(VN>1Z>@Z_\$Y$68:8PR9KV-#U\%R?4,^9PJ/4D
MI/%?F=_Y_/]<YD_;6O'5>GI1GQG)?CA;K2XOKD8L'G1/[O'Y+5^.AU+6SHWX
MU.IG=U:_0;-#JS%Q!D9:LO64KU,&=(10*I#)R\"<FEZ+^R_?KO/Z_=#6];?=
M:ZNM>[V'NV5..665$5RJ7KHT6"=FY5K"Z@I7RCDS2%OX/6@8]'KN&&I/^[1=
M"7KTFO/^,)1#M./.@2JM:< G=WBDEKL5>[N[R@W$-/HDI$F@7>U/'9V'8$,
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M2EOHW+#"8FV!H< ')8$'F8MRV=K[*2:/WFK/+C9,#D@'2.F"N:.XUFY7P3U
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M"<'9!!H3T]QGET3S2,G(K9%M!H$P3&(VG$C@=*(TG:B8!8+UUAGK2Q)ID/%
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M;+RBZ'R9I_.PO*;))YZTY!+09 L*60#'4B711\$L9F>:EKHU6W'T?GD;Z.F
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MQL9#")9#3$*DP"3ZAUF'?YW>1*.@81@KVT+#81Q-*)^4B76B@ <5HP-O"ME
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M,C R,2YH=&U02P$"% ,4    " #;AF-4X?HP^98=  "#K@  '@
M    @ $I(@  97@Q,F]N8RTR,#$W8GEX;&%W<S$V,S8T-3DN:'1M4$L! A0#
M%     @ VX9C5"X.^&&9!   E!,  !T              ( !^S\  &5X,3,Q
M8V5O8V5R=&EF:6-A=&EO;C(P,C$N:'1M4$L! A0#%     @ VX9C5#+.,]^&
M!   *1(  !T              ( !ST0  &5X,3,R8V9O8V5R=&EF:6-A=&EO
M;C(P,C$N:'1M4$L! A0#%     @ VX9C5 EPR.'IK0  <18& !$
M     ( !D$D  &5X,34Q+3(P,C%M9&$N:'1M4$L! A0#%     @ VX9C5%;"
M/]VL!0  EA@  !8              ( !J/<  &5X,34R97DR,#(Q8V]N<V5N
M="YH=&U02P$"% ,4    " #;AF-4MZ-6TKT$  ##"P  '@
M@ &(_0  97@R,65X9&5S8W)I<'1I;VYO9G-E8W5R:70N:'1M4$L! A0#%
M  @ VX9C5"GUX3,,"@  J#<  !X              ( !@0(! &5X-#$X;6%T
M=&-O9F9E>6%M96YD;65N=#,M+FAT;5!+ 0(4 Q0    ( -N&8U3X'U0F$PH
M /,W   >              "  <D, 0!E>#0Q.6MI<FML;V]K86UE;F1M96YT
M,RUE;2YH=&U02P$"% ,4    " #;AF-4E!K,!4X*   0.@  '@
M    @ $8%P$ 97@T,C!A;&QI<V]N:&%G97)M86YA;65N9&TN:'1M4$L! A0#
M%     @ VX9C5#.^\Y!X"@  2SD  !X              ( !HB$! &5X-#(Q
M86YD<F5W9&5G=71T861A=7)O86UE+FAT;5!+ 0(4 Q0    ( -N&8U1F>ZW1
MQ T  ,Q5   >              "  58L 0!E>#0R,G1H;VUA<VAE:6YE;6%N
M86UE;F1M92YH=&U02P$"% ,4    " #;AF-4;^CI>?("  "P#0  &
M        @ %6.@$ 97@X,'-U8G-I9&EA<FEE<S(P,C$N:'1M4$L! A0#%
M  @ VX9C5'\?<X57<@, F=DA !(              ( !?CT! &]N8WEF+3(P
M,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( -R&8U25916[SAH  %HR 0 2
M      "  06P! !O;F-Y9BTR,#(Q,3(S,2YX<V102P$"% ,4    " #<AF-4
MOI(?F$<3  !SL0  %@              @ $#RP0 ;VYC>68M,C R,3$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( -R&8U2LQMU,/V0  '-*!  6
M  "  7[>! !O;F-Y9BTR,#(Q,3(S,5]D968N>&UL4$L! A0#%     @ W(9C
M5+*T;7:G00( AD(" !4              ( !\4(% &]N8WEF+3(P,C$Q,C,Q
M7V<Q+FIP9U!+ 0(4 Q0    ( -R&8U1)YD4$O-0& #L'!P 5
M  "  <N$!P!O;F-Y9BTR,#(Q,3(S,5]G,BYJ<&=02P$"% ,4    " #<AF-4
M]/\&\\H8  "A&0  %0              @ &Z60X ;VYC>68M,C R,3$R,S%?
M9S,N:G!G4$L! A0#%     @ W(9C5/0-<C?<Z   $?\) !8
M ( !MW(. &]N8WEF+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #<AF-4
MY;"EP>^5   TW 8 %@              @ ''6P\ ;VYC>68M,C R,3$R,S%?
=<')E+GAM;%!+!08     &  8 )P&  #J\0\    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
